diff --git "a/classification/cdr/train.json" "b/classification/cdr/train.json"
new file mode 100644--- /dev/null
+++ "b/classification/cdr/train.json"
@@ -0,0 +1,8432 @@
+{
+	"0": {"data": {"text": "CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.", "entity1": "Bupropion", "entity2": "SD", "span1": [13, 22], "span2": [58, 60]}, "bert_text": "CONCLUSIONS: <e1> Bupropion </e1> is an effective treatment for male <e2> SD </e2> induced by SSRIs.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1": {"data": {"text": "CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.", "entity1": "SSRIs", "entity2": "SD", "span1": [72, 77], "span2": [58, 60]}, "bert_text": "CONCLUSIONS: Bupropion is an effective treatment for male SD induced by <e1> SSRIs </e1> <e2> SD </e2> induced by SSRIs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2": {"data": {"text": "A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.\n", "entity1": "haloperidol", "entity2": "psychosis", "span1": [58, 69], "span2": [74, 83]}, "bert_text": "A randomized, placebo-controlled dose-comparison trial of <e1> haloperidol </e1> for <e2> psychosis </e2> and disruptive behaviors in Alzheimer's disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3": {"data": {"text": "A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.\n", "entity1": "haloperidol", "entity2": "disruptive behaviors", "span1": [58, 69], "span2": [88, 108]}, "bert_text": "A randomized, placebo-controlled dose-comparison trial of <e1> haloperidol </e1> for psychosis and <e2> disruptive behaviors </e2> in Alzheimer's disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4": {"data": {"text": "A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.\n", "entity1": "haloperidol", "entity2": "Alzheimer's disease", "span1": [58, 69], "span2": [112, 131]}, "bert_text": "A randomized, placebo-controlled dose-comparison trial of <e1> haloperidol </e1> for psychosis and disruptive behaviors in <e2> Alzheimer's disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5": {"data": {"text": "These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.", "entity1": "5-HT6", "entity2": "schizophrenia", "span1": [132, 137], "span2": [72, 85]}, "bert_text": "These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered <e1> 5-HT6 </e1> <e2> schizophrenia </e2>, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6": {"data": {"text": "These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.", "entity1": "5-HT6", "entity2": "psychotic disorders", "span1": [132, 137], "span2": [187, 206]}, "bert_text": "These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered <e1> 5-HT6 </e1> receptors are involved in the pathophysiology of <e2> psychotic disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7": {"data": {"text": "The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.", "entity1": "ziprasidone", "entity2": "schizophrenia", "span1": [179, 190], "span2": [52, 65]}, "bert_text": "The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated <e1> ziprasidone </e1> <e2> schizophrenia </e2> who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8": {"data": {"text": "The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.", "entity1": "ziprasidone", "entity2": "NMS", "span1": [179, 190], "span2": [102, 105]}, "bert_text": "The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated <e1> ziprasidone </e1> <e2> NMS </e2> after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"9": {"data": {"text": "The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.", "entity1": "curcumin", "entity2": "cognitive impairment", "span1": [26, 34], "span2": [154, 174]}, "bert_text": "The findings suggest that <e1> curcumin </e1> can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing <e2> cognitive impairment </e2> associated with these drugs.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"10": {"data": {"text": "The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.", "entity1": "phenobarbitone", "entity2": "cognitive impairment", "span1": [99, 113], "span2": [154, 174]}, "bert_text": "The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to <e1> phenobarbitone </e1> and carbamazepine therapy in preventing <e2> cognitive impairment </e2> associated with these drugs.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"11": {"data": {"text": "The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.", "entity1": "carbamazepine", "entity2": "cognitive impairment", "span1": [118, 131], "span2": [154, 174]}, "bert_text": "The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and <e1> carbamazepine </e1> therapy in preventing <e2> cognitive impairment </e2> associated with these drugs.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"12": {"data": {"text": "SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [147, 158], "span2": [167, 176]}, "bert_text": "SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat <e1> haloperidol </e1>-induced <e2> catalepsy </e2> model for Parkinson's disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"13": {"data": {"text": "SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.", "entity1": "haloperidol", "entity2": "Parkinson's disease", "span1": [147, 158], "span2": [187, 206]}, "bert_text": "SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat <e1> haloperidol </e1>-induced catalepsy model for <e2> Parkinson's disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"14": {"data": {"text": "Acute blood pressure elevations with caffeine in men with borderline systemic hypertension.\n", "entity1": "caffeine", "entity2": "hypertension", "span1": [37, 45], "span2": [78, 90]}, "bert_text": "Acute blood pressure elevations with <e1> caffeine </e1> in men with borderline systemic <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"15": {"data": {"text": "OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.", "entity1": "haloperidol", "entity2": "psychosis", "span1": [95, 106], "span2": [139, 148]}, "bert_text": "OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of <e1> haloperidol </e1> and placebo in the treatment of <e2> psychosis </e2> and disruptive behaviors in patients with Alzheimer's disease.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"16": {"data": {"text": "OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.", "entity1": "haloperidol", "entity2": "disruptive behaviors", "span1": [95, 106], "span2": [153, 173]}, "bert_text": "OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of <e1> haloperidol </e1> and placebo in the treatment of psychosis and <e2> disruptive behaviors </e2> in patients with Alzheimer's disease.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"17": {"data": {"text": "OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.", "entity1": "haloperidol", "entity2": "Alzheimer's disease", "span1": [95, 106], "span2": [191, 210]}, "bert_text": "OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of <e1> haloperidol </e1> and placebo in the treatment of psychosis and disruptive behaviors in patients with <e2> Alzheimer's disease </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"18": {"data": {"text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "entity1": "cocaine-", "entity2": "seizures", "span1": [17, 25], "span2": [41, 49]}, "bert_text": "The finding that <e1> cocaine- </e1> and BE-induced <e2> seizures </e2> differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"19": {"data": {"text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "entity1": "cocaine-", "entity2": "seizures", "span1": [17, 25], "span2": [130, 138]}, "bert_text": "The finding that <e1> cocaine- </e1> and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced <e2> seizures </e2> and emphasizes the importance of a cocaine metabolite, BE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"20": {"data": {"text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "entity1": "cocaine", "entity2": "seizures", "span1": [114, 121], "span2": [41, 49]}, "bert_text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for <e1> cocaine </e1> <e2> seizures </e2> differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"21": {"data": {"text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "entity1": "cocaine", "entity2": "seizures", "span1": [114, 121], "span2": [130, 138]}, "bert_text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for <e1> cocaine </e1>-induced <e2> seizures </e2> and emphasizes the importance of a cocaine metabolite, BE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"22": {"data": {"text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "entity1": "cocaine", "entity2": "seizures", "span1": [174, 181], "span2": [41, 49]}, "bert_text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a <e1> cocaine </e1> <e2> seizures </e2> differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"23": {"data": {"text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "entity1": "cocaine", "entity2": "seizures", "span1": [174, 181], "span2": [130, 138]}, "bert_text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a <e1> cocaine </e1> <e2> seizures </e2> and emphasizes the importance of a cocaine metabolite, BE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"24": {"data": {"text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "entity1": "BE", "entity2": "seizures", "span1": [30, 32], "span2": [41, 49]}, "bert_text": "The finding that cocaine- and <e1> BE </e1>-induced <e2> seizures </e2> differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"25": {"data": {"text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "entity1": "BE", "entity2": "seizures", "span1": [30, 32], "span2": [130, 138]}, "bert_text": "The finding that cocaine- and <e1> BE </e1>-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced <e2> seizures </e2> and emphasizes the importance of a cocaine metabolite, BE.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"26": {"data": {"text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "entity1": "BE", "entity2": "seizures", "span1": [194, 196], "span2": [41, 49]}, "bert_text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, <e1> BE </e1> <e2> seizures </e2> differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"27": {"data": {"text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "entity1": "BE", "entity2": "seizures", "span1": [194, 196], "span2": [130, 138]}, "bert_text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, <e1> BE </e1> <e2> seizures </e2> and emphasizes the importance of a cocaine metabolite, BE.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"28": {"data": {"text": "A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.", "entity1": "dapsone", "entity2": "leprosy", "span1": [122, 129], "span2": [51, 58]}, "bert_text": "A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of <e1> dapsone </e1> <e2> leprosy </e2> developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"29": {"data": {"text": "A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.", "entity1": "dapsone", "entity2": "hemolytic anemia", "span1": [122, 129], "span2": [82, 98]}, "bert_text": "A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of <e1> dapsone </e1> <e2> hemolytic anemia </e2> while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"30": {"data": {"text": "A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.", "entity1": "dapsone", "entity2": "hemolysis", "span1": [122, 129], "span2": [179, 188]}, "bert_text": "A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of <e1> dapsone </e1> (50 mg/day) not usually associated with clinical <e2> hemolysis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"31": {"data": {"text": "In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.", "entity1": "SSRI", "entity2": "SD", "span1": [109, 113], "span2": [97, 99]}, "bert_text": "In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of <e1> SSRI </e1> <e2> SD </e2>, type of SSRI used and age.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"32": {"data": {"text": "Neuroleptic malignant syndrome with risperidone.\n", "entity1": "risperidone", "entity2": "Neuroleptic malignant syndrome", "span1": [36, 47], "span2": [0, 30]}, "bert_text": "Neuroleptic malignant syndrome with <e1> risperidone </e1> <e2> Neuroleptic malignant syndrome </e2> with risperidone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"33": {"data": {"text": "These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.", "entity1": "ecstasy", "entity2": "neurotoxic", "span1": [6, 13], "span2": [114, 124]}, "bert_text": "These <e1> ecstasy </e1>-specific effects may be related to the vulnerability of isocortical and allocortical regions to the <e2> neurotoxic </e2> effects of ecstasy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"34": {"data": {"text": "These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.", "entity1": "ecstasy", "entity2": "neurotoxic", "span1": [136, 143], "span2": [114, 124]}, "bert_text": "These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of <e1> ecstasy </e1> <e2> neurotoxic </e2> effects of ecstasy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"35": {"data": {"text": "Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.", "entity1": "oxygen", "entity2": "neuronal damage", "span1": [29, 35], "span2": [110, 125]}, "bert_text": "Both, production of reactive <e1> oxygen </e1> species as well as activation of NF-kappaB have been implicated in severe <e2> neuronal damage </e2> in different sub-regions of the hippocampus as well as in the surrounding cortices.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"36": {"data": {"text": "3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).", "entity1": "SNP", "entity2": "HEM", "span1": [25, 28], "span2": [17, 20]}, "bert_text": "3.8 mm Hg in the HEM and <e1> SNP </e1> <e2> HEM </e2> and SNP groups, respectively, during hypotension (P less than 0.02).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"37": {"data": {"text": "3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).", "entity1": "SNP", "entity2": "hypotension", "span1": [25, 28], "span2": [58, 69]}, "bert_text": "3.8 mm Hg in the HEM and <e1> SNP </e1> groups, respectively, during <e2> hypotension </e2> (P less than 0.02).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"38": {"data": {"text": "Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.\n", "entity1": "Selegiline", "entity2": "postural hypotension", "span1": [0, 10], "span2": [19, 39]}, "bert_text": "<e1> Selegiline </e1>-induced <e2> postural hypotension </e2> in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"39": {"data": {"text": "Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.\n", "entity1": "Selegiline", "entity2": "Parkinson's disease", "span1": [0, 10], "span2": [43, 62]}, "bert_text": "<e1> Selegiline </e1>-induced postural hypotension in <e2> Parkinson's disease </e2>: a longitudinal study on the effects of drug withdrawal.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"40": {"data": {"text": "This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.", "entity1": "amiodarone", "entity2": "CHF", "span1": [87, 97], "span2": [104, 107]}, "bert_text": "This case report carries an important clinical application given the frequent usage of <e1> amiodarone </e1> among <e2> CHF </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"41": {"data": {"text": "Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.\n", "entity1": "dopamine", "entity2": "hyperactivity", "span1": [41, 49], "span2": [90, 103]}, "bert_text": "Evidence for an involvement of D1 and D2 <e1> dopamine </e1> receptors in mediating nicotine-induced <e2> hyperactivity </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"42": {"data": {"text": "Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.\n", "entity1": "nicotine", "entity2": "hyperactivity", "span1": [73, 81], "span2": [90, 103]}, "bert_text": "Evidence for an involvement of D1 and D2 dopamine receptors in mediating <e1> nicotine </e1>-induced <e2> hyperactivity </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"43": {"data": {"text": "In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.", "entity1": "serotonin", "entity2": "migraine", "span1": [13, 22], "span2": [63, 71]}, "bert_text": "In contrast, <e1> serotonin </e1> release from platelets does not provoke <e2> migraine </e2>, it may even counteract the headache and the concomitant CGRP release in this model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"44": {"data": {"text": "In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.", "entity1": "serotonin", "entity2": "headache", "span1": [13, 22], "span2": [100, 108]}, "bert_text": "In contrast, <e1> serotonin </e1> release from platelets does not provoke migraine, it may even counteract the <e2> headache </e2> and the concomitant CGRP release in this model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"45": {"data": {"text": "In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.", "entity1": "CGRP", "entity2": "migraine", "span1": [129, 133], "span2": [63, 71]}, "bert_text": "In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant <e1> CGRP </e1> <e2> migraine </e2>, it may even counteract the headache and the concomitant CGRP release in this model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"46": {"data": {"text": "In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.", "entity1": "CGRP", "entity2": "headache", "span1": [129, 133], "span2": [100, 108]}, "bert_text": "In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant <e1> CGRP </e1> <e2> headache </e2> and the concomitant CGRP release in this model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"47": {"data": {"text": "Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.", "entity1": "MPTP", "entity2": "dyskinesia", "span1": [32, 36], "span2": [144, 154]}, "bert_text": "Monkeys with acute (short-term) <e1> MPTP </e1> exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed <e2> dyskinesia </e2> between 11 and 24 days of daily levodopa administration.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"48": {"data": {"text": "Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [117, 125], "span2": [144, 154]}, "bert_text": "Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of <e1> levodopa </e1> therapy developed <e2> dyskinesia </e2> between 11 and 24 days of daily levodopa administration.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"49": {"data": {"text": "Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [187, 195], "span2": [144, 154]}, "bert_text": "Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily <e1> levodopa </e1> <e2> dyskinesia </e2> between 11 and 24 days of daily levodopa administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"50": {"data": {"text": "99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.", "entity1": "99mTc-glucarate", "entity2": "acute myocardial infarction", "span1": [0, 15], "span2": [130, 157]}, "bert_text": "<e1> 99mTc-glucarate </e1> was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced <e2> acute myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"51": {"data": {"text": "99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.", "entity1": "isoproterenol", "entity2": "acute myocardial infarction", "span1": [108, 121], "span2": [130, 157]}, "bert_text": "99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with <e1> isoproterenol </e1>-induced <e2> acute myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"52": {"data": {"text": "We report 19 patients with VPA-associated encephalopathy in Germany from the years 1994 to 2003, none of whom had been published previously.", "entity1": "VPA", "entity2": "encephalopathy", "span1": [27, 30], "span2": [42, 56]}, "bert_text": "We report 19 patients with <e1> VPA </e1>-associated <e2> encephalopathy </e2> in Germany from the years 1994 to 2003, none of whom had been published previously.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"53": {"data": {"text": "Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.", "entity1": "Warfarin", "entity2": "calcification", "span1": [27, 35], "span2": [57, 70]}, "bert_text": "Treatment for 2 weeks with <e1> Warfarin </e1> caused massive focal <e2> calcification </e2> of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"54": {"data": {"text": "Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.", "entity1": "Warfarin", "entity2": "calcification", "span1": [27, 35], "span2": [135, 148]}, "bert_text": "Treatment for 2 weeks with <e1> Warfarin </e1> caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal <e2> calcification </e2> in 42-day-old rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"55": {"data": {"text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "entity1": "5-azacytidine", "entity2": "carcinogenic process", "span1": [134, 147], "span2": [112, 132]}, "bert_text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, <e1> 5-azacytidine </e1> <e2> carcinogenic process </e2>, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"56": {"data": {"text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "entity1": "5-AzC", "entity2": "carcinogenic process", "span1": [149, 154], "span2": [112, 132]}, "bert_text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (<e1> 5-AzC </e1> <e2> carcinogenic process </e2>, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"57": {"data": {"text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "entity1": "benzo[a]-pyrene", "entity2": "carcinogenic process", "span1": [290, 305], "span2": [112, 132]}, "bert_text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, <e1> benzo[a]-pyrene </e1> <e2> carcinogenic process </e2>, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"58": {"data": {"text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "entity1": "N-methyl-N-nitrosourea", "entity2": "carcinogenic process", "span1": [319, 341], "span2": [112, 132]}, "bert_text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), <e1> N-methyl-N-nitrosourea </e1> <e2> carcinogenic process </e2>, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"59": {"data": {"text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "entity1": "1,2-dimethylhydrazine", "entity2": "carcinogenic process", "span1": [357, 378], "span2": [112, 132]}, "bert_text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and <e1> 1,2-dimethylhydrazine </e1> <e2> carcinogenic process </e2>, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"60": {"data": {"text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "entity1": "1,2-DMH", "entity2": "carcinogenic process", "span1": [380, 387], "span2": [112, 132]}, "bert_text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (<e1> 1,2-DMH </e1> <e2> carcinogenic process </e2>, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"61": {"data": {"text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "entity1": "etoricoxib", "entity2": "hypertension", "span1": [113, 123], "span2": [38, 50]}, "bert_text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with <e1> etoricoxib </e1> <e2> hypertension </e2>-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"62": {"data": {"text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "entity1": "etoricoxib", "entity2": "hypertension", "span1": [113, 123], "span2": [219, 231]}, "bert_text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with <e1> etoricoxib </e1> (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for <e2> hypertension </e2> and p<0.01 for oedema).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"63": {"data": {"text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "entity1": "etoricoxib", "entity2": "oedema", "span1": [113, 123], "span2": [63, 69]}, "bert_text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with <e1> etoricoxib </e1> <e2> oedema </e2>-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"64": {"data": {"text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "entity1": "etoricoxib", "entity2": "oedema", "span1": [113, 123], "span2": [247, 253]}, "bert_text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with <e1> etoricoxib </e1> (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for <e2> oedema </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"65": {"data": {"text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "entity1": "diclofenac", "entity2": "hypertension", "span1": [167, 177], "span2": [38, 50]}, "bert_text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with <e1> diclofenac </e1> <e2> hypertension </e2>-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"66": {"data": {"text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "entity1": "diclofenac", "entity2": "hypertension", "span1": [167, 177], "span2": [219, 231]}, "bert_text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with <e1> diclofenac </e1> (1.5% and 0.4% respectively; p<0.001 for <e2> hypertension </e2> and p<0.01 for oedema).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"67": {"data": {"text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "entity1": "diclofenac", "entity2": "oedema", "span1": [167, 177], "span2": [63, 69]}, "bert_text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with <e1> diclofenac </e1> <e2> oedema </e2>-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"68": {"data": {"text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "entity1": "diclofenac", "entity2": "oedema", "span1": [167, 177], "span2": [247, 253]}, "bert_text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with <e1> diclofenac </e1> (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for <e2> oedema </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"69": {"data": {"text": "We conclude that vancomycin, administered appropriately, constitutes safe, effective therapy for infections caused by susceptible bacteria.", "entity1": "vancomycin", "entity2": "infections", "span1": [17, 27], "span2": [97, 107]}, "bert_text": "We conclude that <e1> vancomycin </e1>, administered appropriately, constitutes safe, effective therapy for <e2> infections </e2> caused by susceptible bacteria.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"70": {"data": {"text": "Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.", "entity1": "puromycin aminonucleoside", "entity2": "proteinuria", "span1": [107, 132], "span2": [84, 95]}, "bert_text": "Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by <e1> puromycin aminonucleoside </e1> <e2> proteinuria </e2> invoked by puromycin aminonucleoside in SHR.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"71": {"data": {"text": "Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.\n", "entity1": "carbamazepine", "entity2": "Myoclonic", "span1": [65, 78], "span2": [0, 9]}, "bert_text": "Myoclonic, atonic, and absence seizures following institution of <e1> carbamazepine </e1> <e2> Myoclonic </e2>, atonic, and absence seizures following institution of carbamazepine therapy in children.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"72": {"data": {"text": "Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.\n", "entity1": "carbamazepine", "entity2": "absence seizures", "span1": [65, 78], "span2": [23, 39]}, "bert_text": "Myoclonic, atonic, and absence seizures following institution of <e1> carbamazepine </e1> <e2> absence seizures </e2> following institution of carbamazepine therapy in children.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"73": {"data": {"text": "Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).", "entity1": "pentoxifylline", "entity2": "hyperemia", "span1": [16, 30], "span2": [80, 89]}, "bert_text": "Neither dose of <e1> pentoxifylline </e1> significantly decreased the dipyridamole-induced <e2> hyperemia </e2>, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"74": {"data": {"text": "Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).", "entity1": "dipyridamole", "entity2": "hyperemia", "span1": [59, 71], "span2": [80, 89]}, "bert_text": "Neither dose of pentoxifylline significantly decreased the <e1> dipyridamole </e1>-induced <e2> hyperemia </e2>, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"75": {"data": {"text": "Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).", "entity1": "theophylline", "entity2": "hyperemia", "span1": [152, 164], "span2": [80, 89]}, "bert_text": "Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after <e1> theophylline </e1> <e2> hyperemia </e2>, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"76": {"data": {"text": "Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.\n", "entity1": "Capsaicin", "entity2": "muscle pain", "span1": [0, 9], "span2": [18, 29]}, "bert_text": "<e1> Capsaicin </e1>-induced <e2> muscle pain </e2> alters the excitability of the human jaw-stretch reflex.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"77": {"data": {"text": "Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.", "entity1": "bendrofluazide", "entity2": "hypertension", "span1": [139, 153], "span2": [70, 82]}, "bert_text": "Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: <e1> bendrofluazide </e1> <e2> hypertension </e2> are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"78": {"data": {"text": "Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.", "entity1": "propranolol", "entity2": "hypertension", "span1": [155, 166], "span2": [70, 82]}, "bert_text": "Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, <e1> propranolol </e1> <e2> hypertension </e2> are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"79": {"data": {"text": "In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.", "entity1": "oxygen", "entity2": "myocardial infarction", "span1": [143, 149], "span2": [79, 100]}, "bert_text": "In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial <e1> oxygen </e1> <e2> myocardial infarction </e2> may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"80": {"data": {"text": "In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.", "entity1": "cocaine", "entity2": "myocardial infarction", "span1": [173, 180], "span2": [79, 100]}, "bert_text": "In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with <e1> cocaine </e1> <e2> myocardial infarction </e2> may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"81": {"data": {"text": "Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.", "entity1": "lithium", "entity2": "syncopal attacks", "span1": [6, 13], "span2": [79, 95]}, "bert_text": "Serum <e1> lithium </e1> levels remained under or within the therapeutic range during the <e2> syncopal attacks </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"82": {"data": {"text": "We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.", "entity1": "amoxicillin-clavulanic acid", "entity2": "hepatitis", "span1": [37, 64], "span2": [73, 82]}, "bert_text": "We report the case of a patient with <e1> amoxicillin-clavulanic acid </e1>-induced <e2> hepatitis </e2> with histologic multiple granulomas.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"83": {"data": {"text": "We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.", "entity1": "amoxicillin-clavulanic acid", "entity2": "granulomas", "span1": [37, 64], "span2": [108, 118]}, "bert_text": "We report the case of a patient with <e1> amoxicillin-clavulanic acid </e1>-induced hepatitis with histologic multiple <e2> granulomas </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"84": {"data": {"text": "In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.", "entity1": "procainamide", "entity2": "premature ventricular contractions", "span1": [33, 45], "span2": [95, 129]}, "bert_text": "In the remaining three patients, <e1> procainamide </e1> was administered orally for treatment of chronic <e2> premature ventricular contractions </e2> or atrial flutter.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"85": {"data": {"text": "In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.", "entity1": "procainamide", "entity2": "atrial flutter", "span1": [33, 45], "span2": [133, 147]}, "bert_text": "In the remaining three patients, <e1> procainamide </e1> was administered orally for treatment of chronic premature ventricular contractions or <e2> atrial flutter </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"86": {"data": {"text": "CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.", "entity1": "CY", "entity2": "hemorrhagic cystitis", "span1": [0, 2], "span2": [10, 30]}, "bert_text": "<e1> CY </e1> caused <e2> hemorrhagic cystitis </e2> in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"87": {"data": {"text": "CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.", "entity1": "5-FU", "entity2": "hemorrhagic cystitis", "span1": [105, 109], "span2": [10, 30]}, "bert_text": "CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with <e1> 5-FU </e1> <e2> hemorrhagic cystitis </e2> in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"88": {"data": {"text": "CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.", "entity1": "MTX", "entity2": "hemorrhagic cystitis", "span1": [114, 117], "span2": [10, 30]}, "bert_text": "CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and <e1> MTX </e1> <e2> hemorrhagic cystitis </e2> in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"89": {"data": {"text": "Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.", "entity1": "lidocaine", "entity2": "convulsive", "span1": [21, 30], "span2": [72, 82]}, "bert_text": "Co-administration of <e1> lidocaine </e1> with desipramine reversed the changes of <e2> convulsive </e2> activity of lidocaine and cocaine induced by repeated administration of desipramine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"90": {"data": {"text": "Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.", "entity1": "lidocaine", "entity2": "convulsive", "span1": [95, 104], "span2": [72, 82]}, "bert_text": "Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of <e1> lidocaine </e1> <e2> convulsive </e2> activity of lidocaine and cocaine induced by repeated administration of desipramine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"91": {"data": {"text": "Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.", "entity1": "desipramine", "entity2": "convulsive", "span1": [36, 47], "span2": [72, 82]}, "bert_text": "Co-administration of lidocaine with <e1> desipramine </e1> reversed the changes of <e2> convulsive </e2> activity of lidocaine and cocaine induced by repeated administration of desipramine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"92": {"data": {"text": "Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.", "entity1": "desipramine", "entity2": "convulsive", "span1": [155, 166], "span2": [72, 82]}, "bert_text": "Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of <e1> desipramine </e1> <e2> convulsive </e2> activity of lidocaine and cocaine induced by repeated administration of desipramine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"93": {"data": {"text": "Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.", "entity1": "cocaine", "entity2": "convulsive", "span1": [109, 116], "span2": [72, 82]}, "bert_text": "Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and <e1> cocaine </e1> <e2> convulsive </e2> activity of lidocaine and cocaine induced by repeated administration of desipramine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"94": {"data": {"text": "Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\n", "entity1": "warfarin", "entity2": "hemorrhage", "span1": [80, 88], "span2": [42, 52]}, "bert_text": "Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of <e1> warfarin </e1> <e2> hemorrhage </e2> volume in a mouse model of warfarin-associated intracerebral hemorrhage.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"95": {"data": {"text": "Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.\n", "entity1": "warfarin", "entity2": "intracerebral hemorrhage", "span1": [80, 88], "span2": [100, 124]}, "bert_text": "Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of <e1> warfarin </e1>-associated <e2> intracerebral hemorrhage </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"96": {"data": {"text": "Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.", "entity1": "Haloperidol", "entity2": "parkinsonian", "span1": [0, 11], "span2": [33, 45]}, "bert_text": "<e1> Haloperidol </e1> (1 mg/kg ip) induced <e2> parkinsonian </e2>-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"97": {"data": {"text": "Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.", "entity1": "Haloperidol", "entity2": "muscle rigidity", "span1": [0, 11], "span2": [51, 66]}, "bert_text": "<e1> Haloperidol </e1> (1 mg/kg ip) induced parkinsonian-like <e2> muscle rigidity </e2>, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"98": {"data": {"text": "Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.\n", "entity1": "dexamethasone", "entity2": "neurological dysfunction", "span1": [112, 125], "span2": [6, 30]}, "bert_text": "Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after <e1> dexamethasone </e1> <e2> neurological dysfunction </e2>, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"99": {"data": {"text": "We report the case of a patient in whom troleandomycin-induced hepatitis was followed by prolonged anicteric cholestasis.", "entity1": "troleandomycin", "entity2": "hepatitis", "span1": [40, 54], "span2": [63, 72]}, "bert_text": "We report the case of a patient in whom <e1> troleandomycin </e1>-induced <e2> hepatitis </e2> was followed by prolonged anicteric cholestasis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"100": {"data": {"text": "We report the case of a patient in whom troleandomycin-induced hepatitis was followed by prolonged anicteric cholestasis.", "entity1": "troleandomycin", "entity2": "cholestasis", "span1": [40, 54], "span2": [109, 120]}, "bert_text": "We report the case of a patient in whom <e1> troleandomycin </e1>-induced hepatitis was followed by prolonged anicteric <e2> cholestasis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"101": {"data": {"text": "We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.", "entity1": "dipyridamole", "entity2": "coronary hyperemia", "span1": [50, 62], "span2": [71, 89]}, "bert_text": "We conclude that pentoxyifylline does not inhibit <e1> dipyridamole </e1>-induced <e2> coronary hyperemia </e2> even at high doses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"102": {"data": {"text": "Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.", "entity1": "carbamazepine", "entity2": "epilepsy", "span1": [48, 61], "span2": [66, 74]}, "bert_text": "Five children, aged 3 to 11 years, treated with <e1> carbamazepine </e1> for <e2> epilepsy </e2>, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"103": {"data": {"text": "Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.", "entity1": "carbamazepine", "entity2": "myoclonic", "span1": [48, 61], "span2": [137, 146]}, "bert_text": "Five children, aged 3 to 11 years, treated with <e1> carbamazepine </e1> for epilepsy, had an acute aberrant reaction characterized by the onset of <e2> myoclonic </e2>, atypical absence and/or atonic (minor motor) seizures within a few days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"104": {"data": {"text": "Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.", "entity1": "carbamazepine", "entity2": "seizures", "span1": [48, 61], "span2": [193, 201]}, "bert_text": "Five children, aged 3 to 11 years, treated with <e1> carbamazepine </e1> for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) <e2> seizures </e2> within a few days.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"105": {"data": {"text": "RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).", "entity1": "spironolactone", "entity2": "hyperkalemia", "span1": [72, 86], "span2": [94, 106]}, "bert_text": "RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of <e1> spironolactone </e1> due to <e2> hyperkalemia </e2> (n = 33) or renal failure (n = 34).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"106": {"data": {"text": "RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).", "entity1": "spironolactone", "entity2": "renal failure", "span1": [72, 86], "span2": [119, 132]}, "bert_text": "RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of <e1> spironolactone </e1> due to hyperkalemia (n = 33) or <e2> renal failure </e2> (n = 34).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"107": {"data": {"text": "Clotiazepam-induced acute hepatitis.\n", "entity1": "Clotiazepam", "entity2": "hepatitis", "span1": [0, 11], "span2": [26, 35]}, "bert_text": "<e1> Clotiazepam </e1>-induced acute <e2> hepatitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"108": {"data": {"text": "Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.", "entity1": "cocaine", "entity2": "convulsive", "span1": [152, 159], "span2": [85, 95]}, "bert_text": "Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of <e1> cocaine </e1> <e2> convulsive </e2>, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"109": {"data": {"text": "In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.", "entity1": "procainamide", "entity2": "ventricular tachycardia", "span1": [117, 129], "span2": [31, 54]}, "bert_text": "In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of <e1> procainamide </e1> <e2> ventricular tachycardia </e2> appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"110": {"data": {"text": "In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.", "entity1": "procainamide", "entity2": "ventricular tachycardia", "span1": [117, 129], "span2": [161, 184]}, "bert_text": "In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of <e1> procainamide </e1> for the treatment of sustained <e2> ventricular tachycardia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"111": {"data": {"text": "Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.", "entity1": "sulfasalazine", "entity2": "hepatotoxicity", "span1": [37, 50], "span2": [19, 33]}, "bert_text": "Patients', who had hepatotoxicity on <e1> sulfasalazine </e1> <e2> hepatotoxicity </e2> on sulfasalazine and met a definition of a serious ADR, were identified.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"112": {"data": {"text": "We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.", "entity1": "chloroquine", "entity2": "chorioretinopathy", "span1": [8, 19], "span2": [89, 106]}, "bert_text": "We used <e1> chloroquine </e1> or hydroxychloroquine in 173 of 210 cases and found only one case of <e2> chorioretinopathy </e2> attributable to these drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"113": {"data": {"text": "We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.", "entity1": "hydroxychloroquine", "entity2": "chorioretinopathy", "span1": [23, 41], "span2": [89, 106]}, "bert_text": "We used chloroquine or <e1> hydroxychloroquine </e1> in 173 of 210 cases and found only one case of <e2> chorioretinopathy </e2> attributable to these drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"114": {"data": {"text": "Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.", "entity1": "paracetamol", "entity2": "hyperplasia", "span1": [27, 38], "span2": [62, 73]}, "bert_text": "Additionally, 20 to 25% of <e1> paracetamol </e1>-treated rats developed <e2> hyperplasia </e2> of the bladder epithelium, which was not coincident with the presence of bladder calculi.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"115": {"data": {"text": "Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.", "entity1": "paracetamol", "entity2": "bladder calculi", "span1": [27, 38], "span2": [147, 162]}, "bert_text": "Additionally, 20 to 25% of <e1> paracetamol </e1>-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of <e2> bladder calculi </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"116": {"data": {"text": "Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.", "entity1": "all- trans-retinoic acid", "entity2": "Erythema nodosum", "span1": [33, 57], "span2": [0, 16]}, "bert_text": "Erythema nodosum associated with <e1> all- trans-retinoic acid </e1> <e2> Erythema nodosum </e2> associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"117": {"data": {"text": "Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.", "entity1": "all- trans-retinoic acid", "entity2": "acute promyelocytic leukemia", "span1": [33, 57], "span2": [69, 97]}, "bert_text": "Erythema nodosum associated with <e1> all- trans-retinoic acid </e1> (ATRA) for <e2> acute promyelocytic leukemia </e2> (APL) is very rare.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"118": {"data": {"text": "Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.", "entity1": "all- trans-retinoic acid", "entity2": "APL", "span1": [33, 57], "span2": [99, 102]}, "bert_text": "Erythema nodosum associated with <e1> all- trans-retinoic acid </e1> (ATRA) for acute promyelocytic leukemia (<e2> APL </e2>) is very rare.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"119": {"data": {"text": "Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.", "entity1": "ATRA", "entity2": "Erythema nodosum", "span1": [59, 63], "span2": [0, 16]}, "bert_text": "Erythema nodosum associated with all- trans-retinoic acid (<e1> ATRA </e1> <e2> Erythema nodosum </e2> associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"120": {"data": {"text": "Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.", "entity1": "ATRA", "entity2": "acute promyelocytic leukemia", "span1": [59, 63], "span2": [69, 97]}, "bert_text": "Erythema nodosum associated with all- trans-retinoic acid (<e1> ATRA </e1>) for <e2> acute promyelocytic leukemia </e2> (APL) is very rare.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"121": {"data": {"text": "Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.", "entity1": "ATRA", "entity2": "APL", "span1": [59, 63], "span2": [99, 102]}, "bert_text": "Erythema nodosum associated with all- trans-retinoic acid (<e1> ATRA </e1>) for acute promyelocytic leukemia (<e2> APL </e2>) is very rare.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"122": {"data": {"text": "Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.", "entity1": "sulphasalazine", "entity2": "inflammatory bowel disease", "span1": [95, 109], "span2": [40, 66]}, "bert_text": "Three infants, born of two mothers with inflammatory bowel disease who received treatment with <e1> sulphasalazine </e1> <e2> inflammatory bowel disease </e2> who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"123": {"data": {"text": "Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.", "entity1": "sulphasalazine", "entity2": "congenital anomalies", "span1": [95, 109], "span2": [157, 177]}, "bert_text": "Three infants, born of two mothers with inflammatory bowel disease who received treatment with <e1> sulphasalazine </e1> throughout pregnancy, were found to have major <e2> congenital anomalies </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"124": {"data": {"text": "This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.", "entity1": "risperidone", "entity2": "hyperprolactinemia", "span1": [32, 43], "span2": [52, 70]}, "bert_text": "This is the first study to link <e1> risperidone </e1>-induced <e2> hyperprolactinemia </e2> and SSRI treatment to lower BMD in children and adolescents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"125": {"data": {"text": "Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.\n", "entity1": "oxygen", "entity2": "hemorrhagic cystitis", "span1": [11, 17], "span2": [78, 98]}, "bert_text": "Hyperbaric <e1> oxygen </e1> therapy for control of intractable cyclophosphamide-induced <e2> hemorrhagic cystitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"126": {"data": {"text": "Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.\n", "entity1": "cyclophosphamide", "entity2": "hemorrhagic cystitis", "span1": [53, 69], "span2": [78, 98]}, "bert_text": "Hyperbaric oxygen therapy for control of intractable <e1> cyclophosphamide </e1>-induced <e2> hemorrhagic cystitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"127": {"data": {"text": "In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.", "entity1": "PDTC", "entity2": "neuronal loss", "span1": [55, 59], "span2": [123, 136]}, "bert_text": "In conclusion, the NF-kappaB inhibitor and antioxidant <e1> PDTC </e1> protected the piriform cortex, whereas it did not affect hilar <e2> neuronal loss </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"128": {"data": {"text": "Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.", "entity1": "Remifentanil", "entity2": "pain", "span1": [0, 12], "span2": [87, 91]}, "bert_text": "<e1> Remifentanil </e1>-related complications were assessed during the remifentanil infusion, and <e2> pain </e2> caused by propofol was evaluated using a four-point scale during the propofol infusion.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"129": {"data": {"text": "Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.", "entity1": "remifentanil", "entity2": "pain", "span1": [60, 72], "span2": [87, 91]}, "bert_text": "Remifentanil-related complications were assessed during the <e1> remifentanil </e1> infusion, and <e2> pain </e2> caused by propofol was evaluated using a four-point scale during the propofol infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"130": {"data": {"text": "Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.", "entity1": "propofol", "entity2": "pain", "span1": [102, 110], "span2": [87, 91]}, "bert_text": "Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by <e1> propofol </e1> <e2> pain </e2> caused by propofol was evaluated using a four-point scale during the propofol infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"131": {"data": {"text": "Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.", "entity1": "propofol", "entity2": "pain", "span1": [161, 169], "span2": [87, 91]}, "bert_text": "Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the <e1> propofol </e1> <e2> pain </e2> caused by propofol was evaluated using a four-point scale during the propofol infusion.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"132": {"data": {"text": "Bile duct hamartoma occurring in association with long-term treatment with danazol.\n", "entity1": "danazol", "entity2": "Bile duct hamartoma", "span1": [75, 82], "span2": [0, 19]}, "bert_text": "Bile duct hamartoma occurring in association with long-term treatment with <e1> danazol </e1> <e2> Bile duct hamartoma </e2> occurring in association with long-term treatment with danazol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"133": {"data": {"text": "These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.", "entity1": "betaxolol", "entity2": "depression", "span1": [27, 36], "span2": [56, 66]}, "bert_text": "These results suggest that <e1> betaxolol </e1> could be less of a <e2> depression </e2>-inducer than timolol in predisposed patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"134": {"data": {"text": "These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.", "entity1": "timolol", "entity2": "depression", "span1": [80, 87], "span2": [56, 66]}, "bert_text": "These results suggest that betaxolol could be less of a depression-inducer than <e1> timolol </e1> <e2> depression </e2>-inducer than timolol in predisposed patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"135": {"data": {"text": "None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.", "entity1": "vitamin D3", "entity2": "milk fever", "span1": [30, 40], "span2": [57, 67]}, "bert_text": "None of the cows treated with <e1> vitamin D3 </e1> showed signs of <e2> milk fever </e2> during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"136": {"data": {"text": "None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.", "entity1": "vitamin D3", "entity2": "milk fever", "span1": [30, 40], "span2": [159, 169]}, "bert_text": "None of the cows treated with <e1> vitamin D3 </e1> showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of <e2> milk fever </e2> during this period.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"137": {"data": {"text": "OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.", "entity1": "isoflurane", "entity2": "cholestatic hepatitis", "span1": [109, 119], "span2": [37, 58]}, "bert_text": "OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic <e1> isoflurane </e1> <e2> cholestatic hepatitis </e2> following exposure to the inhalational anesthetic isoflurane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"138": {"data": {"text": "In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.", "entity1": "isoniazid", "entity2": "bradycardia", "span1": [50, 59], "span2": [63, 74]}, "bert_text": "In the present study, the possible enhancement by <e1> isoniazid </e1> of <e2> bradycardia </e2> induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"139": {"data": {"text": "In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.", "entity1": "chloralose", "entity2": "bradycardia", "span1": [158, 168], "span2": [63, 74]}, "bert_text": "In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with <e1> chloralose </e1> <e2> bradycardia </e2> induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"140": {"data": {"text": "In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.", "entity1": "urethane", "entity2": "bradycardia", "span1": [169, 177], "span2": [63, 74]}, "bert_text": "In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-<e1> urethane </e1> <e2> bradycardia </e2> induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"141": {"data": {"text": "In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [104, 112], "span2": [16, 36]}, "bert_text": "In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of <e1> Warfarin </e1> <e2> artery calcification </e2> could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"142": {"data": {"text": "Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.\n", "entity1": "risperidone", "entity2": "hyperprolactinemia", "span1": [13, 24], "span2": [33, 51]}, "bert_text": "Treatment of <e1> risperidone </e1>-induced <e2> hyperprolactinemia </e2> with a dopamine agonist in children.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"143": {"data": {"text": "Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.\n", "entity1": "dopamine", "entity2": "hyperprolactinemia", "span1": [59, 67], "span2": [33, 51]}, "bert_text": "Treatment of risperidone-induced hyperprolactinemia with a <e1> dopamine </e1> <e2> hyperprolactinemia </e2> with a dopamine agonist in children.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"144": {"data": {"text": "BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.", "entity1": "Risperidone", "entity2": "hyperprolactinemia", "span1": [12, 23], "span2": [123, 141]}, "bert_text": "BACKGROUND: <e1> Risperidone </e1>, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with <e2> hyperprolactinemia </e2> in adults and children.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"145": {"data": {"text": "Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.", "entity1": "diphenylhydantoin", "entity2": "overdose", "span1": [33, 50], "span2": [57, 65]}, "bert_text": "Among the common side effects of <e1> diphenylhydantoin </e1> (DPH) <e2> overdose </e2>, the most frequently encountered neurological signs are those of cerebellar dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"146": {"data": {"text": "Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.", "entity1": "diphenylhydantoin", "entity2": "cerebellar dysfunction", "span1": [33, 50], "span2": [131, 153]}, "bert_text": "Among the common side effects of <e1> diphenylhydantoin </e1> (DPH) overdose, the most frequently encountered neurological signs are those of <e2> cerebellar dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"147": {"data": {"text": "Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.", "entity1": "DPH", "entity2": "overdose", "span1": [52, 55], "span2": [57, 65]}, "bert_text": "Among the common side effects of diphenylhydantoin (<e1> DPH </e1>) <e2> overdose </e2>, the most frequently encountered neurological signs are those of cerebellar dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"148": {"data": {"text": "Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.", "entity1": "DPH", "entity2": "cerebellar dysfunction", "span1": [52, 55], "span2": [131, 153]}, "bert_text": "Among the common side effects of diphenylhydantoin (<e1> DPH </e1>) overdose, the most frequently encountered neurological signs are those of <e2> cerebellar dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"149": {"data": {"text": "Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.", "entity1": "lignocaine", "entity2": "neurotoxicity", "span1": [84, 94], "span2": [53, 66]}, "bert_text": "Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% <e1> lignocaine </e1> <e2> neurotoxicity </e2> of hyperbaric 5% lignocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"150": {"data": {"text": "The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.", "entity1": "dexamethasone", "entity2": "neurological dysfunction", "span1": [127, 140], "span2": [48, 72]}, "bert_text": "The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after <e1> dexamethasone </e1> <e2> neurological dysfunction </e2>, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"151": {"data": {"text": "The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.", "entity1": "desferrioxamine", "entity2": "audiovisual toxicity", "span1": [113, 128], "span2": [23, 43]}, "bert_text": "The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving <e1> desferrioxamine </e1> <e2> audiovisual toxicity </e2> is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"152": {"data": {"text": "Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.", "entity1": "Dothiepin", "entity2": "depressive illness", "span1": [0, 9], "span2": [82, 100]}, "bert_text": "<e1> Dothiepin </e1> and amitriptyline were equally effective in alleviating the symptoms of <e2> depressive illness </e2>, and both were significantly superior to placebo.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"153": {"data": {"text": "Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.", "entity1": "amitriptyline", "entity2": "depressive illness", "span1": [14, 27], "span2": [82, 100]}, "bert_text": "Dothiepin and <e1> amitriptyline </e1> were equally effective in alleviating the symptoms of <e2> depressive illness </e2>, and both were significantly superior to placebo.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"154": {"data": {"text": "Stroke followed cocaine use by inhalation, intranasal, intravenous, and intramuscular routes.", "entity1": "cocaine", "entity2": "Stroke", "span1": [16, 23], "span2": [0, 6]}, "bert_text": "Stroke followed <e1> cocaine </e1> <e2> Stroke </e2> followed cocaine use by inhalation, intranasal, intravenous, and intramuscular routes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"155": {"data": {"text": "To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection, we performed a blinded randomized study in patients undergoing cardiac catheterization.", "entity1": "lidocaine", "entity2": "pain", "span1": [73, 82], "span2": [123, 127]}, "bert_text": "To determine if the addition of a buffering solution to adjust the pH of <e1> lidocaine </e1> into the physiologic range would reduce <e2> pain </e2> during injection, we performed a blinded randomized study in patients undergoing cardiac catheterization.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"156": {"data": {"text": "Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.", "entity1": "corticosterone", "entity2": "neuropathy", "span1": [62, 76], "span2": [116, 126]}, "bert_text": "Although low concentrations (less than or equal to 50 ppm) of <e1> corticosterone </e1> had beneficial effects on TOTP-induced <e2> neuropathy </e2>, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"157": {"data": {"text": "Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.", "entity1": "TOTP", "entity2": "neuropathy", "span1": [103, 107], "span2": [116, 126]}, "bert_text": "Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on <e1> TOTP </e1>-induced <e2> neuropathy </e2>, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"158": {"data": {"text": "Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.", "entity1": "TOTP", "entity2": "neuropathy", "span1": [213, 217], "span2": [116, 126]}, "bert_text": "Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either <e1> TOTP </e1> <e2> neuropathy </e2>, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"159": {"data": {"text": "Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.", "entity1": "DFP", "entity2": "neuropathy", "span1": [221, 224], "span2": [116, 126]}, "bert_text": "Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or <e1> DFP </e1> <e2> neuropathy </e2>, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"160": {"data": {"text": "On the other hand, enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.", "entity1": "enflurane", "entity2": "epileptic", "span1": [19, 28], "span2": [77, 86]}, "bert_text": "On the other hand, <e1> enflurane </e1> may prove to be a safe fast acting activator of <e2> epileptic </e2> foci during corticography or depth electrode intraoperative recordings.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"161": {"data": {"text": "Apomorphine: an underutilized therapy for Parkinson's disease.\n", "entity1": "Apomorphine", "entity2": "Parkinson's disease", "span1": [0, 11], "span2": [42, 61]}, "bert_text": "<e1> Apomorphine </e1>: an underutilized therapy for <e2> Parkinson's disease </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"162": {"data": {"text": "Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.", "entity1": "aspirin", "entity2": "Renal papillary necrosis", "span1": [130, 137], "span2": [0, 24]}, "bert_text": "Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with <e1> aspirin </e1> <e2> Renal papillary necrosis </e2> (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"163": {"data": {"text": "Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.", "entity1": "aspirin", "entity2": "RPN", "span1": [130, 137], "span2": [26, 29]}, "bert_text": "Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with <e1> aspirin </e1> <e2> RPN </e2>) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"164": {"data": {"text": "Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.", "entity1": "paracetamol", "entity2": "Renal papillary necrosis", "span1": [142, 153], "span2": [0, 24]}, "bert_text": "Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and <e1> paracetamol </e1> <e2> Renal papillary necrosis </e2> (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"165": {"data": {"text": "Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.", "entity1": "paracetamol", "entity2": "RPN", "span1": [142, 153], "span2": [26, 29]}, "bert_text": "Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and <e1> paracetamol </e1> <e2> RPN </e2>) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"166": {"data": {"text": "Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.\n", "entity1": "lithium", "entity2": "Ebstein's anomaly", "span1": [9, 16], "span2": [30, 47]}, "bert_text": "Maternal <e1> lithium </e1> and neonatal <e2> Ebstein's anomaly </e2>: evaluation with cross-sectional echocardiography.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"167": {"data": {"text": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "entity1": "amphotericin B", "entity2": "seizures", "span1": [54, 68], "span2": [29, 37]}, "bert_text": "To date, only three cases of seizures associated with <e1> amphotericin B </e1> <e2> seizures </e2> associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"168": {"data": {"text": "The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.", "entity1": "NO", "entity2": "pain", "span1": [35, 37], "span2": [57, 61]}, "bert_text": "The results therefore suggest that <e1> NO </e1> is involved in the <e2> pain </e2> mechanisms of migraine with aura.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"169": {"data": {"text": "The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.", "entity1": "NO", "entity2": "migraine with aura", "span1": [35, 37], "span2": [76, 94]}, "bert_text": "The results therefore suggest that <e1> NO </e1> is involved in the pain mechanisms of <e2> migraine with aura </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"170": {"data": {"text": "Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.\n", "entity1": "argatroban", "entity2": "thrombocytopenia", "span1": [30, 40], "span2": [117, 133]}, "bert_text": "Prolonged elevation of plasma <e1> argatroban </e1> in a cardiac transplant patient with a suspected history of heparin-induced <e2> thrombocytopenia </e2> with thrombosis.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"171": {"data": {"text": "Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.\n", "entity1": "argatroban", "entity2": "thrombosis", "span1": [30, 40], "span2": [139, 149]}, "bert_text": "Prolonged elevation of plasma <e1> argatroban </e1> in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with <e2> thrombosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"172": {"data": {"text": "Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.\n", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [101, 108], "span2": [117, 133]}, "bert_text": "Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> with thrombosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"173": {"data": {"text": "Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.\n", "entity1": "heparin", "entity2": "thrombosis", "span1": [101, 108], "span2": [139, 149]}, "bert_text": "Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of <e1> heparin </e1>-induced thrombocytopenia with <e2> thrombosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"174": {"data": {"text": "Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.", "entity1": "disulfiram", "entity2": "flushing", "span1": [40, 50], "span2": [70, 78]}, "bert_text": "Five hours after exposure, he developed <e1> disulfiram </e1>-like syndrome with <e2> flushing </e2>, tachycardia, and arterial hypotension after consuming three glasses of wine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"175": {"data": {"text": "Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.", "entity1": "disulfiram", "entity2": "tachycardia", "span1": [40, 50], "span2": [80, 91]}, "bert_text": "Five hours after exposure, he developed <e1> disulfiram </e1>-like syndrome with flushing, <e2> tachycardia </e2>, and arterial hypotension after consuming three glasses of wine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"176": {"data": {"text": "Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.", "entity1": "disulfiram", "entity2": "hypotension", "span1": [40, 50], "span2": [106, 117]}, "bert_text": "Five hours after exposure, he developed <e1> disulfiram </e1>-like syndrome with flushing, tachycardia, and arterial <e2> hypotension </e2> after consuming three glasses of wine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"177": {"data": {"text": "Lidocaine reduced the area of punctate-evoked hyperalgesia significantly.", "entity1": "Lidocaine", "entity2": "hyperalgesia", "span1": [0, 9], "span2": [46, 58]}, "bert_text": "<e1> Lidocaine </e1> reduced the area of punctate-evoked <e2> hyperalgesia </e2> significantly.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"178": {"data": {"text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).", "entity1": "etoricoxib", "entity2": "GI", "span1": [118, 128], "span2": [77, 79]}, "bert_text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of <e1> etoricoxib </e1> <e2> GI </e2>) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"179": {"data": {"text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).", "entity1": "etoricoxib", "entity2": "rheumatoid arthritis", "span1": [118, 128], "span2": [161, 181]}, "bert_text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of <e1> etoricoxib </e1> and diclofenac in patients with <e2> rheumatoid arthritis </e2> (RA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"180": {"data": {"text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).", "entity1": "etoricoxib", "entity2": "RA", "span1": [118, 128], "span2": [183, 185]}, "bert_text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of <e1> etoricoxib </e1> and diclofenac in patients with rheumatoid arthritis (<e2> RA </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"181": {"data": {"text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).", "entity1": "diclofenac", "entity2": "GI", "span1": [133, 143], "span2": [77, 79]}, "bert_text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and <e1> diclofenac </e1> <e2> GI </e2>) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"182": {"data": {"text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).", "entity1": "diclofenac", "entity2": "rheumatoid arthritis", "span1": [133, 143], "span2": [161, 181]}, "bert_text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and <e1> diclofenac </e1> in patients with <e2> rheumatoid arthritis </e2> (RA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"183": {"data": {"text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).", "entity1": "diclofenac", "entity2": "RA", "span1": [133, 143], "span2": [183, 185]}, "bert_text": "OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and <e1> diclofenac </e1> in patients with rheumatoid arthritis (<e2> RA </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"184": {"data": {"text": "BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.", "entity1": "sevoflurane", "entity2": "postoperative nausea and vomiting", "span1": [94, 105], "span2": [107, 140]}, "bert_text": "BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with <e1> sevoflurane </e1>, <e2> postoperative nausea and vomiting </e2> occurs frequently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"185": {"data": {"text": "We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.", "entity1": "acetylcholine", "entity2": "muscle atrophy", "span1": [129, 142], "span2": [82, 96]}, "bert_text": "We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in <e1> acetylcholine </e1> <e2> muscle atrophy </e2> and derive less from changes in acetylcholine receptor expression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"186": {"data": {"text": "Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.", "entity1": "Nicotine", "entity2": "hyperactivity", "span1": [0, 8], "span2": [17, 30]}, "bert_text": "<e1> Nicotine </e1>-induced <e2> hyperactivity </e2> was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"187": {"data": {"text": "Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.", "entity1": "SCH 23390", "entity2": "hyperactivity", "span1": [74, 83], "span2": [17, 30]}, "bert_text": "Nicotine-induced hyperactivity was blocked by the selective D1 antagonist <e1> SCH 23390 </e1> <e2> hyperactivity </e2> was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"188": {"data": {"text": "Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.", "entity1": "raclopride", "entity2": "hyperactivity", "span1": [113, 123], "span2": [17, 30]}, "bert_text": "Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist <e1> raclopride </e1> <e2> hyperactivity </e2> was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"189": {"data": {"text": "Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.", "entity1": "fluphenazine", "entity2": "hyperactivity", "span1": [149, 161], "span2": [17, 30]}, "bert_text": "Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist <e1> fluphenazine </e1> <e2> hyperactivity </e2> was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"190": {"data": {"text": "These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.", "entity1": "aminophylline", "entity2": "ventricular arrhythmias", "span1": [181, 194], "span2": [98, 121]}, "bert_text": "These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly <e1> aminophylline </e1> <e2> ventricular arrhythmias </e2> in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"191": {"data": {"text": "These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.", "entity1": "aminophylline", "entity2": "respiratory failure", "span1": [181, 194], "span2": [125, 144]}, "bert_text": "These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly <e1> aminophylline </e1> <e2> respiratory failure </e2>, pharmacologic agents, particularly aminophylline, may play a significant role.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"192": {"data": {"text": "WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.", "entity1": "capecitabine", "entity2": "renal and kidney disease", "span1": [82, 94], "span2": [154, 178]}, "bert_text": "WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of <e1> capecitabine </e1> in special populations such as patients with advanced age, <e2> renal and kidney disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"193": {"data": {"text": "In this study naloxone reversed respiratory paralysis induced by thiopental in rats.", "entity1": "naloxone", "entity2": "respiratory paralysis", "span1": [14, 22], "span2": [32, 53]}, "bert_text": "In this study <e1> naloxone </e1> reversed <e2> respiratory paralysis </e2> induced by thiopental in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"194": {"data": {"text": "In this study naloxone reversed respiratory paralysis induced by thiopental in rats.", "entity1": "thiopental", "entity2": "respiratory paralysis", "span1": [65, 75], "span2": [32, 53]}, "bert_text": "In this study naloxone reversed respiratory paralysis induced by <e1> thiopental </e1> <e2> respiratory paralysis </e2> induced by thiopental in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"195": {"data": {"text": "In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).", "entity1": "acetaminophen", "entity2": "platelet aggregation", "span1": [59, 72], "span2": [21, 41]}, "bert_text": "In contrast, maximal platelet aggregation increased in the <e1> acetaminophen </e1> <e2> platelet aggregation </e2> increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"196": {"data": {"text": "In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).", "entity1": "acetaminophen", "entity2": "platelet aggregation", "span1": [59, 72], "span2": [144, 164]}, "bert_text": "In contrast, maximal platelet aggregation increased in the <e1> acetaminophen </e1> group on the third postoperative day as compared with the pretreatment <e2> platelet aggregation </e2> results (P < .05).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"197": {"data": {"text": "Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.\n", "entity1": "oral contraceptive", "entity2": "Thromboembolic", "span1": [42, 60], "span2": [0, 14]}, "bert_text": "Thromboembolic and other complications of <e1> oral contraceptive </e1> <e2> Thromboembolic </e2> and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"198": {"data": {"text": "Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.\n", "entity1": "oral contraceptive", "entity2": "blood coagulation", "span1": [42, 60], "span2": [111, 128]}, "bert_text": "Thromboembolic and other complications of <e1> oral contraceptive </e1> therapy in relationship to pretreatment levels of <e2> blood coagulation </e2> factors: summary report of a ten-year study.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"199": {"data": {"text": "We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.", "entity1": "simvastatinezetimibe", "entity2": "hepatotoxicity", "span1": [39, 59], "span2": [68, 82]}, "bert_text": "We postulate that the mechanism of the <e1> simvastatinezetimibe </e1>-induced <e2> hepatotoxicity </e2> is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"200": {"data": {"text": "We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.", "entity1": "simvastatin", "entity2": "hepatotoxicity", "span1": [100, 111], "span2": [68, 82]}, "bert_text": "We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased <e1> simvastatin </e1> <e2> hepatotoxicity </e2> is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"201": {"data": {"text": "We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.", "entity1": "ezetimibe", "entity2": "hepatotoxicity", "span1": [124, 133], "span2": [68, 82]}, "bert_text": "We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by <e1> ezetimibe </e1> <e2> hepatotoxicity </e2> is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"202": {"data": {"text": "Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.", "entity1": "Apomorphine", "entity2": "Parkinson's disease", "span1": [0, 11], "span2": [75, 94]}, "bert_text": "<e1> Apomorphine </e1> was the first dopaminergic drug ever used to treat symptoms of <e2> Parkinson's disease </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"203": {"data": {"text": "Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [26, 37], "span2": [55, 73]}, "bert_text": "Similar to rats, systemic <e1> pilocarpine </e1> injection causes <e2> status epilepticus </e2> (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"204": {"data": {"text": "Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.", "entity1": "pilocarpine", "entity2": "SE", "span1": [26, 37], "span2": [75, 77]}, "bert_text": "Similar to rats, systemic <e1> pilocarpine </e1> injection causes status epilepticus (<e2> SE </e2>) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"205": {"data": {"text": "Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [26, 37], "span2": [123, 131]}, "bert_text": "Similar to rats, systemic <e1> pilocarpine </e1> injection causes status epilepticus (SE) and the eventual development of spontaneous <e2> seizures </e2> and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"206": {"data": {"text": "To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.", "entity1": "lamivudine", "entity2": "HIV co-infected", "span1": [71, 81], "span2": [122, 137]}, "bert_text": "To the best of our knowledge, this constitutes the first report of HBV <e1> lamivudine </e1>-resistant strains in therapy-na  ve HBV-<e2> HIV co-infected </e2> patients.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"207": {"data": {"text": "To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.", "entity1": "na", "entity2": "HIV co-infected", "span1": [111, 113], "span2": [122, 137]}, "bert_text": "To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-<e1> na </e1>  ve HBV-<e2> HIV co-infected </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"208": {"data": {"text": "Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.", "entity1": "diclofenac", "entity2": "hepatitis", "span1": [147, 157], "span2": [126, 135]}, "bert_text": "Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by <e1> diclofenac </e1> <e2> hepatitis </e2> induced by diclofenac.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"209": {"data": {"text": "The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.", "entity1": "levobupivacaine", "entity2": "seizures", "span1": [24, 39], "span2": [70, 78]}, "bert_text": "The cumulative doses of <e1> levobupivacaine </e1> and ropivacaine that produced <e2> seizures </e2> were similar and were larger than those of bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"210": {"data": {"text": "The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.", "entity1": "ropivacaine", "entity2": "seizures", "span1": [44, 55], "span2": [70, 78]}, "bert_text": "The cumulative doses of levobupivacaine and <e1> ropivacaine </e1> that produced <e2> seizures </e2> were similar and were larger than those of bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"211": {"data": {"text": "The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.", "entity1": "bupivacaine", "entity2": "seizures", "span1": [122, 133], "span2": [70, 78]}, "bert_text": "The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of <e1> bupivacaine </e1> <e2> seizures </e2> were similar and were larger than those of bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"212": {"data": {"text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [107, 115], "span2": [25, 44]}, "bert_text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without <e1> levodopa </e1> <e2> Parkinson's disease </e2> patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"213": {"data": {"text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [107, 115], "span2": [60, 79]}, "bert_text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without <e1> levodopa </e1> <e2> Parkinson's disease </e2> + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"214": {"data": {"text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [107, 115], "span2": [137, 156]}, "bert_text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without <e1> levodopa </e1>-induced dyskinesias (<e2> Parkinson's disease </e2> - LID, n = 10), and age-matched healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"215": {"data": {"text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.", "entity1": "levodopa", "entity2": "LID", "span1": [107, 115], "span2": [82, 85]}, "bert_text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without <e1> levodopa </e1> <e2> LID </e2>, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"216": {"data": {"text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [107, 115], "span2": [124, 135]}, "bert_text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without <e1> levodopa </e1>-induced <e2> dyskinesias </e2> (Parkinson's disease - LID, n = 10), and age-matched healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"217": {"data": {"text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.", "entity1": "levodopa", "entity2": "LID", "span1": [107, 115], "span2": [159, 162]}, "bert_text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without <e1> levodopa </e1>-induced dyskinesias (Parkinson's disease - <e2> LID </e2>, n = 10), and age-matched healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"218": {"data": {"text": "Potential deleterious effect of furosemide in radiocontrast nephropathy.\n", "entity1": "furosemide", "entity2": "nephropathy", "span1": [32, 42], "span2": [60, 71]}, "bert_text": "Potential deleterious effect of <e1> furosemide </e1> in radiocontrast <e2> nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"219": {"data": {"text": "The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy.", "entity1": "furosemide", "entity2": "nephropathy", "span1": [58, 68], "span2": [138, 149]}, "bert_text": "The purpose of the study was to determine the efficacy of <e1> furosemide </e1> in addition to intravenous fluids in the prevention of radiocontrast <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"220": {"data": {"text": "Acute low back pain during intravenous administration of amiodarone: a report of two cases.\n", "entity1": "amiodarone", "entity2": "low back pain", "span1": [57, 67], "span2": [6, 19]}, "bert_text": "Acute low back pain during intravenous administration of <e1> amiodarone </e1> <e2> low back pain </e2> during intravenous administration of amiodarone: a report of two cases.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"221": {"data": {"text": "Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.", "entity1": "Srl", "entity2": "proteinuria", "span1": [0, 3], "span2": [68, 79]}, "bert_text": "<e1> Srl </e1> should be used with ACEi/ARB therapy and patients monitored for <e2> proteinuria </e2> and increased renal dysfunction.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"222": {"data": {"text": "Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.", "entity1": "Srl", "entity2": "renal dysfunction", "span1": [0, 3], "span2": [94, 111]}, "bert_text": "<e1> Srl </e1> should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased <e2> renal dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"223": {"data": {"text": "Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.", "entity1": "ACEi", "entity2": "proteinuria", "span1": [24, 28], "span2": [68, 79]}, "bert_text": "Srl should be used with <e1> ACEi </e1>/ARB therapy and patients monitored for <e2> proteinuria </e2> and increased renal dysfunction.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"224": {"data": {"text": "Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.", "entity1": "ACEi", "entity2": "renal dysfunction", "span1": [24, 28], "span2": [94, 111]}, "bert_text": "Srl should be used with <e1> ACEi </e1>/ARB therapy and patients monitored for proteinuria and increased <e2> renal dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"225": {"data": {"text": "Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.", "entity1": "ARB", "entity2": "proteinuria", "span1": [29, 32], "span2": [68, 79]}, "bert_text": "Srl should be used with ACEi/<e1> ARB </e1> therapy and patients monitored for <e2> proteinuria </e2> and increased renal dysfunction.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"226": {"data": {"text": "Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.", "entity1": "ARB", "entity2": "renal dysfunction", "span1": [29, 32], "span2": [94, 111]}, "bert_text": "Srl should be used with ACEi/<e1> ARB </e1> therapy and patients monitored for proteinuria and increased <e2> renal dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"227": {"data": {"text": "In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.", "entity1": "lithium", "entity2": "polyuria", "span1": [56, 63], "span2": [72, 80]}, "bert_text": "In contrast, mPGES-1 -/- mice were largely resistant to <e1> lithium </e1>-induced <e2> polyuria </e2> and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"228": {"data": {"text": "In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.", "entity1": "PGE(2", "entity2": "polyuria", "span1": [169, 174], "span2": [72, 80]}, "bert_text": "In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine <e1> PGE(2 </e1> <e2> polyuria </e2> and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"229": {"data": {"text": "This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.", "entity1": "ifosfamide", "entity2": "tumors", "span1": [83, 93], "span2": [126, 132]}, "bert_text": "This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of <e1> ifosfamide </e1> in the treatment of mesenchymal <e2> tumors </e2> in children.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"230": {"data": {"text": "PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).", "entity1": "ethambutol", "entity2": "axonal degeneration", "span1": [77, 87], "span2": [54, 73]}, "bert_text": "PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in <e1> ethambutol </e1> <e2> axonal degeneration </e2> in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"231": {"data": {"text": "PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).", "entity1": "ethambutol", "entity2": "optic neuropathy", "span1": [77, 87], "span2": [96, 112]}, "bert_text": "PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in <e1> ethambutol </e1>-induced <e2> optic neuropathy </e2> using optical coherence tomography (OCT).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"232": {"data": {"text": "Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.", "entity1": "cholesterol", "entity2": "gall stones", "span1": [120, 131], "span2": [21, 32]}, "bert_text": "Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% <e1> cholesterol </e1> <e2> gall stones </e2> retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"233": {"data": {"text": "While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.", "entity1": "lovastatin", "entity2": "myopathy", "span1": [6, 16], "span2": [65, 73]}, "bert_text": "While <e1> lovastatin </e1> and simvastatin have been associated with toxic <e2> myopathy </e2>, pravastatin-associated myopathy could represent a distinct, inflammatory entity.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"234": {"data": {"text": "While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.", "entity1": "lovastatin", "entity2": "myopathy", "span1": [6, 16], "span2": [98, 106]}, "bert_text": "While <e1> lovastatin </e1> and simvastatin have been associated with toxic myopathy, pravastatin-associated <e2> myopathy </e2> could represent a distinct, inflammatory entity.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"235": {"data": {"text": "While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.", "entity1": "simvastatin", "entity2": "myopathy", "span1": [21, 32], "span2": [65, 73]}, "bert_text": "While lovastatin and <e1> simvastatin </e1> have been associated with toxic <e2> myopathy </e2>, pravastatin-associated myopathy could represent a distinct, inflammatory entity.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"236": {"data": {"text": "While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.", "entity1": "simvastatin", "entity2": "myopathy", "span1": [21, 32], "span2": [98, 106]}, "bert_text": "While lovastatin and <e1> simvastatin </e1> have been associated with toxic myopathy, pravastatin-associated <e2> myopathy </e2> could represent a distinct, inflammatory entity.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"237": {"data": {"text": "While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.", "entity1": "pravastatin", "entity2": "myopathy", "span1": [75, 86], "span2": [65, 73]}, "bert_text": "While lovastatin and simvastatin have been associated with toxic myopathy, <e1> pravastatin </e1> <e2> myopathy </e2>, pravastatin-associated myopathy could represent a distinct, inflammatory entity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"238": {"data": {"text": "While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.", "entity1": "pravastatin", "entity2": "myopathy", "span1": [75, 86], "span2": [98, 106]}, "bert_text": "While lovastatin and simvastatin have been associated with toxic myopathy, <e1> pravastatin </e1>-associated <e2> myopathy </e2> could represent a distinct, inflammatory entity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"239": {"data": {"text": "Carmofur-induced organic mental disorders.\n", "entity1": "Carmofur", "entity2": "organic mental disorders", "span1": [0, 8], "span2": [17, 41]}, "bert_text": "<e1> Carmofur </e1>-induced <e2> organic mental disorders </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"240": {"data": {"text": "CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.", "entity1": "carboplatin", "entity2": "glioblastomas", "span1": [62, 73], "span2": [88, 101]}, "bert_text": "CASE: A 58-year-old man received an intracarotid injection of <e1> carboplatin </e1> for recurrent <e2> glioblastomas </e2> in his left temporal lobe.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"241": {"data": {"text": "Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).", "entity1": "Azidothymidine", "entity2": "anemia", "span1": [0, 14], "span2": [29, 35]}, "bert_text": "<e1> Azidothymidine </e1> (AZT)-induced <e2> anemia </e2> in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"242": {"data": {"text": "Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).", "entity1": "AZT)-induced", "entity2": "anemia", "span1": [16, 28], "span2": [29, 35]}, "bert_text": "Azidothymidine (<e1> AZT)-induced </e1> <e2> anemia </e2> in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"243": {"data": {"text": "This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.", "entity1": "desferrioxamine", "entity2": "toxicity", "span1": [65, 80], "span2": [5, 13]}, "bert_text": "This toxicity appeared in patients receiving the higher doses of <e1> desferrioxamine </e1> <e2> toxicity </e2> appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"244": {"data": {"text": "Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.", "entity1": "ribavirin", "entity2": "RIHA", "span1": [43, 52], "span2": [74, 78]}, "bert_text": "Questions remain about the optimal dose of <e1> ribavirin </e1> and the incidence of <e2> RIHA </e2> in a real-world population.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"245": {"data": {"text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "entity1": "Carbamazepine", "entity2": "schizophrenic", "span1": [0, 13], "span2": [94, 107]}, "bert_text": "<e1> Carbamazepine </e1> was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat <e2> schizophrenic </e2> or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"246": {"data": {"text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "entity1": "Carbamazepine", "entity2": "organic psychotic", "span1": [0, 13], "span2": [111, 128]}, "bert_text": "<e1> Carbamazepine </e1> was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or <e2> organic psychotic </e2> patients using concomitantly haloperidol, chlorpromazine or clozapine.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"247": {"data": {"text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "entity1": "oxcarbazepine", "entity2": "schizophrenic", "span1": [51, 64], "span2": [94, 107]}, "bert_text": "Carbamazepine was switched to its 10-keto analogue <e1> oxcarbazepine </e1> among six difficult-to-treat <e2> schizophrenic </e2> or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"248": {"data": {"text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "entity1": "oxcarbazepine", "entity2": "organic psychotic", "span1": [51, 64], "span2": [111, 128]}, "bert_text": "Carbamazepine was switched to its 10-keto analogue <e1> oxcarbazepine </e1> among six difficult-to-treat schizophrenic or <e2> organic psychotic </e2> patients using concomitantly haloperidol, chlorpromazine or clozapine.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"249": {"data": {"text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "entity1": "haloperidol", "entity2": "schizophrenic", "span1": [158, 169], "span2": [94, 107]}, "bert_text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly <e1> haloperidol </e1> <e2> schizophrenic </e2> or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"250": {"data": {"text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "entity1": "haloperidol", "entity2": "organic psychotic", "span1": [158, 169], "span2": [111, 128]}, "bert_text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly <e1> haloperidol </e1> <e2> organic psychotic </e2> patients using concomitantly haloperidol, chlorpromazine or clozapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"251": {"data": {"text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "entity1": "chlorpromazine", "entity2": "schizophrenic", "span1": [171, 185], "span2": [94, 107]}, "bert_text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, <e1> chlorpromazine </e1> <e2> schizophrenic </e2> or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"252": {"data": {"text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "entity1": "chlorpromazine", "entity2": "organic psychotic", "span1": [171, 185], "span2": [111, 128]}, "bert_text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, <e1> chlorpromazine </e1> <e2> organic psychotic </e2> patients using concomitantly haloperidol, chlorpromazine or clozapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"253": {"data": {"text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "entity1": "clozapine", "entity2": "schizophrenic", "span1": [189, 198], "span2": [94, 107]}, "bert_text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or <e1> clozapine </e1> <e2> schizophrenic </e2> or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"254": {"data": {"text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.", "entity1": "clozapine", "entity2": "organic psychotic", "span1": [189, 198], "span2": [111, 128]}, "bert_text": "Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or <e1> clozapine </e1> <e2> organic psychotic </e2> patients using concomitantly haloperidol, chlorpromazine or clozapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"255": {"data": {"text": "BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.", "entity1": "methotrexate", "entity2": "leukoencephalopathy", "span1": [176, 188], "span2": [24, 43]}, "bert_text": "BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal <e1> methotrexate </e1> <e2> leukoencephalopathy </e2> mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"256": {"data": {"text": "BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.", "entity1": "methotrexate", "entity2": "cerebrovascular accident", "span1": [176, 188], "span2": [54, 78]}, "bert_text": "BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal <e1> methotrexate </e1> <e2> cerebrovascular accident </e2> has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"257": {"data": {"text": "BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.", "entity1": "methotrexate", "entity2": "leukaemia", "span1": [176, 188], "span2": [203, 212]}, "bert_text": "BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal <e1> methotrexate </e1> for childhood <e2> leukaemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"258": {"data": {"text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "entity1": "potassium", "entity2": "hypertension", "span1": [167, 176], "span2": [86, 98]}, "bert_text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a <e1> potassium </e1> <e2> hypertension </e2> and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"259": {"data": {"text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "entity1": "potassium", "entity2": "coronary artery disease", "span1": [167, 176], "span2": [109, 132]}, "bert_text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a <e1> potassium </e1> <e2> coronary artery disease </e2> after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"260": {"data": {"text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "entity1": "potassium", "entity2": "hypertension", "span1": [235, 244], "span2": [86, 98]}, "bert_text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a <e1> potassium </e1> <e2> hypertension </e2> and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"261": {"data": {"text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "entity1": "potassium", "entity2": "coronary artery disease", "span1": [235, 244], "span2": [109, 132]}, "bert_text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a <e1> potassium </e1> <e2> coronary artery disease </e2> after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"262": {"data": {"text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "entity1": "amiloride", "entity2": "hypertension", "span1": [198, 207], "span2": [86, 98]}, "bert_text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (<e1> amiloride </e1> <e2> hypertension </e2> and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"263": {"data": {"text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "entity1": "amiloride", "entity2": "coronary artery disease", "span1": [198, 207], "span2": [109, 132]}, "bert_text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (<e1> amiloride </e1> <e2> coronary artery disease </e2> after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"264": {"data": {"text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "entity1": "chlorthalidone", "entity2": "hypertension", "span1": [262, 276], "span2": [86, 98]}, "bert_text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (<e1> chlorthalidone </e1> <e2> hypertension </e2> and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"265": {"data": {"text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "entity1": "chlorthalidone", "entity2": "coronary artery disease", "span1": [262, 276], "span2": [109, 132]}, "bert_text": "Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (<e1> chlorthalidone </e1> <e2> coronary artery disease </e2> after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"266": {"data": {"text": "Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.\n", "entity1": "Testosterone", "entity2": "hypertension", "span1": [0, 12], "span2": [23, 35]}, "bert_text": "<e1> Testosterone </e1>-dependent <e2> hypertension </e2> and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"267": {"data": {"text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.", "entity1": "serotonin", "entity2": "muscle rigidity", "span1": [25, 34], "span2": [117, 132]}, "bert_text": "Excessive stimulation of <e1> serotonin </e1> 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, <e2> muscle rigidity </e2>, salivation, confusion, agitation and hyperthermia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"268": {"data": {"text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.", "entity1": "serotonin", "entity2": "confusion", "span1": [25, 34], "span2": [146, 155]}, "bert_text": "Excessive stimulation of <e1> serotonin </e1> 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, <e2> confusion </e2>, agitation and hyperthermia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"269": {"data": {"text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.", "entity1": "serotonin", "entity2": "agitation", "span1": [25, 34], "span2": [157, 166]}, "bert_text": "Excessive stimulation of <e1> serotonin </e1> 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, <e2> agitation </e2> and hyperthermia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"270": {"data": {"text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.", "entity1": "serotonin", "entity2": "hyperthermia", "span1": [25, 34], "span2": [171, 183]}, "bert_text": "Excessive stimulation of <e1> serotonin </e1> 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and <e2> hyperthermia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"271": {"data": {"text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.", "entity1": "serotonin", "entity2": "muscle rigidity", "span1": [72, 81], "span2": [117, 132]}, "bert_text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of <e1> serotonin </e1> excess that consists of shivering, <e2> muscle rigidity </e2>, salivation, confusion, agitation and hyperthermia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"272": {"data": {"text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.", "entity1": "serotonin", "entity2": "confusion", "span1": [72, 81], "span2": [146, 155]}, "bert_text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of <e1> serotonin </e1> excess that consists of shivering, muscle rigidity, salivation, <e2> confusion </e2>, agitation and hyperthermia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"273": {"data": {"text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.", "entity1": "serotonin", "entity2": "agitation", "span1": [72, 81], "span2": [157, 166]}, "bert_text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of <e1> serotonin </e1> excess that consists of shivering, muscle rigidity, salivation, confusion, <e2> agitation </e2> and hyperthermia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"274": {"data": {"text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.", "entity1": "serotonin", "entity2": "hyperthermia", "span1": [72, 81], "span2": [171, 183]}, "bert_text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of <e1> serotonin </e1> excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and <e2> hyperthermia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"275": {"data": {"text": "CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.", "entity1": "dilevalol", "entity2": "liver injury", "span1": [120, 129], "span2": [216, 228]}, "bert_text": "CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared <e1> dilevalol </e1> antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced <e2> liver injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"276": {"data": {"text": "CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.", "entity1": "dilevalol", "entity2": "liver injury", "span1": [198, 207], "span2": [216, 228]}, "bert_text": "CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in <e1> dilevalol </e1>-induced <e2> liver injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"277": {"data": {"text": "Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.\n", "entity1": "Verapamil", "entity2": "myocardial infarction", "span1": [0, 9], "span2": [44, 65]}, "bert_text": "<e1> Verapamil </e1> withdrawal as a possible cause of <e2> myocardial infarction </e2> in a hypertensive woman with a normal coronary angiogram.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"278": {"data": {"text": "Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.\n", "entity1": "Verapamil", "entity2": "hypertensive", "span1": [0, 9], "span2": [71, 83]}, "bert_text": "<e1> Verapamil </e1> withdrawal as a possible cause of myocardial infarction in a <e2> hypertensive </e2> woman with a normal coronary angiogram.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"279": {"data": {"text": "Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [45, 54], "span2": [133, 145]}, "bert_text": "Our findings, showing no interaction between <e1> capsaicin </e1> treatment and attentional modulation suggest that capsaicin-induced secondary <e2> hyperalgesia </e2> and attention might affect mechanical pain through independent mechanisms.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"280": {"data": {"text": "Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.", "entity1": "capsaicin", "entity2": "pain", "span1": [45, 54], "span2": [184, 188]}, "bert_text": "Our findings, showing no interaction between <e1> capsaicin </e1> treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical <e2> pain </e2> through independent mechanisms.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"281": {"data": {"text": "Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [105, 114], "span2": [133, 145]}, "bert_text": "Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that <e1> capsaicin </e1>-induced secondary <e2> hyperalgesia </e2> and attention might affect mechanical pain through independent mechanisms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"282": {"data": {"text": "Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.", "entity1": "capsaicin", "entity2": "pain", "span1": [105, 114], "span2": [184, 188]}, "bert_text": "Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that <e1> capsaicin </e1>-induced secondary hyperalgesia and attention might affect mechanical <e2> pain </e2> through independent mechanisms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"283": {"data": {"text": "The patient developed RS during dose reduction of risperidone.", "entity1": "risperidone", "entity2": "RS", "span1": [50, 61], "span2": [22, 24]}, "bert_text": "The patient developed RS during dose reduction of <e1> risperidone </e1> <e2> RS </e2> during dose reduction of risperidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"284": {"data": {"text": "Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.\n", "entity1": "valproic acid", "entity2": "Confusion", "span1": [55, 68], "span2": [0, 9]}, "bert_text": "Confusion, a rather serious adverse drug reaction with <e1> valproic acid </e1> <e2> Confusion </e2>, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"285": {"data": {"text": "Pemoline induced acute choreoathetosis: case report and review of the literature.\n", "entity1": "Pemoline", "entity2": "acute choreoathetosis", "span1": [0, 8], "span2": [17, 38]}, "bert_text": "<e1> Pemoline </e1> induced <e2> acute choreoathetosis </e2>: case report and review of the literature.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"286": {"data": {"text": "Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?\n", "entity1": "vitamin C", "entity2": "cardiovascular disease", "span1": [18, 27], "span2": [37, 59]}, "bert_text": "Does supplemental <e1> vitamin C </e1> increase <e2> cardiovascular disease </e2> risk in women with diabetes?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"287": {"data": {"text": "Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?\n", "entity1": "vitamin C", "entity2": "diabetes", "span1": [18, 27], "span2": [79, 87]}, "bert_text": "Does supplemental <e1> vitamin C </e1> increase cardiovascular disease risk in women with <e2> diabetes </e2>?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"288": {"data": {"text": "BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.", "entity1": "iopamidol", "entity2": "chronic kidney disease", "span1": [104, 113], "span2": [332, 354]}, "bert_text": "BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium <e1> iopamidol </e1> with that of the iso-osmolality contrast medium iodixanol in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with <e2> chronic kidney disease </e2> (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"289": {"data": {"text": "BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.", "entity1": "iopamidol", "entity2": "chronic kidney disease", "span1": [291, 300], "span2": [332, 354]}, "bert_text": "BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of <e1> iopamidol </e1> and iodixanol in patients with <e2> chronic kidney disease </e2> (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"290": {"data": {"text": "BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.", "entity1": "iodixanol", "entity2": "chronic kidney disease", "span1": [162, 171], "span2": [332, 354]}, "bert_text": "BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium <e1> iodixanol </e1> in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with <e2> chronic kidney disease </e2> (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"291": {"data": {"text": "BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.", "entity1": "iodixanol", "entity2": "chronic kidney disease", "span1": [305, 314], "span2": [332, 354]}, "bert_text": "BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and <e1> iodixanol </e1> in patients with <e2> chronic kidney disease </e2> (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"292": {"data": {"text": "Screening for stimulant use in adult emergency department seizure patients.\nOBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.", "entity1": "cocaine", "entity2": "seizure", "span1": [185, 192], "span2": [58, 65]}, "bert_text": "Screening for stimulant use in adult emergency department seizure patients.\nOBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for <e1> cocaine </e1> <e2> seizure </e2> patients.\nOBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"293": {"data": {"text": "Screening for stimulant use in adult emergency department seizure patients.\nOBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.", "entity1": "cocaine", "entity2": "seizure", "span1": [185, 192], "span2": [238, 245]}, "bert_text": "Screening for stimulant use in adult emergency department seizure patients.\nOBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for <e1> cocaine </e1> or amphetamine in adult emergency department <e2> seizure </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"294": {"data": {"text": "Screening for stimulant use in adult emergency department seizure patients.\nOBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.", "entity1": "amphetamine", "entity2": "seizure", "span1": [196, 207], "span2": [58, 65]}, "bert_text": "Screening for stimulant use in adult emergency department seizure patients.\nOBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or <e1> amphetamine </e1> <e2> seizure </e2> patients.\nOBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"295": {"data": {"text": "Screening for stimulant use in adult emergency department seizure patients.\nOBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.", "entity1": "amphetamine", "entity2": "seizure", "span1": [196, 207], "span2": [238, 245]}, "bert_text": "Screening for stimulant use in adult emergency department seizure patients.\nOBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or <e1> amphetamine </e1> in adult emergency department <e2> seizure </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"296": {"data": {"text": "INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.", "entity1": "Ethambutol", "entity2": "tuberculosis", "span1": [14, 24], "span2": [53, 65]}, "bert_text": "INTRODUCTION: <e1> Ethambutol </e1> is used in the treatment of <e2> tuberculosis </e2>, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"297": {"data": {"text": "INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.", "entity1": "Ethambutol", "entity2": "visual loss", "span1": [14, 24], "span2": [148, 159]}, "bert_text": "INTRODUCTION: <e1> Ethambutol </e1> is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent <e2> visual loss </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"298": {"data": {"text": "Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.\n", "entity1": "amikacin", "entity2": "nephrotoxicity", "span1": [82, 90], "span2": [24, 38]}, "bert_text": "Factors associated with nephrotoxicity and clinical outcome in patients receiving <e1> amikacin </e1> <e2> nephrotoxicity </e2> and clinical outcome in patients receiving amikacin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"299": {"data": {"text": "Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.", "entity1": "U-II", "entity2": "penile erection", "span1": [53, 57], "span2": [126, 141]}, "bert_text": "Whatever was the dose, the central administration of <e1> U-II </e1> had no effect on body temperature, nociception, apomorphine-induced <e2> penile erection </e2> and climbing behavior, and stress-induced plasma corticosterone level.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"300": {"data": {"text": "Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.", "entity1": "apomorphine", "entity2": "penile erection", "span1": [106, 117], "span2": [126, 141]}, "bert_text": "Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, <e1> apomorphine </e1>-induced <e2> penile erection </e2> and climbing behavior, and stress-induced plasma corticosterone level.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"301": {"data": {"text": "Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.", "entity1": "corticosterone", "entity2": "penile erection", "span1": [191, 205], "span2": [126, 141]}, "bert_text": "Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma <e1> corticosterone </e1> <e2> penile erection </e2> and climbing behavior, and stress-induced plasma corticosterone level.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"302": {"data": {"text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.", "entity1": "cocaine", "entity2": "malignant hypertension", "span1": [159, 166], "span2": [27, 49]}, "bert_text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and <e1> cocaine </e1> <e2> malignant hypertension </e2>, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"303": {"data": {"text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.", "entity1": "cocaine", "entity2": "thrombotic microangiopathy", "span1": [159, 166], "span2": [51, 77]}, "bert_text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and <e1> cocaine </e1> <e2> thrombotic microangiopathy </e2>, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"304": {"data": {"text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.", "entity1": "cocaine", "entity2": "lupus nephritis", "span1": [159, 166], "span2": [79, 94]}, "bert_text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and <e1> cocaine </e1> <e2> lupus nephritis </e2>, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"305": {"data": {"text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.", "entity1": "cocaine", "entity2": "Henoch-Schonlein nephritis", "span1": [159, 166], "span2": [96, 122]}, "bert_text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and <e1> cocaine </e1> <e2> Henoch-Schonlein nephritis </e2>, crescentic glomerulonephritis, and cocaine-related acute renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"306": {"data": {"text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.", "entity1": "cocaine", "entity2": "glomerulonephritis", "span1": [159, 166], "span2": [135, 153]}, "bert_text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and <e1> cocaine </e1> <e2> glomerulonephritis </e2>, and cocaine-related acute renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"307": {"data": {"text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.", "entity1": "cocaine", "entity2": "acute renal failure", "span1": [159, 166], "span2": [175, 194]}, "bert_text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and <e1> cocaine </e1>-related <e2> acute renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"308": {"data": {"text": "The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.\n", "entity1": "Ro4368554", "entity2": "memory deficiency", "span1": [40, 49], "span2": [120, 137]}, "bert_text": "The selective 5-HT6 receptor antagonist <e1> Ro4368554 </e1> restores memory performance in cholinergic and serotonergic models of <e2> memory deficiency </e2> in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"309": {"data": {"text": "The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.", "entity1": "suprofen", "entity2": "nephrotoxic", "span1": [60, 68], "span2": [11, 22]}, "bert_text": "The direct nephrotoxic effects of a single dose of 15 mg of <e1> suprofen </e1> <e2> nephrotoxic </e2> effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"310": {"data": {"text": "The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.", "entity1": "uric acid", "entity2": "nephrotoxic", "span1": [198, 207], "span2": [11, 22]}, "bert_text": "The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of <e1> uric acid </e1> <e2> nephrotoxic </e2> effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"311": {"data": {"text": "In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.", "entity1": "SRL", "entity2": "synergistic nephrotoxic", "span1": [41, 44], "span2": [104, 127]}, "bert_text": "In a number of treatment protocols where <e1> SRL </e1> was combined with a calcineurin inhibitor indications of a <e2> synergistic nephrotoxic </e2> effect were described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"312": {"data": {"text": "The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive cystitis.", "entity1": "p-choloroaniline", "entity2": "cystitis", "span1": [52, 68], "span2": [145, 153]}, "bert_text": "The results have shown that the degradation product <e1> p-choloroaniline </e1> is not a significant factor in chlorhexidine-digluconate associated erosive <e2> cystitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"313": {"data": {"text": "The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive cystitis.", "entity1": "chlorhexidine-digluconate", "entity2": "cystitis", "span1": [100, 125], "span2": [145, 153]}, "bert_text": "The results have shown that the degradation product p-choloroaniline is not a significant factor in <e1> chlorhexidine-digluconate </e1> associated erosive <e2> cystitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"314": {"data": {"text": "Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).", "entity1": "PAC", "entity2": "ovarian cancer", "span1": [97, 100], "span2": [12, 26]}, "bert_text": "Forty-three ovarian cancer patients were available for analysis following six cycles of the same <e1> PAC </e1> <e2> ovarian cancer </e2> patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"315": {"data": {"text": "CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.", "entity1": "penicillins", "entity2": "Hypersensitivity myocarditis", "span1": [94, 105], "span2": [13, 41]}, "bert_text": "CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to <e1> penicillins </e1> <e2> Hypersensitivity myocarditis </e2> is a rare and dangerous manifestation of allergy to penicillins.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"316": {"data": {"text": "CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.", "entity1": "penicillins", "entity2": "allergy", "span1": [94, 105], "span2": [83, 90]}, "bert_text": "CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to <e1> penicillins </e1> <e2> allergy </e2> to penicillins.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"317": {"data": {"text": "CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.", "entity1": "DOX", "entity2": "ischemic injury", "span1": [52, 55], "span2": [30, 45]}, "bert_text": "CONCLUSIONS: Among markers of ischemic injury after <e1> DOX </e1> <e2> ischemic injury </e2> after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"318": {"data": {"text": "CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.", "entity1": "DOX", "entity2": "myocardial damage", "span1": [52, 55], "span2": [108, 125]}, "bert_text": "CONCLUSIONS: Among markers of ischemic injury after <e1> DOX </e1> in rats, cTnT showed the greatest ability to detect <e2> myocardial damage </e2> assessed by echocardiographic detection and histological changes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"319": {"data": {"text": "Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.", "entity1": "puromycin aminonucleoside", "entity2": "nephrosis", "span1": [6, 31], "span2": [32, 41]}, "bert_text": "Using <e1> puromycin aminonucleoside </e1> <e2> nephrosis </e2> (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"320": {"data": {"text": "Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.", "entity1": "cimetidine", "entity2": "hematologic toxicity", "span1": [29, 39], "span2": [165, 185]}, "bert_text": "Treatment with high doses of <e1> cimetidine </e1> (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or <e2> hematologic toxicity </e2> or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"321": {"data": {"text": "Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.", "entity1": "cimetidine", "entity2": "hematologic toxicity", "span1": [337, 347], "span2": [165, 185]}, "bert_text": "Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with <e1> cimetidine </e1> <e2> hematologic toxicity </e2> or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"322": {"data": {"text": "Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.", "entity1": "ranitidine", "entity2": "hematologic toxicity", "span1": [81, 91], "span2": [165, 185]}, "bert_text": "Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or <e1> ranitidine </e1> (two to 31 months; median, 14 months) was not associated with hepatic or <e2> hematologic toxicity </e2> or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"323": {"data": {"text": "Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.", "entity1": "ranitidine", "entity2": "hematologic toxicity", "span1": [238, 248], "span2": [165, 185]}, "bert_text": "Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but <e1> ranitidine </e1> <e2> hematologic toxicity </e2> or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"324": {"data": {"text": "Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.", "entity1": "creatinine", "entity2": "hematologic toxicity", "span1": [305, 315], "span2": [165, 185]}, "bert_text": "Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum <e1> creatinine </e1> <e2> hematologic toxicity </e2> or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"325": {"data": {"text": "Three patients on acetazolamide (15%) developed renal calculi.", "entity1": "acetazolamide", "entity2": "renal calculi", "span1": [18, 31], "span2": [48, 61]}, "bert_text": "Three patients on <e1> acetazolamide </e1> (15%) developed <e2> renal calculi </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"326": {"data": {"text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin. Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.", "entity1": "adriamycin", "entity2": "heart failure", "span1": [123, 133], "span2": [90, 103]}, "bert_text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by <e1> adriamycin </e1> <e2> heart failure </e2> in rats induced by adriamycin. Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"327": {"data": {"text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin. Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.", "entity1": "adriamycin", "entity2": "heart failure", "span1": [123, 133], "span2": [194, 207]}, "bert_text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by <e1> adriamycin </e1>. Mitochondrial injury may be involved in the progression of <e2> heart failure </e2> caused by adriamycin via the autophagy pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"328": {"data": {"text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin. Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.", "entity1": "adriamycin", "entity2": "Mitochondrial injury", "span1": [123, 133], "span2": [135, 155]}, "bert_text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by <e1> adriamycin </e1>. <e2> Mitochondrial injury </e2> may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"329": {"data": {"text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin. Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.", "entity1": "adriamycin", "entity2": "heart failure", "span1": [218, 228], "span2": [90, 103]}, "bert_text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin. Mitochondrial injury may be involved in the progression of heart failure caused by <e1> adriamycin </e1> <e2> heart failure </e2> in rats induced by adriamycin. Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"330": {"data": {"text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin. Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.", "entity1": "adriamycin", "entity2": "heart failure", "span1": [218, 228], "span2": [194, 207]}, "bert_text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin. Mitochondrial injury may be involved in the progression of heart failure caused by <e1> adriamycin </e1> <e2> heart failure </e2> caused by adriamycin via the autophagy pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"331": {"data": {"text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin. Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.", "entity1": "adriamycin", "entity2": "Mitochondrial injury", "span1": [218, 228], "span2": [135, 155]}, "bert_text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin. Mitochondrial injury may be involved in the progression of heart failure caused by <e1> adriamycin </e1> <e2> Mitochondrial injury </e2> may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"332": {"data": {"text": "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.\n", "entity1": "potassium", "entity2": "hypokalaemia", "span1": [8, 17], "span2": [27, 39]}, "bert_text": "Initial <e1> potassium </e1> loss and <e2> hypokalaemia </e2> during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"333": {"data": {"text": "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.\n", "entity1": "potassium", "entity2": "hypertension", "span1": [8, 17], "span2": [104, 116]}, "bert_text": "Initial <e1> potassium </e1> loss and hypokalaemia during chlorthalidone administration in patients with essential <e2> hypertension </e2>: the influence of dietary sodium restriction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"334": {"data": {"text": "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.\n", "entity1": "chlorthalidone", "entity2": "hypokalaemia", "span1": [47, 61], "span2": [27, 39]}, "bert_text": "Initial potassium loss and hypokalaemia during <e1> chlorthalidone </e1> <e2> hypokalaemia </e2> during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"335": {"data": {"text": "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.\n", "entity1": "chlorthalidone", "entity2": "hypertension", "span1": [47, 61], "span2": [104, 116]}, "bert_text": "Initial potassium loss and hypokalaemia during <e1> chlorthalidone </e1> administration in patients with essential <e2> hypertension </e2>: the influence of dietary sodium restriction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"336": {"data": {"text": "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.\n", "entity1": "sodium", "entity2": "hypokalaemia", "span1": [143, 149], "span2": [27, 39]}, "bert_text": "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary <e1> sodium </e1> <e2> hypokalaemia </e2> during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"337": {"data": {"text": "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.\n", "entity1": "sodium", "entity2": "hypertension", "span1": [143, 149], "span2": [104, 116]}, "bert_text": "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary <e1> sodium </e1> <e2> hypertension </e2>: the influence of dietary sodium restriction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"338": {"data": {"text": "However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.", "entity1": "benztropine", "entity2": "tardive dyskinesia", "span1": [9, 20], "span2": [68, 86]}, "bert_text": "However, <e1> benztropine </e1> treated patients had a significant increase in <e2> tardive dyskinesia </e2> compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"339": {"data": {"text": "However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.", "entity1": "benztropine", "entity2": "anxiety", "span1": [9, 20], "span2": [170, 177]}, "bert_text": "However, <e1> benztropine </e1> treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more <e2> anxiety </e2> and depression than ethopropazine treated patients.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"340": {"data": {"text": "However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.", "entity1": "benztropine", "entity2": "depression", "span1": [9, 20], "span2": [182, 192]}, "bert_text": "However, <e1> benztropine </e1> treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and <e2> depression </e2> than ethopropazine treated patients.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"341": {"data": {"text": "However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.", "entity1": "ethopropazine", "entity2": "tardive dyskinesia", "span1": [198, 211], "span2": [68, 86]}, "bert_text": "However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than <e1> ethopropazine </e1> <e2> tardive dyskinesia </e2> compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"342": {"data": {"text": "However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.", "entity1": "ethopropazine", "entity2": "anxiety", "span1": [198, 211], "span2": [170, 177]}, "bert_text": "However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than <e1> ethopropazine </e1> <e2> anxiety </e2> and depression than ethopropazine treated patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"343": {"data": {"text": "However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.", "entity1": "ethopropazine", "entity2": "depression", "span1": [198, 211], "span2": [182, 192]}, "bert_text": "However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than <e1> ethopropazine </e1> <e2> depression </e2> than ethopropazine treated patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"344": {"data": {"text": "These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.", "entity1": "isoproterenol", "entity2": "tachycardia", "span1": [31, 44], "span2": [112, 123]}, "bert_text": "These results show that 15-day <e1> isoproterenol </e1> pretreatment not only abolished but reversed bromocriptine-induced <e2> tachycardia </e2> to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"345": {"data": {"text": "These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.", "entity1": "isoproterenol", "entity2": "bradycardia", "span1": [31, 44], "span2": [127, 138]}, "bert_text": "These results show that 15-day <e1> isoproterenol </e1> pretreatment not only abolished but reversed bromocriptine-induced tachycardia to <e2> bradycardia </e2>, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"346": {"data": {"text": "These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.", "entity1": "bromocriptine", "entity2": "tachycardia", "span1": [90, 103], "span2": [112, 123]}, "bert_text": "These results show that 15-day isoproterenol pretreatment not only abolished but reversed <e1> bromocriptine </e1>-induced <e2> tachycardia </e2> to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"347": {"data": {"text": "These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.", "entity1": "bromocriptine", "entity2": "bradycardia", "span1": [90, 103], "span2": [127, 138]}, "bert_text": "These results show that 15-day isoproterenol pretreatment not only abolished but reversed <e1> bromocriptine </e1>-induced tachycardia to <e2> bradycardia </e2>, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"348": {"data": {"text": "GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.", "entity1": "PAN", "entity2": "nephrosis", "span1": [52, 55], "span2": [56, 65]}, "bert_text": "GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat <e1> PAN </e1> <e2> nephrosis </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"349": {"data": {"text": "Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.\n", "entity1": "ciprofloxacin", "entity2": "thrombocytopenia", "span1": [63, 76], "span2": [7, 23]}, "bert_text": "Severe thrombocytopenia and haemolytic anaemia associated with <e1> ciprofloxacin </e1> <e2> thrombocytopenia </e2> and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"350": {"data": {"text": "Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.\n", "entity1": "ciprofloxacin", "entity2": "haemolytic anaemia", "span1": [63, 76], "span2": [28, 46]}, "bert_text": "Severe thrombocytopenia and haemolytic anaemia associated with <e1> ciprofloxacin </e1> <e2> haemolytic anaemia </e2> associated with ciprofloxacin: a case report with fatal outcome.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"351": {"data": {"text": "In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.", "entity1": "FK506", "entity2": "MAHA", "span1": [51, 56], "span2": [163, 167]}, "bert_text": "In our experience and according to the literature, <e1> FK506 </e1> does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce <e2> MAHA </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"352": {"data": {"text": "In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.", "entity1": "cyclosporin A", "entity2": "MAHA", "span1": [91, 104], "span2": [163, 167]}, "bert_text": "In our experience and according to the literature, FK506 does not seem to cross-react with <e1> cyclosporin A </e1> (CyA), an immuno-suppressive drug already known to induce <e2> MAHA </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"353": {"data": {"text": "In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.", "entity1": "CyA", "entity2": "MAHA", "span1": [106, 109], "span2": [163, 167]}, "bert_text": "In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (<e1> CyA </e1>), an immuno-suppressive drug already known to induce <e2> MAHA </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"354": {"data": {"text": "METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.", "entity1": "propylthiouracil", "entity2": "hyperthyroidism", "span1": [87, 103], "span2": [58, 73]}, "bert_text": "METHODS: We present the first case report of a woman with hyperthyroidism treated with <e1> propylthiouracil </e1> <e2> hyperthyroidism </e2> treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"355": {"data": {"text": "METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.", "entity1": "propylthiouracil", "entity2": "pericarditis", "span1": [87, 103], "span2": [126, 138]}, "bert_text": "METHODS: We present the first case report of a woman with hyperthyroidism treated with <e1> propylthiouracil </e1> in whom a syndrome of <e2> pericarditis </e2>, fever, and glomerulonephritis developed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"356": {"data": {"text": "METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.", "entity1": "propylthiouracil", "entity2": "fever", "span1": [87, 103], "span2": [140, 145]}, "bert_text": "METHODS: We present the first case report of a woman with hyperthyroidism treated with <e1> propylthiouracil </e1> in whom a syndrome of pericarditis, <e2> fever </e2>, and glomerulonephritis developed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"357": {"data": {"text": "METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.", "entity1": "propylthiouracil", "entity2": "glomerulonephritis", "span1": [87, 103], "span2": [151, 169]}, "bert_text": "METHODS: We present the first case report of a woman with hyperthyroidism treated with <e1> propylthiouracil </e1> in whom a syndrome of pericarditis, fever, and <e2> glomerulonephritis </e2> developed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"358": {"data": {"text": "A low yield of tumours at various other sites also arose following paracetamol feeding.", "entity1": "paracetamol", "entity2": "tumours", "span1": [67, 78], "span2": [15, 22]}, "bert_text": "A low yield of tumours at various other sites also arose following <e1> paracetamol </e1> <e2> tumours </e2> at various other sites also arose following paracetamol feeding.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"359": {"data": {"text": "Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.", "entity1": "paramethasone", "entity2": "hypersensitivity", "span1": [31, 44], "span2": [59, 75]}, "bert_text": "Corticosteroids different from <e1> paramethasone </e1> also produced <e2> hypersensitivity </e2> reactions in these patients; however, a few of them were tolerated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"360": {"data": {"text": "Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.", "entity1": "amiodarone", "entity2": "VT", "span1": [104, 114], "span2": [57, 59]}, "bert_text": "Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing <e1> amiodarone </e1> <e2> VT </e2> and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"361": {"data": {"text": "None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.", "entity1": "bupivacaine", "entity2": "paralysis", "span1": [34, 45], "span2": [120, 129]}, "bert_text": "None of the animals that received <e1> bupivacaine </e1>, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb <e2> paralysis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"362": {"data": {"text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "entity1": "oral contraceptives", "entity2": "venous thromboembolism", "span1": [105, 124], "span2": [54, 76]}, "bert_text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer <e1> oral contraceptives </e1> <e2> venous thromboembolism </e2> (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"363": {"data": {"text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "entity1": "oral contraceptives", "entity2": "VTE", "span1": [105, 124], "span2": [78, 81]}, "bert_text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer <e1> oral contraceptives </e1> <e2> VTE </e2>) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"364": {"data": {"text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "entity1": "OC", "entity2": "venous thromboembolism", "span1": [126, 128], "span2": [54, 76]}, "bert_text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (<e1> OC </e1> <e2> venous thromboembolism </e2> (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"365": {"data": {"text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "entity1": "OC", "entity2": "VTE", "span1": [126, 128], "span2": [78, 81]}, "bert_text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (<e1> OC </e1> <e2> VTE </e2>) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"366": {"data": {"text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "entity1": "OC", "entity2": "venous thromboembolism", "span1": [170, 172], "span2": [54, 76]}, "bert_text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of <e1> OC </e1> <e2> venous thromboembolism </e2> (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"367": {"data": {"text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "entity1": "OC", "entity2": "VTE", "span1": [170, 172], "span2": [78, 81]}, "bert_text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of <e1> OC </e1> <e2> VTE </e2>) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"368": {"data": {"text": "Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.", "entity1": "alcohol", "entity2": "pain", "span1": [103, 110], "span2": [120, 124]}, "bert_text": "Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, <e1> alcohol </e1> use, and <e2> pain </e2> during the injection had no effect on the incidence of venous complications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"369": {"data": {"text": "Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.", "entity1": "alcohol", "entity2": "venous complications", "span1": [103, 110], "span2": [180, 200]}, "bert_text": "Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, <e1> alcohol </e1> use, and pain during the injection had no effect on the incidence of <e2> venous complications </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"370": {"data": {"text": "Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.\n", "entity1": "Lamotrigine", "entity2": "myoclonus", "span1": [0, 11], "span2": [52, 61]}, "bert_text": "<e1> Lamotrigine </e1> associated with exacerbation or de novo <e2> myoclonus </e2> in idiopathic generalized epilepsies.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"371": {"data": {"text": "Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.\n", "entity1": "Lamotrigine", "entity2": "idiopathic generalized epilepsies", "span1": [0, 11], "span2": [65, 98]}, "bert_text": "<e1> Lamotrigine </e1> associated with exacerbation or de novo myoclonus in <e2> idiopathic generalized epilepsies </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"372": {"data": {"text": "Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).", "entity1": "dextran", "entity2": "hypertension", "span1": [92, 99], "span2": [146, 158]}, "bert_text": "Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled <e1> dextran </e1> before and during phenylephrine-induced acute <e2> hypertension </e2> in rats treated with vehicle and Hoe-140 (0.1 microM).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"373": {"data": {"text": "Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).", "entity1": "phenylephrine", "entity2": "hypertension", "span1": [118, 131], "span2": [146, 158]}, "bert_text": "Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during <e1> phenylephrine </e1>-induced acute <e2> hypertension </e2> in rats treated with vehicle and Hoe-140 (0.1 microM).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"374": {"data": {"text": "Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).", "entity1": "Hoe-140", "entity2": "hypertension", "span1": [192, 199], "span2": [146, 158]}, "bert_text": "Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and <e1> Hoe-140 </e1> <e2> hypertension </e2> in rats treated with vehicle and Hoe-140 (0.1 microM).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"375": {"data": {"text": "Ten and 5 mg/kg i.v. (+)-cibenzoline suppressed digitalis- and adrenaline-induced arrhythmias, respectively.", "entity1": "-cibenzoline", "entity2": "arrhythmias", "span1": [24, 36], "span2": [82, 93]}, "bert_text": "Ten and 5 mg/kg i.v. (+)<e1> -cibenzoline </e1> suppressed digitalis- and adrenaline-induced <e2> arrhythmias </e2>, respectively.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"376": {"data": {"text": "Ten and 5 mg/kg i.v. (+)-cibenzoline suppressed digitalis- and adrenaline-induced arrhythmias, respectively.", "entity1": "adrenaline", "entity2": "arrhythmias", "span1": [63, 73], "span2": [82, 93]}, "bert_text": "Ten and 5 mg/kg i.v. (+)-cibenzoline suppressed digitalis- and <e1> adrenaline </e1>-induced <e2> arrhythmias </e2>, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"377": {"data": {"text": "Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated.", "entity1": "caffeine", "entity2": "hypertensive", "span1": [40, 48], "span2": [65, 77]}, "bert_text": "Whether the vasoconstrictive actions of <e1> caffeine </e1> are enhanced in <e2> hypertensive </e2> persons has not been demonstrated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"378": {"data": {"text": "The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.", "entity1": "dexamethasone", "entity2": "renal injury", "span1": [62, 75], "span2": [132, 144]}, "bert_text": "The purpose of the present study was to determine if prenatal <e1> dexamethasone </e1> programmed a progressive increase in blood pressure and <e2> renal injury </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"379": {"data": {"text": "Myasthenia gravis presenting as weakness after magnesium administration.\n", "entity1": "magnesium", "entity2": "Myasthenia gravis", "span1": [47, 56], "span2": [0, 17]}, "bert_text": "Myasthenia gravis presenting as weakness after <e1> magnesium </e1> <e2> Myasthenia gravis </e2> presenting as weakness after magnesium administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"380": {"data": {"text": "Myasthenia gravis presenting as weakness after magnesium administration.\n", "entity1": "magnesium", "entity2": "weakness", "span1": [47, 56], "span2": [32, 40]}, "bert_text": "Myasthenia gravis presenting as weakness after <e1> magnesium </e1> <e2> weakness </e2> after magnesium administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"381": {"data": {"text": "The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.", "entity1": "zidovudine", "entity2": "HIV", "span1": [86, 96], "span2": [43, 46]}, "bert_text": "The number of patients with suppression of HIV p24 antigenemia in the combination and <e1> zidovudine </e1> <e2> HIV </e2> p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"382": {"data": {"text": "We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.", "entity1": "paclitaxel", "entity2": "toxicity", "span1": [54, 64], "span2": [33, 41]}, "bert_text": "We investigated the efficacy and toxicity of a 3-hour <e1> paclitaxel </e1> <e2> toxicity </e2> of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"383": {"data": {"text": "We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.", "entity1": "paclitaxel", "entity2": "NSCLC", "span1": [54, 64], "span2": [139, 144]}, "bert_text": "We investigated the efficacy and toxicity of a 3-hour <e1> paclitaxel </e1> infusion in a phase II trial in patients with inoperable stage IIIB or IV <e2> NSCLC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"384": {"data": {"text": "Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.", "entity1": "Ca", "entity2": "Adrenaline arrhythmia", "span1": [46, 48], "span2": [0, 21]}, "bert_text": "Adrenaline arrhythmia, which is suppressed by <e1> Ca </e1> <e2> Adrenaline arrhythmia </e2>, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"385": {"data": {"text": "Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.", "entity1": "adrenaline", "entity2": "Adrenaline arrhythmia", "span1": [82, 92], "span2": [0, 21]}, "bert_text": "Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by <e1> adrenaline </e1> <e2> Adrenaline arrhythmia </e2>, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"386": {"data": {"text": "Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.", "entity1": "halothane", "entity2": "Adrenaline arrhythmia", "span1": [105, 114], "span2": [0, 21]}, "bert_text": "Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in <e1> halothane </e1> <e2> Adrenaline arrhythmia </e2>, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"387": {"data": {"text": "These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy.", "entity1": "DOX", "entity2": "cardiomyopathy", "span1": [114, 117], "span2": [118, 132]}, "bert_text": "These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human <e1> DOX </e1> <e2> cardiomyopathy </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"388": {"data": {"text": "PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.", "entity1": "methylprednisolone", "entity2": "cataract", "span1": [98, 116], "span2": [191, 199]}, "bert_text": "PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of <e1> methylprednisolone </e1> and gentamicin into the posterior sub-Tenon's space at the end of routine <e2> cataract </e2> surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"389": {"data": {"text": "PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.", "entity1": "gentamicin", "entity2": "cataract", "span1": [121, 131], "span2": [191, 199]}, "bert_text": "PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and <e1> gentamicin </e1> into the posterior sub-Tenon's space at the end of routine <e2> cataract </e2> surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"390": {"data": {"text": "Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.", "entity1": "oestrogen", "entity2": "venous thrombo-embolism", "span1": [10, 19], "span2": [64, 87]}, "bert_text": "Long-term <e1> oestrogen </e1>-only HT significantly increased the risk of <e2> venous thrombo-embolism </e2>, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"391": {"data": {"text": "Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.", "entity1": "oestrogen", "entity2": "stroke", "span1": [10, 19], "span2": [89, 95]}, "bert_text": "Long-term <e1> oestrogen </e1>-only HT significantly increased the risk of venous thrombo-embolism, <e2> stroke </e2> and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"392": {"data": {"text": "Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.", "entity1": "oestrogen", "entity2": "gallbladder disease", "span1": [10, 19], "span2": [100, 119]}, "bert_text": "Long-term <e1> oestrogen </e1>-only HT significantly increased the risk of venous thrombo-embolism, stroke and <e2> gallbladder disease </e2> (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"393": {"data": {"text": "Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.", "entity1": "oestrogen", "entity2": "breast cancer", "span1": [10, 19], "span2": [240, 253]}, "bert_text": "Long-term <e1> oestrogen </e1>-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of <e2> breast cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"394": {"data": {"text": "Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.\n", "entity1": "estradiol", "entity2": "Hypothalamic", "span1": [182, 191], "span2": [0, 12]}, "bert_text": "Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on <e1> estradiol </e1> <e2> Hypothalamic </e2> prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"395": {"data": {"text": "Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.\n", "entity1": "estradiol", "entity2": "hyperprolactinemic inhibition", "span1": [182, 191], "span2": [92, 121]}, "bert_text": "Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on <e1> estradiol </e1> <e2> hyperprolactinemic inhibition </e2> of pulsatile luteinizing hormone secretion are dependent on estradiol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"396": {"data": {"text": "The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.", "entity1": "epinephrine", "entity2": "myocardial ischemia", "span1": [12, 23], "span2": [37, 56]}, "bert_text": "The role of <e1> epinephrine </e1> in eliciting <e2> myocardial ischemia </e2> was examined in patients with coronary artery disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"397": {"data": {"text": "The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.", "entity1": "epinephrine", "entity2": "coronary artery disease", "span1": [12, 23], "span2": [87, 110]}, "bert_text": "The role of <e1> epinephrine </e1> in eliciting myocardial ischemia was examined in patients with <e2> coronary artery disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"398": {"data": {"text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.", "entity1": "AVP", "entity2": "dehydration", "span1": [131, 134], "span2": [27, 38]}, "bert_text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma <e1> AVP </e1> <e2> dehydration </e2> and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"399": {"data": {"text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.", "entity1": "AVP", "entity2": "diabetes insipidus", "span1": [131, 134], "span2": [220, 238]}, "bert_text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma <e1> AVP </e1> and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced <e2> diabetes insipidus </e2> rat.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"400": {"data": {"text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.", "entity1": "AVP", "entity2": "dehydration", "span1": [159, 162], "span2": [27, 38]}, "bert_text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of <e1> AVP </e1> <e2> dehydration </e2> and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"401": {"data": {"text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.", "entity1": "AVP", "entity2": "diabetes insipidus", "span1": [159, 162], "span2": [220, 238]}, "bert_text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of <e1> AVP </e1> gene expression in the PVN and the SON of the Li-induced <e2> diabetes insipidus </e2> rat.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"402": {"data": {"text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.", "entity1": "Li", "entity2": "dehydration", "span1": [209, 211], "span2": [27, 38]}, "bert_text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the <e1> Li </e1> <e2> dehydration </e2> and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"403": {"data": {"text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.", "entity1": "Li", "entity2": "diabetes insipidus", "span1": [209, 211], "span2": [220, 238]}, "bert_text": "These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the <e1> Li </e1>-induced <e2> diabetes insipidus </e2> rat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"404": {"data": {"text": "This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.", "entity1": "argatroban", "entity2": "coagulopathy", "span1": [43, 53], "span2": [103, 115]}, "bert_text": "This is the first report to measure plasma <e1> argatroban </e1> concentration in the context of CPB and extended <e2> coagulopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"405": {"data": {"text": "CONCLUSIONS: Paracetamol-induced acute liver failure did not affect long-term mortality.", "entity1": "Paracetamol", "entity2": "acute liver failure", "span1": [13, 24], "span2": [33, 52]}, "bert_text": "CONCLUSIONS: <e1> Paracetamol </e1>-induced <e2> acute liver failure </e2> did not affect long-term mortality.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"406": {"data": {"text": "Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.\n", "entity1": "estrogen", "entity2": "hypotension", "span1": [27, 35], "span2": [94, 105]}, "bert_text": "Differential modulation by <e1> estrogen </e1> of alpha2-adrenergic and I1-imidazoline receptor-mediated <e2> hypotension </e2> in female rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"407": {"data": {"text": "Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.\n", "entity1": "I1-imidazoline", "entity2": "hypotension", "span1": [61, 75], "span2": [94, 105]}, "bert_text": "Differential modulation by estrogen of alpha2-adrenergic and <e1> I1-imidazoline </e1> receptor-mediated <e2> hypotension </e2> in female rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"408": {"data": {"text": "Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.\n", "entity1": "tetrandrine", "entity2": "thrombosis", "span1": [11, 22], "span2": [57, 67]}, "bert_text": "Effects of <e1> tetrandrine </e1> and fangchinoline on experimental <e2> thrombosis </e2> in mice and human platelet aggregation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"409": {"data": {"text": "Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.\n", "entity1": "tetrandrine", "entity2": "platelet aggregation", "span1": [11, 22], "span2": [86, 106]}, "bert_text": "Effects of <e1> tetrandrine </e1> and fangchinoline on experimental thrombosis in mice and human <e2> platelet aggregation </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"410": {"data": {"text": "Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.\n", "entity1": "fangchinoline", "entity2": "thrombosis", "span1": [27, 40], "span2": [57, 67]}, "bert_text": "Effects of tetrandrine and <e1> fangchinoline </e1> on experimental <e2> thrombosis </e2> in mice and human platelet aggregation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"411": {"data": {"text": "Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.\n", "entity1": "fangchinoline", "entity2": "platelet aggregation", "span1": [27, 40], "span2": [86, 106]}, "bert_text": "Effects of tetrandrine and <e1> fangchinoline </e1> on experimental thrombosis in mice and human <e2> platelet aggregation </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"412": {"data": {"text": "CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.", "entity1": "ribavirin", "entity2": "adenovirus disease", "span1": [87, 96], "span2": [43, 61]}, "bert_text": "CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous <e1> ribavirin </e1> <e2> adenovirus disease </e2> treated with intravenous ribavirin recovered.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"413": {"data": {"text": "There are no previous reports of clonidine-associated cardiac arrest in a child undergoing induction of anesthesia.", "entity1": "clonidine", "entity2": "cardiac arrest", "span1": [33, 42], "span2": [54, 68]}, "bert_text": "There are no previous reports of <e1> clonidine </e1>-associated <e2> cardiac arrest </e2> in a child undergoing induction of anesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"414": {"data": {"text": "The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.\n", "entity1": "acetylcholine", "entity2": "seizure", "span1": [37, 50], "span2": [112, 119]}, "bert_text": "The relationship between hippocampal <e1> acetylcholine </e1> release and cholinergic convulsant sensitivity in withdrawal <e2> seizure </e2>-prone and withdrawal seizure-resistant selected mouse lines.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"415": {"data": {"text": "The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.\n", "entity1": "acetylcholine", "entity2": "seizure", "span1": [37, 50], "span2": [141, 148]}, "bert_text": "The relationship between hippocampal <e1> acetylcholine </e1> release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal <e2> seizure </e2>-resistant selected mouse lines.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"416": {"data": {"text": "METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.", "entity1": "spironolactone", "entity2": "heart failure", "span1": [82, 96], "span2": [46, 59]}, "bert_text": "METHODS: We performed a case control study of heart failure patients treated with <e1> spironolactone </e1> <e2> heart failure </e2> patients treated with spironolactone in our clinical practice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"417": {"data": {"text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "entity1": "Isoniazid", "entity2": "bradycardia", "span1": [0, 9], "span2": [34, 45]}, "bert_text": "<e1> Isoniazid </e1> significantly increased <e2> bradycardia </e2> after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"418": {"data": {"text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "entity1": "propranolol", "entity2": "bradycardia", "span1": [52, 63], "span2": [34, 45]}, "bert_text": "Isoniazid significantly increased bradycardia after <e1> propranolol </e1> <e2> bradycardia </e2> after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"419": {"data": {"text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "entity1": "pindolol", "entity2": "bradycardia", "span1": [65, 73], "span2": [34, 45]}, "bert_text": "Isoniazid significantly increased bradycardia after propranolol, <e1> pindolol </e1> <e2> bradycardia </e2> after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"420": {"data": {"text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "entity1": "labetalol", "entity2": "bradycardia", "span1": [75, 84], "span2": [34, 45]}, "bert_text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, <e1> labetalol </e1> <e2> bradycardia </e2> after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"421": {"data": {"text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "entity1": "atenolol", "entity2": "bradycardia", "span1": [89, 97], "span2": [34, 45]}, "bert_text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and <e1> atenolol </e1> <e2> bradycardia </e2> after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"422": {"data": {"text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "entity1": "clonidine", "entity2": "bradycardia", "span1": [116, 125], "span2": [34, 45]}, "bert_text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after <e1> clonidine </e1> <e2> bradycardia </e2> after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"423": {"data": {"text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "entity1": "hexamethonium", "entity2": "bradycardia", "span1": [141, 154], "span2": [34, 45]}, "bert_text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after <e1> hexamethonium </e1> <e2> bradycardia </e2> after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"424": {"data": {"text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "entity1": "carbachol", "entity2": "bradycardia", "span1": [158, 167], "span2": [34, 45]}, "bert_text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or <e1> carbachol </e1> <e2> bradycardia </e2> after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"425": {"data": {"text": "Flurbiprofen in the treatment of juvenile rheumatoid arthritis.\n", "entity1": "Flurbiprofen", "entity2": "juvenile rheumatoid arthritis", "span1": [0, 12], "span2": [33, 62]}, "bert_text": "<e1> Flurbiprofen </e1> in the treatment of <e2> juvenile rheumatoid arthritis </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"426": {"data": {"text": "Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.\n", "entity1": "Clarithromycin", "entity2": "visual hallucinations", "span1": [0, 14], "span2": [26, 47]}, "bert_text": "<e1> Clarithromycin </e1>-associated <e2> visual hallucinations </e2> in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"427": {"data": {"text": "Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.\n", "entity1": "Clarithromycin", "entity2": "chronic renal failure", "span1": [0, 14], "span2": [66, 87]}, "bert_text": "<e1> Clarithromycin </e1>-associated visual hallucinations in a patient with <e2> chronic renal failure </e2> on continuous ambulatory peritoneal dialysis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"428": {"data": {"text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "entity1": "amiloride", "entity2": "polydipsia", "span1": [27, 36], "span2": [95, 105]}, "bert_text": "It is concluded that acute <e1> amiloride </e1> administration to lithium-treated patients suffering from <e2> polydipsia </e2> and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"429": {"data": {"text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "entity1": "amiloride", "entity2": "polyuria", "span1": [27, 36], "span2": [110, 118]}, "bert_text": "It is concluded that acute <e1> amiloride </e1> administration to lithium-treated patients suffering from polydipsia and <e2> polyuria </e2> might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"430": {"data": {"text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "entity1": "amiloride", "entity2": "polydipsia", "span1": [162, 171], "span2": [95, 105]}, "bert_text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged <e1> amiloride </e1> <e2> polydipsia </e2> and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"431": {"data": {"text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "entity1": "amiloride", "entity2": "polyuria", "span1": [162, 171], "span2": [110, 118]}, "bert_text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged <e1> amiloride </e1> <e2> polyuria </e2> might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"432": {"data": {"text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "entity1": "lithium", "entity2": "polydipsia", "span1": [55, 62], "span2": [95, 105]}, "bert_text": "It is concluded that acute amiloride administration to <e1> lithium </e1>-treated patients suffering from <e2> polydipsia </e2> and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"433": {"data": {"text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "entity1": "lithium", "entity2": "polyuria", "span1": [55, 62], "span2": [110, 118]}, "bert_text": "It is concluded that acute amiloride administration to <e1> lithium </e1>-treated patients suffering from polydipsia and <e2> polyuria </e2> might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"434": {"data": {"text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "entity1": "lithium", "entity2": "polydipsia", "span1": [213, 220], "span2": [95, 105]}, "bert_text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated <e1> lithium </e1> <e2> polydipsia </e2> and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0, -1, -1], "label": 0},
+	"435": {"data": {"text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "entity1": "lithium", "entity2": "polyuria", "span1": [213, 220], "span2": [110, 118]}, "bert_text": "It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated <e1> lithium </e1> <e2> polyuria </e2> might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, 0, -1, -1], "label": 0},
+	"436": {"data": {"text": "Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.", "entity1": "ifosfamide", "entity2": "toxicity", "span1": [77, 87], "span2": [7, 15]}, "bert_text": "Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of <e1> ifosfamide </e1> <e2> toxicity </e2> was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"437": {"data": {"text": "Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.", "entity1": "ifosfamide", "entity2": "tumor", "span1": [77, 87], "span2": [170, 175]}, "bert_text": "Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of <e1> ifosfamide </e1>, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic <e2> tumor </e2> involvement.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"438": {"data": {"text": "This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.", "entity1": "benztropine", "entity2": "parkinsonian symptoms", "span1": [19, 30], "span2": [113, 134]}, "bert_text": "This suggests that <e1> benztropine </e1> is not the anticholinergic drug of choice in the treatment of neuroleptic-induced <e2> parkinsonian symptoms </e2>, because of its more toxic central and peripheral atropinic effect.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"439": {"data": {"text": "The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.", "entity1": "flumazenil", "entity2": "nausea", "span1": [64, 74], "span2": [37, 43]}, "bert_text": "The most common adverse effects were nausea and vomiting in the <e1> flumazenil </e1> <e2> nausea </e2> and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"440": {"data": {"text": "The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.", "entity1": "flumazenil", "entity2": "nausea", "span1": [64, 74], "span2": [85, 91]}, "bert_text": "The most common adverse effects were nausea and vomiting in the <e1> flumazenil </e1> group and <e2> nausea </e2> and injection-site pain in the placebo group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"441": {"data": {"text": "The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.", "entity1": "flumazenil", "entity2": "vomiting", "span1": [64, 74], "span2": [48, 56]}, "bert_text": "The most common adverse effects were nausea and vomiting in the <e1> flumazenil </e1> <e2> vomiting </e2> in the flumazenil group and nausea and injection-site pain in the placebo group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"442": {"data": {"text": "The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.", "entity1": "flumazenil", "entity2": "pain", "span1": [64, 74], "span2": [111, 115]}, "bert_text": "The most common adverse effects were nausea and vomiting in the <e1> flumazenil </e1> group and nausea and injection-site <e2> pain </e2> in the placebo group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"443": {"data": {"text": "The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.", "entity1": "ifosfamide", "entity2": "asterixis", "span1": [22, 32], "span2": [70, 79]}, "bert_text": "The administration of <e1> ifosfamide </e1> was discontinued and within 12 h the <e2> asterixis </e2> resolved completely.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"444": {"data": {"text": "Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.", "entity1": "clozapine", "entity2": "psychosis", "span1": [17, 26], "span2": [79, 88]}, "bert_text": "Considering that <e1> clozapine </e1> remains the gold standard in treatment of resistant <e2> psychosis </e2>, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"445": {"data": {"text": "In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.", "entity1": "haloperidol", "entity2": "Alzheimer's disease", "span1": [81, 92], "span2": [205, 224]}, "bert_text": "In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), <e1> haloperidol </e1>, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with <e2> Alzheimer's disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"446": {"data": {"text": "In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.", "entity1": "haloperidol", "entity2": "Alzheimer's disease", "span1": [126, 137], "span2": [205, 224]}, "bert_text": "In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and <e1> haloperidol </e1>, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with <e2> Alzheimer's disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"447": {"data": {"text": "In a further series of experiments, haloperidol (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference.", "entity1": "haloperidol", "entity2": "rigidity", "span1": [36, 47], "span2": [176, 184]}, "bert_text": "In a further series of experiments, <e1> haloperidol </e1> (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the <e2> rigidity </e2> without any dopaminergic interference.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"448": {"data": {"text": "The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.", "entity1": "PDTC", "entity2": "status epilepticus", "span1": [14, 18], "span2": [22, 40]}, "bert_text": "The effect of <e1> PDTC </e1> on <e2> status epilepticus </e2>-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"449": {"data": {"text": "The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [139, 150], "span2": [22, 40]}, "bert_text": "The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated <e1> pilocarpine </e1> <e2> status epilepticus </e2>-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"450": {"data": {"text": "A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.", "entity1": "androgen", "entity2": "obstructive sleep apnea", "span1": [19, 27], "span2": [49, 72]}, "bert_text": "A rechallenge with <e1> androgen </e1> produced symptoms of <e2> obstructive sleep apnea </e2> that abated upon withdrawal of the hormone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"451": {"data": {"text": "Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.", "entity1": "ticlopidine", "entity2": "aplastic anemia", "span1": [14, 25], "span2": [34, 49]}, "bert_text": "Treatment for <e1> ticlopidine </e1>-induced <e2> aplastic anemia </e2> with colony-stimulating factors seemed to have little effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"452": {"data": {"text": "Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).", "entity1": "diazepam", "entity2": "Pain", "span1": [73, 81], "span2": [0, 4]}, "bert_text": "Pain at the injection site occurred in 35% (22 of 62) of patients in the <e1> diazepam </e1> <e2> Pain </e2> at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"453": {"data": {"text": "Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).", "entity1": "midazolam", "entity2": "Pain", "span1": [131, 140], "span2": [0, 4]}, "bert_text": "Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the <e1> midazolam </e1> <e2> Pain </e2> at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"454": {"data": {"text": "GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.\n", "entity1": "GABA", "entity2": "respiratory paralysis", "span1": [0, 4], "span2": [49, 70]}, "bert_text": "<e1> GABA </e1> involvement in naloxone induced reversal of <e2> respiratory paralysis </e2> produced by thiopental.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"455": {"data": {"text": "GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.\n", "entity1": "naloxone", "entity2": "respiratory paralysis", "span1": [20, 28], "span2": [49, 70]}, "bert_text": "GABA involvement in <e1> naloxone </e1> induced reversal of <e2> respiratory paralysis </e2> produced by thiopental.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"456": {"data": {"text": "GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.\n", "entity1": "thiopental", "entity2": "respiratory paralysis", "span1": [83, 93], "span2": [49, 70]}, "bert_text": "GABA involvement in naloxone induced reversal of respiratory paralysis produced by <e1> thiopental </e1> <e2> respiratory paralysis </e2> produced by thiopental.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"457": {"data": {"text": "It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.", "entity1": "coenzyme Q10", "entity2": "nephrotoxicity", "span1": [22, 34], "span2": [112, 126]}, "bert_text": "It was concluded that <e1> coenzyme Q10 </e1> represents a potential therapeutic option to protect against acute cisplatin <e2> nephrotoxicity </e2> commonly encountered in clinical practice.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"458": {"data": {"text": "It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [102, 111], "span2": [112, 126]}, "bert_text": "It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute <e1> cisplatin </e1> <e2> nephrotoxicity </e2> commonly encountered in clinical practice.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"459": {"data": {"text": "Complete heart block following a single dose of trazodone.\n", "entity1": "trazodone", "entity2": "heart block", "span1": [48, 57], "span2": [9, 20]}, "bert_text": "Complete heart block following a single dose of <e1> trazodone </e1> <e2> heart block </e2> following a single dose of trazodone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"460": {"data": {"text": "In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).", "entity1": "MPTP", "entity2": "LIDs", "span1": [36, 40], "span2": [179, 183]}, "bert_text": "In contrast, monkeys with long-term <e1> MPTP </e1> exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing <e2> LIDs </e2> (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"461": {"data": {"text": "In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).", "entity1": "MPTP", "entity2": "dyskinesia", "span1": [36, 40], "span2": [191, 201]}, "bert_text": "In contrast, monkeys with long-term <e1> MPTP </e1> exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., <e2> dyskinesia </e2> developed no sooner than 146 days of chronic levodopa administration).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"462": {"data": {"text": "In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).", "entity1": "levodopa", "entity2": "LIDs", "span1": [128, 136], "span2": [179, 183]}, "bert_text": "In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of <e1> levodopa </e1> therapy were more resistant to developing <e2> LIDs </e2> (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"463": {"data": {"text": "In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [128, 136], "span2": [191, 201]}, "bert_text": "In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of <e1> levodopa </e1> therapy were more resistant to developing LIDs (e.g., <e2> dyskinesia </e2> developed no sooner than 146 days of chronic levodopa administration).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"464": {"data": {"text": "In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).", "entity1": "levodopa", "entity2": "LIDs", "span1": [247, 255], "span2": [179, 183]}, "bert_text": "In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic <e1> levodopa </e1> <e2> LIDs </e2> (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"465": {"data": {"text": "In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [247, 255], "span2": [191, 201]}, "bert_text": "In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic <e1> levodopa </e1> <e2> dyskinesia </e2> developed no sooner than 146 days of chronic levodopa administration).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"466": {"data": {"text": "Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.", "entity1": "macrolides", "entity2": "hiccups", "span1": [213, 223], "span2": [275, 282]}, "bert_text": "Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other <e1> macrolides </e1> and the absence of any alternative explanation for <e2> hiccups </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"467": {"data": {"text": "Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [124, 133], "span2": [84, 96]}, "bert_text": "Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of <e1> capsaicin </e1> <e2> hyperalgesia </e2> is very similar to that of capsaicin-untreated, control condition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"468": {"data": {"text": "We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.", "entity1": "ranitidine", "entity2": "interstitial nephritis", "span1": [20, 30], "span2": [45, 67]}, "bert_text": "We report a case of <e1> ranitidine </e1>-induced acute <e2> interstitial nephritis </e2> in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"469": {"data": {"text": "Acute vocal fold palsy after acute disulfiram intoxication.\n", "entity1": "disulfiram", "entity2": "palsy", "span1": [35, 45], "span2": [17, 22]}, "bert_text": "Acute vocal fold palsy after acute <e1> disulfiram </e1> <e2> palsy </e2> after acute disulfiram intoxication.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"470": {"data": {"text": "Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.", "entity1": "alanine", "entity2": "renal toxicity", "span1": [38, 45], "span2": [10, 24]}, "bert_text": "Potential renal toxicity and elevated <e1> alanine </e1> <e2> renal toxicity </e2> and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"471": {"data": {"text": "In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.", "entity1": "ifosfamide", "entity2": "asterixis", "span1": [71, 81], "span2": [42, 51]}, "bert_text": "In the patient described, the presence of asterixis during infusion of <e1> ifosfamide </e1> <e2> asterixis </e2> during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"472": {"data": {"text": "In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.", "entity1": "ifosfamide", "entity2": "myoclonus", "span1": [71, 81], "span2": [225, 234]}, "bert_text": "In the patient described, the presence of asterixis during infusion of <e1> ifosfamide </e1>, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative <e2> myoclonus </e2> is associated with the use of IFX.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"473": {"data": {"text": "In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.", "entity1": "IFX", "entity2": "asterixis", "span1": [265, 268], "span2": [42, 51]}, "bert_text": "In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of <e1> IFX </e1> <e2> asterixis </e2> during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"474": {"data": {"text": "In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.", "entity1": "IFX", "entity2": "myoclonus", "span1": [265, 268], "span2": [225, 234]}, "bert_text": "In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of <e1> IFX </e1> <e2> myoclonus </e2> is associated with the use of IFX.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"475": {"data": {"text": "The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.", "entity1": "heparin", "entity2": "thromboembolism", "span1": [67, 74], "span2": [27, 42]}, "bert_text": "The common factor relating thromboembolism and thrombocytopenia is <e1> heparin </e1> <e2> thromboembolism </e2> and thrombocytopenia is heparin-induced platelet aggregation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"476": {"data": {"text": "The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [67, 74], "span2": [47, 63]}, "bert_text": "The common factor relating thromboembolism and thrombocytopenia is <e1> heparin </e1> <e2> thrombocytopenia </e2> is heparin-induced platelet aggregation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"477": {"data": {"text": "The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.", "entity1": "heparin", "entity2": "platelet aggregation", "span1": [67, 74], "span2": [83, 103]}, "bert_text": "The common factor relating thromboembolism and thrombocytopenia is <e1> heparin </e1>-induced <e2> platelet aggregation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"478": {"data": {"text": "This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.", "entity1": "cisapride", "entity2": "torsade de pointes", "span1": [52, 61], "span2": [28, 46]}, "bert_text": "This patient also developed torsade de pointes when <e1> cisapride </e1> <e2> torsade de pointes </e2> when cisapride and erythromycin were given simultaneously.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"479": {"data": {"text": "This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.", "entity1": "erythromycin", "entity2": "torsade de pointes", "span1": [66, 78], "span2": [28, 46]}, "bert_text": "This patient also developed torsade de pointes when cisapride and <e1> erythromycin </e1> <e2> torsade de pointes </e2> when cisapride and erythromycin were given simultaneously.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"480": {"data": {"text": "Using linear regression we found that no correlation exists between seizure duration, elevation of phenytoin serum levels and cerebellar volume.", "entity1": "phenytoin", "entity2": "seizure", "span1": [99, 108], "span2": [68, 75]}, "bert_text": "Using linear regression we found that no correlation exists between seizure duration, elevation of <e1> phenytoin </e1> <e2> seizure </e2> duration, elevation of phenytoin serum levels and cerebellar volume.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"481": {"data": {"text": "Haloperidol enhanced the rigidity in the A group.", "entity1": "Haloperidol", "entity2": "rigidity", "span1": [0, 11], "span2": [25, 33]}, "bert_text": "<e1> Haloperidol </e1> enhanced the <e2> rigidity </e2> in the A group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"482": {"data": {"text": "In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.", "entity1": "appetite suppressants", "entity2": "primary pulmonary hypertension", "span1": [97, 118], "span2": [31, 61]}, "bert_text": "In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken <e1> appetite suppressants </e1> <e2> primary pulmonary hypertension </e2> was uncertain, 5 of them had taken appetite suppressants.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"483": {"data": {"text": "Fentanyl is a commonly used supplement that may contribute to this, although it may also improve analgesia.", "entity1": "Fentanyl", "entity2": "analgesia", "span1": [0, 8], "span2": [97, 106]}, "bert_text": "<e1> Fentanyl </e1> is a commonly used supplement that may contribute to this, although it may also improve <e2> analgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"484": {"data": {"text": "Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.", "entity1": "MPTP", "entity2": "parkinsonism", "span1": [46, 50], "span2": [59, 71]}, "bert_text": "Using macaque monkeys with different types of <e1> MPTP </e1>-induced <e2> parkinsonism </e2>, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"485": {"data": {"text": "Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.", "entity1": "MPTP", "entity2": "LIDs", "span1": [46, 50], "span2": [255, 259]}, "bert_text": "Using macaque monkeys with different types of <e1> MPTP </e1>-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of <e2> LIDs </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"486": {"data": {"text": "Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.", "entity1": "levodopa", "entity2": "parkinsonism", "span1": [200, 208], "span2": [59, 71]}, "bert_text": "Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of <e1> levodopa </e1> <e2> parkinsonism </e2>, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"487": {"data": {"text": "Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.", "entity1": "levodopa", "entity2": "LIDs", "span1": [200, 208], "span2": [255, 259]}, "bert_text": "Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of <e1> levodopa </e1> therapy may be involved in the development of <e2> LIDs </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"488": {"data": {"text": "Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.", "entity1": "Amiodarone", "entity2": "atrial fibrillation", "span1": [0, 10], "span2": [89, 108]}, "bert_text": "<e1> Amiodarone </e1> represents an effective antiarrhythmic drug for cardioversion of recent-onset <e2> atrial fibrillation </e2> (AF) and maintenance of sinus rhythm.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"489": {"data": {"text": "Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.", "entity1": "Amiodarone", "entity2": "AF", "span1": [0, 10], "span2": [110, 112]}, "bert_text": "<e1> Amiodarone </e1> represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (<e2> AF </e2>) and maintenance of sinus rhythm.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"490": {"data": {"text": "Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.\n", "entity1": "ecstasy", "entity2": "Learning and memory deficits", "span1": [32, 39], "span2": [0, 28]}, "bert_text": "Learning and memory deficits in <e1> ecstasy </e1> <e2> Learning and memory deficits </e2> in ecstasy users and their neural correlates during a face-learning task.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"491": {"data": {"text": "Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.", "entity1": "Gemcitabine", "entity2": "nonsmall cell lung carcinoma", "span1": [0, 11], "span2": [32, 60]}, "bert_text": "<e1> Gemcitabine </e1> plus vinorelbine in <e2> nonsmall cell lung carcinoma </e2> patients age 70 years or older or patients who cannot receive cisplatin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"492": {"data": {"text": "Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.", "entity1": "vinorelbine", "entity2": "nonsmall cell lung carcinoma", "span1": [17, 28], "span2": [32, 60]}, "bert_text": "Gemcitabine plus <e1> vinorelbine </e1> in <e2> nonsmall cell lung carcinoma </e2> patients age 70 years or older or patients who cannot receive cisplatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"493": {"data": {"text": "Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.", "entity1": "cisplatin", "entity2": "nonsmall cell lung carcinoma", "span1": [123, 132], "span2": [32, 60]}, "bert_text": "Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive <e1> cisplatin </e1> <e2> nonsmall cell lung carcinoma </e2> patients age 70 years or older or patients who cannot receive cisplatin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"494": {"data": {"text": "CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.", "entity1": "CC", "entity2": "myocardial infarction", "span1": [98, 100], "span2": [105, 126]}, "bert_text": "CONCLUSION: This appears to be the first reported case documenting a possible association between <e1> CC </e1> and <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"495": {"data": {"text": "Chorea associated with oral contraception.\n", "entity1": "oral contraception", "entity2": "Chorea", "span1": [23, 41], "span2": [0, 6]}, "bert_text": "Chorea associated with <e1> oral contraception </e1> <e2> Chorea </e2> associated with oral contraception.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"496": {"data": {"text": "A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.", "entity1": "paracetamol", "entity2": "metabolic acidosis", "span1": [80, 91], "span2": [10, 28]}, "bert_text": "A case of metabolic acidosis, acute renal failure and hepatic failure following <e1> paracetamol </e1> <e2> metabolic acidosis </e2>, acute renal failure and hepatic failure following paracetamol ingestion is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"497": {"data": {"text": "A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.", "entity1": "paracetamol", "entity2": "acute renal failure", "span1": [80, 91], "span2": [30, 49]}, "bert_text": "A case of metabolic acidosis, acute renal failure and hepatic failure following <e1> paracetamol </e1> <e2> acute renal failure </e2> and hepatic failure following paracetamol ingestion is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"498": {"data": {"text": "A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.", "entity1": "paracetamol", "entity2": "hepatic failure", "span1": [80, 91], "span2": [54, 69]}, "bert_text": "A case of metabolic acidosis, acute renal failure and hepatic failure following <e1> paracetamol </e1> <e2> hepatic failure </e2> following paracetamol ingestion is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"499": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "prostaglandins", "entity2": "seizure", "span1": [35, 49], "span2": [59, 66]}, "bert_text": "To investigate the relationship of <e1> prostaglandins </e1> (PGs) to <e2> seizure </e2> induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"500": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "prostaglandins", "entity2": "convulsions", "span1": [35, 49], "span2": [125, 136]}, "bert_text": "To investigate the relationship of <e1> prostaglandins </e1> (PGs) to seizure induction, the effects of six PG synthetase inhibitors on <e2> convulsions </e2> induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"501": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "PGs", "entity2": "seizure", "span1": [51, 54], "span2": [59, 66]}, "bert_text": "To investigate the relationship of prostaglandins (<e1> PGs </e1>) to <e2> seizure </e2> induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"502": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "PGs", "entity2": "convulsions", "span1": [51, 54], "span2": [125, 136]}, "bert_text": "To investigate the relationship of prostaglandins (<e1> PGs </e1>) to seizure induction, the effects of six PG synthetase inhibitors on <e2> convulsions </e2> induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"503": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "flurothyl", "entity2": "seizure", "span1": [148, 157], "span2": [59, 66]}, "bert_text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by <e1> flurothyl </e1> <e2> seizure </e2> induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"504": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "flurothyl", "entity2": "convulsions", "span1": [148, 157], "span2": [125, 136]}, "bert_text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by <e1> flurothyl </e1> <e2> convulsions </e2> induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"505": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "picrotoxin", "entity2": "seizure", "span1": [159, 169], "span2": [59, 66]}, "bert_text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, <e1> picrotoxin </e1> <e2> seizure </e2> induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"506": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "picrotoxin", "entity2": "convulsions", "span1": [159, 169], "span2": [125, 136]}, "bert_text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, <e1> picrotoxin </e1> <e2> convulsions </e2> induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"507": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "pentetrazol", "entity2": "seizure", "span1": [171, 182], "span2": [59, 66]}, "bert_text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, <e1> pentetrazol </e1> <e2> seizure </e2> induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"508": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "pentetrazol", "entity2": "convulsions", "span1": [171, 182], "span2": [125, 136]}, "bert_text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, <e1> pentetrazol </e1> <e2> convulsions </e2> induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"509": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "PTZ", "entity2": "seizure", "span1": [184, 187], "span2": [59, 66]}, "bert_text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (<e1> PTZ </e1> <e2> seizure </e2> induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"510": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "PTZ", "entity2": "convulsions", "span1": [184, 187], "span2": [125, 136]}, "bert_text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (<e1> PTZ </e1> <e2> convulsions </e2> induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"511": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "bicuculline", "entity2": "seizure", "span1": [206, 217], "span2": [59, 66]}, "bert_text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or <e1> bicuculline </e1> <e2> seizure </e2> induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"512": {"data": {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity1": "bicuculline", "entity2": "convulsions", "span1": [206, 217], "span2": [125, 136]}, "bert_text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or <e1> bicuculline </e1> <e2> convulsions </e2> induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"513": {"data": {"text": "Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.", "entity1": "Rizatriptan", "entity2": "migraine", "span1": [0, 11], "span2": [135, 143]}, "bert_text": "<e1> Rizatriptan </e1> is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of <e2> migraine </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"514": {"data": {"text": "Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.", "entity1": "5-HT(1B/1D", "entity2": "migraine", "span1": [27, 37], "span2": [135, 143]}, "bert_text": "Rizatriptan is a selective <e1> 5-HT(1B/1D </e1>) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of <e2> migraine </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"515": {"data": {"text": "One patient died, having presented in hepatic failure, and another, who had been taking methyldopa for 7 years, showed slower clinical and biochemical resolution over a period of several months.", "entity1": "methyldopa", "entity2": "hepatic failure", "span1": [88, 98], "span2": [38, 53]}, "bert_text": "One patient died, having presented in hepatic failure, and another, who had been taking <e1> methyldopa </e1> <e2> hepatic failure </e2>, and another, who had been taking methyldopa for 7 years, showed slower clinical and biochemical resolution over a period of several months.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"516": {"data": {"text": "Thrombosis might be a rare but hazardous complication of CC.", "entity1": "CC", "entity2": "Thrombosis", "span1": [57, 59], "span2": [0, 10]}, "bert_text": "Thrombosis might be a rare but hazardous complication of <e1> CC </e1> <e2> Thrombosis </e2> might be a rare but hazardous complication of CC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"517": {"data": {"text": "Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia", "entity1": "troleandomycin", "entity2": "Jaundice", "span1": [42, 56], "span2": [0, 8]}, "bert_text": "Jaundice occurred after administration of <e1> troleandomycin </e1> <e2> Jaundice </e2> occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"518": {"data": {"text": "Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.", "entity1": "mycophenolate mofetil", "entity2": "nephrotoxicity", "span1": [49, 70], "span2": [106, 120]}, "bert_text": "Two recently available immunosuppressive agents, <e1> mycophenolate mofetil </e1> and sirolimus (rapamycin), have no <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"519": {"data": {"text": "Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.", "entity1": "rapamycin", "entity2": "nephrotoxicity", "span1": [86, 95], "span2": [106, 120]}, "bert_text": "Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (<e1> rapamycin </e1>), have no <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"520": {"data": {"text": "Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.", "entity1": "sirolimus", "entity2": "nephrotoxicity", "span1": [75, 84], "span2": [106, 120]}, "bert_text": "Two recently available immunosuppressive agents, mycophenolate mofetil and <e1> sirolimus </e1> (rapamycin), have no <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"521": {"data": {"text": "These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "entity1": "carteolol", "entity2": "catalepsy", "span1": [36, 45], "span2": [75, 84]}, "bert_text": "These results strongly suggest that <e1> carteolol </e1> improves haloperidol-induced <e2> catalepsy </e2> via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"522": {"data": {"text": "These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "entity1": "carteolol", "entity2": "akathisia", "span1": [36, 45], "span2": [185, 194]}, "bert_text": "These results strongly suggest that <e1> carteolol </e1> improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of <e2> akathisia </e2> without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"523": {"data": {"text": "These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [55, 66], "span2": [75, 84]}, "bert_text": "These results strongly suggest that carteolol improves <e1> haloperidol </e1>-induced <e2> catalepsy </e2> via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"524": {"data": {"text": "These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "entity1": "haloperidol", "entity2": "akathisia", "span1": [55, 66], "span2": [185, 194]}, "bert_text": "These results strongly suggest that carteolol improves <e1> haloperidol </e1>-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of <e2> akathisia </e2> without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"525": {"data": {"text": "These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "entity1": "dopamine", "entity2": "catalepsy", "span1": [281, 289], "span2": [75, 84]}, "bert_text": "These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic <e1> dopamine </e1> <e2> catalepsy </e2> via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"526": {"data": {"text": "These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "entity1": "dopamine", "entity2": "akathisia", "span1": [281, 289], "span2": [185, 194]}, "bert_text": "These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic <e1> dopamine </e1> <e2> akathisia </e2> without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"527": {"data": {"text": "Three patients developed chorea while receiving oral contraceptives.", "entity1": "oral contraceptives", "entity2": "chorea", "span1": [48, 67], "span2": [25, 31]}, "bert_text": "Three patients developed chorea while receiving <e1> oral contraceptives </e1> <e2> chorea </e2> while receiving oral contraceptives.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"528": {"data": {"text": "If agitation becomes marked, high-potency neuroleptics (i.e., haloperidol) may be effective.", "entity1": "haloperidol", "entity2": "agitation", "span1": [62, 73], "span2": [3, 12]}, "bert_text": "If agitation becomes marked, high-potency neuroleptics (i.e., <e1> haloperidol </e1> <e2> agitation </e2> becomes marked, high-potency neuroleptics (i.e., haloperidol) may be effective.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"529": {"data": {"text": "50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.", "entity1": "thiopental", "entity2": "respiratory arrest", "span1": [15, 25], "span2": [35, 53]}, "bert_text": "50 mg/kg, i.v. <e1> thiopental </e1> produced <e2> respiratory arrest </e2> with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"530": {"data": {"text": "50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.", "entity1": "GABA", "entity2": "respiratory arrest", "span1": [79, 83], "span2": [35, 53]}, "bert_text": "50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in <e1> GABA </e1> <e2> respiratory arrest </e2> with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"531": {"data": {"text": "50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.", "entity1": "amino acids", "entity2": "respiratory arrest", "span1": [170, 181], "span2": [35, 53]}, "bert_text": "50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the <e1> amino acids </e1> <e2> respiratory arrest </e2> with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"532": {"data": {"text": "Since the cranial condition precluded use of more usual methods, lidocaine was given intra-arterially, with careful cardiovascular monitoring, to counteract the vasospasm.", "entity1": "lidocaine", "entity2": "vasospasm", "span1": [65, 74], "span2": [161, 170]}, "bert_text": "Since the cranial condition precluded use of more usual methods, <e1> lidocaine </e1> was given intra-arterially, with careful cardiovascular monitoring, to counteract the <e2> vasospasm </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"533": {"data": {"text": "The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)", "entity1": "D-MED", "entity2": "akinetic", "span1": [14, 19], "span2": [42, 50]}, "bert_text": "The high-dose <e1> D-MED </e1> animals were flaccid, <e2> akinetic </e2>, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"534": {"data": {"text": "The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)", "entity1": "D-MED", "entity2": "startle", "span1": [14, 19], "span2": [65, 72]}, "bert_text": "The high-dose <e1> D-MED </e1> animals were flaccid, akinetic, and lacked a <e2> startle </e2> response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"535": {"data": {"text": "Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.", "entity1": "dopamine", "entity2": "Neuroleptic malignant syndrome", "span1": [60, 68], "span2": [0, 30]}, "bert_text": "Neuroleptic malignant syndrome is thought to be a result of <e1> dopamine </e1> <e2> Neuroleptic malignant syndrome </e2> is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"536": {"data": {"text": "Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.", "entity1": "sulfasalazine", "entity2": "pleural effusions", "span1": [179, 192], "span2": [23, 40]}, "bert_text": "Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term <e1> sulfasalazine </e1> <e2> pleural effusions </e2>, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"537": {"data": {"text": "Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.", "entity1": "sulfasalazine", "entity2": "ulcerative colitis", "span1": [179, 192], "span2": [213, 231]}, "bert_text": "Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term <e1> sulfasalazine </e1> therapy for chronic <e2> ulcerative colitis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"538": {"data": {"text": "Renal failure was associated with weight loss in the furosemide-treated group.", "entity1": "furosemide", "entity2": "Renal failure", "span1": [53, 63], "span2": [0, 13]}, "bert_text": "Renal failure was associated with weight loss in the <e1> furosemide </e1> <e2> Renal failure </e2> was associated with weight loss in the furosemide-treated group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"539": {"data": {"text": "Renal failure was associated with weight loss in the furosemide-treated group.", "entity1": "furosemide", "entity2": "weight loss", "span1": [53, 63], "span2": [34, 45]}, "bert_text": "Renal failure was associated with weight loss in the <e1> furosemide </e1> <e2> weight loss </e2> in the furosemide-treated group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"540": {"data": {"text": "Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.", "entity1": "deferoxamine", "entity2": "auditory abnormality", "span1": [53, 65], "span2": [230, 250]}, "bert_text": "Since 18 of the 22 patients were initially receiving <e1> deferoxamine </e1> doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of <e2> auditory abnormality </e2>, and with the exception of two cases no further toxicity was demonstrated.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"541": {"data": {"text": "Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.", "entity1": "deferoxamine", "entity2": "toxicity", "span1": [53, 65], "span2": [299, 307]}, "bert_text": "Since 18 of the 22 patients were initially receiving <e1> deferoxamine </e1> doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further <e2> toxicity </e2> was demonstrated.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"542": {"data": {"text": "Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.\n", "entity1": "benzodiazepines", "entity2": "myoclonic jerks", "span1": [20, 35], "span2": [72, 87]}, "bert_text": "Serotonergic drugs, <e1> benzodiazepines </e1> and baclofen block muscimol-induced <e2> myoclonic jerks </e2> in a strain of mice.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"543": {"data": {"text": "Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.\n", "entity1": "baclofen", "entity2": "myoclonic jerks", "span1": [40, 48], "span2": [72, 87]}, "bert_text": "Serotonergic drugs, benzodiazepines and <e1> baclofen </e1> block muscimol-induced <e2> myoclonic jerks </e2> in a strain of mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"544": {"data": {"text": "Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.\n", "entity1": "muscimol", "entity2": "myoclonic jerks", "span1": [55, 63], "span2": [72, 87]}, "bert_text": "Serotonergic drugs, benzodiazepines and baclofen block <e1> muscimol </e1>-induced <e2> myoclonic jerks </e2> in a strain of mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"545": {"data": {"text": "BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.", "entity1": "Pemoline", "entity2": "attention deficit disorder", "span1": [12, 20], "span2": [128, 154]}, "bert_text": "BACKGROUND: <e1> Pemoline </e1> is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of <e2> attention deficit disorder </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"546": {"data": {"text": "BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.", "entity1": "oxazolidine", "entity2": "attention deficit disorder", "span1": [27, 38], "span2": [128, 154]}, "bert_text": "BACKGROUND: Pemoline is an <e1> oxazolidine </e1> derivative that is structurally different from amphetamines and used in the treatment of <e2> attention deficit disorder </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"547": {"data": {"text": "BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.", "entity1": "amphetamines", "entity2": "attention deficit disorder", "span1": [86, 98], "span2": [128, 154]}, "bert_text": "BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from <e1> amphetamines </e1> and used in the treatment of <e2> attention deficit disorder </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"548": {"data": {"text": "Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.", "entity1": "D-penicillamine", "entity2": "rheumatoid arthritis", "span1": [110, 125], "span2": [19, 39]}, "bert_text": "Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with <e1> D-penicillamine </e1> <e2> rheumatoid arthritis </e2> developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"549": {"data": {"text": "Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.", "entity1": "D-penicillamine", "entity2": "proteinuria", "span1": [110, 125], "span2": [56, 67]}, "bert_text": "Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with <e1> D-penicillamine </e1> <e2> proteinuria </e2> after five to 12 months of treatment with D-penicillamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"550": {"data": {"text": "Long-term prognosis for transplant-free survivors of paracetamol-induced acute liver failure.\n", "entity1": "paracetamol", "entity2": "acute liver failure", "span1": [53, 64], "span2": [73, 92]}, "bert_text": "Long-term prognosis for transplant-free survivors of <e1> paracetamol </e1>-induced <e2> acute liver failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"551": {"data": {"text": "Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol. 6.", "entity1": "ATP", "entity2": "diabetic", "span1": [130, 133], "span2": [94, 102]}, "bert_text": "Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, <e1> ATP </e1> <e2> diabetic </e2> rats to nerve stimulation, ATP, and bethanechol. 6.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"552": {"data": {"text": "Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol. 6.", "entity1": "bethanechol", "entity2": "diabetic", "span1": [139, 150], "span2": [94, 102]}, "bert_text": "Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and <e1> bethanechol </e1> <e2> diabetic </e2> rats to nerve stimulation, ATP, and bethanechol. 6.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"553": {"data": {"text": "Furosemide may be deleterious in the prevention of radiocontrast nephropathy.", "entity1": "Furosemide", "entity2": "nephropathy", "span1": [0, 10], "span2": [65, 76]}, "bert_text": "<e1> Furosemide </e1> may be deleterious in the prevention of radiocontrast <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"554": {"data": {"text": "Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.\n", "entity1": "steroids", "entity2": "seizures", "span1": [12, 20], "span2": [81, 89]}, "bert_text": "Neuroactive <e1> steroids </e1> protect against pilocarpine- and kainic acid-induced limbic <e2> seizures </e2> and status epilepticus in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"555": {"data": {"text": "Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.\n", "entity1": "steroids", "entity2": "status epilepticus", "span1": [12, 20], "span2": [94, 112]}, "bert_text": "Neuroactive <e1> steroids </e1> protect against pilocarpine- and kainic acid-induced limbic seizures and <e2> status epilepticus </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"556": {"data": {"text": "Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.\n", "entity1": "pilocarpine-", "entity2": "seizures", "span1": [37, 49], "span2": [81, 89]}, "bert_text": "Neuroactive steroids protect against <e1> pilocarpine- </e1> and kainic acid-induced limbic <e2> seizures </e2> and status epilepticus in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"557": {"data": {"text": "Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.\n", "entity1": "pilocarpine-", "entity2": "status epilepticus", "span1": [37, 49], "span2": [94, 112]}, "bert_text": "Neuroactive steroids protect against <e1> pilocarpine- </e1> and kainic acid-induced limbic seizures and <e2> status epilepticus </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"558": {"data": {"text": "Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.\n", "entity1": "kainic acid", "entity2": "seizures", "span1": [54, 65], "span2": [81, 89]}, "bert_text": "Neuroactive steroids protect against pilocarpine- and <e1> kainic acid </e1>-induced limbic <e2> seizures </e2> and status epilepticus in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"559": {"data": {"text": "Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.\n", "entity1": "kainic acid", "entity2": "status epilepticus", "span1": [54, 65], "span2": [94, 112]}, "bert_text": "Neuroactive steroids protect against pilocarpine- and <e1> kainic acid </e1>-induced limbic seizures and <e2> status epilepticus </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"560": {"data": {"text": "We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.", "entity1": "magnesium", "entity2": "neuromuscular disease", "span1": [119, 128], "span2": [46, 67]}, "bert_text": "We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral <e1> magnesium </e1> <e2> neuromuscular disease </e2> who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"561": {"data": {"text": "We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.", "entity1": "magnesium", "entity2": "preeclampsia", "span1": [119, 128], "span2": [148, 160]}, "bert_text": "We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral <e1> magnesium </e1> administration for <e2> preeclampsia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"562": {"data": {"text": "Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.", "entity1": "phosphate", "entity2": "toxicity", "span1": [286, 295], "span2": [146, 154]}, "bert_text": "Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low <e1> phosphate </e1> <e2> toxicity </e2> resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"563": {"data": {"text": "Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.", "entity1": "phosphate", "entity2": "Fanconi's syndrome", "span1": [286, 295], "span2": [168, 186]}, "bert_text": "Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low <e1> phosphate </e1> <e2> Fanconi's syndrome </e2> (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"564": {"data": {"text": "We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.", "entity1": "cyclophosphamide", "entity2": "hemorrhagic cystitis", "span1": [60, 76], "span2": [32, 52]}, "bert_text": "We report a case of intractable hemorrhagic cystitis due to <e1> cyclophosphamide </e1> <e2> hemorrhagic cystitis </e2> due to cyclophosphamide therapy for Wegener's granulomatosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"565": {"data": {"text": "We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.", "entity1": "cyclophosphamide", "entity2": "Wegener's granulomatosis", "span1": [60, 76], "span2": [89, 113]}, "bert_text": "We report a case of intractable hemorrhagic cystitis due to <e1> cyclophosphamide </e1> therapy for <e2> Wegener's granulomatosis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"566": {"data": {"text": "Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.", "entity1": "dexamethasone", "entity2": "glomerular number", "span1": [31, 44], "span2": [96, 113]}, "bert_text": "Offspring of rats administered <e1> dexamethasone </e1> on days 15 and 16 gestation had a 20% reduction in <e2> glomerular number </e2> compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"567": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "acetaminophen", "entity2": "necrotic", "span1": [86, 99], "span2": [58, 66]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during <e1> acetaminophen </e1> <e2> necrotic </e2> cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"568": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "acetaminophen", "entity2": "nephrotoxicity", "span1": [86, 99], "span2": [108, 122]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during <e1> acetaminophen </e1>-induced <e2> nephrotoxicity </e2>, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"569": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "acetaminophen", "entity2": "lung toxicity", "span1": [86, 99], "span2": [143, 156]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during <e1> acetaminophen </e1>-induced nephrotoxicity, amiodarone-induced <e2> lung toxicity </e2> and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"570": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "acetaminophen", "entity2": "cardiotoxicity", "span1": [86, 99], "span2": [181, 195]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during <e1> acetaminophen </e1>-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced <e2> cardiotoxicity </e2> by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"571": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "amiodarone", "entity2": "necrotic", "span1": [124, 134], "span2": [58, 66]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, <e1> amiodarone </e1> <e2> necrotic </e2> cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"572": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "amiodarone", "entity2": "nephrotoxicity", "span1": [124, 134], "span2": [108, 122]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, <e1> amiodarone </e1> <e2> nephrotoxicity </e2>, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"573": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "amiodarone", "entity2": "lung toxicity", "span1": [124, 134], "span2": [143, 156]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, <e1> amiodarone </e1>-induced <e2> lung toxicity </e2> and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"574": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "amiodarone", "entity2": "cardiotoxicity", "span1": [124, 134], "span2": [181, 195]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, <e1> amiodarone </e1>-induced lung toxicity and doxorubicin-induced <e2> cardiotoxicity </e2> by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"575": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "doxorubicin", "entity2": "necrotic", "span1": [161, 172], "span2": [58, 66]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and <e1> doxorubicin </e1> <e2> necrotic </e2> cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"576": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "doxorubicin", "entity2": "nephrotoxicity", "span1": [161, 172], "span2": [108, 122]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and <e1> doxorubicin </e1> <e2> nephrotoxicity </e2>, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"577": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "doxorubicin", "entity2": "lung toxicity", "span1": [161, 172], "span2": [143, 156]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and <e1> doxorubicin </e1> <e2> lung toxicity </e2> and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"578": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [161, 172], "span2": [181, 195]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2> by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"579": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "IH636 grape seed proanthocyanidin extract", "entity2": "necrotic", "span1": [207, 248], "span2": [58, 66]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel <e1> IH636 grape seed proanthocyanidin extract </e1> <e2> necrotic </e2> cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"580": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "IH636 grape seed proanthocyanidin extract", "entity2": "nephrotoxicity", "span1": [207, 248], "span2": [108, 122]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel <e1> IH636 grape seed proanthocyanidin extract </e1> <e2> nephrotoxicity </e2>, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"581": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "IH636 grape seed proanthocyanidin extract", "entity2": "lung toxicity", "span1": [207, 248], "span2": [143, 156]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel <e1> IH636 grape seed proanthocyanidin extract </e1> <e2> lung toxicity </e2> and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"582": {"data": {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n", "entity1": "IH636 grape seed proanthocyanidin extract", "entity2": "cardiotoxicity", "span1": [207, 248], "span2": [181, 195]}, "bert_text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel <e1> IH636 grape seed proanthocyanidin extract </e1> <e2> cardiotoxicity </e2> by a novel IH636 grape seed proanthocyanidin extract.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"583": {"data": {"text": "To our knowledge, this is the first report of a pseudo-allergy caused by paramethasone.", "entity1": "paramethasone", "entity2": "allergy", "span1": [73, 86], "span2": [55, 62]}, "bert_text": "To our knowledge, this is the first report of a pseudo-allergy caused by <e1> paramethasone </e1> <e2> allergy </e2> caused by paramethasone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"584": {"data": {"text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "entity1": "selegiline", "entity2": "Parkinson's Disease", "span1": [180, 190], "span2": [31, 50]}, "bert_text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg <e1> selegiline </e1> <e2> Parkinson's Disease </e2> Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"585": {"data": {"text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "entity1": "selegiline", "entity2": "Parkinson's disease", "span1": [180, 190], "span2": [127, 146]}, "bert_text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg <e1> selegiline </e1> <e2> Parkinson's disease </e2> (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"586": {"data": {"text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "entity1": "selegiline", "entity2": "PD", "span1": [180, 190], "span2": [148, 150]}, "bert_text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg <e1> selegiline </e1> <e2> PD </e2>) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"587": {"data": {"text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "entity1": "L-dopa", "entity2": "Parkinson's Disease", "span1": [203, 209], "span2": [31, 50]}, "bert_text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and <e1> L-dopa </e1> <e2> Parkinson's Disease </e2> Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"588": {"data": {"text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "entity1": "L-dopa", "entity2": "Parkinson's disease", "span1": [203, 209], "span2": [127, 146]}, "bert_text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and <e1> L-dopa </e1> <e2> Parkinson's disease </e2> (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"589": {"data": {"text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "entity1": "L-dopa", "entity2": "PD", "span1": [203, 209], "span2": [148, 150]}, "bert_text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and <e1> L-dopa </e1> <e2> PD </e2>) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"590": {"data": {"text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "entity1": "L-dopa", "entity2": "Parkinson's Disease", "span1": [237, 243], "span2": [31, 50]}, "bert_text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking <e1> L-dopa </e1> <e2> Parkinson's Disease </e2> Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"591": {"data": {"text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "entity1": "L-dopa", "entity2": "Parkinson's disease", "span1": [237, 243], "span2": [127, 146]}, "bert_text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking <e1> L-dopa </e1> <e2> Parkinson's disease </e2> (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"592": {"data": {"text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "entity1": "L-dopa", "entity2": "PD", "span1": [237, 243], "span2": [148, 150]}, "bert_text": "OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking <e1> L-dopa </e1> <e2> PD </e2>) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"593": {"data": {"text": "Renal papillary necrosis due to naproxen.\n", "entity1": "naproxen", "entity2": "Renal papillary necrosis", "span1": [32, 40], "span2": [0, 24]}, "bert_text": "Renal papillary necrosis due to <e1> naproxen </e1> <e2> Renal papillary necrosis </e2> due to naproxen.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"594": {"data": {"text": "METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.", "entity1": "selegiline", "entity2": "PD", "span1": [116, 126], "span2": [94, 96]}, "bert_text": "METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving <e1> selegiline </e1> <e2> PD </e2> patients receiving selegiline and as the drug was withdrawn.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"595": {"data": {"text": "Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.", "entity1": "nitroglycerin", "entity2": "migraine", "span1": [37, 50], "span2": [9, 17]}, "bert_text": "Thus the migraine-inducing effect of <e1> nitroglycerin </e1> <e2> migraine </e2>-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"596": {"data": {"text": "Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.", "entity1": "nitroglycerin", "entity2": "migraine", "span1": [37, 50], "span2": [210, 218]}, "bert_text": "Thus the migraine-inducing effect of <e1> nitroglycerin </e1> seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a <e2> migraine </e2> crisis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"597": {"data": {"text": "Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.", "entity1": "nitroglycerin", "entity2": "pain", "span1": [37, 50], "span2": [113, 117]}, "bert_text": "Thus the migraine-inducing effect of <e1> nitroglycerin </e1> seems to depend on direct stimulation of the habitual site of <e2> pain </e2>, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"598": {"data": {"text": "We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.", "entity1": "citalopram", "entity2": "major depression", "span1": [49, 59], "span2": [86, 102]}, "bert_text": "We report a favorable response to treatment with <e1> citalopram </e1> by a 15-year-old boy with <e2> major depression </e2> who exhibited palpebral twitching during his first 2 weeks of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"599": {"data": {"text": "The data indicate that the effects of streptozotocin-induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment.", "entity1": "streptozotocin", "entity2": "diabetes", "span1": [38, 52], "span2": [61, 69]}, "bert_text": "The data indicate that the effects of <e1> streptozotocin </e1>-induced <e2> diabetes </e2> on urinary bladder function are both prevented and reversed by insulin treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"600": {"data": {"text": "Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.\n", "entity1": "nondepolarizing neuromuscular blocking agents", "entity2": "paralysis", "span1": [27, 72], "span2": [10, 19]}, "bert_text": "Prolonged paralysis due to <e1> nondepolarizing neuromuscular blocking agents </e1> <e2> paralysis </e2> due to nondepolarizing neuromuscular blocking agents and corticosteroids.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"601": {"data": {"text": "Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.\n", "entity1": "corticosteroids", "entity2": "paralysis", "span1": [77, 92], "span2": [10, 19]}, "bert_text": "Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and <e1> corticosteroids </e1> <e2> paralysis </e2> due to nondepolarizing neuromuscular blocking agents and corticosteroids.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"602": {"data": {"text": "CONCLUSIONS: CCNU-associated toxicity in dogs is common, but is usually not life threatening.", "entity1": "CCNU", "entity2": "toxicity", "span1": [13, 17], "span2": [29, 37]}, "bert_text": "CONCLUSIONS: <e1> CCNU </e1>-associated <e2> toxicity </e2> in dogs is common, but is usually not life threatening.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"603": {"data": {"text": "Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.", "entity1": "Pemoline", "entity2": "movement disorders", "span1": [0, 8], "span2": [80, 98]}, "bert_text": "<e1> Pemoline </e1> has not been commonly associated in the literature as a cause of acute <e2> movement disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"604": {"data": {"text": "Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.", "entity1": "deferoxamine", "entity2": "ototoxicity", "span1": [113, 125], "span2": [242, 253]}, "bert_text": "Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving <e1> deferoxamine </e1>, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and <e2> ototoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"605": {"data": {"text": "Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.", "entity1": "deferoxamine", "entity2": "ototoxicity", "span1": [210, 222], "span2": [242, 253]}, "bert_text": "Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between <e1> deferoxamine </e1> administration and <e2> ototoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"606": {"data": {"text": "RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.", "entity1": "3MA", "entity2": "mitochondrial injury", "span1": [9, 12], "span2": [65, 85]}, "bert_text": "RESULTS: <e1> 3MA </e1> significantly improved cardiac function and reduced <e2> mitochondrial injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"607": {"data": {"text": "Thirty minutes after 99mTc-glucarate administration the standardised heart uptake value S(h)UV was 4.7 in infarcted rat heart which is six times more than in normal rats.", "entity1": "99mTc-glucarate", "entity2": "infarcted", "span1": [21, 36], "span2": [106, 115]}, "bert_text": "Thirty minutes after <e1> 99mTc-glucarate </e1> administration the standardised heart uptake value S(h)UV was 4.7 in <e2> infarcted </e2> rat heart which is six times more than in normal rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"608": {"data": {"text": "In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.", "entity1": "STZ", "entity2": "Alzheimer's disease", "span1": [55, 58], "span2": [3, 22]}, "bert_text": "In Alzheimer's disease groups, rats were injected with <e1> STZ </e1> <e2> Alzheimer's disease </e2> groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"609": {"data": {"text": "In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.", "entity1": "STZ", "entity2": "Alzheimer's disease", "span1": [126, 129], "span2": [3, 22]}, "bert_text": "In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar <e1> STZ </e1> <e2> Alzheimer's disease </e2> groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"610": {"data": {"text": "Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.", "entity1": "simvastatin-ezetimibe", "entity2": "hepatotoxicity", "span1": [60, 81], "span2": [40, 54]}, "bert_text": "Clinicians should be aware of potential hepatotoxicity with <e1> simvastatin-ezetimibe </e1> <e2> hepatotoxicity </e2> with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"611": {"data": {"text": "In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.", "entity1": "AAP", "entity2": "liver damage", "span1": [105, 108], "span2": [188, 200]}, "bert_text": "In these animals, only minor increases of serum transaminase activities were measured in the presence of <e1> AAP </e1>, and unlike the exacerbation caused by ethanol in mice on a standard diet, the <e2> liver damage </e2> was inhibited by 50% by ethanol.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"612": {"data": {"text": "In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.", "entity1": "ethanol", "entity2": "liver damage", "span1": [148, 155], "span2": [188, 200]}, "bert_text": "In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by <e1> ethanol </e1> in mice on a standard diet, the <e2> liver damage </e2> was inhibited by 50% by ethanol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"613": {"data": {"text": "In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.", "entity1": "ethanol", "entity2": "liver damage", "span1": [225, 232], "span2": [188, 200]}, "bert_text": "In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by <e1> ethanol </e1> <e2> liver damage </e2> was inhibited by 50% by ethanol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"614": {"data": {"text": "Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.", "entity1": "progesterone", "entity2": "seizures", "span1": [44, 56], "span2": [298, 306]}, "bert_text": "Several structurally related metabolites of <e1> progesterone </e1> (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced <e2> seizures </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"615": {"data": {"text": "Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.", "entity1": "3 alpha-hydroxy pregnane-20-ones", "entity2": "seizures", "span1": [58, 90], "span2": [298, 306]}, "bert_text": "Several structurally related metabolites of progesterone (<e1> 3 alpha-hydroxy pregnane-20-ones </e1>) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced <e2> seizures </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"616": {"data": {"text": "Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.", "entity1": "deoxycorticosterone", "entity2": "seizures", "span1": [96, 115], "span2": [298, 306]}, "bert_text": "Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and <e1> deoxycorticosterone </e1> (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced <e2> seizures </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"617": {"data": {"text": "Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.", "entity1": "3 alpha-hydroxy pregnane-21-diol-20-ones", "entity2": "seizures", "span1": [117, 157], "span2": [298, 306]}, "bert_text": "Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (<e1> 3 alpha-hydroxy pregnane-21-diol-20-ones </e1>) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced <e2> seizures </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"618": {"data": {"text": "Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.", "entity1": "pilocarpine-", "entity2": "seizures", "span1": [231, 243], "span2": [298, 306]}, "bert_text": "Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against <e1> pilocarpine- </e1>, kainic acid- and N-methyl-D-aspartate (NMDA)-induced <e2> seizures </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"619": {"data": {"text": "Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.", "entity1": "kainic acid-", "entity2": "seizures", "span1": [245, 257], "span2": [298, 306]}, "bert_text": "Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, <e1> kainic acid- </e1> and N-methyl-D-aspartate (NMDA)-induced <e2> seizures </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"620": {"data": {"text": "Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.", "entity1": "prostaglandin F2 alpha", "entity2": "hemorrhage", "span1": [99, 121], "span2": [149, 159]}, "bert_text": "Conservative treatment, including bladder irrigation with physiological saline and instillation of <e1> prostaglandin F2 alpha </e1>, failed to totally control <e2> hemorrhage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"621": {"data": {"text": "Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.", "entity1": "epinephrine", "entity2": "myocardial ischemia", "span1": [5, 16], "span2": [39, 58]}, "bert_text": "Both <e1> epinephrine </e1> and exercise produced <e2> myocardial ischemia </e2> as evidenced by ST segment depression and angina.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"622": {"data": {"text": "Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.", "entity1": "epinephrine", "entity2": "depression", "span1": [5, 16], "span2": [86, 96]}, "bert_text": "Both <e1> epinephrine </e1> and exercise produced myocardial ischemia as evidenced by ST segment <e2> depression </e2> and angina.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"623": {"data": {"text": "Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.", "entity1": "epinephrine", "entity2": "angina", "span1": [5, 16], "span2": [101, 107]}, "bert_text": "Both <e1> epinephrine </e1> and exercise produced myocardial ischemia as evidenced by ST segment depression and <e2> angina </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"624": {"data": {"text": "However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.", "entity1": "acetaminophen", "entity2": "chronic renal failure", "span1": [138, 151], "span2": [176, 197]}, "bert_text": "However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of <e1> acetaminophen </e1> is also associated with <e2> chronic renal failure </e2> and ESRD, with a relative risk in the range of 2 to 4.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"625": {"data": {"text": "However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.", "entity1": "acetaminophen", "entity2": "ESRD", "span1": [138, 151], "span2": [202, 206]}, "bert_text": "However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of <e1> acetaminophen </e1> is also associated with chronic renal failure and <e2> ESRD </e2>, with a relative risk in the range of 2 to 4.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"626": {"data": {"text": "During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).", "entity1": "urea", "entity2": "nephrotic syndrome", "span1": [47, 51], "span2": [21, 39]}, "bert_text": "During the course of nephrotic syndrome, serum <e1> urea </e1> <e2> nephrotic syndrome </e2>, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"627": {"data": {"text": "During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).", "entity1": "urea", "entity2": "uremia", "span1": [47, 51], "span2": [150, 156]}, "bert_text": "During the course of nephrotic syndrome, serum <e1> urea </e1> concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to <e2> uremia </e2> and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"628": {"data": {"text": "RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.", "entity1": "COCs", "entity2": "VTE", "span1": [91, 95], "span2": [78, 81]}, "bert_text": "RESULTS: During the time frame of the study, 330 women were found to have had VTE while on <e1> COCs </e1> <e2> VTE </e2> while on COCs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"629": {"data": {"text": "Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.", "entity1": "oxygen", "entity2": "ischemia", "span1": [62, 68], "span2": [19, 27]}, "bert_text": "Objective signs of ischemia and factors increasing myocardial <e1> oxygen </e1> <e2> ischemia </e2> and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"630": {"data": {"text": "Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.", "entity1": "epinephrine", "entity2": "ischemia", "span1": [102, 113], "span2": [19, 27]}, "bert_text": "Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during <e1> epinephrine </e1> <e2> ischemia </e2> and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"631": {"data": {"text": "The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.", "entity1": "nondepolarizing neuromuscular blocking agents", "entity2": "muscle weakness", "span1": [21, 66], "span2": [130, 145]}, "bert_text": "The long-term use of <e1> nondepolarizing neuromuscular blocking agents </e1> (ND-NMBA) has recently been implicated as a cause of prolonged <e2> muscle weakness </e2>, although the site of the lesion and the predisposing factors have been unclear.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"632": {"data": {"text": "The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.", "entity1": "ND-NMBA", "entity2": "muscle weakness", "span1": [68, 75], "span2": [130, 145]}, "bert_text": "The long-term use of nondepolarizing neuromuscular blocking agents (<e1> ND-NMBA </e1>) has recently been implicated as a cause of prolonged <e2> muscle weakness </e2>, although the site of the lesion and the predisposing factors have been unclear.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"633": {"data": {"text": "Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.", "entity1": "Epinephrine", "entity2": "cardiac arrest", "span1": [0, 11], "span2": [33, 47]}, "bert_text": "<e1> Epinephrine </e1> has a proven role in <e2> cardiac arrest </e2> in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"634": {"data": {"text": "Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.", "entity1": "Epinephrine", "entity2": "allergic reaction", "span1": [0, 11], "span2": [123, 140]}, "bert_text": "<e1> Epinephrine </e1> has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected <e2> allergic reaction </e2> and severe hypertension should be viewed with caution.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"635": {"data": {"text": "Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.", "entity1": "Epinephrine", "entity2": "hypertension", "span1": [0, 11], "span2": [152, 164]}, "bert_text": "<e1> Epinephrine </e1> has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe <e2> hypertension </e2> should be viewed with caution.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"636": {"data": {"text": "We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.", "entity1": "flumazenil", "entity2": "tonic-clonic seizure", "span1": [118, 128], "span2": [42, 62]}, "bert_text": "We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of <e1> flumazenil </e1> <e2> tonic-clonic seizure </e2> in a pediatric patient following the administration of flumazenil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"637": {"data": {"text": "Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.\n", "entity1": "indomethacin--", "entity2": "aplastic anemia", "span1": [29, 43], "span2": [6, 21]}, "bert_text": "Fatal aplastic anemia due to <e1> indomethacin-- </e1> <e2> aplastic anemia </e2> due to indomethacin--lymphocyte transformation tests in vitro.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"638": {"data": {"text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "entity1": "lamotrigine", "entity2": "idiopathic generalized epilepsies", "span1": [72, 83], "span2": [19, 52]}, "bert_text": "Five patients with idiopathic generalized epilepsies (IGE) treated with <e1> lamotrigine </e1> <e2> idiopathic generalized epilepsies </e2> (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"639": {"data": {"text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "entity1": "lamotrigine", "entity2": "IGE", "span1": [72, 83], "span2": [54, 57]}, "bert_text": "Five patients with idiopathic generalized epilepsies (IGE) treated with <e1> lamotrigine </e1> <e2> IGE </e2>) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"640": {"data": {"text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "entity1": "lamotrigine", "entity2": "myoclonic jerks", "span1": [72, 83], "span2": [140, 155]}, "bert_text": "Five patients with idiopathic generalized epilepsies (IGE) treated with <e1> lamotrigine </e1> (LTG) experienced exacerbation or de novo appearance of <e2> myoclonic jerks </e2> (MJ).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"641": {"data": {"text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "entity1": "lamotrigine", "entity2": "MJ", "span1": [72, 83], "span2": [157, 159]}, "bert_text": "Five patients with idiopathic generalized epilepsies (IGE) treated with <e1> lamotrigine </e1> (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (<e2> MJ </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"642": {"data": {"text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "entity1": "LTG", "entity2": "idiopathic generalized epilepsies", "span1": [85, 88], "span2": [19, 52]}, "bert_text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (<e1> LTG </e1> <e2> idiopathic generalized epilepsies </e2> (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"643": {"data": {"text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "entity1": "LTG", "entity2": "IGE", "span1": [85, 88], "span2": [54, 57]}, "bert_text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (<e1> LTG </e1> <e2> IGE </e2>) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"644": {"data": {"text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "entity1": "LTG", "entity2": "myoclonic jerks", "span1": [85, 88], "span2": [140, 155]}, "bert_text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (<e1> LTG </e1>) experienced exacerbation or de novo appearance of <e2> myoclonic jerks </e2> (MJ).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"645": {"data": {"text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "entity1": "LTG", "entity2": "MJ", "span1": [85, 88], "span2": [157, 159]}, "bert_text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (<e1> LTG </e1>) experienced exacerbation or de novo appearance of myoclonic jerks (<e2> MJ </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"646": {"data": {"text": "Although the exact mechanism of hepatotoxicity of these agents is not known, the results suggest that trifluoroacetyl-altered liver proteins are involved.", "entity1": "trifluoroacetyl", "entity2": "hepatotoxicity", "span1": [102, 117], "span2": [32, 46]}, "bert_text": "Although the exact mechanism of hepatotoxicity of these agents is not known, the results suggest that <e1> trifluoroacetyl </e1> <e2> hepatotoxicity </e2> of these agents is not known, the results suggest that trifluoroacetyl-altered liver proteins are involved.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"647": {"data": {"text": "Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.", "entity1": "clonidine", "entity2": "bradycardia", "span1": [97, 106], "span2": [142, 153]}, "bert_text": "Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that <e1> clonidine </e1> induces sympathetic withdrawal and <e2> bradycardia </e2>, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"648": {"data": {"text": "Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.", "entity1": "clonidine's", "entity2": "bradycardia", "span1": [176, 187], "span2": [142, 153]}, "bert_text": "Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that <e1> clonidine's </e1> <e2> bradycardia </e2>, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"649": {"data": {"text": "Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.", "entity1": "selegiline", "entity2": "systolic orthostatic hypotension", "span1": [37, 47], "span2": [89, 121]}, "bert_text": "Recently, we found that therapy with <e1> selegiline </e1> and L-dopa was associated with selective <e2> systolic orthostatic hypotension </e2> which was abolished by withdrawal of selegiline.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"650": {"data": {"text": "Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.", "entity1": "selegiline", "entity2": "systolic orthostatic hypotension", "span1": [159, 169], "span2": [89, 121]}, "bert_text": "Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of <e1> selegiline </e1> <e2> systolic orthostatic hypotension </e2> which was abolished by withdrawal of selegiline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"651": {"data": {"text": "Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.", "entity1": "L-dopa", "entity2": "systolic orthostatic hypotension", "span1": [52, 58], "span2": [89, 121]}, "bert_text": "Recently, we found that therapy with selegiline and <e1> L-dopa </e1> was associated with selective <e2> systolic orthostatic hypotension </e2> which was abolished by withdrawal of selegiline.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"652": {"data": {"text": "Cholestatic jaundice associated with the use of metformin.\n", "entity1": "metformin", "entity2": "Cholestatic jaundice", "span1": [48, 57], "span2": [0, 20]}, "bert_text": "Cholestatic jaundice associated with the use of <e1> metformin </e1> <e2> Cholestatic jaundice </e2> associated with the use of metformin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"653": {"data": {"text": "All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.\n", "entity1": "All- trans-retinoic acid", "entity2": "erythema nodosum", "span1": [0, 24], "span2": [33, 49]}, "bert_text": "<e1> All- trans-retinoic acid </e1>-induced <e2> erythema nodosum </e2> in patients with acute promyelocytic leukemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"654": {"data": {"text": "All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.\n", "entity1": "All- trans-retinoic acid", "entity2": "acute promyelocytic leukemia", "span1": [0, 24], "span2": [67, 95]}, "bert_text": "<e1> All- trans-retinoic acid </e1>-induced erythema nodosum in patients with <e2> acute promyelocytic leukemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"655": {"data": {"text": "Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.", "entity1": "Aspirin", "entity2": "developmental anomalies", "span1": [0, 7], "span2": [96, 119]}, "bert_text": "<e1> Aspirin </e1> (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces <e2> developmental anomalies </e2> when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"656": {"data": {"text": "Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.", "entity1": "acetylsalicylic acid", "entity2": "developmental anomalies", "span1": [9, 29], "span2": [96, 119]}, "bert_text": "Aspirin (<e1> acetylsalicylic acid </e1> [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces <e2> developmental anomalies </e2> when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"657": {"data": {"text": "Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.", "entity1": "ASA", "entity2": "developmental anomalies", "span1": [31, 34], "span2": [96, 119]}, "bert_text": "Aspirin (acetylsalicylic acid [<e1> ASA </e1>]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces <e2> developmental anomalies </e2> when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"658": {"data": {"text": "The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.", "entity1": "statins", "entity2": "myopathy", "span1": [77, 84], "span2": [22, 30]}, "bert_text": "The mechanism of this myopathy is uncertain but may involve the induction by <e1> statins </e1> <e2> myopathy </e2> is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"659": {"data": {"text": "Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.", "entity1": "NO", "entity2": "depression", "span1": [63, 65], "span2": [25, 35]}, "bert_text": "Since cortical spreading depression has been shown to liberate <e1> NO </e1> <e2> depression </e2> has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"660": {"data": {"text": "Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.", "entity1": "NO", "entity2": "depression", "span1": [63, 65], "span2": [161, 171]}, "bert_text": "Since cortical spreading depression has been shown to liberate <e1> NO </e1> in animals, this finding may help our understanding of the coupling between cortical spreading <e2> depression </e2> and headache in migraine with aura.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"661": {"data": {"text": "Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.", "entity1": "NO", "entity2": "headache", "span1": [63, 65], "span2": [176, 184]}, "bert_text": "Since cortical spreading depression has been shown to liberate <e1> NO </e1> in animals, this finding may help our understanding of the coupling between cortical spreading depression and <e2> headache </e2> in migraine with aura.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"662": {"data": {"text": "Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.", "entity1": "NO", "entity2": "migraine with aura", "span1": [63, 65], "span2": [188, 206]}, "bert_text": "Since cortical spreading depression has been shown to liberate <e1> NO </e1> in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in <e2> migraine with aura </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"663": {"data": {"text": "Ifosfamide encephalopathy presenting with asterixis.\n", "entity1": "Ifosfamide", "entity2": "encephalopathy", "span1": [0, 10], "span2": [11, 25]}, "bert_text": "<e1> Ifosfamide </e1> <e2> encephalopathy </e2> presenting with asterixis.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"664": {"data": {"text": "Ifosfamide encephalopathy presenting with asterixis.\n", "entity1": "Ifosfamide", "entity2": "asterixis", "span1": [0, 10], "span2": [42, 51]}, "bert_text": "<e1> Ifosfamide </e1> encephalopathy presenting with <e2> asterixis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"665": {"data": {"text": "These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.", "entity1": "vitamin C", "entity2": "diabetic", "span1": [63, 72], "span2": [76, 84]}, "bert_text": "These observations led us to hypothesize that a high intake of <e1> vitamin C </e1> in <e2> diabetic </e2> persons might promote atherosclerosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"666": {"data": {"text": "These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.", "entity1": "vitamin C", "entity2": "atherosclerosis", "span1": [63, 72], "span2": [107, 122]}, "bert_text": "These observations led us to hypothesize that a high intake of <e1> vitamin C </e1> in diabetic persons might promote <e2> atherosclerosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"667": {"data": {"text": "Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.", "entity1": "adenosine diphosphate", "entity2": "platelet aggregation", "span1": [52, 73], "span2": [8, 28]}, "bert_text": "Maximal platelet aggregation induced by 6 microM of <e1> adenosine diphosphate </e1> <e2> platelet aggregation </e2> induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"668": {"data": {"text": "Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.", "entity1": "ketoprofen", "entity2": "platelet aggregation", "span1": [108, 118], "span2": [8, 28]}, "bert_text": "Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of <e1> ketoprofen </e1> <e2> platelet aggregation </e2> induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"669": {"data": {"text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "entity1": "ketoprofen", "entity2": "aneurysmal subarachnoid hemorrhage", "span1": [89, 99], "span2": [14, 48]}, "bert_text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either <e1> ketoprofen </e1> <e2> aneurysmal subarachnoid hemorrhage </e2> (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"670": {"data": {"text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "entity1": "ketoprofen", "entity2": "SAH", "span1": [89, 99], "span2": [50, 53]}, "bert_text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either <e1> ketoprofen </e1> <e2> SAH </e2>) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"671": {"data": {"text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "entity1": "ketoprofen", "entity2": "aneurysmal subarachnoid hemorrhage", "span1": [128, 138], "span2": [14, 48]}, "bert_text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (<e1> ketoprofen </e1> <e2> aneurysmal subarachnoid hemorrhage </e2> (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"672": {"data": {"text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "entity1": "ketoprofen", "entity2": "SAH", "span1": [128, 138], "span2": [50, 53]}, "bert_text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (<e1> ketoprofen </e1> <e2> SAH </e2>) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"673": {"data": {"text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "entity1": "acetaminophen", "entity2": "aneurysmal subarachnoid hemorrhage", "span1": [170, 183], "span2": [14, 48]}, "bert_text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, <e1> acetaminophen </e1> <e2> aneurysmal subarachnoid hemorrhage </e2> (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"674": {"data": {"text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "entity1": "acetaminophen", "entity2": "SAH", "span1": [170, 183], "span2": [50, 53]}, "bert_text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, <e1> acetaminophen </e1> <e2> SAH </e2>) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"675": {"data": {"text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "entity1": "acetaminophen", "entity2": "aneurysmal subarachnoid hemorrhage", "span1": [209, 222], "span2": [14, 48]}, "bert_text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (<e1> acetaminophen </e1> <e2> aneurysmal subarachnoid hemorrhage </e2> (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"676": {"data": {"text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "entity1": "acetaminophen", "entity2": "SAH", "span1": [209, 222], "span2": [50, 53]}, "bert_text": "Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (<e1> acetaminophen </e1> <e2> SAH </e2>) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group,", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"677": {"data": {"text": "Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.", "entity1": "Dipyridamole-thallium-201", "entity2": "peripheral vascular disease", "span1": [0, 25], "span2": [95, 122]}, "bert_text": "<e1> Dipyridamole-thallium-201 </e1> imaging is often performed in patients unable to exercise because of <e2> peripheral vascular disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"678": {"data": {"text": "We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.", "entity1": "ND-NMBAs", "entity2": "respiratory insufficiency", "span1": [142, 150], "span2": [50, 75]}, "bert_text": "We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of <e1> ND-NMBAs </e1> <e2> respiratory insufficiency </e2> who developed prolonged weakness following the discontinuation of ND-NMBAs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"679": {"data": {"text": "We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.", "entity1": "ND-NMBAs", "entity2": "weakness", "span1": [142, 150], "span2": [100, 108]}, "bert_text": "We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of <e1> ND-NMBAs </e1> <e2> weakness </e2> following the discontinuation of ND-NMBAs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"680": {"data": {"text": "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.\n", "entity1": "amphetamine", "entity2": "neurotoxicity", "span1": [19, 30], "span2": [39, 52]}, "bert_text": "Protection against <e1> amphetamine </e1>-induced <e2> neurotoxicity </e2> toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"681": {"data": {"text": "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.\n", "entity1": "dopamine", "entity2": "neurotoxicity", "span1": [69, 77], "span2": [39, 52]}, "bert_text": "Protection against amphetamine-induced neurotoxicity toward striatal <e1> dopamine </e1> <e2> neurotoxicity </e2> toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"682": {"data": {"text": "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.\n", "entity1": "LY274614", "entity2": "neurotoxicity", "span1": [100, 108], "span2": [39, 52]}, "bert_text": "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by <e1> LY274614 </e1> <e2> neurotoxicity </e2> toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"683": {"data": {"text": "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.\n", "entity1": "amino acid", "entity2": "neurotoxicity", "span1": [124, 134], "span2": [39, 52]}, "bert_text": "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory <e1> amino acid </e1> <e2> neurotoxicity </e2> toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"684": {"data": {"text": "METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.", "entity1": "Puromycin aminonucleoside", "entity2": "proteinuria", "span1": [9, 34], "span2": [91, 102]}, "bert_text": "METHODS: <e1> Puromycin aminonucleoside </e1> (PAN) was administered to Sprague Dawley rats to induce <e2> proteinuria </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"685": {"data": {"text": "METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.", "entity1": "PAN", "entity2": "proteinuria", "span1": [36, 39], "span2": [91, 102]}, "bert_text": "METHODS: Puromycin aminonucleoside (<e1> PAN </e1>) was administered to Sprague Dawley rats to induce <e2> proteinuria </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"686": {"data": {"text": "METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.", "entity1": "cisplatin", "entity2": "NSCLC", "span1": [171, 180], "span2": [43, 48]}, "bert_text": "METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving <e1> cisplatin </e1> <e2> NSCLC </e2> were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"687": {"data": {"text": "To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.", "entity1": "ACE inhibitor", "entity2": "hypotension", "span1": [28, 41], "span2": [174, 185]}, "bert_text": "To assess the safety of the <e1> ACE inhibitor </e1> enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic <e2> hypotension </e2> on the first day of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"688": {"data": {"text": "To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.", "entity1": "enalapril", "entity2": "hypotension", "span1": [42, 51], "span2": [174, 185]}, "bert_text": "To assess the safety of the ACE inhibitor <e1> enalapril </e1> a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic <e2> hypotension </e2> on the first day of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"689": {"data": {"text": "To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.", "entity1": "prazosin", "entity2": "hypotension", "span1": [79, 87], "span2": [174, 185]}, "bert_text": "To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, <e1> prazosin </e1>-controlled trial was designed that compared the incidence and severity of symptomatic <e2> hypotension </e2> on the first day of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"690": {"data": {"text": "CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless.", "entity1": "testosterone", "entity2": "atherosclerosis", "span1": [47, 59], "span2": [89, 104]}, "bert_text": "CONCLUSION: Our results suggest that high-dose <e1> testosterone </e1> therapy may adversely affect <e2> atherosclerosis </e2> in postmenopausal women and indicate that androgen replacement in these women may not be harmless.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"691": {"data": {"text": "In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.", "entity1": "sirolimus", "entity2": "nephrotic", "span1": [92, 101], "span2": [125, 134]}, "bert_text": "In 7 of the 28 patients there was a striking temporal association between the initiation of <e1> sirolimus </e1> and the development of <e2> nephrotic </e2>-range proteinuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"692": {"data": {"text": "In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [92, 101], "span2": [141, 152]}, "bert_text": "In 7 of the 28 patients there was a striking temporal association between the initiation of <e1> sirolimus </e1> and the development of nephrotic-range <e2> proteinuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"693": {"data": {"text": "Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.", "entity1": "etoricoxib", "entity2": "GI", "span1": [127, 137], "span2": [88, 90]}, "bert_text": "Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with <e1> etoricoxib </e1> <e2> GI </e2> AEs, were significantly higher with etoricoxib.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"694": {"data": {"text": "INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.", "entity1": "valproic acid", "entity2": "Confusion", "span1": [77, 90], "span2": [14, 23]}, "bert_text": "INTRODUCTION: Confusion is an adverse drug reaction frequently observed with <e1> valproic acid </e1> <e2> Confusion </e2> is an adverse drug reaction frequently observed with valproic acid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"695": {"data": {"text": "The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "entity1": "serotonin", "entity2": "hyperactivity", "span1": [4, 13], "span2": [166, 179]}, "bert_text": "The <e1> serotonin </e1> 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced <e2> hyperactivity </e2> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"696": {"data": {"text": "The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "entity1": "5-HT6", "entity2": "hyperactivity", "span1": [17, 22], "span2": [166, 179]}, "bert_text": "The serotonin 6 (<e1> 5-HT6 </e1>) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced <e2> hyperactivity </e2> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"697": {"data": {"text": "The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "entity1": "5-HT6", "entity2": "hyperactivity", "span1": [229, 234], "span2": [166, 179]}, "bert_text": "The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective <e1> 5-HT6 </e1> <e2> hyperactivity </e2> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"698": {"data": {"text": "The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "entity1": "clozapine", "entity2": "hyperactivity", "span1": [114, 123], "span2": [166, 179]}, "bert_text": "The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as <e1> clozapine </e1> and olanzapine, and d-amphetamine-induced <e2> hyperactivity </e2> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"699": {"data": {"text": "The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "entity1": "olanzapine", "entity2": "hyperactivity", "span1": [128, 138], "span2": [166, 179]}, "bert_text": "The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and <e1> olanzapine </e1>, and d-amphetamine-induced <e2> hyperactivity </e2> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"700": {"data": {"text": "The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "entity1": "d-amphetamine", "entity2": "hyperactivity", "span1": [144, 157], "span2": [166, 179]}, "bert_text": "The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and <e1> d-amphetamine </e1>-induced <e2> hyperactivity </e2> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"701": {"data": {"text": "5-azacytidine potentiates initiation induced by carcinogens in rat liver.\n", "entity1": "5-azacytidine", "entity2": "carcinogens", "span1": [0, 13], "span2": [48, 59]}, "bert_text": "<e1> 5-azacytidine </e1> potentiates initiation induced by <e2> carcinogens </e2> in rat liver.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"702": {"data": {"text": "FK506-associated MAHA is probably rare but physicians must be aware of this severe complication.", "entity1": "FK506-associated", "entity2": "MAHA", "span1": [0, 16], "span2": [17, 21]}, "bert_text": "<e1> FK506-associated </e1> <e2> MAHA </e2> is probably rare but physicians must be aware of this severe complication.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"703": {"data": {"text": "Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.\n", "entity1": "tacrolimus", "entity2": "brachial neuritis", "span1": [12, 22], "span2": [34, 51]}, "bert_text": "Recovery of <e1> tacrolimus </e1>-associated <e2> brachial neuritis </e2> after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"704": {"data": {"text": "Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.\n", "entity1": "everolimus", "entity2": "brachial neuritis", "span1": [72, 82], "span2": [34, 51]}, "bert_text": "Recovery of tacrolimus-associated brachial neuritis after conversion to <e1> everolimus </e1> <e2> brachial neuritis </e2> after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"705": {"data": {"text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.\n", "entity1": "Bradykinin", "entity2": "hyperalgesia", "span1": [0, 10], "span2": [112, 124]}, "bert_text": "<e1> Bradykinin </e1> receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced <e2> hyperalgesia </e2> in chemotherapy and diabetic neuropathy rat model.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"706": {"data": {"text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.\n", "entity1": "Bradykinin", "entity2": "diabetic neuropathy", "span1": [0, 10], "span2": [145, 164]}, "bert_text": "<e1> Bradykinin </e1> receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and <e2> diabetic neuropathy </e2> rat model.\n", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"707": {"data": {"text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.\n", "entity1": "nitric oxide", "entity2": "hyperalgesia", "span1": [37, 49], "span2": [112, 124]}, "bert_text": "Bradykinin receptors antagonists and <e1> nitric oxide </e1> synthase inhibitors in vincristine and streptozotocin induced <e2> hyperalgesia </e2> in chemotherapy and diabetic neuropathy rat model.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"708": {"data": {"text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.\n", "entity1": "nitric oxide", "entity2": "diabetic neuropathy", "span1": [37, 49], "span2": [145, 164]}, "bert_text": "Bradykinin receptors antagonists and <e1> nitric oxide </e1> synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and <e2> diabetic neuropathy </e2> rat model.\n", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"709": {"data": {"text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.\n", "entity1": "vincristine", "entity2": "hyperalgesia", "span1": [73, 84], "span2": [112, 124]}, "bert_text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in <e1> vincristine </e1> and streptozotocin induced <e2> hyperalgesia </e2> in chemotherapy and diabetic neuropathy rat model.\n", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"710": {"data": {"text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.\n", "entity1": "vincristine", "entity2": "diabetic neuropathy", "span1": [73, 84], "span2": [145, 164]}, "bert_text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in <e1> vincristine </e1> and streptozotocin induced hyperalgesia in chemotherapy and <e2> diabetic neuropathy </e2> rat model.\n", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"711": {"data": {"text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.\n", "entity1": "streptozotocin", "entity2": "hyperalgesia", "span1": [89, 103], "span2": [112, 124]}, "bert_text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and <e1> streptozotocin </e1> induced <e2> hyperalgesia </e2> in chemotherapy and diabetic neuropathy rat model.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"712": {"data": {"text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.\n", "entity1": "streptozotocin", "entity2": "diabetic neuropathy", "span1": [89, 103], "span2": [145, 164]}, "bert_text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and <e1> streptozotocin </e1> induced hyperalgesia in chemotherapy and <e2> diabetic neuropathy </e2> rat model.\n", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"713": {"data": {"text": "Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.\n", "entity1": "fentanyl", "entity2": "nausea", "span1": [9, 17], "span2": [26, 32]}, "bert_text": "Omitting <e1> fentanyl </e1> reduces <e2> nausea </e2> and vomiting, without increasing pain, after sevoflurane for day surgery.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"714": {"data": {"text": "Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.\n", "entity1": "fentanyl", "entity2": "vomiting", "span1": [9, 17], "span2": [37, 45]}, "bert_text": "Omitting <e1> fentanyl </e1> reduces nausea and <e2> vomiting </e2>, without increasing pain, after sevoflurane for day surgery.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"715": {"data": {"text": "Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.\n", "entity1": "fentanyl", "entity2": "pain", "span1": [9, 17], "span2": [66, 70]}, "bert_text": "Omitting <e1> fentanyl </e1> reduces nausea and vomiting, without increasing <e2> pain </e2>, after sevoflurane for day surgery.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"716": {"data": {"text": "Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.\n", "entity1": "sevoflurane", "entity2": "nausea", "span1": [78, 89], "span2": [26, 32]}, "bert_text": "Omitting fentanyl reduces nausea and vomiting, without increasing pain, after <e1> sevoflurane </e1> <e2> nausea </e2> and vomiting, without increasing pain, after sevoflurane for day surgery.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"717": {"data": {"text": "Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.\n", "entity1": "sevoflurane", "entity2": "vomiting", "span1": [78, 89], "span2": [37, 45]}, "bert_text": "Omitting fentanyl reduces nausea and vomiting, without increasing pain, after <e1> sevoflurane </e1> <e2> vomiting </e2>, without increasing pain, after sevoflurane for day surgery.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"718": {"data": {"text": "Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.\n", "entity1": "sevoflurane", "entity2": "pain", "span1": [78, 89], "span2": [66, 70]}, "bert_text": "Omitting fentanyl reduces nausea and vomiting, without increasing pain, after <e1> sevoflurane </e1> <e2> pain </e2>, after sevoflurane for day surgery.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"719": {"data": {"text": "A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.", "entity1": "appetite suppressants", "entity2": "primary pulmonary hypertension", "span1": [41, 62], "span2": [106, 136]}, "bert_text": "A policy of unrestricted prescription of <e1> appetite suppressants </e1> may lead to a high incidence of associated <e2> primary pulmonary hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"720": {"data": {"text": "Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.\n", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [120, 130], "span2": [63, 74]}, "bert_text": "Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with <e1> lamivudine </e1> <e2> hepatitis B </e2> virus-related cirrhosis after treatment with lamivudine monotherapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"721": {"data": {"text": "Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.\n", "entity1": "lamivudine", "entity2": "cirrhosis", "span1": [120, 130], "span2": [89, 98]}, "bert_text": "Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with <e1> lamivudine </e1> <e2> cirrhosis </e2> after treatment with lamivudine monotherapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"722": {"data": {"text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "entity1": "bradykinin", "entity2": "diabetic", "span1": [373, 383], "span2": [472, 480]}, "bert_text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] <e1> bradykinin </e1> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of <e2> diabetic </e2> (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"723": {"data": {"text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "entity1": "bradykinin", "entity2": "neuropathy", "span1": [373, 383], "span2": [538, 548]}, "bert_text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] <e1> bradykinin </e1> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) <e2> neuropathy </e2> was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"724": {"data": {"text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "entity1": "HOE 140", "entity2": "diabetic", "span1": [385, 392], "span2": [472, 480]}, "bert_text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (<e1> HOE 140 </e1>; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of <e2> diabetic </e2> (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"725": {"data": {"text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "entity1": "HOE 140", "entity2": "neuropathy", "span1": [385, 392], "span2": [538, 548]}, "bert_text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (<e1> HOE 140 </e1>; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) <e2> neuropathy </e2> was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"726": {"data": {"text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "entity1": "des Arg10 HOE 140", "entity2": "diabetic", "span1": [412, 429], "span2": [472, 480]}, "bert_text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or <e1> des Arg10 HOE 140 </e1> (70 nmol/kg ip) respectively, in model of <e2> diabetic </e2> (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"727": {"data": {"text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "entity1": "des Arg10 HOE 140", "entity2": "neuropathy", "span1": [412, 429], "span2": [538, 548]}, "bert_text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or <e1> des Arg10 HOE 140 </e1> (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) <e2> neuropathy </e2> was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"728": {"data": {"text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "entity1": "streptozotocin", "entity2": "diabetic", "span1": [482, 496], "span2": [472, 480]}, "bert_text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (<e1> streptozotocin </e1> <e2> diabetic </e2> (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"729": {"data": {"text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "entity1": "streptozotocin", "entity2": "neuropathy", "span1": [482, 496], "span2": [538, 548]}, "bert_text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (<e1> streptozotocin </e1>-induced) and toxic (vincristine-induced) <e2> neuropathy </e2> was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"730": {"data": {"text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "entity1": "vincristine", "entity2": "diabetic", "span1": [517, 528], "span2": [472, 480]}, "bert_text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (<e1> vincristine </e1> <e2> diabetic </e2> (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"731": {"data": {"text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.", "entity1": "vincristine", "entity2": "neuropathy", "span1": [517, 528], "span2": [538, 548]}, "bert_text": "PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (<e1> vincristine </e1>-induced) <e2> neuropathy </e2> was investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"732": {"data": {"text": "During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).", "entity1": "propofol", "entity2": "pain", "span1": [44, 52], "span2": [116, 120]}, "bert_text": "During induction of anaesthesia with TCI of <e1> propofol </e1> and remifentanil, a significant reduction in propofol infusion <e2> pain </e2> was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"733": {"data": {"text": "During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).", "entity1": "propofol", "entity2": "pain", "span1": [98, 106], "span2": [116, 120]}, "bert_text": "During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in <e1> propofol </e1> infusion <e2> pain </e2> was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"734": {"data": {"text": "During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).", "entity1": "remifentanil", "entity2": "pain", "span1": [57, 69], "span2": [116, 120]}, "bert_text": "During induction of anaesthesia with TCI of propofol and <e1> remifentanil </e1>, a significant reduction in propofol infusion <e2> pain </e2> was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"735": {"data": {"text": "During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).", "entity1": "remifentanil", "entity2": "pain", "span1": [195, 207], "span2": [116, 120]}, "bert_text": "During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of <e1> remifentanil </e1> <e2> pain </e2> was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"736": {"data": {"text": "METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004. We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.", "entity1": "paracetamol", "entity2": "acute liver injury", "span1": [57, 68], "span2": [77, 95]}, "bert_text": "METHODS: We followed up all transplant-free survivors of <e1> paracetamol </e1>-induced <e2> acute liver injury </e2>, hospitalized in a Danish national referral centre during 1984-2004. We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"737": {"data": {"text": "METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004. We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.", "entity1": "paracetamol", "entity2": "liver injury", "span1": [57, 68], "span2": [272, 284]}, "bert_text": "METHODS: We followed up all transplant-free survivors of <e1> paracetamol </e1>-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004. We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the <e2> liver injury </e2> led to an acute liver failure and those in whom it did not.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"738": {"data": {"text": "METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004. We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.", "entity1": "paracetamol", "entity2": "acute liver failure", "span1": [57, 68], "span2": [295, 314]}, "bert_text": "METHODS: We followed up all transplant-free survivors of <e1> paracetamol </e1>-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004. We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an <e2> acute liver failure </e2> and those in whom it did not.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"739": {"data": {"text": "Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.", "entity1": "PPA", "entity2": "myocardial injury", "span1": [41, 44], "span2": [50, 67]}, "bert_text": "Several reports have linked the abuse of <e1> PPA </e1> with <e2> myocardial injury </e2>, especially when overdose is involved.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"740": {"data": {"text": "Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.", "entity1": "PPA", "entity2": "overdose", "span1": [41, 44], "span2": [85, 93]}, "bert_text": "Several reports have linked the abuse of <e1> PPA </e1> with myocardial injury, especially when <e2> overdose </e2> is involved.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"741": {"data": {"text": "This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [45, 55], "span2": [66, 77]}, "bert_text": "This was an exploratory study to investigate <e1> lamivudine </e1>-resistant <e2> hepatitis B </e2> virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"742": {"data": {"text": "This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.", "entity1": "lamivudine", "entity2": "immunodeficiency virus (HIV) co-infection", "span1": [45, 55], "span2": [164, 205]}, "bert_text": "This was an exploratory study to investigate <e1> lamivudine </e1>-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human <e2> immunodeficiency virus (HIV) co-infection </e2> in South African patients.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"743": {"data": {"text": "This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [110, 120], "span2": [66, 77]}, "bert_text": "This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected <e1> lamivudine </e1> <e2> hepatitis B </e2> virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"744": {"data": {"text": "This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.", "entity1": "lamivudine", "entity2": "immunodeficiency virus (HIV) co-infection", "span1": [110, 120], "span2": [164, 205]}, "bert_text": "This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected <e1> lamivudine </e1>-na  ve HBV carriers with and without human <e2> immunodeficiency virus (HIV) co-infection </e2> in South African patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"745": {"data": {"text": "This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.", "entity1": "na", "entity2": "hepatitis B", "span1": [121, 123], "span2": [66, 77]}, "bert_text": "This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-<e1> na </e1> <e2> hepatitis B </e2> virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"746": {"data": {"text": "This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.", "entity1": "na", "entity2": "immunodeficiency virus (HIV) co-infection", "span1": [121, 123], "span2": [164, 205]}, "bert_text": "This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-<e1> na </e1>  ve HBV carriers with and without human <e2> immunodeficiency virus (HIV) co-infection </e2> in South African patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"747": {"data": {"text": "Fluoxetine-induced akathisia: clinical and theoretical implications.\n", "entity1": "Fluoxetine", "entity2": "akathisia", "span1": [0, 10], "span2": [19, 28]}, "bert_text": "<e1> Fluoxetine </e1>-induced <e2> akathisia </e2>: clinical and theoretical implications.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"748": {"data": {"text": "Mice lacking mPGES-1 are resistant to lithium-induced polyuria.\n", "entity1": "lithium", "entity2": "polyuria", "span1": [38, 45], "span2": [54, 62]}, "bert_text": "Mice lacking mPGES-1 are resistant to <e1> lithium </e1>-induced <e2> polyuria </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"749": {"data": {"text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "entity1": "beta-lactam", "entity2": "allergic", "span1": [171, 182], "span2": [159, 167]}, "bert_text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to <e1> beta-lactam </e1> <e2> allergic </e2> to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"750": {"data": {"text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "entity1": "beta-lactam", "entity2": "allergic", "span1": [171, 182], "span2": [219, 227]}, "bert_text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to <e1> beta-lactam </e1> antibiotics had selective immediate <e2> allergic </e2> responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"751": {"data": {"text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "entity1": "amoxicillin", "entity2": "allergic", "span1": [241, 252], "span2": [159, 167]}, "bert_text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to <e1> amoxicillin </e1> <e2> allergic </e2> to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"752": {"data": {"text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "entity1": "amoxicillin", "entity2": "allergic", "span1": [241, 252], "span2": [219, 227]}, "bert_text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to <e1> amoxicillin </e1> <e2> allergic </e2> responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"753": {"data": {"text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "entity1": "AX", "entity2": "allergic", "span1": [254, 256], "span2": [159, 167]}, "bert_text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (<e1> AX </e1> <e2> allergic </e2> to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"754": {"data": {"text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "entity1": "AX", "entity2": "allergic", "span1": [254, 256], "span2": [219, 227]}, "bert_text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (<e1> AX </e1> <e2> allergic </e2> responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"755": {"data": {"text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "entity1": "penicillin", "entity2": "allergic", "span1": [292, 302], "span2": [159, 167]}, "bert_text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other <e1> penicillin </e1> <e2> allergic </e2> to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"756": {"data": {"text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "entity1": "penicillin", "entity2": "allergic", "span1": [292, 302], "span2": [219, 227]}, "bert_text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other <e1> penicillin </e1> <e2> allergic </e2> responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"757": {"data": {"text": "AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.", "entity1": "mannitol", "entity2": "brain edema", "span1": [23, 31], "span2": [42, 53]}, "bert_text": "AIM: Widespread use of <e1> mannitol </e1> to reduce <e2> brain edema </e2> and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"758": {"data": {"text": "AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.", "entity1": "mannitol", "entity2": "brain tumor", "span1": [23, 31], "span2": [80, 91]}, "bert_text": "AIM: Widespread use of <e1> mannitol </e1> to reduce brain edema and lower elevated ICP in <e2> brain tumor </e2> patients continues to be afflicted by the so-called rebound phenomenon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"759": {"data": {"text": "Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.", "entity1": "amiloride", "entity2": "ventricular ectopic beats", "span1": [12, 21], "span2": [104, 129]}, "bert_text": "Compared to <e1> amiloride </e1> treatment, the chlorthalidone phase was associated with an increased frequency of <e2> ventricular ectopic beats </e2> (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.", "weak_labels": [1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"760": {"data": {"text": "Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.", "entity1": "chlorthalidone", "entity2": "ventricular ectopic beats", "span1": [37, 51], "span2": [104, 129]}, "bert_text": "Compared to amiloride treatment, the <e1> chlorthalidone </e1> phase was associated with an increased frequency of <e2> ventricular ectopic beats </e2> (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"761": {"data": {"text": "Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.", "entity1": "octreotide", "entity2": "acromegalic", "span1": [173, 183], "span2": [192, 203]}, "bert_text": "Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 <e1> octreotide </e1> treated <e2> acromegalic </e2> patients with gall stones.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"762": {"data": {"text": "Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.", "entity1": "octreotide", "entity2": "gall stones", "span1": [173, 183], "span2": [218, 229]}, "bert_text": "Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 <e1> octreotide </e1> treated acromegalic patients with <e2> gall stones </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"763": {"data": {"text": "Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.", "entity1": "OP compound", "entity2": "apnea", "span1": [85, 96], "span2": [10, 15]}, "bert_text": "Prolonged apnea in our case ensued because the information about suicidal attempt by <e1> OP compound </e1> <e2> apnea </e2> in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"764": {"data": {"text": "Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.\n", "entity1": "prilocaine", "entity2": "neurologic symptoms", "span1": [78, 88], "span2": [10, 29]}, "bert_text": "Transient neurologic symptoms after spinal anesthesia: a lower incidence with <e1> prilocaine </e1> <e2> neurologic symptoms </e2> after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"765": {"data": {"text": "Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.\n", "entity1": "bupivacaine", "entity2": "neurologic symptoms", "span1": [93, 104], "span2": [10, 29]}, "bert_text": "Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and <e1> bupivacaine </e1> <e2> neurologic symptoms </e2> after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"766": {"data": {"text": "Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.\n", "entity1": "lidocaine", "entity2": "neurologic symptoms", "span1": [115, 124], "span2": [10, 29]}, "bert_text": "Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with <e1> lidocaine </e1> <e2> neurologic symptoms </e2> after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"767": {"data": {"text": "We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.", "entity1": "streptozotocin", "entity2": "diabetic", "span1": [20, 34], "span2": [35, 43]}, "bert_text": "We conclude that in <e1> streptozotocin </e1>-<e2> diabetic </e2> rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"768": {"data": {"text": "We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.", "entity1": "heparan sulphate", "entity2": "diabetic", "span1": [104, 120], "span2": [35, 43]}, "bert_text": "We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced <e1> heparan sulphate </e1> <e2> diabetic </e2> rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"769": {"data": {"text": "However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.", "entity1": "bromocriptine", "entity2": "adenoma", "span1": [95, 108], "span2": [126, 133]}, "bert_text": "However, only secretory granules showed the positive reaction products for prolactin 6 h after <e1> bromocriptine </e1> treatment of the <e2> adenoma </e2> cells.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"770": {"data": {"text": "High-dose testosterone is associated with atherosclerosis in postmenopausal women.\n", "entity1": "testosterone", "entity2": "atherosclerosis", "span1": [10, 22], "span2": [42, 57]}, "bert_text": "High-dose <e1> testosterone </e1> is associated with <e2> atherosclerosis </e2> in postmenopausal women.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"771": {"data": {"text": "Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.", "entity1": "streptomycin", "entity2": "Abnormal movements", "span1": [275, 287], "span2": [0, 18]}, "bert_text": "Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to <e1> streptomycin </e1> <e2> Abnormal movements </e2> and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"772": {"data": {"text": "Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.", "entity1": "streptomycin", "entity2": "dyskinesias", "span1": [275, 287], "span2": [346, 357]}, "bert_text": "Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to <e1> streptomycin </e1> than the site (vestibular or central) responsible for the <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"773": {"data": {"text": "Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.", "entity1": "streptomycin", "entity2": "deafness", "span1": [275, 287], "span2": [23, 31]}, "bert_text": "Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to <e1> streptomycin </e1> <e2> deafness </e2> occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"774": {"data": {"text": "BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.", "entity1": "Tamoxifen", "entity2": "breast cancer", "span1": [12, 21], "span2": [62, 75]}, "bert_text": "BACKGROUND: <e1> Tamoxifen </e1> is a candidate chemopreventive agent in <e2> breast cancer </e2>, although the drug may be associated with the development of endometrial cancer.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"775": {"data": {"text": "BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.", "entity1": "Tamoxifen", "entity2": "endometrial cancer", "span1": [12, 21], "span2": [137, 155]}, "bert_text": "BACKGROUND: <e1> Tamoxifen </e1> is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of <e2> endometrial cancer </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"776": {"data": {"text": "The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).", "entity1": "FK506", "entity2": "fibrosis", "span1": [4, 9], "span2": [73, 81]}, "bert_text": "The <e1> FK506 </e1> plus SRL combination showed only a marginally higher degree of <e2> fibrosis </e2> as compared with controls (P=0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"777": {"data": {"text": "The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).", "entity1": "SRL", "entity2": "fibrosis", "span1": [15, 18], "span2": [73, 81]}, "bert_text": "The FK506 plus <e1> SRL </e1> combination showed only a marginally higher degree of <e2> fibrosis </e2> as compared with controls (P=0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"778": {"data": {"text": "When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.", "entity1": "cyclophosphamide", "entity2": "tumors", "span1": [47, 63], "span2": [5, 11]}, "bert_text": "When tumors were treated with a single dose of <e1> cyclophosphamide </e1> <e2> tumors </e2> were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"779": {"data": {"text": "When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.", "entity1": "cyclophosphamide", "entity2": "tumors", "span1": [47, 63], "span2": [156, 162]}, "bert_text": "When tumors were treated with a single dose of <e1> cyclophosphamide </e1> (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the <e2> tumors </e2> was observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"780": {"data": {"text": "These observations suggest that statins may initiate an immune-mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy.", "entity1": "statins", "entity2": "myopathy", "span1": [32, 39], "span2": [72, 80]}, "bert_text": "These observations suggest that <e1> statins </e1> may initiate an immune-mediated <e2> myopathy </e2> that persists after withdrawal of the drug and responds to immunosuppressive therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"781": {"data": {"text": "This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.", "entity1": "PAC", "entity2": "peripheral neurotoxicity", "span1": [147, 150], "span2": [119, 143]}, "bert_text": "This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of <e1> PAC </e1> <e2> peripheral neurotoxicity </e2> of PAC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"782": {"data": {"text": "DISCUSSION: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism.", "entity1": "simvastatin", "entity2": "rhabdomyolysis", "span1": [102, 113], "span2": [24, 38]}, "bert_text": "DISCUSSION: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit <e1> simvastatin </e1> <e2> rhabdomyolysis </e2> is increased in the presence of concomitant drugs that inhibit simvastatin metabolism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"783": {"data": {"text": "Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/-", "entity1": "amiodarone", "entity2": "VT", "span1": [56, 66], "span2": [104, 106]}, "bert_text": "Sixty-nine percent of patients continued treatment with <e1> amiodarone </e1> and had no recurrence of symptomatic <e2> VT </e2> or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"784": {"data": {"text": "Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/-", "entity1": "amiodarone", "entity2": "ventricular fibrillation", "span1": [56, 66], "span2": [110, 134]}, "bert_text": "Sixty-nine percent of patients continued treatment with <e1> amiodarone </e1> and had no recurrence of symptomatic VT or <e2> ventricular fibrillation </e2> (VF) over a follow-up of 6 to 52 months (mean +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"785": {"data": {"text": "Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/-", "entity1": "amiodarone", "entity2": "VF", "span1": [56, 66], "span2": [136, 138]}, "bert_text": "Sixty-nine percent of patients continued treatment with <e1> amiodarone </e1> and had no recurrence of symptomatic VT or ventricular fibrillation (<e2> VF </e2>) over a follow-up of 6 to 52 months (mean +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"786": {"data": {"text": "We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.", "entity1": "venlafaxine", "entity2": "depression", "span1": [12, 23], "span2": [135, 145]}, "bert_text": "We report a <e1> venlafaxine </e1>-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for <e2> depression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"787": {"data": {"text": "We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.", "entity1": "serotonin", "entity2": "depression", "span1": [62, 71], "span2": [135, 145]}, "bert_text": "We report a venlafaxine-MAOI interaction that resulted in the <e1> serotonin </e1> syndrome in a 23-y-old male who was taking tranylcypromine for <e2> depression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"788": {"data": {"text": "We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.", "entity1": "tranylcypromine", "entity2": "depression", "span1": [115, 130], "span2": [135, 145]}, "bert_text": "We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking <e1> tranylcypromine </e1> for <e2> depression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"789": {"data": {"text": "We report a case of atracurium-related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids.", "entity1": "atracurium", "entity2": "paralysis", "span1": [20, 30], "span2": [39, 48]}, "bert_text": "We report a case of <e1> atracurium </e1>-related <e2> paralysis </e2> persisting for approximately 50 hours in a patient who was not treated with corticosteroids.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"790": {"data": {"text": "We report a case of atracurium-related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids.", "entity1": "corticosteroids", "entity2": "paralysis", "span1": [125, 140], "span2": [39, 48]}, "bert_text": "We report a case of atracurium-related paralysis persisting for approximately 50 hours in a patient who was not treated with <e1> corticosteroids </e1> <e2> paralysis </e2> persisting for approximately 50 hours in a patient who was not treated with corticosteroids.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"791": {"data": {"text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "entity1": "levobupivacaine", "entity2": "dysrhythmias", "span1": [24, 39], "span2": [54, 66]}, "bert_text": "The cumulative doses of <e1> levobupivacaine </e1> that produced <e2> dysrhythmias </e2> and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"792": {"data": {"text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "entity1": "levobupivacaine", "entity2": "asystole", "span1": [24, 39], "span2": [71, 79]}, "bert_text": "The cumulative doses of <e1> levobupivacaine </e1> that produced dysrhythmias and <e2> asystole </e2> were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"793": {"data": {"text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "entity1": "ropivacaine", "entity2": "dysrhythmias", "span1": [125, 136], "span2": [54, 66]}, "bert_text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of <e1> ropivacaine </e1> <e2> dysrhythmias </e2> and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"794": {"data": {"text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "entity1": "ropivacaine", "entity2": "asystole", "span1": [125, 136], "span2": [71, 79]}, "bert_text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of <e1> ropivacaine </e1> <e2> asystole </e2> were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"795": {"data": {"text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "entity1": "bupivacaine", "entity2": "dysrhythmias", "span1": [173, 184], "span2": [54, 66]}, "bert_text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of <e1> bupivacaine </e1> <e2> dysrhythmias </e2> and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"796": {"data": {"text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "entity1": "bupivacaine", "entity2": "asystole", "span1": [173, 184], "span2": [71, 79]}, "bert_text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of <e1> bupivacaine </e1> <e2> asystole </e2> were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"797": {"data": {"text": "Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.", "entity1": "paracetamol", "entity2": "Papillomas", "span1": [74, 85], "span2": [0, 10]}, "bert_text": "Papillomas of the transitional epithelium of the bladder developed in all <e1> paracetamol </e1> <e2> Papillomas </e2> of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"798": {"data": {"text": "Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.", "entity1": "paracetamol", "entity2": "bladder carcinomas", "span1": [74, 85], "span2": [122, 140]}, "bert_text": "Papillomas of the transitional epithelium of the bladder developed in all <e1> paracetamol </e1>-treated groups, and three rats bore <e2> bladder carcinomas </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"799": {"data": {"text": "Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.\n", "entity1": "verapamil", "entity2": "gastric hemorrhagic ulcers", "span1": [21, 30], "span2": [34, 60]}, "bert_text": "Protective effect of <e1> verapamil </e1> on <e2> gastric hemorrhagic ulcers </e2> in severe atherosclerotic rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"800": {"data": {"text": "Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.\n", "entity1": "verapamil", "entity2": "atherosclerotic", "span1": [21, 30], "span2": [71, 86]}, "bert_text": "Protective effect of <e1> verapamil </e1> on gastric hemorrhagic ulcers in severe <e2> atherosclerotic </e2> rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"801": {"data": {"text": "RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.", "entity1": "haloperidol", "entity2": "Impairment of cognitive function", "span1": [92, 103], "span2": [9, 41]}, "bert_text": "RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of <e1> haloperidol </e1> <e2> Impairment of cognitive function </e2> was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"802": {"data": {"text": "Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.\n", "entity1": "capsaicin", "entity2": "pain", "span1": [54, 63], "span2": [36, 40]}, "bert_text": "Attentional modulation of perceived pain intensity in <e1> capsaicin </e1> <e2> pain </e2> intensity in capsaicin-induced secondary hyperalgesia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"803": {"data": {"text": "Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.\n", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [54, 63], "span2": [82, 94]}, "bert_text": "Attentional modulation of perceived pain intensity in <e1> capsaicin </e1>-induced secondary <e2> hyperalgesia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"804": {"data": {"text": "The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/-", "entity1": "-cibenzoline", "entity2": "arrhythmias", "span1": [50, 62], "span2": [101, 112]}, "bert_text": "The minimum effective plasma concentrations of (+)<e1> -cibenzoline </e1> for digitalis- and adrenaline-induced <e2> arrhythmias </e2> were 1.4 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"805": {"data": {"text": "The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/-", "entity1": "adrenaline", "entity2": "arrhythmias", "span1": [82, 92], "span2": [101, 112]}, "bert_text": "The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and <e1> adrenaline </e1>-induced <e2> arrhythmias </e2> were 1.4 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"806": {"data": {"text": "The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.", "entity1": "capecitabine", "entity2": "diarrhea", "span1": [44, 56], "span2": [61, 69]}, "bert_text": "The most commonly reported toxic effects of <e1> capecitabine </e1> are <e2> diarrhea </e2>, nausea, vomiting, stomatitis and hand-foot syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"807": {"data": {"text": "The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.", "entity1": "capecitabine", "entity2": "nausea", "span1": [44, 56], "span2": [71, 77]}, "bert_text": "The most commonly reported toxic effects of <e1> capecitabine </e1> are diarrhea, <e2> nausea </e2>, vomiting, stomatitis and hand-foot syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"808": {"data": {"text": "The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.", "entity1": "capecitabine", "entity2": "vomiting", "span1": [44, 56], "span2": [79, 87]}, "bert_text": "The most commonly reported toxic effects of <e1> capecitabine </e1> are diarrhea, nausea, <e2> vomiting </e2>, stomatitis and hand-foot syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"809": {"data": {"text": "The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.", "entity1": "capecitabine", "entity2": "stomatitis", "span1": [44, 56], "span2": [89, 99]}, "bert_text": "The most commonly reported toxic effects of <e1> capecitabine </e1> are diarrhea, nausea, vomiting, <e2> stomatitis </e2> and hand-foot syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"810": {"data": {"text": "The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.", "entity1": "capecitabine", "entity2": "hand-foot syndrome", "span1": [44, 56], "span2": [104, 122]}, "bert_text": "The most commonly reported toxic effects of <e1> capecitabine </e1> are diarrhea, nausea, vomiting, stomatitis and <e2> hand-foot syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"811": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "methyldopa", "entity2": "hypertensive", "span1": [68, 78], "span2": [17, 29]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of <e1> methyldopa </e1> <e2> hypertensive </e2>, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"812": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "methyldopa", "entity2": "stroke", "span1": [68, 78], "span2": [31, 37]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of <e1> methyldopa </e1> <e2> stroke </e2>-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"813": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "methyldopa", "entity2": "hypotension", "span1": [68, 78], "span2": [171, 182]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of <e1> methyldopa </e1> into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent <e2> hypotension </e2> of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"814": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "serotonin", "entity2": "hypertensive", "span1": [111, 120], "span2": [17, 29]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 <e1> serotonin </e1> <e2> hypertensive </e2>, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"815": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "serotonin", "entity2": "stroke", "span1": [111, 120], "span2": [31, 37]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 <e1> serotonin </e1> <e2> stroke </e2>-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"816": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "serotonin", "entity2": "hypotension", "span1": [111, 120], "span2": [171, 182]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 <e1> serotonin </e1> cell group in the ventral medulla caused a potent <e2> hypotension </e2> of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"817": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "serotonin", "entity2": "hypertensive", "span1": [269, 278], "span2": [17, 29]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the <e1> serotonin </e1> <e2> hypertensive </e2>, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"818": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "serotonin", "entity2": "stroke", "span1": [269, 278], "span2": [31, 37]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the <e1> serotonin </e1> <e2> stroke </e2>-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"819": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "serotonin", "entity2": "hypotension", "span1": [269, 278], "span2": [171, 182]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the <e1> serotonin </e1> <e2> hypotension </e2> of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"820": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "5,7-dihydroxytryptamine", "entity2": "hypertensive", "span1": [290, 313], "span2": [17, 29]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin <e1> 5,7-dihydroxytryptamine </e1> <e2> hypertensive </e2>, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"821": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "5,7-dihydroxytryptamine", "entity2": "stroke", "span1": [290, 313], "span2": [31, 37]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin <e1> 5,7-dihydroxytryptamine </e1> <e2> stroke </e2>-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"822": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "5,7-dihydroxytryptamine", "entity2": "hypotension", "span1": [290, 313], "span2": [171, 182]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin <e1> 5,7-dihydroxytryptamine </e1> <e2> hypotension </e2> of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"823": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "5,7-DHT", "entity2": "hypertensive", "span1": [315, 322], "span2": [17, 29]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (<e1> 5,7-DHT </e1> <e2> hypertensive </e2>, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"824": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "5,7-DHT", "entity2": "stroke", "span1": [315, 322], "span2": [31, 37]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (<e1> 5,7-DHT </e1> <e2> stroke </e2>-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"825": {"data": {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity1": "5,7-DHT", "entity2": "hypotension", "span1": [315, 322], "span2": [171, 182]}, "bert_text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (<e1> 5,7-DHT </e1> <e2> hypotension </e2> of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"826": {"data": {"text": "OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.", "entity1": "fluconazole", "entity2": "torsade de pointes", "span1": [32, 43], "span2": [55, 73]}, "bert_text": "OBJECTIVE: To present a case of <e1> fluconazole </e1>-associated <e2> torsade de pointes </e2> (TDP) and discuss fluconazole's role in causing TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"827": {"data": {"text": "OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [32, 43], "span2": [75, 78]}, "bert_text": "OBJECTIVE: To present a case of <e1> fluconazole </e1>-associated torsade de pointes (<e2> TDP </e2>) and discuss fluconazole's role in causing TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"828": {"data": {"text": "OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [32, 43], "span2": [122, 125]}, "bert_text": "OBJECTIVE: To present a case of <e1> fluconazole </e1>-associated torsade de pointes (TDP) and discuss fluconazole's role in causing <e2> TDP </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"829": {"data": {"text": "OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.", "entity1": "fluconazole's", "entity2": "torsade de pointes", "span1": [92, 105], "span2": [55, 73]}, "bert_text": "OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss <e1> fluconazole's </e1> <e2> torsade de pointes </e2> (TDP) and discuss fluconazole's role in causing TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"830": {"data": {"text": "OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.", "entity1": "fluconazole's", "entity2": "TDP", "span1": [92, 105], "span2": [75, 78]}, "bert_text": "OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss <e1> fluconazole's </e1> <e2> TDP </e2>) and discuss fluconazole's role in causing TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"831": {"data": {"text": "OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.", "entity1": "fluconazole's", "entity2": "TDP", "span1": [92, 105], "span2": [122, 125]}, "bert_text": "OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss <e1> fluconazole's </e1> role in causing <e2> TDP </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"832": {"data": {"text": "Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.", "entity1": "MTX", "entity2": "nephrotoxicity", "span1": [44, 47], "span2": [26, 40]}, "bert_text": "Our studies indicate that nephrotoxicity of <e1> MTX </e1> <e2> nephrotoxicity </e2> of MTX + 5-FU + CY administered jointly is lower than in monotherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"833": {"data": {"text": "Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.", "entity1": "5-FU", "entity2": "nephrotoxicity", "span1": [50, 54], "span2": [26, 40]}, "bert_text": "Our studies indicate that nephrotoxicity of MTX + <e1> 5-FU </e1> <e2> nephrotoxicity </e2> of MTX + 5-FU + CY administered jointly is lower than in monotherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"834": {"data": {"text": "Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.", "entity1": "CY", "entity2": "nephrotoxicity", "span1": [57, 59], "span2": [26, 40]}, "bert_text": "Our studies indicate that nephrotoxicity of MTX + 5-FU + <e1> CY </e1> <e2> nephrotoxicity </e2> of MTX + 5-FU + CY administered jointly is lower than in monotherapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"835": {"data": {"text": "The pH adjustment of standard lidocaine can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the pain occurring during the infiltration of tissues.", "entity1": "lidocaine", "entity2": "pain", "span1": [30, 39], "span2": [152, 156]}, "bert_text": "The pH adjustment of standard <e1> lidocaine </e1> can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the <e2> pain </e2> occurring during the infiltration of tissues.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"836": {"data": {"text": "Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.\n", "entity1": "Serotonin", "entity2": "psychosis", "span1": [0, 9], "span2": [69, 78]}, "bert_text": "<e1> Serotonin </e1> 6 receptor gene is associated with methamphetamine-induced <e2> psychosis </e2> in a Japanese population.\n", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"837": {"data": {"text": "Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.\n", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [45, 60], "span2": [69, 78]}, "bert_text": "Serotonin 6 receptor gene is associated with <e1> methamphetamine </e1>-induced <e2> psychosis </e2> in a Japanese population.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"838": {"data": {"text": "In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.", "entity1": "lithium", "entity2": "diabetes-insipidus-like syndrome", "span1": [47, 54], "span2": [63, 95]}, "bert_text": "In all the experiments, the attenuation of the <e1> lithium </e1>-induced <e2> diabetes-insipidus-like syndrome </e2> by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"839": {"data": {"text": "In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.", "entity1": "lithium", "entity2": "diabetes-insipidus-like syndrome", "span1": [165, 172], "span2": [63, 95]}, "bert_text": "In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the <e1> lithium </e1> <e2> diabetes-insipidus-like syndrome </e2> by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"840": {"data": {"text": "In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.", "entity1": "amiloride", "entity2": "diabetes-insipidus-like syndrome", "span1": [99, 108], "span2": [63, 95]}, "bert_text": "In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by <e1> amiloride </e1> <e2> diabetes-insipidus-like syndrome </e2> by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"841": {"data": {"text": "In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.", "entity1": "potassium", "entity2": "diabetes-insipidus-like syndrome", "span1": [267, 276], "span2": [63, 95]}, "bert_text": "In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma <e1> potassium </e1> <e2> diabetes-insipidus-like syndrome </e2> by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"842": {"data": {"text": "Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.", "entity1": "folinic acid", "entity2": "neurotoxicity", "span1": [8, 20], "span2": [72, 85]}, "bert_text": "Because <e1> folinic acid </e1> was unlikely to be associated with this condition, <e2> neurotoxicity </e2> due to high-dose 5-fluorouracil was highly suspected.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"843": {"data": {"text": "Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.", "entity1": "5-fluorouracil", "entity2": "neurotoxicity", "span1": [103, 117], "span2": [72, 85]}, "bert_text": "Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose <e1> 5-fluorouracil </e1> <e2> neurotoxicity </e2> due to high-dose 5-fluorouracil was highly suspected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"844": {"data": {"text": "In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.", "entity1": "FK506", "entity2": "MAHA", "span1": [34, 39], "span2": [173, 177]}, "bert_text": "In both cases, discontinuation of <e1> FK506 </e1> and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of <e2> MAHA </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"845": {"data": {"text": "In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.", "entity1": "corticosteroids", "entity2": "MAHA", "span1": [109, 124], "span2": [173, 177]}, "bert_text": "In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, <e1> corticosteroids </e1>, aspirin, and dipyridamole led to resolution of <e2> MAHA </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"846": {"data": {"text": "In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.", "entity1": "aspirin", "entity2": "MAHA", "span1": [126, 133], "span2": [173, 177]}, "bert_text": "In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, <e1> aspirin </e1>, and dipyridamole led to resolution of <e2> MAHA </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"847": {"data": {"text": "In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.", "entity1": "dipyridamole", "entity2": "MAHA", "span1": [139, 151], "span2": [173, 177]}, "bert_text": "In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and <e1> dipyridamole </e1> led to resolution of <e2> MAHA </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"848": {"data": {"text": "We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.", "entity1": "estrogen", "entity2": "hypotensive", "span1": [28, 36], "span2": [62, 73]}, "bert_text": "We have recently shown that <e1> estrogen </e1> negatively modulates the <e2> hypotensive </e2> effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"849": {"data": {"text": "We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.", "entity1": "clonidine", "entity2": "hypotensive", "span1": [84, 93], "span2": [62, 73]}, "bert_text": "We have recently shown that estrogen negatively modulates the hypotensive effect of <e1> clonidine </e1> <e2> hypotensive </e2> effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"850": {"data": {"text": "In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.", "entity1": "mesna", "entity2": "emesis", "span1": [120, 125], "span2": [223, 229]}, "bert_text": "In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary <e1> mesna </e1> concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced <e2> emesis </e2> and is unable to absorb the drug.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"851": {"data": {"text": "In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.", "entity1": "mesna", "entity2": "emesis", "span1": [175, 180], "span2": [223, 229]}, "bert_text": "In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral <e1> mesna </e1> who experiences severe ifosfamide-induced <e2> emesis </e2> and is unable to absorb the drug.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"852": {"data": {"text": "In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.", "entity1": "ifosfamide", "entity2": "emesis", "span1": [204, 214], "span2": [223, 229]}, "bert_text": "In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe <e1> ifosfamide </e1>-induced <e2> emesis </e2> and is unable to absorb the drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"853": {"data": {"text": "Reversal of ammonia coma in rats by L-dopa: a peripheral effect.\n", "entity1": "ammonia", "entity2": "coma", "span1": [12, 19], "span2": [20, 24]}, "bert_text": "Reversal of <e1> ammonia </e1> <e2> coma </e2> in rats by L-dopa: a peripheral effect.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"854": {"data": {"text": "Reversal of ammonia coma in rats by L-dopa: a peripheral effect.\n", "entity1": "L-dopa", "entity2": "coma", "span1": [36, 42], "span2": [20, 24]}, "bert_text": "Reversal of ammonia coma in rats by <e1> L-dopa </e1> <e2> coma </e2> in rats by L-dopa: a peripheral effect.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"855": {"data": {"text": "The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.", "entity1": "ketamine", "entity2": "hyperalgesia", "span1": [28, 36], "span2": [73, 85]}, "bert_text": "The differential effects of <e1> ketamine </e1> and lidocaine on static and dynamic <e2> hyperalgesia </e2> suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"856": {"data": {"text": "The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.", "entity1": "ketamine", "entity2": "hyperalgesia", "span1": [28, 36], "span2": [116, 128]}, "bert_text": "The differential effects of <e1> ketamine </e1> and lidocaine on static and dynamic hyperalgesia suggest that the two types of <e2> hyperalgesia </e2> are mediated by separate mechanisms and have a distinct pharmacology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"857": {"data": {"text": "The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.", "entity1": "lidocaine", "entity2": "hyperalgesia", "span1": [41, 50], "span2": [73, 85]}, "bert_text": "The differential effects of ketamine and <e1> lidocaine </e1> on static and dynamic <e2> hyperalgesia </e2> suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"858": {"data": {"text": "The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.", "entity1": "lidocaine", "entity2": "hyperalgesia", "span1": [41, 50], "span2": [116, 128]}, "bert_text": "The differential effects of ketamine and <e1> lidocaine </e1> on static and dynamic hyperalgesia suggest that the two types of <e2> hyperalgesia </e2> are mediated by separate mechanisms and have a distinct pharmacology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"859": {"data": {"text": "Fluconazole-induced torsade de pointes.\n", "entity1": "Fluconazole", "entity2": "torsade de pointes", "span1": [0, 11], "span2": [20, 38]}, "bert_text": "<e1> Fluconazole </e1>-induced <e2> torsade de pointes </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"860": {"data": {"text": "Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.", "entity1": "diethylstilbestrol", "entity2": "Angiosarcoma", "span1": [136, 154], "span2": [0, 12]}, "bert_text": "Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with <e1> diethylstilbestrol </e1> <e2> Angiosarcoma </e2> of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"861": {"data": {"text": "Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.", "entity1": "diethylstilbestrol", "entity2": "adenocarcinoma", "span1": [136, 154], "span2": [103, 117]}, "bert_text": "Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with <e1> diethylstilbestrol </e1> <e2> adenocarcinoma </e2> of the liver with diethylstilbestrol for 13 years.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"862": {"data": {"text": "Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.\n", "entity1": "BCNU", "entity2": "malignant gliomas", "span1": [15, 19], "span2": [50, 67]}, "bert_text": "Intra-arterial <e1> BCNU </e1> chemotherapy for treatment of <e2> malignant gliomas </e2> of the central nervous system.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"863": {"data": {"text": "Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.", "entity1": "AX", "entity2": "allergic reaction", "span1": [21, 23], "span2": [100, 117]}, "bert_text": "Challenge tests with <e1> AX </e1> were performed in 23 subjects (43%) to establish the diagnosis of immediate <e2> allergic reaction </e2> to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"864": {"data": {"text": "Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.", "entity1": "AX", "entity2": "allergic reaction", "span1": [121, 123], "span2": [100, 117]}, "bert_text": "Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to <e1> AX </e1> <e2> allergic reaction </e2> to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"865": {"data": {"text": "Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.", "entity1": "AX", "entity2": "allergic reaction", "span1": [175, 177], "span2": [100, 117]}, "bert_text": "Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for <e1> AX </e1> <e2> allergic reaction </e2> to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"866": {"data": {"text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "entity1": "5-fluorouracil", "entity2": "allergic reaction", "span1": [88, 102], "span2": [3, 20]}, "bert_text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion <e1> 5-fluorouracil </e1> <e2> allergic reaction </e2> consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"867": {"data": {"text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "entity1": "5-fluorouracil", "entity2": "angioneurotic edema", "span1": [88, 102], "span2": [35, 54]}, "bert_text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion <e1> 5-fluorouracil </e1> <e2> angioneurotic edema </e2> secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"868": {"data": {"text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "entity1": "5-fluorouracil", "entity2": "carcinoma", "span1": [88, 102], "span2": [140, 149]}, "bert_text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion <e1> 5-fluorouracil </e1> occurred in a patient with recurrent <e2> carcinoma </e2> of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"869": {"data": {"text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "entity1": "5-fluorouracil", "entity2": "cirrhosis", "span1": [88, 102], "span2": [170, 179]}, "bert_text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion <e1> 5-fluorouracil </e1> occurred in a patient with recurrent carcinoma of the oral cavity, <e2> cirrhosis </e2>, and cisplatin-induced impaired renal function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"870": {"data": {"text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "entity1": "5-fluorouracil", "entity2": "impaired renal function", "span1": [88, 102], "span2": [203, 226]}, "bert_text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion <e1> 5-fluorouracil </e1> occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced <e2> impaired renal function </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"871": {"data": {"text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "entity1": "cisplatin", "entity2": "allergic reaction", "span1": [185, 194], "span2": [3, 20]}, "bert_text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and <e1> cisplatin </e1> <e2> allergic reaction </e2> consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"872": {"data": {"text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "entity1": "cisplatin", "entity2": "angioneurotic edema", "span1": [185, 194], "span2": [35, 54]}, "bert_text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and <e1> cisplatin </e1> <e2> angioneurotic edema </e2> secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"873": {"data": {"text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "entity1": "cisplatin", "entity2": "carcinoma", "span1": [185, 194], "span2": [140, 149]}, "bert_text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and <e1> cisplatin </e1> <e2> carcinoma </e2> of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"874": {"data": {"text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "entity1": "cisplatin", "entity2": "cirrhosis", "span1": [185, 194], "span2": [170, 179]}, "bert_text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and <e1> cisplatin </e1> <e2> cirrhosis </e2>, and cisplatin-induced impaired renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"875": {"data": {"text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "entity1": "cisplatin", "entity2": "impaired renal function", "span1": [185, 194], "span2": [203, 226]}, "bert_text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and <e1> cisplatin </e1>-induced <e2> impaired renal function </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"876": {"data": {"text": "However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.", "entity1": "epinephrine", "entity2": "myocardial ischemia", "span1": [58, 69], "span2": [27, 46]}, "bert_text": "However, the mechanisms of myocardial ischemia induced by <e1> epinephrine </e1> <e2> myocardial ischemia </e2> induced by epinephrine were significantly different from those of exercise.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"877": {"data": {"text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "entity1": "spironolactone", "entity2": "hypokalemia", "span1": [35, 49], "span2": [96, 107]}, "bert_text": "CONCLUSION: This study showed that <e1> spironolactone </e1> can reduce potassium requirements and prevent <e2> hypokalemia </e2> by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"878": {"data": {"text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "entity1": "spironolactone", "entity2": "neutropenic", "span1": [35, 49], "span2": [146, 157]}, "bert_text": "CONCLUSION: This study showed that <e1> spironolactone </e1> can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in <e2> neutropenic </e2> patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"879": {"data": {"text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "hypokalemia", "span1": [61, 70], "span2": [96, 107]}, "bert_text": "CONCLUSION: This study showed that spironolactone can reduce <e1> potassium </e1> requirements and prevent <e2> hypokalemia </e2> by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"880": {"data": {"text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "neutropenic", "span1": [61, 70], "span2": [146, 157]}, "bert_text": "CONCLUSION: This study showed that spironolactone can reduce <e1> potassium </e1> requirements and prevent hypokalemia by reducing urinary potassium loss in <e2> neutropenic </e2> patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"881": {"data": {"text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "hypokalemia", "span1": [128, 137], "span2": [96, 107]}, "bert_text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary <e1> potassium </e1> <e2> hypokalemia </e2> by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"882": {"data": {"text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "neutropenic", "span1": [128, 137], "span2": [146, 157]}, "bert_text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary <e1> potassium </e1> loss in <e2> neutropenic </e2> patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"883": {"data": {"text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "entity1": "AmB", "entity2": "hypokalemia", "span1": [170, 173], "span2": [96, 107]}, "bert_text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on <e1> AmB </e1> <e2> hypokalemia </e2> by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"884": {"data": {"text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "entity1": "AmB", "entity2": "neutropenic", "span1": [170, 173], "span2": [146, 157]}, "bert_text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on <e1> AmB </e1> <e2> neutropenic </e2> patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"885": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "pegylated interferon", "entity2": "ocular myasthenia", "span1": [40, 60], "span2": [15, 32]}, "bert_text": "Development of ocular myasthenia during <e1> pegylated interferon </e1> <e2> ocular myasthenia </e2> during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"886": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "pegylated interferon", "entity2": "chronic hepatitis C.", "span1": [40, 60], "span2": [89, 109]}, "bert_text": "Development of ocular myasthenia during <e1> pegylated interferon </e1> and ribavirin treatment for <e2> chronic hepatitis C. </e2>\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"887": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "pegylated interferon", "entity2": "chronic hepatitis C", "span1": [40, 60], "span2": [246, 265]}, "bert_text": "Development of ocular myasthenia during <e1> pegylated interferon </e1> and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for <e2> chronic hepatitis C </e2> (CHC).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"888": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "pegylated interferon", "entity2": "CHC", "span1": [40, 60], "span2": [267, 270]}, "bert_text": "Development of ocular myasthenia during <e1> pegylated interferon </e1> and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (<e2> CHC </e2>).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"889": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "pegylated interferon", "entity2": "diplopia", "span1": [40, 60], "span2": [148, 156]}, "bert_text": "Development of ocular myasthenia during <e1> pegylated interferon </e1> and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden <e2> diplopia </e2> after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"890": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "pegylated interferon (IFN) alpha-2b", "entity2": "ocular myasthenia", "span1": [192, 227], "span2": [15, 32]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of <e1> pegylated interferon (IFN) alpha-2b </e1> <e2> ocular myasthenia </e2> during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"891": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "pegylated interferon (IFN) alpha-2b", "entity2": "chronic hepatitis C.", "span1": [192, 227], "span2": [89, 109]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of <e1> pegylated interferon (IFN) alpha-2b </e1> <e2> chronic hepatitis C. </e2>\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"892": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "pegylated interferon (IFN) alpha-2b", "entity2": "chronic hepatitis C", "span1": [192, 227], "span2": [246, 265]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of <e1> pegylated interferon (IFN) alpha-2b </e1> and ribavirin for <e2> chronic hepatitis C </e2> (CHC).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"893": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "pegylated interferon (IFN) alpha-2b", "entity2": "CHC", "span1": [192, 227], "span2": [267, 270]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of <e1> pegylated interferon (IFN) alpha-2b </e1> and ribavirin for chronic hepatitis C (<e2> CHC </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"894": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "pegylated interferon (IFN) alpha-2b", "entity2": "diplopia", "span1": [192, 227], "span2": [148, 156]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of <e1> pegylated interferon (IFN) alpha-2b </e1> <e2> diplopia </e2> after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"895": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "ocular myasthenia", "span1": [65, 74], "span2": [15, 32]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and <e1> ribavirin </e1> <e2> ocular myasthenia </e2> during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"896": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "chronic hepatitis C.", "span1": [65, 74], "span2": [89, 109]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and <e1> ribavirin </e1> treatment for <e2> chronic hepatitis C. </e2>\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"897": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "chronic hepatitis C", "span1": [65, 74], "span2": [246, 265]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and <e1> ribavirin </e1> treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for <e2> chronic hepatitis C </e2> (CHC).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"898": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "CHC", "span1": [65, 74], "span2": [267, 270]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and <e1> ribavirin </e1> treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (<e2> CHC </e2>).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"899": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "diplopia", "span1": [65, 74], "span2": [148, 156]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and <e1> ribavirin </e1> treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden <e2> diplopia </e2> after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"900": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "ocular myasthenia", "span1": [232, 241], "span2": [15, 32]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and <e1> ribavirin </e1> <e2> ocular myasthenia </e2> during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"901": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "chronic hepatitis C.", "span1": [232, 241], "span2": [89, 109]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and <e1> ribavirin </e1> <e2> chronic hepatitis C. </e2>\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"902": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "chronic hepatitis C", "span1": [232, 241], "span2": [246, 265]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and <e1> ribavirin </e1> for <e2> chronic hepatitis C </e2> (CHC).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"903": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "CHC", "span1": [232, 241], "span2": [267, 270]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and <e1> ribavirin </e1> for chronic hepatitis C (<e2> CHC </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"904": {"data": {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "diplopia", "span1": [232, 241], "span2": [148, 156]}, "bert_text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\nA 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and <e1> ribavirin </e1> <e2> diplopia </e2> after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"905": {"data": {"text": "Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?\n", "entity1": "Prostaglandin E2-induced", "entity2": "bladder hyperactivity", "span1": [0, 24], "span2": [25, 46]}, "bert_text": "<e1> Prostaglandin E2-induced </e1> <e2> bladder hyperactivity </e2> in normal, conscious rats: involvement of tachykinins?\n", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"906": {"data": {"text": "Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?\n", "entity1": "tachykinins", "entity2": "bladder hyperactivity", "span1": [89, 100], "span2": [25, 46]}, "bert_text": "Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of <e1> tachykinins </e1> <e2> bladder hyperactivity </e2> in normal, conscious rats: involvement of tachykinins?\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"907": {"data": {"text": "DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.", "entity1": "DOX", "entity2": "cardiac dysfunction", "span1": [0, 3], "span2": [24, 43]}, "bert_text": "<e1> DOX </e1> control mice showed <e2> cardiac dysfunction </e2> measured by pressure-volume loops in vivo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"908": {"data": {"text": "Prenatal dexamethasone programs hypertension and renal injury in the rat.\n", "entity1": "dexamethasone", "entity2": "hypertension", "span1": [9, 22], "span2": [32, 44]}, "bert_text": "Prenatal <e1> dexamethasone </e1> programs <e2> hypertension </e2> and renal injury in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"909": {"data": {"text": "Prenatal dexamethasone programs hypertension and renal injury in the rat.\n", "entity1": "dexamethasone", "entity2": "renal injury", "span1": [9, 22], "span2": [49, 61]}, "bert_text": "Prenatal <e1> dexamethasone </e1> programs hypertension and <e2> renal injury </e2> in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"910": {"data": {"text": "Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.", "entity1": "PDTC", "entity2": "status epilepticus", "span1": [27, 31], "span2": [95, 113]}, "bert_text": "Administration of 50 mg/kg <e1> PDTC </e1> (low-dose) did not exert major effects on the development of a <e2> status epilepticus </e2> or the mortality rate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"911": {"data": {"text": "Previous anecdotal reports have linked creatine to the development of arrhythmia.", "entity1": "creatine", "entity2": "arrhythmia", "span1": [39, 47], "span2": [70, 80]}, "bert_text": "Previous anecdotal reports have linked <e1> creatine </e1> to the development of <e2> arrhythmia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"912": {"data": {"text": "The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.", "entity1": "salvianolic acid A", "entity2": "myocardial infarction", "span1": [77, 95], "span2": [121, 142]}, "bert_text": "The present study was designed to evaluate the cardioprotective potential of <e1> salvianolic acid A </e1> on isoproterenol-induced <e2> myocardial infarction </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"913": {"data": {"text": "The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [99, 112], "span2": [121, 142]}, "bert_text": "The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on <e1> isoproterenol </e1>-induced <e2> myocardial infarction </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"914": {"data": {"text": "Immunopathology of penicillamine-induced glomerular disease.\n", "entity1": "penicillamine", "entity2": "glomerular disease", "span1": [19, 32], "span2": [41, 59]}, "bert_text": "Immunopathology of <e1> penicillamine </e1>-induced <e2> glomerular disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"915": {"data": {"text": "We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.", "entity1": "danazol", "entity2": "bile duct hamartoma", "span1": [95, 102], "span2": [20, 39]}, "bert_text": "We report a case of bile duct hamartoma which developed in a patient who had been on long-term <e1> danazol </e1> <e2> bile duct hamartoma </e2> which developed in a patient who had been on long-term danazol treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"916": {"data": {"text": "Three hundred fifty-five adult male CSS mice, 58 B6, and 39 A/J were tested for susceptibility to pilocarpine-induced seizures.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [98, 109], "span2": [118, 126]}, "bert_text": "Three hundred fifty-five adult male CSS mice, 58 B6, and 39 A/J were tested for susceptibility to <e1> pilocarpine </e1>-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"917": {"data": {"text": "CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.", "entity1": "Dexamethasone", "entity2": "ocular hypertension", "span1": [12, 25], "span2": [104, 123]}, "bert_text": "CONCLUSION: <e1> Dexamethasone </e1> treatment of isolated, perfusion-cultured human eyes led to the generation of <e2> ocular hypertension </e2> in approximately 30% of the dexamethasone-treated eyes.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"918": {"data": {"text": "CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.", "entity1": "dexamethasone", "entity2": "ocular hypertension", "span1": [152, 165], "span2": [104, 123]}, "bert_text": "CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the <e1> dexamethasone </e1> <e2> ocular hypertension </e2> in approximately 30% of the dexamethasone-treated eyes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"919": {"data": {"text": "These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.", "entity1": "cocaine", "entity2": "anxiety", "span1": [98, 105], "span2": [114, 121]}, "bert_text": "These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for <e1> cocaine </e1>-induced <e2> anxiety </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"920": {"data": {"text": "We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.", "entity1": "verapamil", "entity2": "myocardial infarction", "span1": [115, 124], "span2": [26, 47]}, "bert_text": "We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of <e1> verapamil </e1> <e2> myocardial infarction </e2> coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"921": {"data": {"text": "We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.", "entity1": "verapamil", "entity2": "hypertension", "span1": [115, 124], "span2": [172, 184]}, "bert_text": "We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of <e1> verapamil </e1> in a previously asymptomatic woman with severe <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"922": {"data": {"text": "CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.", "entity1": "valproic acid", "entity2": "confusion", "span1": [48, 61], "span2": [33, 42]}, "bert_text": "CONCLUSION: This work shows that confusion with <e1> valproic acid </e1> <e2> confusion </e2> with valproic acid is a serious, rather frequent but reversible adverse drug reaction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"923": {"data": {"text": "Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.\n", "entity1": "adriamycin", "entity2": "functional impairment of mitochondria", "span1": [56, 66], "span2": [15, 52]}, "bert_text": "Structural and functional impairment of mitochondria in <e1> adriamycin </e1> <e2> functional impairment of mitochondria </e2> in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"924": {"data": {"text": "Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.\n", "entity1": "adriamycin", "entity2": "cardiomyopathy", "span1": [56, 66], "span2": [75, 89]}, "bert_text": "Structural and functional impairment of mitochondria in <e1> adriamycin </e1>-induced <e2> cardiomyopathy </e2> in mice: suppression of cytochrome c oxidase II gene expression.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"925": {"data": {"text": "For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.", "entity1": "haloperidol", "entity2": "psychosis", "span1": [57, 68], "span2": [188, 197]}, "bert_text": "For the 60 patients who completed phase A, standard-dose <e1> haloperidol </e1> was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale <e2> psychosis </e2> factor and on psychomotor agitation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"926": {"data": {"text": "For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.", "entity1": "haloperidol", "entity2": "psychomotor agitation", "span1": [57, 68], "span2": [212, 233]}, "bert_text": "For the 60 patients who completed phase A, standard-dose <e1> haloperidol </e1> was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on <e2> psychomotor agitation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"927": {"data": {"text": "For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.", "entity1": "haloperidol", "entity2": "psychosis", "span1": [115, 126], "span2": [188, 197]}, "bert_text": "For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose <e1> haloperidol </e1> and placebo for scores on the Brief Psychiatric Rating Scale <e2> psychosis </e2> factor and on psychomotor agitation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"928": {"data": {"text": "For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.", "entity1": "haloperidol", "entity2": "psychomotor agitation", "span1": [115, 126], "span2": [212, 233]}, "bert_text": "For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose <e1> haloperidol </e1> and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on <e2> psychomotor agitation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"929": {"data": {"text": "Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.\n", "entity1": "docetaxel", "entity2": "venous thromboembolism", "span1": [70, 79], "span2": [23, 45]}, "bert_text": "Increased frequency of venous thromboembolism with the combination of <e1> docetaxel </e1> <e2> venous thromboembolism </e2> with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"930": {"data": {"text": "Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.\n", "entity1": "docetaxel", "entity2": "prostate cancer", "span1": [70, 79], "span2": [145, 160]}, "bert_text": "Increased frequency of venous thromboembolism with the combination of <e1> docetaxel </e1> and thalidomide in patients with metastatic androgen-independent <e2> prostate cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"931": {"data": {"text": "Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.\n", "entity1": "thalidomide", "entity2": "venous thromboembolism", "span1": [84, 95], "span2": [23, 45]}, "bert_text": "Increased frequency of venous thromboembolism with the combination of docetaxel and <e1> thalidomide </e1> <e2> venous thromboembolism </e2> with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"932": {"data": {"text": "Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.\n", "entity1": "thalidomide", "entity2": "prostate cancer", "span1": [84, 95], "span2": [145, 160]}, "bert_text": "Increased frequency of venous thromboembolism with the combination of docetaxel and <e1> thalidomide </e1> in patients with metastatic androgen-independent <e2> prostate cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"933": {"data": {"text": "Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.", "entity1": "nicotine", "entity2": "hyperactivity", "span1": [47, 55], "span2": [64, 77]}, "bert_text": "Pretreatment with the D2 agonist PHNO enhanced <e1> nicotine </e1>-induced <e2> hyperactivity </e2>, whereas the D1 agonist SKF 38393 had no effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"934": {"data": {"text": "Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.", "entity1": "SKF 38393", "entity2": "hyperactivity", "span1": [102, 111], "span2": [64, 77]}, "bert_text": "Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist <e1> SKF 38393 </e1> <e2> hyperactivity </e2>, whereas the D1 agonist SKF 38393 had no effect.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"935": {"data": {"text": "Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.\nSTUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.", "entity1": "prochlorperazine", "entity2": "akathisia", "span1": [30, 46], "span2": [124, 133]}, "bert_text": "Intravenous administration of <e1> prochlorperazine </e1> by 15-minute infusion versus 2-minute bolus does not affect the incidence of <e2> akathisia </e2>: a prospective, randomized, controlled trial.\nSTUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"936": {"data": {"text": "Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.\nSTUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.", "entity1": "prochlorperazine", "entity2": "akathisia", "span1": [30, 46], "span2": [230, 239]}, "bert_text": "Intravenous administration of <e1> prochlorperazine </e1> by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.\nSTUDY OBJECTIVE: We sought to compare the rate of <e2> akathisia </e2> after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"937": {"data": {"text": "Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.\nSTUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.", "entity1": "prochlorperazine", "entity2": "akathisia", "span1": [276, 292], "span2": [124, 133]}, "bert_text": "Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.\nSTUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous <e1> prochlorperazine </e1> <e2> akathisia </e2>: a prospective, randomized, controlled trial.\nSTUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"938": {"data": {"text": "Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.\nSTUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.", "entity1": "prochlorperazine", "entity2": "akathisia", "span1": [276, 292], "span2": [230, 239]}, "bert_text": "Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.\nSTUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous <e1> prochlorperazine </e1> <e2> akathisia </e2> after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"939": {"data": {"text": "Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.", "entity1": "PDTC", "entity2": "status epilepticus", "span1": [25, 29], "span2": [51, 69]}, "bert_text": "Treatment with 150 mg/kg <e1> PDTC </e1> before and following <e2> status epilepticus </e2> significantly increased the mortality rate to 100%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"940": {"data": {"text": "Recurrent dysosmia induced by pyrazinamide.\n", "entity1": "pyrazinamide", "entity2": "dysosmia", "span1": [30, 42], "span2": [10, 18]}, "bert_text": "Recurrent dysosmia induced by <e1> pyrazinamide </e1> <e2> dysosmia </e2> induced by pyrazinamide.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"941": {"data": {"text": "In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.", "entity1": "pentazocine", "entity2": "fibrous myopathy", "span1": [39, 50], "span2": [59, 75]}, "bert_text": "In a 37-year-old woman with documented <e1> pentazocine </e1>-induced <e2> fibrous myopathy </e2> of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"942": {"data": {"text": "In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.", "entity1": "pentazocine", "entity2": "fibrous myopathy", "span1": [39, 50], "span2": [314, 330]}, "bert_text": "In a 37-year-old woman with documented <e1> pentazocine </e1>-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the <e2> fibrous myopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"943": {"data": {"text": "Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.", "entity1": "amikacin", "entity2": "nephrotoxicity", "span1": [35, 43], "span2": [86, 100]}, "bert_text": "Data from 60 patients treated with <e1> amikacin </e1> were analyzed for factors associated with <e2> nephrotoxicity </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"944": {"data": {"text": "We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.", "entity1": "amiodarone", "entity2": "atrial fibrillation", "span1": [179, 189], "span2": [61, 80]}, "bert_text": "We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous <e1> amiodarone </e1> <e2> atrial fibrillation </e2>, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"945": {"data": {"text": "We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.", "entity1": "amiodarone", "entity2": "low back pain", "span1": [179, 189], "span2": [119, 132]}, "bert_text": "We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous <e1> amiodarone </e1> <e2> low back pain </e2> a few minutes after initiation of intravenous amiodarone loading.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"946": {"data": {"text": "In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/-", "entity1": "P", "entity2": "ARF", "span1": [13, 14], "span2": [42, 45]}, "bert_text": "In Group II, <e1> P </e1> did not prevent gentamicin-<e2> ARF </e2> (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/-", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"947": {"data": {"text": "In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/-", "entity1": "P", "entity2": "ARF", "span1": [85, 86], "span2": [42, 45]}, "bert_text": "In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, <e1> P </e1> <e2> ARF </e2> (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1], "label": 0},
+	"948": {"data": {"text": "In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/-", "entity1": "gentamicin", "entity2": "ARF", "span1": [31, 41], "span2": [42, 45]}, "bert_text": "In Group II, P did not prevent <e1> gentamicin </e1>-<e2> ARF </e2> (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"949": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "Lamivudine", "entity2": "hepatitis B", "span1": [0, 10], "span2": [33, 44]}, "bert_text": "<e1> Lamivudine </e1> for the prevention of <e2> hepatitis B </e2> virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"950": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "Lamivudine", "entity2": "Hepatitis B", "span1": [0, 10], "span2": [167, 178]}, "bert_text": "<e1> Lamivudine </e1> for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\n<e2> Hepatitis B </e2> virus (HBV) is one of the major causes of chronic liver disease worldwide.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"951": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "Lamivudine", "entity2": "cancer", "span1": [0, 10], "span2": [116, 122]}, "bert_text": "<e1> Lamivudine </e1> for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive <e2> cancer </e2> patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"952": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "Lamivudine", "entity2": "liver disease", "span1": [0, 10], "span2": [229, 242]}, "bert_text": "<e1> Lamivudine </e1> for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic <e2> liver disease </e2> worldwide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"953": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "hepatitis-B surface antigen", "entity2": "hepatitis B", "span1": [67, 94], "span2": [33, 44]}, "bert_text": "Lamivudine for the prevention of hepatitis B virus reactivation in <e1> hepatitis-B surface antigen </e1> <e2> hepatitis B </e2> virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"954": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "hepatitis-B surface antigen", "entity2": "Hepatitis B", "span1": [67, 94], "span2": [167, 178]}, "bert_text": "Lamivudine for the prevention of hepatitis B virus reactivation in <e1> hepatitis-B surface antigen </e1> (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\n<e2> Hepatitis B </e2> virus (HBV) is one of the major causes of chronic liver disease worldwide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"955": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "hepatitis-B surface antigen", "entity2": "cancer", "span1": [67, 94], "span2": [116, 122]}, "bert_text": "Lamivudine for the prevention of hepatitis B virus reactivation in <e1> hepatitis-B surface antigen </e1> (HBSAG) seropositive <e2> cancer </e2> patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"956": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "hepatitis-B surface antigen", "entity2": "liver disease", "span1": [67, 94], "span2": [229, 242]}, "bert_text": "Lamivudine for the prevention of hepatitis B virus reactivation in <e1> hepatitis-B surface antigen </e1> (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic <e2> liver disease </e2> worldwide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"957": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "HBSAG", "entity2": "hepatitis B", "span1": [96, 101], "span2": [33, 44]}, "bert_text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (<e1> HBSAG </e1> <e2> hepatitis B </e2> virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"958": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "HBSAG", "entity2": "Hepatitis B", "span1": [96, 101], "span2": [167, 178]}, "bert_text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (<e1> HBSAG </e1>) seropositive cancer patients undergoing cytotoxic chemotherapy.\n<e2> Hepatitis B </e2> virus (HBV) is one of the major causes of chronic liver disease worldwide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"959": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "HBSAG", "entity2": "cancer", "span1": [96, 101], "span2": [116, 122]}, "bert_text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (<e1> HBSAG </e1>) seropositive <e2> cancer </e2> patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"960": {"data": {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.", "entity1": "HBSAG", "entity2": "liver disease", "span1": [96, 101], "span2": [229, 242]}, "bert_text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (<e1> HBSAG </e1>) seropositive cancer patients undergoing cytotoxic chemotherapy.\nHepatitis B virus (HBV) is one of the major causes of chronic <e2> liver disease </e2> worldwide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"961": {"data": {"text": "The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.", "entity1": "phenobarbitone", "entity2": "impairment of learning", "span1": [22, 36], "span2": [87, 109]}, "bert_text": "The administration of <e1> phenobarbitone </e1> and carbamazepine for 21days caused a significant <e2> impairment of learning </e2> and memory as well as an increased oxidative stress.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"962": {"data": {"text": "The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.", "entity1": "carbamazepine", "entity2": "impairment of learning", "span1": [41, 54], "span2": [87, 109]}, "bert_text": "The administration of phenobarbitone and <e1> carbamazepine </e1> for 21days caused a significant <e2> impairment of learning </e2> and memory as well as an increased oxidative stress.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"963": {"data": {"text": "Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.", "entity1": "clonidine", "entity2": "anxiety", "span1": [97, 106], "span2": [166, 173]}, "bert_text": "Without the knowledge of the medical personnel, the patient's mother administered three doses of <e1> clonidine </e1> during the evening before and morning of surgery to reduce <e2> anxiety </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"964": {"data": {"text": "METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [93, 102], "span2": [147, 160]}, "bert_text": "METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of <e1> tamoxifen </e1> in women (mainly in Italy) who did not have <e2> breast cancer </e2> and who had had a hysterectomy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"965": {"data": {"text": "The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.", "entity1": "adriamycin", "entity2": "cancer", "span1": [11, 21], "span2": [31, 37]}, "bert_text": "The use of <e1> adriamycin </e1> (ADR) in <e2> cancer </e2> chemotherapy has been limited due to its cumulative cardiovascular toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"966": {"data": {"text": "The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.", "entity1": "adriamycin", "entity2": "cardiovascular toxicity", "span1": [11, 21], "span2": [90, 113]}, "bert_text": "The use of <e1> adriamycin </e1> (ADR) in cancer chemotherapy has been limited due to its cumulative <e2> cardiovascular toxicity </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"967": {"data": {"text": "The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.", "entity1": "ADR", "entity2": "cancer", "span1": [23, 26], "span2": [31, 37]}, "bert_text": "The use of adriamycin (<e1> ADR </e1>) in <e2> cancer </e2> chemotherapy has been limited due to its cumulative cardiovascular toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"968": {"data": {"text": "The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.", "entity1": "ADR", "entity2": "cardiovascular toxicity", "span1": [23, 26], "span2": [90, 113]}, "bert_text": "The use of adriamycin (<e1> ADR </e1>) in cancer chemotherapy has been limited due to its cumulative <e2> cardiovascular toxicity </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"969": {"data": {"text": "BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.", "entity1": "yohimbine", "entity2": "male impotence", "span1": [58, 67], "span2": [135, 149]}, "bert_text": "BACKGROUND: Preclinical and clinical studies suggest that <e1> yohimbine </e1> facilitates sexual behavior and may be helpful in the treatment of <e2> male impotence </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"970": {"data": {"text": "The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment.", "entity1": "nicotine", "entity2": "hyperactivity", "span1": [32, 40], "span2": [72, 85]}, "bert_text": "The results indicate that acute <e1> nicotine </e1> injection induces a pronounced <e2> hyperactivity </e2> in rats habituated to the test environment.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"971": {"data": {"text": "Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.\n", "entity1": "amsacrine", "entity2": "cancer", "span1": [22, 31], "span2": [84, 90]}, "bert_text": "Phase II study of the <e1> amsacrine </e1> analogue CI-921 (NSC 343499) in non-small cell lung <e2> cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"972": {"data": {"text": "Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.\n", "entity1": "CI-921", "entity2": "cancer", "span1": [41, 47], "span2": [84, 90]}, "bert_text": "Phase II study of the amsacrine analogue <e1> CI-921 </e1> (NSC 343499) in non-small cell lung <e2> cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"973": {"data": {"text": "Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.\n", "entity1": "NSC 343499", "entity2": "cancer", "span1": [49, 59], "span2": [84, 90]}, "bert_text": "Phase II study of the amsacrine analogue CI-921 (<e1> NSC 343499 </e1>) in non-small cell lung <e2> cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"974": {"data": {"text": "Mechanisms of FK 506-induced hypertension in the rat.\n-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.", "entity1": "FK 506-induced", "entity2": "hypertension", "span1": [14, 28], "span2": [29, 41]}, "bert_text": "Mechanisms of <e1> FK 506-induced </e1> <e2> hypertension </e2> in the rat.\n-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"975": {"data": {"text": "Mechanisms of FK 506-induced hypertension in the rat.\n-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.", "entity1": "-Tacrolimus", "entity2": "hypertension", "span1": [54, 65], "span2": [29, 41]}, "bert_text": "Mechanisms of FK 506-induced hypertension in the rat.\n<e1> -Tacrolimus </e1> <e2> hypertension </e2> in the rat.\n-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"976": {"data": {"text": "Mechanisms of FK 506-induced hypertension in the rat.\n-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.", "entity1": "FK 506", "entity2": "hypertension", "span1": [67, 73], "span2": [29, 41]}, "bert_text": "Mechanisms of FK 506-induced hypertension in the rat.\n-Tacrolimus (<e1> FK 506 </e1> <e2> hypertension </e2> in the rat.\n-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"977": {"data": {"text": "The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.", "entity1": "FK 506", "entity2": "hypertension", "span1": [24, 30], "span2": [61, 73]}, "bert_text": "The clinical utility of <e1> FK 506 </e1> is complicated by substantial <e2> hypertension </e2> and nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"978": {"data": {"text": "The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.", "entity1": "FK 506", "entity2": "nephrotoxicity", "span1": [24, 30], "span2": [78, 92]}, "bert_text": "The clinical utility of <e1> FK 506 </e1> is complicated by substantial hypertension and <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"979": {"data": {"text": "However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.", "entity1": "5,7-DHT", "entity2": "hypotension", "span1": [34, 41], "span2": [157, 168]}, "bert_text": "However, intraspinal injection of <e1> 5,7-DHT </e1> to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"980": {"data": {"text": "However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.", "entity1": "serotonin", "entity2": "hypotension", "span1": [96, 105], "span2": [157, 168]}, "bert_text": "However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending <e1> serotonin </e1> projections in the spinal cord did not affect this <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"981": {"data": {"text": "In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/-", "entity1": "propranolol", "entity2": "anxiety", "span1": [126, 137], "span2": [162, 169]}, "bert_text": "In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist <e1> propranolol </e1> blocked cocaine-induced <e2> anxiety </e2>-like behavior in Dbh +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"982": {"data": {"text": "In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/-", "entity1": "cocaine", "entity2": "anxiety", "span1": [146, 153], "span2": [162, 169]}, "bert_text": "In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked <e1> cocaine </e1>-induced <e2> anxiety </e2>-like behavior in Dbh +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"983": {"data": {"text": "These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.", "entity1": "Mipafox", "entity2": "neuropathic damage", "span1": [112, 119], "span2": [141, 159]}, "bert_text": "These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after <e1> Mipafox </e1> exposure can predict <e2> neuropathic damage </e2> in rats several weeks later.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"984": {"data": {"text": "CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.", "entity1": "Etoricoxib", "entity2": "GI AEs", "span1": [13, 23], "span2": [105, 111]}, "bert_text": "CONCLUSIONS: <e1> Etoricoxib </e1> 90 mg demonstrated a significantly lower risk for discontinuing treatment due to <e2> GI AEs </e2> compared with diclofenac 150 mg.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"985": {"data": {"text": "CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.", "entity1": "diclofenac", "entity2": "GI AEs", "span1": [126, 136], "span2": [105, 111]}, "bert_text": "CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with <e1> diclofenac </e1> <e2> GI AEs </e2> compared with diclofenac 150 mg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 1},
+	"986": {"data": {"text": "Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.\n", "entity1": "haloperidol", "entity2": "hyperprolactinemia", "span1": [113, 124], "span2": [83, 101]}, "bert_text": "Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by <e1> haloperidol </e1> <e2> hyperprolactinemia </e2> induced by haloperidol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"987": {"data": {"text": "In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.", "entity1": "alcohol", "entity2": "malaise", "span1": [43, 50], "span2": [65, 72]}, "bert_text": "In less than 1 hour after the ingestion of <e1> alcohol </e1>, he developed <e2> malaise </e2> with flushing of the face, tachycardia, and dyspnea.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"988": {"data": {"text": "In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.", "entity1": "alcohol", "entity2": "tachycardia", "span1": [43, 50], "span2": [100, 111]}, "bert_text": "In less than 1 hour after the ingestion of <e1> alcohol </e1>, he developed malaise with flushing of the face, <e2> tachycardia </e2>, and dyspnea.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"989": {"data": {"text": "In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.", "entity1": "alcohol", "entity2": "dyspnea", "span1": [43, 50], "span2": [117, 124]}, "bert_text": "In less than 1 hour after the ingestion of <e1> alcohol </e1>, he developed malaise with flushing of the face, tachycardia, and <e2> dyspnea </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"990": {"data": {"text": "Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.", "entity1": "cyclosporine", "entity2": "TMA", "span1": [31, 43], "span2": [140, 143]}, "bert_text": "Patients who are switched from <e1> cyclosporine </e1> to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent <e2> TMA </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"991": {"data": {"text": "Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.", "entity1": "tacrolimus", "entity2": "TMA", "span1": [47, 57], "span2": [140, 143]}, "bert_text": "Patients who are switched from cyclosporine to <e1> tacrolimus </e1> or vice versa should be closely monitored for the signs and symptoms of recurrent <e2> TMA </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"992": {"data": {"text": "Addition of oral nicorandil reduced his symptoms and maintained stable angina status.", "entity1": "nicorandil", "entity2": "angina", "span1": [17, 27], "span2": [71, 77]}, "bert_text": "Addition of oral <e1> nicorandil </e1> reduced his symptoms and maintained stable <e2> angina </e2> status.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"993": {"data": {"text": "We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.", "entity1": "ketamine", "entity2": "pain", "span1": [58, 66], "span2": [107, 111]}, "bert_text": "We have examined the effect of systemic administration of <e1> ketamine </e1> and lidocaine on brush-evoked (dynamic) <e2> pain </e2> and punctate-evoked (static) hyperalgesia induced by capsaicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"994": {"data": {"text": "We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.", "entity1": "ketamine", "entity2": "hyperalgesia", "span1": [58, 66], "span2": [141, 153]}, "bert_text": "We have examined the effect of systemic administration of <e1> ketamine </e1> and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) <e2> hyperalgesia </e2> induced by capsaicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"995": {"data": {"text": "We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.", "entity1": "lidocaine", "entity2": "pain", "span1": [71, 80], "span2": [107, 111]}, "bert_text": "We have examined the effect of systemic administration of ketamine and <e1> lidocaine </e1> on brush-evoked (dynamic) <e2> pain </e2> and punctate-evoked (static) hyperalgesia induced by capsaicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"996": {"data": {"text": "We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.", "entity1": "lidocaine", "entity2": "hyperalgesia", "span1": [71, 80], "span2": [141, 153]}, "bert_text": "We have examined the effect of systemic administration of ketamine and <e1> lidocaine </e1> on brush-evoked (dynamic) pain and punctate-evoked (static) <e2> hyperalgesia </e2> induced by capsaicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"997": {"data": {"text": "We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.", "entity1": "capsaicin", "entity2": "pain", "span1": [165, 174], "span2": [107, 111]}, "bert_text": "We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by <e1> capsaicin </e1> <e2> pain </e2> and punctate-evoked (static) hyperalgesia induced by capsaicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"998": {"data": {"text": "We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [165, 174], "span2": [141, 153]}, "bert_text": "We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by <e1> capsaicin </e1> <e2> hyperalgesia </e2> induced by capsaicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"999": {"data": {"text": "Experimental cranial pain elicited by capsaicin: a PET study.\n", "entity1": "capsaicin", "entity2": "pain", "span1": [38, 47], "span2": [21, 25]}, "bert_text": "Experimental cranial pain elicited by <e1> capsaicin </e1> <e2> pain </e2> elicited by capsaicin: a PET study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1000": {"data": {"text": "Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.", "entity1": "epinephrine", "entity2": "myocardial ischemia", "span1": [169, 180], "span2": [17, 36]}, "bert_text": "Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while <e1> epinephrine </e1> <e2> myocardial ischemia </e2> was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1001": {"data": {"text": "Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.", "entity1": "epinephrine", "entity2": "ischemia", "span1": [169, 180], "span2": [189, 197]}, "bert_text": "Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while <e1> epinephrine </e1>-induced <e2> ischemia </e2> was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1002": {"data": {"text": "In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.", "entity1": "crocin", "entity2": "learning and memory impairment", "span1": [13, 19], "span2": [73, 103]}, "bert_text": "In addition, <e1> crocin </e1> in the mentioned dose could significantly attenuated <e2> learning and memory impairment </e2> in treated STZ-injected group in passive avoidance test.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1003": {"data": {"text": "In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.", "entity1": "STZ", "entity2": "learning and memory impairment", "span1": [115, 118], "span2": [73, 103]}, "bert_text": "In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated <e1> STZ </e1> <e2> learning and memory impairment </e2> in treated STZ-injected group in passive avoidance test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1004": {"data": {"text": "Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.", "entity1": "ticlopidine", "entity2": "Agranulocytosis", "span1": [56, 67], "span2": [0, 15]}, "bert_text": "Agranulocytosis occurred 3-20 weeks after initiation of <e1> ticlopidine </e1> <e2> Agranulocytosis </e2> occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1005": {"data": {"text": "We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.", "entity1": "metoclopramide", "entity2": "left bundle branch block", "span1": [162, 176], "span2": [59, 83]}, "bert_text": "We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of <e1> metoclopramide </e1> <e2> left bundle branch block </e2> who developed torsade de pointes after intravenous and oral administration of metoclopramide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1006": {"data": {"text": "We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.", "entity1": "metoclopramide", "entity2": "torsade de pointes", "span1": [162, 176], "span2": [98, 116]}, "bert_text": "We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of <e1> metoclopramide </e1> <e2> torsade de pointes </e2> after intravenous and oral administration of metoclopramide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1007": {"data": {"text": "Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.", "entity1": "caffeine", "entity2": "seizure", "span1": [12, 20], "span2": [49, 56]}, "bert_text": "Intravenous <e1> caffeine </e1> is commonly used to improve <e2> seizure </e2> duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1008": {"data": {"text": "Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.", "entity1": "caffeine", "entity2": "ventricular ectopy", "span1": [12, 20], "span2": [178, 196]}, "bert_text": "Intravenous <e1> caffeine </e1> is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign <e2> ventricular ectopy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1009": {"data": {"text": "Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.", "entity1": "Morphine", "entity2": "hyperalgesia", "span1": [0, 8], "span2": [37, 49]}, "bert_text": "<e1> Morphine </e1> did not, however, alter the <e2> hyperalgesia </e2> induced by 8-bromo cyclic adenosine monophosphate.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1010": {"data": {"text": "Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.", "entity1": "8-bromo cyclic adenosine monophosphate", "entity2": "hyperalgesia", "span1": [61, 99], "span2": [37, 49]}, "bert_text": "Morphine did not, however, alter the hyperalgesia induced by <e1> 8-bromo cyclic adenosine monophosphate </e1> <e2> hyperalgesia </e2> induced by 8-bromo cyclic adenosine monophosphate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1011": {"data": {"text": "However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.", "entity1": "ephedrine", "entity2": "tachycardia", "span1": [55, 64], "span2": [16, 27]}, "bert_text": "However, marked tachycardia associated with the use of <e1> ephedrine </e1> <e2> tachycardia </e2> associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1012": {"data": {"text": "However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.", "entity1": "propofol", "entity2": "tachycardia", "span1": [85, 93], "span2": [16, 27]}, "bert_text": "However, marked tachycardia associated with the use of ephedrine in combination with <e1> propofol </e1> <e2> tachycardia </e2> associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1013": {"data": {"text": "In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.", "entity1": "FK506", "entity2": "MAHA", "span1": [34, 39], "span2": [67, 71]}, "bert_text": "In one patient, reintroduction of <e1> FK506 </e1> led to rapid recurrence of <e2> MAHA </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1014": {"data": {"text": "Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.", "entity1": "sirolimus", "entity2": "Proteinuria", "span1": [42, 51], "span2": [0, 11]}, "bert_text": "Proteinuria correlated most strongly with <e1> sirolimus </e1> <e2> Proteinuria </e2> correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1015": {"data": {"text": "The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.", "entity1": "pemoline", "entity2": "choreoathetosis", "span1": [64, 72], "span2": [98, 113]}, "bert_text": "The following case describes two children acutely poisoned with <e1> pemoline </e1> who experienced profound <e2> choreoathetosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1016": {"data": {"text": "BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.", "entity1": "lidocaine", "entity2": "neurologic symptoms", "span1": [97, 106], "span2": [52, 71]}, "bert_text": "BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow <e1> lidocaine </e1> <e2> neurologic symptoms </e2> (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1017": {"data": {"text": "BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.", "entity1": "lidocaine", "entity2": "TNSs", "span1": [97, 106], "span2": [73, 77]}, "bert_text": "BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow <e1> lidocaine </e1> <e2> TNSs </e2>) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1018": {"data": {"text": "BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.", "entity1": "bupivacaine", "entity2": "neurologic symptoms", "span1": [149, 160], "span2": [52, 71]}, "bert_text": "BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with <e1> bupivacaine </e1> <e2> neurologic symptoms </e2> (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1019": {"data": {"text": "BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.", "entity1": "bupivacaine", "entity2": "TNSs", "span1": [149, 160], "span2": [73, 77]}, "bert_text": "BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with <e1> bupivacaine </e1> <e2> TNSs </e2>) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1020": {"data": {"text": "The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.", "entity1": "risperidone", "entity2": "extrapyramidal symptoms", "span1": [87, 98], "span2": [58, 81]}, "bert_text": "The high ratio is believed to impart the low frequency of extrapyramidal symptoms with <e1> risperidone </e1> <e2> extrapyramidal symptoms </e2> with risperidone at low dosages.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1021": {"data": {"text": "OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).", "entity1": "1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea", "entity2": "gastrointestinal toxicities", "span1": [136, 180], "span2": [75, 102]}, "bert_text": "OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving <e1> 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea </e1> <e2> gastrointestinal toxicities </e2> in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1022": {"data": {"text": "OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).", "entity1": "1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea", "entity2": "tumour", "span1": [136, 180], "span2": [106, 112]}, "bert_text": "OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving <e1> 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea </e1> <e2> tumour </e2>-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1023": {"data": {"text": "OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).", "entity1": "CCNU", "entity2": "gastrointestinal toxicities", "span1": [182, 186], "span2": [75, 102]}, "bert_text": "OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (<e1> CCNU </e1> <e2> gastrointestinal toxicities </e2> in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1024": {"data": {"text": "OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).", "entity1": "CCNU", "entity2": "tumour", "span1": [182, 186], "span2": [106, 112]}, "bert_text": "OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (<e1> CCNU </e1> <e2> tumour </e2>-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1025": {"data": {"text": "Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.\n", "entity1": "phenylpropanolamine", "entity2": "Cerebral hemorrhage", "span1": [36, 55], "span2": [0, 19]}, "bert_text": "Cerebral hemorrhage associated with <e1> phenylpropanolamine </e1> <e2> Cerebral hemorrhage </e2> associated with phenylpropanolamine in combination with caffeine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1026": {"data": {"text": "Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.\n", "entity1": "caffeine", "entity2": "Cerebral hemorrhage", "span1": [76, 84], "span2": [0, 19]}, "bert_text": "Cerebral hemorrhage associated with phenylpropanolamine in combination with <e1> caffeine </e1> <e2> Cerebral hemorrhage </e2> associated with phenylpropanolamine in combination with caffeine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1027": {"data": {"text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "entity1": "enflurane", "entity2": "hypersensitivity", "span1": [69, 78], "span2": [113, 129]}, "bert_text": "This supports and extends previous evidence for a mechanism by which <e1> enflurane </e1> and/or isoflurane could produce a <e2> hypersensitivity </e2> condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1028": {"data": {"text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "entity1": "enflurane", "entity2": "hepatitis", "span1": [69, 78], "span2": [169, 178]}, "bert_text": "This supports and extends previous evidence for a mechanism by which <e1> enflurane </e1> and/or isoflurane could produce a hypersensitivity condition similar to that of halothane <e2> hepatitis </e2> either alone or subsequent to halothane administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1029": {"data": {"text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "entity1": "isoflurane", "entity2": "hypersensitivity", "span1": [86, 96], "span2": [113, 129]}, "bert_text": "This supports and extends previous evidence for a mechanism by which enflurane and/or <e1> isoflurane </e1> could produce a <e2> hypersensitivity </e2> condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1030": {"data": {"text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "entity1": "isoflurane", "entity2": "hepatitis", "span1": [86, 96], "span2": [169, 178]}, "bert_text": "This supports and extends previous evidence for a mechanism by which enflurane and/or <e1> isoflurane </e1> could produce a hypersensitivity condition similar to that of halothane <e2> hepatitis </e2> either alone or subsequent to halothane administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1031": {"data": {"text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "entity1": "halothane", "entity2": "hypersensitivity", "span1": [159, 168], "span2": [113, 129]}, "bert_text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of <e1> halothane </e1> <e2> hypersensitivity </e2> condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1032": {"data": {"text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "entity1": "halothane", "entity2": "hepatitis", "span1": [159, 168], "span2": [169, 178]}, "bert_text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of <e1> halothane </e1> <e2> hepatitis </e2> either alone or subsequent to halothane administration.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1033": {"data": {"text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "entity1": "halothane", "entity2": "hypersensitivity", "span1": [209, 218], "span2": [113, 129]}, "bert_text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to <e1> halothane </e1> <e2> hypersensitivity </e2> condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1034": {"data": {"text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "entity1": "halothane", "entity2": "hepatitis", "span1": [209, 218], "span2": [169, 178]}, "bert_text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to <e1> halothane </e1> <e2> hepatitis </e2> either alone or subsequent to halothane administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1035": {"data": {"text": "The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.", "entity1": "valproate", "entity2": "hepatic damage", "span1": [93, 102], "span2": [30, 44]}, "bert_text": "The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of <e1> valproate </e1> <e2> hepatic damage </e2>, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1036": {"data": {"text": "The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.", "entity1": "valproate", "entity2": "hyperammonemia", "span1": [93, 102], "span2": [53, 67]}, "bert_text": "The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of <e1> valproate </e1> <e2> hyperammonemia </e2>, upon the development of valproate encephalopathy is discussed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1037": {"data": {"text": "The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.", "entity1": "valproate", "entity2": "encephalopathy", "span1": [93, 102], "span2": [103, 117]}, "bert_text": "The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of <e1> valproate </e1> <e2> encephalopathy </e2> is discussed.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"1038": {"data": {"text": "Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.\n", "entity1": "lignocaine", "entity2": "Cauda equina syndrome", "span1": [66, 76], "span2": [0, 21]}, "bert_text": "Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% <e1> lignocaine </e1> <e2> Cauda equina syndrome </e2> after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1039": {"data": {"text": "Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.\n", "entity1": "lignocaine", "entity2": "cauda equina syndrome", "span1": [66, 76], "span2": [103, 124]}, "bert_text": "Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% <e1> lignocaine </e1>: a review of six cases of <e2> cauda equina syndrome </e2> reported to the Swedish Pharmaceutical Insurance 1993-1997.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1040": {"data": {"text": "Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.", "entity1": "Reserpine-", "entity2": "orofacial dyskinesia", "span1": [0, 10], "span2": [35, 55]}, "bert_text": "<e1> Reserpine- </e1> and haloperidol-induced <e2> orofacial dyskinesia </e2> are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1041": {"data": {"text": "Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.", "entity1": "Reserpine-", "entity2": "tardive dyskinesia", "span1": [0, 10], "span2": [86, 104]}, "bert_text": "<e1> Reserpine- </e1> and haloperidol-induced orofacial dyskinesia are putative animal models of <e2> tardive dyskinesia </e2> (TD) whose pathophysiology has been related to free radical generation and oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1042": {"data": {"text": "Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.", "entity1": "Reserpine-", "entity2": "TD", "span1": [0, 10], "span2": [106, 108]}, "bert_text": "<e1> Reserpine- </e1> and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (<e2> TD </e2>) whose pathophysiology has been related to free radical generation and oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1043": {"data": {"text": "Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.", "entity1": "haloperidol", "entity2": "orofacial dyskinesia", "span1": [15, 26], "span2": [35, 55]}, "bert_text": "Reserpine- and <e1> haloperidol </e1>-induced <e2> orofacial dyskinesia </e2> are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1044": {"data": {"text": "Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.", "entity1": "haloperidol", "entity2": "tardive dyskinesia", "span1": [15, 26], "span2": [86, 104]}, "bert_text": "Reserpine- and <e1> haloperidol </e1>-induced orofacial dyskinesia are putative animal models of <e2> tardive dyskinesia </e2> (TD) whose pathophysiology has been related to free radical generation and oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1045": {"data": {"text": "Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.", "entity1": "haloperidol", "entity2": "TD", "span1": [15, 26], "span2": [106, 108]}, "bert_text": "Reserpine- and <e1> haloperidol </e1>-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (<e2> TD </e2>) whose pathophysiology has been related to free radical generation and oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1046": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [73, 80], "span2": [55, 61]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to <e1> cocaine </e1> <e2> stroke </e2> related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1047": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [73, 80], "span2": [123, 129]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing; (2) cocaine-associated <e2> stroke </e2> occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1048": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [73, 80], "span2": [168, 174]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) <e2> stroke </e2> may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1049": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [73, 80], "span2": [227, 233]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) <e2> stroke </e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1050": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [73, 80], "span2": [368, 374]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated <e2> stroke </e2>, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1051": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "intracranial aneurysms", "span1": [73, 80], "span2": [282, 304]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with <e2> intracranial aneurysms </e2> and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1052": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "arteriovenous malformations", "span1": [73, 80], "span2": [309, 336]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and <e2> arteriovenous malformations </e2>; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1053": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "intracranial hemorrhage", "span1": [73, 80], "span2": [393, 416]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of <e2> intracranial hemorrhage </e2> exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1054": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "cerebral infarction", "span1": [73, 80], "span2": [433, 452]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to <e1> cocaine </e1> use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of <e2> cerebral infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1055": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [104, 111], "span2": [55, 61]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) <e1> cocaine </e1> <e2> stroke </e2> related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1056": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [104, 111], "span2": [123, 129]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) <e1> cocaine </e1>-associated <e2> stroke </e2> occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1057": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [104, 111], "span2": [168, 174]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) <e1> cocaine </e1>-associated stroke occurs primarily in young adults; (3) <e2> stroke </e2> may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1058": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [104, 111], "span2": [227, 233]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) <e1> cocaine </e1>-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) <e2> stroke </e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1059": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [104, 111], "span2": [368, 374]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) <e1> cocaine </e1>-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated <e2> stroke </e2>, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1060": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "intracranial aneurysms", "span1": [104, 111], "span2": [282, 304]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) <e1> cocaine </e1>-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with <e2> intracranial aneurysms </e2> and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1061": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "arteriovenous malformations", "span1": [104, 111], "span2": [309, 336]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) <e1> cocaine </e1>-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and <e2> arteriovenous malformations </e2>; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1062": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "intracranial hemorrhage", "span1": [104, 111], "span2": [393, 416]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) <e1> cocaine </e1>-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of <e2> intracranial hemorrhage </e2> exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1063": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "cerebral infarction", "span1": [104, 111], "span2": [433, 452]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) <e1> cocaine </e1>-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of <e2> cerebral infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1064": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [199, 206], "span2": [55, 61]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of <e1> cocaine </e1> <e2> stroke </e2> related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1065": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [199, 206], "span2": [123, 129]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of <e1> cocaine </e1> <e2> stroke </e2> occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1066": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [199, 206], "span2": [168, 174]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of <e1> cocaine </e1> <e2> stroke </e2> may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1067": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [199, 206], "span2": [227, 233]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of <e1> cocaine </e1> administration; (4) <e2> stroke </e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1068": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [199, 206], "span2": [368, 374]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of <e1> cocaine </e1> administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated <e2> stroke </e2>, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1069": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "intracranial aneurysms", "span1": [199, 206], "span2": [282, 304]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of <e1> cocaine </e1> administration; (4) stroke after cocaine use is frequently associated with <e2> intracranial aneurysms </e2> and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1070": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "arteriovenous malformations", "span1": [199, 206], "span2": [309, 336]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of <e1> cocaine </e1> administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and <e2> arteriovenous malformations </e2>; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1071": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "intracranial hemorrhage", "span1": [199, 206], "span2": [393, 416]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of <e1> cocaine </e1> administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of <e2> intracranial hemorrhage </e2> exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1072": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "cerebral infarction", "span1": [199, 206], "span2": [433, 452]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of <e1> cocaine </e1> administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of <e2> cerebral infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1073": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [240, 247], "span2": [55, 61]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after <e1> cocaine </e1> <e2> stroke </e2> related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1074": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [240, 247], "span2": [123, 129]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after <e1> cocaine </e1> <e2> stroke </e2> occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1075": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [240, 247], "span2": [168, 174]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after <e1> cocaine </e1> <e2> stroke </e2> may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1076": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [240, 247], "span2": [227, 233]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after <e1> cocaine </e1> <e2> stroke </e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1077": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [240, 247], "span2": [368, 374]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated <e2> stroke </e2>, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1078": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "intracranial aneurysms", "span1": [240, 247], "span2": [282, 304]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after <e1> cocaine </e1> use is frequently associated with <e2> intracranial aneurysms </e2> and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1079": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "arteriovenous malformations", "span1": [240, 247], "span2": [309, 336]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and <e2> arteriovenous malformations </e2>; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1080": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "intracranial hemorrhage", "span1": [240, 247], "span2": [393, 416]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of <e2> intracranial hemorrhage </e2> exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1081": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "cerebral infarction", "span1": [240, 247], "span2": [433, 452]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after <e1> cocaine </e1> use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of <e2> cerebral infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1082": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [349, 356], "span2": [55, 61]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in <e1> cocaine </e1> <e2> stroke </e2> related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1083": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [349, 356], "span2": [123, 129]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in <e1> cocaine </e1> <e2> stroke </e2> occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1084": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [349, 356], "span2": [168, 174]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in <e1> cocaine </e1> <e2> stroke </e2> may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1085": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [349, 356], "span2": [227, 233]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in <e1> cocaine </e1> <e2> stroke </e2> after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1086": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "stroke", "span1": [349, 356], "span2": [368, 374]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in <e1> cocaine </e1>-associated <e2> stroke </e2>, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1087": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "intracranial aneurysms", "span1": [349, 356], "span2": [282, 304]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in <e1> cocaine </e1> <e2> intracranial aneurysms </e2> and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1088": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "arteriovenous malformations", "span1": [349, 356], "span2": [309, 336]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in <e1> cocaine </e1> <e2> arteriovenous malformations </e2>; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1089": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "intracranial hemorrhage", "span1": [349, 356], "span2": [393, 416]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in <e1> cocaine </e1>-associated stroke, the frequency of <e2> intracranial hemorrhage </e2> exceeds that of cerebral infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1090": {"data": {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity1": "cocaine", "entity2": "cerebral infarction", "span1": [349, 356], "span2": [433, 452]}, "bert_text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in <e1> cocaine </e1>-associated stroke, the frequency of intracranial hemorrhage exceeds that of <e2> cerebral infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1091": {"data": {"text": "Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.", "entity1": "-cibenzoline", "entity2": "ventricular arrhythmia", "span1": [29, 41], "span2": [93, 115]}, "bert_text": "Antiarrhythmic effects of (+)<e1> -cibenzoline </e1> and (-)-cibenzoline were examined using two canine <e2> ventricular arrhythmia </e2> models.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1092": {"data": {"text": "Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.", "entity1": "-)-cibenzoline", "entity2": "ventricular arrhythmia", "span1": [47, 61], "span2": [93, 115]}, "bert_text": "Antiarrhythmic effects of (+)-cibenzoline and (<e1> -)-cibenzoline </e1> were examined using two canine <e2> ventricular arrhythmia </e2> models.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1093": {"data": {"text": "Age-related changes in ultrasound production corresponded with changes in cardiovascular variables, including baseline cardiac rate and clonidine-induced bradycardia.", "entity1": "clonidine", "entity2": "bradycardia", "span1": [136, 145], "span2": [154, 165]}, "bert_text": "Age-related changes in ultrasound production corresponded with changes in cardiovascular variables, including baseline cardiac rate and <e1> clonidine </e1>-induced <e2> bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1094": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [143, 154], "span2": [106, 109]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <e1> fluconazole </e1> <e2> TDP </e2> eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1095": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [143, 154], "span2": [197, 200]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <e1> fluconazole </e1> The patient had no other risk factors for <e2> TDP </e2>, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 1},
+	"1096": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [143, 154], "span2": [384, 387]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <e1> fluconazole </e1> The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and <e2> TDP </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1097": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "coronary artery disease", "span1": [143, 154], "span2": [212, 235]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <e1> fluconazole </e1> The patient had no other risk factors for TDP, including <e2> coronary artery disease </e2>, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1098": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "cardiomyopathy", "span1": [143, 154], "span2": [237, 251]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <e1> fluconazole </e1> The patient had no other risk factors for TDP, including coronary artery disease, <e2> cardiomyopathy </e2>, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1099": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "congestive heart failure", "span1": [143, 154], "span2": [253, 277]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <e1> fluconazole </e1> The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, <e2> congestive heart failure </e2>, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1100": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [368, 379], "span2": [106, 109]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> <e2> TDP </e2> eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1101": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [368, 379], "span2": [197, 200]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> <e2> TDP </e2>, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 1},
+	"1102": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [368, 379], "span2": [384, 387]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> and <e2> TDP </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1103": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "coronary artery disease", "span1": [368, 379], "span2": [212, 235]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> <e2> coronary artery disease </e2>, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1104": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "cardiomyopathy", "span1": [368, 379], "span2": [237, 251]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> <e2> cardiomyopathy </e2>, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1105": {"data": {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity1": "fluconazole", "entity2": "congestive heart failure", "span1": [368, 379], "span2": [253, 277]}, "bert_text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> <e2> congestive heart failure </e2>, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1106": {"data": {"text": "In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.", "entity1": "lipopolysaccharide", "entity2": "neurotoxicity", "span1": [40, 58], "span2": [179, 192]}, "bert_text": "In this study, we examined the roles of <e1> lipopolysaccharide </e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1107": {"data": {"text": "In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.", "entity1": "methamphetamine", "entity2": "neurotoxicity", "span1": [132, 147], "span2": [179, 192]}, "bert_text": "In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the <e1> methamphetamine </e1>-induced nigrostriatal dopamine <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1108": {"data": {"text": "In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.", "entity1": "dopamine", "entity2": "neurotoxicity", "span1": [170, 178], "span2": [179, 192]}, "bert_text": "In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e1> dopamine </e1> <e2> neurotoxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1109": {"data": {"text": "Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).", "entity1": "Puromycin aminonucleoside", "entity2": "nephrosis", "span1": [0, 25], "span2": [26, 35]}, "bert_text": "<e1> Puromycin aminonucleoside </e1> <e2> nephrosis </e2> was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1110": {"data": {"text": "Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).", "entity1": "puromycin aminonucleoside", "entity2": "nephrosis", "span1": [87, 112], "span2": [26, 35]}, "bert_text": "Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of <e1> puromycin aminonucleoside </e1> <e2> nephrosis </e2> was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1111": {"data": {"text": "Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).", "entity1": "PAN", "entity2": "nephrosis", "span1": [114, 117], "span2": [26, 35]}, "bert_text": "Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (<e1> PAN </e1> <e2> nephrosis </e2> was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1112": {"data": {"text": "Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.", "entity1": "fentanyl", "entity2": "chest wall rigidity", "span1": [33, 41], "span2": [65, 84]}, "bert_text": "Various reported side effects of <e1> fentanyl </e1> administration include <e2> chest wall rigidity </e2>, hypotension, respiratory depression, and bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1113": {"data": {"text": "Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.", "entity1": "fentanyl", "entity2": "hypotension", "span1": [33, 41], "span2": [86, 97]}, "bert_text": "Various reported side effects of <e1> fentanyl </e1> administration include chest wall rigidity, <e2> hypotension </e2>, respiratory depression, and bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1114": {"data": {"text": "Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.", "entity1": "fentanyl", "entity2": "respiratory depression", "span1": [33, 41], "span2": [99, 121]}, "bert_text": "Various reported side effects of <e1> fentanyl </e1> administration include chest wall rigidity, hypotension, <e2> respiratory depression </e2>, and bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1115": {"data": {"text": "Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.", "entity1": "fentanyl", "entity2": "bradycardia", "span1": [33, 41], "span2": [127, 138]}, "bert_text": "Various reported side effects of <e1> fentanyl </e1> administration include chest wall rigidity, hypotension, respiratory depression, and <e2> bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1116": {"data": {"text": "Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.", "entity1": "Ammonia", "entity2": "coma", "span1": [0, 7], "span2": [8, 12]}, "bert_text": "<e1> Ammonia </e1> <e2> coma </e2> was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1117": {"data": {"text": "Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.", "entity1": "NH4CL", "entity2": "coma", "span1": [101, 106], "span2": [8, 12]}, "bert_text": "Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol <e1> NH4CL </e1> <e2> coma </e2> was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1118": {"data": {"text": "Induction by paracetamol of bladder and liver tumours in the rat.", "entity1": "paracetamol", "entity2": "bladder and liver tumours", "span1": [13, 24], "span2": [28, 53]}, "bert_text": "Induction by <e1> paracetamol </e1> of <e2> bladder and liver tumours </e2> in the rat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1119": {"data": {"text": "Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.", "entity1": "Ammonia", "entity2": "drowsiness", "span1": [0, 7], "span2": [83, 93]}, "bert_text": "<e1> Ammonia </e1> (NH3) was higher in patients who, during continuous therapy, complained of <e2> drowsiness </e2> (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1120": {"data": {"text": "Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.", "entity1": "NH3", "entity2": "drowsiness", "span1": [9, 12], "span2": [83, 93]}, "bert_text": "Ammonia (<e1> NH3 </e1>) was higher in patients who, during continuous therapy, complained of <e2> drowsiness </e2> (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1121": {"data": {"text": "Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.", "entity1": "VPA", "entity2": "drowsiness", "span1": [167, 170], "span2": [83, 93]}, "bert_text": "Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although <e1> VPA </e1> <e2> drowsiness </e2> (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, 0, -1, 0], "label": 1},
+	"1122": {"data": {"text": "Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.)", "entity1": "Na", "entity2": "arrhythmia", "span1": [45, 47], "span2": [10, 20]}, "bert_text": "Digitalis arrhythmia, which is suppressed by <e1> Na </e1> <e2> arrhythmia </e2>, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1123": {"data": {"text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.", "entity1": "5-fluorouracil", "entity2": "colon carcinoma", "span1": [103, 117], "span2": [35, 50]}, "bert_text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after <e1> 5-fluorouracil </e1> <e2> colon carcinoma </e2> and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1124": {"data": {"text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.", "entity1": "5-fluorouracil", "entity2": "liver metastasis", "span1": [103, 117], "span2": [55, 71]}, "bert_text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after <e1> 5-fluorouracil </e1> <e2> liver metastasis </e2> who presented chest pain after 5-fluorouracil (5-FU) administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1125": {"data": {"text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.", "entity1": "5-fluorouracil", "entity2": "chest pain", "span1": [103, 117], "span2": [86, 96]}, "bert_text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after <e1> 5-fluorouracil </e1> <e2> chest pain </e2> after 5-fluorouracil (5-FU) administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1126": {"data": {"text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.", "entity1": "5-FU", "entity2": "colon carcinoma", "span1": [119, 123], "span2": [35, 50]}, "bert_text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (<e1> 5-FU </e1> <e2> colon carcinoma </e2> and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1127": {"data": {"text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.", "entity1": "5-FU", "entity2": "liver metastasis", "span1": [119, 123], "span2": [55, 71]}, "bert_text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (<e1> 5-FU </e1> <e2> liver metastasis </e2> who presented chest pain after 5-fluorouracil (5-FU) administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1128": {"data": {"text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.", "entity1": "5-FU", "entity2": "chest pain", "span1": [119, 123], "span2": [86, 96]}, "bert_text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (<e1> 5-FU </e1> <e2> chest pain </e2> after 5-fluorouracil (5-FU) administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1129": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "toxicity", "span1": [35, 45], "span2": [23, 31]}, "bert_text": "Because of the extreme toxicity of <e1> vitamin D3 </e1> <e2> toxicity </e2> of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1130": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "milk fever", "span1": [35, 45], "span2": [140, 150]}, "bert_text": "Because of the extreme toxicity of <e1> vitamin D3 </e1> in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent <e2> milk fever </e2> and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1131": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "milk fever", "span1": [35, 45], "span2": [173, 183]}, "bert_text": "Because of the extreme toxicity of <e1> vitamin D3 </e1> in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce <e2> milk fever </e2>, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1132": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "milk fever", "span1": [35, 45], "span2": [252, 262]}, "bert_text": "Because of the extreme toxicity of <e1> vitamin D3 </e1> in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent <e2> milk fever </e2> when injected several weeks prepartum.", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1133": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "toxicity", "span1": [116, 126], "span2": [23, 31]}, "bert_text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1> vitamin D3 </e1> <e2> toxicity </e2> of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1134": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "milk fever", "span1": [116, 126], "span2": [140, 150]}, "bert_text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1> vitamin D3 </e1> that prevent <e2> milk fever </e2> and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1135": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "milk fever", "span1": [116, 126], "span2": [173, 183]}, "bert_text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1> vitamin D3 </e1> that prevent milk fever and doses that induce <e2> milk fever </e2>, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1136": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "milk fever", "span1": [116, 126], "span2": [252, 262]}, "bert_text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of <e1> vitamin D3 </e1> that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent <e2> milk fever </e2> when injected several weeks prepartum.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1137": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "toxicity", "span1": [203, 213], "span2": [23, 31]}, "bert_text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that <e1> vitamin D3 </e1> <e2> toxicity </e2> of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1138": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "milk fever", "span1": [203, 213], "span2": [140, 150]}, "bert_text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that <e1> vitamin D3 </e1> <e2> milk fever </e2> and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1139": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "milk fever", "span1": [203, 213], "span2": [173, 183]}, "bert_text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that <e1> vitamin D3 </e1> <e2> milk fever </e2>, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1140": {"data": {"text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.", "entity1": "vitamin D3", "entity2": "milk fever", "span1": [203, 213], "span2": [252, 262]}, "bert_text": "Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that <e1> vitamin D3 </e1> cannot be used practically to prevent <e2> milk fever </e2> when injected several weeks prepartum.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1141": {"data": {"text": "No other medications were involved except for dipyrone for analgesia.", "entity1": "dipyrone", "entity2": "analgesia", "span1": [46, 54], "span2": [59, 68]}, "bert_text": "No other medications were involved except for <e1> dipyrone </e1> for <e2> analgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1142": {"data": {"text": "Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.", "entity1": "cidofovir", "entity2": "renal failure", "span1": [7, 16], "span2": [60, 73]}, "bert_text": "Use of <e1> cidofovir </e1> in 1 child was associated with progressive <e2> renal failure </e2> and neutropenia.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1143": {"data": {"text": "Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.", "entity1": "cidofovir", "entity2": "neutropenia", "span1": [7, 16], "span2": [78, 89]}, "bert_text": "Use of <e1> cidofovir </e1> in 1 child was associated with progressive renal failure and <e2> neutropenia </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1144": {"data": {"text": "In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.", "entity1": "reserpine", "entity2": "orofacial dyskinesia", "span1": [72, 81], "span2": [42, 62]}, "bert_text": "In the present study, the authors induced orofacial dyskinesia by acute <e1> reserpine </e1> <e2> orofacial dyskinesia </e2> by acute reserpine and subchronic haloperidol administration to rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1145": {"data": {"text": "In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.", "entity1": "haloperidol", "entity2": "orofacial dyskinesia", "span1": [97, 108], "span2": [42, 62]}, "bert_text": "In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic <e1> haloperidol </e1> <e2> orofacial dyskinesia </e2> by acute reserpine and subchronic haloperidol administration to rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1146": {"data": {"text": "Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.", "entity1": "Phenylpropanolamine", "entity2": "stroke", "span1": [0, 19], "span2": [97, 103]}, "bert_text": "<e1> Phenylpropanolamine </e1> (PPA) is a drug that has been associated with serious side effects including <e2> stroke </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1147": {"data": {"text": "Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.", "entity1": "PPA", "entity2": "stroke", "span1": [21, 24], "span2": [97, 103]}, "bert_text": "Phenylpropanolamine (<e1> PPA </e1>) is a drug that has been associated with serious side effects including <e2> stroke </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1148": {"data": {"text": "In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.", "entity1": "Mg(2+)-free", "entity2": "SE", "span1": [3, 14], "span2": [276, 278]}, "bert_text": "In <e1> Mg(2+)-free </e1> bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience <e2> SE </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"1149": {"data": {"text": "In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.", "entity1": "bicuculline", "entity2": "SE", "span1": [41, 52], "span2": [276, 278]}, "bert_text": "In Mg(2+)-free bathing medium containing <e1> bicuculline </e1>, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience <e2> SE </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"1150": {"data": {"text": "In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.", "entity1": "pilocarpine", "entity2": "SE", "span1": [227, 238], "span2": [276, 278]}, "bert_text": "In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and <e1> pilocarpine </e1>-treated mice that did not experience <e2> SE </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"1151": {"data": {"text": "Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p", "entity1": "rizatriptan", "entity2": "Headache", "span1": [37, 48], "span2": [0, 8]}, "bert_text": "Headache relief at 2 h was 75.9% for <e1> rizatriptan </e1> <e2> Headache </e2> relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1152": {"data": {"text": "Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p", "entity1": "ergotamine", "entity2": "Headache", "span1": [63, 73], "span2": [0, 8]}, "bert_text": "Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for <e1> ergotamine </e1> <e2> Headache </e2> relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1153": {"data": {"text": "Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p", "entity1": "caffeine", "entity2": "Headache", "span1": [74, 82], "span2": [0, 8]}, "bert_text": "Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/<e1> caffeine </e1> <e2> Headache </e2> relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1154": {"data": {"text": "Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.", "entity1": "Lipopolysaccharide", "entity2": "hyperthermia", "span1": [0, 18], "span2": [102, 114]}, "bert_text": "<e1> Lipopolysaccharide </e1> pretreatment did not affect the basal body temperature or methamphetamine-elicited <e2> hyperthermia </e2> three days later.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1155": {"data": {"text": "Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.", "entity1": "methamphetamine", "entity2": "hyperthermia", "span1": [77, 92], "span2": [102, 114]}, "bert_text": "Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1> methamphetamine </e1>-elicited <e2> hyperthermia </e2> three days later.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1156": {"data": {"text": "PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).", "entity1": "etoricoxib", "entity2": "RA", "span1": [114, 124], "span2": [84, 86]}, "bert_text": "PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received <e1> etoricoxib </e1> <e2> RA </e2> were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1157": {"data": {"text": "PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).", "entity1": "diclofenac", "entity2": "RA", "span1": [151, 161], "span2": [84, 86]}, "bert_text": "PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or <e1> diclofenac </e1> <e2> RA </e2> were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1158": {"data": {"text": "Angiosarcoma of the liver associated with diethylstilbestrol.\n", "entity1": "diethylstilbestrol", "entity2": "Angiosarcoma", "span1": [42, 60], "span2": [0, 12]}, "bert_text": "Angiosarcoma of the liver associated with <e1> diethylstilbestrol </e1> <e2> Angiosarcoma </e2> of the liver associated with diethylstilbestrol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1159": {"data": {"text": "In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).", "entity1": "lamivudine", "entity2": "hepatitis", "span1": [20, 30], "span2": [44, 53]}, "bert_text": "In the prophylactic <e1> lamivudine </e1> group severe <e2> hepatitis </e2> were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1160": {"data": {"text": "An electron microscope study of the livers of paracetamol-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens.", "entity1": "paracetamol", "entity2": "hepatocarcinogens", "span1": [46, 57], "span2": [191, 208]}, "bert_text": "An electron microscope study of the livers of <e1> paracetamol </e1>-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known <e2> hepatocarcinogens </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1161": {"data": {"text": "In most patients, discontinuation of sirolimus resulted in a decrease, but not resolution, of proteinuria.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [37, 46], "span2": [94, 105]}, "bert_text": "In most patients, discontinuation of <e1> sirolimus </e1> resulted in a decrease, but not resolution, of <e2> proteinuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"1162": {"data": {"text": "Patterns of hepatic injury induced by methyldopa.\n", "entity1": "methyldopa", "entity2": "hepatic injury", "span1": [38, 48], "span2": [12, 26]}, "bert_text": "Patterns of hepatic injury induced by <e1> methyldopa </e1> <e2> hepatic injury </e2> induced by methyldopa.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1163": {"data": {"text": "The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).", "entity1": "cyclophosphamide", "entity2": "bladder cancer", "span1": [63, 79], "span2": [12, 26]}, "bert_text": "The risk of bladder cancer doubled for every 10 g increment in <e1> cyclophosphamide </e1> <e2> bladder cancer </e2> doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"1164": {"data": {"text": "The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.", "entity1": "TXA", "entity2": "seizures", "span1": [115, 118], "span2": [129, 137]}, "bert_text": "The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between <e1> TXA </e1> usage and <e2> seizures </e2> after cardiac surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1165": {"data": {"text": "The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.\n", "entity1": "carteolol hydrochloride", "entity2": "catalepsy", "span1": [26, 49], "span2": [106, 115]}, "bert_text": "The attenuating effect of <e1> carteolol hydrochloride </e1>, a beta-adrenoceptor antagonist, on neuroleptic-induced <e2> catalepsy </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1166": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "sulindac", "entity2": "rheumatoid arthritis", "span1": [82, 90], "span2": [23, 43]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with <e1> sulindac </e1> <e2> rheumatoid arthritis </e2>, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1167": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "sulindac", "entity2": "renal papillary necrosis", "span1": [82, 90], "span2": [160, 184]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with <e1> sulindac </e1>, fenoprofen calcium, high dose salicylates and gold salts, developed <e2> renal papillary necrosis </e2> (RPN) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1168": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "sulindac", "entity2": "RPN", "span1": [82, 90], "span2": [186, 189]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with <e1> sulindac </e1>, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (<e2> RPN </e2>) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1169": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "fenoprofen calcium", "entity2": "rheumatoid arthritis", "span1": [92, 110], "span2": [23, 43]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, <e1> fenoprofen calcium </e1> <e2> rheumatoid arthritis </e2>, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1170": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "fenoprofen calcium", "entity2": "renal papillary necrosis", "span1": [92, 110], "span2": [160, 184]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, <e1> fenoprofen calcium </e1>, high dose salicylates and gold salts, developed <e2> renal papillary necrosis </e2> (RPN) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1171": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "fenoprofen calcium", "entity2": "RPN", "span1": [92, 110], "span2": [186, 189]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, <e1> fenoprofen calcium </e1>, high dose salicylates and gold salts, developed renal papillary necrosis (<e2> RPN </e2>) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1172": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "salicylates", "entity2": "rheumatoid arthritis", "span1": [122, 133], "span2": [23, 43]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose <e1> salicylates </e1> <e2> rheumatoid arthritis </e2>, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1173": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "salicylates", "entity2": "renal papillary necrosis", "span1": [122, 133], "span2": [160, 184]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose <e1> salicylates </e1> and gold salts, developed <e2> renal papillary necrosis </e2> (RPN) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1174": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "salicylates", "entity2": "RPN", "span1": [122, 133], "span2": [186, 189]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose <e1> salicylates </e1> and gold salts, developed renal papillary necrosis (<e2> RPN </e2>) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1175": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "gold", "entity2": "rheumatoid arthritis", "span1": [138, 142], "span2": [23, 43]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and <e1> gold </e1> <e2> rheumatoid arthritis </e2>, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1176": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "gold", "entity2": "renal papillary necrosis", "span1": [138, 142], "span2": [160, 184]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and <e1> gold </e1> salts, developed <e2> renal papillary necrosis </e2> (RPN) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1177": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "gold", "entity2": "RPN", "span1": [138, 142], "span2": [186, 189]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and <e1> gold </e1> salts, developed renal papillary necrosis (<e2> RPN </e2>) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1178": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "naproxen", "entity2": "rheumatoid arthritis", "span1": [221, 229], "span2": [23, 43]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of <e1> naproxen </e1> <e2> rheumatoid arthritis </e2>, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1179": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "naproxen", "entity2": "renal papillary necrosis", "span1": [221, 229], "span2": [160, 184]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of <e1> naproxen </e1> <e2> renal papillary necrosis </e2> (RPN) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1180": {"data": {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity1": "naproxen", "entity2": "RPN", "span1": [221, 229], "span2": [186, 189]}, "bert_text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of <e1> naproxen </e1> <e2> RPN </e2>) 4 months after institution of naproxen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1181": {"data": {"text": "We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.", "entity1": "5-azacytidine", "entity2": "exencephaly", "span1": [39, 52], "span2": [16, 27]}, "bert_text": "We observed the exencephaly induced by <e1> 5-azacytidine </e1> <e2> exencephaly </e2> induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1182": {"data": {"text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "entity1": "5-FU", "entity2": "coronary spasm", "span1": [81, 85], "span2": [24, 38]}, "bert_text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to <e1> 5-FU </e1> <e2> coronary spasm </e2> may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1183": {"data": {"text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "entity1": "5-FU", "entity2": "cardiotoxicity", "span1": [81, 85], "span2": [59, 73]}, "bert_text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to <e1> 5-FU </e1> <e2> cardiotoxicity </e2> due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1184": {"data": {"text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "entity1": "5-FU", "entity2": "cardiotoxicity", "span1": [81, 85], "span2": [176, 190]}, "bert_text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to <e1> 5-FU </e1>, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1185": {"data": {"text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "entity1": "5-FU", "entity2": "coronary spasm", "span1": [171, 175], "span2": [24, 38]}, "bert_text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of <e1> 5-FU </e1> <e2> coronary spasm </e2> may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1186": {"data": {"text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "entity1": "5-FU", "entity2": "cardiotoxicity", "span1": [171, 175], "span2": [59, 73]}, "bert_text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of <e1> 5-FU </e1> <e2> cardiotoxicity </e2> due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1187": {"data": {"text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "entity1": "5-FU", "entity2": "cardiotoxicity", "span1": [171, 175], "span2": [176, 190]}, "bert_text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of <e1> 5-FU </e1> <e2> cardiotoxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1188": {"data": {"text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "entity1": "calcium", "entity2": "coronary spasm", "span1": [96, 103], "span2": [24, 38]}, "bert_text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that <e1> calcium </e1> <e2> coronary spasm </e2> may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1189": {"data": {"text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "entity1": "calcium", "entity2": "cardiotoxicity", "span1": [96, 103], "span2": [59, 73]}, "bert_text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that <e1> calcium </e1> <e2> cardiotoxicity </e2> due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1190": {"data": {"text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.", "entity1": "calcium", "entity2": "cardiotoxicity", "span1": [96, 103], "span2": [176, 190]}, "bert_text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that <e1> calcium </e1> antagonists may probably be used in the prevention or treatment of 5-FU <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1191": {"data": {"text": "Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.", "entity1": "acetic acid", "entity2": "edema", "span1": [71, 82], "span2": [145, 150]}, "bert_text": "Acute analgesic and antiinflammatory activities were ascertained using <e1> acetic acid </e1> induced writhing model (mice) and carrageenan-induced rat paw <e2> edema </e2> model, respectively.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1192": {"data": {"text": "Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.", "entity1": "carrageenan", "entity2": "edema", "span1": [117, 128], "span2": [145, 150]}, "bert_text": "Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and <e1> carrageenan </e1>-induced rat paw <e2> edema </e2> model, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1193": {"data": {"text": "The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.", "entity1": "FANFT", "entity2": "carcinogenesis", "span1": [124, 129], "span2": [130, 144]}, "bert_text": "The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in <e1> FANFT </e1> <e2> carcinogenesis </e2> in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1194": {"data": {"text": "The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.", "entity1": "FANFT", "entity2": "carcinogenesis", "span1": [206, 211], "span2": [130, 144]}, "bert_text": "The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on <e1> FANFT </e1> <e2> carcinogenesis </e2> in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1195": {"data": {"text": "The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.", "entity1": "aspirin's", "entity2": "carcinogenesis", "span1": [186, 195], "span2": [130, 144]}, "bert_text": "The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that <e1> aspirin's </e1> <e2> carcinogenesis </e2> in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1196": {"data": {"text": "While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.", "entity1": "apomorphine", "entity2": "Parkinson's disease", "span1": [168, 179], "span2": [114, 133]}, "bert_text": "While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of <e1> apomorphine </e1> <e2> Parkinson's disease </e2> by subcutaneous administration of apomorphine has only recently become the subject of systematic study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1197": {"data": {"text": "Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.", "entity1": "Naloxone", "entity2": "respiratory paralysis", "span1": [0, 8], "span2": [36, 57]}, "bert_text": "<e1> Naloxone </e1> (2.5 mg/kg, i.v.) reversed <e2> respiratory paralysis </e2>, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1198": {"data": {"text": "Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.", "entity1": "GABA", "entity2": "respiratory paralysis", "span1": [73, 77], "span2": [36, 57]}, "bert_text": "Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and <e1> GABA </e1> <e2> respiratory paralysis </e2>, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1199": {"data": {"text": "There was no significant difference in the convulsive threshold between sevoflurane and enflurane.", "entity1": "sevoflurane", "entity2": "convulsive", "span1": [72, 83], "span2": [43, 53]}, "bert_text": "There was no significant difference in the convulsive threshold between <e1> sevoflurane </e1> <e2> convulsive </e2> threshold between sevoflurane and enflurane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1200": {"data": {"text": "There was no significant difference in the convulsive threshold between sevoflurane and enflurane.", "entity1": "enflurane", "entity2": "convulsive", "span1": [88, 97], "span2": [43, 53]}, "bert_text": "There was no significant difference in the convulsive threshold between sevoflurane and <e1> enflurane </e1> <e2> convulsive </e2> threshold between sevoflurane and enflurane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1201": {"data": {"text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.", "entity1": "norepinephrine", "entity2": "tachycardia", "span1": [84, 98], "span2": [45, 56]}, "bert_text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the <e1> norepinephrine </e1> <e2> tachycardia </e2> and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"1202": {"data": {"text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.", "entity1": "norepinephrine", "entity2": "hypotension", "span1": [84, 98], "span2": [191, 202]}, "bert_text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the <e1> norepinephrine </e1> release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable <e2> hypotension </e2> induced by hydralazine or nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1203": {"data": {"text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.", "entity1": "hydralazine", "entity2": "tachycardia", "span1": [214, 225], "span2": [45, 56]}, "bert_text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by <e1> hydralazine </e1> <e2> tachycardia </e2> and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"1204": {"data": {"text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.", "entity1": "hydralazine", "entity2": "hypotension", "span1": [214, 225], "span2": [191, 202]}, "bert_text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by <e1> hydralazine </e1> <e2> hypotension </e2> induced by hydralazine or nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1205": {"data": {"text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.", "entity1": "nitroglycerin", "entity2": "tachycardia", "span1": [229, 242], "span2": [45, 56]}, "bert_text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or <e1> nitroglycerin </e1> <e2> tachycardia </e2> and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"1206": {"data": {"text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.", "entity1": "nitroglycerin", "entity2": "hypotension", "span1": [229, 242], "span2": [191, 202]}, "bert_text": "6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or <e1> nitroglycerin </e1> <e2> hypotension </e2> induced by hydralazine or nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1207": {"data": {"text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "entity1": "yohimbine", "entity2": "startle", "span1": [13, 22], "span2": [42, 49]}, "bert_text": "Furthermore, <e1> yohimbine </e1> increased baseline <e2> startle </e2> amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1208": {"data": {"text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "entity1": "yohimbine", "entity2": "startle", "span1": [13, 22], "span2": [103, 110]}, "bert_text": "Furthermore, <e1> yohimbine </e1> increased baseline startle amplitude in the LES, while mCPP suppressed baseline <e2> startle </e2> in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1209": {"data": {"text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "entity1": "yohimbine", "entity2": "startle", "span1": [13, 22], "span2": [163, 170]}, "bert_text": "Furthermore, <e1> yohimbine </e1> increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline <e2> startle </e2> in the FPS.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1210": {"data": {"text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "entity1": "mCPP", "entity2": "startle", "span1": [78, 82], "span2": [42, 49]}, "bert_text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while <e1> mCPP </e1> <e2> startle </e2> amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1211": {"data": {"text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "entity1": "mCPP", "entity2": "startle", "span1": [78, 82], "span2": [103, 110]}, "bert_text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while <e1> mCPP </e1> suppressed baseline <e2> startle </e2> in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1212": {"data": {"text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "entity1": "mCPP", "entity2": "startle", "span1": [78, 82], "span2": [163, 170]}, "bert_text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while <e1> mCPP </e1> suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline <e2> startle </e2> in the FPS.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1213": {"data": {"text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "entity1": "PTZ", "entity2": "startle", "span1": [139, 142], "span2": [42, 49]}, "bert_text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and <e1> PTZ </e1> <e2> startle </e2> amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1214": {"data": {"text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "entity1": "PTZ", "entity2": "startle", "span1": [139, 142], "span2": [103, 110]}, "bert_text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and <e1> PTZ </e1> <e2> startle </e2> in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1215": {"data": {"text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "entity1": "PTZ", "entity2": "startle", "span1": [139, 142], "span2": [163, 170]}, "bert_text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and <e1> PTZ </e1> suppressed baseline <e2> startle </e2> in the FPS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1216": {"data": {"text": "Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.\n", "entity1": "ritodrine", "entity2": "Ventricular tachyarrhythmias", "span1": [59, 68], "span2": [0, 28]}, "bert_text": "Ventricular tachyarrhythmias during cesarean section after <e1> ritodrine </e1> <e2> Ventricular tachyarrhythmias </e2> during cesarean section after ritodrine therapy: interaction with anesthetics.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1217": {"data": {"text": "CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.", "entity1": "Sirolimus", "entity2": "proteinuria", "span1": [13, 22], "span2": [58, 69]}, "bert_text": "CONCLUSIONS: <e1> Sirolimus </e1> induces or aggravates pre-existing <e2> proteinuria </e2> in an unpredictable subset of renal allograft recipients.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1218": {"data": {"text": "RESULTS: High frequency hippocampal DBS suppressed the acute penicillin-induced cortical epileptic activity independent from stimulus intensity.", "entity1": "penicillin", "entity2": "epileptic", "span1": [61, 71], "span2": [89, 98]}, "bert_text": "RESULTS: High frequency hippocampal DBS suppressed the acute <e1> penicillin </e1>-induced cortical <e2> epileptic </e2> activity independent from stimulus intensity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1219": {"data": {"text": "Seven cases of procainamide-induced polymorphous ventricular tachycardia are presented.", "entity1": "procainamide", "entity2": "ventricular tachycardia", "span1": [15, 27], "span2": [49, 72]}, "bert_text": "Seven cases of <e1> procainamide </e1>-induced polymorphous <e2> ventricular tachycardia </e2> are presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1220": {"data": {"text": "Assessment of the onset and persistence of amnesia during procedural sedation with propofol.\n", "entity1": "propofol", "entity2": "amnesia", "span1": [83, 91], "span2": [43, 50]}, "bert_text": "Assessment of the onset and persistence of amnesia during procedural sedation with <e1> propofol </e1> <e2> amnesia </e2> during procedural sedation with propofol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1221": {"data": {"text": "It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.", "entity1": "fentanyl", "entity2": "muscular rigidity", "span1": [60, 68], "span2": [39, 56]}, "bert_text": "It is speculated that the induction of muscular rigidity by <e1> fentanyl </e1> <e2> muscular rigidity </e2> by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1222": {"data": {"text": "Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [51, 62], "span2": [71, 80]}, "bert_text": "Calcitonin injection resulted in a potentiation of <e1> haloperidol </e1>-induced <e2> catalepsy </e2> and a partial prevention of apomorphine-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1223": {"data": {"text": "Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.", "entity1": "haloperidol", "entity2": "hyperactivity", "span1": [51, 62], "span2": [129, 142]}, "bert_text": "Calcitonin injection resulted in a potentiation of <e1> haloperidol </e1>-induced catalepsy and a partial prevention of apomorphine-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1224": {"data": {"text": "Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [109, 120], "span2": [71, 80]}, "bert_text": "Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of <e1> apomorphine </e1> <e2> catalepsy </e2> and a partial prevention of apomorphine-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1225": {"data": {"text": "Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.", "entity1": "apomorphine", "entity2": "hyperactivity", "span1": [109, 120], "span2": [129, 142]}, "bert_text": "Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of <e1> apomorphine </e1>-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1226": {"data": {"text": "Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.\n", "entity1": "Adriamycin", "entity2": "death", "span1": [0, 10], "span2": [44, 49]}, "bert_text": "<e1> Adriamycin </e1>-induced autophagic cardiomyocyte <e2> death </e2> plays a pathogenic role in a rat model of heart failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1227": {"data": {"text": "Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.\n", "entity1": "Adriamycin", "entity2": "heart failure", "span1": [0, 10], "span2": [92, 105]}, "bert_text": "<e1> Adriamycin </e1>-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of <e2> heart failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1228": {"data": {"text": "Arterial hypertension as a complication of prolonged ketoconazole treatment.\n", "entity1": "ketoconazole", "entity2": "hypertension", "span1": [53, 65], "span2": [9, 21]}, "bert_text": "Arterial hypertension as a complication of prolonged <e1> ketoconazole </e1> <e2> hypertension </e2> as a complication of prolonged ketoconazole treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1229": {"data": {"text": "Zyban caused significant neurological and cardiovascular toxicity in overdose.", "entity1": "Zyban", "entity2": "neurological and cardiovascular toxicity", "span1": [0, 5], "span2": [25, 65]}, "bert_text": "<e1> Zyban </e1> caused significant <e2> neurological and cardiovascular toxicity </e2> in overdose.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1230": {"data": {"text": "Zyban caused significant neurological and cardiovascular toxicity in overdose.", "entity1": "Zyban", "entity2": "overdose", "span1": [0, 5], "span2": [69, 77]}, "bert_text": "<e1> Zyban </e1> caused significant neurological and cardiovascular toxicity in <e2> overdose </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1231": {"data": {"text": "Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.\n", "entity1": "carbamazepine", "entity2": "absence seizures", "span1": [21, 34], "span2": [61, 77]}, "bert_text": "Inappropriate use of <e1> carbamazepine </e1> and vigabatrin in typical <e2> absence seizures </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1232": {"data": {"text": "Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.\n", "entity1": "vigabatrin", "entity2": "absence seizures", "span1": [39, 49], "span2": [61, 77]}, "bert_text": "Inappropriate use of carbamazepine and <e1> vigabatrin </e1> in typical <e2> absence seizures </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1233": {"data": {"text": "Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.\n", "entity1": "digoxin", "entity2": "sexual dysfunction", "span1": [87, 94], "span2": [25, 43]}, "bert_text": "Subjective assessment of sexual dysfunction of patients on long-term administration of <e1> digoxin </e1> <e2> sexual dysfunction </e2> of patients on long-term administration of digoxin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1234": {"data": {"text": "The neural mechanisms and circuitry involved in levodopa-induced dyskinesia are unclear.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [48, 56], "span2": [65, 75]}, "bert_text": "The neural mechanisms and circuitry involved in <e1> levodopa </e1>-induced <e2> dyskinesia </e2> are unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1235": {"data": {"text": "The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.", "entity1": "rizatriptan", "entity2": "pain", "span1": [71, 82], "span2": [33, 37]}, "bert_text": "The co-primary endpoint of being pain free at 2 h was also in favor of <e1> rizatriptan </e1> <e2> pain </e2> free at 2 h was also in favor of rizatriptan.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1236": {"data": {"text": "Cyclooxygenase-2 activity is required for the development of lithium-induced polyuria.", "entity1": "lithium", "entity2": "polyuria", "span1": [61, 68], "span2": [77, 85]}, "bert_text": "Cyclooxygenase-2 activity is required for the development of <e1> lithium </e1>-induced <e2> polyuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1237": {"data": {"text": "CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.", "entity1": "NTG", "entity2": "hypotension", "span1": [57, 60], "span2": [187, 198]}, "bert_text": "CONCLUSION: In a PA retention paradigm, the injection of <e1> NTG </e1> immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced <e2> hypotension </e2> had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1238": {"data": {"text": "CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.", "entity1": "NTG", "entity2": "hypotension", "span1": [57, 60], "span2": [342, 353]}, "bert_text": "CONCLUSION: In a PA retention paradigm, the injection of <e1> NTG </e1> immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1239": {"data": {"text": "CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.", "entity1": "NTG", "entity2": "hypotension", "span1": [292, 295], "span2": [187, 198]}, "bert_text": "CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by <e1> NTG </e1> <e2> hypotension </e2> had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1240": {"data": {"text": "CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.", "entity1": "NTG", "entity2": "hypotension", "span1": [292, 295], "span2": [342, 353]}, "bert_text": "CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by <e1> NTG </e1> but did not improve latency in the absence of <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1241": {"data": {"text": "CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.", "entity1": "NIMO", "entity2": "hypotension", "span1": [214, 218], "span2": [187, 198]}, "bert_text": "CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect. <e1> NIMO </e1> <e2> hypotension </e2> had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1242": {"data": {"text": "CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect. NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.", "entity1": "NIMO", "entity2": "hypotension", "span1": [214, 218], "span2": [342, 353]}, "bert_text": "CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect. <e1> NIMO </e1> attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1243": {"data": {"text": "The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.", "entity1": "Rg1", "entity2": "learning impairment", "span1": [55, 58], "span2": [62, 81]}, "bert_text": "The aim of this study was to investigate the effect of <e1> Rg1 </e1> on <e2> learning impairment </e2> by chronic morphine administration and the mechanism responsible for this effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1244": {"data": {"text": "The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.", "entity1": "morphine", "entity2": "learning impairment", "span1": [93, 101], "span2": [62, 81]}, "bert_text": "The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic <e1> morphine </e1> <e2> learning impairment </e2> by chronic morphine administration and the mechanism responsible for this effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1245": {"data": {"text": "Carbamazepine and vigabatrin are contraindicated in typical absence seizures.", "entity1": "Carbamazepine", "entity2": "absence seizures", "span1": [0, 13], "span2": [60, 76]}, "bert_text": "<e1> Carbamazepine </e1> and vigabatrin are contraindicated in typical <e2> absence seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1246": {"data": {"text": "Carbamazepine and vigabatrin are contraindicated in typical absence seizures.", "entity1": "vigabatrin", "entity2": "absence seizures", "span1": [18, 28], "span2": [60, 76]}, "bert_text": "Carbamazepine and <e1> vigabatrin </e1> are contraindicated in typical <e2> absence seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1247": {"data": {"text": "METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.", "entity1": "sevoflurane", "entity2": "postoperative nausea and vomiting", "span1": [139, 150], "span2": [72, 105]}, "bert_text": "METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after <e1> sevoflurane </e1> <e2> postoperative nausea and vomiting </e2> and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1248": {"data": {"text": "METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.", "entity1": "sevoflurane", "entity2": "pain", "span1": [139, 150], "span2": [110, 114]}, "bert_text": "METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after <e1> sevoflurane </e1> <e2> pain </e2> in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1249": {"data": {"text": "The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.", "entity1": "5-fluorouracil", "entity2": "neurotoxicity", "span1": [20, 34], "span2": [35, 48]}, "bert_text": "The pathogenesis of <e1> 5-fluorouracil </e1> <e2> neurotoxicity </e2> may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1250": {"data": {"text": "The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.", "entity1": "fluoroacetate", "entity2": "neurotoxicity", "span1": [89, 102], "span2": [35, 48]}, "bert_text": "The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by <e1> fluoroacetate </e1> <e2> neurotoxicity </e2> may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1251": {"data": {"text": "The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.", "entity1": "fluorocitrate", "entity2": "neurotoxicity", "span1": [107, 120], "span2": [35, 48]}, "bert_text": "The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and <e1> fluorocitrate </e1> <e2> neurotoxicity </e2> may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1252": {"data": {"text": "The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.", "entity1": "thiamine", "entity2": "neurotoxicity", "span1": [122, 130], "span2": [35, 48]}, "bert_text": "The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, <e1> thiamine </e1> <e2> neurotoxicity </e2> may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1253": {"data": {"text": "The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.", "entity1": "dihydrouracil", "entity2": "neurotoxicity", "span1": [146, 159], "span2": [35, 48]}, "bert_text": "The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or <e1> dihydrouracil </e1> <e2> neurotoxicity </e2> may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1254": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [0, 8], "span2": [17, 37]}, "bert_text": "<e1> Warfarin </e1>-induced <e2> artery calcification </e2> is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1255": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [0, 8], "span2": [168, 188]}, "bert_text": "<e1> Warfarin </e1>-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of <e2> artery calcification </e2> in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1256": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "Warfarin", "entity2": "calcification", "span1": [0, 8], "span2": [288, 301]}, "bert_text": "<e1> Warfarin </e1>-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a <e2> calcification </e2> inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1257": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [223, 231], "span2": [17, 37]}, "bert_text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of <e1> Warfarin </e1> <e2> artery calcification </e2> is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1258": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [223, 231], "span2": [168, 188]}, "bert_text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of <e1> Warfarin </e1> <e2> artery calcification </e2> in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"1259": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "Warfarin", "entity2": "calcification", "span1": [223, 231], "span2": [288, 301]}, "bert_text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of <e1> Warfarin </e1> to inhibit gamma-carboxylation of matrix Gla protein, a <e2> calcification </e2> inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1260": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "vitamin D.", "entity2": "artery calcification", "span1": [67, 77], "span2": [17, 37]}, "bert_text": "Warfarin-induced artery calcification is accelerated by growth and <e1> vitamin D. </e1> <e2> artery calcification </e2> is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1261": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "vitamin D.", "entity2": "artery calcification", "span1": [67, 77], "span2": [168, 188]}, "bert_text": "Warfarin-induced artery calcification is accelerated by growth and <e1> vitamin D. </e1>\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of <e2> artery calcification </e2> in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1262": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "vitamin D.", "entity2": "calcification", "span1": [67, 77], "span2": [288, 301]}, "bert_text": "Warfarin-induced artery calcification is accelerated by growth and <e1> vitamin D. </e1>\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a <e2> calcification </e2> inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1263": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "vitamin D", "entity2": "artery calcification", "span1": [126, 135], "span2": [17, 37]}, "bert_text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and <e1> vitamin D </e1> <e2> artery calcification </e2> is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1264": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "vitamin D", "entity2": "artery calcification", "span1": [126, 135], "span2": [168, 188]}, "bert_text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and <e1> vitamin D </e1> treatment enhance the extent of <e2> artery calcification </e2> in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1265": {"data": {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity1": "vitamin D", "entity2": "calcification", "span1": [126, 135], "span2": [288, 301]}, "bert_text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\nThe present studies demonstrate that growth and <e1> vitamin D </e1> treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a <e2> calcification </e2> inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1266": {"data": {"text": "Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.", "entity1": "Doxorubicin", "entity2": "nephropathy", "span1": [0, 11], "span2": [20, 31]}, "bert_text": "<e1> Doxorubicin </e1>-induced <e2> nephropathy </e2> leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1267": {"data": {"text": "Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.", "entity1": "Doxorubicin", "entity2": "volume retention and renal fibrosis", "span1": [0, 11], "span2": [84, 119]}, "bert_text": "<e1> Doxorubicin </e1>-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent <e2> volume retention and renal fibrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1268": {"data": {"text": "Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.", "entity1": "sodium", "entity2": "nephropathy", "span1": [52, 58], "span2": [20, 31]}, "bert_text": "Doxorubicin-induced nephropathy leads to epithelial <e1> sodium </e1> <e2> nephropathy </e2> leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1269": {"data": {"text": "Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.", "entity1": "sodium", "entity2": "volume retention and renal fibrosis", "span1": [52, 58], "span2": [84, 119]}, "bert_text": "Doxorubicin-induced nephropathy leads to epithelial <e1> sodium </e1> channel (ENaC)-dependent <e2> volume retention and renal fibrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1270": {"data": {"text": "It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.", "entity1": "lamivudine", "entity2": "HBV-HIV co-infected", "span1": [135, 145], "span2": [328, 347]}, "bert_text": "It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when <e1> lamivudine </e1>-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of <e2> HBV-HIV co-infected </e2> patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1271": {"data": {"text": "Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.", "entity1": "ketoconazole", "entity2": "Cushing's syndrome", "span1": [77, 89], "span2": [24, 42]}, "bert_text": "Two of 14 patients with Cushing's syndrome treated on a long-term basis with <e1> ketoconazole </e1> <e2> Cushing's syndrome </e2> treated on a long-term basis with ketoconazole developed sustained hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1272": {"data": {"text": "Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.", "entity1": "ketoconazole", "entity2": "hypertension", "span1": [77, 89], "span2": [110, 122]}, "bert_text": "Two of 14 patients with Cushing's syndrome treated on a long-term basis with <e1> ketoconazole </e1> developed sustained <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1273": {"data": {"text": "Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.\n", "entity1": "prostaglandin", "entity2": "convulsions", "span1": [10, 23], "span2": [72, 83]}, "bert_text": "Effect of <e1> prostaglandin </e1> synthetase inhibitors on experimentally induced <e2> convulsions </e2> in rats.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1274": {"data": {"text": "The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.", "entity1": "NIMO", "entity2": "hypotension", "span1": [23, 27], "span2": [105, 116]}, "bert_text": "The observed effect of <e1> NIMO </e1> may have been attributable to the preservation of calcium homeostasis during <e2> hypotension </e2>, because there were no differences in the PbtO(2) indices among groups.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1275": {"data": {"text": "The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.", "entity1": "calcium", "entity2": "hypotension", "span1": [78, 85], "span2": [105, 116]}, "bert_text": "The observed effect of NIMO may have been attributable to the preservation of <e1> calcium </e1> homeostasis during <e2> hypotension </e2>, because there were no differences in the PbtO(2) indices among groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1276": {"data": {"text": "Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed subpial necrosis; the nerve roots and subarachnoid vessels were normal.", "entity1": "2-chloroprocaine-CE", "entity2": "subpial necrosis", "span1": [52, 71], "span2": [83, 99]}, "bert_text": "Of the 15 spinal cords of the animals that received <e1> 2-chloroprocaine-CE </e1>, 13 showed <e2> subpial necrosis </e2>; the nerve roots and subarachnoid vessels were normal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1277": {"data": {"text": "Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.\n", "entity1": "metronidazole", "entity2": "inferior colliculus lesion", "span1": [41, 54], "span2": [11, 37]}, "bert_text": "Reversible inferior colliculus lesion in <e1> metronidazole </e1> <e2> inferior colliculus lesion </e2> in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1278": {"data": {"text": "Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.\n", "entity1": "metronidazole", "entity2": "encephalopathy", "span1": [41, 54], "span2": [63, 77]}, "bert_text": "Reversible inferior colliculus lesion in <e1> metronidazole </e1>-induced <e2> encephalopathy </e2>: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1279": {"data": {"text": "OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.", "entity1": "metronidazole", "entity2": "inferior colliculus lesions", "span1": [72, 85], "span2": [41, 68]}, "bert_text": "OBJECTIVE: This is to present reversible inferior colliculus lesions in <e1> metronidazole </e1> <e2> inferior colliculus lesions </e2> in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1280": {"data": {"text": "OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.", "entity1": "metronidazole", "entity2": "encephalopathy", "span1": [72, 85], "span2": [94, 108]}, "bert_text": "OBJECTIVE: This is to present reversible inferior colliculus lesions in <e1> metronidazole </e1>-induced <e2> encephalopathy </e2>, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1281": {"data": {"text": "Metamizol potentiates morphine antinociception but not constipation after chronic treatment.\n", "entity1": "Metamizol", "entity2": "constipation", "span1": [0, 9], "span2": [55, 67]}, "bert_text": "<e1> Metamizol </e1> potentiates morphine antinociception but not <e2> constipation </e2> after chronic treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"1282": {"data": {"text": "Metamizol potentiates morphine antinociception but not constipation after chronic treatment.\n", "entity1": "morphine", "entity2": "constipation", "span1": [22, 30], "span2": [55, 67]}, "bert_text": "Metamizol potentiates <e1> morphine </e1> antinociception but not <e2> constipation </e2> after chronic treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"1283": {"data": {"text": "However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.", "entity1": "mesna", "entity2": "HC", "span1": [46, 51], "span2": [125, 127]}, "bert_text": "However, the replacement of last two doses of <e1> mesna </e1> with saline or all of the mesna doses with dexamethasone did not prevent <e2> HC </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"1284": {"data": {"text": "However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.", "entity1": "mesna", "entity2": "HC", "span1": [78, 83], "span2": [125, 127]}, "bert_text": "However, the replacement of last two doses of mesna with saline or all of the <e1> mesna </e1> doses with dexamethasone did not prevent <e2> HC </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"1285": {"data": {"text": "However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.", "entity1": "dexamethasone", "entity2": "HC", "span1": [95, 108], "span2": [125, 127]}, "bert_text": "However, the replacement of last two doses of mesna with saline or all of the mesna doses with <e1> dexamethasone </e1> did not prevent <e2> HC </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"1286": {"data": {"text": "Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.", "entity1": "indomethacin", "entity2": "Hyperkalemia", "span1": [116, 128], "span2": [0, 12]}, "bert_text": "Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as <e1> indomethacin </e1> <e2> Hyperkalemia </e2> has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1287": {"data": {"text": "Ethambutol-associated optic neuropathy.\n", "entity1": "Ethambutol", "entity2": "optic neuropathy", "span1": [0, 10], "span2": [22, 38]}, "bert_text": "<e1> Ethambutol </e1>-associated <e2> optic neuropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1288": {"data": {"text": "This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.", "entity1": "troleandomycin", "entity2": "cholestasis", "span1": [68, 82], "span2": [45, 56]}, "bert_text": "This observation demonstrates that prolonged cholestasis can follow <e1> troleandomycin </e1> <e2> cholestasis </e2> can follow troleandomycin-induced acute hepatitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1289": {"data": {"text": "This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.", "entity1": "troleandomycin", "entity2": "hepatitis", "span1": [68, 82], "span2": [97, 106]}, "bert_text": "This observation demonstrates that prolonged cholestasis can follow <e1> troleandomycin </e1>-induced acute <e2> hepatitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1290": {"data": {"text": "The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.", "entity1": "haloperidol", "entity2": "hyperprolactinemia", "span1": [84, 95], "span2": [53, 71]}, "bert_text": "The aim of the study was to examine the influence of hyperprolactinemia, induced by <e1> haloperidol </e1> <e2> hyperprolactinemia </e2>, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1291": {"data": {"text": "The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.", "entity1": "HAL", "entity2": "hyperprolactinemia", "span1": [97, 100], "span2": [53, 71]}, "bert_text": "The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (<e1> HAL </e1> <e2> hyperprolactinemia </e2>, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1292": {"data": {"text": "These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.", "entity1": "levodopa", "entity2": "LIDs", "span1": [159, 167], "span2": [69, 73]}, "bert_text": "These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to <e1> levodopa </e1> <e2> LIDs </e2> in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1293": {"data": {"text": "These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.", "entity1": "levodopa", "entity2": "LIDs", "span1": [159, 167], "span2": [254, 258]}, "bert_text": "These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to <e1> levodopa </e1> and demonstrate the value of these models for further studying the pathophysiology of <e2> LIDs </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1294": {"data": {"text": "The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success.", "entity1": "methylphenidate", "entity2": "attention deficit disorder", "span1": [102, 117], "span2": [51, 77]}, "bert_text": "The children had a medical history significant for attention deficit disorder previously treated with <e1> methylphenidate </e1> <e2> attention deficit disorder </e2> previously treated with methylphenidate without success.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1295": {"data": {"text": "Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.", "entity1": "Pyrazinamide", "entity2": "hepatic toxicity", "span1": [0, 12], "span2": [46, 62]}, "bert_text": "<e1> Pyrazinamide </e1> can have adverse effects such as <e2> hepatic toxicity </e2>, hyperuricemia or digestive disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1296": {"data": {"text": "Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.", "entity1": "Pyrazinamide", "entity2": "hyperuricemia", "span1": [0, 12], "span2": [64, 77]}, "bert_text": "<e1> Pyrazinamide </e1> can have adverse effects such as hepatic toxicity, <e2> hyperuricemia </e2> or digestive disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1297": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "antidepressant", "entity2": "manic or hypomanic", "span1": [219, 233], "span2": [27, 45]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of <e1> antidepressant </e1> <e2> manic or hypomanic </e2> switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1298": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "antidepressant", "entity2": "DSM-IV bipolar I", "span1": [219, 233], "span2": [142, 158]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of <e1> antidepressant </e1> <e2> DSM-IV bipolar I </e2> vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1299": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "antidepressant", "entity2": "bipolar II", "span1": [219, 233], "span2": [163, 173]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of <e1> antidepressant </e1> <e2> bipolar II </e2>), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1300": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "antidepressant", "entity2": "manic", "span1": [219, 233], "span2": [195, 200]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of <e1> antidepressant </e1> <e2> manic </e2> episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1301": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "antidepressant", "entity2": "manic or hypomanic", "span1": [278, 292], "span2": [27, 45]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. <e1> antidepressant </e1> <e2> manic or hypomanic </e2> switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1302": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "antidepressant", "entity2": "DSM-IV bipolar I", "span1": [278, 292], "span2": [142, 158]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. <e1> antidepressant </e1> <e2> DSM-IV bipolar I </e2> vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1303": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "antidepressant", "entity2": "bipolar II", "span1": [278, 292], "span2": [163, 173]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. <e1> antidepressant </e1> <e2> bipolar II </e2>), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1304": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "antidepressant", "entity2": "manic", "span1": [278, 292], "span2": [195, 200]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. <e1> antidepressant </e1> <e2> manic </e2> episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1305": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "serotonin", "entity2": "manic or hypomanic", "span1": [333, 342], "span2": [27, 45]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective <e1> serotonin </e1> <e2> manic or hypomanic </e2> switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1306": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "serotonin", "entity2": "DSM-IV bipolar I", "span1": [333, 342], "span2": [142, 158]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective <e1> serotonin </e1> <e2> DSM-IV bipolar I </e2> vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1307": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "serotonin", "entity2": "bipolar II", "span1": [333, 342], "span2": [163, 173]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective <e1> serotonin </e1> <e2> bipolar II </e2>), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1308": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "serotonin", "entity2": "manic", "span1": [333, 342], "span2": [195, 200]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective <e1> serotonin </e1> <e2> manic </e2> episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1309": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "SSRIs", "entity2": "manic or hypomanic", "span1": [364, 369], "span2": [27, 45]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [<e1> SSRIs </e1> <e2> manic or hypomanic </e2> switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1310": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "SSRIs", "entity2": "DSM-IV bipolar I", "span1": [364, 369], "span2": [142, 158]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [<e1> SSRIs </e1> <e2> DSM-IV bipolar I </e2> vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1311": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "SSRIs", "entity2": "bipolar II", "span1": [364, 369], "span2": [163, 173]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [<e1> SSRIs </e1> <e2> bipolar II </e2>), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1312": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "SSRIs", "entity2": "manic", "span1": [364, 369], "span2": [195, 200]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [<e1> SSRIs </e1> <e2> manic </e2> episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1313": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "lithium", "entity2": "manic or hypomanic", "span1": [407, 414], "span2": [27, 45]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (<e1> lithium </e1> <e2> manic or hypomanic </e2> switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1314": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "lithium", "entity2": "DSM-IV bipolar I", "span1": [407, 414], "span2": [142, 158]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (<e1> lithium </e1> <e2> DSM-IV bipolar I </e2> vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1315": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "lithium", "entity2": "bipolar II", "span1": [407, 414], "span2": [163, 173]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (<e1> lithium </e1> <e2> bipolar II </e2>), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1316": {"data": {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity1": "lithium", "entity2": "manic", "span1": [407, 414], "span2": [195, 200]}, "bert_text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (<e1> lithium </e1> <e2> manic </e2> episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1317": {"data": {"text": "Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.", "entity1": "lindane", "entity2": "scabies", "span1": [83, 90], "span2": [14, 21]}, "bert_text": "Treatment for scabies is usually initiated by general practitioners; most consider <e1> lindane </e1> <e2> scabies </e2> is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1318": {"data": {"text": "Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.", "entity1": "gamma benzene hexachloride", "entity2": "scabies", "span1": [92, 118], "span2": [14, 21]}, "bert_text": "Treatment for scabies is usually initiated by general practitioners; most consider lindane (<e1> gamma benzene hexachloride </e1> <e2> scabies </e2> is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1319": {"data": {"text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "entity1": "cyclophosphamide", "entity2": "anemia", "span1": [79, 95], "span2": [48, 54]}, "bert_text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of <e1> cyclophosphamide </e1> <e2> anemia </e2> reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1320": {"data": {"text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "entity1": "cyclophosphamide", "entity2": "anemia", "span1": [79, 95], "span2": [129, 135]}, "bert_text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of <e1> cyclophosphamide </e1> in tumors, whereas correction of <e2> anemia </e2> by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1321": {"data": {"text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "entity1": "cyclophosphamide", "entity2": "cytotoxicity", "span1": [79, 95], "span2": [63, 75]}, "bert_text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of <e1> cyclophosphamide </e1> <e2> cytotoxicity </e2> of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1322": {"data": {"text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "entity1": "cyclophosphamide", "entity2": "tumors", "span1": [79, 95], "span2": [99, 105]}, "bert_text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of <e1> cyclophosphamide </e1> in <e2> tumors </e2>, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1323": {"data": {"text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "entity1": "cyclophosphamide", "entity2": "tumor", "span1": [79, 95], "span2": [252, 257]}, "bert_text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of <e1> cyclophosphamide </e1> in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to <e2> tumor </e2> tissue.", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1324": {"data": {"text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "entity1": "oxygen", "entity2": "anemia", "span1": [235, 241], "span2": [48, 54]}, "bert_text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved <e1> oxygen </e1> <e2> anemia </e2> reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1325": {"data": {"text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "entity1": "oxygen", "entity2": "anemia", "span1": [235, 241], "span2": [129, 135]}, "bert_text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved <e1> oxygen </e1> <e2> anemia </e2> by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1326": {"data": {"text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "entity1": "oxygen", "entity2": "cytotoxicity", "span1": [235, 241], "span2": [63, 75]}, "bert_text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved <e1> oxygen </e1> <e2> cytotoxicity </e2> of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1327": {"data": {"text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "entity1": "oxygen", "entity2": "tumors", "span1": [235, 241], "span2": [99, 105]}, "bert_text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved <e1> oxygen </e1> <e2> tumors </e2>, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1328": {"data": {"text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.", "entity1": "oxygen", "entity2": "tumor", "span1": [235, 241], "span2": [252, 257]}, "bert_text": "These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved <e1> oxygen </e1> supply to <e2> tumor </e2> tissue.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1329": {"data": {"text": "Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.", "entity1": "diphenhydramine", "entity2": "allergic reaction", "span1": [5, 20], "span2": [89, 106]}, "bert_text": "Oral <e1> diphenhydramine </e1> and prednisone were ineffective in preventing the recurrence of the <e2> allergic reaction </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1330": {"data": {"text": "Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.", "entity1": "prednisone", "entity2": "allergic reaction", "span1": [25, 35], "span2": [89, 106]}, "bert_text": "Oral diphenhydramine and <e1> prednisone </e1> were ineffective in preventing the recurrence of the <e2> allergic reaction </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1331": {"data": {"text": "By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.", "entity1": "paracetamol", "entity2": "renal papillary necrosis", "span1": [67, 78], "span2": [95, 119]}, "bert_text": "By contrast, we were unable to substantiate an increased risk from <e1> paracetamol </e1> consumption for <e2> renal papillary necrosis </e2> or any of these cancers although there was a suggestion of an association with cancer of the ureter.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1332": {"data": {"text": "By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.", "entity1": "paracetamol", "entity2": "cancers", "span1": [67, 78], "span2": [136, 143]}, "bert_text": "By contrast, we were unable to substantiate an increased risk from <e1> paracetamol </e1> consumption for renal papillary necrosis or any of these <e2> cancers </e2> although there was a suggestion of an association with cancer of the ureter.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1333": {"data": {"text": "By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.", "entity1": "paracetamol", "entity2": "cancer", "span1": [67, 78], "span2": [199, 205]}, "bert_text": "By contrast, we were unable to substantiate an increased risk from <e1> paracetamol </e1> consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with <e2> cancer </e2> of the ureter.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1334": {"data": {"text": "By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.", "entity1": "paracetamol", "entity2": "ureter", "span1": [67, 78], "span2": [213, 219]}, "bert_text": "By contrast, we were unable to substantiate an increased risk from <e1> paracetamol </e1> consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the <e2> ureter </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1335": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "haloperidol", "entity2": "Parkinson's disease", "span1": [252, 263], "span2": [198, 217]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of <e1> haloperidol </e1> <e2> Parkinson's disease </e2> including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1336": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [252, 263], "span2": [272, 281]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of <e1> haloperidol </e1>-induced <e2> catalepsy </e2>, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1337": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "haloperidol", "entity2": "akinesia", "span1": [252, 263], "span2": [316, 324]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of <e1> haloperidol </e1>-induced catalepsy, mouse model of reserpine-induced <e2> akinesia </e2>, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1338": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "reserpine", "entity2": "Parkinson's disease", "span1": [298, 307], "span2": [198, 217]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of <e1> reserpine </e1> <e2> Parkinson's disease </e2> including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1339": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "reserpine", "entity2": "catalepsy", "span1": [298, 307], "span2": [272, 281]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of <e1> reserpine </e1> <e2> catalepsy </e2>, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1340": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "reserpine", "entity2": "akinesia", "span1": [298, 307], "span2": [316, 324]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of <e1> reserpine </e1>-induced <e2> akinesia </e2>, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1341": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "6-hydroxydopamine", "entity2": "Parkinson's disease", "span1": [330, 347], "span2": [198, 217]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat <e1> 6-hydroxydopamine </e1> <e2> Parkinson's disease </e2> including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1342": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "6-hydroxydopamine", "entity2": "catalepsy", "span1": [330, 347], "span2": [272, 281]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat <e1> 6-hydroxydopamine </e1> <e2> catalepsy </e2>, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1343": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "6-hydroxydopamine", "entity2": "akinesia", "span1": [330, 347], "span2": [316, 324]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat <e1> 6-hydroxydopamine </e1> <e2> akinesia </e2>, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1344": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "6-OHDA", "entity2": "Parkinson's disease", "span1": [349, 355], "span2": [198, 217]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (<e1> 6-OHDA </e1> <e2> Parkinson's disease </e2> including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1345": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "6-OHDA", "entity2": "catalepsy", "span1": [349, 355], "span2": [272, 281]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (<e1> 6-OHDA </e1> <e2> catalepsy </e2>, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1346": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "6-OHDA", "entity2": "akinesia", "span1": [349, 355], "span2": [316, 324]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (<e1> 6-OHDA </e1> <e2> akinesia </e2>, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1347": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "MPTP", "entity2": "Parkinson's disease", "span1": [400, 404], "span2": [198, 217]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and <e1> MPTP </e1> <e2> Parkinson's disease </e2> including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1348": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "MPTP", "entity2": "catalepsy", "span1": [400, 404], "span2": [272, 281]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and <e1> MPTP </e1> <e2> catalepsy </e2>, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1349": {"data": {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity1": "MPTP", "entity2": "akinesia", "span1": [400, 404], "span2": [316, 324]}, "bert_text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and <e1> MPTP </e1> <e2> akinesia </e2>, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1350": {"data": {"text": "Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.", "entity1": "enflurane", "entity2": "Epileptic", "span1": [43, 52], "span2": [0, 9]}, "bert_text": "Epileptic foci delineated and activated by <e1> enflurane </e1> <e2> Epileptic </e2> foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1351": {"data": {"text": "Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.", "entity1": "enflurane", "entity2": "seizure", "span1": [43, 52], "span2": [102, 109]}, "bert_text": "Epileptic foci delineated and activated by <e1> enflurane </e1> were surgically ablated and the patients are now <e2> seizure </e2>-free.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1352": {"data": {"text": "Late, late doxorubicin cardiotoxicity.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [11, 22], "span2": [23, 37]}, "bert_text": "Late, late <e1> doxorubicin </e1> <e2> cardiotoxicity </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1353": {"data": {"text": "Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.\n", "entity1": "carbamazepine", "entity2": "Hypersensitivity", "span1": [20, 33], "span2": [0, 16]}, "bert_text": "Hypersensitivity to <e1> carbamazepine </e1> <e2> Hypersensitivity </e2> to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1354": {"data": {"text": "Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.\n", "entity1": "carbamazepine", "entity2": "leukemoid reaction", "span1": [20, 33], "span2": [52, 70]}, "bert_text": "Hypersensitivity to <e1> carbamazepine </e1> presenting with a <e2> leukemoid reaction </e2>, eosinophilia, erythroderma, and renal failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1355": {"data": {"text": "Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.\n", "entity1": "carbamazepine", "entity2": "eosinophilia", "span1": [20, 33], "span2": [72, 84]}, "bert_text": "Hypersensitivity to <e1> carbamazepine </e1> presenting with a leukemoid reaction, <e2> eosinophilia </e2>, erythroderma, and renal failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1356": {"data": {"text": "Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.\n", "entity1": "carbamazepine", "entity2": "erythroderma", "span1": [20, 33], "span2": [86, 98]}, "bert_text": "Hypersensitivity to <e1> carbamazepine </e1> presenting with a leukemoid reaction, eosinophilia, <e2> erythroderma </e2>, and renal failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1357": {"data": {"text": "Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.\n", "entity1": "carbamazepine", "entity2": "renal failure", "span1": [20, 33], "span2": [104, 117]}, "bert_text": "Hypersensitivity to <e1> carbamazepine </e1> presenting with a leukemoid reaction, eosinophilia, erythroderma, and <e2> renal failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1358": {"data": {"text": "These findings indicate that ischemia produced by epinephrine, as may occur during states of emotional distress, has a mechanism distinct from that due to physical exertion.", "entity1": "epinephrine", "entity2": "ischemia", "span1": [50, 61], "span2": [29, 37]}, "bert_text": "These findings indicate that ischemia produced by <e1> epinephrine </e1> <e2> ischemia </e2> produced by epinephrine, as may occur during states of emotional distress, has a mechanism distinct from that due to physical exertion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1359": {"data": {"text": "Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.", "entity1": "oxytocin", "entity2": "Hypotension", "span1": [27, 35], "span2": [0, 11]}, "bert_text": "Hypotension in response to <e1> oxytocin </e1> <e2> Hypotension </e2> in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1360": {"data": {"text": "Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.", "entity1": "oxytocin", "entity2": "stroke", "span1": [27, 35], "span2": [130, 136]}, "bert_text": "Hypotension in response to <e1> oxytocin </e1> was associated with a decrease in systemic vascular resistance and a compensatory increase in <e2> stroke </e2> volume, heart rate and cardiac output.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1361": {"data": {"text": "It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.", "entity1": "lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [157, 164], "span2": [100, 130]}, "bert_text": "It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during <e1> lithium </e1> <e2> nephrogenic diabetes insipidus </e2> and hypothyroidism during lithium treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1362": {"data": {"text": "It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.", "entity1": "lithium", "entity2": "hypothyroidism", "span1": [157, 164], "span2": [135, 149]}, "bert_text": "It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during <e1> lithium </e1> <e2> hypothyroidism </e2> during lithium treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1363": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "thiamine", "entity2": "diabetic", "span1": [13, 21], "span2": [77, 85]}, "bert_text": "We studied a <e1> thiamine </e1>-dependent enzyme, transketolase, from fibroblasts of a <e2> diabetic </e2> patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1364": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "thiamine", "entity2": "Wernicke's encephalopathy", "span1": [13, 21], "span2": [108, 133]}, "bert_text": "We studied a <e1> thiamine </e1>-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed <e2> Wernicke's encephalopathy </e2> when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1365": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "thiamine", "entity2": "Wernicke-Korsakoff syndrome", "span1": [13, 21], "span2": [321, 348]}, "bert_text": "We studied a <e1> thiamine </e1>-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic <e2> Wernicke-Korsakoff syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1366": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "tolazamide", "entity2": "diabetic", "span1": [152, 162], "span2": [77, 85]}, "bert_text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with <e1> tolazamide </e1> <e2> diabetic </e2> patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1367": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "tolazamide", "entity2": "Wernicke's encephalopathy", "span1": [152, 162], "span2": [108, 133]}, "bert_text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with <e1> tolazamide </e1> <e2> Wernicke's encephalopathy </e2> when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1368": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "tolazamide", "entity2": "Wernicke-Korsakoff syndrome", "span1": [152, 162], "span2": [321, 348]}, "bert_text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with <e1> tolazamide </e1>, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic <e2> Wernicke-Korsakoff syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1369": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "thiamine pyrophosphate", "entity2": "diabetic", "span1": [250, 272], "span2": [77, 85]}, "bert_text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for <e1> thiamine pyrophosphate </e1> <e2> diabetic </e2> patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1370": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "thiamine pyrophosphate", "entity2": "Wernicke's encephalopathy", "span1": [250, 272], "span2": [108, 133]}, "bert_text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for <e1> thiamine pyrophosphate </e1> <e2> Wernicke's encephalopathy </e2> when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1371": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "thiamine pyrophosphate", "entity2": "Wernicke-Korsakoff syndrome", "span1": [250, 272], "span2": [321, 348]}, "bert_text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for <e1> thiamine pyrophosphate </e1> (TPP)], as previously reported in postalcoholic <e2> Wernicke-Korsakoff syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1372": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "TPP", "entity2": "diabetic", "span1": [274, 277], "span2": [77, 85]}, "bert_text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (<e1> TPP </e1> <e2> diabetic </e2> patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1373": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "TPP", "entity2": "Wernicke's encephalopathy", "span1": [274, 277], "span2": [108, 133]}, "bert_text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (<e1> TPP </e1> <e2> Wernicke's encephalopathy </e2> when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1374": {"data": {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity1": "TPP", "entity2": "Wernicke-Korsakoff syndrome", "span1": [274, 277], "span2": [321, 348]}, "bert_text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (<e1> TPP </e1>)], as previously reported in postalcoholic <e2> Wernicke-Korsakoff syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1375": {"data": {"text": "Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.", "entity1": "carboplatin", "entity2": "ocular and orbital toxicity", "span1": [11, 22], "span2": [81, 108]}, "bert_text": "Generally, <e1> carboplatin </e1> is said to have milder side effects than cisplatin, whose <e2> ocular and orbital toxicity </e2> are well known.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1376": {"data": {"text": "Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.", "entity1": "cisplatin", "entity2": "ocular and orbital toxicity", "span1": [64, 73], "span2": [81, 108]}, "bert_text": "Generally, carboplatin is said to have milder side effects than <e1> cisplatin </e1>, whose <e2> ocular and orbital toxicity </e2> are well known.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1377": {"data": {"text": "The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.", "entity1": "dobutamine", "entity2": "ischemic", "span1": [44, 54], "span2": [114, 122]}, "bert_text": "The increase in dP/dtejc during infusion of <e1> dobutamine </e1> in this group was severely impaired as compared to the non-<e2> ischemic </e2> group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1378": {"data": {"text": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "entity1": "fluoxetine", "entity2": "obsessive compulsive disorder", "span1": [24, 34], "span2": [56, 85]}, "bert_text": "Five patients receiving <e1> fluoxetine </e1> for the treatment of <e2> obsessive compulsive disorder </e2> or major depression developed akathisia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1379": {"data": {"text": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "entity1": "fluoxetine", "entity2": "major depression", "span1": [24, 34], "span2": [89, 105]}, "bert_text": "Five patients receiving <e1> fluoxetine </e1> for the treatment of obsessive compulsive disorder or <e2> major depression </e2> developed akathisia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1380": {"data": {"text": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "entity1": "fluoxetine", "entity2": "akathisia", "span1": [24, 34], "span2": [116, 125]}, "bert_text": "Five patients receiving <e1> fluoxetine </e1> for the treatment of obsessive compulsive disorder or major depression developed <e2> akathisia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1381": {"data": {"text": "Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.\n", "entity1": "bisphosphonate", "entity2": "proteinuria", "span1": [55, 69], "span2": [8, 19]}, "bert_text": "Massive proteinuria and acute renal failure after oral <e1> bisphosphonate </e1> <e2> proteinuria </e2> and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1382": {"data": {"text": "Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.\n", "entity1": "bisphosphonate", "entity2": "acute renal failure", "span1": [55, 69], "span2": [24, 43]}, "bert_text": "Massive proteinuria and acute renal failure after oral <e1> bisphosphonate </e1> <e2> acute renal failure </e2> after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1383": {"data": {"text": "Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.\n", "entity1": "bisphosphonate", "entity2": "focal segmental glomerulosclerosis", "span1": [55, 69], "span2": [117, 151]}, "bert_text": "Massive proteinuria and acute renal failure after oral <e1> bisphosphonate </e1> (alendronate) administration in a patient with <e2> focal segmental glomerulosclerosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1384": {"data": {"text": "Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.\n", "entity1": "alendronate", "entity2": "proteinuria", "span1": [71, 82], "span2": [8, 19]}, "bert_text": "Massive proteinuria and acute renal failure after oral bisphosphonate (<e1> alendronate </e1> <e2> proteinuria </e2> and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1385": {"data": {"text": "Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.\n", "entity1": "alendronate", "entity2": "acute renal failure", "span1": [71, 82], "span2": [24, 43]}, "bert_text": "Massive proteinuria and acute renal failure after oral bisphosphonate (<e1> alendronate </e1> <e2> acute renal failure </e2> after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1386": {"data": {"text": "Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.\n", "entity1": "alendronate", "entity2": "focal segmental glomerulosclerosis", "span1": [71, 82], "span2": [117, 151]}, "bert_text": "Massive proteinuria and acute renal failure after oral bisphosphonate (<e1> alendronate </e1>) administration in a patient with <e2> focal segmental glomerulosclerosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1387": {"data": {"text": "We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.", "entity1": "estrogen", "entity2": "hyperprolactinemia", "span1": [154, 162], "span2": [32, 50]}, "bert_text": "We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the <e1> estrogen </e1> <e2> hyperprolactinemia </e2> inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1388": {"data": {"text": "We report the first two cases of topiramate-induced nephrolithiasis in the urologic literature.", "entity1": "topiramate", "entity2": "nephrolithiasis", "span1": [33, 43], "span2": [52, 67]}, "bert_text": "We report the first two cases of <e1> topiramate </e1>-induced <e2> nephrolithiasis </e2> in the urologic literature.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1389": {"data": {"text": "To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.", "entity1": "FK 506-induced", "entity2": "hypertension", "span1": [29, 43], "span2": [44, 56]}, "bert_text": "To clarify the mechanisms of <e1> FK 506-induced </e1> <e2> hypertension </e2>, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1390": {"data": {"text": "To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.", "entity1": "FK 506", "entity2": "hypertension", "span1": [92, 98], "span2": [44, 56]}, "bert_text": "To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of <e1> FK 506 </e1> <e2> hypertension </e2>, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1391": {"data": {"text": "To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.", "entity1": "nitric oxide", "entity2": "hypertension", "span1": [231, 243], "span2": [44, 56]}, "bert_text": "To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial <e1> nitric oxide </e1> <e2> hypertension </e2>, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1392": {"data": {"text": "Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.", "entity1": "ritodrine", "entity2": "cardiovascular complications", "span1": [108, 117], "span2": [40, 68]}, "bert_text": "Such interactions may result in serious cardiovascular complications even after cessation of an infusion of <e1> ritodrine </e1> <e2> cardiovascular complications </e2> even after cessation of an infusion of ritodrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1393": {"data": {"text": "Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.", "entity1": "rizatriptan", "entity2": "pain", "span1": [56, 67], "span2": [36, 40]}, "bert_text": "Forty-nine percent of patients were pain free 2 h after <e1> rizatriptan </e1> <e2> pain </e2> free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1394": {"data": {"text": "Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.", "entity1": "rizatriptan", "entity2": "pain", "span1": [140, 151], "span2": [36, 40]}, "bert_text": "Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), <e1> rizatriptan </e1> <e2> pain </e2> free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1395": {"data": {"text": "Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.", "entity1": "ergotamine", "entity2": "pain", "span1": [102, 112], "span2": [36, 40]}, "bert_text": "Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with <e1> ergotamine </e1> <e2> pain </e2> free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1396": {"data": {"text": "Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.", "entity1": "caffeine", "entity2": "pain", "span1": [113, 121], "span2": [36, 40]}, "bert_text": "Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/<e1> caffeine </e1> <e2> pain </e2> free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1397": {"data": {"text": "Chronic active hepatitis associated with diclofenac sodium therapy.\nDiclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.", "entity1": "diclofenac sodium", "entity2": "Chronic active hepatitis", "span1": [41, 58], "span2": [0, 24]}, "bert_text": "Chronic active hepatitis associated with <e1> diclofenac sodium </e1> <e2> Chronic active hepatitis </e2> associated with diclofenac sodium therapy.\nDiclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1398": {"data": {"text": "Chronic active hepatitis associated with diclofenac sodium therapy.\nDiclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.", "entity1": "Diclofenac sodium", "entity2": "Chronic active hepatitis", "span1": [68, 85], "span2": [0, 24]}, "bert_text": "Chronic active hepatitis associated with diclofenac sodium therapy.\n<e1> Diclofenac sodium </e1> <e2> Chronic active hepatitis </e2> associated with diclofenac sodium therapy.\nDiclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1399": {"data": {"text": "Chronic active hepatitis associated with diclofenac sodium therapy.\nDiclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.", "entity1": "Voltarol", "entity2": "Chronic active hepatitis", "span1": [87, 95], "span2": [0, 24]}, "bert_text": "Chronic active hepatitis associated with diclofenac sodium therapy.\nDiclofenac sodium (<e1> Voltarol </e1> <e2> Chronic active hepatitis </e2> associated with diclofenac sodium therapy.\nDiclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1400": {"data": {"text": "Chronic active hepatitis associated with diclofenac sodium therapy.\nDiclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.", "entity1": "phenylacetic acid", "entity2": "Chronic active hepatitis", "span1": [171, 188], "span2": [0, 24]}, "bert_text": "Chronic active hepatitis associated with diclofenac sodium therapy.\nDiclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of <e1> phenylacetic acid </e1> <e2> Chronic active hepatitis </e2> associated with diclofenac sodium therapy.\nDiclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1401": {"data": {"text": "The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.", "entity1": "fluoxetine", "entity2": "restlessness", "span1": [12, 22], "span2": [43, 55]}, "bert_text": "The typical <e1> fluoxetine </e1>-induced symptoms of <e2> restlessness </e2>, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1402": {"data": {"text": "The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.", "entity1": "fluoxetine", "entity2": "anxiety", "span1": [12, 22], "span2": [129, 136]}, "bert_text": "The typical <e1> fluoxetine </e1>-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked <e2> anxiety </e2> were indistinguishable from those of neuroleptic-induced akathisia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1403": {"data": {"text": "The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.", "entity1": "fluoxetine", "entity2": "akathisia", "span1": [12, 22], "span2": [194, 203]}, "bert_text": "The typical <e1> fluoxetine </e1>-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced <e2> akathisia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1404": {"data": {"text": "This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.", "entity1": "methyl dopa", "entity2": "depressions", "span1": [75, 86], "span2": [50, 61]}, "bert_text": "This was accounted for by a significant number of depressions occurring in <e1> methyl dopa </e1> <e2> depressions </e2> occurring in methyl dopa treated patients with psychiatric histories.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1405": {"data": {"text": "This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.", "entity1": "methyl dopa", "entity2": "psychiatric", "span1": [75, 86], "span2": [109, 120]}, "bert_text": "This was accounted for by a significant number of depressions occurring in <e1> methyl dopa </e1> treated patients with <e2> psychiatric </e2> histories.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1406": {"data": {"text": "This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.", "entity1": "ritodrine", "entity2": "preterm labor", "span1": [46, 55], "span2": [60, 73]}, "bert_text": "This case illustrates that patients receiving <e1> ritodrine </e1> for <e2> preterm labor </e2> may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1407": {"data": {"text": "This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.", "entity1": "ritodrine", "entity2": "preterm labor", "span1": [140, 149], "span2": [60, 73]}, "bert_text": "This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of <e1> ritodrine </e1> <e2> preterm labor </e2> may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1408": {"data": {"text": "INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.", "entity1": "Cocaine", "entity2": "neurovascular complications", "span1": [14, 21], "span2": [51, 78]}, "bert_text": "INTRODUCTION: <e1> Cocaine </e1> use has been associated with <e2> neurovascular complications </e2>, including arterial vasoconstriction and vasculitis.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1409": {"data": {"text": "INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.", "entity1": "Cocaine", "entity2": "vasculitis", "span1": [14, 21], "span2": [120, 130]}, "bert_text": "INTRODUCTION: <e1> Cocaine </e1> use has been associated with neurovascular complications, including arterial vasoconstriction and <e2> vasculitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1410": {"data": {"text": "This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.", "entity1": "angiotensin", "entity2": "hypotensive", "span1": [50, 61], "span2": [98, 109]}, "bert_text": "This demonstrates the participation of the renin--<e1> angiotensin </e1> system in antagonizing the combined <e2> hypotensive </e2> effects of halothane and SNP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1411": {"data": {"text": "This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.", "entity1": "halothane", "entity2": "hypotensive", "span1": [121, 130], "span2": [98, 109]}, "bert_text": "This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of <e1> halothane </e1> <e2> hypotensive </e2> effects of halothane and SNP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1412": {"data": {"text": "This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.", "entity1": "SNP", "entity2": "hypotensive", "span1": [135, 138], "span2": [98, 109]}, "bert_text": "This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and <e1> SNP </e1> <e2> hypotensive </e2> effects of halothane and SNP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1413": {"data": {"text": "Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.", "entity1": "ribavirin", "entity2": "adenovirus disease", "span1": [214, 223], "span2": [51, 69]}, "bert_text": "Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous <e1> ribavirin </e1> <e2> adenovirus disease </e2> in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1414": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "levodopa", "entity2": "cerebral haemorrhage", "span1": [137, 145], "span2": [21, 41]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of <e1> levodopa </e1> <e2> cerebral haemorrhage </e2> as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1415": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "levodopa", "entity2": "death", "span1": [137, 145], "span2": [56, 61]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of <e1> levodopa </e1> <e2> death </e2> in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1416": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [137, 145], "span2": [79, 98]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of <e1> levodopa </e1> <e2> Parkinson's disease </e2> may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1417": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "levodopa", "entity2": "parkinsonian", "span1": [137, 145], "span2": [217, 229]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of <e1> levodopa </e1> and a hypotensive mechanism due to reduced noradrenaline levels in the <e2> parkinsonian </e2> brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1418": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "levodopa", "entity2": "hypotensive", "span1": [137, 145], "span2": [115, 126]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of <e1> levodopa </e1> <e2> hypotensive </e2> effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1419": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "levodopa", "entity2": "hypotensive", "span1": [137, 145], "span2": [152, 163]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of <e1> levodopa </e1> and a <e2> hypotensive </e2> mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1420": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "noradrenaline", "entity2": "cerebral haemorrhage", "span1": [189, 202], "span2": [21, 41]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1> noradrenaline </e1> <e2> cerebral haemorrhage </e2> as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1421": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "noradrenaline", "entity2": "death", "span1": [189, 202], "span2": [56, 61]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1> noradrenaline </e1> <e2> death </e2> in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1422": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "noradrenaline", "entity2": "Parkinson's disease", "span1": [189, 202], "span2": [79, 98]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1> noradrenaline </e1> <e2> Parkinson's disease </e2> may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1423": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "noradrenaline", "entity2": "parkinsonian", "span1": [189, 202], "span2": [217, 229]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1> noradrenaline </e1> levels in the <e2> parkinsonian </e2> brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1424": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "noradrenaline", "entity2": "hypotensive", "span1": [189, 202], "span2": [115, 126]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1> noradrenaline </e1> <e2> hypotensive </e2> effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1425": {"data": {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity1": "noradrenaline", "entity2": "hypotensive", "span1": [189, 202], "span2": [152, 163]}, "bert_text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced <e1> noradrenaline </e1> <e2> hypotensive </e2> mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1426": {"data": {"text": "We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.", "entity1": "quinidine phenylethylbarbiturate", "entity2": "hepatitis", "span1": [162, 194], "span2": [74, 83]}, "bert_text": "We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of <e1> quinidine phenylethylbarbiturate </e1> <e2> hepatitis </e2> during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1427": {"data": {"text": "However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported.", "entity1": "carboplatin", "entity2": "ocular and orbital toxicity", "span1": [101, 112], "span2": [41, 68]}, "bert_text": "However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of <e1> carboplatin </e1> <e2> ocular and orbital toxicity </e2> after intracarotid injection of carboplatin, which is infrequently reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1428": {"data": {"text": "Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient.", "entity1": "azithromycin", "entity2": "hiccups", "span1": [53, 65], "span2": [95, 102]}, "bert_text": "Our hypothesis is that a vagal mechanism mediated by <e1> azithromycin </e1> could be the pathogenesis of <e2> hiccups </e2> in our patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1429": {"data": {"text": "We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.", "entity1": "PGE(2", "entity2": "polyuria", "span1": [33, 38], "span2": [65, 73]}, "bert_text": "We conclude that mPGES-1-derived <e1> PGE(2 </e1>) mediates lithium-induced <e2> polyuria </e2> likely via inhibition of AQP2 and NKCC2 expression.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1430": {"data": {"text": "We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.", "entity1": "lithium", "entity2": "polyuria", "span1": [49, 56], "span2": [65, 73]}, "bert_text": "We conclude that mPGES-1-derived PGE(2) mediates <e1> lithium </e1>-induced <e2> polyuria </e2> likely via inhibition of AQP2 and NKCC2 expression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1431": {"data": {"text": "Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.\nOBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.", "entity1": "dietary sodium chloride", "entity2": "hypertensive", "span1": [324, 347], "span2": [111, 123]}, "bert_text": "Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.\nOBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of <e1> dietary sodium chloride </e1> <e2> hypertensive </e2> rats.\nOBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1432": {"data": {"text": "Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.\nOBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.", "entity1": "dietary sodium chloride", "entity2": "hypertensive", "span1": [324, 347], "span2": [214, 226]}, "bert_text": "Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.\nOBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of <e1> dietary sodium chloride </e1> <e2> hypertensive </e2> rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"1433": {"data": {"text": "Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.\nOBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.", "entity1": "dietary sodium chloride", "entity2": "hypertensive", "span1": [324, 347], "span2": [301, 313]}, "bert_text": "Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.\nOBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of <e1> dietary sodium chloride </e1> <e2> hypertensive </e2> effect of dietary sodium chloride supplementation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1434": {"data": {"text": "D-penicillamine-induced angiopathy in rats.", "entity1": "D-penicillamine", "entity2": "angiopathy", "span1": [0, 15], "span2": [24, 34]}, "bert_text": "<e1> D-penicillamine </e1>-induced <e2> angiopathy </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1435": {"data": {"text": "Two patients are presented who suffered progressive hemiparesis due to DPH overdose.", "entity1": "DPH", "entity2": "hemiparesis", "span1": [71, 74], "span2": [52, 63]}, "bert_text": "Two patients are presented who suffered progressive hemiparesis due to <e1> DPH </e1> <e2> hemiparesis </e2> due to DPH overdose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1436": {"data": {"text": "Two patients are presented who suffered progressive hemiparesis due to DPH overdose.", "entity1": "DPH", "entity2": "overdose", "span1": [71, 74], "span2": [75, 83]}, "bert_text": "Two patients are presented who suffered progressive hemiparesis due to <e1> DPH </e1> <e2> overdose </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1437": {"data": {"text": "Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.\n", "entity1": "Pentoxifylline", "entity2": "coronary hyperemia", "span1": [0, 14], "span2": [63, 81]}, "bert_text": "<e1> Pentoxifylline </e1> (Trental) does not inhibit dipyridamole-induced <e2> coronary hyperemia </e2>: implications for dipyridamole-thallium-201 myocardial imaging.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1438": {"data": {"text": "Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.\n", "entity1": "dipyridamole", "entity2": "coronary hyperemia", "span1": [42, 54], "span2": [63, 81]}, "bert_text": "Pentoxifylline (Trental) does not inhibit <e1> dipyridamole </e1>-induced <e2> coronary hyperemia </e2>: implications for dipyridamole-thallium-201 myocardial imaging.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"1439": {"data": {"text": "Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.\n", "entity1": "dipyridamole-thallium-201", "entity2": "coronary hyperemia", "span1": [100, 125], "span2": [63, 81]}, "bert_text": "Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for <e1> dipyridamole-thallium-201 </e1> <e2> coronary hyperemia </e2>: implications for dipyridamole-thallium-201 myocardial imaging.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1440": {"data": {"text": "Mediation of enhanced reflex vagal bradycardia by L-dopa via central dopamine formation in dogs.\n", "entity1": "L-dopa", "entity2": "bradycardia", "span1": [50, 56], "span2": [35, 46]}, "bert_text": "Mediation of enhanced reflex vagal bradycardia by <e1> L-dopa </e1> <e2> bradycardia </e2> by L-dopa via central dopamine formation in dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1441": {"data": {"text": "Mediation of enhanced reflex vagal bradycardia by L-dopa via central dopamine formation in dogs.\n", "entity1": "dopamine", "entity2": "bradycardia", "span1": [69, 77], "span2": [35, 46]}, "bert_text": "Mediation of enhanced reflex vagal bradycardia by L-dopa via central <e1> dopamine </e1> <e2> bradycardia </e2> by L-dopa via central dopamine formation in dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1442": {"data": {"text": "Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.", "entity1": "dopamine", "entity2": "hyperprolactinemia", "span1": [42, 50], "span2": [8, 26]}, "bert_text": "Chronic hyperprolactinemia induced by the <e1> dopamine </e1> <e2> hyperprolactinemia </e2> induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1443": {"data": {"text": "Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.", "entity1": "sulpiride", "entity2": "hyperprolactinemia", "span1": [62, 71], "span2": [8, 26]}, "bert_text": "Chronic hyperprolactinemia induced by the dopamine antagonist <e1> sulpiride </e1> <e2> hyperprolactinemia </e2> induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1444": {"data": {"text": "Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.", "entity1": "estradiol", "entity2": "hyperprolactinemia", "span1": [188, 197], "span2": [8, 26]}, "bert_text": "Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of <e1> estradiol </e1> <e2> hyperprolactinemia </e2> induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1445": {"data": {"text": "In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.", "entity1": "FR 139317", "entity2": "hypertension", "span1": [78, 87], "span2": [106, 118]}, "bert_text": "In addition, the effect of the specific endothelin type A receptor antagonist <e1> FR 139317 </e1> on FK 506-induced <e2> hypertension </e2> in rats was studied.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1446": {"data": {"text": "In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.", "entity1": "FK 506-induced", "entity2": "hypertension", "span1": [91, 105], "span2": [106, 118]}, "bert_text": "In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on <e1> FK 506-induced </e1> <e2> hypertension </e2> in rats was studied.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1447": {"data": {"text": "Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.", "entity1": "urea", "entity2": "Renal damage", "span1": [50, 54], "span2": [0, 12]}, "bert_text": "Renal damage as reflected by an increase in serum <e1> urea </e1> <e2> Renal damage </e2> as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1448": {"data": {"text": "Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.\n", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [67, 76], "span2": [23, 34]}, "bert_text": "Clinically significant proteinuria following the administration of <e1> sirolimus </e1> <e2> proteinuria </e2> following the administration of sirolimus to renal transplant recipients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1449": {"data": {"text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).", "entity1": "FK506", "entity2": "IgA nephropathy", "span1": [210, 215], "span2": [141, 156]}, "bert_text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic <e1> FK506 </e1> <e2> IgA nephropathy </e2> (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1450": {"data": {"text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).", "entity1": "FK506", "entity2": "nephropathy", "span1": [210, 215], "span2": [216, 227]}, "bert_text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic <e1> FK506 </e1> <e2> nephropathy </e2> (n = 9), and mild-type FK506 nephropathy (n = 11).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1451": {"data": {"text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).", "entity1": "FK506", "entity2": "nephropathy", "span1": [210, 215], "span2": [257, 268]}, "bert_text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic <e1> FK506 </e1> nephropathy (n = 9), and mild-type FK506 <e2> nephropathy </e2> (n = 11).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1452": {"data": {"text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).", "entity1": "FK506", "entity2": "IgA nephropathy", "span1": [251, 256], "span2": [141, 156]}, "bert_text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type <e1> FK506 </e1> <e2> IgA nephropathy </e2> (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1453": {"data": {"text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).", "entity1": "FK506", "entity2": "nephropathy", "span1": [251, 256], "span2": [216, 227]}, "bert_text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type <e1> FK506 </e1> <e2> nephropathy </e2> (n = 9), and mild-type FK506 nephropathy (n = 11).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1454": {"data": {"text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).", "entity1": "FK506", "entity2": "nephropathy", "span1": [251, 256], "span2": [257, 268]}, "bert_text": "RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type <e1> FK506 </e1> <e2> nephropathy </e2> (n = 11).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1455": {"data": {"text": "Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.\n", "entity1": "Levodopa", "entity2": "dyskinesias", "span1": [0, 8], "span2": [17, 28]}, "bert_text": "<e1> Levodopa </e1>-induced <e2> dyskinesias </e2> in patients with Parkinson's disease: filling the bench-to-bedside gap.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1456": {"data": {"text": "Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.\n", "entity1": "Levodopa", "entity2": "Parkinson's disease", "span1": [0, 8], "span2": [46, 65]}, "bert_text": "<e1> Levodopa </e1>-induced dyskinesias in patients with <e2> Parkinson's disease </e2>: filling the bench-to-bedside gap.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1457": {"data": {"text": "Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.\n", "entity1": "L-alpha-glyceryl-phosphorylcholine", "entity2": "amnesia", "span1": [10, 44], "span2": [48, 55]}, "bert_text": "Effect of <e1> L-alpha-glyceryl-phosphorylcholine </e1> on <e2> amnesia </e2> caused by scopolamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1458": {"data": {"text": "Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.\n", "entity1": "scopolamine", "entity2": "amnesia", "span1": [66, 77], "span2": [48, 55]}, "bert_text": "Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by <e1> scopolamine </e1> <e2> amnesia </e2> caused by scopolamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1459": {"data": {"text": "Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).", "entity1": "Steroids", "entity2": "seizures", "span1": [0, 8], "span2": [196, 204]}, "bert_text": "<e1> Steroids </e1> with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor <e2> seizures </e2> and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1460": {"data": {"text": "Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).", "entity1": "Steroids", "entity2": "status epilepticus", "span1": [0, 8], "span2": [209, 227]}, "bert_text": "<e1> Steroids </e1> with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and <e2> status epilepticus </e2> (ED50 values, 7.0-18.7 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1461": {"data": {"text": "Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).", "entity1": "pilocarpine", "entity2": "seizures", "span1": [145, 156], "span2": [196, 204]}, "bert_text": "Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against <e1> pilocarpine </e1> (416 mg/kg, s.c.)-induced limbic motor <e2> seizures </e2> and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1462": {"data": {"text": "Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [145, 156], "span2": [209, 227]}, "bert_text": "Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against <e1> pilocarpine </e1> (416 mg/kg, s.c.)-induced limbic motor seizures and <e2> status epilepticus </e2> (ED50 values, 7.0-18.7 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1463": {"data": {"text": "The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.", "entity1": "digoxin", "entity2": "rheumatic heart disease", "span1": [53, 60], "span2": [164, 187]}, "bert_text": "The patients of the study and control group (without <e1> digoxin </e1>) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the <e2> rheumatic heart disease </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1464": {"data": {"text": "The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to lidocaine.", "entity1": "lidocaine", "entity2": "bradyarrhythmias", "span1": [183, 192], "span2": [105, 121]}, "bert_text": "The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to <e1> lidocaine </e1> <e2> bradyarrhythmias </e2>; and, thus, this probably represented a true idiosyncrasy to lidocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1465": {"data": {"text": "Liver disease caused by propylthiouracil.\n", "entity1": "propylthiouracil", "entity2": "Liver disease", "span1": [24, 40], "span2": [0, 13]}, "bert_text": "Liver disease caused by <e1> propylthiouracil </e1> <e2> Liver disease </e2> caused by propylthiouracil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1466": {"data": {"text": "Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.\n", "entity1": "amiodarone", "entity2": "congestive heart failure", "span1": [43, 53], "span2": [7, 31]}, "bert_text": "Severe congestive heart failure patient on <e1> amiodarone </e1> <e2> congestive heart failure </e2> patient on amiodarone presenting with myxedemic coma: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1467": {"data": {"text": "Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.\n", "entity1": "amiodarone", "entity2": "myxedemic coma", "span1": [43, 53], "span2": [70, 84]}, "bert_text": "Severe congestive heart failure patient on <e1> amiodarone </e1> presenting with <e2> myxedemic coma </e2>: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1468": {"data": {"text": "These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.", "entity1": "naloxone", "entity2": "respiratory paralysis", "span1": [19, 27], "span2": [37, 58]}, "bert_text": "These data suggest <e1> naloxone </e1> reverses <e2> respiratory paralysis </e2> produced by thiopental and involves GABA in its action.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1469": {"data": {"text": "These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.", "entity1": "thiopental", "entity2": "respiratory paralysis", "span1": [71, 81], "span2": [37, 58]}, "bert_text": "These data suggest naloxone reverses respiratory paralysis produced by <e1> thiopental </e1> <e2> respiratory paralysis </e2> produced by thiopental and involves GABA in its action.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1470": {"data": {"text": "These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.", "entity1": "GABA", "entity2": "respiratory paralysis", "span1": [95, 99], "span2": [37, 58]}, "bert_text": "These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves <e1> GABA </e1> <e2> respiratory paralysis </e2> produced by thiopental and involves GABA in its action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1471": {"data": {"text": "We describe the largest group of AX-allergic patients who have tolerated PG reported so far.", "entity1": "AX", "entity2": "allergic", "span1": [33, 35], "span2": [36, 44]}, "bert_text": "We describe the largest group of <e1> AX </e1>-<e2> allergic </e2> patients who have tolerated PG reported so far.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1472": {"data": {"text": "We describe the largest group of AX-allergic patients who have tolerated PG reported so far.", "entity1": "PG", "entity2": "allergic", "span1": [73, 75], "span2": [36, 44]}, "bert_text": "We describe the largest group of AX-allergic patients who have tolerated <e1> PG </e1> <e2> allergic </e2> patients who have tolerated PG reported so far.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1473": {"data": {"text": "INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.", "entity1": "HCFCs 123 and 124", "entity2": "liver injury", "span1": [53, 70], "span2": [93, 105]}, "bert_text": "INTERPRETATION: Repeated exposure of human beings to <e1> HCFCs 123 and 124 </e1> can result in serious <e2> liver injury </e2> in a large proportion of the exposed population.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1474": {"data": {"text": "CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.", "entity1": "prochlorperazine", "entity2": "akathisia", "span1": [63, 79], "span2": [48, 57]}, "bert_text": "CONCLUSION: A 50% reduction in the incidence of akathisia when <e1> prochlorperazine </e1> <e2> akathisia </e2> when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1475": {"data": {"text": "The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.", "entity1": "ephedrine", "entity2": "hypotensive", "span1": [16, 25], "span2": [89, 100]}, "bert_text": "The addition of <e1> ephedrine </e1> to propofol appears to be an effective method of obtunding the <e2> hypotensive </e2> response to propofol at all doses used in this study.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1476": {"data": {"text": "The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.", "entity1": "propofol", "entity2": "hypotensive", "span1": [29, 37], "span2": [89, 100]}, "bert_text": "The addition of ephedrine to <e1> propofol </e1> appears to be an effective method of obtunding the <e2> hypotensive </e2> response to propofol at all doses used in this study.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1477": {"data": {"text": "The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.", "entity1": "propofol", "entity2": "hypotensive", "span1": [113, 121], "span2": [89, 100]}, "bert_text": "The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to <e1> propofol </e1> <e2> hypotensive </e2> response to propofol at all doses used in this study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"1478": {"data": {"text": "Amnestic syndrome associated with propranolol toxicity: a case report.\n", "entity1": "propranolol", "entity2": "Amnestic syndrome", "span1": [34, 45], "span2": [0, 17]}, "bert_text": "Amnestic syndrome associated with <e1> propranolol </e1> <e2> Amnestic syndrome </e2> associated with propranolol toxicity: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1479": {"data": {"text": "Amnestic syndrome associated with propranolol toxicity: a case report.\n", "entity1": "propranolol", "entity2": "toxicity", "span1": [34, 45], "span2": [46, 54]}, "bert_text": "Amnestic syndrome associated with <e1> propranolol </e1> <e2> toxicity </e2>: a case report.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1480": {"data": {"text": "Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.", "entity1": "cisplatin", "entity2": "mitochondrial impairment", "span1": [34, 43], "span2": [71, 95]}, "bert_text": "Our results demonstrate that both <e1> cisplatin </e1> and paclitaxel cause early <e2> mitochondrial impairment </e2> with loss of membrane potential and induction of autophagic vacuoles in neurons.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1481": {"data": {"text": "Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.", "entity1": "paclitaxel", "entity2": "mitochondrial impairment", "span1": [48, 58], "span2": [71, 95]}, "bert_text": "Our results demonstrate that both cisplatin and <e1> paclitaxel </e1> cause early <e2> mitochondrial impairment </e2> with loss of membrane potential and induction of autophagic vacuoles in neurons.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1482": {"data": {"text": "Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.", "entity1": "Capecitabine", "entity2": "renal dysfunctions", "span1": [0, 12], "span2": [118, 136]}, "bert_text": "<e1> Capecitabine </e1> has a well-established safety profile and can be given safely to patients with advanced age, hepatic and <e2> renal dysfunctions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1483": {"data": {"text": "In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.", "entity1": "procainamide", "entity2": "ventricular tachycardia", "span1": [100, 112], "span2": [135, 158]}, "bert_text": "In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of <e1> procainamide </e1> therapy, polymorphous <e2> ventricular tachycardia </e2> did not reoccur.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1484": {"data": {"text": "Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.", "entity1": "histamine", "entity2": "gastric hemorrhage", "span1": [36, 45], "span2": [49, 67]}, "bert_text": "Moreover, a positive correlation of <e1> histamine </e1> to <e2> gastric hemorrhage </e2> and to ulcer was found in those atherosclerotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1485": {"data": {"text": "Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.", "entity1": "histamine", "entity2": "ulcer", "span1": [36, 45], "span2": [75, 80]}, "bert_text": "Moreover, a positive correlation of <e1> histamine </e1> to gastric hemorrhage and to <e2> ulcer </e2> was found in those atherosclerotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1486": {"data": {"text": "Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.", "entity1": "histamine", "entity2": "atherosclerotic", "span1": [36, 45], "span2": [100, 115]}, "bert_text": "Moreover, a positive correlation of <e1> histamine </e1> to gastric hemorrhage and to ulcer was found in those <e2> atherosclerotic </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1487": {"data": {"text": "A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.", "entity1": "-)-cibenzoline", "entity2": "arrhythmia", "span1": [33, 47], "span2": [81, 91]}, "bert_text": "A lower dose of 1 mg/kg i.v. of (<e1> -)-cibenzoline </e1> suppressed the digitalis-induced <e2> arrhythmia </e2>, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1488": {"data": {"text": "A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.", "entity1": "-)-cibenzoline", "entity2": "arrhythmias", "span1": [33, 47], "span2": [156, 167]}, "bert_text": "A lower dose of 1 mg/kg i.v. of (<e1> -)-cibenzoline </e1> suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced <e2> arrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1489": {"data": {"text": "A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.", "entity1": "adrenaline", "entity2": "arrhythmia", "span1": [137, 147], "span2": [81, 91]}, "bert_text": "A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress <e1> adrenaline </e1> <e2> arrhythmia </e2>, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1490": {"data": {"text": "A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.", "entity1": "adrenaline", "entity2": "arrhythmias", "span1": [137, 147], "span2": [156, 167]}, "bert_text": "A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress <e1> adrenaline </e1>-induced <e2> arrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1491": {"data": {"text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "entity1": "hepatitis B surface antigen", "entity2": "hepatitis B", "span1": [229, 256], "span2": [61, 72]}, "bert_text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1> <e2> hepatitis B </e2> and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1492": {"data": {"text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "entity1": "hepatitis B surface antigen", "entity2": "hepatitis B", "span1": [229, 256], "span2": [108, 119]}, "bert_text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1> <e2> hepatitis B </e2> vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1493": {"data": {"text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "entity1": "hepatitis B surface antigen", "entity2": "hepatitis B", "span1": [229, 256], "span2": [173, 184]}, "bert_text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1> <e2> hepatitis B </e2> immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1494": {"data": {"text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "entity1": "hepatitis B surface antigen", "entity2": "rubella", "span1": [229, 256], "span2": [77, 84]}, "bert_text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1> <e2> rubella </e2>, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1495": {"data": {"text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "entity1": "hepatitis B surface antigen", "entity2": "rubella", "span1": [229, 256], "span2": [275, 282]}, "bert_text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1>-positive mothers, <e2> rubella </e2> immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1496": {"data": {"text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "entity1": "hepatitis B surface antigen", "entity2": "rubella", "span1": [229, 256], "span2": [338, 345]}, "bert_text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1>-positive mothers, rubella immunity, and administration of in-hospital postpartum <e2> rubella </e2> vaccine to rubella nonimmune women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1497": {"data": {"text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "entity1": "hepatitis B surface antigen", "entity2": "rubella", "span1": [229, 256], "span2": [357, 364]}, "bert_text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1>-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to <e2> rubella </e2> nonimmune women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1498": {"data": {"text": "METHODS: Cholinergic convulsant sensitivity was examined in alcohol-na  ve Withdrawal Seizure-Prone (WSP) and-Resistant (WSR) mice.", "entity1": "alcohol", "entity2": "Seizure", "span1": [60, 67], "span2": [86, 93]}, "bert_text": "METHODS: Cholinergic convulsant sensitivity was examined in <e1> alcohol </e1>-na  ve Withdrawal <e2> Seizure </e2>-Prone (WSP) and-Resistant (WSR) mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1499": {"data": {"text": "METHODS: Cholinergic convulsant sensitivity was examined in alcohol-na  ve Withdrawal Seizure-Prone (WSP) and-Resistant (WSR) mice.", "entity1": "na", "entity2": "Seizure", "span1": [68, 70], "span2": [86, 93]}, "bert_text": "METHODS: Cholinergic convulsant sensitivity was examined in alcohol-<e1> na </e1>  ve Withdrawal <e2> Seizure </e2>-Prone (WSP) and-Resistant (WSR) mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1500": {"data": {"text": "Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.\n", "entity1": "pilocarpine", "entity2": "temporal lobe epilepsy", "span1": [39, 50], "span2": [60, 82]}, "bert_text": "Neuropeptide-Y immunoreactivity in the <e1> pilocarpine </e1> model of <e2> temporal lobe epilepsy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1501": {"data": {"text": "Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.", "entity1": "Desferrioxamine", "entity2": "hearing loss", "span1": [0, 15], "span2": [145, 157]}, "bert_text": "<e1> Desferrioxamine </e1> withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of <e2> hearing loss </e2> in 3 patients and partial recovery in 3.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1502": {"data": {"text": "Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.", "entity1": "cocaine", "entity2": "toxicity", "span1": [24, 31], "span2": [32, 40]}, "bert_text": "Significant blockade of <e1> cocaine </e1> <e2> toxicity </e2> was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1503": {"data": {"text": "Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.", "entity1": "cocaine", "entity2": "seizures", "span1": [24, 31], "span2": [149, 157]}, "bert_text": "Significant blockade of <e1> cocaine </e1> toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, <e2> seizures </e2> up to 77% and death by 72%.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1504": {"data": {"text": "Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.", "entity1": "cocaine", "entity2": "death", "span1": [24, 31], "span2": [172, 177]}, "bert_text": "Significant blockade of <e1> cocaine </e1> toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and <e2> death </e2> by 72%.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1505": {"data": {"text": "These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.", "entity1": "bradykinin", "entity2": "hypertension", "span1": [135, 145], "span2": [79, 91]}, "bert_text": "These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of <e1> bradykinin </e1> <e2> hypertension </e2> is not related to the synthesis/release of bradykinin to activate B2 receptors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1506": {"data": {"text": "We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.", "entity1": "metformin hydrochloride", "entity2": "cholestatic jaundice", "span1": [98, 121], "span2": [34, 54]}, "bert_text": "We report a patient who developed cholestatic jaundice shortly after initiation of treatment with <e1> metformin hydrochloride </e1> <e2> cholestatic jaundice </e2> shortly after initiation of treatment with metformin hydrochloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1507": {"data": {"text": "A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.\n", "entity1": "dothiepin hydrochloride", "entity2": "depressive disorder", "span1": [51, 74], "span2": [101, 120]}, "bert_text": "A double-blind study of the efficacy and safety of <e1> dothiepin hydrochloride </e1> in the treatment of major <e2> depressive disorder </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1508": {"data": {"text": "Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures.", "entity1": "Picloxydine", "entity2": "cystitis", "span1": [0, 11], "span2": [70, 78]}, "bert_text": "<e1> Picloxydine </e1> irrigations appeared to have a lower incidence of erosive <e2> cystitis </e2> but further studies would have to be performed before it could be recommended for use in urological procedures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1509": {"data": {"text": "Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.\n", "entity1": "Acetazolamide", "entity2": "nephrolithiasis", "span1": [0, 13], "span2": [22, 37]}, "bert_text": "<e1> Acetazolamide </e1>-induced <e2> nephrolithiasis </e2>: implications for treatment of neuromuscular disorders.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1510": {"data": {"text": "Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.\n", "entity1": "Acetazolamide", "entity2": "neuromuscular disorders", "span1": [0, 13], "span2": [69, 92]}, "bert_text": "<e1> Acetazolamide </e1>-induced nephrolithiasis: implications for treatment of <e2> neuromuscular disorders </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1511": {"data": {"text": "The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/-", "entity1": "-)-cibenzoline", "entity2": "arrhythmia", "span1": [48, 62], "span2": [101, 111]}, "bert_text": "The minimum effective plasma concentrations of (<e1> -)-cibenzoline </e1> for digitalis- and adrenaline-induced <e2> arrhythmia </e2> were 0.06 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1512": {"data": {"text": "The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/-", "entity1": "adrenaline", "entity2": "arrhythmia", "span1": [82, 92], "span2": [101, 111]}, "bert_text": "The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and <e1> adrenaline </e1>-induced <e2> arrhythmia </e2> were 0.06 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1513": {"data": {"text": "The objective of this study was to determine whether ephedrine, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced sexual dysfunction.", "entity1": "ephedrine", "entity2": "sexual dysfunction", "span1": [53, 62], "span2": [218, 236]}, "bert_text": "The objective of this study was to determine whether <e1> ephedrine </e1>, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced <e2> sexual dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1514": {"data": {"text": "The objective of this study was to determine whether ephedrine, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced sexual dysfunction.", "entity1": "antidepressant", "entity2": "sexual dysfunction", "span1": [195, 209], "span2": [218, 236]}, "bert_text": "The objective of this study was to determine whether ephedrine, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing <e1> antidepressant </e1>-induced <e2> sexual dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1515": {"data": {"text": "CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.", "entity1": "CsA", "entity2": "synergistic nephrotoxic", "span1": [76, 79], "span2": [42, 65]}, "bert_text": "CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of <e1> CsA </e1> <e2> synergistic nephrotoxic </e2> effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1516": {"data": {"text": "CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.", "entity1": "SRL", "entity2": "synergistic nephrotoxic", "span1": [85, 88], "span2": [42, 65]}, "bert_text": "CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus <e1> SRL </e1> <e2> synergistic nephrotoxic </e2> effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1517": {"data": {"text": "CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.", "entity1": "SRL", "entity2": "synergistic nephrotoxic", "span1": [109, 112], "span2": [42, 65]}, "bert_text": "CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus <e1> SRL </e1> <e2> synergistic nephrotoxic </e2> effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1518": {"data": {"text": "CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.", "entity1": "FK506", "entity2": "synergistic nephrotoxic", "span1": [98, 103], "span2": [42, 65]}, "bert_text": "CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas <e1> FK506 </e1> <e2> synergistic nephrotoxic </e2> effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1519": {"data": {"text": "Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.\n", "entity1": "doxorubicin", "entity2": "nephrosis", "span1": [70, 81], "span2": [82, 91]}, "bert_text": "Mitochondrial DNA and its respiratory chain products are defective in <e1> doxorubicin </e1> <e2> nephrosis </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1520": {"data": {"text": "BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.", "entity1": "Doxorubicin", "entity2": "nephropathy", "span1": [12, 23], "span2": [52, 63]}, "bert_text": "BACKGROUND: <e1> Doxorubicin </e1> induces a self-perpetuating <e2> nephropathy </e2> characterized by early glomerular and late-onset tubular lesions in rats.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1521": {"data": {"text": "In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by pilocarpine in rats.", "entity1": "pilocarpine", "entity2": "epilepsy", "span1": [131, 142], "span2": [111, 119]}, "bert_text": "In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by <e1> pilocarpine </e1> <e2> epilepsy </e2> induced by pilocarpine in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1522": {"data": {"text": "BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.", "entity1": "adriamycin", "entity2": "heart failure", "span1": [63, 73], "span2": [38, 51]}, "bert_text": "BACKGROUND: The mechanisms underlying heart failure induced by <e1> adriamycin </e1> <e2> heart failure </e2> induced by adriamycin are very complicated and still unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1523": {"data": {"text": "The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.\n", "entity1": "bupropion", "entity2": "sexual dysfunction", "span1": [30, 39], "span2": [48, 66]}, "bert_text": "The effects of the adjunctive <e1> bupropion </e1> on male <e2> sexual dysfunction </e2> induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1524": {"data": {"text": "The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.\n", "entity1": "serotonin", "entity2": "sexual dysfunction", "span1": [90, 99], "span2": [48, 66]}, "bert_text": "The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective <e1> serotonin </e1> <e2> sexual dysfunction </e2> induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1525": {"data": {"text": "Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.", "entity1": "FK506", "entity2": "nephropathy", "span1": [87, 92], "span2": [93, 104]}, "bert_text": "Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic <e1> FK506 </e1> <e2> nephropathy </e2>, respectively.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1526": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "bupropion", "entity2": "sexual dysfunction", "span1": [62, 71], "span2": [103, 121]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive <e1> bupropion </e1> sustained-release (SR) on male <e2> sexual dysfunction </e2> (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1527": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "bupropion", "entity2": "SD", "span1": [62, 71], "span2": [123, 125]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive <e1> bupropion </e1> sustained-release (SR) on male sexual dysfunction (<e2> SD </e2>) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1528": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "bupropion", "entity2": "SD", "span1": [62, 71], "span2": [190, 192]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive <e1> bupropion </e1> sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as <e2> SD </e2> is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1529": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "serotonin", "entity2": "sexual dysfunction", "span1": [150, 159], "span2": [103, 121]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective <e1> serotonin </e1> <e2> sexual dysfunction </e2> (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1530": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "serotonin", "entity2": "SD", "span1": [150, 159], "span2": [123, 125]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective <e1> serotonin </e1> <e2> SD </e2>) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1531": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "serotonin", "entity2": "SD", "span1": [150, 159], "span2": [190, 192]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective <e1> serotonin </e1> reuptake inhibitor (SSRI), as <e2> SD </e2> is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1532": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "SSRI", "entity2": "sexual dysfunction", "span1": [180, 184], "span2": [103, 121]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (<e1> SSRI </e1> <e2> sexual dysfunction </e2> (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1533": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "SSRI", "entity2": "SD", "span1": [180, 184], "span2": [123, 125]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (<e1> SSRI </e1> <e2> SD </e2>) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1534": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "SSRI", "entity2": "SD", "span1": [180, 184], "span2": [190, 192]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (<e1> SSRI </e1>), as <e2> SD </e2> is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1535": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "SSRIs", "entity2": "sexual dysfunction", "span1": [220, 225], "span2": [103, 121]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of <e1> SSRIs </e1> <e2> sexual dysfunction </e2> (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1536": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "SSRIs", "entity2": "SD", "span1": [220, 225], "span2": [123, 125]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of <e1> SSRIs </e1> <e2> SD </e2>) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1537": {"data": {"text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "entity1": "SSRIs", "entity2": "SD", "span1": [220, 225], "span2": [190, 192]}, "bert_text": "OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of <e1> SSRIs </e1> <e2> SD </e2> is a common side-effect of SSRIs and the most effective treatments have yet to be determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1538": {"data": {"text": "The effects of sevoflurane on lidocaine-induced convulsions.\n", "entity1": "sevoflurane", "entity2": "convulsions", "span1": [15, 26], "span2": [48, 59]}, "bert_text": "The effects of <e1> sevoflurane </e1> on lidocaine-induced <e2> convulsions </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1539": {"data": {"text": "The effects of sevoflurane on lidocaine-induced convulsions.\n", "entity1": "lidocaine", "entity2": "convulsions", "span1": [30, 39], "span2": [48, 59]}, "bert_text": "The effects of sevoflurane on <e1> lidocaine </e1>-induced <e2> convulsions </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1540": {"data": {"text": "In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.", "entity1": "cortisol", "entity2": "hypertension", "span1": [45, 53], "span2": [165, 177]}, "bert_text": "In both cases normal plasma and urinary free <e1> cortisol </e1> levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated <e2> hypertension </e2> 31 (patient 1) and 52 weeks (patient 2) after treatment.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1541": {"data": {"text": "In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.", "entity1": "ketoconazole", "entity2": "hypertension", "span1": [89, 101], "span2": [165, 177]}, "bert_text": "In both cases normal plasma and urinary free cortisol levels had been achieved following <e1> ketoconazole </e1> therapy, yet continuous blood pressure monitoring demonstrated <e2> hypertension </e2> 31 (patient 1) and 52 weeks (patient 2) after treatment.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1542": {"data": {"text": "The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.", "entity1": "sevoflurane", "entity2": "convulsions", "span1": [17, 28], "span2": [50, 61]}, "bert_text": "The influence of <e1> sevoflurane </e1> on lidocaine-induced <e2> convulsions </e2> was studied in cats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1543": {"data": {"text": "The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.", "entity1": "lidocaine", "entity2": "convulsions", "span1": [32, 41], "span2": [50, 61]}, "bert_text": "The influence of sevoflurane on <e1> lidocaine </e1>-induced <e2> convulsions </e2> was studied in cats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1544": {"data": {"text": "The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol.", "entity1": "isoproterenol", "entity2": "infarction", "span1": [119, 132], "span2": [33, 43]}, "bert_text": "The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with <e1> isoproterenol </e1> <e2> infarction </e2> implies artery ligation but chemical induction can be easily obtained with isoproterenol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1545": {"data": {"text": "Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.\n", "entity1": "Dexmedetomidine", "entity2": "muscle rigidity", "span1": [0, 15], "span2": [87, 102]}, "bert_text": "<e1> Dexmedetomidine </e1>, acting through central alpha-2 adrenoceptors, prevents opiate-induced <e2> muscle rigidity </e2> in the rat.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1546": {"data": {"text": "In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.", "entity1": "ADP", "entity2": "respiratory dysfunction", "span1": [108, 111], "span2": [27, 50]}, "bert_text": "In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and <e1> ADP </e1> <e2> respiratory dysfunction </e2> characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1547": {"data": {"text": "In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.", "entity1": "isoproterenol", "entity2": "respiratory dysfunction", "span1": [130, 143], "span2": [27, 50]}, "bert_text": "In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in <e1> isoproterenol </e1> <e2> respiratory dysfunction </e2> characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1548": {"data": {"text": "Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.\n", "entity1": "ifosfamide", "entity2": "renal toxicity", "span1": [23, 33], "span2": [34, 48]}, "bert_text": "Long-term follow-up of <e1> ifosfamide </e1> <e2> renal toxicity </e2> in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1549": {"data": {"text": "Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.\n", "entity1": "ifosfamide", "entity2": "malignant mesenchymal tumors", "span1": [23, 33], "span2": [73, 101]}, "bert_text": "Long-term follow-up of <e1> ifosfamide </e1> renal toxicity in children treated for <e2> malignant mesenchymal tumors </e2>: an International Society of Pediatric Oncology report.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1550": {"data": {"text": "Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.\n", "entity1": "fenoldopam", "entity2": "hypotension", "span1": [65, 75], "span2": [40, 51]}, "bert_text": "Preservation of renal blood flow during hypotension induced with <e1> fenoldopam </e1> <e2> hypotension </e2> induced with fenoldopam in dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1551": {"data": {"text": "Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.\n", "entity1": "Pyrrolidine dithiocarbamate", "entity2": "status epilepticus", "span1": [0, 27], "span2": [76, 94]}, "bert_text": "<e1> Pyrrolidine dithiocarbamate </e1> protects the piriform cortex in the pilocarpine <e2> status epilepticus </e2> model.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1552": {"data": {"text": "Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.\n", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [64, 75], "span2": [76, 94]}, "bert_text": "Pyrrolidine dithiocarbamate protects the piriform cortex in the <e1> pilocarpine </e1> <e2> status epilepticus </e2> model.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1553": {"data": {"text": "These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.", "entity1": "phenacetin", "entity2": "ESRD", "span1": [32, 42], "span2": [93, 97]}, "bert_text": "These studies suggest that both <e1> phenacetin </e1> and acetaminophen may contribute to the burden of <e2> ESRD </e2>, with the risk of the latter being somewhat less than that of the former.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1554": {"data": {"text": "These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.", "entity1": "acetaminophen", "entity2": "ESRD", "span1": [47, 60], "span2": [93, 97]}, "bert_text": "These studies suggest that both phenacetin and <e1> acetaminophen </e1> may contribute to the burden of <e2> ESRD </e2>, with the risk of the latter being somewhat less than that of the former.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1555": {"data": {"text": "Acute cocaine-induced seizures: differential sensitivity of six inbred mouse strains.\n", "entity1": "cocaine", "entity2": "seizures", "span1": [6, 13], "span2": [22, 30]}, "bert_text": "Acute <e1> cocaine </e1>-induced <e2> seizures </e2>: differential sensitivity of six inbred mouse strains.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1556": {"data": {"text": "Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.", "entity1": "indomethacin", "entity2": "aplastic anemia", "span1": [9, 21], "span2": [65, 80]}, "bert_text": "Although <e1> indomethacin </e1> has been implicated as a possible cause of <e2> aplastic anemia </e2> on the basis of a few clinical observations, its role has not been definitely established.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1557": {"data": {"text": "Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.\n", "entity1": "puromycin aminonucleoside", "entity2": "nephrosis", "span1": [109, 134], "span2": [135, 144]}, "bert_text": "Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early <e1> puromycin aminonucleoside </e1> <e2> nephrosis </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1558": {"data": {"text": "The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.", "entity1": "L-alpha-glycerylphosphorylcholine", "entity2": "memory impairment", "span1": [57, 90], "span2": [108, 125]}, "bert_text": "The present study was carried out to test the effects of <e1> L-alpha-glycerylphosphorylcholine </e1> (L-alpha-GFC) on <e2> memory impairment </e2> induced by scopolamine in man.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1559": {"data": {"text": "The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.", "entity1": "L-alpha-GFC", "entity2": "memory impairment", "span1": [92, 103], "span2": [108, 125]}, "bert_text": "The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (<e1> L-alpha-GFC </e1>) on <e2> memory impairment </e2> induced by scopolamine in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1560": {"data": {"text": "The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.", "entity1": "scopolamine", "entity2": "memory impairment", "span1": [137, 148], "span2": [108, 125]}, "bert_text": "The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by <e1> scopolamine </e1> <e2> memory impairment </e2> induced by scopolamine in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1561": {"data": {"text": "As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.", "entity1": "mannitol", "entity2": "brain tumor", "span1": [79, 87], "span2": [130, 141]}, "bert_text": "As a contribution to this issue we decided to research the possible passage of <e1> mannitol </e1> into the brain after administration to 21 <e2> brain tumor </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1562": {"data": {"text": "A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).", "entity1": "CYP", "entity2": "cystitis", "span1": [181, 184], "span2": [193, 201]}, "bert_text": "A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without <e1> CYP </e1>-induced <e2> cystitis </e2> (150 mg/kg; i.p.; 48 h).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1563": {"data": {"text": "In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).", "entity1": "cholesteryl hemisuccinate", "entity2": "hepatotoxic", "span1": [64, 89], "span2": [166, 177]}, "bert_text": "In addition to its use as a stabilizer/rigidifier of membranes, <e1> cholesteryl hemisuccinate </e1>, tris salt (CS) administration has also been shown to protect rats from the <e2> hepatotoxic </e2> effects of carbon tetrachloride (CCl4).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1564": {"data": {"text": "In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).", "entity1": "carbon tetrachloride", "entity2": "hepatotoxic", "span1": [189, 209], "span2": [166, 177]}, "bert_text": "In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of <e1> carbon tetrachloride </e1> <e2> hepatotoxic </e2> effects of carbon tetrachloride (CCl4).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1565": {"data": {"text": "In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).", "entity1": "CCl4", "entity2": "hepatotoxic", "span1": [211, 215], "span2": [166, 177]}, "bert_text": "In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (<e1> CCl4 </e1> <e2> hepatotoxic </e2> effects of carbon tetrachloride (CCl4).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1566": {"data": {"text": "We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.", "entity1": "phenylephrine", "entity2": "hypotension", "span1": [26, 39], "span2": [122, 133]}, "bert_text": "We describe the effect of <e1> phenylephrine </e1> and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1567": {"data": {"text": "We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.", "entity1": "ephedrine", "entity2": "hypotension", "span1": [44, 53], "span2": [122, 133]}, "bert_text": "We describe the effect of phenylephrine and <e1> ephedrine </e1> on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1568": {"data": {"text": "One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.", "entity1": "gamma-HCH", "entity2": "seizure", "span1": [37, 46], "span2": [64, 71]}, "bert_text": "One hour after the administration of <e1> gamma-HCH </e1>, the activity of <e2> seizure </e2>-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1569": {"data": {"text": "One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.", "entity1": "gamma-HCH", "entity2": "seizure", "span1": [151, 160], "span2": [64, 71]}, "bert_text": "One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after <e1> gamma-HCH </e1> <e2> seizure </e2>-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1570": {"data": {"text": "Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.", "entity1": "Tenofovir", "entity2": "Fanconi syndrome", "span1": [0, 9], "span2": [52, 68]}, "bert_text": "<e1> Tenofovir </e1> has been implicated in the development of <e2> Fanconi syndrome </e2> and renal insufficiency because of its effects on the proximal renal tubule.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1571": {"data": {"text": "Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.", "entity1": "Tenofovir", "entity2": "renal insufficiency", "span1": [0, 9], "span2": [73, 92]}, "bert_text": "<e1> Tenofovir </e1> has been implicated in the development of Fanconi syndrome and <e2> renal insufficiency </e2> because of its effects on the proximal renal tubule.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1572": {"data": {"text": "PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures. METHODS: Several biomedical databases were searched including MEDLINE, Cochrane and Ovid.", "entity1": "levofloxacin", "entity2": "seizures", "span1": [103, 115], "span2": [54, 62]}, "bert_text": "PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with <e1> levofloxacin </e1> <e2> seizures </e2> shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures. METHODS: Several biomedical databases were searched including MEDLINE, Cochrane and Ovid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1573": {"data": {"text": "PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures. METHODS: Several biomedical databases were searched including MEDLINE, Cochrane and Ovid.", "entity1": "levofloxacin", "entity2": "seizures", "span1": [103, 115], "span2": [288, 296]}, "bert_text": "PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with <e1> levofloxacin </e1> and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced <e2> seizures </e2>. METHODS: Several biomedical databases were searched including MEDLINE, Cochrane and Ovid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1574": {"data": {"text": "PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures. METHODS: Several biomedical databases were searched including MEDLINE, Cochrane and Ovid.", "entity1": "levofloxacin", "entity2": "seizures", "span1": [267, 279], "span2": [54, 62]}, "bert_text": "PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of <e1> levofloxacin </e1> <e2> seizures </e2> shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures. METHODS: Several biomedical databases were searched including MEDLINE, Cochrane and Ovid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1575": {"data": {"text": "PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures. METHODS: Several biomedical databases were searched including MEDLINE, Cochrane and Ovid.", "entity1": "levofloxacin", "entity2": "seizures", "span1": [267, 279], "span2": [288, 296]}, "bert_text": "PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of <e1> levofloxacin </e1>-induced <e2> seizures </e2>. METHODS: Several biomedical databases were searched including MEDLINE, Cochrane and Ovid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1576": {"data": {"text": "Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [75, 78], "span2": [366, 380]}, "bert_text": "Although there was a discrepancy between the amount of cTnI and cTnT after <e1> DOX </e1>, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced <e2> cardiotoxicity </e2> and possibly for cardioprotective experiments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1577": {"data": {"text": "Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [209, 212], "span2": [366, 380]}, "bert_text": "Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after <e1> DOX </e1> indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced <e2> cardiotoxicity </e2> and possibly for cardioprotective experiments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1578": {"data": {"text": "These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.", "entity1": "DOX", "entity2": "cardiomyopathy", "span1": [50, 53], "span2": [54, 68]}, "bert_text": "These findings suggest that B1R is detrimental in <e1> DOX </e1> <e2> cardiomyopathy </e2> in that it mediates the inflammatory response and apoptosis.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1579": {"data": {"text": "CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.", "entity1": "nimodipine", "entity2": "acute stroke", "span1": [134, 144], "span2": [151, 163]}, "bert_text": "CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose <e1> nimodipine </e1> after <e2> acute stroke </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1580": {"data": {"text": "In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.", "entity1": "gamma-HCH", "entity2": "seizure", "span1": [152, 161], "span2": [49, 56]}, "bert_text": "In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg <e1> gamma-HCH </e1> <e2> seizure </e2>-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1581": {"data": {"text": "METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.", "entity1": "Mannitol", "entity2": "malignant glioma", "span1": [9, 17], "span2": [90, 106]}, "bert_text": "METHODS: <e1> Mannitol </e1> (18% solution; 1 g/kg) was administered as a bolus to patients (ten had <e2> malignant glioma </e2>, seven brain metastases and four meningioma) about 30 minutes before craniotomy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1582": {"data": {"text": "METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.", "entity1": "Mannitol", "entity2": "metastases", "span1": [9, 17], "span2": [120, 130]}, "bert_text": "METHODS: <e1> Mannitol </e1> (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain <e2> metastases </e2> and four meningioma) about 30 minutes before craniotomy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1583": {"data": {"text": "METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.", "entity1": "Mannitol", "entity2": "meningioma", "span1": [9, 17], "span2": [140, 150]}, "bert_text": "METHODS: <e1> Mannitol </e1> (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four <e2> meningioma </e2>) about 30 minutes before craniotomy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1584": {"data": {"text": "HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.", "entity1": "lamivudine", "entity2": "infected chronic hepatitis B", "span1": [4, 14], "span2": [63, 91]}, "bert_text": "HBV <e1> lamivudine </e1>-resistant strains were detected in 3 of 15 mono-<e2> infected chronic hepatitis B </e2> patients and 10 of 20 HBV-HIV co-infected patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1585": {"data": {"text": "HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.", "entity1": "lamivudine", "entity2": "HIV co-infected", "span1": [4, 14], "span2": [118, 133]}, "bert_text": "HBV <e1> lamivudine </e1>-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-<e2> HIV co-infected </e2> patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1586": {"data": {"text": "A randomized comparison of labetalol and nitroprusside for induced hypotension.\n", "entity1": "labetalol", "entity2": "hypotension", "span1": [27, 36], "span2": [67, 78]}, "bert_text": "A randomized comparison of <e1> labetalol </e1> and nitroprusside for induced <e2> hypotension </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1587": {"data": {"text": "A randomized comparison of labetalol and nitroprusside for induced hypotension.\n", "entity1": "nitroprusside", "entity2": "hypotension", "span1": [41, 54], "span2": [67, 78]}, "bert_text": "A randomized comparison of labetalol and <e1> nitroprusside </e1> for induced <e2> hypotension </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1588": {"data": {"text": "A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.", "entity1": "allopurinol", "entity2": "aplastic anemia", "span1": [74, 85], "span2": [16, 31]}, "bert_text": "A case of fatal aplastic anemia is described in which no drugs other than <e1> allopurinol </e1> <e2> aplastic anemia </e2> is described in which no drugs other than allopurinol and indomethacin were given.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1589": {"data": {"text": "A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.", "entity1": "indomethacin", "entity2": "aplastic anemia", "span1": [90, 102], "span2": [16, 31]}, "bert_text": "A case of fatal aplastic anemia is described in which no drugs other than allopurinol and <e1> indomethacin </e1> <e2> aplastic anemia </e2> is described in which no drugs other than allopurinol and indomethacin were given.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1590": {"data": {"text": "A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.", "entity1": "risperidone", "entity2": "neuroleptic malignant syndrome", "span1": [84, 95], "span2": [30, 60]}, "bert_text": "A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with <e1> risperidone </e1> <e2> neuroleptic malignant syndrome </e2> after monotherapy with risperidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1591": {"data": {"text": "Ticlopidine-induced cholestatic hepatitis.\nOBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.", "entity1": "Ticlopidine", "entity2": "cholestatic hepatitis", "span1": [0, 11], "span2": [20, 41]}, "bert_text": "<e1> Ticlopidine </e1>-induced <e2> cholestatic hepatitis </e2>.\nOBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1592": {"data": {"text": "Ticlopidine-induced cholestatic hepatitis.\nOBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.", "entity1": "Ticlopidine", "entity2": "cholestatic hepatitis", "span1": [0, 11], "span2": [95, 116]}, "bert_text": "<e1> Ticlopidine </e1>-induced cholestatic hepatitis.\nOBJECTIVE: To report 2 cases of ticlopidine-induced <e2> cholestatic hepatitis </e2>, investigate its mechanism, and compare the observed main characteristics with those of the published cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1593": {"data": {"text": "Ticlopidine-induced cholestatic hepatitis.\nOBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.", "entity1": "ticlopidine", "entity2": "cholestatic hepatitis", "span1": [75, 86], "span2": [20, 41]}, "bert_text": "Ticlopidine-induced cholestatic hepatitis.\nOBJECTIVE: To report 2 cases of <e1> ticlopidine </e1> <e2> cholestatic hepatitis </e2>.\nOBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1594": {"data": {"text": "Ticlopidine-induced cholestatic hepatitis.\nOBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.", "entity1": "ticlopidine", "entity2": "cholestatic hepatitis", "span1": [75, 86], "span2": [95, 116]}, "bert_text": "Ticlopidine-induced cholestatic hepatitis.\nOBJECTIVE: To report 2 cases of <e1> ticlopidine </e1>-induced <e2> cholestatic hepatitis </e2>, investigate its mechanism, and compare the observed main characteristics with those of the published cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1595": {"data": {"text": "Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).", "entity1": "iopamidol", "entity2": "diabetes", "span1": [53, 62], "span2": [152, 160]}, "bert_text": "Mean post-SCr increases were significantly less with <e1> iopamidol </e1> (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with <e2> diabetes </e2>: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1596": {"data": {"text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "entity1": "Ribavirin", "entity2": "respiratory syncytial virus infection", "span1": [0, 9], "span2": [59, 96]}, "bert_text": "<e1> Ribavirin </e1> is licensed in aerosol form for the treatment of <e2> respiratory syncytial virus infection </e2>, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1597": {"data": {"text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "entity1": "Ribavirin", "entity2": "hepatitis C.", "span1": [0, 9], "span2": [149, 161]}, "bert_text": "<e1> Ribavirin </e1> is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat <e2> hepatitis C. </e2> Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1598": {"data": {"text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "entity1": "Ribavirin", "entity2": "infection", "span1": [0, 9], "span2": [215, 224]}, "bert_text": "<e1> Ribavirin </e1> is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for <e2> infection </e2> with hemorrhagic fever viruses.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1599": {"data": {"text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "entity1": "Ribavirin", "entity2": "hemorrhagic fever viruses", "span1": [0, 9], "span2": [230, 255]}, "bert_text": "<e1> Ribavirin </e1> is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with <e2> hemorrhagic fever viruses </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1600": {"data": {"text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "entity1": "ribavirin", "entity2": "respiratory syncytial virus infection", "span1": [174, 183], "span2": [59, 96]}, "bert_text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous <e1> ribavirin </e1> <e2> respiratory syncytial virus infection </e2>, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1601": {"data": {"text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "entity1": "ribavirin", "entity2": "hepatitis C.", "span1": [174, 183], "span2": [149, 161]}, "bert_text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous <e1> ribavirin </e1> <e2> hepatitis C. </e2> Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1602": {"data": {"text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "entity1": "ribavirin", "entity2": "infection", "span1": [174, 183], "span2": [215, 224]}, "bert_text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous <e1> ribavirin </e1> is the treatment of choice for <e2> infection </e2> with hemorrhagic fever viruses.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1603": {"data": {"text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.", "entity1": "ribavirin", "entity2": "hemorrhagic fever viruses", "span1": [174, 183], "span2": [230, 255]}, "bert_text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous <e1> ribavirin </e1> is the treatment of choice for infection with <e2> hemorrhagic fever viruses </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1604": {"data": {"text": "RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.", "entity1": "Clomipramine", "entity2": "anxiety", "span1": [9, 21], "span2": [126, 133]}, "bert_text": "RESULTS: <e1> Clomipramine </e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced <e2> anxiety </e2> (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1605": {"data": {"text": "RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.", "entity1": "Clomipramine", "entity2": "memory impairment", "span1": [9, 21], "span2": [292, 309]}, "bert_text": "RESULTS: <e1> Clomipramine </e1> exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working <e2> memory impairment </e2> (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1606": {"data": {"text": "Drug-induced arterial spasm relieved by lidocaine.", "entity1": "lidocaine", "entity2": "spasm", "span1": [40, 49], "span2": [22, 27]}, "bert_text": "Drug-induced arterial spasm relieved by <e1> lidocaine </e1> <e2> spasm </e2> relieved by lidocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1607": {"data": {"text": "Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.\n", "entity1": "doxorubicin", "entity2": "myocardial damage", "span1": [81, 92], "span2": [60, 77]}, "bert_text": "Evaluation of cardiac troponin I and T levels as markers of myocardial damage in <e1> doxorubicin </e1> <e2> myocardial damage </e2> in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1608": {"data": {"text": "Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.\n", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [81, 92], "span2": [101, 115]}, "bert_text": "Evaluation of cardiac troponin I and T levels as markers of myocardial damage in <e1> doxorubicin </e1>-induced <e2> cardiomyopathy </e2> rats, and their relationship with echocardiographic and histological findings.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1609": {"data": {"text": "This report presents the clinical, laboratory, and light and electron microscopic observations on a patient with chronic active (aggressive) hepatitis caused by the administration of propylthiouracil.", "entity1": "propylthiouracil", "entity2": "hepatitis", "span1": [183, 199], "span2": [141, 150]}, "bert_text": "This report presents the clinical, laboratory, and light and electron microscopic observations on a patient with chronic active (aggressive) hepatitis caused by the administration of <e1> propylthiouracil </e1> <e2> hepatitis </e2> caused by the administration of propylthiouracil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1610": {"data": {"text": "Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.", "entity1": "carbamazepine", "entity2": "myoclonic jerks", "span1": [62, 75], "span2": [103, 118]}, "bert_text": "Frequency of absences increased in four children treated with <e1> carbamazepine </e1> and two of these developed <e2> myoclonic jerks </e2>, which resolved on withdrawal of carbamazepine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1611": {"data": {"text": "Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.", "entity1": "carbamazepine", "entity2": "myoclonic jerks", "span1": [152, 165], "span2": [103, 118]}, "bert_text": "Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of <e1> carbamazepine </e1> <e2> myoclonic jerks </e2>, which resolved on withdrawal of carbamazepine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"1612": {"data": {"text": "METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.", "entity1": "estrogen-testosterone", "entity2": "aortic atherosclerosis", "span1": [181, 202], "span2": [252, 274]}, "bert_text": "METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose <e1> estrogen-testosterone </e1> therapy (estradiol- and testosterone esters) and <e2> aortic atherosclerosis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1613": {"data": {"text": "METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.", "entity1": "estradiol- and testosterone esters", "entity2": "aortic atherosclerosis", "span1": [212, 246], "span2": [252, 274]}, "bert_text": "METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (<e1> estradiol- and testosterone esters </e1>) and <e2> aortic atherosclerosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1614": {"data": {"text": "RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia. Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.", "entity1": "bradykinin", "entity2": "diabetic hyperalgesia", "span1": [62, 72], "span2": [155, 176]}, "bert_text": "RESULTS: The results of this paper confirm that inhibition of <e1> bradykinin </e1> receptors and inducible NO synthase but not neuronal NO synthase activity reduces <e2> diabetic hyperalgesia </e2>. Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1615": {"data": {"text": "RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia. Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.", "entity1": "HOE 140", "entity2": "diabetic hyperalgesia", "span1": [283, 290], "span2": [155, 176]}, "bert_text": "RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia. Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both <e1> HOE 140 </e1> <e2> diabetic hyperalgesia </e2>. Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1616": {"data": {"text": "RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia. Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.", "entity1": "des Arg10 HOE 140", "entity2": "diabetic hyperalgesia", "span1": [295, 312], "span2": [155, 176]}, "bert_text": "RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia. Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and <e1> des Arg10 HOE 140 </e1> <e2> diabetic hyperalgesia </e2>. Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1617": {"data": {"text": "Repeated transient anuria following losartan administration in a patient with a solitary kidney.\n", "entity1": "losartan", "entity2": "anuria", "span1": [36, 44], "span2": [19, 25]}, "bert_text": "Repeated transient anuria following <e1> losartan </e1> <e2> anuria </e2> following losartan administration in a patient with a solitary kidney.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1618": {"data": {"text": "CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.", "entity1": "metronidazole", "entity2": "inferior colliculus lesions", "span1": [98, 111], "span2": [24, 51]}, "bert_text": "CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for <e1> metronidazole </e1> <e2> inferior colliculus lesions </e2> could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1619": {"data": {"text": "CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.", "entity1": "metronidazole", "entity2": "encephalopathy", "span1": [98, 111], "span2": [120, 134]}, "bert_text": "CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for <e1> metronidazole </e1>-induced <e2> encephalopathy </e2>, next to the dentate nucleus involvement.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1620": {"data": {"text": "A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.", "entity1": "LiCl", "entity2": "polyuria", "span1": [25, 29], "span2": [93, 101]}, "bert_text": "A 2-wk administration of <e1> LiCl </e1> (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked <e2> polyuria </e2> with hyposmotic urine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1621": {"data": {"text": "The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [16, 31], "span2": [47, 56]}, "bert_text": "The symptoms of <e1> methamphetamine </e1> (METH)-induced <e2> psychosis </e2> are similar to those of paranoid type schizophrenia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1622": {"data": {"text": "The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.", "entity1": "methamphetamine", "entity2": "paranoid type schizophrenia", "span1": [16, 31], "span2": [81, 108]}, "bert_text": "The symptoms of <e1> methamphetamine </e1> (METH)-induced psychosis are similar to those of <e2> paranoid type schizophrenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1623": {"data": {"text": "The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.", "entity1": "METH)-induced", "entity2": "psychosis", "span1": [33, 46], "span2": [47, 56]}, "bert_text": "The symptoms of methamphetamine (<e1> METH)-induced </e1> <e2> psychosis </e2> are similar to those of paranoid type schizophrenia.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1624": {"data": {"text": "The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.", "entity1": "METH)-induced", "entity2": "paranoid type schizophrenia", "span1": [33, 46], "span2": [81, 108]}, "bert_text": "The symptoms of methamphetamine (<e1> METH)-induced </e1> psychosis are similar to those of <e2> paranoid type schizophrenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1625": {"data": {"text": "CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.", "entity1": "methylprednisolone", "entity2": "nausea", "span1": [35, 53], "span2": [162, 168]}, "bert_text": "CONCLUSIONS: The administration of <e1> methylprednisolone </e1> and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including <e2> nausea </e2>, vomiting, and headache.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1626": {"data": {"text": "CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.", "entity1": "methylprednisolone", "entity2": "vomiting", "span1": [35, 53], "span2": [170, 178]}, "bert_text": "CONCLUSIONS: The administration of <e1> methylprednisolone </e1> and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, <e2> vomiting </e2>, and headache.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1627": {"data": {"text": "CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.", "entity1": "methylprednisolone", "entity2": "headache", "span1": [35, 53], "span2": [184, 192]}, "bert_text": "CONCLUSIONS: The administration of <e1> methylprednisolone </e1> and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and <e2> headache </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1628": {"data": {"text": "CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.", "entity1": "gentamicin", "entity2": "nausea", "span1": [58, 68], "span2": [162, 168]}, "bert_text": "CONCLUSIONS: The administration of methylprednisolone and <e1> gentamicin </e1> in the posterior sub-Tenon's space was related to a high incidence of side effects including <e2> nausea </e2>, vomiting, and headache.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1629": {"data": {"text": "CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.", "entity1": "gentamicin", "entity2": "vomiting", "span1": [58, 68], "span2": [170, 178]}, "bert_text": "CONCLUSIONS: The administration of methylprednisolone and <e1> gentamicin </e1> in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, <e2> vomiting </e2>, and headache.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1630": {"data": {"text": "CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.", "entity1": "gentamicin", "entity2": "headache", "span1": [58, 68], "span2": [184, 192]}, "bert_text": "CONCLUSIONS: The administration of methylprednisolone and <e1> gentamicin </e1> in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and <e2> headache </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1631": {"data": {"text": "Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.", "entity1": "Edaravone", "entity2": "cerebral infarction", "span1": [0, 9], "span2": [120, 139]}, "bert_text": "<e1> Edaravone </e1>, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat <e2> cerebral infarction </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1632": {"data": {"text": "Of the 20 animals that received subarachnoid injection of 2-chloroprocaine-CE seven (35%) developed hind-limb paralysis.", "entity1": "2-chloroprocaine-CE", "entity2": "paralysis", "span1": [58, 77], "span2": [110, 119]}, "bert_text": "Of the 20 animals that received subarachnoid injection of <e1> 2-chloroprocaine-CE </e1> seven (35%) developed hind-limb <e2> paralysis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1633": {"data": {"text": "Pravastatin-associated myopathy.", "entity1": "Pravastatin", "entity2": "myopathy", "span1": [0, 11], "span2": [23, 31]}, "bert_text": "<e1> Pravastatin </e1>-associated <e2> myopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1634": {"data": {"text": "We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to pilocarpine-induced seizures.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [116, 127], "span2": [136, 144]}, "bert_text": "We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to <e1> pilocarpine </e1>-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1635": {"data": {"text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "entity1": "clozapine", "entity2": "catalepsy", "span1": [0, 9], "span2": [32, 41]}, "bert_text": "<e1> clozapine </e1> significantly induced <e2> catalepsy </e2> in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1636": {"data": {"text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "entity1": "clozapine", "entity2": "catalepsy", "span1": [147, 156], "span2": [32, 41]}, "bert_text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and <e1> clozapine </e1> <e2> catalepsy </e2> in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1637": {"data": {"text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "entity1": "clozapine", "entity2": "catalepsy", "span1": [269, 278], "span2": [32, 41]}, "bert_text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and <e1> clozapine </e1> <e2> catalepsy </e2> in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1638": {"data": {"text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "entity1": "NRA0160", "entity2": "catalepsy", "span1": [135, 142], "span2": [32, 41]}, "bert_text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. <e1> NRA0160 </e1> <e2> catalepsy </e2> in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1639": {"data": {"text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "entity1": "NRA0160", "entity2": "catalepsy", "span1": [257, 264], "span2": [32, 41]}, "bert_text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. <e1> NRA0160 </e1> <e2> catalepsy </e2> in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1640": {"data": {"text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [244, 255], "span2": [32, 41]}, "bert_text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by <e1> apomorphine </e1> <e2> catalepsy </e2> in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1641": {"data": {"text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "entity1": "phencyclidine", "entity2": "catalepsy", "span1": [307, 320], "span2": [32, 41]}, "bert_text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the <e1> phencyclidine </e1> <e2> catalepsy </e2> in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1642": {"data": {"text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "entity1": "PCP)-induced", "entity2": "catalepsy", "span1": [322, 334], "span2": [32, 41]}, "bert_text": "clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (<e1> PCP)-induced </e1> <e2> catalepsy </e2> in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1643": {"data": {"text": "Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.\n", "entity1": "pentazocine", "entity2": "Compression neuropathy", "span1": [50, 61], "span2": [0, 22]}, "bert_text": "Compression neuropathy of the radial nerve due to <e1> pentazocine </e1> <e2> Compression neuropathy </e2> of the radial nerve due to pentazocine-induced fibrous myopathy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1644": {"data": {"text": "Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.\n", "entity1": "pentazocine", "entity2": "fibrous myopathy", "span1": [50, 61], "span2": [70, 86]}, "bert_text": "Compression neuropathy of the radial nerve due to <e1> pentazocine </e1>-induced <e2> fibrous myopathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1645": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "Coenzyme Q10", "entity2": "tumor", "span1": [0, 12], "span2": [208, 213]}, "bert_text": "<e1> Coenzyme Q10 </e1> significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of <e2> tumor </e2> necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1646": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "Coenzyme Q10", "entity2": "necrosis", "span1": [0, 12], "span2": [214, 222]}, "bert_text": "<e1> Coenzyme Q10 </e1> significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor <e2> necrosis </e2> factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1647": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "glutathione", "entity2": "tumor", "span1": [95, 106], "span2": [208, 213]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced <e1> glutathione </e1> level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of <e2> tumor </e2> necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1648": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "glutathione", "entity2": "necrosis", "span1": [95, 106], "span2": [214, 222]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced <e1> glutathione </e1> level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor <e2> necrosis </e2> factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1649": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "superoxide", "entity2": "tumor", "span1": [117, 127], "span2": [208, 213]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and <e1> superoxide </e1> dismutase activity), suppressed lipid peroxidation, decreased the elevations of <e2> tumor </e2> necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1650": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "superoxide", "entity2": "necrosis", "span1": [117, 127], "span2": [214, 222]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and <e1> superoxide </e1> dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor <e2> necrosis </e2> factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1651": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "nitric oxide", "entity2": "tumor", "span1": [237, 249], "span2": [208, 213]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, <e1> nitric oxide </e1> <e2> tumor </e2> necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1652": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "nitric oxide", "entity2": "necrosis", "span1": [237, 249], "span2": [214, 222]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, <e1> nitric oxide </e1> <e2> necrosis </e2> factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1653": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "platinum", "entity2": "tumor", "span1": [254, 262], "span2": [208, 213]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and <e1> platinum </e1> <e2> tumor </e2> necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1654": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "platinum", "entity2": "necrosis", "span1": [254, 262], "span2": [214, 222]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and <e1> platinum </e1> <e2> necrosis </e2> factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1655": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "selenium", "entity2": "tumor", "span1": [315, 323], "span2": [208, 213]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of <e1> selenium </e1> <e2> tumor </e2> necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1656": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "selenium", "entity2": "necrosis", "span1": [315, 323], "span2": [214, 222]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of <e1> selenium </e1> <e2> necrosis </e2> factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1657": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "zinc", "entity2": "tumor", "span1": [328, 332], "span2": [208, 213]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and <e1> zinc </e1> <e2> tumor </e2> necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1658": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "zinc", "entity2": "necrosis", "span1": [328, 332], "span2": [214, 222]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and <e1> zinc </e1> <e2> necrosis </e2> factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1659": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "cisplatin", "entity2": "tumor", "span1": [368, 377], "span2": [208, 213]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from <e1> cisplatin </e1> <e2> tumor </e2> necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1660": {"data": {"text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "entity1": "cisplatin", "entity2": "necrosis", "span1": [368, 377], "span2": [214, 222]}, "bert_text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from <e1> cisplatin </e1> <e2> necrosis </e2> factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1661": {"data": {"text": "The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.", "entity1": "Li", "entity2": "nephropathy", "span1": [26, 28], "span2": [37, 48]}, "bert_text": "The results indicate that <e1> Li </e1>-induced <e2> nephropathy </e2>, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1662": {"data": {"text": "The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.", "entity1": "Li", "entity2": "proteinuria", "span1": [26, 28], "span2": [113, 124]}, "bert_text": "The results indicate that <e1> Li </e1>-induced nephropathy, even when the GFR is only modestly reduced, is associated with <e2> proteinuria </e2> and arterial systolic hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1663": {"data": {"text": "The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.", "entity1": "Li", "entity2": "hypertension", "span1": [26, 28], "span2": [147, 159]}, "bert_text": "The results indicate that <e1> Li </e1>-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1664": {"data": {"text": "The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.", "entity1": "calcium", "entity2": "hyperammonemia", "span1": [46, 53], "span2": [22, 36]}, "bert_text": "The data suggest that hyperammonemia exerts a <e1> calcium </e1> <e2> hyperammonemia </e2> exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1665": {"data": {"text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "entity1": "clozapine", "entity2": "EPS", "span1": [241, 250], "span2": [47, 50]}, "bert_text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily <e1> clozapine </e1> <e2> EPS </e2>, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1666": {"data": {"text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "entity1": "clozapine", "entity2": "weight gain", "span1": [241, 250], "span2": [154, 165]}, "bert_text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily <e1> clozapine </e1> <e2> weight gain </e2>, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1667": {"data": {"text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "entity1": "clozapine", "entity2": "sexual dysfunction", "span1": [241, 250], "span2": [167, 185]}, "bert_text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily <e1> clozapine </e1> <e2> sexual dysfunction </e2>, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1668": {"data": {"text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "entity1": "clozapine", "entity2": "seizure", "span1": [241, 250], "span2": [212, 219]}, "bert_text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily <e1> clozapine </e1> <e2> seizure </e2> threshold (primarily clozapine), and agranulocytosis (clozapine only).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1669": {"data": {"text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "entity1": "clozapine", "entity2": "agranulocytosis", "span1": [241, 250], "span2": [257, 272]}, "bert_text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily <e1> clozapine </e1>), and <e2> agranulocytosis </e2> (clozapine only).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1670": {"data": {"text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "entity1": "clozapine", "entity2": "EPS", "span1": [274, 283], "span2": [47, 50]}, "bert_text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (<e1> clozapine </e1> <e2> EPS </e2>, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1671": {"data": {"text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "entity1": "clozapine", "entity2": "weight gain", "span1": [274, 283], "span2": [154, 165]}, "bert_text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (<e1> clozapine </e1> <e2> weight gain </e2>, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1672": {"data": {"text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "entity1": "clozapine", "entity2": "sexual dysfunction", "span1": [274, 283], "span2": [167, 185]}, "bert_text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (<e1> clozapine </e1> <e2> sexual dysfunction </e2>, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1673": {"data": {"text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "entity1": "clozapine", "entity2": "seizure", "span1": [274, 283], "span2": [212, 219]}, "bert_text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (<e1> clozapine </e1> <e2> seizure </e2> threshold (primarily clozapine), and agranulocytosis (clozapine only).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1674": {"data": {"text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "entity1": "clozapine", "entity2": "agranulocytosis", "span1": [274, 283], "span2": [257, 272]}, "bert_text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (<e1> clozapine </e1> <e2> agranulocytosis </e2> (clozapine only).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1675": {"data": {"text": "Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.", "entity1": "cimetidine", "entity2": "impotence", "span1": [78, 88], "span2": [55, 64]}, "bert_text": "Sixty percent of the males developed breast changes or impotence while taking <e1> cimetidine </e1> <e2> impotence </e2> while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1676": {"data": {"text": "Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.", "entity1": "cimetidine", "entity2": "impotence", "span1": [137, 147], "span2": [55, 64]}, "bert_text": "Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when <e1> cimetidine </e1> <e2> impotence </e2> while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1677": {"data": {"text": "Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.", "entity1": "ranitidine", "entity2": "impotence", "span1": [164, 174], "span2": [55, 64]}, "bert_text": "Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by <e1> ranitidine </e1> <e2> impotence </e2> while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1678": {"data": {"text": "The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.", "entity1": "benzodiazepines", "entity2": "choreoathetoid", "span1": [85, 100], "span2": [130, 144]}, "bert_text": "The children received gastrointestinal decontamination and high doses of intravenous <e1> benzodiazepines </e1> in an attempt to control the <e2> choreoathetoid </e2> movements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1679": {"data": {"text": "Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.", "entity1": "atorvastatin", "entity2": "hypertension", "span1": [6, 18], "span2": [64, 76]}, "bert_text": "Thus, <e1> atorvastatin </e1> prevented and reversed dexamethasone-induced <e2> hypertension </e2> in the rat.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1680": {"data": {"text": "Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.", "entity1": "dexamethasone", "entity2": "hypertension", "span1": [42, 55], "span2": [64, 76]}, "bert_text": "Thus, atorvastatin prevented and reversed <e1> dexamethasone </e1>-induced <e2> hypertension </e2> in the rat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1681": {"data": {"text": "Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.", "entity1": "gentamicin", "entity2": "Nephrotoxic", "span1": [44, 54], "span2": [0, 11]}, "bert_text": "Nephrotoxic doses (40 mg/kg body wt/day) of <e1> gentamicin </e1> <e2> Nephrotoxic </e2> doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1682": {"data": {"text": "RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.", "entity1": "selegiline", "entity2": "systolic orthostatic hypotension", "span1": [107, 117], "span2": [29, 61]}, "bert_text": "RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on <e1> selegiline </e1> <e2> systolic orthostatic hypotension </e2> which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1683": {"data": {"text": "RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.", "entity1": "selegiline", "entity2": "PD", "span1": [107, 117], "span2": [92, 94]}, "bert_text": "RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on <e1> selegiline </e1> <e2> PD </e2> patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1684": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "IH636 grape seed proanthocyanidin extract", "entity2": "nephrotoxicity", "span1": [35, 76], "span2": [123, 137]}, "bert_text": "This study assessed the ability of <e1> IH636 grape seed proanthocyanidin extract </e1> (GSPE) to prevent acetaminophen (AAP)-induced <e2> nephrotoxicity </e2>, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1685": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "IH636 grape seed proanthocyanidin extract", "entity2": "lung toxicity", "span1": [35, 76], "span2": [164, 177]}, "bert_text": "This study assessed the ability of <e1> IH636 grape seed proanthocyanidin extract </e1> (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced <e2> lung toxicity </e2>, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1686": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "IH636 grape seed proanthocyanidin extract", "entity2": "cardiotoxicity", "span1": [35, 76], "span2": [209, 223]}, "bert_text": "This study assessed the ability of <e1> IH636 grape seed proanthocyanidin extract </e1> (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced <e2> cardiotoxicity </e2> in mice.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1687": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "GSPE", "entity2": "nephrotoxicity", "span1": [78, 82], "span2": [123, 137]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (<e1> GSPE </e1>) to prevent acetaminophen (AAP)-induced <e2> nephrotoxicity </e2>, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1688": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "GSPE", "entity2": "lung toxicity", "span1": [78, 82], "span2": [164, 177]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (<e1> GSPE </e1>) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced <e2> lung toxicity </e2>, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1689": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "GSPE", "entity2": "cardiotoxicity", "span1": [78, 82], "span2": [209, 223]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (<e1> GSPE </e1>) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced <e2> cardiotoxicity </e2> in mice.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1690": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "acetaminophen", "entity2": "nephrotoxicity", "span1": [95, 108], "span2": [123, 137]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent <e1> acetaminophen </e1> (AAP)-induced <e2> nephrotoxicity </e2>, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1691": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "acetaminophen", "entity2": "lung toxicity", "span1": [95, 108], "span2": [164, 177]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent <e1> acetaminophen </e1> (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced <e2> lung toxicity </e2>, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1692": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "acetaminophen", "entity2": "cardiotoxicity", "span1": [95, 108], "span2": [209, 223]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent <e1> acetaminophen </e1> (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced <e2> cardiotoxicity </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1693": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "AAP)-induced", "entity2": "nephrotoxicity", "span1": [110, 122], "span2": [123, 137]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (<e1> AAP)-induced </e1> <e2> nephrotoxicity </e2>, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1694": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "AAP)-induced", "entity2": "lung toxicity", "span1": [110, 122], "span2": [164, 177]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (<e1> AAP)-induced </e1> nephrotoxicity, amiodarone (AMI)-induced <e2> lung toxicity </e2>, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1695": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "AAP)-induced", "entity2": "cardiotoxicity", "span1": [110, 122], "span2": [209, 223]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (<e1> AAP)-induced </e1> nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced <e2> cardiotoxicity </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1696": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "amiodarone", "entity2": "nephrotoxicity", "span1": [139, 149], "span2": [123, 137]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, <e1> amiodarone </e1> <e2> nephrotoxicity </e2>, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1697": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "amiodarone", "entity2": "lung toxicity", "span1": [139, 149], "span2": [164, 177]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, <e1> amiodarone </e1> (AMI)-induced <e2> lung toxicity </e2>, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1698": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "amiodarone", "entity2": "cardiotoxicity", "span1": [139, 149], "span2": [209, 223]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, <e1> amiodarone </e1> (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced <e2> cardiotoxicity </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1699": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "AMI)-induced", "entity2": "nephrotoxicity", "span1": [151, 163], "span2": [123, 137]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (<e1> AMI)-induced </e1> <e2> nephrotoxicity </e2>, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1700": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "AMI)-induced", "entity2": "lung toxicity", "span1": [151, 163], "span2": [164, 177]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (<e1> AMI)-induced </e1> <e2> lung toxicity </e2>, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1701": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "AMI)-induced", "entity2": "cardiotoxicity", "span1": [151, 163], "span2": [209, 223]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (<e1> AMI)-induced </e1> lung toxicity, and doxorubicin (DOX)-induced <e2> cardiotoxicity </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1702": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "doxorubicin", "entity2": "nephrotoxicity", "span1": [183, 194], "span2": [123, 137]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and <e1> doxorubicin </e1> <e2> nephrotoxicity </e2>, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1703": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "doxorubicin", "entity2": "lung toxicity", "span1": [183, 194], "span2": [164, 177]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and <e1> doxorubicin </e1> <e2> lung toxicity </e2>, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1704": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [183, 194], "span2": [209, 223]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and <e1> doxorubicin </e1> (DOX)-induced <e2> cardiotoxicity </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1705": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "DOX)-induced", "entity2": "nephrotoxicity", "span1": [196, 208], "span2": [123, 137]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (<e1> DOX)-induced </e1> <e2> nephrotoxicity </e2>, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1706": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "DOX)-induced", "entity2": "lung toxicity", "span1": [196, 208], "span2": [164, 177]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (<e1> DOX)-induced </e1> <e2> lung toxicity </e2>, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1707": {"data": {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity1": "DOX)-induced", "entity2": "cardiotoxicity", "span1": [196, 208], "span2": [209, 223]}, "bert_text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (<e1> DOX)-induced </e1> <e2> cardiotoxicity </e2> in mice.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1708": {"data": {"text": "Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.", "entity1": "glutathione", "entity2": "Liver toxicity", "span1": [60, 71], "span2": [0, 14]}, "bert_text": "Liver toxicity was evaluated based on serum levels of alpha-<e1> glutathione </e1> <e2> Liver toxicity </e2> was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1709": {"data": {"text": "The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.", "entity1": "salvianolic acid A", "entity2": "myocardial infarction", "span1": [38, 56], "span2": [155, 176]}, "bert_text": "The results of our study suggest that <e1> salvianolic acid A </e1> possessing antioxidant activity has a significant protective effect against isoproterenol-induced <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1710": {"data": {"text": "The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [133, 146], "span2": [155, 176]}, "bert_text": "The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against <e1> isoproterenol </e1>-induced <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1711": {"data": {"text": "In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.", "entity1": "ciprofloxacin", "entity2": "interstitial nephritis", "span1": [38, 51], "span2": [60, 82]}, "bert_text": "In this report, we describe a case of <e1> ciprofloxacin </e1>-induced <e2> interstitial nephritis </e2> and autoimmune hemolytic anemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1712": {"data": {"text": "In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.", "entity1": "ciprofloxacin", "entity2": "autoimmune hemolytic anemia", "span1": [38, 51], "span2": [87, 114]}, "bert_text": "In this report, we describe a case of <e1> ciprofloxacin </e1>-induced interstitial nephritis and <e2> autoimmune hemolytic anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1713": {"data": {"text": "CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.", "entity1": "ticlopidine", "entity2": "cholestatic hepatitis", "span1": [87, 98], "span2": [49, 70]}, "bert_text": "CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving <e1> ticlopidine </e1> <e2> cholestatic hepatitis </e2> after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1714": {"data": {"text": "Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.", "entity1": "CBZ", "entity2": "seizures", "span1": [6, 9], "span2": [116, 124]}, "bert_text": "Acute <e1> CBZ </e1> over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1715": {"data": {"text": "Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.", "entity1": "lidocaine", "entity2": "seizures", "span1": [73, 82], "span2": [116, 124]}, "bert_text": "Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed <e1> lidocaine </e1>-kindled or acute cocaine-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1716": {"data": {"text": "Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.", "entity1": "cocaine", "entity2": "seizures", "span1": [100, 107], "span2": [116, 124]}, "bert_text": "Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute <e1> cocaine </e1>-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1717": {"data": {"text": "Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.\n", "entity1": "Dexatrim", "entity2": "myocardial infarction", "span1": [13, 21], "span2": [58, 79]}, "bert_text": "Case report: <e1> Dexatrim </e1> (Phenylpropanolamine) as a cause of <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1718": {"data": {"text": "Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.\n", "entity1": "Phenylpropanolamine", "entity2": "myocardial infarction", "span1": [23, 42], "span2": [58, 79]}, "bert_text": "Case report: Dexatrim (<e1> Phenylpropanolamine </e1>) as a cause of <e2> myocardial infarction </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1719": {"data": {"text": "Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.", "entity1": "lidocaine", "entity2": "depression", "span1": [54, 63], "span2": [106, 116]}, "bert_text": "Intravenous administration of a single 50-mg bolus of <e1> lidocaine </e1> in a 67-year-old man resulted in profound <e2> depression </e2> of the activity of the sinoatrial and atrioventricular nodal pacemakers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1720": {"data": {"text": "Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.", "entity1": "lidocaine", "entity2": "atrioventricular nodal", "span1": [54, 63], "span2": [155, 177]}, "bert_text": "Intravenous administration of a single 50-mg bolus of <e1> lidocaine </e1> in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and <e2> atrioventricular nodal </e2> pacemakers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1721": {"data": {"text": "RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period.", "entity1": "DOX", "entity2": "toxicity", "span1": [25, 28], "span2": [62, 70]}, "bert_text": "RESULTS: Eighteen of the <e1> DOX </e1> rats died prematurely of general <e2> toxicity </e2> during the 9-week period.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1722": {"data": {"text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.", "entity1": "CPA", "entity2": "acne", "span1": [237, 240], "span2": [169, 173]}, "bert_text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with <e1> CPA </e1> <e2> acne </e2>, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1723": {"data": {"text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.", "entity1": "CPA", "entity2": "hirsutism", "span1": [237, 240], "span2": [175, 184]}, "bert_text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with <e1> CPA </e1> <e2> hirsutism </e2> or PCOS to estimate the risk of VTE associated with CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1724": {"data": {"text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.", "entity1": "CPA", "entity2": "PCOS", "span1": [237, 240], "span2": [188, 192]}, "bert_text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with <e1> CPA </e1> <e2> PCOS </e2> to estimate the risk of VTE associated with CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1725": {"data": {"text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.", "entity1": "CPA", "entity2": "VTE", "span1": [237, 240], "span2": [217, 220]}, "bert_text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with <e1> CPA </e1> <e2> VTE </e2> associated with CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"1726": {"data": {"text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.", "entity1": "EE", "entity2": "acne", "span1": [241, 243], "span2": [169, 173]}, "bert_text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/<e1> EE </e1> <e2> acne </e2>, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1727": {"data": {"text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.", "entity1": "EE", "entity2": "hirsutism", "span1": [241, 243], "span2": [175, 184]}, "bert_text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/<e1> EE </e1> <e2> hirsutism </e2> or PCOS to estimate the risk of VTE associated with CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1728": {"data": {"text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.", "entity1": "EE", "entity2": "PCOS", "span1": [241, 243], "span2": [188, 192]}, "bert_text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/<e1> EE </e1> <e2> PCOS </e2> to estimate the risk of VTE associated with CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1729": {"data": {"text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.", "entity1": "EE", "entity2": "VTE", "span1": [241, 243], "span2": [217, 220]}, "bert_text": "Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/<e1> EE </e1> <e2> VTE </e2> associated with CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"1730": {"data": {"text": "Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.", "entity1": "cocaine", "entity2": "aneurysms", "span1": [113, 120], "span2": [129, 138]}, "bert_text": "Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with <e1> cocaine </e1>-related <e2> aneurysms </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1731": {"data": {"text": "In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.", "entity1": "LTG", "entity2": "MJ", "span1": [17, 20], "span2": [33, 35]}, "bert_text": "In two patients, <e1> LTG </e1> exacerbated <e2> MJ </e2> in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1732": {"data": {"text": "In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.", "entity1": "LTG", "entity2": "myoclonic status", "span1": [17, 20], "span2": [78, 94]}, "bert_text": "In two patients, <e1> LTG </e1> exacerbated MJ in a delayed but more severe manner, with <e2> myoclonic status </e2> that only ceased after LTG withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1733": {"data": {"text": "In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.", "entity1": "LTG", "entity2": "MJ", "span1": [118, 121], "span2": [33, 35]}, "bert_text": "In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after <e1> LTG </e1> <e2> MJ </e2> in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1734": {"data": {"text": "In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.", "entity1": "LTG", "entity2": "myoclonic status", "span1": [118, 121], "span2": [78, 94]}, "bert_text": "In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after <e1> LTG </e1> <e2> myoclonic status </e2> that only ceased after LTG withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1735": {"data": {"text": "In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.", "entity1": "UMB24", "entity2": "convulsions", "span1": [63, 68], "span2": [125, 136]}, "bert_text": "In behavioral studies, pretreatment of Swiss Webster mice with <e1> UMB24 </e1> or (+/-)-SM 21 significantly attenuated cocaine-induced <e2> convulsions </e2> and locomotor activity, but not lethality.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1736": {"data": {"text": "In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.", "entity1": "/-)-SM 21", "entity2": "convulsions", "span1": [74, 83], "span2": [125, 136]}, "bert_text": "In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+<e1> /-)-SM 21 </e1> significantly attenuated cocaine-induced <e2> convulsions </e2> and locomotor activity, but not lethality.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1737": {"data": {"text": "In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.", "entity1": "cocaine", "entity2": "convulsions", "span1": [109, 116], "span2": [125, 136]}, "bert_text": "In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated <e1> cocaine </e1>-induced <e2> convulsions </e2> and locomotor activity, but not lethality.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1738": {"data": {"text": "A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.", "entity1": "4'-0-tetrahydropyranyladriamycin", "entity2": "tumors", "span1": [42, 74], "span2": [156, 162]}, "bert_text": "A Phase I study of intravenous (IV) bolus <e1> 4'-0-tetrahydropyranyladriamycin </e1> (Pirarubicin) was done in 55 patients in good performance status with refractory <e2> tumors </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1739": {"data": {"text": "A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.", "entity1": "Pirarubicin", "entity2": "tumors", "span1": [76, 87], "span2": [156, 162]}, "bert_text": "A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (<e1> Pirarubicin </e1>) was done in 55 patients in good performance status with refractory <e2> tumors </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1740": {"data": {"text": "CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.", "entity1": "levofloxacin", "entity2": "sinusitis", "span1": [52, 64], "span2": [138, 147]}, "bert_text": "CONCLUSION: The results of this study indicate that <e1> levofloxacin </e1> 500 mg once daily is an effective and safe treatment for acute bacterial <e2> sinusitis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1741": {"data": {"text": "The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [43, 56], "span2": [65, 86]}, "bert_text": "The effects of exercise on the severity of <e1> isoproterenol </e1>-induced <e2> myocardial infarction </e2> were studied in female albino rats of 20,40,60 and 80 weeks of age.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1742": {"data": {"text": "We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.", "entity1": "pyrazinamide", "entity2": "olfactory disorder", "span1": [61, 73], "span2": [31, 49]}, "bert_text": "We report a case of reversible olfactory disorder related to <e1> pyrazinamide </e1> <e2> olfactory disorder </e2> related to pyrazinamide in a woman, with a positive rechallenge.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1743": {"data": {"text": "Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.", "entity1": "steroid", "entity2": "Hemolytic anemia", "span1": [68, 75], "span2": [0, 16]}, "bert_text": "Hemolytic anemia improved after stopping the drug and initiation of <e1> steroid </e1> <e2> Hemolytic anemia </e2> improved after stopping the drug and initiation of steroid therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1744": {"data": {"text": "Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.", "entity1": "cyclophosphamide", "entity2": "bladder cancer", "span1": [105, 121], "span2": [126, 140]}, "bert_text": "Nested within the cohort, a matched case-control study was performed to estimate the association between <e1> cyclophosphamide </e1> and <e2> bladder cancer </e2> using odds ratios (ORs) as relative risk.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1745": {"data": {"text": "Capsaicin (10 micro g) was injected into the masseter muscle to induce pain in 11 healthy volunteers.", "entity1": "Capsaicin", "entity2": "pain", "span1": [0, 9], "span2": [71, 75]}, "bert_text": "<e1> Capsaicin </e1> (10 micro g) was injected into the masseter muscle to induce <e2> pain </e2> in 11 healthy volunteers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1746": {"data": {"text": "Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.", "entity1": "lidocaine", "entity2": "pain", "span1": [85, 94], "span2": [55, 59]}, "bert_text": "Twenty patients were asked to quantify the severity of pain after receiving standard <e1> lidocaine </e1> <e2> pain </e2> after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1747": {"data": {"text": "Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.", "entity1": "lidocaine", "entity2": "pain", "span1": [128, 137], "span2": [55, 59]}, "bert_text": "Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered <e1> lidocaine </e1> <e2> pain </e2> after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1748": {"data": {"text": "Lidocaine-induced cardiac asystole.\n", "entity1": "Lidocaine", "entity2": "cardiac asystole", "span1": [0, 9], "span2": [18, 34]}, "bert_text": "<e1> Lidocaine </e1>-induced <e2> cardiac asystole </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1749": {"data": {"text": "High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various cancers.", "entity1": "5-fluorouracil", "entity2": "cancers", "span1": [10, 24], "span2": [105, 112]}, "bert_text": "High-dose <e1> 5-fluorouracil </e1>/folinic acid infusion therapy has recently become a popular regimen for various <e2> cancers </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1750": {"data": {"text": "High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various cancers.", "entity1": "folinic acid", "entity2": "cancers", "span1": [25, 37], "span2": [105, 112]}, "bert_text": "High-dose 5-fluorouracil/<e1> folinic acid </e1> infusion therapy has recently become a popular regimen for various <e2> cancers </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1751": {"data": {"text": "In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.", "entity1": "DOX", "entity2": "cardiac dysfunction", "span1": [3, 6], "span2": [22, 41]}, "bert_text": "In <e1> DOX </e1> B1R(-/-) mice, <e2> cardiac dysfunction </e2> was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1752": {"data": {"text": "In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.", "entity1": "DOX", "entity2": "cardiac dysfunction", "span1": [67, 70], "span2": [22, 41]}, "bert_text": "In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to <e1> DOX </e1> <e2> cardiac dysfunction </e2> was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1753": {"data": {"text": "Pain not responsive to morphine is often problematic.", "entity1": "morphine", "entity2": "Pain", "span1": [23, 31], "span2": [0, 4]}, "bert_text": "Pain not responsive to <e1> morphine </e1> <e2> Pain </e2> not responsive to morphine is often problematic.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1754": {"data": {"text": "CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.", "entity1": "Cocaine", "entity2": "aneurysmal rupture", "span1": [12, 19], "span2": [36, 54]}, "bert_text": "CONCLUSION: <e1> Cocaine </e1> use predisposed <e2> aneurysmal rupture </e2> at a significantly earlier age and in much smaller aneurysms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1755": {"data": {"text": "CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.", "entity1": "Cocaine", "entity2": "aneurysms", "span1": [12, 19], "span2": [106, 115]}, "bert_text": "CONCLUSION: <e1> Cocaine </e1> use predisposed aneurysmal rupture at a significantly earlier age and in much smaller <e2> aneurysms </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1756": {"data": {"text": "METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.", "entity1": "cisplatin", "entity2": "breast carcinoma", "span1": [48, 57], "span2": [128, 144]}, "bert_text": "METHODS: A Phase II study of the combination of <e1> cisplatin </e1> plus amifostine was conducted in patients with progressive metastatic <e2> breast carcinoma </e2> who had received one, but not more than one, chemotherapy regimen for metastatic disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"1757": {"data": {"text": "METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.", "entity1": "amifostine", "entity2": "breast carcinoma", "span1": [63, 73], "span2": [128, 144]}, "bert_text": "METHODS: A Phase II study of the combination of cisplatin plus <e1> amifostine </e1> was conducted in patients with progressive metastatic <e2> breast carcinoma </e2> who had received one, but not more than one, chemotherapy regimen for metastatic disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"1758": {"data": {"text": "Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.", "entity1": "rizatriptan", "entity2": "headache", "span1": [110, 121], "span2": [17, 25]}, "bert_text": "Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring <e1> rizatriptan </e1> <e2> headache </e2> was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1759": {"data": {"text": "Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.", "entity1": "ergotamine", "entity2": "headache", "span1": [158, 168], "span2": [17, 25]}, "bert_text": "Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred <e1> ergotamine </e1> <e2> headache </e2> was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1760": {"data": {"text": "Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.", "entity1": "caffeine", "entity2": "headache", "span1": [169, 177], "span2": [17, 25]}, "bert_text": "Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/<e1> caffeine </e1> <e2> headache </e2> was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1761": {"data": {"text": "Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.", "entity1": "Pamidronate", "entity2": "hypocalcemia", "span1": [0, 11], "span2": [63, 75]}, "bert_text": "<e1> Pamidronate </e1> treatment is associated with considerable risk for <e2> hypocalcemia </e2>, even in cases of initially severe hypercalcemia.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1762": {"data": {"text": "Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.", "entity1": "Pamidronate", "entity2": "hypercalcemia", "span1": [0, 11], "span2": [111, 124]}, "bert_text": "<e1> Pamidronate </e1> treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe <e2> hypercalcemia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1763": {"data": {"text": "Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.", "entity1": "metformin", "entity2": "nephrotoxicity", "span1": [53, 62], "span2": [85, 99]}, "bert_text": "Thus, our study suggests that pleiotropic effects of <e1> metformin </e1> can lessen gentamicin <e2> nephrotoxicity </e2> and improve mitochondrial homeostasis.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1764": {"data": {"text": "Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.", "entity1": "gentamicin", "entity2": "nephrotoxicity", "span1": [74, 84], "span2": [85, 99]}, "bert_text": "Thus, our study suggests that pleiotropic effects of metformin can lessen <e1> gentamicin </e1> <e2> nephrotoxicity </e2> and improve mitochondrial homeostasis.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1765": {"data": {"text": "Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.\n", "entity1": "serotonin", "entity2": "hypotensive", "span1": [11, 20], "span2": [59, 70]}, "bert_text": "Midline B3 <e1> serotonin </e1> nerves in rat medulla are involved in <e2> hypotensive </e2> effect of methyldopa.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1766": {"data": {"text": "Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.\n", "entity1": "methyldopa", "entity2": "hypotensive", "span1": [81, 91], "span2": [59, 70]}, "bert_text": "Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of <e1> methyldopa </e1> <e2> hypotensive </e2> effect of methyldopa.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1767": {"data": {"text": "These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.", "entity1": "ethanol", "entity2": "convulsants", "span1": [142, 149], "span2": [107, 118]}, "bert_text": "These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with <e1> ethanol </e1> <e2> convulsants </e2> may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1768": {"data": {"text": "These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.", "entity1": "alcohol", "entity2": "convulsants", "span1": [210, 217], "span2": [107, 118]}, "bert_text": "These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in <e1> alcohol </e1> <e2> convulsants </e2> may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1769": {"data": {"text": "Macula toxicity after intravitreal amikacin.\n", "entity1": "amikacin", "entity2": "toxicity", "span1": [35, 43], "span2": [7, 15]}, "bert_text": "Macula toxicity after intravitreal <e1> amikacin </e1> <e2> toxicity </e2> after intravitreal amikacin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1770": {"data": {"text": "Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.", "entity1": "Sirolimus", "entity2": "nephropathy", "span1": [0, 9], "span2": [124, 135]}, "bert_text": "<e1> Sirolimus </e1> represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1771": {"data": {"text": "Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.\n", "entity1": "alpha-benzene hexachloride", "entity2": "hepatoma", "span1": [78, 104], "span2": [50, 58]}, "bert_text": "Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by <e1> alpha-benzene hexachloride </e1> <e2> hepatoma </e2> of mice induced by alpha-benzene hexachloride.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1772": {"data": {"text": "Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).", "entity1": "PAN", "entity2": "proteinuria", "span1": [68, 71], "span2": [123, 134]}, "bert_text": "Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after <e1> PAN </e1> injection so as to include both the acute phase of <e2> proteinuria </e2> associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1773": {"data": {"text": "Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).", "entity1": "PAN", "entity2": "proteinuria", "span1": [68, 71], "span2": [212, 223]}, "bert_text": "Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after <e1> PAN </e1> injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of <e2> proteinuria </e2> associated with glomerulosclerosis (days 45-126).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1774": {"data": {"text": "Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).", "entity1": "PAN", "entity2": "glomerulosclerosis", "span1": [68, 71], "span2": [240, 258]}, "bert_text": "Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after <e1> PAN </e1> injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with <e2> glomerulosclerosis </e2> (days 45-126).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1775": {"data": {"text": "BE-Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.", "entity1": "BE", "entity2": "seizures", "span1": [0, 2], "span2": [11, 19]}, "bert_text": "<e1> BE </e1>-Induced <e2> seizures </e2> occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1776": {"data": {"text": "BE-Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.", "entity1": "cocaine", "entity2": "seizures", "span1": [127, 134], "span2": [11, 19]}, "bert_text": "BE-Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of <e1> cocaine </e1> <e2> seizures </e2> occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1777": {"data": {"text": "Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.", "entity1": "contrast media", "entity2": "nephropathy", "span1": [39, 53], "span2": [62, 73]}, "bert_text": "Despite increasing reports on nonionic <e1> contrast media </e1>-induced <e2> nephropathy </e2> (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1778": {"data": {"text": "Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.", "entity1": "contrast media", "entity2": "CIN", "span1": [39, 53], "span2": [75, 78]}, "bert_text": "Despite increasing reports on nonionic <e1> contrast media </e1>-induced nephropathy (<e2> CIN </e2>) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1779": {"data": {"text": "BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.", "entity1": "aminoglycosides", "entity2": "endophthalmitis", "span1": [34, 49], "span2": [98, 113]}, "bert_text": "BACKGROUND: Although intravitreal <e1> aminoglycosides </e1> have substantially improved visual prognosis in <e2> endophthalmitis </e2>, macular infarction may impair full visual recovery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1780": {"data": {"text": "BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.", "entity1": "aminoglycosides", "entity2": "infarction", "span1": [34, 49], "span2": [123, 133]}, "bert_text": "BACKGROUND: Although intravitreal <e1> aminoglycosides </e1> have substantially improved visual prognosis in endophthalmitis, macular <e2> infarction </e2> may impair full visual recovery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1781": {"data": {"text": "METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.", "entity1": "amikacin", "entity2": "retinal toxicity", "span1": [39, 47], "span2": [48, 64]}, "bert_text": "METHODS: We present a case of presumed <e1> amikacin </e1> <e2> retinal toxicity </e2> following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1782": {"data": {"text": "METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.", "entity1": "amikacin", "entity2": "haemolytic streptococcal endophthalmitis", "span1": [39, 47], "span2": [124, 164]}, "bert_text": "METHODS: We present a case of presumed <e1> amikacin </e1> retinal toxicity following treatment with amikacin and vancomycin for alpha-<e2> haemolytic streptococcal endophthalmitis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1783": {"data": {"text": "METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.", "entity1": "amikacin", "entity2": "retinal toxicity", "span1": [90, 98], "span2": [48, 64]}, "bert_text": "METHODS: We present a case of presumed amikacin retinal toxicity following treatment with <e1> amikacin </e1> <e2> retinal toxicity </e2> following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1784": {"data": {"text": "METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.", "entity1": "amikacin", "entity2": "haemolytic streptococcal endophthalmitis", "span1": [90, 98], "span2": [124, 164]}, "bert_text": "METHODS: We present a case of presumed amikacin retinal toxicity following treatment with <e1> amikacin </e1> and vancomycin for alpha-<e2> haemolytic streptococcal endophthalmitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1785": {"data": {"text": "METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.", "entity1": "vancomycin", "entity2": "retinal toxicity", "span1": [103, 113], "span2": [48, 64]}, "bert_text": "METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and <e1> vancomycin </e1> <e2> retinal toxicity </e2> following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1786": {"data": {"text": "METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.", "entity1": "vancomycin", "entity2": "haemolytic streptococcal endophthalmitis", "span1": [103, 113], "span2": [124, 164]}, "bert_text": "METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and <e1> vancomycin </e1> for alpha-<e2> haemolytic streptococcal endophthalmitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1787": {"data": {"text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.", "entity1": "ASA", "entity2": "malformation", "span1": [108, 111], "span2": [163, 175]}, "bert_text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when <e1> ASA </e1> is administered on GD 9, 10, or 11; to compare the <e2> malformation </e2> patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1788": {"data": {"text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.", "entity1": "ASA", "entity2": "malformations", "span1": [108, 111], "span2": [364, 377]}, "bert_text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when <e1> ASA </e1> is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence <e2> malformations </e2> with ASA when a multiple dosing paradigm is used.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1789": {"data": {"text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.", "entity1": "ASA", "entity2": "gastrointestinal toxicity", "span1": [108, 111], "span2": [297, 322]}, "bert_text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when <e1> ASA </e1> is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal <e2> gastrointestinal toxicity </e2> confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1790": {"data": {"text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.", "entity1": "ASA", "entity2": "malformation", "span1": [383, 386], "span2": [163, 175]}, "bert_text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with <e1> ASA </e1> <e2> malformation </e2> patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1791": {"data": {"text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.", "entity1": "ASA", "entity2": "malformations", "span1": [383, 386], "span2": [364, 377]}, "bert_text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with <e1> ASA </e1> <e2> malformations </e2> with ASA when a multiple dosing paradigm is used.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1792": {"data": {"text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.", "entity1": "ASA", "entity2": "gastrointestinal toxicity", "span1": [383, 386], "span2": [297, 322]}, "bert_text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with <e1> ASA </e1> <e2> gastrointestinal toxicity </e2> confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1793": {"data": {"text": "This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).", "entity1": "amiodarone", "entity2": "myxedema coma", "span1": [52, 62], "span2": [25, 38]}, "bert_text": "This is a case report of myxedema coma secondary to <e1> amiodarone </e1> <e2> myxedema coma </e2> secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1794": {"data": {"text": "This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).", "entity1": "amiodarone", "entity2": "hypothyroidism", "span1": [52, 62], "span2": [71, 85]}, "bert_text": "This is a case report of myxedema coma secondary to <e1> amiodarone </e1>-induced <e2> hypothyroidism </e2> in a patient with severe congestive heart failure (CHF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1795": {"data": {"text": "This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).", "entity1": "amiodarone", "entity2": "congestive heart failure", "span1": [52, 62], "span2": [111, 135]}, "bert_text": "This is a case report of myxedema coma secondary to <e1> amiodarone </e1>-induced hypothyroidism in a patient with severe <e2> congestive heart failure </e2> (CHF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1796": {"data": {"text": "This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).", "entity1": "amiodarone", "entity2": "CHF", "span1": [52, 62], "span2": [137, 140]}, "bert_text": "This is a case report of myxedema coma secondary to <e1> amiodarone </e1>-induced hypothyroidism in a patient with severe congestive heart failure (<e2> CHF </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1797": {"data": {"text": "Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.", "entity1": "methylphenidate", "entity2": "obsessive-compulsive behavior", "span1": [88, 103], "span2": [12, 41]}, "bert_text": "Significant obsessive-compulsive behavior ensued but diminished over several weeks when <e1> methylphenidate </e1> <e2> obsessive-compulsive behavior </e2> ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1798": {"data": {"text": "Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.", "entity1": "fluvoxamine", "entity2": "obsessive-compulsive behavior", "span1": [120, 131], "span2": [12, 41]}, "bert_text": "Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by <e1> fluvoxamine </e1> <e2> obsessive-compulsive behavior </e2> ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1799": {"data": {"text": "Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.", "entity1": "Vancomycin", "entity2": "nephrotoxicity", "span1": [0, 10], "span2": [11, 25]}, "bert_text": "<e1> Vancomycin </e1> <e2> nephrotoxicity </e2> is infrequent but may result from coadministration with a nephrotoxic agent.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1800": {"data": {"text": "Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.", "entity1": "Vancomycin", "entity2": "nephrotoxic", "span1": [0, 10], "span2": [84, 95]}, "bert_text": "<e1> Vancomycin </e1> nephrotoxicity is infrequent but may result from coadministration with a <e2> nephrotoxic </e2> agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1801": {"data": {"text": "The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.", "entity1": "CYP", "entity2": "bladder inflammation", "span1": [134, 137], "span2": [44, 64]}, "bert_text": "The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with <e1> CYP </e1> <e2> bladder inflammation </e2>, inflammatory mediators are increased above that observed in WT with CYP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1802": {"data": {"text": "A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.", "entity1": "capsaicin", "entity2": "painful", "span1": [18, 27], "span2": [101, 108]}, "bert_text": "A small amount of <e1> capsaicin </e1> was administered subcutaneously in the right forehead to evoke a burning <e2> painful </e2> sensation in the first division of the trigeminal nerve.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1803": {"data": {"text": "Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.", "entity1": "diazepam", "entity2": "seizures", "span1": [37, 45], "span2": [10, 18]}, "bert_text": "Recurrent seizures were treated with <e1> diazepam </e1> <e2> seizures </e2> were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1804": {"data": {"text": "Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.", "entity1": "diazepam", "entity2": "tachycardia", "span1": [37, 45], "span2": [64, 75]}, "bert_text": "Recurrent seizures were treated with <e1> diazepam </e1> and broad complex <e2> tachycardia </e2> was successfully treated with adenosine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1805": {"data": {"text": "Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.", "entity1": "adenosine", "entity2": "seizures", "span1": [106, 115], "span2": [10, 18]}, "bert_text": "Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with <e1> adenosine </e1> <e2> seizures </e2> were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1806": {"data": {"text": "Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.", "entity1": "adenosine", "entity2": "tachycardia", "span1": [106, 115], "span2": [64, 75]}, "bert_text": "Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with <e1> adenosine </e1> <e2> tachycardia </e2> was successfully treated with adenosine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1807": {"data": {"text": "The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.", "entity1": "COCs", "entity2": "VTE", "span1": [106, 110], "span2": [35, 38]}, "bert_text": "The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on <e1> COCs </e1> <e2> VTE </e2> was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"1808": {"data": {"text": "The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.", "entity1": "COCs", "entity2": "VTE", "span1": [197, 201], "span2": [35, 38]}, "bert_text": "The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing <e1> COCs </e1> <e2> VTE </e2> was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"1809": {"data": {"text": "The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.", "entity1": "levonorgestrel", "entity2": "VTE", "span1": [171, 185], "span2": [35, 38]}, "bert_text": "The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on <e1> levonorgestrel </e1> <e2> VTE </e2> was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1810": {"data": {"text": "The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.", "entity1": "CPA", "entity2": "VTE", "span1": [270, 273], "span2": [35, 38]}, "bert_text": "The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on <e1> CPA </e1> <e2> VTE </e2> was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1811": {"data": {"text": "The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.", "entity1": "EE", "entity2": "VTE", "span1": [274, 276], "span2": [35, 38]}, "bert_text": "The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/<e1> EE </e1> <e2> VTE </e2> was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1812": {"data": {"text": "Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.", "entity1": "methyldopa", "entity2": "hypotensive", "span1": [74, 84], "span2": [167, 178]}, "bert_text": "Previous experiments in this laboratory have shown that microinjection of <e1> methyldopa </e1> onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a <e2> hypotensive </e2> response mediated by a projection descending into the spinal cord.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1813": {"data": {"text": "Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.", "entity1": "serotonin", "entity2": "hypotensive", "span1": [124, 133], "span2": [167, 178]}, "bert_text": "Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 <e1> serotonin </e1> neurons in the medulla elicits a <e2> hypotensive </e2> response mediated by a projection descending into the spinal cord.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1814": {"data": {"text": "Ethopropazine and benztropine in neuroleptic-induced parkinsonism.\n", "entity1": "Ethopropazine", "entity2": "parkinsonism", "span1": [0, 13], "span2": [53, 65]}, "bert_text": "<e1> Ethopropazine </e1> and benztropine in neuroleptic-induced <e2> parkinsonism </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1815": {"data": {"text": "Ethopropazine and benztropine in neuroleptic-induced parkinsonism.\n", "entity1": "benztropine", "entity2": "parkinsonism", "span1": [18, 29], "span2": [53, 65]}, "bert_text": "Ethopropazine and <e1> benztropine </e1> in neuroleptic-induced <e2> parkinsonism </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1816": {"data": {"text": "Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.", "entity1": "octreotide", "entity2": "gallstones", "span1": [164, 174], "span2": [127, 137]}, "bert_text": "Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during <e1> octreotide </e1> <e2> gallstones </e2>, and cholecystitis during octreotide therapy in Chinese acromegalic patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1817": {"data": {"text": "Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.", "entity1": "octreotide", "entity2": "cholecystitis", "span1": [164, 174], "span2": [143, 156]}, "bert_text": "Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during <e1> octreotide </e1> <e2> cholecystitis </e2> during octreotide therapy in Chinese acromegalic patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1818": {"data": {"text": "Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.", "entity1": "octreotide", "entity2": "acromegalic", "span1": [164, 174], "span2": [194, 205]}, "bert_text": "Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during <e1> octreotide </e1> therapy in Chinese <e2> acromegalic </e2> patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1819": {"data": {"text": "The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.", "entity1": "ribavirin", "entity2": "RIHA", "span1": [83, 92], "span2": [39, 43]}, "bert_text": "The standard of care for management of RIHA is reduction or discontinuation of the <e1> ribavirin </e1> <e2> RIHA </e2> is reduction or discontinuation of the ribavirin dosage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1820": {"data": {"text": "Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.\n", "entity1": "reserpine", "entity2": "orofacial dyskinesia", "span1": [6, 15], "span2": [108, 128]}, "bert_text": "Acute <e1> reserpine </e1> and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit <e2> orofacial dyskinesia </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1821": {"data": {"text": "Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.\n", "entity1": "haloperidol", "entity2": "orofacial dyskinesia", "span1": [31, 42], "span2": [108, 128]}, "bert_text": "Acute reserpine and subchronic <e1> haloperidol </e1> treatments change synaptosomal brain glutamate uptake and elicit <e2> orofacial dyskinesia </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1822": {"data": {"text": "Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.", "entity1": "vinorelbine", "entity2": "squamous cell esophageal carcinoma", "span1": [18, 29], "span2": [44, 78]}, "bert_text": "Phase II trial of <e1> vinorelbine </e1> in metastatic <e2> squamous cell esophageal carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1823": {"data": {"text": "Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.", "entity1": "Simvastatin", "entity2": "human immunodeficiency virus", "span1": [0, 11], "span2": [43, 71]}, "bert_text": "<e1> Simvastatin </e1>, amiodarone, and the patient's <e2> human immunodeficiency virus </e2> medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1824": {"data": {"text": "Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.", "entity1": "amiodarone", "entity2": "human immunodeficiency virus", "span1": [13, 23], "span2": [43, 71]}, "bert_text": "Simvastatin, <e1> amiodarone </e1>, and the patient's <e2> human immunodeficiency virus </e2> medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1825": {"data": {"text": "OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.", "entity1": "vitamin C", "entity2": "cardiovascular disease", "span1": [61, 70], "span2": [97, 119]}, "bert_text": "OBJECTIVE: The objective was to examine the relation between <e1> vitamin C </e1> intake and mortality from <e2> cardiovascular disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1826": {"data": {"text": "They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.", "entity1": "bromocriptine", "entity2": "tachycardia", "span1": [72, 85], "span2": [57, 68]}, "bert_text": "They suggest that, in normal conscious rats, the central tachycardia of <e1> bromocriptine </e1> <e2> tachycardia </e2> of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1827": {"data": {"text": "They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.", "entity1": "bromocriptine", "entity2": "bradycardia", "span1": [72, 85], "span2": [125, 136]}, "bert_text": "They suggest that, in normal conscious rats, the central tachycardia of <e1> bromocriptine </e1> appears to predominate and to mask the <e2> bradycardia </e2> of this agonist at peripheral dopamine D2 receptors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1828": {"data": {"text": "They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.", "entity1": "dopamine", "entity2": "tachycardia", "span1": [167, 175], "span2": [57, 68]}, "bert_text": "They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral <e1> dopamine </e1> <e2> tachycardia </e2> of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1829": {"data": {"text": "They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.", "entity1": "dopamine", "entity2": "bradycardia", "span1": [167, 175], "span2": [125, 136]}, "bert_text": "They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral <e1> dopamine </e1> <e2> bradycardia </e2> of this agonist at peripheral dopamine D2 receptors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1830": {"data": {"text": "Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.", "entity1": "salvianolic acid A", "entity2": "cardiac dysfunction", "span1": [18, 36], "span2": [107, 126]}, "bert_text": "Administration of <e1> salvianolic acid A </e1> for a period of 8 days significantly attenuated isoproterenol-induced <e2> cardiac dysfunction </e2> and myocardial injury and improved mitochondrial respiratory function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1831": {"data": {"text": "Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.", "entity1": "salvianolic acid A", "entity2": "myocardial injury", "span1": [18, 36], "span2": [131, 148]}, "bert_text": "Administration of <e1> salvianolic acid A </e1> for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and <e2> myocardial injury </e2> and improved mitochondrial respiratory function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1832": {"data": {"text": "Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.", "entity1": "isoproterenol", "entity2": "cardiac dysfunction", "span1": [85, 98], "span2": [107, 126]}, "bert_text": "Administration of salvianolic acid A for a period of 8 days significantly attenuated <e1> isoproterenol </e1>-induced <e2> cardiac dysfunction </e2> and myocardial injury and improved mitochondrial respiratory function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1833": {"data": {"text": "Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.", "entity1": "isoproterenol", "entity2": "myocardial injury", "span1": [85, 98], "span2": [131, 148]}, "bert_text": "Administration of salvianolic acid A for a period of 8 days significantly attenuated <e1> isoproterenol </e1>-induced cardiac dysfunction and <e2> myocardial injury </e2> and improved mitochondrial respiratory function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1834": {"data": {"text": "Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).", "entity1": "valproic acid", "entity2": "Confusion", "span1": [63, 76], "span2": [0, 9]}, "bert_text": "Confusion mostly occurred during the two first weeks following <e1> valproic acid </e1> <e2> Confusion </e2> mostly occurred during the two first weeks following valproic acid exposure (39.7%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1835": {"data": {"text": "Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.\n", "entity1": "tamoxifen", "entity2": "Granulosa cell tumor of the ovary", "span1": [61, 70], "span2": [0, 33]}, "bert_text": "Granulosa cell tumor of the ovary associated with antecedent <e1> tamoxifen </e1> <e2> Granulosa cell tumor of the ovary </e2> associated with antecedent tamoxifen use.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1836": {"data": {"text": "Manic excitement was coincident with the duration of action of triazolam.", "entity1": "triazolam", "entity2": "Manic", "span1": [63, 72], "span2": [0, 5]}, "bert_text": "Manic excitement was coincident with the duration of action of <e1> triazolam </e1> <e2> Manic </e2> excitement was coincident with the duration of action of triazolam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1837": {"data": {"text": "Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.", "entity1": "Steroid", "entity2": "glaucoma", "span1": [0, 7], "span2": [122, 130]}, "bert_text": "<e1> Steroid </e1> treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid <e2> glaucoma </e2> and open angle glaucoma.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1838": {"data": {"text": "Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.", "entity1": "Steroid", "entity2": "open angle glaucoma", "span1": [0, 7], "span2": [135, 154]}, "bert_text": "<e1> Steroid </e1> treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and <e2> open angle glaucoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1839": {"data": {"text": "Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.", "entity1": "pyrazinamide", "entity2": "Dysosmia", "span1": [38, 50], "span2": [0, 8]}, "bert_text": "Dysosmia disappeared completely after <e1> pyrazinamide </e1> <e2> Dysosmia </e2> disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1840": {"data": {"text": "Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.", "entity1": "creatinine", "entity2": "Nephrotoxicity", "span1": [63, 73], "span2": [0, 14]}, "bert_text": "Nephrotoxicity was assessed by measuring the concentrations of <e1> creatinine </e1> <e2> Nephrotoxicity </e2> was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"1841": {"data": {"text": "Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.", "entity1": "urea", "entity2": "Nephrotoxicity", "span1": [78, 82], "span2": [0, 14]}, "bert_text": "Nephrotoxicity was assessed by measuring the concentrations of creatinine and <e1> urea </e1> <e2> Nephrotoxicity </e2> was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"1842": {"data": {"text": "Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.", "entity1": "glutathione", "entity2": "Nephrotoxicity", "span1": [109, 120], "span2": [0, 14]}, "bert_text": "Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced <e1> glutathione </e1> <e2> Nephrotoxicity </e2> was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"1843": {"data": {"text": "Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.", "entity1": "GSH", "entity2": "Nephrotoxicity", "span1": [122, 125], "span2": [0, 14]}, "bert_text": "Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (<e1> GSH </e1> <e2> Nephrotoxicity </e2> was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1844": {"data": {"text": "Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.\n", "entity1": "fluoxetine", "entity2": "fetal pulmonary hypertension", "span1": [21, 31], "span2": [40, 68]}, "bert_text": "Prenatal exposure to <e1> fluoxetine </e1> induces <e2> fetal pulmonary hypertension </e2> in the rat.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1845": {"data": {"text": "The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/-", "entity1": "lidocaine", "entity2": "pain", "span1": [33, 42], "span2": [9, 13]}, "bert_text": "The mean pain score for buffered <e1> lidocaine </e1> <e2> pain </e2> score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1846": {"data": {"text": "The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/-", "entity1": "lidocaine", "entity2": "pain", "span1": [100, 109], "span2": [9, 13]}, "bert_text": "The mean pain score for buffered lidocaine was significantly lower than the mean score for standard <e1> lidocaine </e1> <e2> pain </e2> score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1847": {"data": {"text": "Procainamide-induced polymorphous ventricular tachycardia.\n", "entity1": "Procainamide", "entity2": "ventricular tachycardia", "span1": [0, 12], "span2": [34, 57]}, "bert_text": "<e1> Procainamide </e1>-induced polymorphous <e2> ventricular tachycardia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1848": {"data": {"text": "Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).", "entity1": "FK506", "entity2": "nephropathy", "span1": [8, 13], "span2": [14, 25]}, "bert_text": "Chronic <e1> FK506 </e1> <e2> nephropathy </e2> consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1849": {"data": {"text": "Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).", "entity1": "FK506", "entity2": "focal segmental glomerulosclerosis", "span1": [8, 13], "span2": [163, 197]}, "bert_text": "Chronic <e1> FK506 </e1> nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), <e2> focal segmental glomerulosclerosis </e2> (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1850": {"data": {"text": "Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).", "entity1": "FK506", "entity2": "fibrosis", "span1": [8, 13], "span2": [248, 256]}, "bert_text": "Chronic <e1> FK506 </e1> nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial <e2> fibrosis </e2> (11 biopsies).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1851": {"data": {"text": "It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.", "entity1": "risperidone", "entity2": "neuroleptic malignant syndrome", "span1": [78, 89], "span2": [122, 152]}, "bert_text": "It appears that the protection from extrapyramidal side effects observed with <e1> risperidone </e1> does not ensure protection from <e2> neuroleptic malignant syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"1852": {"data": {"text": "The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.", "entity1": "sulfasalazine", "entity2": "hepatotoxicity", "span1": [44, 57], "span2": [24, 38]}, "bert_text": "The likely frequency of hepatotoxicity with <e1> sulfasalazine </e1> <e2> hepatotoxicity </e2> with sulfasalazine was estimated by making a series of conservative assumptions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1853": {"data": {"text": "PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma.", "entity1": "vinorelbine", "entity2": "squamous cell esophageal carcinoma", "span1": [60, 71], "span2": [123, 157]}, "bert_text": "PURPOSE: To evaluate the response rate and toxic effects of <e1> vinorelbine </e1> (VNB) administered as a single agent in metastatic <e2> squamous cell esophageal carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1854": {"data": {"text": "PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma.", "entity1": "VNB", "entity2": "squamous cell esophageal carcinoma", "span1": [73, 76], "span2": [123, 157]}, "bert_text": "PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (<e1> VNB </e1>) administered as a single agent in metastatic <e2> squamous cell esophageal carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1855": {"data": {"text": "RESULTS: in 11 patients, mutations were found in the BCHE gene, the K-variant being the most frequent.", "entity1": "K", "entity2": "BCHE", "span1": [68, 69], "span2": [53, 57]}, "bert_text": "RESULTS: in 11 patients, mutations were found in the BCHE gene, the <e1> K </e1> <e2> BCHE </e2> gene, the K-variant being the most frequent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1856": {"data": {"text": "One patient in the ketoprofen group developed a postoperative intracranial hematoma.", "entity1": "ketoprofen", "entity2": "postoperative intracranial hematoma", "span1": [19, 29], "span2": [48, 83]}, "bert_text": "One patient in the <e1> ketoprofen </e1> group developed a <e2> postoperative intracranial hematoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1857": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "fentanyl", "entity2": "postoperative nausea and vomiting", "span1": [21, 29], "span2": [70, 103]}, "bert_text": "RESULTS: Omission of <e1> fentanyl </e1> did not reduce the overall incidence of <e2> postoperative nausea and vomiting </e2>, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1858": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "fentanyl", "entity2": "vomiting", "span1": [21, 29], "span2": [137, 145]}, "bert_text": "RESULTS: Omission of <e1> fentanyl </e1> did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of <e2> vomiting </e2> and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1859": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "fentanyl", "entity2": "nausea", "span1": [21, 29], "span2": [172, 178]}, "bert_text": "RESULTS: Omission of <e1> fentanyl </e1> did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe <e2> nausea </e2> prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1860": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "fentanyl", "entity2": "postoperative nausea and vomiting", "span1": [220, 228], "span2": [70, 103]}, "bert_text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with <e1> fentanyl </e1> <e2> postoperative nausea and vomiting </e2>, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1861": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "fentanyl", "entity2": "vomiting", "span1": [220, 228], "span2": [137, 145]}, "bert_text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with <e1> fentanyl </e1> <e2> vomiting </e2> and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1862": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "fentanyl", "entity2": "nausea", "span1": [220, 228], "span2": [172, 178]}, "bert_text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with <e1> fentanyl </e1> <e2> nausea </e2> prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1863": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "fentanyl", "entity2": "postoperative nausea and vomiting", "span1": [233, 241], "span2": [70, 103]}, "bert_text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and <e1> fentanyl </e1> <e2> postoperative nausea and vomiting </e2>, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1864": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "fentanyl", "entity2": "vomiting", "span1": [233, 241], "span2": [137, 145]}, "bert_text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and <e1> fentanyl </e1> <e2> vomiting </e2> and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1865": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "fentanyl", "entity2": "nausea", "span1": [233, 241], "span2": [172, 178]}, "bert_text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and <e1> fentanyl </e1> <e2> nausea </e2> prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1866": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "dexamethasone", "entity2": "postoperative nausea and vomiting", "span1": [242, 255], "span2": [70, 103]}, "bert_text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-<e1> dexamethasone </e1> <e2> postoperative nausea and vomiting </e2>, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1867": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "dexamethasone", "entity2": "vomiting", "span1": [242, 255], "span2": [137, 145]}, "bert_text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-<e1> dexamethasone </e1> <e2> vomiting </e2> and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1868": {"data": {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity1": "dexamethasone", "entity2": "nausea", "span1": [242, 255], "span2": [172, 178]}, "bert_text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-<e1> dexamethasone </e1> <e2> nausea </e2> prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1869": {"data": {"text": "Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.\n", "entity1": "ritanserin", "entity2": "amnesia", "span1": [18, 28], "span2": [93, 100]}, "bert_text": "Microinjection of <e1> ritanserin </e1> into the CA1 region of hippocampus improves scopolamine-induced <e2> amnesia </e2> in adult male rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1870": {"data": {"text": "Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.\n", "entity1": "scopolamine", "entity2": "amnesia", "span1": [73, 84], "span2": [93, 100]}, "bert_text": "Microinjection of ritanserin into the CA1 region of hippocampus improves <e1> scopolamine </e1>-induced <e2> amnesia </e2> in adult male rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1871": {"data": {"text": "A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.", "entity1": "ketoconazole", "entity2": "weakness", "span1": [122, 134], "span2": [29, 37]}, "bert_text": "A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg <e1> ketoconazole </e1> <e2> weakness </e2> of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1872": {"data": {"text": "A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.", "entity1": "ketoconazole", "entity2": "legs paralysis", "span1": [122, 134], "span2": [54, 68]}, "bert_text": "A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg <e1> ketoconazole </e1> <e2> legs paralysis </e2>, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1873": {"data": {"text": "A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.", "entity1": "ketoconazole", "entity2": "dysarthria", "span1": [122, 134], "span2": [70, 80]}, "bert_text": "A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg <e1> ketoconazole </e1> <e2> dysarthria </e2> and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1874": {"data": {"text": "A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.", "entity1": "ketoconazole", "entity2": "tremor", "span1": [122, 134], "span2": [85, 91]}, "bert_text": "A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg <e1> ketoconazole </e1> <e2> tremor </e2> 1 h after ingestion of 200 mg ketoconazole for the first time in his life.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1875": {"data": {"text": "CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.", "entity1": "propylthio- uracil", "entity2": "Pericarditis", "span1": [101, 119], "span2": [12, 24]}, "bert_text": "CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to <e1> propylthio- uracil </e1> <e2> Pericarditis </e2> may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1876": {"data": {"text": "CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.", "entity1": "propylthio- uracil", "entity2": "vasculitis", "span1": [101, 119], "span2": [74, 84]}, "bert_text": "CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to <e1> propylthio- uracil </e1> <e2> vasculitis </e2> attributable to propylthio- uracil therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1877": {"data": {"text": "The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.", "entity1": "potassium", "entity2": "ischaemic heart disease", "span1": [40, 49], "span2": [139, 162]}, "bert_text": "The above results indicate that because <e1> potassium </e1>-losing diuretic therapy can increase myocardial electrical excitability in patients with <e2> ischaemic heart disease </e2>, even minor falls in plasma potassium concentrations are probably best avoided in such patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1878": {"data": {"text": "The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.", "entity1": "potassium", "entity2": "ischaemic heart disease", "span1": [191, 200], "span2": [139, 162]}, "bert_text": "The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma <e1> potassium </e1> <e2> ischaemic heart disease </e2>, even minor falls in plasma potassium concentrations are probably best avoided in such patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1879": {"data": {"text": "Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.", "entity1": "lamivudine", "entity2": "HBV infected", "span1": [12, 22], "span2": [30, 42]}, "bert_text": "Thirty-five <e1> lamivudine </e1>-na  ve <e2> HBV infected </e2> patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1880": {"data": {"text": "Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.", "entity1": "lamivudine", "entity2": "HBV-HIV co-infected", "span1": [12, 22], "span2": [144, 163]}, "bert_text": "Thirty-five <e1> lamivudine </e1>-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 <e2> HBV-HIV co-infected </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1881": {"data": {"text": "Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.", "entity1": "lamivudine", "entity2": "HIV co-infection", "span1": [12, 22], "span2": [68, 84]}, "bert_text": "Thirty-five <e1> lamivudine </e1>-na  ve HBV infected patients with or without <e2> HIV co-infection </e2> were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1882": {"data": {"text": "Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.", "entity1": "na", "entity2": "HBV infected", "span1": [23, 25], "span2": [30, 42]}, "bert_text": "Thirty-five lamivudine-<e1> na </e1>  ve <e2> HBV infected </e2> patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1883": {"data": {"text": "Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.", "entity1": "na", "entity2": "HBV-HIV co-infected", "span1": [23, 25], "span2": [144, 163]}, "bert_text": "Thirty-five lamivudine-<e1> na </e1>  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 <e2> HBV-HIV co-infected </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1884": {"data": {"text": "Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.", "entity1": "na", "entity2": "HIV co-infection", "span1": [23, 25], "span2": [68, 84]}, "bert_text": "Thirty-five lamivudine-<e1> na </e1>  ve HBV infected patients with or without <e2> HIV co-infection </e2> were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1885": {"data": {"text": "A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.", "entity1": "oral contraceptives", "entity2": "hemolytic uremic syndrome", "span1": [76, 95], "span2": [26, 51]}, "bert_text": "A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking <e1> oral contraceptives </e1> <e2> hemolytic uremic syndrome </e2> (HUS) in a woman taking oral contraceptives.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1886": {"data": {"text": "A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.", "entity1": "oral contraceptives", "entity2": "HUS", "span1": [76, 95], "span2": [53, 56]}, "bert_text": "A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking <e1> oral contraceptives </e1> <e2> HUS </e2>) in a woman taking oral contraceptives.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1887": {"data": {"text": "CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.", "entity1": "haloperidol", "entity2": "extrapyramidal signs", "span1": [71, 82], "span2": [156, 176]}, "bert_text": "CONCLUSIONS: The results indicated a favorable therapeutic profile for <e1> haloperidol </e1> in doses of 2-3 mg/day, although a subgroup developed moderate to severe <e2> extrapyramidal signs </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1888": {"data": {"text": "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.", "entity1": "Paclitaxel", "entity2": "tumor", "span1": [0, 10], "span2": [135, 140]}, "bert_text": "<e1> Paclitaxel </e1> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different <e2> tumor </e2> types, notably ovarian and breast carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1889": {"data": {"text": "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.", "entity1": "Paclitaxel", "entity2": "ovarian", "span1": [0, 10], "span2": [156, 163]}, "bert_text": "<e1> Paclitaxel </e1> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably <e2> ovarian </e2> and breast carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1890": {"data": {"text": "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.", "entity1": "Paclitaxel", "entity2": "breast carcinoma", "span1": [0, 10], "span2": [168, 184]}, "bert_text": "<e1> Paclitaxel </e1> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and <e2> breast carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1891": {"data": {"text": "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.", "entity1": "Taxol", "entity2": "tumor", "span1": [12, 17], "span2": [135, 140]}, "bert_text": "Paclitaxel (<e1> Taxol </e1>; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different <e2> tumor </e2> types, notably ovarian and breast carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1892": {"data": {"text": "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.", "entity1": "Taxol", "entity2": "ovarian", "span1": [12, 17], "span2": [156, 163]}, "bert_text": "Paclitaxel (<e1> Taxol </e1>; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably <e2> ovarian </e2> and breast carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1893": {"data": {"text": "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.", "entity1": "Taxol", "entity2": "breast carcinoma", "span1": [12, 17], "span2": [168, 184]}, "bert_text": "Paclitaxel (<e1> Taxol </e1>; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and <e2> breast carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1894": {"data": {"text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "entity1": "CPA", "entity2": "venous thromboembolism", "span1": [101, 104], "span2": [56, 78]}, "bert_text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with <e1> CPA </e1> <e2> venous thromboembolism </e2> (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"1895": {"data": {"text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "entity1": "CPA", "entity2": "VTE", "span1": [101, 104], "span2": [80, 83]}, "bert_text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with <e1> CPA </e1> <e2> VTE </e2>) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1896": {"data": {"text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "entity1": "EE", "entity2": "venous thromboembolism", "span1": [105, 107], "span2": [56, 78]}, "bert_text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/<e1> EE </e1> <e2> venous thromboembolism </e2> (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"1897": {"data": {"text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "entity1": "EE", "entity2": "VTE", "span1": [105, 107], "span2": [80, 83]}, "bert_text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/<e1> EE </e1> <e2> VTE </e2>) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1898": {"data": {"text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "entity1": "oral contraceptives", "entity2": "venous thromboembolism", "span1": [144, 163], "span2": [56, 78]}, "bert_text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined <e1> oral contraceptives </e1> <e2> venous thromboembolism </e2> (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1899": {"data": {"text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "entity1": "oral contraceptives", "entity2": "VTE", "span1": [144, 163], "span2": [80, 83]}, "bert_text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined <e1> oral contraceptives </e1> <e2> VTE </e2>) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1900": {"data": {"text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "entity1": "COCs", "entity2": "venous thromboembolism", "span1": [165, 169], "span2": [56, 78]}, "bert_text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (<e1> COCs </e1> <e2> venous thromboembolism </e2> (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1901": {"data": {"text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "entity1": "COCs", "entity2": "VTE", "span1": [165, 169], "span2": [80, 83]}, "bert_text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (<e1> COCs </e1> <e2> VTE </e2>) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1902": {"data": {"text": "Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.", "entity1": "curcumin", "entity2": "cognitive impairment", "span1": [12, 20], "span2": [50, 70]}, "bert_text": "Concomitant <e1> curcumin </e1> administration prevented the <e2> cognitive impairment </e2> and decreased the increased oxidative stress induced by these antiepileptic drugs.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1903": {"data": {"text": "Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.\n", "entity1": "Doxorubicin", "entity2": "cardiomyopathy", "span1": [0, 11], "span2": [12, 26]}, "bert_text": "<e1> Doxorubicin </e1> <e2> cardiomyopathy </e2> in children with left-sided Wilms tumor.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1904": {"data": {"text": "Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.\n", "entity1": "Doxorubicin", "entity2": "Wilms tumor", "span1": [0, 11], "span2": [55, 66]}, "bert_text": "<e1> Doxorubicin </e1> cardiomyopathy in children with left-sided <e2> Wilms tumor </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1905": {"data": {"text": "Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.\n", "entity1": "paclitaxel", "entity2": "glioblastoma", "span1": [28, 38], "span2": [98, 110]}, "bert_text": "Intracavitary chemotherapy (<e1> paclitaxel </e1>/carboplatin liquid crystalline cubic phases) for recurrent <e2> glioblastoma </e2> -- clinical observations.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1906": {"data": {"text": "Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.\n", "entity1": "carboplatin", "entity2": "glioblastoma", "span1": [39, 50], "span2": [98, 110]}, "bert_text": "Intracavitary chemotherapy (paclitaxel/<e1> carboplatin </e1> liquid crystalline cubic phases) for recurrent <e2> glioblastoma </e2> -- clinical observations.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1907": {"data": {"text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [132, 141], "span2": [234, 245]}, "bert_text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of <e1> sirolimus </e1> on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of <e2> proteinuria </e2> and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1908": {"data": {"text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [132, 141], "span2": [353, 364]}, "bert_text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of <e1> sirolimus </e1> on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if <e2> proteinuria </e2> occurs and withdrawal if needed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1909": {"data": {"text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [168, 177], "span2": [234, 245]}, "bert_text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of <e1> sirolimus </e1> in appropriate patient populations, close monitoring of <e2> proteinuria </e2> and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1910": {"data": {"text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [168, 177], "span2": [353, 364]}, "bert_text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of <e1> sirolimus </e1> in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if <e2> proteinuria </e2> occurs and withdrawal if needed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1911": {"data": {"text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "entity1": "angiotensin", "entity2": "proteinuria", "span1": [273, 284], "span2": [234, 245]}, "bert_text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of <e1> angiotensin </e1> <e2> proteinuria </e2> and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1912": {"data": {"text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "entity1": "angiotensin", "entity2": "proteinuria", "span1": [273, 284], "span2": [353, 364]}, "bert_text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of <e1> angiotensin </e1>-converting enzyme inhibitors or angiotensin II receptor blockers if <e2> proteinuria </e2> occurs and withdrawal if needed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1913": {"data": {"text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "entity1": "angiotensin II", "entity2": "proteinuria", "span1": [317, 331], "span2": [234, 245]}, "bert_text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or <e1> angiotensin II </e1> <e2> proteinuria </e2> and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1914": {"data": {"text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "entity1": "angiotensin II", "entity2": "proteinuria", "span1": [317, 331], "span2": [353, 364]}, "bert_text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or <e1> angiotensin II </e1> receptor blockers if <e2> proteinuria </e2> occurs and withdrawal if needed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1915": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "PTZ", "entity2": "Seizure", "span1": [24, 27], "span2": [0, 7]}, "bert_text": "Seizure activity due to <e1> PTZ </e1> <e2> Seizure </e2> activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1916": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "PTZ", "entity2": "seizure", "span1": [24, 27], "span2": [87, 94]}, "bert_text": "Seizure activity due to <e1> PTZ </e1> and picrotoxin (PTX) was significantly decreased; however, <e2> seizure </e2> activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1917": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "picrotoxin", "entity2": "Seizure", "span1": [32, 42], "span2": [0, 7]}, "bert_text": "Seizure activity due to PTZ and <e1> picrotoxin </e1> <e2> Seizure </e2> activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1918": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "picrotoxin", "entity2": "seizure", "span1": [32, 42], "span2": [87, 94]}, "bert_text": "Seizure activity due to PTZ and <e1> picrotoxin </e1> (PTX) was significantly decreased; however, <e2> seizure </e2> activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1919": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "PTX", "entity2": "Seizure", "span1": [44, 47], "span2": [0, 7]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (<e1> PTX </e1> <e2> Seizure </e2> activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1920": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "PTX", "entity2": "seizure", "span1": [44, 47], "span2": [87, 94]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (<e1> PTX </e1>) was significantly decreased; however, <e2> seizure </e2> activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1921": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "3-mercaptopropionic acid", "entity2": "Seizure", "span1": [111, 135], "span2": [0, 7]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to <e1> 3-mercaptopropionic acid </e1> <e2> Seizure </e2> activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1922": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "3-mercaptopropionic acid", "entity2": "seizure", "span1": [111, 135], "span2": [87, 94]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to <e1> 3-mercaptopropionic acid </e1> <e2> seizure </e2> activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1923": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "MPA", "entity2": "Seizure", "span1": [137, 140], "span2": [0, 7]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (<e1> MPA </e1> <e2> Seizure </e2> activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1924": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "MPA", "entity2": "seizure", "span1": [137, 140], "span2": [87, 94]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (<e1> MPA </e1> <e2> seizure </e2> activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1925": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "bicuculline", "entity2": "Seizure", "span1": [143, 154], "span2": [0, 7]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), <e1> bicuculline </e1> <e2> Seizure </e2> activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1926": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "bicuculline", "entity2": "seizure", "span1": [143, 154], "span2": [87, 94]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), <e1> bicuculline </e1> <e2> seizure </e2> activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1927": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "BCC", "entity2": "Seizure", "span1": [156, 159], "span2": [0, 7]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (<e1> BCC </e1> <e2> Seizure </e2> activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1928": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "BCC", "entity2": "seizure", "span1": [156, 159], "span2": [87, 94]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (<e1> BCC </e1> <e2> seizure </e2> activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1929": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate", "entity2": "Seizure", "span1": [162, 216], "span2": [0, 7]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), <e1> methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate </e1> <e2> Seizure </e2> activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1930": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate", "entity2": "seizure", "span1": [162, 216], "span2": [87, 94]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), <e1> methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate </e1> <e2> seizure </e2> activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1931": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "DMCM", "entity2": "Seizure", "span1": [218, 222], "span2": [0, 7]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (<e1> DMCM </e1> <e2> Seizure </e2> activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1932": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "DMCM", "entity2": "seizure", "span1": [218, 222], "span2": [87, 94]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (<e1> DMCM </e1> <e2> seizure </e2> activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1933": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "strychnine", "entity2": "Seizure", "span1": [228, 238], "span2": [0, 7]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or <e1> strychnine </e1> <e2> Seizure </e2> activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1934": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "strychnine", "entity2": "seizure", "span1": [228, 238], "span2": [87, 94]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or <e1> strychnine </e1> <e2> seizure </e2> activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1935": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "STR", "entity2": "Seizure", "span1": [240, 243], "span2": [0, 7]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (<e1> STR </e1> <e2> Seizure </e2> activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1936": {"data": {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity1": "STR", "entity2": "seizure", "span1": [240, 243], "span2": [87, 94]}, "bert_text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (<e1> STR </e1> <e2> seizure </e2> activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1937": {"data": {"text": "The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).", "entity1": "creatinine", "entity2": "nephropathy", "span1": [10, 20], "span2": [71, 82]}, "bert_text": "The serum <e1> creatinine </e1> levels of patients in the mild-type chronic FK506 <e2> nephropathy </e2> group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1938": {"data": {"text": "The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).", "entity1": "FK506", "entity2": "nephropathy", "span1": [65, 70], "span2": [71, 82]}, "bert_text": "The serum creatinine levels of patients in the mild-type chronic <e1> FK506 </e1> <e2> nephropathy </e2> group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1939": {"data": {"text": "The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).", "entity1": "FK506-nephropathy", "entity2": "nephropathy", "span1": [190, 207], "span2": [71, 82]}, "bert_text": "The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic <e1> FK506-nephropathy </e1> <e2> nephropathy </e2> group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1940": {"data": {"text": "Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.\n", "entity1": "cyclophosphamide", "entity2": "anemia", "span1": [56, 72], "span2": [28, 34]}, "bert_text": "Erythropoietin restores the anemia-induced reduction in <e1> cyclophosphamide </e1> <e2> anemia </e2>-induced reduction in cyclophosphamide cytotoxicity in rat tumors.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1941": {"data": {"text": "Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.\n", "entity1": "cyclophosphamide", "entity2": "cytotoxicity", "span1": [56, 72], "span2": [73, 85]}, "bert_text": "Erythropoietin restores the anemia-induced reduction in <e1> cyclophosphamide </e1> <e2> cytotoxicity </e2> in rat tumors.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1942": {"data": {"text": "Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.\n", "entity1": "cyclophosphamide", "entity2": "tumors", "span1": [56, 72], "span2": [93, 99]}, "bert_text": "Erythropoietin restores the anemia-induced reduction in <e1> cyclophosphamide </e1> cytotoxicity in rat <e2> tumors </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1943": {"data": {"text": "RESULTS: Six cases of levofloxacin-induced seizures have been reported in the literature.", "entity1": "levofloxacin", "entity2": "seizures", "span1": [22, 34], "span2": [43, 51]}, "bert_text": "RESULTS: Six cases of <e1> levofloxacin </e1>-induced <e2> seizures </e2> have been reported in the literature.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1944": {"data": {"text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [16, 25], "span2": [109, 123]}, "bert_text": "Early trials of <e1> cisplatin </e1> and amifostine also suggested that the incidence and severity of cisplatin-induced <e2> nephrotoxicity </e2>, ototoxicity, and neuropathy were reduced.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1945": {"data": {"text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.", "entity1": "cisplatin", "entity2": "ototoxicity", "span1": [16, 25], "span2": [125, 136]}, "bert_text": "Early trials of <e1> cisplatin </e1> and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, <e2> ototoxicity </e2>, and neuropathy were reduced.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1946": {"data": {"text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.", "entity1": "cisplatin", "entity2": "neuropathy", "span1": [16, 25], "span2": [142, 152]}, "bert_text": "Early trials of <e1> cisplatin </e1> and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and <e2> neuropathy </e2> were reduced.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1947": {"data": {"text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [91, 100], "span2": [109, 123]}, "bert_text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of <e1> cisplatin </e1>-induced <e2> nephrotoxicity </e2>, ototoxicity, and neuropathy were reduced.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1948": {"data": {"text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.", "entity1": "cisplatin", "entity2": "ototoxicity", "span1": [91, 100], "span2": [125, 136]}, "bert_text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of <e1> cisplatin </e1>-induced nephrotoxicity, <e2> ototoxicity </e2>, and neuropathy were reduced.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1949": {"data": {"text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.", "entity1": "cisplatin", "entity2": "neuropathy", "span1": [91, 100], "span2": [142, 152]}, "bert_text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of <e1> cisplatin </e1>-induced nephrotoxicity, ototoxicity, and <e2> neuropathy </e2> were reduced.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1950": {"data": {"text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.", "entity1": "amifostine", "entity2": "nephrotoxicity", "span1": [30, 40], "span2": [109, 123]}, "bert_text": "Early trials of cisplatin and <e1> amifostine </e1> also suggested that the incidence and severity of cisplatin-induced <e2> nephrotoxicity </e2>, ototoxicity, and neuropathy were reduced.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1951": {"data": {"text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.", "entity1": "amifostine", "entity2": "ototoxicity", "span1": [30, 40], "span2": [125, 136]}, "bert_text": "Early trials of cisplatin and <e1> amifostine </e1> also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, <e2> ototoxicity </e2>, and neuropathy were reduced.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1952": {"data": {"text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.", "entity1": "amifostine", "entity2": "neuropathy", "span1": [30, 40], "span2": [142, 152]}, "bert_text": "Early trials of cisplatin and <e1> amifostine </e1> also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and <e2> neuropathy </e2> were reduced.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1953": {"data": {"text": "Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.", "entity1": "Antituberculosis", "entity2": "acute liver failure", "span1": [0, 16], "span2": [42, 61]}, "bert_text": "<e1> Antituberculosis </e1> therapy (ATT)-associated <e2> acute liver failure </e2> (ATT-ALF) is the commonest drug-induced ALF in South Asia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1954": {"data": {"text": "Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.", "entity1": "Antituberculosis", "entity2": "ALF", "span1": [0, 16], "span2": [67, 70]}, "bert_text": "<e1> Antituberculosis </e1> therapy (ATT)-associated acute liver failure (ATT-<e2> ALF </e2>) is the commonest drug-induced ALF in South Asia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1955": {"data": {"text": "Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.", "entity1": "Antituberculosis", "entity2": "ALF", "span1": [0, 16], "span2": [102, 105]}, "bert_text": "<e1> Antituberculosis </e1> therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced <e2> ALF </e2> in South Asia.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1956": {"data": {"text": "Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.", "entity1": "iron", "entity2": "Visual and auditory neurotoxicity", "span1": [134, 138], "span2": [0, 33]}, "bert_text": "Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving <e1> iron </e1> <e2> Visual and auditory neurotoxicity </e2> was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1957": {"data": {"text": "Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.", "entity1": "iron", "entity2": "anemia", "span1": [134, 138], "span2": [108, 114]}, "bert_text": "Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving <e1> iron </e1> <e2> anemia </e2> who were receiving iron chelation therapy with daily subcutaneous deferoxamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1958": {"data": {"text": "Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.", "entity1": "deferoxamine", "entity2": "Visual and auditory neurotoxicity", "span1": [181, 193], "span2": [0, 33]}, "bert_text": "Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous <e1> deferoxamine </e1> <e2> Visual and auditory neurotoxicity </e2> was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1959": {"data": {"text": "Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.", "entity1": "deferoxamine", "entity2": "anemia", "span1": [181, 193], "span2": [108, 114]}, "bert_text": "Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous <e1> deferoxamine </e1> <e2> anemia </e2> who were receiving iron chelation therapy with daily subcutaneous deferoxamine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1960": {"data": {"text": "We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.", "entity1": "PCC", "entity2": "ICH", "span1": [40, 43], "span2": [85, 88]}, "bert_text": "We provide experimental data suggesting <e1> PCC </e1> to be an effective acute treatment for W-<e2> ICH </e2> in terms of reducing hemorrhagic blood volume.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1961": {"data": {"text": "She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.", "entity1": "heparin", "entity2": "anuria", "span1": [21, 28], "span2": [167, 173]}, "bert_text": "She was treated with <e1> heparin </e1>, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of <e2> anuria </e2>, dialysis treatment was stopped.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1962": {"data": {"text": "She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.", "entity1": "dipyridamole", "entity2": "anuria", "span1": [30, 42], "span2": [167, 173]}, "bert_text": "She was treated with heparin, <e1> dipyridamole </e1> and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of <e2> anuria </e2>, dialysis treatment was stopped.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1963": {"data": {"text": "Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.", "entity1": "suprofen", "entity2": "acute renal failure", "span1": [9, 17], "span2": [62, 81]}, "bert_text": "Although <e1> suprofen </e1> has been associated with the development of <e2> acute renal failure </e2> in greater than 100 subjects, the mechanism of damage remains unclear.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1964": {"data": {"text": "Seizure after flumazenil administration in a pediatric patient.\n", "entity1": "flumazenil", "entity2": "Seizure", "span1": [14, 24], "span2": [0, 7]}, "bert_text": "Seizure after <e1> flumazenil </e1> <e2> Seizure </e2> after flumazenil administration in a pediatric patient.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1965": {"data": {"text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [22, 33], "span2": [4, 7]}, "bert_text": "The TDP resolved when <e1> fluconazole </e1> <e2> TDP </e2> resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1966": {"data": {"text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [22, 33], "span2": [347, 350]}, "bert_text": "The TDP resolved when <e1> fluconazole </e1> was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of <e2> TDP </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1967": {"data": {"text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "entity1": "fluconazole", "entity2": "premature ventricular contractions", "span1": [22, 33], "span2": [91, 125]}, "bert_text": "The TDP resolved when <e1> fluconazole </e1> was discontinued; however, the patient continued to have <e2> premature ventricular contractions </e2> and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1968": {"data": {"text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "entity1": "fluconazole", "entity2": "ventricular tachycardia", "span1": [22, 33], "span2": [143, 166]}, "bert_text": "The TDP resolved when <e1> fluconazole </e1> was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained <e2> ventricular tachycardia </e2> (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1969": {"data": {"text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "entity1": "fluconazole", "entity2": "NSVT", "span1": [22, 33], "span2": [168, 172]}, "bert_text": "The TDP resolved when <e1> fluconazole </e1> was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (<e2> NSVT </e2>) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1970": {"data": {"text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [312, 323], "span2": [4, 7]}, "bert_text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of <e1> fluconazole </e1> <e2> TDP </e2> resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1971": {"data": {"text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [312, 323], "span2": [347, 350]}, "bert_text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of <e1> fluconazole </e1> and the development of <e2> TDP </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1972": {"data": {"text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "entity1": "fluconazole", "entity2": "premature ventricular contractions", "span1": [312, 323], "span2": [91, 125]}, "bert_text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of <e1> fluconazole </e1> <e2> premature ventricular contractions </e2> and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1973": {"data": {"text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "entity1": "fluconazole", "entity2": "ventricular tachycardia", "span1": [312, 323], "span2": [143, 166]}, "bert_text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of <e1> fluconazole </e1> <e2> ventricular tachycardia </e2> (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1974": {"data": {"text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "entity1": "fluconazole", "entity2": "NSVT", "span1": [312, 323], "span2": [168, 172]}, "bert_text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of <e1> fluconazole </e1> <e2> NSVT </e2>) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1975": {"data": {"text": "Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).", "entity1": "fenoldopam", "entity2": "Arteritis", "span1": [43, 53], "span2": [0, 9]}, "bert_text": "Arteritis induced in rats by vasodilators, <e1> fenoldopam </e1> <e2> Arteritis </e2> induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1976": {"data": {"text": "Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).", "entity1": "fenoldopam", "entity2": "tumor", "span1": [43, 53], "span2": [216, 221]}, "bert_text": "Arteritis induced in rats by vasodilators, <e1> fenoldopam </e1> and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and <e2> tumor </e2> growth factor-beta1 (TGF-beta1).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1977": {"data": {"text": "Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).", "entity1": "theophylline", "entity2": "Arteritis", "span1": [58, 70], "span2": [0, 9]}, "bert_text": "Arteritis induced in rats by vasodilators, fenoldopam and <e1> theophylline </e1> <e2> Arteritis </e2> induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1978": {"data": {"text": "Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).", "entity1": "theophylline", "entity2": "tumor", "span1": [58, 70], "span2": [216, 221]}, "bert_text": "Arteritis induced in rats by vasodilators, fenoldopam and <e1> theophylline </e1>, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and <e2> tumor </e2> growth factor-beta1 (TGF-beta1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1979": {"data": {"text": "Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).", "entity1": "nitric oxide", "entity2": "Arteritis", "span1": [144, 156], "span2": [0, 9]}, "bert_text": "Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of <e1> nitric oxide </e1> <e2> Arteritis </e2> induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1980": {"data": {"text": "Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).", "entity1": "nitric oxide", "entity2": "tumor", "span1": [144, 156], "span2": [216, 221]}, "bert_text": "Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of <e1> nitric oxide </e1> synthase (iNOS), basic fibroblast growth factor (bFGF) and <e2> tumor </e2> growth factor-beta1 (TGF-beta1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1981": {"data": {"text": "The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.", "entity1": "cocaine", "entity2": "cocaine overdose", "span1": [19, 26], "span2": [79, 95]}, "bert_text": "The illicit use of <e1> cocaine </e1> continues in epidemic proportions and treatment for <e2> cocaine overdose </e2> remains elusive.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1982": {"data": {"text": "CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.", "entity1": "Enalapril", "entity2": "decreased renal function", "span1": [13, 22], "span2": [64, 88]}, "bert_text": "CONCLUSIONS: <e1> Enalapril </e1> use caused a 33% increase in the risk of <e2> decreased renal function </e2> in patients with CHF.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1983": {"data": {"text": "CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.", "entity1": "Enalapril", "entity2": "CHF", "span1": [13, 22], "span2": [106, 109]}, "bert_text": "CONCLUSIONS: <e1> Enalapril </e1> use caused a 33% increase in the risk of decreased renal function in patients with <e2> CHF </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1984": {"data": {"text": "Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.", "entity1": "paclitaxel", "entity2": "non-small cell lung cancer", "span1": [31, 41], "span2": [105, 131]}, "bert_text": "Two phase II trials of 24-hour <e1> paclitaxel </e1> infusions in chemotherapy-naive patients with stage IIIB or IV <e2> non-small cell lung cancer </e2> (NSCLC) reported response rates of 21% and 24%.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1985": {"data": {"text": "Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.", "entity1": "paclitaxel", "entity2": "NSCLC", "span1": [31, 41], "span2": [133, 138]}, "bert_text": "Two phase II trials of 24-hour <e1> paclitaxel </e1> infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (<e2> NSCLC </e2>) reported response rates of 21% and 24%.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1986": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "calcium chloride", "entity2": "thoracic aortic aneurysm", "span1": [95, 111], "span2": [61, 85]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by <e1> calcium chloride </e1> <e2> thoracic aortic aneurysm </e2> (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1987": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "calcium chloride", "entity2": "TAA", "span1": [95, 111], "span2": [87, 90]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by <e1> calcium chloride </e1> <e2> TAA </e2>) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1988": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "calcium chloride", "entity2": "TAA", "span1": [95, 111], "span2": [303, 306]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by <e1> calcium chloride </e1> (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in <e2> TAA </e2> formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1989": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "calcium chloride", "entity2": "arterial injury", "span1": [95, 111], "span2": [130, 145]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by <e1> calcium chloride </e1> (CaCl(2))-induced <e2> arterial injury </e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1990": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "CaCl(2))-induced", "entity2": "thoracic aortic aneurysm", "span1": [113, 129], "span2": [61, 85]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1> CaCl(2))-induced </e1> <e2> thoracic aortic aneurysm </e2> (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1991": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "CaCl(2))-induced", "entity2": "TAA", "span1": [113, 129], "span2": [87, 90]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1> CaCl(2))-induced </e1> <e2> TAA </e2>) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1992": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "CaCl(2))-induced", "entity2": "TAA", "span1": [113, 129], "span2": [303, 306]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1> CaCl(2))-induced </e1> arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in <e2> TAA </e2> formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1993": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "CaCl(2))-induced", "entity2": "arterial injury", "span1": [113, 129], "span2": [130, 145]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1> CaCl(2))-induced </e1> <e2> arterial injury </e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1994": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "CaCl(2", "entity2": "thoracic aortic aneurysm", "span1": [390, 396], "span2": [61, 85]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M <e1> CaCl(2 </e1> <e2> thoracic aortic aneurysm </e2> (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1995": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "CaCl(2", "entity2": "TAA", "span1": [390, 396], "span2": [87, 90]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M <e1> CaCl(2 </e1> <e2> TAA </e2>) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1996": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "CaCl(2", "entity2": "TAA", "span1": [390, 396], "span2": [303, 306]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M <e1> CaCl(2 </e1> <e2> TAA </e2> formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1997": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "CaCl(2", "entity2": "arterial injury", "span1": [390, 396], "span2": [130, 145]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M <e1> CaCl(2 </e1> <e2> arterial injury </e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1998": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "NaCl", "entity2": "thoracic aortic aneurysm", "span1": [416, 420], "span2": [61, 85]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (<e1> NaCl </e1> <e2> thoracic aortic aneurysm </e2> (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1999": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "NaCl", "entity2": "TAA", "span1": [416, 420], "span2": [87, 90]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (<e1> NaCl </e1> <e2> TAA </e2>) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2000": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "NaCl", "entity2": "TAA", "span1": [416, 420], "span2": [303, 306]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (<e1> NaCl </e1> <e2> TAA </e2> formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2001": {"data": {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "entity1": "NaCl", "entity2": "arterial injury", "span1": [416, 420], "span2": [130, 145]}, "bert_text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (<e1> NaCl </e1> <e2> arterial injury </e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2002": {"data": {"text": "We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.", "entity1": "vincristine", "entity2": "acute lymphoblastic leucemia", "span1": [55, 66], "span2": [116, 144]}, "bert_text": "We report on two fatal cases of accidental intrathecal <e1> vincristine </e1> instillation in a 5-year old girl with recurrent <e2> acute lymphoblastic leucemia </e2> and a 57-year old man with lymphoblastic lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2003": {"data": {"text": "We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.", "entity1": "vincristine", "entity2": "lymphoblastic lymphoma", "span1": [55, 66], "span2": [172, 194]}, "bert_text": "We report on two fatal cases of accidental intrathecal <e1> vincristine </e1> instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with <e2> lymphoblastic lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2004": {"data": {"text": "Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.\n", "entity1": "deferoxamine", "entity2": "auditory neurotoxicity", "span1": [63, 75], "span2": [18, 40]}, "bert_text": "Serial studies of auditory neurotoxicity in patients receiving <e1> deferoxamine </e1> <e2> auditory neurotoxicity </e2> in patients receiving deferoxamine therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2005": {"data": {"text": "The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.", "entity1": "cocaine", "entity2": "overdose", "span1": [85, 92], "span2": [93, 101]}, "bert_text": "The results support the important potential of GNC92H2 as a therapeutic tool against <e1> cocaine </e1> <e2> overdose </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2006": {"data": {"text": "The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.", "entity1": "bendrofluazide", "entity2": "impotence", "span1": [40, 54], "span2": [69, 78]}, "bert_text": "The results show an association between <e1> bendrofluazide </e1> treatment and <e2> impotence </e2>, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2007": {"data": {"text": "The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.", "entity1": "bendrofluazide", "entity2": "impotence", "span1": [40, 54], "span2": [84, 93]}, "bert_text": "The results show an association between <e1> bendrofluazide </e1> treatment and impotence, and <e2> impotence </e2> also occurred more frequently in patients taking propranolol than in those taking placebos.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2008": {"data": {"text": "The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.", "entity1": "propranolol", "entity2": "impotence", "span1": [143, 154], "span2": [69, 78]}, "bert_text": "The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking <e1> propranolol </e1> <e2> impotence </e2>, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2009": {"data": {"text": "The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.", "entity1": "propranolol", "entity2": "impotence", "span1": [143, 154], "span2": [84, 93]}, "bert_text": "The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking <e1> propranolol </e1> <e2> impotence </e2> also occurred more frequently in patients taking propranolol than in those taking placebos.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2010": {"data": {"text": "Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.", "entity1": "Warfarin", "entity2": "intracerebral hemorrhage", "span1": [0, 8], "span2": [20, 44]}, "bert_text": "<e1> Warfarin </e1>-associated <e2> intracerebral hemorrhage </e2> (W-ICH) is a severe type of stroke.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2011": {"data": {"text": "Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.", "entity1": "Warfarin", "entity2": "ICH", "span1": [0, 8], "span2": [48, 51]}, "bert_text": "<e1> Warfarin </e1>-associated intracerebral hemorrhage (W-<e2> ICH </e2>) is a severe type of stroke.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2012": {"data": {"text": "Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.", "entity1": "Warfarin", "entity2": "stroke", "span1": [0, 8], "span2": [73, 79]}, "bert_text": "<e1> Warfarin </e1>-associated intracerebral hemorrhage (W-ICH) is a severe type of <e2> stroke </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2013": {"data": {"text": "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.\n", "entity1": "netilmicin", "entity2": "toxicity", "span1": [34, 44], "span2": [22, 30]}, "bert_text": "Relative efficacy and toxicity of <e1> netilmicin </e1> <e2> toxicity </e2> of netilmicin and tobramycin in oncology patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2014": {"data": {"text": "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.\n", "entity1": "tobramycin", "entity2": "toxicity", "span1": [49, 59], "span2": [22, 30]}, "bert_text": "Relative efficacy and toxicity of netilmicin and <e1> tobramycin </e1> <e2> toxicity </e2> of netilmicin and tobramycin in oncology patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2015": {"data": {"text": "The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.", "entity1": "phenylephrine", "entity2": "hypotension", "span1": [19, 32], "span2": [44, 55]}, "bert_text": "The utilization of <e1> phenylephrine </e1> to correct <e2> hypotension </e2> induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2016": {"data": {"text": "The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.", "entity1": "ephedrine", "entity2": "hypotension", "span1": [118, 127], "span2": [44, 55]}, "bert_text": "The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while <e1> ephedrine </e1> <e2> hypotension </e2> induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2017": {"data": {"text": "These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.", "entity1": "procainamide", "entity2": "Q-T syndrome", "span1": [35, 47], "span2": [82, 94]}, "bert_text": "These seven cases demonstrate that <e1> procainamide </e1> can produce an acquired prolonged <e2> Q-T syndrome </e2> with polymorphous ventricular tachycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2018": {"data": {"text": "These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.", "entity1": "procainamide", "entity2": "ventricular tachycardia", "span1": [35, 47], "span2": [113, 136]}, "bert_text": "These seven cases demonstrate that <e1> procainamide </e1> can produce an acquired prolonged Q-T syndrome with polymorphous <e2> ventricular tachycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2019": {"data": {"text": "We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.", "entity1": "ziprasidone", "entity2": "neuroleptic malignant syndrome", "span1": [86, 97], "span2": [22, 52]}, "bert_text": "We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of <e1> ziprasidone </e1> <e2> neuroleptic malignant syndrome </e2> (NMS) associated with the use of ziprasidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2020": {"data": {"text": "We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.", "entity1": "ziprasidone", "entity2": "NMS", "span1": [86, 97], "span2": [54, 57]}, "bert_text": "We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of <e1> ziprasidone </e1> <e2> NMS </e2>) associated with the use of ziprasidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2021": {"data": {"text": "Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.", "entity1": "aldosterone", "entity2": "nephrotic", "span1": [7, 18], "span2": [39, 48]}, "bert_text": "Plasma <e1> aldosterone </e1> levels increased in <e2> nephrotic </e2> mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2022": {"data": {"text": "The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "entity1": "phenylephrine", "entity2": "hypertension", "span1": [23, 36], "span2": [45, 57]}, "bert_text": "The data indicate that <e1> phenylephrine </e1>-induced <e2> hypertension </e2> instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2023": {"data": {"text": "The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "entity1": "phenylephrine", "entity2": "MCAO", "span1": [23, 36], "span2": [79, 83]}, "bert_text": "The data indicate that <e1> phenylephrine </e1>-induced hypertension instituted 2 h after <e2> MCAO </e2> does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2024": {"data": {"text": "The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "entity1": "phenylephrine", "entity2": "edema", "span1": [23, 36], "span2": [103, 108]}, "bert_text": "The data indicate that <e1> phenylephrine </e1>-induced hypertension instituted 2 h after MCAO does not aggravate <e2> edema </e2> in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2025": {"data": {"text": "The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "entity1": "phenylephrine", "entity2": "edema", "span1": [23, 36], "span2": [148, 153]}, "bert_text": "The data indicate that <e1> phenylephrine </e1>-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves <e2> edema </e2> in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2026": {"data": {"text": "The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "entity1": "phenylephrine", "entity2": "ischemic", "span1": [23, 36], "span2": [116, 124]}, "bert_text": "The data indicate that <e1> phenylephrine </e1>-induced hypertension instituted 2 h after MCAO does not aggravate edema in the <e2> ischemic </e2> core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2027": {"data": {"text": "The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "entity1": "phenylephrine", "entity2": "ischemic", "span1": [23, 36], "span2": [178, 186]}, "bert_text": "The data indicate that <e1> phenylephrine </e1>-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the <e2> ischemic </e2> territory, and that it reduces the area of histochemical neuronal dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2028": {"data": {"text": "The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "entity1": "phenylephrine", "entity2": "neuronal dysfunction", "span1": [23, 36], "span2": [244, 264]}, "bert_text": "The data indicate that <e1> phenylephrine </e1>-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical <e2> neuronal dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2029": {"data": {"text": "On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.", "entity1": "charcoal", "entity2": "pain", "span1": [148, 156], "span2": [98, 102]}, "bert_text": "On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the <e1> charcoal </e1> <e2> pain </e2>-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2030": {"data": {"text": "We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.", "entity1": "spironolactone", "entity2": "hyperkalemia", "span1": [153, 167], "span2": [77, 89]}, "bert_text": "We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with <e1> spironolactone </e1> <e2> hyperkalemia </e2> and renal insufficiency in heart failure patients treated with spironolactone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2031": {"data": {"text": "We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.", "entity1": "spironolactone", "entity2": "renal insufficiency", "span1": [153, 167], "span2": [94, 113]}, "bert_text": "We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with <e1> spironolactone </e1> <e2> renal insufficiency </e2> in heart failure patients treated with spironolactone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2032": {"data": {"text": "We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.", "entity1": "spironolactone", "entity2": "heart failure", "span1": [153, 167], "span2": [117, 130]}, "bert_text": "We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with <e1> spironolactone </e1> <e2> heart failure </e2> patients treated with spironolactone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2033": {"data": {"text": "Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.\n", "entity1": "Calcium carbonate", "entity2": "toxicity", "span1": [0, 17], "span2": [18, 26]}, "bert_text": "<e1> Calcium carbonate </e1> <e2> toxicity </e2>: the updated milk-alkali syndrome; report of 3 cases and review of the literature.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2034": {"data": {"text": "Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.\n", "entity1": "Calcium carbonate", "entity2": "milk-alkali syndrome", "span1": [0, 17], "span2": [40, 60]}, "bert_text": "<e1> Calcium carbonate </e1> toxicity: the updated <e2> milk-alkali syndrome </e2>; report of 3 cases and review of the literature.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2035": {"data": {"text": "Choreoathetoid movements associated with rapid adjustment to methadone.\n", "entity1": "methadone", "entity2": "Choreoathetoid movements", "span1": [61, 70], "span2": [0, 24]}, "bert_text": "Choreoathetoid movements associated with rapid adjustment to <e1> methadone </e1> <e2> Choreoathetoid movements </e2> associated with rapid adjustment to methadone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2036": {"data": {"text": "The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.", "entity1": "epinephrine", "entity2": "respiratory distress", "span1": [143, 154], "span2": [20, 40]}, "bert_text": "The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous <e1> epinephrine </e1> <e2> respiratory distress </e2>, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2037": {"data": {"text": "The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.", "entity1": "epinephrine", "entity2": "rash", "span1": [143, 154], "span2": [42, 46]}, "bert_text": "The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous <e1> epinephrine </e1> <e2> rash </e2>, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2038": {"data": {"text": "Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.\n", "entity1": "azidothymidine", "entity2": "myelodysplasia", "span1": [32, 46], "span2": [62, 76]}, "bert_text": "Lifetime treatment of mice with <e1> azidothymidine </e1> (AZT) produces <e2> myelodysplasia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2039": {"data": {"text": "Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.\n", "entity1": "AZT", "entity2": "myelodysplasia", "span1": [48, 51], "span2": [62, 76]}, "bert_text": "Lifetime treatment of mice with azidothymidine (<e1> AZT </e1>) produces <e2> myelodysplasia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2040": {"data": {"text": "We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.", "entity1": "FK506", "entity2": "microangiopathic hemolytic anemia", "span1": [101, 106], "span2": [26, 59]}, "bert_text": "We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under <e1> FK506 </e1> <e2> microangiopathic hemolytic anemia </e2> (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2041": {"data": {"text": "We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.", "entity1": "FK506", "entity2": "MAHA", "span1": [101, 106], "span2": [61, 65]}, "bert_text": "We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under <e1> FK506 </e1> <e2> MAHA </e2>) in 2 solid organ recipients under FK506 (tacrolimus) therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2042": {"data": {"text": "We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.", "entity1": "tacrolimus", "entity2": "microangiopathic hemolytic anemia", "span1": [108, 118], "span2": [26, 59]}, "bert_text": "We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (<e1> tacrolimus </e1> <e2> microangiopathic hemolytic anemia </e2> (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2043": {"data": {"text": "We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.", "entity1": "tacrolimus", "entity2": "MAHA", "span1": [108, 118], "span2": [61, 65]}, "bert_text": "We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (<e1> tacrolimus </e1> <e2> MAHA </e2>) in 2 solid organ recipients under FK506 (tacrolimus) therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2044": {"data": {"text": "Sirolimus-associated proteinuria and renal dysfunction.\n", "entity1": "Sirolimus", "entity2": "proteinuria", "span1": [0, 9], "span2": [21, 32]}, "bert_text": "<e1> Sirolimus </e1>-associated <e2> proteinuria </e2> and renal dysfunction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2045": {"data": {"text": "Sirolimus-associated proteinuria and renal dysfunction.\n", "entity1": "Sirolimus", "entity2": "renal dysfunction", "span1": [0, 9], "span2": [37, 54]}, "bert_text": "<e1> Sirolimus </e1>-associated proteinuria and <e2> renal dysfunction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2046": {"data": {"text": "five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.", "entity1": "metoclopramide", "entity2": "asystole", "span1": [146, 160], "span2": [200, 208]}, "bert_text": "five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of <e1> metoclopramide </e1> was immediately (within s) followed by <e2> asystole </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2047": {"data": {"text": "We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.", "entity1": "warfarin", "entity2": "bleeding", "span1": [108, 116], "span2": [29, 37]}, "bert_text": "We report 3 cases of serious bleeding complications that appear to be the result of the interaction between <e1> warfarin </e1> <e2> bleeding </e2> complications that appear to be the result of the interaction between warfarin and levofloxacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2048": {"data": {"text": "We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.", "entity1": "levofloxacin", "entity2": "bleeding", "span1": [121, 133], "span2": [29, 37]}, "bert_text": "We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and <e1> levofloxacin </e1> <e2> bleeding </e2> complications that appear to be the result of the interaction between warfarin and levofloxacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2049": {"data": {"text": "Levodopa is the most effective drug for the treatment of Parkinson's disease.", "entity1": "Levodopa", "entity2": "Parkinson's disease", "span1": [0, 8], "span2": [57, 76]}, "bert_text": "<e1> Levodopa </e1> is the most effective drug for the treatment of <e2> Parkinson's disease </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2050": {"data": {"text": "We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature.", "entity1": "cocaine", "entity2": "stroke", "span1": [35, 42], "span2": [62, 68]}, "bert_text": "We describe eight patients in whom <e1> cocaine </e1> use was related to <e2> stroke </e2> and review 39 cases from the literature.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2051": {"data": {"text": "Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.\n", "entity1": "FK506", "entity2": "Microangiopathic hemolytic anemia", "span1": [47, 52], "span2": [0, 33]}, "bert_text": "Microangiopathic hemolytic anemia complicating <e1> FK506 </e1> <e2> Microangiopathic hemolytic anemia </e2> complicating FK506 (tacrolimus) therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2052": {"data": {"text": "Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.\n", "entity1": "tacrolimus", "entity2": "Microangiopathic hemolytic anemia", "span1": [54, 64], "span2": [0, 33]}, "bert_text": "Microangiopathic hemolytic anemia complicating FK506 (<e1> tacrolimus </e1> <e2> Microangiopathic hemolytic anemia </e2> complicating FK506 (tacrolimus) therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2053": {"data": {"text": "Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.", "entity1": "/-)-PG-9", "entity2": "amnesic", "span1": [23, 31], "span2": [336, 343]}, "bert_text": "Affinity profiles of (+<e1> /-)-PG-9 </e1> for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-<e2> amnesic </e2> effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2054": {"data": {"text": "Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.", "entity1": "/-)-PG-9", "entity2": "amnesic", "span1": [364, 372], "span2": [336, 343]}, "bert_text": "Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+<e1> /-)-PG-9 </e1> <e2> amnesic </e2> effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2055": {"data": {"text": "Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.", "entity1": "acetylcholine", "entity2": "amnesic", "span1": [396, 409], "span2": [336, 343]}, "bert_text": "Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in <e1> acetylcholine </e1> <e2> amnesic </e2> effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2056": {"data": {"text": "Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977.", "entity1": "methyldopa", "entity2": "liver disease", "span1": [46, 56], "span2": [21, 34]}, "bert_text": "Twelve patients with liver disease related to <e1> methyldopa </e1> <e2> liver disease </e2> related to methyldopa were seen between 1967 and 1977.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2057": {"data": {"text": "In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).", "entity1": "fluoxetine", "entity2": "pulmonary arterial muscle contraction", "span1": [10, 20], "span2": [29, 66]}, "bert_text": "In vitro, <e1> fluoxetine </e1> induced <e2> pulmonary arterial muscle contraction </e2> in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2058": {"data": {"text": "In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).", "entity1": "serotonin", "entity2": "pulmonary arterial muscle contraction", "span1": [123, 132], "span2": [29, 66]}, "bert_text": "In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced <e1> serotonin </e1> <e2> pulmonary arterial muscle contraction </e2> in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2059": {"data": {"text": "DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.", "entity1": "vitamin C", "entity2": "cardiovascular disease", "span1": [40, 49], "span2": [82, 104]}, "bert_text": "DESIGN: We studied the relation between <e1> vitamin C </e1> intake and mortality from total <e2> cardiovascular disease </e2> (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2060": {"data": {"text": "DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.", "entity1": "vitamin C", "entity2": "coronary artery disease", "span1": [40, 49], "span2": [116, 139]}, "bert_text": "DESIGN: We studied the relation between <e1> vitamin C </e1> intake and mortality from total cardiovascular disease (n = 281), <e2> coronary artery disease </e2> (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2061": {"data": {"text": "DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.", "entity1": "vitamin C", "entity2": "stroke", "span1": [40, 49], "span2": [155, 161]}, "bert_text": "DESIGN: We studied the relation between <e1> vitamin C </e1> intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and <e2> stroke </e2> (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2062": {"data": {"text": "DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.", "entity1": "vitamin C", "entity2": "diabetic", "span1": [40, 49], "span2": [219, 227]}, "bert_text": "DESIGN: We studied the relation between <e1> vitamin C </e1> intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being <e2> diabetic </e2> at baseline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2063": {"data": {"text": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "entity1": "fluoxetine", "entity2": "Akathisia", "span1": [49, 59], "span2": [0, 9]}, "bert_text": "Akathisia appeared to be a common side effect of <e1> fluoxetine </e1> <e2> Akathisia </e2> appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2064": {"data": {"text": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "entity1": "propranolol", "entity2": "Akathisia", "span1": [138, 149], "span2": [0, 9]}, "bert_text": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist <e1> propranolol </e1> <e2> Akathisia </e2> appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2065": {"data": {"text": "We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.", "entity1": "netilmicin sulfate", "entity2": "infections", "span1": [53, 71], "span2": [189, 199]}, "bert_text": "We prospectively compared the efficacy and safety of <e1> netilmicin sulfate </e1> or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe <e2> infections </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2066": {"data": {"text": "We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.", "entity1": "tobramycin sulfate", "entity2": "infections", "span1": [75, 93], "span2": [189, 199]}, "bert_text": "We prospectively compared the efficacy and safety of netilmicin sulfate or <e1> tobramycin sulfate </e1> in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe <e2> infections </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2067": {"data": {"text": "We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.", "entity1": "piperacillin sodium", "entity2": "infections", "span1": [114, 133], "span2": [189, 199]}, "bert_text": "We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with <e1> piperacillin sodium </e1> in 118 immunocompromised patients with presumed severe <e2> infections </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2068": {"data": {"text": "This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.", "entity1": "allopurinol", "entity2": "hypertension", "span1": [47, 58], "span2": [114, 126]}, "bert_text": "This, together with our previous findings that <e1> allopurinol </e1> failed to prevent adrenocorticotrophic hormone induced <e2> hypertension </e2>, suggests that XO activity is not a major determinant of GC-HT in the rat.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2069": {"data": {"text": "This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.", "entity1": "allopurinol", "entity2": "HT", "span1": [47, 58], "span2": [187, 189]}, "bert_text": "This, together with our previous findings that <e1> allopurinol </e1> failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-<e2> HT </e2> in the rat.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2070": {"data": {"text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "entity1": "paclitaxel", "entity2": "Toxic peripheral neuropathy", "span1": [89, 99], "span2": [0, 27]}, "bert_text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with <e1> paclitaxel </e1> <e2> Toxic peripheral neuropathy </e2> is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2071": {"data": {"text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "entity1": "paclitaxel", "entity2": "neurotoxicity", "span1": [89, 99], "span2": [202, 215]}, "bert_text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with <e1> paclitaxel </e1> (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2072": {"data": {"text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "entity1": "PAC", "entity2": "Toxic peripheral neuropathy", "span1": [101, 104], "span2": [0, 27]}, "bert_text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (<e1> PAC </e1> <e2> Toxic peripheral neuropathy </e2> is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2073": {"data": {"text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "entity1": "PAC", "entity2": "neurotoxicity", "span1": [101, 104], "span2": [202, 215]}, "bert_text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (<e1> PAC </e1>), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2074": {"data": {"text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "entity1": "PAC", "entity2": "Toxic peripheral neuropathy", "span1": [198, 201], "span2": [0, 27]}, "bert_text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate <e1> PAC </e1> <e2> Toxic peripheral neuropathy </e2> is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2075": {"data": {"text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "entity1": "PAC", "entity2": "neurotoxicity", "span1": [198, 201], "span2": [202, 215]}, "bert_text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate <e1> PAC </e1> <e2> neurotoxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2076": {"data": {"text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "entity1": "amino acid", "entity2": "Toxic peripheral neuropathy", "span1": [150, 160], "span2": [0, 27]}, "bert_text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related <e1> amino acid </e1> <e2> Toxic peripheral neuropathy </e2> is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2077": {"data": {"text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "entity1": "amino acid", "entity2": "neurotoxicity", "span1": [150, 160], "span2": [202, 215]}, "bert_text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related <e1> amino acid </e1> glutamine were claimed to ameliorate PAC <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2078": {"data": {"text": "The results suggest that rigidity, which is assumed to be due to an action of morphine in the striatum, can be antagonized by another process leading to dopaminergic activation in the striatum.", "entity1": "morphine", "entity2": "rigidity", "span1": [78, 86], "span2": [25, 33]}, "bert_text": "The results suggest that rigidity, which is assumed to be due to an action of <e1> morphine </e1> <e2> rigidity </e2>, which is assumed to be due to an action of morphine in the striatum, can be antagonized by another process leading to dopaminergic activation in the striatum.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2079": {"data": {"text": "The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.", "entity1": "selegiline", "entity2": "orthostatic hypotension", "span1": [174, 184], "span2": [274, 297]}, "bert_text": "The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping <e1> selegiline </e1> in the expectation that this might shed light on the mechanisms by which the drug causes <e2> orthostatic hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2080": {"data": {"text": "Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.\n", "entity1": "ziprasidone", "entity2": "Neuroleptic malignant syndrome", "span1": [42, 53], "span2": [0, 30]}, "bert_text": "Neuroleptic malignant syndrome induced by <e1> ziprasidone </e1> <e2> Neuroleptic malignant syndrome </e2> induced by ziprasidone on the second day of treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2081": {"data": {"text": "Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.", "entity1": "dexamethasone", "entity2": "glomerular number", "span1": [33, 46], "span2": [198, 215]}, "bert_text": "Male rats that received prenatal <e1> dexamethasone </e1> on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in <e2> glomerular number </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2082": {"data": {"text": "BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.", "entity1": "BE", "entity2": "seizures", "span1": [0, 2], "span2": [35, 43]}, "bert_text": "<e1> BE </e1>-Injected rats that did not have <e2> seizures </e2> had significantly more locomotor activity than cocaine-injected animals without seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2083": {"data": {"text": "BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.", "entity1": "BE", "entity2": "seizures", "span1": [0, 2], "span2": [124, 132]}, "bert_text": "<e1> BE </e1>-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2084": {"data": {"text": "BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.", "entity1": "cocaine", "entity2": "seizures", "span1": [91, 98], "span2": [35, 43]}, "bert_text": "BE-Injected rats that did not have seizures had significantly more locomotor activity than <e1> cocaine </e1> <e2> seizures </e2> had significantly more locomotor activity than cocaine-injected animals without seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2085": {"data": {"text": "BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.", "entity1": "cocaine", "entity2": "seizures", "span1": [91, 98], "span2": [124, 132]}, "bert_text": "BE-Injected rats that did not have seizures had significantly more locomotor activity than <e1> cocaine </e1>-injected animals without <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2086": {"data": {"text": "Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.", "entity1": "pergolide", "entity2": "Valvular heart abnormalities", "span1": [103, 112], "span2": [0, 28]}, "bert_text": "Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with <e1> pergolide </e1> <e2> Valvular heart abnormalities </e2> have been reported in patients with Parkinson's disease (PD) treated with pergolide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2087": {"data": {"text": "Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.", "entity1": "pergolide", "entity2": "Parkinson's disease", "span1": [103, 112], "span2": [65, 84]}, "bert_text": "Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with <e1> pergolide </e1> <e2> Parkinson's disease </e2> (PD) treated with pergolide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2088": {"data": {"text": "Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.", "entity1": "pergolide", "entity2": "PD", "span1": [103, 112], "span2": [86, 88]}, "bert_text": "Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with <e1> pergolide </e1> <e2> PD </e2>) treated with pergolide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2089": {"data": {"text": "Allopurinol did not prevent dex-HT.", "entity1": "Allopurinol", "entity2": "HT", "span1": [0, 11], "span2": [32, 34]}, "bert_text": "<e1> Allopurinol </e1> did not prevent dex-<e2> HT </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2090": {"data": {"text": "Allopurinol did not prevent dex-HT.", "entity1": "dex", "entity2": "HT", "span1": [28, 31], "span2": [32, 34]}, "bert_text": "Allopurinol did not prevent <e1> dex </e1>-<e2> HT </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2091": {"data": {"text": "This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.", "entity1": "surface antigen", "entity2": "hepatitis B", "span1": [128, 143], "span2": [116, 127]}, "bert_text": "This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B <e1> surface antigen </e1> <e2> hepatitis B </e2> surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2092": {"data": {"text": "This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.", "entity1": "HBsAg", "entity2": "hepatitis B", "span1": [145, 150], "span2": [116, 127]}, "bert_text": "This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (<e1> HBsAg </e1> <e2> hepatitis B </e2> surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2093": {"data": {"text": "This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.", "entity1": "hepatitis B e antigen", "entity2": "hepatitis B", "span1": [156, 177], "span2": [116, 127]}, "bert_text": "This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and <e1> hepatitis B e antigen </e1> <e2> hepatitis B </e2> surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2094": {"data": {"text": "This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.", "entity1": "HBeAg", "entity2": "hepatitis B", "span1": [179, 184], "span2": [116, 127]}, "bert_text": "This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (<e1> HBeAg </e1> <e2> hepatitis B </e2> surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2095": {"data": {"text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "entity1": "histamine", "entity2": "gastric hemorrhage", "span1": [87, 96], "span2": [191, 209]}, "bert_text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell <e1> histamine </e1> release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating <e2> gastric hemorrhage </e2> and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2096": {"data": {"text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "entity1": "histamine", "entity2": "ulcer", "span1": [87, 96], "span2": [214, 219]}, "bert_text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell <e1> histamine </e1> release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and <e2> ulcer </e2> in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2097": {"data": {"text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "entity1": "histamine", "entity2": "atherosclerosis", "span1": [87, 96], "span2": [233, 248]}, "bert_text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell <e1> histamine </e1> release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with <e2> atherosclerosis </e2> induced by coadministration of vitamin D2 and cholesterol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2098": {"data": {"text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "entity1": "vitamin D2", "entity2": "gastric hemorrhage", "span1": [280, 290], "span2": [191, 209]}, "bert_text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of <e1> vitamin D2 </e1> <e2> gastric hemorrhage </e2> and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2099": {"data": {"text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "entity1": "vitamin D2", "entity2": "ulcer", "span1": [280, 290], "span2": [214, 219]}, "bert_text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of <e1> vitamin D2 </e1> <e2> ulcer </e2> in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2100": {"data": {"text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "entity1": "vitamin D2", "entity2": "atherosclerosis", "span1": [280, 290], "span2": [233, 248]}, "bert_text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of <e1> vitamin D2 </e1> <e2> atherosclerosis </e2> induced by coadministration of vitamin D2 and cholesterol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2101": {"data": {"text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "entity1": "cholesterol", "entity2": "gastric hemorrhage", "span1": [295, 306], "span2": [191, 209]}, "bert_text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and <e1> cholesterol </e1> <e2> gastric hemorrhage </e2> and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2102": {"data": {"text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "entity1": "cholesterol", "entity2": "ulcer", "span1": [295, 306], "span2": [214, 219]}, "bert_text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and <e1> cholesterol </e1> <e2> ulcer </e2> in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2103": {"data": {"text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "entity1": "cholesterol", "entity2": "atherosclerosis", "span1": [295, 306], "span2": [233, 248]}, "bert_text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and <e1> cholesterol </e1> <e2> atherosclerosis </e2> induced by coadministration of vitamin D2 and cholesterol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2104": {"data": {"text": "Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.\n", "entity1": "atracurium", "entity2": "paralysis", "span1": [44, 54], "span2": [11, 20]}, "bert_text": "Persistent paralysis after prolonged use of <e1> atracurium </e1> <e2> paralysis </e2> after prolonged use of atracurium in the absence of corticosteroids.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2105": {"data": {"text": "Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.\n", "entity1": "corticosteroids", "entity2": "paralysis", "span1": [73, 88], "span2": [11, 20]}, "bert_text": "Persistent paralysis after prolonged use of atracurium in the absence of <e1> corticosteroids </e1> <e2> paralysis </e2> after prolonged use of atracurium in the absence of corticosteroids.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2106": {"data": {"text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.", "entity1": "NRA0160", "entity2": "hyperactivity", "span1": [0, 7], "span2": [216, 229]}, "bert_text": "<e1> NRA0160 </e1> has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor <e2> hyperactivity </e2> induced by methamphetamine (MAP) in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2107": {"data": {"text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.", "entity1": "NRA0160", "entity2": "hyperactivity", "span1": [172, 179], "span2": [216, 229]}, "bert_text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). <e1> NRA0160 </e1> and clozapine antagonized locomotor <e2> hyperactivity </e2> induced by methamphetamine (MAP) in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2108": {"data": {"text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.", "entity1": "dopamine", "entity2": "hyperactivity", "span1": [53, 61], "span2": [216, 229]}, "bert_text": "NRA0160 has negligible affinity for the human cloned <e1> dopamine </e1> D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor <e2> hyperactivity </e2> induced by methamphetamine (MAP) in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2109": {"data": {"text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.", "entity1": "serotonin", "entity2": "hyperactivity", "span1": [90, 99], "span2": [216, 229]}, "bert_text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat <e1> serotonin </e1> (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor <e2> hyperactivity </e2> induced by methamphetamine (MAP) in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2110": {"data": {"text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.", "entity1": "5-HT)2A", "entity2": "hyperactivity", "span1": [101, 108], "span2": [216, 229]}, "bert_text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (<e1> 5-HT)2A </e1> receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor <e2> hyperactivity </e2> induced by methamphetamine (MAP) in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2111": {"data": {"text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.", "entity1": "clozapine", "entity2": "hyperactivity", "span1": [184, 193], "span2": [216, 229]}, "bert_text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and <e1> clozapine </e1> antagonized locomotor <e2> hyperactivity </e2> induced by methamphetamine (MAP) in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2112": {"data": {"text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.", "entity1": "methamphetamine", "entity2": "hyperactivity", "span1": [241, 256], "span2": [216, 229]}, "bert_text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by <e1> methamphetamine </e1> <e2> hyperactivity </e2> induced by methamphetamine (MAP) in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2113": {"data": {"text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.", "entity1": "MAP", "entity2": "hyperactivity", "span1": [258, 261], "span2": [216, 229]}, "bert_text": "NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (<e1> MAP </e1> <e2> hyperactivity </e2> induced by methamphetamine (MAP) in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2114": {"data": {"text": "Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.\n", "entity1": "salvianolic acid A", "entity2": "myocardial infarction", "span1": [27, 45], "span2": [71, 92]}, "bert_text": "Cardioprotective effect of <e1> salvianolic acid A </e1> on isoproterenol-induced <e2> myocardial infarction </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2115": {"data": {"text": "Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.\n", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [49, 62], "span2": [71, 92]}, "bert_text": "Cardioprotective effect of salvianolic acid A on <e1> isoproterenol </e1>-induced <e2> myocardial infarction </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2116": {"data": {"text": "The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin-induced epilepsy model.", "entity1": "penicillin", "entity2": "epileptic", "span1": [112, 122], "span2": [90, 99]}, "bert_text": "The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in <e1> penicillin </e1> <e2> epileptic </e2> activity in penicillin-induced epilepsy model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2117": {"data": {"text": "The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin-induced epilepsy model.", "entity1": "penicillin", "entity2": "epilepsy", "span1": [112, 122], "span2": [131, 139]}, "bert_text": "The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in <e1> penicillin </e1>-induced <e2> epilepsy </e2> model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2118": {"data": {"text": "Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).", "entity1": "bupivacaine", "entity2": "death", "span1": [40, 51], "span2": [179, 184]}, "bert_text": "Administration of the local anaesthetic <e1> bupivacaine </e1> (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to <e2> death </e2> (in 67% or 90% of animals respectively).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2119": {"data": {"text": "Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%).", "entity1": "enalapril", "entity2": "hypotension", "span1": [22, 31], "span2": [104, 115]}, "bert_text": "Patients who received <e1> enalapril </e1> experienced clinically and statistically significantly less symptomatic <e2> hypotension </e2> (5.2%) than the patients who received prazosin (12.9%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2120": {"data": {"text": "Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%).", "entity1": "prazosin", "entity2": "hypotension", "span1": [154, 162], "span2": [104, 115]}, "bert_text": "Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received <e1> prazosin </e1> <e2> hypotension </e2> (5.2%) than the patients who received prazosin (12.9%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2121": {"data": {"text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.", "entity1": "bendrofluazide", "entity2": "impaired glucose tolerance", "span1": [148, 162], "span2": [71, 97]}, "bert_text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with <e1> bendrofluazide </e1> <e2> impaired glucose tolerance </e2> in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2122": {"data": {"text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.", "entity1": "bendrofluazide", "entity2": "gout", "span1": [148, 162], "span2": [119, 123]}, "bert_text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with <e1> bendrofluazide </e1> <e2> gout </e2> in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2123": {"data": {"text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.", "entity1": "bendrofluazide", "entity2": "Raynaud's phenomenon and dyspnoea", "span1": [148, 162], "span2": [178, 211]}, "bert_text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with <e1> bendrofluazide </e1> treatment, and <e2> Raynaud's phenomenon and dyspnoea </e2> in men and women taking propranolol.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2124": {"data": {"text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.", "entity1": "propranolol", "entity2": "impaired glucose tolerance", "span1": [236, 247], "span2": [71, 97]}, "bert_text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking <e1> propranolol </e1> <e2> impaired glucose tolerance </e2> in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2125": {"data": {"text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.", "entity1": "propranolol", "entity2": "gout", "span1": [236, 247], "span2": [119, 123]}, "bert_text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking <e1> propranolol </e1> <e2> gout </e2> in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2126": {"data": {"text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.", "entity1": "propranolol", "entity2": "Raynaud's phenomenon and dyspnoea", "span1": [236, 247], "span2": [178, 211]}, "bert_text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking <e1> propranolol </e1> <e2> Raynaud's phenomenon and dyspnoea </e2> in men and women taking propranolol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2127": {"data": {"text": "In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.", "entity1": "catecholamines", "entity2": "cancer", "span1": [55, 69], "span2": [113, 119]}, "bert_text": "In our patient, both supraphysiologic levels of plasma <e1> catecholamines </e1> and stress related neuropeptides caused by <e2> cancer </e2> diagnosis as well as chemotherapy may have contributed the development of ABS.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2128": {"data": {"text": "In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.", "entity1": "catecholamines", "entity2": "ABS", "span1": [55, 69], "span2": [194, 197]}, "bert_text": "In our patient, both supraphysiologic levels of plasma <e1> catecholamines </e1> and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of <e2> ABS </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2129": {"data": {"text": "Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.\n", "entity1": "BN 52021", "entity2": "cardiovascular impairments", "span1": [71, 79], "span2": [104, 130]}, "bert_text": "Protective effect of a specific platelet-activating factor antagonist, <e1> BN 52021 </e1>, on bupivacaine-induced <e2> cardiovascular impairments </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2130": {"data": {"text": "Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.\n", "entity1": "bupivacaine", "entity2": "cardiovascular impairments", "span1": [84, 95], "span2": [104, 130]}, "bert_text": "Protective effect of a specific platelet-activating factor antagonist, BN 52021, on <e1> bupivacaine </e1>-induced <e2> cardiovascular impairments </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2131": {"data": {"text": "Diffusion-weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus-induced neurotoxicity.", "entity1": "tacrolimus", "entity2": "neurotoxicity", "span1": [86, 96], "span2": [105, 118]}, "bert_text": "Diffusion-weighted imaging may be useful in predicting the outcomes of the lesions of <e1> tacrolimus </e1>-induced <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2132": {"data": {"text": "Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.", "entity1": "Paclitaxel", "entity2": "toxicity", "span1": [0, 10], "span2": [217, 225]}, "bert_text": "<e1> Paclitaxel </e1> is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2133": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "verapamil", "entity2": "analgesia-", "span1": [5, 14], "span2": [72, 82]}, "bert_text": "Both <e1> verapamil </e1> (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine <e2> analgesia- </e2> and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2134": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "verapamil", "entity2": "muscular incoordination", "span1": [5, 14], "span2": [104, 127]}, "bert_text": "Both <e1> verapamil </e1> (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced <e2> muscular incoordination </e2> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2135": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "verapamil", "entity2": "analgesia-", "span1": [192, 201], "span2": [72, 82]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither <e1> verapamil </e1> <e2> analgesia- </e2> and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2136": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "verapamil", "entity2": "muscular incoordination", "span1": [192, 201], "span2": [104, 127]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither <e1> verapamil </e1> <e2> muscular incoordination </e2> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2137": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "NH4Ac", "entity2": "analgesia-", "span1": [35, 40], "span2": [72, 82]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and <e1> NH4Ac </e1> pretreatment enhanced morphine <e2> analgesia- </e2> and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2138": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "NH4Ac", "entity2": "muscular incoordination", "span1": [35, 40], "span2": [104, 127]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and <e1> NH4Ac </e1> pretreatment enhanced morphine analgesia- and diazepam-induced <e2> muscular incoordination </e2> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2139": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "NH4Ac", "entity2": "analgesia-", "span1": [206, 211], "span2": [72, 82]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor <e1> NH4Ac </e1> <e2> analgesia- </e2> and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2140": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "NH4Ac", "entity2": "muscular incoordination", "span1": [206, 211], "span2": [104, 127]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor <e1> NH4Ac </e1> <e2> muscular incoordination </e2> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2141": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "morphine", "entity2": "analgesia-", "span1": [63, 71], "span2": [72, 82]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced <e1> morphine </e1> <e2> analgesia- </e2> and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2142": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "morphine", "entity2": "muscular incoordination", "span1": [63, 71], "span2": [104, 127]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced <e1> morphine </e1> analgesia- and diazepam-induced <e2> muscular incoordination </e2> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2143": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "diazepam", "entity2": "analgesia-", "span1": [87, 95], "span2": [72, 82]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and <e1> diazepam </e1> <e2> analgesia- </e2> and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2144": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "diazepam", "entity2": "muscular incoordination", "span1": [87, 95], "span2": [104, 127]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and <e1> diazepam </e1>-induced <e2> muscular incoordination </e2> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2145": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "amphetamine", "entity2": "analgesia-", "span1": [144, 155], "span2": [72, 82]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized <e1> amphetamine </e1> <e2> analgesia- </e2> and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2146": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "amphetamine", "entity2": "muscular incoordination", "span1": [144, 155], "span2": [104, 127]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized <e1> amphetamine </e1> <e2> muscular incoordination </e2> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2147": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "metrazol", "entity2": "analgesia-", "span1": [246, 254], "span2": [72, 82]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of <e1> metrazol </e1> <e2> analgesia- </e2> and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2148": {"data": {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity1": "metrazol", "entity2": "muscular incoordination", "span1": [246, 254], "span2": [104, 127]}, "bert_text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of <e1> metrazol </e1> <e2> muscular incoordination </e2> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2149": {"data": {"text": "This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.", "entity1": "PAC", "entity2": "peripheral neuropathy", "span1": [88, 91], "span2": [100, 121]}, "bert_text": "This pilot trial aimed to evaluate the role of glutamate supplementation for preventing <e1> PAC </e1>-induced <e2> peripheral neuropathy </e2> in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2150": {"data": {"text": "Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.", "entity1": "5-HT6", "entity2": "psychosis", "span1": [62, 67], "span2": [98, 107]}, "bert_text": "Therefore, we conducted an analysis of the association of the <e1> 5-HT6 </e1> gene (HTR6) with METH-induced <e2> psychosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2151": {"data": {"text": "Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.", "entity1": "METH", "entity2": "psychosis", "span1": [85, 89], "span2": [98, 107]}, "bert_text": "Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with <e1> METH </e1>-induced <e2> psychosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2152": {"data": {"text": "Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.\n", "entity1": "glyceryl trinitrate", "entity2": "sphincter of Oddi spasm", "span1": [10, 29], "span2": [37, 60]}, "bert_text": "Effect of <e1> glyceryl trinitrate </e1> on the <e2> sphincter of Oddi spasm </e2> evoked by prostigmine-morphine administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2153": {"data": {"text": "Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.\n", "entity1": "prostigmine", "entity2": "sphincter of Oddi spasm", "span1": [71, 82], "span2": [37, 60]}, "bert_text": "Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by <e1> prostigmine </e1> <e2> sphincter of Oddi spasm </e2> evoked by prostigmine-morphine administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2154": {"data": {"text": "Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.\n", "entity1": "morphine", "entity2": "sphincter of Oddi spasm", "span1": [83, 91], "span2": [37, 60]}, "bert_text": "Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-<e1> morphine </e1> <e2> sphincter of Oddi spasm </e2> evoked by prostigmine-morphine administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2155": {"data": {"text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.", "entity1": "clonidine", "entity2": "cerebral palsy", "span1": [92, 101], "span2": [45, 59]}, "bert_text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving <e1> clonidine </e1> <e2> cerebral palsy </e2> and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2156": {"data": {"text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.", "entity1": "clonidine", "entity2": "seizure disorder", "span1": [92, 101], "span2": [64, 80]}, "bert_text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving <e1> clonidine </e1> <e2> seizure disorder </e2>, receiving clonidine for restlessness, who presented for placement of a baclofen pump.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2157": {"data": {"text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.", "entity1": "clonidine", "entity2": "restlessness", "span1": [92, 101], "span2": [106, 118]}, "bert_text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving <e1> clonidine </e1> for <e2> restlessness </e2>, who presented for placement of a baclofen pump.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2158": {"data": {"text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.", "entity1": "baclofen", "entity2": "cerebral palsy", "span1": [153, 161], "span2": [45, 59]}, "bert_text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a <e1> baclofen </e1> <e2> cerebral palsy </e2> and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2159": {"data": {"text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.", "entity1": "baclofen", "entity2": "seizure disorder", "span1": [153, 161], "span2": [64, 80]}, "bert_text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a <e1> baclofen </e1> <e2> seizure disorder </e2>, receiving clonidine for restlessness, who presented for placement of a baclofen pump.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2160": {"data": {"text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.", "entity1": "baclofen", "entity2": "restlessness", "span1": [153, 161], "span2": [106, 118]}, "bert_text": "We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a <e1> baclofen </e1> <e2> restlessness </e2>, who presented for placement of a baclofen pump.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2161": {"data": {"text": "Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension, particularly when given as a bolus.", "entity1": "Oxytocin", "entity2": "hypotension", "span1": [0, 8], "span2": [81, 92]}, "bert_text": "<e1> Oxytocin </e1> is a commonly used uterotonic that can cause significant and even fatal <e2> hypotension </e2>, particularly when given as a bolus.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2162": {"data": {"text": "It is concluded that L-dopa enhances reflex bradycardia through central alpha-receptor stimulation.", "entity1": "L-dopa", "entity2": "bradycardia", "span1": [21, 27], "span2": [44, 55]}, "bert_text": "It is concluded that <e1> L-dopa </e1> enhances reflex <e2> bradycardia </e2> through central alpha-receptor stimulation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2163": {"data": {"text": "BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.", "entity1": "Sirolimus", "entity2": "nephrotoxicity", "span1": [12, 21], "span2": [105, 119]}, "bert_text": "BACKGROUND: <e1> Sirolimus </e1> is the latest immunosuppressive agent used to prevent rejection, and may have less <e2> nephrotoxicity </e2> than calcineurin inhibitor (CNI)-based regimens.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2164": {"data": {"text": "Development of apomorphine-induced aggressive behavior: comparison of adult male and female Wistar rats.\n", "entity1": "apomorphine", "entity2": "aggressive behavior", "span1": [15, 26], "span2": [35, 54]}, "bert_text": "Development of <e1> apomorphine </e1>-induced <e2> aggressive behavior </e2>: comparison of adult male and female Wistar rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2165": {"data": {"text": "On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.", "entity1": "d-tubocurarine", "entity2": "tetanic tensions", "span1": [117, 131], "span2": [49, 65]}, "bert_text": "On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of <e1> d-tubocurarine </e1> <e2> tetanic tensions </e2>, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2166": {"data": {"text": "The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.", "entity1": "labetalol", "entity2": "hypotension", "span1": [49, 58], "span2": [26, 37]}, "bert_text": "The results indicate that hypotension induced by <e1> labetalol </e1> <e2> hypotension </e2> induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2167": {"data": {"text": "The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.", "entity1": "isoflurane", "entity2": "hypotension", "span1": [64, 74], "span2": [26, 37]}, "bert_text": "The results indicate that hypotension induced by labetalol with <e1> isoflurane </e1> <e2> hypotension </e2> induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2168": {"data": {"text": "Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.\n", "entity1": "antidepressant", "entity2": "Rabbit syndrome", "span1": [17, 31], "span2": [0, 15]}, "bert_text": "Rabbit syndrome, <e1> antidepressant </e1> <e2> Rabbit syndrome </e2>, antidepressant use, and cerebral perfusion SPECT scan findings.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2169": {"data": {"text": "We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.", "entity1": "NAA", "entity2": "hepatic damage", "span1": [31, 34], "span2": [130, 144]}, "bert_text": "We see the main application of <e1> NAA </e1> as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid <e2> hepatic damage </e2> in patients treated with this widely used analgesic.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2170": {"data": {"text": "We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.", "entity1": "acetaminophen", "entity2": "hepatic damage", "span1": [98, 111], "span2": [130, 144]}, "bert_text": "We see the main application of NAA as for the combinational use in pharmaceutical preparations of <e1> acetaminophen </e1> in order to avoid <e2> hepatic damage </e2> in patients treated with this widely used analgesic.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2171": {"data": {"text": "Components of lemon essential oil attenuate dementia induced by scopolamine.\n", "entity1": "scopolamine", "entity2": "dementia", "span1": [64, 75], "span2": [44, 52]}, "bert_text": "Components of lemon essential oil attenuate dementia induced by <e1> scopolamine </e1> <e2> dementia </e2> induced by scopolamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2172": {"data": {"text": "We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.", "entity1": "penicillamine", "entity2": "myasthenia gravis", "span1": [95, 108], "span2": [71, 88]}, "bert_text": "We have described a unique patient who had reversible and dose-related myasthenia gravis after <e1> penicillamine </e1> <e2> myasthenia gravis </e2> after penicillamine and chloroquine therapy for rheumatoid arthritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2173": {"data": {"text": "We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.", "entity1": "penicillamine", "entity2": "rheumatoid arthritis", "span1": [95, 108], "span2": [137, 157]}, "bert_text": "We have described a unique patient who had reversible and dose-related myasthenia gravis after <e1> penicillamine </e1> and chloroquine therapy for <e2> rheumatoid arthritis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2174": {"data": {"text": "We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.", "entity1": "chloroquine", "entity2": "myasthenia gravis", "span1": [113, 124], "span2": [71, 88]}, "bert_text": "We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and <e1> chloroquine </e1> <e2> myasthenia gravis </e2> after penicillamine and chloroquine therapy for rheumatoid arthritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2175": {"data": {"text": "We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.", "entity1": "chloroquine", "entity2": "rheumatoid arthritis", "span1": [113, 124], "span2": [137, 157]}, "bert_text": "We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and <e1> chloroquine </e1> therapy for <e2> rheumatoid arthritis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2176": {"data": {"text": "Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.", "entity1": "cocaine", "entity2": "Choreatiform hyperkinesias", "span1": [103, 110], "span2": [0, 26]}, "bert_text": "Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with <e1> cocaine </e1> <e2> Choreatiform hyperkinesias </e2> are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2177": {"data": {"text": "In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.", "entity1": "TET", "entity2": "platelet aggregations", "span1": [80, 83], "span2": [19, 40]}, "bert_text": "In the vitro human platelet aggregations induced by the agonists used in tests, <e1> TET </e1> <e2> platelet aggregations </e2> induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2178": {"data": {"text": "In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.", "entity1": "FAN", "entity2": "platelet aggregations", "span1": [88, 91], "span2": [19, 40]}, "bert_text": "In the vitro human platelet aggregations induced by the agonists used in tests, TET and <e1> FAN </e1> <e2> platelet aggregations </e2> induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2179": {"data": {"text": "Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.\n", "entity1": "cibenzoline", "entity2": "ventricular arrhythmias", "span1": [45, 56], "span2": [67, 90]}, "bert_text": "Antiarrhythmic effects of optical isomers of <e1> cibenzoline </e1> on canine <e2> ventricular arrhythmias </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2180": {"data": {"text": "Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.", "entity1": "vitamin D3", "entity2": "toxicity", "span1": [9, 19], "span2": [20, 28]}, "bert_text": "Signs of <e1> vitamin D3 </e1> <e2> toxicity </e2> were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2181": {"data": {"text": "Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.", "entity1": "vitamin D3", "entity2": "toxicity", "span1": [9, 19], "span2": [150, 158]}, "bert_text": "Signs of <e1> vitamin D3 </e1> toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 <e2> toxicity </e2> and 10 of 17 cows died.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2182": {"data": {"text": "Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.", "entity1": "vitamin D3", "entity2": "toxicity", "span1": [139, 149], "span2": [20, 28]}, "bert_text": "Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of <e1> vitamin D3 </e1> <e2> toxicity </e2> were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2183": {"data": {"text": "Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.", "entity1": "vitamin D3", "entity2": "toxicity", "span1": [139, 149], "span2": [150, 158]}, "bert_text": "Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of <e1> vitamin D3 </e1> <e2> toxicity </e2> and 10 of 17 cows died.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2184": {"data": {"text": "The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.", "entity1": "arginine vasopressin", "entity2": "polyuria", "span1": [18, 38], "span2": [158, 166]}, "bert_text": "The expression of <e1> arginine vasopressin </e1> (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced <e2> polyuria </e2>, using in situ hybridization histochemistry and radioimmunoassay.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2185": {"data": {"text": "The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.", "entity1": "AVP", "entity2": "polyuria", "span1": [40, 43], "span2": [158, 166]}, "bert_text": "The expression of arginine vasopressin (<e1> AVP </e1>) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced <e2> polyuria </e2>, using in situ hybridization histochemistry and radioimmunoassay.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2186": {"data": {"text": "The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.", "entity1": "lithium", "entity2": "polyuria", "span1": [137, 144], "span2": [158, 166]}, "bert_text": "The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with <e1> lithium </e1> (Li)-induced <e2> polyuria </e2>, using in situ hybridization histochemistry and radioimmunoassay.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2187": {"data": {"text": "The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.", "entity1": "Li)-induced", "entity2": "polyuria", "span1": [146, 157], "span2": [158, 166]}, "bert_text": "The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (<e1> Li)-induced </e1> <e2> polyuria </e2>, using in situ hybridization histochemistry and radioimmunoassay.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2188": {"data": {"text": "The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.", "entity1": "dexmedetomidine", "entity2": "muscle flaccidity", "span1": [48, 63], "span2": [95, 112]}, "bert_text": "The highly-selective alpha-2 adrenergic agonist <e1> dexmedetomidine </e1> (D-MED) is capable of inducing <e2> muscle flaccidity </e2> and anesthesia in rats and dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2189": {"data": {"text": "The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.", "entity1": "D-MED", "entity2": "muscle flaccidity", "span1": [65, 70], "span2": [95, 112]}, "bert_text": "The highly-selective alpha-2 adrenergic agonist dexmedetomidine (<e1> D-MED </e1>) is capable of inducing <e2> muscle flaccidity </e2> and anesthesia in rats and dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2190": {"data": {"text": "CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.", "entity1": "Haloperidol", "entity2": "cognitive impairment", "span1": [12, 23], "span2": [52, 72]}, "bert_text": "CONCLUSION: <e1> Haloperidol </e1> produced a clear profile of <e2> cognitive impairment </e2> that was not worsened by concomitant sertraline administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2191": {"data": {"text": "CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.", "entity1": "sertraline", "entity2": "cognitive impairment", "span1": [110, 120], "span2": [52, 72]}, "bert_text": "CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant <e1> sertraline </e1> <e2> cognitive impairment </e2> that was not worsened by concomitant sertraline administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2192": {"data": {"text": "A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.", "entity1": "indomethacin", "entity2": "aplastic anemia", "span1": [47, 59], "span2": [134, 149]}, "bert_text": "A positive lymphocyte transformation test with <e1> indomethacin </e1> in vitro further substantiates the potential role of this drug in causing <e2> aplastic anemia </e2> in a susceptible patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2193": {"data": {"text": "This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.", "entity1": "methadone", "entity2": "choreoathetoid movements", "span1": [152, 161], "span2": [38, 62]}, "bert_text": "This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist <e1> methadone </e1> <e2> choreoathetoid movements </e2> both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2194": {"data": {"text": "This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.", "entity1": "heroine", "entity2": "choreoathetoid movements", "span1": [197, 204], "span2": [38, 62]}, "bert_text": "This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing <e1> heroine </e1> <e2> choreoathetoid movements </e2> both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2195": {"data": {"text": "This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.", "entity1": "cocaine", "entity2": "choreoathetoid movements", "span1": [209, 216], "span2": [38, 62]}, "bert_text": "This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and <e1> cocaine </e1> <e2> choreoathetoid movements </e2> both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2196": {"data": {"text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "entity1": "bupivacaine", "entity2": "convulsions", "span1": [89, 100], "span2": [41, 52]}, "bert_text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of <e1> bupivacaine </e1> <e2> convulsions </e2> in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2197": {"data": {"text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "entity1": "bupivacaine", "entity2": "seizures", "span1": [89, 100], "span2": [109, 117]}, "bert_text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of <e1> bupivacaine </e1>-induced <e2> seizures </e2>, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2198": {"data": {"text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "entity1": "chloroprocaine", "entity2": "convulsions", "span1": [133, 147], "span2": [41, 52]}, "bert_text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the <e1> chloroprocaine </e1> <e2> convulsions </e2> in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2199": {"data": {"text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "entity1": "chloroprocaine", "entity2": "seizures", "span1": [133, 147], "span2": [109, 117]}, "bert_text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the <e1> chloroprocaine </e1> <e2> seizures </e2>, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2200": {"data": {"text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "entity1": "lidocaine", "entity2": "convulsions", "span1": [172, 181], "span2": [41, 52]}, "bert_text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the <e1> lidocaine </e1> <e2> convulsions </e2> in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2201": {"data": {"text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "entity1": "lidocaine", "entity2": "seizures", "span1": [172, 181], "span2": [109, 117]}, "bert_text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the <e1> lidocaine </e1> <e2> seizures </e2>, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2202": {"data": {"text": "We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.", "entity1": "risperidone", "entity2": "hyperprolactinemia", "span1": [38, 49], "span2": [58, 76]}, "bert_text": "We report the successful treatment of <e1> risperidone </e1>-induced <e2> hyperprolactinemia </e2> with cabergoline in youth.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2203": {"data": {"text": "We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.", "entity1": "cabergoline", "entity2": "hyperprolactinemia", "span1": [82, 93], "span2": [58, 76]}, "bert_text": "We report the successful treatment of risperidone-induced hyperprolactinemia with <e1> cabergoline </e1> <e2> hyperprolactinemia </e2> with cabergoline in youth.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2204": {"data": {"text": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "entity1": "sulphasalazine", "entity2": "dermatitis", "span1": [144, 158], "span2": [48, 58]}, "bert_text": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral <e1> sulphasalazine </e1> <e2> dermatitis </e2>, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2205": {"data": {"text": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "entity1": "sulphasalazine", "entity2": "fever", "span1": [144, 158], "span2": [60, 65]}, "bert_text": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral <e1> sulphasalazine </e1> <e2> fever </e2>, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2206": {"data": {"text": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "entity1": "sulphasalazine", "entity2": "lymphadenopathy", "span1": [144, 158], "span2": [67, 82]}, "bert_text": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral <e1> sulphasalazine </e1> <e2> lymphadenopathy </e2> and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2207": {"data": {"text": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "entity1": "sulphasalazine", "entity2": "hepatitis", "span1": [144, 158], "span2": [87, 96]}, "bert_text": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral <e1> sulphasalazine </e1> <e2> hepatitis </e2>, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2208": {"data": {"text": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "entity1": "sulphasalazine", "entity2": "rheumatoid arthritis", "span1": [144, 158], "span2": [177, 197]}, "bert_text": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral <e1> sulphasalazine </e1> for sero-negative <e2> rheumatoid arthritis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2209": {"data": {"text": "Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.\n", "entity1": "succinylcholine", "entity2": "apnea", "span1": [76, 91], "span2": [64, 69]}, "bert_text": "Butyrylcholinesterase gene mutations in patients with prolonged apnea after <e1> succinylcholine </e1> <e2> apnea </e2> after succinylcholine for electroconvulsive therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2210": {"data": {"text": "Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.\n", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [49, 57], "span2": [66, 77]}, "bert_text": "Repetitive transcranial magnetic stimulation for <e1> levodopa </e1>-induced <e2> dyskinesias </e2> in Parkinson's disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2211": {"data": {"text": "Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.\n", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [49, 57], "span2": [81, 100]}, "bert_text": "Repetitive transcranial magnetic stimulation for <e1> levodopa </e1>-induced dyskinesias in <e2> Parkinson's disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2212": {"data": {"text": "Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.\n", "entity1": "paclitaxel", "entity2": "cancer", "span1": [68, 78], "span2": [56, 62]}, "bert_text": "Chemotherapy of advanced inoperable non-small cell lung cancer with <e1> paclitaxel </e1> <e2> cancer </e2> with paclitaxel: a phase II trial.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2213": {"data": {"text": "Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.", "entity1": "vancomycin", "entity2": "Renal failure", "span1": [52, 62], "span2": [0, 13]}, "bert_text": "Renal failure developed after a prolonged course of <e1> vancomycin </e1> <e2> Renal failure </e2> developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2214": {"data": {"text": "Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.", "entity1": "tenofovir disoproxil fumarate", "entity2": "Renal failure", "span1": [104, 133], "span2": [0, 13]}, "bert_text": "Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving <e1> tenofovir disoproxil fumarate </e1> <e2> Renal failure </e2> developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2215": {"data": {"text": "Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.\n", "entity1": "Suxamethonium", "entity2": "apnea", "span1": [0, 13], "span2": [32, 37]}, "bert_text": "<e1> Suxamethonium </e1> induced prolonged <e2> apnea </e2> in a patient receiving electroconvulsive therapy.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2216": {"data": {"text": "It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.", "entity1": "octreotide", "entity2": "acromegalic", "span1": [94, 104], "span2": [116, 127]}, "bert_text": "It is therefore very important to follow the changes of gallbladder function during long-term <e1> octreotide </e1> therapy of <e2> acromegalic </e2> patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2217": {"data": {"text": "Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.", "entity1": "isoproterenol", "entity2": "infarct", "span1": [80, 93], "span2": [61, 68]}, "bert_text": "Histological studies demonstrated that the rats developed an infarct 18 h after <e1> isoproterenol </e1> <e2> infarct </e2> 18 h after isoproterenol administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2218": {"data": {"text": "To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [105, 114], "span2": [70, 81]}, "bert_text": "To date there has been little documentation of clinically significant proteinuria linked with the use of <e1> sirolimus </e1> <e2> proteinuria </e2> linked with the use of sirolimus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2219": {"data": {"text": "In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.", "entity1": "ketoconazole", "entity2": "deaths", "span1": [52, 64], "span2": [20, 26]}, "bert_text": "In two of the three deaths probably associated with <e1> ketoconazole </e1> <e2> deaths </e2> probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2220": {"data": {"text": "In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.", "entity1": "ketoconazole", "entity2": "jaundice", "span1": [52, 64], "span2": [122, 130]}, "bert_text": "In two of the three deaths probably associated with <e1> ketoconazole </e1> treatment the drug had been continued after the onset of <e2> jaundice </e2> and other symptoms of hepatitis.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2221": {"data": {"text": "In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.", "entity1": "ketoconazole", "entity2": "hepatitis", "span1": [52, 64], "span2": [153, 162]}, "bert_text": "In two of the three deaths probably associated with <e1> ketoconazole </e1> treatment the drug had been continued after the onset of jaundice and other symptoms of <e2> hepatitis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2222": {"data": {"text": "We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.", "entity1": "carbamazepine", "entity2": "hypersensitivity", "span1": [48, 61], "span2": [28, 44]}, "bert_text": "We report a patient in whom hypersensitivity to <e1> carbamazepine </e1> <e2> hypersensitivity </e2> to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2223": {"data": {"text": "We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.", "entity1": "carbamazepine", "entity2": "erythroderma", "span1": [48, 61], "span2": [89, 101]}, "bert_text": "We report a patient in whom hypersensitivity to <e1> carbamazepine </e1> presented with generalized <e2> erythroderma </e2>, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2224": {"data": {"text": "We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.", "entity1": "carbamazepine", "entity2": "leukemoid reaction", "span1": [48, 61], "span2": [112, 130]}, "bert_text": "We report a patient in whom hypersensitivity to <e1> carbamazepine </e1> presented with generalized erythroderma, a severe <e2> leukemoid reaction </e2>, eosinophilia, hyponatremia, and renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2225": {"data": {"text": "We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.", "entity1": "carbamazepine", "entity2": "eosinophilia", "span1": [48, 61], "span2": [132, 144]}, "bert_text": "We report a patient in whom hypersensitivity to <e1> carbamazepine </e1> presented with generalized erythroderma, a severe leukemoid reaction, <e2> eosinophilia </e2>, hyponatremia, and renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2226": {"data": {"text": "We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.", "entity1": "carbamazepine", "entity2": "hyponatremia", "span1": [48, 61], "span2": [146, 158]}, "bert_text": "We report a patient in whom hypersensitivity to <e1> carbamazepine </e1> presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, <e2> hyponatremia </e2>, and renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2227": {"data": {"text": "We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.", "entity1": "carbamazepine", "entity2": "renal failure", "span1": [48, 61], "span2": [164, 177]}, "bert_text": "We report a patient in whom hypersensitivity to <e1> carbamazepine </e1> presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and <e2> renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2228": {"data": {"text": "VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.", "entity1": "cyclophosphamide", "entity2": "cystitis", "span1": [106, 122], "span2": [137, 145]}, "bert_text": "VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after <e1> cyclophosphamide </e1> (CYP)-induced <e2> cystitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2229": {"data": {"text": "VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.", "entity1": "CYP)-induced", "entity2": "cystitis", "span1": [124, 136], "span2": [137, 145]}, "bert_text": "VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (<e1> CYP)-induced </e1> <e2> cystitis </e2>.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2230": {"data": {"text": "Hyperkalemia associated with sulindac therapy.\n", "entity1": "sulindac", "entity2": "Hyperkalemia", "span1": [29, 37], "span2": [0, 12]}, "bert_text": "Hyperkalemia associated with <e1> sulindac </e1> <e2> Hyperkalemia </e2> associated with sulindac therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2231": {"data": {"text": "Hippocampal ACh also was measured during testing for handling-induced convulsions.", "entity1": "ACh", "entity2": "convulsions", "span1": [12, 15], "span2": [70, 81]}, "bert_text": "Hippocampal <e1> ACh </e1> also was measured during testing for handling-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2232": {"data": {"text": "Additionally, the protective effect of verapamil on this ulcer model was evaluated.", "entity1": "verapamil", "entity2": "ulcer", "span1": [39, 48], "span2": [57, 62]}, "bert_text": "Additionally, the protective effect of <e1> verapamil </e1> on this <e2> ulcer </e2> model was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2233": {"data": {"text": "To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "entity1": "bromocriptine", "entity2": "prolactinoma", "span1": [26, 39], "span2": [43, 55]}, "bert_text": "To clarify the effects of <e1> bromocriptine </e1> on <e2> prolactinoma </e2> cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2234": {"data": {"text": "To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "entity1": "bromocriptine", "entity2": "prolactinoma", "span1": [26, 39], "span2": [173, 185]}, "bert_text": "To clarify the effects of <e1> bromocriptine </e1> on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat <e2> prolactinoma </e2> cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2235": {"data": {"text": "To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "entity1": "bromocriptine", "entity2": "prolactinoma", "span1": [223, 236], "span2": [43, 55]}, "bert_text": "To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of <e1> bromocriptine </e1> <e2> prolactinoma </e2> cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2236": {"data": {"text": "To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "entity1": "bromocriptine", "entity2": "prolactinoma", "span1": [223, 236], "span2": [173, 185]}, "bert_text": "To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of <e1> bromocriptine </e1> <e2> prolactinoma </e2> cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2237": {"data": {"text": "To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "entity1": "estrogen", "entity2": "prolactinoma", "span1": [152, 160], "span2": [43, 55]}, "bert_text": "To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to <e1> estrogen </e1> <e2> prolactinoma </e2> cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2238": {"data": {"text": "To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "entity1": "estrogen", "entity2": "prolactinoma", "span1": [152, 160], "span2": [173, 185]}, "bert_text": "To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to <e1> estrogen </e1>-induced rat <e2> prolactinoma </e2> cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2239": {"data": {"text": "In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat.\n", "entity1": "cyclophosphamide", "entity2": "cystitis", "span1": [74, 90], "span2": [99, 107]}, "bert_text": "In vitro characterization of parasympathetic and sympathetic responses in <e1> cyclophosphamide </e1>-induced <e2> cystitis </e2> in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2240": {"data": {"text": "Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers.\n", "entity1": "cocaine", "entity2": "myocardial injury", "span1": [83, 90], "span2": [33, 50]}, "bert_text": "Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized <e1> cocaine </e1> <e2> myocardial injury </e2> in psychiatrically hospitalized cocaine abusers.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2241": {"data": {"text": "Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.", "entity1": "nicotine", "entity2": "locomotor hypoactivity", "span1": [143, 151], "span2": [110, 132]}, "bert_text": "Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by <e1> nicotine </e1> <e2> locomotor hypoactivity </e2> caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2242": {"data": {"text": "Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.", "entity1": "nicotine", "entity2": "hyperactivity", "span1": [143, 151], "span2": [224, 237]}, "bert_text": "Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by <e1> nicotine </e1> (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced <e2> hyperactivity </e2>, and raised spontaneous nocturnal activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2243": {"data": {"text": "Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.", "entity1": "nicotine", "entity2": "locomotor hypoactivity", "span1": [207, 215], "span2": [110, 132]}, "bert_text": "Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) <e1> nicotine </e1> <e2> locomotor hypoactivity </e2> caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2244": {"data": {"text": "Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.", "entity1": "nicotine", "entity2": "hyperactivity", "span1": [207, 215], "span2": [224, 237]}, "bert_text": "Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) <e1> nicotine </e1>-induced <e2> hyperactivity </e2>, and raised spontaneous nocturnal activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2245": {"data": {"text": "Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.\n", "entity1": "Phenobarbitone", "entity2": "enlargement of the liver", "span1": [0, 14], "span2": [23, 47]}, "bert_text": "<e1> Phenobarbitone </e1>-induced <e2> enlargement of the liver </e2> in the rat: its relationship to carbon tetrachloride-induced cirrhosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2246": {"data": {"text": "Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.\n", "entity1": "Phenobarbitone", "entity2": "cirrhosis", "span1": [0, 14], "span2": [109, 118]}, "bert_text": "<e1> Phenobarbitone </e1>-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced <e2> cirrhosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2247": {"data": {"text": "Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.\n", "entity1": "carbon tetrachloride", "entity2": "enlargement of the liver", "span1": [80, 100], "span2": [23, 47]}, "bert_text": "Phenobarbitone-induced enlargement of the liver in the rat: its relationship to <e1> carbon tetrachloride </e1> <e2> enlargement of the liver </e2> in the rat: its relationship to carbon tetrachloride-induced cirrhosis.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2248": {"data": {"text": "Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.\n", "entity1": "carbon tetrachloride", "entity2": "cirrhosis", "span1": [80, 100], "span2": [109, 118]}, "bert_text": "Phenobarbitone-induced enlargement of the liver in the rat: its relationship to <e1> carbon tetrachloride </e1>-induced <e2> cirrhosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2249": {"data": {"text": "Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.\n", "entity1": "dexamethasone", "entity2": "hemorrhagic cystitis", "span1": [7, 20], "span2": [73, 93]}, "bert_text": "Use of <e1> dexamethasone </e1> with mesna for the prevention of ifosfamide-induced <e2> hemorrhagic cystitis </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2250": {"data": {"text": "Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.\n", "entity1": "mesna", "entity2": "hemorrhagic cystitis", "span1": [26, 31], "span2": [73, 93]}, "bert_text": "Use of dexamethasone with <e1> mesna </e1> for the prevention of ifosfamide-induced <e2> hemorrhagic cystitis </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2251": {"data": {"text": "Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.\n", "entity1": "ifosfamide", "entity2": "hemorrhagic cystitis", "span1": [54, 64], "span2": [73, 93]}, "bert_text": "Use of dexamethasone with mesna for the prevention of <e1> ifosfamide </e1>-induced <e2> hemorrhagic cystitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2252": {"data": {"text": "The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).", "entity1": "s-limonene", "entity2": "dementia", "span1": [29, 39], "span2": [9, 17]}, "bert_text": "The anti-dementia effects of <e1> s-limonene </e1> <e2> dementia </e2> effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2253": {"data": {"text": "The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).", "entity1": "s-perillyl alcohol", "entity2": "dementia", "span1": [44, 62], "span2": [9, 17]}, "bert_text": "The anti-dementia effects of s-limonene and <e1> s-perillyl alcohol </e1> <e2> dementia </e2> effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2254": {"data": {"text": "Epicardial coronary collateral vessels were demonstrated in all four patients; a coronary \"steal\" phenomenon may be the mechanism of the dipyridamole-induced ischemia observed.", "entity1": "dipyridamole", "entity2": "ischemia", "span1": [137, 149], "span2": [158, 166]}, "bert_text": "Epicardial coronary collateral vessels were demonstrated in all four patients; a coronary \"steal\" phenomenon may be the mechanism of the <e1> dipyridamole </e1>-induced <e2> ischemia </e2> observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2255": {"data": {"text": "The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.", "entity1": "salvianolic acid A", "entity2": "myocardial damage", "span1": [23, 41], "span2": [72, 89]}, "bert_text": "The protective role of <e1> salvianolic acid A </e1> against isoproterenol-induced <e2> myocardial damage </e2> was further confirmed by histopathological examination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2256": {"data": {"text": "The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.", "entity1": "isoproterenol", "entity2": "myocardial damage", "span1": [50, 63], "span2": [72, 89]}, "bert_text": "The protective role of salvianolic acid A against <e1> isoproterenol </e1>-induced <e2> myocardial damage </e2> was further confirmed by histopathological examination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2257": {"data": {"text": "Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/-", "entity1": "fenoldopam", "entity2": "hypotension", "span1": [40, 50], "span2": [59, 70]}, "bert_text": "Renal blood flow (RBF) increased during <e1> fenoldopam </e1>-induced <e2> hypotension </e2> 11 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2258": {"data": {"text": "This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.", "entity1": "angiotensin II", "entity2": "renovascular disease", "span1": [46, 60], "span2": [150, 170]}, "bert_text": "This case report highlights the fact that the <e1> angiotensin II </e1> receptor antagonist losartan can cause serious unexpected complications in patients with <e2> renovascular disease </e2> and should be used with extreme caution in this setting.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2259": {"data": {"text": "This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.", "entity1": "losartan", "entity2": "renovascular disease", "span1": [81, 89], "span2": [150, 170]}, "bert_text": "This case report highlights the fact that the angiotensin II receptor antagonist <e1> losartan </e1> can cause serious unexpected complications in patients with <e2> renovascular disease </e2> and should be used with extreme caution in this setting.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2260": {"data": {"text": "The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.", "entity1": "haloperidol", "entity2": "Alzheimer's disease", "span1": [44, 55], "span2": [101, 120]}, "bert_text": "The narrow therapeutic window observed with <e1> haloperidol </e1> may also apply to other neuroleptics used in <e2> Alzheimer's disease </e2> patients with psychosis and disruptive behaviors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2261": {"data": {"text": "The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.", "entity1": "haloperidol", "entity2": "psychosis", "span1": [44, 55], "span2": [135, 144]}, "bert_text": "The narrow therapeutic window observed with <e1> haloperidol </e1> may also apply to other neuroleptics used in Alzheimer's disease patients with <e2> psychosis </e2> and disruptive behaviors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2262": {"data": {"text": "The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.", "entity1": "haloperidol", "entity2": "disruptive behaviors", "span1": [44, 55], "span2": [149, 169]}, "bert_text": "The narrow therapeutic window observed with <e1> haloperidol </e1> may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and <e2> disruptive behaviors </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2263": {"data": {"text": "Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.\n", "entity1": "Simvastatin", "entity2": "bilateral leg compartment syndrome and myonecrosis", "span1": [0, 11], "span2": [20, 70]}, "bert_text": "<e1> Simvastatin </e1>-induced <e2> bilateral leg compartment syndrome and myonecrosis </e2> associated with hypothyroidism.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2264": {"data": {"text": "Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.\n", "entity1": "Simvastatin", "entity2": "hypothyroidism", "span1": [0, 11], "span2": [87, 101]}, "bert_text": "<e1> Simvastatin </e1>-induced bilateral leg compartment syndrome and myonecrosis associated with <e2> hypothyroidism </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2265": {"data": {"text": "Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.", "entity1": "nicotine", "entity2": "tremor", "span1": [26, 34], "span2": [122, 128]}, "bert_text": "Animals were administered <e1> nicotine </e1>, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of <e2> tremor </e2> and clonus were recorded and converted to threshold dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2266": {"data": {"text": "Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.", "entity1": "carbachol", "entity2": "tremor", "span1": [36, 45], "span2": [122, 128]}, "bert_text": "Animals were administered nicotine, <e1> carbachol </e1>, or neostigmine via timed tail vein infusion, and the latencies to onset of <e2> tremor </e2> and clonus were recorded and converted to threshold dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2267": {"data": {"text": "Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.", "entity1": "neostigmine", "entity2": "tremor", "span1": [50, 61], "span2": [122, 128]}, "bert_text": "Animals were administered nicotine, carbachol, or <e1> neostigmine </e1> via timed tail vein infusion, and the latencies to onset of <e2> tremor </e2> and clonus were recorded and converted to threshold dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2268": {"data": {"text": "We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.", "entity1": "losartan", "entity2": "hypertensive", "span1": [161, 169], "span2": [36, 48]}, "bert_text": "We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after <e1> losartan </e1> <e2> hypertensive </e2> man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2269": {"data": {"text": "We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.", "entity1": "losartan", "entity2": "chronic renal insufficiency", "span1": [161, 169], "span2": [80, 107]}, "bert_text": "We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after <e1> losartan </e1> <e2> chronic renal insufficiency </e2> who developed two episodes of transient anuria after losartan administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2270": {"data": {"text": "We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.", "entity1": "losartan", "entity2": "anuria", "span1": [161, 169], "span2": [148, 154]}, "bert_text": "We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after <e1> losartan </e1> <e2> anuria </e2> after losartan administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2271": {"data": {"text": "CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.", "entity1": "FK506", "entity2": "nephropathy", "span1": [50, 55], "span2": [56, 67]}, "bert_text": "CONCLUSIONS: This study demonstrates that chronic <e1> FK506 </e1> <e2> nephropathy </e2> consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2272": {"data": {"text": "CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.", "entity1": "FK506", "entity2": "nephropathy", "span1": [50, 55], "span2": [208, 219]}, "bert_text": "CONCLUSIONS: This study demonstrates that chronic <e1> FK506 </e1> nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 <e2> nephropathy </e2> is a condition which may lead to deterioration of renal allograft function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2273": {"data": {"text": "CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.", "entity1": "FK506", "entity2": "hyalinosis", "span1": [50, 55], "span2": [131, 141]}, "bert_text": "CONCLUSIONS: This study demonstrates that chronic <e1> FK506 </e1> nephropathy consists primarily of arteriolopathy manifesting as insudative <e2> hyalinosis </e2> of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2274": {"data": {"text": "CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.", "entity1": "FK506", "entity2": "nephropathy", "span1": [202, 207], "span2": [56, 67]}, "bert_text": "CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic <e1> FK506 </e1> <e2> nephropathy </e2> consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2275": {"data": {"text": "CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.", "entity1": "FK506", "entity2": "nephropathy", "span1": [202, 207], "span2": [208, 219]}, "bert_text": "CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic <e1> FK506 </e1> <e2> nephropathy </e2> is a condition which may lead to deterioration of renal allograft function.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2276": {"data": {"text": "CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.", "entity1": "FK506", "entity2": "hyalinosis", "span1": [202, 207], "span2": [131, 141]}, "bert_text": "CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic <e1> FK506 </e1> <e2> hyalinosis </e2> of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2277": {"data": {"text": "Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.", "entity1": "ketoconazole", "entity2": "hypertension", "span1": [62, 74], "span2": [139, 151]}, "bert_text": "Our findings show that long-term treatment with high doses of <e1> ketoconazole </e1> may induce enzyme blockade leading to mineralocorticoid-related <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2278": {"data": {"text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.", "entity1": "aspirin", "entity2": "bladder carcinomas", "span1": [25, 32], "span2": [149, 167]}, "bert_text": "The co-administration of <e1> aspirin </e1> with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced <e2> bladder carcinomas </e2> but a concomitant induction of forestomach tumors.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2279": {"data": {"text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.", "entity1": "aspirin", "entity2": "forestomach tumors", "span1": [25, 32], "span2": [199, 217]}, "bert_text": "The co-administration of <e1> aspirin </e1> with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of <e2> forestomach tumors </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2280": {"data": {"text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.", "entity1": "N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide", "entity2": "bladder carcinomas", "span1": [38, 83], "span2": [149, 167]}, "bert_text": "The co-administration of aspirin with <e1> N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide </e1> (FANFT) to rats resulted in a reduced incidence of FANFT-induced <e2> bladder carcinomas </e2> but a concomitant induction of forestomach tumors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2281": {"data": {"text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.", "entity1": "N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide", "entity2": "forestomach tumors", "span1": [38, 83], "span2": [199, 217]}, "bert_text": "The co-administration of aspirin with <e1> N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide </e1> (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of <e2> forestomach tumors </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2282": {"data": {"text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.", "entity1": "FANFT", "entity2": "bladder carcinomas", "span1": [85, 90], "span2": [149, 167]}, "bert_text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (<e1> FANFT </e1>) to rats resulted in a reduced incidence of FANFT-induced <e2> bladder carcinomas </e2> but a concomitant induction of forestomach tumors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2283": {"data": {"text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.", "entity1": "FANFT", "entity2": "forestomach tumors", "span1": [85, 90], "span2": [199, 217]}, "bert_text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (<e1> FANFT </e1>) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of <e2> forestomach tumors </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2284": {"data": {"text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.", "entity1": "FANFT", "entity2": "bladder carcinomas", "span1": [135, 140], "span2": [149, 167]}, "bert_text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of <e1> FANFT </e1>-induced <e2> bladder carcinomas </e2> but a concomitant induction of forestomach tumors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2285": {"data": {"text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.", "entity1": "FANFT", "entity2": "forestomach tumors", "span1": [135, 140], "span2": [199, 217]}, "bert_text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of <e1> FANFT </e1>-induced bladder carcinomas but a concomitant induction of <e2> forestomach tumors </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2286": {"data": {"text": "Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis.\n", "entity1": "Propylthiouracil", "entity2": "vasculitis", "span1": [0, 16], "span2": [95, 105]}, "bert_text": "<e1> Propylthiouracil </e1>-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive <e2> vasculitis </e2> in conjunction with pericarditis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2287": {"data": {"text": "Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis.\n", "entity1": "Propylthiouracil", "entity2": "pericarditis", "span1": [0, 16], "span2": [126, 138]}, "bert_text": "<e1> Propylthiouracil </e1>-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with <e2> pericarditis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2288": {"data": {"text": "OBJECTIVE: To describe a case of propylthiouracil-induced vasculitis manifesting with pericarditis.", "entity1": "propylthiouracil", "entity2": "vasculitis", "span1": [33, 49], "span2": [58, 68]}, "bert_text": "OBJECTIVE: To describe a case of <e1> propylthiouracil </e1>-induced <e2> vasculitis </e2> manifesting with pericarditis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2289": {"data": {"text": "OBJECTIVE: To describe a case of propylthiouracil-induced vasculitis manifesting with pericarditis.", "entity1": "propylthiouracil", "entity2": "pericarditis", "span1": [33, 49], "span2": [86, 98]}, "bert_text": "OBJECTIVE: To describe a case of <e1> propylthiouracil </e1>-induced vasculitis manifesting with <e2> pericarditis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2290": {"data": {"text": "These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.", "entity1": "scopolamine", "entity2": "memory impaired", "span1": [79, 90], "span2": [60, 75]}, "bert_text": "These lemon essential oils showed strong ability to improve memory impaired by <e1> scopolamine </e1> <e2> memory impaired </e2> by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2291": {"data": {"text": "These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.", "entity1": "s-perillyl alcohol", "entity2": "memory impaired", "span1": [101, 119], "span2": [60, 75]}, "bert_text": "These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, <e1> s-perillyl alcohol </e1> <e2> memory impaired </e2> by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2292": {"data": {"text": "(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.", "entity1": "/-)-PG-9", "entity2": "amnesia", "span1": [2, 10], "span2": [52, 59]}, "bert_text": "(+<e1> /-)-PG-9 </e1> (10-40 mg kg-1 i.p.) was able to prevent <e2> amnesia </e2> induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2293": {"data": {"text": "(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [71, 82], "span2": [52, 59]}, "bert_text": "(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by <e1> scopolamine </e1> <e2> amnesia </e2> induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2294": {"data": {"text": "(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.", "entity1": "dicyclomine", "entity2": "amnesia", "span1": [104, 115], "span2": [52, 59]}, "bert_text": "(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and <e1> dicyclomine </e1> <e2> amnesia </e2> induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2295": {"data": {"text": "Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.\n", "entity1": "echothiophate iodide", "entity2": "toxicity", "span1": [59, 79], "span2": [12, 20]}, "bert_text": "Cholinergic toxicity resulting from ocular instillation of <e1> echothiophate iodide </e1> <e2> toxicity </e2> resulting from ocular instillation of echothiophate iodide eye drops.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2296": {"data": {"text": "Clonidine-induced bradycardia in conscious alpha2ABC-/- mice was 32.3% (10", "entity1": "Clonidine", "entity2": "bradycardia", "span1": [0, 9], "span2": [18, 29]}, "bert_text": "<e1> Clonidine </e1>-induced <e2> bradycardia </e2> in conscious alpha2ABC-/- mice was 32.3% (10", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2297": {"data": {"text": "Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.", "entity1": "Oxytocin", "entity2": "abortions", "span1": [0, 8], "span2": [52, 61]}, "bert_text": "<e1> Oxytocin </e1> administration during midtrimester-induced <e2> abortions </e2> is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2298": {"data": {"text": "Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.", "entity1": "Oxytocin", "entity2": "water intoxication", "span1": [0, 8], "span2": [184, 202]}, "bert_text": "<e1> Oxytocin </e1> administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of <e2> water intoxication </e2> and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2299": {"data": {"text": "Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.", "entity1": "Oxytocin", "entity2": "asthenia", "span1": [0, 8], "span2": [287, 295]}, "bert_text": "<e1> Oxytocin </e1> administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as <e2> asthenia </e2>, muscular irritability, or headaches.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2300": {"data": {"text": "Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.", "entity1": "Oxytocin", "entity2": "muscular irritability", "span1": [0, 8], "span2": [297, 318]}, "bert_text": "<e1> Oxytocin </e1> administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, <e2> muscular irritability </e2>, or headaches.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2301": {"data": {"text": "Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.", "entity1": "Oxytocin", "entity2": "headaches", "span1": [0, 8], "span2": [323, 332]}, "bert_text": "<e1> Oxytocin </e1> administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or <e2> headaches </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2302": {"data": {"text": "Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine.", "entity1": "cocaine", "entity2": "seizures", "span1": [138, 145], "span2": [96, 104]}, "bert_text": "Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of <e1> cocaine </e1> <e2> seizures </e2> induced by a single injection of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2303": {"data": {"text": "RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity.", "entity1": "CCNU", "entity2": "toxicity", "span1": [38, 42], "span2": [101, 109]}, "bert_text": "RESULTS: Of the 206 dogs treated with <e1> CCNU </e1>, 185 met the inclusion criteria for at least one class of <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2304": {"data": {"text": "Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.", "entity1": "ribavirin", "entity2": "adenovirus disease", "span1": [21, 30], "span2": [78, 96]}, "bert_text": "Although intravenous <e1> ribavirin </e1> was not effective for all children with severe <e2> adenovirus disease </e2> in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2305": {"data": {"text": "Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.", "entity1": "ribavirin", "entity2": "infection", "span1": [21, 30], "span2": [206, 215]}, "bert_text": "Although intravenous <e1> ribavirin </e1> was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the <e2> infection </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2306": {"data": {"text": "On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.", "entity1": "paracetamol", "entity2": "liver injury", "span1": [89, 100], "span2": [109, 121]}, "bert_text": "On average, age-specific mortality rates were slightly higher for the 101 patients whose <e1> paracetamol </e1>-induced <e2> liver injury </e2> had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2307": {"data": {"text": "On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.", "entity1": "paracetamol", "entity2": "acute liver failure", "span1": [89, 100], "span2": [136, 155]}, "bert_text": "On average, age-specific mortality rates were slightly higher for the 101 patients whose <e1> paracetamol </e1>-induced liver injury had caused an <e2> acute liver failure </e2> (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2308": {"data": {"text": "On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.", "entity1": "paracetamol", "entity2": "acute liver failure", "span1": [89, 100], "span2": [273, 292]}, "bert_text": "On average, age-specific mortality rates were slightly higher for the 101 patients whose <e1> paracetamol </e1>-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of <e2> acute liver failure </e2> died of liver disease, whereas suicides were frequent in both groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2309": {"data": {"text": "On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.", "entity1": "paracetamol", "entity2": "liver disease", "span1": [89, 100], "span2": [301, 314]}, "bert_text": "On average, age-specific mortality rates were slightly higher for the 101 patients whose <e1> paracetamol </e1>-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of <e2> liver disease </e2>, whereas suicides were frequent in both groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2310": {"data": {"text": "RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.", "entity1": "WR242511", "entity2": "methemoglobinemia", "span1": [31, 39], "span2": [68, 85]}, "bert_text": "RESULTS: The selected doses of <e1> WR242511 </e1>, which produced significant <e2> methemoglobinemia </e2> in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2311": {"data": {"text": "In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.", "entity1": "methyldopa", "entity2": "hepatic dysfunction", "span1": [73, 83], "span2": [88, 107]}, "bert_text": "In this latter patient, and in 2 others, the causal relationship between <e1> methyldopa </e1> and <e2> hepatic dysfunction </e2> was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2312": {"data": {"text": "In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.", "entity1": "methyldopa", "entity2": "hepatitis", "span1": [73, 83], "span2": [142, 151]}, "bert_text": "In this latter patient, and in 2 others, the causal relationship between <e1> methyldopa </e1> and hepatic dysfunction was proved with the recurrence of <e2> hepatitis </e2> within 2 weeks of re-exposure to the drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2313": {"data": {"text": "To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.", "entity1": "zidovudine", "entity2": "AIDS", "span1": [197, 207], "span2": [87, 91]}, "bert_text": "To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of <e1> zidovudine </e1> <e2> AIDS </e2> mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2314": {"data": {"text": "To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.", "entity1": "lamivudine", "entity2": "AIDS", "span1": [209, 219], "span2": [87, 91]}, "bert_text": "To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, <e1> lamivudine </e1> <e2> AIDS </e2> mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2315": {"data": {"text": "To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.", "entity1": "indinavir", "entity2": "AIDS", "span1": [225, 234], "span2": [87, 91]}, "bert_text": "To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and <e1> indinavir </e1> <e2> AIDS </e2> mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2316": {"data": {"text": "A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ.", "entity1": "glucaric acid", "entity2": "infarct", "span1": [48, 61], "span2": [6, 13]}, "bert_text": "A new infarct-avid radiopharmaceutical based on <e1> glucaric acid </e1> <e2> infarct </e2>-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2317": {"data": {"text": "Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.\n", "entity1": "angiotensin", "entity2": "renal insufficiency", "span1": [27, 38], "span2": [86, 105]}, "bert_text": "Effects of an inhibitor of <e1> angiotensin </e1> converting enzyme (Captopril) on pulmonary and <e2> renal insufficiency </e2> due to intravascular coagulation in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2318": {"data": {"text": "Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.\n", "entity1": "angiotensin", "entity2": "intravascular coagulation", "span1": [27, 38], "span2": [113, 138]}, "bert_text": "Effects of an inhibitor of <e1> angiotensin </e1> converting enzyme (Captopril) on pulmonary and renal insufficiency due to <e2> intravascular coagulation </e2> in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2319": {"data": {"text": "After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.", "entity1": "PGE1", "entity2": "hypotension", "span1": [15, 19], "span2": [151, 162]}, "bert_text": "After starting <e1> PGE1 </e1> or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of <e2> hypotension </e2> due to PGE1 remained constant until 60 min after its discontinuation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2320": {"data": {"text": "After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.", "entity1": "PGE1", "entity2": "hypotension", "span1": [170, 174], "span2": [151, 162]}, "bert_text": "After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to <e1> PGE1 </e1> <e2> hypotension </e2> due to PGE1 remained constant until 60 min after its discontinuation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2321": {"data": {"text": "After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.", "entity1": "TMP", "entity2": "hypotension", "span1": [23, 26], "span2": [151, 162]}, "bert_text": "After starting PGE1 or <e1> TMP </e1>, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of <e2> hypotension </e2> due to PGE1 remained constant until 60 min after its discontinuation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2322": {"data": {"text": "Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.", "entity1": "netilmicin", "entity2": "Ototoxicity", "span1": [42, 52], "span2": [0, 11]}, "bert_text": "Ototoxicity occurred in four (9.5%) of 42 <e1> netilmicin </e1> <e2> Ototoxicity </e2> occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2323": {"data": {"text": "Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.", "entity1": "piperacillin", "entity2": "Ototoxicity", "span1": [57, 69], "span2": [0, 11]}, "bert_text": "Ototoxicity occurred in four (9.5%) of 42 netilmicin and <e1> piperacillin </e1> <e2> Ototoxicity </e2> occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2324": {"data": {"text": "Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.", "entity1": "piperacillin", "entity2": "Ototoxicity", "span1": [107, 119], "span2": [0, 11]}, "bert_text": "Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and <e1> piperacillin </e1> <e2> Ototoxicity </e2> occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2325": {"data": {"text": "Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.", "entity1": "tobramycin", "entity2": "Ototoxicity", "span1": [92, 102], "span2": [0, 11]}, "bert_text": "Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 <e1> tobramycin </e1> <e2> Ototoxicity </e2> occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2326": {"data": {"text": "The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.", "entity1": "ifosfamide", "entity2": "malignant mesenchymal tumors", "span1": [121, 131], "span2": [39, 67]}, "bert_text": "The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same <e1> ifosfamide </e1> <e2> malignant mesenchymal tumors </e2> in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2327": {"data": {"text": "The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.", "entity1": "ifosfamide", "entity2": "Tumor", "span1": [121, 131], "span2": [221, 226]}, "bert_text": "The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same <e1> ifosfamide </e1> chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal <e2> Tumor </e2> Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2328": {"data": {"text": "One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.", "entity1": "losartan", "entity2": "anuria", "span1": [28, 36], "span2": [146, 152]}, "bert_text": "One week later, by mistake, <e1> losartan </e1> was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient <e2> anuria </e2> lasting 10 hours.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2329": {"data": {"text": "The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.", "entity1": "adriamycin", "entity2": "heart failure", "span1": [119, 129], "span2": [94, 107]}, "bert_text": "The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by <e1> adriamycin </e1> <e2> heart failure </e2> induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2330": {"data": {"text": "The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.", "entity1": "adriamycin", "entity2": "heart failure", "span1": [119, 129], "span2": [185, 198]}, "bert_text": "The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by <e1> adriamycin </e1>, so that we can develop a novel treatment strategy for <e2> heart failure </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2331": {"data": {"text": "It is longer acting than physostigmine and is used in anaesthesia to reverse the non-depolarizing neuromuscular block.", "entity1": "physostigmine", "entity2": "neuromuscular block", "span1": [25, 38], "span2": [98, 117]}, "bert_text": "It is longer acting than <e1> physostigmine </e1> and is used in anaesthesia to reverse the non-depolarizing <e2> neuromuscular block </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2332": {"data": {"text": "Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.", "entity1": "AAP", "entity2": "hepatitis", "span1": [38, 41], "span2": [50, 59]}, "bert_text": "Our results provide evidence that the <e1> AAP </e1>-induced <e2> hepatitis </e2> and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2333": {"data": {"text": "Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.", "entity1": "ethanol", "entity2": "hepatitis", "span1": [84, 91], "span2": [50, 59]}, "bert_text": "Our results provide evidence that the AAP-induced hepatitis and its exacerbation by <e1> ethanol </e1> <e2> hepatitis </e2> and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2334": {"data": {"text": "Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.", "entity1": "NAA", "entity2": "hepatitis", "span1": [151, 154], "span2": [50, 59]}, "bert_text": "Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by <e1> NAA </e1> <e2> hepatitis </e2> and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2335": {"data": {"text": "Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.", "entity1": "NAD", "entity2": "hepatitis", "span1": [205, 208], "span2": [50, 59]}, "bert_text": "Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate <e1> NAD </e1> <e2> hepatitis </e2> and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2336": {"data": {"text": "CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.", "entity1": "Pemoline", "entity2": "movement disorder", "span1": [12, 20], "span2": [32, 49]}, "bert_text": "CONCLUSION: <e1> Pemoline </e1> associated <e2> movement disorder </e2> has been rarely reported in the acute toxicology literature.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2337": {"data": {"text": "CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.", "entity1": "COCs", "entity2": "VTE", "span1": [79, 83], "span2": [53, 56]}, "bert_text": "CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on <e1> COCs </e1> <e2> VTE </e2> among Danish women on COCs is similar to that among women taking CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"2338": {"data": {"text": "CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.", "entity1": "CPA", "entity2": "VTE", "span1": [122, 125], "span2": [53, 56]}, "bert_text": "CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking <e1> CPA </e1> <e2> VTE </e2> among Danish women on COCs is similar to that among women taking CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"2339": {"data": {"text": "CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.", "entity1": "EE", "entity2": "VTE", "span1": [126, 128], "span2": [53, 56]}, "bert_text": "CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/<e1> EE </e1> <e2> VTE </e2> among Danish women on COCs is similar to that among women taking CPA/EE.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"2340": {"data": {"text": "After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia.", "entity1": "phenylephrine", "entity2": "hypotensive", "span1": [120, 133], "span2": [143, 154]}, "bert_text": "After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as <e1> phenylephrine </e1> to treat <e2> hypotensive </e2> patients with tachycardia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2341": {"data": {"text": "After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia.", "entity1": "phenylephrine", "entity2": "tachycardia", "span1": [120, 133], "span2": [169, 180]}, "bert_text": "After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as <e1> phenylephrine </e1> to treat hypotensive patients with <e2> tachycardia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2342": {"data": {"text": "QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [27, 38], "span2": [47, 55]}, "bert_text": "QTLs for susceptibility to <e1> pilocarpine </e1>-induced <e2> seizures </e2>, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2343": {"data": {"text": "QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [27, 38], "span2": [166, 173]}, "bert_text": "QTLs for susceptibility to <e1> pilocarpine </e1>-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize <e2> seizure </e2> susceptibility genes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2344": {"data": {"text": "QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.", "entity1": "pilocarpine", "entity2": "temporal lobe epilepsy", "span1": [27, 38], "span2": [68, 90]}, "bert_text": "QTLs for susceptibility to <e1> pilocarpine </e1>-induced seizures, a model of <e2> temporal lobe epilepsy </e2>, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2345": {"data": {"text": "In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.", "entity1": "estradiol", "entity2": "DM", "span1": [52, 61], "span2": [98, 100]}, "bert_text": "In this case, the authors postulate that the use of <e1> estradiol </e1> and progesterone and the underlying <e2> DM </e2> increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2346": {"data": {"text": "In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.", "entity1": "estradiol", "entity2": "thrombosis", "span1": [52, 61], "span2": [177, 187]}, "bert_text": "In this case, the authors postulate that the use of <e1> estradiol </e1> and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for <e2> thrombosis </e2> of both the ICA and the venous sinus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2347": {"data": {"text": "In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.", "entity1": "estradiol", "entity2": "ICA", "span1": [52, 61], "span2": [200, 203]}, "bert_text": "In this case, the authors postulate that the use of <e1> estradiol </e1> and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the <e2> ICA </e2> and the venous sinus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2348": {"data": {"text": "In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.", "entity1": "progesterone", "entity2": "DM", "span1": [66, 78], "span2": [98, 100]}, "bert_text": "In this case, the authors postulate that the use of estradiol and <e1> progesterone </e1> and the underlying <e2> DM </e2> increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2349": {"data": {"text": "In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.", "entity1": "progesterone", "entity2": "thrombosis", "span1": [66, 78], "span2": [177, 187]}, "bert_text": "In this case, the authors postulate that the use of estradiol and <e1> progesterone </e1> and the underlying DM increased vascular thrombogenicity, which provided a common denominator for <e2> thrombosis </e2> of both the ICA and the venous sinus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2350": {"data": {"text": "In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.", "entity1": "progesterone", "entity2": "ICA", "span1": [66, 78], "span2": [200, 203]}, "bert_text": "In this case, the authors postulate that the use of estradiol and <e1> progesterone </e1> and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the <e2> ICA </e2> and the venous sinus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2351": {"data": {"text": "Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.", "entity1": "sodium pentothal", "entity2": "cerebral ischaemia", "span1": [59, 75], "span2": [114, 132]}, "bert_text": "Following major intracranial surgery in a 35-year-old man, <e1> sodium pentothal </e1> was intravenously infused to minimize <e2> cerebral ischaemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2352": {"data": {"text": "Hypothyroidism developed in eight patients while they were taking lithium.", "entity1": "lithium", "entity2": "Hypothyroidism", "span1": [66, 73], "span2": [0, 14]}, "bert_text": "Hypothyroidism developed in eight patients while they were taking <e1> lithium </e1> <e2> Hypothyroidism </e2> developed in eight patients while they were taking lithium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2353": {"data": {"text": "Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.\n", "entity1": "mesna", "entity2": "hemorrhagic cystitis", "span1": [42, 47], "span2": [78, 98]}, "bert_text": "Continuous subcutaneous administration of <e1> mesna </e1> to prevent ifosfamide-induced <e2> hemorrhagic cystitis </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2354": {"data": {"text": "Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.\n", "entity1": "ifosfamide", "entity2": "hemorrhagic cystitis", "span1": [59, 69], "span2": [78, 98]}, "bert_text": "Continuous subcutaneous administration of mesna to prevent <e1> ifosfamide </e1>-induced <e2> hemorrhagic cystitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2355": {"data": {"text": "METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.", "entity1": "3-methyladenine", "entity2": "heart failure", "span1": [9, 24], "span2": [80, 93]}, "bert_text": "METHODS: <e1> 3-methyladenine </e1> (3MA), a specific inhibitor on autophagy was used in a <e2> heart failure </e2> model of rats induced by adriamycin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2356": {"data": {"text": "METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.", "entity1": "3MA", "entity2": "heart failure", "span1": [26, 29], "span2": [80, 93]}, "bert_text": "METHODS: 3-methyladenine (<e1> 3MA </e1>), a specific inhibitor on autophagy was used in a <e2> heart failure </e2> model of rats induced by adriamycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2357": {"data": {"text": "METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.", "entity1": "adriamycin", "entity2": "heart failure", "span1": [119, 129], "span2": [80, 93]}, "bert_text": "METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by <e1> adriamycin </e1> <e2> heart failure </e2> model of rats induced by adriamycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2358": {"data": {"text": "Variant ventricular tachycardia in desipramine toxicity.\n", "entity1": "desipramine", "entity2": "ventricular tachycardia", "span1": [35, 46], "span2": [8, 31]}, "bert_text": "Variant ventricular tachycardia in <e1> desipramine </e1> <e2> ventricular tachycardia </e2> in desipramine toxicity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2359": {"data": {"text": "Variant ventricular tachycardia in desipramine toxicity.\n", "entity1": "desipramine", "entity2": "toxicity", "span1": [35, 46], "span2": [47, 55]}, "bert_text": "Variant ventricular tachycardia in <e1> desipramine </e1> <e2> toxicity </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2360": {"data": {"text": "Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.\n", "entity1": "Octreotide", "entity2": "hypoxemia", "span1": [0, 10], "span2": [19, 28]}, "bert_text": "<e1> Octreotide </e1>-induced <e2> hypoxemia </e2> and pulmonary hypertension in premature neonates.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2361": {"data": {"text": "Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.\n", "entity1": "Octreotide", "entity2": "pulmonary hypertension", "span1": [0, 10], "span2": [33, 55]}, "bert_text": "<e1> Octreotide </e1>-induced hypoxemia and <e2> pulmonary hypertension </e2> in premature neonates.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2362": {"data": {"text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.", "entity1": "crocin", "entity2": "cognitive deficits", "span1": [70, 76], "span2": [108, 126]}, "bert_text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of <e1> crocin </e1> (30 mg/kg) in antagonizing the <e2> cognitive deficits </e2> caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2363": {"data": {"text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.", "entity1": "crocin", "entity2": "neurodegenerative diseases", "span1": [70, 76], "span2": [191, 217]}, "bert_text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of <e1> crocin </e1> (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of <e2> neurodegenerative diseases </e2> such as Alzheimer's disease.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2364": {"data": {"text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.", "entity1": "crocin", "entity2": "Alzheimer's disease", "span1": [70, 76], "span2": [226, 245]}, "bert_text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of <e1> crocin </e1> (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as <e2> Alzheimer's disease </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2365": {"data": {"text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.", "entity1": "STZ", "entity2": "cognitive deficits", "span1": [137, 140], "span2": [108, 126]}, "bert_text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by <e1> STZ </e1> <e2> cognitive deficits </e2> caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2366": {"data": {"text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.", "entity1": "STZ", "entity2": "neurodegenerative diseases", "span1": [137, 140], "span2": [191, 217]}, "bert_text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by <e1> STZ </e1>-icv in rats and its potential in the treatment of <e2> neurodegenerative diseases </e2> such as Alzheimer's disease.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2367": {"data": {"text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.", "entity1": "STZ", "entity2": "Alzheimer's disease", "span1": [137, 140], "span2": [226, 245]}, "bert_text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by <e1> STZ </e1>-icv in rats and its potential in the treatment of neurodegenerative diseases such as <e2> Alzheimer's disease </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2368": {"data": {"text": "There is no difference in breast-cancer frequency between the placebo (22 cases) and tamoxifen (19) arms.", "entity1": "tamoxifen", "entity2": "breast-cancer", "span1": [85, 94], "span2": [26, 39]}, "bert_text": "There is no difference in breast-cancer frequency between the placebo (22 cases) and <e1> tamoxifen </e1> <e2> breast-cancer </e2> frequency between the placebo (22 cases) and tamoxifen (19) arms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2369": {"data": {"text": "Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.\n", "entity1": "metoclopramide", "entity2": "Cardiac arrest", "span1": [33, 47], "span2": [0, 14]}, "bert_text": "Cardiac arrest after intravenous <e1> metoclopramide </e1> <e2> Cardiac arrest </e2> after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2370": {"data": {"text": "Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.\n", "entity1": "metoclopramide", "entity2": "cardiac arrest", "span1": [33, 47], "span2": [128, 142]}, "bert_text": "Cardiac arrest after intravenous <e1> metoclopramide </e1> - a case of five repeated injections of metoclopramide causing five episodes of <e2> cardiac arrest </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2371": {"data": {"text": "Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.\n", "entity1": "metoclopramide", "entity2": "Cardiac arrest", "span1": [88, 102], "span2": [0, 14]}, "bert_text": "Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of <e1> metoclopramide </e1> <e2> Cardiac arrest </e2> after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2372": {"data": {"text": "Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.\n", "entity1": "metoclopramide", "entity2": "cardiac arrest", "span1": [88, 102], "span2": [128, 142]}, "bert_text": "Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of <e1> metoclopramide </e1> causing five episodes of <e2> cardiac arrest </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2373": {"data": {"text": "All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.", "entity1": "hepatitis B surface antigen", "entity2": "hepatitis B", "span1": [29, 56], "span2": [88, 99]}, "bert_text": "All infants who were born to <e1> hepatitis B surface antigen </e1>-positive mothers also received <e2> hepatitis B </e2> immune globulin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2374": {"data": {"text": "In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.", "entity1": "DA", "entity2": "dopaminergic deficits", "span1": [86, 88], "span2": [119, 140]}, "bert_text": "In addition, we demonstrate that mice genetically engineered to have unilateral brain <e1> DA </e1> deficits develop METH-induced <e2> dopaminergic deficits </e2> that are of comparable magnitude on both sides of the brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2375": {"data": {"text": "In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.", "entity1": "METH", "entity2": "dopaminergic deficits", "span1": [106, 110], "span2": [119, 140]}, "bert_text": "In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop <e1> METH </e1>-induced <e2> dopaminergic deficits </e2> that are of comparable magnitude on both sides of the brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2376": {"data": {"text": "BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.", "entity1": "alcohol", "entity2": "hepatotoxicity", "span1": [33, 40], "span2": [63, 77]}, "bert_text": "BACKGROUND: The possible role of <e1> alcohol </e1> in the development of <e2> hepatotoxicity </e2> associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2377": {"data": {"text": "BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.", "entity1": "paracetamol", "entity2": "hepatotoxicity", "span1": [115, 126], "span2": [63, 77]}, "bert_text": "BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of <e1> paracetamol </e1> <e2> hepatotoxicity </e2> associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2378": {"data": {"text": "BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.", "entity1": "acetaminophen", "entity2": "hepatotoxicity", "span1": [128, 141], "span2": [63, 77]}, "bert_text": "BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (<e1> acetaminophen </e1> <e2> hepatotoxicity </e2> associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2379": {"data": {"text": "In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.", "entity1": "enflurane", "entity2": "seizures", "span1": [16, 25], "span2": [103, 111]}, "bert_text": "In one patient, <e1> enflurane </e1> administered during a donor nephrectomy resulted in unexpected partial motor <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2380": {"data": {"text": "Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.", "entity1": "fluorescein", "entity2": "telangiectasis", "span1": [7, 18], "span2": [71, 85]}, "bert_text": "Fundus <e1> fluorescein </e1> angiography confirmed macular capillary closure and <e2> telangiectasis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2381": {"data": {"text": "OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.", "entity1": "risperidone", "entity2": "hyperprolactinemia", "span1": [73, 84], "span2": [93, 111]}, "bert_text": "OBJECTIVE: The aim of the present study was to investigate the effect of <e1> risperidone </e1>-induced <e2> hyperprolactinemia </e2> on trabecular bone mineral density (BMD) in children and adolescents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2382": {"data": {"text": "Sulpiride-induced tardive dystonia.\n", "entity1": "Sulpiride", "entity2": "tardive dystonia", "span1": [0, 9], "span2": [18, 34]}, "bert_text": "<e1> Sulpiride </e1>-induced <e2> tardive dystonia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2383": {"data": {"text": "Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.\n", "entity1": "ribavirin", "entity2": "adenovirus disease", "span1": [12, 21], "span2": [43, 61]}, "bert_text": "Intravenous <e1> ribavirin </e1> treatment for severe <e2> adenovirus disease </e2> in immunocompromised children.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2384": {"data": {"text": "We have encountered several patients who developed substantial proteinuria associated with sirolimus use.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [91, 100], "span2": [63, 74]}, "bert_text": "We have encountered several patients who developed substantial proteinuria associated with <e1> sirolimus </e1> <e2> proteinuria </e2> associated with sirolimus use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2385": {"data": {"text": "Proteinuria may improve, but does not resolve, when sirolimus is withdrawn.", "entity1": "sirolimus", "entity2": "Proteinuria", "span1": [52, 61], "span2": [0, 11]}, "bert_text": "Proteinuria may improve, but does not resolve, when <e1> sirolimus </e1> <e2> Proteinuria </e2> may improve, but does not resolve, when sirolimus is withdrawn.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2386": {"data": {"text": "Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats.\n", "entity1": "penicillin", "entity2": "epileptic", "span1": [86, 96], "span2": [62, 71]}, "bert_text": "Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in <e1> penicillin </e1> <e2> epileptic </e2> discharges in penicillin - induced epilepsy model in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2387": {"data": {"text": "Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats.\n", "entity1": "penicillin", "entity2": "epilepsy", "span1": [86, 96], "span2": [107, 115]}, "bert_text": "Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in <e1> penicillin </e1> - induced <e2> epilepsy </e2> model in rats.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2388": {"data": {"text": "Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.", "entity1": "chloroacetaldehyde", "entity2": "hemorrhagic cystitis", "span1": [40, 58], "span2": [223, 243]}, "bert_text": "Based on clinical data, indicating that <e1> chloroacetaldehyde </e1> (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of <e2> hemorrhagic cystitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2389": {"data": {"text": "Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.", "entity1": "CAA", "entity2": "hemorrhagic cystitis", "span1": [60, 63], "span2": [223, 243]}, "bert_text": "Based on clinical data, indicating that chloroacetaldehyde (<e1> CAA </e1>) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of <e2> hemorrhagic cystitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2390": {"data": {"text": "Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.", "entity1": "CAA", "entity2": "hemorrhagic cystitis", "span1": [197, 200], "span2": [223, 243]}, "bert_text": "Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of <e1> CAA </e1> in the development of <e2> hemorrhagic cystitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2391": {"data": {"text": "This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.", "entity1": "D-penicillamine", "entity2": "RPGN", "span1": [39, 54], "span2": [17, 21]}, "bert_text": "This new case of RPGN in the course of <e1> D-penicillamine </e1> <e2> RPGN </e2> in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2392": {"data": {"text": "This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.", "entity1": "D-penicillamine", "entity2": "proteinuria", "span1": [39, 54], "span2": [166, 177]}, "bert_text": "This new case of RPGN in the course of <e1> D-penicillamine </e1> treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and <e2> proteinuria </e2> in these patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2393": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "folate", "entity2": "coronary artery disease", "span1": [298, 304], "span2": [98, 121]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of <e1> folate </e1> <e2> coronary artery disease </e2> were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2394": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "folate", "entity2": "cardiovascular disease", "span1": [298, 304], "span2": [190, 212]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of <e1> folate </e1> <e2> cardiovascular disease </e2> risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2395": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "folate", "entity2": "cardiovascular disease", "span1": [298, 304], "span2": [373, 395]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of <e1> folate </e1>, vitamin E, and beta-carotene, the adjusted relative risks of total <e2> cardiovascular disease </e2> mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2396": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "folate", "entity2": "diabetes", "span1": [298, 304], "span2": [235, 243]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of <e1> folate </e1> <e2> diabetes </e2> medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2397": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "folate", "entity2": "diabetes", "span1": [298, 304], "span2": [273, 281]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of <e1> folate </e1> <e2> diabetes </e2>, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2398": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "vitamin E", "entity2": "coronary artery disease", "span1": [306, 315], "span2": [98, 121]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, <e1> vitamin E </e1> <e2> coronary artery disease </e2> were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2399": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "vitamin E", "entity2": "cardiovascular disease", "span1": [306, 315], "span2": [190, 212]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, <e1> vitamin E </e1> <e2> cardiovascular disease </e2> risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2400": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "vitamin E", "entity2": "cardiovascular disease", "span1": [306, 315], "span2": [373, 395]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, <e1> vitamin E </e1>, and beta-carotene, the adjusted relative risks of total <e2> cardiovascular disease </e2> mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2401": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "vitamin E", "entity2": "diabetes", "span1": [306, 315], "span2": [235, 243]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, <e1> vitamin E </e1> <e2> diabetes </e2> medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2402": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "vitamin E", "entity2": "diabetes", "span1": [306, 315], "span2": [273, 281]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, <e1> vitamin E </e1> <e2> diabetes </e2>, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2403": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "beta-carotene", "entity2": "coronary artery disease", "span1": [321, 334], "span2": [98, 121]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and <e1> beta-carotene </e1> <e2> coronary artery disease </e2> were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2404": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "beta-carotene", "entity2": "cardiovascular disease", "span1": [321, 334], "span2": [190, 212]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and <e1> beta-carotene </e1> <e2> cardiovascular disease </e2> risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2405": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "beta-carotene", "entity2": "cardiovascular disease", "span1": [321, 334], "span2": [373, 395]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and <e1> beta-carotene </e1>, the adjusted relative risks of total <e2> cardiovascular disease </e2> mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2406": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "beta-carotene", "entity2": "diabetes", "span1": [321, 334], "span2": [235, 243]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and <e1> beta-carotene </e1> <e2> diabetes </e2> medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2407": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "beta-carotene", "entity2": "diabetes", "span1": [321, 334], "span2": [273, 281]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and <e1> beta-carotene </e1> <e2> diabetes </e2>, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2408": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "vitamin C", "entity2": "coronary artery disease", "span1": [490, 499], "span2": [98, 121]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total <e1> vitamin C </e1> <e2> coronary artery disease </e2> were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2409": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "vitamin C", "entity2": "cardiovascular disease", "span1": [490, 499], "span2": [190, 212]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total <e1> vitamin C </e1> <e2> cardiovascular disease </e2> risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2410": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "vitamin C", "entity2": "cardiovascular disease", "span1": [490, 499], "span2": [373, 395]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total <e1> vitamin C </e1> <e2> cardiovascular disease </e2> mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2411": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "vitamin C", "entity2": "diabetes", "span1": [490, 499], "span2": [235, 243]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total <e1> vitamin C </e1> <e2> diabetes </e2> medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2412": {"data": {"text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity1": "vitamin C", "entity2": "diabetes", "span1": [490, 499], "span2": [273, 281]}, "bert_text": "Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total <e1> vitamin C </e1> <e2> diabetes </e2>, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2413": {"data": {"text": "In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.", "entity1": "cocaine", "entity2": "chest pain", "span1": [31, 38], "span2": [50, 60]}, "bert_text": "In particular, the tendency of <e1> cocaine </e1> to produce <e2> chest pain </e2> ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2414": {"data": {"text": "In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.", "entity1": "cocaine", "entity2": "chest pain", "span1": [31, 38], "span2": [142, 152]}, "bert_text": "In particular, the tendency of <e1> cocaine </e1> to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of <e2> chest pain </e2> who is otherwise at low risk.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2415": {"data": {"text": "Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).", "entity1": "netilmicin", "entity2": "Nephrotoxicity", "span1": [73, 83], "span2": [0, 14]}, "bert_text": "Nephrotoxicity occurred in a similar proportion in patients treated with <e1> netilmicin </e1> <e2> Nephrotoxicity </e2> occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2416": {"data": {"text": "Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).", "entity1": "tobramycin", "entity2": "Nephrotoxicity", "span1": [88, 98], "span2": [0, 14]}, "bert_text": "Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and <e1> tobramycin </e1> <e2> Nephrotoxicity </e2> occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2417": {"data": {"text": "Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy.", "entity1": "lamivudine", "entity2": "cancer", "span1": [37, 47], "span2": [131, 137]}, "bert_text": "Our study suggests that prophylactic <e1> lamivudine </e1> significantly decreases the incidence of HBV reactivation and overall morbidity in <e2> cancer </e2> patients during and after immunosuppressive therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2418": {"data": {"text": "In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.", "entity1": "suprofen", "entity2": "acute declines", "span1": [12, 20], "span2": [28, 42]}, "bert_text": "In summary, <e1> suprofen </e1> causes <e2> acute declines </e2> in renal function, most likely by directly altering the intrarenal distribution of uric acid.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2419": {"data": {"text": "In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.", "entity1": "uric acid", "entity2": "acute declines", "span1": [126, 135], "span2": [28, 42]}, "bert_text": "In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of <e1> uric acid </e1> <e2> acute declines </e2> in renal function, most likely by directly altering the intrarenal distribution of uric acid.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2420": {"data": {"text": "A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.", "entity1": "propylthio- uracil", "entity2": "pericarditis", "span1": [116, 134], "span2": [49, 61]}, "bert_text": "A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with <e1> propylthio- uracil </e1> <e2> pericarditis </e2> in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2421": {"data": {"text": "A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.", "entity1": "propylthio- uracil", "entity2": "vasculitis", "span1": [116, 134], "span2": [89, 99]}, "bert_text": "A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with <e1> propylthio- uracil </e1> <e2> vasculitis </e2> associated with propylthio- uracil therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2422": {"data": {"text": "The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.", "entity1": "fenoldopam", "entity2": "hypotension", "span1": [20, 30], "span2": [55, 66]}, "bert_text": "The hypothesis that <e1> fenoldopam </e1> could be used to induce <e2> hypotension </e2> and preserve blood flow to the kidney was tested.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2423": {"data": {"text": "Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.\n", "entity1": "Clomipramine", "entity2": "sleep disturbance", "span1": [0, 12], "span2": [21, 38]}, "bert_text": "<e1> Clomipramine </e1>-induced <e2> sleep disturbance </e2> does not impair its prolactin-releasing action.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2424": {"data": {"text": "Nephrolithiasis is a complication of acetazolamide but does not preclude its use.", "entity1": "acetazolamide", "entity2": "Nephrolithiasis", "span1": [37, 50], "span2": [0, 15]}, "bert_text": "Nephrolithiasis is a complication of <e1> acetazolamide </e1> <e2> Nephrolithiasis </e2> is a complication of acetazolamide but does not preclude its use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2425": {"data": {"text": "Stroke associated with cocaine use.\n", "entity1": "cocaine", "entity2": "Stroke", "span1": [23, 30], "span2": [0, 6]}, "bert_text": "Stroke associated with <e1> cocaine </e1> <e2> Stroke </e2> associated with cocaine use.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2426": {"data": {"text": "After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.", "entity1": "cholesterol", "entity2": "gall stone", "span1": [173, 184], "span2": [115, 125]}, "bert_text": "After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were <e1> cholesterol </e1> <e2> gall stone </e2> dissolution, suggesting that their stones were cholesterol rich.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2427": {"data": {"text": "To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy.", "entity1": "amiodarone", "entity2": "myxedema coma", "span1": [111, 121], "span2": [80, 93]}, "bert_text": "To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term <e1> amiodarone </e1> <e2> myxedema coma </e2> during long term amiodarone therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2428": {"data": {"text": "We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.", "entity1": "ifosfamide", "entity2": "myoclonus", "span1": [146, 156], "span2": [79, 88]}, "bert_text": "We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of <e1> ifosfamide </e1> <e2> myoclonus </e2> of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2429": {"data": {"text": "We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.", "entity1": "ifosfamide", "entity2": "plasmacytoma", "span1": [146, 156], "span2": [161, 173]}, "bert_text": "We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of <e1> ifosfamide </e1> for <e2> plasmacytoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2430": {"data": {"text": "A deficient L-arginine-nitric oxide system is implicated in cortisol-induced hypertension.", "entity1": "nitric oxide", "entity2": "hypertension", "span1": [23, 35], "span2": [77, 89]}, "bert_text": "A deficient L-arginine-<e1> nitric oxide </e1> system is implicated in cortisol-induced <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2431": {"data": {"text": "A deficient L-arginine-nitric oxide system is implicated in cortisol-induced hypertension.", "entity1": "cortisol", "entity2": "hypertension", "span1": [60, 68], "span2": [77, 89]}, "bert_text": "A deficient L-arginine-nitric oxide system is implicated in <e1> cortisol </e1>-induced <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2432": {"data": {"text": "A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.", "entity1": "steroid", "entity2": "nephrotic syndrome", "span1": [126, 133], "span2": [32, 50]}, "bert_text": "A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to <e1> steroid </e1> <e2> nephrotic syndrome </e2> due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2433": {"data": {"text": "A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.", "entity1": "steroid", "entity2": "glomerulosclerosis", "span1": [126, 133], "span2": [74, 92]}, "bert_text": "A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to <e1> steroid </e1> <e2> glomerulosclerosis </e2> was initially responding well to steroid therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2434": {"data": {"text": "Role of xanthine oxidase in dexamethasone-induced hypertension in rats.\n1.", "entity1": "xanthine", "entity2": "hypertension", "span1": [8, 16], "span2": [50, 62]}, "bert_text": "Role of <e1> xanthine </e1> oxidase in dexamethasone-induced <e2> hypertension </e2> in rats.\n1.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2435": {"data": {"text": "Role of xanthine oxidase in dexamethasone-induced hypertension in rats.\n1.", "entity1": "dexamethasone", "entity2": "hypertension", "span1": [28, 41], "span2": [50, 62]}, "bert_text": "Role of xanthine oxidase in <e1> dexamethasone </e1>-induced <e2> hypertension </e2> in rats.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2436": {"data": {"text": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "entity1": "fluoxetine", "entity2": "akathisia", "span1": [107, 117], "span2": [55, 64]}, "bert_text": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of <e1> fluoxetine </e1> <e2> akathisia </e2> in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2437": {"data": {"text": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "entity1": "fluoxetine", "entity2": "akathisia", "span1": [107, 117], "span2": [126, 135]}, "bert_text": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of <e1> fluoxetine </e1>-induced <e2> akathisia </e2> were identical, although somewhat milder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2438": {"data": {"text": "Valproate-induced encephalopathy.\n", "entity1": "Valproate", "entity2": "encephalopathy", "span1": [0, 9], "span2": [18, 32]}, "bert_text": "<e1> Valproate </e1>-induced <e2> encephalopathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2439": {"data": {"text": "The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.", "entity1": "ketamine", "entity2": "schizophrenia", "span1": [221, 229], "span2": [101, 114]}, "bert_text": "The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist <e1> ketamine </e1> <e2> schizophrenia </e2>. Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2440": {"data": {"text": "The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.", "entity1": "ketamine", "entity2": "schizophrenia", "span1": [221, 229], "span2": [296, 309]}, "bert_text": "The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist <e1> ketamine </e1> leads to psychopathological symptoms similar to those observed in <e2> schizophrenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2441": {"data": {"text": "Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.", "entity1": "corticosteroids", "entity2": "uveitis", "span1": [149, 164], "span2": [65, 72]}, "bert_text": "Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with <e1> corticosteroids </e1> <e2> uveitis </e2> did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2442": {"data": {"text": "Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper.", "entity1": "heparin", "entity2": "bruising", "span1": [34, 41], "span2": [18, 26]}, "bert_text": "Dimensions of the bruising on the <e1> heparin </e1> <e2> bruising </e2> on the heparin applied areas were measured using transparent millimetric measuring paper.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2443": {"data": {"text": "Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.", "entity1": "HOE 140", "entity2": "toxic neuropathy", "span1": [80, 87], "span2": [111, 127]}, "bert_text": "Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of <e1> HOE 140 </e1> or des-Arg10HOE 140 in <e2> toxic neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2444": {"data": {"text": "Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.", "entity1": "des-Arg10HOE 140", "entity2": "toxic neuropathy", "span1": [91, 107], "span2": [111, 127]}, "bert_text": "Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or <e1> des-Arg10HOE 140 </e1> in <e2> toxic neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2445": {"data": {"text": "Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.", "entity1": "nitric oxide", "entity2": "hypertension", "span1": [74, 86], "span2": [23, 35]}, "bert_text": "Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with <e1> nitric oxide </e1> <e2> hypertension </e2> (GC-HT) in the rat is associated with nitric oxide-redox imbalance.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2446": {"data": {"text": "Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.", "entity1": "nitric oxide", "entity2": "HT", "span1": [74, 86], "span2": [40, 42]}, "bert_text": "Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with <e1> nitric oxide </e1> <e2> HT </e2>) in the rat is associated with nitric oxide-redox imbalance.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2447": {"data": {"text": "The possible mechanism is depression of rapidly activating delayed rectifier potassium currents.", "entity1": "potassium", "entity2": "depression", "span1": [77, 86], "span2": [26, 36]}, "bert_text": "The possible mechanism is depression of rapidly activating delayed rectifier <e1> potassium </e1> <e2> depression </e2> of rapidly activating delayed rectifier potassium currents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2448": {"data": {"text": "The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.", "entity1": "clomipramine", "entity2": "sleep disturbance", "span1": [86, 98], "span2": [56, 73]}, "bert_text": "The present study was undertaken to examine the role of sleep disturbance, induced by <e1> clomipramine </e1> <e2> sleep disturbance </e2>, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2449": {"data": {"text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).", "entity1": "crack cocaine", "entity2": "pupillary oscillation", "span1": [94, 107], "span2": [12, 33]}, "bert_text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent <e1> crack cocaine </e1> <e2> pupillary oscillation </e2> were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"2450": {"data": {"text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).", "entity1": "crack cocaine", "entity2": "CIP", "span1": [94, 107], "span2": [131, 134]}, "bert_text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent <e1> crack cocaine </e1> abusers endorsing past <e2> CIP </e2> (n = 32) from another group of crack addicts who denied past CIP (n = 29).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2451": {"data": {"text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).", "entity1": "crack cocaine", "entity2": "CIP", "span1": [94, 107], "span2": [196, 199]}, "bert_text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent <e1> crack cocaine </e1> abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past <e2> CIP </e2> (n = 29).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2452": {"data": {"text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).", "entity1": "crack", "entity2": "pupillary oscillation", "span1": [166, 171], "span2": [12, 33]}, "bert_text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of <e1> crack </e1> <e2> pupillary oscillation </e2> were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2453": {"data": {"text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).", "entity1": "crack", "entity2": "CIP", "span1": [166, 171], "span2": [131, 134]}, "bert_text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of <e1> crack </e1> <e2> CIP </e2> (n = 32) from another group of crack addicts who denied past CIP (n = 29).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2454": {"data": {"text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).", "entity1": "crack", "entity2": "CIP", "span1": [166, 171], "span2": [196, 199]}, "bert_text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of <e1> crack </e1> addicts who denied past <e2> CIP </e2> (n = 29).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2455": {"data": {"text": "Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.", "entity1": "TAM", "entity2": "Hemolysis", "span1": [20, 23], "span2": [0, 9]}, "bert_text": "Hemolysis caused by <e1> TAM </e1> <e2> Hemolysis </e2> caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2456": {"data": {"text": "Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.", "entity1": "TAM", "entity2": "hemolysis", "span1": [20, 23], "span2": [131, 140]}, "bert_text": "Hemolysis caused by <e1> TAM </e1> was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of <e2> hemolysis </e2>, according to the effects on osmotic fragility curves.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2457": {"data": {"text": "Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.", "entity1": "K(+", "entity2": "Hemolysis", "span1": [59, 62], "span2": [0, 9]}, "bert_text": "Hemolysis caused by TAM was not preceded by the leakage of <e1> K(+ </e1> <e2> Hemolysis </e2> caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2458": {"data": {"text": "Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.", "entity1": "K(+", "entity2": "hemolysis", "span1": [59, 62], "span2": [131, 140]}, "bert_text": "Hemolysis caused by TAM was not preceded by the leakage of <e1> K(+ </e1>) from the cells, also excluding a colloid-osmotic type mechanism of <e2> hemolysis </e2>, according to the effects on osmotic fragility curves.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2459": {"data": {"text": "Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.\n", "entity1": "Coenzyme Q10", "entity2": "nephrotoxicity", "span1": [0, 12], "span2": [51, 65]}, "bert_text": "<e1> Coenzyme Q10 </e1> treatment ameliorates acute cisplatin <e2> nephrotoxicity </e2> in mice.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2460": {"data": {"text": "Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.\n", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [41, 50], "span2": [51, 65]}, "bert_text": "Coenzyme Q10 treatment ameliorates acute <e1> cisplatin </e1> <e2> nephrotoxicity </e2> in mice.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2461": {"data": {"text": "However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate.", "entity1": "L-dopa", "entity2": "bradycardia", "span1": [9, 15], "span2": [29, 40]}, "bert_text": "However, <e1> L-dopa </e1> restored the <e2> bradycardia </e2> caused by norepinephrine in addition to decreasing blood pressure and heart rate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2462": {"data": {"text": "However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate.", "entity1": "norepinephrine", "entity2": "bradycardia", "span1": [51, 65], "span2": [29, 40]}, "bert_text": "However, L-dopa restored the bradycardia caused by <e1> norepinephrine </e1> <e2> bradycardia </e2> caused by norepinephrine in addition to decreasing blood pressure and heart rate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2463": {"data": {"text": "Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.\n", "entity1": "sodium", "entity2": "hypertensive", "span1": [27, 33], "span2": [8, 20]}, "bert_text": "Rebound hypertensive after <e1> sodium </e1> <e2> hypertensive </e2> after sodium nitroprusside prevented by saralasin in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2464": {"data": {"text": "Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.\n", "entity1": "nitroprusside", "entity2": "hypertensive", "span1": [34, 47], "span2": [8, 20]}, "bert_text": "Rebound hypertensive after sodium <e1> nitroprusside </e1> <e2> hypertensive </e2> after sodium nitroprusside prevented by saralasin in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2465": {"data": {"text": "Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.\n", "entity1": "saralasin", "entity2": "hypertensive", "span1": [61, 70], "span2": [8, 20]}, "bert_text": "Rebound hypertensive after sodium nitroprusside prevented by <e1> saralasin </e1> <e2> hypertensive </e2> after sodium nitroprusside prevented by saralasin in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2466": {"data": {"text": "CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.", "entity1": "iodixanol", "entity2": "Nephropathy", "span1": [109, 118], "span2": [13, 24]}, "bert_text": "CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when <e1> iodixanol </e1> <e2> Nephropathy </e2> induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2467": {"data": {"text": "Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.\n", "entity1": "Glyceryl trinitrate", "entity2": "migraine without aura", "span1": [0, 19], "span2": [39, 60]}, "bert_text": "<e1> Glyceryl trinitrate </e1> induces attacks of <e2> migraine without aura </e2> in sufferers of migraine with aura.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2468": {"data": {"text": "Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.\n", "entity1": "Glyceryl trinitrate", "entity2": "migraine with aura", "span1": [0, 19], "span2": [77, 95]}, "bert_text": "<e1> Glyceryl trinitrate </e1> induces attacks of migraine without aura in sufferers of <e2> migraine with aura </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2469": {"data": {"text": "There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [86, 95], "span2": [50, 63]}, "bert_text": "There is a statistically significant reduction of breast cancer among women receiving <e1> tamoxifen </e1> <e2> breast cancer </e2> among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2470": {"data": {"text": "There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [86, 95], "span2": [238, 251]}, "bert_text": "There is a statistically significant reduction of breast cancer among women receiving <e1> tamoxifen </e1> who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of <e2> breast cancer </e2> compared with one case among 362 women allocated to tamoxifen.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2471": {"data": {"text": "There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [304, 313], "span2": [50, 63]}, "bert_text": "There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to <e1> tamoxifen </e1> <e2> breast cancer </e2> among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2472": {"data": {"text": "There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [304, 313], "span2": [238, 251]}, "bert_text": "There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to <e1> tamoxifen </e1> <e2> breast cancer </e2> compared with one case among 362 women allocated to tamoxifen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2473": {"data": {"text": "At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.", "entity1": "cAMP", "entity2": "platelet aggregation", "span1": [137, 141], "span2": [81, 101]}, "bert_text": "At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet <e1> cAMP </e1> <e2> platelet aggregation </e2> and determination of intraplatelet cAMP were performed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2474": {"data": {"text": "Allergic reaction to 5-fluorouracil infusion.\n", "entity1": "5-fluorouracil", "entity2": "Allergic reaction", "span1": [21, 35], "span2": [0, 17]}, "bert_text": "Allergic reaction to <e1> 5-fluorouracil </e1> <e2> Allergic reaction </e2> to 5-fluorouracil infusion.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2475": {"data": {"text": "Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.", "entity1": "risperidone", "entity2": "fractures", "span1": [45, 56], "span2": [17, 26]}, "bert_text": "Of 13 documented fractures, 3 occurred after <e1> risperidone </e1> <e2> fractures </e2>, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2476": {"data": {"text": "Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.", "entity1": "risperidone", "entity2": "hyperprolactinemia", "span1": [45, 56], "span2": [116, 134]}, "bert_text": "Of 13 documented fractures, 3 occurred after <e1> risperidone </e1> and SSRIs were started, and none occurred in patients with <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2477": {"data": {"text": "Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.", "entity1": "SSRIs", "entity2": "fractures", "span1": [61, 66], "span2": [17, 26]}, "bert_text": "Of 13 documented fractures, 3 occurred after risperidone and <e1> SSRIs </e1> <e2> fractures </e2>, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2478": {"data": {"text": "Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.", "entity1": "SSRIs", "entity2": "hyperprolactinemia", "span1": [61, 66], "span2": [116, 134]}, "bert_text": "Of 13 documented fractures, 3 occurred after risperidone and <e1> SSRIs </e1> were started, and none occurred in patients with <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2479": {"data": {"text": "Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.\n", "entity1": "tolazamide", "entity2": "Wernicke's encephalopathy", "span1": [29, 39], "span2": [48, 73]}, "bert_text": "Transketolase abnormality in <e1> tolazamide </e1>-induced <e2> Wernicke's encephalopathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2480": {"data": {"text": "Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.", "entity1": "enalapril", "entity2": "Diabetes", "span1": [126, 135], "span2": [0, 8]}, "bert_text": "Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the <e1> enalapril </e1> <e2> Diabetes </e2> was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2481": {"data": {"text": "Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.", "entity1": "enalapril", "entity2": "renal impairment", "span1": [126, 135], "span2": [50, 66]}, "bert_text": "Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the <e1> enalapril </e1> <e2> renal impairment </e2> in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"2482": {"data": {"text": "Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.", "entity1": "enalapril", "entity2": "CHF", "span1": [126, 135], "span2": [88, 91]}, "bert_text": "Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the <e1> enalapril </e1> <e2> CHF </e2>, but this risk was reduced in the enalapril group compared with the placebo group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2483": {"data": {"text": "In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.", "entity1": "PPA", "entity2": "stroke", "span1": [25, 28], "span2": [50, 56]}, "bert_text": "In order to determine if <e1> PPA </e1>/caffeine can lead to <e2> stroke </e2> in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2484": {"data": {"text": "In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.", "entity1": "PPA", "entity2": "hypertensive", "span1": [25, 28], "span2": [80, 92]}, "bert_text": "In order to determine if <e1> PPA </e1>/caffeine can lead to stroke in normotensive and/or <e2> hypertensive </e2> rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2485": {"data": {"text": "In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.", "entity1": "caffeine", "entity2": "stroke", "span1": [29, 37], "span2": [50, 56]}, "bert_text": "In order to determine if PPA/<e1> caffeine </e1> can lead to <e2> stroke </e2> in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2486": {"data": {"text": "In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.", "entity1": "caffeine", "entity2": "hypertensive", "span1": [29, 37], "span2": [80, 92]}, "bert_text": "In order to determine if PPA/<e1> caffeine </e1> can lead to stroke in normotensive and/or <e2> hypertensive </e2> rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2487": {"data": {"text": "Verapamil-induced carbamazepine neurotoxicity.", "entity1": "Verapamil", "entity2": "neurotoxicity", "span1": [0, 9], "span2": [32, 45]}, "bert_text": "<e1> Verapamil </e1>-induced carbamazepine <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2488": {"data": {"text": "Verapamil-induced carbamazepine neurotoxicity.", "entity1": "carbamazepine", "entity2": "neurotoxicity", "span1": [18, 31], "span2": [32, 45]}, "bert_text": "Verapamil-induced <e1> carbamazepine </e1> <e2> neurotoxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2489": {"data": {"text": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "entity1": "serotonin", "entity2": "incontinence", "span1": [114, 123], "span2": [74, 86]}, "bert_text": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective <e1> serotonin </e1> <e2> incontinence </e2> secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2490": {"data": {"text": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "entity1": "paroxetine", "entity2": "incontinence", "span1": [144, 154], "span2": [74, 86]}, "bert_text": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors <e1> paroxetine </e1> <e2> incontinence </e2> secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2491": {"data": {"text": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "entity1": "sertraline", "entity2": "incontinence", "span1": [159, 169], "span2": [74, 86]}, "bert_text": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and <e1> sertraline </e1> <e2> incontinence </e2> secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2492": {"data": {"text": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "entity1": "venlafaxine", "entity2": "incontinence", "span1": [224, 235], "span2": [74, 86]}, "bert_text": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on <e1> venlafaxine </e1> <e2> incontinence </e2> secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2493": {"data": {"text": "Reduction of pain during induction with target-controlled propofol and remifentanil.\n", "entity1": "propofol", "entity2": "pain", "span1": [58, 66], "span2": [13, 17]}, "bert_text": "Reduction of pain during induction with target-controlled <e1> propofol </e1> <e2> pain </e2> during induction with target-controlled propofol and remifentanil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2494": {"data": {"text": "Reduction of pain during induction with target-controlled propofol and remifentanil.\n", "entity1": "remifentanil", "entity2": "pain", "span1": [71, 83], "span2": [13, 17]}, "bert_text": "Reduction of pain during induction with target-controlled propofol and <e1> remifentanil </e1> <e2> pain </e2> during induction with target-controlled propofol and remifentanil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2495": {"data": {"text": "Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.\n", "entity1": "estrogen", "entity2": "prolactinomas", "span1": [70, 78], "span2": [91, 104]}, "bert_text": "Immunohistochemical, electron microscopic and morphometric studies of <e1> estrogen </e1>-induced rat <e2> prolactinomas </e2> after bromocriptine treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2496": {"data": {"text": "Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.\n", "entity1": "bromocriptine", "entity2": "prolactinomas", "span1": [111, 124], "span2": [91, 104]}, "bert_text": "Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after <e1> bromocriptine </e1> <e2> prolactinomas </e2> after bromocriptine treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2497": {"data": {"text": "BACKGROUND: Pain on injection of propofol is unpleasant.", "entity1": "propofol", "entity2": "Pain", "span1": [33, 41], "span2": [12, 16]}, "bert_text": "BACKGROUND: Pain on injection of <e1> propofol </e1> <e2> Pain </e2> on injection of propofol is unpleasant.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2498": {"data": {"text": "The dose levels incorporate escalating paclitaxel doses, and intrapatient escalations within a given dose level are permitted if toxicity permits.", "entity1": "paclitaxel", "entity2": "toxicity", "span1": [39, 49], "span2": [129, 137]}, "bert_text": "The dose levels incorporate escalating <e1> paclitaxel </e1> doses, and intrapatient escalations within a given dose level are permitted if <e2> toxicity </e2> permits.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2499": {"data": {"text": "Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.\n", "entity1": "cyclophosphamide", "entity2": "cystitis", "span1": [114, 130], "span2": [145, 153]}, "bert_text": "Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with <e1> cyclophosphamide </e1> (CYP)-induced <e2> cystitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2500": {"data": {"text": "Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.\n", "entity1": "CYP)-induced", "entity2": "cystitis", "span1": [132, 144], "span2": [145, 153]}, "bert_text": "Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (<e1> CYP)-induced </e1> <e2> cystitis </e2>.\n", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2501": {"data": {"text": "Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.", "entity1": "angiotensin", "entity2": "pulmonary and renal insufficiency", "span1": [50, 61], "span2": [100, 133]}, "bert_text": "Injection of Captopril (1 mg/kg), an inhibitor of <e1> angiotensin </e1> converting enzyme (ACE), reduced both <e2> pulmonary and renal insufficiency </e2> in this rat model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2502": {"data": {"text": "Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.", "entity1": "ifosfamide", "entity2": "Hemorrhagic cystitis", "span1": [54, 64], "span2": [0, 20]}, "bert_text": "Hemorrhagic cystitis is a major potential toxicity of <e1> ifosfamide </e1> <e2> Hemorrhagic cystitis </e2> is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2503": {"data": {"text": "Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.", "entity1": "ifosfamide", "entity2": "toxicity", "span1": [54, 64], "span2": [42, 50]}, "bert_text": "Hemorrhagic cystitis is a major potential toxicity of <e1> ifosfamide </e1> <e2> toxicity </e2> of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2504": {"data": {"text": "Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.", "entity1": "mesna", "entity2": "Hemorrhagic cystitis", "span1": [104, 109], "span2": [0, 20]}, "bert_text": "Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering <e1> mesna </e1> <e2> Hemorrhagic cystitis </e2> is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2505": {"data": {"text": "Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.", "entity1": "mesna", "entity2": "toxicity", "span1": [104, 109], "span2": [42, 50]}, "bert_text": "Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering <e1> mesna </e1> <e2> toxicity </e2> of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2506": {"data": {"text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "entity1": "apomorphine", "entity2": "REM sleep deprivation", "span1": [47, 58], "span2": [15, 36]}, "bert_text": "The effects of REM sleep deprivation (REMD) on <e1> apomorphine </e1> <e2> REM sleep deprivation </e2> (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2507": {"data": {"text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "entity1": "apomorphine", "entity2": "REMD", "span1": [47, 58], "span2": [38, 42]}, "bert_text": "The effects of REM sleep deprivation (REMD) on <e1> apomorphine </e1> <e2> REMD </e2>) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2508": {"data": {"text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "entity1": "apomorphine", "entity2": "aggressiveness", "span1": [47, 58], "span2": [67, 81]}, "bert_text": "The effects of REM sleep deprivation (REMD) on <e1> apomorphine </e1>-induced <e2> aggressiveness </e2> and quipazine-induced head twitches in rats were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2509": {"data": {"text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "entity1": "apomorphine", "entity2": "head twitches", "span1": [47, 58], "span2": [104, 117]}, "bert_text": "The effects of REM sleep deprivation (REMD) on <e1> apomorphine </e1>-induced aggressiveness and quipazine-induced <e2> head twitches </e2> in rats were determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2510": {"data": {"text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "entity1": "quipazine", "entity2": "REM sleep deprivation", "span1": [86, 95], "span2": [15, 36]}, "bert_text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and <e1> quipazine </e1> <e2> REM sleep deprivation </e2> (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2511": {"data": {"text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "entity1": "quipazine", "entity2": "REMD", "span1": [86, 95], "span2": [38, 42]}, "bert_text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and <e1> quipazine </e1> <e2> REMD </e2>) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2512": {"data": {"text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "entity1": "quipazine", "entity2": "aggressiveness", "span1": [86, 95], "span2": [67, 81]}, "bert_text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and <e1> quipazine </e1> <e2> aggressiveness </e2> and quipazine-induced head twitches in rats were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2513": {"data": {"text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "entity1": "quipazine", "entity2": "head twitches", "span1": [86, 95], "span2": [104, 117]}, "bert_text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and <e1> quipazine </e1>-induced <e2> head twitches </e2> in rats were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2514": {"data": {"text": "CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.", "entity1": "amisulpride-", "entity2": "hypertensive", "span1": [70, 82], "span2": [104, 116]}, "bert_text": "CONCLUSIONS: As of March 24, 2005, this is the first reported case of <e1> amisulpride- </e1> and tiapride-induced <e2> hypertensive </e2> crisis in a patient with pheochromocytoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2515": {"data": {"text": "CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.", "entity1": "amisulpride-", "entity2": "pheochromocytoma", "span1": [70, 82], "span2": [142, 158]}, "bert_text": "CONCLUSIONS: As of March 24, 2005, this is the first reported case of <e1> amisulpride- </e1> and tiapride-induced hypertensive crisis in a patient with <e2> pheochromocytoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2516": {"data": {"text": "CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.", "entity1": "tiapride", "entity2": "hypertensive", "span1": [87, 95], "span2": [104, 116]}, "bert_text": "CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and <e1> tiapride </e1>-induced <e2> hypertensive </e2> crisis in a patient with pheochromocytoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2517": {"data": {"text": "CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.", "entity1": "tiapride", "entity2": "pheochromocytoma", "span1": [87, 95], "span2": [142, 158]}, "bert_text": "CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and <e1> tiapride </e1>-induced hypertensive crisis in a patient with <e2> pheochromocytoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2518": {"data": {"text": "Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.", "entity1": "tamoxifen", "entity2": "hypertriglyceridaemia", "span1": [134, 143], "span2": [97, 118]}, "bert_text": "Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on <e1> tamoxifen </e1> <e2> hypertriglyceridaemia </e2> among women on tamoxifen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2519": {"data": {"text": "Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.", "entity1": "histamine", "entity2": "gastric ulcers", "span1": [109, 118], "span2": [7, 21]}, "bert_text": "Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, <e1> histamine </e1> <e2> gastric ulcers </e2> accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2520": {"data": {"text": "Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.", "entity1": "luminal", "entity2": "gastric ulcers", "span1": [147, 154], "span2": [7, 21]}, "bert_text": "Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and <e1> luminal </e1> <e2> gastric ulcers </e2> accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2521": {"data": {"text": "Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.\n", "entity1": "Phlorizin", "entity2": "glycosuria", "span1": [0, 9], "span2": [18, 28]}, "bert_text": "<e1> Phlorizin </e1>-induced <e2> glycosuria </e2> does not prevent gentamicin nephrotoxicity in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2522": {"data": {"text": "Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.\n", "entity1": "Phlorizin", "entity2": "nephrotoxicity", "span1": [0, 9], "span2": [57, 71]}, "bert_text": "<e1> Phlorizin </e1>-induced glycosuria does not prevent gentamicin <e2> nephrotoxicity </e2> in rats.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2523": {"data": {"text": "Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.\n", "entity1": "gentamicin", "entity2": "glycosuria", "span1": [46, 56], "span2": [18, 28]}, "bert_text": "Phlorizin-induced glycosuria does not prevent <e1> gentamicin </e1> <e2> glycosuria </e2> does not prevent gentamicin nephrotoxicity in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2524": {"data": {"text": "Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.\n", "entity1": "gentamicin", "entity2": "nephrotoxicity", "span1": [46, 56], "span2": [57, 71]}, "bert_text": "Phlorizin-induced glycosuria does not prevent <e1> gentamicin </e1> <e2> nephrotoxicity </e2> in rats.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2525": {"data": {"text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "entity1": "streptozotocin", "entity2": "diabetes mellitus", "span1": [18, 32], "span2": [41, 58]}, "bert_text": "Because rats with <e1> streptozotocin </e1>-induced <e2> diabetes mellitus </e2> (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2526": {"data": {"text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "entity1": "streptozotocin", "entity2": "DM", "span1": [18, 32], "span2": [60, 62]}, "bert_text": "Because rats with <e1> streptozotocin </e1>-induced diabetes mellitus (<e2> DM </e2>) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2527": {"data": {"text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "entity1": "streptozotocin", "entity2": "glycosuria", "span1": [18, 32], "span2": [93, 103]}, "bert_text": "Because rats with <e1> streptozotocin </e1>-induced diabetes mellitus (DM) have a high solute diuresis (<e2> glycosuria </e2> of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2528": {"data": {"text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "entity1": "streptozotocin", "entity2": "acute renal failure", "span1": [18, 32], "span2": [222, 241]}, "bert_text": "Because rats with <e1> streptozotocin </e1>-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced <e2> acute renal failure </e2> (ARF).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2529": {"data": {"text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "entity1": "streptozotocin", "entity2": "ARF", "span1": [18, 32], "span2": [243, 246]}, "bert_text": "Because rats with <e1> streptozotocin </e1>-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (<e2> ARF </e2>).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2530": {"data": {"text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "entity1": "gentamicin", "entity2": "diabetes mellitus", "span1": [203, 213], "span2": [41, 58]}, "bert_text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to <e1> gentamicin </e1> <e2> diabetes mellitus </e2> (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2531": {"data": {"text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "entity1": "gentamicin", "entity2": "DM", "span1": [203, 213], "span2": [60, 62]}, "bert_text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to <e1> gentamicin </e1> <e2> DM </e2>) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2532": {"data": {"text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "entity1": "gentamicin", "entity2": "glycosuria", "span1": [203, 213], "span2": [93, 103]}, "bert_text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to <e1> gentamicin </e1> <e2> glycosuria </e2> of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2533": {"data": {"text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "entity1": "gentamicin", "entity2": "acute renal failure", "span1": [203, 213], "span2": [222, 241]}, "bert_text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to <e1> gentamicin </e1>-induced <e2> acute renal failure </e2> (ARF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2534": {"data": {"text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "entity1": "gentamicin", "entity2": "ARF", "span1": [203, 213], "span2": [243, 246]}, "bert_text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to <e1> gentamicin </e1>-induced acute renal failure (<e2> ARF </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2535": {"data": {"text": "Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.\n", "entity1": "isoniazid", "entity2": "neuropathy", "span1": [47, 56], "span2": [57, 67]}, "bert_text": "Remodelling of nerve structure in experimental <e1> isoniazid </e1> <e2> neuropathy </e2> in the rat.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2536": {"data": {"text": "This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.", "entity1": "lead", "entity2": "hypertension", "span1": [75, 79], "span2": [88, 100]}, "bert_text": "This study was designed to discern whether the reduction in urinary NOx in <e1> lead </e1>-induced <e2> hypertension </e2> is, in part, due to depressed NO synthase (NOS) expression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2537": {"data": {"text": "This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.", "entity1": "lead", "entity2": "depressed NO", "span1": [75, 79], "span2": [121, 133]}, "bert_text": "This study was designed to discern whether the reduction in urinary NOx in <e1> lead </e1>-induced hypertension is, in part, due to <e2> depressed NO </e2> synthase (NOS) expression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2538": {"data": {"text": "Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.", "entity1": "androgens", "entity2": "sleep apnea", "span1": [40, 49], "span2": [73, 84]}, "bert_text": "Previous reports have favored a role of <e1> androgens </e1> in the pathogenesis of <e2> sleep apnea </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2539": {"data": {"text": "Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.", "entity1": "Galanthamine hydrobromide", "entity2": "overdosage", "span1": [0, 25], "span2": [180, 190]}, "bert_text": "<e1> Galanthamine hydrobromide </e1>, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) <e2> overdosage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2540": {"data": {"text": "Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.", "entity1": "scopolamine", "entity2": "overdosage", "span1": [157, 168], "span2": [180, 190]}, "bert_text": "Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of <e1> scopolamine </e1> (hyoscine) <e2> overdosage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2541": {"data": {"text": "Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.", "entity1": "hyoscine", "entity2": "overdosage", "span1": [170, 178], "span2": [180, 190]}, "bert_text": "Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (<e1> hyoscine </e1>) <e2> overdosage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2542": {"data": {"text": "Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [6, 15], "span2": [34, 47]}, "bert_text": "Since <e1> tamoxifen </e1> is widely used in <e2> breast cancer </e2> treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2543": {"data": {"text": "Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [6, 15], "span2": [102, 115]}, "bert_text": "Since <e1> tamoxifen </e1> is widely used in breast cancer treatment and has been proposed for the prevention of <e2> breast cancer </e2>, its endometrial iatrogenic effects must be carefully examined.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2544": {"data": {"text": "Bupropion (Zyban) toxicity.\n", "entity1": "Bupropion", "entity2": "toxicity", "span1": [0, 9], "span2": [18, 26]}, "bert_text": "<e1> Bupropion </e1> (Zyban) <e2> toxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2545": {"data": {"text": "Bupropion (Zyban) toxicity.\n", "entity1": "Zyban", "entity2": "toxicity", "span1": [11, 16], "span2": [18, 26]}, "bert_text": "Bupropion (<e1> Zyban </e1>) <e2> toxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2546": {"data": {"text": "Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).", "entity1": "CM", "entity2": "CIN", "span1": [90, 92], "span2": [35, 38]}, "bert_text": "Whereas 33.3% of the patients with CIN were among those who received the proper dosage of <e1> CM </e1> <e2> CIN </e2> were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2547": {"data": {"text": "Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).", "entity1": "CM", "entity2": "CIN", "span1": [90, 92], "span2": [217, 220]}, "bert_text": "Whereas 33.3% of the patients with CIN were among those who received the proper dosage of <e1> CM </e1>, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of <e2> CIN </e2> related to the different dosages of CM (p = 0.014).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2548": {"data": {"text": "Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).", "entity1": "CM", "entity2": "CIN", "span1": [257, 259], "span2": [35, 38]}, "bert_text": "Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of <e1> CM </e1> <e2> CIN </e2> were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2549": {"data": {"text": "Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).", "entity1": "CM", "entity2": "CIN", "span1": [257, 259], "span2": [217, 220]}, "bert_text": "Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of <e1> CM </e1> <e2> CIN </e2> related to the different dosages of CM (p = 0.014).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2550": {"data": {"text": "Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.", "entity1": "Maltolyl p-coumarate", "entity2": "cognitive deficits", "span1": [0, 20], "span2": [44, 62]}, "bert_text": "<e1> Maltolyl p-coumarate </e1> was found to attenuate <e2> cognitive deficits </e2> in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2551": {"data": {"text": "Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.", "entity1": "amyloid beta peptide(1-42)-infused", "entity2": "cognitive deficits", "span1": [181, 215], "span2": [44, 62]}, "bert_text": "Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the <e1> amyloid beta peptide(1-42)-infused </e1> <e2> cognitive deficits </e2> in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2552": {"data": {"text": "OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.", "entity1": "tobramicyn", "entity2": "toxicity", "span1": [84, 94], "span2": [136, 144]}, "bert_text": "OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of <e1> tobramicyn </e1> on steady-state serum concentrations and <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2553": {"data": {"text": "AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).", "entity1": "ifosfamide", "entity2": "Hemorrhagic cystitis", "span1": [78, 88], "span2": [5, 25]}, "bert_text": "AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with <e1> ifosfamide </e1> <e2> Hemorrhagic cystitis </e2> (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2554": {"data": {"text": "AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).", "entity1": "ifosfamide", "entity2": "HC", "span1": [78, 88], "span2": [27, 29]}, "bert_text": "AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with <e1> ifosfamide </e1> <e2> HC </e2>) is a limiting side-effect of chemotherapy with ifosfamide (IFS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2555": {"data": {"text": "AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).", "entity1": "IFS", "entity2": "Hemorrhagic cystitis", "span1": [90, 93], "span2": [5, 25]}, "bert_text": "AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (<e1> IFS </e1> <e2> Hemorrhagic cystitis </e2> (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2556": {"data": {"text": "AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).", "entity1": "IFS", "entity2": "HC", "span1": [90, 93], "span2": [27, 29]}, "bert_text": "AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (<e1> IFS </e1> <e2> HC </e2>) is a limiting side-effect of chemotherapy with ifosfamide (IFS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2557": {"data": {"text": "Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats.", "entity1": "dexamethasone", "entity2": "glomerulosclerosis", "span1": [17, 30], "span2": [86, 104]}, "bert_text": "Adult rats given <e1> dexamethasone </e1> on days 15 and 16 of gestation had more glomeruli with <e2> glomerulosclerosis </e2> than control rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2558": {"data": {"text": "The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.\n", "entity1": "mipafox", "entity2": "neurotoxic", "span1": [59, 66], "span2": [24, 34]}, "bert_text": "The correlation between neurotoxic esterase inhibition and <e1> mipafox </e1> <e2> neurotoxic </e2> esterase inhibition and mipafox-induced neuropathic damage in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2559": {"data": {"text": "The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.\n", "entity1": "mipafox", "entity2": "neuropathic damage", "span1": [59, 66], "span2": [75, 93]}, "bert_text": "The correlation between neurotoxic esterase inhibition and <e1> mipafox </e1>-induced <e2> neuropathic damage </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2560": {"data": {"text": "The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).", "entity1": "choline", "entity2": "Alzheimer's disease", "span1": [4, 11], "span2": [203, 222]}, "bert_text": "The <e1> choline </e1> acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of <e2> Alzheimer's disease </e2> (AD).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2561": {"data": {"text": "The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).", "entity1": "choline", "entity2": "AD", "span1": [4, 11], "span2": [224, 226]}, "bert_text": "The <e1> choline </e1> acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (<e2> AD </e2>).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2562": {"data": {"text": "The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).", "entity1": "acetylcholine", "entity2": "Alzheimer's disease", "span1": [139, 152], "span2": [203, 222]}, "bert_text": "The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of <e1> acetylcholine </e1> (ACh), is an important factor in the treatment of <e2> Alzheimer's disease </e2> (AD).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2563": {"data": {"text": "The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).", "entity1": "acetylcholine", "entity2": "AD", "span1": [139, 152], "span2": [224, 226]}, "bert_text": "The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of <e1> acetylcholine </e1> (ACh), is an important factor in the treatment of Alzheimer's disease (<e2> AD </e2>).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2564": {"data": {"text": "The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).", "entity1": "ACh", "entity2": "Alzheimer's disease", "span1": [154, 157], "span2": [203, 222]}, "bert_text": "The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (<e1> ACh </e1>), is an important factor in the treatment of <e2> Alzheimer's disease </e2> (AD).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2565": {"data": {"text": "The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).", "entity1": "ACh", "entity2": "AD", "span1": [154, 157], "span2": [224, 226]}, "bert_text": "The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (<e1> ACh </e1>), is an important factor in the treatment of Alzheimer's disease (<e2> AD </e2>).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2566": {"data": {"text": "Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.", "entity1": "sulpiride", "entity2": "tardive dyskinesia", "span1": [70, 79], "span2": [88, 106]}, "bert_text": "Although initially thought to be free of extrapyramidal side effects, <e1> sulpiride </e1>-induced <e2> tardive dyskinesia </e2> and parkinsonism have been reported occasionally.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2567": {"data": {"text": "Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.", "entity1": "sulpiride", "entity2": "parkinsonism", "span1": [70, 79], "span2": [111, 123]}, "bert_text": "Although initially thought to be free of extrapyramidal side effects, <e1> sulpiride </e1>-induced tardive dyskinesia and <e2> parkinsonism </e2> have been reported occasionally.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2568": {"data": {"text": "Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.", "entity1": "WR242511", "entity2": "hemoglobinuria", "span1": [90, 98], "span2": [23, 37]}, "bert_text": "Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of <e1> WR242511 </e1> <e2> hemoglobinuria </e2> was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2569": {"data": {"text": "OBJECTIVE: To report a case of venlafaxine overdose.", "entity1": "venlafaxine", "entity2": "overdose", "span1": [31, 42], "span2": [43, 51]}, "bert_text": "OBJECTIVE: To report a case of <e1> venlafaxine </e1> <e2> overdose </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2570": {"data": {"text": "METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.", "entity1": "METH", "entity2": "psychosis", "span1": [165, 169], "span2": [178, 187]}, "bert_text": "METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 <e1> METH </e1>-induced <e2> psychosis </e2> patients and 337 controls) in the Japanese population.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2571": {"data": {"text": "Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.", "entity1": "Doxorubicin", "entity2": "proteinuria", "span1": [0, 11], "span2": [40, 51]}, "bert_text": "<e1> Doxorubicin </e1> treatment resulted in heavy <e2> proteinuria </e2> (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2572": {"data": {"text": "Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.", "entity1": "Doxorubicin", "entity2": "nephrotic syndrome", "span1": [0, 11], "span2": [146, 164]}, "bert_text": "<e1> Doxorubicin </e1> treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe <e2> nephrotic syndrome </e2> with ascites, lipidemia, and hypoalbuminemia in both genotypes.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2573": {"data": {"text": "Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.", "entity1": "Doxorubicin", "entity2": "ascites", "span1": [0, 11], "span2": [170, 177]}, "bert_text": "<e1> Doxorubicin </e1> treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with <e2> ascites </e2>, lipidemia, and hypoalbuminemia in both genotypes.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2574": {"data": {"text": "Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.", "entity1": "Doxorubicin", "entity2": "lipidemia", "span1": [0, 11], "span2": [179, 188]}, "bert_text": "<e1> Doxorubicin </e1> treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, <e2> lipidemia </e2>, and hypoalbuminemia in both genotypes.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2575": {"data": {"text": "Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.", "entity1": "Doxorubicin", "entity2": "hypoalbuminemia", "span1": [0, 11], "span2": [194, 209]}, "bert_text": "<e1> Doxorubicin </e1> treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and <e2> hypoalbuminemia </e2> in both genotypes.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2576": {"data": {"text": "We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.", "entity1": "metoclopramide", "entity2": "asystole", "span1": [53, 67], "span2": [96, 104]}, "bert_text": "We describe a patient where intravenous injection of <e1> metoclopramide </e1> was immediately followed by <e2> asystole </e2> repeatedly.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2577": {"data": {"text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "entity1": "gentamicin", "entity2": "nephrotoxicity", "span1": [20, 30], "span2": [31, 45]}, "bert_text": "The protection from <e1> gentamicin </e1> <e2> nephrotoxicity </e2> was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2578": {"data": {"text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "entity1": "gentamicin", "entity2": "diabetic", "span1": [20, 30], "span2": [65, 73]}, "bert_text": "The protection from <e1> gentamicin </e1> nephrotoxicity was studied in non-<e2> diabetic </e2> rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2579": {"data": {"text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "entity1": "glucose", "entity2": "nephrotoxicity", "span1": [139, 146], "span2": [31, 45]}, "bert_text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular <e1> glucose </e1> <e2> nephrotoxicity </e2> was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2580": {"data": {"text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "entity1": "glucose", "entity2": "diabetic", "span1": [139, 146], "span2": [65, 73]}, "bert_text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular <e1> glucose </e1> <e2> diabetic </e2> rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2581": {"data": {"text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "entity1": "phlorizin", "entity2": "nephrotoxicity", "span1": [165, 174], "span2": [31, 45]}, "bert_text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with <e1> phlorizin </e1> <e2> nephrotoxicity </e2> was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2582": {"data": {"text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "entity1": "phlorizin", "entity2": "diabetic", "span1": [165, 174], "span2": [65, 73]}, "bert_text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with <e1> phlorizin </e1> <e2> diabetic </e2> rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2583": {"data": {"text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "entity1": "P", "entity2": "nephrotoxicity", "span1": [176, 177], "span2": [31, 45]}, "bert_text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (<e1> P </e1> <e2> nephrotoxicity </e2> was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2584": {"data": {"text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "entity1": "P", "entity2": "diabetic", "span1": [176, 177], "span2": [65, 73]}, "bert_text": "The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (<e1> P </e1> <e2> diabetic </e2> rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2585": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "SLE", "span1": [26, 36], "span2": [56, 59]}, "bert_text": "Epileptogenic activity of <e1> folic acid </e1> after drug induces <e2> SLE </e2> (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2586": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "epilepsy", "span1": [26, 36], "span2": [76, 84]}, "bert_text": "Epileptogenic activity of <e1> folic acid </e1> after drug induces SLE (folic acid and <e2> epilepsy </e2>)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2587": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "epileptic", "span1": [26, 36], "span2": [174, 183]}, "bert_text": "Epileptogenic activity of <e1> folic acid </e1> after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in <e2> epileptic </e2> women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2588": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "epilepsy", "span1": [26, 36], "span2": [281, 289]}, "bert_text": "Epileptogenic activity of <e1> folic acid </e1> after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and <e2> epilepsy </e2>-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2589": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "birth defects", "span1": [26, 36], "span2": [263, 276]}, "bert_text": "Epileptogenic activity of <e1> folic acid </e1> after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural <e2> birth defects </e2> and epilepsy-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2590": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "SLE", "span1": [61, 71], "span2": [56, 59]}, "bert_text": "Epileptogenic activity of folic acid after drug induces SLE (<e1> folic acid </e1> <e2> SLE </e2> (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2591": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "epilepsy", "span1": [61, 71], "span2": [76, 84]}, "bert_text": "Epileptogenic activity of folic acid after drug induces SLE (<e1> folic acid </e1> and <e2> epilepsy </e2>)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2592": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "epileptic", "span1": [61, 71], "span2": [174, 183]}, "bert_text": "Epileptogenic activity of folic acid after drug induces SLE (<e1> folic acid </e1> and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in <e2> epileptic </e2> women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2593": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "epilepsy", "span1": [61, 71], "span2": [281, 289]}, "bert_text": "Epileptogenic activity of folic acid after drug induces SLE (<e1> folic acid </e1> and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and <e2> epilepsy </e2>-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2594": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "birth defects", "span1": [61, 71], "span2": [263, 276]}, "bert_text": "Epileptogenic activity of folic acid after drug induces SLE (<e1> folic acid </e1> and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural <e2> birth defects </e2> and epilepsy-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2595": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "SLE", "span1": [120, 130], "span2": [56, 59]}, "bert_text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of <e1> folic acid </e1> <e2> SLE </e2> (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2596": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "epilepsy", "span1": [120, 130], "span2": [76, 84]}, "bert_text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of <e1> folic acid </e1> <e2> epilepsy </e2>)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2597": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "epileptic", "span1": [120, 130], "span2": [174, 183]}, "bert_text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of <e1> folic acid </e1>-containing multivitamin supplementation in <e2> epileptic </e2> women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2598": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "epilepsy", "span1": [120, 130], "span2": [281, 289]}, "bert_text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of <e1> folic acid </e1>-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and <e2> epilepsy </e2>-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2599": {"data": {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity1": "folic acid", "entity2": "birth defects", "span1": [120, 130], "span2": [263, 276]}, "bert_text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\nOBJECTIVE: To study the effect of <e1> folic acid </e1>-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural <e2> birth defects </e2> and epilepsy-related side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2600": {"data": {"text": "In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.", "entity1": "apomorphine", "entity2": "dyskinesias", "span1": [97, 108], "span2": [188, 199]}, "bert_text": "In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous <e1> apomorphine </e1> infusions is associated with marked reductions of preexisting levodopa-induced <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2601": {"data": {"text": "In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [171, 179], "span2": [188, 199]}, "bert_text": "In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting <e1> levodopa </e1>-induced <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2602": {"data": {"text": "CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.", "entity1": "tamoxifen", "entity2": "liver dysfunction", "span1": [26, 35], "span2": [44, 61]}, "bert_text": "CONCLUSION: Patients with <e1> tamoxifen </e1>-induced <e2> liver dysfunction </e2> may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2603": {"data": {"text": "CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.", "entity1": "tamoxifen", "entity2": "granulosa cell tumors", "span1": [26, 35], "span2": [91, 112]}, "bert_text": "CONCLUSION: Patients with <e1> tamoxifen </e1>-induced liver dysfunction may be at increased risk for <e2> granulosa cell tumors </e2> because of alterations in tamoxifen metabolism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2604": {"data": {"text": "CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.", "entity1": "tamoxifen", "entity2": "liver dysfunction", "span1": [139, 148], "span2": [44, 61]}, "bert_text": "CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in <e1> tamoxifen </e1> <e2> liver dysfunction </e2> may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2605": {"data": {"text": "CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.", "entity1": "tamoxifen", "entity2": "granulosa cell tumors", "span1": [139, 148], "span2": [91, 112]}, "bert_text": "CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in <e1> tamoxifen </e1> <e2> granulosa cell tumors </e2> because of alterations in tamoxifen metabolism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2606": {"data": {"text": "Effects of uninephrectomy and high protein feeding on lithium-induced chronic renal failure in rats.\n", "entity1": "lithium", "entity2": "chronic renal failure", "span1": [54, 61], "span2": [70, 91]}, "bert_text": "Effects of uninephrectomy and high protein feeding on <e1> lithium </e1>-induced <e2> chronic renal failure </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2607": {"data": {"text": "METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.", "entity1": "risperidone", "entity2": "hyperprolactinemia", "span1": [72, 83], "span2": [92, 110]}, "bert_text": "METHODS: We undertook a retrospective case review of four children with <e1> risperidone </e1>-induced <e2> hyperprolactinemia </e2> treated with cabergoline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2608": {"data": {"text": "METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.", "entity1": "cabergoline", "entity2": "hyperprolactinemia", "span1": [124, 135], "span2": [92, 110]}, "bert_text": "METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with <e1> cabergoline </e1> <e2> hyperprolactinemia </e2> treated with cabergoline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2609": {"data": {"text": "Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.", "entity1": "Ciprofloxacin", "entity2": "interstitial nephritis", "span1": [0, 13], "span2": [70, 92]}, "bert_text": "<e1> Ciprofloxacin </e1> has been associated with several side effects including <e2> interstitial nephritis </e2> and hemolytic anemia.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2610": {"data": {"text": "Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.", "entity1": "Ciprofloxacin", "entity2": "hemolytic anemia", "span1": [0, 13], "span2": [97, 113]}, "bert_text": "<e1> Ciprofloxacin </e1> has been associated with several side effects including interstitial nephritis and <e2> hemolytic anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2611": {"data": {"text": "Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.\n", "entity1": "lithium", "entity2": "diabetes-insipidus-like syndrome", "span1": [19, 26], "span2": [35, 67]}, "bert_text": "Attenuation of the <e1> lithium </e1>-induced <e2> diabetes-insipidus-like syndrome </e2> by amiloride in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2612": {"data": {"text": "Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.\n", "entity1": "amiloride", "entity2": "diabetes-insipidus-like syndrome", "span1": [71, 80], "span2": [35, 67]}, "bert_text": "Attenuation of the lithium-induced diabetes-insipidus-like syndrome by <e1> amiloride </e1> <e2> diabetes-insipidus-like syndrome </e2> by amiloride in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2613": {"data": {"text": "In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.", "entity1": "norepinephrine", "entity2": "bradycardia", "span1": [51, 65], "span2": [20, 31]}, "bert_text": "In addition, reflex bradycardia caused by injected <e1> norepinephrine </e1> <e2> bradycardia </e2> caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2614": {"data": {"text": "In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.", "entity1": "norepinephrine", "entity2": "bradycardia", "span1": [202, 216], "span2": [20, 31]}, "bert_text": "In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to <e1> norepinephrine </e1> <e2> bradycardia </e2> caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2615": {"data": {"text": "In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.", "entity1": "L-dopa", "entity2": "bradycardia", "span1": [96, 102], "span2": [20, 31]}, "bert_text": "In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by <e1> L-dopa </e1> <e2> bradycardia </e2> caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2616": {"data": {"text": "In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.", "entity1": "DL-Threo-dihydroxyphenylserine", "entity2": "bradycardia", "span1": [104, 134], "span2": [20, 31]}, "bert_text": "In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, <e1> DL-Threo-dihydroxyphenylserine </e1> <e2> bradycardia </e2> caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2617": {"data": {"text": "Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.\n", "entity1": "phenytoin", "entity2": "epileptic", "span1": [75, 84], "span2": [50, 59]}, "bert_text": "Magnetic resonance volumetry of the cerebellum in epileptic patients after <e1> phenytoin </e1> <e2> epileptic </e2> patients after phenytoin overdosages.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2618": {"data": {"text": "Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.\n", "entity1": "phenytoin", "entity2": "overdosages", "span1": [75, 84], "span2": [85, 96]}, "bert_text": "Magnetic resonance volumetry of the cerebellum in epileptic patients after <e1> phenytoin </e1> <e2> overdosages </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2619": {"data": {"text": "These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.", "entity1": "THC", "entity2": "catalepsy", "span1": [118, 121], "span2": [97, 106]}, "bert_text": "These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by <e1> THC </e1> <e2> catalepsy </e2> induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2620": {"data": {"text": "These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.", "entity1": "THC", "entity2": "catalepsy", "span1": [118, 121], "span2": [169, 178]}, "bert_text": "These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by <e1> THC </e1>, whereas dopaminergic neurons are important in <e2> catalepsy </e2> induced by haloperidol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2621": {"data": {"text": "These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [190, 201], "span2": [97, 106]}, "bert_text": "These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by <e1> haloperidol </e1> <e2> catalepsy </e2> induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2622": {"data": {"text": "These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [190, 201], "span2": [169, 178]}, "bert_text": "These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by <e1> haloperidol </e1> <e2> catalepsy </e2> induced by haloperidol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2623": {"data": {"text": "MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.\n", "entity1": "tacrolimus", "entity2": "neurotoxicity", "span1": [50, 60], "span2": [69, 82]}, "bert_text": "MR imaging with quantitative diffusion mapping of <e1> tacrolimus </e1>-induced <e2> neurotoxicity </e2> in organ transplant patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2624": {"data": {"text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "entity1": "sucrose", "entity2": "hyperactive", "span1": [40, 47], "span2": [62, 73]}, "bert_text": "The animals that had experienced cyclic <e1> sucrose </e1> and chow were <e2> hyperactive </e2> in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2625": {"data": {"text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "entity1": "sucrose", "entity2": "hyperactive", "span1": [151, 158], "span2": [62, 73]}, "bert_text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% <e1> sucrose </e1> <e2> hyperactive </e2> in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2626": {"data": {"text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "entity1": "sucrose", "entity2": "hyperactive", "span1": [298, 305], "span2": [62, 73]}, "bert_text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% <e1> sucrose </e1> <e2> hyperactive </e2> in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2627": {"data": {"text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "entity1": "amphetamine", "entity2": "hyperactive", "span1": [89, 100], "span2": [62, 73]}, "bert_text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to <e1> amphetamine </e1> <e2> hyperactive </e2> in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2628": {"data": {"text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "entity1": "amphetamine", "entity2": "hyperactive", "span1": [180, 191], "span2": [62, 73]}, "bert_text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by <e1> amphetamine </e1> <e2> hyperactive </e2> in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2629": {"data": {"text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "entity1": "amphetamine", "entity2": "hyperactive", "span1": [227, 238], "span2": [62, 73]}, "bert_text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by <e1> amphetamine </e1> <e2> hyperactive </e2> in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2630": {"data": {"text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "entity1": "amphetamine", "entity2": "hyperactive", "span1": [271, 282], "span2": [62, 73]}, "bert_text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with <e1> amphetamine </e1> <e2> hyperactive </e2> in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2631": {"data": {"text": "OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.", "entity1": "cyclophosphamide", "entity2": "bladder cancer", "span1": [86, 102], "span2": [50, 64]}, "bert_text": "OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to <e1> cyclophosphamide </e1> <e2> bladder cancer </e2>, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"2632": {"data": {"text": "OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.", "entity1": "cyclophosphamide", "entity2": "Wegener's granulomatosis", "span1": [86, 102], "span2": [121, 145]}, "bert_text": "OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to <e1> cyclophosphamide </e1>, in patients with <e2> Wegener's granulomatosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2633": {"data": {"text": "Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.", "entity1": "adriamycin", "entity2": "leukemia", "span1": [25, 35], "span2": [98, 106]}, "bert_text": "Our results suggest that <e1> adriamycin </e1> is a more potent cardiotoxin in monkeys than in man, and that <e2> leukemia </e2> may be a consequence of prolonged treatment with this drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2634": {"data": {"text": "Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.", "entity1": "fentanyl", "entity2": "urinary bladder retention", "span1": [148, 156], "span2": [17, 42]}, "bert_text": "Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of <e1> fentanyl </e1> <e2> urinary bladder retention </e2> leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2635": {"data": {"text": "Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.", "entity1": "fentanyl", "entity2": "hydronephrosis", "span1": [148, 156], "span2": [95, 109]}, "bert_text": "Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of <e1> fentanyl </e1> <e2> hydronephrosis </e2> as a result of continuous infusion of fentanyl are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2636": {"data": {"text": "It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.", "entity1": "bradykinin", "entity2": "hyperalgesia", "span1": [109, 119], "span2": [136, 148]}, "bert_text": "It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as <e1> bradykinin </e1> are involved in <e2> hyperalgesia </e2> produced by vincristine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2637": {"data": {"text": "It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.", "entity1": "vincristine", "entity2": "hyperalgesia", "span1": [161, 172], "span2": [136, 148]}, "bert_text": "It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by <e1> vincristine </e1> <e2> hyperalgesia </e2> produced by vincristine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2638": {"data": {"text": "Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.", "entity1": "Ketoprofen", "entity2": "SAH", "span1": [0, 10], "span2": [77, 80]}, "bert_text": "<e1> Ketoprofen </e1> but not acetaminophen impaired platelet function in patients with <e2> SAH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2639": {"data": {"text": "Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.", "entity1": "acetaminophen", "entity2": "SAH", "span1": [19, 32], "span2": [77, 80]}, "bert_text": "Ketoprofen but not <e1> acetaminophen </e1> impaired platelet function in patients with <e2> SAH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2640": {"data": {"text": "The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.", "entity1": "bradykinin", "entity2": "hypertension", "span1": [73, 83], "span2": [163, 175]}, "bert_text": "The goal of this study was to determine the role of synthesis/release of <e1> bradykinin </e1> to activate B2 receptors in disruption of the blood-brain barrier during acute <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2641": {"data": {"text": "The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.", "entity1": "pemoline", "entity2": "choreoathetoid", "span1": [94, 102], "span2": [19, 33]}, "bert_text": "The possibility of choreoathetoid movements should be considered in patients presenting after <e1> pemoline </e1> <e2> choreoathetoid </e2> movements should be considered in patients presenting after pemoline overdose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2642": {"data": {"text": "The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.", "entity1": "pemoline", "entity2": "overdose", "span1": [94, 102], "span2": [103, 111]}, "bert_text": "The possibility of choreoathetoid movements should be considered in patients presenting after <e1> pemoline </e1> <e2> overdose </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2643": {"data": {"text": "The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.", "entity1": "sevoflurane", "entity2": "convulsions", "span1": [76, 87], "span2": [145, 156]}, "bert_text": "The rise in blood pressure became less marked when higher concentrations of <e1> sevoflurane </e1> or enflurane were administered and the blood pressure at <e2> convulsions </e2> decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2644": {"data": {"text": "The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.", "entity1": "sevoflurane", "entity2": "convulsions", "span1": [189, 200], "span2": [145, 156]}, "bert_text": "The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% <e1> sevoflurane </e1> <e2> convulsions </e2> decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2645": {"data": {"text": "The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.", "entity1": "enflurane", "entity2": "convulsions", "span1": [91, 100], "span2": [145, 156]}, "bert_text": "The rise in blood pressure became less marked when higher concentrations of sevoflurane or <e1> enflurane </e1> were administered and the blood pressure at <e2> convulsions </e2> decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2646": {"data": {"text": "The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.", "entity1": "enflurane", "entity2": "convulsions", "span1": [223, 232], "span2": [145, 156]}, "bert_text": "The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% <e1> enflurane </e1> <e2> convulsions </e2> decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2647": {"data": {"text": "CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.", "entity1": "CC", "entity2": "chest pain", "span1": [72, 74], "span2": [118, 128]}, "bert_text": "CASE: A 33-year-old woman with a 5-week gestation had recently received <e1> CC </e1> for ovulation induction and presented with <e2> chest pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2648": {"data": {"text": "CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.", "entity1": "cocaine", "entity2": "seizure", "span1": [68, 75], "span2": [102, 109]}, "bert_text": "CONCLUSIONS: During this study period, routine plasma screening for <e1> cocaine </e1> and amphetamines in adult <e2> seizure </e2> patients had a low yield.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2649": {"data": {"text": "CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.", "entity1": "amphetamines", "entity2": "seizure", "span1": [80, 92], "span2": [102, 109]}, "bert_text": "CONCLUSIONS: During this study period, routine plasma screening for cocaine and <e1> amphetamines </e1> in adult <e2> seizure </e2> patients had a low yield.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2650": {"data": {"text": "Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).", "entity1": "superoxide", "entity2": "bacterial infections", "span1": [11, 21], "span2": [98, 118]}, "bert_text": "Defects in <e1> superoxide </e1> and hydrogen peroxide production may be implicated in the high incidence of <e2> bacterial infections </e2> in patients with acute liver failure (ALF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2651": {"data": {"text": "Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).", "entity1": "superoxide", "entity2": "acute liver failure", "span1": [11, 21], "span2": [136, 155]}, "bert_text": "Defects in <e1> superoxide </e1> and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with <e2> acute liver failure </e2> (ALF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2652": {"data": {"text": "Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).", "entity1": "superoxide", "entity2": "ALF", "span1": [11, 21], "span2": [157, 160]}, "bert_text": "Defects in <e1> superoxide </e1> and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (<e2> ALF </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2653": {"data": {"text": "Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).", "entity1": "hydrogen peroxide", "entity2": "bacterial infections", "span1": [26, 43], "span2": [98, 118]}, "bert_text": "Defects in superoxide and <e1> hydrogen peroxide </e1> production may be implicated in the high incidence of <e2> bacterial infections </e2> in patients with acute liver failure (ALF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2654": {"data": {"text": "Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).", "entity1": "hydrogen peroxide", "entity2": "acute liver failure", "span1": [26, 43], "span2": [136, 155]}, "bert_text": "Defects in superoxide and <e1> hydrogen peroxide </e1> production may be implicated in the high incidence of bacterial infections in patients with <e2> acute liver failure </e2> (ALF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2655": {"data": {"text": "Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).", "entity1": "hydrogen peroxide", "entity2": "ALF", "span1": [26, 43], "span2": [157, 160]}, "bert_text": "Defects in superoxide and <e1> hydrogen peroxide </e1> production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (<e2> ALF </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2656": {"data": {"text": "In a randomized study, labetalol-induced hypotension and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.", "entity1": "labetalol", "entity2": "hypotension", "span1": [23, 32], "span2": [41, 52]}, "bert_text": "In a randomized study, <e1> labetalol </e1>-induced <e2> hypotension </e2> and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2657": {"data": {"text": "In a randomized study, labetalol-induced hypotension and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.", "entity1": "labetalol", "entity2": "hypotension", "span1": [23, 32], "span2": [79, 90]}, "bert_text": "In a randomized study, <e1> labetalol </e1>-induced hypotension and nitroprusside-induced <e2> hypotension </e2> were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2658": {"data": {"text": "In a randomized study, labetalol-induced hypotension and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.", "entity1": "nitroprusside", "entity2": "hypotension", "span1": [57, 70], "span2": [41, 52]}, "bert_text": "In a randomized study, labetalol-induced hypotension and <e1> nitroprusside </e1> <e2> hypotension </e2> and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2659": {"data": {"text": "In a randomized study, labetalol-induced hypotension and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.", "entity1": "nitroprusside", "entity2": "hypotension", "span1": [57, 70], "span2": [79, 90]}, "bert_text": "In a randomized study, labetalol-induced hypotension and <e1> nitroprusside </e1>-induced <e2> hypotension </e2> were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2660": {"data": {"text": "Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.", "entity1": "Dopamine", "entity2": "catalepsy", "span1": [0, 8], "span2": [95, 104]}, "bert_text": "<e1> Dopamine </e1> antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2661": {"data": {"text": "Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.", "entity1": "fluphenazine", "entity2": "catalepsy", "span1": [20, 32], "span2": [95, 104]}, "bert_text": "Dopamine antagonist <e1> fluphenazine </e1>, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2662": {"data": {"text": "Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.", "entity1": "SCH 23390", "entity2": "catalepsy", "span1": [49, 58], "span2": [95, 104]}, "bert_text": "Dopamine antagonist fluphenazine, D-1 antagonist <e1> SCH 23390 </e1> or D-2 antagonist sulpiride induced <e2> catalepsy </e2>.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2663": {"data": {"text": "Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.", "entity1": "sulpiride", "entity2": "catalepsy", "span1": [77, 86], "span2": [95, 104]}, "bert_text": "Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist <e1> sulpiride </e1> induced <e2> catalepsy </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2664": {"data": {"text": "None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).", "entity1": "docetaxel", "entity2": "VTE", "span1": [33, 42], "span2": [59, 62]}, "bert_text": "None of 23 patients who received <e1> docetaxel </e1> alone developed <e2> VTE </e2>, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2665": {"data": {"text": "None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).", "entity1": "docetaxel", "entity2": "VTE", "span1": [33, 42], "span2": [145, 148]}, "bert_text": "None of 23 patients who received <e1> docetaxel </e1> alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed <e2> VTE </e2> (p=0.025).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2666": {"data": {"text": "None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).", "entity1": "docetaxel", "entity2": "VTE", "span1": [108, 117], "span2": [59, 62]}, "bert_text": "None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received <e1> docetaxel </e1> <e2> VTE </e2>, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2667": {"data": {"text": "None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).", "entity1": "docetaxel", "entity2": "VTE", "span1": [108, 117], "span2": [145, 148]}, "bert_text": "None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received <e1> docetaxel </e1> plus thalidomide developed <e2> VTE </e2> (p=0.025).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2668": {"data": {"text": "None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).", "entity1": "thalidomide", "entity2": "VTE", "span1": [123, 134], "span2": [59, 62]}, "bert_text": "None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus <e1> thalidomide </e1> <e2> VTE </e2>, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2669": {"data": {"text": "None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).", "entity1": "thalidomide", "entity2": "VTE", "span1": [123, 134], "span2": [145, 148]}, "bert_text": "None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus <e1> thalidomide </e1> developed <e2> VTE </e2> (p=0.025).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2670": {"data": {"text": "The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin-treated rats.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [107, 115], "span2": [83, 103]}, "bert_text": "The first series of experiments examined the influence of age and growth status on artery calcification in <e1> Warfarin </e1> <e2> artery calcification </e2> in Warfarin-treated rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2671": {"data": {"text": "This paper describes the clinical features of six children who developed the haemolytic-uraemic syndrome after treatment with metronidazole.", "entity1": "metronidazole", "entity2": "haemolytic-uraemic syndrome", "span1": [126, 139], "span2": [77, 104]}, "bert_text": "This paper describes the clinical features of six children who developed the haemolytic-uraemic syndrome after treatment with <e1> metronidazole </e1> <e2> haemolytic-uraemic syndrome </e2> after treatment with metronidazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2672": {"data": {"text": "CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.", "entity1": "thalidomide", "entity2": "prostate cancer", "span1": [28, 39], "span2": [73, 88]}, "bert_text": "CONCLUSION: The addition of <e1> thalidomide </e1> to docetaxel in the treatment of <e2> prostate cancer </e2> significantly increases the frequency of VTE.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2673": {"data": {"text": "CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.", "entity1": "thalidomide", "entity2": "VTE", "span1": [28, 39], "span2": [130, 133]}, "bert_text": "CONCLUSION: The addition of <e1> thalidomide </e1> to docetaxel in the treatment of prostate cancer significantly increases the frequency of <e2> VTE </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2674": {"data": {"text": "CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.", "entity1": "docetaxel", "entity2": "prostate cancer", "span1": [43, 52], "span2": [73, 88]}, "bert_text": "CONCLUSION: The addition of thalidomide to <e1> docetaxel </e1> in the treatment of <e2> prostate cancer </e2> significantly increases the frequency of VTE.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2675": {"data": {"text": "CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.", "entity1": "docetaxel", "entity2": "VTE", "span1": [43, 52], "span2": [130, 133]}, "bert_text": "CONCLUSION: The addition of thalidomide to <e1> docetaxel </e1> in the treatment of prostate cancer significantly increases the frequency of <e2> VTE </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2676": {"data": {"text": "CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.", "entity1": "cocaine", "entity2": "vasculitis", "span1": [240, 247], "span2": [139, 149]}, "bert_text": "CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with <e1> cocaine </e1> <e2> vasculitis </e2> could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2677": {"data": {"text": "CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.", "entity1": "cocaine", "entity2": "aneurysmal", "span1": [240, 247], "span2": [209, 219]}, "bert_text": "CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with <e1> cocaine </e1> <e2> aneurysmal </e2> SAH associated with cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2678": {"data": {"text": "CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.", "entity1": "cocaine", "entity2": "SAH", "span1": [240, 247], "span2": [220, 223]}, "bert_text": "CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with <e1> cocaine </e1> <e2> SAH </e2> associated with cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2679": {"data": {"text": "The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.", "entity1": "Hibiscus rosa sinensis", "entity2": "dyskinesia", "span1": [48, 70], "span2": [129, 139]}, "bert_text": "The results of the present study suggested that <e1> Hibiscus rosa sinensis </e1> had a protective role against reserpine-induced orofacial <e2> dyskinesia </e2> and oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2680": {"data": {"text": "The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.", "entity1": "reserpine", "entity2": "dyskinesia", "span1": [101, 110], "span2": [129, 139]}, "bert_text": "The results of the present study suggested that Hibiscus rosa sinensis had a protective role against <e1> reserpine </e1>-induced orofacial <e2> dyskinesia </e2> and oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2681": {"data": {"text": "Seizure resulting from a venlafaxine overdose.\n", "entity1": "venlafaxine", "entity2": "Seizure", "span1": [25, 36], "span2": [0, 7]}, "bert_text": "Seizure resulting from a <e1> venlafaxine </e1> <e2> Seizure </e2> resulting from a venlafaxine overdose.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2682": {"data": {"text": "Seizure resulting from a venlafaxine overdose.\n", "entity1": "venlafaxine", "entity2": "overdose", "span1": [25, 36], "span2": [37, 45]}, "bert_text": "Seizure resulting from a <e1> venlafaxine </e1> <e2> overdose </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2683": {"data": {"text": "d-1) prevented FK 506-induced hypertension in rats.", "entity1": "FK 506-induced", "entity2": "hypertension", "span1": [15, 29], "span2": [30, 42]}, "bert_text": "d-1) prevented <e1> FK 506-induced </e1> <e2> hypertension </e2> in rats.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2684": {"data": {"text": "Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.\n", "entity1": "Ciprofloxacin", "entity2": "interstitial nephritis", "span1": [0, 13], "span2": [28, 50]}, "bert_text": "<e1> Ciprofloxacin </e1>-induced acute <e2> interstitial nephritis </e2> and autoimmune hemolytic anemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2685": {"data": {"text": "Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.\n", "entity1": "Ciprofloxacin", "entity2": "autoimmune hemolytic anemia", "span1": [0, 13], "span2": [55, 82]}, "bert_text": "<e1> Ciprofloxacin </e1>-induced acute interstitial nephritis and <e2> autoimmune hemolytic anemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2686": {"data": {"text": "The electrocardiograms (ECG) of 99 cocaine-abusing patients were compared with the ECGs of 50 schizophrenic controls.", "entity1": "cocaine", "entity2": "schizophrenic", "span1": [35, 42], "span2": [94, 107]}, "bert_text": "The electrocardiograms (ECG) of 99 <e1> cocaine </e1>-abusing patients were compared with the ECGs of 50 <e2> schizophrenic </e2> controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2687": {"data": {"text": "Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.", "entity1": "yohimbine", "entity2": "anxiety", "span1": [16, 25], "span2": [65, 72]}, "bert_text": "Side effects of <e1> yohimbine </e1> included excessive sweating, increased <e2> anxiety </e2>, and a wound-up feeling in some patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2688": {"data": {"text": "The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.", "entity1": "amisulpride", "entity2": "tic-like symptoms", "span1": [71, 82], "span2": [4, 21]}, "bert_text": "The tic-like symptoms resolved completely after we reduced the dose of <e1> amisulpride </e1> <e2> tic-like symptoms </e2> resolved completely after we reduced the dose of amisulpride down to 800 mg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2689": {"data": {"text": "Importantly, GNC92H2 prevented death even post-cocaine injection.", "entity1": "cocaine", "entity2": "death", "span1": [47, 54], "span2": [31, 36]}, "bert_text": "Importantly, GNC92H2 prevented death even post-<e1> cocaine </e1> <e2> death </e2> even post-cocaine injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2690": {"data": {"text": "Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.\n", "entity1": "phenylephrine", "entity2": "myocardial infarction", "span1": [12, 25], "span2": [104, 125]}, "bert_text": "Reversal by <e1> phenylephrine </e1> of the beneficial effects of intravenous nitroglycerin in patients with acute <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2691": {"data": {"text": "Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.\n", "entity1": "nitroglycerin", "entity2": "myocardial infarction", "span1": [67, 80], "span2": [104, 125]}, "bert_text": "Reversal by phenylephrine of the beneficial effects of intravenous <e1> nitroglycerin </e1> in patients with acute <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2692": {"data": {"text": "Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.", "entity1": "carboplatin", "entity2": "tumors", "span1": [16, 27], "span2": [39, 45]}, "bert_text": "Four days after <e1> carboplatin </e1> treatment, <e2> tumors </e2> (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2693": {"data": {"text": "Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.", "entity1": "carboplatin", "entity2": "sarcoma", "span1": [16, 27], "span2": [50, 57]}, "bert_text": "Four days after <e1> carboplatin </e1> treatment, tumors (DS-<e2> sarcoma </e2> of the rat) were implanted s.c. onto the hind food dorsum.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2694": {"data": {"text": "We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.", "entity1": "tamoxifen", "entity2": "endometrial cancer", "span1": [68, 77], "span2": [45, 63]}, "bert_text": "We have investigated the association between endometrial cancer and <e1> tamoxifen </e1> <e2> endometrial cancer </e2> and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2695": {"data": {"text": "We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [68, 77], "span2": [123, 136]}, "bert_text": "We have investigated the association between endometrial cancer and <e1> tamoxifen </e1> use or other treatments in women treated for <e2> breast cancer </e2> in a case-control study.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2696": {"data": {"text": "Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.", "entity1": "Fentanyl", "entity2": "respiratory depression", "span1": [0, 8], "span2": [102, 124]}, "bert_text": "<e1> Fentanyl </e1> did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased <e2> respiratory depression </e2>, hypotension and bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2697": {"data": {"text": "Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.", "entity1": "Fentanyl", "entity2": "hypotension", "span1": [0, 8], "span2": [126, 137]}, "bert_text": "<e1> Fentanyl </e1> did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, <e2> hypotension </e2> and bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2698": {"data": {"text": "Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.", "entity1": "Fentanyl", "entity2": "bradycardia", "span1": [0, 8], "span2": [142, 153]}, "bert_text": "<e1> Fentanyl </e1> did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and <e2> bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2699": {"data": {"text": "Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.", "entity1": "sevoflurane", "entity2": "respiratory depression", "span1": [61, 72], "span2": [102, 124]}, "bert_text": "Fentanyl did reduce minor intraoperative movement but had no <e1> sevoflurane </e1>-sparing effect and increased <e2> respiratory depression </e2>, hypotension and bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2700": {"data": {"text": "Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.", "entity1": "sevoflurane", "entity2": "hypotension", "span1": [61, 72], "span2": [126, 137]}, "bert_text": "Fentanyl did reduce minor intraoperative movement but had no <e1> sevoflurane </e1>-sparing effect and increased respiratory depression, <e2> hypotension </e2> and bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2701": {"data": {"text": "Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.", "entity1": "sevoflurane", "entity2": "bradycardia", "span1": [61, 72], "span2": [142, 153]}, "bert_text": "Fentanyl did reduce minor intraoperative movement but had no <e1> sevoflurane </e1>-sparing effect and increased respiratory depression, hypotension and <e2> bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2702": {"data": {"text": "Possible intramuscular midazolam-associated cardiorespiratory arrest and death.\n", "entity1": "midazolam", "entity2": "cardiorespiratory arrest", "span1": [23, 32], "span2": [44, 68]}, "bert_text": "Possible intramuscular <e1> midazolam </e1>-associated <e2> cardiorespiratory arrest </e2> and death.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2703": {"data": {"text": "Possible intramuscular midazolam-associated cardiorespiratory arrest and death.\n", "entity1": "midazolam", "entity2": "death", "span1": [23, 32], "span2": [73, 78]}, "bert_text": "Possible intramuscular <e1> midazolam </e1>-associated cardiorespiratory arrest and <e2> death </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2704": {"data": {"text": "Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.", "entity1": "paclitaxel", "entity2": "NSCLC", "span1": [30, 40], "span2": [82, 87]}, "bert_text": "Further phase II studies with <e1> paclitaxel </e1> combined with other drugs active against <e2> NSCLC </e2> are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2705": {"data": {"text": "Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.", "entity1": "paclitaxel", "entity2": "NSCLC", "span1": [135, 145], "span2": [82, 87]}, "bert_text": "Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing <e1> paclitaxel </e1> <e2> NSCLC </e2> are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2706": {"data": {"text": "Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.", "entity1": "Renografin", "entity2": "Ventricular fibrillation", "span1": [64, 74], "span2": [0, 24]}, "bert_text": "Ventricular fibrillation occurred significantly more often with <e1> Renografin </e1> <e2> Ventricular fibrillation </e2> occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2707": {"data": {"text": "Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.", "entity1": "Renografin", "entity2": "toxicity", "span1": [64, 74], "span2": [123, 131]}, "bert_text": "Ventricular fibrillation occurred significantly more often with <e1> Renografin </e1>, suggesting that chelating agents contribute to <e2> toxicity </e2> in coronary angiography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2708": {"data": {"text": "Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.\n", "entity1": "superoxide", "entity2": "acute liver failure", "span1": [11, 21], "span2": [72, 91]}, "bert_text": "Neutrophil <e1> superoxide </e1> and hydrogen peroxide production in patients with <e2> acute liver failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2709": {"data": {"text": "Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.\n", "entity1": "hydrogen peroxide", "entity2": "acute liver failure", "span1": [26, 43], "span2": [72, 91]}, "bert_text": "Neutrophil superoxide and <e1> hydrogen peroxide </e1> production in patients with <e2> acute liver failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2710": {"data": {"text": "Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.", "entity1": "erythromycin", "entity2": "Cardiotoxicity", "span1": [87, 99], "span2": [0, 14]}, "bert_text": "Cardiotoxicity has been demonstrated after both intravenous and oral administration of <e1> erythromycin </e1> <e2> Cardiotoxicity </e2> has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2711": {"data": {"text": "Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.", "entity1": "macrolides", "entity2": "Cardiotoxicity", "span1": [143, 153], "span2": [0, 14]}, "bert_text": "Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer <e1> macrolides </e1> <e2> Cardiotoxicity </e2> has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2712": {"data": {"text": "Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.", "entity1": "Nitroglycerin", "entity2": "myocardial infarction", "span1": [0, 13], "span2": [73, 94]}, "bert_text": "<e1> Nitroglycerin </e1> has been shown to reduce ST-segment elevation during acute <e2> myocardial infarction </e2>, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2713": {"data": {"text": "Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.", "entity1": "Nitroglycerin", "entity2": "hypotension", "span1": [0, 13], "span2": [174, 185]}, "bert_text": "<e1> Nitroglycerin </e1> has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2714": {"data": {"text": "Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.", "entity1": "nitroglycerin", "entity2": "myocardial infarction", "span1": [152, 165], "span2": [73, 94]}, "bert_text": "Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse <e1> nitroglycerin </e1> <e2> myocardial infarction </e2>, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2715": {"data": {"text": "Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.", "entity1": "nitroglycerin", "entity2": "hypotension", "span1": [152, 165], "span2": [174, 185]}, "bert_text": "Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse <e1> nitroglycerin </e1>-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2716": {"data": {"text": "Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.", "entity1": "heparin", "entity2": "hypotensive", "span1": [41, 48], "span2": [167, 178]}, "bert_text": "Recently, a number of commercial lots of <e1> heparin </e1> products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a <e2> hypotensive </e2> response in pigs following a single high-dose infusion.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2717": {"data": {"text": "Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.", "entity1": "chondroitin sulfate", "entity2": "hypotensive", "span1": [109, 128], "span2": [167, 178]}, "bert_text": "Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated <e1> chondroitin sulfate </e1> (OSCS) derivative that could elicit a <e2> hypotensive </e2> response in pigs following a single high-dose infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2718": {"data": {"text": "Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma.\n", "entity1": "timolol", "entity2": "glaucoma", "span1": [44, 51], "span2": [129, 137]}, "bert_text": "Comparison of aqueous and gellan ophthalmic <e1> timolol </e1> with placebo on the 24-hour heart rate response in patients on treatment for <e2> glaucoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2719": {"data": {"text": "He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.", "entity1": "VPA", "entity2": "tonic-clonic convulsions", "span1": [19, 22], "span2": [63, 87]}, "bert_text": "He had been taking <e1> VPA </e1> for treatment of idiopathic generalized <e2> tonic-clonic convulsions </e2> since he was 56 years old.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2720": {"data": {"text": "It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.", "entity1": "5-FU", "entity2": "chest pain", "span1": [33, 37], "span2": [131, 141]}, "bert_text": "It is concluded that patients on <e1> 5-FU </e1> treatment should be under close supervision and that the treatment should be discontinued if <e2> chest pain </e2> or tachyarrhythmia is observed.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2721": {"data": {"text": "It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.", "entity1": "5-FU", "entity2": "tachyarrhythmia", "span1": [33, 37], "span2": [145, 160]}, "bert_text": "It is concluded that patients on <e1> 5-FU </e1> treatment should be under close supervision and that the treatment should be discontinued if chest pain or <e2> tachyarrhythmia </e2> is observed.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2722": {"data": {"text": "Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.\n", "entity1": "alcohol", "entity2": "Acute liver failure", "span1": [49, 56], "span2": [0, 19]}, "bert_text": "Acute liver failure in two patients with regular <e1> alcohol </e1> <e2> Acute liver failure </e2> in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2723": {"data": {"text": "Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.\n", "entity1": "paracetamol", "entity2": "Acute liver failure", "span1": [79, 90], "span2": [0, 19]}, "bert_text": "Acute liver failure in two patients with regular alcohol consumption ingesting <e1> paracetamol </e1> <e2> Acute liver failure </e2> in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2724": {"data": {"text": "Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.", "entity1": "carboplatin", "entity2": "tumor", "span1": [8, 19], "span2": [52, 57]}, "bert_text": "Neither <e1> carboplatin </e1> nor rHuEPO treatment influenced <e2> tumor </e2> growth rate per se.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2725": {"data": {"text": "DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.", "entity1": "ticlopidine", "entity2": "Cholestatic hepatitis", "span1": [83, 94], "span2": [12, 33]}, "bert_text": "DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent <e1> ticlopidine </e1> <e2> Cholestatic hepatitis </e2> is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2726": {"data": {"text": "CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.", "entity1": "fentanyl", "entity2": "postoperative nausea and vomiting", "span1": [15, 23], "span2": [36, 69]}, "bert_text": "CONCLUSION: As <e1> fentanyl </e1> exacerbated <e2> postoperative nausea and vomiting </e2> without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2727": {"data": {"text": "CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.", "entity1": "fentanyl", "entity2": "postoperative pain", "span1": [15, 23], "span2": [96, 114]}, "bert_text": "CONCLUSION: As <e1> fentanyl </e1> exacerbated postoperative nausea and vomiting without an improvement in <e2> postoperative pain </e2> and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2728": {"data": {"text": "CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.", "entity1": "sevoflurane", "entity2": "postoperative nausea and vomiting", "span1": [234, 245], "span2": [36, 69]}, "bert_text": "CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to <e1> sevoflurane </e1> <e2> postoperative nausea and vomiting </e2> without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2729": {"data": {"text": "CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.", "entity1": "sevoflurane", "entity2": "postoperative pain", "span1": [234, 245], "span2": [96, 114]}, "bert_text": "CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to <e1> sevoflurane </e1> <e2> postoperative pain </e2> and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2730": {"data": {"text": "Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.\n", "entity1": "ethambutol", "entity2": "axonal loss", "span1": [70, 80], "span2": [41, 52]}, "bert_text": "Optical coherence tomography can measure axonal loss in patients with <e1> ethambutol </e1> <e2> axonal loss </e2> in patients with ethambutol-induced optic neuropathy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"2731": {"data": {"text": "Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.\n", "entity1": "ethambutol", "entity2": "optic neuropathy", "span1": [70, 80], "span2": [89, 105]}, "bert_text": "Optical coherence tomography can measure axonal loss in patients with <e1> ethambutol </e1>-induced <e2> optic neuropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"2732": {"data": {"text": "A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.", "entity1": "echothiophate iodide", "entity2": "muscle weakness", "span1": [66, 86], "span2": [129, 144]}, "bert_text": "A patient developed a severe cholinergic syndrome from the use of <e1> echothiophate iodide </e1> ophthalmic drops, presented with profound <e2> muscle weakness </e2> and was initially given the diagnosis of myasthenia gravis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2733": {"data": {"text": "A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.", "entity1": "echothiophate iodide", "entity2": "myasthenia gravis", "span1": [66, 86], "span2": [186, 203]}, "bert_text": "A patient developed a severe cholinergic syndrome from the use of <e1> echothiophate iodide </e1> ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of <e2> myasthenia gravis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2734": {"data": {"text": "Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).", "entity1": "P", "entity2": "DM", "span1": [9, 10], "span2": [130, 132]}, "bert_text": "Group 1 (<e1> P </e1> alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild <e2> DM </e2> + gentamicin).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2735": {"data": {"text": "Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).", "entity1": "P", "entity2": "DM", "span1": [27, 28], "span2": [130, 132]}, "bert_text": "Group 1 (P alone) received <e1> P </e1>, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild <e2> DM </e2> + gentamicin).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2736": {"data": {"text": "Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).", "entity1": "P", "entity2": "DM", "span1": [65, 66], "span2": [130, 132]}, "bert_text": "Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (<e1> P </e1> + gentamicin); Group III (gentamicin alone) and Group IV (mild <e2> DM </e2> + gentamicin).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2737": {"data": {"text": "Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).", "entity1": "gentamicin", "entity2": "DM", "span1": [69, 79], "span2": [130, 132]}, "bert_text": "Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + <e1> gentamicin </e1>); Group III (gentamicin alone) and Group IV (mild <e2> DM </e2> + gentamicin).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2738": {"data": {"text": "Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).", "entity1": "gentamicin", "entity2": "DM", "span1": [93, 103], "span2": [130, 132]}, "bert_text": "Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (<e1> gentamicin </e1> alone) and Group IV (mild <e2> DM </e2> + gentamicin).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2739": {"data": {"text": "Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).", "entity1": "gentamicin", "entity2": "DM", "span1": [135, 145], "span2": [130, 132]}, "bert_text": "Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + <e1> gentamicin </e1> <e2> DM </e2> + gentamicin).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2740": {"data": {"text": "Postpartum psychosis induced by bromocriptine.\n", "entity1": "bromocriptine", "entity2": "psychosis", "span1": [32, 45], "span2": [11, 20]}, "bert_text": "Postpartum psychosis induced by <e1> bromocriptine </e1> <e2> psychosis </e2> induced by bromocriptine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2741": {"data": {"text": "We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).", "entity1": "sodium valproate", "entity2": "SIADH", "span1": [61, 77], "span2": [180, 185]}, "bert_text": "We report the case of a 62-year-old man who was administered <e1> sodium valproate </e1> (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (<e2> SIADH </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2742": {"data": {"text": "We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).", "entity1": "VPA", "entity2": "SIADH", "span1": [79, 82], "span2": [180, 185]}, "bert_text": "We report the case of a 62-year-old man who was administered sodium valproate (<e1> VPA </e1>) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (<e2> SIADH </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2743": {"data": {"text": "Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.\n", "entity1": "acetaminophen", "entity2": "cerebral edema", "span1": [68, 81], "span2": [8, 22]}, "bert_text": "Massive cerebral edema associated with fulminant hepatic failure in <e1> acetaminophen </e1> <e2> cerebral edema </e2> associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2744": {"data": {"text": "Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.\n", "entity1": "acetaminophen", "entity2": "fulminant hepatic failure", "span1": [68, 81], "span2": [39, 64]}, "bert_text": "Massive cerebral edema associated with fulminant hepatic failure in <e1> acetaminophen </e1> <e2> fulminant hepatic failure </e2> in acetaminophen overdose: possible role of cranial decompression.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2745": {"data": {"text": "Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.\n", "entity1": "acetaminophen", "entity2": "overdose", "span1": [68, 81], "span2": [82, 90]}, "bert_text": "Massive cerebral edema associated with fulminant hepatic failure in <e1> acetaminophen </e1> <e2> overdose </e2>: possible role of cranial decompression.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2746": {"data": {"text": "Central vein thrombosis and topical dipivalyl epinephrine.\n", "entity1": "dipivalyl epinephrine", "entity2": "vein thrombosis", "span1": [36, 57], "span2": [8, 23]}, "bert_text": "Central vein thrombosis and topical <e1> dipivalyl epinephrine </e1> <e2> vein thrombosis </e2> and topical dipivalyl epinephrine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2747": {"data": {"text": "Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.\n", "entity1": "Doxorubicin", "entity2": "cardiomyopathy", "span1": [0, 11], "span2": [12, 26]}, "bert_text": "<e1> Doxorubicin </e1> <e2> cardiomyopathy </e2>-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2748": {"data": {"text": "Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.\n", "entity1": "Doxorubicin", "entity2": "inflammation", "span1": [0, 11], "span2": [35, 47]}, "bert_text": "<e1> Doxorubicin </e1> cardiomyopathy-induced <e2> inflammation </e2> and apoptosis are attenuated by gene deletion of the kinin B1 receptor.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2749": {"data": {"text": "Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.", "entity1": "Adriamycin", "entity2": "bladder tumors", "span1": [0, 10], "span2": [114, 128]}, "bert_text": "<e1> Adriamycin </e1> (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) <e2> bladder tumors </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2750": {"data": {"text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "entity1": "gum Arabic", "entity2": "tubular necrosis", "span1": [54, 64], "span2": [348, 364]}, "bert_text": "The results indicated that concomitant treatment with <e1> gum Arabic </e1> and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2751": {"data": {"text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "entity1": "gum Arabic", "entity2": "tubular necrosis", "span1": [432, 442], "span2": [348, 364]}, "bert_text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with <e1> gum Arabic </e1> <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2752": {"data": {"text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "entity1": "GM", "entity2": "tubular necrosis", "span1": [69, 71], "span2": [348, 364]}, "bert_text": "The results indicated that concomitant treatment with gum Arabic and <e1> GM </e1> significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2753": {"data": {"text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "entity1": "GM", "entity2": "tubular necrosis", "span1": [228, 230], "span2": [348, 364]}, "bert_text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and <e1> GM </e1>), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2754": {"data": {"text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "entity1": "GM", "entity2": "tubular necrosis", "span1": [314, 316], "span2": [348, 364]}, "bert_text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus <e1> GM </e1> group) The GM-induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2755": {"data": {"text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "entity1": "GM", "entity2": "tubular necrosis", "span1": [328, 330], "span2": [348, 364]}, "bert_text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The <e1> GM </e1>-induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2756": {"data": {"text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "entity1": "GM", "entity2": "tubular necrosis", "span1": [415, 417], "span2": [348, 364]}, "bert_text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given <e1> GM </e1> <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2757": {"data": {"text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "entity1": "GM", "entity2": "tubular necrosis", "span1": [463, 465], "span2": [348, 364]}, "bert_text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given <e1> GM </e1> <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2758": {"data": {"text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "entity1": "creatinine", "entity2": "tubular necrosis", "span1": [96, 106], "span2": [348, 364]}, "bert_text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased <e1> creatinine </e1> and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2759": {"data": {"text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "entity1": "urea", "entity2": "tubular necrosis", "span1": [111, 115], "span2": [348, 364]}, "bert_text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and <e1> urea </e1> by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2760": {"data": {"text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "entity1": "GSH", "entity2": "tubular necrosis", "span1": [264, 267], "span2": [348, 364]}, "bert_text": "The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical <e1> GSH </e1> by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal <e2> tubular necrosis </e2> appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2761": {"data": {"text": "A total of 177 patients were diagnosed as allergic to beta-lactam antibiotics.", "entity1": "beta-lactam", "entity2": "allergic", "span1": [54, 65], "span2": [42, 50]}, "bert_text": "A total of 177 patients were diagnosed as allergic to <e1> beta-lactam </e1> <e2> allergic </e2> to beta-lactam antibiotics.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2762": {"data": {"text": "In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).", "entity1": "angiotensin", "entity2": "renal artery stenosis", "span1": [143, 154], "span2": [17, 38]}, "bert_text": "In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-<e1> angiotensin </e1> <e2> renal artery stenosis </e2> combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2763": {"data": {"text": "In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).", "entity1": "angiotensin", "entity2": "heart failure", "span1": [143, 154], "span2": [53, 66]}, "bert_text": "In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-<e1> angiotensin </e1> <e2> heart failure </e2> and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2764": {"data": {"text": "Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.", "entity1": "enflurane", "entity2": "allergic-type hepatic injury", "span1": [29, 38], "span2": [84, 112]}, "bert_text": "Two halogenated anesthetics, <e1> enflurane </e1> and isoflurane, have been associated with an <e2> allergic-type hepatic injury </e2> both alone and following previous exposure to halothane.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2765": {"data": {"text": "Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.", "entity1": "isoflurane", "entity2": "allergic-type hepatic injury", "span1": [43, 53], "span2": [84, 112]}, "bert_text": "Two halogenated anesthetics, enflurane and <e1> isoflurane </e1>, have been associated with an <e2> allergic-type hepatic injury </e2> both alone and following previous exposure to halothane.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2766": {"data": {"text": "Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.", "entity1": "halothane", "entity2": "allergic-type hepatic injury", "span1": [159, 168], "span2": [84, 112]}, "bert_text": "Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to <e1> halothane </e1> <e2> allergic-type hepatic injury </e2> both alone and following previous exposure to halothane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2767": {"data": {"text": "The incidence of extrapyramidal side effects (EPS) was evaluated in 98 patients treated with haloperidol.", "entity1": "haloperidol", "entity2": "EPS", "span1": [93, 104], "span2": [46, 49]}, "bert_text": "The incidence of extrapyramidal side effects (EPS) was evaluated in 98 patients treated with <e1> haloperidol </e1> <e2> EPS </e2>) was evaluated in 98 patients treated with haloperidol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2768": {"data": {"text": "Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.", "entity1": "1-bromo-1-chloro-2,2,2-trifluoroethane", "entity2": "hepatotoxicity", "span1": [50, 88], "span2": [190, 204]}, "bert_text": "Both compounds are metabolised in the same way as <e1> 1-bromo-1-chloro-2,2,2-trifluoroethane </e1> (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the <e2> hepatotoxicity </e2> of halothane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2769": {"data": {"text": "Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.", "entity1": "halothane", "entity2": "hepatotoxicity", "span1": [90, 99], "span2": [190, 204]}, "bert_text": "Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (<e1> halothane </e1>) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the <e2> hepatotoxicity </e2> of halothane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2770": {"data": {"text": "Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.", "entity1": "halothane", "entity2": "hepatotoxicity", "span1": [208, 217], "span2": [190, 204]}, "bert_text": "Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of <e1> halothane </e1> <e2> hepatotoxicity </e2> of halothane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2771": {"data": {"text": "Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.", "entity1": "trifluoroacetyl", "entity2": "hepatotoxicity", "span1": [118, 133], "span2": [190, 204]}, "bert_text": "Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive <e1> trifluoroacetyl </e1> halide intermediates, which have been implicated in the <e2> hepatotoxicity </e2> of halothane.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2772": {"data": {"text": "The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.\n", "entity1": "gum Arabic", "entity2": "nephrotoxicity", "span1": [29, 39], "span2": [54, 68]}, "bert_text": "The effect of treatment with <e1> gum Arabic </e1> on gentamicin <e2> nephrotoxicity </e2> in rats: a preliminary study.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2773": {"data": {"text": "The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.\n", "entity1": "gentamicin", "entity2": "nephrotoxicity", "span1": [43, 53], "span2": [54, 68]}, "bert_text": "The effect of treatment with gum Arabic on <e1> gentamicin </e1> <e2> nephrotoxicity </e2> in rats: a preliminary study.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2774": {"data": {"text": "Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.", "entity1": "curcumin", "entity2": "cognitive impairment", "span1": [82, 90], "span2": [151, 171]}, "bert_text": "Therefore, the present study was carried out to investigate the effect of chronic <e1> curcumin </e1> administration on phenobarbitone- and carbamazepine-induced <e2> cognitive impairment </e2> and oxidative stress in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2775": {"data": {"text": "Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.", "entity1": "phenobarbitone-", "entity2": "cognitive impairment", "span1": [109, 124], "span2": [151, 171]}, "bert_text": "Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on <e1> phenobarbitone- </e1> and carbamazepine-induced <e2> cognitive impairment </e2> and oxidative stress in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2776": {"data": {"text": "Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.", "entity1": "carbamazepine", "entity2": "cognitive impairment", "span1": [129, 142], "span2": [151, 171]}, "bert_text": "Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and <e1> carbamazepine </e1>-induced <e2> cognitive impairment </e2> and oxidative stress in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2777": {"data": {"text": "These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.", "entity1": "amphetamine", "entity2": "contralateral rotation", "span1": [28, 39], "span2": [110, 132]}, "bert_text": "These findings suggest that <e1> amphetamine </e1> has an irreversible effect on the post-lesion DA pool contributing to <e2> contralateral rotation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2778": {"data": {"text": "These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.", "entity1": "DA", "entity2": "contralateral rotation", "span1": [86, 88], "span2": [110, 132]}, "bert_text": "These findings suggest that amphetamine has an irreversible effect on the post-lesion <e1> DA </e1> pool contributing to <e2> contralateral rotation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2779": {"data": {"text": "Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature.\n", "entity1": "Ticlopidine", "entity2": "aplastic anemia", "span1": [0, 11], "span2": [20, 35]}, "bert_text": "<e1> Ticlopidine </e1>-induced <e2> aplastic anemia </e2>: report of three Chinese patients and review of the literature.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2780": {"data": {"text": "The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.", "entity1": "methyldopa", "entity2": "hepatitis", "span1": [141, 151], "span2": [56, 65]}, "bert_text": "The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of <e1> methyldopa </e1> <e2> hepatitis </e2> when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2781": {"data": {"text": "The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.", "entity1": "methyldopa", "entity2": "hepatitis", "span1": [141, 151], "span2": [160, 169]}, "bert_text": "The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of <e1> methyldopa </e1>-induced <e2> hepatitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2782": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "carbon tetrachloride", "entity2": "cirrhosis of the liver", "span1": [285, 305], "span2": [20, 42]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of <e1> carbon tetrachloride </e1> <e2> cirrhosis of the liver </e2> (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2783": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "carbon tetrachloride", "entity2": "ascites", "span1": [285, 305], "span2": [116, 123]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of <e1> carbon tetrachloride </e1> <e2> ascites </e2> greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2784": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "carbon tetrachloride", "entity2": "splenomegaly", "span1": [285, 305], "span2": [179, 191]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of <e1> carbon tetrachloride </e1> <e2> splenomegaly </e2> 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2785": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "carbon tetrachloride", "entity2": "testicular atrophy", "span1": [285, 305], "span2": [214, 232]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of <e1> carbon tetrachloride </e1> <e2> testicular atrophy </e2> approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2786": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "carbon tetrachloride", "entity2": "cirrhosis of the liver", "span1": [436, 456], "span2": [20, 42]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of <e1> carbon tetrachloride </e1> <e2> cirrhosis of the liver </e2> (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2787": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "carbon tetrachloride", "entity2": "ascites", "span1": [436, 456], "span2": [116, 123]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of <e1> carbon tetrachloride </e1> <e2> ascites </e2> greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2788": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "carbon tetrachloride", "entity2": "splenomegaly", "span1": [436, 456], "span2": [179, 191]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of <e1> carbon tetrachloride </e1> <e2> splenomegaly </e2> 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2789": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "carbon tetrachloride", "entity2": "testicular atrophy", "span1": [436, 456], "span2": [214, 232]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of <e1> carbon tetrachloride </e1> <e2> testicular atrophy </e2> approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2790": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "phenobarbitone", "entity2": "cirrhosis of the liver", "span1": [336, 350], "span2": [20, 42]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the <e1> phenobarbitone </e1> <e2> cirrhosis of the liver </e2> (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2791": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "phenobarbitone", "entity2": "ascites", "span1": [336, 350], "span2": [116, 123]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the <e1> phenobarbitone </e1> <e2> ascites </e2> greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2792": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "phenobarbitone", "entity2": "splenomegaly", "span1": [336, 350], "span2": [179, 191]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the <e1> phenobarbitone </e1> <e2> splenomegaly </e2> 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2793": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "phenobarbitone", "entity2": "testicular atrophy", "span1": [336, 350], "span2": [214, 232]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the <e1> phenobarbitone </e1> <e2> testicular atrophy </e2> approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2794": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "phenobarbitone", "entity2": "cirrhosis of the liver", "span1": [476, 490], "span2": [20, 42]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the <e1> phenobarbitone </e1> <e2> cirrhosis of the liver </e2> (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2795": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "phenobarbitone", "entity2": "ascites", "span1": [476, 490], "span2": [116, 123]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the <e1> phenobarbitone </e1> <e2> ascites </e2> greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2796": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "phenobarbitone", "entity2": "splenomegaly", "span1": [476, 490], "span2": [179, 191]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the <e1> phenobarbitone </e1> <e2> splenomegaly </e2> 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2797": {"data": {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity1": "phenobarbitone", "entity2": "testicular atrophy", "span1": [476, 490], "span2": [214, 232]}, "bert_text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the <e1> phenobarbitone </e1> <e2> testicular atrophy </e2> approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2798": {"data": {"text": "The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine.", "entity1": "scopolamine", "entity2": "impairment of attention and memory", "span1": [118, 129], "span2": [72, 106]}, "bert_text": "The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by <e1> scopolamine </e1> <e2> impairment of attention and memory </e2> induced by scopolamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2799": {"data": {"text": "Recurrent reversible acute renal failure from amphotericin.\n", "entity1": "amphotericin", "entity2": "acute renal failure", "span1": [46, 58], "span2": [21, 40]}, "bert_text": "Recurrent reversible acute renal failure from <e1> amphotericin </e1> <e2> acute renal failure </e2> from amphotericin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2800": {"data": {"text": "Progressive myopathy with up-regulation of MHC-I associated with statin therapy.\n", "entity1": "statin", "entity2": "myopathy", "span1": [65, 71], "span2": [12, 20]}, "bert_text": "Progressive myopathy with up-regulation of MHC-I associated with <e1> statin </e1> <e2> myopathy </e2> with up-regulation of MHC-I associated with statin therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2801": {"data": {"text": "Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group.", "entity1": "nitroglycerin", "entity2": "migraine", "span1": [45, 58], "span2": [12, 20]}, "bert_text": "Early onset migraine attacks were induced by <e1> nitroglycerin </e1> <e2> migraine </e2> attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2802": {"data": {"text": "Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.", "entity1": "Levodopa", "entity2": "dyskinesia", "span1": [0, 8], "span2": [17, 27]}, "bert_text": "<e1> Levodopa </e1>-induced <e2> dyskinesia </e2> of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2803": {"data": {"text": "Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.", "entity1": "Levodopa", "entity2": "Parkinsonism", "span1": [0, 8], "span2": [62, 74]}, "bert_text": "<e1> Levodopa </e1>-induced dyskinesia of the limbs in thirteen cases of <e2> Parkinsonism </e2>, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2804": {"data": {"text": "Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.", "entity1": "Levodopa", "entity2": "dystonic", "span1": [0, 8], "span2": [108, 116]}, "bert_text": "<e1> Levodopa </e1>-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or <e2> dystonic </e2> in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2805": {"data": {"text": "A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.", "entity1": "ketamine", "entity2": "cancer", "span1": [37, 45], "span2": [89, 95]}, "bert_text": "A slow bolus of subhypnotic doses of <e1> ketamine </e1> (0.25 mg/kg or 0.50 mg/kg) was given to 10 <e2> cancer </e2> patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2806": {"data": {"text": "A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.", "entity1": "ketamine", "entity2": "pain", "span1": [37, 45], "span2": [111, 115]}, "bert_text": "A slow bolus of subhypnotic doses of <e1> ketamine </e1> (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose <e2> pain </e2> was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2807": {"data": {"text": "A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.", "entity1": "morphine", "entity2": "cancer", "span1": [134, 142], "span2": [89, 95]}, "bert_text": "A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by <e1> morphine </e1> <e2> cancer </e2> patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2808": {"data": {"text": "A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.", "entity1": "morphine", "entity2": "pain", "span1": [134, 142], "span2": [111, 115]}, "bert_text": "A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by <e1> morphine </e1> <e2> pain </e2> was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2809": {"data": {"text": "The most common adverse effect of intravenous ribavirin is reversible mild anemia.", "entity1": "ribavirin", "entity2": "anemia", "span1": [46, 55], "span2": [75, 81]}, "bert_text": "The most common adverse effect of intravenous <e1> ribavirin </e1> is reversible mild <e2> anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2810": {"data": {"text": "We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.", "entity1": "HCFCs 123 and 124", "entity2": "liver disease", "span1": [25, 42], "span2": [65, 78]}, "bert_text": "We aimed to test whether <e1> HCFCs 123 and 124 </e1> can result in serious <e2> liver disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2811": {"data": {"text": "In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.", "entity1": "apomorphine", "entity2": "aggressive behavior", "span1": [26, 37], "span2": [81, 100]}, "bert_text": "In male animals, repeated <e1> apomorphine </e1> treatment induced a gradual development of <e2> aggressive behavior </e2> as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2812": {"data": {"text": "In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.", "entity1": "apomorphine", "entity2": "aggressiveness", "span1": [26, 37], "span2": [144, 158]}, "bert_text": "In male animals, repeated <e1> apomorphine </e1> treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of <e2> aggressiveness </e2> and shortened latency before the first attack toward the opponent.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2813": {"data": {"text": "In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.", "entity1": "gum Arabic", "entity2": "acute renal failure", "span1": [69, 79], "span2": [83, 102]}, "bert_text": "In the present work we assessed the effect of treatment of rats with <e1> gum Arabic </e1> on <e2> acute renal failure </e2> induced by gentamicin (GM) nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2814": {"data": {"text": "In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.", "entity1": "gum Arabic", "entity2": "nephrotoxicity", "span1": [69, 79], "span2": [130, 144]}, "bert_text": "In the present work we assessed the effect of treatment of rats with <e1> gum Arabic </e1> on acute renal failure induced by gentamicin (GM) <e2> nephrotoxicity </e2>.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2815": {"data": {"text": "In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.", "entity1": "gentamicin", "entity2": "acute renal failure", "span1": [114, 124], "span2": [83, 102]}, "bert_text": "In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by <e1> gentamicin </e1> <e2> acute renal failure </e2> induced by gentamicin (GM) nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2816": {"data": {"text": "In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.", "entity1": "gentamicin", "entity2": "nephrotoxicity", "span1": [114, 124], "span2": [130, 144]}, "bert_text": "In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by <e1> gentamicin </e1> (GM) <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2817": {"data": {"text": "In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.", "entity1": "GM", "entity2": "acute renal failure", "span1": [126, 128], "span2": [83, 102]}, "bert_text": "In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (<e1> GM </e1> <e2> acute renal failure </e2> induced by gentamicin (GM) nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2818": {"data": {"text": "In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.", "entity1": "GM", "entity2": "nephrotoxicity", "span1": [126, 128], "span2": [130, 144]}, "bert_text": "In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (<e1> GM </e1>) <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2819": {"data": {"text": "We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.", "entity1": "Dexatrim", "entity2": "myocardial injury", "span1": [33, 41], "span2": [56, 73]}, "bert_text": "We report here the first case of <e1> Dexatrim </e1> (PPA)-induced <e2> myocardial injury </e2> in a young woman who was using it at recommended doses for weight control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2820": {"data": {"text": "We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.", "entity1": "PPA)-induced", "entity2": "myocardial injury", "span1": [43, 55], "span2": [56, 73]}, "bert_text": "We report here the first case of Dexatrim (<e1> PPA)-induced </e1> <e2> myocardial injury </e2> in a young woman who was using it at recommended doses for weight control.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2821": {"data": {"text": "Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.", "entity1": "VPA", "entity2": "necrosis", "span1": [38, 41], "span2": [149, 157]}, "bert_text": "Overall, these findings indicate that <e1> VPA </e1> treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of <e2> necrosis </e2>, steatosis, and elevated levels of serum alpha-GST.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2822": {"data": {"text": "Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.", "entity1": "VPA", "entity2": "steatosis", "span1": [38, 41], "span2": [159, 168]}, "bert_text": "Overall, these findings indicate that <e1> VPA </e1> treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, <e2> steatosis </e2>, and elevated levels of serum alpha-GST.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2823": {"data": {"text": "Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.", "entity1": "15-F(2t)-IsoP", "entity2": "necrosis", "span1": [106, 119], "span2": [149, 157]}, "bert_text": "Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of <e1> 15-F(2t)-IsoP </e1>, which precedes the onset of <e2> necrosis </e2>, steatosis, and elevated levels of serum alpha-GST.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"2824": {"data": {"text": "Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.", "entity1": "15-F(2t)-IsoP", "entity2": "steatosis", "span1": [106, 119], "span2": [159, 168]}, "bert_text": "Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of <e1> 15-F(2t)-IsoP </e1>, which precedes the onset of necrosis, <e2> steatosis </e2>, and elevated levels of serum alpha-GST.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"2825": {"data": {"text": "Halothane hepatitis appears to involve an aberrant immune response.", "entity1": "Halothane", "entity2": "hepatitis", "span1": [0, 9], "span2": [10, 19]}, "bert_text": "<e1> Halothane </e1> <e2> hepatitis </e2> appears to involve an aberrant immune response.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2826": {"data": {"text": "Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.\n", "entity1": "cocaine", "entity2": "locomotor hyperactivity", "span1": [88, 95], "span2": [104, 127]}, "bert_text": "Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the <e1> cocaine </e1>-induced <e2> locomotor hyperactivity </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2827": {"data": {"text": "Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.", "entity1": "nitroglycerin", "entity2": "migraine", "span1": [83, 96], "span2": [14, 22]}, "bert_text": "Twenty common migraine patients received a one sided frontotemporal application of <e1> nitroglycerin </e1> <e2> migraine </e2> patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2828": {"data": {"text": "The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients.", "entity1": "haloperidol", "entity2": "parkinsonism", "span1": [60, 71], "span2": [17, 29]}, "bert_text": "The incidence of parkinsonism was higher at higher doses of <e1> haloperidol </e1> <e2> parkinsonism </e2> was higher at higher doses of haloperidol and in younger patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2829": {"data": {"text": "INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [167, 176], "span2": [115, 128]}, "bert_text": "INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of <e1> tamoxifen </e1> <e2> breast cancer </e2>, the postulated protective effects of tamoxifen are not yet apparent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"2830": {"data": {"text": "The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.", "entity1": "apomorphine", "entity2": "psychiatric", "span1": [38, 49], "span2": [129, 140]}, "bert_text": "The main side effects of subcutaneous <e1> apomorphine </e1> treatment are related to cutaneous tolerability problems, whereas sedation and <e2> psychiatric </e2> complications play a lesser role.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2831": {"data": {"text": "The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.\n", "entity1": "cyproterone acetate", "entity2": "venous thromboembolism", "span1": [55, 74], "span2": [12, 34]}, "bert_text": "The risk of venous thromboembolism in women prescribed <e1> cyproterone acetate </e1> <e2> venous thromboembolism </e2> in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"2832": {"data": {"text": "The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.\n", "entity1": "ethinyl estradiol", "entity2": "venous thromboembolism", "span1": [95, 112], "span2": [12, 34]}, "bert_text": "The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with <e1> ethinyl estradiol </e1> <e2> venous thromboembolism </e2> in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"2833": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "Cyproterone acetate", "entity2": "acne", "span1": [12, 31], "span2": [127, 131]}, "bert_text": "BACKGROUND: <e1> Cyproterone acetate </e1> combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with <e2> acne </e2> and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2834": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "Cyproterone acetate", "entity2": "hirsutism", "span1": [12, 31], "span2": [136, 145]}, "bert_text": "BACKGROUND: <e1> Cyproterone acetate </e1> combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and <e2> hirsutism </e2> and is also a treatment option for polycystic ovary syndrome (PCOS).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2835": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "Cyproterone acetate", "entity2": "polycystic ovary syndrome", "span1": [12, 31], "span2": [181, 206]}, "bert_text": "BACKGROUND: <e1> Cyproterone acetate </e1> combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2> polycystic ovary syndrome </e2> (PCOS).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2836": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "Cyproterone acetate", "entity2": "PCOS", "span1": [12, 31], "span2": [208, 212]}, "bert_text": "BACKGROUND: <e1> Cyproterone acetate </e1> combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (<e2> PCOS </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2837": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "CPA", "entity2": "acne", "span1": [65, 68], "span2": [127, 131]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (<e1> CPA </e1>/EE) is licensed in the UK for the treatment of women with <e2> acne </e2> and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2838": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "CPA", "entity2": "hirsutism", "span1": [65, 68], "span2": [136, 145]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (<e1> CPA </e1>/EE) is licensed in the UK for the treatment of women with acne and <e2> hirsutism </e2> and is also a treatment option for polycystic ovary syndrome (PCOS).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2839": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "CPA", "entity2": "polycystic ovary syndrome", "span1": [65, 68], "span2": [181, 206]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (<e1> CPA </e1>/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2> polycystic ovary syndrome </e2> (PCOS).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2840": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "CPA", "entity2": "PCOS", "span1": [65, 68], "span2": [208, 212]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (<e1> CPA </e1>/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (<e2> PCOS </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2841": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "ethinyl estradiol", "entity2": "acne", "span1": [46, 63], "span2": [127, 131]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with <e1> ethinyl estradiol </e1> (CPA/EE) is licensed in the UK for the treatment of women with <e2> acne </e2> and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2842": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "ethinyl estradiol", "entity2": "hirsutism", "span1": [46, 63], "span2": [136, 145]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with <e1> ethinyl estradiol </e1> (CPA/EE) is licensed in the UK for the treatment of women with acne and <e2> hirsutism </e2> and is also a treatment option for polycystic ovary syndrome (PCOS).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2843": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "ethinyl estradiol", "entity2": "polycystic ovary syndrome", "span1": [46, 63], "span2": [181, 206]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with <e1> ethinyl estradiol </e1> (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2> polycystic ovary syndrome </e2> (PCOS).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2844": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "ethinyl estradiol", "entity2": "PCOS", "span1": [46, 63], "span2": [208, 212]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with <e1> ethinyl estradiol </e1> (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (<e2> PCOS </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2845": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "EE", "entity2": "acne", "span1": [69, 71], "span2": [127, 131]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/<e1> EE </e1>) is licensed in the UK for the treatment of women with <e2> acne </e2> and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2846": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "EE", "entity2": "hirsutism", "span1": [69, 71], "span2": [136, 145]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/<e1> EE </e1>) is licensed in the UK for the treatment of women with acne and <e2> hirsutism </e2> and is also a treatment option for polycystic ovary syndrome (PCOS).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2847": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "EE", "entity2": "polycystic ovary syndrome", "span1": [69, 71], "span2": [181, 206]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/<e1> EE </e1>) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for <e2> polycystic ovary syndrome </e2> (PCOS).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2848": {"data": {"text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).", "entity1": "EE", "entity2": "PCOS", "span1": [69, 71], "span2": [208, 212]}, "bert_text": "BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/<e1> EE </e1>) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (<e2> PCOS </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2849": {"data": {"text": "Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.", "entity1": "Adriamycin", "entity2": "toxicities", "span1": [23, 33], "span2": [80, 90]}, "bert_text": "Thermal enhancement of <e1> Adriamycin </e1>-mediated antitumor activity and normal tissue <e2> toxicities </e2> by whole body hyperthermia were compared using a F344 rat model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2850": {"data": {"text": "Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.", "entity1": "Adriamycin", "entity2": "hyperthermia", "span1": [23, 33], "span2": [105, 117]}, "bert_text": "Thermal enhancement of <e1> Adriamycin </e1>-mediated antitumor activity and normal tissue toxicities by whole body <e2> hyperthermia </e2> were compared using a F344 rat model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2851": {"data": {"text": "Acute liver failure with concurrent bupropion and carbimazole therapy.\n", "entity1": "bupropion", "entity2": "Acute liver failure", "span1": [36, 45], "span2": [0, 19]}, "bert_text": "Acute liver failure with concurrent <e1> bupropion </e1> <e2> Acute liver failure </e2> with concurrent bupropion and carbimazole therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2852": {"data": {"text": "Acute liver failure with concurrent bupropion and carbimazole therapy.\n", "entity1": "carbimazole", "entity2": "Acute liver failure", "span1": [50, 61], "span2": [0, 19]}, "bert_text": "Acute liver failure with concurrent bupropion and <e1> carbimazole </e1> <e2> Acute liver failure </e2> with concurrent bupropion and carbimazole therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2853": {"data": {"text": "Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.", "entity1": "ketamine", "entity2": "pain", "span1": [97, 105], "span2": [167, 171]}, "bert_text": "Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as <e1> ketamine </e1>, may be effective in improving opioid analgesia in difficult <e2> pain </e2> syndromes, such as neuropathic pain.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2854": {"data": {"text": "Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.", "entity1": "ketamine", "entity2": "neuropathic pain", "span1": [97, 105], "span2": [191, 207]}, "bert_text": "Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as <e1> ketamine </e1>, may be effective in improving opioid analgesia in difficult pain syndromes, such as <e2> neuropathic pain </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2855": {"data": {"text": "CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.", "entity1": "venlafaxine", "entity2": "major depression", "span1": [76, 87], "span2": [39, 55]}, "bert_text": "CASE SUMMARY: A 40-year-old woman with major depression took an overdose of <e1> venlafaxine </e1> <e2> major depression </e2> took an overdose of venlafaxine in an apparent suicide attempt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2856": {"data": {"text": "CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.", "entity1": "venlafaxine", "entity2": "overdose", "span1": [76, 87], "span2": [64, 72]}, "bert_text": "CASE SUMMARY: A 40-year-old woman with major depression took an overdose of <e1> venlafaxine </e1> <e2> overdose </e2> of venlafaxine in an apparent suicide attempt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2857": {"data": {"text": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "entity1": "lithium carbonate", "entity2": "incontinence", "span1": [50, 67], "span2": [131, 143]}, "bert_text": "In 2 of the 3 cases the patients were also taking <e1> lithium carbonate </e1> and beta-blockers, both of which could have contributed to the <e2> incontinence </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2858": {"data": {"text": "BACKGROUND: The prognosis for transplant-free survivors of paracetamol-induced acute liver failure remains unknown.", "entity1": "paracetamol", "entity2": "acute liver failure", "span1": [59, 70], "span2": [79, 98]}, "bert_text": "BACKGROUND: The prognosis for transplant-free survivors of <e1> paracetamol </e1>-induced <e2> acute liver failure </e2> remains unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2859": {"data": {"text": "The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.", "entity1": "bisphosphonate", "entity2": "acute renal failure", "span1": [93, 107], "span2": [217, 236]}, "bert_text": "The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral <e1> bisphosphonate </e1> (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with <e2> acute renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2860": {"data": {"text": "The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.", "entity1": "alendronate sodium", "entity2": "acute renal failure", "span1": [109, 127], "span2": [217, 236]}, "bert_text": "The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (<e1> alendronate sodium </e1>) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with <e2> acute renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2861": {"data": {"text": "Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.\n", "entity1": "tiazofurin", "entity2": "cerebral lesions", "span1": [44, 54], "span2": [11, 27]}, "bert_text": "Reversible cerebral lesions associated with <e1> tiazofurin </e1> <e2> cerebral lesions </e2> associated with tiazofurin usage: MR demonstration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2862": {"data": {"text": "RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.", "entity1": "valproic acid", "entity2": "confusion", "span1": [51, 64], "span2": [22, 31]}, "bert_text": "RESULTS: 272 cases of confusion were reported with <e1> valproic acid </e1> <e2> confusion </e2> were reported with valproic acid: 153 women and 119 men.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2863": {"data": {"text": "A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.", "entity1": "buspirone", "entity2": "catalepsy", "span1": [41, 50], "span2": [155, 164]}, "bert_text": "A series of aryl-piperazine analogues of <e1> buspirone </e1> and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2864": {"data": {"text": "A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.", "entity1": "5-hydroxytryptaminergic agonists", "entity2": "catalepsy", "span1": [61, 93], "span2": [155, 164]}, "bert_text": "A series of aryl-piperazine analogues of buspirone and other <e1> 5-hydroxytryptaminergic agonists </e1> were tested for their ability to reverse haloperidol induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2865": {"data": {"text": "A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [135, 146], "span2": [155, 164]}, "bert_text": "A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse <e1> haloperidol </e1> induced <e2> catalepsy </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2866": {"data": {"text": "A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.", "entity1": "pravastatin", "entity2": "inflammatory myopathy", "span1": [65, 76], "span2": [16, 37]}, "bert_text": "A case of acute inflammatory myopathy associated with the use of <e1> pravastatin </e1> <e2> inflammatory myopathy </e2> associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2867": {"data": {"text": "FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.", "entity1": "FLA-63", "entity2": "hypotension", "span1": [0, 6], "span2": [74, 85]}, "bert_text": "<e1> FLA-63 </e1>, a dopamine-beta-oxidase inhibitor, did not have any effect on the <e2> hypotension </e2>, bradycardia or reflex-enhancing effect of L-dopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2868": {"data": {"text": "FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.", "entity1": "FLA-63", "entity2": "bradycardia", "span1": [0, 6], "span2": [87, 98]}, "bert_text": "<e1> FLA-63 </e1>, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, <e2> bradycardia </e2> or reflex-enhancing effect of L-dopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2869": {"data": {"text": "FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.", "entity1": "dopamine", "entity2": "hypotension", "span1": [10, 18], "span2": [74, 85]}, "bert_text": "FLA-63, a <e1> dopamine </e1>-beta-oxidase inhibitor, did not have any effect on the <e2> hypotension </e2>, bradycardia or reflex-enhancing effect of L-dopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2870": {"data": {"text": "FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.", "entity1": "dopamine", "entity2": "bradycardia", "span1": [10, 18], "span2": [87, 98]}, "bert_text": "FLA-63, a <e1> dopamine </e1>-beta-oxidase inhibitor, did not have any effect on the hypotension, <e2> bradycardia </e2> or reflex-enhancing effect of L-dopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2871": {"data": {"text": "FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.", "entity1": "L-dopa", "entity2": "hypotension", "span1": [129, 135], "span2": [74, 85]}, "bert_text": "FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of <e1> L-dopa </e1> <e2> hypotension </e2>, bradycardia or reflex-enhancing effect of L-dopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2872": {"data": {"text": "FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.", "entity1": "L-dopa", "entity2": "bradycardia", "span1": [129, 135], "span2": [87, 98]}, "bert_text": "FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of <e1> L-dopa </e1> <e2> bradycardia </e2> or reflex-enhancing effect of L-dopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2873": {"data": {"text": "A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.", "entity1": "PDTC", "entity2": "status epilepticus", "span1": [109, 113], "span2": [137, 155]}, "bert_text": "A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and <e1> PDTC </e1>-treated rats following <e2> status epilepticus </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2874": {"data": {"text": "Metformin treatment fully blocked gentamicin-mediated acute renal failure.", "entity1": "Metformin", "entity2": "acute renal failure", "span1": [0, 9], "span2": [54, 73]}, "bert_text": "<e1> Metformin </e1> treatment fully blocked gentamicin-mediated <e2> acute renal failure </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2875": {"data": {"text": "Metformin treatment fully blocked gentamicin-mediated acute renal failure.", "entity1": "gentamicin", "entity2": "acute renal failure", "span1": [34, 44], "span2": [54, 73]}, "bert_text": "Metformin treatment fully blocked <e1> gentamicin </e1>-mediated <e2> acute renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2876": {"data": {"text": "Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.", "entity1": "BCNU", "entity2": "vertebral artery", "span1": [38, 42], "span2": [129, 145]}, "bert_text": "Thirty-six patients were treated with <e1> BCNU </e1> every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or <e2> vertebral artery </e2> or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2877": {"data": {"text": "After the ingestion of 26 venlafaxine 50-mg tablets, the patient experienced a witnessed generalized seizure.", "entity1": "venlafaxine", "entity2": "seizure", "span1": [26, 37], "span2": [101, 108]}, "bert_text": "After the ingestion of 26 <e1> venlafaxine </e1> 50-mg tablets, the patient experienced a witnessed generalized <e2> seizure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2878": {"data": {"text": "The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.", "entity1": "iopamidol", "entity2": "nephropathy", "span1": [147, 156], "span2": [29, 40]}, "bert_text": "The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of <e1> iopamidol </e1> <e2> nephropathy </e2>, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2879": {"data": {"text": "The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.", "entity1": "iopamidol", "entity2": "diabetes mellitus", "span1": [147, 156], "span2": [209, 226]}, "bert_text": "The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of <e1> iopamidol </e1> or iodixanol to high-risk patients, with or without <e2> diabetes mellitus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2880": {"data": {"text": "The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.", "entity1": "iodixanol", "entity2": "nephropathy", "span1": [160, 169], "span2": [29, 40]}, "bert_text": "The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or <e1> iodixanol </e1> <e2> nephropathy </e2>, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2881": {"data": {"text": "The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.", "entity1": "iodixanol", "entity2": "diabetes mellitus", "span1": [160, 169], "span2": [209, 226]}, "bert_text": "The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or <e1> iodixanol </e1> to high-risk patients, with or without <e2> diabetes mellitus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2882": {"data": {"text": "A case of massive rhabdomyolysis following molindone administration.\n", "entity1": "molindone", "entity2": "rhabdomyolysis", "span1": [43, 52], "span2": [18, 32]}, "bert_text": "A case of massive rhabdomyolysis following <e1> molindone </e1> <e2> rhabdomyolysis </e2> following molindone administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2883": {"data": {"text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "entity1": "apomorphine", "entity2": "REMD", "span1": [33, 44], "span2": [18, 22]}, "bert_text": "Forty-eight hr of REMD increased <e1> apomorphine </e1> <e2> REMD </e2> increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2884": {"data": {"text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "entity1": "apomorphine", "entity2": "REMD", "span1": [33, 44], "span2": [114, 118]}, "bert_text": "Forty-eight hr of REMD increased <e1> apomorphine </e1>-induced aggressiveness, and reduced (immediately after completing of <e2> REMD </e2>) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2885": {"data": {"text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "entity1": "apomorphine", "entity2": "REMD", "span1": [33, 44], "span2": [160, 164]}, "bert_text": "Forty-eight hr of REMD increased <e1> apomorphine </e1>-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of <e2> REMD </e2>) quipazine-induced head twitches.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2886": {"data": {"text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "entity1": "apomorphine", "entity2": "aggressiveness", "span1": [33, 44], "span2": [53, 67]}, "bert_text": "Forty-eight hr of REMD increased <e1> apomorphine </e1>-induced <e2> aggressiveness </e2>, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2887": {"data": {"text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "entity1": "apomorphine", "entity2": "head twitches", "span1": [33, 44], "span2": [184, 197]}, "bert_text": "Forty-eight hr of REMD increased <e1> apomorphine </e1>-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced <e2> head twitches </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2888": {"data": {"text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "entity1": "quipazine", "entity2": "REMD", "span1": [166, 175], "span2": [18, 22]}, "bert_text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) <e1> quipazine </e1> <e2> REMD </e2> increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2889": {"data": {"text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "entity1": "quipazine", "entity2": "REMD", "span1": [166, 175], "span2": [114, 118]}, "bert_text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) <e1> quipazine </e1> <e2> REMD </e2>) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2890": {"data": {"text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "entity1": "quipazine", "entity2": "REMD", "span1": [166, 175], "span2": [160, 164]}, "bert_text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) <e1> quipazine </e1> <e2> REMD </e2>) quipazine-induced head twitches.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2891": {"data": {"text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "entity1": "quipazine", "entity2": "aggressiveness", "span1": [166, 175], "span2": [53, 67]}, "bert_text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) <e1> quipazine </e1> <e2> aggressiveness </e2>, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2892": {"data": {"text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "entity1": "quipazine", "entity2": "head twitches", "span1": [166, 175], "span2": [184, 197]}, "bert_text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) <e1> quipazine </e1>-induced <e2> head twitches </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2893": {"data": {"text": "METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.", "entity1": "Raloxifene", "entity2": "osteoporosis", "span1": [34, 44], "span2": [145, 157]}, "bert_text": "METHODS: The Multiple Outcomes of <e1> Raloxifene </e1> Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with <e2> osteoporosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2894": {"data": {"text": "A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.\n", "entity1": "D-penicillamine", "entity2": "polymyositis", "span1": [80, 95], "span2": [10, 22]}, "bert_text": "A case of polymyositis in a patient with primary biliary cirrhosis treated with <e1> D-penicillamine </e1> <e2> polymyositis </e2> in a patient with primary biliary cirrhosis treated with D-penicillamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2895": {"data": {"text": "A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.\n", "entity1": "D-penicillamine", "entity2": "primary biliary cirrhosis", "span1": [80, 95], "span2": [41, 66]}, "bert_text": "A case of polymyositis in a patient with primary biliary cirrhosis treated with <e1> D-penicillamine </e1> <e2> primary biliary cirrhosis </e2> treated with D-penicillamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2896": {"data": {"text": "The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.", "entity1": "amino acid", "entity2": "catalepsy", "span1": [55, 65], "span2": [103, 112]}, "bert_text": "The present study examined the influence of excitatory <e1> amino acid </e1>-mediated mechanisms in the IC on the <e2> catalepsy </e2> induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2897": {"data": {"text": "The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.", "entity1": "dopamine", "entity2": "catalepsy", "span1": [128, 136], "span2": [103, 112]}, "bert_text": "The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the <e1> dopamine </e1> <e2> catalepsy </e2> induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2898": {"data": {"text": "The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [154, 165], "span2": [103, 112]}, "bert_text": "The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker <e1> haloperidol </e1> <e2> catalepsy </e2> induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2899": {"data": {"text": "No corneal disease is known to have occurred in the propranolol group.", "entity1": "propranolol", "entity2": "corneal disease", "span1": [52, 63], "span2": [3, 18]}, "bert_text": "No corneal disease is known to have occurred in the <e1> propranolol </e1> <e2> corneal disease </e2> is known to have occurred in the propranolol group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2900": {"data": {"text": "Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.", "entity1": "5-hydroxytryptamine1a", "entity2": "catalepsy", "span1": [37, 58], "span2": [90, 99]}, "bert_text": "Those drugs with strong affinity for <e1> 5-hydroxytryptamine1a </e1> receptors were able to reverse <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2901": {"data": {"text": "We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.", "entity1": "sulpiride", "entity2": "dystonia", "span1": [104, 113], "span2": [64, 72]}, "bert_text": "We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting <e1> sulpiride </e1> <e2> dystonia </e2> within 2 months after starting sulpiride therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2902": {"data": {"text": "AIM: To examine whether paracetamol-induced acute liver failure increases long-term mortality.", "entity1": "paracetamol", "entity2": "acute liver failure", "span1": [24, 35], "span2": [44, 63]}, "bert_text": "AIM: To examine whether <e1> paracetamol </e1>-induced <e2> acute liver failure </e2> increases long-term mortality.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2903": {"data": {"text": "The annual incidence of warfarin-related bleeding at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study.", "entity1": "warfarin", "entity2": "bleeding", "span1": [24, 32], "span2": [41, 49]}, "bert_text": "The annual incidence of <e1> warfarin </e1>-related <e2> bleeding </e2> at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2904": {"data": {"text": "Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.\n", "entity1": "sulfasalazine", "entity2": "Hepatotoxicity", "span1": [31, 44], "span2": [0, 14]}, "bert_text": "Hepatotoxicity associated with <e1> sulfasalazine </e1> <e2> Hepatotoxicity </e2> associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2905": {"data": {"text": "Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.\n", "entity1": "sulfasalazine", "entity2": "arthritis", "span1": [31, 44], "span2": [61, 70]}, "bert_text": "Hepatotoxicity associated with <e1> sulfasalazine </e1> in inflammatory <e2> arthritis </e2>: A case series from a local surveillance of serious adverse events.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2906": {"data": {"text": "A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.", "entity1": "dipivalyl epinephrine", "entity2": "vein thrombosis", "span1": [151, 172], "span2": [64, 79]}, "bert_text": "A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with <e1> dipivalyl epinephrine </e1> <e2> vein thrombosis </e2> in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2907": {"data": {"text": "A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.", "entity1": "dipivalyl epinephrine", "entity2": "glaucoma", "span1": [151, 172], "span2": [186, 194]}, "bert_text": "A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with <e1> dipivalyl epinephrine </e1> for advanced <e2> glaucoma </e2> discovered in the other eye.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2908": {"data": {"text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "entity1": "amiloride", "entity2": "polydipsia", "span1": [14, 23], "span2": [43, 53]}, "bert_text": "The effect of <e1> amiloride </e1> on lithium-induced <e2> polydipsia </e2> and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2909": {"data": {"text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "entity1": "amiloride", "entity2": "polyuria", "span1": [14, 23], "span2": [58, 66]}, "bert_text": "The effect of <e1> amiloride </e1> on lithium-induced polydipsia and <e2> polyuria </e2> and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2910": {"data": {"text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "entity1": "lithium", "entity2": "polydipsia", "span1": [27, 34], "span2": [43, 53]}, "bert_text": "The effect of amiloride on <e1> lithium </e1>-induced <e2> polydipsia </e2> and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2911": {"data": {"text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "entity1": "lithium", "entity2": "polyuria", "span1": [27, 34], "span2": [58, 66]}, "bert_text": "The effect of amiloride on <e1> lithium </e1>-induced polydipsia and <e2> polyuria </e2> and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2912": {"data": {"text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "entity1": "lithium", "entity2": "polydipsia", "span1": [78, 85], "span2": [43, 53]}, "bert_text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the <e1> lithium </e1> <e2> polydipsia </e2> and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2913": {"data": {"text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "entity1": "lithium", "entity2": "polyuria", "span1": [78, 85], "span2": [58, 66]}, "bert_text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the <e1> lithium </e1> <e2> polyuria </e2> and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2914": {"data": {"text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "entity1": "LiCl", "entity2": "polydipsia", "span1": [209, 213], "span2": [43, 53]}, "bert_text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with <e1> LiCl </e1> <e2> polydipsia </e2> and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2915": {"data": {"text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "entity1": "LiCl", "entity2": "polyuria", "span1": [209, 213], "span2": [58, 66]}, "bert_text": "The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with <e1> LiCl </e1> <e2> polyuria </e2> and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2916": {"data": {"text": "Delirium during clozapine treatment: incidence and associated risk factors.\n", "entity1": "clozapine", "entity2": "Delirium", "span1": [16, 25], "span2": [0, 8]}, "bert_text": "Delirium during <e1> clozapine </e1> <e2> Delirium </e2> during clozapine treatment: incidence and associated risk factors.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2917": {"data": {"text": "The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.", "entity1": "calcium", "entity2": "hypocalcemia", "span1": [37, 44], "span2": [145, 157]}, "bert_text": "The 2 patients with the higher serum <e1> calcium </e1> concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe <e2> hypocalcemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2918": {"data": {"text": "The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.", "entity1": "pamidronate", "entity2": "hypocalcemia", "span1": [69, 80], "span2": [145, 157]}, "bert_text": "The 2 patients with the higher serum calcium concentrations received <e1> pamidronate </e1> intravenously (60 and 30 mg, respectively), which caused severe <e2> hypocalcemia </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2919": {"data": {"text": "The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol.", "entity1": "haloperidol", "entity2": "EPS", "span1": [113, 124], "span2": [102, 105]}, "bert_text": "The present study points to patient characteristics that may be of significance in the development of EPS due to <e1> haloperidol </e1> <e2> EPS </e2> due to haloperidol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2920": {"data": {"text": "BACKGROUND: Incidence and risk factors for delirium during clozapine treatment require further clarification", "entity1": "clozapine", "entity2": "delirium", "span1": [59, 68], "span2": [43, 51]}, "bert_text": "BACKGROUND: Incidence and risk factors for delirium during <e1> clozapine </e1> <e2> delirium </e2> during clozapine treatment require further clarification", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2921": {"data": {"text": "Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.", "entity1": "flurbiprofen", "entity2": "juvenile rheumatoid arthritis", "span1": [79, 91], "span2": [26, 55]}, "bert_text": "Thirty-four patients with juvenile rheumatoid arthritis, who were treated with <e1> flurbiprofen </e1> <e2> juvenile rheumatoid arthritis </e2>, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2922": {"data": {"text": "Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.", "entity1": "flurbiprofen", "entity2": "arthritis", "span1": [79, 91], "span2": [185, 194]}, "bert_text": "Thirty-four patients with juvenile rheumatoid arthritis, who were treated with <e1> flurbiprofen </e1> at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 <e2> arthritis </e2> indices after 12 weeks of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2923": {"data": {"text": "We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.", "entity1": "cocaine", "entity2": "seizures", "span1": [54, 61], "span2": [94, 102]}, "bert_text": "We evaluated the potential of the major metabolite of <e1> cocaine </e1>, benzoylecgonine (BE), to cause <e2> seizures </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2924": {"data": {"text": "We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.", "entity1": "benzoylecgonine", "entity2": "seizures", "span1": [63, 78], "span2": [94, 102]}, "bert_text": "We evaluated the potential of the major metabolite of cocaine, <e1> benzoylecgonine </e1> (BE), to cause <e2> seizures </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2925": {"data": {"text": "We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.", "entity1": "BE", "entity2": "seizures", "span1": [80, 82], "span2": [94, 102]}, "bert_text": "We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (<e1> BE </e1>), to cause <e2> seizures </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2926": {"data": {"text": "Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).", "entity1": "Haloperidol", "entity2": "catalepsy", "span1": [0, 11], "span2": [20, 29]}, "bert_text": "<e1> Haloperidol </e1>-induced <e2> catalepsy </e2> was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2927": {"data": {"text": "Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).", "entity1": "MK-801", "entity2": "catalepsy", "span1": [128, 134], "span2": [20, 29]}, "bert_text": "Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, <e1> MK-801 </e1> <e2> catalepsy </e2> was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2928": {"data": {"text": "The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.", "entity1": "cocaine", "entity2": "chest pain", "span1": [39, 46], "span2": [17, 27]}, "bert_text": "The mechanism of chest pain related to <e1> cocaine </e1> <e2> chest pain </e2> related to cocaine use is discussed and treatment dilemmas are discussed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2929": {"data": {"text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "entity1": "PGs", "entity2": "convulsions", "span1": [27, 30], "span2": [102, 113]}, "bert_text": "These results suggest that <e1> PGs </e1> are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced <e2> convulsions </e2>, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2930": {"data": {"text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "entity1": "PGs", "entity2": "convulsions", "span1": [27, 30], "span2": [174, 185]}, "bert_text": "These results suggest that <e1> PGs </e1> are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2931": {"data": {"text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "entity1": "fluorthyl-", "entity2": "convulsions", "span1": [75, 85], "span2": [102, 113]}, "bert_text": "These results suggest that PGs are involved in the mechanism(s) underlying <e1> fluorthyl- </e1> and PTZ-induced <e2> convulsions </e2>, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2932": {"data": {"text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "entity1": "fluorthyl-", "entity2": "convulsions", "span1": [75, 85], "span2": [174, 185]}, "bert_text": "These results suggest that PGs are involved in the mechanism(s) underlying <e1> fluorthyl- </e1> and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2933": {"data": {"text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "entity1": "PTZ", "entity2": "convulsions", "span1": [90, 93], "span2": [102, 113]}, "bert_text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and <e1> PTZ </e1>-induced <e2> convulsions </e2>, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2934": {"data": {"text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "entity1": "PTZ", "entity2": "convulsions", "span1": [90, 93], "span2": [174, 185]}, "bert_text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and <e1> PTZ </e1>-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2935": {"data": {"text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "entity1": "picrotoxin-", "entity2": "convulsions", "span1": [123, 134], "span2": [102, 113]}, "bert_text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not <e1> picrotoxin- </e1> <e2> convulsions </e2>, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2936": {"data": {"text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "entity1": "picrotoxin-", "entity2": "convulsions", "span1": [123, 134], "span2": [174, 185]}, "bert_text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not <e1> picrotoxin- </e1>, electroshock-, or bicuculline-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2937": {"data": {"text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "entity1": "bicuculline", "entity2": "convulsions", "span1": [154, 165], "span2": [102, 113]}, "bert_text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or <e1> bicuculline </e1> <e2> convulsions </e2>, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2938": {"data": {"text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "entity1": "bicuculline", "entity2": "convulsions", "span1": [154, 165], "span2": [174, 185]}, "bert_text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or <e1> bicuculline </e1>-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2939": {"data": {"text": "We interpret this as episodes of cardiac arrest caused by metoclopramide.", "entity1": "metoclopramide", "entity2": "cardiac arrest", "span1": [58, 72], "span2": [33, 47]}, "bert_text": "We interpret this as episodes of cardiac arrest caused by <e1> metoclopramide </e1> <e2> cardiac arrest </e2> caused by metoclopramide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2940": {"data": {"text": "Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.", "entity1": "asenapine", "entity2": "Extrapyramidal symptoms", "span1": [85, 94], "span2": [0, 23]}, "bert_text": "Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the <e1> asenapine </e1> <e2> Extrapyramidal symptoms </e2> reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2941": {"data": {"text": "Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.", "entity1": "haloperidol", "entity2": "Extrapyramidal symptoms", "span1": [115, 126], "span2": [0, 23]}, "bert_text": "Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, <e1> haloperidol </e1> <e2> Extrapyramidal symptoms </e2> reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2942": {"data": {"text": "Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.", "entity1": "dexamethasone", "entity2": "psoriasis", "span1": [105, 118], "span2": [54, 63]}, "bert_text": "Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or <e1> dexamethasone </e1> <e2> psoriasis </e2> tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2943": {"data": {"text": "Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.", "entity1": "sirolimus", "entity2": "psoriasis", "span1": [194, 203], "span2": [54, 63]}, "bert_text": "Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of <e1> sirolimus </e1> <e2> psoriasis </e2> tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2944": {"data": {"text": ". METHODS: We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine (1995-96), reviewed their medical records to score incidence and severity of delirium, and tested associations with potential risk factors.", "entity1": "clozapine", "entity2": "psychiatric", "span1": [107, 116], "span2": [71, 82]}, "bert_text": ". METHODS: We used computerized pharmacy records to identify all adult psychiatric inpatients treated with <e1> clozapine </e1> <e2> psychiatric </e2> inpatients treated with clozapine (1995-96), reviewed their medical records to score incidence and severity of delirium, and tested associations with potential risk factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2945": {"data": {"text": ". METHODS: We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine (1995-96), reviewed their medical records to score incidence and severity of delirium, and tested associations with potential risk factors.", "entity1": "clozapine", "entity2": "delirium", "span1": [107, 116], "span2": [194, 202]}, "bert_text": ". METHODS: We used computerized pharmacy records to identify all adult psychiatric inpatients treated with <e1> clozapine </e1> (1995-96), reviewed their medical records to score incidence and severity of <e2> delirium </e2>, and tested associations with potential risk factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2946": {"data": {"text": "In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.", "entity1": "ketamine", "entity2": "schizophrenia", "span1": [32, 40], "span2": [17, 30]}, "bert_text": "In patients with schizophrenia, <e1> ketamine </e1> <e2> schizophrenia </e2>, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2947": {"data": {"text": "In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.", "entity1": "ketamine", "entity2": "glutamatergic dysfunction", "span1": [32, 40], "span2": [114, 139]}, "bert_text": "In patients with schizophrenia, <e1> ketamine </e1> exacerbates the core symptoms of illness, supporting the hypothesis of a <e2> glutamatergic dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2948": {"data": {"text": "The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).", "entity1": "timolol", "entity2": "myocardial infarction", "span1": [24, 31], "span2": [62, 83]}, "bert_text": "The effect of long-term <e1> timolol </e1> treatment on heart size after <e2> myocardial infarction </e2> was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2949": {"data": {"text": "The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).", "entity1": "timolol", "entity2": "myocardial infarction", "span1": [168, 175], "span2": [62, 83]}, "bert_text": "The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, <e1> timolol </e1> <e2> myocardial infarction </e2> was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2950": {"data": {"text": "CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.", "entity1": "Dexamethasone", "entity2": "HC", "span1": [12, 25], "span2": [90, 92]}, "bert_text": "CONCLUSION: <e1> Dexamethasone </e1> in combination with mesna was efficient in blocking IFS-induced <e2> HC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2951": {"data": {"text": "CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.", "entity1": "mesna", "entity2": "HC", "span1": [46, 51], "span2": [90, 92]}, "bert_text": "CONCLUSION: Dexamethasone in combination with <e1> mesna </e1> was efficient in blocking IFS-induced <e2> HC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2952": {"data": {"text": "CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.", "entity1": "IFS", "entity2": "HC", "span1": [78, 81], "span2": [90, 92]}, "bert_text": "CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking <e1> IFS </e1>-induced <e2> HC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2953": {"data": {"text": "These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.", "entity1": "oxygen", "entity2": "seizure", "span1": [58, 64], "span2": [130, 137]}, "bert_text": "These data might indicate that the generation of reactive <e1> oxygen </e1> species and activation of NF-kappaB plays a more central role in <e2> seizure </e2>-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2954": {"data": {"text": "These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.", "entity1": "oxygen", "entity2": "neuronal damage", "span1": [58, 64], "span2": [149, 164]}, "bert_text": "These data might indicate that the generation of reactive <e1> oxygen </e1> species and activation of NF-kappaB plays a more central role in seizure-associated <e2> neuronal damage </e2> in the temporal cortex as compared to the hippocampal hilus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2955": {"data": {"text": "The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.", "entity1": "diclofenac sodium", "entity2": "hepatitis", "span1": [87, 104], "span2": [47, 56]}, "bert_text": "The patient described developed chronic active hepatitis after six months therapy with <e1> diclofenac sodium </e1> <e2> hepatitis </e2> after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2956": {"data": {"text": "OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.", "entity1": "calcium carbonate", "entity2": "hypercalcemia", "span1": [39, 56], "span2": [65, 78]}, "bert_text": "OBJECTIVE: To describe 3 patients with <e1> calcium carbonate </e1>-induced <e2> hypercalcemia </e2> and gain insights into the cause and management of the milk-alkali syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2957": {"data": {"text": "OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.", "entity1": "calcium carbonate", "entity2": "milk-alkali syndrome", "span1": [39, 56], "span2": [134, 154]}, "bert_text": "OBJECTIVE: To describe 3 patients with <e1> calcium carbonate </e1>-induced hypercalcemia and gain insights into the cause and management of the <e2> milk-alkali syndrome </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2958": {"data": {"text": "Sinus arrest associated with continuous-infusion cimetidine.\n", "entity1": "cimetidine", "entity2": "Sinus arrest", "span1": [49, 59], "span2": [0, 12]}, "bert_text": "Sinus arrest associated with continuous-infusion <e1> cimetidine </e1> <e2> Sinus arrest </e2> associated with continuous-infusion cimetidine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2959": {"data": {"text": "Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.", "entity1": "Terbutaline", "entity2": "arrest preterm labor", "span1": [0, 11], "span2": [50, 70]}, "bert_text": "<e1> Terbutaline </e1>, a beta2-adrenoceptor agonist used to <e2> arrest preterm labor </e2>, has been associated with increased concordance for autism in dizygotic twins.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2960": {"data": {"text": "Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.", "entity1": "Terbutaline", "entity2": "autism", "span1": [0, 11], "span2": [123, 129]}, "bert_text": "<e1> Terbutaline </e1>, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for <e2> autism </e2> in dizygotic twins.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2961": {"data": {"text": "Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.", "entity1": "valproate", "entity2": "encephalopathy", "span1": [96, 105], "span2": [26, 40]}, "bert_text": "Morphological features of encephalopathy after chronic administration of the antiepileptic drug <e1> valproate </e1> <e2> encephalopathy </e2> after chronic administration of the antiepileptic drug valproate to rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2962": {"data": {"text": "Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.", "entity1": "androgen", "entity2": "obstructive sleep apnea syndrome", "span1": [97, 105], "span2": [19, 51]}, "bert_text": "Development of the obstructive sleep apnea syndrome must be considered a possible side effect of <e1> androgen </e1> <e2> obstructive sleep apnea syndrome </e2> must be considered a possible side effect of androgen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2963": {"data": {"text": "It is well known that ceftriaxone leads to pseudolithiasis in some patients.", "entity1": "ceftriaxone", "entity2": "pseudolithiasis", "span1": [22, 33], "span2": [43, 58]}, "bert_text": "It is well known that <e1> ceftriaxone </e1> leads to <e2> pseudolithiasis </e2> in some patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2964": {"data": {"text": "Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.\n", "entity1": "DFU", "entity2": "toxicity", "span1": [125, 128], "span2": [28, 36]}, "bert_text": "Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--<e1> DFU </e1> <e2> toxicity </e2> of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2965": {"data": {"text": "Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.\n", "entity1": "piroxicam", "entity2": "toxicity", "span1": [133, 142], "span2": [28, 36]}, "bert_text": "Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and <e1> piroxicam </e1> <e2> toxicity </e2> of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2966": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "steroids", "entity2": "seizures", "span1": [25, 33], "span2": [133, 141]}, "bert_text": "Although the neuroactive <e1> steroids </e1> were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine <e2> seizures </e2>, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2967": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "steroids", "entity2": "seizure", "span1": [25, 33], "span2": [287, 294]}, "bert_text": "Although the neuroactive <e1> steroids </e1> were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2968": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "steroids", "entity2": "toxicity", "span1": [25, 33], "span2": [390, 398]}, "bert_text": "Although the neuroactive <e1> steroids </e1> were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2969": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "steroids", "entity2": "seizures", "span1": [143, 151], "span2": [133, 141]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, <e1> steroids </e1> <e2> seizures </e2>, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2970": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "steroids", "entity2": "seizure", "span1": [143, 151], "span2": [287, 294]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, <e1> steroids </e1> with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2971": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "steroids", "entity2": "toxicity", "span1": [143, 151], "span2": [390, 398]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, <e1> steroids </e1> with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2972": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "steroids", "entity2": "seizures", "span1": [357, 365], "span2": [133, 141]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive <e1> steroids </e1> <e2> seizures </e2>, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2973": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "steroids", "entity2": "seizure", "span1": [357, 365], "span2": [287, 294]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive <e1> steroids </e1> <e2> seizure </e2> protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2974": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "steroids", "entity2": "toxicity", "span1": [357, 365], "span2": [390, 398]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive <e1> steroids </e1> may have lower relative <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2975": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "benzodiazepine", "entity2": "seizures", "span1": [73, 87], "span2": [133, 141]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the <e1> benzodiazepine </e1> clonazepam in protecting against pilocarpine <e2> seizures </e2>, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2976": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "benzodiazepine", "entity2": "seizure", "span1": [73, 87], "span2": [287, 294]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the <e1> benzodiazepine </e1> clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2977": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "benzodiazepine", "entity2": "toxicity", "span1": [73, 87], "span2": [390, 398]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the <e1> benzodiazepine </e1> clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2978": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "clonazepam", "entity2": "seizures", "span1": [88, 98], "span2": [133, 141]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine <e1> clonazepam </e1> in protecting against pilocarpine <e2> seizures </e2>, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2979": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "clonazepam", "entity2": "seizure", "span1": [88, 98], "span2": [287, 294]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine <e1> clonazepam </e1> in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2980": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "clonazepam", "entity2": "toxicity", "span1": [88, 98], "span2": [390, 398]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine <e1> clonazepam </e1> in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2981": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "clonazepam", "entity2": "seizures", "span1": [312, 322], "span2": [133, 141]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than <e1> clonazepam </e1> <e2> seizures </e2>, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2982": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "clonazepam", "entity2": "seizure", "span1": [312, 322], "span2": [287, 294]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than <e1> clonazepam </e1> <e2> seizure </e2> protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2983": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "clonazepam", "entity2": "toxicity", "span1": [312, 322], "span2": [390, 398]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than <e1> clonazepam </e1>, indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2984": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [121, 132], "span2": [133, 141]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against <e1> pilocarpine </e1> <e2> seizures </e2>, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2985": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [121, 132], "span2": [287, 294]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against <e1> pilocarpine </e1> seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2986": {"data": {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity1": "pilocarpine", "entity2": "toxicity", "span1": [121, 132], "span2": [390, 398]}, "bert_text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against <e1> pilocarpine </e1> seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2987": {"data": {"text": "Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.", "entity1": "Warfarin", "entity2": "calcification", "span1": [49, 57], "span2": [81, 94]}, "bert_text": "Concurrent treatment of both dietary groups with <e1> Warfarin </e1> produced massive focal <e2> calcification </e2> of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2988": {"data": {"text": "Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [49, 57], "span2": [160, 180]}, "bert_text": "Concurrent treatment of both dietary groups with <e1> Warfarin </e1> produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable <e2> artery calcification </e2> in the restricted-diet, growth-inhibited group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2989": {"data": {"text": "Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.", "entity1": "apomorphine", "entity2": "Parkinson's disease", "span1": [52, 63], "span2": [89, 108]}, "bert_text": "Given the marked degree of efficacy of subcutaneous <e1> apomorphine </e1> treatment in fluctuating <e2> Parkinson's disease </e2>, this approach seems to deserve more widespread clinical use.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2990": {"data": {"text": "The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.", "entity1": "LiCl", "entity2": "polyuria", "span1": [53, 57], "span2": [100, 108]}, "bert_text": "The male Wistar rats consuming a diet that contained <e1> LiCl </e1> (60 mmol/kg) for 4 weeks developed marked <e2> polyuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2991": {"data": {"text": "These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.", "entity1": "bromocriptine", "entity2": "psychosis", "span1": [29, 42], "span2": [53, 62]}, "bert_text": "These cases demonstrate that <e1> bromocriptine </e1> may cause <e2> psychosis </e2> even when given in low doses.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2992": {"data": {"text": "Levodopa-induced dyskinesia and thalamotomy.\n", "entity1": "Levodopa", "entity2": "dyskinesia", "span1": [0, 8], "span2": [17, 27]}, "bert_text": "<e1> Levodopa </e1>-induced <e2> dyskinesia </e2> and thalamotomy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2993": {"data": {"text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "entity1": "Na+-extrusion", "entity2": "hypertension", "span1": [85, 98], "span2": [47, 59]}, "bert_text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed <e1> Na+-extrusion </e1> <e2> hypertension </e2> accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2994": {"data": {"text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "entity1": "Na+-extrusion", "entity2": "depressed", "span1": [85, 98], "span2": [75, 84]}, "bert_text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed <e1> Na+-extrusion </e1> <e2> depressed </e2> Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2995": {"data": {"text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "entity1": "Na+-binding", "entity2": "hypertension", "span1": [151, 162], "span2": [47, 59]}, "bert_text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated <e1> Na+-binding </e1> <e2> hypertension </e2> accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2996": {"data": {"text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "entity1": "Na+-binding", "entity2": "depressed", "span1": [151, 162], "span2": [75, 84]}, "bert_text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated <e1> Na+-binding </e1> <e2> depressed </e2> Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2997": {"data": {"text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "entity1": "Na", "entity2": "hypertension", "span1": [182, 184], "span2": [47, 59]}, "bert_text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (<e1> Na </e1> <e2> hypertension </e2> accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2998": {"data": {"text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "entity1": "Na", "entity2": "depressed", "span1": [182, 184], "span2": [75, 84]}, "bert_text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (<e1> Na </e1> <e2> depressed </e2> Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2999": {"data": {"text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "entity1": "K)-ATPase", "entity2": "hypertension", "span1": [185, 194], "span2": [47, 59]}, "bert_text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,<e1> K)-ATPase </e1> <e2> hypertension </e2> accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3000": {"data": {"text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "entity1": "K)-ATPase", "entity2": "depressed", "span1": [185, 194], "span2": [75, 84]}, "bert_text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,<e1> K)-ATPase </e1> <e2> depressed </e2> Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3001": {"data": {"text": "Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.", "entity1": "K(+", "entity2": "hyperkalemia", "span1": [48, 51], "span2": [34, 46]}, "bert_text": "Cases were patients who developed hyperkalemia (<e1> K(+ </e1> <e2> hyperkalemia </e2> (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3002": {"data": {"text": "Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.", "entity1": "K(+", "entity2": "renal insufficiency", "span1": [48, 51], "span2": [68, 87]}, "bert_text": "Cases were patients who developed hyperkalemia (<e1> K(+ </e1>) >5.0 mEq/L) or <e2> renal insufficiency </e2> (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3003": {"data": {"text": "Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.", "entity1": "Cr", "entity2": "hyperkalemia", "span1": [89, 91], "span2": [34, 46]}, "bert_text": "Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (<e1> Cr </e1> <e2> hyperkalemia </e2> (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3004": {"data": {"text": "Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.", "entity1": "Cr", "entity2": "renal insufficiency", "span1": [89, 91], "span2": [68, 87]}, "bert_text": "Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (<e1> Cr </e1> <e2> renal insufficiency </e2> (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3005": {"data": {"text": "Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).", "entity1": "tamoxifen", "entity2": "endometrial cancer", "span1": [23, 32], "span2": [72, 90]}, "bert_text": "Women who had received <e1> tamoxifen </e1> were significantly more likely to have <e2> endometrial cancer </e2> diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3006": {"data": {"text": "Seizures associated with levofloxacin: case presentation and literature review.\n", "entity1": "levofloxacin", "entity2": "Seizures", "span1": [25, 37], "span2": [0, 8]}, "bert_text": "Seizures associated with <e1> levofloxacin </e1> <e2> Seizures </e2> associated with levofloxacin: case presentation and literature review.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3007": {"data": {"text": "These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.", "entity1": "steroid", "entity2": "hyperprolactinemia", "span1": [90, 97], "span2": [66, 84]}, "bert_text": "These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a <e1> steroid </e1> <e2> hyperprolactinemia </e2> in a steroid-dependent manner.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3008": {"data": {"text": "Clarithromycin-induced ventricular tachycardia.\n", "entity1": "Clarithromycin", "entity2": "ventricular tachycardia", "span1": [0, 14], "span2": [23, 46]}, "bert_text": "<e1> Clarithromycin </e1>-induced <e2> ventricular tachycardia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3009": {"data": {"text": "Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.", "entity1": "vitamin D2", "entity2": "atherosclerosis", "span1": [110, 120], "span2": [147, 162]}, "bert_text": "Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing <e1> vitamin D2 </e1> and cholesterol to induce <e2> atherosclerosis </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3010": {"data": {"text": "Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.", "entity1": "cholesterol", "entity2": "atherosclerosis", "span1": [125, 136], "span2": [147, 162]}, "bert_text": "Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and <e1> cholesterol </e1> to induce <e2> atherosclerosis </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3011": {"data": {"text": "Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.\n1.", "entity1": "prazosin", "entity2": "Orthostatic hypotension", "span1": [82, 90], "span2": [0, 23]}, "bert_text": "Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic <e1> prazosin </e1> <e2> Orthostatic hypotension </e2> occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3012": {"data": {"text": "Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.\n1.", "entity1": "prazosin", "entity2": "hypertensive", "span1": [82, 90], "span2": [126, 138]}, "bert_text": "Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic <e1> prazosin </e1>-pretreated conscious spontaneously <e2> hypertensive </e2> rats.\n1.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3013": {"data": {"text": "CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.", "entity1": "penicillins", "entity2": "birth defects", "span1": [27, 38], "span2": [147, 160]}, "bert_text": "CONCLUSIONS: Reassuringly, <e1> penicillins </e1>, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many <e2> birth defects </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"3014": {"data": {"text": "CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.", "entity1": "erythromycins", "entity2": "birth defects", "span1": [40, 53], "span2": [147, 160]}, "bert_text": "CONCLUSIONS: Reassuringly, penicillins, <e1> erythromycins </e1>, and cephalosporins, although used commonly by pregnant women, were not associated with many <e2> birth defects </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"3015": {"data": {"text": "CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.", "entity1": "cephalosporins", "entity2": "birth defects", "span1": [59, 73], "span2": [147, 160]}, "bert_text": "CONCLUSIONS: Reassuringly, penicillins, erythromycins, and <e1> cephalosporins </e1>, although used commonly by pregnant women, were not associated with many <e2> birth defects </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"3016": {"data": {"text": "Subsequently 20 migraine patients, who developed an early onset attack with frontotemporal nitroglycerin, received the drug in a second induction test at other body areas.", "entity1": "nitroglycerin", "entity2": "migraine", "span1": [91, 104], "span2": [16, 24]}, "bert_text": "Subsequently 20 migraine patients, who developed an early onset attack with frontotemporal <e1> nitroglycerin </e1> <e2> migraine </e2> patients, who developed an early onset attack with frontotemporal nitroglycerin, received the drug in a second induction test at other body areas.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3017": {"data": {"text": "Triamterene nephrolithiasis complicating dyazide therapy.\n", "entity1": "Triamterene", "entity2": "nephrolithiasis", "span1": [0, 11], "span2": [12, 27]}, "bert_text": "<e1> Triamterene </e1> <e2> nephrolithiasis </e2> complicating dyazide therapy.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3018": {"data": {"text": "Triamterene nephrolithiasis complicating dyazide therapy.\n", "entity1": "dyazide", "entity2": "nephrolithiasis", "span1": [41, 48], "span2": [12, 27]}, "bert_text": "Triamterene nephrolithiasis complicating <e1> dyazide </e1> <e2> nephrolithiasis </e2> complicating dyazide therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3019": {"data": {"text": "Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats (SHR).", "entity1": "prazosin", "entity2": "hypertensive", "span1": [51, 59], "span2": [189, 201]}, "bert_text": "Studies were performed to evaluate whether chronic <e1> prazosin </e1> treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously <e2> hypertensive </e2> rats (SHR).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3020": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "cyproterone acetate", "entity2": "venous thromboembolism", "span1": [93, 112], "span2": [49, 71]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on <e1> cyproterone acetate </e1> <e2> venous thromboembolism </e2> (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3021": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "cyproterone acetate", "entity2": "VTE", "span1": [93, 112], "span2": [73, 76]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on <e1> cyproterone acetate </e1> <e2> VTE </e2>) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3022": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "CPA", "entity2": "venous thromboembolism", "span1": [136, 139], "span2": [49, 71]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (<e1> CPA </e1> <e2> venous thromboembolism </e2> (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3023": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "CPA", "entity2": "VTE", "span1": [136, 139], "span2": [73, 76]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (<e1> CPA </e1> <e2> VTE </e2>) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3024": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "ethinylestradiol", "entity2": "venous thromboembolism", "span1": [118, 134], "span2": [49, 71]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus <e1> ethinylestradiol </e1> <e2> venous thromboembolism </e2> (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3025": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "ethinylestradiol", "entity2": "VTE", "span1": [118, 134], "span2": [73, 76]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus <e1> ethinylestradiol </e1> <e2> VTE </e2>) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3026": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "EE", "entity2": "venous thromboembolism", "span1": [140, 142], "span2": [49, 71]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/<e1> EE </e1> <e2> venous thromboembolism </e2> (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3027": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "EE", "entity2": "VTE", "span1": [140, 142], "span2": [73, 76]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/<e1> EE </e1> <e2> VTE </e2>) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3028": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "combined oral contraceptives", "entity2": "venous thromboembolism", "span1": [164, 192], "span2": [49, 71]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on <e1> combined oral contraceptives </e1> <e2> venous thromboembolism </e2> (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3029": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "combined oral contraceptives", "entity2": "VTE", "span1": [164, 192], "span2": [73, 76]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on <e1> combined oral contraceptives </e1> <e2> VTE </e2>) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3030": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "COCs", "entity2": "venous thromboembolism", "span1": [194, 198], "span2": [49, 71]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (<e1> COCs </e1> <e2> venous thromboembolism </e2> (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3031": {"data": {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity1": "COCs", "entity2": "VTE", "span1": [194, 198], "span2": [73, 76]}, "bert_text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (<e1> COCs </e1> <e2> VTE </e2>) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3032": {"data": {"text": "Learning of rats under amnesia caused by pentobarbital.\nDissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.", "entity1": "pentobarbital", "entity2": "amnesia", "span1": [41, 54], "span2": [23, 30]}, "bert_text": "Learning of rats under amnesia caused by <e1> pentobarbital </e1> <e2> amnesia </e2> caused by pentobarbital.\nDissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3033": {"data": {"text": "Learning of rats under amnesia caused by pentobarbital.\nDissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.", "entity1": "pentobarbital", "entity2": "amnesia", "span1": [41, 54], "span2": [122, 129]}, "bert_text": "Learning of rats under amnesia caused by <e1> pentobarbital </e1>.\nDissociated learning of rats in the normal state and the state of <e2> amnesia </e2> produced by pentobarbital (15 mg/kg, ip) was carried out.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3034": {"data": {"text": "Learning of rats under amnesia caused by pentobarbital.\nDissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.", "entity1": "pentobarbital", "entity2": "amnesia", "span1": [142, 155], "span2": [23, 30]}, "bert_text": "Learning of rats under amnesia caused by pentobarbital.\nDissociated learning of rats in the normal state and the state of amnesia produced by <e1> pentobarbital </e1> <e2> amnesia </e2> caused by pentobarbital.\nDissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3035": {"data": {"text": "Learning of rats under amnesia caused by pentobarbital.\nDissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.", "entity1": "pentobarbital", "entity2": "amnesia", "span1": [142, 155], "span2": [122, 129]}, "bert_text": "Learning of rats under amnesia caused by pentobarbital.\nDissociated learning of rats in the normal state and the state of amnesia produced by <e1> pentobarbital </e1> <e2> amnesia </e2> produced by pentobarbital (15 mg/kg, ip) was carried out.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3036": {"data": {"text": "The aim of the study was to assess the clinical significance of genetic variants in butyrylcholinesterase gene (BCHE) in patients with a suspected prolonged duration of action of succinylcholine after ECT.", "entity1": "succinylcholine", "entity2": "BCHE", "span1": [179, 194], "span2": [112, 116]}, "bert_text": "The aim of the study was to assess the clinical significance of genetic variants in butyrylcholinesterase gene (BCHE) in patients with a suspected prolonged duration of action of <e1> succinylcholine </e1> <e2> BCHE </e2>) in patients with a suspected prolonged duration of action of succinylcholine after ECT.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3037": {"data": {"text": "Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission.", "entity1": "dopamine", "entity2": "Schizophrenia", "span1": [64, 72], "span2": [0, 13]}, "bert_text": "Schizophrenia has been initially associated with dysfunction in <e1> dopamine </e1> <e2> Schizophrenia </e2> has been initially associated with dysfunction in dopamine neurotransmission.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3038": {"data": {"text": "It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.", "entity1": "doxorubicin", "entity2": "Wilms tumor", "span1": [23, 34], "span2": [81, 92]}, "bert_text": "It is recommended that <e1> doxorubicin </e1> dosage be sharply restricted in children with <e2> Wilms tumor </e2> of the left kidney who receive postoperative irradiation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3039": {"data": {"text": "Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.", "entity1": "metformin", "entity2": "jaundice", "span1": [61, 70], "span2": [23, 31]}, "bert_text": "Given the onset of his jaundice 2 wk after the initiation of <e1> metformin </e1> <e2> jaundice </e2> 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3040": {"data": {"text": "Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.", "entity1": "metformin", "entity2": "hepatotoxicity", "span1": [61, 70], "span2": [144, 158]}, "bert_text": "Given the onset of his jaundice 2 wk after the initiation of <e1> metformin </e1>, we believe that this case represents an example of metformin-associated <e2> hepatotoxicity </e2>, the first such case reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3041": {"data": {"text": "Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.", "entity1": "metformin", "entity2": "jaundice", "span1": [123, 132], "span2": [23, 31]}, "bert_text": "Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of <e1> metformin </e1> <e2> jaundice </e2> 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3042": {"data": {"text": "Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.", "entity1": "metformin", "entity2": "hepatotoxicity", "span1": [123, 132], "span2": [144, 158]}, "bert_text": "Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of <e1> metformin </e1>-associated <e2> hepatotoxicity </e2>, the first such case reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3043": {"data": {"text": "Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.", "entity1": "SKF 38393", "entity2": "catalepsy", "span1": [15, 24], "span2": [88, 97]}, "bert_text": "Combination of <e1> SKF 38393 </e1> with quinpirole did not cause potentiated inhibitory effect on <e2> catalepsy </e2> induced by dopamine antagonists.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3044": {"data": {"text": "Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.", "entity1": "quinpirole", "entity2": "catalepsy", "span1": [30, 40], "span2": [88, 97]}, "bert_text": "Combination of SKF 38393 with <e1> quinpirole </e1> did not cause potentiated inhibitory effect on <e2> catalepsy </e2> induced by dopamine antagonists.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3045": {"data": {"text": "Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.", "entity1": "dopamine", "entity2": "catalepsy", "span1": [109, 117], "span2": [88, 97]}, "bert_text": "Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by <e1> dopamine </e1> <e2> catalepsy </e2> induced by dopamine antagonists.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3046": {"data": {"text": "The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).", "entity1": "ND-NMBA", "entity2": "weakness", "span1": [106, 113], "span2": [4, 12]}, "bert_text": "The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to <e1> ND-NMBA </e1> <e2> weakness </e2> in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3047": {"data": {"text": "The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).", "entity1": "corticosteroids", "entity2": "weakness", "span1": [146, 161], "span2": [4, 12]}, "bert_text": "The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to <e1> corticosteroids </e1> <e2> weakness </e2> in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3048": {"data": {"text": "The administration of lamivudine to patients with HBV-related cirrhosis, like our present case, should be considered as an initial medical therapeutic option, especially in countries where liver transplantation is not reliably available.", "entity1": "lamivudine", "entity2": "cirrhosis", "span1": [22, 32], "span2": [62, 71]}, "bert_text": "The administration of <e1> lamivudine </e1> to patients with HBV-related <e2> cirrhosis </e2>, like our present case, should be considered as an initial medical therapeutic option, especially in countries where liver transplantation is not reliably available.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3049": {"data": {"text": "A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.", "entity1": "triamterene", "entity2": "nephrolithiasis", "span1": [10, 21], "span2": [22, 37]}, "bert_text": "A case of <e1> triamterene </e1> <e2> nephrolithiasis </e2> is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3050": {"data": {"text": "A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.", "entity1": "triamterene", "entity2": "hypertension", "span1": [10, 21], "span2": [120, 132]}, "bert_text": "A case of <e1> triamterene </e1> nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3051": {"data": {"text": "A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.", "entity1": "hydrochlorothiazide-triamterene", "entity2": "nephrolithiasis", "span1": [76, 107], "span2": [22, 37]}, "bert_text": "A case of triamterene nephrolithiasis is reported in a man after 4 years of <e1> hydrochlorothiazide-triamterene </e1> <e2> nephrolithiasis </e2> is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3052": {"data": {"text": "A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.", "entity1": "hydrochlorothiazide-triamterene", "entity2": "hypertension", "span1": [76, 107], "span2": [120, 132]}, "bert_text": "A case of triamterene nephrolithiasis is reported in a man after 4 years of <e1> hydrochlorothiazide-triamterene </e1> therapy for <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3053": {"data": {"text": "CONCLUSIONS: Myocarditis is an increasingly recognized complication associated with the use of clozapine.", "entity1": "clozapine", "entity2": "Myocarditis", "span1": [95, 104], "span2": [13, 24]}, "bert_text": "CONCLUSIONS: Myocarditis is an increasingly recognized complication associated with the use of <e1> clozapine </e1> <e2> Myocarditis </e2> is an increasingly recognized complication associated with the use of clozapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3054": {"data": {"text": "Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.\n", "entity1": "doxorubicin", "entity2": "nephrotic syndrome", "span1": [48, 59], "span2": [68, 86]}, "bert_text": "Serum- and glucocorticoid-inducible kinase 1 in <e1> doxorubicin </e1>-induced <e2> nephrotic syndrome </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3055": {"data": {"text": "Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.", "entity1": "Ketamine", "entity2": "pain", "span1": [0, 8], "span2": [53, 57]}, "bert_text": "<e1> Ketamine </e1> can improve morphine analgesia in difficult <e2> pain </e2> syndromes, such as neuropathic pain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3056": {"data": {"text": "Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.", "entity1": "Ketamine", "entity2": "neuropathic pain", "span1": [0, 8], "span2": [77, 93]}, "bert_text": "<e1> Ketamine </e1> can improve morphine analgesia in difficult pain syndromes, such as <e2> neuropathic pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3057": {"data": {"text": "Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.", "entity1": "morphine", "entity2": "pain", "span1": [21, 29], "span2": [53, 57]}, "bert_text": "Ketamine can improve <e1> morphine </e1> analgesia in difficult <e2> pain </e2> syndromes, such as neuropathic pain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3058": {"data": {"text": "Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.", "entity1": "morphine", "entity2": "neuropathic pain", "span1": [21, 29], "span2": [77, 93]}, "bert_text": "Ketamine can improve <e1> morphine </e1> analgesia in difficult pain syndromes, such as <e2> neuropathic pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3059": {"data": {"text": "CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.", "entity1": "Spironolactone", "entity2": "hyperkalemia", "span1": [13, 27], "span2": [36, 48]}, "bert_text": "CONCLUSIONS: <e1> Spironolactone </e1>-induced <e2> hyperkalemia </e2> and renal insufficiency are more common in our clinical experience than reported previously.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3060": {"data": {"text": "CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.", "entity1": "Spironolactone", "entity2": "renal insufficiency", "span1": [13, 27], "span2": [53, 72]}, "bert_text": "CONCLUSIONS: <e1> Spironolactone </e1>-induced hyperkalemia and <e2> renal insufficiency </e2> are more common in our clinical experience than reported previously.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3061": {"data": {"text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "entity1": "cisplatin", "entity2": "toxicities", "span1": [55, 64], "span2": [84, 94]}, "bert_text": "Although a dose-response effect has been observed with <e1> cisplatin </e1>, the dose-limiting <e2> toxicities </e2> associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3062": {"data": {"text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [55, 64], "span2": [128, 142]}, "bert_text": "Although a dose-response effect has been observed with <e1> cisplatin </e1>, the dose-limiting toxicities associated with cisplatin (e.g., <e2> nephrotoxicity </e2>, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3063": {"data": {"text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "entity1": "cisplatin", "entity2": "ototoxicity", "span1": [55, 64], "span2": [144, 155]}, "bert_text": "Although a dose-response effect has been observed with <e1> cisplatin </e1>, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, <e2> ototoxicity </e2>, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3064": {"data": {"text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "entity1": "cisplatin", "entity2": "neurotoxicity", "span1": [55, 64], "span2": [161, 174]}, "bert_text": "Although a dose-response effect has been observed with <e1> cisplatin </e1>, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and <e2> neurotoxicity </e2>) have limited its use as a treatment for breast carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3065": {"data": {"text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "entity1": "cisplatin", "entity2": "breast carcinoma", "span1": [55, 64], "span2": [216, 232]}, "bert_text": "Although a dose-response effect has been observed with <e1> cisplatin </e1>, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for <e2> breast carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3066": {"data": {"text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "entity1": "cisplatin", "entity2": "toxicities", "span1": [111, 120], "span2": [84, 94]}, "bert_text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with <e1> cisplatin </e1> <e2> toxicities </e2> associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3067": {"data": {"text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [111, 120], "span2": [128, 142]}, "bert_text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with <e1> cisplatin </e1> (e.g., <e2> nephrotoxicity </e2>, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3068": {"data": {"text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "entity1": "cisplatin", "entity2": "ototoxicity", "span1": [111, 120], "span2": [144, 155]}, "bert_text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with <e1> cisplatin </e1> (e.g., nephrotoxicity, <e2> ototoxicity </e2>, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3069": {"data": {"text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "entity1": "cisplatin", "entity2": "neurotoxicity", "span1": [111, 120], "span2": [161, 174]}, "bert_text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with <e1> cisplatin </e1> (e.g., nephrotoxicity, ototoxicity, and <e2> neurotoxicity </e2>) have limited its use as a treatment for breast carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3070": {"data": {"text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "entity1": "cisplatin", "entity2": "breast carcinoma", "span1": [111, 120], "span2": [216, 232]}, "bert_text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with <e1> cisplatin </e1> (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for <e2> breast carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3071": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic syndromes", "span1": [166, 191], "span2": [18, 37]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of <e1> puromycin aminonucleoside </e1> <e2> nephrotic syndromes </e2> such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3072": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "puromycin aminonucleoside", "entity2": "proteinuria", "span1": [166, 191], "span2": [46, 57]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of <e1> puromycin aminonucleoside </e1> <e2> proteinuria </e2>, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3073": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "puromycin aminonucleoside", "entity2": "hypoalbuminemia", "span1": [166, 191], "span2": [59, 74]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of <e1> puromycin aminonucleoside </e1> <e2> hypoalbuminemia </e2>, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3074": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "puromycin aminonucleoside", "entity2": "hypercholesterolemia", "span1": [166, 191], "span2": [76, 96]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of <e1> puromycin aminonucleoside </e1> <e2> hypercholesterolemia </e2> and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3075": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "Dup 753", "entity2": "nephrotic syndromes", "span1": [241, 248], "span2": [18, 37]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1> Dup 753 </e1> <e2> nephrotic syndromes </e2> such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3076": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "Dup 753", "entity2": "proteinuria", "span1": [241, 248], "span2": [46, 57]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1> Dup 753 </e1> <e2> proteinuria </e2>, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3077": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "Dup 753", "entity2": "hypoalbuminemia", "span1": [241, 248], "span2": [59, 74]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1> Dup 753 </e1> <e2> hypoalbuminemia </e2>, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3078": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "Dup 753", "entity2": "hypercholesterolemia", "span1": [241, 248], "span2": [76, 96]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of <e1> Dup 753 </e1> <e2> hypercholesterolemia </e2> and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3079": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "losartan", "entity2": "nephrotic syndromes", "span1": [250, 258], "span2": [18, 37]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (<e1> losartan </e1> <e2> nephrotic syndromes </e2> such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3080": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "losartan", "entity2": "proteinuria", "span1": [250, 258], "span2": [46, 57]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (<e1> losartan </e1> <e2> proteinuria </e2>, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3081": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "losartan", "entity2": "hypoalbuminemia", "span1": [250, 258], "span2": [59, 74]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (<e1> losartan </e1> <e2> hypoalbuminemia </e2>, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3082": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "losartan", "entity2": "hypercholesterolemia", "span1": [250, 258], "span2": [76, 96]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (<e1> losartan </e1> <e2> hypercholesterolemia </e2> and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3083": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "angiotensin II", "entity2": "nephrotic syndromes", "span1": [269, 283], "span2": [18, 37]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel <e1> angiotensin II </e1> <e2> nephrotic syndromes </e2> such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3084": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "angiotensin II", "entity2": "proteinuria", "span1": [269, 283], "span2": [46, 57]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel <e1> angiotensin II </e1> <e2> proteinuria </e2>, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3085": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "angiotensin II", "entity2": "hypoalbuminemia", "span1": [269, 283], "span2": [59, 74]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel <e1> angiotensin II </e1> <e2> hypoalbuminemia </e2>, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3086": {"data": {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity1": "angiotensin II", "entity2": "hypercholesterolemia", "span1": [269, 283], "span2": [76, 96]}, "bert_text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel <e1> angiotensin II </e1> <e2> hypercholesterolemia </e2> and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3087": {"data": {"text": "Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.\n", "entity1": "acetaminophen", "entity2": "chronic renal failure", "span1": [16, 29], "span2": [51, 72]}, "bert_text": "Habitual use of <e1> acetaminophen </e1> as a risk factor for <e2> chronic renal failure </e2>: a comparison with phenacetin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3088": {"data": {"text": "Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.\n", "entity1": "phenacetin", "entity2": "chronic renal failure", "span1": [92, 102], "span2": [51, 72]}, "bert_text": "Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with <e1> phenacetin </e1> <e2> chronic renal failure </e2>: a comparison with phenacetin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3089": {"data": {"text": "Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.", "entity1": "pentoxifylline", "entity2": "coronary hyperemia", "span1": [8, 22], "span2": [53, 71]}, "bert_text": "Whether <e1> pentoxifylline </e1> inhibits dipyridamole-induced <e2> coronary hyperemia </e2> like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3090": {"data": {"text": "Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.", "entity1": "dipyridamole", "entity2": "coronary hyperemia", "span1": [32, 44], "span2": [53, 71]}, "bert_text": "Whether pentoxifylline inhibits <e1> dipyridamole </e1>-induced <e2> coronary hyperemia </e2> like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3091": {"data": {"text": "Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.", "entity1": "dipyridamole-thallium-201", "entity2": "coronary hyperemia", "span1": [151, 176], "span2": [53, 71]}, "bert_text": "Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to <e1> dipyridamole-thallium-201 </e1> <e2> coronary hyperemia </e2> like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3092": {"data": {"text": "Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.", "entity1": "methylxanthines", "entity2": "coronary hyperemia", "span1": [83, 98], "span2": [53, 71]}, "bert_text": "Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other <e1> methylxanthines </e1> <e2> coronary hyperemia </e2> like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3093": {"data": {"text": "Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.", "entity1": "theophylline", "entity2": "coronary hyperemia", "span1": [107, 119], "span2": [53, 71]}, "bert_text": "Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as <e1> theophylline </e1> <e2> coronary hyperemia </e2> like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3094": {"data": {"text": "In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.", "entity1": "oxygen", "entity2": "ALF", "span1": [22, 28], "span2": [65, 68]}, "bert_text": "In the present study, <e1> oxygen </e1> radical production in patients with <e2> ALF </e2> due to paracetamol overdose was compared with that of healthy volunteers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3095": {"data": {"text": "In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.", "entity1": "oxygen", "entity2": "overdose", "span1": [22, 28], "span2": [88, 96]}, "bert_text": "In the present study, <e1> oxygen </e1> radical production in patients with ALF due to paracetamol <e2> overdose </e2> was compared with that of healthy volunteers.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3096": {"data": {"text": "In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.", "entity1": "paracetamol", "entity2": "ALF", "span1": [76, 87], "span2": [65, 68]}, "bert_text": "In the present study, oxygen radical production in patients with ALF due to <e1> paracetamol </e1> <e2> ALF </e2> due to paracetamol overdose was compared with that of healthy volunteers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3097": {"data": {"text": "In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.", "entity1": "paracetamol", "entity2": "overdose", "span1": [76, 87], "span2": [88, 96]}, "bert_text": "In the present study, oxygen radical production in patients with ALF due to <e1> paracetamol </e1> <e2> overdose </e2> was compared with that of healthy volunteers.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3098": {"data": {"text": "In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.", "entity1": "daidzein", "entity2": "impairments of learning and memory", "span1": [39, 47], "span2": [98, 132]}, "bert_text": "In order to investigate the effects of <e1> daidzein </e1> from Pueraria thunbergiana on scopolamine-induced <e2> impairments of learning and memory </e2>, we conducted a series of in vivo tests.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3099": {"data": {"text": "In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.", "entity1": "scopolamine", "entity2": "impairments of learning and memory", "span1": [78, 89], "span2": [98, 132]}, "bert_text": "In order to investigate the effects of daidzein from Pueraria thunbergiana on <e1> scopolamine </e1>-induced <e2> impairments of learning and memory </e2>, we conducted a series of in vivo tests.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3100": {"data": {"text": "The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.", "entity1": "piroxicam", "entity2": "ventricular septal", "span1": [127, 136], "span2": [36, 54]}, "bert_text": "The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to <e1> piroxicam </e1> <e2> ventricular septal </e2> (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3101": {"data": {"text": "The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.", "entity1": "piroxicam", "entity2": "VSD", "span1": [127, 136], "span2": [56, 59]}, "bert_text": "The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to <e1> piroxicam </e1> <e2> VSD </e2>) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3102": {"data": {"text": "The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.", "entity1": "piroxicam", "entity2": "MD", "span1": [127, 136], "span2": [74, 76]}, "bert_text": "The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to <e1> piroxicam </e1> <e2> MD </e2>) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3103": {"data": {"text": "Seizures induced by the cocaine metabolite benzoylecgonine in rats.\n", "entity1": "cocaine", "entity2": "Seizures", "span1": [24, 31], "span2": [0, 8]}, "bert_text": "Seizures induced by the <e1> cocaine </e1> <e2> Seizures </e2> induced by the cocaine metabolite benzoylecgonine in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3104": {"data": {"text": "Seizures induced by the cocaine metabolite benzoylecgonine in rats.\n", "entity1": "benzoylecgonine", "entity2": "Seizures", "span1": [43, 58], "span2": [0, 8]}, "bert_text": "Seizures induced by the cocaine metabolite <e1> benzoylecgonine </e1> <e2> Seizures </e2> induced by the cocaine metabolite benzoylecgonine in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3105": {"data": {"text": "These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.", "entity1": "morphine", "entity2": "chronic pain", "span1": [54, 62], "span2": [176, 188]}, "bert_text": "These findings show a significant interaction between <e1> morphine </e1> and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of <e2> chronic pain </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3106": {"data": {"text": "These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.", "entity1": "metamizol", "entity2": "chronic pain", "span1": [67, 76], "span2": [176, 188]}, "bert_text": "These findings show a significant interaction between morphine and <e1> metamizol </e1> in chronically treated rats, suggesting that this combination could be useful for the treatment of <e2> chronic pain </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3107": {"data": {"text": "Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.", "entity1": "Carteolol", "entity2": "hyperlocomotion", "span1": [0, 9], "span2": [107, 122]}, "bert_text": "<e1> Carteolol </e1> did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and <e2> hyperlocomotion </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3108": {"data": {"text": "Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.", "entity1": "dopamine", "entity2": "hyperlocomotion", "span1": [37, 45], "span2": [107, 122]}, "bert_text": "Carteolol did not evoke postsynaptic <e1> dopamine </e1> receptor-stimulating behavioral signs such as stereotypy and <e2> hyperlocomotion </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3109": {"data": {"text": "Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?\n", "entity1": "ribavirin", "entity2": "hemolytic anemia", "span1": [46, 55], "span2": [67, 83]}, "bert_text": "Can angiogenesis be a target of treatment for <e1> ribavirin </e1> associated <e2> hemolytic anemia </e2>?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3110": {"data": {"text": "Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.\n", "entity1": "desferrioxamine", "entity2": "auditory toxicity", "span1": [64, 79], "span2": [11, 28]}, "bert_text": "Ocular and auditory toxicity in hemodialyzed patients receiving <e1> desferrioxamine </e1> <e2> auditory toxicity </e2> in hemodialyzed patients receiving desferrioxamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3111": {"data": {"text": "Water intoxication associated with oxytocin administration during saline-induced abortion.\n", "entity1": "oxytocin", "entity2": "Water intoxication", "span1": [35, 43], "span2": [0, 18]}, "bert_text": "Water intoxication associated with <e1> oxytocin </e1> <e2> Water intoxication </e2> associated with oxytocin administration during saline-induced abortion.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3112": {"data": {"text": "Water intoxication associated with oxytocin administration during saline-induced abortion.\n", "entity1": "oxytocin", "entity2": "abortion", "span1": [35, 43], "span2": [81, 89]}, "bert_text": "Water intoxication associated with <e1> oxytocin </e1> administration during saline-induced <e2> abortion </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3113": {"data": {"text": "A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\n", "entity1": "maltolyl p-coumarate", "entity2": "cognitive deficits", "span1": [18, 38], "span2": [51, 69]}, "bert_text": "A novel compound, <e1> maltolyl p-coumarate </e1>, attenuates <e2> cognitive deficits </e2> and shows neuroprotective effects in vitro and in vivo dementia models.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3114": {"data": {"text": "A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\n", "entity1": "maltolyl p-coumarate", "entity2": "dementia", "span1": [18, 38], "span2": [125, 133]}, "bert_text": "A novel compound, <e1> maltolyl p-coumarate </e1>, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo <e2> dementia </e2> models.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3115": {"data": {"text": "In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.", "entity1": "cyclophosphamide", "entity2": "cystitis", "span1": [3, 19], "span2": [28, 36]}, "bert_text": "In <e1> cyclophosphamide </e1>-induced <e2> cystitis </e2> in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3116": {"data": {"text": "RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.", "entity1": "piroxicam", "entity2": "toxicity", "span1": [162, 171], "span2": [18, 26]}, "bert_text": "RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of <e1> piroxicam </e1> <e2> toxicity </e2>, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3117": {"data": {"text": "RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.", "entity1": "piroxicam", "entity2": "intrauterine growth retardation", "span1": [162, 171], "span2": [28, 59]}, "bert_text": "RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of <e1> piroxicam </e1> <e2> intrauterine growth retardation </e2>, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3118": {"data": {"text": "The results suggest a possible involvement of the renin-angiotensin system in the development of puromycin aminonucleoside-induced nephrosis.", "entity1": "angiotensin", "entity2": "nephrosis", "span1": [56, 67], "span2": [131, 140]}, "bert_text": "The results suggest a possible involvement of the renin-<e1> angiotensin </e1> system in the development of puromycin aminonucleoside-induced <e2> nephrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3119": {"data": {"text": "The results suggest a possible involvement of the renin-angiotensin system in the development of puromycin aminonucleoside-induced nephrosis.", "entity1": "puromycin aminonucleoside", "entity2": "nephrosis", "span1": [97, 122], "span2": [131, 140]}, "bert_text": "The results suggest a possible involvement of the renin-angiotensin system in the development of <e1> puromycin aminonucleoside </e1>-induced <e2> nephrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3120": {"data": {"text": "Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.", "entity1": "magnesium", "entity2": "paralysis", "span1": [25, 34], "span2": [9, 18]}, "bert_text": "Although paralysis after <e1> magnesium </e1> <e2> paralysis </e2> after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3121": {"data": {"text": "Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.", "entity1": "magnesium", "entity2": "myasthenia gravis", "span1": [25, 34], "span2": [92, 109]}, "bert_text": "Although paralysis after <e1> magnesium </e1> administration has been described in patients with known <e2> myasthenia gravis </e2>, it has not previously been reported to be the initial or only manifestation of the disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3122": {"data": {"text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.", "entity1": "docetaxel", "entity2": "venous thromboembolism", "span1": [160, 169], "span2": [46, 68]}, "bert_text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with <e1> docetaxel </e1> <e2> venous thromboembolism </e2> (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3123": {"data": {"text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.", "entity1": "docetaxel", "entity2": "VTE", "span1": [160, 169], "span2": [70, 73]}, "bert_text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with <e1> docetaxel </e1> <e2> VTE </e2>) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3124": {"data": {"text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.", "entity1": "docetaxel", "entity2": "prostate cancer", "span1": [160, 169], "span2": [122, 137]}, "bert_text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with <e1> docetaxel </e1> <e2> prostate cancer </e2> who were treated with docetaxel alone or in combination with thalidomide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3125": {"data": {"text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.", "entity1": "thalidomide", "entity2": "venous thromboembolism", "span1": [199, 210], "span2": [46, 68]}, "bert_text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with <e1> thalidomide </e1> <e2> venous thromboembolism </e2> (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3126": {"data": {"text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.", "entity1": "thalidomide", "entity2": "VTE", "span1": [199, 210], "span2": [70, 73]}, "bert_text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with <e1> thalidomide </e1> <e2> VTE </e2>) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3127": {"data": {"text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.", "entity1": "thalidomide", "entity2": "prostate cancer", "span1": [199, 210], "span2": [122, 137]}, "bert_text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with <e1> thalidomide </e1> <e2> prostate cancer </e2> who were treated with docetaxel alone or in combination with thalidomide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3128": {"data": {"text": "Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.\n", "entity1": "terbutaline", "entity2": "Neuroinflammation and behavioral abnormalities", "span1": [62, 73], "span2": [0, 46]}, "bert_text": "Neuroinflammation and behavioral abnormalities after neonatal <e1> terbutaline </e1> <e2> Neuroinflammation and behavioral abnormalities </e2> after neonatal terbutaline treatment in rats: implications for autism.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3129": {"data": {"text": "Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.\n", "entity1": "terbutaline", "entity2": "autism", "span1": [62, 73], "span2": [110, 116]}, "bert_text": "Neuroinflammation and behavioral abnormalities after neonatal <e1> terbutaline </e1> treatment in rats: implications for <e2> autism </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3130": {"data": {"text": "In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [123, 131], "span2": [3, 22]}, "bert_text": "In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by <e1> levodopa </e1> <e2> Parkinson's disease </e2> + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3131": {"data": {"text": "In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).", "entity1": "levodopa", "entity2": "LID", "span1": [123, 131], "span2": [25, 28]}, "bert_text": "In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by <e1> levodopa </e1> <e2> LID </e2>, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3132": {"data": {"text": "Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.", "entity1": "fluoxetine", "entity2": "pulmonary hypertension syndrome", "span1": [34, 44], "span2": [104, 135]}, "bert_text": "Epidemiological data suggest that <e1> fluoxetine </e1> exposure prenatally increases the prevalence of persistent <e2> pulmonary hypertension syndrome </e2> of the newborn.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3133": {"data": {"text": "A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.", "entity1": "amphotericin B", "entity2": "cryptogenic cirrhosis", "span1": [143, 157], "span2": [15, 36]}, "bert_text": "A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of <e1> amphotericin B </e1> <e2> cryptogenic cirrhosis </e2> and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3134": {"data": {"text": "A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.", "entity1": "amphotericin B", "entity2": "acute renal failure", "span1": [143, 157], "span2": [79, 98]}, "bert_text": "A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of <e1> amphotericin B </e1> <e2> acute renal failure </e2> immediately following the administration of amphotericin B on four separate occasions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3135": {"data": {"text": "A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).\n", "entity1": "cisplatin", "entity2": "breast carcinoma", "span1": [20, 29], "span2": [71, 87]}, "bert_text": "A Phase II trial of <e1> cisplatin </e1> plus WR-2721 (amifostine) for metastatic <e2> breast carcinoma </e2>: an Eastern Cooperative Oncology Group Study (E8188).\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3136": {"data": {"text": "A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).\n", "entity1": "WR-2721", "entity2": "breast carcinoma", "span1": [35, 42], "span2": [71, 87]}, "bert_text": "A Phase II trial of cisplatin plus <e1> WR-2721 </e1> (amifostine) for metastatic <e2> breast carcinoma </e2>: an Eastern Cooperative Oncology Group Study (E8188).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3137": {"data": {"text": "A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).\n", "entity1": "amifostine", "entity2": "breast carcinoma", "span1": [44, 54], "span2": [71, 87]}, "bert_text": "A Phase II trial of cisplatin plus WR-2721 (<e1> amifostine </e1>) for metastatic <e2> breast carcinoma </e2>: an Eastern Cooperative Oncology Group Study (E8188).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3138": {"data": {"text": "Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.\n", "entity1": "azelastine", "entity2": "spring allergic rhinitis", "span1": [87, 97], "span2": [149, 173]}, "bert_text": "Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of <e1> azelastine </e1>, chlorpheniramine, and placebo in the treatment of <e2> spring allergic rhinitis </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3139": {"data": {"text": "Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.\n", "entity1": "chlorpheniramine", "entity2": "spring allergic rhinitis", "span1": [99, 115], "span2": [149, 173]}, "bert_text": "Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, <e1> chlorpheniramine </e1>, and placebo in the treatment of <e2> spring allergic rhinitis </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3140": {"data": {"text": "Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.\n", "entity1": "tenofovir", "entity2": "Acute renal failure", "span1": [45, 54], "span2": [0, 19]}, "bert_text": "Acute renal failure in patients with AIDS on <e1> tenofovir </e1> <e2> Acute renal failure </e2> in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3141": {"data": {"text": "Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.\n", "entity1": "tenofovir", "entity2": "AIDS", "span1": [45, 54], "span2": [37, 41]}, "bert_text": "Acute renal failure in patients with AIDS on <e1> tenofovir </e1> <e2> AIDS </e2> on tenofovir while receiving prolonged vancomycin course for osteomyelitis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3142": {"data": {"text": "Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.\n", "entity1": "tenofovir", "entity2": "osteomyelitis", "span1": [45, 54], "span2": [103, 116]}, "bert_text": "Acute renal failure in patients with AIDS on <e1> tenofovir </e1> while receiving prolonged vancomycin course for <e2> osteomyelitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3143": {"data": {"text": "Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.\n", "entity1": "vancomycin", "entity2": "Acute renal failure", "span1": [81, 91], "span2": [0, 19]}, "bert_text": "Acute renal failure in patients with AIDS on tenofovir while receiving prolonged <e1> vancomycin </e1> <e2> Acute renal failure </e2> in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3144": {"data": {"text": "Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.\n", "entity1": "vancomycin", "entity2": "AIDS", "span1": [81, 91], "span2": [37, 41]}, "bert_text": "Acute renal failure in patients with AIDS on tenofovir while receiving prolonged <e1> vancomycin </e1> <e2> AIDS </e2> on tenofovir while receiving prolonged vancomycin course for osteomyelitis.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3145": {"data": {"text": "Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.\n", "entity1": "vancomycin", "entity2": "osteomyelitis", "span1": [81, 91], "span2": [103, 116]}, "bert_text": "Acute renal failure in patients with AIDS on tenofovir while receiving prolonged <e1> vancomycin </e1> course for <e2> osteomyelitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3146": {"data": {"text": "Vitamin D3 toxicity in dairy cows.\n", "entity1": "Vitamin D3", "entity2": "toxicity", "span1": [0, 10], "span2": [11, 19]}, "bert_text": "<e1> Vitamin D3 </e1> <e2> toxicity </e2> in dairy cows.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3147": {"data": {"text": "Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.", "entity1": "carmofur", "entity2": "Organic mental disorder", "span1": [105, 113], "span2": [0, 23]}, "bert_text": "Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of <e1> carmofur </e1> <e2> Organic mental disorder </e2> was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3148": {"data": {"text": "Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.", "entity1": "carmofur", "entity2": "leukoencephalopathy", "span1": [105, 113], "span2": [122, 141]}, "bert_text": "Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of <e1> carmofur </e1>-induced <e2> leukoencephalopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3149": {"data": {"text": "Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.", "entity1": "pentazocine", "entity2": "Fibrous myopathy", "span1": [65, 76], "span2": [0, 16]}, "bert_text": "Fibrous myopathy is a common, well-known side effect of repeated <e1> pentazocine </e1> <e2> Fibrous myopathy </e2> is a common, well-known side effect of repeated pentazocine injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3150": {"data": {"text": "Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.", "entity1": "folic acid", "entity2": "epileptic", "span1": [44, 54], "span2": [6, 15]}, "bert_text": "Of 60 epileptic women with periconceptional <e1> folic acid </e1> <e2> epileptic </e2> women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3151": {"data": {"text": "Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.", "entity1": "folic acid", "entity2": "epilepsy", "span1": [44, 54], "span2": [122, 130]}, "bert_text": "Of 60 epileptic women with periconceptional <e1> folic acid </e1> (0.8 mg)-containing multivitamin supplementation, no one developed <e2> epilepsy </e2>-related side effects during the periconception period.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3152": {"data": {"text": "Isoniazid was the most frequent agent in drug-induced neuropathy.", "entity1": "Isoniazid", "entity2": "neuropathy", "span1": [0, 9], "span2": [54, 64]}, "bert_text": "<e1> Isoniazid </e1> was the most frequent agent in drug-induced <e2> neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3153": {"data": {"text": "CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.", "entity1": "tamoxifen", "entity2": "breast carcinoma", "span1": [58, 67], "span2": [108, 124]}, "bert_text": "CASE: A 52-year-old postmenopausal woman was treated with <e1> tamoxifen </e1> for stage II estrogen receptor-positive <e2> breast carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3154": {"data": {"text": "CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.", "entity1": "estrogen", "entity2": "breast carcinoma", "span1": [81, 89], "span2": [108, 124]}, "bert_text": "CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II <e1> estrogen </e1> receptor-positive <e2> breast carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3155": {"data": {"text": "We could not find any previous reports of sulpiride-induced tardive dystonia.", "entity1": "sulpiride", "entity2": "tardive dystonia", "span1": [42, 51], "span2": [60, 76]}, "bert_text": "We could not find any previous reports of <e1> sulpiride </e1>-induced <e2> tardive dystonia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3156": {"data": {"text": "CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.", "entity1": "vitamin C", "entity2": "cardiovascular disease", "span1": [19, 28], "span2": [93, 115]}, "bert_text": "CONCLUSION: A high <e1> vitamin C </e1> intake from supplements is associated with an increased risk of <e2> cardiovascular disease </e2> mortality in postmenopausal women with diabetes.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3157": {"data": {"text": "CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.", "entity1": "vitamin C", "entity2": "diabetes", "span1": [19, 28], "span2": [155, 163]}, "bert_text": "CONCLUSION: A high <e1> vitamin C </e1> intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with <e2> diabetes </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3158": {"data": {"text": "DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.", "entity1": "venlafaxine", "entity2": "overdose", "span1": [65, 76], "span2": [77, 85]}, "bert_text": "DISCUSSION: To our knowledge, this is the first reported case of <e1> venlafaxine </e1> <e2> overdose </e2> that resulted in a generalized seizure.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3159": {"data": {"text": "DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.", "entity1": "venlafaxine", "entity2": "seizure", "span1": [65, 76], "span2": [117, 124]}, "bert_text": "DISCUSSION: To our knowledge, this is the first reported case of <e1> venlafaxine </e1> overdose that resulted in a generalized <e2> seizure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3160": {"data": {"text": "CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).\n", "entity1": "CCNU", "entity2": "toxicity", "span1": [0, 4], "span2": [17, 25]}, "bert_text": "<e1> CCNU </e1> (lomustine) <e2> toxicity </e2> in dogs: a retrospective study (2002-07).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3161": {"data": {"text": "CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).\n", "entity1": "lomustine", "entity2": "toxicity", "span1": [6, 15], "span2": [17, 25]}, "bert_text": "CCNU (<e1> lomustine </e1>) <e2> toxicity </e2> in dogs: a retrospective study (2002-07).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3162": {"data": {"text": "Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (\"valproate encephalopathy\").", "entity1": "sodium valproate", "entity2": "neurological disorders", "span1": [61, 77], "span2": [193, 215]}, "bert_text": "Long-term intragastric application of the antiepileptic drug <e1> sodium valproate </e1> (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed <e2> neurological disorders </e2> indicating cerebellum damage (\"valproate encephalopathy\").", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3163": {"data": {"text": "Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (\"valproate encephalopathy\").", "entity1": "sodium valproate", "entity2": "cerebellum damage", "span1": [61, 77], "span2": [227, 244]}, "bert_text": "Long-term intragastric application of the antiepileptic drug <e1> sodium valproate </e1> (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating <e2> cerebellum damage </e2> (\"valproate encephalopathy\").", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3164": {"data": {"text": "Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (\"valproate encephalopathy\").", "entity1": "sodium valproate", "entity2": "encephalopathy", "span1": [61, 77], "span2": [257, 271]}, "bert_text": "Long-term intragastric application of the antiepileptic drug <e1> sodium valproate </e1> (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (\"valproate <e2> encephalopathy </e2>\").", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3165": {"data": {"text": "Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (\"valproate encephalopathy\").", "entity1": "valproate", "entity2": "neurological disorders", "span1": [247, 256], "span2": [193, 215]}, "bert_text": "Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (\"<e1> valproate </e1> <e2> neurological disorders </e2> indicating cerebellum damage (\"valproate encephalopathy\").", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3166": {"data": {"text": "Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (\"valproate encephalopathy\").", "entity1": "valproate", "entity2": "cerebellum damage", "span1": [247, 256], "span2": [227, 244]}, "bert_text": "Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (\"<e1> valproate </e1> <e2> cerebellum damage </e2> (\"valproate encephalopathy\").", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3167": {"data": {"text": "Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (\"valproate encephalopathy\").", "entity1": "valproate", "entity2": "encephalopathy", "span1": [247, 256], "span2": [257, 271]}, "bert_text": "Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (\"<e1> valproate </e1> <e2> encephalopathy </e2>\").", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3168": {"data": {"text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "entity1": "creatinine", "entity2": "glucosuria", "span1": [142, 152], "span2": [78, 88]}, "bert_text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, <e1> creatinine </e1> <e2> glucosuria </e2>, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3169": {"data": {"text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "entity1": "creatinine", "entity2": "proteinuria", "span1": [142, 152], "span2": [90, 101]}, "bert_text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, <e1> creatinine </e1> <e2> proteinuria </e2>, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3170": {"data": {"text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "entity1": "creatinine", "entity2": "aminoaciduria", "span1": [142, 152], "span2": [103, 116]}, "bert_text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, <e1> creatinine </e1> <e2> aminoaciduria </e2>, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3171": {"data": {"text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "entity1": "phosphate", "entity2": "glucosuria", "span1": [164, 173], "span2": [78, 88]}, "bert_text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, <e1> phosphate </e1> <e2> glucosuria </e2>, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3172": {"data": {"text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "entity1": "phosphate", "entity2": "proteinuria", "span1": [164, 173], "span2": [90, 101]}, "bert_text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, <e1> phosphate </e1> <e2> proteinuria </e2>, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3173": {"data": {"text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "entity1": "phosphate", "entity2": "aminoaciduria", "span1": [164, 173], "span2": [103, 116]}, "bert_text": "Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, <e1> phosphate </e1> <e2> aminoaciduria </e2>, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3174": {"data": {"text": "The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.", "entity1": "pilocarpine", "entity2": "epilepsy", "span1": [4, 15], "span2": [32, 40]}, "bert_text": "The <e1> pilocarpine </e1> (PILO) model of <e2> epilepsy </e2> is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3175": {"data": {"text": "The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [4, 15], "span2": [80, 98]}, "bert_text": "The <e1> pilocarpine </e1> (PILO) model of epilepsy is characterized by an acute period of <e2> status epilepticus </e2> followed by spontaneous recurrent seizures and related brain damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3176": {"data": {"text": "The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [4, 15], "span2": [133, 141]}, "bert_text": "The <e1> pilocarpine </e1> (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent <e2> seizures </e2> and related brain damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3177": {"data": {"text": "The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.", "entity1": "pilocarpine", "entity2": "brain damage", "span1": [4, 15], "span2": [154, 166]}, "bert_text": "The <e1> pilocarpine </e1> (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related <e2> brain damage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3178": {"data": {"text": "The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.", "entity1": "PILO", "entity2": "epilepsy", "span1": [17, 21], "span2": [32, 40]}, "bert_text": "The pilocarpine (<e1> PILO </e1>) model of <e2> epilepsy </e2> is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3179": {"data": {"text": "The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.", "entity1": "PILO", "entity2": "status epilepticus", "span1": [17, 21], "span2": [80, 98]}, "bert_text": "The pilocarpine (<e1> PILO </e1>) model of epilepsy is characterized by an acute period of <e2> status epilepticus </e2> followed by spontaneous recurrent seizures and related brain damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3180": {"data": {"text": "The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.", "entity1": "PILO", "entity2": "seizures", "span1": [17, 21], "span2": [133, 141]}, "bert_text": "The pilocarpine (<e1> PILO </e1>) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent <e2> seizures </e2> and related brain damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3181": {"data": {"text": "The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.", "entity1": "PILO", "entity2": "brain damage", "span1": [17, 21], "span2": [154, 166]}, "bert_text": "The pilocarpine (<e1> PILO </e1>) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related <e2> brain damage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3182": {"data": {"text": "Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/-", "entity1": "Apamin", "entity2": "convulsive", "span1": [0, 6], "span2": [46, 56]}, "bert_text": "<e1> Apamin </e1> (10 ng) had a tendency to decrease the <e2> convulsive </e2> threshold (21.6 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3183": {"data": {"text": "Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.\n", "entity1": "clomiphene citrate", "entity2": "Myocardial infarction", "span1": [51, 69], "span2": [0, 21]}, "bert_text": "Myocardial infarction in pregnancy associated with <e1> clomiphene citrate </e1> <e2> Myocardial infarction </e2> in pregnancy associated with clomiphene citrate for ovulation induction: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3184": {"data": {"text": "METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.", "entity1": "valproic acid", "entity2": "confusion", "span1": [114, 127], "span2": [79, 88]}, "bert_text": "METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with <e1> valproic acid </e1> <e2> confusion </e2> reported since 1985 with valproic acid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3185": {"data": {"text": "In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.", "entity1": "thiazide", "entity2": "hypokalemia", "span1": [28, 36], "span2": [53, 64]}, "bert_text": "In conclusion we found that <e1> thiazide </e1> diuretics cause <e2> hypokalemia </e2> and depletion of body potassium.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3186": {"data": {"text": "In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.", "entity1": "potassium", "entity2": "hypokalemia", "span1": [87, 96], "span2": [53, 64]}, "bert_text": "In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body <e1> potassium </e1> <e2> hypokalemia </e2> and depletion of body potassium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3187": {"data": {"text": "Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.", "entity1": "Sulfonamides", "entity2": "birth defects", "span1": [0, 12], "span2": [62, 75]}, "bert_text": "<e1> Sulfonamides </e1> and nitrofurantoins were associated with several <e2> birth defects </e2>, indicating a need for additional scrutiny.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3188": {"data": {"text": "Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.", "entity1": "nitrofurantoins", "entity2": "birth defects", "span1": [17, 32], "span2": [62, 75]}, "bert_text": "Sulfonamides and <e1> nitrofurantoins </e1> were associated with several <e2> birth defects </e2>, indicating a need for additional scrutiny.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3189": {"data": {"text": "The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.", "entity1": "coenzyme Q10", "entity2": "acute renal injury", "span1": [31, 43], "span2": [74, 92]}, "bert_text": "The nephroprotective effect of <e1> coenzyme Q10 </e1> was investigated in mice with <e2> acute renal injury </e2> induced by a single i.p.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3190": {"data": {"text": "The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents.", "entity1": "fluoxetine", "entity2": "pulmonary hypertension", "span1": [142, 152], "span2": [108, 130]}, "bert_text": "The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a pulmonary hypertension protective <e1> fluoxetine </e1> <e2> pulmonary hypertension </e2> protective fluoxetine effect in adult rodents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3191": {"data": {"text": "Possible azithromycin-associated hiccups.\nOBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.", "entity1": "azithromycin", "entity2": "hiccups", "span1": [9, 21], "span2": [33, 40]}, "bert_text": "Possible <e1> azithromycin </e1>-associated <e2> hiccups </e2>.\nOBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"3192": {"data": {"text": "Possible azithromycin-associated hiccups.\nOBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.", "entity1": "azithromycin", "entity2": "hiccups", "span1": [9, 21], "span2": [84, 91]}, "bert_text": "Possible <e1> azithromycin </e1>-associated hiccups.\nOBJECTIVE: To report a case of persistent <e2> hiccups </e2> associated by azithromycin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3193": {"data": {"text": "Possible azithromycin-associated hiccups.\nOBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.", "entity1": "azithromycin", "entity2": "hiccups", "span1": [106, 118], "span2": [33, 40]}, "bert_text": "Possible azithromycin-associated hiccups.\nOBJECTIVE: To report a case of persistent hiccups associated by <e1> azithromycin </e1> <e2> hiccups </e2>.\nOBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3194": {"data": {"text": "Possible azithromycin-associated hiccups.\nOBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.", "entity1": "azithromycin", "entity2": "hiccups", "span1": [106, 118], "span2": [84, 91]}, "bert_text": "Possible azithromycin-associated hiccups.\nOBJECTIVE: To report a case of persistent hiccups associated by <e1> azithromycin </e1> <e2> hiccups </e2> associated by azithromycin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3195": {"data": {"text": "Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.", "entity1": "histamine", "entity2": "Atherosclerosis", "span1": [120, 129], "span2": [0, 15]}, "bert_text": "Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, <e1> histamine </e1> <e2> Atherosclerosis </e2> could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3196": {"data": {"text": "Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.", "entity1": "histamine", "entity2": "gastric hemorrhagic ulcer", "span1": [120, 129], "span2": [30, 55]}, "bert_text": "Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, <e1> histamine </e1> <e2> gastric hemorrhagic ulcer </e2> via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3197": {"data": {"text": "Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.", "entity1": "verapamil", "entity2": "Atherosclerosis", "span1": [198, 207], "span2": [0, 15]}, "bert_text": "Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by <e1> verapamil </e1> <e2> Atherosclerosis </e2> could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3198": {"data": {"text": "Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.", "entity1": "verapamil", "entity2": "gastric hemorrhagic ulcer", "span1": [198, 207], "span2": [30, 55]}, "bert_text": "Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by <e1> verapamil </e1> <e2> gastric hemorrhagic ulcer </e2> via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3199": {"data": {"text": "Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.", "entity1": "bromocriptine", "entity2": "psychiatric", "span1": [113, 126], "span2": [40, 51]}, "bert_text": "Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received <e1> bromocriptine </e1> <e2> psychiatric </e2> history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3200": {"data": {"text": "Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.", "entity1": "bromocriptine", "entity2": "psychosis", "span1": [113, 126], "span2": [86, 95]}, "bert_text": "Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received <e1> bromocriptine </e1> <e2> psychosis </e2>, having received bromocriptine for inhibition of lactation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3201": {"data": {"text": "Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.", "entity1": "Dexamethasone", "entity2": "postoperative nausea and vomiting", "span1": [0, 13], "span2": [72, 105]}, "bert_text": "<e1> Dexamethasone </e1> had no significant effect on the incidence or severity of <e2> postoperative nausea and vomiting </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3202": {"data": {"text": "The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.", "entity1": "angiotensin", "entity2": "hypotension", "span1": [23, 34], "span2": [146, 157]}, "bert_text": "The role of the renin--<e1> angiotensin </e1> system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced <e2> hypotension </e2> was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3203": {"data": {"text": "The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.", "entity1": "halothane", "entity2": "hypotension", "span1": [86, 95], "span2": [146, 157]}, "bert_text": "The role of the renin--angiotensin system in the maintenance of blood pressure during <e1> halothane </e1> anesthesia and sodium nitroprusside (SNP)-induced <e2> hypotension </e2> was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3204": {"data": {"text": "The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.", "entity1": "sodium nitroprusside", "entity2": "hypotension", "span1": [111, 131], "span2": [146, 157]}, "bert_text": "The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and <e1> sodium nitroprusside </e1> (SNP)-induced <e2> hypotension </e2> was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3205": {"data": {"text": "The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.", "entity1": "SNP)-induced", "entity2": "hypotension", "span1": [133, 145], "span2": [146, 157]}, "bert_text": "The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (<e1> SNP)-induced </e1> <e2> hypotension </e2> was evaluated.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3206": {"data": {"text": "BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.", "entity1": "Cisplatin", "entity2": "breast carcinoma", "span1": [12, 21], "span2": [112, 128]}, "bert_text": "BACKGROUND: <e1> Cisplatin </e1> has minimal antitumor activity when used as second- or third-line treatment of metastatic <e2> breast carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3207": {"data": {"text": "Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.\n", "entity1": "fucoidan", "entity2": "intracerebral hemorrhage", "span1": [10, 18], "span2": [52, 76]}, "bert_text": "Effect of <e1> fucoidan </e1> treatment on collagenase-induced <e2> intracerebral hemorrhage </e2> in rats.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3208": {"data": {"text": "Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.", "entity1": "Isoproterenol", "entity2": "cardiac hypertrophy", "span1": [0, 13], "span2": [46, 65]}, "bert_text": "<e1> Isoproterenol </e1> pretreatment for 15 days caused <e2> cardiac hypertrophy </e2> without affecting baseline blood pressure and heart rate.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3209": {"data": {"text": "Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.", "entity1": "vecuronium bromide", "entity2": "paralysis", "span1": [130, 148], "span2": [22, 31]}, "bert_text": "Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as <e1> vecuronium bromide </e1> <e2> paralysis </e2> after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3210": {"data": {"text": "Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.", "entity1": "corticosteroids", "entity2": "paralysis", "span1": [191, 206], "span2": [22, 31]}, "bert_text": "Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with <e1> corticosteroids </e1> <e2> paralysis </e2> after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3211": {"data": {"text": "Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.", "entity1": "CP", "entity2": "cystitis", "span1": [64, 66], "span2": [75, 83]}, "bert_text": "Overall, these results indicate that this experimental model of <e1> CP </e1>-induced <e2> cystitis </e2> may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3212": {"data": {"text": "Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.", "entity1": "CP", "entity2": "visceral pain", "span1": [64, 66], "span2": [143, 156]}, "bert_text": "Overall, these results indicate that this experimental model of <e1> CP </e1>-induced cystitis may be an interesting new behavioral model of inflammatory <e2> visceral pain </e2>, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3213": {"data": {"text": "Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.", "entity1": "CP", "entity2": "painful syndromes", "span1": [64, 66], "span2": [199, 216]}, "bert_text": "Overall, these results indicate that this experimental model of <e1> CP </e1>-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these <e2> painful syndromes </e2> and thus a better therapeutic approach to them.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3214": {"data": {"text": "Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.", "entity1": "anthracycline", "entity2": "cardiotoxic", "span1": [20, 33], "span2": [70, 81]}, "bert_text": "Clinical use of the <e1> anthracycline </e1> doxorubicin (DOX) is limited by its <e2> cardiotoxic </e2> effects, which are attributed to the induction of apoptosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3215": {"data": {"text": "Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.", "entity1": "doxorubicin", "entity2": "cardiotoxic", "span1": [34, 45], "span2": [70, 81]}, "bert_text": "Clinical use of the anthracycline <e1> doxorubicin </e1> (DOX) is limited by its <e2> cardiotoxic </e2> effects, which are attributed to the induction of apoptosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3216": {"data": {"text": "Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.", "entity1": "DOX", "entity2": "cardiotoxic", "span1": [47, 50], "span2": [70, 81]}, "bert_text": "Clinical use of the anthracycline doxorubicin (<e1> DOX </e1>) is limited by its <e2> cardiotoxic </e2> effects, which are attributed to the induction of apoptosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3217": {"data": {"text": "Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).", "entity1": "oxaloacetate", "entity2": "Liver injuries", "span1": [64, 76], "span2": [0, 14]}, "bert_text": "Liver injuries were quantified as serum activities of glutamate-<e1> oxaloacetate </e1> <e2> Liver injuries </e2> were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3218": {"data": {"text": "Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).", "entity1": "pyruvate", "entity2": "Liver injuries", "span1": [110, 118], "span2": [0, 14]}, "bert_text": "Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-<e1> pyruvate </e1> <e2> Liver injuries </e2> were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3219": {"data": {"text": "Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.", "entity1": "Bromocriptine", "entity2": "psychosis", "span1": [0, 13], "span2": [59, 68]}, "bert_text": "<e1> Bromocriptine </e1> given in high doses has been associated with <e2> psychosis </e2> in patients receiving the drug for Parkinson's disease.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3220": {"data": {"text": "Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.", "entity1": "Bromocriptine", "entity2": "Parkinson's disease", "span1": [0, 13], "span2": [104, 123]}, "bert_text": "<e1> Bromocriptine </e1> given in high doses has been associated with psychosis in patients receiving the drug for <e2> Parkinson's disease </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3221": {"data": {"text": "However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.", "entity1": "pentazocine", "entity2": "compression neuropathy", "span1": [67, 78], "span2": [9, 31]}, "bert_text": "However, compression neuropathy due to fibrotic muscle affected by <e1> pentazocine </e1> <e2> compression neuropathy </e2> due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3222": {"data": {"text": "However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.", "entity1": "pentazocine", "entity2": "myopathy", "span1": [67, 78], "span2": [87, 95]}, "bert_text": "However, compression neuropathy due to fibrotic muscle affected by <e1> pentazocine </e1>-induced <e2> myopathy </e2> has not previously been reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3223": {"data": {"text": "In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.", "entity1": "ceftriaxone", "entity2": "pseudolithiasis", "span1": [141, 152], "span2": [83, 98]}, "bert_text": "In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving <e1> ceftriaxone </e1> <e2> pseudolithiasis </e2> in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3224": {"data": {"text": "Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.", "entity1": "BCNU", "entity2": "astrocytomas", "span1": [164, 168], "span2": [50, 62]}, "bert_text": "Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial <e1> BCNU </e1> <e2> astrocytomas </e2>, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3225": {"data": {"text": "It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.", "entity1": "ASA", "entity2": "malformations", "span1": [211, 214], "span2": [85, 98]}, "bert_text": "It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with <e1> ASA </e1> <e2> malformations </e2> that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3226": {"data": {"text": "During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.", "entity1": "desferrioxamine", "entity2": "audiovisual toxicity", "span1": [70, 85], "span2": [169, 189]}, "bert_text": "During an 18-month period of study 41 hemodialyzed patients receiving <e1> desferrioxamine </e1> (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of <e2> audiovisual toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3227": {"data": {"text": "Remifentanil pretreatment reduces myoclonus after etomidate.\n", "entity1": "Remifentanil", "entity2": "myoclonus", "span1": [0, 12], "span2": [34, 43]}, "bert_text": "<e1> Remifentanil </e1> pretreatment reduces <e2> myoclonus </e2> after etomidate.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3228": {"data": {"text": "Remifentanil pretreatment reduces myoclonus after etomidate.\n", "entity1": "etomidate", "entity2": "myoclonus", "span1": [50, 59], "span2": [34, 43]}, "bert_text": "Remifentanil pretreatment reduces myoclonus after <e1> etomidate </e1> <e2> myoclonus </e2> after etomidate.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3229": {"data": {"text": "In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.", "entity1": "N-acetylcysteine", "entity2": "diabetes mellitus", "span1": [72, 88], "span2": [46, 63]}, "bert_text": "In 414 patients, contrast volume, presence of diabetes mellitus, use of <e1> N-acetylcysteine </e1> <e2> diabetes mellitus </e2>, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3230": {"data": {"text": "Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.\n", "entity1": "Penicillamine", "entity2": "glomerulonephritis", "span1": [0, 13], "span2": [42, 60]}, "bert_text": "<e1> Penicillamine </e1>-induced rapidly progressive <e2> glomerulonephritis </e2> in a patient with rheumatoid arthritis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3231": {"data": {"text": "Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.\n", "entity1": "Penicillamine", "entity2": "rheumatoid arthritis", "span1": [0, 13], "span2": [79, 99]}, "bert_text": "<e1> Penicillamine </e1>-induced rapidly progressive glomerulonephritis in a patient with <e2> rheumatoid arthritis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3232": {"data": {"text": "CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.", "entity1": "carbimazole", "entity2": "hyperthyroidism", "span1": [96, 107], "span2": [58, 73]}, "bert_text": "CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with <e1> carbimazole </e1> <e2> hyperthyroidism </e2> had been treated with carbimazole and propranolol for the past 5 years.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3233": {"data": {"text": "CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.", "entity1": "propranolol", "entity2": "hyperthyroidism", "span1": [112, 123], "span2": [58, 73]}, "bert_text": "CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and <e1> propranolol </e1> <e2> hyperthyroidism </e2> had been treated with carbimazole and propranolol for the past 5 years.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3234": {"data": {"text": "STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.", "entity1": "remifentanil", "entity2": "myoclonus", "span1": [85, 97], "span2": [155, 164]}, "bert_text": "STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with <e1> remifentanil </e1> 1 microg/kg and the effect of gender on the incidence of <e2> myoclonus </e2> after anesthesia induction with etomidate.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3235": {"data": {"text": "STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.", "entity1": "etomidate", "entity2": "myoclonus", "span1": [197, 206], "span2": [155, 164]}, "bert_text": "STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with <e1> etomidate </e1> <e2> myoclonus </e2> after anesthesia induction with etomidate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3236": {"data": {"text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "entity1": "progesterone", "entity2": "headache", "span1": [144, 156], "span2": [51, 59]}, "bert_text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of <e1> progesterone </e1> <e2> headache </e2>, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3237": {"data": {"text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "entity1": "progesterone", "entity2": "nausea", "span1": [144, 156], "span2": [61, 67]}, "bert_text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of <e1> progesterone </e1> <e2> nausea </e2> and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3238": {"data": {"text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "entity1": "progesterone", "entity2": "vomiting", "span1": [144, 156], "span2": [72, 80]}, "bert_text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of <e1> progesterone </e1> <e2> vomiting </e2>, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3239": {"data": {"text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "entity1": "progesterone", "entity2": "hemiparesis", "span1": [144, 156], "span2": [87, 98]}, "bert_text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of <e1> progesterone </e1> <e2> hemiparesis </e2> and seizure two days after parenteral use of progesterone and estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3240": {"data": {"text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "entity1": "progesterone", "entity2": "seizure", "span1": [144, 156], "span2": [103, 110]}, "bert_text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of <e1> progesterone </e1> <e2> seizure </e2> two days after parenteral use of progesterone and estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3241": {"data": {"text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "entity1": "estradiol", "entity2": "headache", "span1": [161, 170], "span2": [51, 59]}, "bert_text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and <e1> estradiol </e1> <e2> headache </e2>, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3242": {"data": {"text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "entity1": "estradiol", "entity2": "nausea", "span1": [161, 170], "span2": [61, 67]}, "bert_text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and <e1> estradiol </e1> <e2> nausea </e2> and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3243": {"data": {"text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "entity1": "estradiol", "entity2": "vomiting", "span1": [161, 170], "span2": [72, 80]}, "bert_text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and <e1> estradiol </e1> <e2> vomiting </e2>, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3244": {"data": {"text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "entity1": "estradiol", "entity2": "hemiparesis", "span1": [161, 170], "span2": [87, 98]}, "bert_text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and <e1> estradiol </e1> <e2> hemiparesis </e2> and seizure two days after parenteral use of progesterone and estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3245": {"data": {"text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.", "entity1": "estradiol", "entity2": "seizure", "span1": [161, 170], "span2": [103, 110]}, "bert_text": "A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and <e1> estradiol </e1> <e2> seizure </e2> two days after parenteral use of progesterone and estradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3246": {"data": {"text": "Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.\n", "entity1": "green tea", "entity2": "myocardial infarction", "span1": [10, 19], "span2": [71, 92]}, "bert_text": "Effect of <e1> green tea </e1> and vitamin E combination in isoproterenol induced <e2> myocardial infarction </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3247": {"data": {"text": "Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.\n", "entity1": "vitamin E", "entity2": "myocardial infarction", "span1": [24, 33], "span2": [71, 92]}, "bert_text": "Effect of green tea and <e1> vitamin E </e1> combination in isoproterenol induced <e2> myocardial infarction </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3248": {"data": {"text": "Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.\n", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [49, 62], "span2": [71, 92]}, "bert_text": "Effect of green tea and vitamin E combination in <e1> isoproterenol </e1> induced <e2> myocardial infarction </e2> in rats.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"3249": {"data": {"text": "Cocaine related chest pain: are we seeing the tip of an iceberg?\n", "entity1": "Cocaine", "entity2": "chest pain", "span1": [0, 7], "span2": [16, 26]}, "bert_text": "<e1> Cocaine </e1> related <e2> chest pain </e2>: are we seeing the tip of an iceberg?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3250": {"data": {"text": "This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.", "entity1": "verapamil", "entity2": "hemorrhagic", "span1": [114, 123], "span2": [5, 16]}, "bert_text": "This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric <e1> verapamil </e1> <e2> hemorrhagic </e2> ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3251": {"data": {"text": "This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.", "entity1": "verapamil", "entity2": "ulcer", "span1": [114, 123], "span2": [17, 22]}, "bert_text": "This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric <e1> verapamil </e1> <e2> ulcer </e2> and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3252": {"data": {"text": "The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.", "entity1": "clarithromycin", "entity2": "chronic renal failure", "span1": [45, 59], "span2": [71, 92]}, "bert_text": "The combination of a relatively high dose of <e1> clarithromycin </e1> in face of <e2> chronic renal failure </e2> in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3253": {"data": {"text": "The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.", "entity1": "clarithromycin", "entity2": "neurotoxic", "span1": [45, 59], "span2": [212, 222]}, "bert_text": "The combination of a relatively high dose of <e1> clarithromycin </e1> in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this <e2> neurotoxic </e2> side effect.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3254": {"data": {"text": "The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.", "entity1": "aluminum", "entity2": "chronic renal failure", "span1": [145, 153], "span2": [71, 92]}, "bert_text": "The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying <e1> aluminum </e1> <e2> chronic renal failure </e2> in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3255": {"data": {"text": "The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.", "entity1": "aluminum", "entity2": "neurotoxic", "span1": [145, 153], "span2": [212, 222]}, "bert_text": "The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying <e1> aluminum </e1> intoxication, may have facilitated the appearance of this <e2> neurotoxic </e2> side effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3256": {"data": {"text": "In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.", "entity1": "D-MED", "entity2": "muscle rigidity", "span1": [63, 68], "span2": [82, 97]}, "bert_text": "In the present study, the authors determined if treatment with <e1> D-MED </e1> prevents the <e2> muscle rigidity </e2> caused by high-dose alfentanil anesthesia in the rat.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3257": {"data": {"text": "In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.", "entity1": "alfentanil", "entity2": "muscle rigidity", "span1": [118, 128], "span2": [82, 97]}, "bert_text": "In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose <e1> alfentanil </e1> <e2> muscle rigidity </e2> caused by high-dose alfentanil anesthesia in the rat.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3258": {"data": {"text": "Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.", "entity1": "phenacetin", "entity2": "chronic renal failure", "span1": [88, 98], "span2": [137, 158]}, "bert_text": "Six epidemiologic studies in the United States and Europe indicate that habitual use of <e1> phenacetin </e1> is associated with the development of <e2> chronic renal failure </e2> and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3259": {"data": {"text": "Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.", "entity1": "phenacetin", "entity2": "end-stage renal disease", "span1": [88, 98], "span2": [163, 186]}, "bert_text": "Six epidemiologic studies in the United States and Europe indicate that habitual use of <e1> phenacetin </e1> is associated with the development of chronic renal failure and <e2> end-stage renal disease </e2> (ESRD), with a relative risk in the range of 4 to 19.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3260": {"data": {"text": "Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.", "entity1": "phenacetin", "entity2": "ESRD", "span1": [88, 98], "span2": [188, 192]}, "bert_text": "Six epidemiologic studies in the United States and Europe indicate that habitual use of <e1> phenacetin </e1> is associated with the development of chronic renal failure and end-stage renal disease (<e2> ESRD </e2>), with a relative risk in the range of 4 to 19.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3261": {"data": {"text": "Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats.\n", "entity1": "isoproterenol", "entity2": "tachycardia", "span1": [39, 52], "span2": [78, 89]}, "bert_text": "Effects of long-term pretreatment with <e1> isoproterenol </e1> on bromocriptine-induced <e2> tachycardia </e2> in conscious rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3262": {"data": {"text": "Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats.\n", "entity1": "bromocriptine", "entity2": "tachycardia", "span1": [56, 69], "span2": [78, 89]}, "bert_text": "Effects of long-term pretreatment with isoproterenol on <e1> bromocriptine </e1>-induced <e2> tachycardia </e2> in conscious rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3263": {"data": {"text": "OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.", "entity1": "bupropion", "entity2": "liver failure", "span1": [94, 103], "span2": [37, 50]}, "bert_text": "OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of <e1> bupropion </e1> <e2> liver failure </e2> possibly associated with concurrent use of bupropion and carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3264": {"data": {"text": "OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.", "entity1": "carbimazole", "entity2": "liver failure", "span1": [108, 119], "span2": [37, 50]}, "bert_text": "OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and <e1> carbimazole </e1> <e2> liver failure </e2> possibly associated with concurrent use of bupropion and carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3265": {"data": {"text": "We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.", "entity1": "olanzapine", "entity2": "psychotic disorder", "span1": [159, 169], "span2": [73, 91]}, "bert_text": "We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of <e1> olanzapine </e1> <e2> psychotic disorder </e2> (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3266": {"data": {"text": "We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.", "entity1": "olanzapine", "entity2": "hypomania", "span1": [159, 169], "span2": [115, 124]}, "bert_text": "We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of <e1> olanzapine </e1> <e2> hypomania </e2> shortly after the introduction of olanzapine treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3267": {"data": {"text": "A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.", "entity1": "D-penicillamine", "entity2": "rheumatoid arthritis", "span1": [120, 135], "span2": [25, 45]}, "bert_text": "A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of <e1> D-penicillamine </e1> <e2> rheumatoid arthritis </e2> presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3268": {"data": {"text": "A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.", "entity1": "D-penicillamine", "entity2": "glomerulonephritis", "span1": [120, 135], "span2": [76, 94]}, "bert_text": "A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of <e1> D-penicillamine </e1> <e2> glomerulonephritis </e2> (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3269": {"data": {"text": "A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.", "entity1": "D-penicillamine", "entity2": "RPGN", "span1": [120, 135], "span2": [96, 100]}, "bert_text": "A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of <e1> D-penicillamine </e1> <e2> RPGN </e2>) after 5 months of D-penicillamine (250 mg/day) treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3270": {"data": {"text": "CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.", "entity1": "Ketamine", "entity2": "fractures", "span1": [13, 21], "span2": [133, 142]}, "bert_text": "CONCLUSIONS: <e1> Ketamine </e1> reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's <e2> fractures </e2> in the emergency department at our institution.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3271": {"data": {"text": "The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.", "entity1": "Sch", "entity2": "tetanic", "span1": [123, 126], "span2": [76, 83]}, "bert_text": "The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when <e1> Sch </e1> <e2> tetanic </e2> stimulation of the ulnar nerve or when Sch 120 mg was exceeded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3272": {"data": {"text": "Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).\n", "entity1": "etoricoxib", "entity2": "rheumatoid arthritis", "span1": [33, 43], "span2": [47, 67]}, "bert_text": "Gastrointestinal tolerability of <e1> etoricoxib </e1> in <e2> rheumatoid arthritis </e2> patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3273": {"data": {"text": "Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).\n", "entity1": "etoricoxib", "entity2": "rheumatoid arthritis", "span1": [93, 103], "span2": [47, 67]}, "bert_text": "Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the <e1> etoricoxib </e1> <e2> rheumatoid arthritis </e2> patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3274": {"data": {"text": "Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).\n", "entity1": "diclofenac sodium", "entity2": "rheumatoid arthritis", "span1": [107, 124], "span2": [47, 67]}, "bert_text": "Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs <e1> diclofenac sodium </e1> <e2> rheumatoid arthritis </e2> patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3275": {"data": {"text": "The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "entity1": "pegylated IFN alpha-2b", "entity2": "ocular myasthenia", "span1": [61, 83], "span2": [4, 21]}, "bert_text": "The ocular myasthenia associated with combination therapy of <e1> pegylated IFN alpha-2b </e1> <e2> ocular myasthenia </e2> associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3276": {"data": {"text": "The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "entity1": "pegylated IFN alpha-2b", "entity2": "CHC", "span1": [61, 83], "span2": [102, 105]}, "bert_text": "The ocular myasthenia associated with combination therapy of <e1> pegylated IFN alpha-2b </e1> and ribavirin for <e2> CHC </e2> is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3277": {"data": {"text": "The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "entity1": "ribavirin", "entity2": "ocular myasthenia", "span1": [88, 97], "span2": [4, 21]}, "bert_text": "The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and <e1> ribavirin </e1> <e2> ocular myasthenia </e2> associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3278": {"data": {"text": "The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "entity1": "ribavirin", "entity2": "CHC", "span1": [88, 97], "span2": [102, 105]}, "bert_text": "The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and <e1> ribavirin </e1> for <e2> CHC </e2> is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3279": {"data": {"text": "The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "entity1": "IFN", "entity2": "ocular myasthenia", "span1": [213, 216], "span2": [4, 21]}, "bert_text": "The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of <e1> IFN </e1> <e2> ocular myasthenia </e2> associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3280": {"data": {"text": "The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "entity1": "IFN", "entity2": "CHC", "span1": [213, 216], "span2": [102, 105]}, "bert_text": "The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of <e1> IFN </e1> <e2> CHC </e2> is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3281": {"data": {"text": "CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.", "entity1": "alcohol", "entity2": "liver failure", "span1": [66, 73], "span2": [92, 105]}, "bert_text": "CASE REPORT: We describe 2 patients who were regular consumers of <e1> alcohol </e1> and who developed <e2> liver failure </e2> within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3282": {"data": {"text": "CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.", "entity1": "alcohol", "entity2": "liver failure", "span1": [157, 164], "span2": [92, 105]}, "bert_text": "CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping <e1> alcohol </e1> <e2> liver failure </e2> within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3283": {"data": {"text": "CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.", "entity1": "paracetamol", "entity2": "liver failure", "span1": [206, 217], "span2": [92, 105]}, "bert_text": "CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g <e1> paracetamol </e1> <e2> liver failure </e2> within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3284": {"data": {"text": "Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.", "entity1": "SCH 23390", "entity2": "catalepsy", "span1": [15, 24], "span2": [55, 64]}, "bert_text": "Combination of <e1> SCH 23390 </e1> with sulpiride did not induce <e2> catalepsy </e2> potentiation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1], "label": 1},
+	"3285": {"data": {"text": "Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.", "entity1": "sulpiride", "entity2": "catalepsy", "span1": [30, 39], "span2": [55, 64]}, "bert_text": "Combination of SCH 23390 with <e1> sulpiride </e1> did not induce <e2> catalepsy </e2> potentiation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, 0, -1, -1, 0, -1], "label": 1},
+	"3286": {"data": {"text": "Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.", "entity1": "D-penicillamine", "entity2": "rheumatologic diseases", "span1": [9, 24], "span2": [48, 70]}, "bert_text": "Although <e1> D-penicillamine </e1> has been used for many <e2> rheumatologic diseases </e2>, toxicity limits its usefulness in many patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3287": {"data": {"text": "Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.", "entity1": "D-penicillamine", "entity2": "toxicity", "span1": [9, 24], "span2": [72, 80]}, "bert_text": "Although <e1> D-penicillamine </e1> has been used for many rheumatologic diseases, <e2> toxicity </e2> limits its usefulness in many patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3288": {"data": {"text": "Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.\n", "entity1": "carbamazepine", "entity2": "seizures", "span1": [8, 21], "span2": [67, 75]}, "bert_text": "Chronic <e1> carbamazepine </e1> inhibits the development of local anesthetic <e2> seizures </e2> kindled by cocaine and lidocaine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3289": {"data": {"text": "Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.\n", "entity1": "cocaine", "entity2": "seizures", "span1": [87, 94], "span2": [67, 75]}, "bert_text": "Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by <e1> cocaine </e1> <e2> seizures </e2> kindled by cocaine and lidocaine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3290": {"data": {"text": "Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.\n", "entity1": "lidocaine", "entity2": "seizures", "span1": [99, 108], "span2": [67, 75]}, "bert_text": "Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and <e1> lidocaine </e1> <e2> seizures </e2> kindled by cocaine and lidocaine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3291": {"data": {"text": "If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.", "entity1": "heparin", "entity2": "platelet aggregation", "span1": [85, 92], "span2": [94, 114]}, "bert_text": "If the platelet count falls to less than 100,000/mm3, while the patient is receiving <e1> heparin </e1>, <e2> platelet aggregation </e2> testing, using the patient's plasma, is indicated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3292": {"data": {"text": "The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.", "entity1": "carbamazepine", "entity2": "seizures", "span1": [15, 28], "span2": [73, 81]}, "bert_text": "The effects of <e1> carbamazepine </e1> (CBZ) treatment on local anesthetic-kindled <e2> seizures </e2> and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3293": {"data": {"text": "The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.", "entity1": "CBZ", "entity2": "seizures", "span1": [30, 33], "span2": [73, 81]}, "bert_text": "The effects of carbamazepine (<e1> CBZ </e1>) treatment on local anesthetic-kindled <e2> seizures </e2> and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3294": {"data": {"text": "The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.", "entity1": "CBZ", "entity2": "seizures", "span1": [186, 189], "span2": [73, 81]}, "bert_text": "The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of <e1> CBZ </e1> <e2> seizures </e2> and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3295": {"data": {"text": "8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).", "entity1": "sodium", "entity2": "hypotension", "span1": [18, 24], "span2": [47, 58]}, "bert_text": "8 per cent during <e1> sodium </e1> nitroprusside-induced <e2> hypotension </e2> (P less than 0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3296": {"data": {"text": "8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).", "entity1": "nitroprusside", "entity2": "hypotension", "span1": [25, 38], "span2": [47, 58]}, "bert_text": "8 per cent during sodium <e1> nitroprusside </e1>-induced <e2> hypotension </e2> (P less than 0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3297": {"data": {"text": "Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.", "entity1": "nitroprusside", "entity2": "hypertension", "span1": [196, 209], "span2": [127, 139]}, "bert_text": "Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of <e1> nitroprusside </e1> <e2> hypertension </e2> was observed in three patients after discontinuation of nitroprusside.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3298": {"data": {"text": "In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.", "entity1": "dexamethasone", "entity2": "hypertensive", "span1": [17, 30], "span2": [39, 51]}, "bert_text": "In contrast, the <e1> dexamethasone </e1>-treated <e2> hypertensive </e2> eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3299": {"data": {"text": "In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.", "entity1": "PPA", "entity2": "myocardial injury", "span1": [44, 47], "span2": [56, 73]}, "bert_text": "In addition, we review the 7 other cases of <e1> PPA </e1> related <e2> myocardial injury </e2> that have been reported so far.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3300": {"data": {"text": "Dipyridamole-induced myocardial ischemia.\n", "entity1": "Dipyridamole", "entity2": "myocardial ischemia", "span1": [0, 12], "span2": [21, 40]}, "bert_text": "<e1> Dipyridamole </e1>-induced <e2> myocardial ischemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3301": {"data": {"text": "Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.\n", "entity1": "sertraline", "entity2": "cognitive impairment", "span1": [21, 31], "span2": [63, 83]}, "bert_text": "Absence of effect of <e1> sertraline </e1> on time-based sensitization of <e2> cognitive impairment </e2> with haloperidol.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3302": {"data": {"text": "Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.\n", "entity1": "haloperidol", "entity2": "cognitive impairment", "span1": [89, 100], "span2": [63, 83]}, "bert_text": "Absence of effect of sertraline on time-based sensitization of cognitive impairment with <e1> haloperidol </e1> <e2> cognitive impairment </e2> with haloperidol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3303": {"data": {"text": "The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.", "entity1": "levodopa", "entity2": "Parkinson's Disease", "span1": [143, 151], "span2": [31, 50]}, "bert_text": "The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF <e1> levodopa </e1> <e2> Parkinson's Disease </e2> Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3304": {"data": {"text": "The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [143, 151], "span2": [67, 77]}, "bert_text": "The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF <e1> levodopa </e1> <e2> dyskinesia </e2> score and force in a grip-lift paradigm were assessed ON and OFF levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3305": {"data": {"text": "Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.\n", "entity1": "cyclophosphamide", "entity2": "Urinary bladder cancer", "span1": [74, 90], "span2": [0, 22]}, "bert_text": "Urinary bladder cancer in Wegener's granulomatosis: risks and relation to <e1> cyclophosphamide </e1> <e2> Urinary bladder cancer </e2> in Wegener's granulomatosis: risks and relation to cyclophosphamide.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3306": {"data": {"text": "Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.\n", "entity1": "cyclophosphamide", "entity2": "Wegener's granulomatosis", "span1": [74, 90], "span2": [26, 50]}, "bert_text": "Urinary bladder cancer in Wegener's granulomatosis: risks and relation to <e1> cyclophosphamide </e1> <e2> Wegener's granulomatosis </e2>: risks and relation to cyclophosphamide.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3307": {"data": {"text": "3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.", "entity1": "SKF 38393", "entity2": "catalepsy", "span1": [15, 24], "span2": [65, 74]}, "bert_text": "3. D-1 agonist <e1> SKF 38393 </e1> or D-2 agonist quinpirole decreased the <e2> catalepsy </e2> induced by fluphenazine, SCH 23390 or sulpiride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3308": {"data": {"text": "3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.", "entity1": "quinpirole", "entity2": "catalepsy", "span1": [40, 50], "span2": [65, 74]}, "bert_text": "3. D-1 agonist SKF 38393 or D-2 agonist <e1> quinpirole </e1> decreased the <e2> catalepsy </e2> induced by fluphenazine, SCH 23390 or sulpiride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3309": {"data": {"text": "3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.", "entity1": "fluphenazine", "entity2": "catalepsy", "span1": [86, 98], "span2": [65, 74]}, "bert_text": "3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by <e1> fluphenazine </e1> <e2> catalepsy </e2> induced by fluphenazine, SCH 23390 or sulpiride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3310": {"data": {"text": "3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.", "entity1": "SCH 23390", "entity2": "catalepsy", "span1": [100, 109], "span2": [65, 74]}, "bert_text": "3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, <e1> SCH 23390 </e1> <e2> catalepsy </e2> induced by fluphenazine, SCH 23390 or sulpiride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3311": {"data": {"text": "3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.", "entity1": "sulpiride", "entity2": "catalepsy", "span1": [113, 122], "span2": [65, 74]}, "bert_text": "3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or <e1> sulpiride </e1> <e2> catalepsy </e2> induced by fluphenazine, SCH 23390 or sulpiride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3312": {"data": {"text": "CONCLUSION: eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE, indicating that this is the possible reason for a prolonged period of apnea.", "entity1": "succinylcholine", "entity2": "BCHE", "span1": [73, 88], "span2": [106, 110]}, "bert_text": "CONCLUSION: eleven of 13 patients with a prolonged duration of action of <e1> succinylcholine </e1> had mutations in <e2> BCHE </e2>, indicating that this is the possible reason for a prolonged period of apnea.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3313": {"data": {"text": "CONCLUSION: eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE, indicating that this is the possible reason for a prolonged period of apnea.", "entity1": "succinylcholine", "entity2": "apnea", "span1": [73, 88], "span2": [182, 187]}, "bert_text": "CONCLUSION: eleven of 13 patients with a prolonged duration of action of <e1> succinylcholine </e1> had mutations in BCHE, indicating that this is the possible reason for a prolonged period of <e2> apnea </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3314": {"data": {"text": "RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.", "entity1": "nicotine", "entity2": "convulsion", "span1": [64, 72], "span2": [32, 42]}, "bert_text": "RESULTS: Sensitivity to several convulsion endpoints induced by <e1> nicotine </e1> <e2> convulsion </e2> endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3315": {"data": {"text": "RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.", "entity1": "carbachol", "entity2": "convulsion", "span1": [74, 83], "span2": [32, 42]}, "bert_text": "RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, <e1> carbachol </e1> <e2> convulsion </e2> endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3316": {"data": {"text": "RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.", "entity1": "neostigmine", "entity2": "convulsion", "span1": [89, 100], "span2": [32, 42]}, "bert_text": "RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and <e1> neostigmine </e1> <e2> convulsion </e2> endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3317": {"data": {"text": "Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.", "entity1": "Sodium nitroprusside", "entity2": "hypotension", "span1": [0, 20], "span2": [156, 167]}, "bert_text": "<e1> Sodium nitroprusside </e1> is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3318": {"data": {"text": "Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.", "entity1": "carbamazepine", "entity2": "neurotoxicity", "span1": [27, 40], "span2": [41, 54]}, "bert_text": "Two patients with signs of <e1> carbamazepine </e1> <e2> neurotoxicity </e2> after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3319": {"data": {"text": "Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.", "entity1": "verapamil", "entity2": "neurotoxicity", "span1": [85, 94], "span2": [41, 54]}, "bert_text": "Two patients with signs of carbamazepine neurotoxicity after combined treatment with <e1> verapamil </e1> <e2> neurotoxicity </e2> after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3320": {"data": {"text": "Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.", "entity1": "calcium", "entity2": "neurotoxicity", "span1": [149, 156], "span2": [41, 54]}, "bert_text": "Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the <e1> calcium </e1> <e2> neurotoxicity </e2> after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3321": {"data": {"text": "Time trends in warfarin-associated hemorrhage.\n", "entity1": "warfarin", "entity2": "hemorrhage", "span1": [15, 23], "span2": [35, 45]}, "bert_text": "Time trends in <e1> warfarin </e1>-associated <e2> hemorrhage </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3322": {"data": {"text": "Triazolam-induced brief episodes of secondary mania in a depressed patient.\n", "entity1": "Triazolam", "entity2": "mania", "span1": [0, 9], "span2": [46, 51]}, "bert_text": "<e1> Triazolam </e1>-induced brief episodes of secondary <e2> mania </e2> in a depressed patient.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3323": {"data": {"text": "Triazolam-induced brief episodes of secondary mania in a depressed patient.\n", "entity1": "Triazolam", "entity2": "depressed", "span1": [0, 9], "span2": [57, 66]}, "bert_text": "<e1> Triazolam </e1>-induced brief episodes of secondary mania in a <e2> depressed </e2> patient.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3324": {"data": {"text": "The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.", "entity1": "amphetamine", "entity2": "neurotoxic", "span1": [63, 74], "span2": [42, 52]}, "bert_text": "The data strengthen the evidence that the neurotoxic effect of <e1> amphetamine </e1> <e2> neurotoxic </e2> effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3325": {"data": {"text": "The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.", "entity1": "dopamine", "entity2": "neurotoxic", "span1": [118, 126], "span2": [42, 52]}, "bert_text": "The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal <e1> dopamine </e1> <e2> neurotoxic </e2> effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3326": {"data": {"text": "The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.", "entity1": "LY274614", "entity2": "neurotoxic", "span1": [168, 176], "span2": [42, 52]}, "bert_text": "The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that <e1> LY274614 </e1> <e2> neurotoxic </e2> effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3327": {"data": {"text": "This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.", "entity1": "oxycodone", "entity2": "chronic pain", "span1": [183, 192], "span2": [77, 89]}, "bert_text": "This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release <e1> oxycodone </e1> <e2> chronic pain </e2>, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"3328": {"data": {"text": "While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.", "entity1": "metronidazole", "entity2": "haemolytic-uraemic syndrome", "span1": [25, 38], "span2": [63, 90]}, "bert_text": "While the involvement of <e1> metronidazole </e1> in the aetiology of the <e2> haemolytic-uraemic syndrome </e2> is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3329": {"data": {"text": "While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.", "entity1": "metronidazole", "entity2": "haemolytic-uraemic syndrome", "span1": [25, 38], "span2": [239, 266]}, "bert_text": "While the involvement of <e1> metronidazole </e1> in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the <e2> haemolytic-uraemic syndrome </e2> suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3330": {"data": {"text": "While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.", "entity1": "metronidazole", "entity2": "haemolytic-uraemic syndrome", "span1": [25, 38], "span2": [345, 372]}, "bert_text": "While the involvement of <e1> metronidazole </e1> in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the <e2> haemolytic-uraemic syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3331": {"data": {"text": "While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.", "entity1": "metronidazole", "entity2": "haemolytic-uraemic syndrome", "span1": [299, 312], "span2": [63, 90]}, "bert_text": "While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between <e1> metronidazole </e1> <e2> haemolytic-uraemic syndrome </e2> is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3332": {"data": {"text": "While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.", "entity1": "metronidazole", "entity2": "haemolytic-uraemic syndrome", "span1": [299, 312], "span2": [239, 266]}, "bert_text": "While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between <e1> metronidazole </e1> <e2> haemolytic-uraemic syndrome </e2> suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3333": {"data": {"text": "While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.", "entity1": "metronidazole", "entity2": "haemolytic-uraemic syndrome", "span1": [299, 312], "span2": [345, 372]}, "bert_text": "While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between <e1> metronidazole </e1> treatment and some cases of the <e2> haemolytic-uraemic syndrome </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3334": {"data": {"text": "Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed.", "entity1": "triamterene", "entity2": "nephrolithiasis", "span1": [18, 29], "span2": [30, 45]}, "bert_text": "Factors affecting <e1> triamterene </e1> <e2> nephrolithiasis </e2> are discussed and 2 previously reported cases are reviewed.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3335": {"data": {"text": "This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.", "entity1": "cimetidine", "entity2": "sinus arrest", "span1": [84, 94], "span2": [35, 47]}, "bert_text": "This is the first reported case of sinus arrest associated with continuous-infusion <e1> cimetidine </e1> <e2> sinus arrest </e2> associated with continuous-infusion cimetidine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3336": {"data": {"text": "We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.", "entity1": "ethinyl estradiol", "entity2": "intrahepatic cholestasis", "span1": [50, 67], "span2": [22, 46]}, "bert_text": "We used rat models of intrahepatic cholestasis by <e1> ethinyl estradiol </e1> <e2> intrahepatic cholestasis </e2> by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3337": {"data": {"text": "We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.", "entity1": "ethinyl estradiol", "entity2": "extrahepatic cholestasis", "span1": [50, 67], "span2": [87, 111]}, "bert_text": "We used rat models of intrahepatic cholestasis by <e1> ethinyl estradiol </e1> (EE) treatment and <e2> extrahepatic cholestasis </e2> by bile duct ligation (BDL) to precisely determine the site of TJ damage.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3338": {"data": {"text": "We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.", "entity1": "EE", "entity2": "intrahepatic cholestasis", "span1": [69, 71], "span2": [22, 46]}, "bert_text": "We used rat models of intrahepatic cholestasis by ethinyl estradiol (<e1> EE </e1> <e2> intrahepatic cholestasis </e2> by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3339": {"data": {"text": "We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.", "entity1": "EE", "entity2": "extrahepatic cholestasis", "span1": [69, 71], "span2": [87, 111]}, "bert_text": "We used rat models of intrahepatic cholestasis by ethinyl estradiol (<e1> EE </e1>) treatment and <e2> extrahepatic cholestasis </e2> by bile duct ligation (BDL) to precisely determine the site of TJ damage.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3340": {"data": {"text": "The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.", "entity1": "cidofovir", "entity2": "adenovirus infection", "span1": [11, 20], "span2": [31, 51]}, "bert_text": "The use of <e1> cidofovir </e1> in severe <e2> adenovirus infection </e2> has been limited by adverse effects, the most significant of which is nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3341": {"data": {"text": "The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.", "entity1": "cidofovir", "entity2": "nephrotoxicity", "span1": [11, 20], "span2": [122, 136]}, "bert_text": "The use of <e1> cidofovir </e1> in severe adenovirus infection has been limited by adverse effects, the most significant of which is <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3342": {"data": {"text": "It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.", "entity1": "DPH", "entity2": "cerebral damage", "span1": [77, 80], "span2": [38, 53]}, "bert_text": "It is assumed that patients with some cerebral damage are liable to manifest <e1> DPH </e1> <e2> cerebral damage </e2> are liable to manifest DPH toxicity as focal neurological signs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3343": {"data": {"text": "It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.", "entity1": "DPH", "entity2": "toxicity", "span1": [77, 80], "span2": [81, 89]}, "bert_text": "It is assumed that patients with some cerebral damage are liable to manifest <e1> DPH </e1> <e2> toxicity </e2> as focal neurological signs.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3344": {"data": {"text": "Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.\n", "entity1": "androgen", "entity2": "obstructive sleep apnea syndrome", "span1": [74, 82], "span2": [17, 49]}, "bert_text": "Induction of the obstructive sleep apnea syndrome in a woman by exogenous <e1> androgen </e1> <e2> obstructive sleep apnea syndrome </e2> in a woman by exogenous androgen administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3345": {"data": {"text": "Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and", "entity1": "fentanyl", "entity2": "postoperative nausea and vomiting", "span1": [18, 26], "span2": [112, 145]}, "bert_text": "Combining the two <e1> fentanyl </e1> groups revealed further significant benefits from the avoidance of opioids, reducing <e2> postoperative nausea and vomiting </e2> and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"3346": {"data": {"text": "Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and", "entity1": "fentanyl", "entity2": "nausea", "span1": [18, 26], "span2": [150, 156]}, "bert_text": "Combining the two <e1> fentanyl </e1> groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and <e2> nausea </e2> prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3347": {"data": {"text": "A conjunction analysis of the encode and recall phases of the task revealed ecstasy-specific hyperactivity in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.", "entity1": "ecstasy", "entity2": "hyperactivity", "span1": [76, 83], "span2": [93, 106]}, "bert_text": "A conjunction analysis of the encode and recall phases of the task revealed <e1> ecstasy </e1>-specific <e2> hyperactivity </e2> in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3348": {"data": {"text": "These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.", "entity1": "tocopherols", "entity2": "hemolysis", "span1": [60, 71], "span2": [47, 56]}, "bert_text": "These effects suggest that the protection from hemolysis by <e1> tocopherols </e1> <e2> hemolysis </e2> by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3349": {"data": {"text": "These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.", "entity1": "TAM", "entity2": "hemolysis", "span1": [98, 101], "span2": [47, 56]}, "bert_text": "These effects suggest that the protection from hemolysis by tocopherols is related to a decreased <e1> TAM </e1> <e2> hemolysis </e2> by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3350": {"data": {"text": "Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32", "entity1": "Steroids", "entity2": "seizures", "span1": [0, 8], "span2": [128, 136]}, "bert_text": "<e1> Steroids </e1> with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic <e2> seizures </e2> induced by kainic acid (32", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3351": {"data": {"text": "Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32", "entity1": "kainic acid", "entity2": "seizures", "span1": [148, 159], "span2": [128, 136]}, "bert_text": "Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by <e1> kainic acid </e1> <e2> seizures </e2> induced by kainic acid (32", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3352": {"data": {"text": "The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and strokes, can occur hours after exposure.", "entity1": "cocaine", "entity2": "seizures", "span1": [24, 31], "span2": [102, 110]}, "bert_text": "The half-life (t1/2) of <e1> cocaine </e1> is relatively short, but some of the consequences of its use, such as <e2> seizures </e2> and strokes, can occur hours after exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3353": {"data": {"text": "The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and strokes, can occur hours after exposure.", "entity1": "cocaine", "entity2": "strokes", "span1": [24, 31], "span2": [115, 122]}, "bert_text": "The half-life (t1/2) of <e1> cocaine </e1> is relatively short, but some of the consequences of its use, such as seizures and <e2> strokes </e2>, can occur hours after exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3354": {"data": {"text": "The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated, but cannot be dismissed.", "entity1": "acetaminophen", "entity2": "ESRD", "span1": [37, 50], "span2": [79, 83]}, "bert_text": "The possibility that habitual use of <e1> acetaminophen </e1> alone increases the risk of <e2> ESRD </e2> has not been clearly demonstrated, but cannot be dismissed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3355": {"data": {"text": "We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.", "entity1": "AX", "entity2": "allergy", "span1": [46, 48], "span2": [49, 56]}, "bert_text": "We selected the 54 (30.5%) cases of immediate <e1> AX </e1> <e2> allergy </e2> with good tolerance of PG.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3356": {"data": {"text": "We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.", "entity1": "PG", "entity2": "allergy", "span1": [80, 82], "span2": [49, 56]}, "bert_text": "We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of <e1> PG </e1> <e2> allergy </e2> with good tolerance of PG.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3357": {"data": {"text": "Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.", "entity1": "ticlopidine", "entity2": "jaundice", "span1": [57, 68], "span2": [23, 31]}, "bert_text": "Our patients developed jaundice following treatment with <e1> ticlopidine </e1> <e2> jaundice </e2> following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3358": {"data": {"text": "Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.", "entity1": "ticlopidine", "entity2": "cholestatic hepatitis", "span1": [57, 68], "span2": [127, 148]}, "bert_text": "Our patients developed jaundice following treatment with <e1> ticlopidine </e1> and showed the clinical and laboratory characteristics of <e2> cholestatic hepatitis </e2>, which resolved after discontinuation of the drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3359": {"data": {"text": "Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.", "entity1": "creatinine", "entity2": "renal insufficiency", "span1": [100, 110], "span2": [23, 42]}, "bert_text": "Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum <e1> creatinine </e1> <e2> renal insufficiency </e2> had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3360": {"data": {"text": "Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.", "entity1": "thiazide", "entity2": "renal insufficiency", "span1": [193, 201], "span2": [23, 42]}, "bert_text": "Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with <e1> thiazide </e1> <e2> renal insufficiency </e2> had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3361": {"data": {"text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.", "entity1": "DOX", "entity2": "cardiomyopathy", "span1": [88, 91], "span2": [92, 106]}, "bert_text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of <e1> DOX </e1> <e2> cardiomyopathy </e2>, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"3362": {"data": {"text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.", "entity1": "DOX", "entity2": "cardiomyopathy", "span1": [88, 91], "span2": [231, 245]}, "bert_text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of <e1> DOX </e1> cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced <e2> cardiomyopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"3363": {"data": {"text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.", "entity1": "DOX", "entity2": "inflammation", "span1": [88, 91], "span2": [173, 185]}, "bert_text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of <e1> DOX </e1> cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac <e2> inflammation </e2> and apoptosis after induction of DOX-induced cardiomyopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3364": {"data": {"text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.", "entity1": "DOX", "entity2": "cardiomyopathy", "span1": [219, 222], "span2": [92, 106]}, "bert_text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of <e1> DOX </e1> <e2> cardiomyopathy </e2>, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3365": {"data": {"text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.", "entity1": "DOX", "entity2": "cardiomyopathy", "span1": [219, 222], "span2": [231, 245]}, "bert_text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of <e1> DOX </e1>-induced <e2> cardiomyopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"3366": {"data": {"text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.", "entity1": "DOX", "entity2": "inflammation", "span1": [219, 222], "span2": [173, 185]}, "bert_text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of <e1> DOX </e1> <e2> inflammation </e2> and apoptosis after induction of DOX-induced cardiomyopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3367": {"data": {"text": "A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.\n", "entity1": "paclitaxel", "entity2": "cancers", "span1": [22, 32], "span2": [88, 95]}, "bert_text": "A phase I/II study of <e1> paclitaxel </e1> plus cisplatin as first-line therapy for head and neck <e2> cancers </e2>: preliminary results.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3368": {"data": {"text": "A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.\n", "entity1": "cisplatin", "entity2": "cancers", "span1": [38, 47], "span2": [88, 95]}, "bert_text": "A phase I/II study of paclitaxel plus <e1> cisplatin </e1> as first-line therapy for head and neck <e2> cancers </e2>: preliminary results.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3369": {"data": {"text": "The neuropathy caused by a single dose of isoniazid in rats was studied with a computer-assisted morphometric method.", "entity1": "isoniazid", "entity2": "neuropathy", "span1": [42, 51], "span2": [4, 14]}, "bert_text": "The neuropathy caused by a single dose of <e1> isoniazid </e1> <e2> neuropathy </e2> caused by a single dose of isoniazid in rats was studied with a computer-assisted morphometric method.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3370": {"data": {"text": "The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.", "entity1": "PILO", "entity2": "TLE", "span1": [174, 178], "span2": [188, 191]}, "bert_text": "The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the <e1> PILO </e1> model of <e2> TLE </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3371": {"data": {"text": "Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.", "entity1": "triazolam", "entity2": "mania", "span1": [15, 24], "span2": [62, 67]}, "bert_text": "Large doses of <e1> triazolam </e1> repeatedly induced brief episodes of <e2> mania </e2> in a depressed elderly woman.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3372": {"data": {"text": "Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.", "entity1": "triazolam", "entity2": "depressed", "span1": [15, 24], "span2": [73, 82]}, "bert_text": "Large doses of <e1> triazolam </e1> repeatedly induced brief episodes of mania in a <e2> depressed </e2> elderly woman.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3373": {"data": {"text": "These data suggest that U-II may be involved in some aspects of psychiatric disorders.", "entity1": "U-II", "entity2": "psychiatric disorders", "span1": [24, 28], "span2": [64, 85]}, "bert_text": "These data suggest that <e1> U-II </e1> may be involved in some aspects of <e2> psychiatric disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3374": {"data": {"text": "The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.", "entity1": "green tea", "entity2": "myocardial infarction", "span1": [67, 76], "span2": [245, 266]}, "bert_text": "The present study was aimed to investigate the combined effects of <e1> green tea </e1> and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced <e2> myocardial infarction </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"3375": {"data": {"text": "The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.", "entity1": "vitamin E", "entity2": "myocardial infarction", "span1": [81, 90], "span2": [245, 266]}, "bert_text": "The present study was aimed to investigate the combined effects of green tea and <e1> vitamin E </e1> on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced <e2> myocardial infarction </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"3376": {"data": {"text": "The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [217, 230], "span2": [245, 266]}, "bert_text": "The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in <e1> isoproterenol </e1> (ISO)-induced <e2> myocardial infarction </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 1},
+	"3377": {"data": {"text": "The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.", "entity1": "ISO)-induced", "entity2": "myocardial infarction", "span1": [232, 244], "span2": [245, 266]}, "bert_text": "The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (<e1> ISO)-induced </e1> <e2> myocardial infarction </e2> in rats.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 1},
+	"3378": {"data": {"text": "We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.", "entity1": "acetaminophen", "entity2": "fulminant hepatic failure", "span1": [32, 45], "span2": [54, 79]}, "bert_text": "We present a patient with fatal <e1> acetaminophen </e1>-induced <e2> fulminant hepatic failure </e2>, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3379": {"data": {"text": "We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.", "entity1": "acetaminophen", "entity2": "cerebral edema", "span1": [32, 45], "span2": [108, 122]}, "bert_text": "We present a patient with fatal <e1> acetaminophen </e1>-induced fulminant hepatic failure, with signs and symptoms of <e2> cerebral edema </e2>, unresponsive to conventional medical therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3380": {"data": {"text": "OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.", "entity1": "ribavirin", "entity2": "adenovirus disease", "span1": [53, 62], "span2": [82, 100]}, "bert_text": "OBJECTIVE: We report our experience with intravenous <e1> ribavirin </e1> therapy for severe <e2> adenovirus disease </e2> in a series of immunocompromised children and review the literature.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3381": {"data": {"text": "Hemolytic-uremic syndrome associated with ingestion of quinine.\n", "entity1": "quinine", "entity2": "Hemolytic-uremic syndrome", "span1": [55, 62], "span2": [0, 25]}, "bert_text": "Hemolytic-uremic syndrome associated with ingestion of <e1> quinine </e1> <e2> Hemolytic-uremic syndrome </e2> associated with ingestion of quinine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3382": {"data": {"text": "Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.\n", "entity1": "Pethidine", "entity2": "seizure", "span1": [0, 9], "span2": [21, 28]}, "bert_text": "<e1> Pethidine </e1>-associated <e2> seizure </e2> in a healthy adolescent receiving pethidine for postoperative pain control.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3383": {"data": {"text": "Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.\n", "entity1": "Pethidine", "entity2": "postoperative pain", "span1": [0, 9], "span2": [77, 95]}, "bert_text": "<e1> Pethidine </e1>-associated seizure in a healthy adolescent receiving pethidine for <e2> postoperative pain </e2> control.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3384": {"data": {"text": "Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.\n", "entity1": "pethidine", "entity2": "seizure", "span1": [63, 72], "span2": [21, 28]}, "bert_text": "Pethidine-associated seizure in a healthy adolescent receiving <e1> pethidine </e1> <e2> seizure </e2> in a healthy adolescent receiving pethidine for postoperative pain control.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3385": {"data": {"text": "Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.\n", "entity1": "pethidine", "entity2": "postoperative pain", "span1": [63, 72], "span2": [77, 95]}, "bert_text": "Pethidine-associated seizure in a healthy adolescent receiving <e1> pethidine </e1> for <e2> postoperative pain </e2> control.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3386": {"data": {"text": "The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.", "entity1": "cyclosporine", "entity2": "thrombotic microangiopathy", "span1": [79, 91], "span2": [19, 45]}, "bert_text": "The development of thrombotic microangiopathy (TMA) associated with the use of <e1> cyclosporine </e1> <e2> thrombotic microangiopathy </e2> (TMA) associated with the use of cyclosporine has been well documented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3387": {"data": {"text": "The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.", "entity1": "cyclosporine", "entity2": "TMA", "span1": [79, 91], "span2": [47, 50]}, "bert_text": "The development of thrombotic microangiopathy (TMA) associated with the use of <e1> cyclosporine </e1> <e2> TMA </e2>) associated with the use of cyclosporine has been well documented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3388": {"data": {"text": "Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.\n", "entity1": "nitric oxide", "entity2": "tumor", "span1": [47, 59], "span2": [110, 115]}, "bert_text": "Immunohistochemical study on inducible type of <e1> nitric oxide </e1> (iNOS), basic fibroblast growth factor (bFGF) and <e2> tumor </e2> growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3389": {"data": {"text": "Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.\n", "entity1": "nitric oxide", "entity2": "arteritis", "span1": [47, 59], "span2": [151, 160]}, "bert_text": "Immunohistochemical study on inducible type of <e1> nitric oxide </e1> (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in <e2> arteritis </e2> induced in rats by fenoldopam and theophylline, vasodilators.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3390": {"data": {"text": "Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.\n", "entity1": "fenoldopam", "entity2": "tumor", "span1": [180, 190], "span2": [110, 115]}, "bert_text": "Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by <e1> fenoldopam </e1> <e2> tumor </e2> growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3391": {"data": {"text": "Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.\n", "entity1": "fenoldopam", "entity2": "arteritis", "span1": [180, 190], "span2": [151, 160]}, "bert_text": "Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by <e1> fenoldopam </e1> <e2> arteritis </e2> induced in rats by fenoldopam and theophylline, vasodilators.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3392": {"data": {"text": "Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.\n", "entity1": "theophylline", "entity2": "tumor", "span1": [195, 207], "span2": [110, 115]}, "bert_text": "Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and <e1> theophylline </e1> <e2> tumor </e2> growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3393": {"data": {"text": "Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.\n", "entity1": "theophylline", "entity2": "arteritis", "span1": [195, 207], "span2": [151, 160]}, "bert_text": "Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and <e1> theophylline </e1> <e2> arteritis </e2> induced in rats by fenoldopam and theophylline, vasodilators.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3394": {"data": {"text": "Valproate-induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals.", "entity1": "Valproate", "entity2": "encephalopathy", "span1": [0, 9], "span2": [18, 32]}, "bert_text": "<e1> Valproate </e1>-induced <e2> encephalopathy </e2> is a rare syndrome that may manifest in otherwise normal epileptic individuals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3395": {"data": {"text": "Valproate-induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals.", "entity1": "Valproate", "entity2": "epileptic", "span1": [0, 9], "span2": [90, 99]}, "bert_text": "<e1> Valproate </e1>-induced encephalopathy is a rare syndrome that may manifest in otherwise normal <e2> epileptic </e2> individuals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3396": {"data": {"text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).", "entity1": "xanthine", "entity2": "hypertension", "span1": [23, 31], "span2": [137, 149]}, "bert_text": "We studied the role of <e1> xanthine </e1> oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced <e2> hypertension </e2> (dex-HT).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3397": {"data": {"text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).", "entity1": "xanthine", "entity2": "HT", "span1": [23, 31], "span2": [155, 157]}, "bert_text": "We studied the role of <e1> xanthine </e1> oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-<e2> HT </e2>).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3398": {"data": {"text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).", "entity1": "oxygen", "entity2": "hypertension", "span1": [96, 102], "span2": [137, 149]}, "bert_text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive <e1> oxygen </e1> species, in dexamethasone-induced <e2> hypertension </e2> (dex-HT).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3399": {"data": {"text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).", "entity1": "oxygen", "entity2": "HT", "span1": [96, 102], "span2": [155, 157]}, "bert_text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive <e1> oxygen </e1> species, in dexamethasone-induced hypertension (dex-<e2> HT </e2>).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3400": {"data": {"text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).", "entity1": "dexamethasone", "entity2": "hypertension", "span1": [115, 128], "span2": [137, 149]}, "bert_text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in <e1> dexamethasone </e1>-induced <e2> hypertension </e2> (dex-HT).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3401": {"data": {"text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).", "entity1": "dexamethasone", "entity2": "HT", "span1": [115, 128], "span2": [155, 157]}, "bert_text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in <e1> dexamethasone </e1>-induced hypertension (dex-<e2> HT </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3402": {"data": {"text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).", "entity1": "dex", "entity2": "hypertension", "span1": [151, 154], "span2": [137, 149]}, "bert_text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (<e1> dex </e1> <e2> hypertension </e2> (dex-HT).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3403": {"data": {"text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).", "entity1": "dex", "entity2": "HT", "span1": [151, 154], "span2": [155, 157]}, "bert_text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (<e1> dex </e1>-<e2> HT </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3404": {"data": {"text": "The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.", "entity1": "adenosine A(2A)/A(1", "entity2": "Parkinson's disease", "span1": [39, 58], "span2": [108, 127]}, "bert_text": "The in vivo characterization of a dual <e1> adenosine A(2A)/A(1 </e1>) receptor antagonist in several animal models of <e2> Parkinson's disease </e2> is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3405": {"data": {"text": "In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.\n", "entity1": "adenosine A2A", "entity2": "Parkinson's disease", "span1": [35, 48], "span2": [92, 111]}, "bert_text": "In vivo characterization of a dual <e1> adenosine A2A </e1>/A1 receptor antagonist in animal models of <e2> Parkinson's disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3406": {"data": {"text": "CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.", "entity1": "ribavirin", "entity2": "anemia", "span1": [116, 125], "span2": [134, 140]}, "bert_text": "CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and <e1> ribavirin </e1> induced <e2> anemia </e2> in patients with hepatitis C and we could not find any relation.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3407": {"data": {"text": "CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.", "entity1": "ribavirin", "entity2": "hepatitis C", "span1": [116, 125], "span2": [158, 169]}, "bert_text": "CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and <e1> ribavirin </e1> induced anemia in patients with <e2> hepatitis C </e2> and we could not find any relation.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3408": {"data": {"text": "Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.", "entity1": "ziprasidone", "entity2": "NMS", "span1": [110, 121], "span2": [71, 74]}, "bert_text": "Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like <e1> ziprasidone </e1> <e2> NMS </e2>, atypical antipsychotic drugs like ziprasidone may also be a cause.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3409": {"data": {"text": "Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [26, 36], "span2": [66, 77]}, "bert_text": "Mutations associated with <e1> lamivudine </e1>-resistance in therapy-na  ve <e2> hepatitis B </e2> virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3410": {"data": {"text": "Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "entity1": "lamivudine", "entity2": "infected", "span1": [26, 36], "span2": [90, 98]}, "bert_text": "Mutations associated with <e1> lamivudine </e1>-resistance in therapy-na  ve hepatitis B virus (HBV) <e2> infected </e2> patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3411": {"data": {"text": "Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "entity1": "lamivudine", "entity2": "HIV co-infection", "span1": [26, 36], "span2": [125, 141]}, "bert_text": "Mutations associated with <e1> lamivudine </e1>-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without <e2> HIV co-infection </e2>: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3412": {"data": {"text": "Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "entity1": "lamivudine", "entity2": "HIV co-infected", "span1": [26, 36], "span2": [194, 209]}, "bert_text": "Mutations associated with <e1> lamivudine </e1>-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and <e2> HIV co-infected </e2> South African patients.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3413": {"data": {"text": "Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "entity1": "na", "entity2": "hepatitis B", "span1": [59, 61], "span2": [66, 77]}, "bert_text": "Mutations associated with lamivudine-resistance in therapy-<e1> na </e1>  ve <e2> hepatitis B </e2> virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3414": {"data": {"text": "Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "entity1": "na", "entity2": "infected", "span1": [59, 61], "span2": [90, 98]}, "bert_text": "Mutations associated with lamivudine-resistance in therapy-<e1> na </e1>  ve hepatitis B virus (HBV) <e2> infected </e2> patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3415": {"data": {"text": "Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "entity1": "na", "entity2": "HIV co-infection", "span1": [59, 61], "span2": [125, 141]}, "bert_text": "Mutations associated with lamivudine-resistance in therapy-<e1> na </e1>  ve hepatitis B virus (HBV) infected patients with and without <e2> HIV co-infection </e2>: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3416": {"data": {"text": "Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.\n", "entity1": "na", "entity2": "HIV co-infected", "span1": [59, 61], "span2": [194, 209]}, "bert_text": "Mutations associated with lamivudine-resistance in therapy-<e1> na </e1>  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and <e2> HIV co-infected </e2> South African patients.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3417": {"data": {"text": "UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.", "entity1": "UM-272", "entity2": "ventricular tachycardias", "span1": [0, 6], "span2": [128, 152]}, "bert_text": "<e1> UM-272 </e1> (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced <e2> ventricular tachycardias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3418": {"data": {"text": "UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.", "entity1": "N,N-dimethylpropranolol", "entity2": "ventricular tachycardias", "span1": [8, 31], "span2": [128, 152]}, "bert_text": "UM-272 (<e1> N,N-dimethylpropranolol </e1>), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced <e2> ventricular tachycardias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3419": {"data": {"text": "UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.", "entity1": "ouabain", "entity2": "ventricular tachycardias", "span1": [112, 119], "span2": [128, 152]}, "bert_text": "UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with <e1> ouabain </e1>-induced <e2> ventricular tachycardias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3420": {"data": {"text": "Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.\n", "entity1": "edaravone", "entity2": "vestibulotoxicity", "span1": [21, 30], "span2": [60, 77]}, "bert_text": "Protective effect of <e1> edaravone </e1> against streptomycin-induced <e2> vestibulotoxicity </e2> in the guinea pig.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3421": {"data": {"text": "Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.\n", "entity1": "streptomycin", "entity2": "vestibulotoxicity", "span1": [39, 51], "span2": [60, 77]}, "bert_text": "Protective effect of edaravone against <e1> streptomycin </e1>-induced <e2> vestibulotoxicity </e2> in the guinea pig.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3422": {"data": {"text": "CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.", "entity1": "CCNU", "entity2": "lymphoma", "span1": [0, 4], "span2": [48, 56]}, "bert_text": "<e1> CCNU </e1> was used most commonly in the treatment of <e2> lymphoma </e2>, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3423": {"data": {"text": "CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.", "entity1": "CCNU", "entity2": "mast cell tumour", "span1": [0, 4], "span2": [58, 74]}, "bert_text": "<e1> CCNU </e1> was used most commonly in the treatment of lymphoma, <e2> mast cell tumour </e2>, brain tumour, histiocytic tumours and epitheliotropic lymphoma.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3424": {"data": {"text": "CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.", "entity1": "CCNU", "entity2": "brain tumour", "span1": [0, 4], "span2": [76, 88]}, "bert_text": "<e1> CCNU </e1> was used most commonly in the treatment of lymphoma, mast cell tumour, <e2> brain tumour </e2>, histiocytic tumours and epitheliotropic lymphoma.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3425": {"data": {"text": "CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.", "entity1": "CCNU", "entity2": "histiocytic tumours and epitheliotropic lymphoma", "span1": [0, 4], "span2": [90, 138]}, "bert_text": "<e1> CCNU </e1> was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, <e2> histiocytic tumours and epitheliotropic lymphoma </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3426": {"data": {"text": "Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.\n", "entity1": "delta 9-tetrahydrocannabinol", "entity2": "catalepsy", "span1": [50, 78], "span2": [29, 38]}, "bert_text": "Noradrenergic involvement in catalepsy induced by <e1> delta 9-tetrahydrocannabinol </e1> <e2> catalepsy </e2> induced by delta 9-tetrahydrocannabinol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3427": {"data": {"text": "In this study, three Chinese patients with ticlopidine-induced aplastic anemia were reported and another 13 patients in the English literature were reviewed.", "entity1": "ticlopidine", "entity2": "aplastic anemia", "span1": [43, 54], "span2": [63, 78]}, "bert_text": "In this study, three Chinese patients with <e1> ticlopidine </e1>-induced <e2> aplastic anemia </e2> were reported and another 13 patients in the English literature were reviewed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3428": {"data": {"text": "Incidence of transient cyclophosphamide-related cardiac toxicity (10%) is comparable to previous recorded literature.", "entity1": "cyclophosphamide", "entity2": "cardiac toxicity", "span1": [23, 39], "span2": [48, 64]}, "bert_text": "Incidence of transient <e1> cyclophosphamide </e1>-related <e2> cardiac toxicity </e2> (10%) is comparable to previous recorded literature.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3429": {"data": {"text": "Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/-", "entity1": "nitroglycerin", "entity2": "myocardial infarctions", "span1": [79, 92], "span2": [35, 57]}, "bert_text": "Ten patients with acute transmural myocardial infarctions received intravenous <e1> nitroglycerin </e1> <e2> myocardial infarctions </e2> received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3430": {"data": {"text": "Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.\n", "entity1": "crocin", "entity2": "Alzheimer's disease", "span1": [53, 59], "span2": [102, 121]}, "bert_text": "Effects of active constituents of Crocus sativus L., <e1> crocin </e1> on streptozocin-induced model of sporadic <e2> Alzheimer's disease </e2> in male rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3431": {"data": {"text": "Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.\n", "entity1": "streptozocin", "entity2": "Alzheimer's disease", "span1": [63, 75], "span2": [102, 121]}, "bert_text": "Effects of active constituents of Crocus sativus L., crocin on <e1> streptozocin </e1>-induced model of sporadic <e2> Alzheimer's disease </e2> in male rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3432": {"data": {"text": "Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.\n", "entity1": "Phenylephrine", "entity2": "hypotension", "span1": [0, 13], "span2": [94, 105]}, "bert_text": "<e1> Phenylephrine </e1> but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced <e2> hypotension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3433": {"data": {"text": "Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.\n", "entity1": "ephedrine", "entity2": "hypotension", "span1": [22, 31], "span2": [94, 105]}, "bert_text": "Phenylephrine but not <e1> ephedrine </e1> reduces frontal lobe oxygenation following anesthesia-induced <e2> hypotension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3434": {"data": {"text": "Hemolytic-uremic syndrome following quinine ingestion is a newly described phenomenon, with just two previous descriptions of 4 cases in the literature.", "entity1": "quinine", "entity2": "Hemolytic-uremic syndrome", "span1": [36, 43], "span2": [0, 25]}, "bert_text": "Hemolytic-uremic syndrome following <e1> quinine </e1> <e2> Hemolytic-uremic syndrome </e2> following quinine ingestion is a newly described phenomenon, with just two previous descriptions of 4 cases in the literature.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3435": {"data": {"text": "METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.", "entity1": "pergolide", "entity2": "PD", "span1": [57, 66], "span2": [13, 15]}, "bert_text": "METHODS: All PD patients in the Amiens area treated with <e1> pergolide </e1> <e2> PD </e2> patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3436": {"data": {"text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.", "entity1": "5-fluorouracil", "entity2": "tumors", "span1": [58, 72], "span2": [135, 141]}, "bert_text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular <e1> 5-fluorouracil </e1> (5-FU), have been the mainstay of treatment for several solid <e2> tumors </e2>, including colorectal, breast and head and neck cancers, for > 40 years.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3437": {"data": {"text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.", "entity1": "5-fluorouracil", "entity2": "cancers", "span1": [58, 72], "span2": [190, 197]}, "bert_text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular <e1> 5-fluorouracil </e1> (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck <e2> cancers </e2>, for > 40 years.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3438": {"data": {"text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.", "entity1": "5-fluorouracil", "entity2": "breast", "span1": [58, 72], "span2": [165, 171]}, "bert_text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular <e1> 5-fluorouracil </e1> (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, <e2> breast </e2> and head and neck cancers, for > 40 years.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3439": {"data": {"text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.", "entity1": "5-FU", "entity2": "tumors", "span1": [74, 78], "span2": [135, 141]}, "bert_text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (<e1> 5-FU </e1>), have been the mainstay of treatment for several solid <e2> tumors </e2>, including colorectal, breast and head and neck cancers, for > 40 years.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3440": {"data": {"text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.", "entity1": "5-FU", "entity2": "cancers", "span1": [74, 78], "span2": [190, 197]}, "bert_text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (<e1> 5-FU </e1>), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck <e2> cancers </e2>, for > 40 years.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3441": {"data": {"text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.", "entity1": "5-FU", "entity2": "breast", "span1": [74, 78], "span2": [165, 171]}, "bert_text": "IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (<e1> 5-FU </e1>), have been the mainstay of treatment for several solid tumors, including colorectal, <e2> breast </e2> and head and neck cancers, for > 40 years.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3442": {"data": {"text": "Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.", "entity1": "Oxytocin", "entity2": "hypotension", "span1": [0, 8], "span2": [17, 28]}, "bert_text": "<e1> Oxytocin </e1>-induced <e2> hypotension </e2> at cesarean delivery may be incorrectly attributed to blood loss.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3443": {"data": {"text": "Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.", "entity1": "Oxytocin", "entity2": "blood loss", "span1": [0, 8], "span2": [83, 93]}, "bert_text": "<e1> Oxytocin </e1>-induced hypotension at cesarean delivery may be incorrectly attributed to <e2> blood loss </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3444": {"data": {"text": "Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.\n", "entity1": "sevoflurane", "entity2": "Cardiac arrest", "span1": [57, 68], "span2": [0, 14]}, "bert_text": "Cardiac arrest in a child with cerebral palsy undergoing <e1> sevoflurane </e1> <e2> Cardiac arrest </e2> in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3445": {"data": {"text": "Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.\n", "entity1": "sevoflurane", "entity2": "cerebral palsy", "span1": [57, 68], "span2": [31, 45]}, "bert_text": "Cardiac arrest in a child with cerebral palsy undergoing <e1> sevoflurane </e1> <e2> cerebral palsy </e2> undergoing sevoflurane induction of anesthesia after preoperative clonidine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3446": {"data": {"text": "Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.\n", "entity1": "clonidine", "entity2": "Cardiac arrest", "span1": [112, 121], "span2": [0, 14]}, "bert_text": "Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative <e1> clonidine </e1> <e2> Cardiac arrest </e2> in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3447": {"data": {"text": "Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.\n", "entity1": "clonidine", "entity2": "cerebral palsy", "span1": [112, 121], "span2": [31, 45]}, "bert_text": "Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative <e1> clonidine </e1> <e2> cerebral palsy </e2> undergoing sevoflurane induction of anesthesia after preoperative clonidine.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3448": {"data": {"text": "Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.", "entity1": "Statins", "entity2": "myopathy", "span1": [0, 7], "span2": [32, 40]}, "bert_text": "<e1> Statins </e1> can cause a necrotizing <e2> myopathy </e2> and hyperCKaemia which is reversible on cessation of the drug.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3449": {"data": {"text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "entity1": "contrast media", "entity2": "CIN", "span1": [72, 86], "span2": [51, 54]}, "bert_text": "This prospective study determined the incidence of CIN for two nonionic <e1> contrast media </e1> <e2> CIN </e2> for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3450": {"data": {"text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "entity1": "contrast media", "entity2": "cyanosis", "span1": [72, 86], "span2": [262, 270]}, "bert_text": "This prospective study determined the incidence of CIN for two nonionic <e1> contrast media </e1> (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2> cyanosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3451": {"data": {"text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "entity1": "CM", "entity2": "CIN", "span1": [88, 90], "span2": [51, 54]}, "bert_text": "This prospective study determined the incidence of CIN for two nonionic contrast media (<e1> CM </e1> <e2> CIN </e2> for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3452": {"data": {"text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "entity1": "CM", "entity2": "cyanosis", "span1": [88, 90], "span2": [262, 270]}, "bert_text": "This prospective study determined the incidence of CIN for two nonionic contrast media (<e1> CM </e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2> cyanosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3453": {"data": {"text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "entity1": "CM", "entity2": "CIN", "span1": [239, 241], "span2": [51, 54]}, "bert_text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of <e1> CM </e1> <e2> CIN </e2> for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3454": {"data": {"text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "entity1": "CM", "entity2": "cyanosis", "span1": [239, 241], "span2": [262, 270]}, "bert_text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of <e1> CM </e1> and the presence of <e2> cyanosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3455": {"data": {"text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "entity1": "iopromide", "entity2": "CIN", "span1": [93, 102], "span2": [51, 54]}, "bert_text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), <e1> iopromide </e1> <e2> CIN </e2> for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3456": {"data": {"text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "entity1": "iopromide", "entity2": "cyanosis", "span1": [93, 102], "span2": [262, 270]}, "bert_text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), <e1> iopromide </e1> and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2> cyanosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3457": {"data": {"text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "entity1": "iohexol", "entity2": "CIN", "span1": [107, 114], "span2": [51, 54]}, "bert_text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and <e1> iohexol </e1> <e2> CIN </e2> for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3458": {"data": {"text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "entity1": "iohexol", "entity2": "cyanosis", "span1": [107, 114], "span2": [262, 270]}, "bert_text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and <e1> iohexol </e1>, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2> cyanosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3459": {"data": {"text": "The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.\n", "entity1": "N-butyl-deoxynojirimycin", "entity2": "HIV-1 infection", "span1": [39, 63], "span2": [107, 122]}, "bert_text": "The safety and efficacy of combination <e1> N-butyl-deoxynojirimycin </e1> (SC-48334) and zidovudine in patients with <e2> HIV-1 infection </e2> and 200-500 CD4 cells/mm3.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3460": {"data": {"text": "The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.\n", "entity1": "SC-48334", "entity2": "HIV-1 infection", "span1": [65, 73], "span2": [107, 122]}, "bert_text": "The safety and efficacy of combination N-butyl-deoxynojirimycin (<e1> SC-48334 </e1>) and zidovudine in patients with <e2> HIV-1 infection </e2> and 200-500 CD4 cells/mm3.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3461": {"data": {"text": "The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.\n", "entity1": "zidovudine", "entity2": "HIV-1 infection", "span1": [79, 89], "span2": [107, 122]}, "bert_text": "The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and <e1> zidovudine </e1> in patients with <e2> HIV-1 infection </e2> and 200-500 CD4 cells/mm3.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3462": {"data": {"text": "Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose.", "entity1": "DFU", "entity2": "toxicity", "span1": [51, 54], "span2": [69, 77]}, "bert_text": "Decrease of fetal length was the only signs of the <e1> DFU </e1> developmental <e2> toxicity </e2> observed in pups exposed to the highest compound dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3463": {"data": {"text": "In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects.", "entity1": "morphine", "entity2": "constipating", "span1": [23, 31], "span2": [186, 198]}, "bert_text": "In independent groups, <e1> morphine </e1> inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the <e2> constipating </e2> effects.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"3464": {"data": {"text": "We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.", "entity1": "propofol", "entity2": "pain", "span1": [21, 29], "span2": [39, 43]}, "bert_text": "We hypothesized that <e1> propofol </e1> infusion <e2> pain </e2> might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3465": {"data": {"text": "We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.", "entity1": "propofol", "entity2": "pain", "span1": [108, 116], "span2": [39, 43]}, "bert_text": "We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the <e1> propofol </e1> <e2> pain </e2> might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3466": {"data": {"text": "We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.", "entity1": "remifentanil", "entity2": "pain", "span1": [75, 87], "span2": [39, 43]}, "bert_text": "We hypothesized that propofol infusion pain might be prevented by infusing <e1> remifentanil </e1> <e2> pain </e2> might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3467": {"data": {"text": "Ketamine elicited psychosis like psychopathology.", "entity1": "Ketamine", "entity2": "psychosis", "span1": [0, 8], "span2": [18, 27]}, "bert_text": "<e1> Ketamine </e1> elicited <e2> psychosis </e2> like psychopathology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3468": {"data": {"text": "CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.", "entity1": "azithromycin", "entity2": "hiccups", "span1": [82, 94], "span2": [58, 65]}, "bert_text": "CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning <e1> azithromycin </e1> <e2> hiccups </e2> after beginning azithromycin for the treatment of pharyngitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3469": {"data": {"text": "CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.", "entity1": "azithromycin", "entity2": "pharyngitis", "span1": [82, 94], "span2": [116, 127]}, "bert_text": "CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning <e1> azithromycin </e1> for the treatment of <e2> pharyngitis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3470": {"data": {"text": "Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).", "entity1": "potassium", "entity2": "hyperkalemia", "span1": [107, 116], "span2": [23, 35]}, "bert_text": "Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum <e1> potassium </e1> <e2> hyperkalemia </e2> were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3471": {"data": {"text": "Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).", "entity1": "potassium", "entity2": "diabetes", "span1": [107, 116], "span2": [71, 79]}, "bert_text": "Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum <e1> potassium </e1> <e2> diabetes </e2>, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3472": {"data": {"text": "Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).", "entity1": "potassium", "entity2": "hyperkalemia", "span1": [143, 152], "span2": [23, 35]}, "bert_text": "Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline <e1> potassium </e1> <e2> hyperkalemia </e2> were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3473": {"data": {"text": "Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).", "entity1": "potassium", "entity2": "diabetes", "span1": [143, 152], "span2": [71, 79]}, "bert_text": "Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline <e1> potassium </e1> <e2> diabetes </e2>, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3474": {"data": {"text": "Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.", "entity1": "CLZ", "entity2": "headache", "span1": [148, 151], "span2": [37, 45]}, "bert_text": "Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of <e1> CLZ </e1> <e2> headache </e2> of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3475": {"data": {"text": "Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.", "entity1": "CLZ", "entity2": "facial flush", "span1": [148, 151], "span2": [79, 91]}, "bert_text": "Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of <e1> CLZ </e1> <e2> facial flush </e2> in one and nausea in one, especially after ingestion of CLZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3476": {"data": {"text": "Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.", "entity1": "CLZ", "entity2": "nausea", "span1": [148, 151], "span2": [103, 109]}, "bert_text": "Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of <e1> CLZ </e1> <e2> nausea </e2> in one, especially after ingestion of CLZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3477": {"data": {"text": "RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.", "entity1": "METH", "entity2": "psychosis", "span1": [39, 43], "span2": [52, 61]}, "bert_text": "RESULTS: rs6693503 was associated with <e1> METH </e1>-induced <e2> psychosis </e2> patients in the allele/genotype-wise analysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3478": {"data": {"text": "Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).", "entity1": "prilocaine", "entity2": "hearing loss", "span1": [15, 25], "span2": [54, 66]}, "bert_text": "Patients given <e1> prilocaine </e1> were more likely to develop <e2> hearing loss </e2> (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3479": {"data": {"text": "Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).", "entity1": "bupivacaine", "entity2": "hearing loss", "span1": [99, 110], "span2": [54, 66]}, "bert_text": "Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given <e1> bupivacaine </e1> <e2> hearing loss </e2> (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3480": {"data": {"text": "Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "entity1": "vitamin D3", "entity2": "hypercalcemia", "span1": [26, 36], "span2": [103, 116]}, "bert_text": "Large parenteral doses of <e1> vitamin D3 </e1> (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged <e2> hypercalcemia </e2>, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3481": {"data": {"text": "Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "entity1": "vitamin D3", "entity2": "hyperphosphatemia", "span1": [26, 36], "span2": [118, 135]}, "bert_text": "Large parenteral doses of <e1> vitamin D3 </e1> (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, <e2> hyperphosphatemia </e2>, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3482": {"data": {"text": "Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "entity1": "vitamin D3", "entity2": "hypercalcemia", "span1": [60, 70], "span2": [103, 116]}, "bert_text": "Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU <e1> vitamin D3 </e1>) were associated with prolonged <e2> hypercalcemia </e2>, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3483": {"data": {"text": "Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "entity1": "vitamin D3", "entity2": "hyperphosphatemia", "span1": [60, 70], "span2": [118, 135]}, "bert_text": "Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU <e1> vitamin D3 </e1>) were associated with prolonged hypercalcemia, <e2> hyperphosphatemia </e2>, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3484": {"data": {"text": "Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "entity1": "vitamin D3", "entity2": "hypercalcemia", "span1": [160, 170], "span2": [103, 116]}, "bert_text": "Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of <e1> vitamin D3 </e1> <e2> hypercalcemia </e2>, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3485": {"data": {"text": "Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "entity1": "vitamin D3", "entity2": "hyperphosphatemia", "span1": [160, 170], "span2": [118, 135]}, "bert_text": "Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of <e1> vitamin D3 </e1> <e2> hyperphosphatemia </e2>, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3486": {"data": {"text": "Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.", "entity1": "D-penicillamine", "entity2": "Polymyositis", "span1": [83, 98], "span2": [0, 12]}, "bert_text": "Polymyositis/dermatomyositis can develop as one of the autoimmune complications of <e1> D-penicillamine </e1> <e2> Polymyositis </e2>/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3487": {"data": {"text": "Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.", "entity1": "D-penicillamine", "entity2": "dermatomyositis", "span1": [83, 98], "span2": [13, 28]}, "bert_text": "Polymyositis/dermatomyositis can develop as one of the autoimmune complications of <e1> D-penicillamine </e1> <e2> dermatomyositis </e2> can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3488": {"data": {"text": "As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.", "entity1": "tacrolimus", "entity2": "TMA", "span1": [26, 36], "span2": [128, 131]}, "bert_text": "As a result, switching to <e1> tacrolimus </e1> has been reported to be a viable therapeutic option in the setting of cyclosporine-induced <e2> TMA </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3489": {"data": {"text": "As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.", "entity1": "cyclosporine", "entity2": "TMA", "span1": [107, 119], "span2": [128, 131]}, "bert_text": "As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of <e1> cyclosporine </e1>-induced <e2> TMA </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3490": {"data": {"text": "Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.", "entity1": "U-II", "entity2": "hypertension", "span1": [46, 50], "span2": [58, 70]}, "bert_text": "Intracerebroventricular (i.c.v.) injection of <e1> U-II </e1> causes <e2> hypertension </e2> and bradycardia and stimulates prolactin and thyrotropin secretion.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3491": {"data": {"text": "Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.", "entity1": "U-II", "entity2": "bradycardia", "span1": [46, 50], "span2": [75, 86]}, "bert_text": "Intracerebroventricular (i.c.v.) injection of <e1> U-II </e1> causes hypertension and <e2> bradycardia </e2> and stimulates prolactin and thyrotropin secretion.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3492": {"data": {"text": "The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.", "entity1": "phenobarbitone", "entity2": "cognitive impairment", "span1": [25, 39], "span2": [82, 102]}, "bert_text": "The antiepileptic drugs, <e1> phenobarbitone </e1> and carbamazepine are well known to cause <e2> cognitive impairment </e2> on chronic use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3493": {"data": {"text": "The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.", "entity1": "carbamazepine", "entity2": "cognitive impairment", "span1": [44, 57], "span2": [82, 102]}, "bert_text": "The antiepileptic drugs, phenobarbitone and <e1> carbamazepine </e1> are well known to cause <e2> cognitive impairment </e2> on chronic use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3494": {"data": {"text": "L-arginine transport in humans with cortisol-induced hypertension.\n", "entity1": "cortisol", "entity2": "hypertension", "span1": [36, 44], "span2": [53, 65]}, "bert_text": "L-arginine transport in humans with <e1> cortisol </e1>-induced <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3495": {"data": {"text": "A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.", "entity1": "remifentanil", "entity2": "pain", "span1": [131, 143], "span2": [159, 163]}, "bert_text": "A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of <e1> remifentanil </e1> to prevent the <e2> pain </e2> without producing complications.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3496": {"data": {"text": "What is less well known is a phenomenon whereby statins may induce a myopathy, which persists or may progress after stopping the drug.", "entity1": "statins", "entity2": "myopathy", "span1": [48, 55], "span2": [69, 77]}, "bert_text": "What is less well known is a phenomenon whereby <e1> statins </e1> may induce a <e2> myopathy </e2>, which persists or may progress after stopping the drug.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3497": {"data": {"text": "RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.", "entity1": "methotrexate", "entity2": "leukoencephalopathy", "span1": [88, 100], "span2": [43, 62]}, "bert_text": "RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with <e1> methotrexate </e1> <e2> leukoencephalopathy </e2> in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3498": {"data": {"text": "RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.", "entity1": "5-fluorouracil", "entity2": "leukoencephalopathy", "span1": [126, 140], "span2": [43, 62]}, "bert_text": "RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), <e1> 5-fluorouracil </e1> <e2> leukoencephalopathy </e2> in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3499": {"data": {"text": "RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.", "entity1": "carmofur", "entity2": "leukoencephalopathy", "span1": [160, 168], "span2": [43, 62]}, "bert_text": "RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative <e1> carmofur </e1> <e2> leukoencephalopathy </e2> in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3500": {"data": {"text": "RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.", "entity1": "capecitabine", "entity2": "leukoencephalopathy", "span1": [174, 186], "span2": [43, 62]}, "bert_text": "RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and <e1> capecitabine </e1> <e2> leukoencephalopathy </e2> in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3501": {"data": {"text": "Using both contaminated heparin products and the synthetically produced derivative, we showed that the OSCS produces dose-dependent hypotension in pigs.", "entity1": "heparin", "entity2": "hypotension", "span1": [24, 31], "span2": [132, 143]}, "bert_text": "Using both contaminated <e1> heparin </e1> products and the synthetically produced derivative, we showed that the OSCS produces dose-dependent <e2> hypotension </e2> in pigs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3502": {"data": {"text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "entity1": "serotonin", "entity2": "obsessive compulsive disorder", "span1": [168, 177], "span2": [33, 62]}, "bert_text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with <e1> serotonin </e1> <e2> obsessive compulsive disorder </e2>, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3503": {"data": {"text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "entity1": "serotonin", "entity2": "trichotillomania", "span1": [168, 177], "span2": [64, 80]}, "bert_text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with <e1> serotonin </e1> <e2> trichotillomania </e2>, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3504": {"data": {"text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "entity1": "serotonin", "entity2": "anxiety", "span1": [168, 177], "span2": [82, 89]}, "bert_text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with <e1> serotonin </e1> <e2> anxiety </e2>, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3505": {"data": {"text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "entity1": "serotonin", "entity2": "affective disorders", "span1": [168, 177], "span2": [94, 113]}, "bert_text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with <e1> serotonin </e1> <e2> affective disorders </e2> who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3506": {"data": {"text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "entity1": "yohimbine", "entity2": "obsessive compulsive disorder", "span1": [207, 216], "span2": [33, 62]}, "bert_text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given <e1> yohimbine </e1> <e2> obsessive compulsive disorder </e2>, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3507": {"data": {"text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "entity1": "yohimbine", "entity2": "trichotillomania", "span1": [207, 216], "span2": [64, 80]}, "bert_text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given <e1> yohimbine </e1> <e2> trichotillomania </e2>, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3508": {"data": {"text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "entity1": "yohimbine", "entity2": "anxiety", "span1": [207, 216], "span2": [82, 89]}, "bert_text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given <e1> yohimbine </e1> <e2> anxiety </e2>, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3509": {"data": {"text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "entity1": "yohimbine", "entity2": "affective disorders", "span1": [207, 216], "span2": [94, 113]}, "bert_text": "METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given <e1> yohimbine </e1> <e2> affective disorders </e2> who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3510": {"data": {"text": "We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.", "entity1": "clotiazepam", "entity2": "hepatitis", "span1": [148, 159], "span2": [52, 61]}, "bert_text": "We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of <e1> clotiazepam </e1> <e2> hepatitis </e2> with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3511": {"data": {"text": "We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.", "entity1": "clotiazepam", "entity2": "extensive hepatocellular necrosis", "span1": [148, 159], "span2": [67, 100]}, "bert_text": "We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of <e1> clotiazepam </e1> <e2> extensive hepatocellular necrosis </e2>, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3512": {"data": {"text": "We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.", "entity1": "thienodiazepine", "entity2": "hepatitis", "span1": [163, 178], "span2": [52, 61]}, "bert_text": "We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a <e1> thienodiazepine </e1> <e2> hepatitis </e2> with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3513": {"data": {"text": "We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.", "entity1": "thienodiazepine", "entity2": "extensive hepatocellular necrosis", "span1": [163, 178], "span2": [67, 100]}, "bert_text": "We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a <e1> thienodiazepine </e1> <e2> extensive hepatocellular necrosis </e2>, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3514": {"data": {"text": "Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved hypertensive BP levels after caffeine ingestion.", "entity1": "caffeine", "entity2": "hypertensive", "span1": [171, 179], "span2": [142, 154]}, "bert_text": "Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved hypertensive BP levels after <e1> caffeine </e1> <e2> hypertensive </e2> BP levels after caffeine ingestion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3515": {"data": {"text": "Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.", "entity1": "Valproic acid", "entity2": "epileptic", "span1": [0, 13], "span2": [36, 45]}, "bert_text": "<e1> Valproic acid </e1> (VPA) was given to 24 <e2> epileptic </e2> patients who were already being treated with other antiepileptic drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3516": {"data": {"text": "Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.", "entity1": "VPA", "entity2": "epileptic", "span1": [15, 18], "span2": [36, 45]}, "bert_text": "Valproic acid (<e1> VPA </e1>) was given to 24 <e2> epileptic </e2> patients who were already being treated with other antiepileptic drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3517": {"data": {"text": "The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.", "entity1": "morphine", "entity2": "constipation", "span1": [73, 81], "span2": [181, 193]}, "bert_text": "The combination inhibited intestinal transit similar to that produced by <e1> morphine </e1> regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced <e2> constipation </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"3518": {"data": {"text": "The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.", "entity1": "morphine", "entity2": "constipation", "span1": [164, 172], "span2": [181, 193]}, "bert_text": "The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate <e1> morphine </e1>-induced <e2> constipation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, 0, -1, -1, 0, -1], "label": 1},
+	"3519": {"data": {"text": "The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.", "entity1": "metamizol", "entity2": "constipation", "span1": [135, 144], "span2": [181, 193]}, "bert_text": "The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that <e1> metamizol </e1> did not potentiate morphine-induced <e2> constipation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3520": {"data": {"text": "Additional studies of these murine strains may be useful for investigating genetic influences on cocaine-induced seizures.", "entity1": "cocaine", "entity2": "seizures", "span1": [97, 104], "span2": [113, 121]}, "bert_text": "Additional studies of these murine strains may be useful for investigating genetic influences on <e1> cocaine </e1>-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3521": {"data": {"text": "Review of the literature reveals an association between tamoxifen use and gynecologic tumors.", "entity1": "tamoxifen", "entity2": "tumors", "span1": [56, 65], "span2": [86, 92]}, "bert_text": "Review of the literature reveals an association between <e1> tamoxifen </e1> use and gynecologic <e2> tumors </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3522": {"data": {"text": "Prolonged cholestasis after troleandomycin-induced acute hepatitis.\n", "entity1": "troleandomycin", "entity2": "cholestasis", "span1": [28, 42], "span2": [10, 21]}, "bert_text": "Prolonged cholestasis after <e1> troleandomycin </e1> <e2> cholestasis </e2> after troleandomycin-induced acute hepatitis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3523": {"data": {"text": "Prolonged cholestasis after troleandomycin-induced acute hepatitis.\n", "entity1": "troleandomycin", "entity2": "hepatitis", "span1": [28, 42], "span2": [57, 66]}, "bert_text": "Prolonged cholestasis after <e1> troleandomycin </e1>-induced acute <e2> hepatitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3524": {"data": {"text": "However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.", "entity1": "steroid", "entity2": "seizures", "span1": [35, 42], "span2": [143, 151]}, "bert_text": "However, when a second dose of the <e1> steroid </e1> was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic <e2> seizures </e2> and status epilepticus was obtained.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3525": {"data": {"text": "However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.", "entity1": "steroid", "entity2": "status epilepticus", "span1": [35, 42], "span2": [156, 174]}, "bert_text": "However, when a second dose of the <e1> steroid </e1> was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and <e2> status epilepticus </e2> was obtained.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3526": {"data": {"text": "However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.", "entity1": "kainic acid", "entity2": "seizures", "span1": [116, 127], "span2": [143, 151]}, "bert_text": "However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the <e1> kainic acid </e1>-induced limbic <e2> seizures </e2> and status epilepticus was obtained.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3527": {"data": {"text": "However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.", "entity1": "kainic acid", "entity2": "status epilepticus", "span1": [116, 127], "span2": [156, 174]}, "bert_text": "However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the <e1> kainic acid </e1>-induced limbic seizures and <e2> status epilepticus </e2> was obtained.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3528": {"data": {"text": "Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl.", "entity1": "nitroprusside", "entity2": "hypotension", "span1": [46, 59], "span2": [68, 79]}, "bert_text": "Suppression of irCRF secretion in response to <e1> nitroprusside </e1>-induced <e2> hypotension </e2> is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3529": {"data": {"text": "Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl.", "entity1": "corticosterone", "entity2": "hypotension", "span1": [115, 129], "span2": [68, 79]}, "bert_text": "Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma <e1> corticosterone </e1> <e2> hypotension </e2> is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3530": {"data": {"text": "Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).", "entity1": "Superoxide", "entity2": "ALF", "span1": [0, 10], "span2": [47, 50]}, "bert_text": "<e1> Superoxide </e1> and hydrogen peroxide production by <e2> ALF </e2> neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3531": {"data": {"text": "Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).", "entity1": "Superoxide", "entity2": "ALF", "span1": [0, 10], "span2": [102, 105]}, "bert_text": "<e1> Superoxide </e1> and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with <e2> ALF </e2> serum was significantly reduced compared with the control subjects (P < 0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3532": {"data": {"text": "Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).", "entity1": "hydrogen peroxide", "entity2": "ALF", "span1": [15, 32], "span2": [47, 50]}, "bert_text": "Superoxide and <e1> hydrogen peroxide </e1> production by <e2> ALF </e2> neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3533": {"data": {"text": "Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).", "entity1": "hydrogen peroxide", "entity2": "ALF", "span1": [15, 32], "span2": [102, 105]}, "bert_text": "Superoxide and <e1> hydrogen peroxide </e1> production by ALF neutrophils stimulated with zymosan opsonized with <e2> ALF </e2> serum was significantly reduced compared with the control subjects (P < 0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3534": {"data": {"text": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "entity1": "fluoxetine", "entity2": "akathisia", "span1": [25, 35], "span2": [44, 53]}, "bert_text": "The authors suggest that <e1> fluoxetine </e1>-induced <e2> akathisia </e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3535": {"data": {"text": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "entity1": "fluoxetine", "entity2": "akathisia", "span1": [25, 35], "span2": [193, 202]}, "bert_text": "The authors suggest that <e1> fluoxetine </e1>-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced <e2> akathisia </e2> and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3536": {"data": {"text": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "entity1": "fluoxetine", "entity2": "akathisia", "span1": [174, 184], "span2": [44, 53]}, "bert_text": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1> fluoxetine </e1> <e2> akathisia </e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3537": {"data": {"text": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "entity1": "fluoxetine", "entity2": "akathisia", "span1": [174, 184], "span2": [193, 202]}, "bert_text": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1> fluoxetine </e1>-induced <e2> akathisia </e2> and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3538": {"data": {"text": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "entity1": "antidepressant", "entity2": "akathisia", "span1": [217, 231], "span2": [44, 53]}, "bert_text": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic <e1> antidepressant </e1> <e2> akathisia </e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3539": {"data": {"text": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "entity1": "antidepressant", "entity2": "akathisia", "span1": [217, 231], "span2": [193, 202]}, "bert_text": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic <e1> antidepressant </e1> <e2> akathisia </e2> and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3540": {"data": {"text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "entity1": "lactate", "entity2": "cardiomyopathy", "span1": [105, 112], "span2": [62, 76]}, "bert_text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma <e1> lactate </e1> <e2> cardiomyopathy </e2> (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"3541": {"data": {"text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "entity1": "lactate", "entity2": "CM", "span1": [105, 112], "span2": [78, 80]}, "bert_text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma <e1> lactate </e1> <e2> CM </e2>) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"3542": {"data": {"text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "entity1": "lactate", "entity2": "AIDS", "span1": [105, 112], "span2": [121, 125]}, "bert_text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma <e1> lactate </e1> (LA) in <e2> AIDS </e2> through mechanisms of mitochondrial dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3543": {"data": {"text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "entity1": "lactate", "entity2": "mitochondrial dysfunction", "span1": [105, 112], "span2": [148, 173]}, "bert_text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma <e1> lactate </e1> (LA) in AIDS through mechanisms of <e2> mitochondrial dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3544": {"data": {"text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "entity1": "LA", "entity2": "cardiomyopathy", "span1": [114, 116], "span2": [62, 76]}, "bert_text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (<e1> LA </e1> <e2> cardiomyopathy </e2> (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"3545": {"data": {"text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "entity1": "LA", "entity2": "CM", "span1": [114, 116], "span2": [78, 80]}, "bert_text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (<e1> LA </e1> <e2> CM </e2>) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"3546": {"data": {"text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "entity1": "LA", "entity2": "AIDS", "span1": [114, 116], "span2": [121, 125]}, "bert_text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (<e1> LA </e1>) in <e2> AIDS </e2> through mechanisms of mitochondrial dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3547": {"data": {"text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.", "entity1": "LA", "entity2": "mitochondrial dysfunction", "span1": [114, 116], "span2": [148, 173]}, "bert_text": "Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (<e1> LA </e1>) in AIDS through mechanisms of <e2> mitochondrial dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3548": {"data": {"text": "Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "entity1": "alcohol", "entity2": "seizure disorder", "span1": [52, 59], "span2": [68, 84]}, "bert_text": "Patient demographics, history of underlying drug or <e1> alcohol </e1>-related <e2> seizure disorder </e2>, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3549": {"data": {"text": "Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "entity1": "alcohol", "entity2": "seizure", "span1": [52, 59], "span2": [106, 113]}, "bert_text": "Patient demographics, history of underlying drug or <e1> alcohol </e1>-related seizure disorder, estimated time from <e2> seizure </e2> to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3550": {"data": {"text": "Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "entity1": "alcohol", "entity2": "amphetamine abuse", "span1": [52, 59], "span2": [171, 188]}, "bert_text": "Patient demographics, history of underlying drug or <e1> alcohol </e1>-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or <e2> amphetamine abuse </e2>, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3551": {"data": {"text": "Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "entity1": "cocaine", "entity2": "seizure disorder", "span1": [160, 167], "span2": [68, 84]}, "bert_text": "Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of <e1> cocaine </e1> <e2> seizure disorder </e2>, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3552": {"data": {"text": "Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "entity1": "cocaine", "entity2": "seizure", "span1": [160, 167], "span2": [106, 113]}, "bert_text": "Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of <e1> cocaine </e1> <e2> seizure </e2> to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3553": {"data": {"text": "Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "entity1": "cocaine", "entity2": "amphetamine abuse", "span1": [160, 167], "span2": [171, 188]}, "bert_text": "Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of <e1> cocaine </e1> or <e2> amphetamine abuse </e2>, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3554": {"data": {"text": "Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.", "entity1": "sodium bicarbonate", "entity2": "penile pain", "span1": [27, 45], "span2": [93, 104]}, "bert_text": "Of the 19 patients without <e1> sodium bicarbonate </e1> added to the medication 11 (58%) complained of <e2> penile pain </e2> due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3555": {"data": {"text": "Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.", "entity1": "sodium bicarbonate", "entity2": "penile pain", "span1": [27, 45], "span2": [206, 217]}, "bert_text": "Of the 19 patients without <e1> sodium bicarbonate </e1> added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of <e2> penile pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3556": {"data": {"text": "Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.", "entity1": "sodium bicarbonate", "entity2": "penile pain", "span1": [173, 191], "span2": [93, 104]}, "bert_text": "Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received <e1> sodium bicarbonate </e1> <e2> penile pain </e2> due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3557": {"data": {"text": "Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.", "entity1": "sodium bicarbonate", "entity2": "penile pain", "span1": [173, 191], "span2": [206, 217]}, "bert_text": "Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received <e1> sodium bicarbonate </e1> complained of <e2> penile pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3558": {"data": {"text": "Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.\n", "entity1": "ribavirin", "entity2": "hemolytic anemia", "span1": [26, 35], "span2": [44, 60]}, "bert_text": "Management strategies for <e1> ribavirin </e1>-induced <e2> hemolytic anemia </e2> in the treatment of hepatitis C: clinical and economic implications.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3559": {"data": {"text": "Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.\n", "entity1": "ribavirin", "entity2": "hepatitis C", "span1": [26, 35], "span2": [81, 92]}, "bert_text": "Management strategies for <e1> ribavirin </e1>-induced hemolytic anemia in the treatment of <e2> hepatitis C </e2>: clinical and economic implications.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3560": {"data": {"text": "CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.", "entity1": "venlafaxine", "entity2": "overdose", "span1": [17, 28], "span2": [29, 37]}, "bert_text": "CONCLUSIONS: The <e1> venlafaxine </e1> <e2> overdose </e2> in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3561": {"data": {"text": "CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.", "entity1": "venlafaxine", "entity2": "seizure", "span1": [17, 28], "span2": [97, 104]}, "bert_text": "CONCLUSIONS: The <e1> venlafaxine </e1> overdose in our patient resulted in a single episode of generalized <e2> seizure </e2> but elicited no further sequelae.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3562": {"data": {"text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).", "entity1": "interferon", "entity2": "chronic hepatitis C", "span1": [127, 137], "span2": [224, 243]}, "bert_text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with <e1> interferon </e1> and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of <e2> chronic hepatitis C </e2> (CHC).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3563": {"data": {"text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).", "entity1": "interferon", "entity2": "CHC", "span1": [127, 137], "span2": [245, 248]}, "bert_text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with <e1> interferon </e1> and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (<e2> CHC </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3564": {"data": {"text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "chronic hepatitis C", "span1": [151, 160], "span2": [224, 243]}, "bert_text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/<e1> ribavirin </e1> compared with interferon-alpha monotherapy in the treatment of <e2> chronic hepatitis C </e2> (CHC).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3565": {"data": {"text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).", "entity1": "ribavirin", "entity2": "CHC", "span1": [151, 160], "span2": [245, 248]}, "bert_text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/<e1> ribavirin </e1> compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (<e2> CHC </e2>).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3566": {"data": {"text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).", "entity1": "interferon-alpha", "entity2": "chronic hepatitis C", "span1": [175, 191], "span2": [224, 243]}, "bert_text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with <e1> interferon-alpha </e1> monotherapy in the treatment of <e2> chronic hepatitis C </e2> (CHC).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3567": {"data": {"text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).", "entity1": "interferon-alpha", "entity2": "CHC", "span1": [175, 191], "span2": [245, 248]}, "bert_text": "OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with <e1> interferon-alpha </e1> monotherapy in the treatment of chronic hepatitis C (<e2> CHC </e2>).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3568": {"data": {"text": "Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.\n", "entity1": "vasopressin", "entity2": "diabetes insipidus", "span1": [34, 45], "span2": [119, 137]}, "bert_text": "Upregulation of the expression of <e1> vasopressin </e1> gene in the paraventricular and supraoptic nuclei of the lithium-induced <e2> diabetes insipidus </e2> rat.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3569": {"data": {"text": "Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.\n", "entity1": "lithium", "entity2": "diabetes insipidus", "span1": [103, 110], "span2": [119, 137]}, "bert_text": "Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the <e1> lithium </e1>-induced <e2> diabetes insipidus </e2> rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3570": {"data": {"text": "The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.", "entity1": "aldosterone", "entity2": "fibrosis", "span1": [4, 15], "span2": [152, 160]}, "bert_text": "The <e1> aldosterone </e1>-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal <e2> fibrosis </e2> following mineralocorticoid and salt excess.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3571": {"data": {"text": "Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.", "entity1": "lithium", "entity2": "nephropathy", "span1": [10, 17], "span2": [26, 37]}, "bert_text": "Rats with <e1> lithium </e1>-induced <e2> nephropathy </e2> were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3572": {"data": {"text": "Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.", "entity1": "lithium", "entity2": "renal failure", "span1": [10, 17], "span2": [208, 221]}, "bert_text": "Rats with <e1> lithium </e1>-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of <e2> renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3573": {"data": {"text": "BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.", "entity1": "gold", "entity2": "aplastic anemia", "span1": [65, 69], "span2": [29, 44]}, "bert_text": "BMT was used to treat severe aplastic anemia which was caused by <e1> gold </e1> <e2> aplastic anemia </e2> which was caused by gold in one case and D-penicillamine in the other.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3574": {"data": {"text": "BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.", "entity1": "D-penicillamine", "entity2": "aplastic anemia", "span1": [86, 101], "span2": [29, 44]}, "bert_text": "BMT was used to treat severe aplastic anemia which was caused by gold in one case and <e1> D-penicillamine </e1> <e2> aplastic anemia </e2> which was caused by gold in one case and D-penicillamine in the other.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3575": {"data": {"text": "Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.", "entity1": "carteolol", "entity2": "catalepsy", "span1": [26, 35], "span2": [92, 101]}, "bert_text": "Therefore, the effects of <e1> carteolol </e1>, a beta-adrenoceptor antagonist, on haloperidol-induced <e2> catalepsy </e2> in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3576": {"data": {"text": "Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [72, 83], "span2": [92, 101]}, "bert_text": "Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on <e1> haloperidol </e1>-induced <e2> catalepsy </e2> in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3577": {"data": {"text": "Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.", "entity1": "propranolol", "entity2": "catalepsy", "span1": [163, 174], "span2": [92, 101]}, "bert_text": "Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of <e1> propranolol </e1> <e2> catalepsy </e2> in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3578": {"data": {"text": "Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.", "entity1": "biperiden", "entity2": "catalepsy", "span1": [179, 188], "span2": [92, 101]}, "bert_text": "Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and <e1> biperiden </e1> <e2> catalepsy </e2> in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3579": {"data": {"text": "Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.\n", "entity1": "contrast media", "entity2": "nephropathy", "span1": [50, 64], "span2": [8, 19]}, "bert_text": "Risk of nephropathy after consumption of nonionic <e1> contrast media </e1> <e2> nephropathy </e2> after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"3580": {"data": {"text": "Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.", "entity1": "dopamine-1", "entity2": "hypotension", "span1": [26, 36], "span2": [191, 202]}, "bert_text": "Fenoldopam is a selective <e1> dopamine-1 </e1> (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3581": {"data": {"text": "Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.", "entity1": "DA1", "entity2": "hypotension", "span1": [38, 41], "span2": [191, 202]}, "bert_text": "Fenoldopam is a selective dopamine-1 (<e1> DA1 </e1>) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3582": {"data": {"text": "Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.", "entity1": "DA1", "entity2": "hypotension", "span1": [123, 126], "span2": [191, 202]}, "bert_text": "Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with <e1> DA1 </e1> receptors and preserves blood flow to the kidney during induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3583": {"data": {"text": "In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.", "entity1": "dexamethasone", "entity2": "HC", "span1": [56, 69], "span2": [130, 132]}, "bert_text": "In the study presented here, we investigated the use of <e1> dexamethasone </e1> in combination with mesna for the prevention of IFS-induced <e2> HC </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3584": {"data": {"text": "In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.", "entity1": "mesna", "entity2": "HC", "span1": [90, 95], "span2": [130, 132]}, "bert_text": "In the study presented here, we investigated the use of dexamethasone in combination with <e1> mesna </e1> for the prevention of IFS-induced <e2> HC </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3585": {"data": {"text": "In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.", "entity1": "IFS", "entity2": "HC", "span1": [118, 121], "span2": [130, 132]}, "bert_text": "In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of <e1> IFS </e1>-induced <e2> HC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"3586": {"data": {"text": "Valvular heart disease in patients with Parkinson's disease treated with pergolide.", "entity1": "pergolide", "entity2": "Valvular heart disease", "span1": [73, 82], "span2": [0, 22]}, "bert_text": "Valvular heart disease in patients with Parkinson's disease treated with <e1> pergolide </e1> <e2> Valvular heart disease </e2> in patients with Parkinson's disease treated with pergolide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3587": {"data": {"text": "Valvular heart disease in patients with Parkinson's disease treated with pergolide.", "entity1": "pergolide", "entity2": "Parkinson's disease", "span1": [73, 82], "span2": [40, 59]}, "bert_text": "Valvular heart disease in patients with Parkinson's disease treated with <e1> pergolide </e1> <e2> Parkinson's disease </e2> treated with pergolide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3588": {"data": {"text": "Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.\n", "entity1": "Nimodipine", "entity2": "memory impairment", "span1": [0, 10], "span2": [20, 37]}, "bert_text": "<e1> Nimodipine </e1> prevents <e2> memory impairment </e2> caused by nitroglycerin-induced hypotension in adult mice.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3589": {"data": {"text": "Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.\n", "entity1": "Nimodipine", "entity2": "hypotension", "span1": [0, 10], "span2": [70, 81]}, "bert_text": "<e1> Nimodipine </e1> prevents memory impairment caused by nitroglycerin-induced <e2> hypotension </e2> in adult mice.\n", "weak_labels": [1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3590": {"data": {"text": "Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.\n", "entity1": "nitroglycerin", "entity2": "memory impairment", "span1": [48, 61], "span2": [20, 37]}, "bert_text": "Nimodipine prevents memory impairment caused by <e1> nitroglycerin </e1> <e2> memory impairment </e2> caused by nitroglycerin-induced hypotension in adult mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3591": {"data": {"text": "Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.\n", "entity1": "nitroglycerin", "entity2": "hypotension", "span1": [48, 61], "span2": [70, 81]}, "bert_text": "Nimodipine prevents memory impairment caused by <e1> nitroglycerin </e1>-induced <e2> hypotension </e2> in adult mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3592": {"data": {"text": "Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.", "entity1": "Flumazenil", "entity2": "respiratory depression", "span1": [0, 10], "span2": [80, 102]}, "bert_text": "<e1> Flumazenil </e1> is a benzodiazepine receptor antagonist used to reverse sedation and <e2> respiratory depression </e2> induced by benzodiazepines.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3593": {"data": {"text": "Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.", "entity1": "benzodiazepine", "entity2": "respiratory depression", "span1": [16, 30], "span2": [80, 102]}, "bert_text": "Flumazenil is a <e1> benzodiazepine </e1> receptor antagonist used to reverse sedation and <e2> respiratory depression </e2> induced by benzodiazepines.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3594": {"data": {"text": "Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.", "entity1": "benzodiazepines", "entity2": "respiratory depression", "span1": [114, 129], "span2": [80, 102]}, "bert_text": "Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by <e1> benzodiazepines </e1> <e2> respiratory depression </e2> induced by benzodiazepines.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3595": {"data": {"text": "It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.", "entity1": "gum Arabic", "entity2": "nephrotoxicity", "span1": [26, 36], "span2": [139, 153]}, "bert_text": "It could be inferred that <e1> gum Arabic </e1> treatment has induced a modest amelioration of some of the histological and biochemical indices of GM <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3596": {"data": {"text": "It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.", "entity1": "GM", "entity2": "nephrotoxicity", "span1": [136, 138], "span2": [139, 153]}, "bert_text": "It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of <e1> GM </e1> <e2> nephrotoxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3597": {"data": {"text": "CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.", "entity1": "cyclophosphamide", "entity2": "bladder cancer", "span1": [70, 86], "span2": [103, 117]}, "bert_text": "CONCLUSION: The results indicate a dose-response relationship between <e1> cyclophosphamide </e1> and the risk of <e2> bladder cancer </e2>, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3598": {"data": {"text": "CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.", "entity1": "cyclophosphamide", "entity2": "Wegener's granulomatosis", "span1": [70, 86], "span2": [226, 250]}, "bert_text": "CONCLUSION: The results indicate a dose-response relationship between <e1> cyclophosphamide </e1> and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before <e2> Wegener's granulomatosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3599": {"data": {"text": "The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.", "entity1": "steroids", "entity2": "seizures", "span1": [4, 12], "span2": [137, 145]}, "bert_text": "The <e1> steroids </e1> also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA <e2> seizures </e2> or lethality.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3600": {"data": {"text": "Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.\n", "entity1": "Dopamine", "entity2": "neurotoxicity", "span1": [0, 8], "span2": [73, 86]}, "bert_text": "<e1> Dopamine </e1> is not essential for the development of methamphetamine-induced <e2> neurotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3601": {"data": {"text": "Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.\n", "entity1": "methamphetamine", "entity2": "neurotoxicity", "span1": [49, 64], "span2": [73, 86]}, "bert_text": "Dopamine is not essential for the development of <e1> methamphetamine </e1>-induced <e2> neurotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3602": {"data": {"text": "We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.", "entity1": "PPA", "entity2": "cerebral infarction", "span1": [106, 109], "span2": [51, 70]}, "bert_text": "We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of <e1> PPA </e1> <e2> cerebral infarction </e2> after taking a single oral dose of PPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3603": {"data": {"text": "The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.", "entity1": "cocaine", "entity2": "hyperactivity", "span1": [206, 213], "span2": [181, 194]}, "bert_text": "The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by <e1> cocaine </e1> <e2> hyperactivity </e2> induced by cocaine in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3604": {"data": {"text": "A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.", "entity1": "pethidine", "entity2": "postoperative pain", "span1": [67, 76], "span2": [141, 159]}, "bert_text": "A healthy 17-year-old male received standard intermittent doses of <e1> pethidine </e1> via a patient-controlled analgesia (PCA) pump for management of <e2> postoperative pain </e2> control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3605": {"data": {"text": "These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.", "entity1": "curcumin", "entity2": "cognitive functions", "span1": [24, 32], "span2": [90, 109]}, "bert_text": "These results show that <e1> curcumin </e1> has beneficial effect in mitigating the deterioration of <e2> cognitive functions </e2> and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3606": {"data": {"text": "These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.", "entity1": "phenobarbitone", "entity2": "cognitive functions", "span1": [152, 166], "span2": [90, 109]}, "bert_text": "These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with <e1> phenobarbitone </e1> <e2> cognitive functions </e2> and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3607": {"data": {"text": "These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.", "entity1": "carbamazepine", "entity2": "cognitive functions", "span1": [171, 184], "span2": [90, 109]}, "bert_text": "These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and <e1> carbamazepine </e1> <e2> cognitive functions </e2> and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3608": {"data": {"text": "Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.", "entity1": "perhexiline maleate", "entity2": "Peripheral neuropathy", "span1": [71, 90], "span2": [0, 21]}, "bert_text": "Peripheral neuropathy has been noted as a complication of therapy with <e1> perhexiline maleate </e1> <e2> Peripheral neuropathy </e2> has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3609": {"data": {"text": "Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.", "entity1": "perhexiline maleate", "entity2": "angina pectoris", "span1": [71, 90], "span2": [201, 216]}, "bert_text": "Peripheral neuropathy has been noted as a complication of therapy with <e1> perhexiline maleate </e1>, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of <e2> angina pectoris </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3610": {"data": {"text": "This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.", "entity1": "carbamazepine", "entity2": "epileptic", "span1": [61, 74], "span2": [17, 26]}, "bert_text": "This 22-year-old epileptic woman was treated continuously by <e1> carbamazepine </e1> <e2> epileptic </e2> woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3611": {"data": {"text": "This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.", "entity1": "folic acid", "entity2": "epileptic", "span1": [81, 91], "span2": [17, 26]}, "bert_text": "This 22-year-old epileptic woman was treated continuously by carbamazepine and a <e1> folic acid </e1> <e2> epileptic </e2> woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3612": {"data": {"text": "DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.", "entity1": "benzamide", "entity2": "pheochromocytoma", "span1": [103, 112], "span2": [37, 53]}, "bert_text": "DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted <e1> benzamide </e1> <e2> pheochromocytoma </e2> are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3613": {"data": {"text": "Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.", "entity1": "benzodiazepine", "entity2": "Akathisia", "span1": [32, 46], "span2": [0, 9]}, "bert_text": "Akathisia was controlled by the <e1> benzodiazepine </e1> <e2> Akathisia </e2> was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3614": {"data": {"text": "Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.", "entity1": "lorazepam", "entity2": "Akathisia", "span1": [47, 56], "span2": [0, 9]}, "bert_text": "Akathisia was controlled by the benzodiazepine <e1> lorazepam </e1> <e2> Akathisia </e2> was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3615": {"data": {"text": "Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.", "entity1": "diphenylhydantoin", "entity2": "hemiparesis", "span1": [47, 64], "span2": [10, 21]}, "bert_text": "Transient hemiparesis: a rare manifestation of <e1> diphenylhydantoin </e1> <e2> hemiparesis </e2>: a rare manifestation of diphenylhydantoin toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3616": {"data": {"text": "Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.", "entity1": "diphenylhydantoin", "entity2": "toxicity", "span1": [47, 64], "span2": [65, 73]}, "bert_text": "Transient hemiparesis: a rare manifestation of <e1> diphenylhydantoin </e1> <e2> toxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3617": {"data": {"text": "These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [107, 118], "span2": [127, 136]}, "bert_text": "These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence <e1> haloperidol </e1>-induced <e2> catalepsy </e2> and participate in the regulation of motor activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3618": {"data": {"text": "When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.", "entity1": "ACh", "entity2": "convulsions", "span1": [17, 20], "span2": [70, 81]}, "bert_text": "When hippocampal <e1> ACh </e1> was measured during testing for handling-induced <e2> convulsions </e2>, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3619": {"data": {"text": "When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.", "entity1": "ACh", "entity2": "convulsions", "span1": [97, 100], "span2": [70, 81]}, "bert_text": "When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular <e1> ACh </e1> <e2> convulsions </e2>, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"3620": {"data": {"text": "Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.", "entity1": "DA", "entity2": "neurotoxicity", "span1": [75, 77], "span2": [91, 104]}, "bert_text": "Further, we show that mice genetically engineered to be deficient in brain <e1> DA </e1> develop METH <e2> neurotoxicity </e2>, as long as the thermic effects of METH are preserved.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3621": {"data": {"text": "Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.", "entity1": "METH", "entity2": "neurotoxicity", "span1": [86, 90], "span2": [91, 104]}, "bert_text": "Further, we show that mice genetically engineered to be deficient in brain DA develop <e1> METH </e1> <e2> neurotoxicity </e2>, as long as the thermic effects of METH are preserved.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3622": {"data": {"text": "Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.", "entity1": "METH", "entity2": "neurotoxicity", "span1": [140, 144], "span2": [91, 104]}, "bert_text": "Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of <e1> METH </e1> <e2> neurotoxicity </e2>, as long as the thermic effects of METH are preserved.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3623": {"data": {"text": "Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.\n", "entity1": "azidothymidine", "entity2": "anemia", "span1": [65, 79], "span2": [88, 94]}, "bert_text": "Antagonism between interleukin 3 and erythropoietin in mice with <e1> azidothymidine </e1>-induced <e2> anemia </e2> and in bone marrow endothelial cells.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3624": {"data": {"text": "Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.", "entity1": "ribavirin", "entity2": "hemolysis", "span1": [9, 18], "span2": [161, 170]}, "bert_text": "Recently <e1> ribavirin </e1> has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute <e2> hemolysis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3625": {"data": {"text": "Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.", "entity1": "sunitinib", "entity2": "hemolysis", "span1": [106, 115], "span2": [161, 170]}, "bert_text": "Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as <e1> sunitinib </e1> and sorafenib have been found to cause acute <e2> hemolysis </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3626": {"data": {"text": "Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.", "entity1": "sorafenib", "entity2": "hemolysis", "span1": [120, 129], "span2": [161, 170]}, "bert_text": "Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and <e1> sorafenib </e1> have been found to cause acute <e2> hemolysis </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3627": {"data": {"text": "In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).", "entity1": "iopamidol", "entity2": "diabetes", "span1": [92, 101], "span2": [17, 25]}, "bert_text": "In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with <e1> iopamidol </e1> <e2> diabetes </e2>, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3628": {"data": {"text": "In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).", "entity1": "iodixanol", "entity2": "diabetes", "span1": [137, 146], "span2": [17, 25]}, "bert_text": "In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with <e1> iodixanol </e1> <e2> diabetes </e2>, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3629": {"data": {"text": "We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.", "entity1": "pegylated interferon alpha 2a", "entity2": "anemia", "span1": [279, 308], "span2": [184, 190]}, "bert_text": "We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by <e1> pegylated interferon alpha 2a </e1> <e2> anemia </e2>. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3630": {"data": {"text": "We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.", "entity1": "pegylated interferon alpha 2a", "entity2": "chronically infected with hepatitis C virus", "span1": [279, 308], "span2": [219, 262]}, "bert_text": "We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by <e1> pegylated interferon alpha 2a </e1> <e2> chronically infected with hepatitis C virus </e2> were treated by pegylated interferon alpha 2a and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3631": {"data": {"text": "We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.", "entity1": "ribavirin", "entity2": "anemia", "span1": [313, 322], "span2": [184, 190]}, "bert_text": "We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and <e1> ribavirin </e1> <e2> anemia </e2>. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3632": {"data": {"text": "We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.", "entity1": "ribavirin", "entity2": "chronically infected with hepatitis C virus", "span1": [313, 322], "span2": [219, 262]}, "bert_text": "We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and <e1> ribavirin </e1> <e2> chronically infected with hepatitis C virus </e2> were treated by pegylated interferon alpha 2a and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3633": {"data": {"text": "Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.\n", "entity1": "methamphetamine", "entity2": "neurotoxicity", "span1": [15, 30], "span2": [66, 79]}, "bert_text": "Attenuation of <e1> methamphetamine </e1>-induced nigrostriatal dopaminergic <e2> neurotoxicity </e2> in mice by lipopolysaccharide pretreatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3634": {"data": {"text": "Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.\n", "entity1": "lipopolysaccharide", "entity2": "neurotoxicity", "span1": [91, 109], "span2": [66, 79]}, "bert_text": "Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by <e1> lipopolysaccharide </e1> <e2> neurotoxicity </e2> in mice by lipopolysaccharide pretreatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3635": {"data": {"text": "We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.", "entity1": "amphotericin", "entity2": "acute renal failure", "span1": [16, 28], "span2": [147, 166]}, "bert_text": "We propose that <e1> amphotericin </e1>, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to <e2> acute renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3636": {"data": {"text": "Serotonin syndrome from venlafaxine-tranylcypromine interaction.\n", "entity1": "venlafaxine", "entity2": "Serotonin syndrome", "span1": [24, 35], "span2": [0, 18]}, "bert_text": "Serotonin syndrome from <e1> venlafaxine </e1> <e2> Serotonin syndrome </e2> from venlafaxine-tranylcypromine interaction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3637": {"data": {"text": "Serotonin syndrome from venlafaxine-tranylcypromine interaction.\n", "entity1": "tranylcypromine", "entity2": "Serotonin syndrome", "span1": [36, 51], "span2": [0, 18]}, "bert_text": "Serotonin syndrome from venlafaxine-<e1> tranylcypromine </e1> <e2> Serotonin syndrome </e2> from venlafaxine-tranylcypromine interaction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3638": {"data": {"text": "Cardiac toxicity of 5-fluorouracil.", "entity1": "5-fluorouracil", "entity2": "Cardiac toxicity", "span1": [20, 34], "span2": [0, 16]}, "bert_text": "Cardiac toxicity of <e1> 5-fluorouracil </e1> <e2> Cardiac toxicity </e2> of 5-fluorouracil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3639": {"data": {"text": "Busulfan-induced hemorrhagic cystitis.\n", "entity1": "Busulfan", "entity2": "hemorrhagic cystitis", "span1": [0, 8], "span2": [17, 37]}, "bert_text": "<e1> Busulfan </e1>-induced <e2> hemorrhagic cystitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3640": {"data": {"text": "Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.\n", "entity1": "Curcumin", "entity2": "cognitive dysfunction", "span1": [0, 8], "span2": [21, 42]}, "bert_text": "<e1> Curcumin </e1> ameliorates <e2> cognitive dysfunction </e2> and oxidative damage in phenobarbitone and carbamazepine administered rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3641": {"data": {"text": "Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.\n", "entity1": "phenobarbitone", "entity2": "cognitive dysfunction", "span1": [67, 81], "span2": [21, 42]}, "bert_text": "Curcumin ameliorates cognitive dysfunction and oxidative damage in <e1> phenobarbitone </e1> <e2> cognitive dysfunction </e2> and oxidative damage in phenobarbitone and carbamazepine administered rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3642": {"data": {"text": "Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.\n", "entity1": "carbamazepine", "entity2": "cognitive dysfunction", "span1": [86, 99], "span2": [21, 42]}, "bert_text": "Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and <e1> carbamazepine </e1> <e2> cognitive dysfunction </e2> and oxidative damage in phenobarbitone and carbamazepine administered rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3643": {"data": {"text": "RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).", "entity1": "raloxifene", "entity2": "venous thromboembolism", "span1": [47, 57], "span2": [100, 122]}, "bert_text": "RESULTS: During a mean follow-up of 3.3 years, <e1> raloxifene </e1> was associated with an increased risk for <e2> venous thromboembolism </e2> (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3644": {"data": {"text": "In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.", "entity1": "amisulpride", "entity2": "hypertensive", "span1": [120, 131], "span2": [96, 108]}, "bert_text": "In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and <e1> amisulpride </e1> <e2> hypertensive </e2> crisis and amisulpride and tiapride therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3645": {"data": {"text": "In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.", "entity1": "tiapride", "entity2": "hypertensive", "span1": [136, 144], "span2": [96, 108]}, "bert_text": "In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and <e1> tiapride </e1> <e2> hypertensive </e2> crisis and amisulpride and tiapride therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3646": {"data": {"text": "5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.", "entity1": "norepinephrine", "entity2": "bradycardia", "span1": [101, 115], "span2": [86, 97]}, "bert_text": "5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to <e1> norepinephrine </e1> <e2> bradycardia </e2> to norepinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3647": {"data": {"text": "Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.", "entity1": "ammonium acetate", "entity2": "incoordination", "span1": [18, 34], "span2": [172, 186]}, "bert_text": "Pretreatment with <e1> ammonium acetate </e1> (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular <e2> incoordination </e2> by diazepam, but NH4Ac treatment alone had no effect.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3648": {"data": {"text": "Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.", "entity1": "NH4Ac", "entity2": "incoordination", "span1": [36, 41], "span2": [172, 186]}, "bert_text": "Pretreatment with ammonium acetate (<e1> NH4Ac </e1>) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular <e2> incoordination </e2> by diazepam, but NH4Ac treatment alone had no effect.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3649": {"data": {"text": "Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.", "entity1": "NH4Ac", "entity2": "incoordination", "span1": [204, 209], "span2": [172, 186]}, "bert_text": "Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but <e1> NH4Ac </e1> <e2> incoordination </e2> by diazepam, but NH4Ac treatment alone had no effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3650": {"data": {"text": "Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.", "entity1": "morphine", "entity2": "incoordination", "span1": [91, 99], "span2": [172, 186]}, "bert_text": "Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time <e1> morphine </e1>-treated mice remained on a hot surface and similarly increased muscular <e2> incoordination </e2> by diazepam, but NH4Ac treatment alone had no effect.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3651": {"data": {"text": "Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.", "entity1": "diazepam", "entity2": "incoordination", "span1": [190, 198], "span2": [172, 186]}, "bert_text": "Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by <e1> diazepam </e1> <e2> incoordination </e2> by diazepam, but NH4Ac treatment alone had no effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3652": {"data": {"text": "A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [65, 76], "span2": [85, 93]}, "bert_text": "A comparable overexpression of Pgp in the BBB was obtained after <e1> pilocarpine </e1>-induced <e2> seizures </e2> in wild-type Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3653": {"data": {"text": "The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.", "entity1": "CM", "entity2": "cyanosis", "span1": [73, 75], "span2": [100, 108]}, "bert_text": "The incidence depends on dosage but not on the type of consumed nonionic <e1> CM </e1>, nor on the presence of <e2> cyanosis </e2>, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3654": {"data": {"text": "The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.", "entity1": "CM", "entity2": "CIN", "span1": [73, 75], "span2": [123, 126]}, "bert_text": "The incidence depends on dosage but not on the type of consumed nonionic <e1> CM </e1>, nor on the presence of cyanosis, and although <e2> CIN </e2> usually is reversible, more concern is needed for the prevention of such a complication in children.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3655": {"data": {"text": "A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.", "entity1": "NAA", "entity2": "hepatitis", "span1": [56, 59], "span2": [27, 36]}, "bert_text": "A further 64% reduction of hepatitis was observed, when <e1> NAA </e1> <e2> hepatitis </e2> was observed, when NAA was given to ethanol/AAP-mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3656": {"data": {"text": "A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.", "entity1": "ethanol", "entity2": "hepatitis", "span1": [73, 80], "span2": [27, 36]}, "bert_text": "A further 64% reduction of hepatitis was observed, when NAA was given to <e1> ethanol </e1> <e2> hepatitis </e2> was observed, when NAA was given to ethanol/AAP-mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3657": {"data": {"text": "A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.", "entity1": "AAP", "entity2": "hepatitis", "span1": [81, 84], "span2": [27, 36]}, "bert_text": "A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/<e1> AAP </e1> <e2> hepatitis </e2> was observed, when NAA was given to ethanol/AAP-mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3658": {"data": {"text": "The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.", "entity1": "amphotericin B", "entity2": "nephrotoxic", "span1": [29, 43], "span2": [4, 15]}, "bert_text": "The nephrotoxic potential of <e1> amphotericin B </e1> <e2> nephrotoxic </e2> potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3659": {"data": {"text": "The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.", "entity1": "cyclophosphamide", "entity2": "anemia", "span1": [147, 163], "span2": [51, 57]}, "bert_text": "The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of <e1> cyclophosphamide </e1> <e2> anemia </e2> prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3660": {"data": {"text": "The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.", "entity1": "cyclophosphamide", "entity2": "cytotoxicity", "span1": [147, 163], "span2": [131, 143]}, "bert_text": "The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of <e1> cyclophosphamide </e1> <e2> cytotoxicity </e2> of cyclophosphamide in solid experimental tumors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"3661": {"data": {"text": "The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.", "entity1": "cyclophosphamide", "entity2": "tumors", "span1": [147, 163], "span2": [186, 192]}, "bert_text": "The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of <e1> cyclophosphamide </e1> in solid experimental <e2> tumors </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"3662": {"data": {"text": "This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.", "entity1": "dexamethasone", "entity2": "glomerular number", "span1": [31, 44], "span2": [79, 96]}, "bert_text": "This study shows that prenatal <e1> dexamethasone </e1> in rats results in a reduction in <e2> glomerular number </e2>, glomerulosclerosis, and hypertension when administered at specific points during gestation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3663": {"data": {"text": "This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.", "entity1": "dexamethasone", "entity2": "glomerulosclerosis", "span1": [31, 44], "span2": [98, 116]}, "bert_text": "This study shows that prenatal <e1> dexamethasone </e1> in rats results in a reduction in glomerular number, <e2> glomerulosclerosis </e2>, and hypertension when administered at specific points during gestation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3664": {"data": {"text": "This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.", "entity1": "dexamethasone", "entity2": "hypertension", "span1": [31, 44], "span2": [122, 134]}, "bert_text": "This study shows that prenatal <e1> dexamethasone </e1> in rats results in a reduction in glomerular number, glomerulosclerosis, and <e2> hypertension </e2> when administered at specific points during gestation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3665": {"data": {"text": "Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.", "entity1": "histamine", "entity2": "ulcer", "span1": [53, 62], "span2": [137, 142]}, "bert_text": "Gastric acid back-diffusion, mucosal LPO generation, <e1> histamine </e1> concentration, microvascular permeability, luminal hemoglobin content and <e2> ulcer </e2> areas were determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3666": {"data": {"text": "Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.", "entity1": "luminal", "entity2": "ulcer", "span1": [106, 113], "span2": [137, 142]}, "bert_text": "Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, <e1> luminal </e1> hemoglobin content and <e2> ulcer </e2> areas were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3667": {"data": {"text": "Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses.", "entity1": "Ketamine", "entity2": "pain", "span1": [0, 8], "span2": [61, 65]}, "bert_text": "<e1> Ketamine </e1>, but not saline solution, significantly reduced the <e2> pain </e2> intensity in almost all the patients at both doses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3668": {"data": {"text": "In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.", "entity1": "heparin", "entity2": "ICH", "span1": [47, 54], "span2": [3, 6]}, "bert_text": "In ICH induction using 0.014-unit collagenase, <e1> heparin </e1> <e2> ICH </e2> induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3669": {"data": {"text": "In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.", "entity1": "heparin", "entity2": "ICH", "span1": [47, 54], "span2": [119, 122]}, "bert_text": "In ICH induction using 0.014-unit collagenase, <e1> heparin </e1> enhanced the hematoma volume 3.4-fold over that seen in control <e2> ICH </e2> animals and the bleeding 7.6-fold.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3670": {"data": {"text": "In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.", "entity1": "heparin", "entity2": "hematoma", "span1": [47, 54], "span2": [68, 76]}, "bert_text": "In ICH induction using 0.014-unit collagenase, <e1> heparin </e1> enhanced the <e2> hematoma </e2> volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3671": {"data": {"text": "In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.", "entity1": "heparin", "entity2": "bleeding", "span1": [47, 54], "span2": [139, 147]}, "bert_text": "In ICH induction using 0.014-unit collagenase, <e1> heparin </e1> enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the <e2> bleeding </e2> 7.6-fold.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3672": {"data": {"text": "The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.", "entity1": "cholesterol", "entity2": "diabetes", "span1": [67, 78], "span2": [57, 65]}, "bert_text": "The association remained after additional adjustment for diabetes, <e1> cholesterol </e1> <e2> diabetes </e2>, cholesterol level, systolic blood pressure, or alcohol use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3673": {"data": {"text": "The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.", "entity1": "alcohol", "entity2": "diabetes", "span1": [114, 121], "span2": [57, 65]}, "bert_text": "The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or <e1> alcohol </e1> <e2> diabetes </e2>, cholesterol level, systolic blood pressure, or alcohol use.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3674": {"data": {"text": "The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.", "entity1": "gamma-HCH", "entity2": "seizure", "span1": [100, 109], "span2": [72, 79]}, "bert_text": "The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after <e1> gamma-HCH </e1> <e2> seizure </e2> activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3675": {"data": {"text": "The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.", "entity1": "GABA", "entity2": "seizure", "span1": [121, 125], "span2": [72, 79]}, "bert_text": "The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the <e1> GABA </e1> <e2> seizure </e2> activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3676": {"data": {"text": "The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.", "entity1": "chloride", "entity2": "seizure", "span1": [144, 152], "span2": [72, 79]}, "bert_text": "The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked <e1> chloride </e1> <e2> seizure </e2> activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3677": {"data": {"text": "Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).", "entity1": "GTN", "entity2": "Headache", "span1": [90, 93], "span2": [0, 8]}, "bert_text": "Headache was more severe in migraineurs than in the controls during and immediately after <e1> GTN </e1> <e2> Headache </e2> was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3678": {"data": {"text": "Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).", "entity1": "GTN", "entity2": "migraineurs", "span1": [90, 93], "span2": [28, 39]}, "bert_text": "Headache was more severe in migraineurs than in the controls during and immediately after <e1> GTN </e1> <e2> migraineurs </e2> than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3679": {"data": {"text": "Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.\n", "entity1": "Metformin", "entity2": "nephropathy", "span1": [0, 9], "span2": [51, 62]}, "bert_text": "<e1> Metformin </e1> prevents experimental gentamicin-induced <e2> nephropathy </e2> by a mitochondria-dependent pathway.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3680": {"data": {"text": "Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.\n", "entity1": "gentamicin", "entity2": "nephropathy", "span1": [32, 42], "span2": [51, 62]}, "bert_text": "Metformin prevents experimental <e1> gentamicin </e1>-induced <e2> nephropathy </e2> by a mitochondria-dependent pathway.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3681": {"data": {"text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "entity1": "lamivudine", "entity2": "cancer", "span1": [133, 143], "span2": [15, 21]}, "bert_text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent <e1> lamivudine </e1> <e2> cancer </e2> patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3682": {"data": {"text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "entity1": "lamivudine", "entity2": "hematological malignancies", "span1": [133, 143], "span2": [50, 76]}, "bert_text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent <e1> lamivudine </e1> <e2> hematological malignancies </e2> with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3683": {"data": {"text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "entity1": "lamivudine", "entity2": "HBV infection", "span1": [133, 143], "span2": [90, 103]}, "bert_text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent <e1> lamivudine </e1> <e2> HBV infection </e2> received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3684": {"data": {"text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "entity1": "lamivudine", "entity2": "cancer", "span1": [223, 233], "span2": [15, 21]}, "bert_text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive <e1> lamivudine </e1> <e2> cancer </e2> patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3685": {"data": {"text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "entity1": "lamivudine", "entity2": "hematological malignancies", "span1": [223, 233], "span2": [50, 76]}, "bert_text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive <e1> lamivudine </e1> <e2> hematological malignancies </e2> with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3686": {"data": {"text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "entity1": "lamivudine", "entity2": "HBV infection", "span1": [223, 233], "span2": [90, 103]}, "bert_text": "In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive <e1> lamivudine </e1> <e2> HBV infection </e2> received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3687": {"data": {"text": "He assumed pravastatin (20 mg/day) because of hypercholesterolemia.", "entity1": "pravastatin", "entity2": "hypercholesterolemia", "span1": [11, 22], "span2": [46, 66]}, "bert_text": "He assumed <e1> pravastatin </e1> (20 mg/day) because of <e2> hypercholesterolemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3688": {"data": {"text": "Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.", "entity1": "Metformin hydrochloride", "entity2": "jaundice", "span1": [0, 23], "span2": [60, 68]}, "bert_text": "<e1> Metformin hydrochloride </e1> was discontinued, and the patient's <e2> jaundice </e2> resolved slowly over a period of several months.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3689": {"data": {"text": "Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.\n", "entity1": "Antituberculosis", "entity2": "acute liver failure", "span1": [0, 16], "span2": [33, 52]}, "bert_text": "<e1> Antituberculosis </e1> therapy-induced <e2> acute liver failure </e2>: magnitude, profile, prognosis, and predictors of outcome.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3690": {"data": {"text": "We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.", "entity1": "D-penicillamine", "entity2": "primary biliary cirrhosis", "span1": [95, 110], "span2": [25, 50]}, "bert_text": "We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving <e1> D-penicillamine </e1> <e2> primary biliary cirrhosis </e2>, who developed polymyositis while receiving D-penicillamine therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3691": {"data": {"text": "We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.", "entity1": "D-penicillamine", "entity2": "polymyositis", "span1": [95, 110], "span2": [66, 78]}, "bert_text": "We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving <e1> D-penicillamine </e1> <e2> polymyositis </e2> while receiving D-penicillamine therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3692": {"data": {"text": "The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<", "entity1": "etoricoxib", "entity2": "GI", "span1": [79, 89], "span2": [43, 45]}, "bert_text": "The cumulative discontinuation rate due to GI AEs was significantly lower with <e1> etoricoxib </e1> <e2> GI </e2> AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3693": {"data": {"text": "The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<", "entity1": "diclofenac", "entity2": "GI", "span1": [95, 105], "span2": [43, 45]}, "bert_text": "The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than <e1> diclofenac </e1> <e2> GI </e2> AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3694": {"data": {"text": "The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.", "entity1": "prilocaine", "entity2": "hearing loss", "span1": [70, 80], "span2": [12, 24]}, "bert_text": "The average hearing loss for speech frequencies was about 10 dB after <e1> prilocaine </e1> <e2> hearing loss </e2> for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3695": {"data": {"text": "The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.", "entity1": "bupivacaine", "entity2": "hearing loss", "span1": [97, 108], "span2": [12, 24]}, "bert_text": "The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after <e1> bupivacaine </e1> <e2> hearing loss </e2> for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3696": {"data": {"text": "We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.", "entity1": "androgens", "entity2": "obstructive sleep apnea", "span1": [238, 247], "span2": [179, 202]}, "bert_text": "We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous <e1> androgens </e1> <e2> obstructive sleep apnea </e2> while being administered exogenous androgens.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3697": {"data": {"text": "The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.", "entity1": "gamma-aminobutyric acid", "entity2": "absence epilepsy", "span1": [4, 27], "span2": [133, 149]}, "bert_text": "The <e1> gamma-aminobutyric acid </e1>-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the <e2> absence epilepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3698": {"data": {"text": "CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.", "entity1": "sirolimus", "entity2": "fever", "span1": [39, 48], "span2": [57, 62]}, "bert_text": "CONCLUSIONS: Severe adverse effects of <e1> sirolimus </e1> include <e2> fever </e2>, anemia, and capillary leak syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3699": {"data": {"text": "CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.", "entity1": "sirolimus", "entity2": "anemia", "span1": [39, 48], "span2": [64, 70]}, "bert_text": "CONCLUSIONS: Severe adverse effects of <e1> sirolimus </e1> include fever, <e2> anemia </e2>, and capillary leak syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3700": {"data": {"text": "CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.", "entity1": "sirolimus", "entity2": "capillary leak syndrome", "span1": [39, 48], "span2": [76, 99]}, "bert_text": "CONCLUSIONS: Severe adverse effects of <e1> sirolimus </e1> include fever, anemia, and <e2> capillary leak syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3701": {"data": {"text": "After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.", "entity1": "dexamethasone", "entity2": "neurological dysfunctions", "span1": [6, 19], "span2": [70, 95]}, "bert_text": "After <e1> dexamethasone </e1> treatment, children showed a higher rate of minor <e2> neurological dysfunctions </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3702": {"data": {"text": "In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.", "entity1": "GTN", "entity2": "headache", "span1": [21, 24], "span2": [33, 41]}, "bert_text": "In the controls, the <e1> GTN </e1>-induced <e2> headache </e2> gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3703": {"data": {"text": "In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.", "entity1": "GTN", "entity2": "headache", "span1": [21, 24], "span2": [93, 101]}, "bert_text": "In the controls, the <e1> GTN </e1>-induced headache gradually disappeared, whereas in migraineurs peak <e2> headache </e2> intensity occurred at a mean time of 240 min post-infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3704": {"data": {"text": "In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.", "entity1": "GTN", "entity2": "migraineurs", "span1": [21, 24], "span2": [76, 87]}, "bert_text": "In the controls, the <e1> GTN </e1>-induced headache gradually disappeared, whereas in <e2> migraineurs </e2> peak headache intensity occurred at a mean time of 240 min post-infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3705": {"data": {"text": "In Group I, P induced a moderate and stable glycosuria (3.9 +/-", "entity1": "P", "entity2": "glycosuria", "span1": [12, 13], "span2": [44, 54]}, "bert_text": "In Group I, <e1> P </e1> induced a moderate and stable <e2> glycosuria </e2> (3.9 +/-", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3706": {"data": {"text": "In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.", "entity1": "Ro4368554", "entity2": "memory deficit", "span1": [24, 33], "span2": [129, 143]}, "bert_text": "In conclusion, although <e1> Ro4368554 </e1> did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic <e2> memory deficit </e2>, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3707": {"data": {"text": "In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.", "entity1": "Ro4368554", "entity2": "memory deficit", "span1": [233, 242], "span2": [129, 143]}, "bert_text": "In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by <e1> Ro4368554 </e1> <e2> memory deficit </e2>, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3708": {"data": {"text": "In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.", "entity1": "5-HT(6", "entity2": "memory deficit", "span1": [264, 270], "span2": [129, 143]}, "bert_text": "In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other <e1> 5-HT(6 </e1> <e2> memory deficit </e2>, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3709": {"data": {"text": "In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.", "entity1": "ethopropazine", "entity2": "parkinsonism", "span1": [30, 43], "span2": [92, 104]}, "bert_text": "In a 12-week controlled study <e1> ethopropazine </e1> was compared to benztropine in the treatment of <e2> parkinsonism </e2> induced by fluphenazine enanthate in 60 schizophrenic outpatients.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3710": {"data": {"text": "In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.", "entity1": "ethopropazine", "entity2": "schizophrenic", "span1": [30, 43], "span2": [145, 158]}, "bert_text": "In a 12-week controlled study <e1> ethopropazine </e1> was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 <e2> schizophrenic </e2> outpatients.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3711": {"data": {"text": "In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.", "entity1": "benztropine", "entity2": "parkinsonism", "span1": [60, 71], "span2": [92, 104]}, "bert_text": "In a 12-week controlled study ethopropazine was compared to <e1> benztropine </e1> in the treatment of <e2> parkinsonism </e2> induced by fluphenazine enanthate in 60 schizophrenic outpatients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3712": {"data": {"text": "In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.", "entity1": "benztropine", "entity2": "schizophrenic", "span1": [60, 71], "span2": [145, 158]}, "bert_text": "In a 12-week controlled study ethopropazine was compared to <e1> benztropine </e1> in the treatment of parkinsonism induced by fluphenazine enanthate in 60 <e2> schizophrenic </e2> outpatients.", "weak_labels": [1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3713": {"data": {"text": "In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.", "entity1": "fluphenazine enanthate", "entity2": "parkinsonism", "span1": [116, 138], "span2": [92, 104]}, "bert_text": "In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by <e1> fluphenazine enanthate </e1> <e2> parkinsonism </e2> induced by fluphenazine enanthate in 60 schizophrenic outpatients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3714": {"data": {"text": "In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.", "entity1": "fluphenazine enanthate", "entity2": "schizophrenic", "span1": [116, 138], "span2": [145, 158]}, "bert_text": "In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by <e1> fluphenazine enanthate </e1> in 60 <e2> schizophrenic </e2> outpatients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3715": {"data": {"text": "Age-dependent sensitivity of the rat to neurotoxic effects of streptomycin.\n", "entity1": "streptomycin", "entity2": "neurotoxic", "span1": [62, 74], "span2": [40, 50]}, "bert_text": "Age-dependent sensitivity of the rat to neurotoxic effects of <e1> streptomycin </e1> <e2> neurotoxic </e2> effects of streptomycin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3716": {"data": {"text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "entity1": "CPA", "entity2": "VTE", "span1": [86, 89], "span2": [55, 58]}, "bert_text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of <e1> CPA </e1> <e2> VTE </e2> associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"3717": {"data": {"text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "entity1": "CPA", "entity2": "acne", "span1": [86, 89], "span2": [107, 111]}, "bert_text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of <e1> CPA </e1>/EE in women with <e2> acne </e2>, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3718": {"data": {"text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "entity1": "CPA", "entity2": "hirsutism", "span1": [86, 89], "span2": [113, 122]}, "bert_text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of <e1> CPA </e1>/EE in women with acne, <e2> hirsutism </e2> or PCOS although residual confounding by indication cannot be excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3719": {"data": {"text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "entity1": "CPA", "entity2": "PCOS", "span1": [86, 89], "span2": [126, 130]}, "bert_text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of <e1> CPA </e1>/EE in women with acne, hirsutism or <e2> PCOS </e2> although residual confounding by indication cannot be excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3720": {"data": {"text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "entity1": "EE", "entity2": "VTE", "span1": [90, 92], "span2": [55, 58]}, "bert_text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/<e1> EE </e1> <e2> VTE </e2> associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"3721": {"data": {"text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "entity1": "EE", "entity2": "acne", "span1": [90, 92], "span2": [107, 111]}, "bert_text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/<e1> EE </e1> in women with <e2> acne </e2>, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3722": {"data": {"text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "entity1": "EE", "entity2": "hirsutism", "span1": [90, 92], "span2": [113, 122]}, "bert_text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/<e1> EE </e1> in women with acne, <e2> hirsutism </e2> or PCOS although residual confounding by indication cannot be excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3723": {"data": {"text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "entity1": "EE", "entity2": "PCOS", "span1": [90, 92], "span2": [126, 130]}, "bert_text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/<e1> EE </e1> in women with acne, hirsutism or <e2> PCOS </e2> although residual confounding by indication cannot be excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3724": {"data": {"text": "More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [65, 74], "span2": [15, 26]}, "bert_text": "More recently, proteinuria has been reported as a consequence of <e1> sirolimus </e1> <e2> proteinuria </e2> has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3725": {"data": {"text": "Cauda equina syndrome after epidural steroid injection: a case report.\n", "entity1": "steroid", "entity2": "Cauda equina syndrome", "span1": [37, 44], "span2": [0, 21]}, "bert_text": "Cauda equina syndrome after epidural <e1> steroid </e1> <e2> Cauda equina syndrome </e2> after epidural steroid injection: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3726": {"data": {"text": "Catalepsy induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.\n", "entity1": "ketamine", "entity2": "Catalepsy", "span1": [37, 45], "span2": [0, 9]}, "bert_text": "Catalepsy induced by combinations of <e1> ketamine </e1> <e2> Catalepsy </e2> induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3727": {"data": {"text": "Catalepsy induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.\n", "entity1": "morphine", "entity2": "Catalepsy", "span1": [50, 58], "span2": [0, 9]}, "bert_text": "Catalepsy induced by combinations of ketamine and <e1> morphine </e1> <e2> Catalepsy </e2> induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3728": {"data": {"text": "Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.\n", "entity1": "heparin", "entity2": "thromboembolism", "span1": [56, 63], "span2": [9, 24]}, "bert_text": "Arterial thromboembolism in patients receiving systemic <e1> heparin </e1> <e2> thromboembolism </e2> in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3729": {"data": {"text": "Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.\n", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [56, 63], "span2": [120, 136]}, "bert_text": "Arterial thromboembolism in patients receiving systemic <e1> heparin </e1> therapy: a complication associated with heparin-induced <e2> thrombocytopenia </e2>.\n", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3730": {"data": {"text": "Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.\n", "entity1": "heparin", "entity2": "thromboembolism", "span1": [104, 111], "span2": [9, 24]}, "bert_text": "Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with <e1> heparin </e1> <e2> thromboembolism </e2> in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3731": {"data": {"text": "Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.\n", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [104, 111], "span2": [120, 136]}, "bert_text": "Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with <e1> heparin </e1>-induced <e2> thrombocytopenia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3732": {"data": {"text": "Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.\n", "entity1": "ampicillin", "entity2": "Erythema multiforme", "span1": [63, 73], "span2": [0, 19]}, "bert_text": "Erythema multiforme and hypersensitivity myocarditis caused by <e1> ampicillin </e1> <e2> Erythema multiforme </e2> and hypersensitivity myocarditis caused by ampicillin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3733": {"data": {"text": "Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.\n", "entity1": "ampicillin", "entity2": "hypersensitivity myocarditis", "span1": [63, 73], "span2": [24, 52]}, "bert_text": "Erythema multiforme and hypersensitivity myocarditis caused by <e1> ampicillin </e1> <e2> hypersensitivity myocarditis </e2> caused by ampicillin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3734": {"data": {"text": "However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.", "entity1": "BZDs", "entity2": "dizziness", "span1": [16, 20], "span2": [45, 54]}, "bert_text": "However, use of <e1> BZDs </e1>/RDs was associated with <e2> dizziness </e2>, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3735": {"data": {"text": "However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.", "entity1": "BZDs", "entity2": "depressive symptoms", "span1": [16, 20], "span2": [181, 200]}, "bert_text": "However, use of <e1> BZDs </e1>/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger <e2> depressive symptoms </e2> measured at the beginning of the hospital stay.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3736": {"data": {"text": "Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.\n", "entity1": "Atorvastatin", "entity2": "hypertension", "span1": [0, 12], "span2": [58, 70]}, "bert_text": "<e1> Atorvastatin </e1> prevented and reversed dexamethasone-induced <e2> hypertension </e2> in the rat.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3737": {"data": {"text": "Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.\n", "entity1": "dexamethasone", "entity2": "hypertension", "span1": [36, 49], "span2": [58, 70]}, "bert_text": "Atorvastatin prevented and reversed <e1> dexamethasone </e1>-induced <e2> hypertension </e2> in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3738": {"data": {"text": "Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.", "entity1": "sirolimus", "entity2": "nephrotoxic", "span1": [8, 17], "span2": [136, 147]}, "bert_text": "Because <e1> sirolimus </e1> does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-<e2> nephrotoxic </e2> drug'.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3739": {"data": {"text": "CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.", "entity1": "fluconazole", "entity2": "TDP", "span1": [45, 56], "span2": [131, 134]}, "bert_text": "CONCLUSIONS: Clinicians should be aware that <e1> fluconazole </e1>, even at low doses, may cause prolongation of the QT interval, leading to <e2> TDP </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3740": {"data": {"text": "These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.", "entity1": "edaravone", "entity2": "vestibulotoxicity", "span1": [27, 36], "span2": [69, 86]}, "bert_text": "These results suggest that <e1> edaravone </e1> suppresses streptomycin-induced <e2> vestibulotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3741": {"data": {"text": "These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.", "entity1": "streptomycin", "entity2": "vestibulotoxicity", "span1": [48, 60], "span2": [69, 86]}, "bert_text": "These results suggest that edaravone suppresses <e1> streptomycin </e1>-induced <e2> vestibulotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3742": {"data": {"text": "DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.", "entity1": "P", "entity2": "DM", "span1": [63, 64], "span2": [0, 2]}, "bert_text": "DM rats with mild glycosuria (similar in degree to that of the <e1> P </e1> <e2> DM </e2> rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3743": {"data": {"text": "DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.", "entity1": "P", "entity2": "glycosuria", "span1": [63, 64], "span2": [18, 28]}, "bert_text": "DM rats with mild glycosuria (similar in degree to that of the <e1> P </e1> <e2> glycosuria </e2> (similar in degree to that of the P treated animals) were also studied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3744": {"data": {"text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "entity1": "ASA", "entity2": "ventricular septal defects", "span1": [272, 275], "span2": [55, 81]}, "bert_text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though <e1> ASA </e1> <e2> ventricular septal defects </e2> (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3745": {"data": {"text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "entity1": "ASA", "entity2": "VSDs", "span1": [272, 275], "span2": [83, 87]}, "bert_text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though <e1> ASA </e1> <e2> VSDs </e2>) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3746": {"data": {"text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "entity1": "ASA", "entity2": "VSDs", "span1": [272, 275], "span2": [163, 167]}, "bert_text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though <e1> ASA </e1> <e2> VSDs </e2> in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3747": {"data": {"text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "entity1": "ASA", "entity2": "midline defects", "span1": [272, 275], "span2": [93, 108]}, "bert_text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though <e1> ASA </e1> <e2> midline defects </e2> (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3748": {"data": {"text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "entity1": "ASA", "entity2": "MDs", "span1": [272, 275], "span2": [110, 113]}, "bert_text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though <e1> ASA </e1> <e2> MDs </e2>) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3749": {"data": {"text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "entity1": "ASA", "entity2": "MDs", "span1": [272, 275], "span2": [154, 157]}, "bert_text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though <e1> ASA </e1> <e2> MDs </e2>, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3750": {"data": {"text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "entity1": "ASA", "entity2": "diaphragmatic hernia", "span1": [272, 275], "span2": [127, 147]}, "bert_text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though <e1> ASA </e1> <e2> diaphragmatic hernia </e2> (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3751": {"data": {"text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "entity1": "ASA", "entity2": "DH", "span1": [272, 275], "span2": [149, 151]}, "bert_text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though <e1> ASA </e1> <e2> DH </e2>), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3752": {"data": {"text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "entity1": "ASA", "entity2": "malformations", "span1": [272, 275], "span2": [245, 258]}, "bert_text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though <e1> ASA </e1> <e2> malformations </e2>, even though ASA induces several other low-incidence malformations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3753": {"data": {"text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "entity1": "ASA", "entity2": "malformations", "span1": [272, 275], "span2": [312, 325]}, "bert_text": "The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though <e1> ASA </e1> induces several other low-incidence <e2> malformations </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3754": {"data": {"text": "Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.", "entity1": "Ethopropazine", "entity2": "parkinsonian symptoms", "span1": [0, 13], "span2": [80, 101]}, "bert_text": "<e1> Ethopropazine </e1> and benztropine were found to be equally effective in controlling <e2> parkinsonian symptoms </e2> and were as efficacious as procyclidine, their previous antiparkinsonian drug.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3755": {"data": {"text": "Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.", "entity1": "benztropine", "entity2": "parkinsonian symptoms", "span1": [18, 29], "span2": [80, 101]}, "bert_text": "Ethopropazine and <e1> benztropine </e1> were found to be equally effective in controlling <e2> parkinsonian symptoms </e2> and were as efficacious as procyclidine, their previous antiparkinsonian drug.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3756": {"data": {"text": "Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.", "entity1": "procyclidine", "entity2": "parkinsonian symptoms", "span1": [129, 141], "span2": [80, 101]}, "bert_text": "Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as <e1> procyclidine </e1> <e2> parkinsonian symptoms </e2> and were as efficacious as procyclidine, their previous antiparkinsonian drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3757": {"data": {"text": "Patients receiving D-penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis/dermatomyositis.", "entity1": "D-penicillamine", "entity2": "polymyositis", "span1": [19, 34], "span2": [125, 137]}, "bert_text": "Patients receiving <e1> D-penicillamine </e1> therapy should be followed carefully for the development of autoimmune complications like <e2> polymyositis </e2>/dermatomyositis.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3758": {"data": {"text": "Patients receiving D-penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis/dermatomyositis.", "entity1": "D-penicillamine", "entity2": "dermatomyositis", "span1": [19, 34], "span2": [138, 153]}, "bert_text": "Patients receiving <e1> D-penicillamine </e1> therapy should be followed carefully for the development of autoimmune complications like polymyositis/<e2> dermatomyositis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3759": {"data": {"text": "With regard to spasm, the clinical findings are largely circumstantial, and the locus of cocaine-induced vasoconstriction remains speculative.", "entity1": "cocaine", "entity2": "spasm", "span1": [89, 96], "span2": [15, 20]}, "bert_text": "With regard to spasm, the clinical findings are largely circumstantial, and the locus of <e1> cocaine </e1> <e2> spasm </e2>, the clinical findings are largely circumstantial, and the locus of cocaine-induced vasoconstriction remains speculative.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3760": {"data": {"text": "Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.\n1.", "entity1": "dopamine", "entity2": "catalepsy", "span1": [29, 37], "span2": [59, 68]}, "bert_text": "Blockade of both D-1 and D-2 <e1> dopamine </e1> receptors may induce <e2> catalepsy </e2> in mice.\n1.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3761": {"data": {"text": "Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.", "entity1": "tenofovir", "entity2": "renal failure", "span1": [32, 41], "span2": [64, 77]}, "bert_text": "Clinicians should be aware that <e1> tenofovir </e1> may raise the risk of <e2> renal failure </e2> during prolonged administration of vancomycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3762": {"data": {"text": "Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.", "entity1": "vancomycin", "entity2": "renal failure", "span1": [113, 123], "span2": [64, 77]}, "bert_text": "Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of <e1> vancomycin </e1> <e2> renal failure </e2> during prolonged administration of vancomycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"3763": {"data": {"text": "The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [159, 170], "span2": [4, 18]}, "bert_text": "The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of <e1> doxorubicin </e1> <e2> cardiomyopathy </e2> is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3764": {"data": {"text": "The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.", "entity1": "doxorubicin", "entity2": "Wilms tumor", "span1": [159, 170], "span2": [79, 90]}, "bert_text": "The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of <e1> doxorubicin </e1> <e2> Wilms tumor </e2> include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3765": {"data": {"text": "These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.", "entity1": "PPA", "entity2": "cerebral hemorrhage", "span1": [27, 30], "span2": [52, 71]}, "bert_text": "These results suggest that <e1> PPA </e1>/caffeine can lead to <e2> cerebral hemorrhage </e2> in previously hypertensive animals when administered in greater than the allowed dosage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3766": {"data": {"text": "These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.", "entity1": "PPA", "entity2": "hypertensive", "span1": [27, 30], "span2": [86, 98]}, "bert_text": "These results suggest that <e1> PPA </e1>/caffeine can lead to cerebral hemorrhage in previously <e2> hypertensive </e2> animals when administered in greater than the allowed dosage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3767": {"data": {"text": "These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.", "entity1": "caffeine", "entity2": "cerebral hemorrhage", "span1": [31, 39], "span2": [52, 71]}, "bert_text": "These results suggest that PPA/<e1> caffeine </e1> can lead to <e2> cerebral hemorrhage </e2> in previously hypertensive animals when administered in greater than the allowed dosage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3768": {"data": {"text": "These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.", "entity1": "caffeine", "entity2": "hypertensive", "span1": [31, 39], "span2": [86, 98]}, "bert_text": "These results suggest that PPA/<e1> caffeine </e1> can lead to cerebral hemorrhage in previously <e2> hypertensive </e2> animals when administered in greater than the allowed dosage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3769": {"data": {"text": "Arterial thromboembolism is a recognized complication of systemic heparin therapy.", "entity1": "heparin", "entity2": "thromboembolism", "span1": [66, 73], "span2": [9, 24]}, "bert_text": "Arterial thromboembolism is a recognized complication of systemic <e1> heparin </e1> <e2> thromboembolism </e2> is a recognized complication of systemic heparin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3770": {"data": {"text": "Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.", "entity1": "anthracycline", "entity2": "Wilms tumor", "span1": [68, 81], "span2": [18, 29]}, "bert_text": "Two children with Wilms tumor of the left kidney experienced severe <e1> anthracycline </e1> <e2> Wilms tumor </e2> of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3771": {"data": {"text": "Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.", "entity1": "anthracycline", "entity2": "cardiomyopathy", "span1": [68, 81], "span2": [82, 96]}, "bert_text": "Two children with Wilms tumor of the left kidney experienced severe <e1> anthracycline </e1> <e2> cardiomyopathy </e2> after irradiation to the tumor bed and conventional dosage of doxorubicin.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3772": {"data": {"text": "Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.", "entity1": "anthracycline", "entity2": "tumor", "span1": [68, 81], "span2": [122, 127]}, "bert_text": "Two children with Wilms tumor of the left kidney experienced severe <e1> anthracycline </e1> cardiomyopathy after irradiation to the <e2> tumor </e2> bed and conventional dosage of doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3773": {"data": {"text": "Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.", "entity1": "doxorubicin", "entity2": "Wilms tumor", "span1": [159, 170], "span2": [18, 29]}, "bert_text": "Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of <e1> doxorubicin </e1> <e2> Wilms tumor </e2> of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3774": {"data": {"text": "Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [159, 170], "span2": [82, 96]}, "bert_text": "Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of <e1> doxorubicin </e1> <e2> cardiomyopathy </e2> after irradiation to the tumor bed and conventional dosage of doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3775": {"data": {"text": "Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.", "entity1": "doxorubicin", "entity2": "tumor", "span1": [159, 170], "span2": [122, 127]}, "bert_text": "Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of <e1> doxorubicin </e1> <e2> tumor </e2> bed and conventional dosage of doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3776": {"data": {"text": "Cerebral infarction with a single oral dose of phenylpropanolamine.\n", "entity1": "phenylpropanolamine", "entity2": "Cerebral infarction", "span1": [47, 66], "span2": [0, 19]}, "bert_text": "Cerebral infarction with a single oral dose of <e1> phenylpropanolamine </e1> <e2> Cerebral infarction </e2> with a single oral dose of phenylpropanolamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3777": {"data": {"text": "The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.", "entity1": "dopamine", "entity2": "catalepsy", "span1": [25, 33], "span2": [4, 13]}, "bert_text": "The catalepsy induced by <e1> dopamine </e1> <e2> catalepsy </e2> induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3778": {"data": {"text": "The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.", "entity1": "dopamine", "entity2": "catalepsy", "span1": [25, 33], "span2": [109, 118]}, "bert_text": "The catalepsy induced by <e1> dopamine </e1> antagonists has been tested and the possible dopamine subtypes involved in <e2> catalepsy </e2> was determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3779": {"data": {"text": "The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.", "entity1": "dopamine", "entity2": "catalepsy", "span1": [79, 87], "span2": [4, 13]}, "bert_text": "The catalepsy induced by dopamine antagonists has been tested and the possible <e1> dopamine </e1> <e2> catalepsy </e2> induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3780": {"data": {"text": "The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.", "entity1": "dopamine", "entity2": "catalepsy", "span1": [79, 87], "span2": [109, 118]}, "bert_text": "The catalepsy induced by dopamine antagonists has been tested and the possible <e1> dopamine </e1> subtypes involved in <e2> catalepsy </e2> was determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3781": {"data": {"text": "Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.\n", "entity1": "NAD", "entity2": "hepatotoxicity", "span1": [26, 29], "span2": [58, 72]}, "bert_text": "Influence of diet free of <e1> NAD </e1>-precursors on acetaminophen <e2> hepatotoxicity </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3782": {"data": {"text": "Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.\n", "entity1": "acetaminophen", "entity2": "hepatotoxicity", "span1": [44, 57], "span2": [58, 72]}, "bert_text": "Influence of diet free of NAD-precursors on <e1> acetaminophen </e1> <e2> hepatotoxicity </e2> in mice.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3783": {"data": {"text": "Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.", "entity1": "tamoxifen", "entity2": "endometrial cancer", "span1": [50, 59], "span2": [14, 32]}, "bert_text": "Women who had endometrial cancer and had received <e1> tamoxifen </e1> <e2> endometrial cancer </e2> and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3784": {"data": {"text": "Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.", "entity1": "tamoxifen", "entity2": "endometrial cancer", "span1": [50, 59], "span2": [123, 141]}, "bert_text": "Women who had endometrial cancer and had received <e1> tamoxifen </e1> had more advanced disease and poorer prognosis than those with <e2> endometrial cancer </e2> who had not received this treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3785": {"data": {"text": "In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.", "entity1": "fluconazole", "entity2": "QT prolongation", "span1": [257, 268], "span2": [74, 89]}, "bert_text": "In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests <e1> fluconazole </e1> <e2> QT prolongation </e2> or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3786": {"data": {"text": "In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.", "entity1": "fluconazole", "entity2": "TDP", "span1": [257, 268], "span2": [93, 96]}, "bert_text": "In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests <e1> fluconazole </e1> <e2> TDP </e2> The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3787": {"data": {"text": "In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.", "entity1": "fluconazole", "entity2": "NSVT", "span1": [257, 268], "span2": [127, 131]}, "bert_text": "In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests <e1> fluconazole </e1> <e2> NSVT </e2> and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3788": {"data": {"text": "In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.", "entity1": "fluconazole", "entity2": "premature ventricular contractions", "span1": [257, 268], "span2": [136, 170]}, "bert_text": "In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests <e1> fluconazole </e1> <e2> premature ventricular contractions </e2> followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3789": {"data": {"text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "entity1": "amisulpride", "entity2": "hypertension", "span1": [136, 147], "span2": [56, 68]}, "bert_text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of <e1> amisulpride </e1> <e2> hypertension </e2> with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3790": {"data": {"text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "entity1": "amisulpride", "entity2": "headache", "span1": [136, 147], "span2": [81, 89]}, "bert_text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of <e1> amisulpride </e1> <e2> headache </e2> and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3791": {"data": {"text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "entity1": "amisulpride", "entity2": "vomiting", "span1": [136, 147], "span2": [94, 102]}, "bert_text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of <e1> amisulpride </e1> <e2> vomiting </e2> 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3792": {"data": {"text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "entity1": "tiapride", "entity2": "hypertension", "span1": [159, 167], "span2": [56, 68]}, "bert_text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and <e1> tiapride </e1> <e2> hypertension </e2> with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3793": {"data": {"text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "entity1": "tiapride", "entity2": "headache", "span1": [159, 167], "span2": [81, 89]}, "bert_text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and <e1> tiapride </e1> <e2> headache </e2> and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3794": {"data": {"text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "entity1": "tiapride", "entity2": "vomiting", "span1": [159, 167], "span2": [94, 102]}, "bert_text": ". CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and <e1> tiapride </e1> <e2> vomiting </e2> 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3795": {"data": {"text": "Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.\n", "entity1": "bradykinin", "entity2": "hypertension", "span1": [22, 32], "span2": [100, 112]}, "bert_text": "Role of activation of <e1> bradykinin </e1> B2 receptors in disruption of the blood-brain barrier during acute <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3796": {"data": {"text": "CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.", "entity1": "vigabatrin", "entity2": "visual field constriction", "span1": [75, 85], "span2": [19, 44]}, "bert_text": "CONCLUSION: Marked visual field constriction appears to be associated with <e1> vigabatrin </e1> <e2> visual field constriction </e2> appears to be associated with vigabatrin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3797": {"data": {"text": "The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.", "entity1": "triamcinolone", "entity2": "cauda equina syndrome", "span1": [97, 110], "span2": [34, 55]}, "bert_text": "The following case is a report of cauda equina syndrome possibly caused by epidural injection of <e1> triamcinolone </e1> <e2> cauda equina syndrome </e2> possibly caused by epidural injection of triamcinolone and bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3798": {"data": {"text": "The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.", "entity1": "bupivacaine", "entity2": "cauda equina syndrome", "span1": [115, 126], "span2": [34, 55]}, "bert_text": "The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and <e1> bupivacaine </e1> <e2> cauda equina syndrome </e2> possibly caused by epidural injection of triamcinolone and bupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3799": {"data": {"text": "METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.", "entity1": "bupropion HCl", "entity2": "convulsive", "span1": [85, 98], "span2": [118, 128]}, "bert_text": "METHODS: We investigated the effect of varying the intraperitoneal infusion rates of <e1> bupropion HCl </e1> 120 mg/kg, a known <e2> convulsive </e2> dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3800": {"data": {"text": "METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.", "entity1": "bupropion HCl", "entity2": "convulsions", "span1": [85, 98], "span2": [196, 207]}, "bert_text": "METHODS: We investigated the effect of varying the intraperitoneal infusion rates of <e1> bupropion HCl </e1> 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced <e2> convulsions </e2> in the Swiss albino mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3801": {"data": {"text": "METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.", "entity1": "bupropion", "entity2": "convulsive", "span1": [178, 187], "span2": [118, 128]}, "bert_text": "METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of <e1> bupropion </e1> <e2> convulsive </e2> dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3802": {"data": {"text": "METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.", "entity1": "bupropion", "entity2": "convulsions", "span1": [178, 187], "span2": [196, 207]}, "bert_text": "METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of <e1> bupropion </e1>-induced <e2> convulsions </e2> in the Swiss albino mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3803": {"data": {"text": "Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.\n", "entity1": "penicillamine", "entity2": "Myasthenia gravis", "span1": [28, 41], "span2": [0, 17]}, "bert_text": "Myasthenia gravis caused by <e1> penicillamine </e1> <e2> Myasthenia gravis </e2> caused by penicillamine and chloroquine therapy for rheumatoid arthritis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3804": {"data": {"text": "Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.\n", "entity1": "penicillamine", "entity2": "rheumatoid arthritis", "span1": [28, 41], "span2": [70, 90]}, "bert_text": "Myasthenia gravis caused by <e1> penicillamine </e1> and chloroquine therapy for <e2> rheumatoid arthritis </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3805": {"data": {"text": "Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.\n", "entity1": "chloroquine", "entity2": "Myasthenia gravis", "span1": [46, 57], "span2": [0, 17]}, "bert_text": "Myasthenia gravis caused by penicillamine and <e1> chloroquine </e1> <e2> Myasthenia gravis </e2> caused by penicillamine and chloroquine therapy for rheumatoid arthritis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3806": {"data": {"text": "Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.\n", "entity1": "chloroquine", "entity2": "rheumatoid arthritis", "span1": [46, 57], "span2": [70, 90]}, "bert_text": "Myasthenia gravis caused by penicillamine and <e1> chloroquine </e1> therapy for <e2> rheumatoid arthritis </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3807": {"data": {"text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "entity1": "calcium", "entity2": "hypercalcemia", "span1": [123, 130], "span2": [92, 105]}, "bert_text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum <e1> calcium </e1> <e2> hypercalcemia </e2> (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3808": {"data": {"text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "entity1": "calcium", "entity2": "milk-alkali syndrome", "span1": [123, 130], "span2": [187, 207]}, "bert_text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum <e1> calcium </e1> > or = 14 mg/dL) and review the pertinent literature on <e2> milk-alkali syndrome </e2>. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3809": {"data": {"text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "entity1": "calcium", "entity2": "acute renal insufficiency", "span1": [123, 130], "span2": [237, 262]}, "bert_text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum <e1> calcium </e1> > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had <e2> acute renal insufficiency </e2>, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3810": {"data": {"text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "entity1": "calcium", "entity2": "metabolic alkalosis", "span1": [123, 130], "span2": [273, 292]}, "bert_text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum <e1> calcium </e1> > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative <e2> metabolic alkalosis </e2>, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3811": {"data": {"text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "entity1": "1,25-dihydroxyvitamin", "entity2": "hypercalcemia", "span1": [354, 375], "span2": [92, 105]}, "bert_text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and <e1> 1,25-dihydroxyvitamin </e1> <e2> hypercalcemia </e2> (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3812": {"data": {"text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "entity1": "1,25-dihydroxyvitamin", "entity2": "milk-alkali syndrome", "span1": [354, 375], "span2": [187, 207]}, "bert_text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and <e1> 1,25-dihydroxyvitamin </e1> <e2> milk-alkali syndrome </e2>. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3813": {"data": {"text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "entity1": "1,25-dihydroxyvitamin", "entity2": "acute renal insufficiency", "span1": [354, 375], "span2": [237, 262]}, "bert_text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and <e1> 1,25-dihydroxyvitamin </e1> <e2> acute renal insufficiency </e2>, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3814": {"data": {"text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "entity1": "1,25-dihydroxyvitamin", "entity2": "metabolic alkalosis", "span1": [354, 375], "span2": [273, 292]}, "bert_text": "METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and <e1> 1,25-dihydroxyvitamin </e1> <e2> metabolic alkalosis </e2>, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3815": {"data": {"text": "The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.", "entity1": "MPEP", "entity2": "toxicity", "span1": [65, 69], "span2": [136, 144]}, "bert_text": "The results of this study suggest that the blockade of mGluR5 by <e1> MPEP </e1> may protect dopaminergic neurones against methamphetamine-induced <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3816": {"data": {"text": "The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.", "entity1": "methamphetamine", "entity2": "toxicity", "span1": [112, 127], "span2": [136, 144]}, "bert_text": "The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against <e1> methamphetamine </e1>-induced <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3817": {"data": {"text": "Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.\n", "entity1": "Levodopa", "entity2": "dystonia", "span1": [0, 8], "span2": [31, 39]}, "bert_text": "<e1> Levodopa </e1>-induced oromandibular <e2> dystonia </e2> in progressive supranuclear palsy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3818": {"data": {"text": "Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.\n", "entity1": "Levodopa", "entity2": "supranuclear palsy", "span1": [0, 8], "span2": [55, 73]}, "bert_text": "<e1> Levodopa </e1>-induced oromandibular dystonia in progressive <e2> supranuclear palsy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3819": {"data": {"text": "The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.", "entity1": "sirolimus", "entity2": "acute renal dysfunction", "span1": [44, 53], "span2": [4, 27]}, "bert_text": "The acute renal dysfunction associated with <e1> sirolimus </e1> <e2> acute renal dysfunction </e2> associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3820": {"data": {"text": "However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.", "entity1": "amiodarone", "entity2": "VT", "span1": [164, 174], "span2": [122, 124]}, "bert_text": "However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with <e1> amiodarone </e1> <e2> VT </e2> or VF can be successfully managed with amiodarone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3821": {"data": {"text": "However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.", "entity1": "amiodarone", "entity2": "VF", "span1": [164, 174], "span2": [128, 130]}, "bert_text": "However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with <e1> amiodarone </e1> <e2> VF </e2> can be successfully managed with amiodarone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3822": {"data": {"text": "Finally, the contribution of a primary, thrombotic effect of cocaine has not been excluded.", "entity1": "cocaine", "entity2": "thrombotic", "span1": [61, 68], "span2": [40, 50]}, "bert_text": "Finally, the contribution of a primary, thrombotic effect of <e1> cocaine </e1> <e2> thrombotic </e2> effect of cocaine has not been excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3823": {"data": {"text": "Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.", "entity1": "dipyridamole", "entity2": "Angina", "span1": [87, 99], "span2": [0, 6]}, "bert_text": "Angina and ischemic electrocardiographic changes occurred after administration of oral <e1> dipyridamole </e1> <e2> Angina </e2> and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3824": {"data": {"text": "Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.", "entity1": "dipyridamole", "entity2": "ischemic", "span1": [87, 99], "span2": [11, 19]}, "bert_text": "Angina and ischemic electrocardiographic changes occurred after administration of oral <e1> dipyridamole </e1> <e2> ischemic </e2> electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3825": {"data": {"text": "He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.", "entity1": "pravastatin", "entity2": "myopathy", "span1": [90, 101], "span2": [27, 35]}, "bert_text": "He was admitted with acute myopathy of the lower limbs which resolved in a few days after <e1> pravastatin </e1> <e2> myopathy </e2> of the lower limbs which resolved in a few days after pravastatin discontinuation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3826": {"data": {"text": "Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.\n", "entity1": "Cocaine", "entity2": "mood disorder", "span1": [0, 7], "span2": [16, 29]}, "bert_text": "<e1> Cocaine </e1>-induced <e2> mood disorder </e2>: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3827": {"data": {"text": "Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.\n", "entity1": "Cocaine", "entity2": "psychiatric", "span1": [0, 7], "span2": [52, 63]}, "bert_text": "<e1> Cocaine </e1>-induced mood disorder: prevalence rates and <e2> psychiatric </e2> symptoms in an outpatient cocaine-dependent sample.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3828": {"data": {"text": "Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.\n", "entity1": "cocaine", "entity2": "mood disorder", "span1": [90, 97], "span2": [16, 29]}, "bert_text": "Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient <e1> cocaine </e1> <e2> mood disorder </e2>: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3829": {"data": {"text": "Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.\n", "entity1": "cocaine", "entity2": "psychiatric", "span1": [90, 97], "span2": [52, 63]}, "bert_text": "Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient <e1> cocaine </e1> <e2> psychiatric </e2> symptoms in an outpatient cocaine-dependent sample.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3830": {"data": {"text": "To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [48, 56], "span2": [65, 85]}, "bert_text": "To directly examine the importance of growth to <e1> Warfarin </e1>-induced <e2> artery calcification </e2> in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3831": {"data": {"text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [113, 121], "span2": [46, 65]}, "bert_text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of <e1> levodopa </e1> <e2> Parkinson's disease </e2> and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3832": {"data": {"text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [113, 121], "span2": [164, 175]}, "bert_text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of <e1> levodopa </e1> therapy, particularly to levodopa-induced <e2> dyskinesias </e2> (LID).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3833": {"data": {"text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).", "entity1": "levodopa", "entity2": "LID", "span1": [113, 121], "span2": [177, 180]}, "bert_text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of <e1> levodopa </e1> therapy, particularly to levodopa-induced dyskinesias (<e2> LID </e2>).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3834": {"data": {"text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [147, 155], "span2": [46, 65]}, "bert_text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to <e1> levodopa </e1> <e2> Parkinson's disease </e2> and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3835": {"data": {"text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [147, 155], "span2": [164, 175]}, "bert_text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to <e1> levodopa </e1>-induced <e2> dyskinesias </e2> (LID).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3836": {"data": {"text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).", "entity1": "levodopa", "entity2": "LID", "span1": [147, 155], "span2": [177, 180]}, "bert_text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to <e1> levodopa </e1>-induced dyskinesias (<e2> LID </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3837": {"data": {"text": "It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.", "entity1": "heparin", "entity2": "bruising", "span1": [122, 129], "span2": [59, 67]}, "bert_text": "It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of <e1> heparin </e1> <e2> bruising </e2> and pain following the subcutaneous administration of heparin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3838": {"data": {"text": "It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.", "entity1": "heparin", "entity2": "pain", "span1": [122, 129], "span2": [72, 76]}, "bert_text": "It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of <e1> heparin </e1> <e2> pain </e2> following the subcutaneous administration of heparin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3839": {"data": {"text": "CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.", "entity1": "steroid", "entity2": "low back and right leg pain", "span1": [99, 106], "span2": [44, 71]}, "bert_text": "CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural <e1> steroid </e1> <e2> low back and right leg pain </e2> was scheduled for epidural steroid injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3840": {"data": {"text": "To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.", "entity1": "methylprednisolone", "entity2": "myopathy", "span1": [84, 102], "span2": [156, 164]}, "bert_text": "To our knowledge, this is the first discussion considering the possibility that the <e1> methylprednisolone </e1> recommended by NASCIS may cause acute corticosteroid <e2> myopathy </e2>.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3841": {"data": {"text": "To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.", "entity1": "corticosteroid", "entity2": "myopathy", "span1": [141, 155], "span2": [156, 164]}, "bert_text": "To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute <e1> corticosteroid </e1> <e2> myopathy </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3842": {"data": {"text": "It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.", "entity1": "sevoflurane", "entity2": "convulsive", "span1": [21, 32], "span2": [45, 55]}, "bert_text": "It is suggested that <e1> sevoflurane </e1> reduces the <e2> convulsive </e2> effect of lidocaine toxicity but carries some risk due to circulatory depression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3843": {"data": {"text": "It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.", "entity1": "sevoflurane", "entity2": "toxicity", "span1": [21, 32], "span2": [76, 84]}, "bert_text": "It is suggested that <e1> sevoflurane </e1> reduces the convulsive effect of lidocaine <e2> toxicity </e2> but carries some risk due to circulatory depression.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3844": {"data": {"text": "It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.", "entity1": "sevoflurane", "entity2": "depression", "span1": [21, 32], "span2": [126, 136]}, "bert_text": "It is suggested that <e1> sevoflurane </e1> reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory <e2> depression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3845": {"data": {"text": "It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.", "entity1": "lidocaine", "entity2": "convulsive", "span1": [66, 75], "span2": [45, 55]}, "bert_text": "It is suggested that sevoflurane reduces the convulsive effect of <e1> lidocaine </e1> <e2> convulsive </e2> effect of lidocaine toxicity but carries some risk due to circulatory depression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3846": {"data": {"text": "It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.", "entity1": "lidocaine", "entity2": "toxicity", "span1": [66, 75], "span2": [76, 84]}, "bert_text": "It is suggested that sevoflurane reduces the convulsive effect of <e1> lidocaine </e1> <e2> toxicity </e2> but carries some risk due to circulatory depression.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3847": {"data": {"text": "It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.", "entity1": "lidocaine", "entity2": "depression", "span1": [66, 75], "span2": [126, 136]}, "bert_text": "It is suggested that sevoflurane reduces the convulsive effect of <e1> lidocaine </e1> toxicity but carries some risk due to circulatory <e2> depression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3848": {"data": {"text": "Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.", "entity1": "mexiletine", "entity2": "tremor", "span1": [113, 123], "span2": [49, 55]}, "bert_text": "Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the <e1> mexiletine </e1> <e2> tremor </e2> and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3849": {"data": {"text": "Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.", "entity1": "mexiletine", "entity2": "gastrointestinal problems", "span1": [113, 123], "span2": [60, 85]}, "bert_text": "Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the <e1> mexiletine </e1> <e2> gastrointestinal problems </e2>, were more frequent in the mexiletine group than in the placebo group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3850": {"data": {"text": "CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.", "entity1": "folic acid", "entity2": "epileptic", "span1": [180, 190], "span2": [17, 26]}, "bert_text": "CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of <e1> folic acid </e1> <e2> epileptic </e2> pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3851": {"data": {"text": "CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.", "entity1": "folic acid", "entity2": "autoimmune disease", "span1": [180, 190], "span2": [46, 64]}, "bert_text": "CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of <e1> folic acid </e1> <e2> autoimmune disease </e2> (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3852": {"data": {"text": "CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.", "entity1": "folic acid", "entity2": "lupus", "span1": [180, 190], "span2": [88, 93]}, "bert_text": "CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of <e1> folic acid </e1> <e2> lupus </e2>) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3853": {"data": {"text": "CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.", "entity1": "folic acid", "entity2": "seizures", "span1": [180, 190], "span2": [214, 222]}, "bert_text": "CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of <e1> folic acid </e1> triggered a cluster of <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3854": {"data": {"text": "Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.", "entity1": "amifostine", "entity2": "tumor", "span1": [107, 117], "span2": [10, 15]}, "bert_text": "Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of <e1> amifostine </e1> <e2> tumor </e2>-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3855": {"data": {"text": "Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.", "entity1": "amifostine", "entity2": "toxicity", "span1": [107, 117], "span2": [46, 54]}, "bert_text": "Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of <e1> amifostine </e1> <e2> toxicity </e2> to normal tissues was observed with the addition of amifostine to cisplatin in this trial.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3856": {"data": {"text": "Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.", "entity1": "cisplatin", "entity2": "tumor", "span1": [121, 130], "span2": [10, 15]}, "bert_text": "Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to <e1> cisplatin </e1> <e2> tumor </e2>-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3857": {"data": {"text": "Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.", "entity1": "cisplatin", "entity2": "toxicity", "span1": [121, 130], "span2": [46, 54]}, "bert_text": "Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to <e1> cisplatin </e1> <e2> toxicity </e2> to normal tissues was observed with the addition of amifostine to cisplatin in this trial.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3858": {"data": {"text": "Early adjuvant adriamycin in superficial bladder carcinoma.\n", "entity1": "adriamycin", "entity2": "bladder carcinoma", "span1": [15, 25], "span2": [41, 58]}, "bert_text": "Early adjuvant <e1> adriamycin </e1> in superficial <e2> bladder carcinoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3859": {"data": {"text": "We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.", "entity1": "phenytoin", "entity2": "overdosage", "span1": [17, 26], "span2": [27, 37]}, "bert_text": "We conclude that <e1> phenytoin </e1> <e2> overdosage </e2> does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3860": {"data": {"text": "We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.", "entity1": "phenytoin", "entity2": "cerebellar atrophy", "span1": [17, 26], "span2": [69, 87]}, "bert_text": "We conclude that <e1> phenytoin </e1> overdosage does not necessarily result in <e2> cerebellar atrophy </e2> and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3861": {"data": {"text": "We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.", "entity1": "phenytoin", "entity2": "cerebellar atrophy", "span1": [17, 26], "span2": [155, 173]}, "bert_text": "We conclude that <e1> phenytoin </e1> overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of <e2> cerebellar atrophy </e2> in the remaining patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3862": {"data": {"text": "We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.", "entity1": "phenytoin", "entity2": "overdosage", "span1": [112, 121], "span2": [27, 37]}, "bert_text": "We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that <e1> phenytoin </e1> <e2> overdosage </e2> does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3863": {"data": {"text": "We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.", "entity1": "phenytoin", "entity2": "cerebellar atrophy", "span1": [112, 121], "span2": [69, 87]}, "bert_text": "We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that <e1> phenytoin </e1> <e2> cerebellar atrophy </e2> and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3864": {"data": {"text": "We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.", "entity1": "phenytoin", "entity2": "cerebellar atrophy", "span1": [112, 121], "span2": [155, 173]}, "bert_text": "We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that <e1> phenytoin </e1> medication was the only cause of <e2> cerebellar atrophy </e2> in the remaining patients.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3865": {"data": {"text": "However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.", "entity1": "capsaicin", "entity2": "pain", "span1": [86, 95], "span2": [34, 38]}, "bert_text": "However, it is not known that how pain intensity ratings are affected by attention in <e1> capsaicin </e1> <e2> pain </e2> intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3866": {"data": {"text": "However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [86, 95], "span2": [114, 126]}, "bert_text": "However, it is not known that how pain intensity ratings are affected by attention in <e1> capsaicin </e1>-induced secondary <e2> hyperalgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3867": {"data": {"text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "entity1": "octreotide", "entity2": "gall stones", "span1": [15, 25], "span2": [34, 45]}, "bert_text": "In conclusion, <e1> octreotide </e1> induced <e2> gall stones </e2> are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3868": {"data": {"text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "entity1": "octreotide", "entity2": "gall stone disease", "span1": [15, 25], "span2": [135, 153]}, "bert_text": "In conclusion, <e1> octreotide </e1> induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous <e2> gall stone disease </e2>, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3869": {"data": {"text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "entity1": "octreotide", "entity2": "gall stones", "span1": [15, 25], "span2": [226, 237]}, "bert_text": "In conclusion, <e1> octreotide </e1> induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some <e2> gall stones </e2> containing calcium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3870": {"data": {"text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "entity1": "cholesterol", "entity2": "gall stones", "span1": [81, 92], "span2": [34, 45]}, "bert_text": "In conclusion, octreotide induced gall stones are generally small, multiple, and <e1> cholesterol </e1> <e2> gall stones </e2> are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3871": {"data": {"text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "entity1": "cholesterol", "entity2": "gall stone disease", "span1": [81, 92], "span2": [135, 153]}, "bert_text": "In conclusion, octreotide induced gall stones are generally small, multiple, and <e1> cholesterol </e1> rich although, in common with spontaneous <e2> gall stone disease </e2>, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3872": {"data": {"text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "entity1": "cholesterol", "entity2": "gall stones", "span1": [81, 92], "span2": [226, 237]}, "bert_text": "In conclusion, octreotide induced gall stones are generally small, multiple, and <e1> cholesterol </e1> rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some <e2> gall stones </e2> containing calcium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3873": {"data": {"text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "entity1": "calcium", "entity2": "gall stones", "span1": [249, 256], "span2": [34, 45]}, "bert_text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing <e1> calcium </e1> <e2> gall stones </e2> are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3874": {"data": {"text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "entity1": "calcium", "entity2": "gall stone disease", "span1": [249, 256], "span2": [135, 153]}, "bert_text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing <e1> calcium </e1> <e2> gall stone disease </e2>, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3875": {"data": {"text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "entity1": "calcium", "entity2": "gall stones", "span1": [249, 256], "span2": [226, 237]}, "bert_text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing <e1> calcium </e1> <e2> gall stones </e2> containing calcium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3876": {"data": {"text": "DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.", "entity1": "ribavirin", "entity2": "adenovirus disease", "span1": [103, 112], "span2": [135, 153]}, "bert_text": "DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous <e1> ribavirin </e1> for documented severe <e2> adenovirus disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3877": {"data": {"text": "Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.", "entity1": "calcium", "entity2": "atherosclerotic", "span1": [51, 58], "span2": [9, 24]}, "bert_text": "Elevated atherosclerotic parameters, such as serum <e1> calcium </e1> <e2> atherosclerotic </e2> parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3878": {"data": {"text": "Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.", "entity1": "calcium", "entity2": "atherosclerotic", "span1": [51, 58], "span2": [137, 152]}, "bert_text": "Elevated atherosclerotic parameters, such as serum <e1> calcium </e1>, total cholesterol and low-density lipoprotein concentration were obtained in <e2> atherosclerotic </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3879": {"data": {"text": "Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.", "entity1": "cholesterol", "entity2": "atherosclerotic", "span1": [66, 77], "span2": [9, 24]}, "bert_text": "Elevated atherosclerotic parameters, such as serum calcium, total <e1> cholesterol </e1> <e2> atherosclerotic </e2> parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3880": {"data": {"text": "Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.", "entity1": "cholesterol", "entity2": "atherosclerotic", "span1": [66, 77], "span2": [137, 152]}, "bert_text": "Elevated atherosclerotic parameters, such as serum calcium, total <e1> cholesterol </e1> and low-density lipoprotein concentration were obtained in <e2> atherosclerotic </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3881": {"data": {"text": "They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.", "entity1": "risperidone", "entity2": "visual disturbances", "span1": [125, 136], "span2": [47, 66]}, "bert_text": "They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with <e1> risperidone </e1> <e2> visual disturbances </e2>, which appeared immediately after starting treatment with risperidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3882": {"data": {"text": "CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.", "entity1": "Tolterodine", "entity2": "OAB", "span1": [12, 23], "span2": [107, 110]}, "bert_text": "CONCLUSION: <e1> Tolterodine </e1> was well tolerated and its effects improved the quality of life in Thai women with <e2> OAB </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3883": {"data": {"text": "The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.", "entity1": "benzodiazepines", "entity2": "hepatitis", "span1": [30, 45], "span2": [148, 157]}, "bert_text": "The administration of several <e1> benzodiazepines </e1>, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of <e2> hepatitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3884": {"data": {"text": "The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.", "entity1": "clotiazepam", "entity2": "hepatitis", "span1": [69, 80], "span2": [148, 157]}, "bert_text": "The administration of several benzodiazepines, chemically related to <e1> clotiazepam </e1>, did not interfere with recovery and did not induce any relapse of <e2> hepatitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"3885": {"data": {"text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "entity1": "nitrogranulogen", "entity2": "nephrotoxic", "span1": [51, 66], "span2": [4, 15]}, "bert_text": "The nephrotoxic action of anticancer drugs such as <e1> nitrogranulogen </e1> <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3886": {"data": {"text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "entity1": "NG", "entity2": "nephrotoxic", "span1": [68, 70], "span2": [4, 15]}, "bert_text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (<e1> NG </e1> <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3887": {"data": {"text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "entity1": "methotrexate", "entity2": "nephrotoxic", "span1": [73, 85], "span2": [4, 15]}, "bert_text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), <e1> methotrexate </e1> <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3888": {"data": {"text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "entity1": "MTX", "entity2": "nephrotoxic", "span1": [87, 90], "span2": [4, 15]}, "bert_text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (<e1> MTX </e1> <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3889": {"data": {"text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "entity1": "MTX", "entity2": "nephrotoxic", "span1": [179, 182], "span2": [4, 15]}, "bert_text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [<e1> MTX </e1> <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3890": {"data": {"text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "entity1": "5-fluorouracil", "entity2": "nephrotoxic", "span1": [93, 107], "span2": [4, 15]}, "bert_text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), <e1> 5-fluorouracil </e1> <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3891": {"data": {"text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "entity1": "5-FU", "entity2": "nephrotoxic", "span1": [109, 113], "span2": [4, 15]}, "bert_text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (<e1> 5-FU </e1> <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3892": {"data": {"text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "entity1": "5-FU", "entity2": "nephrotoxic", "span1": [185, 189], "span2": [4, 15]}, "bert_text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + <e1> 5-FU </e1> <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3893": {"data": {"text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "entity1": "cyclophosphamide", "entity2": "nephrotoxic", "span1": [119, 135], "span2": [4, 15]}, "bert_text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and <e1> cyclophosphamide </e1> <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3894": {"data": {"text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "entity1": "CY", "entity2": "nephrotoxic", "span1": [137, 139], "span2": [4, 15]}, "bert_text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (<e1> CY </e1> <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3895": {"data": {"text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "entity1": "CY", "entity2": "nephrotoxic", "span1": [192, 194], "span2": [4, 15]}, "bert_text": "The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + <e1> CY </e1> <e2> nephrotoxic </e2> action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3896": {"data": {"text": "Therefore, TAM-induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane.", "entity1": "TAM", "entity2": "hemolysis", "span1": [11, 14], "span2": [23, 32]}, "bert_text": "Therefore, <e1> TAM </e1>-induced <e2> hemolysis </e2> results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3897": {"data": {"text": "These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.", "entity1": "SRL", "entity2": "nephrotoxic", "span1": [27, 30], "span2": [10, 21]}, "bert_text": "These are nephrotoxic, but <e1> SRL </e1> <e2> nephrotoxic </e2>, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3898": {"data": {"text": "These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.", "entity1": "SRL", "entity2": "nephrotoxic", "span1": [27, 30], "span2": [78, 89]}, "bert_text": "These are nephrotoxic, but <e1> SRL </e1> seems to act differently displaying only minor <e2> nephrotoxic </e2> effects, although this question is still open.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3899": {"data": {"text": "We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).", "entity1": "1,1-dichloro-2,2,2-trifluoroethane", "entity2": "liver disease", "span1": [129, 163], "span2": [31, 44]}, "bert_text": "We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of <e1> 1,1-dichloro-2,2,2-trifluoroethane </e1> <e2> liver disease </e2> in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3900": {"data": {"text": "We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).", "entity1": "HCFC 123", "entity2": "liver disease", "span1": [165, 173], "span2": [31, 44]}, "bert_text": "We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (<e1> HCFC 123 </e1> <e2> liver disease </e2> in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3901": {"data": {"text": "We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).", "entity1": "1-chloro-1,2,2,2-tetrafluoroethane", "entity2": "liver disease", "span1": [179, 213], "span2": [31, 44]}, "bert_text": "We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and <e1> 1-chloro-1,2,2,2-tetrafluoroethane </e1> <e2> liver disease </e2> in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3902": {"data": {"text": "We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).", "entity1": "HCFC 124", "entity2": "liver disease", "span1": [215, 223], "span2": [31, 44]}, "bert_text": "We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (<e1> HCFC 124 </e1> <e2> liver disease </e2> in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3903": {"data": {"text": "This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.", "entity1": "clotiazepam", "entity2": "hepatitis", "span1": [28, 39], "span2": [57, 66]}, "bert_text": "This observation shows that <e1> clotiazepam </e1> can induce acute <e2> hepatitis </e2> and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3904": {"data": {"text": "This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.", "entity1": "clotiazepam", "entity2": "hepatotoxicity", "span1": [28, 39], "span2": [103, 117]}, "bert_text": "This observation shows that <e1> clotiazepam </e1> can induce acute hepatitis and suggests that there is no cross <e2> hepatotoxicity </e2> between clotiazepam and several benzodiazepines.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 1},
+	"3905": {"data": {"text": "This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.", "entity1": "clotiazepam", "entity2": "hepatitis", "span1": [126, 137], "span2": [57, 66]}, "bert_text": "This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between <e1> clotiazepam </e1> <e2> hepatitis </e2> and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3906": {"data": {"text": "This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.", "entity1": "clotiazepam", "entity2": "hepatotoxicity", "span1": [126, 137], "span2": [103, 117]}, "bert_text": "This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between <e1> clotiazepam </e1> <e2> hepatotoxicity </e2> between clotiazepam and several benzodiazepines.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 1},
+	"3907": {"data": {"text": "This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.", "entity1": "benzodiazepines", "entity2": "hepatitis", "span1": [150, 165], "span2": [57, 66]}, "bert_text": "This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several <e1> benzodiazepines </e1> <e2> hepatitis </e2> and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3908": {"data": {"text": "This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.", "entity1": "benzodiazepines", "entity2": "hepatotoxicity", "span1": [150, 165], "span2": [103, 117]}, "bert_text": "This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several <e1> benzodiazepines </e1> <e2> hepatotoxicity </e2> between clotiazepam and several benzodiazepines.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"3909": {"data": {"text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "entity1": "streptozotocin", "entity2": "hyperalgesia", "span1": [3, 17], "span2": [26, 38]}, "bert_text": "In <e1> streptozotocin </e1>-induced <e2> hyperalgesia </e2>, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3910": {"data": {"text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "entity1": "streptozotocin", "entity2": "hyperalgesia", "span1": [3, 17], "span2": [148, 160]}, "bert_text": "In <e1> streptozotocin </e1>-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced <e2> hyperalgesia </e2> bradykinin seemed to activate neuronal NO synthase pathway.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3911": {"data": {"text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "entity1": "bradykinin", "entity2": "hyperalgesia", "span1": [105, 115], "span2": [26, 38]}, "bert_text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of <e1> bradykinin </e1> <e2> hyperalgesia </e2>, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3912": {"data": {"text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "entity1": "bradykinin", "entity2": "hyperalgesia", "span1": [105, 115], "span2": [148, 160]}, "bert_text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of <e1> bradykinin </e1>, whereas in vincristine-induced <e2> hyperalgesia </e2> bradykinin seemed to activate neuronal NO synthase pathway.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3913": {"data": {"text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "entity1": "bradykinin", "entity2": "hyperalgesia", "span1": [161, 171], "span2": [26, 38]}, "bert_text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia <e1> bradykinin </e1> <e2> hyperalgesia </e2>, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3914": {"data": {"text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "entity1": "bradykinin", "entity2": "hyperalgesia", "span1": [161, 171], "span2": [148, 160]}, "bert_text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia <e1> bradykinin </e1> <e2> hyperalgesia </e2> bradykinin seemed to activate neuronal NO synthase pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3915": {"data": {"text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "entity1": "vincristine", "entity2": "hyperalgesia", "span1": [128, 139], "span2": [26, 38]}, "bert_text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in <e1> vincristine </e1> <e2> hyperalgesia </e2>, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3916": {"data": {"text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "entity1": "vincristine", "entity2": "hyperalgesia", "span1": [128, 139], "span2": [148, 160]}, "bert_text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in <e1> vincristine </e1>-induced <e2> hyperalgesia </e2> bradykinin seemed to activate neuronal NO synthase pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3917": {"data": {"text": "Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.", "entity1": "Azelastine", "entity2": "spring allergic rhinitis", "span1": [0, 10], "span2": [144, 168]}, "bert_text": "<e1> Azelastine </e1>, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of <e2> spring allergic rhinitis </e2> in a multicenter, double-blind, multiple-dose, parallel-groups study.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3918": {"data": {"text": "Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.", "entity1": "chlorpheniramine maleate", "entity2": "spring allergic rhinitis", "span1": [63, 87], "span2": [144, 168]}, "bert_text": "Azelastine, a novel antiallergic medication, was compared with <e1> chlorpheniramine maleate </e1> and placebo for efficacy and safety in the treatment of <e2> spring allergic rhinitis </e2> in a multicenter, double-blind, multiple-dose, parallel-groups study.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3919": {"data": {"text": "The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.", "entity1": "phenytoin", "entity2": "cerebellar atrophy", "span1": [63, 72], "span2": [88, 106]}, "bert_text": "The aim of this study was to evaluate the relationship between <e1> phenytoin </e1> medication and <e2> cerebellar atrophy </e2> in patients who had experienced clinical intoxication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3920": {"data": {"text": "Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).", "entity1": "Dexmedetomidine", "entity2": "myocardial infarction", "span1": [0, 15], "span2": [148, 169]}, "bert_text": "<e1> Dexmedetomidine </e1> was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal <e2> myocardial infarction </e2> (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3921": {"data": {"text": "Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).", "entity1": "Dexmedetomidine", "entity2": "myocardial ischaemia", "span1": [0, 15], "span2": [213, 233]}, "bert_text": "<e1> Dexmedetomidine </e1> was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and <e2> myocardial ischaemia </e2> (OR 0.65, 95% CI 0.26-1.63, p = 0.36).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3922": {"data": {"text": "Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.", "entity1": "alpha-benzene hexachloride", "entity2": "hepatomas", "span1": [97, 123], "span2": [15, 24]}, "bert_text": "Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm <e1> alpha-benzene hexachloride </e1> <e2> hepatomas </e2> and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3923": {"data": {"text": "Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.", "entity1": "alpha-benzene hexachloride", "entity2": "hyperplastic preneoplastic liver lesions", "span1": [97, 123], "span2": [29, 69]}, "bert_text": "Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm <e1> alpha-benzene hexachloride </e1> <e2> hyperplastic preneoplastic liver lesions </e2> induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3924": {"data": {"text": "Pheochromocytoma unmasked by amisulpride and tiapride.\n", "entity1": "amisulpride", "entity2": "Pheochromocytoma", "span1": [29, 40], "span2": [0, 16]}, "bert_text": "Pheochromocytoma unmasked by <e1> amisulpride </e1> <e2> Pheochromocytoma </e2> unmasked by amisulpride and tiapride.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3925": {"data": {"text": "Pheochromocytoma unmasked by amisulpride and tiapride.\n", "entity1": "tiapride", "entity2": "Pheochromocytoma", "span1": [45, 53], "span2": [0, 16]}, "bert_text": "Pheochromocytoma unmasked by amisulpride and <e1> tiapride </e1> <e2> Pheochromocytoma </e2> unmasked by amisulpride and tiapride.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3926": {"data": {"text": "Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.", "entity1": "caffeine", "entity2": "hypertensive", "span1": [63, 71], "span2": [20, 32]}, "bert_text": "Thus, in borderline hypertensive men, exaggerated responses to <e1> caffeine </e1> <e2> hypertensive </e2> men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3927": {"data": {"text": "Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.", "entity1": "caffeine", "entity2": "hypertensives", "span1": [63, 71], "span2": [219, 232]}, "bert_text": "Thus, in borderline hypertensive men, exaggerated responses to <e1> caffeine </e1> were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline <e2> hypertensives </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3928": {"data": {"text": "CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.", "entity1": "ampicillin", "entity2": "septicemia", "span1": [49, 59], "span2": [96, 106]}, "bert_text": "CASE SUMMARY: A 13-year-old boy was treated with <e1> ampicillin </e1> and gentamicin because of suspected <e2> septicemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3929": {"data": {"text": "CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.", "entity1": "gentamicin", "entity2": "septicemia", "span1": [64, 74], "span2": [96, 106]}, "bert_text": "CASE SUMMARY: A 13-year-old boy was treated with ampicillin and <e1> gentamicin </e1> because of suspected <e2> septicemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3930": {"data": {"text": "A case of a busulfan-induced hemorrhage cystitis is reported.", "entity1": "busulfan", "entity2": "hemorrhage cystitis", "span1": [12, 20], "span2": [29, 48]}, "bert_text": "A case of a <e1> busulfan </e1>-induced <e2> hemorrhage cystitis </e2> is reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3931": {"data": {"text": "Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.", "entity1": "daidzein", "entity2": "amnesia", "span1": [18, 26], "span2": [114, 121]}, "bert_text": "Administration of <e1> daidzein </e1> (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced <e2> amnesia </e2>, according to the results of a Y-maze test.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3932": {"data": {"text": "Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [94, 105], "span2": [114, 121]}, "bert_text": "Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse <e1> scopolamine </e1>-induced <e2> amnesia </e2>, according to the results of a Y-maze test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3933": {"data": {"text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.", "entity1": "tranexamic acid", "entity2": "intravascular coagulation", "span1": [99, 114], "span2": [13, 38]}, "bert_text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and <e1> tranexamic acid </e1> <e2> intravascular coagulation </e2> and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3934": {"data": {"text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.", "entity1": "tranexamic acid", "entity2": "pulmonary and renal insufficiency", "span1": [99, 114], "span2": [147, 180]}, "bert_text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and <e1> tranexamic acid </e1> (AMCA) in the rat gives rise to <e2> pulmonary and renal insufficiency </e2> resembling that occurring after trauma or sepsis in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3935": {"data": {"text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.", "entity1": "tranexamic acid", "entity2": "trauma", "span1": [99, 114], "span2": [213, 219]}, "bert_text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and <e1> tranexamic acid </e1> (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after <e2> trauma </e2> or sepsis in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3936": {"data": {"text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.", "entity1": "tranexamic acid", "entity2": "sepsis", "span1": [99, 114], "span2": [223, 229]}, "bert_text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and <e1> tranexamic acid </e1> (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or <e2> sepsis </e2> in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3937": {"data": {"text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.", "entity1": "AMCA", "entity2": "intravascular coagulation", "span1": [116, 120], "span2": [13, 38]}, "bert_text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (<e1> AMCA </e1> <e2> intravascular coagulation </e2> and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3938": {"data": {"text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.", "entity1": "AMCA", "entity2": "pulmonary and renal insufficiency", "span1": [116, 120], "span2": [147, 180]}, "bert_text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (<e1> AMCA </e1>) in the rat gives rise to <e2> pulmonary and renal insufficiency </e2> resembling that occurring after trauma or sepsis in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3939": {"data": {"text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.", "entity1": "AMCA", "entity2": "trauma", "span1": [116, 120], "span2": [213, 219]}, "bert_text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (<e1> AMCA </e1>) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after <e2> trauma </e2> or sepsis in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3940": {"data": {"text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.", "entity1": "AMCA", "entity2": "sepsis", "span1": [116, 120], "span2": [223, 229]}, "bert_text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (<e1> AMCA </e1>) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or <e2> sepsis </e2> in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3941": {"data": {"text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "entity1": "steroids", "entity2": "seizures", "span1": [29, 37], "span2": [118, 126]}, "bert_text": "We conclude that neuroactive <e1> steroids </e1> are highly effective in protecting against pilocarpine- and kainic acid-induced <e2> seizures </e2> and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3942": {"data": {"text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "entity1": "steroids", "entity2": "status epilepticus", "span1": [29, 37], "span2": [131, 149]}, "bert_text": "We conclude that neuroactive <e1> steroids </e1> are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and <e2> status epilepticus </e2> in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3943": {"data": {"text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "entity1": "steroids", "entity2": "status epilepticus", "span1": [29, 37], "span2": [215, 233]}, "bert_text": "We conclude that neuroactive <e1> steroids </e1> are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of <e2> status epilepticus </e2> in humans.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3944": {"data": {"text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "entity1": "pilocarpine-", "entity2": "seizures", "span1": [81, 93], "span2": [118, 126]}, "bert_text": "We conclude that neuroactive steroids are highly effective in protecting against <e1> pilocarpine- </e1> and kainic acid-induced <e2> seizures </e2> and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3945": {"data": {"text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "entity1": "pilocarpine-", "entity2": "status epilepticus", "span1": [81, 93], "span2": [131, 149]}, "bert_text": "We conclude that neuroactive steroids are highly effective in protecting against <e1> pilocarpine- </e1> and kainic acid-induced seizures and <e2> status epilepticus </e2> in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3946": {"data": {"text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "entity1": "pilocarpine-", "entity2": "status epilepticus", "span1": [81, 93], "span2": [215, 233]}, "bert_text": "We conclude that neuroactive steroids are highly effective in protecting against <e1> pilocarpine- </e1> and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of <e2> status epilepticus </e2> in humans.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3947": {"data": {"text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "entity1": "kainic acid", "entity2": "seizures", "span1": [98, 109], "span2": [118, 126]}, "bert_text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and <e1> kainic acid </e1>-induced <e2> seizures </e2> and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3948": {"data": {"text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "entity1": "kainic acid", "entity2": "status epilepticus", "span1": [98, 109], "span2": [131, 149]}, "bert_text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and <e1> kainic acid </e1>-induced seizures and <e2> status epilepticus </e2> in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3949": {"data": {"text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "entity1": "kainic acid", "entity2": "status epilepticus", "span1": [98, 109], "span2": [215, 233]}, "bert_text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and <e1> kainic acid </e1>-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of <e2> status epilepticus </e2> in humans.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3950": {"data": {"text": "Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.", "entity1": "Carteolol", "entity2": "catalepsy", "span1": [0, 9], "span2": [83, 92]}, "bert_text": "<e1> Carteolol </e1>, as well as propranolol and biperiden, inhibited the haloperidol-induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3951": {"data": {"text": "Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.", "entity1": "propranolol", "entity2": "catalepsy", "span1": [22, 33], "span2": [83, 92]}, "bert_text": "Carteolol, as well as <e1> propranolol </e1> and biperiden, inhibited the haloperidol-induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3952": {"data": {"text": "Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.", "entity1": "biperiden", "entity2": "catalepsy", "span1": [38, 47], "span2": [83, 92]}, "bert_text": "Carteolol, as well as propranolol and <e1> biperiden </e1>, inhibited the haloperidol-induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3953": {"data": {"text": "Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [63, 74], "span2": [83, 92]}, "bert_text": "Carteolol, as well as propranolol and biperiden, inhibited the <e1> haloperidol </e1>-induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3954": {"data": {"text": "We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).", "entity1": "amisulpride", "entity2": "schizophrenic", "span1": [120, 131], "span2": [30, 43]}, "bert_text": "We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of <e1> amisulpride </e1> <e2> schizophrenic </e2> who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3955": {"data": {"text": "We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).", "entity1": "amisulpride", "entity2": "involuntary eye-blinking movements", "span1": [120, 131], "span2": [67, 101]}, "bert_text": "We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of <e1> amisulpride </e1> <e2> involuntary eye-blinking movements </e2> after 5 months of amisulpride treatment (1000 mg per day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3956": {"data": {"text": "Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution.", "entity1": "lidocaine", "entity2": "pain", "span1": [75, 84], "span2": [37, 41]}, "bert_text": "Previous reports have suggested that pain associated with the injection of <e1> lidocaine </e1> <e2> pain </e2> associated with the injection of lidocaine is related to the acidic pH of the solution.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3957": {"data": {"text": "Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.", "entity1": "maltolyl p-coumarate", "entity2": "Alzheimer's disease", "span1": [76, 96], "span2": [142, 161]}, "bert_text": "Taking these in vitro and in vivo results together, our study suggests that <e1> maltolyl p-coumarate </e1> is a potentially effective candidate against <e2> Alzheimer's disease </e2> that is characterized by wide spread neuronal death and progressive decline of cognitive function.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3958": {"data": {"text": "Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.", "entity1": "maltolyl p-coumarate", "entity2": "neuronal death", "span1": [76, 96], "span2": [199, 213]}, "bert_text": "Taking these in vitro and in vivo results together, our study suggests that <e1> maltolyl p-coumarate </e1> is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread <e2> neuronal death </e2> and progressive decline of cognitive function.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3959": {"data": {"text": "Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.", "entity1": "tamoxifen", "entity2": "endometrial cancer", "span1": [37, 46], "span2": [50, 68]}, "bert_text": "Our results suggest a causal role of <e1> tamoxifen </e1> in <e2> endometrial cancer </e2>, particularly when used as currently proposed for breast cancer prevention.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3960": {"data": {"text": "Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [37, 46], "span2": [119, 132]}, "bert_text": "Our results suggest a causal role of <e1> tamoxifen </e1> in endometrial cancer, particularly when used as currently proposed for <e2> breast cancer </e2> prevention.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3961": {"data": {"text": "Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.", "entity1": "paracetamol", "entity2": "hepatic failure", "span1": [160, 171], "span2": [138, 153]}, "bert_text": "Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after <e1> paracetamol </e1> <e2> hepatic failure </e2> after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3962": {"data": {"text": "Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.", "entity1": "paracetamol", "entity2": "fulminant hepatic failure", "span1": [160, 171], "span2": [241, 266]}, "bert_text": "Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after <e1> paracetamol </e1> overdose, whereas activities were increased equally in patients with <e2> fulminant hepatic failure </e2> due to viral hepatitis whether or not they survived.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3963": {"data": {"text": "Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.", "entity1": "paracetamol", "entity2": "overdose", "span1": [160, 171], "span2": [172, 180]}, "bert_text": "Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after <e1> paracetamol </e1> <e2> overdose </e2>, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3964": {"data": {"text": "Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.", "entity1": "paracetamol", "entity2": "viral hepatitis", "span1": [160, 171], "span2": [274, 289]}, "bert_text": "Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after <e1> paracetamol </e1> overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to <e2> viral hepatitis </e2> whether or not they survived.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3965": {"data": {"text": "Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).", "entity1": "ASA", "entity2": "malformations", "span1": [47, 50], "span2": [15, 28]}, "bert_text": "Variations and malformations were similar when <e1> ASA </e1> <e2> malformations </e2> were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3966": {"data": {"text": "OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.", "entity1": "ampicillin", "entity2": "erythema multiforme", "span1": [94, 104], "span2": [31, 50]}, "bert_text": "OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by <e1> ampicillin </e1> <e2> erythema multiforme </e2> and hypersensitivity myocarditis caused by ampicillin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3967": {"data": {"text": "OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.", "entity1": "ampicillin", "entity2": "hypersensitivity myocarditis", "span1": [94, 104], "span2": [55, 83]}, "bert_text": "OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by <e1> ampicillin </e1> <e2> hypersensitivity myocarditis </e2> caused by ampicillin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3968": {"data": {"text": "OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride", "entity1": "amisulpride", "entity2": "pheochromocytoma", "span1": [83, 94], "span2": [40, 56]}, "bert_text": "OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with <e1> amisulpride </e1> <e2> pheochromocytoma </e2> in a patient treated with amisulpride and tiapride", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3969": {"data": {"text": "To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.", "entity1": "VPA", "entity2": "hepatotoxicity", "span1": [63, 66], "span2": [99, 113]}, "bert_text": "To determine whether there was a temporal relationship between <e1> VPA </e1>-associated oxidative stress and <e2> hepatotoxicity </e2>, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3970": {"data": {"text": "To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.", "entity1": "VPA", "entity2": "hepatotoxicity", "span1": [167, 170], "span2": [99, 113]}, "bert_text": "To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with <e1> VPA </e1> <e2> hepatotoxicity </e2>, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3971": {"data": {"text": "Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.\n", "entity1": "paclitaxel", "entity2": "peripheral neurotoxicity", "span1": [90, 100], "span2": [62, 86]}, "bert_text": "Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of <e1> paclitaxel </e1> <e2> peripheral neurotoxicity </e2> of paclitaxel.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3972": {"data": {"text": "Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.", "entity1": "adriamycin", "entity2": "Cardiac toxicity", "span1": [65, 75], "span2": [0, 16]}, "bert_text": "Cardiac toxicity is a major complication which limits the use of <e1> adriamycin </e1> <e2> Cardiac toxicity </e2> is a major complication which limits the use of adriamycin as a chemotherapeutic agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3973": {"data": {"text": "The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.", "entity1": "MK-801", "entity2": "catalepsy", "span1": [58, 64], "span2": [149, 158]}, "bert_text": "The results showed that intracollicular microinjection of <e1> MK-801 </e1> and AP7 previous to systemic injections of haloperidol significantly attenuated the <e2> catalepsy </e2>, as indicated by a reduced latency to step down from a horizontal bar.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3974": {"data": {"text": "The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [108, 119], "span2": [149, 158]}, "bert_text": "The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of <e1> haloperidol </e1> significantly attenuated the <e2> catalepsy </e2>, as indicated by a reduced latency to step down from a horizontal bar.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3975": {"data": {"text": "Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.", "entity1": "DA", "entity2": "neurotoxicity", "span1": [48, 50], "span2": [117, 130]}, "bert_text": "Taken together, these findings demonstrate that <e1> DA </e1> is not essential for the development of METH-induced dopaminergic <e2> neurotoxicity </e2> and suggest that mechanisms independent of DA warrant more intense investigation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3976": {"data": {"text": "Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.", "entity1": "DA", "entity2": "neurotoxicity", "span1": [174, 176], "span2": [117, 130]}, "bert_text": "Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of <e1> DA </e1> <e2> neurotoxicity </e2> and suggest that mechanisms independent of DA warrant more intense investigation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3977": {"data": {"text": "Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.", "entity1": "METH", "entity2": "neurotoxicity", "span1": [91, 95], "span2": [117, 130]}, "bert_text": "Taken together, these findings demonstrate that DA is not essential for the development of <e1> METH </e1>-induced dopaminergic <e2> neurotoxicity </e2> and suggest that mechanisms independent of DA warrant more intense investigation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3978": {"data": {"text": "Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia, particularly in frontal and temporal brain regions.", "entity1": "Ketamine", "entity2": "schizophrenia", "span1": [0, 8], "span2": [99, 112]}, "bert_text": "<e1> Ketamine </e1> induces activation changes in healthy subjects similar to those observed in patients with <e2> schizophrenia </e2>, particularly in frontal and temporal brain regions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3979": {"data": {"text": "The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.", "entity1": "ritanserin", "entity2": "amnesia", "span1": [14, 24], "span2": [103, 110]}, "bert_text": "The effect of <e1> ritanserin </e1> (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced <e2> amnesia </e2> in Morris water maze (MWM) was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3980": {"data": {"text": "The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [47, 58], "span2": [103, 110]}, "bert_text": "The effect of ritanserin (5-HT2 antagonist) on <e1> scopolamine </e1> (muscarinic cholinergic antagonist)-induced <e2> amnesia </e2> in Morris water maze (MWM) was investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3981": {"data": {"text": "Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.", "entity1": "ethyl-alpha-p-chlorophenoxyisobutyrate", "entity2": "hepatomas", "span1": [150, 188], "span2": [21, 30]}, "bert_text": "Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to <e1> ethyl-alpha-p-chlorophenoxyisobutyrate </e1> <e2> hepatomas </e2> were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3982": {"data": {"text": "Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.", "entity1": "ethyl-alpha-p-chlorophenoxyisobutyrate", "entity2": "tumors", "span1": [150, 188], "span2": [56, 62]}, "bert_text": "Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to <e1> ethyl-alpha-p-chlorophenoxyisobutyrate </e1> <e2> tumors </e2> and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3983": {"data": {"text": "Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.", "entity1": "ethyl-alpha-p-chlorophenoxyisobutyrate", "entity2": "tumor", "span1": [150, 188], "span2": [119, 124]}, "bert_text": "Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to <e1> ethyl-alpha-p-chlorophenoxyisobutyrate </e1> <e2> tumor </e2> cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3984": {"data": {"text": "An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.", "entity1": "trifluoroacetyl", "entity2": "hepatitis", "span1": [67, 82], "span2": [122, 131]}, "bert_text": "An antibody response to a protein-bound biotransformation product (<e1> trifluoroacetyl </e1> adduct) has been detected on halothane <e2> hepatitis </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3985": {"data": {"text": "An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.", "entity1": "halothane", "entity2": "hepatitis", "span1": [112, 121], "span2": [122, 131]}, "bert_text": "An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on <e1> halothane </e1> <e2> hepatitis </e2> patients.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3986": {"data": {"text": "Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.", "entity1": "nicotinic acid amide", "entity2": "liver injury", "span1": [58, 78], "span2": [239, 251]}, "bert_text": "Recently, we demonstrated the hepatoprotective effects of <e1> nicotinic acid amide </e1>, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced <e2> liver injury </e2> involves a step which depends on adenoribosylation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3987": {"data": {"text": "Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.", "entity1": "poly(ADP-ribose", "entity2": "liver injury", "span1": [105, 120], "span2": [239, 251]}, "bert_text": "Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of <e1> poly(ADP-ribose </e1>) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced <e2> liver injury </e2> involves a step which depends on adenoribosylation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3988": {"data": {"text": "Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.", "entity1": "acetaminophen", "entity2": "liver injury", "span1": [176, 189], "span2": [239, 251]}, "bert_text": "Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from <e1> acetaminophen </e1> (AAP)-hepatitis, suggesting that the AAP-induced <e2> liver injury </e2> involves a step which depends on adenoribosylation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3989": {"data": {"text": "Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.", "entity1": "AAP)-hepatitis", "entity2": "liver injury", "span1": [191, 205], "span2": [239, 251]}, "bert_text": "Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (<e1> AAP)-hepatitis </e1>, suggesting that the AAP-induced <e2> liver injury </e2> involves a step which depends on adenoribosylation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3990": {"data": {"text": "Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.", "entity1": "AAP", "entity2": "liver injury", "span1": [227, 230], "span2": [239, 251]}, "bert_text": "Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the <e1> AAP </e1>-induced <e2> liver injury </e2> involves a step which depends on adenoribosylation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3991": {"data": {"text": "Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.", "entity1": "cocaine", "entity2": "myocardial injury", "span1": [14, 21], "span2": [87, 104]}, "bert_text": "Eleven of the <e1> cocaine </e1> abusers and none of the controls had ECG evidence of significant <e2> myocardial injury </e2> defined as myocardial infarction, ischemia, and bundle branch block.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3992": {"data": {"text": "Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.", "entity1": "cocaine", "entity2": "myocardial infarction", "span1": [14, 21], "span2": [116, 137]}, "bert_text": "Eleven of the <e1> cocaine </e1> abusers and none of the controls had ECG evidence of significant myocardial injury defined as <e2> myocardial infarction </e2>, ischemia, and bundle branch block.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3993": {"data": {"text": "Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.", "entity1": "cocaine", "entity2": "ischemia", "span1": [14, 21], "span2": [139, 147]}, "bert_text": "Eleven of the <e1> cocaine </e1> abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, <e2> ischemia </e2>, and bundle branch block.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3994": {"data": {"text": "Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.", "entity1": "cocaine", "entity2": "bundle branch block", "span1": [14, 21], "span2": [153, 172]}, "bert_text": "Eleven of the <e1> cocaine </e1> abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and <e2> bundle branch block </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3995": {"data": {"text": "Nephrotoxicity of combined cephalothin-gentamicin regimen.\n", "entity1": "cephalothin", "entity2": "Nephrotoxicity", "span1": [27, 38], "span2": [0, 14]}, "bert_text": "Nephrotoxicity of combined <e1> cephalothin </e1> <e2> Nephrotoxicity </e2> of combined cephalothin-gentamicin regimen.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3996": {"data": {"text": "Nephrotoxicity of combined cephalothin-gentamicin regimen.\n", "entity1": "gentamicin", "entity2": "Nephrotoxicity", "span1": [39, 49], "span2": [0, 14]}, "bert_text": "Nephrotoxicity of combined cephalothin-<e1> gentamicin </e1> <e2> Nephrotoxicity </e2> of combined cephalothin-gentamicin regimen.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3997": {"data": {"text": "Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).", "entity1": "cocaine", "entity2": "abuse", "span1": [99, 106], "span2": [122, 127]}, "bert_text": "Positive test results were more common in patient visits where there was a history or suspicion of <e1> cocaine </e1> or amphetamine <e2> abuse </e2> (p < 0.0005).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3998": {"data": {"text": "Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).", "entity1": "amphetamine", "entity2": "abuse", "span1": [110, 121], "span2": [122, 127]}, "bert_text": "Positive test results were more common in patient visits where there was a history or suspicion of cocaine or <e1> amphetamine </e1> <e2> abuse </e2> (p < 0.0005).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3999": {"data": {"text": "Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.", "entity1": "folic acid", "entity2": "epileptic", "span1": [30, 40], "span2": [64, 73]}, "bert_text": "Physiological dose (<1 mg) of <e1> folic acid </e1> both in healthy and 60 <e2> epileptic </e2> women, all without any autoimmune disease, did not increase the risk for epileptic seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4000": {"data": {"text": "Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.", "entity1": "folic acid", "entity2": "epileptic seizures", "span1": [30, 40], "span2": [147, 165]}, "bert_text": "Physiological dose (<1 mg) of <e1> folic acid </e1> both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for <e2> epileptic seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"4001": {"data": {"text": "Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.", "entity1": "folic acid", "entity2": "autoimmune disease", "span1": [30, 40], "span2": [97, 115]}, "bert_text": "Physiological dose (<1 mg) of <e1> folic acid </e1> both in healthy and 60 epileptic women, all without any <e2> autoimmune disease </e2>, did not increase the risk for epileptic seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4002": {"data": {"text": "Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.\n", "entity1": "Spironolactone", "entity2": "renal insufficiency", "span1": [0, 14], "span2": [23, 42]}, "bert_text": "<e1> Spironolactone </e1>-induced <e2> renal insufficiency </e2> and hyperkalemia in patients with heart failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4003": {"data": {"text": "Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.\n", "entity1": "Spironolactone", "entity2": "hyperkalemia", "span1": [0, 14], "span2": [47, 59]}, "bert_text": "<e1> Spironolactone </e1>-induced renal insufficiency and <e2> hyperkalemia </e2> in patients with heart failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4004": {"data": {"text": "Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.\n", "entity1": "Spironolactone", "entity2": "heart failure", "span1": [0, 14], "span2": [77, 90]}, "bert_text": "<e1> Spironolactone </e1>-induced renal insufficiency and hyperkalemia in patients with <e2> heart failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4005": {"data": {"text": "This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.", "entity1": "enflurane", "entity2": "hypersensitivity", "span1": [63, 72], "span2": [97, 113]}, "bert_text": "This study was performed to determine cross-reactivity between <e1> enflurane </e1> and isoflurane with the <e2> hypersensitivity </e2> induced by halothane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4006": {"data": {"text": "This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.", "entity1": "isoflurane", "entity2": "hypersensitivity", "span1": [77, 87], "span2": [97, 113]}, "bert_text": "This study was performed to determine cross-reactivity between enflurane and <e1> isoflurane </e1> with the <e2> hypersensitivity </e2> induced by halothane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4007": {"data": {"text": "This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.", "entity1": "halothane", "entity2": "hypersensitivity", "span1": [125, 134], "span2": [97, 113]}, "bert_text": "This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by <e1> halothane </e1> <e2> hypersensitivity </e2> induced by halothane.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4008": {"data": {"text": "The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate.", "entity1": "MFL regimen", "entity2": "toxicity", "span1": [4, 15], "span2": [70, 78]}, "bert_text": "The <e1> MFL regimen </e1> achieves little palliative benefit and induces severe <e2> toxicity </e2> at a fairly high rate.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4009": {"data": {"text": "As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.", "entity1": "potassium", "entity2": "hyperkalemia", "span1": [46, 55], "span2": [178, 190]}, "bert_text": "As no other medications known to effect serum <e1> potassium </e1> had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and <e2> hyperkalemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4010": {"data": {"text": "As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.", "entity1": "sulindac", "entity2": "hyperkalemia", "span1": [165, 173], "span2": [178, 190]}, "bert_text": "As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between <e1> sulindac </e1> and <e2> hyperkalemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4011": {"data": {"text": "These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.", "entity1": "metformin", "entity2": "kidney dysfunction", "span1": [68, 77], "span2": [25, 43]}, "bert_text": "These in vivo markers of kidney dysfunction and their correction by <e1> metformin </e1> <e2> kidney dysfunction </e2> and their correction by metformin were complemented by in vitro studies of mitochondrial function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4012": {"data": {"text": "In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.", "entity1": "DXR", "entity2": "CM myocardial damage", "span1": [3, 6], "span2": [7, 27]}, "bert_text": "In <e1> DXR </e1>-<e2> CM myocardial damage </e2> is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4013": {"data": {"text": "In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.", "entity1": "DXR", "entity2": "CM myocardial damage", "span1": [79, 82], "span2": [7, 27]}, "bert_text": "In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (<e1> DXR </e1> <e2> CM myocardial damage </e2> is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4014": {"data": {"text": "Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.", "entity1": "Vitamin C", "entity2": "cardiovascular disease", "span1": [0, 9], "span2": [49, 71]}, "bert_text": "<e1> Vitamin C </e1> intake was unrelated to mortality from <e2> cardiovascular disease </e2> in the nondiabetic subjects at baseline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4015": {"data": {"text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "entity1": "lidocaine", "entity2": "postoperative myalgia", "span1": [4, 13], "span2": [45, 66]}, "bert_text": "Can <e1> lidocaine </e1> reduce succinylcholine induced <e2> postoperative myalgia </e2>?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4016": {"data": {"text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "entity1": "lidocaine", "entity2": "myalgia", "span1": [4, 13], "span2": [184, 191]}, "bert_text": "Can <e1> lidocaine </e1> reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced <e2> myalgia </e2> in patients undergoing general anesthesia for gynecological surgery.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4017": {"data": {"text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "entity1": "lidocaine", "entity2": "postoperative myalgia", "span1": [121, 130], "span2": [45, 66]}, "bert_text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of <e1> lidocaine </e1> <e2> postoperative myalgia </e2>?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4018": {"data": {"text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "entity1": "lidocaine", "entity2": "myalgia", "span1": [121, 130], "span2": [184, 191]}, "bert_text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of <e1> lidocaine </e1> pretreatment on reduction of succinylcholine-induced <e2> myalgia </e2> in patients undergoing general anesthesia for gynecological surgery.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4019": {"data": {"text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "entity1": "succinylcholine", "entity2": "postoperative myalgia", "span1": [21, 36], "span2": [45, 66]}, "bert_text": "Can lidocaine reduce <e1> succinylcholine </e1> induced <e2> postoperative myalgia </e2>?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4020": {"data": {"text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "entity1": "succinylcholine", "entity2": "myalgia", "span1": [21, 36], "span2": [184, 191]}, "bert_text": "Can lidocaine reduce <e1> succinylcholine </e1> induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced <e2> myalgia </e2> in patients undergoing general anesthesia for gynecological surgery.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4021": {"data": {"text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "entity1": "succinylcholine", "entity2": "postoperative myalgia", "span1": [160, 175], "span2": [45, 66]}, "bert_text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of <e1> succinylcholine </e1> <e2> postoperative myalgia </e2>?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4022": {"data": {"text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.", "entity1": "succinylcholine", "entity2": "myalgia", "span1": [160, 175], "span2": [184, 191]}, "bert_text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?\nThis study was undertaken to determine the effect of lidocaine pretreatment on reduction of <e1> succinylcholine </e1>-induced <e2> myalgia </e2> in patients undergoing general anesthesia for gynecological surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4023": {"data": {"text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "entity1": "didanosine", "entity2": "toxicity", "span1": [24, 34], "span2": [12, 20]}, "bert_text": "The use and toxicity of <e1> didanosine </e1> <e2> toxicity </e2> of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4024": {"data": {"text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "entity1": "ddI", "entity2": "toxicity", "span1": [36, 39], "span2": [12, 20]}, "bert_text": "The use and toxicity of didanosine (<e1> ddI </e1> <e2> toxicity </e2> of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4025": {"data": {"text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "entity1": "didanosine", "entity2": "toxicity", "span1": [184, 194], "span2": [12, 20]}, "bert_text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received <e1> didanosine </e1> <e2> toxicity </e2> of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4026": {"data": {"text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "entity1": "ddI", "entity2": "toxicity", "span1": [196, 199], "span2": [12, 20]}, "bert_text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (<e1> ddI </e1> <e2> toxicity </e2> of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4027": {"data": {"text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "entity1": "zidovudine", "entity2": "toxicity", "span1": [92, 102], "span2": [12, 20]}, "bert_text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to <e1> zidovudine </e1> <e2> toxicity </e2> of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4028": {"data": {"text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "entity1": "AZT", "entity2": "toxicity", "span1": [104, 107], "span2": [12, 20]}, "bert_text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (<e1> AZT </e1> <e2> toxicity </e2> of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4029": {"data": {"text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "entity1": "zidovudine", "entity2": "toxicity", "span1": [158, 168], "span2": [12, 20]}, "bert_text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to <e1> zidovudine </e1> <e2> toxicity </e2> of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4030": {"data": {"text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "entity1": "AZT", "entity2": "toxicity", "span1": [170, 173], "span2": [12, 20]}, "bert_text": "The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (<e1> AZT </e1> <e2> toxicity </e2> of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)\nOne hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4031": {"data": {"text": "99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.\n", "entity1": "99mTc-glucarate", "entity2": "myocardial infarction", "span1": [0, 15], "span2": [55, 76]}, "bert_text": "<e1> 99mTc-glucarate </e1> for detection of isoproterenol-induced <e2> myocardial infarction </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4032": {"data": {"text": "99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.\n", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [33, 46], "span2": [55, 76]}, "bert_text": "99mTc-glucarate for detection of <e1> isoproterenol </e1>-induced <e2> myocardial infarction </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4033": {"data": {"text": "Pain severity and analgesic requirements were unaffected by the omission of fentanyl.", "entity1": "fentanyl", "entity2": "Pain", "span1": [76, 84], "span2": [0, 4]}, "bert_text": "Pain severity and analgesic requirements were unaffected by the omission of <e1> fentanyl </e1> <e2> Pain </e2> severity and analgesic requirements were unaffected by the omission of fentanyl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4034": {"data": {"text": "A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.\n", "entity1": "bupivacaine", "entity2": "neurological deficit", "span1": [82, 93], "span2": [12, 32]}, "bert_text": "A transient neurological deficit following intrathecal injection of 1% hyperbaric <e1> bupivacaine </e1> <e2> neurological deficit </e2> following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4035": {"data": {"text": "Suxamethonium infusion rate and observed fasciculations.", "entity1": "Suxamethonium", "entity2": "fasciculations", "span1": [0, 13], "span2": [41, 55]}, "bert_text": "<e1> Suxamethonium </e1> infusion rate and observed <e2> fasciculations </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4036": {"data": {"text": "This imagery resembled visual disturbances previously experienced as \"flashbacks\" related to prior LSD consumption.", "entity1": "LSD", "entity2": "visual disturbances", "span1": [99, 102], "span2": [23, 42]}, "bert_text": "This imagery resembled visual disturbances previously experienced as \"flashbacks\" related to prior <e1> LSD </e1> <e2> visual disturbances </e2> previously experienced as \"flashbacks\" related to prior LSD consumption.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4037": {"data": {"text": "The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.", "entity1": "NAD", "entity2": "hepatitis", "span1": [75, 78], "span2": [143, 152]}, "bert_text": "The present study investigates the effects of a diet free of precursors of <e1> NAD </e1>, the substrate on which PARP acts, in female NMRI mice with AAP <e2> hepatitis </e2> and evaluates the influence of simultaneous ethanol consumption in these animals.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4038": {"data": {"text": "The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.", "entity1": "AAP", "entity2": "hepatitis", "span1": [139, 142], "span2": [143, 152]}, "bert_text": "The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with <e1> AAP </e1> <e2> hepatitis </e2> and evaluates the influence of simultaneous ethanol consumption in these animals.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4039": {"data": {"text": "The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.", "entity1": "ethanol", "entity2": "hepatitis", "span1": [197, 204], "span2": [143, 152]}, "bert_text": "The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous <e1> ethanol </e1> <e2> hepatitis </e2> and evaluates the influence of simultaneous ethanol consumption in these animals.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4040": {"data": {"text": "This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.", "entity1": "streptomycin", "entity2": "vestibulotoxicity", "span1": [39, 51], "span2": [60, 77]}, "bert_text": "This study investigated alleviation of <e1> streptomycin </e1>-induced <e2> vestibulotoxicity </e2> by edaravone in guinea pigs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4041": {"data": {"text": "This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.", "entity1": "edaravone", "entity2": "vestibulotoxicity", "span1": [81, 90], "span2": [60, 77]}, "bert_text": "This study investigated alleviation of streptomycin-induced vestibulotoxicity by <e1> edaravone </e1> <e2> vestibulotoxicity </e2> by edaravone in guinea pigs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4042": {"data": {"text": "In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.", "entity1": "crocins", "entity2": "Alzheimer's disease", "span1": [36, 43], "span2": [56, 75]}, "bert_text": "In the present study, the effect of <e1> crocins </e1> on sporadic <e2> Alzheimer's disease </e2> induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4043": {"data": {"text": "In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.", "entity1": "streptozocin", "entity2": "Alzheimer's disease", "span1": [117, 129], "span2": [56, 75]}, "bert_text": "In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) <e1> streptozocin </e1> <e2> Alzheimer's disease </e2> induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4044": {"data": {"text": "In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.", "entity1": "STZ", "entity2": "Alzheimer's disease", "span1": [131, 134], "span2": [56, 75]}, "bert_text": "In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (<e1> STZ </e1> <e2> Alzheimer's disease </e2> induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4045": {"data": {"text": "Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.", "entity1": "calcium", "entity2": "depression", "span1": [19, 26], "span2": [40, 50]}, "bert_text": "Addition of excess <e1> calcium </e1> reversed the <e2> depression </e2> in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4046": {"data": {"text": "Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.", "entity1": "calcium", "entity2": "depression", "span1": [72, 79], "span2": [40, 50]}, "bert_text": "Addition of excess calcium reversed the depression in both tissues, but <e1> calcium </e1> <e2> depression </e2> in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4047": {"data": {"text": "Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.", "entity1": "catecholamine", "entity2": "depression", "span1": [92, 105], "span2": [40, 50]}, "bert_text": "Addition of excess calcium reversed the depression in both tissues, but calcium-independent <e1> catecholamine </e1> <e2> depression </e2> in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4048": {"data": {"text": "Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.", "entity1": "acetaldehyde", "entity2": "depression", "span1": [117, 129], "span2": [40, 50]}, "bert_text": "Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by <e1> acetaldehyde </e1> <e2> depression </e2> in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4049": {"data": {"text": "Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.", "entity1": "NH4Ac", "entity2": "depression", "span1": [149, 154], "span2": [40, 50]}, "bert_text": "Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by <e1> NH4Ac </e1> <e2> depression </e2> in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4050": {"data": {"text": "Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.", "entity1": "methylprednisolone", "entity2": "Spinal Cord Injury", "span1": [77, 95], "span2": [30, 48]}, "bert_text": "Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose <e1> methylprednisolone </e1> <e2> Spinal Cord Injury </e2> Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4051": {"data": {"text": "Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.", "entity1": "methylprednisolone", "entity2": "spinal cord injury", "span1": [77, 95], "span2": [138, 156]}, "bert_text": "Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose <e1> methylprednisolone </e1> became the standard of care for the acute <e2> spinal cord injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4052": {"data": {"text": "Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.", "entity1": "cephalothin sodium", "entity2": "acute tubular necrosis", "span1": [148, 166], "span2": [23, 45]}, "bert_text": "Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of <e1> cephalothin sodium </e1> <e2> acute tubular necrosis </e2>, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4053": {"data": {"text": "Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.", "entity1": "cephalothin sodium", "entity2": "oliguric renal failure", "span1": [148, 166], "span2": [81, 103]}, "bert_text": "Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of <e1> cephalothin sodium </e1> <e2> oliguric renal failure </e2>, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4054": {"data": {"text": "Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.", "entity1": "gentamicin sulfate", "entity2": "acute tubular necrosis", "span1": [171, 189], "span2": [23, 45]}, "bert_text": "Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and <e1> gentamicin sulfate </e1> <e2> acute tubular necrosis </e2>, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4055": {"data": {"text": "Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.", "entity1": "gentamicin sulfate", "entity2": "oliguric renal failure", "span1": [171, 189], "span2": [81, 103]}, "bert_text": "Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and <e1> gentamicin sulfate </e1> <e2> oliguric renal failure </e2>, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4056": {"data": {"text": "Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.", "entity1": "carboplatin", "entity2": "Anemia", "span1": [42, 53], "span2": [0, 6]}, "bert_text": "Anemia was induced using a single dose of <e1> carboplatin </e1> <e2> Anemia </e2> was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4057": {"data": {"text": "To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.", "entity1": "dipyridamole", "entity2": "myocardial ischemia", "span1": [89, 101], "span2": [141, 160]}, "bert_text": "To our knowledge, this has not previously been reported as a side effect of preoperative <e1> dipyridamole </e1> therapy, although dipyridamole-induced <e2> myocardial ischemia </e2> has been demonstrated to occur in animals and humans with coronary artery disease.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4058": {"data": {"text": "To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.", "entity1": "dipyridamole", "entity2": "coronary artery disease", "span1": [89, 101], "span2": [219, 242]}, "bert_text": "To our knowledge, this has not previously been reported as a side effect of preoperative <e1> dipyridamole </e1> therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with <e2> coronary artery disease </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4059": {"data": {"text": "To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.", "entity1": "dipyridamole", "entity2": "myocardial ischemia", "span1": [120, 132], "span2": [141, 160]}, "bert_text": "To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although <e1> dipyridamole </e1>-induced <e2> myocardial ischemia </e2> has been demonstrated to occur in animals and humans with coronary artery disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4060": {"data": {"text": "To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.", "entity1": "dipyridamole", "entity2": "coronary artery disease", "span1": [120, 132], "span2": [219, 242]}, "bert_text": "To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although <e1> dipyridamole </e1>-induced myocardial ischemia has been demonstrated to occur in animals and humans with <e2> coronary artery disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4061": {"data": {"text": "One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.", "entity1": "amlodipine", "entity2": "telangiectasia", "span1": [39, 49], "span2": [84, 98]}, "bert_text": "One commenced the closely related drug <e1> amlodipine </e1> 3 years later, with recurrence of <e2> telangiectasia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4062": {"data": {"text": "Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.", "entity1": "gentamicin", "entity2": "toxicity", "span1": [68, 78], "span2": [79, 87]}, "bert_text": "Here we tested whether it has a beneficial effect in a rat model of <e1> gentamicin </e1> <e2> toxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4063": {"data": {"text": "Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.\n", "entity1": "Valproic acid", "entity2": "liver toxicity", "span1": [0, 13], "span2": [63, 77]}, "bert_text": "<e1> Valproic acid </e1> I: time course of lipid peroxidation biomarkers, <e2> liver toxicity </e2>, and valproic acid metabolite levels in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4064": {"data": {"text": "Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.\n", "entity1": "valproic acid", "entity2": "liver toxicity", "span1": [83, 96], "span2": [63, 77]}, "bert_text": "Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and <e1> valproic acid </e1> <e2> liver toxicity </e2>, and valproic acid metabolite levels in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4065": {"data": {"text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "entity1": "phosphate", "entity2": "artery calcification", "span1": [183, 192], "span2": [53, 73]}, "bert_text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum <e1> phosphate </e1> <e2> artery calcification </e2> and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4066": {"data": {"text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "entity1": "phosphate", "entity2": "artery calcification", "span1": [183, 192], "span2": [215, 235]}, "bert_text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum <e1> phosphate </e1> and susceptibility to <e2> artery calcification </e2>, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4067": {"data": {"text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "entity1": "phosphate", "entity2": "artery calcification", "span1": [183, 192], "span2": [383, 403]}, "bert_text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum <e1> phosphate </e1> and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced <e2> artery calcification </e2>, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4068": {"data": {"text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "entity1": "phosphate", "entity2": "artery calcification", "span1": [269, 278], "span2": [53, 73]}, "bert_text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum <e1> phosphate </e1> <e2> artery calcification </e2> and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4069": {"data": {"text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "entity1": "phosphate", "entity2": "artery calcification", "span1": [269, 278], "span2": [215, 235]}, "bert_text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum <e1> phosphate </e1> <e2> artery calcification </e2>, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4070": {"data": {"text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "entity1": "phosphate", "entity2": "artery calcification", "span1": [269, 278], "span2": [383, 403]}, "bert_text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum <e1> phosphate </e1> in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced <e2> artery calcification </e2>, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4071": {"data": {"text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [366, 374], "span2": [53, 73]}, "bert_text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to <e1> Warfarin </e1> <e2> artery calcification </e2> and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4072": {"data": {"text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [366, 374], "span2": [215, 235]}, "bert_text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to <e1> Warfarin </e1> <e2> artery calcification </e2>, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4073": {"data": {"text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [366, 374], "span2": [383, 403]}, "bert_text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to <e1> Warfarin </e1>-induced <e2> artery calcification </e2>, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4074": {"data": {"text": "Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.\n", "entity1": "cytosine arabinoside", "entity2": "Peripheral neuropathy", "span1": [42, 62], "span2": [0, 21]}, "bert_text": "Peripheral neuropathy caused by high-dose <e1> cytosine arabinoside </e1> <e2> Peripheral neuropathy </e2> caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4075": {"data": {"text": "Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.\n", "entity1": "cytosine arabinoside", "entity2": "acute myeloid leukemia", "span1": [42, 62], "span2": [91, 113]}, "bert_text": "Peripheral neuropathy caused by high-dose <e1> cytosine arabinoside </e1> treatment in a patient with <e2> acute myeloid leukemia </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4076": {"data": {"text": "All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.", "entity1": "PG", "entity2": "MDM", "span1": [113, 115], "span2": [86, 89]}, "bert_text": "All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to <e1> PG </e1> <e2> MDM </e2>, and 44 of 46 (96%) to PG.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4077": {"data": {"text": "Force overflow and levodopa-induced dyskinesias in Parkinson's disease.\n", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [19, 27], "span2": [36, 47]}, "bert_text": "Force overflow and <e1> levodopa </e1>-induced <e2> dyskinesias </e2> in Parkinson's disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4078": {"data": {"text": "Force overflow and levodopa-induced dyskinesias in Parkinson's disease.\n", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [19, 27], "span2": [51, 70]}, "bert_text": "Force overflow and <e1> levodopa </e1>-induced dyskinesias in <e2> Parkinson's disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4079": {"data": {"text": "Proteinuria after conversion to sirolimus in renal transplant recipients.\nSirolimus (SRL) is a new, potent immunosuppressive agent.", "entity1": "sirolimus", "entity2": "Proteinuria", "span1": [32, 41], "span2": [0, 11]}, "bert_text": "Proteinuria after conversion to <e1> sirolimus </e1> <e2> Proteinuria </e2> after conversion to sirolimus in renal transplant recipients.\nSirolimus (SRL) is a new, potent immunosuppressive agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4080": {"data": {"text": "Proteinuria after conversion to sirolimus in renal transplant recipients.\nSirolimus (SRL) is a new, potent immunosuppressive agent.", "entity1": "Sirolimus", "entity2": "Proteinuria", "span1": [74, 83], "span2": [0, 11]}, "bert_text": "Proteinuria after conversion to sirolimus in renal transplant recipients.\n<e1> Sirolimus </e1> <e2> Proteinuria </e2> after conversion to sirolimus in renal transplant recipients.\nSirolimus (SRL) is a new, potent immunosuppressive agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4081": {"data": {"text": "Proteinuria after conversion to sirolimus in renal transplant recipients.\nSirolimus (SRL) is a new, potent immunosuppressive agent.", "entity1": "SRL", "entity2": "Proteinuria", "span1": [85, 88], "span2": [0, 11]}, "bert_text": "Proteinuria after conversion to sirolimus in renal transplant recipients.\nSirolimus (<e1> SRL </e1> <e2> Proteinuria </e2> after conversion to sirolimus in renal transplant recipients.\nSirolimus (SRL) is a new, potent immunosuppressive agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4082": {"data": {"text": "We describe 4 patients in whom hyperkalemia ranging from 6.1 to 6.9 mEq/l developed within 3 to 8 days of sulindac administration.", "entity1": "sulindac", "entity2": "hyperkalemia", "span1": [106, 114], "span2": [31, 43]}, "bert_text": "We describe 4 patients in whom hyperkalemia ranging from 6.1 to 6.9 mEq/l developed within 3 to 8 days of <e1> sulindac </e1> <e2> hyperkalemia </e2> ranging from 6.1 to 6.9 mEq/l developed within 3 to 8 days of sulindac administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4083": {"data": {"text": "Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.", "entity1": "oxytocin", "entity2": "water intoxication", "span1": [52, 60], "span2": [14, 32]}, "bert_text": "Four cases of water intoxication in connection with <e1> oxytocin </e1> <e2> water intoxication </e2> in connection with oxytocin administration during saline-induced abortions are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4084": {"data": {"text": "Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.", "entity1": "oxytocin", "entity2": "abortions", "span1": [52, 60], "span2": [98, 107]}, "bert_text": "Four cases of water intoxication in connection with <e1> oxytocin </e1> administration during saline-induced <e2> abortions </e2> are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4085": {"data": {"text": "Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.", "entity1": "Diazepam", "entity2": "hallucinations", "span1": [0, 8], "span2": [215, 229]}, "bert_text": "<e1> Diazepam </e1>, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative <e2> hallucinations </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4086": {"data": {"text": "Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.", "entity1": "ketamine", "entity2": "hallucinations", "span1": [92, 100], "span2": [215, 229]}, "bert_text": "Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to <e1> ketamine </e1> as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative <e2> hallucinations </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4087": {"data": {"text": "Palpebral twitching in a depressed adolescent on citalopram.\n", "entity1": "citalopram", "entity2": "Palpebral twitching", "span1": [49, 59], "span2": [0, 19]}, "bert_text": "Palpebral twitching in a depressed adolescent on <e1> citalopram </e1> <e2> Palpebral twitching </e2> in a depressed adolescent on citalopram.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4088": {"data": {"text": "Palpebral twitching in a depressed adolescent on citalopram.\n", "entity1": "citalopram", "entity2": "depressed", "span1": [49, 59], "span2": [25, 34]}, "bert_text": "Palpebral twitching in a depressed adolescent on <e1> citalopram </e1> <e2> depressed </e2> adolescent on citalopram.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4089": {"data": {"text": "Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.", "entity1": "CC", "entity2": "Thromboembolism", "span1": [114, 116], "span2": [0, 15]}, "bert_text": "Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with <e1> CC </e1> <e2> Thromboembolism </e2> is a rare but life-threatening complication that has been reported after ovulation induction with CC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4090": {"data": {"text": "The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).", "entity1": "lithium", "entity2": "polyuria", "span1": [43, 50], "span2": [59, 67]}, "bert_text": "The present study was undertaken to assess <e1> lithium </e1>-induced <e2> polyuria </e2> in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4091": {"data": {"text": "The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).", "entity1": "prostaglandin E", "entity2": "polyuria", "span1": [100, 115], "span2": [59, 67]}, "bert_text": "The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal <e1> prostaglandin E </e1> <e2> polyuria </e2> in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4092": {"data": {"text": "Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.\n", "entity1": "amphetamine", "entity2": "left ventricular apical ballooning syndrome", "span1": [134, 145], "span2": [20, 63]}, "bert_text": "Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of <e1> amphetamine </e1> <e2> left ventricular apical ballooning syndrome </e2> (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4093": {"data": {"text": "Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.\n", "entity1": "amphetamine", "entity2": "Takotsubo cardiomyopathy", "span1": [134, 145], "span2": [73, 97]}, "bert_text": "Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of <e1> amphetamine </e1> <e2> Takotsubo cardiomyopathy </e2>) in a young woman in the setting of amphetamine use.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4094": {"data": {"text": "The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.", "entity1": "metformin", "entity2": "vascular dysfunction", "span1": [22, 31], "span2": [116, 136]}, "bert_text": "The antidiabetic drug <e1> metformin </e1> can diminish apoptosis induced by oxidative stress in endothelial cells and prevent <e2> vascular dysfunction </e2> even in nondiabetic patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4095": {"data": {"text": "In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.", "entity1": "corticosteroid", "entity2": "myopathy", "span1": [71, 85], "span2": [86, 94]}, "bert_text": "In the NASCIS, there was no mention regarding the possibility of acute <e1> corticosteroid </e1> <e2> myopathy </e2> that high-dose methylprednisolone may cause.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4096": {"data": {"text": "In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.", "entity1": "methylprednisolone", "entity2": "myopathy", "span1": [110, 128], "span2": [86, 94]}, "bert_text": "In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose <e1> methylprednisolone </e1> <e2> myopathy </e2> that high-dose methylprednisolone may cause.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4097": {"data": {"text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "entity1": "5-fluorouracil", "entity2": "mental confusion", "span1": [195, 209], "span2": [42, 58]}, "bert_text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of <e1> 5-fluorouracil </e1> <e2> mental confusion </e2>, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4098": {"data": {"text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "entity1": "5-fluorouracil", "entity2": "irritability", "span1": [195, 209], "span2": [79, 91]}, "bert_text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of <e1> 5-fluorouracil </e1> <e2> irritability </e2>, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4099": {"data": {"text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "entity1": "5-fluorouracil", "entity2": "coma", "span1": [195, 209], "span2": [121, 125]}, "bert_text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of <e1> 5-fluorouracil </e1> <e2> coma </e2>, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4100": {"data": {"text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "entity1": "folinic acid", "entity2": "mental confusion", "span1": [214, 226], "span2": [42, 58]}, "bert_text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and <e1> folinic acid </e1> <e2> mental confusion </e2>, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4101": {"data": {"text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "entity1": "folinic acid", "entity2": "irritability", "span1": [214, 226], "span2": [79, 91]}, "bert_text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and <e1> folinic acid </e1> <e2> irritability </e2>, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4102": {"data": {"text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "entity1": "folinic acid", "entity2": "coma", "span1": [214, 226], "span2": [121, 125]}, "bert_text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and <e1> folinic acid </e1> <e2> coma </e2>, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4103": {"data": {"text": "We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.", "entity1": "cyclosporine", "entity2": "TMA", "span1": [76, 88], "span2": [97, 100]}, "bert_text": "We report a case of a living donor renal transplant recipient who developed <e1> cyclosporine </e1>-induced <e2> TMA </e2> that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4104": {"data": {"text": "We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.", "entity1": "cyclosporine", "entity2": "TMA", "span1": [137, 149], "span2": [97, 100]}, "bert_text": "We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of <e1> cyclosporine </e1> <e2> TMA </e2> that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4105": {"data": {"text": "The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.", "entity1": "cytosine arabinoside", "entity2": "toxicity", "span1": [49, 69], "span2": [27, 35]}, "bert_text": "The central nervous system toxicity of high-dose <e1> cytosine arabinoside </e1> <e2> toxicity </e2> of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4106": {"data": {"text": "The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.", "entity1": "cytosine arabinoside", "entity2": "toxicity", "span1": [49, 69], "span2": [98, 106]}, "bert_text": "The central nervous system toxicity of high-dose <e1> cytosine arabinoside </e1> is well recognized, but the <e2> toxicity </e2> of cytosine arabinoside in the peripheral nervous system has been infrequently reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4107": {"data": {"text": "The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.", "entity1": "cytosine arabinoside", "entity2": "toxicity", "span1": [110, 130], "span2": [27, 35]}, "bert_text": "The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of <e1> cytosine arabinoside </e1> <e2> toxicity </e2> of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4108": {"data": {"text": "The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.", "entity1": "cytosine arabinoside", "entity2": "toxicity", "span1": [110, 130], "span2": [98, 106]}, "bert_text": "The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of <e1> cytosine arabinoside </e1> <e2> toxicity </e2> of cytosine arabinoside in the peripheral nervous system has been infrequently reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4109": {"data": {"text": "Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.\n", "entity1": "labetalol", "entity2": "hypotension", "span1": [45, 54], "span2": [22, 33]}, "bert_text": "Effects of deliberate hypotension induced by <e1> labetalol </e1> <e2> hypotension </e2> induced by labetalol with isoflurane on neuropsychological function.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4110": {"data": {"text": "Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.\n", "entity1": "isoflurane", "entity2": "hypotension", "span1": [60, 70], "span2": [22, 33]}, "bert_text": "Effects of deliberate hypotension induced by labetalol with <e1> isoflurane </e1> <e2> hypotension </e2> induced by labetalol with isoflurane on neuropsychological function.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4111": {"data": {"text": "Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.", "entity1": "testosterone", "entity2": "hyperprolactinemia", "span1": [6, 18], "span2": [88, 106]}, "bert_text": "Serum <e1> testosterone </e1> concentration increased with pubertal status but was not affected by <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4112": {"data": {"text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.", "entity1": "PTZ", "entity2": "seizure", "span1": [99, 102], "span2": [71, 78]}, "bert_text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by <e1> PTZ </e1> <e2> seizure </e2> activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4113": {"data": {"text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.", "entity1": "PTZ", "entity2": "seizure", "span1": [99, 102], "span2": [170, 177]}, "bert_text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by <e1> PTZ </e1> and PTX 24 h after gamma-HCH, since the response to only these two <e2> seizure </e2>-inducing agents is decreased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4114": {"data": {"text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.", "entity1": "PTX", "entity2": "seizure", "span1": [107, 110], "span2": [71, 78]}, "bert_text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and <e1> PTX </e1> <e2> seizure </e2> activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4115": {"data": {"text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.", "entity1": "PTX", "entity2": "seizure", "span1": [107, 110], "span2": [170, 177]}, "bert_text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and <e1> PTX </e1> 24 h after gamma-HCH, since the response to only these two <e2> seizure </e2>-inducing agents is decreased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4116": {"data": {"text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.", "entity1": "gamma-HCH", "entity2": "seizure", "span1": [122, 131], "span2": [71, 78]}, "bert_text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after <e1> gamma-HCH </e1> <e2> seizure </e2> activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4117": {"data": {"text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.", "entity1": "gamma-HCH", "entity2": "seizure", "span1": [122, 131], "span2": [170, 177]}, "bert_text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after <e1> gamma-HCH </e1>, since the response to only these two <e2> seizure </e2>-inducing agents is decreased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4118": {"data": {"text": "Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.\n", "entity1": "Succinylcholine", "entity2": "masseter muscle rigidity", "span1": [0, 15], "span2": [24, 48]}, "bert_text": "<e1> Succinylcholine </e1>-induced <e2> masseter muscle rigidity </e2> during bronchoscopic removal of a tracheal foreign body.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4119": {"data": {"text": "OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.", "entity1": "steroid", "entity2": "radiculopathy", "span1": [102, 109], "span2": [57, 70]}, "bert_text": "OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural <e1> steroid </e1> <e2> radiculopathy </e2> are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4120": {"data": {"text": "METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.", "entity1": "iodixanol", "entity2": "nephrotoxic", "span1": [169, 178], "span2": [95, 106]}, "bert_text": "METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, <e1> iodixanol </e1> <e2> nephrotoxic </e2> effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4121": {"data": {"text": "METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.", "entity1": "iohexol", "entity2": "nephrotoxic", "span1": [246, 253], "span2": [95, 106]}, "bert_text": "METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, <e1> iohexol </e1> <e2> nephrotoxic </e2> effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4122": {"data": {"text": "We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.", "entity1": "suxamethonium", "entity2": "myotonia congenita", "span1": [189, 202], "span2": [33, 51]}, "bert_text": "We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous <e1> suxamethonium </e1> <e2> myotonia congenita </e2> in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4123": {"data": {"text": "We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.", "entity1": "suxamethonium", "entity2": "masseter spasm", "span1": [189, 202], "span2": [133, 147]}, "bert_text": "We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous <e1> suxamethonium </e1> <e2> masseter spasm </e2> following a standard dose of intravenous suxamethonium for induction of anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4124": {"data": {"text": "Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.", "entity1": "Suxamethonium", "entity2": "apnea", "span1": [0, 13], "span2": [31, 36]}, "bert_text": "<e1> Suxamethonium </e1> causes prolonged <e2> apnea </e2> in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4125": {"data": {"text": "Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.", "entity1": "organophosphorus (OP) poisons", "entity2": "apnea", "span1": [105, 134], "span2": [31, 36]}, "bert_text": "Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by <e1> organophosphorus (OP) poisons </e1> <e2> apnea </e2> in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4126": {"data": {"text": "This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.", "entity1": "ziprasidone", "entity2": "NMS", "span1": [63, 74], "span2": [52, 55]}, "bert_text": "This case is the earliest (second day of treatment) NMS due to <e1> ziprasidone </e1> <e2> NMS </e2> due to ziprasidone reported in the literature.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"4127": {"data": {"text": "Perhexiline maleate and peripheral neuropathy.\n", "entity1": "Perhexiline maleate", "entity2": "peripheral neuropathy", "span1": [0, 19], "span2": [24, 45]}, "bert_text": "<e1> Perhexiline maleate </e1> and <e2> peripheral neuropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4128": {"data": {"text": "We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.", "entity1": "nimodipine", "entity2": "hypotension", "span1": [30, 40], "span2": [105, 116]}, "bert_text": "We tested the hypothesis that <e1> nimodipine </e1> (NIMO) administered at the onset of nitroglycerin (NTG)-induced <e2> hypotension </e2> would preserve long-term associative memory.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4129": {"data": {"text": "We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.", "entity1": "NIMO", "entity2": "hypotension", "span1": [42, 46], "span2": [105, 116]}, "bert_text": "We tested the hypothesis that nimodipine (<e1> NIMO </e1>) administered at the onset of nitroglycerin (NTG)-induced <e2> hypotension </e2> would preserve long-term associative memory.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4130": {"data": {"text": "We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.", "entity1": "nitroglycerin", "entity2": "hypotension", "span1": [77, 90], "span2": [105, 116]}, "bert_text": "We tested the hypothesis that nimodipine (NIMO) administered at the onset of <e1> nitroglycerin </e1> (NTG)-induced <e2> hypotension </e2> would preserve long-term associative memory.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4131": {"data": {"text": "We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.", "entity1": "NTG)-induced", "entity2": "hypotension", "span1": [92, 104], "span2": [105, 116]}, "bert_text": "We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (<e1> NTG)-induced </e1> <e2> hypotension </e2> would preserve long-term associative memory.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4132": {"data": {"text": "However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [66, 75], "span2": [95, 106]}, "bert_text": "However, clinical reports suggest that, under some circumstances, <e1> sirolimus </e1> is associated with <e2> proteinuria </e2> and acute renal dysfunction.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4133": {"data": {"text": "However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.", "entity1": "sirolimus", "entity2": "acute renal dysfunction", "span1": [66, 75], "span2": [111, 134]}, "bert_text": "However, clinical reports suggest that, under some circumstances, <e1> sirolimus </e1> is associated with proteinuria and <e2> acute renal dysfunction </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4134": {"data": {"text": "Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.", "entity1": "angiotensin", "entity2": "congestive heart failure", "span1": [26, 37], "span2": [120, 144]}, "bert_text": "Since the introduction of <e1> angiotensin </e1> converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with <e2> congestive heart failure </e2>, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4135": {"data": {"text": "Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.", "entity1": "angiotensin", "entity2": "hypotension", "span1": [26, 37], "span2": [162, 173]}, "bert_text": "Since the introduction of <e1> angiotensin </e1> converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe <e2> hypotension </e2>, especially on the first day of treatment, have occasionally been reported.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4136": {"data": {"text": "We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.", "entity1": "paclitaxel", "entity2": "toxicity", "span1": [85, 95], "span2": [62, 70]}, "bert_text": "We initiated a phase I/II trial to determine the response and toxicity of escalating <e1> paclitaxel </e1> <e2> toxicity </e2> of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4137": {"data": {"text": "We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.", "entity1": "paclitaxel", "entity2": "neck carcinoma", "span1": [85, 95], "span2": [252, 266]}, "bert_text": "We initiated a phase I/II trial to determine the response and toxicity of escalating <e1> paclitaxel </e1> doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and <e2> neck carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4138": {"data": {"text": "We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.", "entity1": "cisplatin", "entity2": "toxicity", "span1": [127, 136], "span2": [62, 70]}, "bert_text": "We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose <e1> cisplatin </e1> <e2> toxicity </e2> of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4139": {"data": {"text": "We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.", "entity1": "cisplatin", "entity2": "neck carcinoma", "span1": [127, 136], "span2": [252, 266]}, "bert_text": "We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose <e1> cisplatin </e1> with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and <e2> neck carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4140": {"data": {"text": "Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.\n", "entity1": "cyproterone acetate", "entity2": "venous thromboembolism", "span1": [78, 97], "span2": [34, 56]}, "bert_text": "Absolute and attributable risk of venous thromboembolism in women on combined <e1> cyproterone acetate </e1> <e2> venous thromboembolism </e2> in women on combined cyproterone acetate and ethinylestradiol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"4141": {"data": {"text": "Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.\n", "entity1": "ethinylestradiol", "entity2": "venous thromboembolism", "span1": [102, 118], "span2": [34, 56]}, "bert_text": "Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and <e1> ethinylestradiol </e1> <e2> venous thromboembolism </e2> in women on combined cyproterone acetate and ethinylestradiol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"4142": {"data": {"text": "These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.", "entity1": "TAM", "entity2": "hemolytic anemia", "span1": [100, 103], "span2": [118, 134]}, "bert_text": "These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by <e1> TAM </e1>, resulting in <e2> hemolytic anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4143": {"data": {"text": "Moreover, it transiently diminished the methamphetamine (10 mg/kg sc)-induced hyperthermia and reduced basal body temperature.", "entity1": "methamphetamine", "entity2": "hyperthermia", "span1": [40, 55], "span2": [78, 90]}, "bert_text": "Moreover, it transiently diminished the <e1> methamphetamine </e1> (10 mg/kg sc)-induced <e2> hyperthermia </e2> and reduced basal body temperature.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4144": {"data": {"text": "In conclusion, the present study demonstrates gender differences in the development of the apomorphine-induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method.", "entity1": "apomorphine", "entity2": "aggressive behavior", "span1": [91, 102], "span2": [111, 130]}, "bert_text": "In conclusion, the present study demonstrates gender differences in the development of the <e1> apomorphine </e1>-induced <e2> aggressive behavior </e2> and indicates that the female rats do not fill the validation criteria for use in this method.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4145": {"data": {"text": "In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.", "entity1": "AZT", "entity2": "cardiac dilation", "span1": [13, 16], "span2": [48, 64]}, "bert_text": "In contrast, <e1> AZT </e1>-treated FasL Tg mice developed <e2> cardiac dilation </e2> and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4146": {"data": {"text": "Nitroprusside-induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation.", "entity1": "Nitroprusside", "entity2": "hypotension", "span1": [0, 13], "span2": [22, 33]}, "bert_text": "<e1> Nitroprusside </e1>-induced <e2> hypotension </e2> evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4147": {"data": {"text": "Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.", "entity1": "heparin", "entity2": "arterial occlusion", "span1": [153, 160], "span2": [32, 50]}, "bert_text": "Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of <e1> heparin </e1> <e2> arterial occlusion </e2> by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4148": {"data": {"text": "Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.", "entity1": "heparin", "entity2": "thrombi", "span1": [153, 160], "span2": [70, 77]}, "bert_text": "Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of <e1> heparin </e1> <e2> thrombi </e2> with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4149": {"data": {"text": "Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.", "entity1": "heparin", "entity2": "ischemia", "span1": [153, 160], "span2": [90, 98]}, "bert_text": "Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of <e1> heparin </e1> <e2> ischemia </e2> occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4150": {"data": {"text": "Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [153, 160], "span2": [191, 207]}, "bert_text": "Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of <e1> heparin </e1> therapy, preceded by profound <e2> thrombocytopenia </e2> with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4151": {"data": {"text": "Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.", "entity1": "ketamine", "entity2": "analgesia", "span1": [40, 48], "span2": [70, 79]}, "bert_text": "Previous studies demonstrated that both <e1> ketamine </e1> and morphine induced <e2> analgesia </e2> and catalepsy in the rat.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4152": {"data": {"text": "Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.", "entity1": "ketamine", "entity2": "catalepsy", "span1": [40, 48], "span2": [84, 93]}, "bert_text": "Previous studies demonstrated that both <e1> ketamine </e1> and morphine induced analgesia and <e2> catalepsy </e2> in the rat.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4153": {"data": {"text": "Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.", "entity1": "morphine", "entity2": "analgesia", "span1": [53, 61], "span2": [70, 79]}, "bert_text": "Previous studies demonstrated that both ketamine and <e1> morphine </e1> induced <e2> analgesia </e2> and catalepsy in the rat.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4154": {"data": {"text": "Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.", "entity1": "morphine", "entity2": "catalepsy", "span1": [53, 61], "span2": [84, 93]}, "bert_text": "Previous studies demonstrated that both ketamine and <e1> morphine </e1> induced analgesia and <e2> catalepsy </e2> in the rat.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4155": {"data": {"text": "Haemolytic-uraemic syndrome after treatment with metronidazole.\n", "entity1": "metronidazole", "entity2": "Haemolytic-uraemic syndrome", "span1": [49, 62], "span2": [0, 27]}, "bert_text": "Haemolytic-uraemic syndrome after treatment with <e1> metronidazole </e1> <e2> Haemolytic-uraemic syndrome </e2> after treatment with metronidazole.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4156": {"data": {"text": "The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.", "entity1": "molindone", "entity2": "schizophrenic", "span1": [130, 139], "span2": [14, 27]}, "bert_text": "The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following <e1> molindone </e1> <e2> schizophrenic </e2> patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4157": {"data": {"text": "The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.", "entity1": "molindone", "entity2": "rhabdomyolysis", "span1": [130, 139], "span2": [70, 84]}, "bert_text": "The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following <e1> molindone </e1> <e2> rhabdomyolysis </e2> and subsequent acute renal failure following molindone administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4158": {"data": {"text": "The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.", "entity1": "molindone", "entity2": "acute renal failure", "span1": [130, 139], "span2": [100, 119]}, "bert_text": "The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following <e1> molindone </e1> <e2> acute renal failure </e2> following molindone administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4159": {"data": {"text": "Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization.\n", "entity1": "lidocaine", "entity2": "pain", "span1": [43, 52], "span2": [23, 27]}, "bert_text": "Reduction in injection pain using buffered <e1> lidocaine </e1> <e2> pain </e2> using buffered lidocaine as a local anesthetic before cardiac catheterization.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4160": {"data": {"text": "A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.", "entity1": "PPA", "entity2": "hypertension", "span1": [9, 12], "span2": [63, 75]}, "bert_text": "A single <e1> PPA </e1>/caffeine administration (same dose) lead to acute <e2> hypertension </e2> in both the normotensive and hypertensive animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4161": {"data": {"text": "A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.", "entity1": "PPA", "entity2": "hypertensive", "span1": [9, 12], "span2": [105, 117]}, "bert_text": "A single <e1> PPA </e1>/caffeine administration (same dose) lead to acute hypertension in both the normotensive and <e2> hypertensive </e2> animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4162": {"data": {"text": "A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.", "entity1": "caffeine", "entity2": "hypertension", "span1": [13, 21], "span2": [63, 75]}, "bert_text": "A single PPA/<e1> caffeine </e1> administration (same dose) lead to acute <e2> hypertension </e2> in both the normotensive and hypertensive animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4163": {"data": {"text": "A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.", "entity1": "caffeine", "entity2": "hypertensive", "span1": [13, 21], "span2": [105, 117]}, "bert_text": "A single PPA/<e1> caffeine </e1> administration (same dose) lead to acute hypertension in both the normotensive and <e2> hypertensive </e2> animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4164": {"data": {"text": "In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.", "entity1": "D-MED", "entity2": "muscle rigidity", "span1": [13, 18], "span2": [48, 63]}, "bert_text": "In contrast, <e1> D-MED </e1> prevented alfentanil-induced <e2> muscle rigidity </e2> in a dose-dependent fashion.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4165": {"data": {"text": "In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.", "entity1": "alfentanil", "entity2": "muscle rigidity", "span1": [29, 39], "span2": [48, 63]}, "bert_text": "In contrast, D-MED prevented <e1> alfentanil </e1>-induced <e2> muscle rigidity </e2> in a dose-dependent fashion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4166": {"data": {"text": "Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.", "entity1": "Levodopa", "entity2": "dyskinesias", "span1": [0, 8], "span2": [17, 28]}, "bert_text": "<e1> Levodopa </e1>-induced <e2> dyskinesias </e2> have been reported in Parkinson's disease and multiple system atrophy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4167": {"data": {"text": "Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.", "entity1": "Levodopa", "entity2": "Parkinson's disease", "span1": [0, 8], "span2": [51, 70]}, "bert_text": "<e1> Levodopa </e1>-induced dyskinesias have been reported in <e2> Parkinson's disease </e2> and multiple system atrophy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4168": {"data": {"text": "Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.", "entity1": "Levodopa", "entity2": "multiple system atrophy", "span1": [0, 8], "span2": [75, 98]}, "bert_text": "<e1> Levodopa </e1>-induced dyskinesias have been reported in Parkinson's disease and <e2> multiple system atrophy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4169": {"data": {"text": "Fatal intracranial bleeding associated with prehospital use of epinephrine.\n", "entity1": "epinephrine", "entity2": "intracranial bleeding", "span1": [63, 74], "span2": [6, 27]}, "bert_text": "Fatal intracranial bleeding associated with prehospital use of <e1> epinephrine </e1> <e2> intracranial bleeding </e2> associated with prehospital use of epinephrine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4170": {"data": {"text": "Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.", "entity1": "ADR", "entity2": "cardiovascular arrhythmias", "span1": [53, 56], "span2": [64, 90]}, "bert_text": "Our results indicated that 1) treatment of mice with <e1> ADR </e1> caused <e2> cardiovascular arrhythmias </e2> characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4171": {"data": {"text": "Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.", "entity1": "ADR", "entity2": "bradycardia", "span1": [53, 56], "span2": [108, 119]}, "bert_text": "Our results indicated that 1) treatment of mice with <e1> ADR </e1> caused cardiovascular arrhythmias characterized by <e2> bradycardia </e2>, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4172": {"data": {"text": "Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.", "entity1": "ADR", "entity2": "swelling", "span1": [53, 56], "span2": [295, 303]}, "bert_text": "Our results indicated that 1) treatment of mice with <e1> ADR </e1> caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent <e2> swelling </e2>, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4173": {"data": {"text": "This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.", "entity1": "bisphosphonates", "entity2": "proteinuria", "span1": [66, 81], "span2": [96, 107]}, "bert_text": "This report demonstrates that not only intravenous, but also oral <e1> bisphosphonates </e1> can aggravate <e2> proteinuria </e2> and acute renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4174": {"data": {"text": "This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.", "entity1": "bisphosphonates", "entity2": "acute renal failure", "span1": [66, 81], "span2": [112, 131]}, "bert_text": "This report demonstrates that not only intravenous, but also oral <e1> bisphosphonates </e1> can aggravate proteinuria and <e2> acute renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4175": {"data": {"text": "Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [11, 19], "span2": [28, 39]}, "bert_text": "Control of <e1> levodopa </e1>-induced <e2> dyskinesias </e2> by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4176": {"data": {"text": "Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.", "entity1": "levodopa", "entity2": "thalamic lesions", "span1": [11, 19], "span2": [43, 59]}, "bert_text": "Control of <e1> levodopa </e1>-induced dyskinesias by <e2> thalamic lesions </e2> in the course of routine treatment of Parkinsonism is discussed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4177": {"data": {"text": "Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.", "entity1": "levodopa", "entity2": "Parkinsonism", "span1": [11, 19], "span2": [98, 110]}, "bert_text": "Control of <e1> levodopa </e1>-induced dyskinesias by thalamic lesions in the course of routine treatment of <e2> Parkinsonism </e2> is discussed.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4178": {"data": {"text": "These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.", "entity1": "PGE1", "entity2": "hypotensive", "span1": [27, 31], "span2": [61, 72]}, "bert_text": "These results suggest that <e1> PGE1 </e1> may be preferable to TMP for <e2> hypotensive </e2> anaesthesia in spinal surgery because TMP decreased EBF.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4179": {"data": {"text": "These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.", "entity1": "TMP", "entity2": "hypotensive", "span1": [53, 56], "span2": [61, 72]}, "bert_text": "These results suggest that PGE1 may be preferable to <e1> TMP </e1> for <e2> hypotensive </e2> anaesthesia in spinal surgery because TMP decreased EBF.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4180": {"data": {"text": "These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.", "entity1": "TMP", "entity2": "hypotensive", "span1": [111, 114], "span2": [61, 72]}, "bert_text": "These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because <e1> TMP </e1> <e2> hypotensive </e2> anaesthesia in spinal surgery because TMP decreased EBF.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4181": {"data": {"text": "CONCLUSIONS: Delirium was found in 10 % of clozapine-treated inpatients, particularly in older patients exposed to other central anticholinergics.", "entity1": "clozapine", "entity2": "Delirium", "span1": [43, 52], "span2": [13, 21]}, "bert_text": "CONCLUSIONS: Delirium was found in 10 % of <e1> clozapine </e1> <e2> Delirium </e2> was found in 10 % of clozapine-treated inpatients, particularly in older patients exposed to other central anticholinergics.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4182": {"data": {"text": "Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.", "entity1": "paracetamol", "entity2": "hepatotoxicity", "span1": [106, 117], "span2": [45, 59]}, "bert_text": "Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of <e1> paracetamol </e1> <e2> hepatotoxicity </e2> in patients treated with therapeutic doses of paracetamol are discussed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4183": {"data": {"text": "A case of valproate-induced encephalopathy is presented.", "entity1": "valproate", "entity2": "encephalopathy", "span1": [10, 19], "span2": [28, 42]}, "bert_text": "A case of <e1> valproate </e1>-induced <e2> encephalopathy </e2> is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4184": {"data": {"text": "In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.", "entity1": "METH", "entity2": "psychosis", "span1": [172, 176], "span2": [185, 194]}, "bert_text": "In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and <e1> METH </e1>-induced <e2> psychosis </e2> patients, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4185": {"data": {"text": "Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.", "entity1": "fluconazole", "entity2": "ventricular arrhythmias", "span1": [62, 73], "span2": [122, 145]}, "bert_text": "Serial electrocardiographic monitoring may be considered when <e1> fluconazole </e1> is administered in patients who are at risk for <e2> ventricular arrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4186": {"data": {"text": "Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.", "entity1": "amiodarone", "entity2": "VT", "span1": [20, 30], "span2": [81, 83]}, "bert_text": "Although large-dose <e1> amiodarone </e1> is highly effective in the long-term treatment of <e2> VT </e2> or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4187": {"data": {"text": "Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.", "entity1": "amiodarone", "entity2": "VF", "span1": [20, 30], "span2": [87, 89]}, "bert_text": "Although large-dose <e1> amiodarone </e1> is highly effective in the long-term treatment of VT or <e2> VF </e2> refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4188": {"data": {"text": "Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.", "entity1": "amiodarone", "entity2": "toxicity", "span1": [20, 30], "span2": [161, 169]}, "bert_text": "Although large-dose <e1> amiodarone </e1> is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant <e2> toxicity </e2> in approximately 50% of patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4189": {"data": {"text": "We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.", "entity1": "bupivacaine", "entity2": "neurological deficit", "span1": [130, 141], "span2": [32, 52]}, "bert_text": "We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric <e1> bupivacaine </e1> <e2> neurological deficit </e2> that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4190": {"data": {"text": "Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.", "entity1": "cocaine", "entity2": "seizures", "span1": [8, 15], "span2": [24, 32]}, "bert_text": "Whereas <e1> cocaine </e1>-induced <e2> seizures </e2> were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4191": {"data": {"text": "Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.", "entity1": "cocaine", "entity2": "death", "span1": [8, 15], "span2": [106, 111]}, "bert_text": "Whereas <e1> cocaine </e1>-induced seizures were best characterized as brief, generalized, and tonic and resulted in <e2> death </e2>, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4192": {"data": {"text": "Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.", "entity1": "cocaine", "entity2": "death", "span1": [8, 15], "span2": [206, 211]}, "bert_text": "Whereas <e1> cocaine </e1>-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in <e2> death </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4193": {"data": {"text": "Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.", "entity1": "BE", "entity2": "seizures", "span1": [130, 132], "span2": [24, 32]}, "bert_text": "Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by <e1> BE </e1> <e2> seizures </e2> were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4194": {"data": {"text": "Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.", "entity1": "BE", "entity2": "death", "span1": [130, 132], "span2": [106, 111]}, "bert_text": "Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by <e1> BE </e1> <e2> death </e2>, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4195": {"data": {"text": "Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.", "entity1": "BE", "entity2": "death", "span1": [130, 132], "span2": [206, 211]}, "bert_text": "Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by <e1> BE </e1> were prolonged, often multiple and mixed in type, and rarely resulted in <e2> death </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4196": {"data": {"text": "Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.", "entity1": "spironolactone", "entity2": "heart failure", "span1": [72, 86], "span2": [23, 36]}, "bert_text": "Because treatments for heart failure have changed since the benefits of <e1> spironolactone </e1> <e2> heart failure </e2> have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4197": {"data": {"text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "entity1": "paclitaxel", "entity2": "neck cancer", "span1": [83, 93], "span2": [202, 213]}, "bert_text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent <e1> paclitaxel </e1> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and <e2> neck cancer </e2>, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4198": {"data": {"text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "entity1": "paclitaxel", "entity2": "ovarian cancer", "span1": [83, 93], "span2": [342, 356]}, "bert_text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent <e1> paclitaxel </e1> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in <e2> ovarian cancer </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4199": {"data": {"text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "entity1": "Taxol", "entity2": "neck cancer", "span1": [95, 100], "span2": [202, 213]}, "bert_text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (<e1> Taxol </e1>; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and <e2> neck cancer </e2>, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4200": {"data": {"text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "entity1": "Taxol", "entity2": "ovarian cancer", "span1": [95, 100], "span2": [342, 356]}, "bert_text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (<e1> Taxol </e1>; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in <e2> ovarian cancer </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4201": {"data": {"text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "entity1": "paclitaxel", "entity2": "neck cancer", "span1": [223, 233], "span2": [202, 213]}, "bert_text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the <e1> paclitaxel </e1> <e2> neck cancer </e2>, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4202": {"data": {"text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "entity1": "paclitaxel", "entity2": "ovarian cancer", "span1": [223, 233], "span2": [342, 356]}, "bert_text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the <e1> paclitaxel </e1>/cisplatin combination has been used successfully and has significantly improved median response duration in <e2> ovarian cancer </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4203": {"data": {"text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "entity1": "cisplatin", "entity2": "neck cancer", "span1": [234, 243], "span2": [202, 213]}, "bert_text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/<e1> cisplatin </e1> <e2> neck cancer </e2>, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4204": {"data": {"text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.", "entity1": "cisplatin", "entity2": "ovarian cancer", "span1": [234, 243], "span2": [342, 356]}, "bert_text": "Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/<e1> cisplatin </e1> combination has been used successfully and has significantly improved median response duration in <e2> ovarian cancer </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4205": {"data": {"text": "Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.", "entity1": "bradykinin", "entity2": "neuropathic pain", "span1": [56, 66], "span2": [150, 166]}, "bert_text": "Therefore, concomitant administration of small doses of <e1> bradykinin </e1> receptor antagonists and NO synthase inhibitors can be effective in alleviation of <e2> neuropathic pain </e2>, even in hospital care.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4206": {"data": {"text": "Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.\n", "entity1": "corticosterone", "entity2": "neuropathy", "span1": [55, 69], "span2": [106, 116]}, "bert_text": "Dose-related beneficial and adverse effects of dietary <e1> corticosterone </e1> on organophosphorus-induced delayed <e2> neuropathy </e2> in chickens.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4207": {"data": {"text": "Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.\n", "entity1": "organophosphorus", "entity2": "neuropathy", "span1": [73, 89], "span2": [106, 116]}, "bert_text": "Dose-related beneficial and adverse effects of dietary corticosterone on <e1> organophosphorus </e1>-induced delayed <e2> neuropathy </e2> in chickens.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4208": {"data": {"text": "Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.", "entity1": "BCNU", "entity2": "malignant gliomas", "span1": [43, 47], "span2": [211, 228]}, "bert_text": "Because of the rapid systemic clearance of <e1> BCNU </e1> (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of <e2> malignant gliomas </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4209": {"data": {"text": "Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.", "entity1": "1,3-bis-(2-chloroethyl)-1-nitrosourea", "entity2": "malignant gliomas", "span1": [49, 86], "span2": [211, 228]}, "bert_text": "Because of the rapid systemic clearance of BCNU (<e1> 1,3-bis-(2-chloroethyl)-1-nitrosourea </e1>), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of <e2> malignant gliomas </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4210": {"data": {"text": "To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.", "entity1": "atorvastatin", "entity2": "hypertension", "span1": [37, 49], "span2": [90, 102]}, "bert_text": "To assess the antioxidant effects of <e1> atorvastatin </e1> (atorva) on dexamethasone (dex)-induced <e2> hypertension </e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4211": {"data": {"text": "To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.", "entity1": "atorva", "entity2": "hypertension", "span1": [51, 57], "span2": [90, 102]}, "bert_text": "To assess the antioxidant effects of atorvastatin (<e1> atorva </e1>) on dexamethasone (dex)-induced <e2> hypertension </e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4212": {"data": {"text": "To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.", "entity1": "atorva", "entity2": "hypertension", "span1": [150, 156], "span2": [90, 102]}, "bert_text": "To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with <e1> atorva </e1> <e2> hypertension </e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4213": {"data": {"text": "To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.", "entity1": "dexamethasone", "entity2": "hypertension", "span1": [62, 75], "span2": [90, 102]}, "bert_text": "To assess the antioxidant effects of atorvastatin (atorva) on <e1> dexamethasone </e1> (dex)-induced <e2> hypertension </e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4214": {"data": {"text": "To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.", "entity1": "dex)-induced", "entity2": "hypertension", "span1": [77, 89], "span2": [90, 102]}, "bert_text": "To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (<e1> dex)-induced </e1> <e2> hypertension </e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4215": {"data": {"text": "BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).", "entity1": "spironolactone", "entity2": "heart failure", "span1": [73, 87], "span2": [91, 104]}, "bert_text": "BACKGROUND: A previous randomized controlled trial evaluating the use of <e1> spironolactone </e1> in <e2> heart failure </e2> patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4216": {"data": {"text": "BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).", "entity1": "spironolactone", "entity2": "hyperkalemia", "span1": [73, 87], "span2": [137, 149]}, "bert_text": "BACKGROUND: A previous randomized controlled trial evaluating the use of <e1> spironolactone </e1> in heart failure patients reported a low risk of <e2> hyperkalemia </e2> (2%) and renal insufficiency (0%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4217": {"data": {"text": "BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).", "entity1": "spironolactone", "entity2": "renal insufficiency", "span1": [73, 87], "span2": [159, 178]}, "bert_text": "BACKGROUND: A previous randomized controlled trial evaluating the use of <e1> spironolactone </e1> in heart failure patients reported a low risk of hyperkalemia (2%) and <e2> renal insufficiency </e2> (0%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4218": {"data": {"text": "Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.", "entity1": "Atracurium besylate", "entity2": "paralysis", "span1": [0, 19], "span2": [166, 175]}, "bert_text": "<e1> Atracurium besylate </e1>, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent <e2> paralysis </e2>, but only when used with corticosteroids.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4219": {"data": {"text": "Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.", "entity1": "corticosteroids", "entity2": "paralysis", "span1": [201, 216], "span2": [166, 175]}, "bert_text": "Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with <e1> corticosteroids </e1> <e2> paralysis </e2>, but only when used with corticosteroids.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4220": {"data": {"text": "Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.", "entity1": "apomorphine", "entity2": "Parkinson disease", "span1": [291, 302], "span2": [135, 152]}, "bert_text": "Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous <e1> apomorphine </e1> <e2> Parkinson disease </e2>, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4221": {"data": {"text": "Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.", "entity1": "apomorphine", "entity2": "dyskinetic", "span1": [291, 302], "span2": [252, 262]}, "bert_text": "Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous <e1> apomorphine </e1> <e2> dyskinetic </e2> state induced by continuous apomorphine infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4222": {"data": {"text": "Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.\n", "entity1": "aminonucleoside", "entity2": "proteinuria", "span1": [40, 55], "span2": [64, 75]}, "bert_text": "Effect of captopril on pre-existing and <e1> aminonucleoside </e1>-induced <e2> proteinuria </e2> in spontaneously hypertensive rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4223": {"data": {"text": "Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.\n", "entity1": "aminonucleoside", "entity2": "hypertensive", "span1": [40, 55], "span2": [93, 105]}, "bert_text": "Effect of captopril on pre-existing and <e1> aminonucleoside </e1>-induced proteinuria in spontaneously <e2> hypertensive </e2> rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4224": {"data": {"text": "Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.", "entity1": "thiamine", "entity2": "Peripheral neuropathy", "span1": [55, 63], "span2": [0, 21]}, "bert_text": "Peripheral neuropathy due to nutritional deficiency of <e1> thiamine </e1> <e2> Peripheral neuropathy </e2> due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4225": {"data": {"text": "Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.", "entity1": "thiamine", "entity2": "nutritional deficiency", "span1": [55, 63], "span2": [29, 51]}, "bert_text": "Peripheral neuropathy due to nutritional deficiency of <e1> thiamine </e1> <e2> nutritional deficiency </e2> of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4226": {"data": {"text": "Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.", "entity1": "thiamine", "entity2": "sensori-motor neuropathy", "span1": [55, 63], "span2": [134, 158]}, "bert_text": "Peripheral neuropathy due to nutritional deficiency of <e1> thiamine </e1> and riboflavin was common (10.1%) and presented mainly as sensory and <e2> sensori-motor neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4227": {"data": {"text": "Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.", "entity1": "riboflavin", "entity2": "Peripheral neuropathy", "span1": [68, 78], "span2": [0, 21]}, "bert_text": "Peripheral neuropathy due to nutritional deficiency of thiamine and <e1> riboflavin </e1> <e2> Peripheral neuropathy </e2> due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4228": {"data": {"text": "Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.", "entity1": "riboflavin", "entity2": "nutritional deficiency", "span1": [68, 78], "span2": [29, 51]}, "bert_text": "Peripheral neuropathy due to nutritional deficiency of thiamine and <e1> riboflavin </e1> <e2> nutritional deficiency </e2> of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4229": {"data": {"text": "Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.", "entity1": "riboflavin", "entity2": "sensori-motor neuropathy", "span1": [68, 78], "span2": [134, 158]}, "bert_text": "Peripheral neuropathy due to nutritional deficiency of thiamine and <e1> riboflavin </e1> was common (10.1%) and presented mainly as sensory and <e2> sensori-motor neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4230": {"data": {"text": "Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.", "entity1": "amiodarone", "entity2": "CHF", "span1": [21, 31], "span2": [14, 17]}, "bert_text": "Patients with CHF on <e1> amiodarone </e1> <e2> CHF </e2> on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4231": {"data": {"text": "Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.", "entity1": "amiodarone", "entity2": "hypothyroidism", "span1": [21, 31], "span2": [80, 94]}, "bert_text": "Patients with CHF on <e1> amiodarone </e1> may suffer serious morbidity and mortality from <e2> hypothyroidism </e2>, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4232": {"data": {"text": "Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.\n", "entity1": "morphine", "entity2": "Hyperalgesia", "span1": [91, 99], "span2": [0, 12]}, "bert_text": "Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous <e1> morphine </e1> <e2> Hyperalgesia </e2> and myoclonus in terminal cancer patients treated with continuous intravenous morphine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4233": {"data": {"text": "Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.\n", "entity1": "morphine", "entity2": "myoclonus", "span1": [91, 99], "span2": [17, 26]}, "bert_text": "Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous <e1> morphine </e1> <e2> myoclonus </e2> in terminal cancer patients treated with continuous intravenous morphine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4234": {"data": {"text": "Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.\n", "entity1": "morphine", "entity2": "cancer", "span1": [91, 99], "span2": [39, 45]}, "bert_text": "Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous <e1> morphine </e1> <e2> cancer </e2> patients treated with continuous intravenous morphine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4235": {"data": {"text": "This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.", "entity1": "midazolam", "entity2": "cardiorespiratory arrest", "span1": [133, 142], "span2": [50, 74]}, "bert_text": "This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of <e1> midazolam </e1> <e2> cardiorespiratory arrest </e2> and death associated with intramuscular administration of midazolam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4236": {"data": {"text": "This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.", "entity1": "midazolam", "entity2": "death", "span1": [133, 142], "span2": [79, 84]}, "bert_text": "This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of <e1> midazolam </e1> <e2> death </e2> associated with intramuscular administration of midazolam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4237": {"data": {"text": "Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.\n", "entity1": "daunorubicin", "entity2": "Kaposi's sarcoma", "span1": [10, 22], "span2": [35, 51]}, "bert_text": "Liposomal <e1> daunorubicin </e1> in advanced <e2> Kaposi's sarcoma </e2>: a phase II study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4238": {"data": {"text": "Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.", "entity1": "carmofur", "entity2": "leukoencephalopathy", "span1": [14, 22], "span2": [31, 50]}, "bert_text": "Consequently, <e1> carmofur </e1>-induced <e2> leukoencephalopathy </e2> may uncommonly result in organic personality syndrome in the residual state.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4239": {"data": {"text": "Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.", "entity1": "carmofur", "entity2": "organic personality syndrome", "span1": [14, 22], "span2": [76, 104]}, "bert_text": "Consequently, <e1> carmofur </e1>-induced leukoencephalopathy may uncommonly result in <e2> organic personality syndrome </e2> in the residual state.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4240": {"data": {"text": "CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.", "entity1": "METH", "entity2": "psychosis", "span1": [70, 74], "span2": [83, 92]}, "bert_text": "CONCLUSION: HTR6 may play an important role in the pathophysiology of <e1> METH </e1>-induced <e2> psychosis </e2> in the Japanese population.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4241": {"data": {"text": "Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.", "entity1": "tacrolimus", "entity2": "neurologic complications", "span1": [111, 121], "span2": [136, 160]}, "bert_text": "Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving <e1> tacrolimus </e1> who developed <e2> neurologic complications </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4242": {"data": {"text": "CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.", "entity1": "alcohol", "entity2": "liver failure", "span1": [71, 78], "span2": [80, 93]}, "bert_text": "CONCLUSION: In patients with risk factors, e.g. regular consumption of <e1> alcohol </e1>, <e2> liver failure </e2> is possible when therapeutic doses are ingested.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4243": {"data": {"text": "Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.", "entity1": "terbutaline", "entity2": "cardiovascular complications", "span1": [83, 94], "span2": [7, 35]}, "bert_text": "Severe cardiovascular complications occurred in eight of 160 patients treated with <e1> terbutaline </e1> <e2> cardiovascular complications </e2> occurred in eight of 160 patients treated with terbutaline for preterm labor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4244": {"data": {"text": "Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.", "entity1": "terbutaline", "entity2": "preterm labor", "span1": [83, 94], "span2": [99, 112]}, "bert_text": "Severe cardiovascular complications occurred in eight of 160 patients treated with <e1> terbutaline </e1> for <e2> preterm labor </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4245": {"data": {"text": "Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [37, 44], "span2": [53, 69]}, "bert_text": "Delayed recognition and treatment of <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> contribute to poor patient outcomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4246": {"data": {"text": "RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.", "entity1": "cyclophosphamide", "entity2": "CHF", "span1": [96, 112], "span2": [71, 74]}, "bert_text": "RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional <e1> cyclophosphamide </e1> <e2> CHF </e2> following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4247": {"data": {"text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "entity1": "potassium", "entity2": "hypokalemia", "span1": [147, 156], "span2": [13, 24]}, "bert_text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by <e1> potassium </e1> <e2> hypokalemia </e2> may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4248": {"data": {"text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "entity1": "potassium", "entity2": "muscle weakness", "span1": [147, 156], "span2": [35, 50]}, "bert_text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by <e1> potassium </e1> <e2> muscle weakness </e2>, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4249": {"data": {"text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "entity1": "potassium", "entity2": "hypomagnesemia", "span1": [147, 156], "span2": [59, 73]}, "bert_text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by <e1> potassium </e1> <e2> hypomagnesemia </e2> is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4250": {"data": {"text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "entity1": "potassium", "entity2": "muscle spasms", "span1": [147, 156], "span2": [93, 106]}, "bert_text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by <e1> potassium </e1> <e2> muscle spasms </e2> and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4251": {"data": {"text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "entity1": "potassium", "entity2": "tetany", "span1": [147, 156], "span2": [111, 117]}, "bert_text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by <e1> potassium </e1> <e2> tetany </e2> which cannot be corrected by potassium and calcium supplementation alone (1,2).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4252": {"data": {"text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "entity1": "calcium", "entity2": "hypokalemia", "span1": [161, 168], "span2": [13, 24]}, "bert_text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and <e1> calcium </e1> <e2> hypokalemia </e2> may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4253": {"data": {"text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "entity1": "calcium", "entity2": "muscle weakness", "span1": [161, 168], "span2": [35, 50]}, "bert_text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and <e1> calcium </e1> <e2> muscle weakness </e2>, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4254": {"data": {"text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "entity1": "calcium", "entity2": "hypomagnesemia", "span1": [161, 168], "span2": [59, 73]}, "bert_text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and <e1> calcium </e1> <e2> hypomagnesemia </e2> is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4255": {"data": {"text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "entity1": "calcium", "entity2": "muscle spasms", "span1": [161, 168], "span2": [93, 106]}, "bert_text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and <e1> calcium </e1> <e2> muscle spasms </e2> and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4256": {"data": {"text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).", "entity1": "calcium", "entity2": "tetany", "span1": [161, 168], "span2": [111, 117]}, "bert_text": "While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and <e1> calcium </e1> <e2> tetany </e2> which cannot be corrected by potassium and calcium supplementation alone (1,2).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4257": {"data": {"text": "Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.", "entity1": "CBZ", "entity2": "seizures", "span1": [13, 16], "span2": [82, 90]}, "bert_text": "Chronic oral <e1> CBZ </e1> inhibited the development of both lidocaine- and cocaine-induced <e2> seizures </e2>, but had little effect on the fully developed local anesthetic seizures.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4258": {"data": {"text": "Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.", "entity1": "CBZ", "entity2": "seizures", "span1": [13, 16], "span2": [154, 162]}, "bert_text": "Chronic oral <e1> CBZ </e1> inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4259": {"data": {"text": "Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.", "entity1": "lidocaine-", "entity2": "seizures", "span1": [51, 61], "span2": [82, 90]}, "bert_text": "Chronic oral CBZ inhibited the development of both <e1> lidocaine- </e1> and cocaine-induced <e2> seizures </e2>, but had little effect on the fully developed local anesthetic seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4260": {"data": {"text": "Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.", "entity1": "lidocaine-", "entity2": "seizures", "span1": [51, 61], "span2": [154, 162]}, "bert_text": "Chronic oral CBZ inhibited the development of both <e1> lidocaine- </e1> and cocaine-induced seizures, but had little effect on the fully developed local anesthetic <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4261": {"data": {"text": "Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.", "entity1": "cocaine", "entity2": "seizures", "span1": [66, 73], "span2": [82, 90]}, "bert_text": "Chronic oral CBZ inhibited the development of both lidocaine- and <e1> cocaine </e1>-induced <e2> seizures </e2>, but had little effect on the fully developed local anesthetic seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4262": {"data": {"text": "Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.", "entity1": "cocaine", "entity2": "seizures", "span1": [66, 73], "span2": [154, 162]}, "bert_text": "Chronic oral CBZ inhibited the development of both lidocaine- and <e1> cocaine </e1>-induced seizures, but had little effect on the fully developed local anesthetic <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4263": {"data": {"text": "Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.", "entity1": "bupropion HCl", "entity2": "convulsions", "span1": [145, 158], "span2": [211, 222]}, "bert_text": "Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of <e1> bupropion HCl </e1> 120 mg/kg was associated with a 91% reduced odds of <e2> convulsions </e2> at infusion times of 15 to 90 min compared to bolus injection.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4264": {"data": {"text": "A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.", "entity1": "dacarbazine", "entity2": "veno-occlusive disease", "span1": [71, 82], "span2": [10, 32]}, "bert_text": "A case of veno-occlusive disease of the liver with fatal outcome after <e1> dacarbazine </e1> <e2> veno-occlusive disease </e2> of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4265": {"data": {"text": "A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.", "entity1": "dacarbazine", "entity2": "melanoma", "span1": [71, 82], "span2": [102, 110]}, "bert_text": "A case of veno-occlusive disease of the liver with fatal outcome after <e1> dacarbazine </e1> (DTIC) therapy for <e2> melanoma </e2> is reported.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4266": {"data": {"text": "A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.", "entity1": "DTIC", "entity2": "veno-occlusive disease", "span1": [84, 88], "span2": [10, 32]}, "bert_text": "A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (<e1> DTIC </e1> <e2> veno-occlusive disease </e2> of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4267": {"data": {"text": "A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.", "entity1": "DTIC", "entity2": "melanoma", "span1": [84, 88], "span2": [102, 110]}, "bert_text": "A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (<e1> DTIC </e1>) therapy for <e2> melanoma </e2> is reported.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4268": {"data": {"text": "Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.\n", "entity1": "lactate", "entity2": "cardiomyopathy", "span1": [74, 81], "span2": [39, 53]}, "bert_text": "Combined antiretroviral therapy causes cardiomyopathy and elevates plasma <e1> lactate </e1> <e2> cardiomyopathy </e2> and elevates plasma lactate in transgenic AIDS mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4269": {"data": {"text": "Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.\n", "entity1": "lactate", "entity2": "AIDS", "span1": [74, 81], "span2": [96, 100]}, "bert_text": "Combined antiretroviral therapy causes cardiomyopathy and elevates plasma <e1> lactate </e1> in transgenic <e2> AIDS </e2> mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4270": {"data": {"text": "Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.", "entity1": "PREGS", "entity2": "amnesia", "span1": [72, 77], "span2": [184, 191]}, "bert_text": "Moreover, enantioselectivity was demonstrated by the ability of natural <e1> PREGS </e1> to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4271": {"data": {"text": "Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [164, 175], "span2": [184, 191]}, "bert_text": "Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing <e1> scopolamine </e1>-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4272": {"data": {"text": "There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.", "entity1": "azathioprine", "entity2": "rheumatoid arthritis", "span1": [93, 105], "span2": [59, 79]}, "bert_text": "There have been several long-term studies of patients with rheumatoid arthritis treated with <e1> azathioprine </e1> <e2> rheumatoid arthritis </e2> treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4273": {"data": {"text": "There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.", "entity1": "azathioprine", "entity2": "cancers", "span1": [93, 105], "span2": [167, 174]}, "bert_text": "There have been several long-term studies of patients with rheumatoid arthritis treated with <e1> azathioprine </e1> and cyclophosphamide and the incidence of most of the common <e2> cancers </e2> is not increased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4274": {"data": {"text": "There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.", "entity1": "cyclophosphamide", "entity2": "rheumatoid arthritis", "span1": [110, 126], "span2": [59, 79]}, "bert_text": "There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and <e1> cyclophosphamide </e1> <e2> rheumatoid arthritis </e2> treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4275": {"data": {"text": "There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.", "entity1": "cyclophosphamide", "entity2": "cancers", "span1": [110, 126], "span2": [167, 174]}, "bert_text": "There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and <e1> cyclophosphamide </e1> and the incidence of most of the common <e2> cancers </e2> is not increased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4276": {"data": {"text": "Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.", "entity1": "morphine", "entity2": "cancer", "span1": [99, 107], "span2": [6, 12]}, "bert_text": "Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous <e1> morphine </e1> <e2> cancer </e2> patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4277": {"data": {"text": "Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.", "entity1": "morphine", "entity2": "hyperalgesia", "span1": [99, 107], "span2": [118, 130]}, "bert_text": "Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous <e1> morphine </e1> developed <e2> hyperalgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4278": {"data": {"text": "To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.", "entity1": "cocaine", "entity2": "convulsive", "span1": [49, 56], "span2": [231, 241]}, "bert_text": "To further validate the hypothesis that the anti-<e1> cocaine </e1> effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the <e2> convulsive </e2> and locomotor stimulatory effects of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4279": {"data": {"text": "To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.", "entity1": "cocaine", "entity2": "convulsive", "span1": [279, 286], "span2": [231, 241]}, "bert_text": "To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of <e1> cocaine </e1> <e2> convulsive </e2> and locomotor stimulatory effects of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4280": {"data": {"text": "To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.", "entity1": "oligodeoxynucleotide", "entity2": "convulsive", "span1": [139, 159], "span2": [231, 241]}, "bert_text": "To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense <e1> oligodeoxynucleotide </e1> against sigma1 receptors was also shown to significantly attenuate the <e2> convulsive </e2> and locomotor stimulatory effects of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4281": {"data": {"text": "Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.\n", "entity1": "ifosfamide", "entity2": "urothelial toxicity", "span1": [13, 23], "span2": [32, 51]}, "bert_text": "Treatment of <e1> ifosfamide </e1>-induced <e2> urothelial toxicity </e2> by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4282": {"data": {"text": "Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.\n", "entity1": "ifosfamide", "entity2": "lung cancer", "span1": [13, 23], "span2": [149, 160]}, "bert_text": "Treatment of <e1> ifosfamide </e1>-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable <e2> lung cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4283": {"data": {"text": "Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.\n", "entity1": "sodium 2-mercaptoethane sulphonate", "entity2": "urothelial toxicity", "span1": [78, 112], "span2": [32, 51]}, "bert_text": "Treatment of ifosfamide-induced urothelial toxicity by oral administration of <e1> sodium 2-mercaptoethane sulphonate </e1> <e2> urothelial toxicity </e2> by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4284": {"data": {"text": "Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.\n", "entity1": "sodium 2-mercaptoethane sulphonate", "entity2": "lung cancer", "span1": [78, 112], "span2": [149, 160]}, "bert_text": "Treatment of ifosfamide-induced urothelial toxicity by oral administration of <e1> sodium 2-mercaptoethane sulphonate </e1> (MESNA) to patients with inoperable <e2> lung cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4285": {"data": {"text": "Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.\n", "entity1": "MESNA", "entity2": "urothelial toxicity", "span1": [114, 119], "span2": [32, 51]}, "bert_text": "Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (<e1> MESNA </e1> <e2> urothelial toxicity </e2> by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4286": {"data": {"text": "Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.\n", "entity1": "MESNA", "entity2": "lung cancer", "span1": [114, 119], "span2": [149, 160]}, "bert_text": "Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (<e1> MESNA </e1>) to patients with inoperable <e2> lung cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4287": {"data": {"text": "Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.", "entity1": "morphine", "entity2": "acute pain", "span1": [15, 23], "span2": [102, 112]}, "bert_text": "Enhancement of <e1> morphine </e1> antinociception by dextromethorphan was seen in both males and females in the <e2> acute pain </e2> models, with the magnitude of this effect being greater in males.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4288": {"data": {"text": "Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.", "entity1": "dextromethorphan", "entity2": "acute pain", "span1": [43, 59], "span2": [102, 112]}, "bert_text": "Enhancement of morphine antinociception by <e1> dextromethorphan </e1> was seen in both males and females in the <e2> acute pain </e2> models, with the magnitude of this effect being greater in males.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4289": {"data": {"text": "These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline-induced cardiotoxicity.", "entity1": "anthracycline", "entity2": "cardiotoxicity", "span1": [96, 109], "span2": [118, 132]}, "bert_text": "These preliminary results suggest that BNP may be useful as an early and sensitive indicator of <e1> anthracycline </e1>-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4290": {"data": {"text": "The mechanisms of this ticlopidine-induced cholestasis are unclear.", "entity1": "ticlopidine", "entity2": "cholestasis", "span1": [23, 34], "span2": [43, 54]}, "bert_text": "The mechanisms of this <e1> ticlopidine </e1>-induced <e2> cholestasis </e2> are unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4291": {"data": {"text": "In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).", "entity1": "MDMA", "entity2": "memory deficits", "span1": [71, 75], "span2": [24, 39]}, "bert_text": "In recent years working memory deficits have been reported in users of <e1> MDMA </e1> <e2> memory deficits </e2> have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4292": {"data": {"text": "In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).", "entity1": "3,4-methylenedioxymethamphetamine", "entity2": "memory deficits", "span1": [77, 110], "span2": [24, 39]}, "bert_text": "In recent years working memory deficits have been reported in users of MDMA (<e1> 3,4-methylenedioxymethamphetamine </e1> <e2> memory deficits </e2> have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4293": {"data": {"text": "In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).", "entity1": "ecstasy", "entity2": "memory deficits", "span1": [112, 119], "span2": [24, 39]}, "bert_text": "In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, <e1> ecstasy </e1> <e2> memory deficits </e2> have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4294": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "non-Hodgkin lymphomas", "span1": [0, 11], "span2": [81, 102]}, "bert_text": "<e1> Thalidomide </e1> has limited single-agent activity in relapsed or refractory indolent <e2> non-Hodgkin lymphomas </e2>: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4295": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "Cancer", "span1": [0, 11], "span2": [128, 134]}, "bert_text": "<e1> Thalidomide </e1> has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the <e2> Cancer </e2> and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4296": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "Leukemia", "span1": [0, 11], "span2": [139, 147]}, "bert_text": "<e1> Thalidomide </e1> has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and <e2> Leukemia </e2> Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4297": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "multiple myeloma", "span1": [0, 11], "span2": [228, 244]}, "bert_text": "<e1> Thalidomide </e1> has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in <e2> multiple myeloma </e2>, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4298": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "mantle cell lymphoma", "span1": [0, 11], "span2": [246, 266]}, "bert_text": "<e1> Thalidomide </e1> has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, <e2> mantle cell lymphoma </e2> and lymphoplasmacytic lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4299": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "lymphoplasmacytic lymphoma", "span1": [0, 11], "span2": [271, 297]}, "bert_text": "<e1> Thalidomide </e1> has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and <e2> lymphoplasmacytic lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4300": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "non-Hodgkin lymphomas", "span1": [157, 168], "span2": [81, 102]}, "bert_text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\n<e1> Thalidomide </e1> <e2> non-Hodgkin lymphomas </e2>: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4301": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "Cancer", "span1": [157, 168], "span2": [128, 134]}, "bert_text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\n<e1> Thalidomide </e1> <e2> Cancer </e2> and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4302": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "Leukemia", "span1": [157, 168], "span2": [139, 147]}, "bert_text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\n<e1> Thalidomide </e1> <e2> Leukemia </e2> Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4303": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "multiple myeloma", "span1": [157, 168], "span2": [228, 244]}, "bert_text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\n<e1> Thalidomide </e1> is an immunomodulatory agent with demonstrated activity in <e2> multiple myeloma </e2>, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4304": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "mantle cell lymphoma", "span1": [157, 168], "span2": [246, 266]}, "bert_text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\n<e1> Thalidomide </e1> is an immunomodulatory agent with demonstrated activity in multiple myeloma, <e2> mantle cell lymphoma </e2> and lymphoplasmacytic lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4305": {"data": {"text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\nThalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.", "entity1": "Thalidomide", "entity2": "lymphoplasmacytic lymphoma", "span1": [157, 168], "span2": [271, 297]}, "bert_text": "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.\n<e1> Thalidomide </e1> is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and <e2> lymphoplasmacytic lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4306": {"data": {"text": "The patient had suffered a previous episode of \"acute hepatitis of unknown origin,\" that occurred after telithromycin usage.", "entity1": "telithromycin", "entity2": "hepatitis", "span1": [104, 117], "span2": [54, 63]}, "bert_text": "The patient had suffered a previous episode of \"acute hepatitis of unknown origin,\" that occurred after <e1> telithromycin </e1> <e2> hepatitis </e2> of unknown origin,\" that occurred after telithromycin usage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4307": {"data": {"text": "mice were partially resistant to nicotine-induced seizures when compared to wild-type littermates.", "entity1": "nicotine", "entity2": "seizures", "span1": [33, 41], "span2": [50, 58]}, "bert_text": "mice were partially resistant to <e1> nicotine </e1>-induced <e2> seizures </e2> when compared to wild-type littermates.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4308": {"data": {"text": "DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.", "entity1": "Fluoxetine", "entity2": "hyperprolactinemia", "span1": [8, 18], "span2": [107, 125]}, "bert_text": "DESIGN: <e1> Fluoxetine </e1>, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4309": {"data": {"text": "DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.", "entity1": "serotonin", "entity2": "hyperprolactinemia", "span1": [22, 31], "span2": [107, 125]}, "bert_text": "DESIGN: Fluoxetine, a <e1> serotonin </e1> reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4310": {"data": {"text": "Cardiovascular complications associated with terbutaline treatment for preterm labor.\n", "entity1": "terbutaline", "entity2": "Cardiovascular complications", "span1": [45, 56], "span2": [0, 28]}, "bert_text": "Cardiovascular complications associated with <e1> terbutaline </e1> <e2> Cardiovascular complications </e2> associated with terbutaline treatment for preterm labor.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4311": {"data": {"text": "Cardiovascular complications associated with terbutaline treatment for preterm labor.\n", "entity1": "terbutaline", "entity2": "preterm labor", "span1": [45, 56], "span2": [71, 84]}, "bert_text": "Cardiovascular complications associated with <e1> terbutaline </e1> treatment for <e2> preterm labor </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4312": {"data": {"text": "The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).", "entity1": "succinylcholine", "entity2": "myalgia", "span1": [30, 45], "span2": [57, 64]}, "bert_text": "The incidence and severity of <e1> succinylcholine </e1>-associated <e2> myalgia </e2> was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4313": {"data": {"text": "The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).", "entity1": "succinylcholine", "entity2": "myalgia", "span1": [142, 157], "span2": [57, 64]}, "bert_text": "The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before <e1> succinylcholine </e1> <e2> myalgia </e2> was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4314": {"data": {"text": "The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).", "entity1": "dexamethasone", "entity2": "myalgia", "span1": [121, 134], "span2": [57, 64]}, "bert_text": "The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or <e1> dexamethasone </e1> <e2> myalgia </e2> was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4315": {"data": {"text": "Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy.\n", "entity1": "AZT", "entity2": "cardiomyopathy", "span1": [61, 64], "span2": [73, 87]}, "bert_text": "Myocardial Fas ligand expression increases susceptibility to <e1> AZT </e1>-induced <e2> cardiomyopathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4316": {"data": {"text": "Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.\n", "entity1": "penicillamine", "entity2": "rheumatoid arthritis", "span1": [25, 38], "span2": [67, 87]}, "bert_text": "Multiple side effects of <e1> penicillamine </e1> therapy in one patient with <e2> rheumatoid arthritis </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4317": {"data": {"text": "Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.", "entity1": "Modafinil", "entity2": "daytime sleepiness", "span1": [0, 9], "span2": [159, 177]}, "bert_text": "<e1> Modafinil </e1> was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective <e2> daytime sleepiness </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4318": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "thiol", "entity2": "urothelial toxicity", "span1": [52, 57], "span2": [118, 137]}, "bert_text": "The protective effect of oral administration of the <e1> thiol </e1> compound sodium 2-mercaptoethane sulphonate (MESNA) against <e2> urothelial toxicity </e2> induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4319": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "thiol", "entity2": "lung cancer", "span1": [52, 57], "span2": [218, 229]}, "bert_text": "The protective effect of oral administration of the <e1> thiol </e1> compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable <e2> lung cancer </e2> under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4320": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "sodium 2-mercaptoethane sulphonate", "entity2": "urothelial toxicity", "span1": [67, 101], "span2": [118, 137]}, "bert_text": "The protective effect of oral administration of the thiol compound <e1> sodium 2-mercaptoethane sulphonate </e1> (MESNA) against <e2> urothelial toxicity </e2> induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4321": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "sodium 2-mercaptoethane sulphonate", "entity2": "lung cancer", "span1": [67, 101], "span2": [218, 229]}, "bert_text": "The protective effect of oral administration of the thiol compound <e1> sodium 2-mercaptoethane sulphonate </e1> (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable <e2> lung cancer </e2> under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4322": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "MESNA", "entity2": "urothelial toxicity", "span1": [103, 108], "span2": [118, 137]}, "bert_text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (<e1> MESNA </e1>) against <e2> urothelial toxicity </e2> induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4323": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "MESNA", "entity2": "lung cancer", "span1": [103, 108], "span2": [218, 229]}, "bert_text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (<e1> MESNA </e1>) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable <e2> lung cancer </e2> under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4324": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "ifosfamide", "entity2": "urothelial toxicity", "span1": [149, 159], "span2": [118, 137]}, "bert_text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by <e1> ifosfamide </e1> <e2> urothelial toxicity </e2> induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4325": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "ifosfamide", "entity2": "lung cancer", "span1": [149, 159], "span2": [218, 229]}, "bert_text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by <e1> ifosfamide </e1> (IF) was tested in a group of 45 patients with inoperable <e2> lung cancer </e2> under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4326": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "IF", "entity2": "urothelial toxicity", "span1": [161, 163], "span2": [118, 137]}, "bert_text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (<e1> IF </e1> <e2> urothelial toxicity </e2> induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4327": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "IF", "entity2": "lung cancer", "span1": [161, 163], "span2": [218, 229]}, "bert_text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (<e1> IF </e1>) was tested in a group of 45 patients with inoperable <e2> lung cancer </e2> under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4328": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "IF", "entity2": "urothelial toxicity", "span1": [251, 253], "span2": [118, 137]}, "bert_text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with <e1> IF </e1> <e2> urothelial toxicity </e2> induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4329": {"data": {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity1": "IF", "entity2": "lung cancer", "span1": [251, 253], "span2": [218, 229]}, "bert_text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with <e1> IF </e1> <e2> lung cancer </e2> under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4330": {"data": {"text": "The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.", "entity1": "isoproterenol", "entity2": "myocardial damage", "span1": [17, 30], "span2": [39, 56]}, "bert_text": "The mechanism of <e1> isoproterenol </e1>-induced <e2> myocardial damage </e2> is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4331": {"data": {"text": "The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.", "entity1": "isoproterenol", "entity2": "myocardial hyperactivity", "span1": [17, 30], "span2": [147, 171]}, "bert_text": "The mechanism of <e1> isoproterenol </e1>-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and <e2> myocardial hyperactivity </e2> is the best explanation for the complex morphological alterations observed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4332": {"data": {"text": "The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.", "entity1": "isoproterenol", "entity2": "hypotension", "span1": [17, 30], "span2": [131, 142]}, "bert_text": "The mechanism of <e1> isoproterenol </e1>-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary <e2> hypotension </e2> and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4333": {"data": {"text": "The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.", "entity1": "oxygen", "entity2": "myocardial damage", "span1": [87, 93], "span2": [39, 56]}, "bert_text": "The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of <e1> oxygen </e1> <e2> myocardial damage </e2> is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4334": {"data": {"text": "The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.", "entity1": "oxygen", "entity2": "myocardial hyperactivity", "span1": [87, 93], "span2": [147, 171]}, "bert_text": "The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of <e1> oxygen </e1> supply vs. demand following coronary hypotension and <e2> myocardial hyperactivity </e2> is the best explanation for the complex morphological alterations observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4335": {"data": {"text": "The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.", "entity1": "oxygen", "entity2": "hypotension", "span1": [87, 93], "span2": [131, 142]}, "bert_text": "The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of <e1> oxygen </e1> supply vs. demand following coronary <e2> hypotension </e2> and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4336": {"data": {"text": "Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.", "entity1": "alkylating agents", "entity2": "malignancy", "span1": [194, 211], "span2": [39, 49]}, "bert_text": "Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly <e1> alkylating agents </e1> <e2> malignancy </e2> in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"4337": {"data": {"text": "Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.", "entity1": "alkylating agents", "entity2": "rheumatoid arthritis", "span1": [194, 211], "span2": [53, 73]}, "bert_text": "Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly <e1> alkylating agents </e1> <e2> rheumatoid arthritis </e2> are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4338": {"data": {"text": "Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.", "entity1": "alkylating agents", "entity2": "rheumatoid arthritis", "span1": [194, 211], "span2": [233, 253]}, "bert_text": "Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly <e1> alkylating agents </e1>, in the treatment of <e2> rheumatoid arthritis </e2> should be reserved for patients with severe progressive disease or life-threatening complications.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"4339": {"data": {"text": "Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.", "entity1": "alkylating agents", "entity2": "disease", "span1": [194, 211], "span2": [310, 317]}, "bert_text": "Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly <e1> alkylating agents </e1>, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive <e2> disease </e2> or life-threatening complications.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"4340": {"data": {"text": "CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.", "entity1": "adenosine", "entity2": "hypersensitivity", "span1": [68, 77], "span2": [81, 97]}, "bert_text": "CONCLUSIONS: These results show selective inhibition by intrathecal <e1> adenosine </e1> of <e2> hypersensitivity </e2>, presumed to reflect central sensitization in humans after peripheral capsaicin injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4341": {"data": {"text": "CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.", "entity1": "capsaicin", "entity2": "hypersensitivity", "span1": [168, 177], "span2": [81, 97]}, "bert_text": "CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral <e1> capsaicin </e1> <e2> hypersensitivity </e2>, presumed to reflect central sensitization in humans after peripheral capsaicin injection.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4342": {"data": {"text": "In several models of hypertension, elevation of intracellular sodium level was documented in cardiac tissue.", "entity1": "sodium", "entity2": "hypertension", "span1": [62, 68], "span2": [21, 33]}, "bert_text": "In several models of hypertension, elevation of intracellular <e1> sodium </e1> <e2> hypertension </e2>, elevation of intracellular sodium level was documented in cardiac tissue.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4343": {"data": {"text": "However, a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis.", "entity1": "epinephrine", "entity2": "hypertensive", "span1": [20, 31], "span2": [84, 96]}, "bert_text": "However, a bolus of <e1> epinephrine </e1> injected through an alternative catheter provoked a <e2> hypertensive </e2> crisis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4344": {"data": {"text": "Desipramine-induced delirium at \"subtherapeutic\" concentrations: a case report.\n", "entity1": "Desipramine", "entity2": "delirium", "span1": [0, 11], "span2": [20, 28]}, "bert_text": "<e1> Desipramine </e1>-induced <e2> delirium </e2> at \"subtherapeutic\" concentrations: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4345": {"data": {"text": "The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.", "entity1": "busulfan", "entity2": "cystitis", "span1": [53, 61], "span2": [62, 70]}, "bert_text": "The similarity between the histologic appearances of <e1> busulfan </e1> <e2> cystitis </e2> and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4346": {"data": {"text": "The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.", "entity1": "busulfan", "entity2": "cystitis", "span1": [53, 61], "span2": [119, 127]}, "bert_text": "The similarity between the histologic appearances of <e1> busulfan </e1> cystitis and both radiation and cyclophosphamide-induced <e2> cystitis </e2> is discussed and the world literature reviewed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4347": {"data": {"text": "The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.", "entity1": "cyclophosphamide", "entity2": "cystitis", "span1": [94, 110], "span2": [62, 70]}, "bert_text": "The similarity between the histologic appearances of busulfan cystitis and both radiation and <e1> cyclophosphamide </e1> <e2> cystitis </e2> and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4348": {"data": {"text": "The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.", "entity1": "cyclophosphamide", "entity2": "cystitis", "span1": [94, 110], "span2": [119, 127]}, "bert_text": "The similarity between the histologic appearances of busulfan cystitis and both radiation and <e1> cyclophosphamide </e1>-induced <e2> cystitis </e2> is discussed and the world literature reviewed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4349": {"data": {"text": "We report a case of combined levomepromazine-fluvoxamine treatment-induced seizures.", "entity1": "levomepromazine", "entity2": "seizures", "span1": [29, 44], "span2": [75, 83]}, "bert_text": "We report a case of combined <e1> levomepromazine </e1>-fluvoxamine treatment-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"4350": {"data": {"text": "We report a case of combined levomepromazine-fluvoxamine treatment-induced seizures.", "entity1": "fluvoxamine", "entity2": "seizures", "span1": [45, 56], "span2": [75, 83]}, "bert_text": "We report a case of combined levomepromazine-<e1> fluvoxamine </e1> treatment-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"4351": {"data": {"text": "Two pituitary tumors were discovered after testosterone determination.", "entity1": "testosterone", "entity2": "pituitary tumors", "span1": [43, 55], "span2": [4, 20]}, "bert_text": "Two pituitary tumors were discovered after <e1> testosterone </e1> <e2> pituitary tumors </e2> were discovered after testosterone determination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4352": {"data": {"text": "Acetaminophen-induced hypotension.\n", "entity1": "Acetaminophen", "entity2": "hypotension", "span1": [0, 13], "span2": [22, 33]}, "bert_text": "<e1> Acetaminophen </e1>-induced <e2> hypotension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4353": {"data": {"text": "EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.", "entity1": "cocaine", "entity2": "EDDs", "span1": [27, 34], "span2": [0, 4]}, "bert_text": "EDDs had concentrations of <e1> cocaine </e1> <e2> EDDs </e2> had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4354": {"data": {"text": "EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.", "entity1": "benzoylecgonine", "entity2": "EDDs", "span1": [39, 54], "span2": [0, 4]}, "bert_text": "EDDs had concentrations of cocaine and <e1> benzoylecgonine </e1> <e2> EDDs </e2> had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4355": {"data": {"text": "Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.", "entity1": "glyburide", "entity2": "type II diabetes mellitus", "span1": [112, 121], "span2": [18, 43]}, "bert_text": "Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of <e1> glyburide </e1> <e2> type II diabetes mellitus </e2> developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4356": {"data": {"text": "Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.", "entity1": "glyburide", "entity2": "hepatitis-like syndrome", "span1": [112, 121], "span2": [63, 86]}, "bert_text": "Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of <e1> glyburide </e1> <e2> hepatitis-like syndrome </e2> soon after initiation of glyburide therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4357": {"data": {"text": "Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.", "entity1": "warfarin", "entity2": "femoral nerve palsy", "span1": [77, 85], "span2": [22, 41]}, "bert_text": "Anticoagulant-induced femoral nerve palsy represents the most common form of <e1> warfarin </e1> <e2> femoral nerve palsy </e2> represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4358": {"data": {"text": "Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.", "entity1": "warfarin", "entity2": "peripheral neuropathy", "span1": [77, 85], "span2": [94, 115]}, "bert_text": "Anticoagulant-induced femoral nerve palsy represents the most common form of <e1> warfarin </e1>-induced <e2> peripheral neuropathy </e2>; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4359": {"data": {"text": "Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.", "entity1": "warfarin", "entity2": "pain", "span1": [77, 85], "span2": [147, 151]}, "bert_text": "Anticoagulant-induced femoral nerve palsy represents the most common form of <e1> warfarin </e1>-induced peripheral neuropathy; it is characterized by severe <e2> pain </e2> in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4360": {"data": {"text": "Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.", "entity1": "warfarin", "entity2": "sensory impairment", "span1": [77, 85], "span2": [205, 223]}, "bert_text": "Anticoagulant-induced femoral nerve palsy represents the most common form of <e1> warfarin </e1>-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and <e2> sensory impairment </e2>, and flexure contracture of the involved extremity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4361": {"data": {"text": "To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.", "entity1": "Na+", "entity2": "hypertension", "span1": [79, 82], "span2": [149, 161]}, "bert_text": "To assess the molecular basis of disturbances in transmembraneous transport of <e1> Na+ </e1>, we studied the response of cardiac (Na,K)-ATPase to NO-deficient <e2> hypertension </e2> induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4362": {"data": {"text": "To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.", "entity1": "Na", "entity2": "hypertension", "span1": [120, 122], "span2": [149, 161]}, "bert_text": "To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (<e1> Na </e1>,K)-ATPase to NO-deficient <e2> hypertension </e2> induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4363": {"data": {"text": "To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.", "entity1": "K)-ATPase", "entity2": "hypertension", "span1": [123, 132], "span2": [149, 161]}, "bert_text": "To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,<e1> K)-ATPase </e1> to NO-deficient <e2> hypertension </e2> induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4364": {"data": {"text": "We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.", "entity1": "valdecoxib", "entity2": "osteoarthritis", "span1": [43, 53], "span2": [122, 136]}, "bert_text": "We evaluated cardiovascular event data for <e1> valdecoxib </e1>, a new COX-2-specific inhibitor in approximately 8000 patients with <e2> osteoarthritis </e2> and rheumatoid arthritis treated with this agent in randomized clinical trials.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4365": {"data": {"text": "We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.", "entity1": "valdecoxib", "entity2": "rheumatoid arthritis", "span1": [43, 53], "span2": [141, 161]}, "bert_text": "We evaluated cardiovascular event data for <e1> valdecoxib </e1>, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and <e2> rheumatoid arthritis </e2> treated with this agent in randomized clinical trials.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4366": {"data": {"text": "This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.", "entity1": "oxycodone", "entity2": "pain", "span1": [116, 125], "span2": [255, 259]}, "bert_text": "This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release <e1> oxycodone </e1> in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily <e2> pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4367": {"data": {"text": "Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.", "entity1": "Testosterone", "entity2": "hypertension", "span1": [0, 12], "span2": [47, 59]}, "bert_text": "<e1> Testosterone </e1> contributes to the development of <e2> hypertension </e2> and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4368": {"data": {"text": "Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.", "entity1": "Testosterone", "entity2": "renal injury", "span1": [0, 12], "span2": [64, 76]}, "bert_text": "<e1> Testosterone </e1> contributes to the development of hypertension and <e2> renal injury </e2> in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4369": {"data": {"text": "Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.", "entity1": "angiotensin", "entity2": "hypertension", "span1": [158, 169], "span2": [47, 59]}, "bert_text": "Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-<e1> angiotensin </e1> <e2> hypertension </e2> and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4370": {"data": {"text": "Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.", "entity1": "angiotensin", "entity2": "renal injury", "span1": [158, 169], "span2": [64, 76]}, "bert_text": "Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-<e1> angiotensin </e1> <e2> renal injury </e2> in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4371": {"data": {"text": "Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.", "entity1": "Dothiepin", "entity2": "depressed", "span1": [0, 9], "span2": [138, 147]}, "bert_text": "<e1> Dothiepin </e1> thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of <e2> depressed </e2> outpatients.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4372": {"data": {"text": "Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.", "entity1": "antidepressant", "entity2": "depressed", "span1": [44, 58], "span2": [138, 147]}, "bert_text": "Dothiepin thus was found to be an effective <e1> antidepressant </e1> drug associated with fewer side effects than amitriptyline in the treatment of <e2> depressed </e2> outpatients.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4373": {"data": {"text": "Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.", "entity1": "amitriptyline", "entity2": "depressed", "span1": [104, 117], "span2": [138, 147]}, "bert_text": "Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than <e1> amitriptyline </e1> in the treatment of <e2> depressed </e2> outpatients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4374": {"data": {"text": "Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.", "entity1": "Srl", "entity2": "proteinuria", "span1": [77, 80], "span2": [6, 17]}, "bert_text": "Thus, proteinuria may develop in cardiac transplant patients after switch to <e1> Srl </e1> <e2> proteinuria </e2> may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4375": {"data": {"text": "A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.", "entity1": "pergolide", "entity2": "valvular regurgitation", "span1": [75, 84], "span2": [25, 47]}, "bert_text": "A restrictive pattern of valvular regurgitation, suggestive of the role of <e1> pergolide </e1> <e2> valvular regurgitation </e2>, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4376": {"data": {"text": "A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.", "entity1": "pergolide", "entity2": "heart failure", "span1": [75, 84], "span2": [142, 155]}, "bert_text": "A restrictive pattern of valvular regurgitation, suggestive of the role of <e1> pergolide </e1>, was observed in 12/30 (40%) patients including two with <e2> heart failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4377": {"data": {"text": "Complete atrioventricular block secondary to lithium therapy.\n", "entity1": "lithium", "entity2": "atrioventricular block", "span1": [45, 52], "span2": [9, 31]}, "bert_text": "Complete atrioventricular block secondary to <e1> lithium </e1> <e2> atrioventricular block </e2> secondary to lithium therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4378": {"data": {"text": "This is the first case report of pseudoacromegaly as a side effect of minoxidil use.", "entity1": "minoxidil", "entity2": "pseudoacromegaly", "span1": [70, 79], "span2": [33, 49]}, "bert_text": "This is the first case report of pseudoacromegaly as a side effect of <e1> minoxidil </e1> <e2> pseudoacromegaly </e2> as a side effect of minoxidil use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4379": {"data": {"text": "Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.", "entity1": "asenapine", "entity2": "extrapyramidal symptoms", "span1": [59, 68], "span2": [133, 156]}, "bert_text": "Post hoc analyses indicated that efficacy was similar with <e1> asenapine </e1> and haloperidol; greater contrasts were seen in AEs, especially <e2> extrapyramidal symptoms </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4380": {"data": {"text": "Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.", "entity1": "haloperidol", "entity2": "extrapyramidal symptoms", "span1": [73, 84], "span2": [133, 156]}, "bert_text": "Post hoc analyses indicated that efficacy was similar with asenapine and <e1> haloperidol </e1>; greater contrasts were seen in AEs, especially <e2> extrapyramidal symptoms </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4381": {"data": {"text": "In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites, periodic urinary cytology is suggested in patients on long-term therapy.", "entity1": "busulfan", "entity2": "carcinoma", "span1": [33, 41], "span2": [72, 81]}, "bert_text": "In view of the known tendency of <e1> busulfan </e1> to induce cellular atypia and <e2> carcinoma </e2> in other sites, periodic urinary cytology is suggested in patients on long-term therapy.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4382": {"data": {"text": "Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.", "entity1": "Pergolide", "entity2": "valvular heart disease", "span1": [0, 9], "span2": [47, 69]}, "bert_text": "<e1> Pergolide </e1> was discontinued in 10 patients with <e2> valvular heart disease </e2>, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4383": {"data": {"text": "Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.", "entity1": "Pergolide", "entity2": "heart failure", "span1": [0, 9], "span2": [192, 205]}, "bert_text": "<e1> Pergolide </e1> was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with <e2> heart failure </e2> returned to nearly normal clinical examination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4384": {"data": {"text": "Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.\n", "entity1": "dacarbazine", "entity2": "Veno-occlusive liver disease", "span1": [35, 46], "span2": [0, 28]}, "bert_text": "Veno-occlusive liver disease after <e1> dacarbazine </e1> <e2> Veno-occlusive liver disease </e2> after dacarbazine therapy (DTIC) for melanoma.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4385": {"data": {"text": "Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.\n", "entity1": "dacarbazine", "entity2": "melanoma", "span1": [35, 46], "span2": [66, 74]}, "bert_text": "Veno-occlusive liver disease after <e1> dacarbazine </e1> therapy (DTIC) for <e2> melanoma </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4386": {"data": {"text": "Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.\n", "entity1": "DTIC", "entity2": "Veno-occlusive liver disease", "span1": [56, 60], "span2": [0, 28]}, "bert_text": "Veno-occlusive liver disease after dacarbazine therapy (<e1> DTIC </e1> <e2> Veno-occlusive liver disease </e2> after dacarbazine therapy (DTIC) for melanoma.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4387": {"data": {"text": "Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.\n", "entity1": "DTIC", "entity2": "melanoma", "span1": [56, 60], "span2": [66, 74]}, "bert_text": "Veno-occlusive liver disease after dacarbazine therapy (<e1> DTIC </e1>) for <e2> melanoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4388": {"data": {"text": "In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.", "entity1": "bromocriptine", "entity2": "hypotension", "span1": [29, 42], "span2": [79, 90]}, "bert_text": "In control rats, intravenous <e1> bromocriptine </e1> (150 microg/kg) induced significant <e2> hypotension </e2> and tachycardia.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4389": {"data": {"text": "In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.", "entity1": "bromocriptine", "entity2": "tachycardia", "span1": [29, 42], "span2": [95, 106]}, "bert_text": "In control rats, intravenous <e1> bromocriptine </e1> (150 microg/kg) induced significant hypotension and <e2> tachycardia </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4390": {"data": {"text": "The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.", "entity1": "AZT", "entity2": "anaemia", "span1": [42, 45], "span2": [94, 101]}, "bert_text": "The mean plasma levels of EPO observed in <e1> AZT </e1> treated mice were appropriate for the degree of <e2> anaemia </e2> observed when compared with phenylhydrazine (PHZ) treated mice.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4391": {"data": {"text": "The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.", "entity1": "phenylhydrazine", "entity2": "anaemia", "span1": [130, 145], "span2": [94, 101]}, "bert_text": "The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with <e1> phenylhydrazine </e1> <e2> anaemia </e2> observed when compared with phenylhydrazine (PHZ) treated mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4392": {"data": {"text": "The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.", "entity1": "PHZ", "entity2": "anaemia", "span1": [147, 150], "span2": [94, 101]}, "bert_text": "The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine (<e1> PHZ </e1> <e2> anaemia </e2> observed when compared with phenylhydrazine (PHZ) treated mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4393": {"data": {"text": "CONCLUSION: Individual differences in renal ACE activity predict the severity of adriamycin-induced renal damage in this outbred rat strain.", "entity1": "adriamycin", "entity2": "renal damage", "span1": [81, 91], "span2": [100, 112]}, "bert_text": "CONCLUSION: Individual differences in renal ACE activity predict the severity of <e1> adriamycin </e1>-induced <e2> renal damage </e2> in this outbred rat strain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4394": {"data": {"text": "Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.", "entity1": "lithium", "entity2": "Sinus node dysfunction", "span1": [101, 108], "span2": [0, 22]}, "bert_text": "Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of <e1> lithium </e1> <e2> Sinus node dysfunction </e2> has been reported most frequently among the adverse cardiovascular effects of lithium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4395": {"data": {"text": "Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.\n", "entity1": "diazepam", "entity2": "panic disorder", "span1": [22, 30], "span2": [64, 78]}, "bert_text": "Behavioral effects of <e1> diazepam </e1> and propranolol in patients with <e2> panic disorder </e2> and agoraphobia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4396": {"data": {"text": "Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.\n", "entity1": "diazepam", "entity2": "agoraphobia", "span1": [22, 30], "span2": [83, 94]}, "bert_text": "Behavioral effects of <e1> diazepam </e1> and propranolol in patients with panic disorder and <e2> agoraphobia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4397": {"data": {"text": "Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.\n", "entity1": "propranolol", "entity2": "panic disorder", "span1": [35, 46], "span2": [64, 78]}, "bert_text": "Behavioral effects of diazepam and <e1> propranolol </e1> in patients with <e2> panic disorder </e2> and agoraphobia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4398": {"data": {"text": "Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.\n", "entity1": "propranolol", "entity2": "agoraphobia", "span1": [35, 46], "span2": [83, 94]}, "bert_text": "Behavioral effects of diazepam and <e1> propranolol </e1> in patients with panic disorder and <e2> agoraphobia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4399": {"data": {"text": "While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of \"normality,\" which can lead to toxicity.", "entity1": "levodopa", "entity2": "toxicity", "span1": [51, 59], "span2": [272, 280]}, "bert_text": "While there is no single correct starting dose for <e1> levodopa </e1> therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of \"normality,\" which can lead to <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4400": {"data": {"text": "While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of \"normality,\" which can lead to toxicity.", "entity1": "levodopa", "entity2": "toxicity", "span1": [216, 224], "span2": [272, 280]}, "bert_text": "While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-<e1> levodopa </e1> to the point of \"normality,\" which can lead to <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4401": {"data": {"text": "While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of \"normality,\" which can lead to toxicity.", "entity1": "carbidopa", "entity2": "toxicity", "span1": [206, 215], "span2": [272, 280]}, "bert_text": "While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate <e1> carbidopa </e1>-levodopa to the point of \"normality,\" which can lead to <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4402": {"data": {"text": "Recurrent dysphonia and acitretin.\n", "entity1": "acitretin", "entity2": "dysphonia", "span1": [24, 33], "span2": [10, 19]}, "bert_text": "Recurrent dysphonia and <e1> acitretin </e1> <e2> dysphonia </e2> and acitretin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4403": {"data": {"text": "Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.", "entity1": "Adriamycin", "entity2": "hyperthermia", "span1": [66, 76], "span2": [11, 23]}, "bert_text": "Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both <e1> Adriamycin </e1> <e2> hyperthermia </e2> (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4404": {"data": {"text": "Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.", "entity1": "prostaglandin E2-induced", "entity2": "hyperalgesia", "span1": [12, 36], "span2": [37, 49]}, "bert_text": "Conversely, <e1> prostaglandin E2-induced </e1> <e2> hyperalgesia </e2> was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4405": {"data": {"text": "Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.", "entity1": "AH6809", "entity2": "hyperalgesia", "span1": [65, 71], "span2": [37, 49]}, "bert_text": "Conversely, prostaglandin E2-induced hyperalgesia was blocked by <e1> AH6809 </e1> <e2> hyperalgesia </e2> was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4406": {"data": {"text": "Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.", "entity1": "tamoxifen", "entity2": "Endometrial cancers", "span1": [52, 61], "span2": [0, 19]}, "bert_text": "Endometrial cancers diagnosed in women treated with <e1> tamoxifen </e1> <e2> Endometrial cancers </e2> diagnosed in women treated with tamoxifen have poorer prognosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4407": {"data": {"text": "Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.\n", "entity1": "amiodarone", "entity2": "toxicity", "span1": [45, 55], "span2": [23, 31]}, "bert_text": "Long-term efficacy and toxicity of high-dose <e1> amiodarone </e1> <e2> toxicity </e2> of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4408": {"data": {"text": "Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.\n", "entity1": "amiodarone", "entity2": "ventricular tachycardia", "span1": [45, 55], "span2": [68, 91]}, "bert_text": "Long-term efficacy and toxicity of high-dose <e1> amiodarone </e1> therapy for <e2> ventricular tachycardia </e2> or ventricular fibrillation.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4409": {"data": {"text": "Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.\n", "entity1": "amiodarone", "entity2": "ventricular fibrillation", "span1": [45, 55], "span2": [95, 119]}, "bert_text": "Long-term efficacy and toxicity of high-dose <e1> amiodarone </e1> therapy for ventricular tachycardia or <e2> ventricular fibrillation </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4410": {"data": {"text": "These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.", "entity1": "noradrenaline", "entity2": "hypertension", "span1": [65, 78], "span2": [27, 39]}, "bert_text": "These results suggest that hypertension after chronic intrarenal <e1> noradrenaline </e1> <e2> hypertension </e2> after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4411": {"data": {"text": "These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.", "entity1": "noradrenaline", "entity2": "hypertension", "span1": [143, 156], "span2": [27, 39]}, "bert_text": "These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating <e1> noradrenaline </e1> <e2> hypertension </e2> after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4412": {"data": {"text": "Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.", "entity1": "Amiodarone", "entity2": "ventricular tachycardia", "span1": [0, 10], "span2": [75, 98]}, "bert_text": "<e1> Amiodarone </e1> was administered to 154 patients who had sustained, symptomatic <e2> ventricular tachycardia </e2> (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4413": {"data": {"text": "Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.", "entity1": "Amiodarone", "entity2": "VT", "span1": [0, 10], "span2": [100, 102]}, "bert_text": "<e1> Amiodarone </e1> was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (<e2> VT </e2>) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4414": {"data": {"text": "Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.", "entity1": "Amiodarone", "entity2": "cardiac arrest", "span1": [0, 10], "span2": [119, 133]}, "bert_text": "<e1> Amiodarone </e1> was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a <e2> cardiac arrest </e2> (n = 36) and who were refractory to conventional antiarrhythmic drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4415": {"data": {"text": "A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.", "entity1": "calcium", "entity2": "cardiovascular malformations", "span1": [96, 103], "span2": [19, 47]}, "bert_text": "A low incidence of cardiovascular malformations was observed after exposure to each of the four <e1> calcium </e1> <e2> cardiovascular malformations </e2> was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4416": {"data": {"text": "A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.", "entity1": "verapamil", "entity2": "cardiovascular malformations", "span1": [180, 189], "span2": [19, 47]}, "bert_text": "A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for <e1> verapamil </e1> <e2> cardiovascular malformations </e2> was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4417": {"data": {"text": "A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.", "entity1": "nifedipine", "entity2": "cardiovascular malformations", "span1": [194, 204], "span2": [19, 47]}, "bert_text": "A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and <e1> nifedipine </e1> <e2> cardiovascular malformations </e2> was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4418": {"data": {"text": "Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.\n", "entity1": "adriamycin", "entity2": "hyperthermia", "span1": [10, 20], "span2": [46, 58]}, "bert_text": "Effect of <e1> adriamycin </e1> combined with whole body <e2> hyperthermia </e2> on tumor and normal tissues.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4419": {"data": {"text": "Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.\n", "entity1": "adriamycin", "entity2": "tumor", "span1": [10, 20], "span2": [62, 67]}, "bert_text": "Effect of <e1> adriamycin </e1> combined with whole body hyperthermia on <e2> tumor </e2> and normal tissues.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4420": {"data": {"text": "We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.", "entity1": "SRL", "entity2": "proteinuria", "span1": [128, 131], "span2": [110, 121]}, "bert_text": "We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after <e1> SRL </e1> <e2> proteinuria </e2> after SRL conversion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4421": {"data": {"text": "We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.", "entity1": "ATRA", "entity2": "APL", "span1": [81, 85], "span2": [39, 42]}, "bert_text": "We describe four patients with classic APL who developed erythema nodosum during <e1> ATRA </e1> <e2> APL </e2> who developed erythema nodosum during ATRA therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4422": {"data": {"text": "We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.", "entity1": "ATRA", "entity2": "erythema nodosum", "span1": [81, 85], "span2": [57, 73]}, "bert_text": "We describe four patients with classic APL who developed erythema nodosum during <e1> ATRA </e1> <e2> erythema nodosum </e2> during ATRA therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4423": {"data": {"text": "We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.", "entity1": "tacrolimus", "entity2": "rosacea-like dermatitis eruptions", "span1": [104, 114], "span2": [44, 77]}, "bert_text": "We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% <e1> tacrolimus </e1> <e2> rosacea-like dermatitis eruptions </e2> while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4424": {"data": {"text": "We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.", "entity1": "tacrolimus", "entity2": "dermatitis", "span1": [104, 114], "span2": [135, 145]}, "bert_text": "We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% <e1> tacrolimus </e1> ointment for facial <e2> dermatitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4425": {"data": {"text": "Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.\n", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [52, 63], "span2": [64, 78]}, "bert_text": "Dose-effect and structure-function relationships in <e1> doxorubicin </e1> <e2> cardiomyopathy </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4426": {"data": {"text": "The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.", "entity1": "bilirubin", "entity2": "toxicities", "span1": [77, 86], "span2": [16, 26]}, "bert_text": "The most common toxicities encountered were transient serum transaminase and <e1> bilirubin </e1> <e2> toxicities </e2> encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4427": {"data": {"text": "The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.", "entity1": "bilirubin", "entity2": "neutropenia", "span1": [77, 86], "span2": [99, 110]}, "bert_text": "The most common toxicities encountered were transient serum transaminase and <e1> bilirubin </e1> elevations, <e2> neutropenia </e2>, and mucositis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4428": {"data": {"text": "The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.", "entity1": "bilirubin", "entity2": "mucositis", "span1": [77, 86], "span2": [116, 125]}, "bert_text": "The most common toxicities encountered were transient serum transaminase and <e1> bilirubin </e1> elevations, neutropenia, and <e2> mucositis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4429": {"data": {"text": "These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.", "entity1": "ipratropium", "entity2": "chronic airflow obstruction", "span1": [24, 35], "span2": [108, 135]}, "bert_text": "These results show that <e1> ipratropium </e1> is a more potent bronchodilator than oral theophylline in patients with <e2> chronic airflow obstruction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4430": {"data": {"text": "These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.", "entity1": "theophylline", "entity2": "chronic airflow obstruction", "span1": [78, 90], "span2": [108, 135]}, "bert_text": "These results show that ipratropium is a more potent bronchodilator than oral <e1> theophylline </e1> in patients with <e2> chronic airflow obstruction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4431": {"data": {"text": "Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.", "entity1": "pyridoxine", "entity2": "hyperkinesis", "span1": [23, 33], "span2": [68, 80]}, "bert_text": "Periodic withdrawal of <e1> pyridoxine </e1> was associated with return of the <e2> hyperkinesis </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4432": {"data": {"text": "Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [18, 27], "span2": [32, 45]}, "bert_text": "Women who receive <e1> tamoxifen </e1> for <e2> breast cancer </e2> should be offered gynaecological surveillance during and after treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4433": {"data": {"text": "Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).", "entity1": "labetalol", "entity2": "hypotension", "span1": [102, 111], "span2": [79, 90]}, "bert_text": "Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by <e1> labetalol </e1> <e2> hypotension </e2> induced by labetalol with isoflurane (hypotensive group).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4434": {"data": {"text": "Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).", "entity1": "labetalol", "entity2": "hypotensive", "span1": [102, 111], "span2": [129, 140]}, "bert_text": "Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by <e1> labetalol </e1> with isoflurane (<e2> hypotensive </e2> group).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4435": {"data": {"text": "Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).", "entity1": "isoflurane", "entity2": "hypotension", "span1": [117, 127], "span2": [79, 90]}, "bert_text": "Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with <e1> isoflurane </e1> <e2> hypotension </e2> induced by labetalol with isoflurane (hypotensive group).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4436": {"data": {"text": "Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).", "entity1": "isoflurane", "entity2": "hypotensive", "span1": [117, 127], "span2": [129, 140]}, "bert_text": "Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with <e1> isoflurane </e1> (<e2> hypotensive </e2> group).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4437": {"data": {"text": "Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.", "entity1": "tacrolimus", "entity2": "TMA", "span1": [16, 26], "span2": [99, 102]}, "bert_text": "Introduction of <e1> tacrolimus </e1> as an alternative immunosuppressive agent resulted in the recurrence of <e2> TMA </e2> and the subsequent loss of the renal allograft.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4438": {"data": {"text": "Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.", "entity1": "Hibiscus rosa sinensis", "entity2": "dyskinesia", "span1": [32, 54], "span2": [114, 124]}, "bert_text": "Effect of methanolic extract of <e1> Hibiscus rosa sinensis </e1> (100-300 mg/kg) was studied on reserpine-induced orofacial <e2> dyskinesia </e2> and neurochemical alterations.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4439": {"data": {"text": "Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.", "entity1": "reserpine", "entity2": "dyskinesia", "span1": [86, 95], "span2": [114, 124]}, "bert_text": "Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on <e1> reserpine </e1>-induced orofacial <e2> dyskinesia </e2> and neurochemical alterations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4440": {"data": {"text": "The epidemiology of the acute flank pain syndrome from suprofen.\n", "entity1": "suprofen", "entity2": "flank pain", "span1": [55, 63], "span2": [30, 40]}, "bert_text": "The epidemiology of the acute flank pain syndrome from <e1> suprofen </e1> <e2> flank pain </e2> syndrome from suprofen.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4441": {"data": {"text": "This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.", "entity1": "methylprednisolone", "entity2": "neuropathy", "span1": [234, 252], "span2": [5, 15]}, "bert_text": "This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to <e1> methylprednisolone </e1> <e2> neuropathy </e2> was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4442": {"data": {"text": "This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.", "entity1": "methylprednisolone", "entity2": "graft-versus-host disease", "span1": [234, 252], "span2": [164, 189]}, "bert_text": "This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to <e1> methylprednisolone </e1> <e2> graft-versus-host disease </e2>, and the symptoms subsequently responded to methylprednisolone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4443": {"data": {"text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "entity1": "verapamil", "entity2": "ischaemic heart disease", "span1": [137, 146], "span2": [20, 43]}, "bert_text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with <e1> verapamil </e1> <e2> ischaemic heart disease </e2> developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4444": {"data": {"text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "entity1": "verapamil", "entity2": "cardiac failure", "span1": [137, 146], "span2": [63, 78]}, "bert_text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with <e1> verapamil </e1> <e2> cardiac failure </e2>, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4445": {"data": {"text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "entity1": "verapamil", "entity2": "hypotension", "span1": [137, 146], "span2": [80, 91]}, "bert_text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with <e1> verapamil </e1> <e2> hypotension </e2> and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4446": {"data": {"text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "entity1": "verapamil", "entity2": "bradycardia", "span1": [137, 146], "span2": [96, 107]}, "bert_text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with <e1> verapamil </e1> <e2> bradycardia </e2> during combined therapy with verapamil and beta-adrenergic blocking drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4447": {"data": {"text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "entity1": "beta-adrenergic blocking drugs", "entity2": "ischaemic heart disease", "span1": [151, 181], "span2": [20, 43]}, "bert_text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and <e1> beta-adrenergic blocking drugs </e1> <e2> ischaemic heart disease </e2> developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4448": {"data": {"text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "entity1": "beta-adrenergic blocking drugs", "entity2": "cardiac failure", "span1": [151, 181], "span2": [63, 78]}, "bert_text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and <e1> beta-adrenergic blocking drugs </e1> <e2> cardiac failure </e2>, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4449": {"data": {"text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "entity1": "beta-adrenergic blocking drugs", "entity2": "hypotension", "span1": [151, 181], "span2": [80, 91]}, "bert_text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and <e1> beta-adrenergic blocking drugs </e1> <e2> hypotension </e2> and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4450": {"data": {"text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "entity1": "beta-adrenergic blocking drugs", "entity2": "bradycardia", "span1": [151, 181], "span2": [96, 107]}, "bert_text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and <e1> beta-adrenergic blocking drugs </e1> <e2> bradycardia </e2> during combined therapy with verapamil and beta-adrenergic blocking drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4451": {"data": {"text": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "entity1": "phenytoin", "entity2": "seizures", "span1": [26, 35], "span2": [55, 63]}, "bert_text": "Despite administration of <e1> phenytoin </e1> and lorazepam, the <e2> seizures </e2> persisted and occurred only during amphotercin B administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4452": {"data": {"text": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "entity1": "lorazepam", "entity2": "seizures", "span1": [40, 49], "span2": [55, 63]}, "bert_text": "Despite administration of phenytoin and <e1> lorazepam </e1>, the <e2> seizures </e2> persisted and occurred only during amphotercin B administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4453": {"data": {"text": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "entity1": "amphotercin B", "entity2": "seizures", "span1": [99, 112], "span2": [55, 63]}, "bert_text": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during <e1> amphotercin B </e1> <e2> seizures </e2> persisted and occurred only during amphotercin B administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4454": {"data": {"text": "OBJECTIVE: To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin-induced thrombocytopenia are delayed.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [109, 116], "span2": [125, 141]}, "bert_text": "OBJECTIVE: To describe and increase awareness of a clinical scenario in which the onset or manifestations of <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> are delayed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4455": {"data": {"text": "Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.", "entity1": "Aventyl", "entity2": "left bundle branch block", "span1": [0, 7], "span2": [65, 89]}, "bert_text": "<e1> Aventyl </e1> (nortriptyline) and Elavil (amitriptyline) each produced <e2> left bundle branch block </e2> in a 73 year old woman.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4456": {"data": {"text": "Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.", "entity1": "nortriptyline", "entity2": "left bundle branch block", "span1": [9, 22], "span2": [65, 89]}, "bert_text": "Aventyl (<e1> nortriptyline </e1>) and Elavil (amitriptyline) each produced <e2> left bundle branch block </e2> in a 73 year old woman.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4457": {"data": {"text": "Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.", "entity1": "Elavil", "entity2": "left bundle branch block", "span1": [28, 34], "span2": [65, 89]}, "bert_text": "Aventyl (nortriptyline) and <e1> Elavil </e1> (amitriptyline) each produced <e2> left bundle branch block </e2> in a 73 year old woman.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4458": {"data": {"text": "Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.", "entity1": "amitriptyline", "entity2": "left bundle branch block", "span1": [36, 49], "span2": [65, 89]}, "bert_text": "Aventyl (nortriptyline) and Elavil (<e1> amitriptyline </e1>) each produced <e2> left bundle branch block </e2> in a 73 year old woman.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4459": {"data": {"text": "Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.", "entity1": "carbimazole", "entity2": "cholestatic", "span1": [71, 82], "span2": [24, 35]}, "bert_text": "Two others had a mixed (cholestatic and cytolytic) hepatitis following <e1> carbimazole </e1> <e2> cholestatic </e2> and cytolytic) hepatitis following carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4460": {"data": {"text": "Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.", "entity1": "carbimazole", "entity2": "hepatitis", "span1": [71, 82], "span2": [51, 60]}, "bert_text": "Two others had a mixed (cholestatic and cytolytic) hepatitis following <e1> carbimazole </e1> <e2> hepatitis </e2> following carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4461": {"data": {"text": "While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.", "entity1": "naloxone", "entity2": "catalepsy", "span1": [217, 225], "span2": [98, 107]}, "bert_text": "While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for <e1> naloxone </e1> <e2> catalepsy </e2>, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4462": {"data": {"text": "While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.", "entity1": "naloxone", "entity2": "rigidity", "span1": [217, 225], "span2": [133, 141]}, "bert_text": "While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for <e1> naloxone </e1> <e2> rigidity </e2> and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4463": {"data": {"text": "The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups. CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction.", "entity1": "creatinine", "entity2": "renal dysfunction", "span1": [28, 38], "span2": [297, 314]}, "bert_text": "The mean increments in BUN, <e1> creatinine </e1>, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups. CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related <e2> renal dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4464": {"data": {"text": "The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups. CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction.", "entity1": "K", "entity2": "renal dysfunction", "span1": [44, 45], "span2": [297, 314]}, "bert_text": "The mean increments in BUN, creatinine, and <e1> K </e1> were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups. CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related <e2> renal dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4465": {"data": {"text": "The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups. CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction.", "entity1": "indomethacin", "entity2": "renal dysfunction", "span1": [276, 288], "span2": [297, 314]}, "bert_text": "The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups. CONCLUSION: Hospitalized elderly patients are at risk for developing <e1> indomethacin </e1> related <e2> renal dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4466": {"data": {"text": "Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.\n", "entity1": "co-trimoxazole", "entity2": "cholestasis", "span1": [52, 66], "span2": [24, 35]}, "bert_text": "Severe and long lasting cholestasis after high-dose <e1> co-trimoxazole </e1> <e2> cholestasis </e2> after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4467": {"data": {"text": "Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.\n", "entity1": "co-trimoxazole", "entity2": "Pneumocystis pneumonia", "span1": [52, 66], "span2": [81, 103]}, "bert_text": "Severe and long lasting cholestasis after high-dose <e1> co-trimoxazole </e1> treatment for <e2> Pneumocystis pneumonia </e2> in HIV-infected patients--a report of two cases.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4468": {"data": {"text": "Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.\n", "entity1": "co-trimoxazole", "entity2": "HIV-infected", "span1": [52, 66], "span2": [107, 119]}, "bert_text": "Severe and long lasting cholestasis after high-dose <e1> co-trimoxazole </e1> treatment for Pneumocystis pneumonia in <e2> HIV-infected </e2> patients--a report of two cases.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4469": {"data": {"text": "In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy.", "entity1": "ribavirin", "entity2": "hemolysis", "span1": [84, 93], "span2": [121, 130]}, "bert_text": "In this clinical retrospective cohort study we have examined the suitable timing of <e1> ribavirin </e1> reduction in patients with <e2> hemolysis </e2> during combination therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4470": {"data": {"text": "Thus, high cimetidine levels alone do not always induce dementia.", "entity1": "cimetidine", "entity2": "dementia", "span1": [11, 21], "span2": [56, 64]}, "bert_text": "Thus, high <e1> cimetidine </e1> levels alone do not always induce <e2> dementia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1], "label": 1},
+	"4471": {"data": {"text": "An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the \"subtherapeutic\" range.", "entity1": "Desipramine", "entity2": "delirium", "span1": [41, 52], "span2": [65, 73]}, "bert_text": "An elderly patient treated with low dose <e1> Desipramine </e1> developed a <e2> delirium </e2> while her plasma level was in the \"subtherapeutic\" range.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4472": {"data": {"text": "We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.", "entity1": "VPA", "entity2": "SIADH", "span1": [166, 169], "span2": [28, 33]}, "bert_text": "We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of <e1> VPA </e1> <e2> SIADH </e2> to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4473": {"data": {"text": "Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.", "entity1": "prednisolone", "entity2": "neuromuscular dysfunction", "span1": [61, 73], "span2": [29, 54]}, "bert_text": "Our results suggest that the neuromuscular dysfunction after <e1> prednisolone </e1> <e2> neuromuscular dysfunction </e2> after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4474": {"data": {"text": "Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.", "entity1": "prednisolone", "entity2": "muscle atrophy", "span1": [61, 73], "span2": [120, 134]}, "bert_text": "Our results suggest that the neuromuscular dysfunction after <e1> prednisolone </e1> is dose-dependent, and derives primarily from <e2> muscle atrophy </e2> and derives less so from changes in AChR expression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4475": {"data": {"text": "Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.\n", "entity1": "everolimus", "entity2": "Graft-versus-host disease", "span1": [43, 53], "span2": [0, 25]}, "bert_text": "Graft-versus-host disease prophylaxis with <e1> everolimus </e1> <e2> Graft-versus-host disease </e2> prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4476": {"data": {"text": "Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.\n", "entity1": "everolimus", "entity2": "sinusoidal obstruction syndrome", "span1": [43, 53], "span2": [108, 139]}, "bert_text": "Graft-versus-host disease prophylaxis with <e1> everolimus </e1> and tacrolimus is associated with a high incidence of <e2> sinusoidal obstruction syndrome </e2> and microangiopathy: results of the EVTAC trial.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4477": {"data": {"text": "Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.\n", "entity1": "everolimus", "entity2": "microangiopathy", "span1": [43, 53], "span2": [144, 159]}, "bert_text": "Graft-versus-host disease prophylaxis with <e1> everolimus </e1> and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and <e2> microangiopathy </e2>: results of the EVTAC trial.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4478": {"data": {"text": "Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.\n", "entity1": "tacrolimus", "entity2": "Graft-versus-host disease", "span1": [58, 68], "span2": [0, 25]}, "bert_text": "Graft-versus-host disease prophylaxis with everolimus and <e1> tacrolimus </e1> <e2> Graft-versus-host disease </e2> prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4479": {"data": {"text": "Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.\n", "entity1": "tacrolimus", "entity2": "sinusoidal obstruction syndrome", "span1": [58, 68], "span2": [108, 139]}, "bert_text": "Graft-versus-host disease prophylaxis with everolimus and <e1> tacrolimus </e1> is associated with a high incidence of <e2> sinusoidal obstruction syndrome </e2> and microangiopathy: results of the EVTAC trial.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4480": {"data": {"text": "Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.\n", "entity1": "tacrolimus", "entity2": "microangiopathy", "span1": [58, 68], "span2": [144, 159]}, "bert_text": "Graft-versus-host disease prophylaxis with everolimus and <e1> tacrolimus </e1> is associated with a high incidence of sinusoidal obstruction syndrome and <e2> microangiopathy </e2>: results of the EVTAC trial.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4481": {"data": {"text": "It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.", "entity1": "phenylephrine", "entity2": "aggressiveness", "span1": [49, 62], "span2": [147, 161]}, "bert_text": "It increases the behaviour stimulation evoked by <e1> phenylephrine </e1> (given intraventricularly) in rats, evaluated in the open field test as well as the <e2> aggressiveness </e2> evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4482": {"data": {"text": "It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.", "entity1": "clonidine", "entity2": "aggressiveness", "span1": [172, 181], "span2": [147, 161]}, "bert_text": "It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by <e1> clonidine </e1> <e2> aggressiveness </e2> evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4483": {"data": {"text": "Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.", "entity1": "cytosine arabinoside", "entity2": "peripheral neuropathy", "span1": [78, 98], "span2": [27, 48]}, "bert_text": "Although the mechanisms of peripheral neuropathy are still unclear, high-dose <e1> cytosine arabinoside </e1> <e2> peripheral neuropathy </e2> are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4484": {"data": {"text": "METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.", "entity1": "ethambutol", "entity2": "optic neuropathy", "span1": [42, 52], "span2": [67, 83]}, "bert_text": "METHODS: Three subjects with a history of <e1> ethambutol </e1> (EMB)-induced <e2> optic neuropathy </e2> of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4485": {"data": {"text": "METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.", "entity1": "ethambutol", "entity2": "visual deficits", "span1": [42, 52], "span2": [124, 139]}, "bert_text": "METHODS: Three subjects with a history of <e1> ethambutol </e1> (EMB)-induced optic neuropathy of short-, intermediate-, and long-term <e2> visual deficits </e2> were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4486": {"data": {"text": "METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.", "entity1": "EMB)-induced", "entity2": "optic neuropathy", "span1": [54, 66], "span2": [67, 83]}, "bert_text": "METHODS: Three subjects with a history of ethambutol (<e1> EMB)-induced </e1> <e2> optic neuropathy </e2> of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4487": {"data": {"text": "METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.", "entity1": "EMB)-induced", "entity2": "visual deficits", "span1": [54, 66], "span2": [124, 139]}, "bert_text": "METHODS: Three subjects with a history of ethambutol (<e1> EMB)-induced </e1> optic neuropathy of short-, intermediate-, and long-term <e2> visual deficits </e2> were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4488": {"data": {"text": "Therefore, certain limitations for malaria prophylaxis and treatment with mefloquine are recommended.", "entity1": "mefloquine", "entity2": "malaria", "span1": [74, 84], "span2": [35, 42]}, "bert_text": "Therefore, certain limitations for malaria prophylaxis and treatment with <e1> mefloquine </e1> <e2> malaria </e2> prophylaxis and treatment with mefloquine are recommended.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4489": {"data": {"text": "Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.", "entity1": "TAM", "entity2": "cytotoxicity", "span1": [139, 142], "span2": [57, 69]}, "bert_text": "Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by <e1> TAM </e1> <e2> cytotoxicity </e2>, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4490": {"data": {"text": "To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.", "entity1": "prostaglandin E1", "entity2": "hypotension", "span1": [26, 42], "span2": [80, 91]}, "bert_text": "To evaluate the effect of <e1> prostaglandin E1 </e1> (PGE1) or trimethaphan (TMP) induced <e2> hypotension </e2> on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4491": {"data": {"text": "To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.", "entity1": "PGE1", "entity2": "hypotension", "span1": [44, 48], "span2": [80, 91]}, "bert_text": "To evaluate the effect of prostaglandin E1 (<e1> PGE1 </e1>) or trimethaphan (TMP) induced <e2> hypotension </e2> on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4492": {"data": {"text": "To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.", "entity1": "trimethaphan", "entity2": "hypotension", "span1": [53, 65], "span2": [80, 91]}, "bert_text": "To evaluate the effect of prostaglandin E1 (PGE1) or <e1> trimethaphan </e1> (TMP) induced <e2> hypotension </e2> on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4493": {"data": {"text": "To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.", "entity1": "TMP", "entity2": "hypotension", "span1": [67, 70], "span2": [80, 91]}, "bert_text": "To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (<e1> TMP </e1>) induced <e2> hypotension </e2> on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4494": {"data": {"text": "To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.", "entity1": "isoflurane", "entity2": "hypotension", "span1": [261, 271], "span2": [80, 91]}, "bert_text": "To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under <e1> isoflurane </e1> <e2> hypotension </e2> on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4495": {"data": {"text": "Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.", "entity1": "risperidone", "entity2": "parkinsonism", "span1": [64, 75], "span2": [13, 25]}, "bert_text": "Drug-induced parkinsonism was observed in subjects treated with <e1> risperidone </e1> <e2> parkinsonism </e2> was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4496": {"data": {"text": "Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.", "entity1": "haloperidol", "entity2": "parkinsonism", "span1": [86, 97], "span2": [13, 25]}, "bert_text": "Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and <e1> haloperidol </e1> <e2> parkinsonism </e2> was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4497": {"data": {"text": "Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.", "entity1": "co-trimoxazole", "entity2": "Pneumocystis pneumonia", "span1": [132, 146], "span2": [0, 22]}, "bert_text": "Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of <e1> co-trimoxazole </e1> <e2> Pneumocystis pneumonia </e2> (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4498": {"data": {"text": "Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.", "entity1": "co-trimoxazole", "entity2": "PCP", "span1": [132, 146], "span2": [24, 27]}, "bert_text": "Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of <e1> co-trimoxazole </e1> <e2> PCP </e2>), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4499": {"data": {"text": "Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.", "entity1": "co-trimoxazole", "entity2": "opportunistic infection", "span1": [132, 146], "span2": [39, 62]}, "bert_text": "Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of <e1> co-trimoxazole </e1> <e2> opportunistic infection </e2> in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4500": {"data": {"text": "Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.", "entity1": "co-trimoxazole", "entity2": "HIV-infected", "span1": [132, 146], "span2": [66, 78]}, "bert_text": "Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of <e1> co-trimoxazole </e1> <e2> HIV-infected </e2> individuals, is generally treated with high doses of co-trimoxazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4501": {"data": {"text": "One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.", "entity1": "Benzylthiouracil", "entity2": "hepatitis", "span1": [94, 110], "span2": [63, 72]}, "bert_text": "One of the latter two patients further experienced a cytolytic hepatitis which appeared after <e1> Benzylthiouracil </e1> <e2> hepatitis </e2> which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4502": {"data": {"text": "One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.", "entity1": "Basd  ne", "entity2": "hepatitis", "span1": [112, 120], "span2": [63, 72]}, "bert_text": "One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (<e1> Basd  ne </e1> <e2> hepatitis </e2> which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4503": {"data": {"text": "One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.", "entity1": "carbimazole", "entity2": "hepatitis", "span1": [135, 146], "span2": [63, 72]}, "bert_text": "One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced <e1> carbimazole </e1> <e2> hepatitis </e2> which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4504": {"data": {"text": "The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.", "entity1": "creatinine", "entity2": "diabetes", "span1": [57, 67], "span2": [37, 45]}, "bert_text": "The study involved 129 patients with diabetes with serum <e1> creatinine </e1> <e2> diabetes </e2> with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4505": {"data": {"text": "Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.", "entity1": "Melatonin", "entity2": "narcosis", "span1": [0, 9], "span2": [62, 70]}, "bert_text": "<e1> Melatonin </e1> pre-treatment affected in a dual manner barbiturate <e2> narcosis </e2>, however, no dose-effect correlation was found.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4506": {"data": {"text": "Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.", "entity1": "barbiturate", "entity2": "narcosis", "span1": [50, 61], "span2": [62, 70]}, "bert_text": "Melatonin pre-treatment affected in a dual manner <e1> barbiturate </e1> <e2> narcosis </e2>, however, no dose-effect correlation was found.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4507": {"data": {"text": "Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.\nOBJECTIVE:", "entity1": "telmisartan", "entity2": "hypertension", "span1": [172, 183], "span2": [260, 272]}, "bert_text": "Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of <e1> telmisartan </e1> and amlodipine versus amlodipine monotherapy in Indian adults with stage II <e2> hypertension </e2>.\nOBJECTIVE:", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4508": {"data": {"text": "Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.\nOBJECTIVE:", "entity1": "amlodipine", "entity2": "hypertension", "span1": [188, 198], "span2": [260, 272]}, "bert_text": "Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and <e1> amlodipine </e1> versus amlodipine monotherapy in Indian adults with stage II <e2> hypertension </e2>.\nOBJECTIVE:", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4509": {"data": {"text": "Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.\nOBJECTIVE:", "entity1": "amlodipine", "entity2": "hypertension", "span1": [206, 216], "span2": [260, 272]}, "bert_text": "Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus <e1> amlodipine </e1> monotherapy in Indian adults with stage II <e2> hypertension </e2>.\nOBJECTIVE:", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4510": {"data": {"text": "Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.\n", "entity1": "fenfluramine", "entity2": "valvular heart disease", "span1": [47, 59], "span2": [9, 31]}, "bert_text": "Risk for valvular heart disease among users of <e1> fenfluramine </e1> <e2> valvular heart disease </e2> among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4511": {"data": {"text": "Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.\n", "entity1": "dexfenfluramine", "entity2": "valvular heart disease", "span1": [64, 79], "span2": [9, 31]}, "bert_text": "Risk for valvular heart disease among users of fenfluramine and <e1> dexfenfluramine </e1> <e2> valvular heart disease </e2> among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4512": {"data": {"text": "The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.", "entity1": "telmisartan", "entity2": "hypertension", "span1": [109, 120], "span2": [236, 248]}, "bert_text": "The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of <e1> telmisartan </e1> 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"4513": {"data": {"text": "The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.", "entity1": "amlodipine", "entity2": "hypertension", "span1": [129, 139], "span2": [236, 248]}, "bert_text": "The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + <e1> amlodipine </e1> 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"4514": {"data": {"text": "The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.", "entity1": "amlodipine", "entity2": "hypertension", "span1": [165, 175], "span2": [236, 248]}, "bert_text": "The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with <e1> amlodipine </e1> 5-mg monotherapy (A) in adult Indian patients with stage II <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"4515": {"data": {"text": "The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).", "entity1": "SRL", "entity2": "nephropathy", "span1": [55, 58], "span2": [107, 118]}, "bert_text": "The patient cohort (14 men, 11 women) was treated with <e1> SRL </e1> as conversion therapy, due to chronic allograft <e2> nephropathy </e2> (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4516": {"data": {"text": "The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).", "entity1": "SRL", "entity2": "neoplasia", "span1": [55, 58], "span2": [134, 143]}, "bert_text": "The patient cohort (14 men, 11 women) was treated with <e1> SRL </e1> as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) <e2> neoplasia </e2> (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4517": {"data": {"text": "The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).", "entity1": "SRL", "entity2": "cancers", "span1": [55, 58], "span2": [181, 188]}, "bert_text": "The patient cohort (14 men, 11 women) was treated with <e1> SRL </e1> as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin <e2> cancers </e2>, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4518": {"data": {"text": "The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).", "entity1": "SRL", "entity2": "Kaposi's sarcoma", "span1": [55, 58], "span2": [153, 169]}, "bert_text": "The patient cohort (14 men, 11 women) was treated with <e1> SRL </e1> as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); <e2> Kaposi's sarcoma </e2>, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4519": {"data": {"text": "The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).", "entity1": "SRL", "entity2": "intestinal tumors", "span1": [55, 58], "span2": [194, 211]}, "bert_text": "The patient cohort (14 men, 11 women) was treated with <e1> SRL </e1> as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One <e2> intestinal tumors </e2>, One renal cell carsinom) or BK virus nephropathy (n = 2).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4520": {"data": {"text": "The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).", "entity1": "SRL", "entity2": "virus nephropathy", "span1": [55, 58], "span2": [244, 261]}, "bert_text": "The patient cohort (14 men, 11 women) was treated with <e1> SRL </e1> as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK <e2> virus nephropathy </e2> (n = 2).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4521": {"data": {"text": "Conversely, enalapril had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with diabetes.", "entity1": "enalapril", "entity2": "diabetes", "span1": [12, 21], "span2": [154, 162]}, "bert_text": "Conversely, <e1> enalapril </e1> had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with <e2> diabetes </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4522": {"data": {"text": "In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.", "entity1": "lithium", "entity2": "atrioventricular (AV) block", "span1": [103, 110], "span2": [30, 57]}, "bert_text": "In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to <e1> lithium </e1> <e2> atrioventricular (AV) block </e2> with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4523": {"data": {"text": "In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.", "entity1": "lithium", "entity2": "syncopal attacks", "span1": [103, 110], "span2": [63, 79]}, "bert_text": "In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to <e1> lithium </e1> <e2> syncopal attacks </e2> developed secondary to lithium therapy, necessitating permanent pacemaker implantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4524": {"data": {"text": "Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.", "entity1": "serotonin", "entity2": "migraine", "span1": [9, 18], "span2": [100, 108]}, "bert_text": "Platelet <e1> serotonin </e1> content decreased significantly (P<0.01) after nitroglycerin in subjects with no <e2> migraine </e2> attack but no consistent change was observed in patients with migraine attack.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4525": {"data": {"text": "Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.", "entity1": "serotonin", "entity2": "migraine", "span1": [9, 18], "span2": [171, 179]}, "bert_text": "Platelet <e1> serotonin </e1> content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with <e2> migraine </e2> attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4526": {"data": {"text": "Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.", "entity1": "nitroglycerin", "entity2": "migraine", "span1": [66, 79], "span2": [100, 108]}, "bert_text": "Platelet serotonin content decreased significantly (P<0.01) after <e1> nitroglycerin </e1> in subjects with no <e2> migraine </e2> attack but no consistent change was observed in patients with migraine attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4527": {"data": {"text": "Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.", "entity1": "nitroglycerin", "entity2": "migraine", "span1": [66, 79], "span2": [171, 179]}, "bert_text": "Platelet serotonin content decreased significantly (P<0.01) after <e1> nitroglycerin </e1> in subjects with no migraine attack but no consistent change was observed in patients with <e2> migraine </e2> attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4528": {"data": {"text": "Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.", "entity1": "bendrofluazide", "entity2": "hypertension", "span1": [21, 35], "span2": [78, 90]}, "bert_text": "Adverse reactions to <e1> bendrofluazide </e1> and propranolol for the treatment of mild <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4529": {"data": {"text": "Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.", "entity1": "propranolol", "entity2": "hypertension", "span1": [40, 51], "span2": [78, 90]}, "bert_text": "Adverse reactions to bendrofluazide and <e1> propranolol </e1> for the treatment of mild <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4530": {"data": {"text": "A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.", "entity1": "warfarin", "entity2": "haemorrhage", "span1": [2, 10], "span2": [58, 69]}, "bert_text": "A <e1> warfarin </e1>-drug interaction could have contributed to the <e2> haemorrhage </e2> in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4531": {"data": {"text": "A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.", "entity1": "warfarin", "entity2": "bleeding", "span1": [2, 10], "span2": [135, 143]}, "bert_text": "A <e1> warfarin </e1>-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the <e2> bleeding </e2> complication was considered being possible to avoid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4532": {"data": {"text": "A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.", "entity1": "warfarin", "entity2": "haemorrhage", "span1": [89, 97], "span2": [58, 69]}, "bert_text": "A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the <e1> warfarin </e1> <e2> haemorrhage </e2> in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4533": {"data": {"text": "A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.", "entity1": "warfarin", "entity2": "bleeding", "span1": [89, 97], "span2": [135, 143]}, "bert_text": "A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the <e1> warfarin </e1> patients and in 7 of these (12%) the <e2> bleeding </e2> complication was considered being possible to avoid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4534": {"data": {"text": "In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.", "entity1": "levodopa", "entity2": "Oromandibular dystonia", "span1": [57, 65], "span2": [74, 96]}, "bert_text": "In this report we describe an unusual case of reversible <e1> levodopa </e1>-induced <e2> Oromandibular dystonia </e2> (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4535": {"data": {"text": "In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.", "entity1": "levodopa", "entity2": "OMD", "span1": [57, 65], "span2": [98, 101]}, "bert_text": "In this report we describe an unusual case of reversible <e1> levodopa </e1>-induced Oromandibular dystonia (<e2> OMD </e2>) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4536": {"data": {"text": "In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.", "entity1": "levodopa", "entity2": "PSP", "span1": [57, 65], "span2": [108, 111]}, "bert_text": "In this report we describe an unusual case of reversible <e1> levodopa </e1>-induced Oromandibular dystonia (OMD) in a <e2> PSP </e2> patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4537": {"data": {"text": "In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.", "entity1": "levodopa", "entity2": "PSP", "span1": [57, 65], "span2": [215, 218]}, "bert_text": "In this report we describe an unusual case of reversible <e1> levodopa </e1>-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of <e2> PSP </e2>, and discuss the possible underlying pathophysiology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4538": {"data": {"text": "After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.", "entity1": "bupropion", "entity2": "tonic clonic seizure", "span1": [17, 26], "span2": [70, 90]}, "bert_text": "After 5 weeks of <e1> bupropion </e1> use, the subject experienced a generalized <e2> tonic clonic seizure </e2> after staying up nearly all night packing and moving to a new residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4539": {"data": {"text": "Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).", "entity1": "dexamethasone", "entity2": "myalgia", "span1": [106, 119], "span2": [26, 33]}, "bert_text": "Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the <e1> dexamethasone </e1> <e2> myalgia </e2> did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4540": {"data": {"text": "Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).", "entity1": "dexamethasone", "entity2": "myalgia", "span1": [106, 119], "span2": [140, 147]}, "bert_text": "Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the <e1> dexamethasone </e1> group complained of <e2> myalgia </e2> compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4541": {"data": {"text": "Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).", "entity1": "dexamethasone", "entity2": "myalgia", "span1": [106, 119], "span2": [206, 213]}, "bert_text": "Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the <e1> dexamethasone </e1> group complained of myalgia compared with 18 patients in the saline group, and severe <e2> myalgia </e2> was reported by five patients and three patients, respectively (not significant).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4542": {"data": {"text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "entity1": "calcium chloride", "entity2": "mydriasis", "span1": [14, 30], "span2": [233, 242]}, "bert_text": "The effect of <e1> calcium chloride </e1> injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), <e2> mydriasis </e2>, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4543": {"data": {"text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "entity1": "calcium chloride", "entity2": "tremor", "span1": [14, 30], "span2": [244, 250]}, "bert_text": "The effect of <e1> calcium chloride </e1> injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, <e2> tremor </e2> and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4544": {"data": {"text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "entity1": "calcium chloride", "entity2": "clonic-tonic convulsions", "span1": [14, 30], "span2": [255, 279]}, "bert_text": "The effect of <e1> calcium chloride </e1> injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and <e2> clonic-tonic convulsions </e2> produced by carbachol and eserine injected similarly was investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4545": {"data": {"text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "entity1": "carbachol", "entity2": "mydriasis", "span1": [292, 301], "span2": [233, 242]}, "bert_text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by <e1> carbachol </e1> <e2> mydriasis </e2>, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4546": {"data": {"text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "entity1": "carbachol", "entity2": "tremor", "span1": [292, 301], "span2": [244, 250]}, "bert_text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by <e1> carbachol </e1> <e2> tremor </e2> and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4547": {"data": {"text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "entity1": "carbachol", "entity2": "clonic-tonic convulsions", "span1": [292, 301], "span2": [255, 279]}, "bert_text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by <e1> carbachol </e1> <e2> clonic-tonic convulsions </e2> produced by carbachol and eserine injected similarly was investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4548": {"data": {"text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "entity1": "eserine", "entity2": "mydriasis", "span1": [306, 313], "span2": [233, 242]}, "bert_text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and <e1> eserine </e1> <e2> mydriasis </e2>, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4549": {"data": {"text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "entity1": "eserine", "entity2": "tremor", "span1": [306, 313], "span2": [244, 250]}, "bert_text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and <e1> eserine </e1> <e2> tremor </e2> and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4550": {"data": {"text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "entity1": "eserine", "entity2": "clonic-tonic convulsions", "span1": [306, 313], "span2": [255, 279]}, "bert_text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and <e1> eserine </e1> <e2> clonic-tonic convulsions </e2> produced by carbachol and eserine injected similarly was investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4551": {"data": {"text": "Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin.", "entity1": "rifampin", "entity2": "proteinuria", "span1": [80, 88], "span2": [12, 23]}, "bert_text": "Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with <e1> rifampin </e1> <e2> proteinuria </e2> was found in 9 of 17 tuberculosis patients treated with rifampin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4552": {"data": {"text": "Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin.", "entity1": "rifampin", "entity2": "tuberculosis", "span1": [80, 88], "span2": [45, 57]}, "bert_text": "Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with <e1> rifampin </e1> <e2> tuberculosis </e2> patients treated with rifampin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4553": {"data": {"text": "These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.", "entity1": "aniracetam", "entity2": "impaired cognitive functions", "span1": [87, 97], "span2": [40, 68]}, "bert_text": "These improvements or normalizations of impaired cognitive functions were seen at oral <e1> aniracetam </e1> <e2> impaired cognitive functions </e2> were seen at oral aniracetam doses of 10-100 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4554": {"data": {"text": "With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.", "entity1": "tacrolimus", "entity2": "TMA", "span1": [40, 50], "span2": [99, 102]}, "bert_text": "With the more widespread application of <e1> tacrolimus </e1> in organ transplantation, tacrolimus-associated <e2> TMA </e2> has also been recognized.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4555": {"data": {"text": "With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.", "entity1": "tacrolimus", "entity2": "TMA", "span1": [77, 87], "span2": [99, 102]}, "bert_text": "With the more widespread application of tacrolimus in organ transplantation, <e1> tacrolimus </e1>-associated <e2> TMA </e2> has also been recognized.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4556": {"data": {"text": "As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).", "entity1": "fluoxetine", "entity2": "fetal pulmonary hypertension", "span1": [27, 37], "span2": [59, 87]}, "bert_text": "As compared with controls, <e1> fluoxetine </e1> exposure resulted in <e2> fetal pulmonary hypertension </e2> as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4557": {"data": {"text": "We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.", "entity1": "ketoconazole", "entity2": "TdP.", "span1": [66, 78], "span2": [120, 124]}, "bert_text": "We postulate that by virtue of its direct blocking action on IKr, <e1> ketoconazole </e1> alone may prolong QT interval and induce <e2> TdP. </e2> This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4558": {"data": {"text": "We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.", "entity1": "ketoconazole", "entity2": "long QT syndrome", "span1": [66, 78], "span2": [227, 243]}, "bert_text": "We postulate that by virtue of its direct blocking action on IKr, <e1> ketoconazole </e1> alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired <e2> long QT syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4559": {"data": {"text": "We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.", "entity1": "ketoconazole", "entity2": "TdP.", "span1": [155, 167], "span2": [120, 124]}, "bert_text": "We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when <e1> ketoconazole </e1> <e2> TdP. </e2> This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4560": {"data": {"text": "We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.", "entity1": "ketoconazole", "entity2": "long QT syndrome", "span1": [155, 167], "span2": [227, 243]}, "bert_text": "We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when <e1> ketoconazole </e1> is administered to patients with risk factors for acquired <e2> long QT syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4561": {"data": {"text": "Saline-pretreated controls given a test dose of morphine (20 mg/kg i.p.) showed a pronounced rigidity recorded as tonic activity in the electromyogram.", "entity1": "morphine", "entity2": "rigidity", "span1": [48, 56], "span2": [93, 101]}, "bert_text": "Saline-pretreated controls given a test dose of <e1> morphine </e1> (20 mg/kg i.p.) showed a pronounced <e2> rigidity </e2> recorded as tonic activity in the electromyogram.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4562": {"data": {"text": "We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.", "entity1": "testosterone", "entity2": "low sexual desire", "span1": [41, 53], "span2": [85, 102]}, "bert_text": "We now advocate that before age 50 years <e1> testosterone </e1> be determined only in cases of <e2> low sexual desire </e2> and abnormal physical examination but that it be measured in all men older than 50 years.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4563": {"data": {"text": "Case report: pentamidine and polymorphic ventricular tachycardia revisited.\n", "entity1": "pentamidine", "entity2": "ventricular tachycardia", "span1": [13, 24], "span2": [41, 64]}, "bert_text": "Case report: <e1> pentamidine </e1> and polymorphic <e2> ventricular tachycardia </e2> revisited.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4564": {"data": {"text": "Amisulpride related tic-like symptoms in an adolescent schizophrenic.\n", "entity1": "Amisulpride", "entity2": "tic-like symptoms", "span1": [0, 11], "span2": [20, 37]}, "bert_text": "<e1> Amisulpride </e1> related <e2> tic-like symptoms </e2> in an adolescent schizophrenic.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4565": {"data": {"text": "Amisulpride related tic-like symptoms in an adolescent schizophrenic.\n", "entity1": "Amisulpride", "entity2": "schizophrenic", "span1": [0, 11], "span2": [55, 68]}, "bert_text": "<e1> Amisulpride </e1> related tic-like symptoms in an adolescent <e2> schizophrenic </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4566": {"data": {"text": "Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.", "entity1": "dopamine", "entity2": "coma", "span1": [29, 37], "span2": [124, 128]}, "bert_text": "Intraventricular infusion of <e1> dopamine </e1> sufficient to raise the brain dopamine to the same extent did not prevent the ammonia <e2> coma </e2> nor affect the blood and brain ammonia concentrations.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4567": {"data": {"text": "Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.", "entity1": "dopamine", "entity2": "coma", "span1": [68, 76], "span2": [124, 128]}, "bert_text": "Intraventricular infusion of dopamine sufficient to raise the brain <e1> dopamine </e1> to the same extent did not prevent the ammonia <e2> coma </e2> nor affect the blood and brain ammonia concentrations.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4568": {"data": {"text": "Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.", "entity1": "ammonia", "entity2": "coma", "span1": [116, 123], "span2": [124, 128]}, "bert_text": "Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the <e1> ammonia </e1> <e2> coma </e2> nor affect the blood and brain ammonia concentrations.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4569": {"data": {"text": "Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.", "entity1": "ammonia", "entity2": "coma", "span1": [160, 167], "span2": [124, 128]}, "bert_text": "Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain <e1> ammonia </e1> <e2> coma </e2> nor affect the blood and brain ammonia concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1], "label": 0},
+	"4570": {"data": {"text": "When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.", "entity1": "aminophylline", "entity2": "respiratory failure", "span1": [130, 143], "span2": [5, 24]}, "bert_text": "When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of <e1> aminophylline </e1> <e2> respiratory failure </e2> was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4571": {"data": {"text": "When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.", "entity1": "aminophylline", "entity2": "hypoventilation", "span1": [130, 143], "span2": [41, 56]}, "bert_text": "When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of <e1> aminophylline </e1> <e2> hypoventilation </e2> (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4572": {"data": {"text": "When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.", "entity1": "aminophylline", "entity2": "ventricular fibrillation", "span1": [130, 143], "span2": [184, 208]}, "bert_text": "When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of <e1> aminophylline </e1> resulted in an even greater decrease in <e2> ventricular fibrillation </e2> threshold to 60 percent of the control level.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4573": {"data": {"text": "The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.", "entity1": "alcohol", "entity2": "alcohol abuse", "span1": [44, 51], "span2": [29, 42]}, "bert_text": "The patient had a history of alcohol abuse; <e1> alcohol </e1> <e2> alcohol abuse </e2>; alcohol intake as well as withdrawal can also cause seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4574": {"data": {"text": "The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.", "entity1": "alcohol", "entity2": "seizures", "span1": [44, 51], "span2": [96, 104]}, "bert_text": "The patient had a history of alcohol abuse; <e1> alcohol </e1> intake as well as withdrawal can also cause <e2> seizures </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4575": {"data": {"text": "Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.\n", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic syndrome", "span1": [110, 135], "span2": [69, 87]}, "bert_text": "Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by <e1> puromycin aminonucleoside </e1> <e2> nephrotic syndrome </e2> induced in the rat by puromycin aminonucleoside.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4576": {"data": {"text": "Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.", "entity1": "LA", "entity2": "CM", "span1": [73, 75], "span2": [56, 58]}, "bert_text": "Results show that cumulative HAART caused mitochondrial CM with elevated <e1> LA </e1> <e2> CM </e2> with elevated LA in AIDS transgenic mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4577": {"data": {"text": "Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.", "entity1": "LA", "entity2": "AIDS", "span1": [73, 75], "span2": [79, 83]}, "bert_text": "Results show that cumulative HAART caused mitochondrial CM with elevated <e1> LA </e1> in <e2> AIDS </e2> transgenic mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4578": {"data": {"text": "In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.", "entity1": "rilmenidine", "entity2": "hypotension", "span1": [23, 34], "span2": [72, 83]}, "bert_text": "In sham-operated rats, <e1> rilmenidine </e1> or alpha-methyldopa elicited similar <e2> hypotension </e2> that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4579": {"data": {"text": "In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.", "entity1": "alpha-methyldopa", "entity2": "hypotension", "span1": [38, 54], "span2": [72, 83]}, "bert_text": "In sham-operated rats, rilmenidine or <e1> alpha-methyldopa </e1> elicited similar <e2> hypotension </e2> that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4580": {"data": {"text": "Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).", "entity1": "diazepam", "entity2": "venous complications", "span1": [54, 62], "span2": [9, 29]}, "bert_text": "Overall, venous complications were more frequent with <e1> diazepam </e1> <e2> venous complications </e2> were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4581": {"data": {"text": "Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).", "entity1": "midazolam", "entity2": "venous complications", "span1": [93, 102], "span2": [9, 29]}, "bert_text": "Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with <e1> midazolam </e1> <e2> venous complications </e2> were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4582": {"data": {"text": "Glyburide-induced hepatitis.\n", "entity1": "Glyburide", "entity2": "hepatitis", "span1": [0, 9], "span2": [18, 27]}, "bert_text": "<e1> Glyburide </e1>-induced <e2> hepatitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4583": {"data": {"text": "A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.", "entity1": "phenothiazines", "entity2": "cardiac complications", "span1": [110, 124], "span2": [66, 87]}, "bert_text": "A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving <e1> phenothiazines </e1> <e2> cardiac complications </e2> to patients receiving phenothiazines or tricyclic antidepressant drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"4584": {"data": {"text": "Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.", "entity1": "rapamycin", "entity2": "nephropathy", "span1": [120, 129], "span2": [225, 236]}, "bert_text": "Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of <e1> rapamycin </e1> (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4585": {"data": {"text": "Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.", "entity1": "sirolimus", "entity2": "nephropathy", "span1": [160, 169], "span2": [225, 236]}, "bert_text": "Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially <e1> sirolimus </e1>, in renal transplant recipients with chronic allograft <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4586": {"data": {"text": "Serial epilepsy caused by levodopa/carbidopa administration in two patients on hemodialysis.\n", "entity1": "levodopa/carbidopa", "entity2": "epilepsy", "span1": [26, 44], "span2": [7, 15]}, "bert_text": "Serial epilepsy caused by <e1> levodopa/carbidopa </e1> <e2> epilepsy </e2> caused by levodopa/carbidopa administration in two patients on hemodialysis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4587": {"data": {"text": "RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.", "entity1": "streptozotocin", "entity2": "diabetic nephropathy", "span1": [169, 183], "span2": [76, 96]}, "bert_text": "RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a <e1> streptozotocin </e1> <e2> diabetic nephropathy </e2> using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4588": {"data": {"text": "RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.", "entity1": "streptozotocin", "entity2": "diabetic nephropathy", "span1": [169, 183], "span2": [136, 156]}, "bert_text": "RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a <e1> streptozotocin </e1> <e2> diabetic nephropathy </e2> patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4589": {"data": {"text": "RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.", "entity1": "streptozotocin", "entity2": "diabetic nephropathy", "span1": [169, 183], "span2": [192, 212]}, "bert_text": "RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a <e1> streptozotocin </e1>-induced <e2> diabetic nephropathy </e2> model in Nrf2(-/-) mice, and cultured human mesangial cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4590": {"data": {"text": "Hepatotoxicity of amiodarone.\n", "entity1": "amiodarone", "entity2": "Hepatotoxicity", "span1": [18, 28], "span2": [0, 14]}, "bert_text": "Hepatotoxicity of <e1> amiodarone </e1> <e2> Hepatotoxicity </e2> of amiodarone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4591": {"data": {"text": "Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.\n", "entity1": "tizanidine", "entity2": "Hypotension", "span1": [40, 50], "span2": [0, 11]}, "bert_text": "Hypotension following the initiation of <e1> tizanidine </e1> <e2> Hypotension </e2> following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4592": {"data": {"text": "Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.\n", "entity1": "tizanidine", "entity2": "hypertension", "span1": [40, 50], "span2": [132, 144]}, "bert_text": "Hypotension following the initiation of <e1> tizanidine </e1> in a patient treated with an angiotensin converting enzyme inhibitor for chronic <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4593": {"data": {"text": "Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.\n", "entity1": "angiotensin", "entity2": "Hypotension", "span1": [80, 91], "span2": [0, 11]}, "bert_text": "Hypotension following the initiation of tizanidine in a patient treated with an <e1> angiotensin </e1> <e2> Hypotension </e2> following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4594": {"data": {"text": "Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.\n", "entity1": "angiotensin", "entity2": "hypertension", "span1": [80, 91], "span2": [132, 144]}, "bert_text": "Hypotension following the initiation of tizanidine in a patient treated with an <e1> angiotensin </e1> converting enzyme inhibitor for chronic <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4595": {"data": {"text": "The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.", "entity1": "cyclosporine", "entity2": "Pain", "span1": [91, 103], "span2": [34, 38]}, "bert_text": "The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of <e1> cyclosporine </e1> <e2> Pain </e2> Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4596": {"data": {"text": "The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.", "entity1": "tacrolimus", "entity2": "Pain", "span1": [107, 117], "span2": [34, 38]}, "bert_text": "The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or <e1> tacrolimus </e1> <e2> Pain </e2> Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4597": {"data": {"text": "We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.", "entity1": "daunorubicin", "entity2": "AIDS", "span1": [98, 110], "span2": [143, 147]}, "bert_text": "We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal <e1> daunorubicin </e1> (DaunoXome) in the treatment of <e2> AIDS </e2> related Kaposi's sarcoma.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4598": {"data": {"text": "We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.", "entity1": "daunorubicin", "entity2": "Kaposi's sarcoma", "span1": [98, 110], "span2": [156, 172]}, "bert_text": "We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal <e1> daunorubicin </e1> (DaunoXome) in the treatment of AIDS related <e2> Kaposi's sarcoma </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4599": {"data": {"text": "Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.\n", "entity1": "lopinavir/ritonavir", "entity2": "cardiac toxicity", "span1": [55, 74], "span2": [27, 43]}, "bert_text": "Twin preterm neonates with cardiac toxicity related to <e1> lopinavir/ritonavir </e1> <e2> cardiac toxicity </e2> related to lopinavir/ritonavir therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4600": {"data": {"text": "Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.\n", "entity1": "sodium", "entity2": "hypertension", "span1": [11, 17], "span2": [106, 118]}, "bert_text": "Changes of <e1> sodium </e1> and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4601": {"data": {"text": "Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.\n", "entity1": "Na", "entity2": "hypertension", "span1": [53, 55], "span2": [106, 118]}, "bert_text": "Changes of sodium and ATP affinities of the cardiac (<e1> Na </e1>,K)-ATPase during and after nitric oxide deficient <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4602": {"data": {"text": "Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.\n", "entity1": "ATP", "entity2": "hypertension", "span1": [22, 25], "span2": [106, 118]}, "bert_text": "Changes of sodium and <e1> ATP </e1> affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4603": {"data": {"text": "Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.\n", "entity1": "K)-ATPase", "entity2": "hypertension", "span1": [56, 65], "span2": [106, 118]}, "bert_text": "Changes of sodium and ATP affinities of the cardiac (Na,<e1> K)-ATPase </e1> during and after nitric oxide deficient <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4604": {"data": {"text": "Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.\n", "entity1": "nitric oxide", "entity2": "hypertension", "span1": [83, 95], "span2": [106, 118]}, "bert_text": "Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after <e1> nitric oxide </e1> deficient <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4605": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "cisplatin", "entity2": "carcinoma", "span1": [191, 200], "span2": [19, 28]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with <e1> cisplatin </e1> <e2> carcinoma </e2> developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4606": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "cisplatin", "entity2": "thrombotic microangiopathy", "span1": [191, 200], "span2": [39, 65]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with <e1> cisplatin </e1> <e2> thrombotic microangiopathy </e2> (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4607": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "cisplatin", "entity2": "renal insufficiency", "span1": [191, 200], "span2": [84, 103]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with <e1> cisplatin </e1> <e2> renal insufficiency </e2>, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4608": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "cisplatin", "entity2": "microangiopathic hemolytic anemia", "span1": [191, 200], "span2": [105, 138]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with <e1> cisplatin </e1> <e2> microangiopathic hemolytic anemia </e2>, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4609": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "cisplatin", "entity2": "thrombocytopenia", "span1": [191, 200], "span2": [152, 168]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with <e1> cisplatin </e1> <e2> thrombocytopenia </e2>) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4610": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "bleomycin", "entity2": "carcinoma", "span1": [202, 211], "span2": [19, 28]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, <e1> bleomycin </e1> <e2> carcinoma </e2> developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4611": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "bleomycin", "entity2": "thrombotic microangiopathy", "span1": [202, 211], "span2": [39, 65]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, <e1> bleomycin </e1> <e2> thrombotic microangiopathy </e2> (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4612": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "bleomycin", "entity2": "renal insufficiency", "span1": [202, 211], "span2": [84, 103]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, <e1> bleomycin </e1> <e2> renal insufficiency </e2>, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4613": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "bleomycin", "entity2": "microangiopathic hemolytic anemia", "span1": [202, 211], "span2": [105, 138]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, <e1> bleomycin </e1> <e2> microangiopathic hemolytic anemia </e2>, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4614": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "bleomycin", "entity2": "thrombocytopenia", "span1": [202, 211], "span2": [152, 168]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, <e1> bleomycin </e1> <e2> thrombocytopenia </e2>) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4615": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "vinca alkaloid", "entity2": "carcinoma", "span1": [219, 233], "span2": [19, 28]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a <e1> vinca alkaloid </e1> <e2> carcinoma </e2> developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4616": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "vinca alkaloid", "entity2": "thrombotic microangiopathy", "span1": [219, 233], "span2": [39, 65]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a <e1> vinca alkaloid </e1> <e2> thrombotic microangiopathy </e2> (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4617": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "vinca alkaloid", "entity2": "renal insufficiency", "span1": [219, 233], "span2": [84, 103]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a <e1> vinca alkaloid </e1> <e2> renal insufficiency </e2>, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4618": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "vinca alkaloid", "entity2": "microangiopathic hemolytic anemia", "span1": [219, 233], "span2": [105, 138]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a <e1> vinca alkaloid </e1> <e2> microangiopathic hemolytic anemia </e2>, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4619": {"data": {"text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "entity1": "vinca alkaloid", "entity2": "thrombocytopenia", "span1": [219, 233], "span2": [152, 168]}, "bert_text": "Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a <e1> vinca alkaloid </e1> <e2> thrombocytopenia </e2>) after treatment with cisplatin, bleomycin, and a vinca alkaloid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4620": {"data": {"text": "Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.", "entity1": "carbidopa/levodopa", "entity2": "chronic renal failure", "span1": [201, 219], "span2": [77, 98]}, "bert_text": "Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a <e1> carbidopa/levodopa </e1> <e2> chronic renal failure </e2>, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4621": {"data": {"text": "Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.", "entity1": "carbidopa/levodopa", "entity2": "hallucinosis", "span1": [201, 219], "span2": [259, 271]}, "bert_text": "Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a <e1> carbidopa/levodopa </e1> preparation; and both had the onset of <e2> hallucinosis </e2> and recurrent seizures, which were refractory to anticonvulsants.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4622": {"data": {"text": "Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.", "entity1": "carbidopa/levodopa", "entity2": "seizures", "span1": [201, 219], "span2": [286, 294]}, "bert_text": "Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a <e1> carbidopa/levodopa </e1> preparation; and both had the onset of hallucinosis and recurrent <e2> seizures </e2>, which were refractory to anticonvulsants.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4623": {"data": {"text": "Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.", "entity1": "creatinine", "entity2": "nephrotoxicity", "span1": [16, 26], "span2": [115, 129]}, "bert_text": "Increased serum <e1> creatinine </e1> was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4624": {"data": {"text": "Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.\n", "entity1": "nelarabine", "entity2": "T-cell lymphoblastic leukaemia and lymphoma", "span1": [21, 31], "span2": [99, 142]}, "bert_text": "Salvage therapy with <e1> nelarabine </e1>, etoposide, and cyclophosphamide in relapsed/refractory paediatric <e2> T-cell lymphoblastic leukaemia and lymphoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4625": {"data": {"text": "Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.\n", "entity1": "etoposide", "entity2": "T-cell lymphoblastic leukaemia and lymphoma", "span1": [33, 42], "span2": [99, 142]}, "bert_text": "Salvage therapy with nelarabine, <e1> etoposide </e1>, and cyclophosphamide in relapsed/refractory paediatric <e2> T-cell lymphoblastic leukaemia and lymphoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4626": {"data": {"text": "Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.\n", "entity1": "cyclophosphamide", "entity2": "T-cell lymphoblastic leukaemia and lymphoma", "span1": [48, 64], "span2": [99, 142]}, "bert_text": "Salvage therapy with nelarabine, etoposide, and <e1> cyclophosphamide </e1> in relapsed/refractory paediatric <e2> T-cell lymphoblastic leukaemia and lymphoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4627": {"data": {"text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.", "entity1": "aminoglycoside", "entity2": "Thrombophlebitis", "span1": [144, 158], "span2": [0, 16]}, "bert_text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an <e1> aminoglycoside </e1> <e2> Thrombophlebitis </e2> occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4628": {"data": {"text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.", "entity1": "aminoglycoside", "entity2": "nephrotoxicity", "span1": [144, 158], "span2": [74, 88]}, "bert_text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an <e1> aminoglycoside </e1> <e2> nephrotoxicity </e2> and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4629": {"data": {"text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.", "entity1": "aminoglycoside", "entity2": "ototoxicity", "span1": [144, 158], "span2": [93, 104]}, "bert_text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an <e1> aminoglycoside </e1> <e2> ototoxicity </e2> were confined to patients receiving an aminoglycoside plus vancomycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4630": {"data": {"text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.", "entity1": "vancomycin", "entity2": "Thrombophlebitis", "span1": [164, 174], "span2": [0, 16]}, "bert_text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus <e1> vancomycin </e1> <e2> Thrombophlebitis </e2> occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4631": {"data": {"text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.", "entity1": "vancomycin", "entity2": "nephrotoxicity", "span1": [164, 174], "span2": [74, 88]}, "bert_text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus <e1> vancomycin </e1> <e2> nephrotoxicity </e2> and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4632": {"data": {"text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.", "entity1": "vancomycin", "entity2": "ototoxicity", "span1": [164, 174], "span2": [93, 104]}, "bert_text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus <e1> vancomycin </e1> <e2> ototoxicity </e2> were confined to patients receiving an aminoglycoside plus vancomycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4633": {"data": {"text": "RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.", "entity1": "bupropion HCl", "entity2": "convulsions", "span1": [54, 67], "span2": [105, 116]}, "bert_text": "RESULTS: The results showed that IP administration of <e1> bupropion HCl </e1> 120 mg/kg by bolus injection induced <e2> convulsions </e2> in 6 out of 10 mice (60% of convulsing mice) in group 1.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4634": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "ASA", "entity2": "atrial fibrillation", "span1": [157, 160], "span2": [46, 65]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, <e1> ASA </e1> <e2> atrial fibrillation </e2>, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4635": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "ASA", "entity2": "agitation", "span1": [157, 160], "span2": [67, 76]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, <e1> ASA </e1> <e2> agitation </e2>, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4636": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "ASA", "entity2": "loss of consciousness", "span1": [157, 160], "span2": [106, 127]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, <e1> ASA </e1> <e2> loss of consciousness </e2>, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4637": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "ASA", "entity2": "Dupuytren's contracture", "span1": [157, 160], "span2": [336, 359]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, <e1> ASA </e1> classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of <e2> Dupuytren's contracture </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4638": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "mepivacaine", "entity2": "atrial fibrillation", "span1": [267, 278], "span2": [46, 65]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with <e1> mepivacaine </e1> <e2> atrial fibrillation </e2>, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4639": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "mepivacaine", "entity2": "agitation", "span1": [267, 278], "span2": [67, 76]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with <e1> mepivacaine </e1> <e2> agitation </e2>, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4640": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "mepivacaine", "entity2": "loss of consciousness", "span1": [267, 278], "span2": [106, 127]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with <e1> mepivacaine </e1> <e2> loss of consciousness </e2>, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4641": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "mepivacaine", "entity2": "Dupuytren's contracture", "span1": [267, 278], "span2": [336, 359]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with <e1> mepivacaine </e1> 850 mg containing adrenaline 0.225 mg, for correction of <e2> Dupuytren's contracture </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4642": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "adrenaline", "entity2": "atrial fibrillation", "span1": [297, 307], "span2": [46, 65]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing <e1> adrenaline </e1> <e2> atrial fibrillation </e2>, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4643": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "adrenaline", "entity2": "agitation", "span1": [297, 307], "span2": [67, 76]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing <e1> adrenaline </e1> <e2> agitation </e2>, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4644": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "adrenaline", "entity2": "loss of consciousness", "span1": [297, 307], "span2": [106, 127]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing <e1> adrenaline </e1> <e2> loss of consciousness </e2>, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4645": {"data": {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity1": "adrenaline", "entity2": "Dupuytren's contracture", "span1": [297, 307], "span2": [336, 359]}, "bert_text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing <e1> adrenaline </e1> 0.225 mg, for correction of <e2> Dupuytren's contracture </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4646": {"data": {"text": "BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.", "entity1": "fenfluramine", "entity2": "valvular disease", "span1": [103, 115], "span2": [140, 156]}, "bert_text": "BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of <e1> fenfluramine </e1> and dexfenfluramine had <e2> valvular disease </e2>, these drugs were withdrawn from the market.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4647": {"data": {"text": "BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.", "entity1": "dexfenfluramine", "entity2": "valvular disease", "span1": [120, 135], "span2": [140, 156]}, "bert_text": "BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and <e1> dexfenfluramine </e1> had <e2> valvular disease </e2>, these drugs were withdrawn from the market.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4648": {"data": {"text": "Rosaceiform dermatitis associated with topical tacrolimus treatment.\n", "entity1": "tacrolimus", "entity2": "dermatitis", "span1": [47, 57], "span2": [12, 22]}, "bert_text": "Rosaceiform dermatitis associated with topical <e1> tacrolimus </e1> <e2> dermatitis </e2> associated with topical tacrolimus treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4649": {"data": {"text": "Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [31, 40], "span2": [8, 19]}, "bert_text": "Whether proteinuria was due to <e1> sirolimus </e1> <e2> proteinuria </e2> was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4650": {"data": {"text": "Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [31, 40], "span2": [135, 146]}, "bert_text": "Whether proteinuria was due to <e1> sirolimus </e1> or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range <e2> proteinuria </e2> has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4651": {"data": {"text": "Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [172, 181], "span2": [8, 19]}, "bert_text": "Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during <e1> sirolimus </e1> <e2> proteinuria </e2> was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4652": {"data": {"text": "Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [172, 181], "span2": [135, 146]}, "bert_text": "Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during <e1> sirolimus </e1> <e2> proteinuria </e2> has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4653": {"data": {"text": "Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [244, 253], "span2": [8, 19]}, "bert_text": "Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received <e1> sirolimus </e1> <e2> proteinuria </e2> was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4654": {"data": {"text": "Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [244, 253], "span2": [135, 146]}, "bert_text": "Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received <e1> sirolimus </e1> <e2> proteinuria </e2> has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4655": {"data": {"text": "Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.", "entity1": "ketamine", "entity2": "depression", "span1": [14, 22], "span2": [86, 96]}, "bert_text": "Injections of <e1> ketamine </e1> in doses from 100 microgram to 3 mg into the artery produced a <e2> depression </e2> of the SA nodal activity by a direct action.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4656": {"data": {"text": "In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).", "entity1": "asenapine", "entity2": "schizophrenia", "span1": [122, 131], "span2": [56, 69]}, "bert_text": "In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with <e1> asenapine </e1> <e2> schizophrenia </e2> were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4657": {"data": {"text": "In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).", "entity1": "asenapine", "entity2": "schizophrenia", "span1": [159, 168], "span2": [56, 69]}, "bert_text": "In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), <e1> asenapine </e1> <e2> schizophrenia </e2> were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4658": {"data": {"text": "In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).", "entity1": "haloperidol", "entity2": "schizophrenia", "span1": [195, 206], "span2": [56, 69]}, "bert_text": "In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or <e1> haloperidol </e1> <e2> schizophrenia </e2> were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4659": {"data": {"text": "The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.", "entity1": "AZT", "entity2": "anaemia", "span1": [97, 100], "span2": [146, 153]}, "bert_text": "The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in <e1> AZT </e1> and PHZ treated mice with similar degrees of <e2> anaemia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4660": {"data": {"text": "The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.", "entity1": "PHZ", "entity2": "anaemia", "span1": [105, 108], "span2": [146, 153]}, "bert_text": "The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and <e1> PHZ </e1> treated mice with similar degrees of <e2> anaemia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4661": {"data": {"text": "However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.", "entity1": "quetiapine", "entity2": "tic-like symptoms", "span1": [134, 144], "span2": [46, 63]}, "bert_text": "However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with <e1> quetiapine </e1> <e2> tic-like symptoms </e2>, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4662": {"data": {"text": "However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.", "entity1": "clozapine", "entity2": "tic-like symptoms", "span1": [148, 157], "span2": [46, 63]}, "bert_text": "However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or <e1> clozapine </e1> <e2> tic-like symptoms </e2>, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4663": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "Urd", "entity2": "toxicities", "span1": [59, 62], "span2": [24, 34]}, "bert_text": "Because of the clinical toxicities associated with chronic <e1> Urd </e1> <e2> toxicities </e2> associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4664": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "Urd", "entity2": "anemia", "span1": [59, 62], "span2": [152, 158]}, "bert_text": "Because of the clinical toxicities associated with chronic <e1> Urd </e1> administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced <e2> anemia </e2> and leukopenia was assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4665": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "Urd", "entity2": "leukopenia", "span1": [59, 62], "span2": [163, 173]}, "bert_text": "Because of the clinical toxicities associated with chronic <e1> Urd </e1> administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and <e2> leukopenia </e2> was assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4666": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "benzylacyclouridine", "entity2": "toxicities", "span1": [94, 113], "span2": [24, 34]}, "bert_text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of <e1> benzylacyclouridine </e1> <e2> toxicities </e2> associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4667": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "benzylacyclouridine", "entity2": "anemia", "span1": [94, 113], "span2": [152, 158]}, "bert_text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of <e1> benzylacyclouridine </e1> (BAU) to effect, in vivo, AZT-induced <e2> anemia </e2> and leukopenia was assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4668": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "benzylacyclouridine", "entity2": "leukopenia", "span1": [94, 113], "span2": [163, 173]}, "bert_text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of <e1> benzylacyclouridine </e1> (BAU) to effect, in vivo, AZT-induced anemia and <e2> leukopenia </e2> was assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4669": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "BAU", "entity2": "toxicities", "span1": [115, 118], "span2": [24, 34]}, "bert_text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (<e1> BAU </e1> <e2> toxicities </e2> associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4670": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "BAU", "entity2": "anemia", "span1": [115, 118], "span2": [152, 158]}, "bert_text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (<e1> BAU </e1>) to effect, in vivo, AZT-induced <e2> anemia </e2> and leukopenia was assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4671": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "BAU", "entity2": "leukopenia", "span1": [115, 118], "span2": [163, 173]}, "bert_text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (<e1> BAU </e1>) to effect, in vivo, AZT-induced anemia and <e2> leukopenia </e2> was assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4672": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "AZT", "entity2": "toxicities", "span1": [140, 143], "span2": [24, 34]}, "bert_text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, <e1> AZT </e1> <e2> toxicities </e2> associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4673": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "AZT", "entity2": "anemia", "span1": [140, 143], "span2": [152, 158]}, "bert_text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, <e1> AZT </e1>-induced <e2> anemia </e2> and leukopenia was assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4674": {"data": {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity1": "AZT", "entity2": "leukopenia", "span1": [140, 143], "span2": [163, 173]}, "bert_text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, <e1> AZT </e1>-induced anemia and <e2> leukopenia </e2> was assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4675": {"data": {"text": "A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.", "entity1": "clozapine", "entity2": "schizophrenia", "span1": [100, 109], "span2": [24, 37]}, "bert_text": "A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of <e1> clozapine </e1> <e2> schizophrenia </e2> developed a sudden onset of myocarditis after commencement of clozapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4676": {"data": {"text": "A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.", "entity1": "clozapine", "entity2": "myocarditis", "span1": [100, 109], "span2": [66, 77]}, "bert_text": "A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of <e1> clozapine </e1> <e2> myocarditis </e2> after commencement of clozapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4677": {"data": {"text": "Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.", "entity1": "sulfonylureas", "entity2": "hepatotoxicity", "span1": [87, 100], "span2": [13, 27]}, "bert_text": "Drug-induced hepatotoxicity, although common, has been reported only infrequently with <e1> sulfonylureas </e1> <e2> hepatotoxicity </e2>, although common, has been reported only infrequently with sulfonylureas.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4678": {"data": {"text": "Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary.", "entity1": "dopamine", "entity2": "catatonia", "span1": [13, 21], "span2": [102, 111]}, "bert_text": "Furthermore, <e1> dopamine </e1> appeared to act on systems more closely involved with the induction of ketamine <e2> catatonia </e2> rather than directly on the pituitary.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4679": {"data": {"text": "Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary.", "entity1": "ketamine", "entity2": "catatonia", "span1": [93, 101], "span2": [102, 111]}, "bert_text": "Furthermore, dopamine appeared to act on systems more closely involved with the induction of <e1> ketamine </e1> <e2> catatonia </e2> rather than directly on the pituitary.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4680": {"data": {"text": "Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction.", "entity1": "cocaine", "entity2": "acute myocardial infarction", "span1": [94, 101], "span2": [116, 143]}, "bert_text": "Clinical and experimental data published to date suggest several possible mechanisms by which <e1> cocaine </e1> may result in <e2> acute myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"4681": {"data": {"text": "However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.", "entity1": "cyclosporine", "entity2": "TMA", "span1": [105, 117], "span2": [65, 68]}, "bert_text": "However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to <e1> cyclosporine </e1> <e2> TMA </e2> in patients exposed sequentially to cyclosporine and tacrolimus is limited.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4682": {"data": {"text": "However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.", "entity1": "tacrolimus", "entity2": "TMA", "span1": [122, 132], "span2": [65, 68]}, "bert_text": "However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and <e1> tacrolimus </e1> <e2> TMA </e2> in patients exposed sequentially to cyclosporine and tacrolimus is limited.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4683": {"data": {"text": "Assessment of a new non-invasive index of cardiac performance for detection of dobutamine-induced myocardial ischemia.\n", "entity1": "dobutamine", "entity2": "myocardial ischemia", "span1": [79, 89], "span2": [98, 117]}, "bert_text": "Assessment of a new non-invasive index of cardiac performance for detection of <e1> dobutamine </e1>-induced <e2> myocardial ischemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4684": {"data": {"text": "BACKGROUND: Electrocardiography has a very low sensitivity in detecting dobutamine-induced myocardial ischemia.", "entity1": "dobutamine", "entity2": "myocardial ischemia", "span1": [72, 82], "span2": [91, 110]}, "bert_text": "BACKGROUND: Electrocardiography has a very low sensitivity in detecting <e1> dobutamine </e1>-induced <e2> myocardial ischemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4685": {"data": {"text": "Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.", "entity1": "6-thioguanine", "entity2": "veno-occlusive disease", "span1": [165, 178], "span2": [22, 44]}, "bert_text": "Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with <e1> 6-thioguanine </e1> <e2> veno-occlusive disease </e2> of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4686": {"data": {"text": "Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.", "entity1": "6-thioguanine", "entity2": "acute lymphocytic leukemia", "span1": [165, 178], "span2": [94, 120]}, "bert_text": "Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with <e1> 6-thioguanine </e1> <e2> acute lymphocytic leukemia </e2> after 10 months of maintenance therapy with 6-thioguanine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4687": {"data": {"text": "Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.\n", "entity1": "Ginsenoside Rg1", "entity2": "impairment of learning", "span1": [0, 15], "span2": [29, 51]}, "bert_text": "<e1> Ginsenoside Rg1 </e1> restores the <e2> impairment of learning </e2> induced by chronic morphine administration in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4688": {"data": {"text": "Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.\n", "entity1": "morphine", "entity2": "impairment of learning", "span1": [71, 79], "span2": [29, 51]}, "bert_text": "Ginsenoside Rg1 restores the impairment of learning induced by chronic <e1> morphine </e1> <e2> impairment of learning </e2> induced by chronic morphine administration in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4689": {"data": {"text": "A long-term evaluation of the risk-benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [52, 61], "span2": [92, 105]}, "bert_text": "A long-term evaluation of the risk-benefit ratio of <e1> tamoxifen </e1> as a preventive treatment for <e2> breast cancer </e2> is clearly warranted.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4690": {"data": {"text": "Explicit episodic memory for sensory-discriminative components of capsaicin-induced pain: immediate and delayed ratings.\n", "entity1": "capsaicin", "entity2": "pain", "span1": [66, 75], "span2": [84, 88]}, "bert_text": "Explicit episodic memory for sensory-discriminative components of <e1> capsaicin </e1>-induced <e2> pain </e2>: immediate and delayed ratings.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4691": {"data": {"text": "Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.", "entity1": "risperidone", "entity2": "Tic disorders", "span1": [76, 87], "span2": [0, 13]}, "bert_text": "Tic disorders can be effectively treated by atypical antipsychotics such as <e1> risperidone </e1> <e2> Tic disorders </e2> can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4692": {"data": {"text": "Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.", "entity1": "olanzapine", "entity2": "Tic disorders", "span1": [89, 99], "span2": [0, 13]}, "bert_text": "Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, <e1> olanzapine </e1> <e2> Tic disorders </e2> can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4693": {"data": {"text": "Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.", "entity1": "ziprasidone", "entity2": "Tic disorders", "span1": [104, 115], "span2": [0, 13]}, "bert_text": "Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and <e1> ziprasidone </e1> <e2> Tic disorders </e2> can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4694": {"data": {"text": "For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.", "entity1": "glyburide", "entity2": "hepatotoxicity", "span1": [4, 13], "span2": [75, 89]}, "bert_text": "For <e1> glyburide </e1>, a second-generation sulfonylurea, only two brief reports of <e2> hepatotoxicity </e2> exist.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4695": {"data": {"text": "For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.", "entity1": "sulfonylurea", "entity2": "hepatotoxicity", "span1": [35, 47], "span2": [75, 89]}, "bert_text": "For glyburide, a second-generation <e1> sulfonylurea </e1>, only two brief reports of <e2> hepatotoxicity </e2> exist.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4696": {"data": {"text": "A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.", "entity1": "trihexyphenidyl hydrochloride", "entity2": "schizophrenic", "span1": [74, 103], "span2": [10, 23]}, "bert_text": "A chronic schizophrenic patient was treated with an anticholinergic drug, <e1> trihexyphenidyl hydrochloride </e1> <e2> schizophrenic </e2> patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4697": {"data": {"text": "A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.", "entity1": "ciprofloxacin", "entity2": "abdominal pain", "span1": [105, 118], "span2": [42, 56]}, "bert_text": "A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral <e1> ciprofloxacin </e1> <e2> abdominal pain </e2> and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4698": {"data": {"text": "A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.", "entity1": "ciprofloxacin", "entity2": "jaundice", "span1": [105, 118], "span2": [61, 69]}, "bert_text": "A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral <e1> ciprofloxacin </e1> <e2> jaundice </e2> after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4699": {"data": {"text": "A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.", "entity1": "ciprofloxacin", "entity2": "urinary tract infection", "span1": [105, 118], "span2": [136, 159]}, "bert_text": "A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral <e1> ciprofloxacin </e1> for a suspect of <e2> urinary tract infection </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4700": {"data": {"text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "entity1": "methyldopa", "entity2": "hypotension", "span1": [82, 92], "span2": [101, 112]}, "bert_text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a <e1> methyldopa </e1>-induced <e2> hypotension </e2> via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4701": {"data": {"text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "entity1": "methyldopa", "entity2": "hypotensive", "span1": [82, 92], "span2": [205, 216]}, "bert_text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a <e1> methyldopa </e1>-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the <e2> hypotensive </e2> action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4702": {"data": {"text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "entity1": "methyldopa", "entity2": "hypotension", "span1": [227, 237], "span2": [101, 112]}, "bert_text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of <e1> methyldopa </e1> <e2> hypotension </e2> via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4703": {"data": {"text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "entity1": "methyldopa", "entity2": "hypotensive", "span1": [227, 237], "span2": [205, 216]}, "bert_text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of <e1> methyldopa </e1> <e2> hypotensive </e2> action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4704": {"data": {"text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "entity1": "serotonin", "entity2": "hypotension", "span1": [153, 162], "span2": [101, 112]}, "bert_text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline <e1> serotonin </e1> <e2> hypotension </e2> via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4705": {"data": {"text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "entity1": "serotonin", "entity2": "hypotensive", "span1": [153, 162], "span2": [205, 216]}, "bert_text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline <e1> serotonin </e1> B3 cells in the medulla contribute to the <e2> hypotensive </e2> action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4706": {"data": {"text": "significantly improved the amnesia induced by scopolamine (0.5 mg/kg s.c.) in rats performing a passive avoidance task.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [46, 57], "span2": [27, 34]}, "bert_text": "significantly improved the amnesia induced by <e1> scopolamine </e1> <e2> amnesia </e2> induced by scopolamine (0.5 mg/kg s.c.) in rats performing a passive avoidance task.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, 0, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4707": {"data": {"text": "Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.", "entity1": "prilocaine", "entity2": "TNSs", "span1": [66, 76], "span2": [164, 168]}, "bert_text": "Accordingly, the present, prospective double-blind study compares <e1> prilocaine </e1> with lidocaine and bupivacaine with respect to duration of action and relative risk of <e2> TNSs </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4708": {"data": {"text": "Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.", "entity1": "lidocaine", "entity2": "TNSs", "span1": [82, 91], "span2": [164, 168]}, "bert_text": "Accordingly, the present, prospective double-blind study compares prilocaine with <e1> lidocaine </e1> and bupivacaine with respect to duration of action and relative risk of <e2> TNSs </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4709": {"data": {"text": "Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.", "entity1": "bupivacaine", "entity2": "TNSs", "span1": [96, 107], "span2": [164, 168]}, "bert_text": "Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and <e1> bupivacaine </e1> with respect to duration of action and relative risk of <e2> TNSs </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4710": {"data": {"text": "Clinical nephrotoxicity of tobramycin and gentamicin.", "entity1": "tobramycin", "entity2": "nephrotoxicity", "span1": [27, 37], "span2": [9, 23]}, "bert_text": "Clinical nephrotoxicity of <e1> tobramycin </e1> <e2> nephrotoxicity </e2> of tobramycin and gentamicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4711": {"data": {"text": "Clinical nephrotoxicity of tobramycin and gentamicin.", "entity1": "gentamicin", "entity2": "nephrotoxicity", "span1": [42, 52], "span2": [9, 23]}, "bert_text": "Clinical nephrotoxicity of tobramycin and <e1> gentamicin </e1> <e2> nephrotoxicity </e2> of tobramycin and gentamicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4712": {"data": {"text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "entity1": "mitoxantrone", "entity2": "breast cancer", "span1": [60, 72], "span2": [43, 56]}, "bert_text": "Treatment of previously treated metastatic breast cancer by <e1> mitoxantrone </e1> <e2> breast cancer </e2> by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4713": {"data": {"text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "entity1": "mitoxantrone", "entity2": "toxicity", "span1": [60, 72], "span2": [195, 203]}, "bert_text": "Treatment of previously treated metastatic breast cancer by <e1> mitoxantrone </e1> and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related <e2> toxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4714": {"data": {"text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "entity1": "5-FU", "entity2": "breast cancer", "span1": [118, 122], "span2": [43, 56]}, "bert_text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose <e1> 5-FU </e1> <e2> breast cancer </e2> by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4715": {"data": {"text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "entity1": "5-FU", "entity2": "toxicity", "span1": [118, 122], "span2": [195, 203]}, "bert_text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose <e1> 5-FU </e1> and leucovorin (MFL): low palliative benefit and high treatment-related <e2> toxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4716": {"data": {"text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "entity1": "leucovorin", "entity2": "breast cancer", "span1": [127, 137], "span2": [43, 56]}, "bert_text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and <e1> leucovorin </e1> <e2> breast cancer </e2> by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4717": {"data": {"text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "entity1": "leucovorin", "entity2": "toxicity", "span1": [127, 137], "span2": [195, 203]}, "bert_text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and <e1> leucovorin </e1> (MFL): low palliative benefit and high treatment-related <e2> toxicity </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4718": {"data": {"text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "entity1": "MFL", "entity2": "breast cancer", "span1": [139, 142], "span2": [43, 56]}, "bert_text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (<e1> MFL </e1> <e2> breast cancer </e2> by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4719": {"data": {"text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.\n", "entity1": "MFL", "entity2": "toxicity", "span1": [139, 142], "span2": [195, 203]}, "bert_text": "Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (<e1> MFL </e1>): low palliative benefit and high treatment-related <e2> toxicity </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4720": {"data": {"text": "This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.", "entity1": "bupropion", "entity2": "seizure", "span1": [83, 92], "span2": [41, 48]}, "bert_text": "This case report describes a generalized seizure associated with sustained-release <e1> bupropion </e1> <e2> seizure </e2> associated with sustained-release bupropion use and sleep deprivation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4721": {"data": {"text": "This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.", "entity1": "bupropion", "entity2": "sleep deprivation", "span1": [83, 92], "span2": [101, 118]}, "bert_text": "This case report describes a generalized seizure associated with sustained-release <e1> bupropion </e1> use and <e2> sleep deprivation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4722": {"data": {"text": "Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.\n", "entity1": "rifampin", "entity2": "proteinuria", "span1": [58, 66], "span2": [12, 23]}, "bert_text": "Light chain proteinuria and cellular mediated immunity in <e1> rifampin </e1> <e2> proteinuria </e2> and cellular mediated immunity in rifampin treated patients with tuberculosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4723": {"data": {"text": "Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.\n", "entity1": "rifampin", "entity2": "tuberculosis", "span1": [58, 66], "span2": [89, 101]}, "bert_text": "Light chain proteinuria and cellular mediated immunity in <e1> rifampin </e1> treated patients with <e2> tuberculosis </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4724": {"data": {"text": "Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.", "entity1": "EMB", "entity2": "optic neuropathy", "span1": [40, 43], "span2": [52, 68]}, "bert_text": "Additionally, in terms of management of <e1> EMB </e1>-induced <e2> optic neuropathy </e2>, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4725": {"data": {"text": "Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.", "entity1": "EMB", "entity2": "renal impairment", "span1": [40, 43], "span2": [140, 156]}, "bert_text": "Additionally, in terms of management of <e1> EMB </e1>-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with <e2> renal impairment </e2> and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4726": {"data": {"text": "Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.", "entity1": "ethambutol", "entity2": "optic neuropathy", "span1": [105, 115], "span2": [52, 68]}, "bert_text": "Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage <e1> ethambutol </e1> <e2> optic neuropathy </e2>, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4727": {"data": {"text": "Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.", "entity1": "ethambutol", "entity2": "renal impairment", "span1": [105, 115], "span2": [140, 156]}, "bert_text": "Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage <e1> ethambutol </e1> dosing in patients with <e2> renal impairment </e2> and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4728": {"data": {"text": "Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function.\n", "entity1": "Hydrocortisone", "entity2": "hypertension", "span1": [0, 14], "span2": [23, 35]}, "bert_text": "<e1> Hydrocortisone </e1>-induced <e2> hypertension </e2> in humans: pressor responsiveness and sympathetic function.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4729": {"data": {"text": "BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.", "entity1": "adenosine", "entity2": "chronic pain", "span1": [47, 56], "span2": [115, 127]}, "bert_text": "BACKGROUND: Preclinical studies of intrathecal <e1> adenosine </e1> suggest it may be effective in the treatment of acute and <e2> chronic pain </e2> in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4730": {"data": {"text": "BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.", "entity1": "adenosine", "entity2": "hypersensitivity", "span1": [47, 56], "span2": [262, 278]}, "bert_text": "BACKGROUND: Preclinical studies of intrathecal <e1> adenosine </e1> suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in <e2> hypersensitivity </e2> states but not with acute noxious stimulation.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4731": {"data": {"text": "BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.", "entity1": "adenosine", "entity2": "chronic pain", "span1": [220, 229], "span2": [115, 127]}, "bert_text": "BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of <e1> adenosine </e1> <e2> chronic pain </e2> in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"4732": {"data": {"text": "BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.", "entity1": "adenosine", "entity2": "hypersensitivity", "span1": [220, 229], "span2": [262, 278]}, "bert_text": "BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of <e1> adenosine </e1> suggests it may be effective in <e2> hypersensitivity </e2> states but not with acute noxious stimulation.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4733": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "3,4-methylenedioxymethamphetamine", "entity2": "neurotoxic lesions", "span1": [9, 42], "span2": [219, 237]}, "bert_text": "Although <e1> 3,4-methylenedioxymethamphetamine </e1> (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4734": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "MDMA", "entity2": "neurotoxic lesions", "span1": [44, 48], "span2": [219, 237]}, "bert_text": "Although 3,4-methylenedioxymethamphetamine (<e1> MDMA </e1> or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4735": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "ecstasy", "entity2": "neurotoxic lesions", "span1": [52, 59], "span2": [219, 237]}, "bert_text": "Although 3,4-methylenedioxymethamphetamine (MDMA or <e1> ecstasy </e1>) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4736": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "MDMA", "entity2": "neurotoxic lesions", "span1": [201, 205], "span2": [219, 237]}, "bert_text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of <e1> MDMA </e1>-induced 5-HT <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4737": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "MDMA", "entity2": "neurotoxic lesions", "span1": [569, 573], "span2": [219, 237]}, "bert_text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of <e1> MDMA </e1> <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4738": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "serotonin", "entity2": "neurotoxic lesions", "span1": [92, 101], "span2": [219, 237]}, "bert_text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain <e1> serotonin </e1> (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4739": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "5-HT", "entity2": "neurotoxic lesions", "span1": [103, 107], "span2": [219, 237]}, "bert_text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (<e1> 5-HT </e1>) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4740": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "5-HT", "entity2": "neurotoxic lesions", "span1": [214, 218], "span2": [219, 237]}, "bert_text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced <e1> 5-HT </e1> <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4741": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "5-HT", "entity2": "neurotoxic lesions", "span1": [260, 264], "span2": [219, 237]}, "bert_text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which <e1> 5-HT </e1> <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4742": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "5-HT", "entity2": "neurotoxic lesions", "span1": [314, 318], "span2": [219, 237]}, "bert_text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because <e1> 5-HT </e1> <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4743": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "5-HT", "entity2": "neurotoxic lesions", "span1": [381, 385], "span2": [219, 237]}, "bert_text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic <e1> 5-HT </e1> <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4744": {"data": {"text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "entity1": "5-HT", "entity2": "neurotoxic lesions", "span1": [491, 495], "span2": [219, 237]}, "bert_text": "Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the <e1> 5-HT </e1> <e2> neurotoxic lesions </e2> on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4745": {"data": {"text": "Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.", "entity1": "Ximelagatran", "entity2": "abnormal liver function", "span1": [0, 12], "span2": [188, 211]}, "bert_text": "<e1> Ximelagatran </e1>, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of <e2> abnormal liver function </e2> tests.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4746": {"data": {"text": "Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.", "entity1": "vitamin K", "entity2": "abnormal liver function", "span1": [81, 90], "span2": [188, 211]}, "bert_text": "Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as <e1> vitamin K </e1> antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of <e2> abnormal liver function </e2> tests.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4747": {"data": {"text": "Men experience increased incidence of myoclonus than women after etomidate administration.", "entity1": "etomidate", "entity2": "myoclonus", "span1": [65, 74], "span2": [38, 47]}, "bert_text": "Men experience increased incidence of myoclonus than women after <e1> etomidate </e1> <e2> myoclonus </e2> than women after etomidate administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4748": {"data": {"text": "A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.", "entity1": "cisplatinum", "entity2": "gastric adenocarcinoma", "span1": [74, 85], "span2": [181, 203]}, "bert_text": "A 61-year-old man was treated with combination chemotherapy incorporating <e1> cisplatinum </e1>, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable <e2> gastric adenocarcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4749": {"data": {"text": "A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.", "entity1": "etoposide", "entity2": "gastric adenocarcinoma", "span1": [87, 96], "span2": [181, 203]}, "bert_text": "A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, <e1> etoposide </e1>, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable <e2> gastric adenocarcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4750": {"data": {"text": "A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.", "entity1": "5-fluorouracil", "entity2": "gastric adenocarcinoma", "span1": [108, 122], "span2": [181, 203]}, "bert_text": "A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose <e1> 5-fluorouracil </e1> (2,250 mg/m2/24 hours) and folinic acid for an inoperable <e2> gastric adenocarcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4751": {"data": {"text": "A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.", "entity1": "folinic acid", "entity2": "gastric adenocarcinoma", "span1": [150, 162], "span2": [181, 203]}, "bert_text": "A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and <e1> folinic acid </e1> for an inoperable <e2> gastric adenocarcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4752": {"data": {"text": "Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes.\n", "entity1": "Dexamethasone", "entity2": "ocular hypertension", "span1": [0, 13], "span2": [22, 41]}, "bert_text": "<e1> Dexamethasone </e1>-induced <e2> ocular hypertension </e2> in perfusion-cultured human eyes.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4753": {"data": {"text": "Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.", "entity1": "L-dihydroxyphenylalanine", "entity2": "neurotoxicity", "span1": [51, 75], "span2": [158, 171]}, "bert_text": "Here we show that the recently reported ability of <e1> L-dihydroxyphenylalanine </e1> to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA <e2> neurotoxicity </e2> is also confounded by drug effects on body temperature.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4754": {"data": {"text": "Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.", "entity1": "METH", "entity2": "neurotoxicity", "span1": [142, 146], "span2": [158, 171]}, "bert_text": "Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on <e1> METH </e1>-induced DA <e2> neurotoxicity </e2> is also confounded by drug effects on body temperature.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4755": {"data": {"text": "Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.", "entity1": "DA", "entity2": "neurotoxicity", "span1": [155, 157], "span2": [158, 171]}, "bert_text": "Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced <e1> DA </e1> <e2> neurotoxicity </e2> is also confounded by drug effects on body temperature.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4756": {"data": {"text": "Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/-", "entity1": "nitrendipine", "entity2": "glomerulosclerosis", "span1": [73, 85], "span2": [13, 31]}, "bert_text": "Furthermore, glomerulosclerosis index was significantly increased in the <e1> nitrendipine </e1> <e2> glomerulosclerosis </e2> index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4757": {"data": {"text": "Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/-", "entity1": "nitrendipine", "entity2": "hypertensive", "span1": [73, 85], "span2": [118, 130]}, "bert_text": "Furthermore, glomerulosclerosis index was significantly increased in the <e1> nitrendipine </e1>-treated group compared with the <e2> hypertensive </e2> controls (0.38 +/-", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4758": {"data": {"text": "In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.", "entity1": "testosterone", "entity2": "renal injury", "span1": [144, 156], "span2": [194, 206]}, "bert_text": "In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by <e1> testosterone </e1> that also causes increases in BP and <e2> renal injury </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4759": {"data": {"text": "Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.\n", "entity1": "Suxamethonium", "entity2": "cardiac arrest", "span1": [0, 13], "span2": [22, 36]}, "bert_text": "<e1> Suxamethonium </e1>-induced <e2> cardiac arrest </e2> and death following 5 days of immobilization.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4760": {"data": {"text": "Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.\n", "entity1": "Suxamethonium", "entity2": "death", "span1": [0, 13], "span2": [41, 46]}, "bert_text": "<e1> Suxamethonium </e1>-induced cardiac arrest and <e2> death </e2> following 5 days of immobilization.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4761": {"data": {"text": "High-dose methylprednisolone may do more harm for spinal cord injury.\n", "entity1": "methylprednisolone", "entity2": "spinal cord injury", "span1": [10, 28], "span2": [50, 68]}, "bert_text": "High-dose <e1> methylprednisolone </e1> may do more harm for <e2> spinal cord injury </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4762": {"data": {"text": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "entity1": "amphotericin B", "entity2": "seizure", "span1": [97, 111], "span2": [52, 59]}, "bert_text": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following <e1> amphotericin B </e1> <e2> seizure </e2> activity in an AIDS patent following amphotericin B infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4763": {"data": {"text": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "entity1": "amphotericin B", "entity2": "AIDS", "span1": [97, 111], "span2": [75, 79]}, "bert_text": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following <e1> amphotericin B </e1> <e2> AIDS </e2> patent following amphotericin B infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4764": {"data": {"text": "Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.\n", "entity1": "Prednisolone", "entity2": "muscle dysfunction", "span1": [0, 12], "span2": [21, 39]}, "bert_text": "<e1> Prednisolone </e1>-induced <e2> muscle dysfunction </e2> is caused more by atrophy than by altered acetylcholine receptor expression.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4765": {"data": {"text": "Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.\n", "entity1": "Prednisolone", "entity2": "atrophy", "span1": [0, 12], "span2": [58, 65]}, "bert_text": "<e1> Prednisolone </e1>-induced muscle dysfunction is caused more by <e2> atrophy </e2> than by altered acetylcholine receptor expression.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4766": {"data": {"text": "Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.\n", "entity1": "acetylcholine", "entity2": "muscle dysfunction", "span1": [82, 95], "span2": [21, 39]}, "bert_text": "Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered <e1> acetylcholine </e1> <e2> muscle dysfunction </e2> is caused more by atrophy than by altered acetylcholine receptor expression.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4767": {"data": {"text": "Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.\n", "entity1": "acetylcholine", "entity2": "atrophy", "span1": [82, 95], "span2": [58, 65]}, "bert_text": "Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered <e1> acetylcholine </e1> <e2> atrophy </e2> than by altered acetylcholine receptor expression.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4768": {"data": {"text": "BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.", "entity1": "Ca(2", "entity2": "Atrial tachycardia", "span1": [139, 143], "span2": [12, 30]}, "bert_text": "BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type <e1> Ca(2 </e1> <e2> Atrial tachycardia </e2>-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4769": {"data": {"text": "BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.", "entity1": "Ca(2", "entity2": "atrial fibrillation", "span1": [139, 143], "span2": [93, 112]}, "bert_text": "BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type <e1> Ca(2 </e1> <e2> atrial fibrillation </e2> (AF) and decreases L-type Ca(2+) current.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4770": {"data": {"text": "BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.", "entity1": "Ca(2", "entity2": "AF", "span1": [139, 143], "span2": [114, 116]}, "bert_text": "BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type <e1> Ca(2 </e1> <e2> AF </e2>) and decreases L-type Ca(2+) current.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4771": {"data": {"text": "Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.", "entity1": "prochlorperazine", "entity2": "headache", "span1": [45, 61], "span2": [66, 74]}, "bert_text": "Patients aged 18 years or older treated with <e1> prochlorperazine </e1> for <e2> headache </e2>, nausea, or vomiting were eligible for inclusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4772": {"data": {"text": "Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.", "entity1": "prochlorperazine", "entity2": "nausea", "span1": [45, 61], "span2": [76, 82]}, "bert_text": "Patients aged 18 years or older treated with <e1> prochlorperazine </e1> for headache, <e2> nausea </e2>, or vomiting were eligible for inclusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4773": {"data": {"text": "Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.", "entity1": "prochlorperazine", "entity2": "vomiting", "span1": [45, 61], "span2": [87, 95]}, "bert_text": "Patients aged 18 years or older treated with <e1> prochlorperazine </e1> for headache, nausea, or <e2> vomiting </e2> were eligible for inclusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4774": {"data": {"text": "We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection.", "entity1": "citrate", "entity2": "toxicity", "span1": [27, 34], "span2": [35, 43]}, "bert_text": "We report a case of severe <e1> citrate </e1> <e2> toxicity </e2> during volunteer donor apheresis platelet collection.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4775": {"data": {"text": "The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.", "entity1": "prostaglandin D2", "entity2": "hyperalgesic", "span1": [27, 43], "span2": [4, 16]}, "bert_text": "The hyperalgesic effect of <e1> prostaglandin D2 </e1> <e2> hyperalgesic </e2> effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4776": {"data": {"text": "The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.", "entity1": "AH6809", "entity2": "hyperalgesic", "span1": [155, 161], "span2": [4, 16]}, "bert_text": "The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by <e1> AH6809 </e1> <e2> hyperalgesic </e2> effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4777": {"data": {"text": "Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).", "entity1": "alcohol", "entity2": "hay fever", "span1": [338, 345], "span2": [107, 116]}, "bert_text": "Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use <e1> alcohol </e1> <e2> hay fever </e2> and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4778": {"data": {"text": "Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).", "entity1": "alcohol", "entity2": "asthma", "span1": [338, 345], "span2": [121, 127]}, "bert_text": "Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use <e1> alcohol </e1> <e2> asthma </e2> (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4779": {"data": {"text": "Angioedema due to ACE inhibitors: common and inadequately diagnosed.\n", "entity1": "ACE inhibitors", "entity2": "Angioedema", "span1": [18, 32], "span2": [0, 10]}, "bert_text": "Angioedema due to <e1> ACE inhibitors </e1> <e2> Angioedema </e2> due to ACE inhibitors: common and inadequately diagnosed.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4780": {"data": {"text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [56, 67], "span2": [4, 18]}, "bert_text": "The cardiomyopathy (CM) produced by the anticancer drug <e1> doxorubicin </e1> <e2> cardiomyopathy </e2> (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4781": {"data": {"text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "entity1": "doxorubicin", "entity2": "CM", "span1": [56, 67], "span2": [20, 22]}, "bert_text": "The cardiomyopathy (CM) produced by the anticancer drug <e1> doxorubicin </e1> <e2> CM </e2>) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4782": {"data": {"text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "entity1": "doxorubicin", "entity2": "myocardial disease", "span1": [56, 67], "span2": [199, 217]}, "bert_text": "The cardiomyopathy (CM) produced by the anticancer drug <e1> doxorubicin </e1> (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of <e2> myocardial disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4783": {"data": {"text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "entity1": "DXR", "entity2": "cardiomyopathy", "span1": [69, 72], "span2": [4, 18]}, "bert_text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (<e1> DXR </e1> <e2> cardiomyopathy </e2> (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4784": {"data": {"text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "entity1": "DXR", "entity2": "CM", "span1": [69, 72], "span2": [20, 22]}, "bert_text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (<e1> DXR </e1> <e2> CM </e2>) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4785": {"data": {"text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "entity1": "DXR", "entity2": "myocardial disease", "span1": [69, 72], "span2": [199, 217]}, "bert_text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (<e1> DXR </e1>) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of <e2> myocardial disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4786": {"data": {"text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "entity1": "Adriamycin", "entity2": "cardiomyopathy", "span1": [75, 85], "span2": [4, 18]}, "bert_text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (<e1> Adriamycin </e1> <e2> cardiomyopathy </e2> (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4787": {"data": {"text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "entity1": "Adriamycin", "entity2": "CM", "span1": [75, 85], "span2": [20, 22]}, "bert_text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (<e1> Adriamycin </e1> <e2> CM </e2>) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4788": {"data": {"text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "entity1": "Adriamycin", "entity2": "myocardial disease", "span1": [75, 85], "span2": [199, 217]}, "bert_text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (<e1> Adriamycin </e1>) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of <e2> myocardial disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4789": {"data": {"text": "CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.", "entity1": "bupropion", "entity2": "convulsive", "span1": [128, 137], "span2": [109, 119]}, "bert_text": "CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of <e1> bupropion </e1> <e2> convulsive </e2> dose of bupropion and the risk of convulsions in a prospective study is novel.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4790": {"data": {"text": "CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.", "entity1": "bupropion", "entity2": "convulsions", "span1": [128, 137], "span2": [154, 165]}, "bert_text": "CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of <e1> bupropion </e1> and the risk of <e2> convulsions </e2> in a prospective study is novel.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4791": {"data": {"text": "This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.", "entity1": "clioquinol", "entity2": "acrodermatitis enteropathica", "span1": [70, 80], "span2": [98, 126]}, "bert_text": "This was most frequently found in children, many of whom had received <e1> clioquinol </e1> as treatment for <e2> acrodermatitis enteropathica </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4792": {"data": {"text": "Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.\n", "entity1": "steroids", "entity2": "seizures", "span1": [35, 43], "span2": [68, 76]}, "bert_text": "Protective efficacy of neuroactive <e1> steroids </e1> against cocaine kindled-<e2> seizures </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4793": {"data": {"text": "Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.\n", "entity1": "cocaine", "entity2": "seizures", "span1": [52, 59], "span2": [68, 76]}, "bert_text": "Protective efficacy of neuroactive steroids against <e1> cocaine </e1> kindled-<e2> seizures </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4794": {"data": {"text": "During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema.", "entity1": "metoprolol", "entity2": "angioedema", "span1": [71, 81], "span2": [113, 123]}, "bert_text": "During the first day of hospitalization (while intubated), intravenous <e1> metoprolol </e1> was given, resulting in severe <e2> angioedema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4795": {"data": {"text": "This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic syndrome", "span1": [125, 150], "span2": [95, 113]}, "bert_text": "This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by <e1> puromycin aminonucleoside </e1> <e2> nephrotic syndrome </e2> induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4796": {"data": {"text": "This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic syndrome", "span1": [125, 150], "span2": [163, 181]}, "bert_text": "This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by <e1> puromycin aminonucleoside </e1> were due to <e2> nephrotic syndrome </e2> per se, or, at least in part, to the aminonucleoside.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4797": {"data": {"text": "This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.", "entity1": "aminonucleoside", "entity2": "nephrotic syndrome", "span1": [219, 234], "span2": [95, 113]}, "bert_text": "This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the <e1> aminonucleoside </e1> <e2> nephrotic syndrome </e2> induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4798": {"data": {"text": "This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.", "entity1": "aminonucleoside", "entity2": "nephrotic syndrome", "span1": [219, 234], "span2": [163, 181]}, "bert_text": "This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the <e1> aminonucleoside </e1> <e2> nephrotic syndrome </e2> per se, or, at least in part, to the aminonucleoside.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4799": {"data": {"text": "Acetazolamide-induced Gerstmann syndrome.\n", "entity1": "Acetazolamide", "entity2": "Gerstmann syndrome", "span1": [0, 13], "span2": [22, 40]}, "bert_text": "<e1> Acetazolamide </e1>-induced <e2> Gerstmann syndrome </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4800": {"data": {"text": "Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.", "entity1": "PGE1", "entity2": "hypotension", "span1": [58, 62], "span2": [11, 22]}, "bert_text": "Controlled hypotension in groups A and C was induced with <e1> PGE1 </e1> <e2> hypotension </e2> in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4801": {"data": {"text": "Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.", "entity1": "AraG", "entity2": "neurological toxicity", "span1": [45, 49], "span2": [128, 149]}, "bert_text": "Our experience supports the safety of giving <e1> AraG </e1> as salvage therapy in synchrony with etoposide and cyclophosphamide, although <e2> neurological toxicity </e2> must be closely monitored.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4802": {"data": {"text": "Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.", "entity1": "etoposide", "entity2": "neurological toxicity", "span1": [87, 96], "span2": [128, 149]}, "bert_text": "Our experience supports the safety of giving AraG as salvage therapy in synchrony with <e1> etoposide </e1> and cyclophosphamide, although <e2> neurological toxicity </e2> must be closely monitored.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4803": {"data": {"text": "Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.", "entity1": "cyclophosphamide", "entity2": "neurological toxicity", "span1": [101, 117], "span2": [128, 149]}, "bert_text": "Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and <e1> cyclophosphamide </e1>, although <e2> neurological toxicity </e2> must be closely monitored.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4804": {"data": {"text": "The renal pathology in a case of lithium-induced diabetes insipidus.\n", "entity1": "lithium", "entity2": "diabetes insipidus", "span1": [33, 40], "span2": [49, 67]}, "bert_text": "The renal pathology in a case of <e1> lithium </e1>-induced <e2> diabetes insipidus </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4805": {"data": {"text": "The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.", "entity1": "steroids", "entity2": "angioedema", "span1": [55, 63], "span2": [4, 14]}, "bert_text": "The angioedema resolved after therapy with intravenous <e1> steroids </e1> <e2> angioedema </e2> resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4806": {"data": {"text": "The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.", "entity1": "diphenhydramine hydrochloride", "entity2": "angioedema", "span1": [68, 97], "span2": [4, 14]}, "bert_text": "The angioedema resolved after therapy with intravenous steroids and <e1> diphenhydramine hydrochloride </e1> <e2> angioedema </e2> resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4807": {"data": {"text": "Development of clear cell adenocarcinoma in DES-exposed offspring under observation.\n", "entity1": "DES", "entity2": "clear cell adenocarcinoma", "span1": [44, 47], "span2": [15, 40]}, "bert_text": "Development of clear cell adenocarcinoma in <e1> DES </e1> <e2> clear cell adenocarcinoma </e2> in DES-exposed offspring under observation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4808": {"data": {"text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.", "entity1": "MIBG", "entity2": "myocardial impairment", "span1": [168, 172], "span2": [88, 109]}, "bert_text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that <e1> MIBG </e1> <e2> myocardial impairment </e2> (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4809": {"data": {"text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.", "entity1": "MIBG", "entity2": "cardiomyopathy", "span1": [168, 172], "span2": [245, 259]}, "bert_text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that <e1> MIBG </e1> scintigraphy may be a useful method for detection of adriamycin-induced <e2> cardiomyopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4810": {"data": {"text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.", "entity1": "MIBG", "entity2": "vacuolar degeneration", "span1": [168, 172], "span2": [130, 151]}, "bert_text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that <e1> MIBG </e1> <e2> vacuolar degeneration </e2>) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4811": {"data": {"text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.", "entity1": "adriamycin", "entity2": "myocardial impairment", "span1": [226, 236], "span2": [88, 109]}, "bert_text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of <e1> adriamycin </e1> <e2> myocardial impairment </e2> (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4812": {"data": {"text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.", "entity1": "adriamycin", "entity2": "cardiomyopathy", "span1": [226, 236], "span2": [245, 259]}, "bert_text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of <e1> adriamycin </e1>-induced <e2> cardiomyopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4813": {"data": {"text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.", "entity1": "adriamycin", "entity2": "vacuolar degeneration", "span1": [226, 236], "span2": [130, 151]}, "bert_text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of <e1> adriamycin </e1> <e2> vacuolar degeneration </e2>) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4814": {"data": {"text": "In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "entity1": "cefonicid", "entity2": "toxicity", "span1": [69, 78], "span2": [17, 25]}, "bert_text": "In four subacute toxicity studies, the intravenous administration of <e1> cefonicid </e1> <e2> toxicity </e2> studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4815": {"data": {"text": "In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "entity1": "cefonicid", "entity2": "anemia", "span1": [69, 78], "span2": [145, 151]}, "bert_text": "In four subacute toxicity studies, the intravenous administration of <e1> cefonicid </e1> or cefazedone to beagle dogs caused a dose-dependent incidence of <e2> anemia </e2>, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4816": {"data": {"text": "In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "entity1": "cefonicid", "entity2": "neutropenia", "span1": [69, 78], "span2": [153, 164]}, "bert_text": "In four subacute toxicity studies, the intravenous administration of <e1> cefonicid </e1> or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, <e2> neutropenia </e2>, and thrombocytopenia after 1-3 months of treatment.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4817": {"data": {"text": "In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "entity1": "cefonicid", "entity2": "thrombocytopenia", "span1": [69, 78], "span2": [170, 186]}, "bert_text": "In four subacute toxicity studies, the intravenous administration of <e1> cefonicid </e1> or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and <e2> thrombocytopenia </e2> after 1-3 months of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4818": {"data": {"text": "In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "entity1": "cefazedone", "entity2": "toxicity", "span1": [82, 92], "span2": [17, 25]}, "bert_text": "In four subacute toxicity studies, the intravenous administration of cefonicid or <e1> cefazedone </e1> <e2> toxicity </e2> studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4819": {"data": {"text": "In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "entity1": "cefazedone", "entity2": "anemia", "span1": [82, 92], "span2": [145, 151]}, "bert_text": "In four subacute toxicity studies, the intravenous administration of cefonicid or <e1> cefazedone </e1> to beagle dogs caused a dose-dependent incidence of <e2> anemia </e2>, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4820": {"data": {"text": "In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "entity1": "cefazedone", "entity2": "neutropenia", "span1": [82, 92], "span2": [153, 164]}, "bert_text": "In four subacute toxicity studies, the intravenous administration of cefonicid or <e1> cefazedone </e1> to beagle dogs caused a dose-dependent incidence of anemia, <e2> neutropenia </e2>, and thrombocytopenia after 1-3 months of treatment.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4821": {"data": {"text": "In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "entity1": "cefazedone", "entity2": "thrombocytopenia", "span1": [82, 92], "span2": [170, 186]}, "bert_text": "In four subacute toxicity studies, the intravenous administration of cefonicid or <e1> cefazedone </e1> to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and <e2> thrombocytopenia </e2> after 1-3 months of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4822": {"data": {"text": "METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.", "entity1": "dopamine", "entity2": "anxiety", "span1": [56, 64], "span2": [245, 252]}, "bert_text": "METHODS: In this study, we evaluated the performance of <e1> dopamine </e1> beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced <e2> anxiety </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4823": {"data": {"text": "METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.", "entity1": "norepinephrine", "entity2": "anxiety", "span1": [118, 132], "span2": [245, 252]}, "bert_text": "METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack <e1> norepinephrine </e1> (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced <e2> anxiety </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4824": {"data": {"text": "METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.", "entity1": "NE", "entity2": "anxiety", "span1": [134, 136], "span2": [245, 252]}, "bert_text": "METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (<e1> NE </e1>), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced <e2> anxiety </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4825": {"data": {"text": "METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.", "entity1": "cocaine", "entity2": "anxiety", "span1": [229, 236], "span2": [245, 252]}, "bert_text": "METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to <e1> cocaine </e1>-induced <e2> anxiety </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4826": {"data": {"text": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "entity1": "amphotericin B", "entity2": "seizures", "span1": [121, 135], "span2": [81, 89]}, "bert_text": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of <e1> amphotericin B </e1> <e2> seizures </e2> during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4827": {"data": {"text": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "entity1": "amphotericin B", "entity2": "seizures", "span1": [121, 135], "span2": [152, 160]}, "bert_text": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of <e1> amphotericin B </e1>, then petit mal <e2> seizures </e2> as the infusion was stopped and the drug concentrations decreased with time.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4828": {"data": {"text": "Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.", "entity1": "bupivacaine", "entity2": "PAF", "span1": [82, 93], "span2": [50, 53]}, "bert_text": "Thus, consistent with its direct effect on heart, PAF appears to be implicated in <e1> bupivacaine </e1> <e2> PAF </e2> appears to be implicated in bupivacaine-induced cardiovascular alterations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4829": {"data": {"text": "These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.", "entity1": "doxorubicin", "entity2": "heart failure", "span1": [86, 97], "span2": [148, 161]}, "bert_text": "These findings demonstrate that overexpression of p300 protects cardiac myocytes from <e1> doxorubicin </e1>-induced apoptosis and reduces the extent of acute <e2> heart failure </e2> in adult mice in vivo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4830": {"data": {"text": "This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.", "entity1": "lignocaine", "entity2": "IST", "span1": [81, 91], "span2": [44, 47]}, "bert_text": "This paper presents the results of treating IST by intratympanic instillation of <e1> lignocaine </e1> <e2> IST </e2> by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4831": {"data": {"text": "This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.", "entity1": "lidocaine", "entity2": "IST", "span1": [93, 102], "span2": [44, 47]}, "bert_text": "This paper presents the results of treating IST by intratympanic instillation of lignocaine (<e1> lidocaine </e1> <e2> IST </e2> by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4832": {"data": {"text": "VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.", "entity1": "VPU", "entity2": "seizure", "span1": [0, 3], "span2": [135, 142]}, "bert_text": "<e1> VPU </e1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <e2> seizure </e2> whereas the corresponding value for VPA was 322 mg/kg.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4833": {"data": {"text": "VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.", "entity1": "VPA", "entity2": "seizure", "span1": [25, 28], "span2": [135, 142]}, "bert_text": "VPU was more potent than <e1> VPA </e1>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <e2> seizure </e2> whereas the corresponding value for VPA was 322 mg/kg.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4834": {"data": {"text": "VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.", "entity1": "VPA", "entity2": "seizure", "span1": [179, 182], "span2": [135, 142]}, "bert_text": "VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for <e1> VPA </e1> <e2> seizure </e2> whereas the corresponding value for VPA was 322 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4835": {"data": {"text": "VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [115, 126], "span2": [135, 142]}, "bert_text": "VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e1> pilocarpine </e1>-induced <e2> seizure </e2> whereas the corresponding value for VPA was 322 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4836": {"data": {"text": "ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.", "entity1": "angiotensin", "entity2": "proteinuria", "span1": [18, 29], "span2": [70, 81]}, "bert_text": "ACE inhibitor and <e1> angiotensin </e1>-releasing blocker (ARB) therapy reduced <e2> proteinuria </e2> development.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4837": {"data": {"text": "ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.", "entity1": "ARB", "entity2": "proteinuria", "span1": [49, 52], "span2": [70, 81]}, "bert_text": "ACE inhibitor and angiotensin-releasing blocker (<e1> ARB </e1>) therapy reduced <e2> proteinuria </e2> development.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4838": {"data": {"text": "Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.", "entity1": "steroid", "entity2": "neurologic deterioration", "span1": [89, 96], "span2": [49, 73]}, "bert_text": "Clinical examination and continued vigilance for neurologic deterioration after epidural <e1> steroid </e1> <e2> neurologic deterioration </e2> after epidural steroid injections is important.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4839": {"data": {"text": "Increase of Parkinson disability after fluoxetine medication.\n", "entity1": "fluoxetine", "entity2": "Parkinson disability", "span1": [39, 49], "span2": [12, 32]}, "bert_text": "Increase of Parkinson disability after <e1> fluoxetine </e1> <e2> Parkinson disability </e2> after fluoxetine medication.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4840": {"data": {"text": "Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.", "entity1": "UM-272", "entity2": "ventricular tachycardia", "span1": [11, 17], "span2": [28, 51]}, "bert_text": "Sublingual <e1> UM-272 </e1> converted <e2> ventricular tachycardia </e2> to sinus rhythm in all 5 dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4841": {"data": {"text": "Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.", "entity1": "steroids", "entity2": "psychiatric disorders", "span1": [12, 20], "span2": [108, 129]}, "bert_text": "Neuroactive <e1> steroids </e1> demonstrate pharmacological actions that have relevance for a host of neurological and <e2> psychiatric disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4842": {"data": {"text": "Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.", "entity1": "acetazolamide", "entity2": "confusion", "span1": [27, 40], "span2": [6, 15]}, "bert_text": "Acute confusion induced by <e1> acetazolamide </e1> <e2> confusion </e2> induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4843": {"data": {"text": "Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.", "entity1": "acetazolamide", "entity2": "renal impairment", "span1": [27, 40], "span2": [96, 112]}, "bert_text": "Acute confusion induced by <e1> acetazolamide </e1> is a well known adverse drug reaction in patients with <e2> renal impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4844": {"data": {"text": "RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.", "entity1": "Verapamil", "entity2": "AF", "span1": [9, 18], "span2": [26, 28]}, "bert_text": "RESULTS: <e1> Verapamil </e1> caused <e2> AF </e2> promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4845": {"data": {"text": "RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.", "entity1": "Verapamil", "entity2": "AF", "span1": [9, 18], "span2": [80, 82]}, "bert_text": "RESULTS: <e1> Verapamil </e1> caused AF promotion in six dogs, increasing mean duration of <e2> AF </e2> induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4846": {"data": {"text": "The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.", "entity1": "adenosine", "entity2": "hypersensitivity", "span1": [83, 92], "span2": [182, 198]}, "bert_text": "The purpose of this study was to screen for efficacy of a different formulation of <e1> adenosine </e1> marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical <e2> hypersensitivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4847": {"data": {"text": "The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.", "entity1": "capsaicin", "entity2": "hypersensitivity", "span1": [154, 163], "span2": [182, 198]}, "bert_text": "The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and <e1> capsaicin </e1>-evoked mechanical <e2> hypersensitivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4848": {"data": {"text": "Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.", "entity1": "PGF2alpha", "entity2": "OAB", "span1": [13, 22], "span2": [94, 97]}, "bert_text": "Urinary NGF, <e1> PGF2alpha </e1> and PGI2 did not correlate with urodynamic parameters in patients with <e2> OAB </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4849": {"data": {"text": "Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.", "entity1": "PGI2", "entity2": "OAB", "span1": [27, 31], "span2": [94, 97]}, "bert_text": "Urinary NGF, PGF2alpha and <e1> PGI2 </e1> did not correlate with urodynamic parameters in patients with <e2> OAB </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4850": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "dopamine", "entity2": "toxicity", "span1": [27, 35], "span2": [81, 89]}, "bert_text": "It is widely believed that <e1> dopamine </e1> (DA) mediates methamphetamine (METH)-induced <e2> toxicity </e2> to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4851": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "dopamine", "entity2": "toxicity", "span1": [27, 35], "span2": [185, 193]}, "bert_text": "It is widely believed that <e1> dopamine </e1> (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease <e2> toxicity </e2>, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4852": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "dopamine", "entity2": "toxicity", "span1": [27, 35], "span2": [252, 260]}, "bert_text": "It is widely believed that <e1> dopamine </e1> (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4853": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "DA", "entity2": "toxicity", "span1": [37, 39], "span2": [81, 89]}, "bert_text": "It is widely believed that dopamine (<e1> DA </e1>) mediates methamphetamine (METH)-induced <e2> toxicity </e2> to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4854": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "DA", "entity2": "toxicity", "span1": [37, 39], "span2": [185, 193]}, "bert_text": "It is widely believed that dopamine (<e1> DA </e1>) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease <e2> toxicity </e2>, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4855": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "DA", "entity2": "toxicity", "span1": [37, 39], "span2": [252, 260]}, "bert_text": "It is widely believed that dopamine (<e1> DA </e1>) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4856": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "DA", "entity2": "toxicity", "span1": [155, 157], "span2": [81, 89]}, "bert_text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with <e1> DA </e1> <e2> toxicity </e2> to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4857": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "DA", "entity2": "toxicity", "span1": [155, 157], "span2": [185, 193]}, "bert_text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with <e1> DA </e1> neurotransmission decrease <e2> toxicity </e2>, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4858": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "DA", "entity2": "toxicity", "span1": [155, 157], "span2": [252, 260]}, "bert_text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with <e1> DA </e1> neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4859": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "DA", "entity2": "toxicity", "span1": [223, 225], "span2": [81, 89]}, "bert_text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase <e1> DA </e1> <e2> toxicity </e2> to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4860": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "DA", "entity2": "toxicity", "span1": [223, 225], "span2": [185, 193]}, "bert_text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase <e1> DA </e1> <e2> toxicity </e2>, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4861": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "DA", "entity2": "toxicity", "span1": [223, 225], "span2": [252, 260]}, "bert_text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase <e1> DA </e1> neurotransmission enhance <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4862": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "methamphetamine", "entity2": "toxicity", "span1": [50, 65], "span2": [81, 89]}, "bert_text": "It is widely believed that dopamine (DA) mediates <e1> methamphetamine </e1> (METH)-induced <e2> toxicity </e2> to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4863": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "methamphetamine", "entity2": "toxicity", "span1": [50, 65], "span2": [185, 193]}, "bert_text": "It is widely believed that dopamine (DA) mediates <e1> methamphetamine </e1> (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease <e2> toxicity </e2>, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4864": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "methamphetamine", "entity2": "toxicity", "span1": [50, 65], "span2": [252, 260]}, "bert_text": "It is widely believed that dopamine (DA) mediates <e1> methamphetamine </e1> (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4865": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "METH)-induced", "entity2": "toxicity", "span1": [67, 80], "span2": [81, 89]}, "bert_text": "It is widely believed that dopamine (DA) mediates methamphetamine (<e1> METH)-induced </e1> <e2> toxicity </e2> to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4866": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "METH)-induced", "entity2": "toxicity", "span1": [67, 80], "span2": [185, 193]}, "bert_text": "It is widely believed that dopamine (DA) mediates methamphetamine (<e1> METH)-induced </e1> toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease <e2> toxicity </e2>, whereas drugs that increase DA neurotransmission enhance toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4867": {"data": {"text": "It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.", "entity1": "METH)-induced", "entity2": "toxicity", "span1": [67, 80], "span2": [252, 260]}, "bert_text": "It is widely believed that dopamine (DA) mediates methamphetamine (<e1> METH)-induced </e1> toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4868": {"data": {"text": "Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.\n", "entity1": "aniracetam", "entity2": "impaired learning and memory", "span1": [30, 40], "span2": [59, 87]}, "bert_text": "Effects of the novel compound <e1> aniracetam </e1> (Ro 13-5057) upon <e2> impaired learning and memory </e2> in rodents.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4869": {"data": {"text": "Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.\n", "entity1": "Ro 13-5057", "entity2": "impaired learning and memory", "span1": [42, 52], "span2": [59, 87]}, "bert_text": "Effects of the novel compound aniracetam (<e1> Ro 13-5057 </e1>) upon <e2> impaired learning and memory </e2> in rodents.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4870": {"data": {"text": "We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.", "entity1": "droperidol", "entity2": "drug allergies", "span1": [228, 238], "span2": [73, 87]}, "bert_text": "We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of <e1> droperidol </e1> <e2> drug allergies </e2> in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4871": {"data": {"text": "We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.", "entity1": "droperidol", "entity2": "angioedema", "span1": [228, 238], "span2": [96, 106]}, "bert_text": "We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of <e1> droperidol </e1> <e2> angioedema </e2> with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4872": {"data": {"text": "We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.", "entity1": "droperidol", "entity2": "tongue swelling", "span1": [228, 238], "span2": [124, 139]}, "bert_text": "We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of <e1> droperidol </e1> <e2> tongue swelling </e2> and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4873": {"data": {"text": "Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).", "entity1": "carbimazole", "entity2": "cholestatic hepatitis", "span1": [52, 63], "span2": [19, 40]}, "bert_text": "Two patients had a cholestatic hepatitis induced by <e1> carbimazole </e1> <e2> cholestatic hepatitis </e2> induced by carbimazole (N  omercazole).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4874": {"data": {"text": "Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).", "entity1": "N  omercazole", "entity2": "cholestatic hepatitis", "span1": [65, 78], "span2": [19, 40]}, "bert_text": "Two patients had a cholestatic hepatitis induced by carbimazole (<e1> N  omercazole </e1> <e2> cholestatic hepatitis </e2> induced by carbimazole (N  omercazole).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4875": {"data": {"text": "Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.\n", "entity1": "lamivudine", "entity2": "rheumatologic disorders", "span1": [20, 30], "span2": [74, 97]}, "bert_text": "Prophylactic use of <e1> lamivudine </e1> with chronic immunosuppressive therapy for <e2> rheumatologic disorders </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4876": {"data": {"text": "In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [277, 288], "span2": [73, 91]}, "bert_text": "In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the <e1> pilocarpine </e1> <e2> status epilepticus </e2> would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4877": {"data": {"text": "In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.", "entity1": "pilocarpine", "entity2": "temporal lobe epilepsy", "span1": [277, 288], "span2": [298, 320]}, "bert_text": "In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the <e1> pilocarpine </e1> model of <e2> temporal lobe epilepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4878": {"data": {"text": "RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.", "entity1": "CBDCA", "entity2": "peripheral neurotoxicity", "span1": [9, 14], "span2": [53, 77]}, "bert_text": "RESULTS: <e1> CBDCA </e1> administration induced dose-dependent <e2> peripheral neurotoxicity </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4879": {"data": {"text": "The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered.", "entity1": "ethanol", "entity2": "visual loss", "span1": [70, 77], "span2": [17, 28]}, "bert_text": "The frequency of visual loss decreased after the concentration of the <e1> ethanol </e1> <e2> visual loss </e2> decreased after the concentration of the ethanol diluent was lowered.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4880": {"data": {"text": "OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).", "entity1": "clomiphene citrate", "entity2": "retinal vein occlusion", "span1": [78, 96], "span2": [39, 61]}, "bert_text": "OBJECTIVE: To report a case of central retinal vein occlusion associated with <e1> clomiphene citrate </e1> <e2> retinal vein occlusion </e2> associated with clomiphene citrate (CC).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4881": {"data": {"text": "OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).", "entity1": "CC", "entity2": "retinal vein occlusion", "span1": [98, 100], "span2": [39, 61]}, "bert_text": "OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (<e1> CC </e1> <e2> retinal vein occlusion </e2> associated with clomiphene citrate (CC).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4882": {"data": {"text": "The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.", "entity1": "mexiletine", "entity2": "myocardial infarction", "span1": [60, 70], "span2": [178, 199]}, "bert_text": "The antiarrhythmic effects of the sustained release form of <e1> mexiletine </e1> (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4883": {"data": {"text": "The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.", "entity1": "Mexitil-Perlongets", "entity2": "myocardial infarction", "span1": [72, 90], "span2": [178, 199]}, "bert_text": "The antiarrhythmic effects of the sustained release form of mexiletine (<e1> Mexitil-Perlongets </e1>) were evaluated in a double-blind placebo trial in 630 patients with recent documented <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4884": {"data": {"text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "entity1": "penicillamine", "entity2": "Skin rashes", "span1": [134, 147], "span2": [0, 11]}, "bert_text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of <e1> penicillamine </e1> <e2> Skin rashes </e2>, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4885": {"data": {"text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "entity1": "penicillamine", "entity2": "proteinuria", "span1": [134, 147], "span2": [13, 24]}, "bert_text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of <e1> penicillamine </e1> <e2> proteinuria </e2>, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4886": {"data": {"text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "entity1": "penicillamine", "entity2": "systemic lupus erythematosus", "span1": [134, 147], "span2": [26, 54]}, "bert_text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of <e1> penicillamine </e1> <e2> systemic lupus erythematosus </e2>, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4887": {"data": {"text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "entity1": "penicillamine", "entity2": "polymyositis", "span1": [134, 147], "span2": [56, 68]}, "bert_text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of <e1> penicillamine </e1> <e2> polymyositis </e2> and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4888": {"data": {"text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "entity1": "penicillamine", "entity2": "myasthenia gravis", "span1": [134, 147], "span2": [73, 90]}, "bert_text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of <e1> penicillamine </e1> <e2> myasthenia gravis </e2> have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4889": {"data": {"text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "entity1": "penicillamine", "entity2": "rheumatoid arthritis", "span1": [134, 147], "span2": [173, 193]}, "bert_text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of <e1> penicillamine </e1> therapy in patients with <e2> rheumatoid arthritis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4890": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "aniracetam", "entity2": "impaired cognitive functions", "span1": [14, 24], "span2": [112, 140]}, "bert_text": "The effect of <e1> aniracetam </e1> (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally <e2> impaired cognitive functions </e2> (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4891": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "aniracetam", "entity2": "hypercapnia", "span1": [14, 24], "span2": [324, 335]}, "bert_text": "The effect of <e1> aniracetam </e1> (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal <e2> hypercapnia </e2> immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4892": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "aniracetam", "entity2": "hypercapnia", "span1": [14, 24], "span2": [1178, 1189]}, "bert_text": "The effect of <e1> aniracetam </e1> (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4893": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "aniracetam", "entity2": "amnesia", "span1": [14, 24], "span2": [467, 474]}, "bert_text": "The effect of <e1> aniracetam </e1> (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term <e2> amnesia </e2> for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4894": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "aniracetam", "entity2": "amnesia", "span1": [14, 24], "span2": [537, 544]}, "bert_text": "The effect of <e1> aniracetam </e1> (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4895": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "aniracetam", "entity2": "electroconvulsive shock", "span1": [14, 24], "span2": [595, 618]}, "bert_text": "The effect of <e1> aniracetam </e1> (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to <e2> electroconvulsive shock </e2> immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4896": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "Ro 13-5057", "entity2": "impaired cognitive functions", "span1": [26, 36], "span2": [112, 140]}, "bert_text": "The effect of aniracetam (<e1> Ro 13-5057 </e1>, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally <e2> impaired cognitive functions </e2> (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4897": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "Ro 13-5057", "entity2": "hypercapnia", "span1": [26, 36], "span2": [324, 335]}, "bert_text": "The effect of aniracetam (<e1> Ro 13-5057 </e1>, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal <e2> hypercapnia </e2> immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4898": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "Ro 13-5057", "entity2": "hypercapnia", "span1": [26, 36], "span2": [1178, 1189]}, "bert_text": "The effect of aniracetam (<e1> Ro 13-5057 </e1>, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4899": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "Ro 13-5057", "entity2": "amnesia", "span1": [26, 36], "span2": [467, 474]}, "bert_text": "The effect of aniracetam (<e1> Ro 13-5057 </e1>, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term <e2> amnesia </e2> for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4900": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "Ro 13-5057", "entity2": "amnesia", "span1": [26, 36], "span2": [537, 544]}, "bert_text": "The effect of aniracetam (<e1> Ro 13-5057 </e1>, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4901": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "Ro 13-5057", "entity2": "electroconvulsive shock", "span1": [26, 36], "span2": [595, 618]}, "bert_text": "The effect of aniracetam (<e1> Ro 13-5057 </e1>, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to <e2> electroconvulsive shock </e2> immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4902": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "1-anisoyl-2-pyrrolidinone", "entity2": "impaired cognitive functions", "span1": [38, 63], "span2": [112, 140]}, "bert_text": "The effect of aniracetam (Ro 13-5057, <e1> 1-anisoyl-2-pyrrolidinone </e1>) was studied on various forms of experimentally <e2> impaired cognitive functions </e2> (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4903": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "1-anisoyl-2-pyrrolidinone", "entity2": "hypercapnia", "span1": [38, 63], "span2": [324, 335]}, "bert_text": "The effect of aniracetam (Ro 13-5057, <e1> 1-anisoyl-2-pyrrolidinone </e1>) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal <e2> hypercapnia </e2> immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4904": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "1-anisoyl-2-pyrrolidinone", "entity2": "hypercapnia", "span1": [38, 63], "span2": [1178, 1189]}, "bert_text": "The effect of aniracetam (Ro 13-5057, <e1> 1-anisoyl-2-pyrrolidinone </e1>) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4905": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "1-anisoyl-2-pyrrolidinone", "entity2": "amnesia", "span1": [38, 63], "span2": [467, 474]}, "bert_text": "The effect of aniracetam (Ro 13-5057, <e1> 1-anisoyl-2-pyrrolidinone </e1>) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term <e2> amnesia </e2> for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4906": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "1-anisoyl-2-pyrrolidinone", "entity2": "amnesia", "span1": [38, 63], "span2": [537, 544]}, "bert_text": "The effect of aniracetam (Ro 13-5057, <e1> 1-anisoyl-2-pyrrolidinone </e1>) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4907": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "1-anisoyl-2-pyrrolidinone", "entity2": "electroconvulsive shock", "span1": [38, 63], "span2": [595, 618]}, "bert_text": "The effect of aniracetam (Ro 13-5057, <e1> 1-anisoyl-2-pyrrolidinone </e1>) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to <e2> electroconvulsive shock </e2> immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4908": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "scopolamine", "entity2": "impaired cognitive functions", "span1": [436, 447], "span2": [112, 140]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the <e1> scopolamine </e1> <e2> impaired cognitive functions </e2> (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4909": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "scopolamine", "entity2": "hypercapnia", "span1": [436, 447], "span2": [324, 335]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the <e1> scopolamine </e1> <e2> hypercapnia </e2> immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4910": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "scopolamine", "entity2": "hypercapnia", "span1": [436, 447], "span2": [1178, 1189]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the <e1> scopolamine </e1>-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4911": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "scopolamine", "entity2": "amnesia", "span1": [436, 447], "span2": [467, 474]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the <e1> scopolamine </e1>-induced short-term <e2> amnesia </e2> for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4912": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "scopolamine", "entity2": "amnesia", "span1": [436, 447], "span2": [537, 544]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the <e1> scopolamine </e1>-induced short-term amnesia for a passive avoidance task; (3) complete protection against <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4913": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "scopolamine", "entity2": "electroconvulsive shock", "span1": [436, 447], "span2": [595, 618]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the <e1> scopolamine </e1>-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to <e2> electroconvulsive shock </e2> immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4914": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "chloramphenicol", "entity2": "impaired cognitive functions", "span1": [781, 796], "span2": [112, 140]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by <e1> chloramphenicol </e1> <e2> impaired cognitive functions </e2> (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4915": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "chloramphenicol", "entity2": "hypercapnia", "span1": [781, 796], "span2": [324, 335]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by <e1> chloramphenicol </e1> <e2> hypercapnia </e2> immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4916": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "chloramphenicol", "entity2": "hypercapnia", "span1": [781, 796], "span2": [1178, 1189]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by <e1> chloramphenicol </e1> or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4917": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "chloramphenicol", "entity2": "amnesia", "span1": [781, 796], "span2": [467, 474]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by <e1> chloramphenicol </e1> <e2> amnesia </e2> for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"4918": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "chloramphenicol", "entity2": "amnesia", "span1": [781, 796], "span2": [537, 544]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by <e1> chloramphenicol </e1> <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4919": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "chloramphenicol", "entity2": "electroconvulsive shock", "span1": [781, 796], "span2": [595, 618]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by <e1> chloramphenicol </e1> <e2> electroconvulsive shock </e2> immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4920": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "impaired cognitive functions", "span1": [800, 813], "span2": [112, 140]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or <e1> cycloheximide </e1> <e2> impaired cognitive functions </e2> (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4921": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "hypercapnia", "span1": [800, 813], "span2": [324, 335]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or <e1> cycloheximide </e1> <e2> hypercapnia </e2> immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4922": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "hypercapnia", "span1": [800, 813], "span2": [1178, 1189]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or <e1> cycloheximide </e1> administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4923": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "amnesia", "span1": [800, 813], "span2": [467, 474]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or <e1> cycloheximide </e1> <e2> amnesia </e2> for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"4924": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "amnesia", "span1": [800, 813], "span2": [537, 544]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or <e1> cycloheximide </e1> <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4925": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "electroconvulsive shock", "span1": [800, 813], "span2": [595, 618]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or <e1> cycloheximide </e1> <e2> electroconvulsive shock </e2> immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4926": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "impaired cognitive functions", "span1": [1012, 1025], "span2": [112, 140]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by <e1> cycloheximide </e1> <e2> impaired cognitive functions </e2> (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4927": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "hypercapnia", "span1": [1012, 1025], "span2": [324, 335]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by <e1> cycloheximide </e1> <e2> hypercapnia </e2> immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4928": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "hypercapnia", "span1": [1012, 1025], "span2": [1178, 1189]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by <e1> cycloheximide </e1> injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4929": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "amnesia", "span1": [1012, 1025], "span2": [467, 474]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by <e1> cycloheximide </e1> <e2> amnesia </e2> for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"4930": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "amnesia", "span1": [1012, 1025], "span2": [537, 544]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by <e1> cycloheximide </e1> <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4931": {"data": {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity1": "cycloheximide", "entity2": "electroconvulsive shock", "span1": [1012, 1025], "span2": [595, 618]}, "bert_text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by <e1> cycloheximide </e1> <e2> electroconvulsive shock </e2> immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4932": {"data": {"text": "This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [59, 67], "span2": [76, 96]}, "bert_text": "This observation suggests that increased susceptibility to <e1> Warfarin </e1>-induced <e2> artery calcification </e2> could be related to higher serum phosphate levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4933": {"data": {"text": "This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.", "entity1": "phosphate", "entity2": "artery calcification", "span1": [130, 139], "span2": [76, 96]}, "bert_text": "This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum <e1> phosphate </e1> <e2> artery calcification </e2> could be related to higher serum phosphate levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4934": {"data": {"text": "In addition to our highlighted cases, we review the history, classification, pathophysiologic features, and treatment of milk-alkali syndrome and summarize the cases reported from early 1995 to November 2003. CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.", "entity1": "calcium carbonate", "entity2": "milk-alkali syndrome", "span1": [353, 370], "span2": [121, 141]}, "bert_text": "In addition to our highlighted cases, we review the history, classification, pathophysiologic features, and treatment of milk-alkali syndrome and summarize the cases reported from early 1995 to November 2003. CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested <e1> calcium carbonate </e1> <e2> milk-alkali syndrome </e2> and summarize the cases reported from early 1995 to November 2003. CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"4935": {"data": {"text": "In addition to our highlighted cases, we review the history, classification, pathophysiologic features, and treatment of milk-alkali syndrome and summarize the cases reported from early 1995 to November 2003. CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.", "entity1": "calcium carbonate", "entity2": "Milk-alkali syndrome", "span1": [353, 370], "span2": [221, 241]}, "bert_text": "In addition to our highlighted cases, we review the history, classification, pathophysiologic features, and treatment of milk-alkali syndrome and summarize the cases reported from early 1995 to November 2003. CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested <e1> calcium carbonate </e1> <e2> Milk-alkali syndrome </e2> may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4936": {"data": {"text": "In addition to our highlighted cases, we review the history, classification, pathophysiologic features, and treatment of milk-alkali syndrome and summarize the cases reported from early 1995 to November 2003. CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.", "entity1": "calcium carbonate", "entity2": "hypercalcemia", "span1": [353, 370], "span2": [279, 292]}, "bert_text": "In addition to our highlighted cases, we review the history, classification, pathophysiologic features, and treatment of milk-alkali syndrome and summarize the cases reported from early 1995 to November 2003. CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested <e1> calcium carbonate </e1> <e2> hypercalcemia </e2> and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4937": {"data": {"text": "Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.\n", "entity1": "L-dopa", "entity2": "dyskinesias", "span1": [35, 41], "span2": [50, 61]}, "bert_text": "Effect of nondopaminergic drugs on <e1> L-dopa </e1>-induced <e2> dyskinesias </e2> in MPTP-treated monkeys.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4938": {"data": {"text": "Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.\n", "entity1": "MPTP", "entity2": "dyskinesias", "span1": [65, 69], "span2": [50, 61]}, "bert_text": "Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in <e1> MPTP </e1> <e2> dyskinesias </e2> in MPTP-treated monkeys.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4939": {"data": {"text": "Seizure associated with sleep deprivation and sustained-release bupropion.\n", "entity1": "bupropion", "entity2": "Seizure", "span1": [64, 73], "span2": [0, 7]}, "bert_text": "Seizure associated with sleep deprivation and sustained-release <e1> bupropion </e1> <e2> Seizure </e2> associated with sleep deprivation and sustained-release bupropion.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4940": {"data": {"text": "Seizure associated with sleep deprivation and sustained-release bupropion.\n", "entity1": "bupropion", "entity2": "sleep deprivation", "span1": [64, 73], "span2": [24, 41]}, "bert_text": "Seizure associated with sleep deprivation and sustained-release <e1> bupropion </e1> <e2> sleep deprivation </e2> and sustained-release bupropion.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4941": {"data": {"text": "BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.", "entity1": "RAPA", "entity2": "toxicity", "span1": [64, 68], "span2": [142, 150]}, "bert_text": "BACKGROUND: The aim of this study is to evaluate the effects of <e1> RAPA </e1> conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4942": {"data": {"text": "BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.", "entity1": "cyclosporine", "entity2": "toxicity", "span1": [103, 115], "span2": [142, 150]}, "bert_text": "BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing <e1> cyclosporine </e1> (CsA) or tacrolimus (Tac) <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4943": {"data": {"text": "BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.", "entity1": "CsA", "entity2": "toxicity", "span1": [117, 120], "span2": [142, 150]}, "bert_text": "BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (<e1> CsA </e1>) or tacrolimus (Tac) <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4944": {"data": {"text": "BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.", "entity1": "tacrolimus", "entity2": "toxicity", "span1": [125, 135], "span2": [142, 150]}, "bert_text": "BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or <e1> tacrolimus </e1> (Tac) <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4945": {"data": {"text": "BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.", "entity1": "Tac", "entity2": "toxicity", "span1": [137, 140], "span2": [142, 150]}, "bert_text": "BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (<e1> Tac </e1>) <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4946": {"data": {"text": "Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.", "entity1": "nicotine", "entity2": "seizures", "span1": [88, 96], "span2": [105, 113]}, "bert_text": "Together, these results suggest that the beta4 and the alpha3 subunits are mediators of <e1> nicotine </e1>-induced <e2> seizures </e2> and hypolocomotion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4947": {"data": {"text": "Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.", "entity1": "nicotine", "entity2": "hypolocomotion", "span1": [88, 96], "span2": [118, 132]}, "bert_text": "Together, these results suggest that the beta4 and the alpha3 subunits are mediators of <e1> nicotine </e1>-induced seizures and <e2> hypolocomotion </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4948": {"data": {"text": "In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D-treated rats at 3 and 4 days.", "entity1": "Warfarin", "entity2": "calcification", "span1": [103, 111], "span2": [164, 177]}, "bert_text": "In the current study, we investigated the synergy between these 2 treatments and found that concurrent <e1> Warfarin </e1> administration dramatically increased the extent of <e2> calcification </e2> in the media of vitamin D-treated rats at 3 and 4 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4949": {"data": {"text": "In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D-treated rats at 3 and 4 days.", "entity1": "vitamin D", "entity2": "calcification", "span1": [194, 203], "span2": [164, 177]}, "bert_text": "In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of <e1> vitamin D </e1> <e2> calcification </e2> in the media of vitamin D-treated rats at 3 and 4 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4950": {"data": {"text": "The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.", "entity1": "cytosine arabinoside", "entity2": "numbness", "span1": [30, 50], "span2": [159, 167]}, "bert_text": "The first course of high-dose <e1> cytosine arabinoside </e1> resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of <e2> numbness </e2> in his right foot.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4951": {"data": {"text": "Cyclosporine and tacrolimus-associated thrombotic microangiopathy.\n", "entity1": "Cyclosporine", "entity2": "thrombotic microangiopathy", "span1": [0, 12], "span2": [39, 65]}, "bert_text": "<e1> Cyclosporine </e1> and tacrolimus-associated <e2> thrombotic microangiopathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4952": {"data": {"text": "Cyclosporine and tacrolimus-associated thrombotic microangiopathy.\n", "entity1": "tacrolimus", "entity2": "thrombotic microangiopathy", "span1": [17, 27], "span2": [39, 65]}, "bert_text": "Cyclosporine and <e1> tacrolimus </e1>-associated <e2> thrombotic microangiopathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4953": {"data": {"text": "Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.", "entity1": "ouabain", "entity2": "coronary artery disease", "span1": [11, 18], "span2": [83, 106]}, "bert_text": "Effects of <e1> ouabain </e1> on myocardial oxygen supply and demand in patients with chronic <e2> coronary artery disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4954": {"data": {"text": "Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.", "entity1": "oxygen", "entity2": "coronary artery disease", "span1": [33, 39], "span2": [83, 106]}, "bert_text": "Effects of ouabain on myocardial <e1> oxygen </e1> supply and demand in patients with chronic <e2> coronary artery disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4955": {"data": {"text": "We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p.", "entity1": "diazepam", "entity2": "seizures", "span1": [12, 20], "span2": [181, 189]}, "bert_text": "We measured <e1> diazepam </e1>-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced <e2> seizures </e2> after i.p.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"4956": {"data": {"text": "We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p.", "entity1": "diazepam", "entity2": "seizures", "span1": [74, 82], "span2": [181, 189]}, "bert_text": "We measured diazepam-induced anxiolysis with the elevated plus-maze test, <e1> diazepam </e1>-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced <e2> seizures </e2> after i.p.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"4957": {"data": {"text": "We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p.", "entity1": "picrotoxin-", "entity2": "seizures", "span1": [139, 150], "span2": [181, 189]}, "bert_text": "We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and <e1> picrotoxin- </e1> and pentylenetetrazol-induced <e2> seizures </e2> after i.p.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4958": {"data": {"text": "We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p.", "entity1": "pentylenetetrazol", "entity2": "seizures", "span1": [155, 172], "span2": [181, 189]}, "bert_text": "We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and <e1> pentylenetetrazol </e1>-induced <e2> seizures </e2> after i.p.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4959": {"data": {"text": "The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.", "entity1": "adenosine", "entity2": "neuropathic pain", "span1": [163, 172], "span2": [105, 121]}, "bert_text": "The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of <e1> adenosine </e1> <e2> neuropathic pain </e2> and is not due to prolonged residence of adenosine in cerebrospinal fluid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4960": {"data": {"text": "Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.\n", "entity1": "acetylsalicylic acid", "entity2": "myocardial injury", "span1": [11, 31], "span2": [89, 106]}, "bert_text": "Effects of <e1> acetylsalicylic acid </e1>, dipyridamole, and hydrocortisone on epinephrine-induced <e2> myocardial injury </e2> in dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4961": {"data": {"text": "Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.\n", "entity1": "dipyridamole", "entity2": "myocardial injury", "span1": [33, 45], "span2": [89, 106]}, "bert_text": "Effects of acetylsalicylic acid, <e1> dipyridamole </e1>, and hydrocortisone on epinephrine-induced <e2> myocardial injury </e2> in dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4962": {"data": {"text": "Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.\n", "entity1": "hydrocortisone", "entity2": "myocardial injury", "span1": [51, 65], "span2": [89, 106]}, "bert_text": "Effects of acetylsalicylic acid, dipyridamole, and <e1> hydrocortisone </e1> on epinephrine-induced <e2> myocardial injury </e2> in dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4963": {"data": {"text": "Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.\n", "entity1": "epinephrine", "entity2": "myocardial injury", "span1": [69, 80], "span2": [89, 106]}, "bert_text": "Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on <e1> epinephrine </e1>-induced <e2> myocardial injury </e2> in dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4964": {"data": {"text": "CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.", "entity1": "ticlopidine", "entity2": "Cholestatic hepatitis", "span1": [63, 74], "span2": [13, 34]}, "bert_text": "CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of <e1> ticlopidine </e1> <e2> Cholestatic hepatitis </e2> is a rare adverse effect of ticlopidine that may be immune mediated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4965": {"data": {"text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "entity1": "steroid", "entity2": "myopathy", "span1": [9, 16], "span2": [17, 25]}, "bert_text": "Further, <e1> steroid </e1> <e2> myopathy </e2> recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4966": {"data": {"text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "entity1": "steroid", "entity2": "myopathy", "span1": [9, 16], "span2": [170, 178]}, "bert_text": "Further, <e1> steroid </e1> myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid <e2> myopathy </e2>, instead of any protection that methylprednisolone offers to the spinal cord injury.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4967": {"data": {"text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "entity1": "steroid", "entity2": "spinal cord injury", "span1": [9, 16], "span2": [244, 262]}, "bert_text": "Further, <e1> steroid </e1> myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the <e2> spinal cord injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4968": {"data": {"text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "entity1": "steroid", "entity2": "myopathy", "span1": [162, 169], "span2": [17, 25]}, "bert_text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the <e1> steroid </e1> <e2> myopathy </e2> recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4969": {"data": {"text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "entity1": "steroid", "entity2": "myopathy", "span1": [162, 169], "span2": [170, 178]}, "bert_text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the <e1> steroid </e1> <e2> myopathy </e2>, instead of any protection that methylprednisolone offers to the spinal cord injury.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4970": {"data": {"text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "entity1": "steroid", "entity2": "spinal cord injury", "span1": [162, 169], "span2": [244, 262]}, "bert_text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the <e1> steroid </e1> myopathy, instead of any protection that methylprednisolone offers to the <e2> spinal cord injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4971": {"data": {"text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "entity1": "methylprednisolone", "entity2": "myopathy", "span1": [211, 229], "span2": [17, 25]}, "bert_text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that <e1> methylprednisolone </e1> <e2> myopathy </e2> recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4972": {"data": {"text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "entity1": "methylprednisolone", "entity2": "myopathy", "span1": [211, 229], "span2": [170, 178]}, "bert_text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that <e1> methylprednisolone </e1> <e2> myopathy </e2>, instead of any protection that methylprednisolone offers to the spinal cord injury.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4973": {"data": {"text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "entity1": "methylprednisolone", "entity2": "spinal cord injury", "span1": [211, 229], "span2": [244, 262]}, "bert_text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that <e1> methylprednisolone </e1> offers to the <e2> spinal cord injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4974": {"data": {"text": "One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.", "entity1": "lopinavir/ritonavir", "entity2": "heart block", "span1": [86, 105], "span2": [36, 47]}, "bert_text": "One of the twins developed complete heart block and dilated cardiomyopathy related to <e1> lopinavir/ritonavir </e1> <e2> heart block </e2> and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4975": {"data": {"text": "One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.", "entity1": "lopinavir/ritonavir", "entity2": "dilated cardiomyopathy", "span1": [86, 105], "span2": [52, 74]}, "bert_text": "One of the twins developed complete heart block and dilated cardiomyopathy related to <e1> lopinavir/ritonavir </e1> <e2> dilated cardiomyopathy </e2> related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4976": {"data": {"text": "One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.", "entity1": "lopinavir/ritonavir", "entity2": "bradycardia", "span1": [86, 105], "span2": [187, 198]}, "bert_text": "One of the twins developed complete heart block and dilated cardiomyopathy related to <e1> lopinavir/ritonavir </e1> therapy, a boosted protease-inhibitor agent, while the other twin developed mild <e2> bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4977": {"data": {"text": "BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.", "entity1": "Methamphetamine", "entity2": "cardiac dysrhythmias", "span1": [12, 27], "span2": [155, 175]}, "bert_text": "BACKGROUND: <e1> Methamphetamine </e1> is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as <e2> cardiac dysrhythmias </e2>, hypertension, hallucinations, and violent behavior.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4978": {"data": {"text": "BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.", "entity1": "Methamphetamine", "entity2": "hypertension", "span1": [12, 27], "span2": [177, 189]}, "bert_text": "BACKGROUND: <e1> Methamphetamine </e1> is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, <e2> hypertension </e2>, hallucinations, and violent behavior.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4979": {"data": {"text": "BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.", "entity1": "Methamphetamine", "entity2": "hallucinations", "span1": [12, 27], "span2": [191, 205]}, "bert_text": "BACKGROUND: <e1> Methamphetamine </e1> is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, <e2> hallucinations </e2>, and violent behavior.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4980": {"data": {"text": "METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.", "entity1": "papaverine", "entity2": "vasospasm", "span1": [150, 160], "span2": [165, 174]}, "bert_text": "METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical <e1> papaverine </e1> for <e2> vasospasm </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4981": {"data": {"text": "In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.", "entity1": "DA", "entity2": "epilepsy", "span1": [51, 53], "span2": [85, 93]}, "bert_text": "In this respect, little is known about the role of <e1> DA </e1> receptors in the occurrence of <e2> epilepsy </e2>-induced neuronal cell death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4982": {"data": {"text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.", "entity1": "CPA", "entity2": "poisoning", "span1": [15, 18], "span2": [112, 121]}, "bert_text": "In conclusion, <e1> CPA </e1>, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of <e2> poisoning </e2> and thus reduced the toxicity of DFP in rat.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4983": {"data": {"text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.", "entity1": "CPA", "entity2": "toxicity", "span1": [15, 18], "span2": [143, 151]}, "bert_text": "In conclusion, <e1> CPA </e1>, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the <e2> toxicity </e2> of DFP in rat.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4984": {"data": {"text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.", "entity1": "diazepam", "entity2": "poisoning", "span1": [20, 28], "span2": [112, 121]}, "bert_text": "In conclusion, CPA, <e1> diazepam </e1> and 2PAM in combination with atropine prevented the occurrence of serious signs of <e2> poisoning </e2> and thus reduced the toxicity of DFP in rat.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4985": {"data": {"text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.", "entity1": "diazepam", "entity2": "toxicity", "span1": [20, 28], "span2": [143, 151]}, "bert_text": "In conclusion, CPA, <e1> diazepam </e1> and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the <e2> toxicity </e2> of DFP in rat.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4986": {"data": {"text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.", "entity1": "2PAM", "entity2": "poisoning", "span1": [33, 37], "span2": [112, 121]}, "bert_text": "In conclusion, CPA, diazepam and <e1> 2PAM </e1> in combination with atropine prevented the occurrence of serious signs of <e2> poisoning </e2> and thus reduced the toxicity of DFP in rat.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4987": {"data": {"text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.", "entity1": "2PAM", "entity2": "toxicity", "span1": [33, 37], "span2": [143, 151]}, "bert_text": "In conclusion, CPA, diazepam and <e1> 2PAM </e1> in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the <e2> toxicity </e2> of DFP in rat.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4988": {"data": {"text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.", "entity1": "atropine", "entity2": "poisoning", "span1": [58, 66], "span2": [112, 121]}, "bert_text": "In conclusion, CPA, diazepam and 2PAM in combination with <e1> atropine </e1> prevented the occurrence of serious signs of <e2> poisoning </e2> and thus reduced the toxicity of DFP in rat.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4989": {"data": {"text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.", "entity1": "atropine", "entity2": "toxicity", "span1": [58, 66], "span2": [143, 151]}, "bert_text": "In conclusion, CPA, diazepam and 2PAM in combination with <e1> atropine </e1> prevented the occurrence of serious signs of poisoning and thus reduced the <e2> toxicity </e2> of DFP in rat.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4990": {"data": {"text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.", "entity1": "DFP", "entity2": "poisoning", "span1": [155, 158], "span2": [112, 121]}, "bert_text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of <e1> DFP </e1> <e2> poisoning </e2> and thus reduced the toxicity of DFP in rat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4991": {"data": {"text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.", "entity1": "DFP", "entity2": "toxicity", "span1": [155, 158], "span2": [143, 151]}, "bert_text": "In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of <e1> DFP </e1> <e2> toxicity </e2> of DFP in rat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4992": {"data": {"text": "Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).", "entity1": "Diuretic", "entity2": "decreased renal function", "span1": [0, 8], "span2": [64, 88]}, "bert_text": "<e1> Diuretic </e1> therapy was likewise associated with a greater risk of <e2> decreased renal function </e2> in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).", "weak_labels": [1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4993": {"data": {"text": "Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).", "entity1": "enalapril", "entity2": "decreased renal function", "span1": [96, 105], "span2": [64, 88]}, "bert_text": "Diuretic therapy was likewise associated with a greater risk of decreased renal function in the <e1> enalapril </e1> <e2> decreased renal function </e2> in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, 1, 0, -1, 0], "label": 1},
+	"4994": {"data": {"text": "Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.", "entity1": "ribavirin", "entity2": "hemolysis", "span1": [57, 66], "span2": [75, 84]}, "bert_text": "Hemoglobin concentrations decrease mainly as a result of <e1> ribavirin </e1>-induced <e2> hemolysis </e2>, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4995": {"data": {"text": "Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.", "entity1": "ribavirin", "entity2": "anemia", "span1": [57, 66], "span2": [95, 101]}, "bert_text": "Hemoglobin concentrations decrease mainly as a result of <e1> ribavirin </e1>-induced hemolysis, and this <e2> anemia </e2> can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4996": {"data": {"text": "Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.", "entity1": "ribavirin", "entity2": "HCV infection", "span1": [57, 66], "span2": [138, 151]}, "bert_text": "Hemoglobin concentrations decrease mainly as a result of <e1> ribavirin </e1>-induced hemolysis, and this anemia can be problematic in patients with <e2> HCV infection </e2>, especially those who have comorbid renal or cardiovascular disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4997": {"data": {"text": "Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.", "entity1": "ribavirin", "entity2": "cardiovascular disorders", "span1": [57, 66], "span2": [197, 221]}, "bert_text": "Hemoglobin concentrations decrease mainly as a result of <e1> ribavirin </e1>-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or <e2> cardiovascular disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4998": {"data": {"text": "Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.", "entity1": "Diazepam-", "entity2": "amnesia", "span1": [0, 9], "span2": [43, 50]}, "bert_text": "<e1> Diazepam- </e1>, scopolamine- and ageing-induced <e2> amnesia </e2> served as the interoceptive behavioral models.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4999": {"data": {"text": "Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.", "entity1": "scopolamine-", "entity2": "amnesia", "span1": [11, 23], "span2": [43, 50]}, "bert_text": "Diazepam-, <e1> scopolamine- </e1> and ageing-induced <e2> amnesia </e2> served as the interoceptive behavioral models.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5000": {"data": {"text": "Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.", "entity1": "Superoxide", "entity2": "ALF", "span1": [0, 10], "span2": [138, 141]}, "bert_text": "<e1> Superoxide </e1> and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 <e2> ALF </e2> patients was unaffected compared with control neutrophils.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5001": {"data": {"text": "Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.", "entity1": "hydrogen peroxide", "entity2": "ALF", "span1": [15, 32], "span2": [138, 141]}, "bert_text": "Superoxide and <e1> hydrogen peroxide </e1> production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 <e2> ALF </e2> patients was unaffected compared with control neutrophils.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5002": {"data": {"text": "Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.", "entity1": "formyl-methionyl-leucyl-phenylalanine", "entity2": "ALF", "span1": [75, 112], "span2": [138, 141]}, "bert_text": "Superoxide and hydrogen peroxide production in neutrophils stimulated with <e1> formyl-methionyl-leucyl-phenylalanine </e1> (fMLP) from a further 18 <e2> ALF </e2> patients was unaffected compared with control neutrophils.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5003": {"data": {"text": "Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.", "entity1": "fMLP", "entity2": "ALF", "span1": [114, 118], "span2": [138, 141]}, "bert_text": "Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (<e1> fMLP </e1>) from a further 18 <e2> ALF </e2> patients was unaffected compared with control neutrophils.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5004": {"data": {"text": "On the other hand, pretreatment with p-chlorophenylalamine (3 X 320 mg/kg i.p., 24 hr), a serotonin depletor, caused no significant change in the hyperactivity.", "entity1": "serotonin", "entity2": "hyperactivity", "span1": [90, 99], "span2": [146, 159]}, "bert_text": "On the other hand, pretreatment with p-chlorophenylalamine (3 X 320 mg/kg i.p., 24 hr), a <e1> serotonin </e1> depletor, caused no significant change in the <e2> hyperactivity </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5005": {"data": {"text": "The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.", "entity1": "suxamethonium", "entity2": "cardiac arrest", "span1": [125, 138], "span2": [39, 53]}, "bert_text": "The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of <e1> suxamethonium </e1> <e2> cardiac arrest </e2> and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5006": {"data": {"text": "The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.", "entity1": "suxamethonium", "entity2": "death", "span1": [125, 138], "span2": [69, 74]}, "bert_text": "The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of <e1> suxamethonium </e1> <e2> death </e2> as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5007": {"data": {"text": "The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.", "entity1": "suxamethonium", "entity2": "hyperkalaemia", "span1": [125, 138], "span2": [90, 103]}, "bert_text": "The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of <e1> suxamethonium </e1> <e2> hyperkalaemia </e2> following the use of suxamethonium in a 23-year-old Malawian woman.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5008": {"data": {"text": "In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.", "entity1": "etomidate", "entity2": "myoclonus", "span1": [110, 119], "span2": [94, 103]}, "bert_text": "In the placebo group, male patients were associated with significantly increased incidence of myoclonus after <e1> etomidate </e1> <e2> myoclonus </e2> after etomidate administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5009": {"data": {"text": "The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.", "entity1": "buspirone", "entity2": "catalepsy", "span1": [27, 36], "span2": [47, 56]}, "bert_text": "The novel anxiolytic drug, <e1> buspirone </e1>, reverses <e2> catalepsy </e2> induced by haloperidol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5010": {"data": {"text": "The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [68, 79], "span2": [47, 56]}, "bert_text": "The novel anxiolytic drug, buspirone, reverses catalepsy induced by <e1> haloperidol </e1> <e2> catalepsy </e2> induced by haloperidol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5011": {"data": {"text": "After re-infarction, heart size increased in the placebo group and remained unchanged in the timolol group.", "entity1": "timolol", "entity2": "infarction", "span1": [93, 100], "span2": [9, 19]}, "bert_text": "After re-infarction, heart size increased in the placebo group and remained unchanged in the <e1> timolol </e1> <e2> infarction </e2>, heart size increased in the placebo group and remained unchanged in the timolol group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5012": {"data": {"text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.", "entity1": "AmB", "entity2": "hematological disorders", "span1": [118, 121], "span2": [48, 71]}, "bert_text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous <e1> AmB </e1> <e2> hematological disorders </e2> were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5013": {"data": {"text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.", "entity1": "AmB", "entity2": "fungal infection", "span1": [118, 121], "span2": [216, 232]}, "bert_text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous <e1> AmB </e1> alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected <e2> fungal infection </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5014": {"data": {"text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.", "entity1": "AmB", "entity2": "hematological disorders", "span1": [131, 134], "span2": [48, 71]}, "bert_text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or <e1> AmB </e1> <e2> hematological disorders </e2> were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5015": {"data": {"text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.", "entity1": "AmB", "entity2": "fungal infection", "span1": [131, 134], "span2": [216, 232]}, "bert_text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or <e1> AmB </e1> and oral spironolactone 100 mg twice daily when developing a proven or suspected <e2> fungal infection </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5016": {"data": {"text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.", "entity1": "spironolactone", "entity2": "hematological disorders", "span1": [144, 158], "span2": [48, 71]}, "bert_text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral <e1> spironolactone </e1> <e2> hematological disorders </e2> were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5017": {"data": {"text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.", "entity1": "spironolactone", "entity2": "fungal infection", "span1": [144, 158], "span2": [216, 232]}, "bert_text": "METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral <e1> spironolactone </e1> 100 mg twice daily when developing a proven or suspected <e2> fungal infection </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5018": {"data": {"text": "This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [181, 192], "span2": [129, 142]}, "bert_text": "This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, <e1> amphetamine </e1> <e2> hyperactivity </e2>, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5019": {"data": {"text": "This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).", "entity1": "MK-801", "entity2": "hyperactivity", "span1": [197, 203], "span2": [129, 142]}, "bert_text": "This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and <e1> MK-801 </e1> <e2> hyperactivity </e2>, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5020": {"data": {"text": "The potential for acetaminophen to produce cardiovascular toxicities is very low.", "entity1": "acetaminophen", "entity2": "cardiovascular toxicities", "span1": [18, 31], "span2": [43, 68]}, "bert_text": "The potential for <e1> acetaminophen </e1> to produce <e2> cardiovascular toxicities </e2> is very low.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5021": {"data": {"text": "While side effects were rare, those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems.", "entity1": "theophylline", "entity2": "gastrointestinal systems", "span1": [54, 66], "span2": [106, 130]}, "bert_text": "While side effects were rare, those experienced after <e1> theophylline </e1> use did involve the cardiovascular and <e2> gastrointestinal systems </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5022": {"data": {"text": "A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.", "entity1": "epinephrine", "entity2": "myocardial injury", "span1": [62, 73], "span2": [43, 60]}, "bert_text": "A reproducible model for producing diffuse myocardial injury (<e1> epinephrine </e1> <e2> myocardial injury </e2> (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5023": {"data": {"text": "A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.", "entity1": "epinephrine", "entity2": "myocardial infarction", "span1": [62, 73], "span2": [205, 226]}, "bert_text": "A reproducible model for producing diffuse myocardial injury (<e1> epinephrine </e1> infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5024": {"data": {"text": "Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.", "entity1": "ibuprofen", "entity2": "renal disease", "span1": [95, 104], "span2": [119, 132]}, "bert_text": "Possible risk factors included young age, concurrent use of other analgesic agents (especially <e1> ibuprofen </e1>), preexisting <e2> renal disease </e2>, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"5025": {"data": {"text": "Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.", "entity1": "ibuprofen", "entity2": "kidney stones", "span1": [95, 104], "span2": [147, 160]}, "bert_text": "Possible risk factors included young age, concurrent use of other analgesic agents (especially <e1> ibuprofen </e1>), preexisting renal disease, a history of <e2> kidney stones </e2>, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"5026": {"data": {"text": "In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [69, 77], "span2": [14, 33]}, "bert_text": "In late-stage Parkinson's disease, pallidotomy significantly reduces <e1> levodopa </e1> <e2> Parkinson's disease </e2>, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5027": {"data": {"text": "In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [69, 77], "span2": [86, 97]}, "bert_text": "In late-stage Parkinson's disease, pallidotomy significantly reduces <e1> levodopa </e1>-induced <e2> dyskinesias </e2> and off-period disability.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5028": {"data": {"text": "Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.", "entity1": "ATRA", "entity2": "Fever", "span1": [133, 137], "span2": [0, 5]}, "bert_text": "Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after <e1> ATRA </e1> <e2> Fever </e2> and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5029": {"data": {"text": "Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.", "entity1": "ATRA", "entity2": "painful erythematous nodules", "span1": [133, 137], "span2": [30, 58]}, "bert_text": "Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after <e1> ATRA </e1> <e2> painful erythematous nodules </e2> over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5030": {"data": {"text": "Addition of misoprostol can minimize this renal impairment without affecting pain control.", "entity1": "misoprostol", "entity2": "renal impairment", "span1": [12, 23], "span2": [42, 58]}, "bert_text": "Addition of <e1> misoprostol </e1> can minimize this <e2> renal impairment </e2> without affecting pain control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5031": {"data": {"text": "Addition of misoprostol can minimize this renal impairment without affecting pain control.", "entity1": "misoprostol", "entity2": "pain", "span1": [12, 23], "span2": [77, 81]}, "bert_text": "Addition of <e1> misoprostol </e1> can minimize this renal impairment without affecting <e2> pain </e2> control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5032": {"data": {"text": "It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.", "entity1": "WR242511", "entity2": "poisoning", "span1": [21, 29], "span2": [77, 86]}, "bert_text": "It is concluded that <e1> WR242511 </e1> should not be pursued as a pretreatment for CN <e2> poisoning </e2> unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5033": {"data": {"text": "It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.", "entity1": "WR242511", "entity2": "toxicity", "span1": [21, 29], "span2": [204, 212]}, "bert_text": "It is concluded that <e1> WR242511 </e1> should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5034": {"data": {"text": "The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.", "entity1": "TAM", "entity2": "hemolysis", "span1": [81, 84], "span2": [17, 26]}, "bert_text": "The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM <e1> TAM </e1> <e2> hemolysis </e2> is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5035": {"data": {"text": "The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.", "entity1": "TAM", "entity2": "hemolysis", "span1": [81, 84], "span2": [99, 108]}, "bert_text": "The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM <e1> TAM </e1> induces total <e2> hemolysis </e2> of all tested suspensions.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5036": {"data": {"text": "However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.", "entity1": "cyclophosphamide", "entity2": "heart damage", "span1": [34, 50], "span2": [138, 150]}, "bert_text": "However, caution is required when <e1> cyclophosphamide </e1> or anthracyclines such as mitoxantrone are used in patients with a possible underlying <e2> heart damage </e2>, for example, systemic sclerosis patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5037": {"data": {"text": "However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.", "entity1": "cyclophosphamide", "entity2": "systemic sclerosis", "span1": [34, 50], "span2": [165, 183]}, "bert_text": "However, caution is required when <e1> cyclophosphamide </e1> or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, <e2> systemic sclerosis </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5038": {"data": {"text": "However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.", "entity1": "anthracyclines", "entity2": "heart damage", "span1": [54, 68], "span2": [138, 150]}, "bert_text": "However, caution is required when cyclophosphamide or <e1> anthracyclines </e1> such as mitoxantrone are used in patients with a possible underlying <e2> heart damage </e2>, for example, systemic sclerosis patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5039": {"data": {"text": "However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.", "entity1": "anthracyclines", "entity2": "systemic sclerosis", "span1": [54, 68], "span2": [165, 183]}, "bert_text": "However, caution is required when cyclophosphamide or <e1> anthracyclines </e1> such as mitoxantrone are used in patients with a possible underlying heart damage, for example, <e2> systemic sclerosis </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5040": {"data": {"text": "However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.", "entity1": "mitoxantrone", "entity2": "heart damage", "span1": [77, 89], "span2": [138, 150]}, "bert_text": "However, caution is required when cyclophosphamide or anthracyclines such as <e1> mitoxantrone </e1> are used in patients with a possible underlying <e2> heart damage </e2>, for example, systemic sclerosis patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5041": {"data": {"text": "However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.", "entity1": "mitoxantrone", "entity2": "systemic sclerosis", "span1": [77, 89], "span2": [165, 183]}, "bert_text": "However, caution is required when cyclophosphamide or anthracyclines such as <e1> mitoxantrone </e1> are used in patients with a possible underlying heart damage, for example, <e2> systemic sclerosis </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5042": {"data": {"text": "To our knowledge, this is the first case report of simvastatin-ezetimibe-induced liver failure that resulted in liver transplantation.", "entity1": "simvastatin-ezetimibe", "entity2": "liver failure", "span1": [51, 72], "span2": [81, 94]}, "bert_text": "To our knowledge, this is the first case report of <e1> simvastatin-ezetimibe </e1>-induced <e2> liver failure </e2> that resulted in liver transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5043": {"data": {"text": "BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations. Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.", "entity1": "Papaverine hydrochloride", "entity2": "vasospasm", "span1": [12, 36], "span2": [83, 92]}, "bert_text": "BACKGROUND: <e1> Papaverine hydrochloride </e1> is a direct-acting vasodilator used to manage <e2> vasospasm </e2> during various neurosurgical operations. Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5044": {"data": {"text": "BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations. Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.", "entity1": "Papaverine hydrochloride", "entity2": "cranial nerve dysfunction", "span1": [12, 36], "span2": [144, 169]}, "bert_text": "BACKGROUND: <e1> Papaverine hydrochloride </e1> is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations. Transient <e2> cranial nerve dysfunction </e2> has been described in a few cases with topical papaverine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5045": {"data": {"text": "BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations. Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.", "entity1": "papaverine", "entity2": "vasospasm", "span1": [217, 227], "span2": [83, 92]}, "bert_text": "BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations. Transient cranial nerve dysfunction has been described in a few cases with topical <e1> papaverine </e1> <e2> vasospasm </e2> during various neurosurgical operations. Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5046": {"data": {"text": "BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations. Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.", "entity1": "papaverine", "entity2": "cranial nerve dysfunction", "span1": [217, 227], "span2": [144, 169]}, "bert_text": "BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations. Transient cranial nerve dysfunction has been described in a few cases with topical <e1> papaverine </e1> <e2> cranial nerve dysfunction </e2> has been described in a few cases with topical papaverine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5047": {"data": {"text": "The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.", "entity1": "nifedipine", "entity2": "nephrotoxicity", "span1": [32, 42], "span2": [59, 73]}, "bert_text": "The observed positive impact of <e1> nifedipine </e1> on reducing the <e2> nephrotoxicity </e2> associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5048": {"data": {"text": "The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.", "entity1": "nifedipine", "entity2": "hypertension", "span1": [32, 42], "span2": [193, 205]}, "bert_text": "The observed positive impact of <e1> nifedipine </e1> on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat <e2> hypertension </e2> in this population.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5049": {"data": {"text": "The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.", "entity1": "tacrolimus", "entity2": "nephrotoxicity", "span1": [90, 100], "span2": [59, 73]}, "bert_text": "The observed positive impact of nifedipine on reducing the nephrotoxicity associated with <e1> tacrolimus </e1> <e2> nephrotoxicity </e2> associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5050": {"data": {"text": "The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.", "entity1": "tacrolimus", "entity2": "hypertension", "span1": [90, 100], "span2": [193, 205]}, "bert_text": "The observed positive impact of nifedipine on reducing the nephrotoxicity associated with <e1> tacrolimus </e1> in liver transplant recipients should be an important factor in selecting an agent to treat <e2> hypertension </e2> in this population.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5051": {"data": {"text": "The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.", "entity1": "piroxicam", "entity2": "toxicity", "span1": [91, 100], "span2": [60, 68]}, "bert_text": "The aim of the experiment was to evaluate the developmental toxicity of the non-selective (<e1> piroxicam </e1> <e2> toxicity </e2> of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5052": {"data": {"text": "The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.", "entity1": "DFU", "entity2": "toxicity", "span1": [117, 120], "span2": [60, 68]}, "bert_text": "The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (<e1> DFU </e1> <e2> toxicity </e2> of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5053": {"data": {"text": "The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.", "entity1": "5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon", "entity2": "toxicity", "span1": [122, 196], "span2": [60, 68]}, "bert_text": "The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; <e1> 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon </e1> <e2> toxicity </e2> of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5054": {"data": {"text": "These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.", "entity1": "methylergonovine", "entity2": "spasm", "span1": [117, 133], "span2": [27, 32]}, "bert_text": "These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of <e1> methylergonovine </e1> <e2> spasm </e2> provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5055": {"data": {"text": "These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.", "entity1": "methylergonovine", "entity2": "variant angina", "span1": [117, 133], "span2": [162, 176]}, "bert_text": "These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of <e1> methylergonovine </e1>, have a high sensitivity in <e2> variant angina </e2> and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5056": {"data": {"text": "CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.", "entity1": "bupropion", "entity2": "acute liver insult", "span1": [92, 101], "span2": [62, 80]}, "bert_text": "CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by <e1> bupropion </e1> <e2> acute liver insult </e2> induced by bupropion given concurrently with other hepatotoxic drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5057": {"data": {"text": "CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.", "entity1": "bupropion", "entity2": "hepatotoxic", "span1": [92, 101], "span2": [132, 143]}, "bert_text": "CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by <e1> bupropion </e1> given concurrently with other <e2> hepatotoxic </e2> drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5058": {"data": {"text": "We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.", "entity1": "methylphenidate", "entity2": "vasculitis", "span1": [17, 32], "span2": [42, 52]}, "bert_text": "We conclude that <e1> methylphenidate </e1> mediated <e2> vasculitis </e2> should be considered in patients with neurological symptoms and a history of methylphenidate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5059": {"data": {"text": "We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.", "entity1": "methylphenidate", "entity2": "neurological symptoms", "span1": [17, 32], "span2": [91, 112]}, "bert_text": "We conclude that <e1> methylphenidate </e1> mediated vasculitis should be considered in patients with <e2> neurological symptoms </e2> and a history of methylphenidate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5060": {"data": {"text": "We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.", "entity1": "methylphenidate", "entity2": "vasculitis", "span1": [130, 145], "span2": [42, 52]}, "bert_text": "We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of <e1> methylphenidate </e1> <e2> vasculitis </e2> should be considered in patients with neurological symptoms and a history of methylphenidate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5061": {"data": {"text": "We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.", "entity1": "methylphenidate", "entity2": "neurological symptoms", "span1": [130, 145], "span2": [91, 112]}, "bert_text": "We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of <e1> methylphenidate </e1> <e2> neurological symptoms </e2> and a history of methylphenidate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5062": {"data": {"text": "We discuss the possible renal mechanisms and the implications for management of patients with lithium-induced nephrogenic diabetes insipidus.", "entity1": "lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [94, 101], "span2": [110, 140]}, "bert_text": "We discuss the possible renal mechanisms and the implications for management of patients with <e1> lithium </e1>-induced <e2> nephrogenic diabetes insipidus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"5063": {"data": {"text": "Cocaine-induced myocardial infarction: clinical observations and pathogenetic considerations.\n", "entity1": "Cocaine", "entity2": "myocardial infarction", "span1": [0, 7], "span2": [16, 37]}, "bert_text": "<e1> Cocaine </e1>-induced <e2> myocardial infarction </e2>: clinical observations and pathogenetic considerations.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5064": {"data": {"text": "Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.", "entity1": "CBZ", "entity2": "seizure", "span1": [8, 11], "span2": [44, 51]}, "bert_text": "Chronic <e1> CBZ </e1> also decreased the incidence of <e2> seizure </e2>-related mortality in the cocaine-injected rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5065": {"data": {"text": "Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.", "entity1": "cocaine", "entity2": "seizure", "span1": [77, 84], "span2": [44, 51]}, "bert_text": "Chronic CBZ also decreased the incidence of seizure-related mortality in the <e1> cocaine </e1> <e2> seizure </e2>-related mortality in the cocaine-injected rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5066": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "valdecoxib", "entity2": "cardiovascular thrombotic", "span1": [160, 170], "span2": [17, 42]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled <e1> valdecoxib </e1> <e2> cardiovascular thrombotic </e2> events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5067": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "valdecoxib", "entity2": "thrombotic", "span1": [160, 170], "span2": [113, 123]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled <e1> valdecoxib </e1> <e2> thrombotic </e2>) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5068": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "valdecoxib", "entity2": "osteoarthritis", "span1": [160, 170], "span2": [313, 327]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled <e1> valdecoxib </e1> (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized <e2> osteoarthritis </e2> and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5069": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "valdecoxib", "entity2": "rheumatoid arthritis", "span1": [160, 170], "span2": [332, 352]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled <e1> valdecoxib </e1> (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and <e2> rheumatoid arthritis </e2> trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5070": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "diclofenac", "entity2": "cardiovascular thrombotic", "span1": [209, 219], "span2": [17, 42]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (<e1> diclofenac </e1> <e2> cardiovascular thrombotic </e2> events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5071": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "diclofenac", "entity2": "thrombotic", "span1": [209, 219], "span2": [113, 123]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (<e1> diclofenac </e1> <e2> thrombotic </e2>) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5072": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "diclofenac", "entity2": "osteoarthritis", "span1": [209, 219], "span2": [313, 327]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (<e1> diclofenac </e1> 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized <e2> osteoarthritis </e2> and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5073": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "diclofenac", "entity2": "rheumatoid arthritis", "span1": [209, 219], "span2": [332, 352]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (<e1> diclofenac </e1> 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and <e2> rheumatoid arthritis </e2> trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5074": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "ibuprofen", "entity2": "cardiovascular thrombotic", "span1": [231, 240], "span2": [17, 42]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, <e1> ibuprofen </e1> <e2> cardiovascular thrombotic </e2> events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5075": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "ibuprofen", "entity2": "thrombotic", "span1": [231, 240], "span2": [113, 123]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, <e1> ibuprofen </e1> <e2> thrombotic </e2>) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5076": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "ibuprofen", "entity2": "osteoarthritis", "span1": [231, 240], "span2": [313, 327]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, <e1> ibuprofen </e1> 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized <e2> osteoarthritis </e2> and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5077": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "ibuprofen", "entity2": "rheumatoid arthritis", "span1": [231, 240], "span2": [332, 352]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, <e1> ibuprofen </e1> 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and <e2> rheumatoid arthritis </e2> trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5078": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "naproxen", "entity2": "cardiovascular thrombotic", "span1": [256, 264], "span2": [17, 42]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or <e1> naproxen </e1> <e2> cardiovascular thrombotic </e2> events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5079": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "naproxen", "entity2": "thrombotic", "span1": [256, 264], "span2": [113, 123]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or <e1> naproxen </e1> <e2> thrombotic </e2>) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5080": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "naproxen", "entity2": "osteoarthritis", "span1": [256, 264], "span2": [313, 327]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or <e1> naproxen </e1> 500 mg bid) and placebo data from 10 randomized <e2> osteoarthritis </e2> and rheumatoid arthritis trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5081": {"data": {"text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.", "entity1": "naproxen", "entity2": "rheumatoid arthritis", "span1": [256, 264], "span2": [332, 352]}, "bert_text": "The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or <e1> naproxen </e1> 500 mg bid) and placebo data from 10 randomized osteoarthritis and <e2> rheumatoid arthritis </e2> trials that were 6-52 weeks in duration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5082": {"data": {"text": "Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.", "entity1": "MPEP", "entity2": "hyperthermia", "span1": [28, 32], "span2": [201, 213]}, "bert_text": "Neuroprotection rendered by <e1> MPEP </e1> may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in <e2> hyperthermia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5083": {"data": {"text": "Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.", "entity1": "methamphetamine", "entity2": "hyperthermia", "span1": [77, 92], "span2": [201, 213]}, "bert_text": "Neuroprotection rendered by MPEP may be associated with the reduction of the <e1> methamphetamine </e1>-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in <e2> hyperthermia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5084": {"data": {"text": "Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.", "entity1": "dopamine", "entity2": "hyperthermia", "span1": [101, 109], "span2": [201, 213]}, "bert_text": "Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced <e1> dopamine </e1> efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in <e2> hyperthermia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5085": {"data": {"text": "Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.\n", "entity1": "enalapril", "entity2": "congestive heart failure", "span1": [51, 60], "span2": [122, 146]}, "bert_text": "Design and analysis of the HYPREN-trial: safety of <e1> enalapril </e1> and prazosin in the initial treatment phase of patients with <e2> congestive heart failure </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5086": {"data": {"text": "Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.\n", "entity1": "prazosin", "entity2": "congestive heart failure", "span1": [65, 73], "span2": [122, 146]}, "bert_text": "Design and analysis of the HYPREN-trial: safety of enalapril and <e1> prazosin </e1> in the initial treatment phase of patients with <e2> congestive heart failure </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5087": {"data": {"text": "Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.\n", "entity1": "poly(ADP-ribose", "entity2": "heart failure", "span1": [14, 29], "span2": [92, 105]}, "bert_text": "Activation of <e1> poly(ADP-ribose </e1>) polymerase contributes to development of doxorubicin-induced <e2> heart failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5088": {"data": {"text": "Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.\n", "entity1": "doxorubicin", "entity2": "heart failure", "span1": [72, 83], "span2": [92, 105]}, "bert_text": "Activation of poly(ADP-ribose) polymerase contributes to development of <e1> doxorubicin </e1>-induced <e2> heart failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5089": {"data": {"text": "Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.", "entity1": "tacrolimus", "entity2": "dermatitis", "span1": [51, 61], "span2": [133, 143]}, "bert_text": "Continuous topical use of immunomodulators such as <e1> tacrolimus </e1> or pimecrolimus should be regarded as a potential cause of rosaceiform <e2> dermatitis </e2>, although many cases have not been reported.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5090": {"data": {"text": "Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.", "entity1": "pimecrolimus", "entity2": "dermatitis", "span1": [65, 77], "span2": [133, 143]}, "bert_text": "Continuous topical use of immunomodulators such as tacrolimus or <e1> pimecrolimus </e1> should be regarded as a potential cause of rosaceiform <e2> dermatitis </e2>, although many cases have not been reported.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5091": {"data": {"text": "OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.", "entity1": "fenfluramine", "entity2": "valvular abnormalities", "span1": [92, 104], "span2": [54, 76]}, "bert_text": "OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of <e1> fenfluramine </e1> <e2> valvular abnormalities </e2> among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5092": {"data": {"text": "OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.", "entity1": "dexfenfluramine", "entity2": "valvular abnormalities", "span1": [108, 123], "span2": [54, 76]}, "bert_text": "OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or <e1> dexfenfluramine </e1> <e2> valvular abnormalities </e2> among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5093": {"data": {"text": "Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.", "entity1": "aminoglycosides", "entity2": "Ototoxicity", "span1": [121, 136], "span2": [0, 11]}, "bert_text": "Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly <e1> aminoglycosides </e1> <e2> Ototoxicity </e2> appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5094": {"data": {"text": "Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.", "entity1": "aminoglycosides", "entity2": "ototoxic", "span1": [121, 136], "span2": [92, 100]}, "bert_text": "Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly <e1> aminoglycosides </e1> <e2> ototoxic </e2> drugs, particularly aminoglycosides and furosemide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5095": {"data": {"text": "Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.", "entity1": "furosemide", "entity2": "Ototoxicity", "span1": [141, 151], "span2": [0, 11]}, "bert_text": "Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and <e1> furosemide </e1> <e2> Ototoxicity </e2> appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5096": {"data": {"text": "Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.", "entity1": "furosemide", "entity2": "ototoxic", "span1": [141, 151], "span2": [92, 100]}, "bert_text": "Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and <e1> furosemide </e1> <e2> ototoxic </e2> drugs, particularly aminoglycosides and furosemide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5097": {"data": {"text": "Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.", "entity1": "cyclosporine", "entity2": "nephrotoxicity", "span1": [106, 118], "span2": [55, 69]}, "bert_text": "Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with <e1> cyclosporine </e1> <e2> nephrotoxicity </e2> secondary to long-term therapy with cyclosporine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5098": {"data": {"text": "Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.", "entity1": "Amiodarone", "entity2": "cardiac tachyarrhythmias", "span1": [0, 10], "span2": [77, 101]}, "bert_text": "<e1> Amiodarone </e1> has proved very effective in the treatment of otherwise resistant <e2> cardiac tachyarrhythmias </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5099": {"data": {"text": "Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.\n", "entity1": "kainate", "entity2": "pain", "span1": [43, 50], "span2": [106, 110]}, "bert_text": "Two prodrugs of potent and selective GluR5 <e1> kainate </e1> receptor antagonists actives in three animal models of <e2> pain </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5100": {"data": {"text": "A group of four monkeys was rendered parkinsonian with the toxin MPTP.", "entity1": "MPTP", "entity2": "parkinsonian", "span1": [65, 69], "span2": [37, 49]}, "bert_text": "A group of four monkeys was rendered parkinsonian with the toxin <e1> MPTP </e1> <e2> parkinsonian </e2> with the toxin MPTP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5101": {"data": {"text": "In contrast, no evidence of memory impairment was observed in moderate MDMA users.", "entity1": "MDMA", "entity2": "memory impairment", "span1": [71, 75], "span2": [28, 45]}, "bert_text": "In contrast, no evidence of memory impairment was observed in moderate <e1> MDMA </e1> <e2> memory impairment </e2> was observed in moderate MDMA users.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"5102": {"data": {"text": "Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.\n", "entity1": "L-DOPA", "entity2": "dyskinesia", "span1": [60, 66], "span2": [75, 85]}, "bert_text": "Proteomic analysis of striatal proteins in the rat model of <e1> L-DOPA </e1>-induced <e2> dyskinesia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5103": {"data": {"text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "entity1": "L-DOPA", "entity2": "dyskinesia", "span1": [0, 6], "span2": [15, 25]}, "bert_text": "<e1> L-DOPA </e1>-induced <e2> dyskinesia </e2> (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5104": {"data": {"text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "entity1": "L-DOPA", "entity2": "LID", "span1": [0, 6], "span2": [27, 30]}, "bert_text": "<e1> L-DOPA </e1>-induced dyskinesia (<e2> LID </e2>) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5105": {"data": {"text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "entity1": "L-DOPA", "entity2": "Parkinson's disease", "span1": [0, 6], "span2": [79, 98]}, "bert_text": "<e1> L-DOPA </e1>-induced dyskinesia (LID) is among the motor complications that arise in <e2> Parkinson's disease </e2> (PD) patients after a prolonged treatment with L-DOPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5106": {"data": {"text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "entity1": "L-DOPA", "entity2": "PD", "span1": [0, 6], "span2": [100, 102]}, "bert_text": "<e1> L-DOPA </e1>-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (<e2> PD </e2>) patients after a prolonged treatment with L-DOPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5107": {"data": {"text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "entity1": "L-DOPA", "entity2": "dyskinesia", "span1": [146, 152], "span2": [15, 25]}, "bert_text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with <e1> L-DOPA </e1> <e2> dyskinesia </e2> (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5108": {"data": {"text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "entity1": "L-DOPA", "entity2": "LID", "span1": [146, 152], "span2": [27, 30]}, "bert_text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with <e1> L-DOPA </e1> <e2> LID </e2>) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5109": {"data": {"text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "entity1": "L-DOPA", "entity2": "Parkinson's disease", "span1": [146, 152], "span2": [79, 98]}, "bert_text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with <e1> L-DOPA </e1> <e2> Parkinson's disease </e2> (PD) patients after a prolonged treatment with L-DOPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5110": {"data": {"text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "entity1": "L-DOPA", "entity2": "PD", "span1": [146, 152], "span2": [100, 102]}, "bert_text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with <e1> L-DOPA </e1> <e2> PD </e2>) patients after a prolonged treatment with L-DOPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5111": {"data": {"text": "OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.", "entity1": "dobutamine", "entity2": "myocardial ischemia", "span1": [198, 208], "span2": [217, 236]}, "bert_text": "OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting <e1> dobutamine </e1>-induced <e2> myocardial ischemia </e2>, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5112": {"data": {"text": "OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.", "entity1": "dobutamine", "entity2": "ischemia", "span1": [198, 208], "span2": [375, 383]}, "bert_text": "OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting <e1> dobutamine </e1>-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of <e2> ischemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5113": {"data": {"text": "OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.", "entity1": "Tc99m-Sestamibi", "entity2": "myocardial ischemia", "span1": [244, 259], "span2": [217, 236]}, "bert_text": "OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using <e1> Tc99m-Sestamibi </e1> <e2> myocardial ischemia </e2>, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5114": {"data": {"text": "OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.", "entity1": "Tc99m-Sestamibi", "entity2": "ischemia", "span1": [244, 259], "span2": [375, 383]}, "bert_text": "OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using <e1> Tc99m-Sestamibi </e1> single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of <e2> ischemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5115": {"data": {"text": "Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.\n", "entity1": "cyclosporin A", "entity2": "Nephrotoxicity", "span1": [18, 31], "span2": [0, 14]}, "bert_text": "Nephrotoxicity of <e1> cyclosporin A </e1> <e2> Nephrotoxicity </e2> of cyclosporin A and FK506: inhibition of calcineurin phosphatase.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5116": {"data": {"text": "Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.\n", "entity1": "FK506", "entity2": "Nephrotoxicity", "span1": [36, 41], "span2": [0, 14]}, "bert_text": "Nephrotoxicity of cyclosporin A and <e1> FK506 </e1> <e2> Nephrotoxicity </e2> of cyclosporin A and FK506: inhibition of calcineurin phosphatase.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5117": {"data": {"text": "Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.", "entity1": "VPA", "entity2": "seizure", "span1": [16, 19], "span2": [221, 228]}, "bert_text": "Therefore, like <e1> VPA </e1>, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced <e2> seizure </e2> in experimental animals.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5118": {"data": {"text": "Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.", "entity1": "VPU", "entity2": "seizure", "span1": [38, 41], "span2": [221, 228]}, "bert_text": "Therefore, like VPA, the finding that <e1> VPU </e1> could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced <e2> seizure </e2> in experimental animals.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5119": {"data": {"text": "Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [67, 78], "span2": [221, 228]}, "bert_text": "Therefore, like VPA, the finding that VPU could drastically reduce <e1> pilocarpine </e1>-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced <e2> seizure </e2> in experimental animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5120": {"data": {"text": "Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [201, 212], "span2": [221, 228]}, "bert_text": "Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in <e1> pilocarpine </e1>-induced <e2> seizure </e2> in experimental animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5121": {"data": {"text": "Mazindol doses not slow the progression of weakness in Duchenne dystrophy.", "entity1": "Mazindol", "entity2": "weakness", "span1": [0, 8], "span2": [43, 51]}, "bert_text": "<e1> Mazindol </e1> doses not slow the progression of <e2> weakness </e2> in Duchenne dystrophy.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"5122": {"data": {"text": "Mazindol doses not slow the progression of weakness in Duchenne dystrophy.", "entity1": "Mazindol", "entity2": "Duchenne dystrophy", "span1": [0, 8], "span2": [55, 73]}, "bert_text": "<e1> Mazindol </e1> doses not slow the progression of weakness in <e2> Duchenne dystrophy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5123": {"data": {"text": "A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.\n", "entity1": "mitomycin C.", "entity2": "cardiotoxicity", "span1": [72, 84], "span2": [46, 60]}, "bert_text": "A prospective study on the dose dependency of cardiotoxicity induced by <e1> mitomycin C. </e1> <e2> cardiotoxicity </e2> induced by mitomycin C.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5124": {"data": {"text": "Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.\n", "entity1": "ribavirin", "entity2": "Argentine hemorrhagic fever", "span1": [34, 43], "span2": [61, 88]}, "bert_text": "Tolerance and antiviral effect of <e1> ribavirin </e1> in patients with <e2> Argentine hemorrhagic fever </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5125": {"data": {"text": "Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.", "entity1": "Bromocriptine", "entity2": "hypotension", "span1": [0, 13], "span2": [22, 33]}, "bert_text": "<e1> Bromocriptine </e1>-induced <e2> hypotension </e2> was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5126": {"data": {"text": "Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.", "entity1": "Bromocriptine", "entity2": "tachycardia", "span1": [0, 13], "span2": [86, 97]}, "bert_text": "<e1> Bromocriptine </e1>-induced hypotension was unaffected by isoproterenol pretreatment, while <e2> tachycardia </e2> was reversed to significant bradycardia, an effect that was partly reduced by i.v.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5127": {"data": {"text": "Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.", "entity1": "Bromocriptine", "entity2": "bradycardia", "span1": [0, 13], "span2": [126, 137]}, "bert_text": "<e1> Bromocriptine </e1>-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant <e2> bradycardia </e2>, an effect that was partly reduced by i.v.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5128": {"data": {"text": "Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.", "entity1": "isoproterenol", "entity2": "hypotension", "span1": [52, 65], "span2": [22, 33]}, "bert_text": "Bromocriptine-induced hypotension was unaffected by <e1> isoproterenol </e1> <e2> hypotension </e2> was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5129": {"data": {"text": "Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.", "entity1": "isoproterenol", "entity2": "tachycardia", "span1": [52, 65], "span2": [86, 97]}, "bert_text": "Bromocriptine-induced hypotension was unaffected by <e1> isoproterenol </e1> pretreatment, while <e2> tachycardia </e2> was reversed to significant bradycardia, an effect that was partly reduced by i.v.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5130": {"data": {"text": "Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.", "entity1": "isoproterenol", "entity2": "bradycardia", "span1": [52, 65], "span2": [126, 137]}, "bert_text": "Bromocriptine-induced hypotension was unaffected by <e1> isoproterenol </e1> pretreatment, while tachycardia was reversed to significant <e2> bradycardia </e2>, an effect that was partly reduced by i.v.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5131": {"data": {"text": "GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.", "entity1": "GR 55562", "entity2": "locomotor hyperactivity", "span1": [0, 8], "span2": [140, 163]}, "bert_text": "<e1> GR 55562 </e1> (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced <e2> locomotor hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5132": {"data": {"text": "GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.", "entity1": "cocaine", "entity2": "locomotor hyperactivity", "span1": [75, 82], "span2": [140, 163]}, "bert_text": "GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to <e1> cocaine </e1>, dose-dependently attenuated the psychostimulant-induced <e2> locomotor hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5133": {"data": {"text": "Lithium-induced polyuria seems to be related to extrarenal as well as to renal effects.", "entity1": "Lithium", "entity2": "polyuria", "span1": [0, 7], "span2": [16, 24]}, "bert_text": "<e1> Lithium </e1>-induced <e2> polyuria </e2> seems to be related to extrarenal as well as to renal effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5134": {"data": {"text": "Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.", "entity1": "suxamethonium", "entity2": "bradycardia", "span1": [33, 46], "span2": [48, 59]}, "bert_text": "Forty seconds after injection of <e1> suxamethonium </e1>, <e2> bradycardia </e2> and cardiac arrest occurred.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5135": {"data": {"text": "Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.", "entity1": "suxamethonium", "entity2": "cardiac arrest", "span1": [33, 46], "span2": [64, 78]}, "bert_text": "Forty seconds after injection of <e1> suxamethonium </e1>, bradycardia and <e2> cardiac arrest </e2> occurred.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5136": {"data": {"text": "Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.", "entity1": "azelastine", "entity2": "Drowsiness", "span1": [104, 114], "span2": [0, 10]}, "bert_text": "Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose <e1> azelastine </e1> <e2> Drowsiness </e2> and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5137": {"data": {"text": "However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.", "entity1": "AZT", "entity2": "reticulocytosis", "span1": [81, 84], "span2": [9, 24]}, "bert_text": "However, reticulocytosis was inappropriate for the degree of anaemia observed in <e1> AZT </e1> <e2> reticulocytosis </e2> was inappropriate for the degree of anaemia observed in AZT treated infected mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5138": {"data": {"text": "However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.", "entity1": "AZT", "entity2": "anaemia", "span1": [81, 84], "span2": [61, 68]}, "bert_text": "However, reticulocytosis was inappropriate for the degree of anaemia observed in <e1> AZT </e1> <e2> anaemia </e2> observed in AZT treated infected mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5139": {"data": {"text": "However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.", "entity1": "AZT", "entity2": "infected", "span1": [81, 84], "span2": [93, 101]}, "bert_text": "However, reticulocytosis was inappropriate for the degree of anaemia observed in <e1> AZT </e1> treated <e2> infected </e2> mice.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5140": {"data": {"text": "Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.", "entity1": "erythromycin", "entity2": "gastroenteritis", "span1": [36, 48], "span2": [75, 90]}, "bert_text": "Although the side-effect profile of <e1> erythromycin </e1> is established, including <e2> gastroenteritis </e2> and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5141": {"data": {"text": "Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.", "entity1": "macrolides", "entity2": "gastroenteritis", "span1": [205, 215], "span2": [75, 90]}, "bert_text": "Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer <e1> macrolides </e1> <e2> gastroenteritis </e2> and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5142": {"data": {"text": "The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).", "entity1": "ketamine", "entity2": "fracture", "span1": [52, 60], "span2": [84, 92]}, "bert_text": "The average time from intravenous administration of <e1> ketamine </e1> to manipulation of the <e2> fracture </e2> or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5143": {"data": {"text": "The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).", "entity1": "ketamine", "entity2": "dislocation", "span1": [52, 60], "span2": [96, 107]}, "bert_text": "The average time from intravenous administration of <e1> ketamine </e1> to manipulation of the fracture or <e2> dislocation </e2> was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5144": {"data": {"text": "The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.", "entity1": "creatinine", "entity2": "nephrotoxicity", "span1": [66, 76], "span2": [18, 32]}, "bert_text": "The occurrence of nephrotoxicity by means of an increase in serum <e1> creatinine </e1> <e2> nephrotoxicity </e2> by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5145": {"data": {"text": "The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.", "entity1": "amikacin", "entity2": "nephrotoxicity", "span1": [108, 116], "span2": [18, 32]}, "bert_text": "The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via <e1> amikacin </e1> <e2> nephrotoxicity </e2> by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5146": {"data": {"text": "Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).", "entity1": "Nitrofurantoins", "entity2": "anophthalmia", "span1": [0, 15], "span2": [37, 49]}, "bert_text": "<e1> Nitrofurantoins </e1> were associated with <e2> anophthalmia </e2> or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5147": {"data": {"text": "Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).", "entity1": "Nitrofurantoins", "entity2": "hypoplastic left heart syndrome", "span1": [0, 15], "span2": [99, 130]}, "bert_text": "<e1> Nitrofurantoins </e1> were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), <e2> hypoplastic left heart syndrome </e2> (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5148": {"data": {"text": "Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).", "entity1": "Nitrofurantoins", "entity2": "atrial septal defects", "span1": [0, 15], "span2": [161, 182]}, "bert_text": "<e1> Nitrofurantoins </e1> were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), <e2> atrial septal defects </e2> (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5149": {"data": {"text": "Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).", "entity1": "Nitrofurantoins", "entity2": "cleft lip", "span1": [0, 15], "span2": [217, 226]}, "bert_text": "<e1> Nitrofurantoins </e1> were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and <e2> cleft lip </e2> with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5150": {"data": {"text": "Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).", "entity1": "Nitrofurantoins", "entity2": "cleft palate", "span1": [0, 15], "span2": [232, 244]}, "bert_text": "<e1> Nitrofurantoins </e1> were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with <e2> cleft palate </e2> (AOR = 2.1; 95% CI, 1.2-3.9).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5151": {"data": {"text": "Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.\n", "entity1": "Dup 753", "entity2": "nephrosis", "span1": [0, 7], "span2": [70, 79]}, "bert_text": "<e1> Dup 753 </e1> prevents the development of puromycin aminonucleoside-induced <e2> nephrosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5152": {"data": {"text": "Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.\n", "entity1": "puromycin aminonucleoside", "entity2": "nephrosis", "span1": [36, 61], "span2": [70, 79]}, "bert_text": "Dup 753 prevents the development of <e1> puromycin aminonucleoside </e1>-induced <e2> nephrosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5153": {"data": {"text": "Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.", "entity1": "Apomorphine", "entity2": "hypothermia", "span1": [0, 11], "span2": [121, 132]}, "bert_text": "<e1> Apomorphine </e1>, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce <e2> hypothermia </e2>, and to produce distinct changes to dopamine turnover in the rodent brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5154": {"data": {"text": "Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.", "entity1": "dopamine agonist", "entity2": "hypothermia", "span1": [28, 44], "span2": [121, 132]}, "bert_text": "Apomorphine, a nonselective <e1> dopamine agonist </e1>, was selected due to its biphasic behavioral effects, its ability to induce <e2> hypothermia </e2>, and to produce distinct changes to dopamine turnover in the rodent brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5155": {"data": {"text": "Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.", "entity1": "dopamine", "entity2": "hypothermia", "span1": [169, 177], "span2": [121, 132]}, "bert_text": "Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to <e1> dopamine </e1> <e2> hypothermia </e2>, and to produce distinct changes to dopamine turnover in the rodent brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5156": {"data": {"text": "Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis, but evidence among humans is too inadequate to be definitive about such an effect.", "entity1": "nicotine", "entity2": "atherosclerosis", "span1": [53, 61], "span2": [96, 111]}, "bert_text": "Animal studies and mechanistic studies indicate that <e1> nicotine </e1> could play a role in accelerating <e2> atherosclerosis </e2>, but evidence among humans is too inadequate to be definitive about such an effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5157": {"data": {"text": "The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.", "entity1": "Renografin 76%", "entity2": "toxicity", "span1": [16, 30], "span2": [4, 12]}, "bert_text": "The toxicity of <e1> Renografin 76% </e1> <e2> toxicity </e2> of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5158": {"data": {"text": "The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.", "entity1": "Hypaque 76%", "entity2": "toxicity", "span1": [57, 68], "span2": [4, 12]}, "bert_text": "The toxicity of Renografin 76% was compared with that of <e1> Hypaque 76% </e1> <e2> toxicity </e2> of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5159": {"data": {"text": "Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.", "entity1": "CGRP", "entity2": "migraine", "span1": [6, 10], "span2": [125, 133]}, "bert_text": "Basal <e1> CGRP </e1> concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a <e2> migraine </e2> attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5160": {"data": {"text": "Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.", "entity1": "5-HT", "entity2": "migraine", "span1": [63, 67], "span2": [125, 133]}, "bert_text": "Basal CGRP concentration was significantly higher and platelet <e1> 5-HT </e1> content tended to be lower in subjects who experienced a <e2> migraine </e2> attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5161": {"data": {"text": "We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.", "entity1": "lipopolysaccharide", "entity2": "neurotoxicity", "span1": [49, 67], "span2": [169, 182]}, "bert_text": "We concluded a critical time window for systemic <e1> lipopolysaccharide </e1> pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5162": {"data": {"text": "We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.", "entity1": "methamphetamine", "entity2": "neurotoxicity", "span1": [122, 137], "span2": [169, 182]}, "bert_text": "We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against <e1> methamphetamine </e1>-induced nigrostriatal dopamine <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5163": {"data": {"text": "We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.", "entity1": "dopamine", "entity2": "neurotoxicity", "span1": [160, 168], "span2": [169, 182]}, "bert_text": "We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal <e1> dopamine </e1> <e2> neurotoxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5164": {"data": {"text": "Overall, in high-risk patients, warfarin is superior to aspirin in preventing strokes, with a relative risk reduction of 36%.", "entity1": "warfarin", "entity2": "strokes", "span1": [32, 40], "span2": [78, 85]}, "bert_text": "Overall, in high-risk patients, <e1> warfarin </e1> is superior to aspirin in preventing <e2> strokes </e2>, with a relative risk reduction of 36%.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5165": {"data": {"text": "Overall, in high-risk patients, warfarin is superior to aspirin in preventing strokes, with a relative risk reduction of 36%.", "entity1": "aspirin", "entity2": "strokes", "span1": [56, 63], "span2": [78, 85]}, "bert_text": "Overall, in high-risk patients, warfarin is superior to <e1> aspirin </e1> in preventing <e2> strokes </e2>, with a relative risk reduction of 36%.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5166": {"data": {"text": "A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.", "entity1": "cefonicid", "entity2": "anemia", "span1": [135, 144], "span2": [18, 24]}, "bert_text": "A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg <e1> cefonicid </e1> <e2> anemia </e2> was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5167": {"data": {"text": "A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.", "entity1": "cefonicid", "entity2": "cytopenias", "span1": [135, 144], "span2": [58, 68]}, "bert_text": "A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg <e1> cefonicid </e1> <e2> cytopenias </e2> and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5168": {"data": {"text": "A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.", "entity1": "cefazedone", "entity2": "anemia", "span1": [162, 172], "span2": [18, 24]}, "bert_text": "A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg <e1> cefazedone </e1> <e2> anemia </e2> was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5169": {"data": {"text": "A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.", "entity1": "cefazedone", "entity2": "cytopenias", "span1": [162, 172], "span2": [58, 68]}, "bert_text": "A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg <e1> cefazedone </e1> <e2> cytopenias </e2> and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5170": {"data": {"text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.", "entity1": "Allopregnanolone", "entity2": "seizures", "span1": [0, 16], "span2": [361, 369]}, "bert_text": "<e1> Allopregnanolone </e1> (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled <e2> seizures </e2> in male, Swiss-Webster mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5171": {"data": {"text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.", "entity1": "3alpha-hydroxy-5alpha-pregnan-20-one", "entity2": "seizures", "span1": [18, 54], "span2": [361, 369]}, "bert_text": "Allopregnanolone (<e1> 3alpha-hydroxy-5alpha-pregnan-20-one </e1>), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled <e2> seizures </e2> in male, Swiss-Webster mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5172": {"data": {"text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.", "entity1": "pregnanolone", "entity2": "seizures", "span1": [57, 69], "span2": [361, 369]}, "bert_text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), <e1> pregnanolone </e1> (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled <e2> seizures </e2> in male, Swiss-Webster mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5173": {"data": {"text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.", "entity1": "3alpha-hydroxy-5beta-pregnan-20-one", "entity2": "seizures", "span1": [71, 106], "span2": [361, 369]}, "bert_text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (<e1> 3alpha-hydroxy-5beta-pregnan-20-one </e1>) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled <e2> seizures </e2> in male, Swiss-Webster mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5174": {"data": {"text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.", "entity1": "ganaxolone", "entity2": "seizures", "span1": [112, 122], "span2": [361, 369]}, "bert_text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and <e1> ganaxolone </e1> (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled <e2> seizures </e2> in male, Swiss-Webster mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5175": {"data": {"text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.", "entity1": "allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one", "entity2": "seizures", "span1": [150, 216], "span2": [361, 369]}, "bert_text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of <e1> allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one </e1>) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled <e2> seizures </e2> in male, Swiss-Webster mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5176": {"data": {"text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.", "entity1": "cocaine", "entity2": "seizures", "span1": [345, 352], "span2": [361, 369]}, "bert_text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of <e1> cocaine </e1>-kindled <e2> seizures </e2> in male, Swiss-Webster mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5177": {"data": {"text": "Sixty-two patients with a heparin-induced thrombocytopenia are reported.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [26, 33], "span2": [42, 58]}, "bert_text": "Sixty-two patients with a <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5178": {"data": {"text": "PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.", "entity1": "testosterone", "entity2": "erectile dysfunction", "span1": [42, 54], "span2": [121, 141]}, "bert_text": "PURPOSE: We reviewed the results of serum <e1> testosterone </e1> and prolactin determination in 1,022 patients referred because of <e2> erectile dysfunction </e2> and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5179": {"data": {"text": "Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).", "entity1": "enalapril", "entity2": "decreased renal function", "span1": [133, 142], "span2": [59, 83]}, "bert_text": "Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the <e1> enalapril </e1> <e2> decreased renal function </e2> in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5180": {"data": {"text": "Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).", "entity1": "enalapril", "entity2": "decreased renal function", "span1": [150, 159], "span2": [59, 83]}, "bert_text": "Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (<e1> enalapril </e1> <e2> decreased renal function </e2> in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5181": {"data": {"text": "Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).", "entity1": "enalapril", "entity2": "decreased renal function", "span1": [240, 249], "span2": [59, 83]}, "bert_text": "Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with <e1> enalapril </e1> <e2> decreased renal function </e2> in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5182": {"data": {"text": "Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.\n", "entity1": "Lithium", "entity2": "cognitive and functional deficits", "span1": [0, 7], "span2": [19, 52]}, "bert_text": "<e1> Lithium </e1>-associated <e2> cognitive and functional deficits </e2> reduced by a switch to divalproex sodium: a case series.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5183": {"data": {"text": "Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.\n", "entity1": "divalproex sodium", "entity2": "cognitive and functional deficits", "span1": [76, 93], "span2": [19, 52]}, "bert_text": "Lithium-associated cognitive and functional deficits reduced by a switch to <e1> divalproex sodium </e1> <e2> cognitive and functional deficits </e2> reduced by a switch to divalproex sodium: a case series.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5184": {"data": {"text": "Atorva reversed dex-induced hypertension (129 +/-", "entity1": "Atorva", "entity2": "hypertension", "span1": [0, 6], "span2": [28, 40]}, "bert_text": "<e1> Atorva </e1> reversed dex-induced <e2> hypertension </e2> (129 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5185": {"data": {"text": "Atorva reversed dex-induced hypertension (129 +/-", "entity1": "dex", "entity2": "hypertension", "span1": [16, 19], "span2": [28, 40]}, "bert_text": "Atorva reversed <e1> dex </e1>-induced <e2> hypertension </e2> (129 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5186": {"data": {"text": "Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.", "entity1": "cresyl violet", "entity2": "neuronal degeneration", "span1": [47, 60], "span2": [71, 92]}, "bert_text": "Additional neuronanatomical studies, including <e1> cresyl violet </e1> staining, <e2> neuronal degeneration </e2> methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5187": {"data": {"text": "Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.", "entity1": "cresyl violet", "entity2": "neuronal loss", "span1": [47, 60], "span2": [257, 270]}, "bert_text": "Additional neuronanatomical studies, including <e1> cresyl violet </e1> staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to <e2> neuronal loss </e2> rather than to a decrease in GAD mRNA levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5188": {"data": {"text": "AZT produced anaemia in both groups, in a dose-dependent fashion.", "entity1": "AZT", "entity2": "anaemia", "span1": [0, 3], "span2": [13, 20]}, "bert_text": "<e1> AZT </e1> produced <e2> anaemia </e2> in both groups, in a dose-dependent fashion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5189": {"data": {"text": "Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.", "entity1": "heparin", "entity2": "hemorrhage", "span1": [125, 132], "span2": [49, 59]}, "bert_text": "Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving <e1> heparin </e1> <e2> hemorrhage </e2> or, more frequently, thromboembolic events in patients receiving heparin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5190": {"data": {"text": "Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.", "entity1": "heparin", "entity2": "thromboembolic", "span1": [125, 132], "span2": [81, 95]}, "bert_text": "Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving <e1> heparin </e1> <e2> thromboembolic </e2> events in patients receiving heparin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5191": {"data": {"text": "Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.", "entity1": "Rg1", "entity2": "learning impairment", "span1": [0, 3], "span2": [77, 96]}, "bert_text": "<e1> Rg1 </e1>, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial <e2> learning impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5192": {"data": {"text": "Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.", "entity1": "ginsenoside", "entity2": "learning impairment", "span1": [10, 21], "span2": [77, 96]}, "bert_text": "Rg1, as a <e1> ginsenoside </e1> extracted from Panax ginseng, could ameliorate spatial <e2> learning impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5193": {"data": {"text": "Visual hallucinations associated with zonisamide.\n", "entity1": "zonisamide", "entity2": "Visual hallucinations", "span1": [38, 48], "span2": [0, 21]}, "bert_text": "Visual hallucinations associated with <e1> zonisamide </e1> <e2> Visual hallucinations </e2> associated with zonisamide.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5194": {"data": {"text": "Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.\n", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [43, 52], "span2": [15, 26]}, "bert_text": "Development of proteinuria after switch to <e1> sirolimus </e1> <e2> proteinuria </e2> after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5195": {"data": {"text": "The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).", "entity1": "steroid", "entity2": "seizure", "span1": [88, 95], "span2": [288, 295]}, "bert_text": "The present study was designed to evaluate two endogenous and one synthetic neuroactive <e1> steroid </e1> that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (<e2> seizure </e2> kindling).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5196": {"data": {"text": "The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).", "entity1": "gamma-aminobutyric acid", "entity2": "seizure", "span1": [125, 148], "span2": [288, 295]}, "bert_text": "The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the <e1> gamma-aminobutyric acid </e1> (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (<e2> seizure </e2> kindling).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5197": {"data": {"text": "The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).", "entity1": "GABA(A", "entity2": "seizure", "span1": [150, 156], "span2": [288, 295]}, "bert_text": "The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (<e1> GABA(A </e1>)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (<e2> seizure </e2> kindling).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5198": {"data": {"text": "The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).", "entity1": "cocaine", "entity2": "seizure", "span1": [233, 240], "span2": [288, 295]}, "bert_text": "The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of <e1> cocaine </e1> engendered by repeated cocaine administration (<e2> seizure </e2> kindling).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5199": {"data": {"text": "The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).", "entity1": "cocaine", "entity2": "seizure", "span1": [264, 271], "span2": [288, 295]}, "bert_text": "The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated <e1> cocaine </e1> administration (<e2> seizure </e2> kindling).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5200": {"data": {"text": "A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.", "entity1": "nifedipine", "entity2": "neuromuscular blockade", "span1": [38, 48], "span2": [59, 81]}, "bert_text": "A patient who received tocolysis with <e1> nifedipine </e1> developed <e2> neuromuscular blockade </e2> after 500 mg of magnesium sulfate was administered.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5201": {"data": {"text": "A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.", "entity1": "magnesium sulfate", "entity2": "neuromuscular blockade", "span1": [98, 115], "span2": [59, 81]}, "bert_text": "A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of <e1> magnesium sulfate </e1> <e2> neuromuscular blockade </e2> after 500 mg of magnesium sulfate was administered.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5202": {"data": {"text": "Recommendations to avoid potential cranial nerve deficits from papaverine are provided.", "entity1": "papaverine", "entity2": "cranial nerve deficits", "span1": [63, 73], "span2": [35, 57]}, "bert_text": "Recommendations to avoid potential cranial nerve deficits from <e1> papaverine </e1> <e2> cranial nerve deficits </e2> from papaverine are provided.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5203": {"data": {"text": "Immediate allergic reactions to amoxicillin.\n", "entity1": "amoxicillin", "entity2": "allergic reactions", "span1": [32, 43], "span2": [10, 28]}, "bert_text": "Immediate allergic reactions to <e1> amoxicillin </e1> <e2> allergic reactions </e2> to amoxicillin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5204": {"data": {"text": "The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.", "entity1": "Clopidogrel", "entity2": "Atrial Fibrillation", "span1": [34, 45], "span2": [14, 33]}, "bert_text": "The ACTIVE-W (Atrial Fibrillation <e1> Clopidogrel </e1> <e2> Atrial Fibrillation </e2> Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5205": {"data": {"text": "The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.", "entity1": "clopidogrel", "entity2": "Atrial Fibrillation", "span1": [173, 184], "span2": [14, 33]}, "bert_text": "The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (<e1> clopidogrel </e1> <e2> Atrial Fibrillation </e2> Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5206": {"data": {"text": "The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.", "entity1": "Irbesartan", "entity2": "Atrial Fibrillation", "span1": [57, 67], "span2": [14, 33]}, "bert_text": "The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with <e1> Irbesartan </e1> <e2> Atrial Fibrillation </e2> Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5207": {"data": {"text": "The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.", "entity1": "warfarin", "entity2": "Atrial Fibrillation", "span1": [131, 139], "span2": [14, 33]}, "bert_text": "The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that <e1> warfarin </e1> <e2> Atrial Fibrillation </e2> Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5208": {"data": {"text": "The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.", "entity1": "aspirin", "entity2": "Atrial Fibrillation", "span1": [190, 197], "span2": [14, 33]}, "bert_text": "The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus <e1> aspirin </e1> <e2> Atrial Fibrillation </e2> Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5209": {"data": {"text": "In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis.", "entity1": "barbiturate", "entity2": "narcosis", "span1": [78, 89], "span2": [90, 98]}, "bert_text": "In particular, low doses reduced the latency to and prolonged the duration of <e1> barbiturate </e1> <e2> narcosis </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5210": {"data": {"text": "CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.", "entity1": "sulfasalazine", "entity2": "hepatotoxicity", "span1": [51, 64], "span2": [20, 34]}, "bert_text": "CONCLUSION: Serious hepatotoxicity associated with <e1> sulfasalazine </e1> <e2> hepatotoxicity </e2> associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5211": {"data": {"text": "Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following pilocarpine-induced seizures.\n", "entity1": "pilocarpine", "entity2": "seizures", "span1": [91, 102], "span2": [111, 119]}, "bert_text": "Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following <e1> pilocarpine </e1>-induced <e2> seizures </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5212": {"data": {"text": "After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.", "entity1": "Na", "entity2": "hypertension", "span1": [51, 53], "span2": [20, 32]}, "bert_text": "After recovery from hypertension, the activity of (<e1> Na </e1> <e2> hypertension </e2>, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5213": {"data": {"text": "After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.", "entity1": "K)-ATPase", "entity2": "hypertension", "span1": [54, 63], "span2": [20, 32]}, "bert_text": "After recovery from hypertension, the activity of (Na,<e1> K)-ATPase </e1> <e2> hypertension </e2>, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5214": {"data": {"text": "After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.", "entity1": "ATP", "entity2": "hypertension", "span1": [105, 108], "span2": [20, 32]}, "bert_text": "After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the <e1> ATP </e1> <e2> hypertension </e2>, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5215": {"data": {"text": "After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.", "entity1": "ATP", "entity2": "hypertension", "span1": [165, 168], "span2": [20, 32]}, "bert_text": "After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for <e1> ATP </e1> <e2> hypertension </e2>, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5216": {"data": {"text": "This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium.", "entity1": "nifedipine", "entity2": "toxicity", "span1": [32, 42], "span2": [72, 80]}, "bert_text": "This reaction demonstrates that <e1> nifedipine </e1> can seriously potentiate the <e2> toxicity </e2> of magnesium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5217": {"data": {"text": "This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium.", "entity1": "magnesium", "entity2": "toxicity", "span1": [84, 93], "span2": [72, 80]}, "bert_text": "This reaction demonstrates that nifedipine can seriously potentiate the toxicity of <e1> magnesium </e1> <e2> toxicity </e2> of magnesium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5218": {"data": {"text": "By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.", "entity1": "enalapril", "entity2": "diabetes", "span1": [50, 59], "span2": [100, 108]}, "bert_text": "By multivariate analysis, in both the placebo and <e1> enalapril </e1> groups older age, diuretic therapy, and <e2> diabetes </e2> were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5219": {"data": {"text": "By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.", "entity1": "enalapril", "entity2": "decreased renal function", "span1": [50, 59], "span2": [130, 154]}, "bert_text": "By multivariate analysis, in both the placebo and <e1> enalapril </e1> groups older age, diuretic therapy, and diabetes were associated with <e2> decreased renal function </e2>, whereas beta-blocker therapy and higher ejection fraction were renoprotective.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5220": {"data": {"text": "By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.", "entity1": "diuretic", "entity2": "diabetes", "span1": [78, 86], "span2": [100, 108]}, "bert_text": "By multivariate analysis, in both the placebo and enalapril groups older age, <e1> diuretic </e1> therapy, and <e2> diabetes </e2> were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5221": {"data": {"text": "By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.", "entity1": "diuretic", "entity2": "decreased renal function", "span1": [78, 86], "span2": [130, 154]}, "bert_text": "By multivariate analysis, in both the placebo and enalapril groups older age, <e1> diuretic </e1> therapy, and diabetes were associated with <e2> decreased renal function </e2>, whereas beta-blocker therapy and higher ejection fraction were renoprotective.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5222": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "GVG", "entity2": "substance abuse", "span1": [218, 221], "span2": [55, 70]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose <e1> GVG </e1> <e2> substance abuse </e2> and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"5223": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "GVG", "entity2": "visual field defects", "span1": [218, 221], "span2": [97, 117]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose <e1> GVG </e1> <e2> visual field defects </e2> (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, 0, -1, 0], "label": 1},
+	"5224": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "GVG", "entity2": "VFD", "span1": [218, 221], "span2": [119, 122]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose <e1> GVG </e1> <e2> VFD </e2>) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5225": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "cocaine", "entity2": "substance abuse", "span1": [225, 232], "span2": [55, 70]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on <e1> cocaine </e1> <e2> substance abuse </e2> and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"5226": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "cocaine", "entity2": "visual field defects", "span1": [225, 232], "span2": [97, 117]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on <e1> cocaine </e1> <e2> visual field defects </e2> (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, 0, -1, 0], "label": 0},
+	"5227": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "cocaine", "entity2": "VFD", "span1": [225, 232], "span2": [119, 122]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on <e1> cocaine </e1> <e2> VFD </e2>) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5228": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "dopamine", "entity2": "substance abuse", "span1": [279, 287], "span2": [55, 70]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) <e1> dopamine </e1> <e2> substance abuse </e2> and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"5229": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "dopamine", "entity2": "visual field defects", "span1": [279, 287], "span2": [97, 117]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) <e1> dopamine </e1> <e2> visual field defects </e2> (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 0, -1, 0], "label": 0},
+	"5230": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "dopamine", "entity2": "VFD", "span1": [279, 287], "span2": [119, 122]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) <e1> dopamine </e1> <e2> VFD </e2>) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5231": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "DA", "entity2": "substance abuse", "span1": [289, 291], "span2": [55, 70]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (<e1> DA </e1> <e2> substance abuse </e2> and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"5232": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "DA", "entity2": "visual field defects", "span1": [289, 291], "span2": [97, 117]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (<e1> DA </e1> <e2> visual field defects </e2> (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 0, -1, 0], "label": 0},
+	"5233": {"data": {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity1": "DA", "entity2": "VFD", "span1": [289, 291], "span2": [119, 122]}, "bert_text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (<e1> DA </e1> <e2> VFD </e2>) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5234": {"data": {"text": "Quinine-associated hemolytic-uremic syndrome probably occurs more often than is recognized.", "entity1": "Quinine", "entity2": "hemolytic-uremic syndrome", "span1": [0, 7], "span2": [19, 44]}, "bert_text": "<e1> Quinine </e1>-associated <e2> hemolytic-uremic syndrome </e2> probably occurs more often than is recognized.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5235": {"data": {"text": "Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.", "entity1": "diethylstilbestrol", "entity2": "clear cell adenocarcinoma of the vagina", "span1": [110, 128], "span2": [13, 52]}, "bert_text": "Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to <e1> diethylstilbestrol </e1> <e2> clear cell adenocarcinoma of the vagina </e2> detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5236": {"data": {"text": "However, acetaminophen has been demonstrated to produce symptoms of anaphylaxis, including hypotension, in sensitive individuals.", "entity1": "acetaminophen", "entity2": "anaphylaxis", "span1": [9, 22], "span2": [68, 79]}, "bert_text": "However, <e1> acetaminophen </e1> has been demonstrated to produce symptoms of <e2> anaphylaxis </e2>, including hypotension, in sensitive individuals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5237": {"data": {"text": "However, acetaminophen has been demonstrated to produce symptoms of anaphylaxis, including hypotension, in sensitive individuals.", "entity1": "acetaminophen", "entity2": "hypotension", "span1": [9, 22], "span2": [91, 102]}, "bert_text": "However, <e1> acetaminophen </e1> has been demonstrated to produce symptoms of anaphylaxis, including <e2> hypotension </e2>, in sensitive individuals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5238": {"data": {"text": "This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.", "entity1": "pergolide", "entity2": "valve regurgitation", "span1": [102, 111], "span2": [54, 73]}, "bert_text": "This study supports the high frequency of restrictive valve regurgitation in PD patients treated with <e1> pergolide </e1> <e2> valve regurgitation </e2> in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5239": {"data": {"text": "This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.", "entity1": "pergolide", "entity2": "PD", "span1": [102, 111], "span2": [77, 79]}, "bert_text": "This study supports the high frequency of restrictive valve regurgitation in PD patients treated with <e1> pergolide </e1> <e2> PD </e2> patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5240": {"data": {"text": "This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.", "entity1": "dopamine", "entity2": "valve regurgitation", "span1": [209, 217], "span2": [54, 73]}, "bert_text": "This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot <e1> dopamine </e1> <e2> valve regurgitation </e2> in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5241": {"data": {"text": "This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.", "entity1": "dopamine", "entity2": "PD", "span1": [209, 217], "span2": [77, 79]}, "bert_text": "This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot <e1> dopamine </e1> <e2> PD </e2> patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5242": {"data": {"text": "A large group of patients with suspected allergic reactions to beta-lactam antibiotics was evaluated.", "entity1": "beta-lactam", "entity2": "allergic reactions", "span1": [63, 74], "span2": [41, 59]}, "bert_text": "A large group of patients with suspected allergic reactions to <e1> beta-lactam </e1> <e2> allergic reactions </e2> to beta-lactam antibiotics was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5243": {"data": {"text": "The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.", "entity1": "sulfasalazine", "entity2": "hepatotoxicity", "span1": [52, 65], "span2": [32, 46]}, "bert_text": "The likely frequency of serious hepatotoxicity with <e1> sulfasalazine </e1> <e2> hepatotoxicity </e2> with sulfasalazine was estimated at 0.4% of treated patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5244": {"data": {"text": "Ketamine sedation for the reduction of children's fractures in the emergency department.\n", "entity1": "Ketamine", "entity2": "fractures", "span1": [0, 8], "span2": [50, 59]}, "bert_text": "<e1> Ketamine </e1> sedation for the reduction of children's <e2> fractures </e2> in the emergency department.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5245": {"data": {"text": "We report the case of a woman complaining of dysphonia while she was treated by acitretin.", "entity1": "acitretin", "entity2": "dysphonia", "span1": [80, 89], "span2": [45, 54]}, "bert_text": "We report the case of a woman complaining of dysphonia while she was treated by <e1> acitretin </e1> <e2> dysphonia </e2> while she was treated by acitretin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5246": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "A-86929", "entity2": "parkinsonism", "span1": [24, 31], "span2": [79, 91]}, "bert_text": "Acute administration of <e1> A-86929 </e1> was as efficacious in alleviating MPTP-induced <e2> parkinsonism </e2> as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5247": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "A-86929", "entity2": "dyskinesias", "span1": [24, 31], "span2": [173, 184]}, "bert_text": "Acute administration of <e1> A-86929 </e1> was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced <e2> dyskinesias </e2> in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5248": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "MPTP", "entity2": "parkinsonism", "span1": [66, 70], "span2": [79, 91]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating <e1> MPTP </e1>-induced <e2> parkinsonism </e2> as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5249": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "MPTP", "entity2": "dyskinesias", "span1": [66, 70], "span2": [173, 184]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating <e1> MPTP </e1>-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced <e2> dyskinesias </e2> in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5250": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "levodopa", "entity2": "parkinsonism", "span1": [95, 103], "span2": [79, 91]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as <e1> levodopa </e1> <e2> parkinsonism </e2> as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5251": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [95, 103], "span2": [173, 184]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as <e1> levodopa </e1> and LY-171555, but was less likely to reproduce the levodopa-induced <e2> dyskinesias </e2> in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5252": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "levodopa", "entity2": "parkinsonism", "span1": [156, 164], "span2": [79, 91]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the <e1> levodopa </e1> <e2> parkinsonism </e2> as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5253": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [156, 164], "span2": [173, 184]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the <e1> levodopa </e1>-induced <e2> dyskinesias </e2> in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5254": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "levodopa", "entity2": "parkinsonism", "span1": [256, 264], "span2": [79, 91]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of <e1> levodopa </e1> <e2> parkinsonism </e2> as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5255": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [256, 264], "span2": [173, 184]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of <e1> levodopa </e1> <e2> dyskinesias </e2> in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5256": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "LY-171555", "entity2": "parkinsonism", "span1": [108, 117], "span2": [79, 91]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and <e1> LY-171555 </e1> <e2> parkinsonism </e2> as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5257": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "LY-171555", "entity2": "dyskinesias", "span1": [108, 117], "span2": [173, 184]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and <e1> LY-171555 </e1>, but was less likely to reproduce the levodopa-induced <e2> dyskinesias </e2> in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5258": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "LY-171555", "entity2": "parkinsonism", "span1": [219, 228], "span2": [79, 91]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either <e1> LY-171555 </e1> <e2> parkinsonism </e2> as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5259": {"data": {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity1": "LY-171555", "entity2": "dyskinesias", "span1": [219, 228], "span2": [173, 184]}, "bert_text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either <e1> LY-171555 </e1> <e2> dyskinesias </e2> in these animals than with either LY-171555 or subsequent challenge of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5260": {"data": {"text": "No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [14, 25], "span2": [34, 43]}, "bert_text": "No changes in <e1> haloperidol </e1>-induced <e2> catalepsy </e2> or MK-801-induced locomotion were seen following PD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"5261": {"data": {"text": "No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.", "entity1": "MK-801-induced", "entity2": "catalepsy", "span1": [47, 61], "span2": [34, 43]}, "bert_text": "No changes in haloperidol-induced catalepsy or <e1> MK-801-induced </e1> <e2> catalepsy </e2> or MK-801-induced locomotion were seen following PD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5262": {"data": {"text": "Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.", "entity1": "L-dopa", "entity2": "coma", "span1": [58, 64], "span2": [108, 112]}, "bert_text": "Bilateral nephrectomy eliminated the beneficial effect of <e1> L-dopa </e1> on blood and brain ammonia and the ammonia <e2> coma </e2> was not prevented.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5263": {"data": {"text": "Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.", "entity1": "ammonia", "entity2": "coma", "span1": [84, 91], "span2": [108, 112]}, "bert_text": "Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain <e1> ammonia </e1> and the ammonia <e2> coma </e2> was not prevented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5264": {"data": {"text": "Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.", "entity1": "ammonia", "entity2": "coma", "span1": [100, 107], "span2": [108, 112]}, "bert_text": "Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the <e1> ammonia </e1> <e2> coma </e2> was not prevented.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5265": {"data": {"text": "Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.", "entity1": "Metoclopramide", "entity2": "torsade de pointes", "span1": [0, 14], "span2": [68, 86]}, "bert_text": "<e1> Metoclopramide </e1> should be used cautiously in patients with a risk of <e2> torsade de pointes </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5266": {"data": {"text": "In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.", "entity1": "lead", "entity2": "hypertension", "span1": [15, 19], "span2": [28, 40]}, "bert_text": "In conclusion, <e1> lead </e1>-induced <e2> hypertension </e2> in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5267": {"data": {"text": "Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [33, 42], "span2": [14, 27]}, "bert_text": "Prevention of breast cancer with <e1> tamoxifen </e1> <e2> breast cancer </e2> with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"5268": {"data": {"text": "Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.\n1.", "entity1": "atorvastatin", "entity2": "hypertension", "span1": [24, 36], "span2": [62, 74]}, "bert_text": "Anti-oxidant effects of <e1> atorvastatin </e1> in dexamethasone-induced <e2> hypertension </e2> in the rat.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5269": {"data": {"text": "Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.\n1.", "entity1": "dexamethasone", "entity2": "hypertension", "span1": [40, 53], "span2": [62, 74]}, "bert_text": "Anti-oxidant effects of atorvastatin in <e1> dexamethasone </e1>-induced <e2> hypertension </e2> in the rat.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5270": {"data": {"text": "In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).", "entity1": "clonidine", "entity2": "hypertensive", "span1": [56, 65], "span2": [38, 50]}, "bert_text": "In brain membranes from spontaneously hypertensive rats <e1> clonidine </e1> <e2> hypertensive </e2> rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5271": {"data": {"text": "In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).", "entity1": "clonidine", "entity2": "hypertensive", "span1": [206, 215], "span2": [38, 50]}, "bert_text": "In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence <e1> clonidine </e1> <e2> hypertensive </e2> rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5272": {"data": {"text": "In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).", "entity1": "[3H]-naloxone", "entity2": "hypertensive", "span1": [132, 145], "span2": [38, 50]}, "bert_text": "In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of <e1> [3H]-naloxone </e1> <e2> hypertensive </e2> rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5273": {"data": {"text": "In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).", "entity1": "naloxone", "entity2": "hypertensive", "span1": [158, 166], "span2": [38, 50]}, "bert_text": "In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and <e1> naloxone </e1> <e2> hypertensive </e2> rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5274": {"data": {"text": "Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "entity1": "Dexamethasone", "entity2": "hypertension", "span1": [0, 13], "span2": [28, 40]}, "bert_text": "<e1> Dexamethasone </e1> (Dex)-induced <e2> hypertension </e2> is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5275": {"data": {"text": "Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "entity1": "Dex)-induced", "entity2": "hypertension", "span1": [15, 27], "span2": [28, 40]}, "bert_text": "Dexamethasone (<e1> Dex)-induced </e1> <e2> hypertension </e2> is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5276": {"data": {"text": "Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "entity1": "nitric oxide", "entity2": "hypertension", "span1": [101, 113], "span2": [28, 40]}, "bert_text": "Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with <e1> nitric oxide </e1> <e2> hypertension </e2> is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5277": {"data": {"text": "Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "entity1": "NO", "entity2": "hypertension", "span1": [115, 117], "span2": [28, 40]}, "bert_text": "Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (<e1> NO </e1> <e2> hypertension </e2> is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5278": {"data": {"text": "Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "entity1": "superoxide", "entity2": "hypertension", "span1": [144, 154], "span2": [28, 40]}, "bert_text": "Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased <e1> superoxide </e1> <e2> hypertension </e2> is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5279": {"data": {"text": "Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "entity1": "O2-", "entity2": "hypertension", "span1": [156, 159], "span2": [28, 40]}, "bert_text": "Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (<e1> O2- </e1> <e2> hypertension </e2> is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5280": {"data": {"text": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "entity1": "venlafaxine", "entity2": "incontinence", "span1": [72, 83], "span2": [46, 58]}, "bert_text": "This concerns 2 male patients who experienced incontinence while taking <e1> venlafaxine </e1> <e2> incontinence </e2> while taking venlafaxine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5281": {"data": {"text": "Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).", "entity1": "morphine", "entity2": "rigidity", "span1": [30, 38], "span2": [152, 160]}, "bert_text": "Rats treated for 11 days with <e1> morphine </e1> and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a <e2> rigidity </e2> after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5282": {"data": {"text": "Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).", "entity1": "morphine", "entity2": "akinetic", "span1": [30, 38], "span2": [255, 263]}, "bert_text": "Rats treated for 11 days with <e1> morphine </e1> and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were <e2> akinetic </e2> (A group).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5283": {"data": {"text": "Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).", "entity1": "morphine", "entity2": "rigidity", "span1": [184, 192], "span2": [152, 160]}, "bert_text": "Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of <e1> morphine </e1> <e2> rigidity </e2> after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5284": {"data": {"text": "Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).", "entity1": "morphine", "entity2": "akinetic", "span1": [184, 192], "span2": [255, 263]}, "bert_text": "Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of <e1> morphine </e1> that was not significantly less than in the controls and were <e2> akinetic </e2> (A group).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5285": {"data": {"text": "The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic syndrome", "span1": [128, 153], "span2": [210, 228]}, "bert_text": "The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of <e1> puromycin aminonucleoside </e1> (20 mg/kg for 7 days) and the subsequent development of <e2> nephrotic syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5286": {"data": {"text": "There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.", "entity1": "Ca(2", "entity2": "AF", "span1": [54, 58], "span2": [89, 91]}, "bert_text": "There is also a clinical suggestion that acute L-type <e1> Ca(2 </e1>) channel blockade can promote <e2> AF </e2>, consistent with an AF promoting effect of Ca(2+) channel inhibition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5287": {"data": {"text": "There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.", "entity1": "Ca(2", "entity2": "AF", "span1": [54, 58], "span2": [112, 114]}, "bert_text": "There is also a clinical suggestion that acute L-type <e1> Ca(2 </e1>) channel blockade can promote AF, consistent with an <e2> AF </e2> promoting effect of Ca(2+) channel inhibition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5288": {"data": {"text": "There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.", "entity1": "Ca(2", "entity2": "AF", "span1": [135, 139], "span2": [89, 91]}, "bert_text": "There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of <e1> Ca(2 </e1> <e2> AF </e2>, consistent with an AF promoting effect of Ca(2+) channel inhibition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5289": {"data": {"text": "There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.", "entity1": "Ca(2", "entity2": "AF", "span1": [135, 139], "span2": [112, 114]}, "bert_text": "There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of <e1> Ca(2 </e1> <e2> AF </e2> promoting effect of Ca(2+) channel inhibition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5290": {"data": {"text": "Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.\n", "entity1": "misoprostol", "entity2": "renal dysfunction", "span1": [21, 32], "span2": [57, 74]}, "bert_text": "Protective effect of <e1> misoprostol </e1> on indomethacin induced <e2> renal dysfunction </e2> in elderly patients.\n", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5291": {"data": {"text": "Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.\n", "entity1": "indomethacin", "entity2": "renal dysfunction", "span1": [36, 48], "span2": [57, 74]}, "bert_text": "Protective effect of misoprostol on <e1> indomethacin </e1> induced <e2> renal dysfunction </e2> in elderly patients.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5292": {"data": {"text": "An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.", "entity1": "ciprofloxacin", "entity2": "acute renal failure", "span1": [133, 146], "span2": [155, 174]}, "bert_text": "An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of <e1> ciprofloxacin </e1>-induced <e2> acute renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5293": {"data": {"text": "The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.", "entity1": "ketamine", "entity2": "fractures", "span1": [75, 83], "span2": [128, 137]}, "bert_text": "The purpose of the present study was to examine the safety and efficacy of <e1> ketamine </e1> for sedation in the treatment of children's <e2> fractures </e2> in the emergency department.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5294": {"data": {"text": "Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.", "entity1": "dopamine", "entity2": "dyskinesias", "span1": [148, 156], "span2": [314, 325]}, "bert_text": "Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, <e1> dopamine </e1> receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5295": {"data": {"text": "Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [297, 305], "span2": [314, 325]}, "bert_text": "Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of <e1> levodopa </e1>-induced <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5296": {"data": {"text": "A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.", "entity1": "dopamine", "entity2": "dyskinetic", "span1": [68, 76], "span2": [135, 145]}, "bert_text": "A series of agents acting primarily on neurotransmitters other than <e1> dopamine </e1> were then tested in combination with L-DOPA to see if the <e2> dyskinetic </e2> movements would be modified.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5297": {"data": {"text": "A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.", "entity1": "L-DOPA", "entity2": "dyskinetic", "span1": [114, 120], "span2": [135, 145]}, "bert_text": "A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with <e1> L-DOPA </e1> to see if the <e2> dyskinetic </e2> movements would be modified.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5298": {"data": {"text": "Didanosine also has a potential for inducing seizures.", "entity1": "Didanosine", "entity2": "seizures", "span1": [0, 10], "span2": [45, 53]}, "bert_text": "<e1> Didanosine </e1> also has a potential for inducing <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5299": {"data": {"text": "Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.\n", "entity1": "ketamine", "entity2": "cancer", "span1": [32, 40], "span2": [44, 50]}, "bert_text": "Analgesic effect of intravenous <e1> ketamine </e1> in <e2> cancer </e2> patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5300": {"data": {"text": "Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.\n", "entity1": "morphine", "entity2": "cancer", "span1": [63, 71], "span2": [44, 50]}, "bert_text": "Analgesic effect of intravenous ketamine in cancer patients on <e1> morphine </e1> <e2> cancer </e2> patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5301": {"data": {"text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "entity1": "formalin", "entity2": "pain", "span1": [85, 93], "span2": [67, 71]}, "bert_text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of <e1> formalin </e1> <e2> pain </e2>: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5302": {"data": {"text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "entity1": "formalin", "entity2": "thermal hyperalgesia", "span1": [85, 93], "span2": [135, 155]}, "bert_text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of <e1> formalin </e1>-induced paw licking, carrageenan-induced <e2> thermal hyperalgesia </e2>, and capsaicin-induced mechanical hyperalgesia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5303": {"data": {"text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "entity1": "formalin", "entity2": "mechanical hyperalgesia", "span1": [85, 93], "span2": [179, 202]}, "bert_text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of <e1> formalin </e1>-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced <e2> mechanical hyperalgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5304": {"data": {"text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "entity1": "carrageenan", "entity2": "pain", "span1": [115, 126], "span2": [67, 71]}, "bert_text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, <e1> carrageenan </e1> <e2> pain </e2>: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5305": {"data": {"text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "entity1": "carrageenan", "entity2": "thermal hyperalgesia", "span1": [115, 126], "span2": [135, 155]}, "bert_text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, <e1> carrageenan </e1>-induced <e2> thermal hyperalgesia </e2>, and capsaicin-induced mechanical hyperalgesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5306": {"data": {"text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "entity1": "carrageenan", "entity2": "mechanical hyperalgesia", "span1": [115, 126], "span2": [179, 202]}, "bert_text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, <e1> carrageenan </e1>-induced thermal hyperalgesia, and capsaicin-induced <e2> mechanical hyperalgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5307": {"data": {"text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "entity1": "capsaicin", "entity2": "pain", "span1": [161, 170], "span2": [67, 71]}, "bert_text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and <e1> capsaicin </e1> <e2> pain </e2>: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5308": {"data": {"text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "entity1": "capsaicin", "entity2": "thermal hyperalgesia", "span1": [161, 170], "span2": [135, 155]}, "bert_text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and <e1> capsaicin </e1> <e2> thermal hyperalgesia </e2>, and capsaicin-induced mechanical hyperalgesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5309": {"data": {"text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "entity1": "capsaicin", "entity2": "mechanical hyperalgesia", "span1": [161, 170], "span2": [179, 202]}, "bert_text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and <e1> capsaicin </e1>-induced <e2> mechanical hyperalgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5310": {"data": {"text": "One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.", "entity1": "calcium carbon-ate", "entity2": "acute hypercalcaemia", "span1": [139, 157], "span2": [12, 32]}, "bert_text": "One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of <e1> calcium carbon-ate </e1> <e2> acute hypercalcaemia </e2> and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5311": {"data": {"text": "One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.", "entity1": "calcium carbon-ate", "entity2": "nephrolithiasis", "span1": [139, 157], "span2": [54, 69]}, "bert_text": "One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of <e1> calcium carbon-ate </e1> <e2> nephrolithiasis </e2> are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5312": {"data": {"text": "One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.", "entity1": "sodium bicarbonate", "entity2": "acute hypercalcaemia", "span1": [158, 176], "span2": [12, 32]}, "bert_text": "One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-<e1> sodium bicarbonate </e1> <e2> acute hypercalcaemia </e2> and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5313": {"data": {"text": "One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.", "entity1": "sodium bicarbonate", "entity2": "nephrolithiasis", "span1": [158, 176], "span2": [54, 69]}, "bert_text": "One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-<e1> sodium bicarbonate </e1> <e2> nephrolithiasis </e2> are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5314": {"data": {"text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "entity1": "adenosine", "entity2": "pain", "span1": [214, 223], "span2": [377, 381]}, "bert_text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal <e1> adenosine </e1> doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and <e2> pain </e2> ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5315": {"data": {"text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "entity1": "adenosine", "entity2": "mechanical hyperalgesia", "span1": [214, 223], "span2": [437, 460]}, "bert_text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal <e1> adenosine </e1> doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of <e2> mechanical hyperalgesia </e2> and allodynia after intradermal capsaicin injection were determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5316": {"data": {"text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "entity1": "adenosine", "entity2": "allodynia", "span1": [214, 223], "span2": [465, 474]}, "bert_text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal <e1> adenosine </e1> doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and <e2> allodynia </e2> after intradermal capsaicin injection were determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5317": {"data": {"text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "entity1": "adenosine", "entity2": "pain", "span1": [293, 302], "span2": [377, 381]}, "bert_text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of <e1> adenosine </e1>, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and <e2> pain </e2> ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5318": {"data": {"text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "entity1": "adenosine", "entity2": "mechanical hyperalgesia", "span1": [293, 302], "span2": [437, 460]}, "bert_text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of <e1> adenosine </e1>, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of <e2> mechanical hyperalgesia </e2> and allodynia after intradermal capsaicin injection were determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5319": {"data": {"text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "entity1": "adenosine", "entity2": "allodynia", "span1": [293, 302], "span2": [465, 474]}, "bert_text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of <e1> adenosine </e1>, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and <e2> allodynia </e2> after intradermal capsaicin injection were determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5320": {"data": {"text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "entity1": "capsaicin", "entity2": "pain", "span1": [493, 502], "span2": [377, 381]}, "bert_text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal <e1> capsaicin </e1> <e2> pain </e2> ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5321": {"data": {"text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "entity1": "capsaicin", "entity2": "mechanical hyperalgesia", "span1": [493, 502], "span2": [437, 460]}, "bert_text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal <e1> capsaicin </e1> <e2> mechanical hyperalgesia </e2> and allodynia after intradermal capsaicin injection were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5322": {"data": {"text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "entity1": "capsaicin", "entity2": "allodynia", "span1": [493, 502], "span2": [465, 474]}, "bert_text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal <e1> capsaicin </e1> <e2> allodynia </e2> after intradermal capsaicin injection were determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5323": {"data": {"text": "The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).", "entity1": "levodopa", "entity2": "parkinsonian", "span1": [186, 194], "span2": [157, 169]}, "bert_text": "The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and <e1> levodopa </e1> <e2> parkinsonian </e2> 'off' signs and levodopa-induced dyskinesias (LID).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5324": {"data": {"text": "The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [186, 194], "span2": [203, 214]}, "bert_text": "The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and <e1> levodopa </e1>-induced <e2> dyskinesias </e2> (LID).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5325": {"data": {"text": "The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).", "entity1": "levodopa", "entity2": "LID", "span1": [186, 194], "span2": [216, 219]}, "bert_text": "The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and <e1> levodopa </e1>-induced dyskinesias (<e2> LID </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5326": {"data": {"text": "Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.", "entity1": "Simvastatinezetimibe", "entity2": "depression", "span1": [0, 20], "span2": [64, 74]}, "bert_text": "<e1> Simvastatinezetimibe </e1> and escitalopram (which she was taking for <e2> depression </e2>) were discontinued, and other potential causes of hepatotoxicity were excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5327": {"data": {"text": "Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.", "entity1": "Simvastatinezetimibe", "entity2": "hepatotoxicity", "span1": [0, 20], "span2": [125, 139]}, "bert_text": "<e1> Simvastatinezetimibe </e1> and escitalopram (which she was taking for depression) were discontinued, and other potential causes of <e2> hepatotoxicity </e2> were excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5328": {"data": {"text": "Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.", "entity1": "escitalopram", "entity2": "depression", "span1": [25, 37], "span2": [64, 74]}, "bert_text": "Simvastatinezetimibe and <e1> escitalopram </e1> (which she was taking for <e2> depression </e2>) were discontinued, and other potential causes of hepatotoxicity were excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5329": {"data": {"text": "Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.", "entity1": "escitalopram", "entity2": "hepatotoxicity", "span1": [25, 37], "span2": [125, 139]}, "bert_text": "Simvastatinezetimibe and <e1> escitalopram </e1> (which she was taking for depression) were discontinued, and other potential causes of <e2> hepatotoxicity </e2> were excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5330": {"data": {"text": "However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.", "entity1": "5-HT", "entity2": "catalepsy", "span1": [36, 40], "span2": [97, 106]}, "bert_text": "However, inhibition of postsynaptic <e1> 5-HT </e1> receptors neither inhibited nor potentiated reversal of <e2> catalepsy </e2> and leaves open the question as to the site or mechanism for this effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5331": {"data": {"text": "A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.", "entity1": "nelarabine", "entity2": "T-cell leukaemia or lymphoma", "span1": [24, 34], "span2": [212, 240]}, "bert_text": "A combination of 5 d of <e1> nelarabine </e1> (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T-cell leukaemia or lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5332": {"data": {"text": "A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.", "entity1": "AraG", "entity2": "T-cell leukaemia or lymphoma", "span1": [36, 40], "span2": [212, 240]}, "bert_text": "A combination of 5 d of nelarabine (<e1> AraG </e1>) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T-cell leukaemia or lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5333": {"data": {"text": "A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.", "entity1": "etoposide", "entity2": "T-cell leukaemia or lymphoma", "span1": [54, 63], "span2": [212, 240]}, "bert_text": "A combination of 5 d of nelarabine (AraG) with 5 d of <e1> etoposide </e1> (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T-cell leukaemia or lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5334": {"data": {"text": "A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.", "entity1": "VP", "entity2": "T-cell leukaemia or lymphoma", "span1": [65, 67], "span2": [212, 240]}, "bert_text": "A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (<e1> VP </e1>) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T-cell leukaemia or lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5335": {"data": {"text": "A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.", "entity1": "cyclophosphamide", "entity2": "T-cell leukaemia or lymphoma", "span1": [73, 89], "span2": [212, 240]}, "bert_text": "A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and <e1> cyclophosphamide </e1> (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T-cell leukaemia or lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5336": {"data": {"text": "A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.", "entity1": "CPM", "entity2": "T-cell leukaemia or lymphoma", "span1": [91, 94], "span2": [212, 240]}, "bert_text": "A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (<e1> CPM </e1>) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed <e2> T-cell leukaemia or lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5337": {"data": {"text": "Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.", "entity1": "cyclosporine", "entity2": "toxicity", "span1": [35, 47], "span2": [61, 69]}, "bert_text": "Other causes include drug-related (<e1> cyclosporine </e1>, tacrolimus) <e2> toxicity </e2>, procoagulant status, and antibody-mediated rejection.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5338": {"data": {"text": "Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.", "entity1": "tacrolimus", "entity2": "toxicity", "span1": [49, 59], "span2": [61, 69]}, "bert_text": "Other causes include drug-related (cyclosporine, <e1> tacrolimus </e1>) <e2> toxicity </e2>, procoagulant status, and antibody-mediated rejection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5339": {"data": {"text": "Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.\n", "entity1": "adriamycin", "entity2": "Cardiotoxic", "span1": [49, 59], "span2": [0, 11]}, "bert_text": "Cardiotoxic and possible leukemogenic effects of <e1> adriamycin </e1> <e2> Cardiotoxic </e2> and possible leukemogenic effects of adriamycin in nonhuman primates.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5340": {"data": {"text": "This is, in part, due to ROS-mediated NO inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with hypertension.", "entity1": "lead", "entity2": "hypertension", "span1": [55, 59], "span2": [173, 185]}, "bert_text": "This is, in part, due to ROS-mediated NO inactivation, <e1> lead </e1>-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5341": {"data": {"text": "Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.\n", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [85, 95], "span2": [106, 117]}, "bert_text": "Differential impact of immune escape mutations G145R and P120T on the replication of <e1> lamivudine </e1>-resistant <e2> hepatitis B </e2> virus e antigen-positive and -negative strains.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5342": {"data": {"text": "METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).", "entity1": "timolol", "entity2": "open-angle glaucoma", "span1": [271, 278], "span2": [53, 72]}, "bert_text": "METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), <e1> timolol </e1> <e2> open-angle glaucoma </e2> or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5343": {"data": {"text": "METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).", "entity1": "timolol", "entity2": "ocular hypertension", "span1": [271, 278], "span2": [76, 95]}, "bert_text": "METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), <e1> timolol </e1> <e2> ocular hypertension </e2> with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5344": {"data": {"text": "METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).", "entity1": "timolol", "entity2": "open-angle glaucoma", "span1": [327, 334], "span2": [53, 72]}, "bert_text": "METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or <e1> timolol </e1> <e2> open-angle glaucoma </e2> or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5345": {"data": {"text": "METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).", "entity1": "timolol", "entity2": "ocular hypertension", "span1": [327, 334], "span2": [76, 95]}, "bert_text": "METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or <e1> timolol </e1> <e2> ocular hypertension </e2> with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5346": {"data": {"text": "Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.", "entity1": "Atorvastatin", "entity2": "hypertension", "span1": [0, 12], "span2": [192, 204]}, "bert_text": "<e1> Atorvastatin </e1> (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5347": {"data": {"text": "Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.", "entity1": "Ato", "entity2": "hypertension", "span1": [14, 17], "span2": [192, 204]}, "bert_text": "Atorvastatin (<e1> Ato </e1>) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5348": {"data": {"text": "Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.", "entity1": "NO", "entity2": "hypertension", "span1": [142, 144], "span2": [192, 204]}, "bert_text": "Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of <e1> NO </e1> and reduced O2- production in various forms of <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5349": {"data": {"text": "Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.", "entity1": "O2-", "entity2": "hypertension", "span1": [157, 160], "span2": [192, 204]}, "bert_text": "Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced <e1> O2- </e1> production in various forms of <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5350": {"data": {"text": "Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?\n", "entity1": "nitroglycerin", "entity2": "hypotension", "span1": [39, 52], "span2": [24, 35]}, "bert_text": "Provocation of postural hypotension by <e1> nitroglycerin </e1> <e2> hypotension </e2> by nitroglycerin in diabetic autonomic neuropathy?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5351": {"data": {"text": "Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?\n", "entity1": "nitroglycerin", "entity2": "diabetic autonomic neuropathy", "span1": [39, 52], "span2": [56, 85]}, "bert_text": "Provocation of postural hypotension by <e1> nitroglycerin </e1> in <e2> diabetic autonomic neuropathy </e2>?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5352": {"data": {"text": "From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.", "entity1": "HBs Ag", "entity2": "rheumatologic diseases", "span1": [35, 41], "span2": [65, 87]}, "bert_text": "From June 2004 to October 2006, 11 <e1> HBs Ag </e1> positive patients with <e2> rheumatologic diseases </e2>, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5353": {"data": {"text": "From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.", "entity1": "lamivudine", "entity2": "rheumatologic diseases", "span1": [141, 151], "span2": [65, 87]}, "bert_text": "From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic <e1> lamivudine </e1> <e2> rheumatologic diseases </e2>, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5354": {"data": {"text": "Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.\n", "entity1": "verapamil", "entity2": "atrioventricular reentrant tachycardia", "span1": [80, 89], "span2": [35, 73]}, "bert_text": "Iatrogenically induced intractable atrioventricular reentrant tachycardia after <e1> verapamil </e1> <e2> atrioventricular reentrant tachycardia </e2> after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5355": {"data": {"text": "Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.\n", "entity1": "verapamil", "entity2": "Wolff-Parkinson-White syndrome", "span1": [80, 89], "span2": [130, 160]}, "bert_text": "Iatrogenically induced intractable atrioventricular reentrant tachycardia after <e1> verapamil </e1> and catheter ablation in a patient with <e2> Wolff-Parkinson-White syndrome </e2> and idiopathic dilated cardiomyopathy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5356": {"data": {"text": "Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.\n", "entity1": "verapamil", "entity2": "idiopathic dilated cardiomyopathy", "span1": [80, 89], "span2": [165, 198]}, "bert_text": "Iatrogenically induced intractable atrioventricular reentrant tachycardia after <e1> verapamil </e1> and catheter ablation in a patient with Wolff-Parkinson-White syndrome and <e2> idiopathic dilated cardiomyopathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5357": {"data": {"text": "Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.", "entity1": "alpha-methyldopa", "entity2": "hypotensive", "span1": [55, 71], "span2": [31, 42]}, "bert_text": "Ovx significantly enhanced the hypotensive response to <e1> alpha-methyldopa </e1> <e2> hypotensive </e2> response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5358": {"data": {"text": "Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.", "entity1": "alpha-methyldopa", "entity2": "hypotension", "span1": [55, 71], "span2": [113, 124]}, "bert_text": "Ovx significantly enhanced the hypotensive response to <e1> alpha-methyldopa </e1>, in contrast to no effect on rilmenidine <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"5359": {"data": {"text": "Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.", "entity1": "rilmenidine", "entity2": "hypotensive", "span1": [101, 112], "span2": [31, 42]}, "bert_text": "Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on <e1> rilmenidine </e1> <e2> hypotensive </e2> response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5360": {"data": {"text": "Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.", "entity1": "rilmenidine", "entity2": "hypotension", "span1": [101, 112], "span2": [113, 124]}, "bert_text": "Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on <e1> rilmenidine </e1> <e2> hypotension </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"5361": {"data": {"text": "In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.", "entity1": "fat", "entity2": "obesity", "span1": [95, 98], "span2": [125, 132]}, "bert_text": "In the current study, we investigated whether a physiological intervention by feeding 40% high <e1> fat </e1> diet (HFD), which induces <e2> obesity </e2> in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5362": {"data": {"text": "In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.", "entity1": "fat", "entity2": "cardiotoxicity", "span1": [95, 98], "span2": [208, 222]}, "bert_text": "In the current study, we investigated whether a physiological intervention by feeding 40% high <e1> fat </e1> diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5363": {"data": {"text": "In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.", "entity1": "doxorubicin", "entity2": "obesity", "span1": [188, 199], "span2": [125, 132]}, "bert_text": "In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to <e1> doxorubicin </e1> <e2> obesity </e2> in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5364": {"data": {"text": "In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [188, 199], "span2": [208, 222]}, "bert_text": "In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5365": {"data": {"text": "The morbidity and mortality associated with heparin-induced thrombosis remain high despite numerous empirical therapies.", "entity1": "heparin", "entity2": "thrombosis", "span1": [44, 51], "span2": [60, 70]}, "bert_text": "The morbidity and mortality associated with <e1> heparin </e1>-induced <e2> thrombosis </e2> remain high despite numerous empirical therapies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5366": {"data": {"text": "Prostaglandin F2 alpha had little effect on pain responses.", "entity1": "Prostaglandin F2 alpha", "entity2": "pain", "span1": [0, 22], "span2": [44, 48]}, "bert_text": "<e1> Prostaglandin F2 alpha </e1> had little effect on <e2> pain </e2> responses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5367": {"data": {"text": "Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.", "entity1": "alkylating agents", "entity2": "acute nonlymphocytic leukemia", "span1": [22, 39], "span2": [81, 110]}, "bert_text": "Patients treated with <e1> alkylating agents </e1> have an increased risk of development of <e2> acute nonlymphocytic leukemia </e2>, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5368": {"data": {"text": "Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.", "entity1": "alkylating agents", "entity2": "non-Hodgkin's lymphoma", "span1": [22, 39], "span2": [195, 217]}, "bert_text": "Patients treated with <e1> alkylating agents </e1> have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of <e2> non-Hodgkin's lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5369": {"data": {"text": "Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.", "entity1": "alkylating agents", "entity2": "acute nonlymphocytic leukemia", "span1": [121, 138], "span2": [81, 110]}, "bert_text": "Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both <e1> alkylating agents </e1> <e2> acute nonlymphocytic leukemia </e2>, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5370": {"data": {"text": "Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.", "entity1": "alkylating agents", "entity2": "non-Hodgkin's lymphoma", "span1": [121, 138], "span2": [195, 217]}, "bert_text": "Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both <e1> alkylating agents </e1> and azathioprine are associated with the development of <e2> non-Hodgkin's lymphoma </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5371": {"data": {"text": "Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.", "entity1": "azathioprine", "entity2": "acute nonlymphocytic leukemia", "span1": [143, 155], "span2": [81, 110]}, "bert_text": "Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and <e1> azathioprine </e1> <e2> acute nonlymphocytic leukemia </e2>, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5372": {"data": {"text": "Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.", "entity1": "azathioprine", "entity2": "non-Hodgkin's lymphoma", "span1": [143, 155], "span2": [195, 217]}, "bert_text": "Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and <e1> azathioprine </e1> are associated with the development of <e2> non-Hodgkin's lymphoma </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5373": {"data": {"text": "Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.\n", "entity1": "valdecoxib", "entity2": "thrombotic", "span1": [51, 61], "span2": [136, 146]}, "bert_text": "Effects of the cyclooxygenase-2 specific inhibitor <e1> valdecoxib </e1> versus nonsteroidal antiinflammatory agents and placebo on cardiovascular <e2> thrombotic </e2> events in patients with arthritis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5374": {"data": {"text": "Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.\n", "entity1": "valdecoxib", "entity2": "arthritis", "span1": [51, 61], "span2": [171, 180]}, "bert_text": "Effects of the cyclooxygenase-2 specific inhibitor <e1> valdecoxib </e1> versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with <e2> arthritis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5375": {"data": {"text": "In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.", "entity1": "fatty acids", "entity2": "nephrotic", "span1": [43, 54], "span2": [7, 16]}, "bert_text": "In pre-nephrotic stage the plasma level of <e1> fatty acids </e1> <e2> nephrotic </e2> stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5376": {"data": {"text": "In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.", "entity1": "triacylglycerol", "entity2": "nephrotic", "span1": [56, 71], "span2": [7, 16]}, "bert_text": "In pre-nephrotic stage the plasma level of fatty acids, <e1> triacylglycerol </e1> <e2> nephrotic </e2> stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5377": {"data": {"text": "In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.", "entity1": "cholesteryl esters", "entity2": "nephrotic", "span1": [119, 137], "span2": [7, 16]}, "bert_text": "In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, <e1> cholesteryl esters </e1> <e2> nephrotic </e2> stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5378": {"data": {"text": "The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.", "entity1": "lamivudine", "entity2": "rheumatologic disease", "span1": [124, 134], "span2": [204, 225]}, "bert_text": "The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of <e1> lamivudine </e1> in hepatitis B virus surface antigen (HBs Ag) positive patients with <e2> rheumatologic disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5379": {"data": {"text": "The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.", "entity1": "hepatitis B virus surface antigen", "entity2": "rheumatologic disease", "span1": [138, 171], "span2": [204, 225]}, "bert_text": "The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in <e1> hepatitis B virus surface antigen </e1> (HBs Ag) positive patients with <e2> rheumatologic disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5380": {"data": {"text": "The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.", "entity1": "HBs Ag", "entity2": "rheumatologic disease", "span1": [173, 179], "span2": [204, 225]}, "bert_text": "The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (<e1> HBs Ag </e1>) positive patients with <e2> rheumatologic disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5381": {"data": {"text": "Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.", "entity1": "magnesium", "entity2": "hypokalemia", "span1": [131, 140], "span2": [12, 23]}, "bert_text": "Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of <e1> magnesium </e1> <e2> hypokalemia </e2> has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5382": {"data": {"text": "Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.", "entity1": "magnesium", "entity2": "hypocalcemia", "span1": [131, 140], "span2": [81, 93]}, "bert_text": "Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of <e1> magnesium </e1> <e2> hypocalcemia </e2> was observed (8), but the effects of magnesium depletion were not noted in these patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5383": {"data": {"text": "These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.", "entity1": "green tea", "entity2": "myocardial infarction", "span1": [61, 70], "span2": [104, 125]}, "bert_text": "These findings indicate the synergistic protective effect of <e1> green tea </e1> and vitamin E during ISO induced <e2> myocardial infarction </e2> in rats.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5384": {"data": {"text": "These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.", "entity1": "vitamin E", "entity2": "myocardial infarction", "span1": [75, 84], "span2": [104, 125]}, "bert_text": "These findings indicate the synergistic protective effect of green tea and <e1> vitamin E </e1> during ISO induced <e2> myocardial infarction </e2> in rats.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5385": {"data": {"text": "These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.", "entity1": "ISO", "entity2": "myocardial infarction", "span1": [92, 95], "span2": [104, 125]}, "bert_text": "These findings indicate the synergistic protective effect of green tea and vitamin E during <e1> ISO </e1> induced <e2> myocardial infarction </e2> in rats.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5386": {"data": {"text": "Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).", "entity1": "Raloxifene", "entity2": "cataracts", "span1": [0, 10], "span2": [37, 46]}, "bert_text": "<e1> Raloxifene </e1> did not increase risk for <e2> cataracts </e2> (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"5387": {"data": {"text": "Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).", "entity1": "Raloxifene", "entity2": "gallbladder disease", "span1": [0, 10], "span2": [73, 92]}, "bert_text": "<e1> Raloxifene </e1> did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), <e2> gallbladder disease </e2> (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5388": {"data": {"text": "Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).", "entity1": "Raloxifene", "entity2": "endometrial hyperplasia", "span1": [0, 10], "span2": [119, 142]}, "bert_text": "<e1> Raloxifene </e1> did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), <e2> endometrial hyperplasia </e2> (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5389": {"data": {"text": "Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).", "entity1": "Raloxifene", "entity2": "endometrial cancer", "span1": [0, 10], "span2": [172, 190]}, "bert_text": "<e1> Raloxifene </e1> did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or <e2> endometrial cancer </e2> (RR 0.9; 95% CI 0.3-2.7).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5390": {"data": {"text": "Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.\n", "entity1": "sodium", "entity2": "nephrotic syndrome", "span1": [11, 17], "span2": [116, 134]}, "bert_text": "Epithelial <e1> sodium </e1> channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced <e2> nephrotic syndrome </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5391": {"data": {"text": "Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.\n", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic syndrome", "span1": [82, 107], "span2": [116, 134]}, "bert_text": "Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with <e1> puromycin aminonucleoside </e1>-induced <e2> nephrotic syndrome </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5392": {"data": {"text": "The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.", "entity1": "alpha-methyldopa", "entity2": "hypotension", "span1": [13, 29], "span2": [30, 41]}, "bert_text": "The enhanced <e1> alpha-methyldopa </e1> <e2> hypotension </e2> in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5393": {"data": {"text": "During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.", "entity1": "octreotide", "entity2": "gallstones", "span1": [22, 32], "span2": [71, 81]}, "bert_text": "During treatment with <e1> octreotide </e1>, 17 patients developed sludge, 10 had <e2> gallstones </e2>, and 1 developed acute cholecystitis requiring surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5394": {"data": {"text": "During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.", "entity1": "octreotide", "entity2": "acute cholecystitis", "span1": [22, 32], "span2": [99, 118]}, "bert_text": "During treatment with <e1> octreotide </e1>, 17 patients developed sludge, 10 had gallstones, and 1 developed <e2> acute cholecystitis </e2> requiring surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5395": {"data": {"text": "This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.", "entity1": "valproate", "entity2": "language delay", "span1": [222, 231], "span2": [42, 56]}, "bert_text": "This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of <e1> valproate </e1> <e2> language delay </e2> and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5396": {"data": {"text": "This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.", "entity1": "valproate", "entity2": "mental retardation", "span1": [222, 231], "span2": [61, 79]}, "bert_text": "This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of <e1> valproate </e1> <e2> mental retardation </e2>, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5397": {"data": {"text": "This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.", "entity1": "valproate", "entity2": "nonketotic hyperglycinemia", "span1": [222, 231], "span2": [103, 129]}, "bert_text": "This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of <e1> valproate </e1> <e2> nonketotic hyperglycinemia </e2> following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5398": {"data": {"text": "This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.", "entity1": "valproate", "entity2": "encephalopathy", "span1": [222, 231], "span2": [168, 182]}, "bert_text": "This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of <e1> valproate </e1> <e2> encephalopathy </e2> and chorea shortly after initiation of valproate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5399": {"data": {"text": "This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.", "entity1": "valproate", "entity2": "chorea", "span1": [222, 231], "span2": [187, 193]}, "bert_text": "This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of <e1> valproate </e1> <e2> chorea </e2> shortly after initiation of valproate therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5400": {"data": {"text": "Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.", "entity1": "ketamine", "entity2": "cataleptic", "span1": [19, 27], "span2": [169, 179]}, "bert_text": "Pre-treatment with <e1> ketamine </e1> produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the <e2> cataleptic </e2> response; this augmentation was attributed to residual morphine in the brain.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5401": {"data": {"text": "Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.", "entity1": "ketamine", "entity2": "cataleptic", "span1": [135, 143], "span2": [169, 179]}, "bert_text": "Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to <e1> ketamine </e1> but rather augmented the <e2> cataleptic </e2> response; this augmentation was attributed to residual morphine in the brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5402": {"data": {"text": "Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.", "entity1": "morphine", "entity2": "cataleptic", "span1": [56, 64], "span2": [169, 179]}, "bert_text": "Pre-treatment with ketamine produced cross-tolerance to <e1> morphine </e1>, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the <e2> cataleptic </e2> response; this augmentation was attributed to residual morphine in the brain.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5403": {"data": {"text": "Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.", "entity1": "morphine", "entity2": "cataleptic", "span1": [92, 100], "span2": [169, 179]}, "bert_text": "Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with <e1> morphine </e1> did not induce cross-tolerance to ketamine but rather augmented the <e2> cataleptic </e2> response; this augmentation was attributed to residual morphine in the brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5404": {"data": {"text": "Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.", "entity1": "morphine", "entity2": "cataleptic", "span1": [235, 243], "span2": [169, 179]}, "bert_text": "Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual <e1> morphine </e1> <e2> cataleptic </e2> response; this augmentation was attributed to residual morphine in the brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5405": {"data": {"text": "Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.\n", "entity1": "propafenone", "entity2": "overdose", "span1": [57, 68], "span2": [69, 77]}, "bert_text": "Transient platypnea-orthodeoxia-like syndrome induced by <e1> propafenone </e1> <e2> overdose </e2> in a young woman with Ebstein's anomaly.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5406": {"data": {"text": "Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.\n", "entity1": "propafenone", "entity2": "Ebstein's anomaly", "span1": [57, 68], "span2": [100, 117]}, "bert_text": "Transient platypnea-orthodeoxia-like syndrome induced by <e1> propafenone </e1> overdose in a young woman with <e2> Ebstein's anomaly </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5407": {"data": {"text": "Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.", "entity1": "Testosterone", "entity2": "renal injury", "span1": [0, 12], "span2": [60, 72]}, "bert_text": "<e1> Testosterone </e1> replacement in castrated DS rats increased BP, <e2> renal injury </e2>, and upregulation of renal angiotensinogen associated with HS diet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5408": {"data": {"text": "Failure of ancrod in the treatment of heparin-induced arterial thrombosis.\n", "entity1": "heparin", "entity2": "thrombosis", "span1": [38, 45], "span2": [63, 73]}, "bert_text": "Failure of ancrod in the treatment of <e1> heparin </e1>-induced arterial <e2> thrombosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5409": {"data": {"text": "In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.", "entity1": "daunorubicin", "entity2": "Kaposi's sarcoma", "span1": [40, 52], "span2": [115, 131]}, "bert_text": "In this small patient sample, liposomal <e1> daunorubicin </e1> was an effective and well tolerated agent in the treatment of <e2> Kaposi's sarcoma </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5410": {"data": {"text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "entity1": "cocaine", "entity2": "agitation", "span1": [80, 87], "span2": [182, 191]}, "bert_text": "The epidemiologic findings are most consistent with the hypothesis that chronic <e1> cocaine </e1> use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate <e2> agitation </e2>, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5411": {"data": {"text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "entity1": "cocaine", "entity2": "delirium", "span1": [80, 87], "span2": [193, 201]}, "bert_text": "The epidemiologic findings are most consistent with the hypothesis that chronic <e1> cocaine </e1> use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, <e2> delirium </e2>, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5412": {"data": {"text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "entity1": "cocaine", "entity2": "rhabdomyolysis", "span1": [80, 87], "span2": [230, 244]}, "bert_text": "The epidemiologic findings are most consistent with the hypothesis that chronic <e1> cocaine </e1> use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, <e2> rhabdomyolysis </e2>, and sudden death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5413": {"data": {"text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "entity1": "cocaine", "entity2": "sudden death", "span1": [80, 87], "span2": [250, 262]}, "bert_text": "The epidemiologic findings are most consistent with the hypothesis that chronic <e1> cocaine </e1> use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and <e2> sudden death </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5414": {"data": {"text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "entity1": "cocaine", "entity2": "agitation", "span1": [153, 160], "span2": [182, 191]}, "bert_text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent <e1> cocaine </e1> use, may precipitate <e2> agitation </e2>, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5415": {"data": {"text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "entity1": "cocaine", "entity2": "delirium", "span1": [153, 160], "span2": [193, 201]}, "bert_text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent <e1> cocaine </e1> use, may precipitate agitation, <e2> delirium </e2>, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5416": {"data": {"text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "entity1": "cocaine", "entity2": "rhabdomyolysis", "span1": [153, 160], "span2": [230, 244]}, "bert_text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent <e1> cocaine </e1> use, may precipitate agitation, delirium, aberrant thermoregulation, <e2> rhabdomyolysis </e2>, and sudden death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5417": {"data": {"text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "entity1": "cocaine", "entity2": "sudden death", "span1": [153, 160], "span2": [250, 262]}, "bert_text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent <e1> cocaine </e1> use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and <e2> sudden death </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5418": {"data": {"text": "Persistent nephrogenic diabetes insipidus following lithium therapy.\n", "entity1": "lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [52, 59], "span2": [11, 41]}, "bert_text": "Persistent nephrogenic diabetes insipidus following <e1> lithium </e1> <e2> nephrogenic diabetes insipidus </e2> following lithium therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5419": {"data": {"text": "PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.", "entity1": "vigabatrin", "entity2": "visual field constriction", "span1": [77, 87], "span2": [21, 46]}, "bert_text": "PURPOSE: Symptomatic visual field constriction thought to be associated with <e1> vigabatrin </e1> <e2> visual field constriction </e2> thought to be associated with vigabatrin has been reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5420": {"data": {"text": "Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.", "entity1": "suxamethonium", "entity2": "hyperkalaemia", "span1": [213, 226], "span2": [167, 180]}, "bert_text": "Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of <e1> suxamethonium </e1> <e2> hyperkalaemia </e2> following the administration of suxamethonium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5421": {"data": {"text": "The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.", "entity1": "NIK-247", "entity2": "amnesia", "span1": [15, 22], "span2": [62, 69]}, "bert_text": "The effects of <e1> NIK-247 </e1> on cholinesterase, scopolamine-induced <e2> amnesia </e2> and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5422": {"data": {"text": "The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [42, 53], "span2": [62, 69]}, "bert_text": "The effects of NIK-247 on cholinesterase, <e1> scopolamine </e1>-induced <e2> amnesia </e2> and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5423": {"data": {"text": "The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.", "entity1": "tacrine", "entity2": "amnesia", "span1": [177, 184], "span2": [62, 69]}, "bert_text": "The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors <e1> tacrine </e1> <e2> amnesia </e2> and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5424": {"data": {"text": "The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.", "entity1": "E-2020", "entity2": "amnesia", "span1": [189, 195], "span2": [62, 69]}, "bert_text": "The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and <e1> E-2020 </e1> <e2> amnesia </e2> and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5425": {"data": {"text": "During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.", "entity1": "ribavirin", "entity2": "chronic hepatitis C", "span1": [69, 78], "span2": [20, 39]}, "bert_text": "During treatment of chronic hepatitis C patients with interferon and <e1> ribavirin </e1> <e2> chronic hepatitis C </e2> patients with interferon and ribavirin, a lot of side effects are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"5426": {"data": {"text": "CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.", "entity1": "Warfarin", "entity2": "cerebral haemorrhages", "span1": [13, 21], "span2": [30, 51]}, "bert_text": "CONCLUSIONS: <e1> Warfarin </e1>-induced <e2> cerebral haemorrhages </e2> are a major clinical problem with a high fatality rate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5427": {"data": {"text": "A case of lithium-induced diabetes insipidus is reported.", "entity1": "lithium", "entity2": "diabetes insipidus", "span1": [10, 17], "span2": [26, 44]}, "bert_text": "A case of <e1> lithium </e1>-induced <e2> diabetes insipidus </e2> is reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5428": {"data": {"text": "In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.", "entity1": "terbutaline", "entity2": "hypokalemia", "span1": [19, 30], "span2": [81, 92]}, "bert_text": "In spite of higher <e1> terbutaline </e1> concentrations after oxprenolol pretreatment, the <e2> hypokalemia </e2> was almost completely antagonized by the beta 2-blocking action.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5429": {"data": {"text": "In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.", "entity1": "oxprenolol", "entity2": "hypokalemia", "span1": [52, 62], "span2": [81, 92]}, "bert_text": "In spite of higher terbutaline concentrations after <e1> oxprenolol </e1> pretreatment, the <e2> hypokalemia </e2> was almost completely antagonized by the beta 2-blocking action.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5430": {"data": {"text": "In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.", "entity1": "CGRP", "entity2": "migraine headache", "span1": [36, 40], "span2": [100, 117]}, "bert_text": "In conclusion, the fact that plasma <e1> CGRP </e1> concentration correlates with the timing and severity of a <e2> migraine headache </e2> suggests a direct relationship between CGRP and migraine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5431": {"data": {"text": "In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.", "entity1": "CGRP", "entity2": "migraine", "span1": [36, 40], "span2": [166, 174]}, "bert_text": "In conclusion, the fact that plasma <e1> CGRP </e1> concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and <e2> migraine </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5432": {"data": {"text": "In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.", "entity1": "CGRP", "entity2": "migraine headache", "span1": [157, 161], "span2": [100, 117]}, "bert_text": "In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between <e1> CGRP </e1> <e2> migraine headache </e2> suggests a direct relationship between CGRP and migraine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5433": {"data": {"text": "In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.", "entity1": "CGRP", "entity2": "migraine", "span1": [157, 161], "span2": [166, 174]}, "bert_text": "In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between <e1> CGRP </e1> and <e2> migraine </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5434": {"data": {"text": "8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.", "entity1": "adriamycin", "entity2": "congestive heart failure", "span1": [80, 90], "span2": [30, 54]}, "bert_text": "8 of the 10 monkeys developed congestive heart failure at an average cumulative <e1> adriamycin </e1> <e2> congestive heart failure </e2> at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5435": {"data": {"text": "BACKGROUND: It is not known if there is a relationship between input rate and incidence of bupropion-induced seizures.", "entity1": "bupropion", "entity2": "seizures", "span1": [91, 100], "span2": [109, 117]}, "bert_text": "BACKGROUND: It is not known if there is a relationship between input rate and incidence of <e1> bupropion </e1>-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5436": {"data": {"text": "In multivariate analysis, three factors independently predicted mortality: serum bilirubin (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV encephalopathy at presentation.", "entity1": "bilirubin", "entity2": "encephalopathy", "span1": [81, 90], "span2": [179, 193]}, "bert_text": "In multivariate analysis, three factors independently predicted mortality: serum <e1> bilirubin </e1> (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV <e2> encephalopathy </e2> at presentation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5437": {"data": {"text": "Nicotine-induced nystagmus correlates with midpontine activation.\n", "entity1": "Nicotine", "entity2": "nystagmus", "span1": [0, 8], "span2": [17, 26]}, "bert_text": "<e1> Nicotine </e1>-induced <e2> nystagmus </e2> correlates with midpontine activation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5438": {"data": {"text": "During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.", "entity1": "aminophylline", "entity2": "ventricular fibrillation", "span1": [23, 36], "span2": [42, 66]}, "bert_text": "During the infusion of <e1> aminophylline </e1>, the <e2> ventricular fibrillation </e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5439": {"data": {"text": "During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.", "entity1": "oxygen", "entity2": "ventricular fibrillation", "span1": [157, 163], "span2": [42, 66]}, "bert_text": "During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of <e1> oxygen </e1> <e2> ventricular fibrillation </e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5440": {"data": {"text": "During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.", "entity1": "PO2", "entity2": "ventricular fibrillation", "span1": [165, 168], "span2": [42, 66]}, "bert_text": "During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (<e1> PO2 </e1> <e2> ventricular fibrillation </e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5441": {"data": {"text": "During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.", "entity1": "carbon dioxide", "entity2": "ventricular fibrillation", "span1": [174, 188], "span2": [42, 66]}, "bert_text": "During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and <e1> carbon dioxide </e1> <e2> ventricular fibrillation </e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5442": {"data": {"text": "During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.", "entity1": "CO2", "entity2": "ventricular fibrillation", "span1": [190, 193], "span2": [42, 66]}, "bert_text": "During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (<e1> CO2 </e1> <e2> ventricular fibrillation </e2> threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5443": {"data": {"text": "Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.", "entity1": "BN 52021", "entity2": "HR", "span1": [28, 36], "span2": [82, 84]}, "bert_text": "Since the administration of <e1> BN 52021 </e1>, at all doses studied, did not alter MBP and <e2> HR </e2> at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"5444": {"data": {"text": "Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.", "entity1": "BN 52021", "entity2": "cardiovascular toxicity", "span1": [28, 36], "span2": [241, 264]}, "bert_text": "Since the administration of <e1> BN 52021 </e1>, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced <e2> cardiovascular toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5445": {"data": {"text": "Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.", "entity1": "BN 52021", "entity2": "HR", "span1": [173, 181], "span2": [82, 84]}, "bert_text": "Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of <e1> BN 52021 </e1> <e2> HR </e2> at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"5446": {"data": {"text": "Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.", "entity1": "BN 52021", "entity2": "cardiovascular toxicity", "span1": [173, 181], "span2": [241, 264]}, "bert_text": "Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of <e1> BN 52021 </e1>, a specific antagonist of PAF, against bupivacaine-induced <e2> cardiovascular toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5447": {"data": {"text": "Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.", "entity1": "bupivacaine", "entity2": "HR", "span1": [221, 232], "span2": [82, 84]}, "bert_text": "Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against <e1> bupivacaine </e1> <e2> HR </e2> at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"5448": {"data": {"text": "Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.", "entity1": "bupivacaine", "entity2": "cardiovascular toxicity", "span1": [221, 232], "span2": [241, 264]}, "bert_text": "Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against <e1> bupivacaine </e1>-induced <e2> cardiovascular toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5449": {"data": {"text": "CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.", "entity1": "CBDCA", "entity2": "neurotoxic", "span1": [13, 18], "span2": [22, 32]}, "bert_text": "CONCLUSIONS: <e1> CBDCA </e1> is <e2> neurotoxic </e2> in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5450": {"data": {"text": "CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.", "entity1": "CBDCA", "entity2": "neurotoxicity", "span1": [13, 18], "span2": [167, 180]}, "bert_text": "CONCLUSIONS: <e1> CBDCA </e1> is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that <e2> neurotoxicity </e2> is induced in the two drugs by the same mechanism.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5451": {"data": {"text": "CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.", "entity1": "CDDP", "entity2": "neurotoxic", "span1": [137, 141], "span2": [22, 32]}, "bert_text": "CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by <e1> CDDP </e1> <e2> neurotoxic </e2> in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5452": {"data": {"text": "CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.", "entity1": "CDDP", "entity2": "neurotoxicity", "span1": [137, 141], "span2": [167, 180]}, "bert_text": "CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by <e1> CDDP </e1> that it is probable that <e2> neurotoxicity </e2> is induced in the two drugs by the same mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5453": {"data": {"text": "Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).", "entity1": "Diltiazem", "entity2": "AF", "span1": [0, 9], "span2": [30, 32]}, "bert_text": "<e1> Diltiazem </e1> did not affect ERP, <e2> AF </e2> cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"5454": {"data": {"text": "Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).", "entity1": "Diltiazem", "entity2": "AF", "span1": [0, 9], "span2": [49, 51]}, "bert_text": "<e1> Diltiazem </e1> did not affect ERP, AF cycle length or <e2> AF </e2> duration, but produced conduction acceleration similar to that caused by verapamil (n=5).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5455": {"data": {"text": "Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).", "entity1": "verapamil", "entity2": "AF", "span1": [125, 134], "span2": [30, 32]}, "bert_text": "Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by <e1> verapamil </e1> <e2> AF </e2> cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"5456": {"data": {"text": "Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).", "entity1": "verapamil", "entity2": "AF", "span1": [125, 134], "span2": [49, 51]}, "bert_text": "Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by <e1> verapamil </e1> <e2> AF </e2> duration, but produced conduction acceleration similar to that caused by verapamil (n=5).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5457": {"data": {"text": "The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [18, 27], "span2": [39, 50]}, "bert_text": "The mechanisms of <e1> sirolimus </e1>-associated <e2> proteinuria </e2> are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5458": {"data": {"text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "entity1": "carbachol", "entity2": "mydriasis", "span1": [76, 85], "span2": [19, 28]}, "bert_text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by <e1> carbachol </e1> <e2> mydriasis </e2>, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5459": {"data": {"text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "entity1": "carbachol", "entity2": "tremor", "span1": [76, 85], "span2": [30, 36]}, "bert_text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by <e1> carbachol </e1> <e2> tremor </e2> and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5460": {"data": {"text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "entity1": "carbachol", "entity2": "clonic-tonic convulsions", "span1": [76, 85], "span2": [41, 65]}, "bert_text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by <e1> carbachol </e1> <e2> clonic-tonic convulsions </e2> evoked by carbachol and eserine were not significantly changed by calcium chloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5461": {"data": {"text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "entity1": "eserine", "entity2": "mydriasis", "span1": [90, 97], "span2": [19, 28]}, "bert_text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and <e1> eserine </e1> <e2> mydriasis </e2>, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5462": {"data": {"text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "entity1": "eserine", "entity2": "tremor", "span1": [90, 97], "span2": [30, 36]}, "bert_text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and <e1> eserine </e1> <e2> tremor </e2> and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5463": {"data": {"text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "entity1": "eserine", "entity2": "clonic-tonic convulsions", "span1": [90, 97], "span2": [41, 65]}, "bert_text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and <e1> eserine </e1> <e2> clonic-tonic convulsions </e2> evoked by carbachol and eserine were not significantly changed by calcium chloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5464": {"data": {"text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "entity1": "calcium chloride", "entity2": "mydriasis", "span1": [132, 148], "span2": [19, 28]}, "bert_text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by <e1> calcium chloride </e1> <e2> mydriasis </e2>, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5465": {"data": {"text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "entity1": "calcium chloride", "entity2": "tremor", "span1": [132, 148], "span2": [30, 36]}, "bert_text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by <e1> calcium chloride </e1> <e2> tremor </e2> and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5466": {"data": {"text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "entity1": "calcium chloride", "entity2": "clonic-tonic convulsions", "span1": [132, 148], "span2": [41, 65]}, "bert_text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by <e1> calcium chloride </e1> <e2> clonic-tonic convulsions </e2> evoked by carbachol and eserine were not significantly changed by calcium chloride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5467": {"data": {"text": "This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.", "entity1": "acetaminophen", "entity2": "hypotension", "span1": [140, 153], "span2": [81, 92]}, "bert_text": "This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of <e1> acetaminophen </e1> <e2> hypotension </e2> reproducibly developed after administration of acetaminophen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5468": {"data": {"text": "Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (\"meth mouth\"), and excessive tooth wear.", "entity1": "methamphetamine", "entity2": "xerostomia", "span1": [24, 39], "span2": [76, 86]}, "bert_text": "Dental patients abusing <e1> methamphetamine </e1> can present with poor oral hygiene, <e2> xerostomia </e2>, rampant caries (\"meth mouth\"), and excessive tooth wear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5469": {"data": {"text": "Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (\"meth mouth\"), and excessive tooth wear.", "entity1": "methamphetamine", "entity2": "tooth wear", "span1": [24, 39], "span2": [133, 143]}, "bert_text": "Dental patients abusing <e1> methamphetamine </e1> can present with poor oral hygiene, xerostomia, rampant caries (\"meth mouth\"), and excessive <e2> tooth wear </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5470": {"data": {"text": "We report a case of variant ventricular tachycardia induced by desipramine toxicity.", "entity1": "desipramine", "entity2": "ventricular tachycardia", "span1": [63, 74], "span2": [28, 51]}, "bert_text": "We report a case of variant ventricular tachycardia induced by <e1> desipramine </e1> <e2> ventricular tachycardia </e2> induced by desipramine toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5471": {"data": {"text": "We report a case of variant ventricular tachycardia induced by desipramine toxicity.", "entity1": "desipramine", "entity2": "toxicity", "span1": [63, 74], "span2": [75, 83]}, "bert_text": "We report a case of variant ventricular tachycardia induced by <e1> desipramine </e1> <e2> toxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5472": {"data": {"text": "Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.", "entity1": "papaverine", "entity2": "vasospasm", "span1": [8, 18], "span2": [69, 78]}, "bert_text": "Topical <e1> papaverine </e1> was used as a direct therapeutic action to manage <e2> vasospasm </e2> in a total of 11 patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5473": {"data": {"text": "An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.\n", "entity1": "pegylated interferon alpha-2b", "entity2": "delusional parasitosis", "span1": [89, 118], "span2": [26, 48]}, "bert_text": "An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during <e1> pegylated interferon alpha-2b </e1> <e2> delusional parasitosis </e2> in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5474": {"data": {"text": "An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.\n", "entity1": "pegylated interferon alpha-2b", "entity2": "chronic hepatitis C", "span1": [89, 118], "span2": [54, 73]}, "bert_text": "An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during <e1> pegylated interferon alpha-2b </e1> <e2> chronic hepatitis C </e2> patient during pegylated interferon alpha-2b and ribavirin treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5475": {"data": {"text": "An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.\n", "entity1": "ribavirin", "entity2": "delusional parasitosis", "span1": [123, 132], "span2": [26, 48]}, "bert_text": "An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and <e1> ribavirin </e1> <e2> delusional parasitosis </e2> in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5476": {"data": {"text": "An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.\n", "entity1": "ribavirin", "entity2": "chronic hepatitis C", "span1": [123, 132], "span2": [54, 73]}, "bert_text": "An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and <e1> ribavirin </e1> <e2> chronic hepatitis C </e2> patient during pegylated interferon alpha-2b and ribavirin treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5477": {"data": {"text": "Effect of polyethylene glycol 400 on adriamycin toxicity in mice.\n", "entity1": "polyethylene glycol 400", "entity2": "toxicity", "span1": [10, 33], "span2": [48, 56]}, "bert_text": "Effect of <e1> polyethylene glycol 400 </e1> on adriamycin <e2> toxicity </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5478": {"data": {"text": "Effect of polyethylene glycol 400 on adriamycin toxicity in mice.\n", "entity1": "adriamycin", "entity2": "toxicity", "span1": [37, 47], "span2": [48, 56]}, "bert_text": "Effect of polyethylene glycol 400 on <e1> adriamycin </e1> <e2> toxicity </e2> in mice.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5479": {"data": {"text": "High-dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia.", "entity1": "methotrexate", "entity2": "acute lymphoblastic leukemia", "span1": [22, 34], "span2": [119, 147]}, "bert_text": "High-dose intravenous <e1> methotrexate </e1> is an effective treatment for the induction of remission after meningeal relapse in <e2> acute lymphoblastic leukemia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5480": {"data": {"text": "DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.", "entity1": "timolol", "entity2": "glaucoma", "span1": [65, 72], "span2": [256, 264]}, "bert_text": "DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous <e1> timolol </e1> (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for <e2> glaucoma </e2> to quantify the reduction in mean heart rate.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5481": {"data": {"text": "DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.", "entity1": "timolol", "entity2": "glaucoma", "span1": [74, 81], "span2": [256, 264]}, "bert_text": "DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (<e1> timolol </e1> solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for <e2> glaucoma </e2> to quantify the reduction in mean heart rate.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5482": {"data": {"text": "DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.", "entity1": "timolol", "entity2": "glaucoma", "span1": [103, 110], "span2": [256, 264]}, "bert_text": "DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% <e1> timolol </e1> suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for <e2> glaucoma </e2> to quantify the reduction in mean heart rate.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5483": {"data": {"text": "DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.", "entity1": "timolol", "entity2": "glaucoma", "span1": [174, 181], "span2": [256, 264]}, "bert_text": "DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (<e1> timolol </e1> gellan) on the 24-hour heart rate in patients currently being treated for <e2> glaucoma </e2> to quantify the reduction in mean heart rate.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5484": {"data": {"text": "Methylphenidate-induced obsessive-compulsive symptoms in an elderly man.\n", "entity1": "Methylphenidate", "entity2": "obsessive-compulsive symptoms", "span1": [0, 15], "span2": [24, 53]}, "bert_text": "<e1> Methylphenidate </e1>-induced <e2> obsessive-compulsive symptoms </e2> in an elderly man.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5485": {"data": {"text": "Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.", "entity1": "fusidic acid", "entity2": "Crohn's disease", "span1": [161, 173], "span2": [62, 77]}, "bert_text": "Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of <e1> fusidic acid </e1> <e2> Crohn's disease </e2>, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"5486": {"data": {"text": "PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [56, 63], "span2": [72, 88]}, "bert_text": "PATIENTS: 14 patients seen over a 3-year period in whom <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5487": {"data": {"text": "PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "entity1": "heparin", "entity2": "thromboembolic", "span1": [56, 63], "span2": [134, 148]}, "bert_text": "PATIENTS: 14 patients seen over a 3-year period in whom <e1> heparin </e1>-induced thrombocytopenia became apparent on delayed presentation with <e2> thromboembolic </e2> complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5488": {"data": {"text": "PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "entity1": "heparin", "entity2": "thromboembolism", "span1": [56, 63], "span2": [227, 242]}, "bert_text": "PATIENTS: 14 patients seen over a 3-year period in whom <e1> heparin </e1>-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined <e2> thromboembolism </e2>, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5489": {"data": {"text": "PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [255, 262], "span2": [72, 88]}, "bert_text": "PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of <e1> heparin </e1> <e2> thrombocytopenia </e2> became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5490": {"data": {"text": "PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "entity1": "heparin", "entity2": "thromboembolic", "span1": [255, 262], "span2": [134, 148]}, "bert_text": "PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of <e1> heparin </e1> <e2> thromboembolic </e2> complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5491": {"data": {"text": "PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "entity1": "heparin", "entity2": "thromboembolism", "span1": [255, 262], "span2": [227, 242]}, "bert_text": "PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications. MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of <e1> heparin </e1> <e2> thromboembolism </e2>, results of heparin-induced platelet factor 4 antibody tests, and outcomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"5492": {"data": {"text": "The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).", "entity1": "remifentanil", "entity2": "myoclonus", "span1": [58, 70], "span2": [17, 26]}, "bert_text": "The incidence of myoclonus was significantly lower in the <e1> remifentanil </e1> <e2> myoclonus </e2> was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5493": {"data": {"text": "Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.", "entity1": "lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [51, 58], "span2": [67, 97]}, "bert_text": "Ten years previously he had been diagnosed to have <e1> lithium </e1>-induced <e2> nephrogenic diabetes insipidus </e2>, and lithium therapy had been discontinued.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5494": {"data": {"text": "Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.", "entity1": "lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [103, 110], "span2": [67, 97]}, "bert_text": "Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and <e1> lithium </e1> <e2> nephrogenic diabetes insipidus </e2>, and lithium therapy had been discontinued.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5495": {"data": {"text": "These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.", "entity1": "morphine", "entity2": "pain", "span1": [89, 97], "span2": [114, 118]}, "bert_text": "These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and <e1> morphine </e1> in a persistent <e2> pain </e2> model that can be distinguished from those observed in acute pain models.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5496": {"data": {"text": "These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.", "entity1": "morphine", "entity2": "acute pain", "span1": [89, 97], "span2": [174, 184]}, "bert_text": "These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and <e1> morphine </e1> in a persistent pain model that can be distinguished from those observed in <e2> acute pain </e2> models.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5497": {"data": {"text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.", "entity1": "clonidine", "entity2": "dyskinetic", "span1": [25, 34], "span2": [119, 129]}, "bert_text": "Several drugs, including <e1> clonidine </e1>, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the <e2> dyskinetic </e2> movements but at the cost of a return of parkinsonian symptomatology.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5498": {"data": {"text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.", "entity1": "clonidine", "entity2": "parkinsonian", "span1": [25, 34], "span2": [171, 183]}, "bert_text": "Several drugs, including <e1> clonidine </e1>, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of <e2> parkinsonian </e2> symptomatology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5499": {"data": {"text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.", "entity1": "physostigmine", "entity2": "dyskinetic", "span1": [36, 49], "span2": [119, 129]}, "bert_text": "Several drugs, including clonidine, <e1> physostigmine </e1>, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the <e2> dyskinetic </e2> movements but at the cost of a return of parkinsonian symptomatology.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5500": {"data": {"text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.", "entity1": "physostigmine", "entity2": "parkinsonian", "span1": [36, 49], "span2": [171, 183]}, "bert_text": "Several drugs, including clonidine, <e1> physostigmine </e1>, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of <e2> parkinsonian </e2> symptomatology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5501": {"data": {"text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.", "entity1": "methysergide", "entity2": "dyskinetic", "span1": [51, 63], "span2": [119, 129]}, "bert_text": "Several drugs, including clonidine, physostigmine, <e1> methysergide </e1>, 5-MDOT, propranolol, and MK-801, markedly reduced the <e2> dyskinetic </e2> movements but at the cost of a return of parkinsonian symptomatology.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5502": {"data": {"text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.", "entity1": "methysergide", "entity2": "parkinsonian", "span1": [51, 63], "span2": [171, 183]}, "bert_text": "Several drugs, including clonidine, physostigmine, <e1> methysergide </e1>, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of <e2> parkinsonian </e2> symptomatology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5503": {"data": {"text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.", "entity1": "propranolol", "entity2": "dyskinetic", "span1": [73, 84], "span2": [119, 129]}, "bert_text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, <e1> propranolol </e1>, and MK-801, markedly reduced the <e2> dyskinetic </e2> movements but at the cost of a return of parkinsonian symptomatology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5504": {"data": {"text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.", "entity1": "propranolol", "entity2": "parkinsonian", "span1": [73, 84], "span2": [171, 183]}, "bert_text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, <e1> propranolol </e1>, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of <e2> parkinsonian </e2> symptomatology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5505": {"data": {"text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.", "entity1": "MK-801", "entity2": "dyskinetic", "span1": [90, 96], "span2": [119, 129]}, "bert_text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and <e1> MK-801 </e1>, markedly reduced the <e2> dyskinetic </e2> movements but at the cost of a return of parkinsonian symptomatology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5506": {"data": {"text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.", "entity1": "MK-801", "entity2": "parkinsonian", "span1": [90, 96], "span2": [171, 183]}, "bert_text": "Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and <e1> MK-801 </e1>, markedly reduced the dyskinetic movements but at the cost of a return of <e2> parkinsonian </e2> symptomatology.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5507": {"data": {"text": "Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.", "entity1": "Lithium", "entity2": "proteinuria", "span1": [0, 7], "span2": [20, 31]}, "bert_text": "<e1> Lithium </e1> also caused <e2> proteinuria </e2> and systolic hypertension in absence of glomerulosclerosis.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5508": {"data": {"text": "Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.", "entity1": "Lithium", "entity2": "hypertension", "span1": [0, 7], "span2": [45, 57]}, "bert_text": "<e1> Lithium </e1> also caused proteinuria and systolic <e2> hypertension </e2> in absence of glomerulosclerosis.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5509": {"data": {"text": "Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.", "entity1": "Lithium", "entity2": "glomerulosclerosis", "span1": [0, 7], "span2": [72, 90]}, "bert_text": "<e1> Lithium </e1> also caused proteinuria and systolic hypertension in absence of <e2> glomerulosclerosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5510": {"data": {"text": "These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.", "entity1": "paracetamol", "entity2": "ALF", "span1": [60, 71], "span2": [49, 52]}, "bert_text": "These results demonstrate a neutrophil defect in ALF due to <e1> paracetamol </e1> <e2> ALF </e2> due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5511": {"data": {"text": "These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.", "entity1": "paracetamol", "entity2": "overdose", "span1": [60, 71], "span2": [72, 80]}, "bert_text": "These results demonstrate a neutrophil defect in ALF due to <e1> paracetamol </e1> <e2> overdose </e2>, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5512": {"data": {"text": "Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.", "entity1": "lometrexol", "entity2": "tumours", "span1": [65, 75], "span2": [97, 104]}, "bert_text": "Extensive experimental and limited clinical data have shown that <e1> lometrexol </e1> has activity against <e2> tumours </e2> which are refractory to other drugs, notably methotrexate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5513": {"data": {"text": "Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.", "entity1": "methotrexate", "entity2": "tumours", "span1": [150, 162], "span2": [97, 104]}, "bert_text": "Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably <e1> methotrexate </e1> <e2> tumours </e2> which are refractory to other drugs, notably methotrexate.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5514": {"data": {"text": "Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism.", "entity1": "KF17837", "entity2": "parkinsonism", "span1": [13, 20], "span2": [62, 74]}, "bert_text": "Furthermore, <e1> KF17837 </e1> may be a useful drug in the treatment of <e2> parkinsonism </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5515": {"data": {"text": "RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.", "entity1": "ADR", "entity2": "inflammation", "span1": [75, 78], "span2": [155, 167]}, "bert_text": "RESULTS: Histopathological examination of the kidneys of rats treated with <e1> ADR </e1> revealed focal areas of mesangial proliferation and mild tubulointerstitial <e2> inflammation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5516": {"data": {"text": "These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.", "entity1": "daidzein", "entity2": "amnesia", "span1": [28, 36], "span2": [155, 162]}, "bert_text": "These results indicate that <e1> daidzein </e1> might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5517": {"data": {"text": "These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.", "entity1": "acetylcholine", "entity2": "amnesia", "span1": [58, 71], "span2": [155, 162]}, "bert_text": "These results indicate that daidzein might play a role in <e1> acetylcholine </e1> biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5518": {"data": {"text": "These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [135, 146], "span2": [155, 162]}, "bert_text": "These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates <e1> scopolamine </e1>-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5519": {"data": {"text": "Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).", "entity1": "Sulfonamides", "entity2": "anencephaly", "span1": [0, 12], "span2": [34, 45]}, "bert_text": "<e1> Sulfonamides </e1> were associated with <e2> anencephaly </e2> (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5520": {"data": {"text": "Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).", "entity1": "Sulfonamides", "entity2": "hypoplastic left heart syndrome", "span1": [0, 12], "span2": [112, 143]}, "bert_text": "<e1> Sulfonamides </e1> were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), <e2> hypoplastic left heart syndrome </e2> (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5521": {"data": {"text": "Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).", "entity1": "Sulfonamides", "entity2": "coarctation of the aorta", "span1": [0, 12], "span2": [174, 198]}, "bert_text": "<e1> Sulfonamides </e1> were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), <e2> coarctation of the aorta </e2> (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5522": {"data": {"text": "Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).", "entity1": "Sulfonamides", "entity2": "choanal atresia", "span1": [0, 12], "span2": [229, 244]}, "bert_text": "<e1> Sulfonamides </e1> were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), <e2> choanal atresia </e2> (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5523": {"data": {"text": "Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).", "entity1": "Sulfonamides", "entity2": "diaphragmatic hernia", "span1": [0, 12], "span2": [337, 357]}, "bert_text": "<e1> Sulfonamides </e1> were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and <e2> diaphragmatic hernia </e2> (AOR = 2.4; 95% CI, 1.1-5.4).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5524": {"data": {"text": "Recurrent acute interstitial nephritis induced by azithromycin.\n", "entity1": "azithromycin", "entity2": "interstitial nephritis", "span1": [50, 62], "span2": [16, 38]}, "bert_text": "Recurrent acute interstitial nephritis induced by <e1> azithromycin </e1> <e2> interstitial nephritis </e2> induced by azithromycin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5525": {"data": {"text": "We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.", "entity1": "mazindol", "entity2": "Duchenne dystrophy", "span1": [44, 52], "span2": [117, 135]}, "bert_text": "We conducted a 12-month controlled trial of <e1> mazindol </e1>, a putative growth hormone secretion inhibitor, in 83 boys with <e2> Duchenne dystrophy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5526": {"data": {"text": "Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.", "entity1": "DA", "entity2": "PD", "span1": [7, 9], "span2": [166, 168]}, "bert_text": "Potent <e1> DA </e1> D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in <e2> PD </e2> and merit further attention.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5527": {"data": {"text": "Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.", "entity1": "A-86929", "entity2": "PD", "span1": [79, 86], "span2": [166, 168]}, "bert_text": "Potent DA D1 receptor agents with an intermediate duration of efficacy such as <e1> A-86929 </e1> (approximately 4 hr at higher doses tested) are potential therapeutic tools in <e2> PD </e2> and merit further attention.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5528": {"data": {"text": "RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).", "entity1": "enalapril", "entity2": "decreased renal function", "span1": [39, 48], "span2": [81, 105]}, "bert_text": "RESULTS: Patients randomly assigned to <e1> enalapril </e1> had a 33% greater likelihood of <e2> decreased renal function </e2> than controls (P =.003).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5529": {"data": {"text": "Ranitidine-induced acute interstitial nephritis in a cadaveric renal allograft.\n", "entity1": "Ranitidine", "entity2": "interstitial nephritis", "span1": [0, 10], "span2": [25, 47]}, "bert_text": "<e1> Ranitidine </e1>-induced acute <e2> interstitial nephritis </e2> in a cadaveric renal allograft.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5530": {"data": {"text": "Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.", "entity1": "Azelastine", "entity2": "seasonal allergic rhinitis", "span1": [0, 10], "span2": [60, 86]}, "bert_text": "<e1> Azelastine </e1> appears to be a safe, efficacious medication for <e2> seasonal allergic rhinitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5531": {"data": {"text": "In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.", "entity1": "nitric oxide", "entity2": "pain", "span1": [79, 91], "span2": [112, 116]}, "bert_text": "In recent years, increasing evidence has suggested that the messenger molecule <e1> nitric oxide </e1> (NO) is involved in <e2> pain </e2> mechanisms of migraine without aura.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5532": {"data": {"text": "In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.", "entity1": "nitric oxide", "entity2": "migraine without aura", "span1": [79, 91], "span2": [131, 152]}, "bert_text": "In recent years, increasing evidence has suggested that the messenger molecule <e1> nitric oxide </e1> (NO) is involved in pain mechanisms of <e2> migraine without aura </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5533": {"data": {"text": "In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.", "entity1": "NO", "entity2": "pain", "span1": [93, 95], "span2": [112, 116]}, "bert_text": "In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (<e1> NO </e1>) is involved in <e2> pain </e2> mechanisms of migraine without aura.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5534": {"data": {"text": "In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.", "entity1": "NO", "entity2": "migraine without aura", "span1": [93, 95], "span2": [131, 152]}, "bert_text": "In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (<e1> NO </e1>) is involved in pain mechanisms of <e2> migraine without aura </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5535": {"data": {"text": "It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.", "entity1": "suxamethonium", "entity2": "death", "span1": [66, 79], "span2": [26, 31]}, "bert_text": "It is postulated that her death was caused by hypersensitivity to <e1> suxamethonium </e1> <e2> death </e2> was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5536": {"data": {"text": "It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.", "entity1": "suxamethonium", "entity2": "hypersensitivity", "span1": [66, 79], "span2": [46, 62]}, "bert_text": "It is postulated that her death was caused by hypersensitivity to <e1> suxamethonium </e1> <e2> hypersensitivity </e2> to suxamethonium, associated with her 5-day immobilization.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5537": {"data": {"text": "There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.", "entity1": "VPA", "entity2": "encephalopathy", "span1": [47, 50], "span2": [68, 82]}, "bert_text": "There is still no proof of causative effect of <e1> VPA </e1> in patients with <e2> encephalopathy </e2>, but only of an association with an assumed causal relation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5538": {"data": {"text": "OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.", "entity1": "simvastatin", "entity2": "rhabdomyolysis", "span1": [60, 71], "span2": [113, 127]}, "bert_text": "OBJECTIVE: To report a case of a severe interaction between <e1> simvastatin </e1>, amiodarone, and atazanavir resulting in <e2> rhabdomyolysis </e2> and acute renal failure.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5539": {"data": {"text": "OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.", "entity1": "simvastatin", "entity2": "acute renal failure", "span1": [60, 71], "span2": [132, 151]}, "bert_text": "OBJECTIVE: To report a case of a severe interaction between <e1> simvastatin </e1>, amiodarone, and atazanavir resulting in rhabdomyolysis and <e2> acute renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5540": {"data": {"text": "OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.", "entity1": "amiodarone", "entity2": "rhabdomyolysis", "span1": [73, 83], "span2": [113, 127]}, "bert_text": "OBJECTIVE: To report a case of a severe interaction between simvastatin, <e1> amiodarone </e1>, and atazanavir resulting in <e2> rhabdomyolysis </e2> and acute renal failure.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5541": {"data": {"text": "OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.", "entity1": "amiodarone", "entity2": "acute renal failure", "span1": [73, 83], "span2": [132, 151]}, "bert_text": "OBJECTIVE: To report a case of a severe interaction between simvastatin, <e1> amiodarone </e1>, and atazanavir resulting in rhabdomyolysis and <e2> acute renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5542": {"data": {"text": "OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.", "entity1": "atazanavir", "entity2": "rhabdomyolysis", "span1": [89, 99], "span2": [113, 127]}, "bert_text": "OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and <e1> atazanavir </e1> resulting in <e2> rhabdomyolysis </e2> and acute renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5543": {"data": {"text": "OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.", "entity1": "atazanavir", "entity2": "acute renal failure", "span1": [89, 99], "span2": [132, 151]}, "bert_text": "OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and <e1> atazanavir </e1> resulting in rhabdomyolysis and <e2> acute renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5544": {"data": {"text": "Naloxone inhibited the induced cataleptic effects.", "entity1": "Naloxone", "entity2": "cataleptic", "span1": [0, 8], "span2": [31, 41]}, "bert_text": "<e1> Naloxone </e1> inhibited the induced <e2> cataleptic </e2> effects.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5545": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "ribavirin", "entity2": "hemolysis", "span1": [19, 28], "span2": [56, 65]}, "bert_text": "Adequate timing of <e1> ribavirin </e1> reduction in patients with <e2> hemolysis </e2> during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5546": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "ribavirin", "entity2": "chronic hepatitis C.", "span1": [19, 28], "span2": [125, 145]}, "bert_text": "Adequate timing of <e1> ribavirin </e1> reduction in patients with hemolysis during combination therapy of interferon and ribavirin for <e2> chronic hepatitis C. </e2>\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5547": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "ribavirin", "entity2": "Hemolytic anemia", "span1": [19, 28], "span2": [158, 174]}, "bert_text": "Adequate timing of <e1> ribavirin </e1> reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: <e2> Hemolytic anemia </e2> is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5548": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "ribavirin", "entity2": "hemolysis", "span1": [111, 120], "span2": [56, 65]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and <e1> ribavirin </e1> <e2> hemolysis </e2> during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5549": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "ribavirin", "entity2": "chronic hepatitis C.", "span1": [111, 120], "span2": [125, 145]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and <e1> ribavirin </e1> for <e2> chronic hepatitis C. </e2>\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5550": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "ribavirin", "entity2": "Hemolytic anemia", "span1": [111, 120], "span2": [158, 174]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and <e1> ribavirin </e1> for chronic hepatitis C.\nBACKGROUND: <e2> Hemolytic anemia </e2> is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5551": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "ribavirin", "entity2": "hemolysis", "span1": [255, 264], "span2": [56, 65]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and <e1> ribavirin </e1> <e2> hemolysis </e2> during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5552": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "ribavirin", "entity2": "chronic hepatitis C.", "span1": [255, 264], "span2": [125, 145]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and <e1> ribavirin </e1> <e2> chronic hepatitis C. </e2>\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5553": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "ribavirin", "entity2": "Hemolytic anemia", "span1": [255, 264], "span2": [158, 174]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and <e1> ribavirin </e1> <e2> Hemolytic anemia </e2> is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5554": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "interferon", "entity2": "hemolysis", "span1": [96, 106], "span2": [56, 65]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of <e1> interferon </e1> <e2> hemolysis </e2> during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5555": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "interferon", "entity2": "chronic hepatitis C.", "span1": [96, 106], "span2": [125, 145]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of <e1> interferon </e1> and ribavirin for <e2> chronic hepatitis C. </e2>\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5556": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "interferon", "entity2": "Hemolytic anemia", "span1": [96, 106], "span2": [158, 174]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of <e1> interferon </e1> and ribavirin for chronic hepatitis C.\nBACKGROUND: <e2> Hemolytic anemia </e2> is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5557": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "interferon", "entity2": "hemolysis", "span1": [240, 250], "span2": [56, 65]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of <e1> interferon </e1> <e2> hemolysis </e2> during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5558": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "interferon", "entity2": "chronic hepatitis C.", "span1": [240, 250], "span2": [125, 145]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of <e1> interferon </e1> <e2> chronic hepatitis C. </e2>\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5559": {"data": {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity1": "interferon", "entity2": "Hemolytic anemia", "span1": [240, 250], "span2": [158, 174]}, "bert_text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\nBACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of <e1> interferon </e1> <e2> Hemolytic anemia </e2> is one of the major adverse events of the combination therapy of interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5560": {"data": {"text": "Cocaine-induced anxiety was also attenuated in Dbh +/-", "entity1": "Cocaine", "entity2": "anxiety", "span1": [0, 7], "span2": [16, 23]}, "bert_text": "<e1> Cocaine </e1>-induced <e2> anxiety </e2> was also attenuated in Dbh +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5561": {"data": {"text": "HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.", "entity1": "creatinine", "entity2": "renal failure", "span1": [109, 119], "span2": [40, 53]}, "bert_text": "HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma <e1> creatinine </e1> <e2> renal failure </e2> and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5562": {"data": {"text": "HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.", "entity1": "lithium", "entity2": "renal failure", "span1": [130, 137], "span2": [40, 53]}, "bert_text": "HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in <e1> lithium </e1> <e2> renal failure </e2> and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5563": {"data": {"text": "While the use of MDMA in quantities that may be considered \"moderate\" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.", "entity1": "MDMA", "entity2": "impaired memory functioning", "span1": [17, 21], "span2": [93, 120]}, "bert_text": "While the use of <e1> MDMA </e1> in quantities that may be considered \"moderate\" is not associated with <e2> impaired memory functioning </e2>, heavy use of MDMA use may lead to long lasting memory impairments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"5564": {"data": {"text": "While the use of MDMA in quantities that may be considered \"moderate\" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.", "entity1": "MDMA", "entity2": "memory impairments", "span1": [17, 21], "span2": [169, 187]}, "bert_text": "While the use of <e1> MDMA </e1> in quantities that may be considered \"moderate\" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting <e2> memory impairments </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5565": {"data": {"text": "While the use of MDMA in quantities that may be considered \"moderate\" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.", "entity1": "MDMA", "entity2": "impaired memory functioning", "span1": [135, 139], "span2": [93, 120]}, "bert_text": "While the use of MDMA in quantities that may be considered \"moderate\" is not associated with impaired memory functioning, heavy use of <e1> MDMA </e1> <e2> impaired memory functioning </e2>, heavy use of MDMA use may lead to long lasting memory impairments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"5566": {"data": {"text": "While the use of MDMA in quantities that may be considered \"moderate\" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.", "entity1": "MDMA", "entity2": "memory impairments", "span1": [135, 139], "span2": [169, 187]}, "bert_text": "While the use of MDMA in quantities that may be considered \"moderate\" is not associated with impaired memory functioning, heavy use of <e1> MDMA </e1> use may lead to long lasting <e2> memory impairments </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5567": {"data": {"text": "Acute myocarditis associated with clozapine.\n", "entity1": "clozapine", "entity2": "myocarditis", "span1": [34, 43], "span2": [6, 17]}, "bert_text": "Acute myocarditis associated with <e1> clozapine </e1> <e2> myocarditis </e2> associated with clozapine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5568": {"data": {"text": "CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.", "entity1": "testosterone", "entity2": "erectile dysfunction", "span1": [48, 60], "span2": [83, 103]}, "bert_text": "CONCLUSIONS: Low prevalences and effects of low <e1> testosterone </e1> and high prolactin in <e2> erectile dysfunction </e2> cannot justify their routine determination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5569": {"data": {"text": "Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.\n", "entity1": "Warfarin", "entity2": "hemorrhage", "span1": [0, 8], "span2": [27, 37]}, "bert_text": "<e1> Warfarin </e1>-induced iliopsoas <e2> hemorrhage </e2> with subsequent femoral nerve palsy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5570": {"data": {"text": "Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.\n", "entity1": "Warfarin", "entity2": "femoral nerve palsy", "span1": [0, 8], "span2": [54, 73]}, "bert_text": "<e1> Warfarin </e1>-induced iliopsoas hemorrhage with subsequent <e2> femoral nerve palsy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5571": {"data": {"text": "The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.", "entity1": "smoking", "entity2": "hearing loss", "span1": [17, 24], "span2": [145, 157]}, "bert_text": "The influence of <e1> smoking </e1> during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with <e2> hearing loss </e2> in adults.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5572": {"data": {"text": "The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.", "entity1": "smoking", "entity2": "hearing loss", "span1": [101, 108], "span2": [145, 157]}, "bert_text": "The influence of smoking during pregnancy on the developing cochlea has not been estimated, although <e1> smoking </e1> has been positively associated with <e2> hearing loss </e2> in adults.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5573": {"data": {"text": "Ventricular fibrillation from diatrizoate with and without chelating agents.\n", "entity1": "diatrizoate", "entity2": "Ventricular fibrillation", "span1": [30, 41], "span2": [0, 24]}, "bert_text": "Ventricular fibrillation from <e1> diatrizoate </e1> <e2> Ventricular fibrillation </e2> from diatrizoate with and without chelating agents.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5574": {"data": {"text": "He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.", "entity1": "lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [54, 61], "span2": [191, 221]}, "bert_text": "He remained thirsty and polyuric despite cessation of <e1> lithium </e1> and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of <e2> nephrogenic diabetes insipidus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5575": {"data": {"text": "He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.", "entity1": "vasopressin", "entity2": "nephrogenic diabetes insipidus", "span1": [145, 156], "span2": [191, 221]}, "bert_text": "He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and <e1> vasopressin </e1> secretion, with clear evidence of <e2> nephrogenic diabetes insipidus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5576": {"data": {"text": "OBJECTIVE: A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors.", "entity1": "clozapine", "entity2": "myocarditis", "span1": [75, 84], "span2": [27, 38]}, "bert_text": "OBJECTIVE: A case of acute myocarditis associated with the commencement of <e1> clozapine </e1> <e2> myocarditis </e2> associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5577": {"data": {"text": "Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.", "entity1": "fluoxetine", "entity2": "sexually dysfunctional", "span1": [55, 65], "span2": [9, 31]}, "bert_text": "Nineteen sexually dysfunctional women receiving either <e1> fluoxetine </e1> <e2> sexually dysfunctional </e2> women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5578": {"data": {"text": "Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.", "entity1": "sertraline", "entity2": "sexually dysfunctional", "span1": [67, 77], "span2": [9, 31]}, "bert_text": "Nineteen sexually dysfunctional women receiving either fluoxetine, <e1> sertraline </e1> <e2> sexually dysfunctional </e2> women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5579": {"data": {"text": "Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.", "entity1": "paroxetine", "entity2": "sexually dysfunctional", "span1": [82, 92], "span2": [9, 31]}, "bert_text": "Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or <e1> paroxetine </e1> <e2> sexually dysfunctional </e2> women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5580": {"data": {"text": "Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.", "entity1": "ephedrine", "entity2": "sexually dysfunctional", "span1": [193, 202], "span2": [9, 31]}, "bert_text": "Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of <e1> ephedrine </e1> <e2> sexually dysfunctional </e2> women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5581": {"data": {"text": "The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment.", "entity1": "cimetidine", "entity2": "arrhythmias", "span1": [43, 53], "span2": [4, 15]}, "bert_text": "The arrhythmias were temporally related to <e1> cimetidine </e1> <e2> arrhythmias </e2> were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5582": {"data": {"text": "The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment.", "entity1": "ranitidine", "entity2": "arrhythmias", "span1": [126, 136], "span2": [4, 15]}, "bert_text": "The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during <e1> ranitidine </e1> <e2> arrhythmias </e2> were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5583": {"data": {"text": "The estimated incidence of angioedema during angiotensin-converting enzyme (ACE) inhibitor treatment is between 1 and 7 per thousand patients.", "entity1": "angiotensin", "entity2": "angioedema", "span1": [45, 56], "span2": [27, 37]}, "bert_text": "The estimated incidence of angioedema during <e1> angiotensin </e1> <e2> angioedema </e2> during angiotensin-converting enzyme (ACE) inhibitor treatment is between 1 and 7 per thousand patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5584": {"data": {"text": "However, urinary PGI2 was not different between controls and patients with OAB.", "entity1": "PGI2", "entity2": "OAB", "span1": [17, 21], "span2": [75, 78]}, "bert_text": "However, urinary <e1> PGI2 </e1> was not different between controls and patients with <e2> OAB </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5585": {"data": {"text": "This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.", "entity1": "alcohol", "entity2": "fetal growth impairment", "span1": [58, 65], "span2": [74, 97]}, "bert_text": "This study examined the utility of biometry for detecting <e1> alcohol </e1>-related <e2> fetal growth impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5586": {"data": {"text": "Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.", "entity1": "Vitamin E", "entity2": "hypertension", "span1": [0, 9], "span2": [38, 50]}, "bert_text": "<e1> Vitamin E </e1> supplementation ameliorated <e2> hypertension </e2>, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5587": {"data": {"text": "Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.", "entity1": "MDA", "entity2": "hypertension", "span1": [67, 70], "span2": [38, 50]}, "bert_text": "Vitamin E supplementation ameliorated hypertension, lowered plasma <e1> MDA </e1> <e2> hypertension </e2>, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5588": {"data": {"text": "injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.", "entity1": "CBZ", "entity2": "seizures", "span1": [13, 16], "span2": [104, 112]}, "bert_text": "injection of <e1> CBZ </e1> (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5589": {"data": {"text": "injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.", "entity1": "lidocaine-", "entity2": "seizures", "span1": [74, 84], "span2": [104, 112]}, "bert_text": "injection of CBZ (15 mg/kg) also was without effect on the development of <e1> lidocaine- </e1> or cocaine-kindled <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5590": {"data": {"text": "injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.", "entity1": "cocaine", "entity2": "seizures", "span1": [88, 95], "span2": [104, 112]}, "bert_text": "injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or <e1> cocaine </e1>-kindled <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5591": {"data": {"text": "Angioedema following the intravenous administration of metoprolol.\n", "entity1": "metoprolol", "entity2": "Angioedema", "span1": [55, 65], "span2": [0, 10]}, "bert_text": "Angioedema following the intravenous administration of <e1> metoprolol </e1> <e2> Angioedema </e2> following the intravenous administration of metoprolol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5592": {"data": {"text": "This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis.", "entity1": "oxygen", "entity2": "hemolysis", "span1": [41, 47], "span2": [130, 139]}, "bert_text": "This was further evidenced by absence of <e1> oxygen </e1> consumption and hemoglobin oxidation both determined in parallel with TAM-induced <e2> hemolysis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5593": {"data": {"text": "This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis.", "entity1": "TAM", "entity2": "hemolysis", "span1": [118, 121], "span2": [130, 139]}, "bert_text": "This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with <e1> TAM </e1>-induced <e2> hemolysis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5594": {"data": {"text": "The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.", "entity1": "CBZ", "entity2": "seizure", "span1": [28, 31], "span2": [56, 63]}, "bert_text": "The differential effects of <e1> CBZ </e1> depending upon stage of <e2> seizure </e2> development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5595": {"data": {"text": "The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.", "entity1": "CBZ", "entity2": "seizures", "span1": [28, 31], "span2": [181, 189]}, "bert_text": "The differential effects of <e1> CBZ </e1> depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5596": {"data": {"text": "Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.", "entity1": "telithromycin", "entity2": "hepatitis", "span1": [78, 91], "span2": [124, 133]}, "bert_text": "Based on a score of 8 on the Naranjo adverse drug reaction probability scale, <e1> telithromycin </e1> was the probable cause of acute <e2> hepatitis </e2> in this patient, and pathological findings suggested drug-induced toxic hepatitis.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5597": {"data": {"text": "Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.", "entity1": "telithromycin", "entity2": "toxic hepatitis", "span1": [78, 91], "span2": [200, 215]}, "bert_text": "Based on a score of 8 on the Naranjo adverse drug reaction probability scale, <e1> telithromycin </e1> was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced <e2> toxic hepatitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5598": {"data": {"text": "The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.", "entity1": "oral contraceptives", "entity2": "myocardial infarction", "span1": [67, 86], "span2": [12, 33]}, "bert_text": "The risk of myocardial infarction was similar among women who used <e1> oral contraceptives </e1> <e2> myocardial infarction </e2> was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"5599": {"data": {"text": "Effects of calcium channel blockers on bupivacaine-induced toxicity.\n", "entity1": "calcium", "entity2": "toxicity", "span1": [11, 18], "span2": [59, 67]}, "bert_text": "Effects of <e1> calcium </e1> channel blockers on bupivacaine-induced <e2> toxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5600": {"data": {"text": "Effects of calcium channel blockers on bupivacaine-induced toxicity.\n", "entity1": "bupivacaine", "entity2": "toxicity", "span1": [39, 50], "span2": [59, 67]}, "bert_text": "Effects of calcium channel blockers on <e1> bupivacaine </e1>-induced <e2> toxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5601": {"data": {"text": "Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.", "entity1": "MK-801", "entity2": "hyperactivity", "span1": [128, 134], "span2": [57, 70]}, "bert_text": "Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, <e1> MK-801 </e1> <e2> hyperactivity </e2> induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5602": {"data": {"text": "Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.", "entity1": "MK-801", "entity2": "hyperactivity", "span1": [128, 134], "span2": [170, 183]}, "bert_text": "Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, <e1> MK-801 </e1> and partially reversed spontaneous <e2> hyperactivity </e2> of NMDA Nr1(neo-/-) mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5603": {"data": {"text": "High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.", "entity1": "vitamin K", "entity2": "calcification", "span1": [18, 27], "span2": [72, 85]}, "bert_text": "High doses of the <e1> vitamin K </e1> antagonist Warfarin are also known to cause <e2> calcification </e2> of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5604": {"data": {"text": "High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.", "entity1": "Warfarin", "entity2": "calcification", "span1": [39, 47], "span2": [72, 85]}, "bert_text": "High doses of the vitamin K antagonist <e1> Warfarin </e1> are also known to cause <e2> calcification </e2> of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5605": {"data": {"text": "Reduction in caffeine toxicity by acetaminophen.\n", "entity1": "caffeine", "entity2": "toxicity", "span1": [13, 21], "span2": [22, 30]}, "bert_text": "Reduction in <e1> caffeine </e1> <e2> toxicity </e2> by acetaminophen.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5606": {"data": {"text": "Reduction in caffeine toxicity by acetaminophen.\n", "entity1": "acetaminophen", "entity2": "toxicity", "span1": [34, 47], "span2": [22, 30]}, "bert_text": "Reduction in caffeine toxicity by <e1> acetaminophen </e1> <e2> toxicity </e2> by acetaminophen.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5607": {"data": {"text": "The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.", "entity1": "bupivacaine", "entity2": "convulsions", "span1": [27, 38], "span2": [159, 170]}, "bert_text": "The convulsant activity of <e1> bupivacaine </e1> was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced <e2> convulsions </e2>; this effect was less pronounced with bepridil.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5608": {"data": {"text": "The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.", "entity1": "bupivacaine", "entity2": "convulsions", "span1": [139, 150], "span2": [159, 170]}, "bert_text": "The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain <e1> bupivacaine </e1>-induced <e2> convulsions </e2>; this effect was less pronounced with bepridil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5609": {"data": {"text": "The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.", "entity1": "calcium", "entity2": "convulsions", "span1": [74, 81], "span2": [159, 170]}, "bert_text": "The convulsant activity of bupivacaine was not significantly modified but <e1> calcium </e1> channel blockers decreased the time of latency to obtain bupivacaine-induced <e2> convulsions </e2>; this effect was less pronounced with bepridil.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5610": {"data": {"text": "The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.", "entity1": "bepridil", "entity2": "convulsions", "span1": [209, 217], "span2": [159, 170]}, "bert_text": "The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with <e1> bepridil </e1> <e2> convulsions </e2>; this effect was less pronounced with bepridil.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5611": {"data": {"text": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "entity1": "Amphotericin B", "entity2": "seizures", "span1": [13, 27], "span2": [66, 74]}, "bert_text": "CONCLUSIONS: <e1> Amphotericin B </e1> seems to be the probable cause of the <e2> seizures </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5612": {"data": {"text": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "entity1": "amphotericin B", "entity2": "seizures", "span1": [41, 55], "span2": [77, 85]}, "bert_text": "The time course of events suggested that <e1> amphotericin B </e1> was the cause of the <e2> seizures </e2> in this AIDS patient.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5613": {"data": {"text": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "entity1": "amphotericin B", "entity2": "AIDS", "span1": [41, 55], "span2": [94, 98]}, "bert_text": "The time course of events suggested that <e1> amphotericin B </e1> was the cause of the seizures in this <e2> AIDS </e2> patient.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5614": {"data": {"text": "When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.", "entity1": "CPA", "entity2": "poisoning", "span1": [5, 8], "span2": [153, 162]}, "bert_text": "When <e1> CPA </e1>, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of <e2> poisoning </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5615": {"data": {"text": "When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.", "entity1": "diazepam", "entity2": "poisoning", "span1": [10, 18], "span2": [153, 162]}, "bert_text": "When CPA, <e1> diazepam </e1> or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of <e2> poisoning </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5616": {"data": {"text": "When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.", "entity1": "2PAM", "entity2": "poisoning", "span1": [22, 26], "span2": [153, 162]}, "bert_text": "When CPA, diazepam or <e1> 2PAM </e1> was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of <e2> poisoning </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5617": {"data": {"text": "When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.", "entity1": "DFP", "entity2": "poisoning", "span1": [55, 58], "span2": [153, 162]}, "bert_text": "When CPA, diazepam or 2PAM was given immediately after <e1> DFP </e1>-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of <e2> poisoning </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5618": {"data": {"text": "When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.", "entity1": "atropine", "entity2": "poisoning", "span1": [59, 67], "span2": [153, 162]}, "bert_text": "When CPA, diazepam or 2PAM was given immediately after DFP-<e1> atropine </e1>, these treatments prevented, delayed or shortened the occurrence of serious signs of <e2> poisoning </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5619": {"data": {"text": "Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).", "entity1": "ribavirin", "entity2": "hemolytic anemia", "span1": [78, 87], "span2": [96, 112]}, "bert_text": "Combination therapy is associated with a clinically important adverse effect: <e1> ribavirin </e1>-induced <e2> hemolytic anemia </e2> (RIHA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"5620": {"data": {"text": "Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).", "entity1": "ribavirin", "entity2": "RIHA", "span1": [78, 87], "span2": [114, 118]}, "bert_text": "Combination therapy is associated with a clinically important adverse effect: <e1> ribavirin </e1>-induced hemolytic anemia (<e2> RIHA </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"5621": {"data": {"text": "Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks.", "entity1": "clonidine", "entity2": "Drowsiness", "span1": [25, 34], "span2": [0, 10]}, "bert_text": "Drowsiness was common on <e1> clonidine </e1> <e2> Drowsiness </e2> was common on clonidine, but generally resolved by 6 to 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5622": {"data": {"text": "Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.", "entity1": "Paclitaxel", "entity2": "neck cancer", "span1": [0, 10], "span2": [93, 104]}, "bert_text": "<e1> Paclitaxel </e1>/cisplatin is an effective first-line regimen for locoregionally advanced head and <e2> neck cancer </e2> and continued study is warranted.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5623": {"data": {"text": "Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.", "entity1": "cisplatin", "entity2": "neck cancer", "span1": [11, 20], "span2": [93, 104]}, "bert_text": "Paclitaxel/<e1> cisplatin </e1> is an effective first-line regimen for locoregionally advanced head and <e2> neck cancer </e2> and continued study is warranted.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5624": {"data": {"text": "The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.", "entity1": "bupropion", "entity2": "hepatotoxicity", "span1": [20, 29], "span2": [38, 52]}, "bert_text": "The likelihood that <e1> bupropion </e1> induced <e2> hepatotoxicity </e2> in our patient was possible, based on the Naranjo probability scale.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5625": {"data": {"text": "Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.\n", "entity1": "cyclophosphamide", "entity2": "haemorrhagic myocarditis", "span1": [44, 60], "span2": [6, 30]}, "bert_text": "Fatal haemorrhagic myocarditis secondary to <e1> cyclophosphamide </e1> <e2> haemorrhagic myocarditis </e2> secondary to cyclophosphamide therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5626": {"data": {"text": "respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o.", "entity1": "scopolamine", "entity2": "memory deficits", "span1": [50, 61], "span2": [23, 38]}, "bert_text": "respectively) reversed memory deficits induced by <e1> scopolamine </e1> <e2> memory deficits </e2> induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5627": {"data": {"text": "Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.", "entity1": "vincristine", "entity2": "Non-Hodgkin's Lymphoma", "span1": [56, 67], "span2": [20, 42]}, "bert_text": "Forty patients with Non-Hodgkin's Lymphoma treated with <e1> vincristine </e1> <e2> Non-Hodgkin's Lymphoma </e2> treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5628": {"data": {"text": "Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.", "entity1": "vincristine", "entity2": "Non-Hodgkin's Lymphoma", "span1": [193, 204], "span2": [20, 42]}, "bert_text": "Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of <e1> vincristine </e1> <e2> Non-Hodgkin's Lymphoma </e2> treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5629": {"data": {"text": "From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.", "entity1": "cocaine", "entity2": "EDDs", "span1": [23, 30], "span2": [90, 94]}, "bert_text": "From a registry of all <e1> cocaine </e1>-related deaths in Dade County, Florida, from 1969-1990, 58 <e2> EDDs </e2> were compared with 125 victims of accidental cocaine overdose without excited delirium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5630": {"data": {"text": "From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.", "entity1": "cocaine", "entity2": "delirium", "span1": [23, 30], "span2": [173, 181]}, "bert_text": "From a registry of all <e1> cocaine </e1>-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited <e2> delirium </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5631": {"data": {"text": "From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.", "entity1": "cocaine", "entity2": "overdose", "span1": [23, 30], "span2": [148, 156]}, "bert_text": "From a registry of all <e1> cocaine </e1>-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine <e2> overdose </e2> without excited delirium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5632": {"data": {"text": "From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.", "entity1": "cocaine", "entity2": "EDDs", "span1": [140, 147], "span2": [90, 94]}, "bert_text": "From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental <e1> cocaine </e1> <e2> EDDs </e2> were compared with 125 victims of accidental cocaine overdose without excited delirium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5633": {"data": {"text": "From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.", "entity1": "cocaine", "entity2": "delirium", "span1": [140, 147], "span2": [173, 181]}, "bert_text": "From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental <e1> cocaine </e1> overdose without excited <e2> delirium </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5634": {"data": {"text": "From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.", "entity1": "cocaine", "entity2": "overdose", "span1": [140, 147], "span2": [148, 156]}, "bert_text": "From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental <e1> cocaine </e1> <e2> overdose </e2> without excited delirium.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5635": {"data": {"text": "Although ribavirin-associated anemia can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates.", "entity1": "ribavirin", "entity2": "anemia", "span1": [9, 18], "span2": [30, 36]}, "bert_text": "Although <e1> ribavirin </e1>-associated <e2> anemia </e2> can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5636": {"data": {"text": "BACKGROUND: Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder.", "entity1": "Lithium", "entity2": "bipolar disorder", "span1": [12, 19], "span2": [94, 110]}, "bert_text": "BACKGROUND: <e1> Lithium </e1> remains a first-line treatment for the acute and maintenance treatment of <e2> bipolar disorder </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5637": {"data": {"text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.", "entity1": "bupropion", "entity2": "hepatotoxicity", "span1": [79, 88], "span2": [53, 67]}, "bert_text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by <e1> bupropion </e1> <e2> hepatotoxicity </e2> induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5638": {"data": {"text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.", "entity1": "bupropion", "entity2": "acute liver failure", "span1": [79, 88], "span2": [155, 174]}, "bert_text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by <e1> bupropion </e1>, this is the first case of fatality that could have resulted from <e2> acute liver failure </e2> in a patient receiving bupropion while on concomitant treatment with carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5639": {"data": {"text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.", "entity1": "bupropion", "entity2": "hepatotoxicity", "span1": [198, 207], "span2": [53, 67]}, "bert_text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving <e1> bupropion </e1> <e2> hepatotoxicity </e2> induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5640": {"data": {"text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.", "entity1": "bupropion", "entity2": "acute liver failure", "span1": [198, 207], "span2": [155, 174]}, "bert_text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving <e1> bupropion </e1> <e2> acute liver failure </e2> in a patient receiving bupropion while on concomitant treatment with carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5641": {"data": {"text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.", "entity1": "carbimazole", "entity2": "hepatotoxicity", "span1": [244, 255], "span2": [53, 67]}, "bert_text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with <e1> carbimazole </e1> <e2> hepatotoxicity </e2> induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5642": {"data": {"text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.", "entity1": "carbimazole", "entity2": "acute liver failure", "span1": [244, 255], "span2": [155, 174]}, "bert_text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with <e1> carbimazole </e1> <e2> acute liver failure </e2> in a patient receiving bupropion while on concomitant treatment with carbimazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5643": {"data": {"text": "We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.", "entity1": "cyclosporine", "entity2": "nephrotoxicity", "span1": [42, 54], "span2": [73, 87]}, "bert_text": "We think that even these lower dosages of <e1> cyclosporine </e1> can cause chronic <e2> nephrotoxicity </e2> and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5644": {"data": {"text": "In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.", "entity1": "sodium bicarbonate", "entity2": "penile pain", "span1": [275, 293], "span2": [35, 46]}, "bert_text": "In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of <e1> sodium bicarbonate </e1> <e2> penile pain </e2> associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5645": {"data": {"text": "In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.", "entity1": "sodium bicarbonate", "entity2": "penile pain", "span1": [275, 293], "span2": [195, 206]}, "bert_text": "In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of <e1> sodium bicarbonate </e1> <e2> penile pain </e2> following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5646": {"data": {"text": "We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.", "entity1": "ritonavir", "entity2": "atherosclerotic lesion", "span1": [37, 46], "span2": [67, 89]}, "bert_text": "We have previously demonstrated that <e1> ritonavir </e1> treatment increases <e2> atherosclerotic lesion </e2> formation in male mice to a greater extent than in female mice.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5647": {"data": {"text": "Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.", "entity1": "anthracycline", "entity2": "myocardial lesions", "span1": [70, 83], "span2": [20, 38]}, "bert_text": "Histologically, the myocardial lesions resembled those found in human <e1> anthracycline </e1> <e2> myocardial lesions </e2> resembled those found in human anthracycline-induced cardiomyopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5648": {"data": {"text": "Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.", "entity1": "anthracycline", "entity2": "cardiomyopathy", "span1": [70, 83], "span2": [92, 106]}, "bert_text": "Histologically, the myocardial lesions resembled those found in human <e1> anthracycline </e1>-induced <e2> cardiomyopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5649": {"data": {"text": "AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.", "entity1": "AZT", "entity2": "anaemia", "span1": [0, 3], "span2": [23, 30]}, "bert_text": "<e1> AZT </e1>-induced peripheral <e2> anaemia </e2> in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5650": {"data": {"text": "To our knowledge, this is the first case of acitretin-induced dysphonia.", "entity1": "acitretin", "entity2": "dysphonia", "span1": [44, 53], "span2": [62, 71]}, "bert_text": "To our knowledge, this is the first case of <e1> acitretin </e1>-induced <e2> dysphonia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5651": {"data": {"text": "Thiopentone pretreatment for propofol injection pain in ambulatory patients.\n", "entity1": "Thiopentone", "entity2": "pain", "span1": [0, 11], "span2": [48, 52]}, "bert_text": "<e1> Thiopentone </e1> pretreatment for propofol injection <e2> pain </e2> in ambulatory patients.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5652": {"data": {"text": "Thiopentone pretreatment for propofol injection pain in ambulatory patients.\n", "entity1": "propofol", "entity2": "pain", "span1": [29, 37], "span2": [48, 52]}, "bert_text": "Thiopentone pretreatment for <e1> propofol </e1> injection <e2> pain </e2> in ambulatory patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5653": {"data": {"text": "CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.", "entity1": "VNB", "entity2": "esophageal squamous cell carcinoma", "span1": [37, 40], "span2": [74, 108]}, "bert_text": "CONCLUSION: These data indicate that <e1> VNB </e1> is an active agent in metastatic <e2> esophageal squamous cell carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5654": {"data": {"text": "Photodistributed nifedipine-induced facial telangiectasia.\n", "entity1": "nifedipine", "entity2": "telangiectasia", "span1": [17, 27], "span2": [43, 57]}, "bert_text": "Photodistributed <e1> nifedipine </e1>-induced facial <e2> telangiectasia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5655": {"data": {"text": "The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.", "entity1": "penicillamine", "entity2": "elastosis perforans serpiginosa", "span1": [198, 211], "span2": [26, 57]}, "bert_text": "The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with <e1> penicillamine </e1> <e2> elastosis perforans serpiginosa </e2>, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5656": {"data": {"text": "The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.", "entity1": "penicillamine", "entity2": "Wilson's disease", "span1": [198, 211], "span2": [122, 138]}, "bert_text": "The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with <e1> penicillamine </e1> <e2> Wilson's disease </e2> but not in patients with rheumatoid arthritis treated with penicillamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5657": {"data": {"text": "The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.", "entity1": "penicillamine", "entity2": "rheumatoid arthritis", "span1": [198, 211], "span2": [164, 184]}, "bert_text": "The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with <e1> penicillamine </e1> <e2> rheumatoid arthritis </e2> treated with penicillamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"5658": {"data": {"text": "Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.\n", "entity1": "Heparin", "entity2": "thrombocytopenia", "span1": [0, 7], "span2": [16, 32]}, "bert_text": "<e1> Heparin </e1>-induced <e2> thrombocytopenia </e2>, thrombosis, and hemorrhage.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5659": {"data": {"text": "Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.\n", "entity1": "Heparin", "entity2": "thrombosis", "span1": [0, 7], "span2": [34, 44]}, "bert_text": "<e1> Heparin </e1>-induced thrombocytopenia, <e2> thrombosis </e2>, and hemorrhage.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5660": {"data": {"text": "Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.\n", "entity1": "Heparin", "entity2": "hemorrhage", "span1": [0, 7], "span2": [50, 60]}, "bert_text": "<e1> Heparin </e1>-induced thrombocytopenia, thrombosis, and <e2> hemorrhage </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5661": {"data": {"text": "Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.", "entity1": "PREGS", "entity2": "amnesic", "span1": [10, 15], "span2": [39, 46]}, "bert_text": "Moreover, <e1> PREGS </e1> is able to reverse the <e2> amnesic </e2>-like effects of NMDAR and GABA(A)R ligands.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5662": {"data": {"text": "Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.", "entity1": "GABA(A)R", "entity2": "amnesic", "span1": [73, 81], "span2": [39, 46]}, "bert_text": "Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and <e1> GABA(A)R </e1> <e2> amnesic </e2>-like effects of NMDAR and GABA(A)R ligands.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5663": {"data": {"text": "Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.", "entity1": "alprazolam", "entity2": "depression", "span1": [32, 42], "span2": [100, 110]}, "bert_text": "Compared with placebo subjects, <e1> alprazolam </e1> patients developed more adverse reactions (21% v. 0%) of <e2> depression </e2>, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5664": {"data": {"text": "Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.", "entity1": "alprazolam", "entity2": "enuresis", "span1": [32, 42], "span2": [112, 120]}, "bert_text": "Compared with placebo subjects, <e1> alprazolam </e1> patients developed more adverse reactions (21% v. 0%) of depression, <e2> enuresis </e2>, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5665": {"data": {"text": "Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.", "entity1": "alprazolam", "entity2": "aggression", "span1": [32, 42], "span2": [140, 150]}, "bert_text": "Compared with placebo subjects, <e1> alprazolam </e1> patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and <e2> aggression </e2>; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5666": {"data": {"text": "Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.", "entity1": "alprazolam", "entity2": "irritability", "span1": [32, 42], "span2": [198, 210]}, "bert_text": "Compared with placebo subjects, <e1> alprazolam </e1> patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, <e2> irritability </e2>, impaired memory, weight loss and ataxia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5667": {"data": {"text": "Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.", "entity1": "alprazolam", "entity2": "impaired memory", "span1": [32, 42], "span2": [212, 227]}, "bert_text": "Compared with placebo subjects, <e1> alprazolam </e1> patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, <e2> impaired memory </e2>, weight loss and ataxia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5668": {"data": {"text": "Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.", "entity1": "alprazolam", "entity2": "weight loss", "span1": [32, 42], "span2": [229, 240]}, "bert_text": "Compared with placebo subjects, <e1> alprazolam </e1> patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, <e2> weight loss </e2> and ataxia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5669": {"data": {"text": "Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.", "entity1": "alprazolam", "entity2": "ataxia", "span1": [32, 42], "span2": [245, 251]}, "bert_text": "Compared with placebo subjects, <e1> alprazolam </e1> patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and <e2> ataxia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5670": {"data": {"text": "Atropine-MK801 did not offer any additional protection against DFP toxicity.", "entity1": "Atropine", "entity2": "toxicity", "span1": [0, 8], "span2": [67, 75]}, "bert_text": "<e1> Atropine </e1>-MK801 did not offer any additional protection against DFP <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5671": {"data": {"text": "Atropine-MK801 did not offer any additional protection against DFP toxicity.", "entity1": "MK801", "entity2": "toxicity", "span1": [9, 14], "span2": [67, 75]}, "bert_text": "Atropine-<e1> MK801 </e1> did not offer any additional protection against DFP <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5672": {"data": {"text": "Atropine-MK801 did not offer any additional protection against DFP toxicity.", "entity1": "DFP", "entity2": "toxicity", "span1": [63, 66], "span2": [67, 75]}, "bert_text": "Atropine-MK801 did not offer any additional protection against <e1> DFP </e1> <e2> toxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5673": {"data": {"text": "Sodium status influences chronic amphotericin B nephrotoxicity in rats.\n", "entity1": "Sodium", "entity2": "nephrotoxicity", "span1": [0, 6], "span2": [48, 62]}, "bert_text": "<e1> Sodium </e1> status influences chronic amphotericin B <e2> nephrotoxicity </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5674": {"data": {"text": "Sodium status influences chronic amphotericin B nephrotoxicity in rats.\n", "entity1": "amphotericin B", "entity2": "nephrotoxicity", "span1": [33, 47], "span2": [48, 62]}, "bert_text": "Sodium status influences chronic <e1> amphotericin B </e1> <e2> nephrotoxicity </e2> in rats.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5675": {"data": {"text": "Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.", "entity1": "Gentamicin sulfate", "entity2": "ototoxicity", "span1": [0, 18], "span2": [66, 77]}, "bert_text": "<e1> Gentamicin sulfate </e1> and tobramycin sulfate continue to demonstrate <e2> ototoxicity </e2> and nephrotoxicity in both animal and clinical studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5676": {"data": {"text": "Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.", "entity1": "Gentamicin sulfate", "entity2": "nephrotoxicity", "span1": [0, 18], "span2": [82, 96]}, "bert_text": "<e1> Gentamicin sulfate </e1> and tobramycin sulfate continue to demonstrate ototoxicity and <e2> nephrotoxicity </e2> in both animal and clinical studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5677": {"data": {"text": "Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.", "entity1": "tobramycin", "entity2": "ototoxicity", "span1": [23, 33], "span2": [66, 77]}, "bert_text": "Gentamicin sulfate and <e1> tobramycin </e1> sulfate continue to demonstrate <e2> ototoxicity </e2> and nephrotoxicity in both animal and clinical studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5678": {"data": {"text": "Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.", "entity1": "tobramycin", "entity2": "nephrotoxicity", "span1": [23, 33], "span2": [82, 96]}, "bert_text": "Gentamicin sulfate and <e1> tobramycin </e1> sulfate continue to demonstrate ototoxicity and <e2> nephrotoxicity </e2> in both animal and clinical studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5679": {"data": {"text": "On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).", "entity1": "DNR", "entity2": "heart failure", "span1": [84, 87], "span2": [64, 77]}, "bert_text": "On the other hand, BNP did not increase in the patients without heart failure given <e1> DNR </e1> <e2> heart failure </e2> given DNR, even at more than 700 mg/m(2).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5680": {"data": {"text": "Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.", "entity1": "tacrolimus", "entity2": "renal acidosis", "span1": [9, 19], "span2": [74, 88]}, "bert_text": "Although <e1> tacrolimus </e1> was suspected to be the cause of late post-transplant <e2> renal acidosis </e2> and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5681": {"data": {"text": "Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.", "entity1": "tacrolimus", "entity2": "acidosis", "span1": [9, 19], "span2": [120, 128]}, "bert_text": "Although <e1> tacrolimus </e1> was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, <e2> acidosis </e2>, and electrolyte imbalance got worse.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5682": {"data": {"text": "Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.", "entity1": "sirolimus", "entity2": "renal acidosis", "span1": [109, 118], "span2": [74, 88]}, "bert_text": "Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by <e1> sirolimus </e1> <e2> renal acidosis </e2> and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5683": {"data": {"text": "Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.", "entity1": "sirolimus", "entity2": "acidosis", "span1": [109, 118], "span2": [120, 128]}, "bert_text": "Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by <e1> sirolimus </e1>, <e2> acidosis </e2>, and electrolyte imbalance got worse.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5684": {"data": {"text": "Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure.\n", "entity1": "tamoxifen", "entity2": "Hemolysis", "span1": [43, 52], "span2": [0, 9]}, "bert_text": "Hemolysis of human erythrocytes induced by <e1> tamoxifen </e1> <e2> Hemolysis </e2> of human erythrocytes induced by tamoxifen is related to disruption of membrane structure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5685": {"data": {"text": "A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.", "entity1": "warfarin", "entity2": "cerebral haemorrhages", "span1": [28, 36], "span2": [45, 66]}, "bert_text": "A significant proportion of <e1> warfarin </e1>-related <e2> cerebral haemorrhages </e2> might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5686": {"data": {"text": "A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.", "entity1": "warfarin", "entity2": "cerebral haemorrhages", "span1": [173, 181], "span2": [45, 66]}, "bert_text": "A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with <e1> warfarin </e1> <e2> cerebral haemorrhages </e2> might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5687": {"data": {"text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "entity1": "Adenosine", "entity2": "pain", "span1": [9, 18], "span2": [41, 45]}, "bert_text": "RESULTS: <e1> Adenosine </e1> produced no effect on <e2> pain </e2> report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"5688": {"data": {"text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "entity1": "Adenosine", "entity2": "hyperalgesia", "span1": [9, 18], "span2": [125, 137]}, "bert_text": "RESULTS: <e1> Adenosine </e1> produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical <e2> hyperalgesia </e2> and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5689": {"data": {"text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "entity1": "Adenosine", "entity2": "allodynia", "span1": [9, 18], "span2": [142, 151]}, "bert_text": "RESULTS: <e1> Adenosine </e1> produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and <e2> allodynia </e2> from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5690": {"data": {"text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "entity1": "adenosine", "entity2": "pain", "span1": [239, 248], "span2": [41, 45]}, "bert_text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of <e1> adenosine </e1> <e2> pain </e2> report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"5691": {"data": {"text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "entity1": "adenosine", "entity2": "hyperalgesia", "span1": [239, 248], "span2": [125, 137]}, "bert_text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of <e1> adenosine </e1> <e2> hyperalgesia </e2> and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5692": {"data": {"text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "entity1": "adenosine", "entity2": "allodynia", "span1": [239, 248], "span2": [142, 151]}, "bert_text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of <e1> adenosine </e1> <e2> allodynia </e2> from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5693": {"data": {"text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "entity1": "capsaicin", "entity2": "pain", "span1": [169, 178], "span2": [41, 45]}, "bert_text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal <e1> capsaicin </e1> <e2> pain </e2> report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"5694": {"data": {"text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [169, 178], "span2": [125, 137]}, "bert_text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal <e1> capsaicin </e1> <e2> hyperalgesia </e2> and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5695": {"data": {"text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "entity1": "capsaicin", "entity2": "allodynia", "span1": [169, 178], "span2": [142, 151]}, "bert_text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal <e1> capsaicin </e1> <e2> allodynia </e2> from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5696": {"data": {"text": "A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.", "entity1": "epinephrine", "entity2": "left ventricular systolic and diastolic dysfunction", "span1": [79, 90], "span2": [206, 257]}, "bert_text": "A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of <e1> epinephrine </e1> developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, <e2> left ventricular systolic and diastolic dysfunction </e2>, and only modestly elevated biochemical markers of myocardial necrosis.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5697": {"data": {"text": "A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.", "entity1": "epinephrine", "entity2": "myocardial necrosis", "span1": [79, 90], "span2": [309, 328]}, "bert_text": "A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of <e1> epinephrine </e1> developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of <e2> myocardial necrosis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5698": {"data": {"text": "Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.", "entity1": "mitomycin C", "entity2": "cardiotoxic", "span1": [11, 22], "span2": [54, 65]}, "bert_text": "Since 1975 <e1> mitomycin C </e1> (MMC) has been suggested to be <e2> cardiotoxic </e2>, especially when combined with or given following doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5699": {"data": {"text": "Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.", "entity1": "MMC", "entity2": "cardiotoxic", "span1": [24, 27], "span2": [54, 65]}, "bert_text": "Since 1975 mitomycin C (<e1> MMC </e1>) has been suggested to be <e2> cardiotoxic </e2>, especially when combined with or given following doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5700": {"data": {"text": "Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.", "entity1": "doxorubicin", "entity2": "cardiotoxic", "span1": [116, 127], "span2": [54, 65]}, "bert_text": "Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following <e1> doxorubicin </e1> <e2> cardiotoxic </e2>, especially when combined with or given following doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5701": {"data": {"text": "METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.", "entity1": "prostigmine", "entity2": "Sphincter of Oddi spasm", "span1": [47, 58], "span2": [8, 31]}, "bert_text": "METHOD: Sphincter of Oddi spasm was induced by <e1> prostigmine </e1> <e2> Sphincter of Oddi spasm </e2> was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5702": {"data": {"text": "METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.", "entity1": "prostigmine", "entity2": "Sphincter of Oddi spasm", "span1": [91, 102], "span2": [8, 31]}, "bert_text": "METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg <e1> prostigmine </e1> <e2> Sphincter of Oddi spasm </e2> was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5703": {"data": {"text": "METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.", "entity1": "morphine", "entity2": "Sphincter of Oddi spasm", "span1": [59, 67], "span2": [8, 31]}, "bert_text": "METHOD: Sphincter of Oddi spasm was induced by prostigmine-<e1> morphine </e1> <e2> Sphincter of Oddi spasm </e2> was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5704": {"data": {"text": "METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.", "entity1": "morphine", "entity2": "Sphincter of Oddi spasm", "span1": [129, 137], "span2": [8, 31]}, "bert_text": "METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg <e1> morphine </e1> <e2> Sphincter of Oddi spasm </e2> was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5705": {"data": {"text": "Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.", "entity1": "capsaicin", "entity2": "pain", "span1": [79, 88], "span2": [44, 48]}, "bert_text": "Subjects were able to reliably discriminate pain magnitude and duration across <e1> capsaicin </e1> <e2> pain </e2> magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5706": {"data": {"text": "All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.", "entity1": "GABA(A", "entity2": "seizures", "span1": [22, 28], "span2": [78, 86]}, "bert_text": "All of these positive <e1> GABA(A </e1>) modulators suppressed the expression of kindled <e2> seizures </e2>, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5707": {"data": {"text": "All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.", "entity1": "allopregnanolone", "entity2": "seizures", "span1": [101, 117], "span2": [78, 86]}, "bert_text": "All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only <e1> allopregnanolone </e1> <e2> seizures </e2>, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5708": {"data": {"text": "All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.", "entity1": "ganaxolone", "entity2": "seizures", "span1": [122, 132], "span2": [78, 86]}, "bert_text": "All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and <e1> ganaxolone </e1> <e2> seizures </e2>, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5709": {"data": {"text": "The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.", "entity1": "cimetidine", "entity2": "bradyarrhythmias", "span1": [60, 70], "span2": [122, 138]}, "bert_text": "The administration of intermittent intravenous infusions of <e1> cimetidine </e1> is infrequently associated with the development of <e2> bradyarrhythmias </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5710": {"data": {"text": "In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.", "entity1": "PAN", "entity2": "nephrotic syndrome", "span1": [125, 128], "span2": [137, 155]}, "bert_text": "In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of <e1> PAN </e1>-induced <e2> nephrotic syndrome </e2> in rats, but appears to escape from the regulation by aldosterone after day 3.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5711": {"data": {"text": "In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.", "entity1": "aldosterone", "entity2": "nephrotic syndrome", "span1": [210, 221], "span2": [137, 155]}, "bert_text": "In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by <e1> aldosterone </e1> <e2> nephrotic syndrome </e2> in rats, but appears to escape from the regulation by aldosterone after day 3.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5712": {"data": {"text": "Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa-induced dyskinesias, their pathogenesis is still unclear.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [138, 146], "span2": [155, 166]}, "bert_text": "Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying <e1> levodopa </e1>-induced <e2> dyskinesias </e2>, their pathogenesis is still unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5713": {"data": {"text": "When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.", "entity1": "BN 52021", "entity2": "HR", "span1": [5, 13], "span2": [131, 133]}, "bert_text": "When <e1> BN 52021 </e1> (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and <e2> HR </e2> was observed, whereas the dose of 10 mg/kg was ineffective.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5714": {"data": {"text": "When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.", "entity1": "bupivacaine", "entity2": "HR", "span1": [61, 72], "span2": [131, 133]}, "bert_text": "When BN 52021 (20 mg/kg i.v.) was injected immediately after <e1> bupivacaine </e1> (2 mg/kg), a partial reversion of the decrease of MBP and <e2> HR </e2> was observed, whereas the dose of 10 mg/kg was ineffective.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5715": {"data": {"text": "OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.", "entity1": "salbutamol", "entity2": "tremor", "span1": [43, 53], "span2": [20, 26]}, "bert_text": "OBJECTIVE: To study tremor side effects of <e1> salbutamol </e1> <e2> tremor </e2> side effects of salbutamol an easily applicable, quick and low-priced method is needed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5716": {"data": {"text": "Remission induction of meningeal leukemia with high-dose intravenous methotrexate.\n", "entity1": "methotrexate", "entity2": "meningeal leukemia", "span1": [69, 81], "span2": [23, 41]}, "bert_text": "Remission induction of meningeal leukemia with high-dose intravenous <e1> methotrexate </e1> <e2> meningeal leukemia </e2> with high-dose intravenous methotrexate.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5717": {"data": {"text": "Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.", "entity1": "ammonia", "entity2": "coma", "span1": [39, 46], "span2": [77, 81]}, "bert_text": "Thus, the reduction in blood and brain <e1> ammonia </e1> and the prevention of ammonia <e2> coma </e2> after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5718": {"data": {"text": "Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.", "entity1": "ammonia", "entity2": "coma", "span1": [69, 76], "span2": [77, 81]}, "bert_text": "Thus, the reduction in blood and brain ammonia and the prevention of <e1> ammonia </e1> <e2> coma </e2> after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5719": {"data": {"text": "Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.", "entity1": "L-dopa", "entity2": "coma", "span1": [88, 94], "span2": [77, 81]}, "bert_text": "Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after <e1> L-dopa </e1> <e2> coma </e2> after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"5720": {"data": {"text": "Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.", "entity1": "dopamine", "entity2": "coma", "span1": [145, 153], "span2": [77, 81]}, "bert_text": "Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of <e1> dopamine </e1> <e2> coma </e2> after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"5721": {"data": {"text": "However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.", "entity1": "coniine", "entity2": "arthrogryposis", "span1": [9, 16], "span2": [39, 53]}, "bert_text": "However, <e1> coniine </e1> has failed to produce <e2> arthrogryposis </e2> in rats or mice and is only weakly teratogenic in rabbits.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5722": {"data": {"text": "Association of nitric oxide production and apoptosis in a model of experimental nephropathy.\n", "entity1": "nitric oxide", "entity2": "nephropathy", "span1": [15, 27], "span2": [80, 91]}, "bert_text": "Association of <e1> nitric oxide </e1> production and apoptosis in a model of experimental <e2> nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5723": {"data": {"text": "Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.\n", "entity1": "cyclophosphamide", "entity2": "Cardiac toxicity", "span1": [56, 72], "span2": [0, 16]}, "bert_text": "Cardiac toxicity observed in association with high-dose <e1> cyclophosphamide </e1> <e2> Cardiac toxicity </e2> observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5724": {"data": {"text": "Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.\n", "entity1": "cyclophosphamide", "entity2": "breast cancer", "span1": [56, 72], "span2": [107, 120]}, "bert_text": "Cardiac toxicity observed in association with high-dose <e1> cyclophosphamide </e1>-based chemotherapy for metastatic <e2> breast cancer </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5725": {"data": {"text": "In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.", "entity1": "haloperidol", "entity2": "psychotic syndromes belonging", "span1": [31, 42], "span2": [114, 143]}, "bert_text": "In the double blind study with <e1> haloperidol </e1>, both substances were found to be highly effective in the treatment of <e2> psychotic syndromes belonging </e2> predominantly to the schizophrenia group.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5726": {"data": {"text": "In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.", "entity1": "haloperidol", "entity2": "schizophrenia", "span1": [31, 42], "span2": [165, 178]}, "bert_text": "In the double blind study with <e1> haloperidol </e1>, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the <e2> schizophrenia </e2> group.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5727": {"data": {"text": "Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.\n", "entity1": "carboplatin", "entity2": "ocular and orbital toxicity", "span1": [67, 78], "span2": [7, 34]}, "bert_text": "Severe ocular and orbital toxicity after intracarotid injection of <e1> carboplatin </e1> <e2> ocular and orbital toxicity </e2> after intracarotid injection of carboplatin for recurrent glioblastomas.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5728": {"data": {"text": "Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.\n", "entity1": "carboplatin", "entity2": "glioblastomas", "span1": [67, 78], "span2": [93, 106]}, "bert_text": "Severe ocular and orbital toxicity after intracarotid injection of <e1> carboplatin </e1> for recurrent <e2> glioblastomas </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5729": {"data": {"text": "These differences may be caused by timolol-induced bradycardia and a compensatory increase in end-diastolic volume.", "entity1": "timolol", "entity2": "bradycardia", "span1": [35, 42], "span2": [51, 62]}, "bert_text": "These differences may be caused by <e1> timolol </e1>-induced <e2> bradycardia </e2> and a compensatory increase in end-diastolic volume.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5730": {"data": {"text": "RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.", "entity1": "fenfluramine", "entity2": "valvular heart disease", "span1": [63, 75], "span2": [98, 120]}, "bert_text": "RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving <e1> fenfluramine </e1>-phentermine developed <e2> valvular heart disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5731": {"data": {"text": "RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.", "entity1": "phentermine", "entity2": "valvular heart disease", "span1": [76, 87], "span2": [98, 120]}, "bert_text": "RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-<e1> phentermine </e1> developed <e2> valvular heart disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5732": {"data": {"text": "Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.\n", "entity1": "prostaglandin E1", "entity2": "hypotension", "span1": [27, 43], "span2": [68, 79]}, "bert_text": "Epidural blood flow during <e1> prostaglandin E1 </e1> or trimethaphan induced <e2> hypotension </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5733": {"data": {"text": "Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.\n", "entity1": "trimethaphan", "entity2": "hypotension", "span1": [47, 59], "span2": [68, 79]}, "bert_text": "Epidural blood flow during prostaglandin E1 or <e1> trimethaphan </e1> induced <e2> hypotension </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5734": {"data": {"text": "A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.", "entity1": "cimetidine", "entity2": "leukemia", "span1": [163, 173], "span2": [23, 31]}, "bert_text": "A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion <e1> cimetidine </e1> <e2> leukemia </e2> and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5735": {"data": {"text": "A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.", "entity1": "cimetidine", "entity2": "cardiac disease", "span1": [163, 173], "span2": [50, 65]}, "bert_text": "A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion <e1> cimetidine </e1> <e2> cardiac disease </e2> developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"5736": {"data": {"text": "A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.", "entity1": "cimetidine", "entity2": "sinus arrest", "span1": [163, 173], "span2": [114, 126]}, "bert_text": "A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion <e1> cimetidine </e1> <e2> sinus arrest </e2> while receiving continuous-infusion cimetidine 50 mg/hour.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5737": {"data": {"text": "In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.", "entity1": "gentamicin sulfate", "entity2": "renal failure", "span1": [109, 127], "span2": [255, 268]}, "bert_text": "In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of <e1> gentamicin sulfate </e1> or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related <e2> renal failure </e2>, defined as at least a one-third reduction in renal function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5738": {"data": {"text": "In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.", "entity1": "tobramycin sulfate", "entity2": "renal failure", "span1": [131, 149], "span2": [255, 268]}, "bert_text": "In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or <e1> tobramycin sulfate </e1> for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related <e2> renal failure </e2>, defined as at least a one-third reduction in renal function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5739": {"data": {"text": "In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.", "entity1": "aminoglycoside", "entity2": "renal failure", "span1": [232, 246], "span2": [255, 268]}, "bert_text": "In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of <e1> aminoglycoside </e1>-related <e2> renal failure </e2>, defined as at least a one-third reduction in renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5740": {"data": {"text": "Glyburide can produce an acute hepatitis-like illness in some persons.", "entity1": "Glyburide", "entity2": "hepatitis-like illness", "span1": [0, 9], "span2": [31, 53]}, "bert_text": "<e1> Glyburide </e1> can produce an acute <e2> hepatitis-like illness </e2> in some persons.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5741": {"data": {"text": "We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.", "entity1": "simvastatin", "entity2": "fulminant hepatic failure", "span1": [148, 159], "span2": [55, 80]}, "bert_text": "We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from <e1> simvastatin </e1> <e2> fulminant hepatic failure </e2> necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5742": {"data": {"text": "We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.", "entity1": "simvastatin", "entity2": "fulminant hepatic failure", "span1": [173, 184], "span2": [55, 80]}, "bert_text": "We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to <e1> simvastatin </e1> <e2> fulminant hepatic failure </e2> necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5743": {"data": {"text": "We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.", "entity1": "ezetimibe", "entity2": "fulminant hepatic failure", "span1": [191, 200], "span2": [55, 80]}, "bert_text": "We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-<e1> ezetimibe </e1> <e2> fulminant hepatic failure </e2> necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5744": {"data": {"text": "High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.", "entity1": "vitamin D", "entity2": "artery calcification", "span1": [98, 107], "span2": [56, 76]}, "bert_text": "High levels of matrix Gla protein are found at sites of artery calcification in rats treated with <e1> vitamin D </e1> <e2> artery calcification </e2> in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5745": {"data": {"text": "High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [113, 121], "span2": [56, 76]}, "bert_text": "High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus <e1> Warfarin </e1> <e2> artery calcification </e2> in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5746": {"data": {"text": "High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.", "entity1": "gamma-carboxylated", "entity2": "artery calcification", "span1": [201, 219], "span2": [56, 76]}, "bert_text": "High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not <e1> gamma-carboxylated </e1> <e2> artery calcification </e2> in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5747": {"data": {"text": "The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.", "entity1": "TCR", "entity2": "myocardial infarction", "span1": [67, 70], "span2": [97, 118]}, "bert_text": "The present study was done to investigate the protective effect of <e1> TCR </e1> on experimentally induced <e2> myocardial infarction </e2> in rats.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5748": {"data": {"text": "AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.", "entity1": "bilirubin", "entity2": "hypotension", "span1": [307, 316], "span2": [212, 223]}, "bert_text": "AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total <e1> bilirubin </e1> <e2> hypotension </e2> and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5749": {"data": {"text": "Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [23, 34], "span2": [83, 97]}, "bert_text": "Often, chemotherapy by <e1> doxorubicin </e1> (Adriamycin) is limited due to life threatening <e2> cardiotoxicity </e2> in patients during and posttherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5750": {"data": {"text": "Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.", "entity1": "Adriamycin", "entity2": "cardiotoxicity", "span1": [36, 46], "span2": [83, 97]}, "bert_text": "Often, chemotherapy by doxorubicin (<e1> Adriamycin </e1>) is limited due to life threatening <e2> cardiotoxicity </e2> in patients during and posttherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5751": {"data": {"text": "OUTCOME: Following discontinuation of LEV, EEG and neuropsychological findings improved and seizure frequency decreased.", "entity1": "LEV", "entity2": "seizure", "span1": [38, 41], "span2": [92, 99]}, "bert_text": "OUTCOME: Following discontinuation of <e1> LEV </e1>, EEG and neuropsychological findings improved and <e2> seizure </e2> frequency decreased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5752": {"data": {"text": "Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [81, 92], "span2": [63, 77]}, "bert_text": "Increased oxidative stress is a major factor implicated in the cardiotoxicity of <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5753": {"data": {"text": "Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [94, 97], "span2": [63, 77]}, "bert_text": "Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (<e1> DOX </e1> <e2> cardiotoxicity </e2> of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5754": {"data": {"text": "Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.", "entity1": "anthracycline", "entity2": "cardiotoxicity", "span1": [124, 137], "span2": [63, 77]}, "bert_text": "Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor <e1> anthracycline </e1> <e2> cardiotoxicity </e2> of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5755": {"data": {"text": "The risk of serious thrombotic events was also similar for each valdecoxib dose.", "entity1": "valdecoxib", "entity2": "thrombotic", "span1": [64, 74], "span2": [20, 30]}, "bert_text": "The risk of serious thrombotic events was also similar for each <e1> valdecoxib </e1> <e2> thrombotic </e2> events was also similar for each valdecoxib dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5756": {"data": {"text": "To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [70, 79], "span2": [24, 36]}, "bert_text": "To this end, persistent hyperalgesia was induced by administration of <e1> capsaicin </e1> <e2> hyperalgesia </e2> was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5757": {"data": {"text": "CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.", "entity1": "superoxide", "entity2": "renal lesions", "span1": [187, 197], "span2": [221, 234]}, "bert_text": "CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of <e1> superoxide </e1> in doxorubicin-induced <e2> renal lesions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5758": {"data": {"text": "CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.", "entity1": "doxorubicin", "entity2": "renal lesions", "span1": [201, 212], "span2": [221, 234]}, "bert_text": "CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in <e1> doxorubicin </e1>-induced <e2> renal lesions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5759": {"data": {"text": "Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).", "entity1": "testosterone", "entity2": "hypothalamic dysfunction", "span1": [22, 34], "span2": [75, 99]}, "bert_text": "Most of the other low <e1> testosterone </e1> levels seemed to result from nonorganic <e2> hypothalamic dysfunction </e2> because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5760": {"data": {"text": "Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).", "entity1": "testosterone", "entity2": "erectile dysfunction", "span1": [22, 34], "span2": [191, 211]}, "bert_text": "Most of the other low <e1> testosterone </e1> levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in <e2> erectile dysfunction </e2> (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5761": {"data": {"text": "A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.", "entity1": "etoposide", "entity2": "acute T-lymphocytic leukemia", "span1": [24, 33], "span2": [83, 111]}, "bert_text": "A synergistic effect of <e1> etoposide </e1> and cyclosporin A was observed in a patient with <e2> acute T-lymphocytic leukemia </e2> in relapse.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5762": {"data": {"text": "A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.", "entity1": "cyclosporin A", "entity2": "acute T-lymphocytic leukemia", "span1": [38, 51], "span2": [83, 111]}, "bert_text": "A synergistic effect of etoposide and <e1> cyclosporin A </e1> was observed in a patient with <e2> acute T-lymphocytic leukemia </e2> in relapse.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5763": {"data": {"text": "In summary, the chick embryo provides a reliable and simple experimental animal model of coniine-induced arthrogryposis.", "entity1": "coniine", "entity2": "arthrogryposis", "span1": [89, 96], "span2": [105, 119]}, "bert_text": "In summary, the chick embryo provides a reliable and simple experimental animal model of <e1> coniine </e1>-induced <e2> arthrogryposis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5764": {"data": {"text": "We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.", "entity1": "bupropion", "entity2": "sleep deprivation", "span1": [57, 66], "span2": [16, 33]}, "bert_text": "We suggest that sleep deprivation may add to the risk of <e1> bupropion </e1> <e2> sleep deprivation </e2> may add to the risk of bupropion-associated seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5765": {"data": {"text": "We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.", "entity1": "bupropion", "entity2": "seizures", "span1": [57, 66], "span2": [78, 86]}, "bert_text": "We suggest that sleep deprivation may add to the risk of <e1> bupropion </e1>-associated <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5766": {"data": {"text": "Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.", "entity1": "haloperidol", "entity2": "hyperactivity", "span1": [29, 40], "span2": [149, 162]}, "bert_text": "Importantly, both classical (<e1> haloperidol </e1>) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5767": {"data": {"text": "Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.", "entity1": "olanzapine", "entity2": "hyperactivity", "span1": [56, 66], "span2": [149, 162]}, "bert_text": "Importantly, both classical (haloperidol) and atypical (<e1> olanzapine </e1>, clozapine and aripiprazole) antipsychotics were effective in all these models of <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5768": {"data": {"text": "Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.", "entity1": "clozapine", "entity2": "hyperactivity", "span1": [68, 77], "span2": [149, 162]}, "bert_text": "Importantly, both classical (haloperidol) and atypical (olanzapine, <e1> clozapine </e1> and aripiprazole) antipsychotics were effective in all these models of <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5769": {"data": {"text": "Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.", "entity1": "aripiprazole", "entity2": "hyperactivity", "span1": [82, 94], "span2": [149, 162]}, "bert_text": "Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and <e1> aripiprazole </e1>) antipsychotics were effective in all these models of <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5770": {"data": {"text": "Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.\n", "entity1": "ceftriaxone", "entity2": "hepatitis", "span1": [84, 95], "span2": [6, 15]}, "bert_text": "Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by <e1> ceftriaxone </e1> <e2> hepatitis </e2>, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5771": {"data": {"text": "Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.\n", "entity1": "ceftriaxone", "entity2": "autoimmune hemolytic anemia", "span1": [84, 95], "span2": [17, 44]}, "bert_text": "Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by <e1> ceftriaxone </e1> <e2> autoimmune hemolytic anemia </e2>, and erythroblastocytopenia induced by ceftriaxone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5772": {"data": {"text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.", "entity1": "remifentanil", "entity2": "myoclonus", "span1": [30, 42], "span2": [63, 72]}, "bert_text": "CONCLUSION: Pretreatment with <e1> remifentanil </e1> 1 microg/kg reduced <e2> myoclonus </e2> after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5773": {"data": {"text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.", "entity1": "remifentanil", "entity2": "apnea", "span1": [30, 42], "span2": [138, 143]}, "bert_text": "CONCLUSION: Pretreatment with <e1> remifentanil </e1> 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, <e2> apnea </e2>, nausea, or pruritus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5774": {"data": {"text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.", "entity1": "remifentanil", "entity2": "nausea", "span1": [30, 42], "span2": [145, 151]}, "bert_text": "CONCLUSION: Pretreatment with <e1> remifentanil </e1> 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, <e2> nausea </e2>, or pruritus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5775": {"data": {"text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.", "entity1": "remifentanil", "entity2": "pruritus", "span1": [30, 42], "span2": [156, 164]}, "bert_text": "CONCLUSION: Pretreatment with <e1> remifentanil </e1> 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or <e2> pruritus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5776": {"data": {"text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.", "entity1": "etomidate", "entity2": "myoclonus", "span1": [79, 88], "span2": [63, 72]}, "bert_text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after <e1> etomidate </e1> <e2> myoclonus </e2> after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"5777": {"data": {"text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.", "entity1": "etomidate", "entity2": "apnea", "span1": [79, 88], "span2": [138, 143]}, "bert_text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after <e1> etomidate </e1> induction without side effects such as sedation, <e2> apnea </e2>, nausea, or pruritus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5778": {"data": {"text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.", "entity1": "etomidate", "entity2": "nausea", "span1": [79, 88], "span2": [145, 151]}, "bert_text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after <e1> etomidate </e1> induction without side effects such as sedation, apnea, <e2> nausea </e2>, or pruritus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5779": {"data": {"text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.", "entity1": "etomidate", "entity2": "pruritus", "span1": [79, 88], "span2": [156, 164]}, "bert_text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after <e1> etomidate </e1> induction without side effects such as sedation, apnea, nausea, or <e2> pruritus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5780": {"data": {"text": "Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.", "entity1": "Prostaglandin D2", "entity2": "hyperalgesic", "span1": [0, 16], "span2": [40, 52]}, "bert_text": "<e1> Prostaglandin D2 </e1> (0.5-3 ng/mouse) had a <e2> hyperalgesic </e2> action on the response to a hot plate during a 3-60 min period after injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5781": {"data": {"text": "These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.", "entity1": "prostaglandin D2", "entity2": "hyperalgesia", "span1": [36, 52], "span2": [80, 92]}, "bert_text": "These results demonstrate that both <e1> prostaglandin D2 </e1> and prostaglandin E2 exert <e2> hyperalgesia </e2> in the spinal cord, but in different ways.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5782": {"data": {"text": "These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.", "entity1": "prostaglandin E2", "entity2": "hyperalgesia", "span1": [57, 73], "span2": [80, 92]}, "bert_text": "These results demonstrate that both prostaglandin D2 and <e1> prostaglandin E2 </e1> exert <e2> hyperalgesia </e2> in the spinal cord, but in different ways.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5783": {"data": {"text": "OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.", "entity1": "tolterodine", "entity2": "overactive bladder", "span1": [120, 131], "span2": [89, 107]}, "bert_text": "OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after <e1> tolterodine </e1> <e2> overactive bladder </e2> (OAB) after tolterodine treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5784": {"data": {"text": "OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.", "entity1": "tolterodine", "entity2": "OAB", "span1": [120, 131], "span2": [109, 112]}, "bert_text": "OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after <e1> tolterodine </e1> <e2> OAB </e2>) after tolterodine treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5785": {"data": {"text": "In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.", "entity1": "sodium", "entity2": "nephrotic syndrome", "span1": [44, 50], "span2": [16, 34]}, "bert_text": "In experimental nephrotic syndrome, urinary <e1> sodium </e1> <e2> nephrotic syndrome </e2>, urinary sodium excretion is decreased during the early phase of the disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5786": {"data": {"text": "Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.\n", "entity1": "neurotensin", "entity2": "parkinsonian catalepsy", "span1": [20, 31], "span2": [55, 77]}, "bert_text": "Effects of pallidal <e1> neurotensin </e1> on haloperidol-induced <e2> parkinsonian catalepsy </e2>: behavioral and electrophysiological studies.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5787": {"data": {"text": "Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.\n", "entity1": "haloperidol", "entity2": "parkinsonian catalepsy", "span1": [35, 46], "span2": [55, 77]}, "bert_text": "Effects of pallidal neurotensin on <e1> haloperidol </e1>-induced <e2> parkinsonian catalepsy </e2>: behavioral and electrophysiological studies.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5788": {"data": {"text": "The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.", "entity1": "etoposide", "entity2": "leukemic infiltration", "span1": [34, 43], "span2": [109, 130]}, "bert_text": "The concomitant administration of <e1> etoposide </e1> and cyclosporin A resulted in eradication of hitherto refractory <e2> leukemic infiltration </e2> of bone marrow.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5789": {"data": {"text": "The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.", "entity1": "cyclosporin A", "entity2": "leukemic infiltration", "span1": [48, 61], "span2": [109, 130]}, "bert_text": "The concomitant administration of etoposide and <e1> cyclosporin A </e1> resulted in eradication of hitherto refractory <e2> leukemic infiltration </e2> of bone marrow.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5790": {"data": {"text": "A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.", "entity1": "amiodarone", "entity2": "cholestatic hepatitis", "span1": [44, 54], "span2": [15, 36]}, "bert_text": "A patient with cholestatic hepatitis due to <e1> amiodarone </e1> <e2> cholestatic hepatitis </e2> due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5791": {"data": {"text": "A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.", "entity1": "amiodarone", "entity2": "hepatotoxicity", "span1": [44, 54], "span2": [104, 118]}, "bert_text": "A patient with cholestatic hepatitis due to <e1> amiodarone </e1> treatment is presented below and a review of the <e2> hepatotoxicity </e2> of amiodarone is given.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5792": {"data": {"text": "A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.", "entity1": "amiodarone", "entity2": "cholestatic hepatitis", "span1": [122, 132], "span2": [15, 36]}, "bert_text": "A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of <e1> amiodarone </e1> <e2> cholestatic hepatitis </e2> due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5793": {"data": {"text": "A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.", "entity1": "amiodarone", "entity2": "hepatotoxicity", "span1": [122, 132], "span2": [104, 118]}, "bert_text": "A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of <e1> amiodarone </e1> <e2> hepatotoxicity </e2> of amiodarone is given.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"5794": {"data": {"text": "Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.", "entity1": "testosterone", "entity2": "low sexual desire", "span1": [12, 24], "span2": [42, 59]}, "bert_text": "Determining <e1> testosterone </e1> only in cases of <e2> low sexual desire </e2> or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5795": {"data": {"text": "Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.", "entity1": "testosterone", "entity2": "low sexual desire", "span1": [137, 149], "span2": [42, 59]}, "bert_text": "Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low <e1> testosterone </e1> <e2> low sexual desire </e2> or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5796": {"data": {"text": "The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.", "entity1": "PGE1-induced", "entity2": "hypotension", "span1": [73, 85], "span2": [86, 97]}, "bert_text": "The results suggest that a prolonged combination of more than 120 min of <e1> PGE1-induced </e1> <e2> hypotension </e2> and moderate haemodilution would cause impairment of hepatic function.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"5797": {"data": {"text": "The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE.", "entity1": "silver", "entity2": "SE", "span1": [14, 20], "span2": [88, 90]}, "bert_text": "The extent of <e1> silver </e1>-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after <e2> SE </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5798": {"data": {"text": "The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.", "entity1": "simvastatin", "entity2": "hepatotoxicity", "span1": [51, 62], "span2": [119, 133]}, "bert_text": "The patient's lipid panel had been maintained with <e1> simvastatin </e1> for 18 months before the conversion without evidence of <e2> hepatotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5799": {"data": {"text": "Central retinal vein occlusion associated with clomiphene-induced ovulation.\n", "entity1": "clomiphene", "entity2": "retinal vein occlusion", "span1": [47, 57], "span2": [8, 30]}, "bert_text": "Central retinal vein occlusion associated with <e1> clomiphene </e1> <e2> retinal vein occlusion </e2> associated with clomiphene-induced ovulation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5800": {"data": {"text": "Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.", "entity1": "phenylephrine", "entity2": "acute myocardial infarction", "span1": [37, 50], "span2": [120, 147]}, "bert_text": "Our results suggest that addition of <e1> phenylephrine </e1> to nitroglycerin is not beneficial in the treatment of patients with <e2> acute myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5801": {"data": {"text": "Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.", "entity1": "nitroglycerin", "entity2": "acute myocardial infarction", "span1": [54, 67], "span2": [120, 147]}, "bert_text": "Our results suggest that addition of phenylephrine to <e1> nitroglycerin </e1> is not beneficial in the treatment of patients with <e2> acute myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5802": {"data": {"text": "Recently, we have shown that moderate diet restriction remarkably protects against doxorubicin-induced cardiotoxicity.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [83, 94], "span2": [103, 117]}, "bert_text": "Recently, we have shown that moderate diet restriction remarkably protects against <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5803": {"data": {"text": "Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside-induced hypotension in ventilated dogs.\n", "entity1": "sodium nitroprusside", "entity2": "hemorrhage", "span1": [69, 89], "span2": [46, 56]}, "bert_text": "Systolic pressure variation is greater during hemorrhage than during <e1> sodium nitroprusside </e1> <e2> hemorrhage </e2> than during sodium nitroprusside-induced hypotension in ventilated dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5804": {"data": {"text": "Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside-induced hypotension in ventilated dogs.\n", "entity1": "sodium nitroprusside", "entity2": "hypotension", "span1": [69, 89], "span2": [98, 109]}, "bert_text": "Systolic pressure variation is greater during hemorrhage than during <e1> sodium nitroprusside </e1>-induced <e2> hypotension </e2> in ventilated dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5805": {"data": {"text": "This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.", "entity1": "Urd", "entity2": "toxicity", "span1": [20, 23], "span2": [139, 147]}, "bert_text": "This agent inhibits <e1> Urd </e1> catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5806": {"data": {"text": "This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.", "entity1": "Urd", "entity2": "toxicity", "span1": [87, 90], "span2": [139, 147]}, "bert_text": "This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of <e1> Urd </e1> in a dose-dependent manner, without Urd-related <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5807": {"data": {"text": "This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.", "entity1": "Urd", "entity2": "toxicity", "span1": [127, 130], "span2": [139, 147]}, "bert_text": "This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without <e1> Urd </e1>-related <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5808": {"data": {"text": "RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.", "entity1": "lidocaine", "entity2": "TNSs", "span1": [39, 48], "span2": [61, 65]}, "bert_text": "RESULTS: Nine of 30 patients receiving <e1> lidocaine </e1> experienced <e2> TNSs </e2>, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5809": {"data": {"text": "RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.", "entity1": "lidocaine", "entity2": "TNSs", "span1": [39, 48], "span2": [176, 180]}, "bert_text": "RESULTS: Nine of 30 patients receiving <e1> lidocaine </e1> experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had <e2> TNSs </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5810": {"data": {"text": "RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.", "entity1": "prilocaine", "entity2": "TNSs", "span1": [94, 104], "span2": [61, 65]}, "bert_text": "RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving <e1> prilocaine </e1> <e2> TNSs </e2>, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5811": {"data": {"text": "RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.", "entity1": "prilocaine", "entity2": "TNSs", "span1": [94, 104], "span2": [176, 180]}, "bert_text": "RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving <e1> prilocaine </e1> (P = 0.03) had them, and none of 30 patients receiving bupivacaine had <e2> TNSs </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5812": {"data": {"text": "RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.", "entity1": "bupivacaine", "entity2": "TNSs", "span1": [160, 171], "span2": [61, 65]}, "bert_text": "RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving <e1> bupivacaine </e1> <e2> TNSs </e2>, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5813": {"data": {"text": "RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.", "entity1": "bupivacaine", "entity2": "TNSs", "span1": [160, 171], "span2": [176, 180]}, "bert_text": "RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving <e1> bupivacaine </e1> had <e2> TNSs </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5814": {"data": {"text": "These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.", "entity1": "isoproterenol", "entity2": "ischaemic injury", "span1": [191, 204], "span2": [26, 42]}, "bert_text": "These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by <e1> isoproterenol </e1> <e2> ischaemic injury </e2>, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5815": {"data": {"text": "The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.", "entity1": "diazepam", "entity2": "panic disorders", "span1": [29, 37], "span2": [233, 248]}, "bert_text": "The effects of oral doses of <e1> diazepam </e1> (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with <e2> panic disorders </e2> and agoraphobia were investigated in a double-blind, randomized and crossover design.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5816": {"data": {"text": "The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.", "entity1": "diazepam", "entity2": "agoraphobia", "span1": [29, 37], "span2": [253, 264]}, "bert_text": "The effects of oral doses of <e1> diazepam </e1> (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and <e2> agoraphobia </e2> were investigated in a double-blind, randomized and crossover design.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5817": {"data": {"text": "The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.", "entity1": "propranolol", "entity2": "panic disorders", "span1": [108, 119], "span2": [233, 248]}, "bert_text": "The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and <e1> propranolol </e1> (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with <e2> panic disorders </e2> and agoraphobia were investigated in a double-blind, randomized and crossover design.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5818": {"data": {"text": "The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.", "entity1": "propranolol", "entity2": "agoraphobia", "span1": [108, 119], "span2": [253, 264]}, "bert_text": "The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and <e1> propranolol </e1> (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and <e2> agoraphobia </e2> were investigated in a double-blind, randomized and crossover design.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5819": {"data": {"text": "We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.", "entity1": "acetazolamide", "entity2": "Gerstmann syndrome", "span1": [20, 33], "span2": [42, 60]}, "bert_text": "We report a case of <e1> acetazolamide </e1>-induced <e2> Gerstmann syndrome </e2> in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5820": {"data": {"text": "CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.", "entity1": "PGs", "entity2": "OAB", "span1": [21, 24], "span2": [68, 71]}, "bert_text": "CONCLUSIONS: NGF and <e1> PGs </e1> have important roles in the development of <e2> OAB </e2> symptoms in female patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5821": {"data": {"text": "We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.", "entity1": "antidepressant", "entity2": "idiopathic Parkinson's disease", "span1": [126, 140], "span2": [73, 103]}, "bert_text": "We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the <e1> antidepressant </e1> <e2> idiopathic Parkinson's disease </e2> after exposure to the antidepressant fluoxetine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5822": {"data": {"text": "We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.", "entity1": "fluoxetine", "entity2": "idiopathic Parkinson's disease", "span1": [141, 151], "span2": [73, 103]}, "bert_text": "We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant <e1> fluoxetine </e1> <e2> idiopathic Parkinson's disease </e2> after exposure to the antidepressant fluoxetine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5823": {"data": {"text": "Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.", "entity1": "Pentamidine isethionate", "entity2": "ventricular tachyarrhythmias", "span1": [0, 23], "span2": [49, 77]}, "bert_text": "<e1> Pentamidine isethionate </e1> has been associated with <e2> ventricular tachyarrhythmias </e2>, including torsade de pointes.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5824": {"data": {"text": "Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.", "entity1": "Pentamidine isethionate", "entity2": "torsade de pointes", "span1": [0, 23], "span2": [89, 107]}, "bert_text": "<e1> Pentamidine isethionate </e1> has been associated with ventricular tachyarrhythmias, including <e2> torsade de pointes </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5825": {"data": {"text": "alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.", "entity1": "alpha-TC", "entity2": "hyperthermia", "span1": [0, 8], "span2": [43, 55]}, "bert_text": "<e1> alpha-TC </e1> and DFO attenuated the MA-induced <e2> hyperthermia </e2> as well as the alterations in the locomotor activity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5826": {"data": {"text": "alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.", "entity1": "DFO", "entity2": "hyperthermia", "span1": [13, 16], "span2": [43, 55]}, "bert_text": "alpha-TC and <e1> DFO </e1> attenuated the MA-induced <e2> hyperthermia </e2> as well as the alterations in the locomotor activity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5827": {"data": {"text": "alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.", "entity1": "MA", "entity2": "hyperthermia", "span1": [32, 34], "span2": [43, 55]}, "bert_text": "alpha-TC and DFO attenuated the <e1> MA </e1>-induced <e2> hyperthermia </e2> as well as the alterations in the locomotor activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5828": {"data": {"text": "Rats treated with L-DOPA were allocated to two groups based on the presence or absence of LID.", "entity1": "L-DOPA", "entity2": "LID", "span1": [18, 24], "span2": [90, 93]}, "bert_text": "Rats treated with <e1> L-DOPA </e1> were allocated to two groups based on the presence or absence of <e2> LID </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5829": {"data": {"text": "Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.", "entity1": "succinylcholine", "entity2": "masseter muscle rigidity", "span1": [81, 96], "span2": [35, 59]}, "bert_text": "Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after <e1> succinylcholine </e1> <e2> masseter muscle rigidity </e2> (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5830": {"data": {"text": "Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.", "entity1": "Sch", "entity2": "masseter muscle rigidity", "span1": [98, 101], "span2": [35, 59]}, "bert_text": "Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (<e1> Sch </e1> <e2> masseter muscle rigidity </e2> (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5831": {"data": {"text": "CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.", "entity1": "Ethambutol", "entity2": "visual loss", "span1": [13, 23], "span2": [59, 70]}, "bert_text": "CONCLUSIONS: <e1> Ethambutol </e1> usage is associated with permanent <e2> visual loss </e2> and should be avoided if possible or used with caution and proper ophthalmological follow-up.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5832": {"data": {"text": "The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.", "entity1": "nitroglycerin", "entity2": "diabetic", "span1": [14, 27], "span2": [108, 116]}, "bert_text": "The effect of <e1> nitroglycerin </e1> on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 <e2> diabetic </e2> subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5833": {"data": {"text": "The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.", "entity1": "nitroglycerin", "entity2": "diabetic", "span1": [14, 27], "span2": [162, 170]}, "bert_text": "The effect of <e1> nitroglycerin </e1> on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 <e2> diabetic </e2> subjects with autonomic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5834": {"data": {"text": "The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.", "entity1": "nitroglycerin", "entity2": "autonomic neuropathy", "span1": [14, 27], "span2": [134, 154]}, "bert_text": "The effect of <e1> nitroglycerin </e1> on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without <e2> autonomic neuropathy </e2>, and 5 diabetic subjects with autonomic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5835": {"data": {"text": "The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.", "entity1": "nitroglycerin", "entity2": "autonomic neuropathy", "span1": [14, 27], "span2": [185, 205]}, "bert_text": "The effect of <e1> nitroglycerin </e1> on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with <e2> autonomic neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5836": {"data": {"text": "Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.\n", "entity1": "tolterodine", "entity2": "overactive bladder", "span1": [89, 100], "span2": [64, 82]}, "bert_text": "Urinary symptoms and quality of life changes in Thai women with overactive bladder after <e1> tolterodine </e1> <e2> overactive bladder </e2> after tolterodine treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5837": {"data": {"text": "Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.", "entity1": "prazosin", "entity2": "muscular rigidity", "span1": [208, 216], "span2": [16, 33]}, "bert_text": "Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, <e1> prazosin </e1> <e2> muscular rigidity </e2> by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5838": {"data": {"text": "The concentration for adrenaline-induced arrhythmia was significantly higher than those for the other types of arrhythmias.", "entity1": "adrenaline", "entity2": "arrhythmia", "span1": [22, 32], "span2": [41, 51]}, "bert_text": "The concentration for <e1> adrenaline </e1>-induced <e2> arrhythmia </e2> was significantly higher than those for the other types of arrhythmias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5839": {"data": {"text": "The concentration for adrenaline-induced arrhythmia was significantly higher than those for the other types of arrhythmias.", "entity1": "adrenaline", "entity2": "arrhythmias", "span1": [22, 32], "span2": [111, 122]}, "bert_text": "The concentration for <e1> adrenaline </e1>-induced arrhythmia was significantly higher than those for the other types of <e2> arrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5840": {"data": {"text": "A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [20, 31], "span2": [104, 118]}, "bert_text": "A LD(10) dose (8 mg <e1> doxorubicin </e1>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher <e2> cardiotoxicity </e2>, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5841": {"data": {"text": "A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.", "entity1": "doxorubicin", "entity2": "cardiac dysfunction", "span1": [20, 31], "span2": [120, 139]}, "bert_text": "A LD(10) dose (8 mg <e1> doxorubicin </e1>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, <e2> cardiac dysfunction </e2>, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5842": {"data": {"text": "A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.", "entity1": "doxorubicin", "entity2": "obese", "span1": [20, 31], "span2": [186, 191]}, "bert_text": "A LD(10) dose (8 mg <e1> doxorubicin </e1>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the <e2> obese </e2> (OB) rats in the absence of any significant renal or hepatic toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5843": {"data": {"text": "A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.", "entity1": "doxorubicin", "entity2": "OB", "span1": [20, 31], "span2": [193, 195]}, "bert_text": "A LD(10) dose (8 mg <e1> doxorubicin </e1>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (<e2> OB </e2>) rats in the absence of any significant renal or hepatic toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5844": {"data": {"text": "A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.", "entity1": "doxorubicin", "entity2": "hepatic toxicity", "span1": [20, 31], "span2": [245, 261]}, "bert_text": "A LD(10) dose (8 mg <e1> doxorubicin </e1>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or <e2> hepatic toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5845": {"data": {"text": "Thus, while whole body hyperthermia enhances Adriamycin-mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded.", "entity1": "Adriamycin", "entity2": "hyperthermia", "span1": [45, 55], "span2": [23, 35]}, "bert_text": "Thus, while whole body hyperthermia enhances <e1> Adriamycin </e1> <e2> hyperthermia </e2> enhances Adriamycin-mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5846": {"data": {"text": "Thus, while whole body hyperthermia enhances Adriamycin-mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded.", "entity1": "Adriamycin", "entity2": "toxicity", "span1": [45, 55], "span2": [97, 105]}, "bert_text": "Thus, while whole body hyperthermia enhances <e1> Adriamycin </e1>-mediated antitumor effect, normal tissue <e2> toxicity </e2> is also increased, and the potential therapeutic gain of the combined modality treatment is eroded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5847": {"data": {"text": "OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.", "entity1": "modafinil", "entity2": "daytime sleepiness", "span1": [89, 98], "span2": [112, 130]}, "bert_text": "OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed <e1> modafinil </e1> on sleep and <e2> daytime sleepiness </e2> in chronic cocaine users.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5848": {"data": {"text": "OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.", "entity1": "cocaine", "entity2": "daytime sleepiness", "span1": [142, 149], "span2": [112, 130]}, "bert_text": "OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic <e1> cocaine </e1> <e2> daytime sleepiness </e2> in chronic cocaine users.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5849": {"data": {"text": "ATRA seemed to be the most possible etiology of erythema nodosum in our patients.", "entity1": "ATRA", "entity2": "erythema nodosum", "span1": [0, 4], "span2": [48, 64]}, "bert_text": "<e1> ATRA </e1> seemed to be the most possible etiology of <e2> erythema nodosum </e2> in our patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5850": {"data": {"text": "Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.\n", "entity1": "tacrolimus", "entity2": "myocardial hypertrophy", "span1": [45, 55], "span2": [11, 33]}, "bert_text": "Reversible myocardial hypertrophy induced by <e1> tacrolimus </e1> <e2> myocardial hypertrophy </e2> induced by tacrolimus in a pediatric heart transplant recipient: case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5851": {"data": {"text": "Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.", "entity1": "DCE", "entity2": "cognitive dysfunctions", "span1": [11, 14], "span2": [69, 91]}, "bert_text": "Therefore, <e1> DCE </e1> may prove to be a useful remedy for the management of <e2> cognitive dysfunctions </e2> on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5852": {"data": {"text": "Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.", "entity1": "cholesterol", "entity2": "cognitive dysfunctions", "span1": [178, 189], "span2": [69, 91]}, "bert_text": "Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, <e1> cholesterol </e1> <e2> cognitive dysfunctions </e2> on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5853": {"data": {"text": "Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.\n", "entity1": "Methamphetamine", "entity2": "neurotoxicity", "span1": [0, 15], "span2": [24, 37]}, "bert_text": "<e1> Methamphetamine </e1>-induced <e2> neurotoxicity </e2> and microglial activation are not mediated by fractalkine receptor signaling.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5854": {"data": {"text": "Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.", "entity1": "morphine", "entity2": "hyperalgesia", "span1": [109, 117], "span2": [68, 80]}, "bert_text": "Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of <e1> morphine </e1> <e2> hyperalgesia </e2>/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5855": {"data": {"text": "Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.", "entity1": "morphine", "entity2": "myoclonus", "span1": [109, 117], "span2": [81, 90]}, "bert_text": "Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of <e1> morphine </e1> <e2> myoclonus </e2> and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5856": {"data": {"text": "Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.", "entity1": "morphine", "entity2": "hyperalgesia", "span1": [189, 197], "span2": [68, 80]}, "bert_text": "Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that <e1> morphine </e1> <e2> hyperalgesia </e2>/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5857": {"data": {"text": "Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.", "entity1": "morphine", "entity2": "myoclonus", "span1": [189, 197], "span2": [81, 90]}, "bert_text": "Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that <e1> morphine </e1> <e2> myoclonus </e2> and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5858": {"data": {"text": "Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.\n", "entity1": "N-(2-propylpentanoyl)urea", "entity2": "seizure", "span1": [17, 42], "span2": [110, 117]}, "bert_text": "Acute effects of <e1> N-(2-propylpentanoyl)urea </e1> on hippocampal amino acid neurotransmitters in pilocarpine-induced <e2> seizure </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5859": {"data": {"text": "Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.\n", "entity1": "amino acid", "entity2": "seizure", "span1": [58, 68], "span2": [110, 117]}, "bert_text": "Acute effects of N-(2-propylpentanoyl)urea on hippocampal <e1> amino acid </e1> neurotransmitters in pilocarpine-induced <e2> seizure </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5860": {"data": {"text": "Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.\n", "entity1": "pilocarpine", "entity2": "seizure", "span1": [90, 101], "span2": [110, 117]}, "bert_text": "Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in <e1> pilocarpine </e1>-induced <e2> seizure </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5861": {"data": {"text": "The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.", "entity1": "dopamine", "entity2": "Parkinson's disease", "span1": [41, 49], "span2": [89, 108]}, "bert_text": "The possibility of a clinically relevant <e1> dopamine </e1>-antagonistic capacity of fluoxetine in <e2> Parkinson's disease </e2> patients must be considered.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5862": {"data": {"text": "The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.", "entity1": "fluoxetine", "entity2": "Parkinson's disease", "span1": [75, 85], "span2": [89, 108]}, "bert_text": "The possibility of a clinically relevant dopamine-antagonistic capacity of <e1> fluoxetine </e1> in <e2> Parkinson's disease </e2> patients must be considered.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5863": {"data": {"text": "Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.", "entity1": "Idraparinux", "entity2": "atrial fibrillation", "span1": [0, 11], "span2": [72, 91]}, "bert_text": "<e1> Idraparinux </e1>, a Factor Xa inhibitor, is being evaluated in patients with <e2> atrial fibrillation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5864": {"data": {"text": "15 cases of cimetidine-associated mental confusion have been reported.", "entity1": "cimetidine", "entity2": "confusion", "span1": [12, 22], "span2": [41, 50]}, "bert_text": "15 cases of <e1> cimetidine </e1>-associated mental <e2> confusion </e2> have been reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5865": {"data": {"text": "Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.\n", "entity1": "NIK-247", "entity2": "amnesia", "span1": [11, 18], "span2": [61, 68]}, "bert_text": "Effects of <e1> NIK-247 </e1> on cholinesterase and scopolamine-induced <e2> amnesia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5866": {"data": {"text": "Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.\n", "entity1": "scopolamine", "entity2": "amnesia", "span1": [41, 52], "span2": [61, 68]}, "bert_text": "Effects of NIK-247 on cholinesterase and <e1> scopolamine </e1>-induced <e2> amnesia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5867": {"data": {"text": "Ciprofloxacin-induced nephrotoxicity in patients with cancer.\n", "entity1": "Ciprofloxacin", "entity2": "nephrotoxicity", "span1": [0, 13], "span2": [22, 36]}, "bert_text": "<e1> Ciprofloxacin </e1>-induced <e2> nephrotoxicity </e2> in patients with cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5868": {"data": {"text": "Ciprofloxacin-induced nephrotoxicity in patients with cancer.\n", "entity1": "Ciprofloxacin", "entity2": "cancer", "span1": [0, 13], "span2": [54, 60]}, "bert_text": "<e1> Ciprofloxacin </e1>-induced nephrotoxicity in patients with <e2> cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5869": {"data": {"text": "STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.", "entity1": "paclitaxel", "entity2": "breast cancer", "span1": [26, 36], "span2": [176, 189]}, "bert_text": "STUDY DESIGN: We combined <e1> paclitaxel </e1>, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic <e2> breast cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5870": {"data": {"text": "STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.", "entity1": "melphalan", "entity2": "breast cancer", "span1": [38, 47], "span2": [176, 189]}, "bert_text": "STUDY DESIGN: We combined paclitaxel, <e1> melphalan </e1> and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic <e2> breast cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5871": {"data": {"text": "STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.", "entity1": "cyclophosphamide", "entity2": "breast cancer", "span1": [62, 78], "span2": [176, 189]}, "bert_text": "STUDY DESIGN: We combined paclitaxel, melphalan and high-dose <e1> cyclophosphamide </e1>, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic <e2> breast cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5872": {"data": {"text": "STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.", "entity1": "thiotepa", "entity2": "breast cancer", "span1": [80, 88], "span2": [176, 189]}, "bert_text": "STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, <e1> thiotepa </e1>, and carboplatin in a triple sequential high-dose regimen for patients with metastatic <e2> breast cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5873": {"data": {"text": "STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.", "entity1": "carboplatin", "entity2": "breast cancer", "span1": [94, 105], "span2": [176, 189]}, "bert_text": "STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and <e1> carboplatin </e1> in a triple sequential high-dose regimen for patients with metastatic <e2> breast cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"5874": {"data": {"text": "However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [9, 20], "span2": [29, 37]}, "bert_text": "However, <e1> pilocarpine </e1>-induced <e2> seizures </e2> result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5875": {"data": {"text": "However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.", "entity1": "pilocarpine", "entity2": "neuronal death", "span1": [9, 20], "span2": [66, 80]}, "bert_text": "However, <e1> pilocarpine </e1>-induced seizures result in a more widespread <e2> neuronal death </e2> in both WT and D2R -/- brains in comparison to KA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5876": {"data": {"text": "However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.", "entity1": "KA", "entity2": "seizures", "span1": [128, 130], "span2": [29, 37]}, "bert_text": "However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to <e1> KA </e1> <e2> seizures </e2> result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5877": {"data": {"text": "However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.", "entity1": "KA", "entity2": "neuronal death", "span1": [128, 130], "span2": [66, 80]}, "bert_text": "However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to <e1> KA </e1> <e2> neuronal death </e2> in both WT and D2R -/- brains in comparison to KA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5878": {"data": {"text": "It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.", "entity1": "bromocriptine", "entity2": "tachycardia", "span1": [23, 36], "span2": [45, 56]}, "bert_text": "It has been shown that <e1> bromocriptine </e1>-induced <e2> tachycardia </e2>, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5879": {"data": {"text": "It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.", "entity1": "dopamine", "entity2": "tachycardia", "span1": [122, 130], "span2": [45, 56]}, "bert_text": "It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central <e1> dopamine </e1> <e2> tachycardia </e2>, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5880": {"data": {"text": "It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.", "entity1": "isoproterenol", "entity2": "tachycardia", "span1": [180, 193], "span2": [45, 56]}, "bert_text": "It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day <e1> isoproterenol </e1> <e2> tachycardia </e2>, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5881": {"data": {"text": "The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.", "entity1": "levodopa", "entity2": "parkinsonian", "span1": [37, 45], "span2": [80, 92]}, "bert_text": "The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of <e2> parkinsonian </e2> 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5882": {"data": {"text": "The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.", "entity1": "levodopa", "entity2": "parkinsonian", "span1": [37, 45], "span2": [190, 202]}, "bert_text": "The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and <e2> parkinsonian </e2> 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5883": {"data": {"text": "The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.", "entity1": "levodopa", "entity2": "parkinsonian", "span1": [37, 45], "span2": [324, 336]}, "bert_text": "The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of <e2> parkinsonian </e2> 'off' signs and dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5884": {"data": {"text": "The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.", "entity1": "levodopa", "entity2": "LID", "span1": [37, 45], "span2": [109, 112]}, "bert_text": "The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of parkinsonian 'off' signs and <e2> LID </e2> and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5885": {"data": {"text": "The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [37, 45], "span2": [174, 185]}, "bert_text": "The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with <e2> dyskinesias </e2> and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5886": {"data": {"text": "The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [37, 45], "span2": [353, 364]}, "bert_text": "The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5887": {"data": {"text": "Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.\n", "entity1": "amphetamine", "entity2": "contralateral rotation", "span1": [147, 158], "span2": [10, 32]}, "bert_text": "Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by <e1> amphetamine </e1> <e2> contralateral rotation </e2> following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5888": {"data": {"text": "Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.\n", "entity1": "methylergonovine", "entity2": "variant angina", "span1": [49, 65], "span2": [95, 109]}, "bert_text": "Effect of direct intracoronary administration of <e1> methylergonovine </e1> in patients with and without <e2> variant angina </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5889": {"data": {"text": "Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.", "entity1": "SRL", "entity2": "proteinuria", "span1": [46, 49], "span2": [6, 17]}, "bert_text": "Heavy proteinuria was common after the use of <e1> SRL </e1> <e2> proteinuria </e2> was common after the use of SRL as rescue therapy for renal transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5890": {"data": {"text": "The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).", "entity1": "methylergonovine", "entity2": "variant angina", "span1": [47, 63], "span2": [97, 111]}, "bert_text": "The effects of intracoronary administration of <e1> methylergonovine </e1> were studied in 21 patients with <e2> variant angina </e2> and 22 patients with atypical chest pain and in others without angina pectoris (control group).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5891": {"data": {"text": "The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).", "entity1": "methylergonovine", "entity2": "chest pain", "span1": [47, 63], "span2": [142, 152]}, "bert_text": "The effects of intracoronary administration of <e1> methylergonovine </e1> were studied in 21 patients with variant angina and 22 patients with atypical <e2> chest pain </e2> and in others without angina pectoris (control group).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5892": {"data": {"text": "The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).", "entity1": "methylergonovine", "entity2": "angina pectoris", "span1": [47, 63], "span2": [175, 190]}, "bert_text": "The effects of intracoronary administration of <e1> methylergonovine </e1> were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without <e2> angina pectoris </e2> (control group).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5893": {"data": {"text": "Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.", "entity1": "propranolol", "entity2": "Parkinson's disease", "span1": [108, 119], "span2": [30, 49]}, "bert_text": "Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose <e1> propranolol </e1> <e2> Parkinson's disease </e2> (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5894": {"data": {"text": "Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.", "entity1": "propranolol", "entity2": "PD", "span1": [108, 119], "span2": [51, 53]}, "bert_text": "Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose <e1> propranolol </e1> <e2> PD </e2>) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5895": {"data": {"text": "Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.", "entity1": "propranolol", "entity2": "dyskinesia", "span1": [108, 119], "span2": [79, 89]}, "bert_text": "Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose <e1> propranolol </e1> <e2> dyskinesia </e2> received low-dose propranolol as an adjunct to the currently used medical treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5896": {"data": {"text": "Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.\n", "entity1": "halogenated hydroxyquinolines", "entity2": "Neurotoxicity", "span1": [17, 46], "span2": [0, 13]}, "bert_text": "Neurotoxicity of <e1> halogenated hydroxyquinolines </e1> <e2> Neurotoxicity </e2> of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5897": {"data": {"text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.", "entity1": "heparin", "entity2": "thrombosis", "span1": [101, 108], "span2": [73, 83]}, "bert_text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with <e1> heparin </e1> <e2> thrombosis </e2> in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5898": {"data": {"text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.", "entity1": "heparin", "entity2": "thrombosis syndrome", "span1": [101, 108], "span2": [230, 249]}, "bert_text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with <e1> heparin </e1> induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the <e2> thrombosis syndrome </e2> is not well defined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5899": {"data": {"text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.", "entity1": "heparin", "entity2": "platelet aggregation", "span1": [101, 108], "span2": [117, 137]}, "bert_text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with <e1> heparin </e1> induced <e2> platelet aggregation </e2> who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5900": {"data": {"text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.", "entity1": "heparin", "entity2": "thrombosis", "span1": [170, 177], "span2": [73, 83]}, "bert_text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to <e1> heparin </e1> <e2> thrombosis </e2> in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5901": {"data": {"text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.", "entity1": "heparin", "entity2": "thrombosis syndrome", "span1": [170, 177], "span2": [230, 249]}, "bert_text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to <e1> heparin </e1>, but its success in patients who have developed the <e2> thrombosis syndrome </e2> is not well defined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5902": {"data": {"text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.", "entity1": "heparin", "entity2": "platelet aggregation", "span1": [170, 177], "span2": [117, 137]}, "bert_text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to <e1> heparin </e1> <e2> platelet aggregation </e2> who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5903": {"data": {"text": "An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.", "entity1": "ceftriaxone", "entity2": "hepatitis", "span1": [72, 83], "span2": [33, 42]}, "bert_text": "An 80-yr-old man developed acute hepatitis shortly after ingesting oral <e1> ceftriaxone </e1> <e2> hepatitis </e2> shortly after ingesting oral ceftriaxone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5904": {"data": {"text": "Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.", "entity1": "ribavirin", "entity2": "Argentine hemorrhagic fever", "span1": [34, 43], "span2": [75, 102]}, "bert_text": "Tolerance and antiviral effect of <e1> ribavirin </e1> was studied in 6 patients with <e2> Argentine hemorrhagic fever </e2> (AHF) of more than 8 days of evolution.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5905": {"data": {"text": "Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.", "entity1": "ribavirin", "entity2": "AHF", "span1": [34, 43], "span2": [104, 107]}, "bert_text": "Tolerance and antiviral effect of <e1> ribavirin </e1> was studied in 6 patients with Argentine hemorrhagic fever (<e2> AHF </e2>) of more than 8 days of evolution.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5906": {"data": {"text": "243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "entity1": "cocaine", "entity2": "mood disorder", "span1": [4, 11], "span2": [55, 68]}, "bert_text": "243 <e1> cocaine </e1>-dependent outpatients with cocaine-induced <e2> mood disorder </e2> (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5907": {"data": {"text": "243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "entity1": "cocaine", "entity2": "mood disorders", "span1": [4, 11], "span2": [83, 97]}, "bert_text": "243 <e1> cocaine </e1>-dependent outpatients with cocaine-induced mood disorder (CIMD), other <e2> mood disorders </e2>, or no mood disorder were compared on measures of psychiatric symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5908": {"data": {"text": "243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "entity1": "cocaine", "entity2": "mood disorder", "span1": [4, 11], "span2": [105, 118]}, "bert_text": "243 <e1> cocaine </e1>-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no <e2> mood disorder </e2> were compared on measures of psychiatric symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"5909": {"data": {"text": "243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "entity1": "cocaine", "entity2": "CIMD", "span1": [4, 11], "span2": [70, 74]}, "bert_text": "243 <e1> cocaine </e1>-dependent outpatients with cocaine-induced mood disorder (<e2> CIMD </e2>), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5910": {"data": {"text": "243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "entity1": "cocaine", "entity2": "psychiatric", "span1": [4, 11], "span2": [148, 159]}, "bert_text": "243 <e1> cocaine </e1>-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of <e2> psychiatric </e2> symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5911": {"data": {"text": "243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "entity1": "cocaine", "entity2": "mood disorder", "span1": [39, 46], "span2": [55, 68]}, "bert_text": "243 cocaine-dependent outpatients with <e1> cocaine </e1>-induced <e2> mood disorder </e2> (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5912": {"data": {"text": "243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "entity1": "cocaine", "entity2": "mood disorders", "span1": [39, 46], "span2": [83, 97]}, "bert_text": "243 cocaine-dependent outpatients with <e1> cocaine </e1>-induced mood disorder (CIMD), other <e2> mood disorders </e2>, or no mood disorder were compared on measures of psychiatric symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5913": {"data": {"text": "243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "entity1": "cocaine", "entity2": "mood disorder", "span1": [39, 46], "span2": [105, 118]}, "bert_text": "243 cocaine-dependent outpatients with <e1> cocaine </e1>-induced mood disorder (CIMD), other mood disorders, or no <e2> mood disorder </e2> were compared on measures of psychiatric symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"5914": {"data": {"text": "243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "entity1": "cocaine", "entity2": "CIMD", "span1": [39, 46], "span2": [70, 74]}, "bert_text": "243 cocaine-dependent outpatients with <e1> cocaine </e1>-induced mood disorder (<e2> CIMD </e2>), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5915": {"data": {"text": "243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "entity1": "cocaine", "entity2": "psychiatric", "span1": [39, 46], "span2": [148, 159]}, "bert_text": "243 cocaine-dependent outpatients with <e1> cocaine </e1>-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of <e2> psychiatric </e2> symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5916": {"data": {"text": "CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.", "entity1": "Raloxifene", "entity2": "venous thromboembolism", "span1": [12, 22], "span2": [65, 87]}, "bert_text": "CONCLUSION: <e1> Raloxifene </e1> was associated with an increased risk for <e2> venous thromboembolism </e2>, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5917": {"data": {"text": "CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.", "entity1": "Raloxifene", "entity2": "cataracts", "span1": [12, 22], "span2": [125, 134]}, "bert_text": "CONCLUSION: <e1> Raloxifene </e1> was associated with an increased risk for venous thromboembolism, but there was no increased risk for <e2> cataracts </e2>, gallbladder disease, endometrial hyperplasia, or endometrial cancer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"5918": {"data": {"text": "CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.", "entity1": "Raloxifene", "entity2": "gallbladder disease", "span1": [12, 22], "span2": [136, 155]}, "bert_text": "CONCLUSION: <e1> Raloxifene </e1> was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, <e2> gallbladder disease </e2>, endometrial hyperplasia, or endometrial cancer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5919": {"data": {"text": "CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.", "entity1": "Raloxifene", "entity2": "endometrial hyperplasia", "span1": [12, 22], "span2": [157, 180]}, "bert_text": "CONCLUSION: <e1> Raloxifene </e1> was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, <e2> endometrial hyperplasia </e2>, or endometrial cancer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5920": {"data": {"text": "CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.", "entity1": "Raloxifene", "entity2": "endometrial cancer", "span1": [12, 22], "span2": [185, 203]}, "bert_text": "CONCLUSION: <e1> Raloxifene </e1> was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or <e2> endometrial cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5921": {"data": {"text": "In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.", "entity1": "DEN", "entity2": "tumor", "span1": [3, 6], "span2": [61, 66]}, "bert_text": "In <e1> DEN </e1> + PB treated rats, the survival was prolonged and the <e2> tumor </e2> incidence decreased as compared with the results obtained by DEN alone.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5922": {"data": {"text": "In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.", "entity1": "DEN", "entity2": "tumor", "span1": [128, 131], "span2": [61, 66]}, "bert_text": "In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by <e1> DEN </e1> <e2> tumor </e2> incidence decreased as compared with the results obtained by DEN alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"5923": {"data": {"text": "In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.", "entity1": "PB", "entity2": "tumor", "span1": [9, 11], "span2": [61, 66]}, "bert_text": "In DEN + <e1> PB </e1> treated rats, the survival was prolonged and the <e2> tumor </e2> incidence decreased as compared with the results obtained by DEN alone.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5924": {"data": {"text": "METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).", "entity1": "zidovudine", "entity2": "DCM", "span1": [73, 83], "span2": [222, 225]}, "bert_text": "METHODS AND RESULTS: In order to investigate whether the HAART component <e1> zidovudine </e1> (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2> DCM </e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5925": {"data": {"text": "METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).", "entity1": "3'-azido-2',3'-deoxythymidine", "entity2": "DCM", "span1": [85, 114], "span2": [222, 225]}, "bert_text": "METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (<e1> 3'-azido-2',3'-deoxythymidine </e1>; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2> DCM </e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5926": {"data": {"text": "METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).", "entity1": "AZT", "entity2": "DCM", "span1": [116, 119], "span2": [222, 225]}, "bert_text": "METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; <e1> AZT </e1>) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2> DCM </e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5927": {"data": {"text": "METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).", "entity1": "AZT", "entity2": "DCM", "span1": [395, 398], "span2": [222, 225]}, "bert_text": "METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of <e1> AZT </e1> <e2> DCM </e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5928": {"data": {"text": "Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.", "entity1": "cocaine", "entity2": "hyperlocomotion", "span1": [27, 34], "span2": [43, 58]}, "bert_text": "Our findings indicate that <e1> cocaine </e1> induced <e2> hyperlocomotion </e2> is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5929": {"data": {"text": "Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.", "entity1": "GR 55562", "entity2": "hyperlocomotion", "span1": [255, 263], "span2": [43, 58]}, "bert_text": "Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (<e1> GR 55562 </e1> <e2> hyperlocomotion </e2> is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5930": {"data": {"text": "Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.", "entity1": "CP 93129", "entity2": "hyperlocomotion", "span1": [278, 286], "span2": [43, 58]}, "bert_text": "Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (<e1> CP 93129 </e1> <e2> hyperlocomotion </e2> is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5931": {"data": {"text": "Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.", "entity1": "methotrexate", "entity2": "Impotence", "span1": [127, 139], "span2": [0, 9]}, "bert_text": "Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of <e1> methotrexate </e1> <e2> Impotence </e2> was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5932": {"data": {"text": "Mitomycin C associated hemolytic uremic syndrome.\n", "entity1": "Mitomycin C", "entity2": "hemolytic uremic syndrome", "span1": [0, 11], "span2": [23, 48]}, "bert_text": "<e1> Mitomycin C </e1> associated <e2> hemolytic uremic syndrome </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5933": {"data": {"text": "Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.\n", "entity1": "cimetidine", "entity2": "confusion", "span1": [54, 64], "span2": [83, 92]}, "bert_text": "Pharmacokinetic and clinical studies in patients with <e1> cimetidine </e1>-associated mental <e2> confusion </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5934": {"data": {"text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "entity1": "cyclophosphamide", "entity2": "breast cancer", "span1": [115, 131], "span2": [75, 88]}, "bert_text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional <e1> cyclophosphamide </e1> <e2> breast cancer </e2> receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"5935": {"data": {"text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "entity1": "cyclophosphamide", "entity2": "congestive heart failure", "span1": [115, 131], "span2": [238, 262]}, "bert_text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional <e1> cyclophosphamide </e1> as part of a triple sequential high-dose regimen to assess association between presence of peritransplant <e2> congestive heart failure </e2> (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5936": {"data": {"text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "entity1": "cyclophosphamide", "entity2": "CHF", "span1": [115, 131], "span2": [264, 267]}, "bert_text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional <e1> cyclophosphamide </e1> as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (<e2> CHF </e2>) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5937": {"data": {"text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "entity1": "cyclophosphamide", "entity2": "hypertension", "span1": [115, 131], "span2": [373, 385]}, "bert_text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional <e1> cyclophosphamide </e1> as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, <e2> hypertension </e2>, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5938": {"data": {"text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "entity1": "cyclophosphamide", "entity2": "diabetes mellitus", "span1": [115, 131], "span2": [419, 436]}, "bert_text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional <e1> cyclophosphamide </e1> as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, <e2> diabetes mellitus </e2>, prior use of anthracyclines, and left-sided chest irradiation.", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5939": {"data": {"text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "entity1": "anthracyclines", "entity2": "breast cancer", "span1": [451, 465], "span2": [75, 88]}, "bert_text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of <e1> anthracyclines </e1> <e2> breast cancer </e2> receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"5940": {"data": {"text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "entity1": "anthracyclines", "entity2": "congestive heart failure", "span1": [451, 465], "span2": [238, 262]}, "bert_text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of <e1> anthracyclines </e1> <e2> congestive heart failure </e2> (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5941": {"data": {"text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "entity1": "anthracyclines", "entity2": "CHF", "span1": [451, 465], "span2": [264, 267]}, "bert_text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of <e1> anthracyclines </e1> <e2> CHF </e2>) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5942": {"data": {"text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "entity1": "anthracyclines", "entity2": "hypertension", "span1": [451, 465], "span2": [373, 385]}, "bert_text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of <e1> anthracyclines </e1> <e2> hypertension </e2>, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5943": {"data": {"text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "entity1": "anthracyclines", "entity2": "diabetes mellitus", "span1": [451, 465], "span2": [419, 436]}, "bert_text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of <e1> anthracyclines </e1> <e2> diabetes mellitus </e2>, prior use of anthracyclines, and left-sided chest irradiation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5944": {"data": {"text": "L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.", "entity1": "gentamicin", "entity2": "hearing loss", "span1": [15, 25], "span2": [34, 46]}, "bert_text": "L-NAME reduced <e1> gentamicin </e1>-induced <e2> hearing loss </e2> in the high-frequency range, but gave no protection in the middle or low frequencies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5945": {"data": {"text": "Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.", "entity1": "Chlordiazepoxide", "entity2": "rigidity", "span1": [0, 16], "span2": [79, 87]}, "bert_text": "<e1> Chlordiazepoxide </e1> at doses up to 10 mg/kg failed to significantly influence the <e2> rigidity </e2> produced by alfentanil.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5946": {"data": {"text": "Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.", "entity1": "alfentanil", "entity2": "rigidity", "span1": [100, 110], "span2": [79, 87]}, "bert_text": "Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by <e1> alfentanil </e1> <e2> rigidity </e2> produced by alfentanil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5947": {"data": {"text": "Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.\n", "entity1": "calcium chloride", "entity2": "toxicity", "span1": [10, 26], "span2": [70, 78]}, "bert_text": "Effect of <e1> calcium chloride </e1> and 4-aminopyridine therapy on desipramine <e2> toxicity </e2> in rats.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5948": {"data": {"text": "Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.\n", "entity1": "4-aminopyridine", "entity2": "toxicity", "span1": [31, 46], "span2": [70, 78]}, "bert_text": "Effect of calcium chloride and <e1> 4-aminopyridine </e1> therapy on desipramine <e2> toxicity </e2> in rats.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5949": {"data": {"text": "Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.\n", "entity1": "desipramine", "entity2": "toxicity", "span1": [58, 69], "span2": [70, 78]}, "bert_text": "Effect of calcium chloride and 4-aminopyridine therapy on <e1> desipramine </e1> <e2> toxicity </e2> in rats.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5950": {"data": {"text": "We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.", "entity1": "cyclosporine", "entity2": "thrombotic microangiopathy", "span1": [106, 118], "span2": [41, 67]}, "bert_text": "We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to <e1> cyclosporine </e1> <e2> thrombotic microangiopathy </e2> was drug related, secondary mainly to cyclosporine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5951": {"data": {"text": "Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.", "entity1": "calcium", "entity2": "cardiovascular alterations", "span1": [59, 66], "span2": [104, 130]}, "bert_text": "Preclinical toxicologic investigation suggested that a new <e1> calcium </e1> channel blocker, Ro 40-5967, induced <e2> cardiovascular alterations </e2> in rat fetuses exposed to this agent during organogenesis.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5952": {"data": {"text": "Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.", "entity1": "Ro 40-5967", "entity2": "cardiovascular alterations", "span1": [84, 94], "span2": [104, 130]}, "bert_text": "Preclinical toxicologic investigation suggested that a new calcium channel blocker, <e1> Ro 40-5967 </e1>, induced <e2> cardiovascular alterations </e2> in rat fetuses exposed to this agent during organogenesis.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5953": {"data": {"text": "Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.", "entity1": "AraG", "entity2": "toxicity", "span1": [61, 65], "span2": [15, 23]}, "bert_text": "Haematological toxicity was greater for the combination than <e1> AraG </e1> <e2> toxicity </e2> was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5954": {"data": {"text": "BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.", "entity1": "cyclosporine", "entity2": "nephrotoxic", "span1": [39, 51], "span2": [88, 99]}, "bert_text": "BACKGROUND: The calcineurin inhibitors <e1> cyclosporine </e1> and tacrolimus are both known to be <e2> nephrotoxic </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5955": {"data": {"text": "BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.", "entity1": "tacrolimus", "entity2": "nephrotoxic", "span1": [56, 66], "span2": [88, 99]}, "bert_text": "BACKGROUND: The calcineurin inhibitors cyclosporine and <e1> tacrolimus </e1> are both known to be <e2> nephrotoxic </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5956": {"data": {"text": "The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.", "entity1": "calcium", "entity2": "malformations", "span1": [66, 73], "span2": [124, 137]}, "bert_text": "The present study was designed to investigate the hypothesis that <e1> calcium </e1> channel blockers in general induce cardiovascular <e2> malformations </e2> indicating a pharmacologic class effect.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5957": {"data": {"text": "This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.", "entity1": "disulfiram", "entity2": "acute palsy", "span1": [149, 159], "span2": [19, 30]}, "bert_text": "This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose <e1> disulfiram </e1> <e2> acute palsy </e2> of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5958": {"data": {"text": "This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.", "entity1": "disulfiram", "entity2": "sensorimotor axonal polyneuropathy", "span1": [149, 159], "span2": [94, 128]}, "bert_text": "This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose <e1> disulfiram </e1> <e2> sensorimotor axonal polyneuropathy </e2> caused by high-dose disulfiram intoxication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5959": {"data": {"text": "Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.", "entity1": "beta lactam", "entity2": "autoimmune hemolytic anemia", "span1": [80, 91], "span2": [208, 235]}, "bert_text": "Although the transaminases gradually returned to baseline after withholding the <e1> beta lactam </e1> antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an <e2> autoimmune hemolytic anemia </e2> and erythroblastocytopenia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5960": {"data": {"text": "Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.", "entity1": "bilirubin", "entity2": "autoimmune hemolytic anemia", "span1": [142, 151], "span2": [208, 235]}, "bert_text": "Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum <e1> bilirubin </e1> and a decrease in hemoglobin concentration caused by an <e2> autoimmune hemolytic anemia </e2> and erythroblastocytopenia.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"5961": {"data": {"text": "Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.", "entity1": "Zonisamide", "entity2": "seizures", "span1": [0, 10], "span2": [81, 89]}, "bert_text": "<e1> Zonisamide </e1> is a broad-spectrum antiepileptic drug used to treat various types of <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5962": {"data": {"text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "entity1": "CCl4", "entity2": "hepatotoxic", "span1": [155, 159], "span2": [132, 143]}, "bert_text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of <e1> CCl4 </e1> <e2> hepatotoxic </e2> effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5963": {"data": {"text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "entity1": "CCl4", "entity2": "cardiotoxic", "span1": [155, 159], "span2": [239, 250]}, "bert_text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of <e1> CCl4 </e1>, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably <e2> cardiotoxic </e2>) effect of adriamycin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5964": {"data": {"text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "entity1": "CHCl3", "entity2": "hepatotoxic", "span1": [161, 166], "span2": [132, 143]}, "bert_text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, <e1> CHCl3 </e1> <e2> hepatotoxic </e2> effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5965": {"data": {"text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "entity1": "CHCl3", "entity2": "cardiotoxic", "span1": [161, 166], "span2": [239, 250]}, "bert_text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, <e1> CHCl3 </e1>, acetaminophen and galactosamine and against the lethal (and presumably <e2> cardiotoxic </e2>) effect of adriamycin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5966": {"data": {"text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "entity1": "acetaminophen", "entity2": "hepatotoxic", "span1": [168, 181], "span2": [132, 143]}, "bert_text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, <e1> acetaminophen </e1> <e2> hepatotoxic </e2> effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5967": {"data": {"text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "entity1": "acetaminophen", "entity2": "cardiotoxic", "span1": [168, 181], "span2": [239, 250]}, "bert_text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, <e1> acetaminophen </e1> and galactosamine and against the lethal (and presumably <e2> cardiotoxic </e2>) effect of adriamycin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5968": {"data": {"text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "entity1": "galactosamine", "entity2": "hepatotoxic", "span1": [186, 199], "span2": [132, 143]}, "bert_text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and <e1> galactosamine </e1> <e2> hepatotoxic </e2> effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5969": {"data": {"text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "entity1": "galactosamine", "entity2": "cardiotoxic", "span1": [186, 199], "span2": [239, 250]}, "bert_text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and <e1> galactosamine </e1> and against the lethal (and presumably <e2> cardiotoxic </e2>) effect of adriamycin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5970": {"data": {"text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "entity1": "adriamycin", "entity2": "hepatotoxic", "span1": [262, 272], "span2": [132, 143]}, "bert_text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of <e1> adriamycin </e1> <e2> hepatotoxic </e2> effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5971": {"data": {"text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "entity1": "adriamycin", "entity2": "cardiotoxic", "span1": [262, 272], "span2": [239, 250]}, "bert_text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of <e1> adriamycin </e1> <e2> cardiotoxic </e2>) effect of adriamycin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5972": {"data": {"text": "In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).", "entity1": "verapamil", "entity2": "AF", "span1": [22, 31], "span2": [288, 290]}, "bert_text": "In these experiments, <e1> verapamil </e1> shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of <e2> AF </e2> (94+/-4 to 84+/-3 ms, P<0.005).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5973": {"data": {"text": "In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [65, 76], "span2": [40, 53]}, "bert_text": "In contrast, SSR103800 failed to affect hyperactivity induced by <e1> amphetamine </e1> <e2> hyperactivity </e2> induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5974": {"data": {"text": "In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).", "entity1": "dopamine", "entity2": "hyperactivity", "span1": [102, 110], "span2": [40, 53]}, "bert_text": "In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in <e1> dopamine </e1> <e2> hyperactivity </e2> induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5975": {"data": {"text": "Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.\n", "entity1": "Ceftriaxone", "entity2": "biliary pseudolithiasis", "span1": [0, 11], "span2": [23, 46]}, "bert_text": "<e1> Ceftriaxone </e1>-associated <e2> biliary pseudolithiasis </e2> in paediatric surgical patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5976": {"data": {"text": "Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).", "entity1": "nitrite", "entity2": "nephropathy", "span1": [6, 13], "span2": [61, 72]}, "bert_text": "Urine <e1> nitrite </e1> levels were significantly increased in the ADR-<e2> nephropathy </e2> group (P < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5977": {"data": {"text": "Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).", "entity1": "ADR", "entity2": "nephropathy", "span1": [57, 60], "span2": [61, 72]}, "bert_text": "Urine nitrite levels were significantly increased in the <e1> ADR </e1>-<e2> nephropathy </e2> group (P < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5978": {"data": {"text": "Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.", "entity1": "zonisamide", "entity2": "visual hallucinations", "span1": [195, 205], "span2": [9, 30]}, "bert_text": "Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after <e1> zonisamide </e1> <e2> visual hallucinations </e2> have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5979": {"data": {"text": "Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.", "entity1": "zonisamide", "entity2": "visual hallucinations", "span1": [195, 205], "span2": [141, 162]}, "bert_text": "Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after <e1> zonisamide </e1> <e2> visual hallucinations </e2> and altered mental status after zonisamide treatment was begun or its dosage increased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"5980": {"data": {"text": "Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.", "entity1": "ribavirin", "entity2": "hemolytic anemia", "span1": [11, 20], "span2": [29, 45]}, "bert_text": "Because of <e1> ribavirin </e1>-related <e2> hemolytic anemia </e2>, dose reduction is a common event in this therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5981": {"data": {"text": "1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.", "entity1": "adriamycin", "entity2": "acute myeloblastic leukemia", "span1": [87, 97], "span2": [30, 57]}, "bert_text": "1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of <e1> adriamycin </e1> <e2> acute myeloblastic leukemia </e2> after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5982": {"data": {"text": "Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [60, 67], "span2": [101, 117]}, "bert_text": "Patients went home after hospitalizations that had included <e1> heparin </e1> exposure--in most cases, with no <e2> thrombocytopenia </e2> recognized--only to return to the hospital (median, day 14) with thromboembolic complications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"5983": {"data": {"text": "Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.", "entity1": "heparin", "entity2": "thromboembolic", "span1": [60, 67], "span2": [183, 197]}, "bert_text": "Patients went home after hospitalizations that had included <e1> heparin </e1> exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with <e2> thromboembolic </e2> complications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5984": {"data": {"text": "The third patient had acute amphetamine-induced chorea after prolonged oral contraception.", "entity1": "amphetamine", "entity2": "chorea", "span1": [28, 39], "span2": [48, 54]}, "bert_text": "The third patient had acute <e1> amphetamine </e1>-induced <e2> chorea </e2> after prolonged oral contraception.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5985": {"data": {"text": "The third patient had acute amphetamine-induced chorea after prolonged oral contraception.", "entity1": "oral contraception", "entity2": "chorea", "span1": [71, 89], "span2": [48, 54]}, "bert_text": "The third patient had acute amphetamine-induced chorea after prolonged <e1> oral contraception </e1> <e2> chorea </e2> after prolonged oral contraception.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5986": {"data": {"text": "Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.", "entity1": "cyclophosphamide", "entity2": "Haemorrhagic myocarditis", "span1": [65, 81], "span2": [0, 24]}, "bert_text": "Haemorrhagic myocarditis is a rare but important complication of <e1> cyclophosphamide </e1> <e2> Haemorrhagic myocarditis </e2> is a rare but important complication of cyclophosphamide therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5987": {"data": {"text": "An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.", "entity1": "methylphenidate", "entity2": "depression", "span1": [100, 115], "span2": [44, 54]}, "bert_text": "An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on <e1> methylphenidate </e1> <e2> depression </e2> and early Alzheimer's disease was started on methylphenidate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"5988": {"data": {"text": "An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.", "entity1": "methylphenidate", "entity2": "Alzheimer's disease", "span1": [100, 115], "span2": [65, 84]}, "bert_text": "An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on <e1> methylphenidate </e1> <e2> Alzheimer's disease </e2> was started on methylphenidate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"5989": {"data": {"text": "Chloroquine related complete heart block with blindness: case report.\n", "entity1": "Chloroquine", "entity2": "heart block", "span1": [0, 11], "span2": [29, 40]}, "bert_text": "<e1> Chloroquine </e1> related complete <e2> heart block </e2> with blindness: case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5990": {"data": {"text": "Chloroquine related complete heart block with blindness: case report.\n", "entity1": "Chloroquine", "entity2": "blindness", "span1": [0, 11], "span2": [46, 55]}, "bert_text": "<e1> Chloroquine </e1> related complete heart block with <e2> blindness </e2>: case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5991": {"data": {"text": "The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.", "entity1": "AraG", "entity2": "neuropathy", "span1": [49, 53], "span2": [95, 105]}, "bert_text": "The most common side effects attributable to the <e1> AraG </e1> included Grade 2 and 3 sensory and motor <e2> neuropathy </e2> and musculoskeletal pain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5992": {"data": {"text": "The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.", "entity1": "AraG", "entity2": "musculoskeletal pain", "span1": [49, 53], "span2": [110, 130]}, "bert_text": "The most common side effects attributable to the <e1> AraG </e1> included Grade 2 and 3 sensory and motor neuropathy and <e2> musculoskeletal pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5993": {"data": {"text": "Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.", "entity1": "Prostaglandin E2", "entity2": "hyperalgesic", "span1": [0, 16], "span2": [26, 38]}, "bert_text": "<e1> Prostaglandin E2 </e1> showed a <e2> hyperalgesic </e2> effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5994": {"data": {"text": "Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.", "entity1": "pg", "entity2": "hyperalgesic", "span1": [60, 62], "span2": [26, 38]}, "bert_text": "Prostaglandin E2 showed a hyperalgesic effect at doses of 1 <e1> pg </e1> <e2> hyperalgesic </e2> effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5995": {"data": {"text": "Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.", "entity1": "prostaglandin D2", "entity2": "hyperalgesic", "span1": [133, 149], "span2": [26, 38]}, "bert_text": "Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of <e1> prostaglandin D2 </e1> <e2> hyperalgesic </e2> effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"5996": {"data": {"text": "Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.", "entity1": "ATP", "entity2": "diabetic", "span1": [136, 139], "span2": [100, 108]}, "bert_text": "Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, <e1> ATP </e1> <e2> diabetic </e2> rats to nerve stimulation, ATP, and bethanechol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5997": {"data": {"text": "Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.", "entity1": "bethanechol", "entity2": "diabetic", "span1": [145, 156], "span2": [100, 108]}, "bert_text": "Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and <e1> bethanechol </e1> <e2> diabetic </e2> rats to nerve stimulation, ATP, and bethanechol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5998": {"data": {"text": "Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage.\n", "entity1": "adriamycin", "entity2": "renal damage", "span1": [87, 97], "span2": [106, 118]}, "bert_text": "Individual differences in renal ACE activity in healthy rats predict susceptibility to <e1> adriamycin </e1>-induced <e2> renal damage </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5999": {"data": {"text": "The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.", "entity1": "calcium", "entity2": "toxicity", "span1": [62, 69], "span2": [116, 124]}, "bert_text": "The purpose of this study was to investigate the influence of <e1> calcium </e1> channel blockers on bupivacaine-induced acute <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6000": {"data": {"text": "The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.", "entity1": "bupivacaine", "entity2": "toxicity", "span1": [90, 101], "span2": [116, 124]}, "bert_text": "The purpose of this study was to investigate the influence of calcium channel blockers on <e1> bupivacaine </e1>-induced acute <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6001": {"data": {"text": "Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.", "entity1": "lindane", "entity2": "aplastic anaemia", "span1": [30, 37], "span2": [108, 124]}, "bert_text": "Evidence is accumulating that <e1> lindane </e1> can be toxic to the central nervous system and may be associated with <e2> aplastic anaemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6002": {"data": {"text": "Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time.", "entity1": "telithromycin", "entity2": "hepatitis", "span1": [143, 156], "span2": [14, 23]}, "bert_text": "Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed <e1> telithromycin </e1> <e2> hepatitis </e2> attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6003": {"data": {"text": "Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.", "entity1": "Rosen's T5", "entity2": "malignant bone tumors", "span1": [108, 118], "span2": [56, 77]}, "bert_text": "Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to <e1> Rosen's T5 </e1> <e2> malignant bone tumors </e2> who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6004": {"data": {"text": "Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.", "entity1": "doxorubicin", "entity2": "malignant bone tumors", "span1": [151, 162], "span2": [56, 77]}, "bert_text": "Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including <e1> doxorubicin </e1> <e2> malignant bone tumors </e2> who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6005": {"data": {"text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.", "entity1": "glyceryl trinitrate", "entity2": "migraine with aura", "span1": [151, 170], "span2": [49, 67]}, "bert_text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of <e1> glyceryl trinitrate </e1> <e2> migraine with aura </e2>, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6006": {"data": {"text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.", "entity1": "glyceryl trinitrate", "entity2": "migraine with aura", "span1": [151, 170], "span2": [227, 245]}, "bert_text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of <e1> glyceryl trinitrate </e1> (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of <e2> migraine with aura </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6007": {"data": {"text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.", "entity1": "glyceryl trinitrate", "entity2": "headache", "span1": [151, 170], "span2": [106, 114]}, "bert_text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of <e1> glyceryl trinitrate </e1> <e2> headache </e2> response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6008": {"data": {"text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.", "entity1": "GTN", "entity2": "migraine with aura", "span1": [172, 175], "span2": [49, 67]}, "bert_text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (<e1> GTN </e1> <e2> migraine with aura </e2>, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6009": {"data": {"text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.", "entity1": "GTN", "entity2": "migraine with aura", "span1": [172, 175], "span2": [227, 245]}, "bert_text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (<e1> GTN </e1>) (0.5 microg/kg/min for 20 min) in 12 sufferers of <e2> migraine with aura </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6010": {"data": {"text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.", "entity1": "GTN", "entity2": "headache", "span1": [172, 175], "span2": [106, 114]}, "bert_text": "In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (<e1> GTN </e1> <e2> headache </e2> response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6011": {"data": {"text": "Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.", "entity1": "oxygen", "entity2": "nephropathy", "span1": [9, 15], "span2": [114, 125]}, "bert_text": "Reactive <e1> oxygen </e1> species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced <e2> nephropathy </e2>, with antioxidants significantly reducing the proteinuria.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6012": {"data": {"text": "Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.", "entity1": "oxygen", "entity2": "proteinuria", "span1": [9, 15], "span2": [172, 183]}, "bert_text": "Reactive <e1> oxygen </e1> species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the <e2> proteinuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6013": {"data": {"text": "Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.", "entity1": "puromycin aminonucleoside", "entity2": "nephropathy", "span1": [74, 99], "span2": [114, 125]}, "bert_text": "Reactive oxygen species have been implicated in the pathogenesis of acute <e1> puromycin aminonucleoside </e1> (PAN)-induced <e2> nephropathy </e2>, with antioxidants significantly reducing the proteinuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6014": {"data": {"text": "Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.", "entity1": "puromycin aminonucleoside", "entity2": "proteinuria", "span1": [74, 99], "span2": [172, 183]}, "bert_text": "Reactive oxygen species have been implicated in the pathogenesis of acute <e1> puromycin aminonucleoside </e1> (PAN)-induced nephropathy, with antioxidants significantly reducing the <e2> proteinuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6015": {"data": {"text": "Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.", "entity1": "PAN)-induced", "entity2": "nephropathy", "span1": [101, 113], "span2": [114, 125]}, "bert_text": "Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (<e1> PAN)-induced </e1> <e2> nephropathy </e2>, with antioxidants significantly reducing the proteinuria.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6016": {"data": {"text": "Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.", "entity1": "PAN)-induced", "entity2": "proteinuria", "span1": [101, 113], "span2": [172, 183]}, "bert_text": "Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (<e1> PAN)-induced </e1> nephropathy, with antioxidants significantly reducing the <e2> proteinuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6017": {"data": {"text": "Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "entity1": "Cyclosporin A", "entity2": "hypertrophy", "span1": [0, 13], "span2": [239, 250]}, "bert_text": "<e1> Cyclosporin A </e1> (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6018": {"data": {"text": "Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "entity1": "CsA", "entity2": "hypertrophy", "span1": [15, 18], "span2": [239, 250]}, "bert_text": "Cyclosporin A (<e1> CsA </e1>; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6019": {"data": {"text": "Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "entity1": "Fujimycine", "entity2": "hypertrophy", "span1": [34, 44], "span2": [239, 250]}, "bert_text": "Cyclosporin A (CsA; 50 mg/kg) and <e1> Fujimycine </e1> (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6020": {"data": {"text": "Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "entity1": "FK506", "entity2": "hypertrophy", "span1": [46, 51], "span2": [239, 250]}, "bert_text": "Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (<e1> FK506 </e1>; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6021": {"data": {"text": "Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "entity1": "macrolide", "entity2": "hypertrophy", "span1": [83, 92], "span2": [239, 250]}, "bert_text": "Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related <e1> macrolide </e1> immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6022": {"data": {"text": "Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "entity1": "rapamycin", "entity2": "hypertrophy", "span1": [111, 120], "span2": [239, 250]}, "bert_text": "Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant <e1> rapamycin </e1> (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6023": {"data": {"text": "The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.", "entity1": "morphine", "entity2": "hyperactivity", "span1": [4, 12], "span2": [21, 34]}, "bert_text": "The <e1> morphine </e1>-induced <e2> hyperactivity </e2> was potentiated by scopolamine and attenuated by physostigmine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6024": {"data": {"text": "The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.", "entity1": "scopolamine", "entity2": "hyperactivity", "span1": [54, 65], "span2": [21, 34]}, "bert_text": "The morphine-induced hyperactivity was potentiated by <e1> scopolamine </e1> <e2> hyperactivity </e2> was potentiated by scopolamine and attenuated by physostigmine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6025": {"data": {"text": "The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.", "entity1": "physostigmine", "entity2": "hyperactivity", "span1": [84, 97], "span2": [21, 34]}, "bert_text": "The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by <e1> physostigmine </e1> <e2> hyperactivity </e2> was potentiated by scopolamine and attenuated by physostigmine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6026": {"data": {"text": "Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.", "entity1": "methotrexate", "entity2": "acute lymphoblastic leukemia", "span1": [124, 136], "span2": [21, 49]}, "bert_text": "Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous <e1> methotrexate </e1> <e2> acute lymphoblastic leukemia </e2> who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6027": {"data": {"text": "Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.", "entity1": "methotrexate", "entity2": "meningeal disease", "span1": [124, 136], "span2": [64, 81]}, "bert_text": "Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous <e1> methotrexate </e1> <e2> meningeal disease </e2> were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6028": {"data": {"text": "Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.", "entity1": "methotrexate", "entity2": "acute lymphoblastic leukemia", "span1": [191, 203], "span2": [21, 49]}, "bert_text": "Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF <e1> methotrexate </e1> <e2> acute lymphoblastic leukemia </e2> who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6029": {"data": {"text": "Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.", "entity1": "methotrexate", "entity2": "meningeal disease", "span1": [191, 203], "span2": [64, 81]}, "bert_text": "Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF <e1> methotrexate </e1> <e2> meningeal disease </e2> were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6030": {"data": {"text": "OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).", "entity1": "sirolimus", "entity2": "capillary leak syndrome", "span1": [59, 68], "span2": [77, 100]}, "bert_text": "OBSERVATIONS: A keratome skin specimen from 1 patient with <e1> sirolimus </e1>-induced <e2> capillary leak syndrome </e2> had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6031": {"data": {"text": "OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).", "entity1": "sirolimus", "entity2": "psoriasis", "span1": [59, 68], "span2": [226, 235]}, "bert_text": "OBSERVATIONS: A keratome skin specimen from 1 patient with <e1> sirolimus </e1>-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with <e2> psoriasis </e2> (21%).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6032": {"data": {"text": "OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).", "entity1": "sirolimus", "entity2": "capillary leak syndrome", "span1": [195, 204], "span2": [77, 100]}, "bert_text": "OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected <e1> sirolimus </e1> <e2> capillary leak syndrome </e2> had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6033": {"data": {"text": "OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).", "entity1": "sirolimus", "entity2": "psoriasis", "span1": [195, 204], "span2": [226, 235]}, "bert_text": "OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected <e1> sirolimus </e1>-treated patient with <e2> psoriasis </e2> (21%).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6034": {"data": {"text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "entity1": "desipramine", "entity2": "nausea", "span1": [64, 75], "span2": [175, 181]}, "bert_text": "Fewer subjects reported adverse events following treatment with <e1> desipramine </e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (<e2> nausea </e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6035": {"data": {"text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "entity1": "desipramine", "entity2": "headache", "span1": [64, 75], "span2": [186, 194]}, "bert_text": "Fewer subjects reported adverse events following treatment with <e1> desipramine </e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and <e2> headache </e2>) have been reported for patients treated with either desipramine or cinacalcet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6036": {"data": {"text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "entity1": "desipramine", "entity2": "nausea", "span1": [102, 113], "span2": [175, 181]}, "bert_text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving <e1> desipramine </e1> with cinacalcet (33 versus 86%), the most frequent of which (<e2> nausea </e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6037": {"data": {"text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "entity1": "desipramine", "entity2": "headache", "span1": [102, 113], "span2": [186, 194]}, "bert_text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving <e1> desipramine </e1> with cinacalcet (33 versus 86%), the most frequent of which (nausea and <e2> headache </e2>) have been reported for patients treated with either desipramine or cinacalcet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6038": {"data": {"text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "entity1": "desipramine", "entity2": "nausea", "span1": [248, 259], "span2": [175, 181]}, "bert_text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either <e1> desipramine </e1> <e2> nausea </e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6039": {"data": {"text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "entity1": "desipramine", "entity2": "headache", "span1": [248, 259], "span2": [186, 194]}, "bert_text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either <e1> desipramine </e1> <e2> headache </e2>) have been reported for patients treated with either desipramine or cinacalcet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6040": {"data": {"text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "entity1": "cinacalcet", "entity2": "nausea", "span1": [119, 129], "span2": [175, 181]}, "bert_text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1> cinacalcet </e1> (33 versus 86%), the most frequent of which (<e2> nausea </e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6041": {"data": {"text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "entity1": "cinacalcet", "entity2": "headache", "span1": [119, 129], "span2": [186, 194]}, "bert_text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1> cinacalcet </e1> (33 versus 86%), the most frequent of which (nausea and <e2> headache </e2>) have been reported for patients treated with either desipramine or cinacalcet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6042": {"data": {"text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "entity1": "cinacalcet", "entity2": "nausea", "span1": [263, 273], "span2": [175, 181]}, "bert_text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or <e1> cinacalcet </e1> <e2> nausea </e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6043": {"data": {"text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "entity1": "cinacalcet", "entity2": "headache", "span1": [263, 273], "span2": [186, 194]}, "bert_text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or <e1> cinacalcet </e1> <e2> headache </e2>) have been reported for patients treated with either desipramine or cinacalcet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6044": {"data": {"text": "A 14-year-old girl is reported with recurrent, azithromycin-induced, acute interstitial nephritis.", "entity1": "azithromycin", "entity2": "interstitial nephritis", "span1": [47, 59], "span2": [75, 97]}, "bert_text": "A 14-year-old girl is reported with recurrent, <e1> azithromycin </e1>-induced, acute <e2> interstitial nephritis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6045": {"data": {"text": "Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.", "entity1": "clonidine", "entity2": "bradycardia", "span1": [23, 32], "span2": [52, 63]}, "bert_text": "Physicians prescribing <e1> clonidine </e1> should monitor for <e2> bradycardia </e2> and advise patients about the high likelihood of initial drowsiness.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6046": {"data": {"text": "Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.", "entity1": "clonidine", "entity2": "drowsiness", "span1": [23, 32], "span2": [121, 131]}, "bert_text": "Physicians prescribing <e1> clonidine </e1> should monitor for bradycardia and advise patients about the high likelihood of initial <e2> drowsiness </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6047": {"data": {"text": "During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.", "entity1": "SNP", "entity2": "HEM", "span1": [140, 143], "span2": [7, 10]}, "bert_text": "During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the <e1> SNP </e1> <e2> HEM </e2>-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6048": {"data": {"text": "During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.", "entity1": "SNP", "entity2": "hypotension", "span1": [140, 143], "span2": [19, 30]}, "bert_text": "During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the <e1> SNP </e1> <e2> hypotension </e2> the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6049": {"data": {"text": "METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.", "entity1": "Ca(2", "entity2": "AF", "span1": [65, 69], "span2": [49, 51]}, "bert_text": "METHODS: To evaluate the potential mechanisms of AF promotion by <e1> Ca(2 </e1> <e2> AF </e2> promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6050": {"data": {"text": "METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.", "entity1": "verapamil", "entity2": "AF", "span1": [106, 115], "span2": [49, 51]}, "bert_text": "METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered <e1> verapamil </e1> <e2> AF </e2> promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6051": {"data": {"text": "METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.", "entity1": "morphine", "entity2": "AF", "span1": [119, 127], "span2": [49, 51]}, "bert_text": "METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to <e1> morphine </e1> <e2> AF </e2> promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6052": {"data": {"text": "METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.", "entity1": "chloralose", "entity2": "AF", "span1": [128, 138], "span2": [49, 51]}, "bert_text": "METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-<e1> chloralose </e1> <e2> AF </e2> promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6053": {"data": {"text": "The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.", "entity1": "vitamin D", "entity2": "artery calcification", "span1": [68, 77], "span2": [94, 114]}, "bert_text": "The second set of experiments examined the possible synergy between <e1> vitamin D </e1> and Warfarin in <e2> artery calcification </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6054": {"data": {"text": "The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.", "entity1": "Warfarin", "entity2": "artery calcification", "span1": [82, 90], "span2": [94, 114]}, "bert_text": "The second set of experiments examined the possible synergy between vitamin D and <e1> Warfarin </e1> in <e2> artery calcification </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"6055": {"data": {"text": "CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.", "entity1": "argatroban", "entity2": "coagulopathy", "span1": [35, 45], "span2": [230, 242]}, "bert_text": "CONCLUSIONS: Correlation of plasma <e1> argatroban </e1> concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended <e2> coagulopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6056": {"data": {"text": "CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.", "entity1": "argatroban", "entity2": "coagulopathy", "span1": [172, 182], "span2": [230, 242]}, "bert_text": "CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma <e1> argatroban </e1> may have contributed to the patient's extended <e2> coagulopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6057": {"data": {"text": "Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.", "entity1": "glucose", "entity2": "papillary damage", "span1": [25, 32], "span2": [165, 181]}, "bert_text": "Alkaline phosphatase and <e1> glucose </e1> were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in <e2> papillary damage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6058": {"data": {"text": "Coronary aneurysm after implantation of a paclitaxel-eluting stent.\n", "entity1": "paclitaxel", "entity2": "Coronary aneurysm", "span1": [42, 52], "span2": [0, 17]}, "bert_text": "Coronary aneurysm after implantation of a <e1> paclitaxel </e1> <e2> Coronary aneurysm </e2> after implantation of a paclitaxel-eluting stent.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6059": {"data": {"text": "Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.", "entity1": "benzodiazepines", "entity2": "myoclonic jerks", "span1": [7, 22], "span2": [136, 151]}, "bert_text": "Of the <e1> benzodiazepines </e1>, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the <e2> myoclonic jerks </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6060": {"data": {"text": "Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.", "entity1": "clonazepam", "entity2": "myoclonic jerks", "span1": [24, 34], "span2": [136, 151]}, "bert_text": "Of the benzodiazepines, <e1> clonazepam </e1> (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the <e2> myoclonic jerks </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6061": {"data": {"text": "Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.", "entity1": "diazepam", "entity2": "myoclonic jerks", "span1": [97, 105], "span2": [136, 151]}, "bert_text": "Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than <e1> diazepam </e1> (0.3-3 mg/kg) in blocking the <e2> myoclonic jerks </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6062": {"data": {"text": "Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages.", "entity1": "ribavirin", "entity2": "anemia", "span1": [57, 66], "span2": [78, 84]}, "bert_text": "Recombinant human erythropoietin has been used to manage <e1> ribavirin </e1>-associated <e2> anemia </e2> but has other potential disadvantages.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6063": {"data": {"text": "We report the first case of sorafenib-induced coronary artery spasm.", "entity1": "sorafenib", "entity2": "coronary artery spasm", "span1": [28, 37], "span2": [46, 67]}, "bert_text": "We report the first case of <e1> sorafenib </e1>-induced <e2> coronary artery spasm </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6064": {"data": {"text": "The degree of these seizures increased with increasing concentration of tAMCA.", "entity1": "tAMCA", "entity2": "seizures", "span1": [72, 77], "span2": [20, 28]}, "bert_text": "The degree of these seizures increased with increasing concentration of <e1> tAMCA </e1> <e2> seizures </e2> increased with increasing concentration of tAMCA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6065": {"data": {"text": "Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.", "entity1": "Pilocarpine", "entity2": "status epilepticus", "span1": [0, 11], "span2": [34, 52]}, "bert_text": "<e1> Pilocarpine </e1> on either day induced <e2> status epilepticus </e2>; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6066": {"data": {"text": "Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.", "entity1": "Pilocarpine", "entity2": "status epilepticus", "span1": [0, 11], "span2": [54, 72]}, "bert_text": "<e1> Pilocarpine </e1> on either day induced status epilepticus; <e2> status epilepticus </e2> at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6067": {"data": {"text": "Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.", "entity1": "Pilocarpine", "entity2": "seizures", "span1": [0, 11], "span2": [122, 130]}, "bert_text": "<e1> Pilocarpine </e1> on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous <e2> seizures </e2>, whereas P20 rats had no cell loss or spontaneous seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6068": {"data": {"text": "Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.", "entity1": "Pilocarpine", "entity2": "seizures", "span1": [0, 11], "span2": [181, 189]}, "bert_text": "<e1> Pilocarpine </e1> on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"6069": {"data": {"text": "We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "entity1": "everolimus", "entity2": "myelodysplastic syndrome", "span1": [30, 40], "span2": [106, 130]}, "bert_text": "We report on a combination of <e1> everolimus </e1> and tacrolimus in 24 patients (median age, 62 years) with either <e2> myelodysplastic syndrome </e2> (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6070": {"data": {"text": "We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "entity1": "everolimus", "entity2": "MDS", "span1": [30, 40], "span2": [132, 135]}, "bert_text": "We report on a combination of <e1> everolimus </e1> and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (<e2> MDS </e2>; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6071": {"data": {"text": "We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "entity1": "everolimus", "entity2": "acute myeloid leukemia", "span1": [30, 40], "span2": [148, 170]}, "bert_text": "We report on a combination of <e1> everolimus </e1> and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or <e2> acute myeloid leukemia </e2> (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6072": {"data": {"text": "We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "entity1": "everolimus", "entity2": "AML", "span1": [30, 40], "span2": [172, 175]}, "bert_text": "We report on a combination of <e1> everolimus </e1> and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (<e2> AML </e2>; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6073": {"data": {"text": "We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "entity1": "tacrolimus", "entity2": "myelodysplastic syndrome", "span1": [45, 55], "span2": [106, 130]}, "bert_text": "We report on a combination of everolimus and <e1> tacrolimus </e1> in 24 patients (median age, 62 years) with either <e2> myelodysplastic syndrome </e2> (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6074": {"data": {"text": "We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "entity1": "tacrolimus", "entity2": "MDS", "span1": [45, 55], "span2": [132, 135]}, "bert_text": "We report on a combination of everolimus and <e1> tacrolimus </e1> in 24 patients (median age, 62 years) with either myelodysplastic syndrome (<e2> MDS </e2>; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6075": {"data": {"text": "We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "entity1": "tacrolimus", "entity2": "acute myeloid leukemia", "span1": [45, 55], "span2": [148, 170]}, "bert_text": "We report on a combination of everolimus and <e1> tacrolimus </e1> in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or <e2> acute myeloid leukemia </e2> (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6076": {"data": {"text": "We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "entity1": "tacrolimus", "entity2": "AML", "span1": [45, 55], "span2": [172, 175]}, "bert_text": "We report on a combination of everolimus and <e1> tacrolimus </e1> in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (<e2> AML </e2>; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6077": {"data": {"text": "Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products.\n", "entity1": "Caffeine", "entity2": "cardiac arrhythmia", "span1": [0, 8], "span2": [17, 35]}, "bert_text": "<e1> Caffeine </e1>-induced <e2> cardiac arrhythmia </e2>: an unrecognised danger of healthfood products.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6078": {"data": {"text": "(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.", "entity1": "acid", "entity2": "RS)-1-aminoindan-1,5-dicarboxylic", "span1": [35, 39], "span2": [1, 34]}, "bert_text": "(RS)-1-aminoindan-1,5-dicarboxylic <e1> acid </e1> <e2> RS)-1-aminoindan-1,5-dicarboxylic </e2> acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6079": {"data": {"text": "(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.", "entity1": "AIDA", "entity2": "RS)-1-aminoindan-1,5-dicarboxylic", "span1": [41, 45], "span2": [1, 34]}, "bert_text": "(RS)-1-aminoindan-1,5-dicarboxylic acid (<e1> AIDA </e1> <e2> RS)-1-aminoindan-1,5-dicarboxylic </e2> acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6080": {"data": {"text": "(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.", "entity1": "haloperidol", "entity2": "RS)-1-aminoindan-1,5-dicarboxylic", "span1": [280, 291], "span2": [1, 34]}, "bert_text": "(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of <e1> haloperidol </e1> <e2> RS)-1-aminoindan-1,5-dicarboxylic </e2> acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6081": {"data": {"text": "The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.", "entity1": "nitroglycerin", "entity2": "diabetic", "span1": [110, 123], "span2": [155, 163]}, "bert_text": "The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1> nitroglycerin </e1> were similar in the normal and <e2> diabetic </e2> subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6082": {"data": {"text": "The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.", "entity1": "nitroglycerin", "entity2": "diabetic", "span1": [110, 123], "span2": [309, 317]}, "bert_text": "The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1> nitroglycerin </e1> were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the <e2> diabetic </e2> subjects with autonomic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6083": {"data": {"text": "The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.", "entity1": "nitroglycerin", "entity2": "autonomic neuropathy", "span1": [110, 123], "span2": [181, 201]}, "bert_text": "The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1> nitroglycerin </e1> were similar in the normal and diabetic subjects without <e2> autonomic neuropathy </e2>, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6084": {"data": {"text": "The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.", "entity1": "nitroglycerin", "entity2": "autonomic neuropathy", "span1": [110, 123], "span2": [332, 352]}, "bert_text": "The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after <e1> nitroglycerin </e1> were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with <e2> autonomic neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6085": {"data": {"text": "These observations indicate that although the gamma-carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor, they are not required for its accumulation at calcification sites.", "entity1": "gamma-carboxyglutamate", "entity2": "calcification", "span1": [46, 68], "span2": [146, 159]}, "bert_text": "These observations indicate that although the <e1> gamma-carboxyglutamate </e1> residues of matrix Gla protein are apparently required for its function as a <e2> calcification </e2> inhibitor, they are not required for its accumulation at calcification sites.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6086": {"data": {"text": "These observations indicate that although the gamma-carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor, they are not required for its accumulation at calcification sites.", "entity1": "gamma-carboxyglutamate", "entity2": "calcification", "span1": [46, 68], "span2": [217, 230]}, "bert_text": "These observations indicate that although the <e1> gamma-carboxyglutamate </e1> residues of matrix Gla protein are apparently required for its function as a calcification inhibitor, they are not required for its accumulation at <e2> calcification </e2> sites.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6087": {"data": {"text": "Changes in heart size during long-term timolol treatment after myocardial infarction.\n", "entity1": "timolol", "entity2": "myocardial infarction", "span1": [39, 46], "span2": [63, 84]}, "bert_text": "Changes in heart size during long-term <e1> timolol </e1> treatment after <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6088": {"data": {"text": "A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.", "entity1": "ibuprofen", "entity2": "vanishing bile duct syndrome", "span1": [194, 203], "span2": [76, 104]}, "bert_text": "A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with <e1> ibuprofen </e1> <e2> vanishing bile duct syndrome </e2> shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6089": {"data": {"text": "A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.", "entity1": "ibuprofen", "entity2": "Stevens-Johnson syndrome", "span1": [194, 203], "span2": [119, 143]}, "bert_text": "A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with <e1> ibuprofen </e1> <e2> Stevens-Johnson syndrome </e2> is described; this was temporally associated with ibuprofen use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6090": {"data": {"text": "Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease.", "entity1": "Iron", "entity2": "Parkinson's disease", "span1": [0, 4], "span2": [70, 89]}, "bert_text": "<e1> Iron </e1> accumulation is considered to be involved in the pathogenesis of <e2> Parkinson's disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6091": {"data": {"text": "A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.", "entity1": "ergot", "entity2": "gangrene", "span1": [31, 36], "span2": [87, 95]}, "bert_text": "A discussion of the history of <e1> ergot </e1> includes its original discovery, the epidemics of <e2> gangrene </e2> that it has caused through the ages and its past and present role in the management of migraine headache.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6092": {"data": {"text": "A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.", "entity1": "ergot", "entity2": "migraine headache", "span1": [31, 36], "span2": [183, 200]}, "bert_text": "A discussion of the history of <e1> ergot </e1> includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of <e2> migraine headache </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6093": {"data": {"text": "This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia.", "entity1": "propofol", "entity2": "pain", "span1": [24, 32], "span2": [43, 47]}, "bert_text": "This study investigated <e1> propofol </e1> injection <e2> pain </e2> in patients undergoing ambulatory anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6094": {"data": {"text": "We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.", "entity1": "clarithromycin", "entity2": "ventricular dysrhythmias", "span1": [90, 104], "span2": [20, 44]}, "bert_text": "We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of <e1> clarithromycin </e1> <e2> ventricular dysrhythmias </e2> that occurred after six therapeutic doses of clarithromycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6095": {"data": {"text": "Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.", "entity1": "adriamycin", "entity2": "albuminuria", "span1": [33, 43], "span2": [101, 112]}, "bert_text": "Rats were given a single dose of <e1> adriamycin </e1> and one month later divided into four groups matched for <e2> albuminuria </e2>, blood pressure, and plasma albumin concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6096": {"data": {"text": "Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.", "entity1": "ketamine", "entity2": "rigidity", "span1": [114, 122], "span2": [40, 48]}, "bert_text": "Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of <e1> ketamine </e1> <e2> rigidity </e2> and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6097": {"data": {"text": "Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.", "entity1": "morphine", "entity2": "rigidity", "span1": [126, 134], "span2": [40, 48]}, "bert_text": "Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or <e1> morphine </e1> <e2> rigidity </e2> and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6098": {"data": {"text": "Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.\n", "entity1": "methylphenidate", "entity2": "Cerebral vasculitis", "span1": [35, 50], "span2": [0, 19]}, "bert_text": "Cerebral vasculitis following oral <e1> methylphenidate </e1> <e2> Cerebral vasculitis </e2> following oral methylphenidate intake in an adult: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6099": {"data": {"text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "entity1": "simvastatin", "entity2": "rhabdomyolysis", "span1": [78, 89], "span2": [7, 21]}, "bert_text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of <e1> simvastatin </e1> <e2> rhabdomyolysis </e2> and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6100": {"data": {"text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "entity1": "simvastatin", "entity2": "acute renal failure", "span1": [78, 89], "span2": [26, 45]}, "bert_text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of <e1> simvastatin </e1> <e2> acute renal failure </e2> secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6101": {"data": {"text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "entity1": "amiodarone", "entity2": "rhabdomyolysis", "span1": [91, 101], "span2": [7, 21]}, "bert_text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, <e1> amiodarone </e1> <e2> rhabdomyolysis </e2> and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6102": {"data": {"text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "entity1": "amiodarone", "entity2": "acute renal failure", "span1": [91, 101], "span2": [26, 45]}, "bert_text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, <e1> amiodarone </e1> <e2> acute renal failure </e2> secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6103": {"data": {"text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "entity1": "atazanavir", "entity2": "rhabdomyolysis", "span1": [107, 117], "span2": [7, 21]}, "bert_text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and <e1> atazanavir </e1> <e2> rhabdomyolysis </e2> and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6104": {"data": {"text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "entity1": "atazanavir", "entity2": "acute renal failure", "span1": [107, 117], "span2": [26, 45]}, "bert_text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and <e1> atazanavir </e1> <e2> acute renal failure </e2> secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6105": {"data": {"text": "Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.", "entity1": "Nicotine", "entity2": "cardiovascular disease", "span1": [0, 8], "span2": [86, 108]}, "bert_text": "<e1> Nicotine </e1> activates the sympathetic nervous system and in this way could contribute to <e2> cardiovascular disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6106": {"data": {"text": "Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.\n", "entity1": "bupropion hydrochloride", "entity2": "seizures", "span1": [55, 78], "span2": [87, 95]}, "bert_text": "Effect of increasing intraperitoneal infusion rates on <e1> bupropion hydrochloride </e1>-induced <e2> seizures </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6107": {"data": {"text": "The authors present a case of failure of ancrod treatment in a patient with heparin-induced thrombosis.", "entity1": "heparin", "entity2": "thrombosis", "span1": [76, 83], "span2": [92, 102]}, "bert_text": "The authors present a case of failure of ancrod treatment in a patient with <e1> heparin </e1>-induced <e2> thrombosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6108": {"data": {"text": "Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.", "entity1": "creatinine", "entity2": "Decreased renal function", "span1": [56, 66], "span2": [0, 24]}, "bert_text": "Decreased renal function was defined as a rise in serum <e1> creatinine </e1> <e2> Decreased renal function </e2> was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6109": {"data": {"text": "CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.", "entity1": "Clonidine", "entity2": "ADHD", "span1": [13, 22], "span2": [105, 109]}, "bert_text": "CONCLUSIONS: <e1> Clonidine </e1>, used alone or with methylphenidate, appears safe and well tolerated in childhood <e2> ADHD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6110": {"data": {"text": "CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.", "entity1": "methylphenidate", "entity2": "ADHD", "span1": [43, 58], "span2": [105, 109]}, "bert_text": "CONCLUSIONS: Clonidine, used alone or with <e1> methylphenidate </e1>, appears safe and well tolerated in childhood <e2> ADHD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6111": {"data": {"text": "To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.", "entity1": "iron", "entity2": "neuron loss", "span1": [51, 55], "span2": [82, 93]}, "bert_text": "To demonstrate the relationship between peripheral <e1> iron </e1> overload and dopaminergic <e2> neuron loss </e2> in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6112": {"data": {"text": "To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.", "entity1": "iron", "entity2": "neuron loss", "span1": [233, 237], "span2": [82, 93]}, "bert_text": "To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' <e1> iron </e1> <e2> neuron loss </e2> in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6113": {"data": {"text": "To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.", "entity1": "iron", "entity2": "neuron loss", "span1": [381, 385], "span2": [82, 93]}, "bert_text": "To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased <e1> iron </e1> <e2> neuron loss </e2> in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6114": {"data": {"text": "To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.", "entity1": "iron dextran", "entity2": "neuron loss", "span1": [407, 419], "span2": [82, 93]}, "bert_text": "To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of <e1> iron dextran </e1> <e2> neuron loss </e2> in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6115": {"data": {"text": "Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.", "entity1": "didanosine", "entity2": "diabetes", "span1": [158, 168], "span2": [68, 76]}, "bert_text": "Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing <e1> didanosine </e1> <e2> diabetes </e2> but these were mild, did not require treatment and returned to normal on ceasing didanosine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6116": {"data": {"text": "beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for pilocarpine-induced seizures, but seemed normal in other neurological tests.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [114, 125], "span2": [54, 62]}, "bert_text": "beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for <e1> pilocarpine </e1> <e2> seizures </e2>, as indicated by reduced latency and threshold for pilocarpine-induced seizures, but seemed normal in other neurological tests.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6117": {"data": {"text": "beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for pilocarpine-induced seizures, but seemed normal in other neurological tests.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [114, 125], "span2": [134, 142]}, "bert_text": "beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for <e1> pilocarpine </e1>-induced <e2> seizures </e2>, but seemed normal in other neurological tests.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6118": {"data": {"text": "In conclusion, there is no evidence for an inflammatory origin of succinylcholine-associated myalgia.", "entity1": "succinylcholine", "entity2": "myalgia", "span1": [66, 81], "span2": [93, 100]}, "bert_text": "In conclusion, there is no evidence for an inflammatory origin of <e1> succinylcholine </e1>-associated <e2> myalgia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6119": {"data": {"text": "Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.\n", "entity1": "calcium", "entity2": "Cardiovascular alterations", "span1": [53, 60], "span2": [0, 26]}, "bert_text": "Cardiovascular alterations in rat fetuses exposed to <e1> calcium </e1> <e2> Cardiovascular alterations </e2> in rat fetuses exposed to calcium channel blockers.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6120": {"data": {"text": "Hemolytic anemia associated with the use of omeprazole.\n", "entity1": "omeprazole", "entity2": "Hemolytic anemia", "span1": [44, 54], "span2": [0, 16]}, "bert_text": "Hemolytic anemia associated with the use of <e1> omeprazole </e1> <e2> Hemolytic anemia </e2> associated with the use of omeprazole.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6121": {"data": {"text": "Thirty patients without prior chemotherapy and 16 pretreated with cisplatin-based chemotherapy were assessable for toxicity and response.", "entity1": "cisplatin", "entity2": "toxicity", "span1": [66, 75], "span2": [115, 123]}, "bert_text": "Thirty patients without prior chemotherapy and 16 pretreated with <e1> cisplatin </e1>-based chemotherapy were assessable for <e2> toxicity </e2> and response.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6122": {"data": {"text": "This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.", "entity1": "lometrexol", "entity2": "toxicity", "span1": [54, 64], "span2": [132, 140]}, "bert_text": "This observation prompted a Phase I clinical study of <e1> lometrexol </e1> given with folic acid supplementation which has confirmed that the <e2> toxicity </e2> of lometrexol can be markedly reduced by folic acid supplementation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6123": {"data": {"text": "This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.", "entity1": "lometrexol", "entity2": "toxicity", "span1": [144, 154], "span2": [132, 140]}, "bert_text": "This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of <e1> lometrexol </e1> <e2> toxicity </e2> of lometrexol can be markedly reduced by folic acid supplementation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6124": {"data": {"text": "This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.", "entity1": "folic acid", "entity2": "toxicity", "span1": [76, 86], "span2": [132, 140]}, "bert_text": "This observation prompted a Phase I clinical study of lometrexol given with <e1> folic acid </e1> supplementation which has confirmed that the <e2> toxicity </e2> of lometrexol can be markedly reduced by folic acid supplementation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6125": {"data": {"text": "This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.", "entity1": "folic acid", "entity2": "toxicity", "span1": [182, 192], "span2": [132, 140]}, "bert_text": "This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by <e1> folic acid </e1> <e2> toxicity </e2> of lometrexol can be markedly reduced by folic acid supplementation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6126": {"data": {"text": "However, yohimbine and meperidine reduced predominantly the dyskinetic movements.", "entity1": "yohimbine", "entity2": "dyskinetic", "span1": [9, 18], "span2": [60, 70]}, "bert_text": "However, <e1> yohimbine </e1> and meperidine reduced predominantly the <e2> dyskinetic </e2> movements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6127": {"data": {"text": "However, yohimbine and meperidine reduced predominantly the dyskinetic movements.", "entity1": "meperidine", "entity2": "dyskinetic", "span1": [23, 33], "span2": [60, 70]}, "bert_text": "However, yohimbine and <e1> meperidine </e1> reduced predominantly the <e2> dyskinetic </e2> movements.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6128": {"data": {"text": "Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.\n", "entity1": "Paclitaxel", "entity2": "ovarian cancer", "span1": [0, 10], "span2": [77, 91]}, "bert_text": "<e1> Paclitaxel </e1> combined with carboplatin in the first-line treatment of advanced <e2> ovarian cancer </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6129": {"data": {"text": "Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.\n", "entity1": "carboplatin", "entity2": "ovarian cancer", "span1": [25, 36], "span2": [77, 91]}, "bert_text": "Paclitaxel combined with <e1> carboplatin </e1> in the first-line treatment of advanced <e2> ovarian cancer </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6130": {"data": {"text": "Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.\n", "entity1": "Steroid", "entity2": "amnesic", "span1": [0, 7], "span2": [68, 75]}, "bert_text": "<e1> Steroid </e1> structure and pharmacological properties determine the anti-<e2> amnesic </e2> effects of pregnenolone sulphate in the passive avoidance task in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6131": {"data": {"text": "Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.\n", "entity1": "pregnenolone sulphate", "entity2": "amnesic", "span1": [87, 108], "span2": [68, 75]}, "bert_text": "Steroid structure and pharmacological properties determine the anti-amnesic effects of <e1> pregnenolone sulphate </e1> <e2> amnesic </e2> effects of pregnenolone sulphate in the passive avoidance task in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6132": {"data": {"text": "Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.", "entity1": "nifedipine", "entity2": "telangiectasia", "span1": [27, 37], "span2": [95, 109]}, "bert_text": "Five months after starting <e1> nifedipine </e1> (Adalat), two patients developed photodistributed facial <e2> telangiectasia </e2>, which became more noticeable with time.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6133": {"data": {"text": "Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.", "entity1": "Adalat", "entity2": "telangiectasia", "span1": [39, 45], "span2": [95, 109]}, "bert_text": "Five months after starting nifedipine (<e1> Adalat </e1>), two patients developed photodistributed facial <e2> telangiectasia </e2>, which became more noticeable with time.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6134": {"data": {"text": "In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).", "entity1": "PGE2", "entity2": "OAB", "span1": [29, 33], "span2": [17, 20]}, "bert_text": "In patients with OAB urinary <e1> PGE2 </e1> <e2> OAB </e2> urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6135": {"data": {"text": "Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.", "entity1": "HCBD", "entity2": "papillary damage", "span1": [34, 38], "span2": [43, 59]}, "bert_text": "Proximal tubular damage caused by <e1> HCBD </e1> and <e2> papillary damage </e2> caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6136": {"data": {"text": "Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.", "entity1": "BEA", "entity2": "papillary damage", "span1": [70, 73], "span2": [43, 59]}, "bert_text": "Proximal tubular damage caused by HCBD and papillary damage caused by <e1> BEA </e1> <e2> papillary damage </e2> caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6137": {"data": {"text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.", "entity1": "TAM", "entity2": "hemolysis", "span1": [24, 27], "span2": [196, 205]}, "bert_text": "The hemolytic effect of <e1> TAM </e1> is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced <e2> hemolysis </e2> is not related to oxidative membrane damage.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6138": {"data": {"text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.", "entity1": "TAM", "entity2": "hemolysis", "span1": [184, 187], "span2": [196, 205]}, "bert_text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that <e1> TAM </e1>-induced <e2> hemolysis </e2> is not related to oxidative membrane damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6139": {"data": {"text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.", "entity1": "alpha-tocopherol", "entity2": "hemolysis", "span1": [66, 82], "span2": [196, 205]}, "bert_text": "The hemolytic effect of TAM is prevented by low concentrations of <e1> alpha-tocopherol </e1> (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced <e2> hemolysis </e2> is not related to oxidative membrane damage.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6140": {"data": {"text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.", "entity1": "alpha-T", "entity2": "hemolysis", "span1": [84, 91], "span2": [196, 205]}, "bert_text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (<e1> alpha-T </e1>) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced <e2> hemolysis </e2> is not related to oxidative membrane damage.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6141": {"data": {"text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.", "entity1": "alpha-tocopherol acetate", "entity2": "hemolysis", "span1": [97, 121], "span2": [196, 205]}, "bert_text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and <e1> alpha-tocopherol acetate </e1> (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced <e2> hemolysis </e2> is not related to oxidative membrane damage.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6142": {"data": {"text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.", "entity1": "alpha-TAc", "entity2": "hemolysis", "span1": [123, 132], "span2": [196, 205]}, "bert_text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (<e1> alpha-TAc </e1>) (inactivated functional hydroxyl) indicating that TAM-induced <e2> hemolysis </e2> is not related to oxidative membrane damage.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6143": {"data": {"text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.", "entity1": "hydroxyl", "entity2": "hemolysis", "span1": [158, 166], "span2": [196, 205]}, "bert_text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional <e1> hydroxyl </e1>) indicating that TAM-induced <e2> hemolysis </e2> is not related to oxidative membrane damage.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6144": {"data": {"text": "This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine-induced tachycardia in conscious rats.", "entity1": "isoproterenol", "entity2": "tachycardia", "span1": [72, 85], "span2": [122, 133]}, "bert_text": "This study was conducted to examine whether prolonged pretreatment with <e1> isoproterenol </e1> could abolish bromocriptine-induced <e2> tachycardia </e2> in conscious rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6145": {"data": {"text": "This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine-induced tachycardia in conscious rats.", "entity1": "bromocriptine", "entity2": "tachycardia", "span1": [100, 113], "span2": [122, 133]}, "bert_text": "This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish <e1> bromocriptine </e1>-induced <e2> tachycardia </e2> in conscious rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6146": {"data": {"text": "4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (", "entity1": "enalapril", "entity2": "hypertensive", "span1": [90, 99], "span2": [59, 71]}, "bert_text": "4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), <e1> enalapril </e1> <e2> hypertensive </e2> controls (n = 8), enalapril-treated (", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6147": {"data": {"text": "Thirteen patients with acute leukemia were treated with a DNR-containing regimen.", "entity1": "DNR", "entity2": "acute leukemia", "span1": [58, 61], "span2": [23, 37]}, "bert_text": "Thirteen patients with acute leukemia were treated with a <e1> DNR </e1> <e2> acute leukemia </e2> were treated with a DNR-containing regimen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6148": {"data": {"text": "Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.\n", "entity1": "Daidzein", "entity2": "amnesia", "span1": [0, 8], "span2": [89, 96]}, "bert_text": "<e1> Daidzein </e1> activates choline acetyltransferase from MC-IXC cells and improves drug-induced <e2> amnesia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6149": {"data": {"text": "Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.\n", "entity1": "choline", "entity2": "amnesia", "span1": [19, 26], "span2": [89, 96]}, "bert_text": "Daidzein activates <e1> choline </e1> acetyltransferase from MC-IXC cells and improves drug-induced <e2> amnesia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6150": {"data": {"text": "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.\n", "entity1": "ozone", "entity2": "liver disease", "span1": [69, 74], "span2": [12, 25]}, "bert_text": "Epidemic of liver disease caused by hydrochlorofluorocarbons used as <e1> ozone </e1> <e2> liver disease </e2> caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6151": {"data": {"text": "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.\n", "entity1": "chlorofluorocarbons", "entity2": "liver disease", "span1": [98, 117], "span2": [12, 25]}, "bert_text": "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of <e1> chlorofluorocarbons </e1> <e2> liver disease </e2> caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6152": {"data": {"text": "TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).", "entity1": "terfenadine", "entity2": "TDP", "span1": [87, 98], "span2": [0, 3]}, "bert_text": "TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. <e1> terfenadine </e1> <e2> TDP </e2> is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6153": {"data": {"text": "TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).", "entity1": "terodiline", "entity2": "TDP", "span1": [103, 113], "span2": [0, 3]}, "bert_text": "TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and <e1> terodiline </e1> <e2> TDP </e2> is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6154": {"data": {"text": "Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.", "entity1": "ursodeoxycholic acid", "entity2": "cholestatic disease", "span1": [21, 41], "span2": [80, 99]}, "bert_text": "Despite therapy with <e1> ursodeoxycholic acid </e1>, prednisone, and then tacrolimus, her <e2> cholestatic disease </e2> was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6155": {"data": {"text": "Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.", "entity1": "ursodeoxycholic acid", "entity2": "cirrhosis", "span1": [21, 41], "span2": [122, 131]}, "bert_text": "Despite therapy with <e1> ursodeoxycholic acid </e1>, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with <e2> cirrhosis </e2> shown by biopsy 6 months after presentation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6156": {"data": {"text": "Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.", "entity1": "prednisone", "entity2": "cholestatic disease", "span1": [43, 53], "span2": [80, 99]}, "bert_text": "Despite therapy with ursodeoxycholic acid, <e1> prednisone </e1>, and then tacrolimus, her <e2> cholestatic disease </e2> was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6157": {"data": {"text": "Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.", "entity1": "prednisone", "entity2": "cirrhosis", "span1": [43, 53], "span2": [122, 131]}, "bert_text": "Despite therapy with ursodeoxycholic acid, <e1> prednisone </e1>, and then tacrolimus, her cholestatic disease was unrelenting, with <e2> cirrhosis </e2> shown by biopsy 6 months after presentation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6158": {"data": {"text": "Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.", "entity1": "tacrolimus", "entity2": "cholestatic disease", "span1": [64, 74], "span2": [80, 99]}, "bert_text": "Despite therapy with ursodeoxycholic acid, prednisone, and then <e1> tacrolimus </e1>, her <e2> cholestatic disease </e2> was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6159": {"data": {"text": "Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.", "entity1": "tacrolimus", "entity2": "cirrhosis", "span1": [64, 74], "span2": [122, 131]}, "bert_text": "Despite therapy with ursodeoxycholic acid, prednisone, and then <e1> tacrolimus </e1>, her cholestatic disease was unrelenting, with <e2> cirrhosis </e2> shown by biopsy 6 months after presentation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6160": {"data": {"text": "In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.", "entity1": "propylene glycol", "entity2": "seizures", "span1": [58, 74], "span2": [160, 168]}, "bert_text": "In the course of developing this model, a common vehicle, <e1> propylene glycol </e1>, by itself in high doses, was found to exhibit protective properties against induced <e2> seizures </e2> and inhibited weight gain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6161": {"data": {"text": "In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.", "entity1": "propylene glycol", "entity2": "weight gain", "span1": [58, 74], "span2": [183, 194]}, "bert_text": "In the course of developing this model, a common vehicle, <e1> propylene glycol </e1>, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited <e2> weight gain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6162": {"data": {"text": "A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).", "entity1": "methotrexate", "entity2": "graft-versus-host disease", "span1": [38, 50], "span2": [83, 108]}, "bert_text": "A calcineurin inhibitor combined with <e1> methotrexate </e1> is the standard prophylaxis for <e2> graft-versus-host disease </e2> (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6163": {"data": {"text": "A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).", "entity1": "methotrexate", "entity2": "GVHD", "span1": [38, 50], "span2": [110, 114]}, "bert_text": "A calcineurin inhibitor combined with <e1> methotrexate </e1> is the standard prophylaxis for graft-versus-host disease (<e2> GVHD </e2>) after allogeneic hematopoietic stem cell transplantation (HSCT).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6164": {"data": {"text": "Short-term use of steroid is very effective in ATRA-induced erythema nodosum.", "entity1": "steroid", "entity2": "erythema nodosum", "span1": [18, 25], "span2": [60, 76]}, "bert_text": "Short-term use of <e1> steroid </e1> is very effective in ATRA-induced <e2> erythema nodosum </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6165": {"data": {"text": "Short-term use of steroid is very effective in ATRA-induced erythema nodosum.", "entity1": "ATRA", "entity2": "erythema nodosum", "span1": [47, 51], "span2": [60, 76]}, "bert_text": "Short-term use of steroid is very effective in <e1> ATRA </e1>-induced <e2> erythema nodosum </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6166": {"data": {"text": "Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)", "entity1": "noradrenaline", "entity2": "bradycardia", "span1": [50, 63], "span2": [17, 28]}, "bert_text": "Furthermore, the bradycardia that accompanied the <e1> noradrenaline </e1> <e2> bradycardia </e2> that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6167": {"data": {"text": "Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)", "entity1": "prazosin", "entity2": "bradycardia", "span1": [131, 139], "span2": [17, 28]}, "bert_text": "Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic <e1> prazosin </e1> <e2> bradycardia </e2> that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6168": {"data": {"text": "Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.", "entity1": "Lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [0, 7], "span2": [16, 46]}, "bert_text": "<e1> Lithium </e1> induced <e2> nephrogenic diabetes insipidus </e2> is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6169": {"data": {"text": "Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.", "entity1": "Lithium", "entity2": "polyuria", "span1": [0, 7], "span2": [106, 114]}, "bert_text": "<e1> Lithium </e1> induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but <e2> polyuria </e2> persisted in this patient for ten years after lithium was stopped.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6170": {"data": {"text": "Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.", "entity1": "lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [161, 168], "span2": [16, 46]}, "bert_text": "Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after <e1> lithium </e1> <e2> nephrogenic diabetes insipidus </e2> is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6171": {"data": {"text": "Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.", "entity1": "lithium", "entity2": "polyuria", "span1": [161, 168], "span2": [106, 114]}, "bert_text": "Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after <e1> lithium </e1> <e2> polyuria </e2> persisted in this patient for ten years after lithium was stopped.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"6172": {"data": {"text": "Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.", "entity1": "acetylcholine", "entity2": "seizures", "span1": [89, 102], "span2": [50, 58]}, "bert_text": "Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and <e1> acetylcholine </e1> <e2> seizures </e2> induced by both glutamate and acetylcholine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6173": {"data": {"text": "Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.\n", "entity1": "heparan sulphate", "entity2": "diabetic nephropathy", "span1": [13, 29], "span2": [127, 147]}, "bert_text": "Reduction of <e1> heparan sulphate </e1>-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced <e2> diabetic nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6174": {"data": {"text": "Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.\n", "entity1": "streptozotocin", "entity2": "diabetic nephropathy", "span1": [104, 118], "span2": [127, 147]}, "bert_text": "Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with <e1> streptozotocin </e1>-induced <e2> diabetic nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6175": {"data": {"text": "In rats, detection of apomorphine-induced hyperactivity was facilitated by a period of acclimatization to the test conditions.", "entity1": "apomorphine", "entity2": "hyperactivity", "span1": [22, 33], "span2": [42, 55]}, "bert_text": "In rats, detection of <e1> apomorphine </e1>-induced <e2> hyperactivity </e2> was facilitated by a period of acclimatization to the test conditions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6176": {"data": {"text": "Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.", "entity1": "AZT", "entity2": "anaemia", "span1": [68, 71], "span2": [12, 19]}, "bert_text": "Despite the anaemia, the number of splenic and bone marrow BFU-e in <e1> AZT </e1> <e2> anaemia </e2>, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6177": {"data": {"text": "Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.", "entity1": "salicylates", "entity2": "Reye syndrome", "span1": [90, 101], "span2": [0, 13]}, "bert_text": "Reye syndrome may be disappearing from Australia despite a total lack of association with <e1> salicylates </e1> <e2> Reye syndrome </e2> may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6178": {"data": {"text": "Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.", "entity1": "aspirin", "entity2": "Reye syndrome", "span1": [105, 112], "span2": [0, 13]}, "bert_text": "Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or <e1> aspirin </e1> <e2> Reye syndrome </e2> may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6179": {"data": {"text": "PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.", "entity1": "DOX", "entity2": "cardiac complications", "span1": [121, 124], "span2": [79, 100]}, "bert_text": "PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the <e1> DOX </e1> <e2> cardiac complications </e2> associated with the DOX treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6180": {"data": {"text": "Atropine converted the dystonic movements into chorea.", "entity1": "Atropine", "entity2": "dystonic", "span1": [0, 8], "span2": [23, 31]}, "bert_text": "<e1> Atropine </e1> converted the <e2> dystonic </e2> movements into chorea.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6181": {"data": {"text": "Atropine converted the dystonic movements into chorea.", "entity1": "Atropine", "entity2": "chorea", "span1": [0, 8], "span2": [47, 53]}, "bert_text": "<e1> Atropine </e1> converted the dystonic movements into <e2> chorea </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6182": {"data": {"text": "In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.", "entity1": "phenylephrine", "entity2": "nephropathy", "span1": [12, 25], "span2": [101, 112]}, "bert_text": "In the IPRK <e1> phenylephrine </e1> and acetylcholine related responses were significantly impaired in the ADR-<e2> nephropathy </e2> group.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6183": {"data": {"text": "In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.", "entity1": "acetylcholine", "entity2": "nephropathy", "span1": [30, 43], "span2": [101, 112]}, "bert_text": "In the IPRK phenylephrine and <e1> acetylcholine </e1> related responses were significantly impaired in the ADR-<e2> nephropathy </e2> group.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6184": {"data": {"text": "In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.", "entity1": "ADR", "entity2": "nephropathy", "span1": [97, 100], "span2": [101, 112]}, "bert_text": "In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the <e1> ADR </e1>-<e2> nephropathy </e2> group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6185": {"data": {"text": "These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.", "entity1": "PAN", "entity2": "NS", "span1": [132, 135], "span2": [118, 120]}, "bert_text": "These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by <e1> PAN </e1> <e2> NS </e2> induced by PAN.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6186": {"data": {"text": "It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.", "entity1": "PB", "entity2": "carcinogenesis", "span1": [21, 23], "span2": [40, 54]}, "bert_text": "It is concluded that <e1> PB </e1>, which promotes <e2> carcinogenesis </e2> when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6187": {"data": {"text": "It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.", "entity1": "DEN", "entity2": "carcinogenesis", "span1": [83, 86], "span2": [40, 54]}, "bert_text": "It is concluded that PB, which promotes carcinogenesis when administered after the <e1> DEN </e1> <e2> carcinogenesis </e2> when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6188": {"data": {"text": "It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.", "entity1": "DEN", "entity2": "carcinogenesis", "span1": [159, 162], "span2": [40, 54]}, "bert_text": "It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with <e1> DEN </e1> <e2> carcinogenesis </e2> when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6189": {"data": {"text": "3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [89, 97], "span2": [106, 117]}, "bert_text": "3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and <e1> levodopa </e1>-induced <e2> dyskinesias </e2> were selected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6190": {"data": {"text": "Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.", "entity1": "risperidone's", "entity2": "psychotic symptoms", "span1": [45, 58], "span2": [124, 142]}, "bert_text": "Previous clinical studies have proposed that <e1> risperidone's </e1> pharmacologic profile may produce improved efficacy for negative <e2> psychotic symptoms </e2> and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6191": {"data": {"text": "Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.", "entity1": "Pentamidine", "entity2": "torsade de pointes", "span1": [0, 11], "span2": [20, 38]}, "bert_text": "<e1> Pentamidine </e1>-induced <e2> torsade de pointes </e2> may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6192": {"data": {"text": "Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.", "entity1": "Pentamidine", "entity2": "hypomagnesemia", "span1": [0, 11], "span2": [84, 98]}, "bert_text": "<e1> Pentamidine </e1>-induced torsade de pointes may be related to serum magnesium levels and <e2> hypomagnesemia </e2> may synergistically induce torsade.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6193": {"data": {"text": "Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.", "entity1": "magnesium", "entity2": "torsade de pointes", "span1": [63, 72], "span2": [20, 38]}, "bert_text": "Pentamidine-induced torsade de pointes may be related to serum <e1> magnesium </e1> <e2> torsade de pointes </e2> may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6194": {"data": {"text": "Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.", "entity1": "magnesium", "entity2": "hypomagnesemia", "span1": [63, 72], "span2": [84, 98]}, "bert_text": "Pentamidine-induced torsade de pointes may be related to serum <e1> magnesium </e1> levels and <e2> hypomagnesemia </e2> may synergistically induce torsade.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6195": {"data": {"text": "Prazosin-induced stress incontinence.\n", "entity1": "Prazosin", "entity2": "stress incontinence", "span1": [0, 8], "span2": [17, 36]}, "bert_text": "<e1> Prazosin </e1>-induced <e2> stress incontinence </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6196": {"data": {"text": "Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.", "entity1": "valdecoxib", "entity2": "thrombotic", "span1": [117, 127], "span2": [184, 194]}, "bert_text": "Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) <e1> valdecoxib </e1> doses was not associated with an increased incidence of <e2> thrombotic </e2> events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6197": {"data": {"text": "Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.", "entity1": "valdecoxib", "entity2": "osteoarthritis", "span1": [117, 127], "span2": [248, 262]}, "bert_text": "Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) <e1> valdecoxib </e1> doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in <e2> osteoarthritis </e2> and rheumatoid arthritis patients in controlled clinical trials.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6198": {"data": {"text": "Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.", "entity1": "valdecoxib", "entity2": "rheumatoid arthritis", "span1": [117, 127], "span2": [267, 287]}, "bert_text": "Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) <e1> valdecoxib </e1> doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and <e2> rheumatoid arthritis </e2> patients in controlled clinical trials.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6199": {"data": {"text": "Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.", "entity1": "mazindol", "entity2": "contractures", "span1": [139, 147], "span2": [17, 29]}, "bert_text": "Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with <e1> mazindol </e1> <e2> contractures </e2>, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6200": {"data": {"text": "The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.", "entity1": "amantadine", "entity2": "depressed", "span1": [20, 30], "span2": [31, 40]}, "bert_text": "The initial dose of <e1> amantadine </e1> <e2> depressed </e2> locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6201": {"data": {"text": "IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.", "entity1": "dexamethasone", "entity2": "postoperative myalgia", "span1": [32, 45], "span2": [158, 179]}, "bert_text": "IMPLICATIONS: Administration of <e1> dexamethasone </e1> before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced <e2> postoperative myalgia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6202": {"data": {"text": "IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.", "entity1": "succinylcholine", "entity2": "postoperative myalgia", "span1": [53, 68], "span2": [158, 179]}, "bert_text": "IMPLICATIONS: Administration of dexamethasone before <e1> succinylcholine </e1> was not effective in decreasing the incidence or the severity of succinylcholine-induced <e2> postoperative myalgia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6203": {"data": {"text": "IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.", "entity1": "succinylcholine", "entity2": "postoperative myalgia", "span1": [134, 149], "span2": [158, 179]}, "bert_text": "IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of <e1> succinylcholine </e1>-induced <e2> postoperative myalgia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6204": {"data": {"text": "CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.", "entity1": "telithromycin", "entity2": "hepatitis", "span1": [100, 113], "span2": [43, 52]}, "bert_text": "CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of <e1> telithromycin </e1> <e2> hepatitis </e2> probably associated with the administration of telithromycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6205": {"data": {"text": "Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.", "entity1": "Heparan sulphate", "entity2": "diabetes", "span1": [0, 16], "span2": [127, 135]}, "bert_text": "<e1> Heparan sulphate </e1>-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of <e2> diabetes </e2> by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6206": {"data": {"text": "Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.", "entity1": "streptozotocin", "entity2": "diabetes", "span1": [139, 153], "span2": [127, 135]}, "bert_text": "Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by <e1> streptozotocin </e1> <e2> diabetes </e2> by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6207": {"data": {"text": "Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.", "entity1": "cuprolinic blue", "entity2": "diabetes", "span1": [223, 238], "span2": [127, 135]}, "bert_text": "Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye <e1> cuprolinic blue </e1> <e2> diabetes </e2> by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6208": {"data": {"text": "Heparin-induced thrombocytopenia after liver transplantation.\n", "entity1": "Heparin", "entity2": "thrombocytopenia", "span1": [0, 7], "span2": [16, 32]}, "bert_text": "<e1> Heparin </e1>-induced <e2> thrombocytopenia </e2> after liver transplantation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6209": {"data": {"text": "Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?\n", "entity1": "Spironolactone", "entity2": "hypokalemia", "span1": [0, 14], "span2": [80, 91]}, "bert_text": "<e1> Spironolactone </e1>: is it a novel drug for the prevention of amphotericin B-related <e2> hypokalemia </e2> in cancer patients?\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6210": {"data": {"text": "Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?\n", "entity1": "Spironolactone", "entity2": "cancer", "span1": [0, 14], "span2": [95, 101]}, "bert_text": "<e1> Spironolactone </e1>: is it a novel drug for the prevention of amphotericin B-related hypokalemia in <e2> cancer </e2> patients?\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6211": {"data": {"text": "Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?\n", "entity1": "amphotericin B", "entity2": "hypokalemia", "span1": [57, 71], "span2": [80, 91]}, "bert_text": "Spironolactone: is it a novel drug for the prevention of <e1> amphotericin B </e1>-related <e2> hypokalemia </e2> in cancer patients?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6212": {"data": {"text": "Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?\n", "entity1": "amphotericin B", "entity2": "cancer", "span1": [57, 71], "span2": [95, 101]}, "bert_text": "Spironolactone: is it a novel drug for the prevention of <e1> amphotericin B </e1>-related hypokalemia in <e2> cancer </e2> patients?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6213": {"data": {"text": "BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.", "entity1": "Unfractionated heparin sodium", "entity2": "thrombosis", "span1": [12, 41], "span2": [157, 167]}, "bert_text": "BACKGROUND: <e1> Unfractionated heparin sodium </e1> (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent <e2> thrombosis </e2> after liver transplantation.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6214": {"data": {"text": "BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.", "entity1": "UFH", "entity2": "thrombosis", "span1": [43, 46], "span2": [157, 167]}, "bert_text": "BACKGROUND: Unfractionated heparin sodium (<e1> UFH </e1>) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent <e2> thrombosis </e2> after liver transplantation.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6215": {"data": {"text": "BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.", "entity1": "low-molecular weight heparin", "entity2": "thrombosis", "span1": [51, 79], "span2": [157, 167]}, "bert_text": "BACKGROUND: Unfractionated heparin sodium (UFH) or <e1> low-molecular weight heparin </e1> (LMWH) is used in anticoagulant protocols at several institutions to prevent <e2> thrombosis </e2> after liver transplantation.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6216": {"data": {"text": "BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.", "entity1": "LMWH", "entity2": "thrombosis", "span1": [81, 85], "span2": [157, 167]}, "bert_text": "BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (<e1> LMWH </e1>) is used in anticoagulant protocols at several institutions to prevent <e2> thrombosis </e2> after liver transplantation.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6217": {"data": {"text": "Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected, untreated mice.", "entity1": "AZT", "entity2": "infected", "span1": [113, 116], "span2": [135, 143]}, "bert_text": "Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving <e1> AZT </e1> for 15 d than for <e2> infected </e2>, untreated mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6218": {"data": {"text": "Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.", "entity1": "Vitamin B12", "entity2": "myelotoxicity", "span1": [0, 11], "span2": [119, 132]}, "bert_text": "<e1> Vitamin B12 </e1> and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced <e2> myelotoxicity </e2> in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6219": {"data": {"text": "Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.", "entity1": "folinic acid", "entity2": "myelotoxicity", "span1": [16, 28], "span2": [119, 132]}, "bert_text": "Vitamin B12 and <e1> folinic acid </e1> supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced <e2> myelotoxicity </e2> in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6220": {"data": {"text": "Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.", "entity1": "ZDV", "entity2": "myelotoxicity", "span1": [48, 51], "span2": [119, 132]}, "bert_text": "Vitamin B12 and folinic acid supplementation of <e1> ZDV </e1> therapy does not seem useful in preventing or reducing ZDV-induced <e2> myelotoxicity </e2> in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6221": {"data": {"text": "Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.", "entity1": "ZDV", "entity2": "myelotoxicity", "span1": [107, 110], "span2": [119, 132]}, "bert_text": "Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing <e1> ZDV </e1>-induced <e2> myelotoxicity </e2> in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6222": {"data": {"text": "Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [72, 75], "span2": [84, 98]}, "bert_text": "Thus, we hypothesized that the activation of PARP may contribute to the <e1> DOX </e1>-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6223": {"data": {"text": "Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.", "entity1": "lithium", "entity2": "polyuria", "span1": [90, 97], "span2": [107, 115]}, "bert_text": "Although much has been written about the management of the more common adverse effects of <e1> lithium </e1>, such as <e2> polyuria </e2> and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6224": {"data": {"text": "Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.", "entity1": "lithium", "entity2": "tremor", "span1": [90, 97], "span2": [120, 126]}, "bert_text": "Although much has been written about the management of the more common adverse effects of <e1> lithium </e1>, such as polyuria and <e2> tremor </e2>, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6225": {"data": {"text": "Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.", "entity1": "lithium", "entity2": "cognitive deficits", "span1": [90, 97], "span2": [169, 187]}, "bert_text": "Although much has been written about the management of the more common adverse effects of <e1> lithium </e1>, such as polyuria and tremor, more subtle lithium side effects such as <e2> cognitive deficits </e2>, loss of creativity, and functional impairments remain understudied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6226": {"data": {"text": "Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.", "entity1": "lithium", "entity2": "polyuria", "span1": [140, 147], "span2": [107, 115]}, "bert_text": "Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle <e1> lithium </e1> <e2> polyuria </e2> and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6227": {"data": {"text": "Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.", "entity1": "lithium", "entity2": "tremor", "span1": [140, 147], "span2": [120, 126]}, "bert_text": "Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle <e1> lithium </e1> <e2> tremor </e2>, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6228": {"data": {"text": "Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.", "entity1": "lithium", "entity2": "cognitive deficits", "span1": [140, 147], "span2": [169, 187]}, "bert_text": "Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle <e1> lithium </e1> side effects such as <e2> cognitive deficits </e2>, loss of creativity, and functional impairments remain understudied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6229": {"data": {"text": "Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.", "entity1": "valdecoxib", "entity2": "thrombotic", "span1": [77, 87], "span2": [42, 52]}, "bert_text": "Crude and exposure-adjusted incidences of thrombotic events were similar for <e1> valdecoxib </e1> <e2> thrombotic </e2> events were similar for valdecoxib, NSAIDs, and placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6230": {"data": {"text": "We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.", "entity1": "levodopa", "entity2": "LID", "span1": [68, 76], "span2": [360, 363]}, "bert_text": "We found significant positive correlations between the preoperative <e1> levodopa </e1> responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in <e2> LID </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6231": {"data": {"text": "We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.", "entity1": "levodopa", "entity2": "LID", "span1": [115, 123], "span2": [360, 363]}, "bert_text": "We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the <e1> levodopa </e1> responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in <e2> LID </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6232": {"data": {"text": "Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.\n", "entity1": "adriamycin", "entity2": "cardiomyopathy", "span1": [60, 70], "span2": [79, 93]}, "bert_text": "Detection of abnormal cardiac adrenergic neuron activity in <e1> adriamycin </e1>-induced <e2> cardiomyopathy </e2> with iodine-125-metaiodobenzylguanidine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6233": {"data": {"text": "Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.\n", "entity1": "iodine-125-metaiodobenzylguanidine", "entity2": "cardiomyopathy", "span1": [99, 133], "span2": [79, 93]}, "bert_text": "Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with <e1> iodine-125-metaiodobenzylguanidine </e1> <e2> cardiomyopathy </e2> with iodine-125-metaiodobenzylguanidine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6234": {"data": {"text": "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.\n", "entity1": "chloramphenicol", "entity2": "aplastic anemia", "span1": [69, 84], "span2": [6, 21]}, "bert_text": "Fatal aplastic anemia following topical administration of ophthalmic <e1> chloramphenicol </e1> <e2> aplastic anemia </e2> following topical administration of ophthalmic chloramphenicol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6235": {"data": {"text": "Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.\n", "entity1": "mangiferin", "entity2": "myocardial infarction", "span1": [8, 18], "span2": [94, 115]}, "bert_text": "Role of <e1> mangiferin </e1> on biochemical alterations and antioxidant status in isoproterenol-induced <e2> myocardial infarction </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6236": {"data": {"text": "Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.\n", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [72, 85], "span2": [94, 115]}, "bert_text": "Role of mangiferin on biochemical alterations and antioxidant status in <e1> isoproterenol </e1>-induced <e2> myocardial infarction </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6237": {"data": {"text": "After stopping the beta-agonist, and after a week with the atenolol, the arrhythmia disappeared.", "entity1": "atenolol", "entity2": "arrhythmia", "span1": [59, 67], "span2": [73, 83]}, "bert_text": "After stopping the beta-agonist, and after a week with the <e1> atenolol </e1>, the <e2> arrhythmia </e2> disappeared.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6238": {"data": {"text": "Disulfiram-induced transient optic and peripheral neuropathy: a case report.\n", "entity1": "Disulfiram", "entity2": "peripheral neuropathy", "span1": [0, 10], "span2": [39, 60]}, "bert_text": "<e1> Disulfiram </e1>-induced transient optic and <e2> peripheral neuropathy </e2>: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6239": {"data": {"text": "He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.", "entity1": "telithromycin", "entity2": "upper respiratory tract infection", "span1": [23, 36], "span2": [61, 94]}, "bert_text": "He had been prescribed <e1> telithromycin </e1> 400 mg/d PO to treat an <e2> upper respiratory tract infection </e2> 7 days prior.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6240": {"data": {"text": "RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.", "entity1": "SSRIs", "entity2": "hypomania or mania", "span1": [134, 139], "span2": [21, 39]}, "bert_text": "RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with <e1> SSRIs </e1> <e2> hypomania or mania </e2> occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6241": {"data": {"text": "RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.", "entity1": "SSRIs", "entity2": "manic", "span1": [134, 139], "span2": [173, 178]}, "bert_text": "RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with <e1> SSRIs </e1> [8/33]); 16% (N = 7) experienced <e2> manic </e2> episodes, and 11% (N = 5) experienced hypomanic episodes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6242": {"data": {"text": "RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.", "entity1": "SSRIs", "entity2": "hypomanic episodes", "span1": [134, 139], "span2": [217, 235]}, "bert_text": "RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with <e1> SSRIs </e1> [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced <e2> hypomanic episodes </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6243": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "AZT", "entity2": "anemic and leukopenic", "span1": [64, 67], "span2": [17, 38]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of <e1> AZT </e1> <e2> anemic and leukopenic </e2> by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6244": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "AZT", "entity2": "leukopenia", "span1": [64, 67], "span2": [224, 234]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of <e1> AZT </e1> for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and <e2> leukopenia </e2> (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6245": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "AZT", "entity2": "anemia", "span1": [64, 67], "span2": [213, 219]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of <e1> AZT </e1> for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced <e2> anemia </e2> and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6246": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "AZT", "entity2": "anemic and leukopenic", "span1": [143, 146], "span2": [17, 38]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of <e1> AZT </e1> <e2> anemic and leukopenic </e2> by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6247": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "AZT", "entity2": "leukopenia", "span1": [143, 146], "span2": [224, 234]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of <e1> AZT </e1> plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and <e2> leukopenia </e2> (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6248": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "AZT", "entity2": "anemia", "span1": [143, 146], "span2": [213, 219]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of <e1> AZT </e1> plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced <e2> anemia </e2> and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6249": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "AZT", "entity2": "anemic and leukopenic", "span1": [201, 204], "span2": [17, 38]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed <e1> AZT </e1> <e2> anemic and leukopenic </e2> by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6250": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "AZT", "entity2": "leukopenia", "span1": [201, 204], "span2": [224, 234]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed <e1> AZT </e1>-induced anemia and <e2> leukopenia </e2> (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6251": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "AZT", "entity2": "anemia", "span1": [201, 204], "span2": [213, 219]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed <e1> AZT </e1>-induced <e2> anemia </e2> and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6252": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "BAU", "entity2": "anemic and leukopenic", "span1": [158, 161], "span2": [17, 38]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily <e1> BAU </e1> <e2> anemic and leukopenic </e2> by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6253": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "BAU", "entity2": "leukopenia", "span1": [158, 161], "span2": [224, 234]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily <e1> BAU </e1> (300 mg/kg, orally) partially reversed AZT-induced anemia and <e2> leukopenia </e2> (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6254": {"data": {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity1": "BAU", "entity2": "anemia", "span1": [158, 161], "span2": [213, 219]}, "bert_text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily <e1> BAU </e1> (300 mg/kg, orally) partially reversed AZT-induced <e2> anemia </e2> and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6255": {"data": {"text": "It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.", "entity1": "amiodarone", "entity2": "hepatic injury", "span1": [68, 78], "span2": [46, 60]}, "bert_text": "It is concluded that solid evidence exists of hepatic injury due to <e1> amiodarone </e1> <e2> hepatic injury </e2> due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6256": {"data": {"text": "It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.", "entity1": "amiodarone", "entity2": "alcoholic hepatitis", "span1": [68, 78], "span2": [134, 153]}, "bert_text": "It is concluded that solid evidence exists of hepatic injury due to <e1> amiodarone </e1> treatment, including steatosis, alterations resembling <e2> alcoholic hepatitis </e2>, cholestatic hepatitis and micronodular cirrhosis of the liver.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6257": {"data": {"text": "It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.", "entity1": "amiodarone", "entity2": "cholestatic hepatitis", "span1": [68, 78], "span2": [155, 176]}, "bert_text": "It is concluded that solid evidence exists of hepatic injury due to <e1> amiodarone </e1> treatment, including steatosis, alterations resembling alcoholic hepatitis, <e2> cholestatic hepatitis </e2> and micronodular cirrhosis of the liver.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6258": {"data": {"text": "It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.", "entity1": "amiodarone", "entity2": "steatosis", "span1": [68, 78], "span2": [100, 109]}, "bert_text": "It is concluded that solid evidence exists of hepatic injury due to <e1> amiodarone </e1> treatment, including <e2> steatosis </e2>, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6259": {"data": {"text": "It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.", "entity1": "amiodarone", "entity2": "cirrhosis of the liver", "span1": [68, 78], "span2": [194, 216]}, "bert_text": "It is concluded that solid evidence exists of hepatic injury due to <e1> amiodarone </e1> treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular <e2> cirrhosis of the liver </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6260": {"data": {"text": "The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.", "entity1": "cyclosporine-", "entity2": "pain", "span1": [17, 30], "span2": [127, 131]}, "bert_text": "The reduction of <e1> cyclosporine- </e1> or tacrolimus trough levels and the administration of calcium channel blockers led to relief of <e2> pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6261": {"data": {"text": "The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.", "entity1": "tacrolimus", "entity2": "pain", "span1": [34, 44], "span2": [127, 131]}, "bert_text": "The reduction of cyclosporine- or <e1> tacrolimus </e1> trough levels and the administration of calcium channel blockers led to relief of <e2> pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6262": {"data": {"text": "The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.", "entity1": "calcium", "entity2": "pain", "span1": [85, 92], "span2": [127, 131]}, "bert_text": "The reduction of cyclosporine- or tacrolimus trough levels and the administration of <e1> calcium </e1> channel blockers led to relief of <e2> pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6263": {"data": {"text": "Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.", "entity1": "Viramidine", "entity2": "hemolytic anemia", "span1": [0, 10], "span2": [147, 163]}, "bert_text": "<e1> Viramidine </e1>, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of <e2> hemolytic anemia </e2> in patients with chronic hepatitis C.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6264": {"data": {"text": "Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.", "entity1": "Viramidine", "entity2": "chronic hepatitis", "span1": [0, 10], "span2": [181, 198]}, "bert_text": "<e1> Viramidine </e1>, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with <e2> chronic hepatitis </e2> C.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6265": {"data": {"text": "Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.", "entity1": "ribavirin", "entity2": "hemolytic anemia", "span1": [41, 50], "span2": [147, 163]}, "bert_text": "Viramidine, a liver-targeting prodrug of <e1> ribavirin </e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of <e2> hemolytic anemia </e2> in patients with chronic hepatitis C.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6266": {"data": {"text": "Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.", "entity1": "ribavirin", "entity2": "chronic hepatitis", "span1": [41, 50], "span2": [181, 198]}, "bert_text": "Viramidine, a liver-targeting prodrug of <e1> ribavirin </e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with <e2> chronic hepatitis </e2> C.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6267": {"data": {"text": "Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.", "entity1": "ribavirin", "entity2": "hemolytic anemia", "span1": [108, 117], "span2": [147, 163]}, "bert_text": "Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of <e1> ribavirin </e1> while decreasing the risk of <e2> hemolytic anemia </e2> in patients with chronic hepatitis C.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6268": {"data": {"text": "Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.", "entity1": "ribavirin", "entity2": "chronic hepatitis", "span1": [108, 117], "span2": [181, 198]}, "bert_text": "Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of <e1> ribavirin </e1> while decreasing the risk of hemolytic anemia in patients with <e2> chronic hepatitis </e2> C.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6269": {"data": {"text": "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.\n", "entity1": "alpha-tocopherol", "entity2": "neurotoxicity", "span1": [10, 26], "span2": [71, 84]}, "bert_text": "Effect of <e1> alpha-tocopherol </e1> and deferoxamine on methamphetamine-induced <e2> neurotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6270": {"data": {"text": "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.\n", "entity1": "deferoxamine", "entity2": "neurotoxicity", "span1": [31, 43], "span2": [71, 84]}, "bert_text": "Effect of alpha-tocopherol and <e1> deferoxamine </e1> on methamphetamine-induced <e2> neurotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6271": {"data": {"text": "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.\n", "entity1": "methamphetamine", "entity2": "neurotoxicity", "span1": [47, 62], "span2": [71, 84]}, "bert_text": "Effect of alpha-tocopherol and deferoxamine on <e1> methamphetamine </e1>-induced <e2> neurotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6272": {"data": {"text": "The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.", "entity1": "nicotine", "entity2": "nystagmus", "span1": [22, 30], "span2": [39, 48]}, "bert_text": "The pathomechanism of <e1> nicotine </e1>-induced <e2> nystagmus </e2> (NIN) is unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6273": {"data": {"text": "The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.", "entity1": "nicotine", "entity2": "NIN", "span1": [22, 30], "span2": [50, 53]}, "bert_text": "The pathomechanism of <e1> nicotine </e1>-induced nystagmus (<e2> NIN </e2>) is unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6274": {"data": {"text": "These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).", "entity1": "cimetidine", "entity2": "renal and liver dysfunction", "span1": [85, 95], "span2": [26, 53]}, "bert_text": "These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as <e1> cimetidine </e1> <e2> renal and liver dysfunction </e2> (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6275": {"data": {"text": "Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.", "entity1": "angiotensin II", "entity2": "atrial fibrillation", "span1": [45, 59], "span2": [100, 119]}, "bert_text": "Angiotensin-converting enzyme inhibitors and <e1> angiotensin II </e1> receptor-blocking drugs hold promise in <e2> atrial fibrillation </e2> through cardiac remodelling.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6276": {"data": {"text": "CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.", "entity1": "Prilocaine", "entity2": "TNSs", "span1": [13, 23], "span2": [154, 158]}, "bert_text": "CONCLUSIONS: <e1> Prilocaine </e1> may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of <e2> TNSs </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6277": {"data": {"text": "CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.", "entity1": "lidocaine", "entity2": "TNSs", "span1": [45, 54], "span2": [154, 158]}, "bert_text": "CONCLUSIONS: Prilocaine may be preferable to <e1> lidocaine </e1> for short surgical procedures because it has a similar duration of action but a lower incidence of <e2> TNSs </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6278": {"data": {"text": "Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.\n", "entity1": "Dapsone", "entity2": "hemolytic anemia", "span1": [0, 7], "span2": [30, 46]}, "bert_text": "<e1> Dapsone </e1>-associated Heinz body <e2> hemolytic anemia </e2> in a Cambodian woman with hemoglobin E trait.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6279": {"data": {"text": "Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.", "entity1": "Mitomycin C", "entity2": "Hemolytic Uremic Syndrome", "span1": [0, 11], "span2": [23, 48]}, "bert_text": "<e1> Mitomycin C </e1> associated <e2> Hemolytic Uremic Syndrome </e2> (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6280": {"data": {"text": "Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.", "entity1": "Mitomycin C", "entity2": "HUS", "span1": [0, 11], "span2": [50, 53]}, "bert_text": "<e1> Mitomycin C </e1> associated Hemolytic Uremic Syndrome (<e2> HUS </e2>) is a potentially fatal but uncommon condition that is not yet widely recognised.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6281": {"data": {"text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.", "entity1": "amphotericin B", "entity2": "dilated cardiomyopathy", "span1": [128, 142], "span2": [36, 58]}, "bert_text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with <e1> amphotericin B </e1> <e2> dilated cardiomyopathy </e2> and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6282": {"data": {"text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.", "entity1": "amphotericin B", "entity2": "congestive heart failure", "span1": [128, 142], "span2": [72, 96]}, "bert_text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with <e1> amphotericin B </e1> <e2> congestive heart failure </e2> after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6283": {"data": {"text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.", "entity1": "amphotericin B", "entity2": "coccidioidomycosis", "span1": [128, 142], "span2": [166, 184]}, "bert_text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with <e1> amphotericin B </e1> (AmB) for disseminated <e2> coccidioidomycosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6284": {"data": {"text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.", "entity1": "AmB", "entity2": "dilated cardiomyopathy", "span1": [144, 147], "span2": [36, 58]}, "bert_text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (<e1> AmB </e1> <e2> dilated cardiomyopathy </e2> and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6285": {"data": {"text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.", "entity1": "AmB", "entity2": "congestive heart failure", "span1": [144, 147], "span2": [72, 96]}, "bert_text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (<e1> AmB </e1> <e2> congestive heart failure </e2> after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6286": {"data": {"text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.", "entity1": "AmB", "entity2": "coccidioidomycosis", "span1": [144, 147], "span2": [166, 184]}, "bert_text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (<e1> AmB </e1>) for disseminated <e2> coccidioidomycosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6287": {"data": {"text": "QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.", "entity1": "verapamil", "entity2": "AVRT", "span1": [67, 76], "span2": [178, 182]}, "bert_text": "QRS without preexcitation, caused by junctional escape beats after <e1> verapamil </e1> or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent <e2> AVRT </e2> attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6288": {"data": {"text": "When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.", "entity1": "carbamazepine", "entity2": "seizures", "span1": [9, 22], "span2": [130, 138]}, "bert_text": "When the <e1> carbamazepine </e1> was discontinued, two of the children returned to their former state very quickly, two had the minor motor <e2> seizures </e2> resolve in 3 and 6 months, and one had the seizures persist.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6289": {"data": {"text": "When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.", "entity1": "carbamazepine", "entity2": "seizures", "span1": [9, 22], "span2": [182, 190]}, "bert_text": "When the <e1> carbamazepine </e1> was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the <e2> seizures </e2> persist.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6290": {"data": {"text": "This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.", "entity1": "propafenone", "entity2": "overdose", "span1": [146, 157], "span2": [158, 166]}, "bert_text": "This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a <e1> propafenone </e1> <e2> overdose </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6291": {"data": {"text": "Regional localization of the antagonism of amphetamine-induced hyperactivity by intracerebral calcitonin injections.\n", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [43, 54], "span2": [63, 76]}, "bert_text": "Regional localization of the antagonism of <e1> amphetamine </e1>-induced <e2> hyperactivity </e2> by intracerebral calcitonin injections.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6292": {"data": {"text": "Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).", "entity1": "THP", "entity2": "catalepsy", "span1": [18, 21], "span2": [122, 131]}, "bert_text": "Administration of <e1> THP </e1> (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the <e2> catalepsy </e2> times (P < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6293": {"data": {"text": "Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [65, 76], "span2": [122, 131]}, "bert_text": "Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to <e1> haloperidol </e1> resulted in a dose-dependent increase in the <e2> catalepsy </e2> times (P < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6294": {"data": {"text": "It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.", "entity1": "mitomycin C", "entity2": "microangiopathic hemolytic anemia", "span1": [113, 124], "span2": [15, 48]}, "bert_text": "It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with <e1> mitomycin C </e1> <e2> microangiopathic hemolytic anemia </e2>, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6295": {"data": {"text": "It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.", "entity1": "mitomycin C", "entity2": "thrombocytopenia", "span1": [113, 124], "span2": [50, 66]}, "bert_text": "It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with <e1> mitomycin C </e1> <e2> thrombocytopenia </e2> and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6296": {"data": {"text": "It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.", "entity1": "mitomycin C", "entity2": "renal failure", "span1": [113, 124], "span2": [83, 96]}, "bert_text": "It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with <e1> mitomycin C </e1> <e2> renal failure </e2> associated with mitomycin C treatment and affects about 10% of patients treated with this agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6297": {"data": {"text": "Nephrotoxicity associated with ciprofloxacin is uncommon.", "entity1": "ciprofloxacin", "entity2": "Nephrotoxicity", "span1": [31, 44], "span2": [0, 14]}, "bert_text": "Nephrotoxicity associated with <e1> ciprofloxacin </e1> <e2> Nephrotoxicity </e2> associated with ciprofloxacin is uncommon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6298": {"data": {"text": "High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.", "entity1": "vitamin D", "entity2": "calcification", "span1": [14, 23], "span2": [43, 56]}, "bert_text": "High doses of <e1> vitamin D </e1> are known to cause <e2> calcification </e2> of the artery media in as little as 3 to 4 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6299": {"data": {"text": "Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.", "entity1": "disulfiram", "entity2": "peripheral neuropathy", "span1": [40, 50], "span2": [6, 27]}, "bert_text": "Acute peripheral neuropathy caused by a <e1> disulfiram </e1> <e2> peripheral neuropathy </e2> caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6300": {"data": {"text": "Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.", "entity1": "disulfiram", "entity2": "overdose", "span1": [40, 50], "span2": [51, 59]}, "bert_text": "Acute peripheral neuropathy caused by a <e1> disulfiram </e1> <e2> overdose </e2> is very rare and there is no report of it leading to vocal fold palsy.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6301": {"data": {"text": "Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.", "entity1": "disulfiram", "entity2": "palsy", "span1": [40, 50], "span2": [124, 129]}, "bert_text": "Acute peripheral neuropathy caused by a <e1> disulfiram </e1> overdose is very rare and there is no report of it leading to vocal fold <e2> palsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6302": {"data": {"text": "BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [126, 133], "span2": [142, 158]}, "bert_text": "BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6303": {"data": {"text": "BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).", "entity1": "heparin", "entity2": "HIT", "span1": [126, 133], "span2": [160, 163]}, "bert_text": "BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of <e1> heparin </e1>-induced thrombocytopenia (<e2> HIT </e2>) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6304": {"data": {"text": "BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).", "entity1": "heparin", "entity2": "HIT", "span1": [126, 133], "span2": [168, 171]}, "bert_text": "BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of <e1> heparin </e1>-induced thrombocytopenia (HIT) or <e2> HIT </e2> with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6305": {"data": {"text": "BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).", "entity1": "heparin", "entity2": "thrombosis", "span1": [126, 133], "span2": [177, 187]}, "bert_text": "BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of <e1> heparin </e1>-induced thrombocytopenia (HIT) or HIT with <e2> thrombosis </e2> (HITT) undergoing cardiopulmonary bypass (CPB).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6306": {"data": {"text": "BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).", "entity1": "heparin", "entity2": "HITT", "span1": [126, 133], "span2": [189, 193]}, "bert_text": "BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of <e1> heparin </e1>-induced thrombocytopenia (HIT) or HIT with thrombosis (<e2> HITT </e2>) undergoing cardiopulmonary bypass (CPB).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6307": {"data": {"text": "AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.", "entity1": "disulfiram", "entity2": "peripheral neuropathy", "span1": [78, 88], "span2": [35, 56]}, "bert_text": "AIM: To report a case of optic and peripheral neuropathy after chronic use of <e1> disulfiram </e1> <e2> peripheral neuropathy </e2> after chronic use of disulfiram for alcohol dependence management.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6308": {"data": {"text": "Treatment of psoriasis with azathioprine.\n", "entity1": "azathioprine", "entity2": "psoriasis", "span1": [28, 40], "span2": [13, 22]}, "bert_text": "Treatment of psoriasis with <e1> azathioprine </e1> <e2> psoriasis </e2> with azathioprine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6309": {"data": {"text": "After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.", "entity1": "PAN", "entity2": "proteinuria", "span1": [14, 17], "span2": [48, 59]}, "bert_text": "After 7 days, <e1> PAN </e1> treatment induced significant <e2> proteinuria </e2>, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6310": {"data": {"text": "After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.", "entity1": "PAN", "entity2": "hypoalbuminemia", "span1": [14, 17], "span2": [61, 76]}, "bert_text": "After 7 days, <e1> PAN </e1> treatment induced significant proteinuria, <e2> hypoalbuminemia </e2>, decreased urinary sodium excretion, and extensive ascites.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6311": {"data": {"text": "After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.", "entity1": "PAN", "entity2": "ascites", "span1": [14, 17], "span2": [128, 135]}, "bert_text": "After 7 days, <e1> PAN </e1> treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive <e2> ascites </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6312": {"data": {"text": "After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.", "entity1": "sodium", "entity2": "proteinuria", "span1": [96, 102], "span2": [48, 59]}, "bert_text": "After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary <e1> sodium </e1> <e2> proteinuria </e2>, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6313": {"data": {"text": "After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.", "entity1": "sodium", "entity2": "hypoalbuminemia", "span1": [96, 102], "span2": [61, 76]}, "bert_text": "After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary <e1> sodium </e1> <e2> hypoalbuminemia </e2>, decreased urinary sodium excretion, and extensive ascites.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6314": {"data": {"text": "After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.", "entity1": "sodium", "entity2": "ascites", "span1": [96, 102], "span2": [128, 135]}, "bert_text": "After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary <e1> sodium </e1> excretion, and extensive <e2> ascites </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6315": {"data": {"text": "The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.", "entity1": "Mesna", "entity2": "hematuria", "span1": [132, 137], "span2": [36, 45]}, "bert_text": "The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding <e1> Mesna </e1> <e2> hematuria </e2> are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6316": {"data": {"text": "The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.", "entity1": "Mesna", "entity2": "hematuria", "span1": [132, 137], "span2": [182, 191]}, "bert_text": "The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding <e1> Mesna </e1> to the infusate in patients with persistent <e2> hematuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6317": {"data": {"text": "High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.\n", "entity1": "tranexamic Acid", "entity2": "seizures", "span1": [10, 25], "span2": [66, 74]}, "bert_text": "High-dose <e1> tranexamic Acid </e1> is associated with nonischemic clinical <e2> seizures </e2> in cardiac surgical patients.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6318": {"data": {"text": "Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.", "entity1": "thalidomide", "entity2": "lymphomas", "span1": [77, 88], "span2": [101, 110]}, "bert_text": "Our results failed to demonstrate an important response rate to single agent <e1> thalidomide </e1> in indolent <e2> lymphomas </e2> and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6319": {"data": {"text": "Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.", "entity1": "lenalidomide", "entity2": "lymphomas", "span1": [215, 227], "span2": [101, 110]}, "bert_text": "Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, <e1> lenalidomide </e1> <e2> lymphomas </e2> and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6320": {"data": {"text": "Reversible dilated cardiomyopathy related to amphotericin B therapy.\n", "entity1": "amphotericin B", "entity2": "dilated cardiomyopathy", "span1": [45, 59], "span2": [11, 33]}, "bert_text": "Reversible dilated cardiomyopathy related to <e1> amphotericin B </e1> <e2> dilated cardiomyopathy </e2> related to amphotericin B therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6321": {"data": {"text": "Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.", "entity1": "DOX", "entity2": "fibrosis", "span1": [54, 57], "span2": [127, 135]}, "bert_text": "Histological evaluation of hearts from all rats given <e1> DOX </e1> revealed significant slight degrees of perivascular and interstitial <e2> fibrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6322": {"data": {"text": "The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin.", "entity1": "acetaminophen", "entity2": "hypotension", "span1": [59, 72], "span2": [90, 101]}, "bert_text": "The reports illustrate the need for clinicians to consider <e1> acetaminophen </e1> in patients with <e2> hypotension </e2> of unknown origin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6323": {"data": {"text": "Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.\n", "entity1": "L-dopa", "entity2": "parkinsonian", "span1": [60, 66], "span2": [33, 45]}, "bert_text": "Cortical motor overactivation in parkinsonian patients with <e1> L-dopa </e1> <e2> parkinsonian </e2> patients with L-dopa-induced peak-dose dyskinesia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6324": {"data": {"text": "Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.\n", "entity1": "L-dopa", "entity2": "dyskinesia", "span1": [60, 66], "span2": [85, 95]}, "bert_text": "Cortical motor overactivation in parkinsonian patients with <e1> L-dopa </e1>-induced peak-dose <e2> dyskinesia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6325": {"data": {"text": "When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.", "entity1": "AZT", "entity2": "marrow toxicity", "span1": [25, 28], "span2": [92, 107]}, "bert_text": "When coadministered with <e1> AZT </e1> from the onset of drug administration, BAU reduced AZT-induced <e2> marrow toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6326": {"data": {"text": "When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.", "entity1": "AZT", "entity2": "marrow toxicity", "span1": [80, 83], "span2": [92, 107]}, "bert_text": "When coadministered with AZT from the onset of drug administration, BAU reduced <e1> AZT </e1>-induced <e2> marrow toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6327": {"data": {"text": "When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.", "entity1": "BAU", "entity2": "marrow toxicity", "span1": [68, 71], "span2": [92, 107]}, "bert_text": "When coadministered with AZT from the onset of drug administration, <e1> BAU </e1> reduced AZT-induced <e2> marrow toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6328": {"data": {"text": "Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.", "entity1": "Flestolol", "entity2": "tachycardia", "span1": [0, 9], "span2": [73, 84]}, "bert_text": "<e1> Flestolol </e1> produced a dose-dependent attenuation of isoproterenol-induced <e2> tachycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6329": {"data": {"text": "Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.", "entity1": "isoproterenol", "entity2": "tachycardia", "span1": [51, 64], "span2": [73, 84]}, "bert_text": "Flestolol produced a dose-dependent attenuation of <e1> isoproterenol </e1>-induced <e2> tachycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6330": {"data": {"text": "Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.\n", "entity1": "Cyclophosphamide", "entity2": "cystitis", "span1": [0, 16], "span2": [25, 33]}, "bert_text": "<e1> Cyclophosphamide </e1>-induced <e2> cystitis </e2> in freely-moving conscious rats: behavioral approach to a new model of visceral pain.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6331": {"data": {"text": "Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.\n", "entity1": "Cyclophosphamide", "entity2": "visceral pain", "span1": [0, 16], "span2": [105, 118]}, "bert_text": "<e1> Cyclophosphamide </e1>-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of <e2> visceral pain </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6332": {"data": {"text": "We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.", "entity1": "diltiazem", "entity2": "tetany", "span1": [108, 117], "span2": [36, 42]}, "bert_text": "We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous <e1> diltiazem </e1> <e2> tetany </e2> with sudden respiratory arrest after the infusion of intravenous diltiazem.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6333": {"data": {"text": "We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.", "entity1": "diltiazem", "entity2": "sudden respiratory arrest", "span1": [108, 117], "span2": [48, 73]}, "bert_text": "We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous <e1> diltiazem </e1> <e2> sudden respiratory arrest </e2> after the infusion of intravenous diltiazem.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6334": {"data": {"text": "Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.", "entity1": "testosterone", "entity2": "low sexual desire", "span1": [87, 99], "span2": [48, 65]}, "bert_text": "Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or <e1> testosterone </e1> <e2> low sexual desire </e2>, gynecomastia and/or testosterone less than 4 ng./ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6335": {"data": {"text": "Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.", "entity1": "testosterone", "entity2": "gynecomastia", "span1": [87, 99], "span2": [67, 79]}, "bert_text": "Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or <e1> testosterone </e1> <e2> gynecomastia </e2> and/or testosterone less than 4 ng./ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6336": {"data": {"text": "Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.", "entity1": "isoflurane", "entity2": "hypertensive", "span1": [6, 16], "span2": [57, 69]}, "bert_text": "Under <e1> isoflurane </e1> anesthesia, the MCA of 14 spontaneously <e2> hypertensive </e2> rats was occluded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6337": {"data": {"text": "The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.", "entity1": "lidocaine", "entity2": "ventricular arrhythmias", "span1": [71, 80], "span2": [4, 27]}, "bert_text": "The ventricular arrhythmias responded to intravenous administration of <e1> lidocaine </e1> <e2> ventricular arrhythmias </e2> responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6338": {"data": {"text": "The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.", "entity1": "propranolol", "entity2": "ventricular arrhythmias", "span1": [203, 214], "span2": [4, 27]}, "bert_text": "The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of <e1> propranolol </e1> <e2> ventricular arrhythmias </e2> responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6339": {"data": {"text": "Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).", "entity1": "aspirin", "entity2": "Thrombotic", "span1": [53, 60], "span2": [0, 10]}, "bert_text": "Thrombotic risk was consistently higher for users of <e1> aspirin </e1> <e2> Thrombotic </e2> risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6340": {"data": {"text": "Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).", "entity1": "aspirin", "entity2": "Thrombotic", "span1": [84, 91], "span2": [0, 10]}, "bert_text": "Thrombotic risk was consistently higher for users of aspirin users than nonusers of <e1> aspirin </e1> <e2> Thrombotic </e2> risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6341": {"data": {"text": "Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).", "entity1": "valdecoxib", "entity2": "Thrombotic", "span1": [115, 125], "span2": [0, 10]}, "bert_text": "Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; <e1> valdecoxib </e1> <e2> Thrombotic </e2> risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6342": {"data": {"text": "Anginal episodes were rare: only one patient had angina (during 5-FU infusion).", "entity1": "5-FU", "entity2": "Anginal", "span1": [64, 68], "span2": [0, 7]}, "bert_text": "Anginal episodes were rare: only one patient had angina (during <e1> 5-FU </e1> <e2> Anginal </e2> episodes were rare: only one patient had angina (during 5-FU infusion).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6343": {"data": {"text": "Anginal episodes were rare: only one patient had angina (during 5-FU infusion).", "entity1": "5-FU", "entity2": "angina", "span1": [64, 68], "span2": [49, 55]}, "bert_text": "Anginal episodes were rare: only one patient had angina (during <e1> 5-FU </e1> <e2> angina </e2> (during 5-FU infusion).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6344": {"data": {"text": "This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.", "entity1": "lithium", "entity2": "bipolar", "span1": [73, 80], "span2": [51, 58]}, "bert_text": "This report summarizes our experience in switching bipolar patients from <e1> lithium </e1> <e2> bipolar </e2> patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6345": {"data": {"text": "This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.", "entity1": "lithium", "entity2": "cognitive and functional impairments", "span1": [73, 80], "span2": [120, 156]}, "bert_text": "This report summarizes our experience in switching bipolar patients from <e1> lithium </e1> to divalproex sodium to alleviate such <e2> cognitive and functional impairments </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6346": {"data": {"text": "This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.", "entity1": "divalproex sodium", "entity2": "bipolar", "span1": [84, 101], "span2": [51, 58]}, "bert_text": "This report summarizes our experience in switching bipolar patients from lithium to <e1> divalproex sodium </e1> <e2> bipolar </e2> patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6347": {"data": {"text": "This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.", "entity1": "divalproex sodium", "entity2": "cognitive and functional impairments", "span1": [84, 101], "span2": [120, 156]}, "bert_text": "This report summarizes our experience in switching bipolar patients from lithium to <e1> divalproex sodium </e1> to alleviate such <e2> cognitive and functional impairments </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6348": {"data": {"text": "Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.\n", "entity1": "Alpha-lipoic acid", "entity2": "neurotoxicity", "span1": [0, 17], "span2": [52, 65]}, "bert_text": "<e1> Alpha-lipoic acid </e1> prevents mitochondrial damage and <e2> neurotoxicity </e2> in experimental chemotherapy neuropathy.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6349": {"data": {"text": "Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.\n", "entity1": "Alpha-lipoic acid", "entity2": "neuropathy", "span1": [0, 17], "span2": [95, 105]}, "bert_text": "<e1> Alpha-lipoic acid </e1> prevents mitochondrial damage and neurotoxicity in experimental chemotherapy <e2> neuropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6350": {"data": {"text": "She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.", "entity1": "methamphetamine", "entity2": "carious", "span1": [24, 39], "span2": [89, 96]}, "bert_text": "She reported her use of <e1> methamphetamine </e1> for five years and had not experienced any major <e2> carious </e2> episodes before she started using the drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"6351": {"data": {"text": "Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.", "entity1": "calcium", "entity2": "cardiovascular malformations", "span1": [45, 52], "span2": [167, 195]}, "bert_text": "Pregnant rats were administered one of these <e1> calcium </e1> channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for <e2> cardiovascular malformations </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6352": {"data": {"text": "Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy.", "entity1": "Doxorubicin", "entity2": "cardiomyopathy", "span1": [0, 11], "span2": [95, 109]}, "bert_text": "<e1> Doxorubicin </e1> is an effective anticancer chemotherapeutic agent known to cause acute and chronic <e2> cardiomyopathy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6353": {"data": {"text": "Thiazide diuretics, hypokalemia and cardiac arrhythmias.\n", "entity1": "Thiazide", "entity2": "hypokalemia", "span1": [0, 8], "span2": [20, 31]}, "bert_text": "<e1> Thiazide </e1> diuretics, <e2> hypokalemia </e2> and cardiac arrhythmias.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6354": {"data": {"text": "Thiazide diuretics, hypokalemia and cardiac arrhythmias.\n", "entity1": "Thiazide", "entity2": "cardiac arrhythmias", "span1": [0, 8], "span2": [36, 55]}, "bert_text": "<e1> Thiazide </e1> diuretics, hypokalemia and <e2> cardiac arrhythmias </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6355": {"data": {"text": "Stroke and cocaine or amphetamine use.\n", "entity1": "cocaine", "entity2": "Stroke", "span1": [11, 18], "span2": [0, 6]}, "bert_text": "Stroke and <e1> cocaine </e1> <e2> Stroke </e2> and cocaine or amphetamine use.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6356": {"data": {"text": "Stroke and cocaine or amphetamine use.\n", "entity1": "amphetamine", "entity2": "Stroke", "span1": [22, 33], "span2": [0, 6]}, "bert_text": "Stroke and cocaine or <e1> amphetamine </e1> <e2> Stroke </e2> and cocaine or amphetamine use.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6357": {"data": {"text": "The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.", "entity1": "metoprolol", "entity2": "hypokalemia", "span1": [46, 56], "span2": [80, 91]}, "bert_text": "The drug effect studied was the antagonism by <e1> metoprolol </e1> of terbutaline-induced <e2> hypokalemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6358": {"data": {"text": "The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.", "entity1": "terbutaline", "entity2": "hypokalemia", "span1": [60, 71], "span2": [80, 91]}, "bert_text": "The drug effect studied was the antagonism by metoprolol of <e1> terbutaline </e1>-induced <e2> hypokalemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6359": {"data": {"text": "Tremor side effects of salbutamol, quantified by a laser pointer technique.\n", "entity1": "salbutamol", "entity2": "Tremor", "span1": [23, 33], "span2": [0, 6]}, "bert_text": "Tremor side effects of <e1> salbutamol </e1> <e2> Tremor </e2> side effects of salbutamol, quantified by a laser pointer technique.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6360": {"data": {"text": "Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.", "entity1": "fluorouracil", "entity2": "cardiac toxicity", "span1": [79, 91], "span2": [46, 62]}, "bert_text": "Although there have been anecdotal reports of cardiac toxicity associated with <e1> fluorouracil </e1> <e2> cardiac toxicity </e2> associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6361": {"data": {"text": "Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.", "entity1": "5-FU", "entity2": "cardiac toxicity", "span1": [93, 97], "span2": [46, 62]}, "bert_text": "Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (<e1> 5-FU </e1> <e2> cardiac toxicity </e2> associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6362": {"data": {"text": "After the clipping of the aneurysm the isoflurane concentration was reduced to 0.75%.", "entity1": "isoflurane", "entity2": "aneurysm", "span1": [39, 49], "span2": [26, 34]}, "bert_text": "After the clipping of the aneurysm the <e1> isoflurane </e1> <e2> aneurysm </e2> the isoflurane concentration was reduced to 0.75%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6363": {"data": {"text": "Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.", "entity1": "tacrolimus", "entity2": "myocardial hypertrophy", "span1": [63, 73], "span2": [29, 51]}, "bert_text": "Herein we describe transient myocardial hypertrophy induced by <e1> tacrolimus </e1> <e2> myocardial hypertrophy </e2> induced by tacrolimus after heart transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6364": {"data": {"text": "Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.", "entity1": "thiazide", "entity2": "Hypokalemia", "span1": [71, 79], "span2": [0, 11]}, "bert_text": "Hypokalemia is a commonly encountered metabolic consequence of chronic <e1> thiazide </e1> <e2> Hypokalemia </e2> is a commonly encountered metabolic consequence of chronic thiazide therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6365": {"data": {"text": "We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic syndrome", "span1": [64, 89], "span2": [104, 122]}, "bert_text": "We examined the abundance of ENaC subunit mRNAs and proteins in <e1> puromycin aminonucleoside </e1> (PAN)-induced <e2> nephrotic syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6366": {"data": {"text": "We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.", "entity1": "PAN)-induced", "entity2": "nephrotic syndrome", "span1": [91, 103], "span2": [104, 122]}, "bert_text": "We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (<e1> PAN)-induced </e1> <e2> nephrotic syndrome </e2>.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6367": {"data": {"text": "The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.", "entity1": "calcium chloride", "entity2": "tetany", "span1": [22, 38], "span2": [70, 76]}, "bert_text": "The administration of <e1> calcium chloride </e1> rapidly resolved the patient's <e2> tetany </e2> with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6368": {"data": {"text": "Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.\n", "entity1": "phenobarbital", "entity2": "carcinogenic", "span1": [28, 41], "span2": [5, 17]}, "bert_text": "Anti-carcinogenic action of <e1> phenobarbital </e1> <e2> carcinogenic </e2> action of phenobarbital given simultaneously with diethylnitrosamine in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6369": {"data": {"text": "Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.\n", "entity1": "diethylnitrosamine", "entity2": "carcinogenic", "span1": [68, 86], "span2": [5, 17]}, "bert_text": "Anti-carcinogenic action of phenobarbital given simultaneously with <e1> diethylnitrosamine </e1> <e2> carcinogenic </e2> action of phenobarbital given simultaneously with diethylnitrosamine in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6370": {"data": {"text": "However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).", "entity1": "prazosin", "entity2": "orthostatic hypotension", "span1": [82, 90], "span2": [34, 57]}, "bert_text": "However, the head-up tilt induced orthostatic hypotension in the SHR treated with <e1> prazosin </e1> <e2> orthostatic hypotension </e2> in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6371": {"data": {"text": "However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).", "entity1": "rauwolscine", "entity2": "orthostatic hypotension", "span1": [142, 153], "span2": [34, 57]}, "bert_text": "However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with <e1> rauwolscine </e1> <e2> orthostatic hypotension </e2> in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6372": {"data": {"text": "A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.", "entity1": "chloroquine", "entity2": "dyspnoea", "span1": [52, 63], "span2": [146, 154]}, "bert_text": "A 27-year old African woman with history of regular <e1> chloroquine </e1> ingestion presented with progressive deterioration of vision, easy fatiguability, <e2> dyspnoea </e2>, dizziness progressing to syncopal attacks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6373": {"data": {"text": "A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.", "entity1": "chloroquine", "entity2": "dizziness", "span1": [52, 63], "span2": [156, 165]}, "bert_text": "A 27-year old African woman with history of regular <e1> chloroquine </e1> ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, <e2> dizziness </e2> progressing to syncopal attacks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6374": {"data": {"text": "A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.", "entity1": "chloroquine", "entity2": "syncopal attacks", "span1": [52, 63], "span2": [181, 197]}, "bert_text": "A 27-year old African woman with history of regular <e1> chloroquine </e1> ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to <e2> syncopal attacks </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6375": {"data": {"text": "Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.", "entity1": "morphine", "entity2": "apnoea", "span1": [121, 129], "span2": [48, 54]}, "bert_text": "Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a <e1> morphine </e1> <e2> apnoea </e2> (P less than 0.05) occurred more frequently in patients who had a morphine infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6376": {"data": {"text": "In order to address long-term pain memory, nine healthy male volunteers received intradermal injections of three doses of capsaicin (0.05, 1 and 20 microg, separated by 15 min breaks), each given three times in a balanced design across three sessions at one week intervals.", "entity1": "capsaicin", "entity2": "pain", "span1": [122, 131], "span2": [30, 34]}, "bert_text": "In order to address long-term pain memory, nine healthy male volunteers received intradermal injections of three doses of <e1> capsaicin </e1> <e2> pain </e2> memory, nine healthy male volunteers received intradermal injections of three doses of capsaicin (0.05, 1 and 20 microg, separated by 15 min breaks), each given three times in a balanced design across three sessions at one week intervals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6377": {"data": {"text": "Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.", "entity1": "ketoconazole", "entity2": "hepatitis", "span1": [126, 138], "span2": [73, 82]}, "bert_text": "Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with <e1> ketoconazole </e1> <e2> hepatitis </e2> is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6378": {"data": {"text": "Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.", "entity1": "ketoconazole", "entity2": "hepatic injury", "span1": [126, 138], "span2": [167, 181]}, "bert_text": "Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with <e1> ketoconazole </e1> to prevent possible serious <e2> hepatic injury </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6379": {"data": {"text": "We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.", "entity1": "5-FU", "entity2": "tumors", "span1": [90, 94], "span2": [127, 133]}, "bert_text": "We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing <e1> 5-FU </e1> infusion for treatment of solid <e2> tumors </e2> in order to assess the incidence of ischemic ST changes.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6380": {"data": {"text": "We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.", "entity1": "5-FU", "entity2": "ischemic", "span1": [90, 94], "span2": [170, 178]}, "bert_text": "We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing <e1> 5-FU </e1> infusion for treatment of solid tumors in order to assess the incidence of <e2> ischemic </e2> ST changes.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6381": {"data": {"text": "None of the subjects/patients developed UFH-related HIT.", "entity1": "UFH", "entity2": "HIT", "span1": [40, 43], "span2": [52, 55]}, "bert_text": "None of the subjects/patients developed <e1> UFH </e1>-related <e2> HIT </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6382": {"data": {"text": "The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.", "entity1": "PREGS", "entity2": "amnesia", "span1": [32, 37], "span2": [135, 142]}, "bert_text": "The memory-enhancing effects of <e1> PREGS </e1> and its analogs were tested in the passive avoidance task using the model of scopolamine-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6383": {"data": {"text": "The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [115, 126], "span2": [135, 142]}, "bert_text": "The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of <e1> scopolamine </e1>-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6384": {"data": {"text": "However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.", "entity1": "ACTH", "entity2": "depression", "span1": [90, 94], "span2": [298, 308]}, "bert_text": "However, it is not certain as to the following: (a) what receptors were stimulated by the <e1> ACTH </e1> N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term <e2> depression </e2> at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6385": {"data": {"text": "However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.", "entity1": "ACTH", "entity2": "movement disorder", "span1": [90, 94], "span2": [410, 427]}, "bert_text": "However, it is not certain as to the following: (a) what receptors were stimulated by the <e1> ACTH </e1> N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the <e2> movement disorder </e2>; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6386": {"data": {"text": "Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.", "entity1": "PAN", "entity2": "NS", "span1": [100, 103], "span2": [120, 122]}, "bert_text": "Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after <e1> PAN </e1> injection, when <e2> NS </e2> was clearly established, hepatic Ao mRNA levels did not change.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6387": {"data": {"text": "These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.", "entity1": "ISO", "entity2": "hypertrophic", "span1": [50, 53], "span2": [69, 81]}, "bert_text": "These data indicate that the adaptive response to <e1> ISO </e1> shows an early <e2> hypertrophic </e2> phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6388": {"data": {"text": "In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.", "entity1": "methscopolamine", "entity2": "hyperactivity", "span1": [18, 33], "span2": [120, 133]}, "bert_text": "In contrast, both <e1> methscopolamine </e1> and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the <e2> hyperactivity </e2> produced by morphine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"6389": {"data": {"text": "In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.", "entity1": "neostigmine", "entity2": "hyperactivity", "span1": [38, 49], "span2": [120, 133]}, "bert_text": "In contrast, both methscopolamine and <e1> neostigmine </e1>, which do not penetrate the blood-brain barrier, had no effect on the <e2> hyperactivity </e2> produced by morphine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"6390": {"data": {"text": "In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.", "entity1": "morphine", "entity2": "hyperactivity", "span1": [146, 154], "span2": [120, 133]}, "bert_text": "In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by <e1> morphine </e1> <e2> hyperactivity </e2> produced by morphine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"6391": {"data": {"text": "We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.", "entity1": "omeprazole", "entity2": "hemolytic anemia", "span1": [82, 92], "span2": [94, 110]}, "bert_text": "We report the first case of a serious short-term adverse reaction with the use of <e1> omeprazole </e1>: <e2> hemolytic anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6392": {"data": {"text": "Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.", "entity1": "Desipramine", "entity2": "seizures", "span1": [0, 11], "span2": [47, 55]}, "bert_text": "<e1> Desipramine </e1>-induced sensitization of lidocaine <e2> seizures </e2> may have a mechanism distinct from kindling resulting from repeated administration of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6393": {"data": {"text": "Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.", "entity1": "lidocaine", "entity2": "seizures", "span1": [37, 46], "span2": [47, 55]}, "bert_text": "Desipramine-induced sensitization of <e1> lidocaine </e1> <e2> seizures </e2> may have a mechanism distinct from kindling resulting from repeated administration of cocaine.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6394": {"data": {"text": "Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.", "entity1": "cocaine", "entity2": "seizures", "span1": [142, 149], "span2": [47, 55]}, "bert_text": "Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of <e1> cocaine </e1> <e2> seizures </e2> may have a mechanism distinct from kindling resulting from repeated administration of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6395": {"data": {"text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.", "entity1": "naloxazone", "entity2": "hypotension", "span1": [10, 20], "span2": [67, 78]}, "bert_text": "Moreover, <e1> naloxazone </e1> significantly attenuated the morphine-induced <e2> hypotension </e2> and respiratory depression, whereas morphine-induced bradycardia was less affected.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6396": {"data": {"text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.", "entity1": "naloxazone", "entity2": "respiratory depression", "span1": [10, 20], "span2": [83, 105]}, "bert_text": "Moreover, <e1> naloxazone </e1> significantly attenuated the morphine-induced hypotension and <e2> respiratory depression </e2>, whereas morphine-induced bradycardia was less affected.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6397": {"data": {"text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.", "entity1": "naloxazone", "entity2": "bradycardia", "span1": [10, 20], "span2": [132, 143]}, "bert_text": "Moreover, <e1> naloxazone </e1> significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced <e2> bradycardia </e2> was less affected.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6398": {"data": {"text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.", "entity1": "morphine", "entity2": "hypotension", "span1": [50, 58], "span2": [67, 78]}, "bert_text": "Moreover, naloxazone significantly attenuated the <e1> morphine </e1>-induced <e2> hypotension </e2> and respiratory depression, whereas morphine-induced bradycardia was less affected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6399": {"data": {"text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.", "entity1": "morphine", "entity2": "respiratory depression", "span1": [50, 58], "span2": [83, 105]}, "bert_text": "Moreover, naloxazone significantly attenuated the <e1> morphine </e1>-induced hypotension and <e2> respiratory depression </e2>, whereas morphine-induced bradycardia was less affected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6400": {"data": {"text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.", "entity1": "morphine", "entity2": "bradycardia", "span1": [50, 58], "span2": [132, 143]}, "bert_text": "Moreover, naloxazone significantly attenuated the <e1> morphine </e1>-induced hypotension and respiratory depression, whereas morphine-induced <e2> bradycardia </e2> was less affected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6401": {"data": {"text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.", "entity1": "morphine", "entity2": "hypotension", "span1": [115, 123], "span2": [67, 78]}, "bert_text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas <e1> morphine </e1> <e2> hypotension </e2> and respiratory depression, whereas morphine-induced bradycardia was less affected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6402": {"data": {"text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.", "entity1": "morphine", "entity2": "respiratory depression", "span1": [115, 123], "span2": [83, 105]}, "bert_text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas <e1> morphine </e1> <e2> respiratory depression </e2>, whereas morphine-induced bradycardia was less affected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6403": {"data": {"text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.", "entity1": "morphine", "entity2": "bradycardia", "span1": [115, 123], "span2": [132, 143]}, "bert_text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas <e1> morphine </e1>-induced <e2> bradycardia </e2> was less affected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6404": {"data": {"text": "Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.", "entity1": "lometrexol", "entity2": "toxicity", "span1": [61, 71], "span2": [49, 57]}, "bert_text": "Preclinical murine studies demonstrated that the toxicity of <e1> lometrexol </e1> <e2> toxicity </e2> of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6405": {"data": {"text": "Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.", "entity1": "folic acid", "entity2": "toxicity", "span1": [101, 111], "span2": [49, 57]}, "bert_text": "Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose <e1> folic acid </e1> <e2> toxicity </e2> of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6406": {"data": {"text": "We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.", "entity1": "5-FU", "entity2": "ischemia", "span1": [17, 21], "span2": [118, 126]}, "bert_text": "We conclude that <e1> 5-FU </e1> infusion is associated with a significant increase in silent ST segment deviation suggestive of <e2> ischemia </e2>, particularly among patients with coronary artery disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6407": {"data": {"text": "We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.", "entity1": "5-FU", "entity2": "coronary artery disease", "span1": [17, 21], "span2": [161, 184]}, "bert_text": "We conclude that <e1> 5-FU </e1> infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with <e2> coronary artery disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6408": {"data": {"text": "Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.", "entity1": "paclitaxel", "entity2": "NSCLC", "span1": [175, 185], "span2": [66, 71]}, "bert_text": "Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of <e1> paclitaxel </e1> <e2> NSCLC </e2> and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6409": {"data": {"text": "Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.", "entity1": "cisplatin", "entity2": "NSCLC", "span1": [241, 250], "span2": [66, 71]}, "bert_text": "Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, <e1> cisplatin </e1> <e2> NSCLC </e2> and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6410": {"data": {"text": "Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.", "entity1": "gemcitabine", "entity2": "NSCLC", "span1": [310, 321], "span2": [66, 71]}, "bert_text": "Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and <e1> gemcitabine </e1> <e2> NSCLC </e2> and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6411": {"data": {"text": "Thyroxine abuse: an unusual case of thyrotoxicosis in pregnancy.\n", "entity1": "Thyroxine", "entity2": "thyrotoxicosis", "span1": [0, 9], "span2": [36, 50]}, "bert_text": "<e1> Thyroxine </e1> abuse: an unusual case of <e2> thyrotoxicosis </e2> in pregnancy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6412": {"data": {"text": "Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.", "entity1": "antithymocyte globulin", "entity2": "aplastic anemia", "span1": [7, 29], "span2": [86, 101]}, "bert_text": "Use of <e1> antithymocyte globulin </e1> may be the optimal treatment of D-penicillamine-induced <e2> aplastic anemia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6413": {"data": {"text": "Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.", "entity1": "D-penicillamine", "entity2": "aplastic anemia", "span1": [62, 77], "span2": [86, 101]}, "bert_text": "Use of antithymocyte globulin may be the optimal treatment of <e1> D-penicillamine </e1>-induced <e2> aplastic anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6414": {"data": {"text": "Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.", "entity1": "propofol", "entity2": "malignant hyperthermia", "span1": [43, 51], "span2": [117, 139]}, "bert_text": "Anesthesia was continued uneventfully with <e1> propofol </e1> infusion while all facilities were available to detect and treat <e2> malignant hyperthermia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6415": {"data": {"text": "Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.", "entity1": "tAMCA", "entity2": "seizures", "span1": [31, 36], "span2": [56, 64]}, "bert_text": "Thus, FS containing 47.5 mg/ml <e1> tAMCA </e1> evoked generalized <e2> seizures </e2> in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6416": {"data": {"text": "Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.", "entity1": "tAMCA", "entity2": "convulsive", "span1": [31, 36], "span2": [188, 198]}, "bert_text": "Thus, FS containing 47.5 mg/ml <e1> tAMCA </e1> evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated <e2> convulsive </e2> potentials in 1 of 6 rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6417": {"data": {"text": "Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.", "entity1": "tAMCA", "entity2": "seizures", "span1": [124, 129], "span2": [56, 64]}, "bert_text": "Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of <e1> tAMCA </e1> <e2> seizures </e2> in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6418": {"data": {"text": "Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.", "entity1": "tAMCA", "entity2": "convulsive", "span1": [124, 129], "span2": [188, 198]}, "bert_text": "Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of <e1> tAMCA </e1> (0.5 mg/ml) only evoked brief episodes of jerk-correlated <e2> convulsive </e2> potentials in 1 of 6 rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6419": {"data": {"text": "Vancomycin was curative in 95% of 43 patients with proven infection.", "entity1": "Vancomycin", "entity2": "infection", "span1": [0, 10], "span2": [58, 67]}, "bert_text": "<e1> Vancomycin </e1> was curative in 95% of 43 patients with proven <e2> infection </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6420": {"data": {"text": "In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.", "entity1": "EMB", "entity2": "optic neuropathy", "span1": [32, 35], "span2": [44, 60]}, "bert_text": "In all subjects with history of <e1> EMB </e1>-induced <e2> optic neuropathy </e2>, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6421": {"data": {"text": "In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.", "entity1": "EMB", "entity2": "visual deficits", "span1": [32, 35], "span2": [247, 262]}, "bert_text": "In all subjects with history of <e1> EMB </e1>-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate <e2> visual deficits </e2>, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6422": {"data": {"text": "In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.", "entity1": "EMB", "entity2": "visual deficits", "span1": [32, 35], "span2": [298, 313]}, "bert_text": "In all subjects with history of <e1> EMB </e1>-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic <e2> visual deficits </e2>, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6423": {"data": {"text": "Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.\n", "entity1": "lignocaine", "entity2": "tinnitus", "span1": [55, 65], "span2": [13, 21]}, "bert_text": "Treatment of tinnitus by intratympanic instillation of <e1> lignocaine </e1> <e2> tinnitus </e2> by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6424": {"data": {"text": "Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.\n", "entity1": "lidocaine", "entity2": "tinnitus", "span1": [67, 76], "span2": [13, 21]}, "bert_text": "Treatment of tinnitus by intratympanic instillation of lignocaine (<e1> lidocaine </e1> <e2> tinnitus </e2> by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6425": {"data": {"text": "We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.", "entity1": "METH", "entity2": "neurotoxicity", "span1": [71, 75], "span2": [76, 89]}, "bert_text": "We conclude from these studies that CX3CR1 signaling does not modulate <e1> METH </e1> <e2> neurotoxicity </e2> or microglial activation.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"6426": {"data": {"text": "Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).\n", "entity1": "8-aminoquinoline", "entity2": "Toxicity", "span1": [59, 75], "span2": [0, 8]}, "bert_text": "Toxicity in rhesus monkeys following administration of the <e1> 8-aminoquinoline </e1> <e2> Toxicity </e2> in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6427": {"data": {"text": "Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).\n", "entity1": "8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline", "entity2": "Toxicity", "span1": [76, 152], "span2": [0, 8]}, "bert_text": "Toxicity in rhesus monkeys following administration of the 8-aminoquinoline <e1> 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline </e1> <e2> Toxicity </e2> in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6428": {"data": {"text": "Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).\n", "entity1": "WR242511", "entity2": "Toxicity", "span1": [154, 162], "span2": [0, 8]}, "bert_text": "Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (<e1> WR242511 </e1> <e2> Toxicity </e2> in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6429": {"data": {"text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.", "entity1": "L-dopa", "entity2": "parkinsonian", "span1": [220, 226], "span2": [195, 207]}, "bert_text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on <e1> L-dopa </e1> <e2> parkinsonian </e2> patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6430": {"data": {"text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.", "entity1": "L-dopa", "entity2": "dyskinesia", "span1": [220, 226], "span2": [276, 286]}, "bert_text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on <e1> L-dopa </e1> medication, the first one without L-dopa induced <e2> dyskinesia </e2> (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6431": {"data": {"text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.", "entity1": "L-dopa", "entity2": "dyskinesia", "span1": [220, 226], "span2": [334, 344]}, "bert_text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on <e1> L-dopa </e1> medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose <e2> dyskinesia </e2> (n = 15), and of a group of 14 normal subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6432": {"data": {"text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.", "entity1": "L-dopa", "entity2": "parkinsonian", "span1": [261, 267], "span2": [195, 207]}, "bert_text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without <e1> L-dopa </e1> <e2> parkinsonian </e2> patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6433": {"data": {"text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.", "entity1": "L-dopa", "entity2": "dyskinesia", "span1": [261, 267], "span2": [276, 286]}, "bert_text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without <e1> L-dopa </e1> induced <e2> dyskinesia </e2> (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6434": {"data": {"text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.", "entity1": "L-dopa", "entity2": "dyskinesia", "span1": [261, 267], "span2": [334, 344]}, "bert_text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without <e1> L-dopa </e1> induced dyskinesia (n = 23) and the other with moderate peak-dose <e2> dyskinesia </e2> (n = 15), and of a group of 14 normal subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6435": {"data": {"text": "A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.", "entity1": "isoniazid", "entity2": "behavioral deterioration", "span1": [147, 156], "span2": [22, 46]}, "bert_text": "A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of <e1> isoniazid </e1> <e2> behavioral deterioration </e2>, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6436": {"data": {"text": "A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.", "entity1": "isoniazid", "entity2": "irritability", "span1": [147, 156], "span2": [67, 79]}, "bert_text": "A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of <e1> isoniazid </e1> <e2> irritability </e2>, and sleeping difficulties after the therapeutic administration of isoniazid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6437": {"data": {"text": "A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.", "entity1": "isoniazid", "entity2": "hyperkinesis", "span1": [147, 156], "span2": [53, 65]}, "bert_text": "A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of <e1> isoniazid </e1> <e2> hyperkinesis </e2>, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6438": {"data": {"text": "A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.", "entity1": "isoniazid", "entity2": "sleeping difficulties", "span1": [147, 156], "span2": [85, 106]}, "bert_text": "A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of <e1> isoniazid </e1> <e2> sleeping difficulties </e2> after the therapeutic administration of isoniazid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6439": {"data": {"text": "In future, this form of therapy can offer a safe alternative in the treatment of cyclophosphamide-induced hemorrhagic cystitis.", "entity1": "cyclophosphamide", "entity2": "hemorrhagic cystitis", "span1": [81, 97], "span2": [106, 126]}, "bert_text": "In future, this form of therapy can offer a safe alternative in the treatment of <e1> cyclophosphamide </e1>-induced <e2> hemorrhagic cystitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6440": {"data": {"text": "A history of angioedema secondary to lisinopril therapy was elicited.", "entity1": "lisinopril", "entity2": "angioedema", "span1": [37, 47], "span2": [13, 23]}, "bert_text": "A history of angioedema secondary to <e1> lisinopril </e1> <e2> angioedema </e2> secondary to lisinopril therapy was elicited.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6441": {"data": {"text": "Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.\n", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic syndrome", "span1": [68, 93], "span2": [102, 120]}, "bert_text": "Increased expression and apical targeting of renal ENaC subunits in <e1> puromycin aminonucleoside </e1>-induced <e2> nephrotic syndrome </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6442": {"data": {"text": "Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.", "entity1": "KF17837", "entity2": "cataleptic", "span1": [23, 30], "span2": [88, 98]}, "bert_text": "Oral administration of <e1> KF17837 </e1> (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the <e2> cataleptic </e2> responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6443": {"data": {"text": "Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.", "entity1": "adenosine", "entity2": "cataleptic", "span1": [165, 174], "span2": [88, 98]}, "bert_text": "Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an <e1> adenosine </e1> <e2> cataleptic </e2> responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6444": {"data": {"text": "Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.", "entity1": "CGS 21680", "entity2": "cataleptic", "span1": [197, 206], "span2": [88, 98]}, "bert_text": "Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, <e1> CGS 21680 </e1> <e2> cataleptic </e2> responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6445": {"data": {"text": "The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.", "entity1": "histamine", "entity2": "catalepsy", "span1": [54, 63], "span2": [109, 118]}, "bert_text": "The present study was designed to study the effect of <e1> histamine </e1> H(3)-receptor ligands on neuroleptic-induced <e2> catalepsy </e2>, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6446": {"data": {"text": "The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [120, 131], "span2": [109, 118]}, "bert_text": "The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, <e1> apomorphine </e1> <e2> catalepsy </e2>, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6447": {"data": {"text": "The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.", "entity1": "amphetamine", "entity2": "catalepsy", "span1": [162, 173], "span2": [109, 118]}, "bert_text": "The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and <e1> amphetamine </e1> <e2> catalepsy </e2>, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6448": {"data": {"text": "Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.", "entity1": "CSA", "entity2": "nephrotoxicity", "span1": [36, 39], "span2": [10, 24]}, "bert_text": "Thus, the nephrotoxicity induced by <e1> CSA </e1> <e2> nephrotoxicity </e2> induced by CSA has a different pathogenetic mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6449": {"data": {"text": "Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.\nRabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.", "entity1": "risperidone", "entity2": "Withdrawal-emergent rabbit syndrome", "span1": [61, 72], "span2": [0, 35]}, "bert_text": "Withdrawal-emergent rabbit syndrome during dose reduction of <e1> risperidone </e1> <e2> Withdrawal-emergent rabbit syndrome </e2> during dose reduction of risperidone.\nRabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6450": {"data": {"text": "Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.\nRabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.", "entity1": "risperidone", "entity2": "Rabbit syndrome", "span1": [61, 72], "span2": [74, 89]}, "bert_text": "Withdrawal-emergent rabbit syndrome during dose reduction of <e1> risperidone </e1>.\n<e2> Rabbit syndrome </e2> (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6451": {"data": {"text": "Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.\nRabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.", "entity1": "risperidone", "entity2": "RS", "span1": [61, 72], "span2": [91, 93]}, "bert_text": "Withdrawal-emergent rabbit syndrome during dose reduction of <e1> risperidone </e1>.\nRabbit syndrome (<e2> RS </e2>) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6452": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "CsA", "entity2": "nephrotoxicity", "span1": [40, 43], "span2": [51, 65]}, "bert_text": "The indications for switch were chronic <e1> CsA </e1> or Tac <e2> nephrotoxicity </e2> (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6453": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "CsA", "entity2": "toxicity", "span1": [40, 43], "span2": [89, 97]}, "bert_text": "The indications for switch were chronic <e1> CsA </e1> or Tac nephrotoxicity (12), acute CsA or Tac <e2> toxicity </e2> (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6454": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "CsA", "entity2": "lymphoproliferative disorder", "span1": [40, 43], "span2": [149, 177]}, "bert_text": "The indications for switch were chronic <e1> CsA </e1> or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant <e2> lymphoproliferative disorder </e2> (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6455": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "CsA", "entity2": "PTLD", "span1": [40, 43], "span2": [179, 183]}, "bert_text": "The indications for switch were chronic <e1> CsA </e1> or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (<e2> PTLD </e2>) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6456": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "CsA", "entity2": "hepatotoxicity", "span1": [40, 43], "span2": [207, 221]}, "bert_text": "The indications for switch were chronic <e1> CsA </e1> or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and <e2> hepatotoxicity </e2> in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6457": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "CsA", "entity2": "nephrotoxicity", "span1": [78, 81], "span2": [51, 65]}, "bert_text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute <e1> CsA </e1> <e2> nephrotoxicity </e2> (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6458": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "CsA", "entity2": "toxicity", "span1": [78, 81], "span2": [89, 97]}, "bert_text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute <e1> CsA </e1> or Tac <e2> toxicity </e2> (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6459": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "CsA", "entity2": "lymphoproliferative disorder", "span1": [78, 81], "span2": [149, 177]}, "bert_text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute <e1> CsA </e1> or Tac toxicity (3), severe facial dysmorphism (2), posttransplant <e2> lymphoproliferative disorder </e2> (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6460": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "CsA", "entity2": "PTLD", "span1": [78, 81], "span2": [179, 183]}, "bert_text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute <e1> CsA </e1> or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (<e2> PTLD </e2>) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6461": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "CsA", "entity2": "hepatotoxicity", "span1": [78, 81], "span2": [207, 221]}, "bert_text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute <e1> CsA </e1> or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and <e2> hepatotoxicity </e2> in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6462": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "Tac", "entity2": "nephrotoxicity", "span1": [47, 50], "span2": [51, 65]}, "bert_text": "The indications for switch were chronic CsA or <e1> Tac </e1> <e2> nephrotoxicity </e2> (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6463": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "Tac", "entity2": "toxicity", "span1": [47, 50], "span2": [89, 97]}, "bert_text": "The indications for switch were chronic CsA or <e1> Tac </e1> nephrotoxicity (12), acute CsA or Tac <e2> toxicity </e2> (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6464": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "Tac", "entity2": "lymphoproliferative disorder", "span1": [47, 50], "span2": [149, 177]}, "bert_text": "The indications for switch were chronic CsA or <e1> Tac </e1> nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant <e2> lymphoproliferative disorder </e2> (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6465": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "Tac", "entity2": "PTLD", "span1": [47, 50], "span2": [179, 183]}, "bert_text": "The indications for switch were chronic CsA or <e1> Tac </e1> nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (<e2> PTLD </e2>) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6466": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "Tac", "entity2": "hepatotoxicity", "span1": [47, 50], "span2": [207, 221]}, "bert_text": "The indications for switch were chronic CsA or <e1> Tac </e1> nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and <e2> hepatotoxicity </e2> in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6467": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "Tac", "entity2": "nephrotoxicity", "span1": [85, 88], "span2": [51, 65]}, "bert_text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or <e1> Tac </e1> <e2> nephrotoxicity </e2> (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6468": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "Tac", "entity2": "toxicity", "span1": [85, 88], "span2": [89, 97]}, "bert_text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or <e1> Tac </e1> <e2> toxicity </e2> (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6469": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "Tac", "entity2": "lymphoproliferative disorder", "span1": [85, 88], "span2": [149, 177]}, "bert_text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or <e1> Tac </e1> toxicity (3), severe facial dysmorphism (2), posttransplant <e2> lymphoproliferative disorder </e2> (PTLD) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6470": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "Tac", "entity2": "PTLD", "span1": [85, 88], "span2": [179, 183]}, "bert_text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or <e1> Tac </e1> toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (<e2> PTLD </e2>) in remission (2), and hepatotoxicity in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6471": {"data": {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity1": "Tac", "entity2": "hepatotoxicity", "span1": [85, 88], "span2": [207, 221]}, "bert_text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or <e1> Tac </e1> toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and <e2> hepatotoxicity </e2> in 1.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6472": {"data": {"text": "Thus, PARP activation contributes to the cardiotoxicity of DOX.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [59, 62], "span2": [41, 55]}, "bert_text": "Thus, PARP activation contributes to the cardiotoxicity of <e1> DOX </e1> <e2> cardiotoxicity </e2> of DOX.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6473": {"data": {"text": "The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.", "entity1": "sodium", "entity2": "proteinuria", "span1": [28, 34], "span2": [83, 94]}, "bert_text": "The time courses of urinary <e1> sodium </e1> excretion, plasma aldosterone concentration and <e2> proteinuria </e2> were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6474": {"data": {"text": "The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.", "entity1": "aldosterone", "entity2": "proteinuria", "span1": [53, 64], "span2": [83, 94]}, "bert_text": "The time courses of urinary sodium excretion, plasma <e1> aldosterone </e1> concentration and <e2> proteinuria </e2> were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6475": {"data": {"text": "The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.", "entity1": "PAN", "entity2": "proteinuria", "span1": [173, 176], "span2": [83, 94]}, "bert_text": "The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either <e1> PAN </e1> <e2> proteinuria </e2> were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6476": {"data": {"text": "Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.", "entity1": "Octreotide", "entity2": "acromegaly", "span1": [0, 10], "span2": [39, 49]}, "bert_text": "<e1> Octreotide </e1>, an effective treatment for <e2> acromegaly </e2>, induces gall bladder stones in 13-60% of patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6477": {"data": {"text": "Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.", "entity1": "Octreotide", "entity2": "gall bladder stones", "span1": [0, 10], "span2": [59, 78]}, "bert_text": "<e1> Octreotide </e1>, an effective treatment for acromegaly, induces <e2> gall bladder stones </e2> in 13-60% of patients.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6478": {"data": {"text": "There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.", "entity1": "cimetidine", "entity2": "dementia", "span1": [52, 62], "span2": [27, 35]}, "bert_text": "There was only one case of dementia possibly due to <e1> cimetidine </e1> <e2> dementia </e2> possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6479": {"data": {"text": "There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.", "entity1": "cimetidine", "entity2": "liver or kidney disease", "span1": [52, 62], "span2": [155, 178]}, "bert_text": "There was only one case of dementia possibly due to <e1> cimetidine </e1> (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without <e2> liver or kidney disease </e2> who had cimetidine levels above 1.25 microgram/ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6480": {"data": {"text": "There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.", "entity1": "cimetidine", "entity2": "dementia", "span1": [187, 197], "span2": [27, 35]}, "bert_text": "There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had <e1> cimetidine </e1> <e2> dementia </e2> possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6481": {"data": {"text": "There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.", "entity1": "cimetidine", "entity2": "liver or kidney disease", "span1": [187, 197], "span2": [155, 178]}, "bert_text": "There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had <e1> cimetidine </e1> <e2> liver or kidney disease </e2> who had cimetidine levels above 1.25 microgram/ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6482": {"data": {"text": "Rats were stratified into control groups and ADR-induced nephropathy groups.", "entity1": "ADR", "entity2": "nephropathy", "span1": [45, 48], "span2": [57, 68]}, "bert_text": "Rats were stratified into control groups and <e1> ADR </e1>-induced <e2> nephropathy </e2> groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6483": {"data": {"text": "KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).", "entity1": "KF17837", "entity2": "catalepsy", "span1": [0, 7], "span2": [25, 34]}, "bert_text": "<e1> KF17837 </e1> also reduced the <e2> catalepsy </e2> induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6484": {"data": {"text": "KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [46, 57], "span2": [25, 34]}, "bert_text": "KF17837 also reduced the catalepsy induced by <e1> haloperidol </e1> <e2> catalepsy </e2> induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6485": {"data": {"text": "KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).", "entity1": "reserpine", "entity2": "catalepsy", "span1": [80, 89], "span2": [25, 34]}, "bert_text": "KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by <e1> reserpine </e1> <e2> catalepsy </e2> induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6486": {"data": {"text": "Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.", "entity1": "Ketamine", "entity2": "hyperalgesia", "span1": [0, 8], "span2": [67, 79]}, "bert_text": "<e1> Ketamine </e1> reduced both the area of brush-evoked and punctate-evoked <e2> hyperalgesia </e2> significantly and it tended to reduce brush-evoked pain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6487": {"data": {"text": "Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.", "entity1": "Ketamine", "entity2": "pain", "span1": [0, 8], "span2": [131, 135]}, "bert_text": "<e1> Ketamine </e1> reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked <e2> pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6488": {"data": {"text": "Acute psychosis due to treatment with phenytoin in a nonepileptic patient.\n", "entity1": "phenytoin", "entity2": "psychosis", "span1": [38, 47], "span2": [6, 15]}, "bert_text": "Acute psychosis due to treatment with <e1> phenytoin </e1> <e2> psychosis </e2> due to treatment with phenytoin in a nonepileptic patient.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6489": {"data": {"text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "entity1": "calcium chloride", "entity2": "mydriasis", "span1": [20, 36], "span2": [123, 132]}, "bert_text": "It is apparent that <e1> calcium chloride </e1> can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as <e2> mydriasis </e2>, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6490": {"data": {"text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "entity1": "calcium chloride", "entity2": "tremor", "span1": [20, 36], "span2": [134, 140]}, "bert_text": "It is apparent that <e1> calcium chloride </e1> can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, <e2> tremor </e2> and clonic-tonic convulsions caused by carbachol and eserine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6491": {"data": {"text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "entity1": "calcium chloride", "entity2": "clonic-tonic convulsions", "span1": [20, 36], "span2": [145, 169]}, "bert_text": "It is apparent that <e1> calcium chloride </e1> can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and <e2> clonic-tonic convulsions </e2> caused by carbachol and eserine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6492": {"data": {"text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "entity1": "carbachol", "entity2": "mydriasis", "span1": [180, 189], "span2": [123, 132]}, "bert_text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by <e1> carbachol </e1> <e2> mydriasis </e2>, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6493": {"data": {"text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "entity1": "carbachol", "entity2": "tremor", "span1": [180, 189], "span2": [134, 140]}, "bert_text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by <e1> carbachol </e1> <e2> tremor </e2> and clonic-tonic convulsions caused by carbachol and eserine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6494": {"data": {"text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "entity1": "carbachol", "entity2": "clonic-tonic convulsions", "span1": [180, 189], "span2": [145, 169]}, "bert_text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by <e1> carbachol </e1> <e2> clonic-tonic convulsions </e2> caused by carbachol and eserine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6495": {"data": {"text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "entity1": "eserine", "entity2": "mydriasis", "span1": [194, 201], "span2": [123, 132]}, "bert_text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and <e1> eserine </e1> <e2> mydriasis </e2>, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6496": {"data": {"text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "entity1": "eserine", "entity2": "tremor", "span1": [194, 201], "span2": [134, 140]}, "bert_text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and <e1> eserine </e1> <e2> tremor </e2> and clonic-tonic convulsions caused by carbachol and eserine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6497": {"data": {"text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "entity1": "eserine", "entity2": "clonic-tonic convulsions", "span1": [194, 201], "span2": [145, 169]}, "bert_text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and <e1> eserine </e1> <e2> clonic-tonic convulsions </e2> caused by carbachol and eserine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6498": {"data": {"text": "Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.", "entity1": "Baclofen", "entity2": "dystonic", "span1": [0, 8], "span2": [54, 62]}, "bert_text": "<e1> Baclofen </e1> was also useful in one monkey against a more <e2> dystonic </e2> form of dyskinesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6499": {"data": {"text": "Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.", "entity1": "Baclofen", "entity2": "dyskinesia", "span1": [0, 8], "span2": [71, 81]}, "bert_text": "<e1> Baclofen </e1> was also useful in one monkey against a more dystonic form of <e2> dyskinesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6500": {"data": {"text": "Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.", "entity1": "Mellaril", "entity2": "ventricular tachycardia", "span1": [53, 61], "span2": [122, 145]}, "bert_text": "Although most patients were receiving several drugs, <e1> Mellaril </e1> (thioridazine) appeared to be responsible for five cases of <e2> ventricular tachycardia </e2>, one of which was fatal in a 35 year old woman.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6501": {"data": {"text": "Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.", "entity1": "thioridazine", "entity2": "ventricular tachycardia", "span1": [63, 75], "span2": [122, 145]}, "bert_text": "Although most patients were receiving several drugs, Mellaril (<e1> thioridazine </e1>) appeared to be responsible for five cases of <e2> ventricular tachycardia </e2>, one of which was fatal in a 35 year old woman.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6502": {"data": {"text": "Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.", "entity1": "quinine", "entity2": "nocturnal leg cramps", "span1": [132, 139], "span2": [75, 95]}, "bert_text": "Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, <e1> quinine </e1> <e2> nocturnal leg cramps </e2> due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6503": {"data": {"text": "RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.", "entity1": "NaHCO3", "entity2": "hypotension", "span1": [9, 15], "span2": [41, 52]}, "bert_text": "RESULTS: <e1> NaHCO3 </e1> briefly (5 min) reversed <e2> hypotension </e2> and QRS prolongation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6504": {"data": {"text": "An evaluation of amikacin nephrotoxicity in the hematology/oncology population.\n", "entity1": "amikacin", "entity2": "nephrotoxicity", "span1": [17, 25], "span2": [26, 40]}, "bert_text": "An evaluation of <e1> amikacin </e1> <e2> nephrotoxicity </e2> in the hematology/oncology population.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6505": {"data": {"text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "entity1": "vitamin D", "entity2": "artery calcification", "span1": [49, 58], "span2": [67, 87]}, "bert_text": "There was a close parallel between the effect of <e1> vitamin D </e1> dose on <e2> artery calcification </e2> and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6506": {"data": {"text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "entity1": "vitamin D", "entity2": "artery calcification", "span1": [49, 58], "span2": [197, 217]}, "bert_text": "There was a close parallel between the effect of <e1> vitamin D </e1> dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce <e2> artery calcification </e2> through its effect on serum calcium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6507": {"data": {"text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "entity1": "vitamin D", "entity2": "artery calcification", "span1": [106, 115], "span2": [67, 87]}, "bert_text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of <e1> vitamin D </e1> <e2> artery calcification </e2> and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6508": {"data": {"text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "entity1": "vitamin D", "entity2": "artery calcification", "span1": [106, 115], "span2": [197, 217]}, "bert_text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of <e1> vitamin D </e1> dose on the elevation of serum calcium, which suggests that vitamin D may induce <e2> artery calcification </e2> through its effect on serum calcium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6509": {"data": {"text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "entity1": "vitamin D", "entity2": "artery calcification", "span1": [176, 185], "span2": [67, 87]}, "bert_text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that <e1> vitamin D </e1> <e2> artery calcification </e2> and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6510": {"data": {"text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "entity1": "vitamin D", "entity2": "artery calcification", "span1": [176, 185], "span2": [197, 217]}, "bert_text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that <e1> vitamin D </e1> may induce <e2> artery calcification </e2> through its effect on serum calcium.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6511": {"data": {"text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "entity1": "calcium", "entity2": "artery calcification", "span1": [147, 154], "span2": [67, 87]}, "bert_text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum <e1> calcium </e1> <e2> artery calcification </e2> and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6512": {"data": {"text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "entity1": "calcium", "entity2": "artery calcification", "span1": [147, 154], "span2": [197, 217]}, "bert_text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum <e1> calcium </e1>, which suggests that vitamin D may induce <e2> artery calcification </e2> through its effect on serum calcium.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6513": {"data": {"text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "entity1": "calcium", "entity2": "artery calcification", "span1": [246, 253], "span2": [67, 87]}, "bert_text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum <e1> calcium </e1> <e2> artery calcification </e2> and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6514": {"data": {"text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.", "entity1": "calcium", "entity2": "artery calcification", "span1": [246, 253], "span2": [197, 217]}, "bert_text": "There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum <e1> calcium </e1> <e2> artery calcification </e2> through its effect on serum calcium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6515": {"data": {"text": "Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.\n", "entity1": "methylprednisolone", "entity2": "arthralgia", "span1": [9, 27], "span2": [49, 59]}, "bert_text": "Value of <e1> methylprednisolone </e1> in prevention of the <e2> arthralgia </e2>-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6516": {"data": {"text": "Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.\n", "entity1": "methylprednisolone", "entity2": "myalgia syndrome", "span1": [9, 27], "span2": [60, 76]}, "bert_text": "Value of <e1> methylprednisolone </e1> in prevention of the arthralgia-<e2> myalgia syndrome </e2> associated with the total dose infusion of iron dextran: a double blind randomized trial.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6517": {"data": {"text": "Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.\n", "entity1": "iron dextran", "entity2": "arthralgia", "span1": [120, 132], "span2": [49, 59]}, "bert_text": "Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of <e1> iron dextran </e1> <e2> arthralgia </e2>-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"6518": {"data": {"text": "Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.\n", "entity1": "iron dextran", "entity2": "myalgia syndrome", "span1": [120, 132], "span2": [60, 76]}, "bert_text": "Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of <e1> iron dextran </e1> <e2> myalgia syndrome </e2> associated with the total dose infusion of iron dextran: a double blind randomized trial.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6519": {"data": {"text": "Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.", "entity1": "calcium", "entity2": "migraine", "span1": [22, 29], "span2": [132, 140]}, "bert_text": "Despite the advent of <e1> calcium </e1> channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in <e2> migraine </e2> therapy, so that the danger of St. Anthony's fire persists.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6520": {"data": {"text": "Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.", "entity1": "ergot", "entity2": "migraine", "span1": [80, 85], "span2": [132, 140]}, "bert_text": "Despite the advent of calcium channel blockers and beta-adrenergic antagonists, <e1> ergot </e1> preparations continue to play a major role in <e2> migraine </e2> therapy, so that the danger of St. Anthony's fire persists.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6521": {"data": {"text": "MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.", "entity1": "CC", "entity2": "retinal vein occlusion", "span1": [87, 89], "span2": [33, 55]}, "bert_text": "MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with <e1> CC </e1> <e2> retinal vein occlusion </e2> after ovulation induction with CC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"6522": {"data": {"text": "However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.", "entity1": "lometrexol", "entity2": "toxicities", "span1": [45, 55], "span2": [121, 131]}, "bert_text": "However, the initial clinical development of <e1> lometrexol </e1> was curtailed because of severe and cumulative antiproliferative <e2> toxicities </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6523": {"data": {"text": "Acute cholestatic hepatitis after exposure to isoflurane.\n", "entity1": "isoflurane", "entity2": "cholestatic hepatitis", "span1": [46, 56], "span2": [6, 27]}, "bert_text": "Acute cholestatic hepatitis after exposure to <e1> isoflurane </e1> <e2> cholestatic hepatitis </e2> after exposure to isoflurane.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6524": {"data": {"text": "Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.\n", "entity1": "Isoproterenol", "entity2": "myocardial injury", "span1": [0, 13], "span2": [81, 98]}, "bert_text": "<e1> Isoproterenol </e1> induces primary loss of dystrophin in rat hearts: correlation with <e2> myocardial injury </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6525": {"data": {"text": "Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/-", "entity1": "isoflurane", "entity2": "hypotension", "span1": [94, 104], "span2": [11, 22]}, "bert_text": "Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of <e1> isoflurane </e1> <e2> hypotension </e2> to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6526": {"data": {"text": "Time course of lipid peroxidation in puromycin aminonucleoside-induced nephropathy.\n", "entity1": "puromycin aminonucleoside", "entity2": "nephropathy", "span1": [37, 62], "span2": [71, 82]}, "bert_text": "Time course of lipid peroxidation in <e1> puromycin aminonucleoside </e1>-induced <e2> nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6527": {"data": {"text": "Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.", "entity1": "Methimazole", "entity2": "cholestasis", "span1": [0, 11], "span2": [20, 31]}, "bert_text": "<e1> Methimazole </e1>-induced <e2> cholestasis </e2> was diagnosed, and propranolol therapy was resumed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6528": {"data": {"text": "Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.", "entity1": "propranolol", "entity2": "cholestasis", "span1": [51, 62], "span2": [20, 31]}, "bert_text": "Methimazole-induced cholestasis was diagnosed, and <e1> propranolol </e1> <e2> cholestasis </e2> was diagnosed, and propranolol therapy was resumed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6529": {"data": {"text": "Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).", "entity1": "rizatriptan", "entity2": "pain", "span1": [30, 41], "span2": [47, 51]}, "bert_text": "Almost 36% of patients taking <e1> rizatriptan </e1> were <e2> pain </e2> free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6530": {"data": {"text": "Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).", "entity1": "ergotamine", "entity2": "pain", "span1": [164, 174], "span2": [47, 51]}, "bert_text": "Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on <e1> ergotamine </e1> <e2> pain </e2> free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6531": {"data": {"text": "Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).", "entity1": "caffeine", "entity2": "pain", "span1": [175, 183], "span2": [47, 51]}, "bert_text": "Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/<e1> caffeine </e1> <e2> pain </e2> free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6532": {"data": {"text": "From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.", "entity1": "mitoxantrone", "entity2": "breast cancer", "span1": [124, 136], "span2": [107, 120]}, "bert_text": "From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by <e1> mitoxantrone </e1> <e2> breast cancer </e2> by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6533": {"data": {"text": "From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.", "entity1": "5-FU", "entity2": "breast cancer", "span1": [184, 188], "span2": [107, 120]}, "bert_text": "From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of <e1> 5-FU </e1> <e2> breast cancer </e2> by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6534": {"data": {"text": "From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.", "entity1": "leucovorin", "entity2": "breast cancer", "span1": [216, 226], "span2": [107, 120]}, "bert_text": "From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with <e1> leucovorin </e1> <e2> breast cancer </e2> by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6535": {"data": {"text": "METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).", "entity1": "nimodipine", "entity2": "ischemic stroke", "span1": [156, 166], "span2": [47, 62]}, "bert_text": "METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) <e1> nimodipine </e1> <e2> ischemic stroke </e2> (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6536": {"data": {"text": "METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).", "entity1": "nimodipine", "entity2": "ischemic stroke", "span1": [198, 208], "span2": [47, 62]}, "bert_text": "METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) <e1> nimodipine </e1> <e2> ischemic stroke </e2> (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6537": {"data": {"text": "We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.", "entity1": "creatinine", "entity2": "hypertension", "span1": [146, 156], "span2": [211, 223]}, "bert_text": "We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline <e1> creatinine </e1>, low systolic blood pressure (<100 mm Hg), history of <e2> hypertension </e2>, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6538": {"data": {"text": "We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.", "entity1": "creatinine", "entity2": "diabetes", "span1": [146, 156], "span2": [225, 233]}, "bert_text": "We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline <e1> creatinine </e1>, low systolic blood pressure (<100 mm Hg), history of hypertension, <e2> diabetes </e2>, and use of antiplatelet, diuretic, and beta-blocker therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6539": {"data": {"text": "We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.", "entity1": "diuretic", "entity2": "hypertension", "span1": [260, 268], "span2": [211, 223]}, "bert_text": "We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, <e1> diuretic </e1> <e2> hypertension </e2>, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6540": {"data": {"text": "We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.", "entity1": "diuretic", "entity2": "diabetes", "span1": [260, 268], "span2": [225, 233]}, "bert_text": "We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, <e1> diuretic </e1> <e2> diabetes </e2>, and use of antiplatelet, diuretic, and beta-blocker therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6541": {"data": {"text": "RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.", "entity1": "CC", "entity2": "retinal vein occlusion", "span1": [103, 105], "span2": [57, 79]}, "bert_text": "RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of <e1> CC </e1> <e2> retinal vein occlusion </e2> after eight courses of CC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6542": {"data": {"text": "CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.", "entity1": "Salbutamol", "entity2": "SIAT", "span1": [12, 22], "span2": [67, 71]}, "bert_text": "CONCLUSION: <e1> Salbutamol </e1> is presented here as a possible trigger for <e2> SIAT </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6543": {"data": {"text": "Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.", "entity1": "angiotensin", "entity2": "hypotension", "span1": [32, 43], "span2": [114, 125]}, "bert_text": "Adults chronically treated with <e1> angiotensin </e1> converting enzyme inhibitors may have a limited ability to respond to <e2> hypotension </e2> when the sympathetic response is simultaneously blocked.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6544": {"data": {"text": "The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.", "entity1": "OC", "entity2": "VTE", "span1": [68, 70], "span2": [27, 30]}, "bert_text": "The adjusted rate ratio of VTE for repeat users of third generation <e1> OC </e1> <e2> VTE </e2> for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6545": {"data": {"text": "An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.", "entity1": "propranolol", "entity2": "Alzheimer", "span1": [78, 89], "span2": [30, 39]}, "bert_text": "An elderly woman developed an Alzheimer-like subacute dementia as a result of <e1> propranolol </e1> <e2> Alzheimer </e2>-like subacute dementia as a result of propranolol toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6546": {"data": {"text": "An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.", "entity1": "propranolol", "entity2": "dementia", "span1": [78, 89], "span2": [54, 62]}, "bert_text": "An elderly woman developed an Alzheimer-like subacute dementia as a result of <e1> propranolol </e1> <e2> dementia </e2> as a result of propranolol toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6547": {"data": {"text": "An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.", "entity1": "propranolol", "entity2": "toxicity", "span1": [78, 89], "span2": [90, 98]}, "bert_text": "An elderly woman developed an Alzheimer-like subacute dementia as a result of <e1> propranolol </e1> <e2> toxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6548": {"data": {"text": "Phenobarbital-induced dyskinesia in a neurologically-impaired child.\n", "entity1": "Phenobarbital", "entity2": "dyskinesia", "span1": [0, 13], "span2": [22, 32]}, "bert_text": "<e1> Phenobarbital </e1>-induced <e2> dyskinesia </e2> in a neurologically-impaired child.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6549": {"data": {"text": "An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.", "entity1": "halogenated hydroxyquinolines", "entity2": "neurotoxic", "span1": [74, 103], "span2": [50, 60]}, "bert_text": "An analysis is presented of 220 cases of possible neurotoxic reactions to <e1> halogenated hydroxyquinolines </e1> <e2> neurotoxic </e2> reactions to halogenated hydroxyquinolines reported from outside Japan.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6550": {"data": {"text": "Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.", "entity1": "PJ34", "entity2": "cardiac dysfunction", "span1": [136, 140], "span2": [200, 219]}, "bert_text": "Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor <e1> PJ34 </e1>, we now demonstrate the role of PARP in the development of <e2> cardiac dysfunction </e2> induced by DOX.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6551": {"data": {"text": "Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.", "entity1": "DOX", "entity2": "cardiac dysfunction", "span1": [231, 234], "span2": [200, 219]}, "bert_text": "Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by <e1> DOX </e1> <e2> cardiac dysfunction </e2> induced by DOX.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6552": {"data": {"text": "Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.", "entity1": "Ezetimibe", "entity2": "hepatotoxicity", "span1": [0, 9], "span2": [258, 272]}, "bert_text": "<e1> Ezetimibe </e1> undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent <e2> hepatotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6553": {"data": {"text": "Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.", "entity1": "uridine diphosphate", "entity2": "hepatotoxicity", "span1": [49, 68], "span2": [258, 272]}, "bert_text": "Ezetimibe undergoes extensive glucuronidation by <e1> uridine diphosphate </e1> glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent <e2> hepatotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6554": {"data": {"text": "Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.", "entity1": "simvastatin hydroxy acid", "entity2": "hepatotoxicity", "span1": [173, 197], "span2": [258, 272]}, "bert_text": "Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of <e1> simvastatin hydroxy acid </e1>, resulting in increased simvastatin exposure and subsequent <e2> hepatotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6555": {"data": {"text": "Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.", "entity1": "simvastatin", "entity2": "hepatotoxicity", "span1": [222, 233], "span2": [258, 272]}, "bert_text": "Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased <e1> simvastatin </e1> exposure and subsequent <e2> hepatotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6556": {"data": {"text": "Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.\n", "entity1": "penicillin", "entity2": "epileptiform activity", "span1": [38, 48], "span2": [57, 78]}, "bert_text": "Detailed spectral profile analysis of <e1> penicillin </e1>-induced <e2> epileptiform activity </e2> in anesthetized rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6557": {"data": {"text": "Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats. METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats.", "entity1": "adriamycin", "entity2": "renal damage", "span1": [132, 142], "span2": [86, 98]}, "bert_text": "Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of <e1> adriamycin </e1> <e2> renal damage </e2> induced by a single injection of adriamycin in rats. METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6558": {"data": {"text": "Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats. METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats.", "entity1": "Hip-His-Leu", "entity2": "renal damage", "span1": [181, 192], "span2": [86, 98]}, "bert_text": "Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats. METHODS: Renal ACE activity (<e1> Hip-His-Leu </e1> <e2> renal damage </e2> induced by a single injection of adriamycin in rats. METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6559": {"data": {"text": "The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.", "entity1": "cocaine", "entity2": "hemorrhagic", "span1": [19, 26], "span2": [52, 63]}, "bert_text": "The association of <e1> cocaine </e1> and amphetamine use with <e2> hemorrhagic </e2> and ischemic stroke is based almost solely on data from case series.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6560": {"data": {"text": "The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.", "entity1": "cocaine", "entity2": "ischemic stroke", "span1": [19, 26], "span2": [68, 83]}, "bert_text": "The association of <e1> cocaine </e1> and amphetamine use with hemorrhagic and <e2> ischemic stroke </e2> is based almost solely on data from case series.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6561": {"data": {"text": "The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.", "entity1": "amphetamine", "entity2": "hemorrhagic", "span1": [31, 42], "span2": [52, 63]}, "bert_text": "The association of cocaine and <e1> amphetamine </e1> use with <e2> hemorrhagic </e2> and ischemic stroke is based almost solely on data from case series.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6562": {"data": {"text": "The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.", "entity1": "amphetamine", "entity2": "ischemic stroke", "span1": [31, 42], "span2": [68, 83]}, "bert_text": "The association of cocaine and <e1> amphetamine </e1> use with hemorrhagic and <e2> ischemic stroke </e2> is based almost solely on data from case series.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6563": {"data": {"text": "Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.", "entity1": "Levodopa", "entity2": "dyskinesias", "span1": [0, 8], "span2": [17, 28]}, "bert_text": "<e1> Levodopa </e1>-induced <e2> dyskinesias </e2> (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6564": {"data": {"text": "Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.", "entity1": "Levodopa", "entity2": "LIDs", "span1": [0, 8], "span2": [30, 34]}, "bert_text": "<e1> Levodopa </e1>-induced dyskinesias (<e2> LIDs </e2>) present a major problem for the long-term management of Parkinson's disease (PD) patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6565": {"data": {"text": "Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.", "entity1": "Levodopa", "entity2": "Parkinson's disease", "span1": [0, 8], "span2": [92, 111]}, "bert_text": "<e1> Levodopa </e1>-induced dyskinesias (LIDs) present a major problem for the long-term management of <e2> Parkinson's disease </e2> (PD) patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6566": {"data": {"text": "Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.", "entity1": "Levodopa", "entity2": "PD", "span1": [0, 8], "span2": [113, 115]}, "bert_text": "<e1> Levodopa </e1>-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (<e2> PD </e2>) patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6567": {"data": {"text": "Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.", "entity1": "AZT", "entity2": "myelodysplastic syndrome", "span1": [16, 19], "span2": [167, 191]}, "bert_text": "Above mentioned <e1> AZT </e1> incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the <e2> myelodysplastic syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6568": {"data": {"text": "This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.", "entity1": "rizatriptan", "entity2": "migraine", "span1": [87, 98], "span2": [191, 199]}, "bert_text": "This randomized double- blind crossover outpatient study assessed the preference for 1 <e1> rizatriptan </e1> 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single <e2> migraine </e2> attack with each therapy.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6569": {"data": {"text": "This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.", "entity1": "ergotamine", "entity2": "migraine", "span1": [117, 127], "span2": [191, 199]}, "bert_text": "This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 <e1> ergotamine </e1> 1 mg/caffeine 100 mg tablets in 439 patients treating a single <e2> migraine </e2> attack with each therapy.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6570": {"data": {"text": "This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.", "entity1": "caffeine", "entity2": "migraine", "span1": [133, 141], "span2": [191, 199]}, "bert_text": "This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/<e1> caffeine </e1> 100 mg tablets in 439 patients treating a single <e2> migraine </e2> attack with each therapy.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6571": {"data": {"text": "In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.", "entity1": "sodium", "entity2": "nephrotic syndrome", "span1": [196, 202], "span2": [241, 259]}, "bert_text": "In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the <e1> sodium </e1> retention associated with PAN-induced <e2> nephrotic syndrome </e2>.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6572": {"data": {"text": "In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.", "entity1": "PAN", "entity2": "nephrotic syndrome", "span1": [229, 232], "span2": [241, 259]}, "bert_text": "In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with <e1> PAN </e1>-induced <e2> nephrotic syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"6573": {"data": {"text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.", "entity1": "doxorubicin", "entity2": "cardiac damage", "span1": [87, 98], "span2": [65, 79]}, "bert_text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to <e1> doxorubicin </e1> <e2> cardiac damage </e2> due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6574": {"data": {"text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.", "entity1": "doxorubicin", "entity2": "cancer", "span1": [87, 98], "span2": [218, 224]}, "bert_text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to <e1> doxorubicin </e1>, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood <e2> cancer </e2> treated with doxorubicin from healthy control subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6575": {"data": {"text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.", "entity1": "doxorubicin", "entity2": "cardiac damage", "span1": [238, 249], "span2": [65, 79]}, "bert_text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with <e1> doxorubicin </e1> <e2> cardiac damage </e2> due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6576": {"data": {"text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.", "entity1": "doxorubicin", "entity2": "cancer", "span1": [238, 249], "span2": [218, 224]}, "bert_text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with <e1> doxorubicin </e1> <e2> cancer </e2> treated with doxorubicin from healthy control subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6577": {"data": {"text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.", "entity1": "dobutamine", "entity2": "cardiac damage", "span1": [135, 145], "span2": [65, 79]}, "bert_text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using <e1> dobutamine </e1> <e2> cardiac damage </e2> due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6578": {"data": {"text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.", "entity1": "dobutamine", "entity2": "cancer", "span1": [135, 145], "span2": [218, 224]}, "bert_text": "To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using <e1> dobutamine </e1> infusion to differentiate asymptomatic long-term survivors of childhood <e2> cancer </e2> treated with doxorubicin from healthy control subjects.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6579": {"data": {"text": "The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.", "entity1": "mitomycin C", "entity2": "renal failure", "span1": [65, 76], "span2": [4, 17]}, "bert_text": "The renal failure usually develops about 8-10 mth after start of <e1> mitomycin C </e1> <e2> renal failure </e2> usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6580": {"data": {"text": "The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.", "entity1": "mitomycin C", "entity2": "renal failure", "span1": [65, 76], "span2": [131, 144]}, "bert_text": "The renal failure usually develops about 8-10 mth after start of <e1> mitomycin C </e1> treatment and the mortality is approximately 60% from <e2> renal failure </e2> or pulmonary edema.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6581": {"data": {"text": "The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.", "entity1": "mitomycin C", "entity2": "pulmonary edema", "span1": [65, 76], "span2": [148, 163]}, "bert_text": "The renal failure usually develops about 8-10 mth after start of <e1> mitomycin C </e1> treatment and the mortality is approximately 60% from renal failure or <e2> pulmonary edema </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6582": {"data": {"text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum. Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.", "entity1": "caffeine", "entity2": "toxicity", "span1": [114, 122], "span2": [460, 468]}, "bert_text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, <e1> caffeine </e1>, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum. Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS <e2> toxicity </e2> of caffeine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6583": {"data": {"text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum. Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.", "entity1": "caffeine", "entity2": "toxicity", "span1": [225, 233], "span2": [460, 468]}, "bert_text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of <e1> caffeine </e1> per mL of serum. Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS <e2> toxicity </e2> of caffeine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6584": {"data": {"text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum. Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.", "entity1": "caffeine", "entity2": "toxicity", "span1": [328, 336], "span2": [460, 468]}, "bert_text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum. Because salicylates have been reported to augment the stimulatory effects of <e1> caffeine </e1> on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS <e2> toxicity </e2> of caffeine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6585": {"data": {"text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum. Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.", "entity1": "caffeine", "entity2": "toxicity", "span1": [472, 480], "span2": [460, 468]}, "bert_text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum. Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of <e1> caffeine </e1> <e2> toxicity </e2> of caffeine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6586": {"data": {"text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum. Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.", "entity1": "acetaminophen", "entity2": "toxicity", "span1": [128, 141], "span2": [460, 468]}, "bert_text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and <e1> acetaminophen </e1> displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum. Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS <e2> toxicity </e2> of caffeine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6587": {"data": {"text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum. Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.", "entity1": "acetaminophen", "entity2": "toxicity", "span1": [411, 424], "span2": [460, 468]}, "bert_text": "A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum. Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of <e1> acetaminophen </e1> (52 micrograms/mL) reduced the CNS <e2> toxicity </e2> of caffeine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6588": {"data": {"text": "There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.", "entity1": "folate", "entity2": "toxicity", "span1": [83, 89], "span2": [49, 57]}, "bert_text": "There was no clear relationship between clinical toxicity and the extent of plasma <e1> folate </e1> <e2> toxicity </e2> and the extent of plasma folate elevation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6589": {"data": {"text": "Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.", "entity1": "glycopyrronium", "entity2": "bradycardias", "span1": [7, 21], "span2": [177, 189]}, "bert_text": "Use of <e1> glycopyrronium </e1> 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced <e2> bradycardias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6590": {"data": {"text": "Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.", "entity1": "edrophonium", "entity2": "bradycardias", "span1": [110, 121], "span2": [177, 189]}, "bert_text": "Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the <e1> edrophonium </e1>, was sufficient to minimize early, edrophonium-induced <e2> bradycardias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6591": {"data": {"text": "Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.", "entity1": "edrophonium", "entity2": "bradycardias", "span1": [157, 168], "span2": [177, 189]}, "bert_text": "Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, <e1> edrophonium </e1>-induced <e2> bradycardias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6592": {"data": {"text": "However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.", "entity1": "macrolide", "entity2": "hiccups", "span1": [9, 18], "span2": [75, 82]}, "bert_text": "However, <e1> macrolide </e1> antimicrobials have been reported to be associated with <e2> hiccups </e2> and vagal mechanism could explain the development of this side-effect.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6593": {"data": {"text": "There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.", "entity1": "MESNA", "entity2": "toxicity", "span1": [50, 55], "span2": [153, 161]}, "bert_text": "There were no appreciable differences between the <e1> MESNA </e1> series and the conventional prophylaxis series with respect to either haematological or systemic <e2> toxicity </e2> of the cytostatic treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6594": {"data": {"text": "Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.", "entity1": "pentamidine", "entity2": "Torsade de pointes", "span1": [74, 85], "span2": [0, 18]}, "bert_text": "Torsade de pointes occurred after an average of 10 days of treatment with <e1> pentamidine </e1> <e2> Torsade de pointes </e2> occurred after an average of 10 days of treatment with pentamidine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6595": {"data": {"text": "Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.", "entity1": "ciprofloxacin", "entity2": "cancer", "span1": [89, 102], "span2": [19, 25]}, "bert_text": "Five patients with cancer who developed acute renal failure that followed treatment with <e1> ciprofloxacin </e1> <e2> cancer </e2> who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6596": {"data": {"text": "Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.", "entity1": "ciprofloxacin", "entity2": "acute renal failure", "span1": [89, 102], "span2": [40, 59]}, "bert_text": "Five patients with cancer who developed acute renal failure that followed treatment with <e1> ciprofloxacin </e1> <e2> acute renal failure </e2> that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6597": {"data": {"text": "The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.", "entity1": "cocaine", "entity2": "stroke", "span1": [65, 72], "span2": [47, 53]}, "bert_text": "The limited number of epidemiologic studies of stroke and use of <e1> cocaine </e1> <e2> stroke </e2> and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6598": {"data": {"text": "The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.", "entity1": "amphetamine", "entity2": "stroke", "span1": [80, 91], "span2": [47, 53]}, "bert_text": "The limited number of epidemiologic studies of stroke and use of cocaine and/or <e1> amphetamine </e1> <e2> stroke </e2> and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6599": {"data": {"text": "We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.", "entity1": "caffeine", "entity2": "cardiac disease", "span1": [163, 171], "span2": [50, 65]}, "bert_text": "We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after <e1> caffeine </e1> <e2> cardiac disease </e2> or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"6600": {"data": {"text": "We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.", "entity1": "caffeine", "entity2": "arrhythmia", "span1": [163, 171], "span2": [69, 79]}, "bert_text": "We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after <e1> caffeine </e1> <e2> arrhythmia </e2> who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6601": {"data": {"text": "We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.", "entity1": "caffeine", "entity2": "ventricular tachycardia", "span1": [163, 171], "span2": [133, 156]}, "bert_text": "We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after <e1> caffeine </e1> <e2> ventricular tachycardia </e2> after caffeine administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6602": {"data": {"text": "Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.\n", "entity1": "Cocaine", "entity2": "learning impairments", "span1": [0, 7], "span2": [26, 46]}, "bert_text": "<e1> Cocaine </e1> causes memory and <e2> learning impairments </e2> in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6603": {"data": {"text": "Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.\n", "entity1": "topiramate", "entity2": "learning impairments", "span1": [134, 144], "span2": [26, 46]}, "bert_text": "Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by <e1> topiramate </e1> <e2> learning impairments </e2> in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6604": {"data": {"text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [20, 31], "span2": [75, 82]}, "bert_text": "Similarly, pre-test <e1> scopolamine </e1> partially reversed the scopolamine-induced <e2> amnesia </e2>, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6605": {"data": {"text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [20, 31], "span2": [178, 185]}, "bert_text": "Similarly, pre-test <e1> scopolamine </e1> partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6606": {"data": {"text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [55, 66], "span2": [75, 82]}, "bert_text": "Similarly, pre-test scopolamine partially reversed the <e1> scopolamine </e1>-induced <e2> amnesia </e2>, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6607": {"data": {"text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [55, 66], "span2": [178, 185]}, "bert_text": "Similarly, pre-test scopolamine partially reversed the <e1> scopolamine </e1>-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6608": {"data": {"text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "entity1": "cycloheximide", "entity2": "amnesia", "span1": [120, 133], "span2": [75, 82]}, "bert_text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test <e1> cycloheximide </e1> <e2> amnesia </e2>, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6609": {"data": {"text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "entity1": "cycloheximide", "entity2": "amnesia", "span1": [120, 133], "span2": [178, 185]}, "bert_text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test <e1> cycloheximide </e1> failed to reverse the cycloheximide-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6610": {"data": {"text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "entity1": "cycloheximide", "entity2": "amnesia", "span1": [156, 169], "span2": [75, 82]}, "bert_text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the <e1> cycloheximide </e1> <e2> amnesia </e2>, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6611": {"data": {"text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "entity1": "cycloheximide", "entity2": "amnesia", "span1": [156, 169], "span2": [178, 185]}, "bert_text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the <e1> cycloheximide </e1>-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6612": {"data": {"text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "entity1": "acetaminophen", "entity2": "convulsions", "span1": [57, 70], "span2": [190, 201]}, "bert_text": "Studies in DBA/2J mice showed that: 1) pretreatment with <e1> acetaminophen </e1> (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal <e2> convulsions </e2> by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6613": {"data": {"text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "entity1": "acetaminophen", "entity2": "seizures", "span1": [57, 70], "span2": [314, 322]}, "bert_text": "Studies in DBA/2J mice showed that: 1) pretreatment with <e1> acetaminophen </e1> (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic <e2> seizures </e2> produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6614": {"data": {"text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "entity1": "acetaminophen", "entity2": "convulsions", "span1": [253, 266], "span2": [190, 201]}, "bert_text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with <e1> acetaminophen </e1> <e2> convulsions </e2> by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6615": {"data": {"text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "entity1": "acetaminophen", "entity2": "seizures", "span1": [253, 266], "span2": [314, 322]}, "bert_text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with <e1> acetaminophen </e1> (75 mg/kg) reduced the incidence of audiogenic <e2> seizures </e2> produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6616": {"data": {"text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "entity1": "caffeine", "entity2": "convulsions", "span1": [136, 144], "span2": [190, 201]}, "bert_text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of <e1> caffeine </e1> (300 to 450 mg/kg IP) and the onset of fatal <e2> convulsions </e2> by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6617": {"data": {"text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "entity1": "caffeine", "entity2": "seizures", "span1": [136, 144], "span2": [314, 322]}, "bert_text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of <e1> caffeine </e1> (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic <e2> seizures </e2> produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6618": {"data": {"text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "entity1": "caffeine", "entity2": "convulsions", "span1": [351, 359], "span2": [190, 201]}, "bert_text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of <e1> caffeine </e1> <e2> convulsions </e2> by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6619": {"data": {"text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "entity1": "caffeine", "entity2": "seizures", "span1": [351, 359], "span2": [314, 322]}, "bert_text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of <e1> caffeine </e1> <e2> seizures </e2> produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6620": {"data": {"text": "Given its excellent tolerance profile and low toxicity, further evaluation of VNB in combination therapy is warranted.", "entity1": "VNB", "entity2": "toxicity", "span1": [78, 81], "span2": [46, 54]}, "bert_text": "Given its excellent tolerance profile and low toxicity, further evaluation of <e1> VNB </e1> <e2> toxicity </e2>, further evaluation of VNB in combination therapy is warranted.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6621": {"data": {"text": "Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.", "entity1": "lometrexol", "entity2": "toxicity", "span1": [37, 47], "span2": [172, 180]}, "bert_text": "Associated studies demonstrated that <e1> lometrexol </e1> plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce <e2> toxicity </e2> by enhancing lometrexol plasma clearance.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6622": {"data": {"text": "Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.", "entity1": "lometrexol", "entity2": "toxicity", "span1": [194, 204], "span2": [172, 180]}, "bert_text": "Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing <e1> lometrexol </e1> <e2> toxicity </e2> by enhancing lometrexol plasma clearance.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6623": {"data": {"text": "Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.", "entity1": "folic acid", "entity2": "toxicity", "span1": [92, 102], "span2": [172, 180]}, "bert_text": "Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by <e1> folic acid </e1> administration indicating that supplementation is unlikely to reduce <e2> toxicity </e2> by enhancing lometrexol plasma clearance.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6624": {"data": {"text": "In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.", "entity1": "paclitaxel", "entity2": "ovarian cancer", "span1": [62, 72], "span2": [235, 249]}, "bert_text": "In a phase I study to determine the maximum tolerated dose of <e1> paclitaxel </e1> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced <e2> ovarian cancer </e2>, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6625": {"data": {"text": "In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.", "entity1": "Taxol", "entity2": "ovarian cancer", "span1": [74, 79], "span2": [235, 249]}, "bert_text": "In a phase I study to determine the maximum tolerated dose of paclitaxel (<e1> Taxol </e1>; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced <e2> ovarian cancer </e2>, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6626": {"data": {"text": "In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.", "entity1": "paclitaxel", "entity2": "ovarian cancer", "span1": [251, 261], "span2": [235, 249]}, "bert_text": "In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, <e1> paclitaxel </e1> <e2> ovarian cancer </e2>, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6627": {"data": {"text": "In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.", "entity1": "carboplatin", "entity2": "ovarian cancer", "span1": [173, 184], "span2": [235, 249]}, "bert_text": "In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with <e1> carboplatin </e1> administered every 21 days to women with advanced <e2> ovarian cancer </e2>, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"6628": {"data": {"text": "Additionally, this may have been the first report on AMI-induced apoptotic death in the lung tissue.", "entity1": "AMI", "entity2": "death", "span1": [53, 56], "span2": [75, 80]}, "bert_text": "Additionally, this may have been the first report on <e1> AMI </e1>-induced apoptotic <e2> death </e2> in the lung tissue.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6629": {"data": {"text": "The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.", "entity1": "calcium", "entity2": "hypocalcemia", "span1": [52, 59], "span2": [136, 148]}, "bert_text": "The events are consistent with a severe reaction to <e1> calcium </e1> chelation by sodium citrate anticoagulant resulting in symptomatic systemic <e2> hypocalcemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6630": {"data": {"text": "The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.", "entity1": "sodium citrate", "entity2": "hypocalcemia", "span1": [73, 87], "span2": [136, 148]}, "bert_text": "The events are consistent with a severe reaction to calcium chelation by <e1> sodium citrate </e1> anticoagulant resulting in symptomatic systemic <e2> hypocalcemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6631": {"data": {"text": "The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.", "entity1": "digitalis glycosides", "entity2": "obstructive coronary artery disease", "span1": [15, 35], "span2": [121, 156]}, "bert_text": "The effects of <e1> digitalis glycosides </e1> on myocardial oxygen supply and demand are of particular interest in the presence of <e2> obstructive coronary artery disease </e2>, but have not been measured previously in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6632": {"data": {"text": "The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.", "entity1": "oxygen", "entity2": "obstructive coronary artery disease", "span1": [50, 56], "span2": [121, 156]}, "bert_text": "The effects of digitalis glycosides on myocardial <e1> oxygen </e1> supply and demand are of particular interest in the presence of <e2> obstructive coronary artery disease </e2>, but have not been measured previously in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6633": {"data": {"text": "Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.", "entity1": "quetiapine", "entity2": "tic-like symptoms", "span1": [185, 195], "span2": [67, 84]}, "bert_text": "Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as <e1> quetiapine </e1> <e2> tic-like symptoms </e2> might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6634": {"data": {"text": "Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.", "entity1": "clozapine", "entity2": "tic-like symptoms", "span1": [197, 206], "span2": [67, 84]}, "bert_text": "Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, <e1> clozapine </e1> <e2> tic-like symptoms </e2> might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6635": {"data": {"text": "Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.", "entity1": "amisulpride", "entity2": "tic-like symptoms", "span1": [211, 222], "span2": [67, 84]}, "bert_text": "Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or <e1> amisulpride </e1> <e2> tic-like symptoms </e2> might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6636": {"data": {"text": "After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.)", "entity1": "adriamycin", "entity2": "proteinuria", "span1": [53, 63], "span2": [26, 37]}, "bert_text": "After 1 week of recovery, proteinuria was induced by <e1> adriamycin </e1> <e2> proteinuria </e2> was induced by adriamycin [1.5 mg/kg intravenously (i.v.)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6637": {"data": {"text": "Penicillin model is a widely used experimental model for epilepsy research.", "entity1": "Penicillin", "entity2": "epilepsy", "span1": [0, 10], "span2": [57, 65]}, "bert_text": "<e1> Penicillin </e1> model is a widely used experimental model for <e2> epilepsy </e2> research.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6638": {"data": {"text": "Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.\n", "entity1": "lignocaine", "entity2": "Leg and back pain", "span1": [67, 77], "span2": [0, 17]}, "bert_text": "Leg and back pain after spinal anaesthesia involving hyperbaric 5% <e1> lignocaine </e1> <e2> Leg and back pain </e2> after spinal anaesthesia involving hyperbaric 5% lignocaine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6639": {"data": {"text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "entity1": "risperidone", "entity2": "RS", "span1": [127, 138], "span2": [48, 50]}, "bert_text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of <e1> risperidone </e1> <e2> RS </e2> in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6640": {"data": {"text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "entity1": "risperidone", "entity2": "RS", "span1": [127, 138], "span2": [261, 263]}, "bert_text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of <e1> risperidone </e1>, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of <e2> RS </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6641": {"data": {"text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "entity1": "serotonin", "entity2": "RS", "span1": [142, 151], "span2": [48, 50]}, "bert_text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a <e1> serotonin </e1> <e2> RS </e2> in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6642": {"data": {"text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "entity1": "serotonin", "entity2": "RS", "span1": [142, 151], "span2": [261, 263]}, "bert_text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a <e1> serotonin </e1>-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of <e2> RS </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6643": {"data": {"text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "entity1": "serotonin", "entity2": "RS", "span1": [222, 231], "span2": [48, 50]}, "bert_text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the <e1> serotonin </e1> <e2> RS </e2> in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6644": {"data": {"text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "entity1": "serotonin", "entity2": "RS", "span1": [222, 231], "span2": [261, 263]}, "bert_text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the <e1> serotonin </e1> system in the development of <e2> RS </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6645": {"data": {"text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "entity1": "dopamine", "entity2": "RS", "span1": [152, 160], "span2": [48, 50]}, "bert_text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-<e1> dopamine </e1> <e2> RS </e2> in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6646": {"data": {"text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "entity1": "dopamine", "entity2": "RS", "span1": [152, 160], "span2": [261, 263]}, "bert_text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-<e1> dopamine </e1> antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of <e2> RS </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6647": {"data": {"text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "entity1": "rizatriptan", "entity2": "dizziness", "span1": [72, 83], "span2": [128, 137]}, "bert_text": "The most common adverse events (incidence > or = 5% in one group) after <e1> rizatriptan </e1> and ergotamine/caffeine, respectively, were <e2> dizziness </e2> (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6648": {"data": {"text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "entity1": "rizatriptan", "entity2": "nausea", "span1": [72, 83], "span2": [154, 160]}, "bert_text": "The most common adverse events (incidence > or = 5% in one group) after <e1> rizatriptan </e1> and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), <e2> nausea </e2> (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6649": {"data": {"text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "entity1": "rizatriptan", "entity2": "somnolence", "span1": [72, 83], "span2": [180, 190]}, "bert_text": "The most common adverse events (incidence > or = 5% in one group) after <e1> rizatriptan </e1> and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and <e2> somnolence </e2> (5.5 and 2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6650": {"data": {"text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "entity1": "ergotamine", "entity2": "dizziness", "span1": [88, 98], "span2": [128, 137]}, "bert_text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and <e1> ergotamine </e1>/caffeine, respectively, were <e2> dizziness </e2> (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6651": {"data": {"text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "entity1": "ergotamine", "entity2": "nausea", "span1": [88, 98], "span2": [154, 160]}, "bert_text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and <e1> ergotamine </e1>/caffeine, respectively, were dizziness (6.7 and 5.3%), <e2> nausea </e2> (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6652": {"data": {"text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "entity1": "ergotamine", "entity2": "somnolence", "span1": [88, 98], "span2": [180, 190]}, "bert_text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and <e1> ergotamine </e1>/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and <e2> somnolence </e2> (5.5 and 2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6653": {"data": {"text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "entity1": "caffeine", "entity2": "dizziness", "span1": [99, 107], "span2": [128, 137]}, "bert_text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/<e1> caffeine </e1>, respectively, were <e2> dizziness </e2> (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6654": {"data": {"text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "entity1": "caffeine", "entity2": "nausea", "span1": [99, 107], "span2": [154, 160]}, "bert_text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/<e1> caffeine </e1>, respectively, were dizziness (6.7 and 5.3%), <e2> nausea </e2> (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6655": {"data": {"text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "entity1": "caffeine", "entity2": "somnolence", "span1": [99, 107], "span2": [180, 190]}, "bert_text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/<e1> caffeine </e1>, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and <e2> somnolence </e2> (5.5 and 2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6656": {"data": {"text": "PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [132, 139], "span2": [80, 96]}, "bert_text": "PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to <e1> heparin </e1> <e2> thrombocytopenia </e2> (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6657": {"data": {"text": "PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [256, 263], "span2": [80, 96]}, "bert_text": "PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of <e1> heparin </e1> <e2> thrombocytopenia </e2> (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6658": {"data": {"text": "We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.", "entity1": "17beta-estradiol", "entity2": "SE", "span1": [27, 43], "span2": [130, 132]}, "bert_text": "We compared the effects of <e1> 17beta-estradiol </e1> in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced <e2> SE </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6659": {"data": {"text": "We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.", "entity1": "lithium", "entity2": "SE", "span1": [102, 109], "span2": [130, 132]}, "bert_text": "We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to <e1> lithium </e1>-pilocarpine-induced <e2> SE </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6660": {"data": {"text": "We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.", "entity1": "pilocarpine", "entity2": "SE", "span1": [110, 121], "span2": [130, 132]}, "bert_text": "We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-<e1> pilocarpine </e1>-induced <e2> SE </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6661": {"data": {"text": "From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.", "entity1": "ribavirin", "entity2": "AHF", "span1": [37, 46], "span2": [92, 95]}, "bert_text": "From these results, we conclude that <e1> ribavirin </e1> has an antiviral effect in advanced cases of <e2> AHF </e2>, and that anemia, the only secondary reaction observed, can be easily managed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6662": {"data": {"text": "From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.", "entity1": "ribavirin", "entity2": "anemia", "span1": [37, 46], "span2": [106, 112]}, "bert_text": "From these results, we conclude that <e1> ribavirin </e1> has an antiviral effect in advanced cases of AHF, and that <e2> anemia </e2>, the only secondary reaction observed, can be easily managed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6663": {"data": {"text": "This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.", "entity1": "chloramphenicol", "entity2": "aplastic anemia", "span1": [81, 96], "span2": [36, 51]}, "bert_text": "This was the second report of fatal aplastic anemia after topical treatment with <e1> chloramphenicol </e1> <e2> aplastic anemia </e2> after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6664": {"data": {"text": "This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.", "entity1": "chloramphenicol", "entity2": "bone marrow hypoplasia", "span1": [81, 96], "span2": [153, 175]}, "bert_text": "This was the second report of fatal aplastic anemia after topical treatment with <e1> chloramphenicol </e1> for ocular conditions, although two cases of reversible <e2> bone marrow hypoplasia </e2> have also been reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6665": {"data": {"text": "Blood was collected from the antecubital vein four times: 60 min before and after the nitroglycerin application, and 60 and 120 min after the beginning of the migraine attack (mean 344 and 404 min; 12 subjects).", "entity1": "nitroglycerin", "entity2": "migraine", "span1": [86, 99], "span2": [159, 167]}, "bert_text": "Blood was collected from the antecubital vein four times: 60 min before and after the <e1> nitroglycerin </e1> application, and 60 and 120 min after the beginning of the <e2> migraine </e2> attack (mean 344 and 404 min; 12 subjects).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6666": {"data": {"text": "Characterization of estrogen-induced adenohypophyseal tumors in the Fischer 344 rat.\n", "entity1": "estrogen", "entity2": "adenohypophyseal tumors", "span1": [20, 28], "span2": [37, 60]}, "bert_text": "Characterization of <e1> estrogen </e1>-induced <e2> adenohypophyseal tumors </e2> in the Fischer 344 rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6667": {"data": {"text": "Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.", "entity1": "testosterone", "entity2": "prostate cancer", "span1": [37, 49], "span2": [99, 114]}, "bert_text": "Conventional LW rats, implanted with <e1> testosterone </e1> at age 4 months, developed a higher incidence of <e2> prostate cancer </e2> after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6668": {"data": {"text": "Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.", "entity1": "testosterone", "entity2": "tumors", "span1": [37, 49], "span2": [179, 185]}, "bert_text": "Conventional LW rats, implanted with <e1> testosterone </e1> at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross <e2> tumors </e2>, and 40% when it included microscopic tumors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6669": {"data": {"text": "Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.", "entity1": "testosterone", "entity2": "tumors", "span1": [37, 49], "span2": [224, 230]}, "bert_text": "Conventional LW rats, implanted with <e1> testosterone </e1> at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic <e2> tumors </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6670": {"data": {"text": "CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.", "entity1": "CaCl(2", "entity2": "TAA", "span1": [63, 69], "span2": [37, 40]}, "bert_text": "CONCLUSION: This study establishes a TAA model by periarterial <e1> CaCl(2 </e1> <e2> TAA </e2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6671": {"data": {"text": "Metabolic involvement in adriamycin cardiotoxicity.\n", "entity1": "adriamycin", "entity2": "cardiotoxicity", "span1": [25, 35], "span2": [36, 50]}, "bert_text": "Metabolic involvement in <e1> adriamycin </e1> <e2> cardiotoxicity </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6672": {"data": {"text": "RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-", "entity1": "cocaine", "entity2": "anxiety", "span1": [23, 30], "span2": [58, 65]}, "bert_text": "RESULTS: We found that <e1> cocaine </e1> dose-dependently increased <e2> anxiety </e2>-like behavior in control (Dbh +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6673": {"data": {"text": "Amphotericin B-induced seizures in a patient with AIDS.\n", "entity1": "Amphotericin B", "entity2": "seizures", "span1": [0, 14], "span2": [23, 31]}, "bert_text": "<e1> Amphotericin B </e1>-induced <e2> seizures </e2> in a patient with AIDS.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6674": {"data": {"text": "Amphotericin B-induced seizures in a patient with AIDS.\n", "entity1": "Amphotericin B", "entity2": "AIDS", "span1": [0, 14], "span2": [50, 54]}, "bert_text": "<e1> Amphotericin B </e1>-induced seizures in a patient with <e2> AIDS </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6675": {"data": {"text": "Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).", "entity1": "sodium nitroprusside", "entity2": "hemorrhage", "span1": [127, 147], "span2": [74, 84]}, "bert_text": "Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of <e1> sodium nitroprusside </e1> <e2> hemorrhage </e2> (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6676": {"data": {"text": "Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).", "entity1": "sodium nitroprusside", "entity2": "HEM", "span1": [127, 147], "span2": [86, 89]}, "bert_text": "Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of <e1> sodium nitroprusside </e1> <e2> HEM </e2>, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6677": {"data": {"text": "Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).", "entity1": "SNP", "entity2": "hemorrhage", "span1": [149, 152], "span2": [74, 84]}, "bert_text": "Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (<e1> SNP </e1> <e2> hemorrhage </e2> (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6678": {"data": {"text": "Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).", "entity1": "SNP", "entity2": "HEM", "span1": [149, 152], "span2": [86, 89]}, "bert_text": "Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (<e1> SNP </e1> <e2> HEM </e2>, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6679": {"data": {"text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.", "entity1": "tacrolimus", "entity2": "tubular dysfunction", "span1": [134, 144], "span2": [30, 49]}, "bert_text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by <e1> tacrolimus </e1> <e2> tubular dysfunction </e2> and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6680": {"data": {"text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.", "entity1": "tacrolimus", "entity2": "myopathy", "span1": [134, 144], "span2": [54, 62]}, "bert_text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by <e1> tacrolimus </e1> <e2> myopathy </e2> may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6681": {"data": {"text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.", "entity1": "tacrolimus", "entity2": "mitochondrial dysfunction", "span1": [134, 144], "span2": [86, 111]}, "bert_text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by <e1> tacrolimus </e1> <e2> mitochondrial dysfunction </e2> which is triggered by tacrolimus and augmented by lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6682": {"data": {"text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.", "entity1": "lamivudine", "entity2": "tubular dysfunction", "span1": [162, 172], "span2": [30, 49]}, "bert_text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by <e1> lamivudine </e1> <e2> tubular dysfunction </e2> and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6683": {"data": {"text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.", "entity1": "lamivudine", "entity2": "myopathy", "span1": [162, 172], "span2": [54, 62]}, "bert_text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by <e1> lamivudine </e1> <e2> myopathy </e2> may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6684": {"data": {"text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.", "entity1": "lamivudine", "entity2": "mitochondrial dysfunction", "span1": [162, 172], "span2": [86, 111]}, "bert_text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by <e1> lamivudine </e1> <e2> mitochondrial dysfunction </e2> which is triggered by tacrolimus and augmented by lamivudine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6685": {"data": {"text": "Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.", "entity1": "cisplatin", "entity2": "renal failure", "span1": [178, 187], "span2": [145, 158]}, "bert_text": "Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to <e1> cisplatin </e1> <e2> renal failure </e2> may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"6686": {"data": {"text": "Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [178, 187], "span2": [188, 202]}, "bert_text": "Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to <e1> cisplatin </e1> <e2> nephrotoxicity </e2> and the anemia and thrombocytopenia to drug-induced bone marrow suppression.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6687": {"data": {"text": "Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.", "entity1": "cisplatin", "entity2": "anemia", "span1": [178, 187], "span2": [211, 217]}, "bert_text": "Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to <e1> cisplatin </e1> nephrotoxicity and the <e2> anemia </e2> and thrombocytopenia to drug-induced bone marrow suppression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6688": {"data": {"text": "Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.", "entity1": "cisplatin", "entity2": "thrombocytopenia", "span1": [178, 187], "span2": [222, 238]}, "bert_text": "Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to <e1> cisplatin </e1> nephrotoxicity and the anemia and <e2> thrombocytopenia </e2> to drug-induced bone marrow suppression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6689": {"data": {"text": "Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.", "entity1": "cisplatin", "entity2": "bone marrow suppression", "span1": [178, 187], "span2": [255, 278]}, "bert_text": "Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to <e1> cisplatin </e1> nephrotoxicity and the anemia and thrombocytopenia to drug-induced <e2> bone marrow suppression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6690": {"data": {"text": "Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.", "entity1": "lithium", "entity2": "cardiac malformations", "span1": [67, 74], "span2": [190, 211]}, "bert_text": "Cross-sectional echocardiographic screening of newborns exposed to <e1> lithium </e1> during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced <e2> cardiac malformations </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6691": {"data": {"text": "Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.", "entity1": "lithium", "entity2": "cardiac malformations", "span1": [174, 181], "span2": [190, 211]}, "bert_text": "Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of <e1> lithium </e1>-induced <e2> cardiac malformations </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6692": {"data": {"text": "There was no correlation between vitamin B12 or folate levels and development of myelosuppression.", "entity1": "vitamin B12", "entity2": "myelosuppression", "span1": [33, 44], "span2": [81, 97]}, "bert_text": "There was no correlation between <e1> vitamin B12 </e1> or folate levels and development of <e2> myelosuppression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6693": {"data": {"text": "There was no correlation between vitamin B12 or folate levels and development of myelosuppression.", "entity1": "folate", "entity2": "myelosuppression", "span1": [48, 54], "span2": [81, 97]}, "bert_text": "There was no correlation between vitamin B12 or <e1> folate </e1> levels and development of <e2> myelosuppression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6694": {"data": {"text": "Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits.\n", "entity1": "sodium", "entity2": "seizures", "span1": [8, 14], "span2": [108, 116]}, "bert_text": "Reduced <e1> sodium </e1> channel density, altered voltage dependence of inactivation, and increased susceptibility to <e2> seizures </e2> in mice lacking sodium channel beta 2-subunits.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6695": {"data": {"text": "Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits.\n", "entity1": "sodium", "entity2": "seizures", "span1": [133, 139], "span2": [108, 116]}, "bert_text": "Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking <e1> sodium </e1> <e2> seizures </e2> in mice lacking sodium channel beta 2-subunits.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6696": {"data": {"text": "On repeat challenge with phenobarbital, the dyskinesia recurred.", "entity1": "phenobarbital", "entity2": "dyskinesia", "span1": [25, 38], "span2": [44, 54]}, "bert_text": "On repeat challenge with <e1> phenobarbital </e1>, the <e2> dyskinesia </e2> recurred.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6697": {"data": {"text": "To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.", "entity1": "potassium", "entity2": "hypokalaemia", "span1": [27, 36], "span2": [61, 73]}, "bert_text": "To investigate the initial <e1> potassium </e1> loss and development of <e2> hypokalaemia </e2> during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6698": {"data": {"text": "To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.", "entity1": "potassium", "entity2": "hypokalaemia", "span1": [27, 36], "span2": [220, 232]}, "bert_text": "To investigate the initial <e1> potassium </e1> loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown <e2> hypokalaemia </e2> under prior oral diuretic treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6699": {"data": {"text": "To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.", "entity1": "potassium", "entity2": "hypertension", "span1": [27, 36], "span2": [193, 205]}, "bert_text": "To investigate the initial <e1> potassium </e1> loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential <e2> hypertension </e2> who had shown hypokalaemia under prior oral diuretic treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6700": {"data": {"text": "To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.", "entity1": "diuretic", "entity2": "hypokalaemia", "span1": [250, 258], "span2": [61, 73]}, "bert_text": "To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral <e1> diuretic </e1> <e2> hypokalaemia </e2> during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6701": {"data": {"text": "To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.", "entity1": "diuretic", "entity2": "hypokalaemia", "span1": [250, 258], "span2": [220, 232]}, "bert_text": "To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral <e1> diuretic </e1> <e2> hypokalaemia </e2> under prior oral diuretic treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6702": {"data": {"text": "To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.", "entity1": "diuretic", "entity2": "hypertension", "span1": [250, 258], "span2": [193, 205]}, "bert_text": "To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral <e1> diuretic </e1> <e2> hypertension </e2> who had shown hypokalaemia under prior oral diuretic treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6703": {"data": {"text": "Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.", "entity1": "chloramphenicol", "entity2": "ocular toxicity", "span1": [79, 94], "span2": [29, 44]}, "bert_text": "Any other suspected cases of ocular toxicity associated with topically applied <e1> chloramphenicol </e1> <e2> ocular toxicity </e2> associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6704": {"data": {"text": "Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.", "entity1": "creatinine", "entity2": "ESRD", "span1": [70, 80], "span2": [21, 25]}, "bert_text": "Patients who develop ESRD have a higher preoperative and 1-year serum <e1> creatinine </e1> <e2> ESRD </e2> have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6705": {"data": {"text": "Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.", "entity1": "creatinine", "entity2": "hepatorenal syndrome", "span1": [70, 80], "span2": [109, 129]}, "bert_text": "Patients who develop ESRD have a higher preoperative and 1-year serum <e1> creatinine </e1> and are more likely to have <e2> hepatorenal syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6706": {"data": {"text": "Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.", "entity1": "testosterone", "entity2": "low sexual desire", "span1": [31, 43], "span2": [96, 113]}, "bert_text": "Every patient was screened for <e1> testosterone </e1> and 451 were screened for prolactin on the basis of <e2> low sexual desire </e2>, gynecomastia or testosterone less than 4 ng./ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6707": {"data": {"text": "Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.", "entity1": "testosterone", "entity2": "gynecomastia", "span1": [31, 43], "span2": [115, 127]}, "bert_text": "Every patient was screened for <e1> testosterone </e1> and 451 were screened for prolactin on the basis of low sexual desire, <e2> gynecomastia </e2> or testosterone less than 4 ng./ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6708": {"data": {"text": "Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.", "entity1": "testosterone", "entity2": "low sexual desire", "span1": [131, 143], "span2": [96, 113]}, "bert_text": "Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or <e1> testosterone </e1> <e2> low sexual desire </e2>, gynecomastia or testosterone less than 4 ng./ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6709": {"data": {"text": "Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.", "entity1": "testosterone", "entity2": "gynecomastia", "span1": [131, 143], "span2": [115, 127]}, "bert_text": "Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or <e1> testosterone </e1> <e2> gynecomastia </e2> or testosterone less than 4 ng./ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6710": {"data": {"text": "Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.", "entity1": "ribavirin", "entity2": "viremia", "span1": [18, 27], "span2": [60, 67]}, "bert_text": "Administration of <e1> ribavirin </e1> resulted in a neutralization of <e2> viremia </e2> and a drop of endogenous interferon titers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6711": {"data": {"text": "Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.\n", "entity1": "methylprednisolone", "entity2": "Hypotension", "span1": [67, 85], "span2": [0, 11]}, "bert_text": "Hypotension, bradycardia, and asystole after high-dose intravenous <e1> methylprednisolone </e1> <e2> Hypotension </e2>, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6712": {"data": {"text": "Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.\n", "entity1": "methylprednisolone", "entity2": "bradycardia", "span1": [67, 85], "span2": [13, 24]}, "bert_text": "Hypotension, bradycardia, and asystole after high-dose intravenous <e1> methylprednisolone </e1> <e2> bradycardia </e2>, and asystole after high-dose intravenous methylprednisolone in a monitored patient.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6713": {"data": {"text": "Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.\n", "entity1": "methylprednisolone", "entity2": "asystole", "span1": [67, 85], "span2": [30, 38]}, "bert_text": "Hypotension, bradycardia, and asystole after high-dose intravenous <e1> methylprednisolone </e1> <e2> asystole </e2> after high-dose intravenous methylprednisolone in a monitored patient.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6714": {"data": {"text": "We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.", "entity1": "methylprednisolone", "entity2": "hypotension", "span1": [105, 123], "span2": [20, 31]}, "bert_text": "We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose <e1> methylprednisolone </e1> <e2> hypotension </e2>, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6715": {"data": {"text": "We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.", "entity1": "methylprednisolone", "entity2": "bradycardia", "span1": [105, 123], "span2": [33, 44]}, "bert_text": "We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose <e1> methylprednisolone </e1> <e2> bradycardia </e2>, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6716": {"data": {"text": "We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.", "entity1": "methylprednisolone", "entity2": "asystole", "span1": [105, 123], "span2": [50, 58]}, "bert_text": "We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose <e1> methylprednisolone </e1> <e2> asystole </e2> after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6717": {"data": {"text": "In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.", "entity1": "melatonin", "entity2": "narcosis", "span1": [33, 42], "span2": [153, 161]}, "bert_text": "In contrast, the highest dose of <e1> melatonin </e1> (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of <e2> narcosis </e2>, and a reduction in mortality rate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6718": {"data": {"text": "Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.\n", "entity1": "Sodium bicarbonate", "entity2": "penile pain", "span1": [0, 18], "span2": [30, 41]}, "bert_text": "<e1> Sodium bicarbonate </e1> alleviates <e2> penile pain </e2> induced by intracavernous injections for erectile dysfunction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6719": {"data": {"text": "Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.\n", "entity1": "Sodium bicarbonate", "entity2": "erectile dysfunction", "span1": [0, 18], "span2": [83, 103]}, "bert_text": "<e1> Sodium bicarbonate </e1> alleviates penile pain induced by intracavernous injections for <e2> erectile dysfunction </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6720": {"data": {"text": "These variables returned to baseline when rigidity was abolished with metocurine.", "entity1": "metocurine", "entity2": "rigidity", "span1": [70, 80], "span2": [42, 50]}, "bert_text": "These variables returned to baseline when rigidity was abolished with <e1> metocurine </e1> <e2> rigidity </e2> was abolished with metocurine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6721": {"data": {"text": "CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.", "entity1": "TXA", "entity2": "seizures", "span1": [54, 57], "span2": [180, 188]}, "bert_text": "CONCLUSION: Our results suggest that use of high-dose <e1> TXA </e1> in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical <e2> seizures </e2> in susceptible patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6722": {"data": {"text": "Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.", "entity1": "benzodiazepines", "entity2": "myoclonus", "span1": [40, 55], "span2": [119, 128]}, "bert_text": "Considering the fact that 5-HTP and the <e1> benzodiazepines </e1> have been found to be beneficial in the management of clinical <e2> myoclonus </e2>, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6723": {"data": {"text": "Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.", "entity1": "benzodiazepines", "entity2": "myoclonus", "span1": [40, 55], "span2": [151, 160]}, "bert_text": "Considering the fact that 5-HTP and the <e1> benzodiazepines </e1> have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced <e2> myoclonus </e2> seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6724": {"data": {"text": "Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.", "entity1": "muscimol", "entity2": "myoclonus", "span1": [134, 142], "span2": [119, 128]}, "bert_text": "Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the <e1> muscimol </e1> <e2> myoclonus </e2>, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6725": {"data": {"text": "Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.", "entity1": "muscimol", "entity2": "myoclonus", "span1": [134, 142], "span2": [151, 160]}, "bert_text": "Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the <e1> muscimol </e1>-induced <e2> myoclonus </e2> seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6726": {"data": {"text": "Venous complications of midazolam versus diazepam.\n", "entity1": "midazolam", "entity2": "Venous complications", "span1": [24, 33], "span2": [0, 20]}, "bert_text": "Venous complications of <e1> midazolam </e1> <e2> Venous complications </e2> of midazolam versus diazepam.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6727": {"data": {"text": "Venous complications of midazolam versus diazepam.\n", "entity1": "diazepam", "entity2": "Venous complications", "span1": [41, 49], "span2": [0, 20]}, "bert_text": "Venous complications of midazolam versus <e1> diazepam </e1> <e2> Venous complications </e2> of midazolam versus diazepam.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6728": {"data": {"text": "International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings.", "entity1": "mexiletine", "entity2": "arrhythmia", "span1": [14, 24], "span2": [81, 91]}, "bert_text": "International <e1> mexiletine </e1> and placebo antiarrhythmic coronary trial: I. Report on <e2> arrhythmia </e2> and other findings.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6729": {"data": {"text": "Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced hypothermia.", "entity1": "apomorphine", "entity2": "hypothermia", "span1": [75, 86], "span2": [108, 119]}, "bert_text": "Moreover, test conditions can impact upon other physiological responses to <e1> apomorphine </e1> such as drug-induced <e2> hypothermia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6730": {"data": {"text": "Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.", "entity1": "cocaine", "entity2": "toxicity", "span1": [45, 52], "span2": [53, 61]}, "bert_text": "Different mechanisms have been suggested for <e1> cocaine </e1> <e2> toxicity </e2> including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6731": {"data": {"text": "Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.", "entity1": "cocaine", "entity2": "toxicity", "span1": [166, 173], "span2": [53, 61]}, "bert_text": "Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and <e1> cocaine </e1> <e2> toxicity </e2> including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6732": {"data": {"text": "Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.\n", "entity1": "cyclosporine", "entity2": "nephrotoxicity", "span1": [13, 25], "span2": [26, 40]}, "bert_text": "Experimental <e1> cyclosporine </e1> <e2> nephrotoxicity </e2>: risk of concomitant chemotherapy.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6733": {"data": {"text": "We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a \"natural energy\" guarana health drink containing a high concentration of caffeine.", "entity1": "caffeine", "entity2": "mitral valve prolapse", "span1": [214, 222], "span2": [50, 71]}, "bert_text": "We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a \"natural energy\" guarana health drink containing a high concentration of <e1> caffeine </e1> <e2> mitral valve prolapse </e2> who developed intractable ventricular fibrillation after consuming a \"natural energy\" guarana health drink containing a high concentration of caffeine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6734": {"data": {"text": "We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a \"natural energy\" guarana health drink containing a high concentration of caffeine.", "entity1": "caffeine", "entity2": "ventricular fibrillation", "span1": [214, 222], "span2": [98, 122]}, "bert_text": "We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a \"natural energy\" guarana health drink containing a high concentration of <e1> caffeine </e1> <e2> ventricular fibrillation </e2> after consuming a \"natural energy\" guarana health drink containing a high concentration of caffeine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6735": {"data": {"text": "Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.", "entity1": "Doxorubicin", "entity2": "OB", "span1": [0, 11], "span2": [154, 156]}, "bert_text": "<e1> Doxorubicin </e1> toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and <e2> OB </e2> hearts.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6736": {"data": {"text": "Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.", "entity1": "doxorubicin", "entity2": "OB", "span1": [73, 84], "span2": [154, 156]}, "bert_text": "Doxorubicin toxicokinetics studies revealed no change in accumulation of <e1> doxorubicin </e1> and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and <e2> OB </e2> hearts.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6737": {"data": {"text": "Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.", "entity1": "doxorubicinol", "entity2": "OB", "span1": [89, 102], "span2": [154, 156]}, "bert_text": "Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and <e1> doxorubicinol </e1> (toxic metabolite) in the normal diet-fed (ND) and <e2> OB </e2> hearts.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6738": {"data": {"text": "Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.", "entity1": "METH", "entity2": "neurotoxicity", "span1": [141, 145], "span2": [172, 185]}, "bert_text": "Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with <e1> METH </e1> and examined for striatal <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6739": {"data": {"text": "There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.", "entity1": "morphine", "entity2": "tachyarrhythmias", "span1": [129, 137], "span2": [37, 53]}, "bert_text": "There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the <e1> morphine </e1> <e2> tachyarrhythmias </e2> (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6740": {"data": {"text": "There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.", "entity1": "morphine", "entity2": "ventricular ectopic beats", "span1": [129, 137], "span2": [77, 102]}, "bert_text": "There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the <e1> morphine </e1> <e2> ventricular ectopic beats </e2> (P less than 0.05) in the morphine infusion group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6741": {"data": {"text": "Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.", "entity1": "ketanserin", "entity2": "rigidity", "span1": [55, 65], "span2": [23, 31]}, "bert_text": "Despite the absence of rigidity, animals that received <e1> ketanserin </e1> <e2> rigidity </e2>, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6742": {"data": {"text": "Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.", "entity1": "alfentanil", "entity2": "rigidity", "span1": [109, 119], "span2": [23, 31]}, "bert_text": "Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by <e1> alfentanil </e1> <e2> rigidity </e2>, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6743": {"data": {"text": "Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.", "entity1": "alfentanil", "entity2": "rigidity", "span1": [214, 224], "span2": [23, 31]}, "bert_text": "Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving <e1> alfentanil </e1> <e2> rigidity </e2>, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6744": {"data": {"text": "It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.", "entity1": "sulfasalazine", "entity2": "lupus", "span1": [37, 50], "span2": [59, 64]}, "bert_text": "It is suggested that the patient had <e1> sulfasalazine </e1>-induced <e2> lupus </e2>, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6745": {"data": {"text": "It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.", "entity1": "sulfasalazine", "entity2": "serositis", "span1": [37, 50], "span2": [88, 97]}, "bert_text": "It is suggested that the patient had <e1> sulfasalazine </e1>-induced lupus, which manifested with <e2> serositis </e2> and pulmonary parenchymal involvement in the absence of joint symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6746": {"data": {"text": "Various ocular symptoms and findings caused by carboplatin toxicity were seen.", "entity1": "carboplatin", "entity2": "toxicity", "span1": [47, 58], "span2": [59, 67]}, "bert_text": "Various ocular symptoms and findings caused by <e1> carboplatin </e1> <e2> toxicity </e2> were seen.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6747": {"data": {"text": "mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.", "entity1": "nicotine", "entity2": "seizures", "span1": [43, 51], "span2": [186, 194]}, "bert_text": "mice were less sensitive to the effects of <e1> nicotine </e1> both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6748": {"data": {"text": "mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.", "entity1": "nicotine", "entity2": "seizures", "span1": [169, 177], "span2": [186, 194]}, "bert_text": "mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to <e1> nicotine </e1>-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"6749": {"data": {"text": "The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.", "entity1": "cyclosporine", "entity2": "renal toxicity", "span1": [12, 24], "span2": [108, 122]}, "bert_text": "The role of <e1> cyclosporine </e1> (CSA) alone or in combination with various chemotherapeutics in the development of <e2> renal toxicity </e2> was evaluated in rats.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6750": {"data": {"text": "The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.", "entity1": "CSA", "entity2": "renal toxicity", "span1": [26, 29], "span2": [108, 122]}, "bert_text": "The role of cyclosporine (<e1> CSA </e1>) alone or in combination with various chemotherapeutics in the development of <e2> renal toxicity </e2> was evaluated in rats.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6751": {"data": {"text": "Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.", "entity1": "Anthracyclines", "entity2": "cardiotoxicity", "span1": [0, 14], "span2": [90, 104]}, "bert_text": "<e1> Anthracyclines </e1> are effective antineoplastic drugs, but they frequently cause dose-related <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6752": {"data": {"text": "In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.", "entity1": "verapamil", "entity2": "AF", "span1": [39, 48], "span2": [67, 69]}, "bert_text": "In the presence of autonomic blockade, <e1> verapamil </e1> failed to promote <e2> AF </e2> and increased, rather than decreasing, refractoriness.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6753": {"data": {"text": "BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.", "entity1": "ifosfamide", "entity2": "Hallucinations", "span1": [113, 123], "span2": [12, 26]}, "bert_text": "BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of <e1> ifosfamide </e1> <e2> Hallucinations </e2> as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6754": {"data": {"text": "BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.", "entity1": "ifosfamide", "entity2": "neurotoxicity", "span1": [113, 123], "span2": [51, 64]}, "bert_text": "BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of <e1> ifosfamide </e1> <e2> neurotoxicity </e2> are a known but poorly described side effect of ifosfamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6755": {"data": {"text": "Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/-", "entity1": "cephalosporin", "entity2": "hematologic syndrome", "span1": [29, 42], "span2": [48, 68]}, "bert_text": "Upon rechallenge with either <e1> cephalosporin </e1>, the <e2> hematologic syndrome </e2> was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6756": {"data": {"text": "Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/-", "entity1": "cefonicid", "entity2": "hematologic syndrome", "span1": [105, 114], "span2": [48, 68]}, "bert_text": "Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; <e1> cefonicid </e1> <e2> hematologic syndrome </e2> was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6757": {"data": {"text": "Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/-", "entity1": "cefazedone)-treated", "entity2": "hematologic syndrome", "span1": [124, 143], "span2": [48, 68]}, "bert_text": "Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not <e1> cefazedone)-treated </e1> <e2> hematologic syndrome </e2> was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6758": {"data": {"text": "This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease.", "entity1": "rifampin", "entity2": "glomerulonephritis", "span1": [124, 132], "span2": [79, 97]}, "bert_text": "This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with <e1> rifampin </e1> <e2> glomerulonephritis </e2> in a patient treated with rifampin who had no other identifiable causes for developing this disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6759": {"data": {"text": "Hallucinations and ifosfamide-induced neurotoxicity.\n", "entity1": "ifosfamide", "entity2": "Hallucinations", "span1": [19, 29], "span2": [0, 14]}, "bert_text": "Hallucinations and <e1> ifosfamide </e1> <e2> Hallucinations </e2> and ifosfamide-induced neurotoxicity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6760": {"data": {"text": "Hallucinations and ifosfamide-induced neurotoxicity.\n", "entity1": "ifosfamide", "entity2": "neurotoxicity", "span1": [19, 29], "span2": [38, 51]}, "bert_text": "Hallucinations and <e1> ifosfamide </e1>-induced <e2> neurotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6761": {"data": {"text": "The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.", "entity1": "alpha-lipoic acid", "entity2": "neurotoxicity", "span1": [223, 240], "span2": [92, 105]}, "bert_text": "The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of <e1> alpha-lipoic acid </e1> <e2> neurotoxicity </e2>, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6762": {"data": {"text": "Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.", "entity1": "Heparin", "entity2": "thrombocytopenia", "span1": [0, 7], "span2": [16, 32]}, "bert_text": "<e1> Heparin </e1>-induced <e2> thrombocytopenia </e2> (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6763": {"data": {"text": "Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.", "entity1": "Heparin", "entity2": "HIT", "span1": [0, 7], "span2": [34, 37]}, "bert_text": "<e1> Heparin </e1>-induced thrombocytopenia (<e2> HIT </e2>) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6764": {"data": {"text": "Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [81, 88], "span2": [16, 32]}, "bert_text": "Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to <e1> heparin </e1> <e2> thrombocytopenia </e2> (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6765": {"data": {"text": "Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.", "entity1": "heparin", "entity2": "HIT", "span1": [81, 88], "span2": [34, 37]}, "bert_text": "Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to <e1> heparin </e1> <e2> HIT </e2>) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6766": {"data": {"text": "A study on the effect of the duration of subcutaneous heparin injection on bruising and pain.\n", "entity1": "heparin", "entity2": "bruising", "span1": [54, 61], "span2": [75, 83]}, "bert_text": "A study on the effect of the duration of subcutaneous <e1> heparin </e1> injection on <e2> bruising </e2> and pain.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6767": {"data": {"text": "A study on the effect of the duration of subcutaneous heparin injection on bruising and pain.\n", "entity1": "heparin", "entity2": "pain", "span1": [54, 61], "span2": [88, 92]}, "bert_text": "A study on the effect of the duration of subcutaneous <e1> heparin </e1> injection on bruising and <e2> pain </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6768": {"data": {"text": "The molecular mechanisms of CsA and FK506 toxicity were investigated.", "entity1": "CsA", "entity2": "toxicity", "span1": [28, 31], "span2": [42, 50]}, "bert_text": "The molecular mechanisms of <e1> CsA </e1> and FK506 <e2> toxicity </e2> were investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6769": {"data": {"text": "The molecular mechanisms of CsA and FK506 toxicity were investigated.", "entity1": "FK506", "entity2": "toxicity", "span1": [36, 41], "span2": [42, 50]}, "bert_text": "The molecular mechanisms of CsA and <e1> FK506 </e1> <e2> toxicity </e2> were investigated.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6770": {"data": {"text": "AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.", "entity1": "heparin", "entity2": "bruising", "span1": [161, 168], "span2": [81, 89]}, "bert_text": "AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of <e1> heparin </e1> <e2> bruising </e2> and pain following the administration of the subcutaneous injection of heparin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6771": {"data": {"text": "AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.", "entity1": "heparin", "entity2": "pain", "span1": [161, 168], "span2": [94, 98]}, "bert_text": "AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of <e1> heparin </e1> <e2> pain </e2> following the administration of the subcutaneous injection of heparin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6772": {"data": {"text": "Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.", "entity1": "cibenzoline", "entity2": "hypotensive", "span1": [8, 19], "span2": [34, 45]}, "bert_text": "Because <e1> cibenzoline </e1> had only weak <e2> hypotensive </e2> and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6773": {"data": {"text": "Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.", "entity1": "cibenzoline", "entity2": "depressive", "span1": [8, 19], "span2": [61, 71]}, "bert_text": "Because <e1> cibenzoline </e1> had only weak hypotensive and sinus node <e2> depressive </e2> effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6774": {"data": {"text": "Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.", "entity1": "cibenzoline", "entity2": "arrhythmia", "span1": [8, 19], "span2": [146, 156]}, "bert_text": "Because <e1> cibenzoline </e1> had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation <e2> arrhythmia </e2> dogs, its clinical usefulness is expected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6775": {"data": {"text": "Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.", "entity1": "ritanserin", "entity2": "amnesia", "span1": [41, 51], "span2": [124, 131]}, "bert_text": "Our findings show that microinjection of <e1> ritanserin </e1> into the CA1 region of the hippocampus improves the scopolamine-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6776": {"data": {"text": "Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [104, 115], "span2": [124, 131]}, "bert_text": "Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the <e1> scopolamine </e1>-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6777": {"data": {"text": "The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.", "entity1": "prostaglandins", "entity2": "pain", "span1": [45, 59], "span2": [63, 67]}, "bert_text": "The effects of intrathecal administration of <e1> prostaglandins </e1> on <e2> pain </e2> responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6778": {"data": {"text": "The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.", "entity1": "acetic acid", "entity2": "pain", "span1": [134, 145], "span2": [63, 67]}, "bert_text": "The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and <e1> acetic acid </e1> <e2> pain </e2> responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6779": {"data": {"text": "We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.", "entity1": "paclitaxel", "entity2": "coronary aneurysm", "span1": [119, 129], "span2": [45, 62]}, "bert_text": "We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a <e1> paclitaxel </e1> <e2> coronary aneurysm </e2> in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6780": {"data": {"text": "A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.", "entity1": "chloramphenicol", "entity2": "aplastic anemia", "span1": [137, 152], "span2": [28, 43]}, "bert_text": "A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with <e1> chloramphenicol </e1> <e2> aplastic anemia </e2> less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6781": {"data": {"text": "A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.", "entity1": "chloramphenicol", "entity2": "cataract", "span1": [137, 152], "span2": [82, 90]}, "bert_text": "A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with <e1> chloramphenicol </e1> <e2> cataract </e2> extraction and beginning topical therapy with chloramphenicol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6782": {"data": {"text": "Intracranial pressure increases during alfentanil-induced rigidity.\nIntracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.", "entity1": "alfentanil", "entity2": "rigidity", "span1": [39, 49], "span2": [58, 66]}, "bert_text": "Intracranial pressure increases during <e1> alfentanil </e1>-induced <e2> rigidity </e2>.\nIntracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6783": {"data": {"text": "Intracranial pressure increases during alfentanil-induced rigidity.\nIntracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.", "entity1": "alfentanil", "entity2": "rigidity", "span1": [39, 49], "span2": [135, 143]}, "bert_text": "Intracranial pressure increases during <e1> alfentanil </e1>-induced rigidity.\nIntracranial pressure (ICP) was measured during alfentanil-induced <e2> rigidity </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6784": {"data": {"text": "Intracranial pressure increases during alfentanil-induced rigidity.\nIntracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.", "entity1": "alfentanil", "entity2": "rigidity", "span1": [116, 126], "span2": [58, 66]}, "bert_text": "Intracranial pressure increases during alfentanil-induced rigidity.\nIntracranial pressure (ICP) was measured during <e1> alfentanil </e1> <e2> rigidity </e2>.\nIntracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"6785": {"data": {"text": "Intracranial pressure increases during alfentanil-induced rigidity.\nIntracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.", "entity1": "alfentanil", "entity2": "rigidity", "span1": [116, 126], "span2": [135, 143]}, "bert_text": "Intracranial pressure increases during alfentanil-induced rigidity.\nIntracranial pressure (ICP) was measured during <e1> alfentanil </e1>-induced <e2> rigidity </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"6786": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "entity2": "dyskinesias", "span1": [69, 113], "span2": [183, 194]}, "bert_text": "We therefore conducted the present acute dose-response study in four <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6787": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "entity2": "dyskinetic", "span1": [69, 113], "span2": [225, 235]}, "bert_text": "We therefore conducted the present acute dose-response study in four <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and <e2> dyskinetic </e2> effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6788": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "MPTP)-exposed", "entity2": "dyskinesias", "span1": [115, 128], "span2": [183, 194]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (<e1> MPTP)-exposed </e1> cynomolgus monkeys primed to exhibit levodopa-induced <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6789": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "MPTP)-exposed", "entity2": "dyskinetic", "span1": [115, 128], "span2": [225, 235]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (<e1> MPTP)-exposed </e1> cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and <e2> dyskinetic </e2> effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6790": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [166, 174], "span2": [183, 194]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit <e1> levodopa </e1>-induced <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6791": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "levodopa", "entity2": "dyskinetic", "span1": [166, 174], "span2": [225, 235]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit <e1> levodopa </e1>-induced dyskinesias to evaluate the locomotor and <e2> dyskinetic </e2> effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6792": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "A-86929", "entity2": "dyskinesias", "span1": [301, 308], "span2": [183, 194]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of <e1> A-86929 </e1> <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6793": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "A-86929", "entity2": "dyskinetic", "span1": [301, 308], "span2": [225, 235]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of <e1> A-86929 </e1> <e2> dyskinetic </e2> effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6794": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+", "entity2": "dyskinesias", "span1": [311, 369], "span2": [183, 194]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([<e1> -]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ </e1> <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6795": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+", "entity2": "dyskinetic", "span1": [311, 369], "span2": [225, 235]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([<e1> -]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ </e1> <e2> dyskinetic </e2> effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6796": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "ena[c]phenathrene-9-10-diol", "entity2": "dyskinesias", "span1": [388, 415], "span2": [183, 194]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- <e1> ena[c]phenathrene-9-10-diol </e1> <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6797": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "ena[c]phenathrene-9-10-diol", "entity2": "dyskinetic", "span1": [388, 415], "span2": [225, 235]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- <e1> ena[c]phenathrene-9-10-diol </e1> <e2> dyskinetic </e2> effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6798": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "DA", "entity2": "dyskinesias", "span1": [439, 441], "span2": [183, 194]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full <e1> DA </e1> <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6799": {"data": {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity1": "DA", "entity2": "dyskinetic", "span1": [439, 441], "span2": [225, 235]}, "bert_text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full <e1> DA </e1> <e2> dyskinetic </e2> effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6800": {"data": {"text": "The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.", "entity1": "anthracycline", "entity2": "cardiotoxicity", "span1": [35, 48], "span2": [4, 18]}, "bert_text": "The cardiotoxicity of conventional <e1> anthracycline </e1> <e2> cardiotoxicity </e2> of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6801": {"data": {"text": "The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.", "entity1": "anthracycline", "entity2": "cardiac dysfunction", "span1": [35, 48], "span2": [149, 168]}, "bert_text": "The cardiotoxicity of conventional <e1> anthracycline </e1> therapy highlights a need to search for methods that are highly sensitive and capable of predicting <e2> cardiac dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6802": {"data": {"text": "Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.", "entity1": "co-trimoxazole", "entity2": "HIV-infected", "span1": [214, 228], "span2": [56, 68]}, "bert_text": "Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during <e1> co-trimoxazole </e1> <e2> HIV-infected </e2> patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"6803": {"data": {"text": "Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.", "entity1": "co-trimoxazole", "entity2": "intrahepatic cholestasis", "span1": [214, 228], "span2": [99, 123]}, "bert_text": "Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during <e1> co-trimoxazole </e1> <e2> intrahepatic cholestasis </e2>, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"6804": {"data": {"text": "Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.", "entity1": "co-trimoxazole", "entity2": "liver abscess", "span1": [214, 228], "span2": [162, 175]}, "bert_text": "Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during <e1> co-trimoxazole </e1> <e2> liver abscess </e2> formation on radiologic exams, during co-trimoxazole treatment for PCP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6805": {"data": {"text": "Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.", "entity1": "co-trimoxazole", "entity2": "PCP", "span1": [214, 228], "span2": [243, 246]}, "bert_text": "Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during <e1> co-trimoxazole </e1> treatment for <e2> PCP </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6806": {"data": {"text": "We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.", "entity1": "pegylated interferon alpha-2b", "entity2": "delusional parasitosis", "span1": [92, 121], "span2": [47, 69]}, "bert_text": "We present a 49-year-old woman who developed a delusional parasitosis during treatment with <e1> pegylated interferon alpha-2b </e1> <e2> delusional parasitosis </e2> during treatment with pegylated interferon alpha-2b weekly and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6807": {"data": {"text": "We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.", "entity1": "ribavirin", "entity2": "delusional parasitosis", "span1": [133, 142], "span2": [47, 69]}, "bert_text": "We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and <e1> ribavirin </e1> <e2> delusional parasitosis </e2> during treatment with pegylated interferon alpha-2b weekly and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6808": {"data": {"text": "Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.", "entity1": "Amikacin", "entity2": "febrile neutropenia", "span1": [0, 8], "span2": [100, 119]}, "bert_text": "<e1> Amikacin </e1> is an aminoglycoside commonly used to provide empirical double gram-negative treatment for <e2> febrile neutropenia </e2> and other suspected infections.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6809": {"data": {"text": "Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.", "entity1": "Amikacin", "entity2": "infections", "span1": [0, 8], "span2": [140, 150]}, "bert_text": "<e1> Amikacin </e1> is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected <e2> infections </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6810": {"data": {"text": "Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.", "entity1": "aminoglycoside", "entity2": "febrile neutropenia", "span1": [15, 29], "span2": [100, 119]}, "bert_text": "Amikacin is an <e1> aminoglycoside </e1> commonly used to provide empirical double gram-negative treatment for <e2> febrile neutropenia </e2> and other suspected infections.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6811": {"data": {"text": "Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.", "entity1": "aminoglycoside", "entity2": "infections", "span1": [15, 29], "span2": [140, 150]}, "bert_text": "Amikacin is an <e1> aminoglycoside </e1> commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected <e2> infections </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6812": {"data": {"text": "No ototoxic factor, other than DFO, was present in any of the patients.", "entity1": "DFO", "entity2": "ototoxic", "span1": [31, 34], "span2": [3, 11]}, "bert_text": "No ototoxic factor, other than <e1> DFO </e1> <e2> ototoxic </e2> factor, other than DFO, was present in any of the patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"6813": {"data": {"text": "This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.", "entity1": "rifampin", "entity2": "pulmonary tuberculosis", "span1": [45, 53], "span2": [72, 94]}, "bert_text": "This patient underwent a 10-month regimen of <e1> rifampin </e1> and isoniazid for <e2> pulmonary tuberculosis </e2> and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6814": {"data": {"text": "This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.", "entity1": "rifampin", "entity2": "renal failure", "span1": [45, 53], "span2": [148, 161]}, "bert_text": "This patient underwent a 10-month regimen of <e1> rifampin </e1> and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe <e2> renal failure </e2> five weeks after completion of therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6815": {"data": {"text": "This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.", "entity1": "isoniazid", "entity2": "pulmonary tuberculosis", "span1": [58, 67], "span2": [72, 94]}, "bert_text": "This patient underwent a 10-month regimen of rifampin and <e1> isoniazid </e1> for <e2> pulmonary tuberculosis </e2> and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6816": {"data": {"text": "This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.", "entity1": "isoniazid", "entity2": "renal failure", "span1": [58, 67], "span2": [148, 161]}, "bert_text": "This patient underwent a 10-month regimen of rifampin and <e1> isoniazid </e1> for pulmonary tuberculosis and was discovered to have developed signs of severe <e2> renal failure </e2> five weeks after completion of therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6817": {"data": {"text": "RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).", "entity1": "mannitol", "entity2": "glioma", "span1": [34, 42], "span2": [17, 23]}, "bert_text": "RESULTS: In most glioma patients, <e1> mannitol </e1> <e2> glioma </e2> patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6818": {"data": {"text": "At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.", "entity1": "morphine", "entity2": "edema", "span1": [33, 41], "span2": [126, 131]}, "bert_text": "At the time of administration of <e1> morphine </e1>, histological modifications of the bladder wall, such as chorionic and muscle layer <e2> edema </e2>, were observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6819": {"data": {"text": "In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.", "entity1": "succinylcholine", "entity2": "postoperative myalgia", "span1": [21, 36], "span2": [123, 144]}, "bert_text": "In conclusion, where <e1> succinylcholine </e1> is used, lidocaine is proven to be the useful pretreatment agent for the reduction of <e2> postoperative myalgia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6820": {"data": {"text": "In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.", "entity1": "lidocaine", "entity2": "postoperative myalgia", "span1": [46, 55], "span2": [123, 144]}, "bert_text": "In conclusion, where succinylcholine is used, <e1> lidocaine </e1> is proven to be the useful pretreatment agent for the reduction of <e2> postoperative myalgia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6821": {"data": {"text": "A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.", "entity1": "CC", "entity2": "thromboembolic", "span1": [66, 68], "span2": [34, 48]}, "bert_text": "A search of the literature on the thromboembolic complications of <e1> CC </e1> <e2> thromboembolic </e2> complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6822": {"data": {"text": "A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.", "entity1": "CC", "entity2": "visual disturbance", "span1": [66, 68], "span2": [137, 155]}, "bert_text": "A search of the literature on the thromboembolic complications of <e1> CC </e1> does not include this severe ophthalmic complication, although mild <e2> visual disturbance </e2> after CC intake is not uncommon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6823": {"data": {"text": "A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.", "entity1": "CC", "entity2": "thromboembolic", "span1": [162, 164], "span2": [34, 48]}, "bert_text": "A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after <e1> CC </e1> <e2> thromboembolic </e2> complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6824": {"data": {"text": "A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.", "entity1": "CC", "entity2": "visual disturbance", "span1": [162, 164], "span2": [137, 155]}, "bert_text": "A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after <e1> CC </e1> <e2> visual disturbance </e2> after CC intake is not uncommon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6825": {"data": {"text": "Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.", "entity1": "quinine", "entity2": "neurological complications", "span1": [60, 67], "span2": [80, 106]}, "bert_text": "Numerous anecdotal reports suggest that products containing <e1> quinine </e1> may produce <e2> neurological complications </e2>, including confusion, altered mental status, seizures, and coma, particularly in older women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6826": {"data": {"text": "Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.", "entity1": "quinine", "entity2": "confusion", "span1": [60, 67], "span2": [118, 127]}, "bert_text": "Numerous anecdotal reports suggest that products containing <e1> quinine </e1> may produce neurological complications, including <e2> confusion </e2>, altered mental status, seizures, and coma, particularly in older women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6827": {"data": {"text": "Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.", "entity1": "quinine", "entity2": "seizures", "span1": [60, 67], "span2": [152, 160]}, "bert_text": "Numerous anecdotal reports suggest that products containing <e1> quinine </e1> may produce neurological complications, including confusion, altered mental status, <e2> seizures </e2>, and coma, particularly in older women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6828": {"data": {"text": "Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.", "entity1": "quinine", "entity2": "coma", "span1": [60, 67], "span2": [166, 170]}, "bert_text": "Numerous anecdotal reports suggest that products containing <e1> quinine </e1> may produce neurological complications, including confusion, altered mental status, seizures, and <e2> coma </e2>, particularly in older women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6829": {"data": {"text": "Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.\n", "entity1": "salbutamol", "entity2": "atrial tachyarrhythmia", "span1": [55, 65], "span2": [19, 41]}, "bert_text": "Swallowing-induced atrial tachyarrhythmia triggered by <e1> salbutamol </e1> <e2> atrial tachyarrhythmia </e2> triggered by salbutamol: case report and review of the literature.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6830": {"data": {"text": "The rats treated with DFP-atropine showed severe typical OP-induced toxicity signs.", "entity1": "DFP", "entity2": "toxicity", "span1": [22, 25], "span2": [68, 76]}, "bert_text": "The rats treated with <e1> DFP </e1>-atropine showed severe typical OP-induced <e2> toxicity </e2> signs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6831": {"data": {"text": "The rats treated with DFP-atropine showed severe typical OP-induced toxicity signs.", "entity1": "atropine", "entity2": "toxicity", "span1": [26, 34], "span2": [68, 76]}, "bert_text": "The rats treated with DFP-<e1> atropine </e1> showed severe typical OP-induced <e2> toxicity </e2> signs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6832": {"data": {"text": "The rats treated with DFP-atropine showed severe typical OP-induced toxicity signs.", "entity1": "OP", "entity2": "toxicity", "span1": [57, 59], "span2": [68, 76]}, "bert_text": "The rats treated with DFP-atropine showed severe typical <e1> OP </e1>-induced <e2> toxicity </e2> signs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6833": {"data": {"text": "These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.", "entity1": "estrogen", "entity2": "hypotension", "span1": [28, 36], "span2": [88, 99]}, "bert_text": "These findings suggest that <e1> estrogen </e1> downregulates alpha2- but not I1-receptor-mediated <e2> hypotension </e2> and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"6834": {"data": {"text": "These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.", "entity1": "estrogen", "entity2": "hypotension", "span1": [175, 183], "span2": [88, 99]}, "bert_text": "These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-<e1> estrogen </e1> <e2> hypotension </e2> and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"6835": {"data": {"text": "These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.", "entity1": "alpha-methyldopa", "entity2": "hypotension", "span1": [158, 174], "span2": [88, 99]}, "bert_text": "These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in <e1> alpha-methyldopa </e1> <e2> hypotension </e2> and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"6836": {"data": {"text": "In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.", "entity1": "thyroxine", "entity2": "eating disorders", "span1": [180, 189], "span2": [94, 110]}, "bert_text": "In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, <e1> thyroxine </e1> <e2> eating disorders </e2> and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6837": {"data": {"text": "In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.", "entity1": "thyroxine", "entity2": "thyrotoxicosis", "span1": [180, 189], "span2": [148, 162]}, "bert_text": "In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, <e1> thyroxine </e1> <e2> thyrotoxicosis </e2> remains obscure, thyroxine abuse should be considered and explored.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6838": {"data": {"text": "Although intravenous caffeine is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias.", "entity1": "caffeine", "entity2": "ventricular arrhythmias", "span1": [21, 29], "span2": [136, 159]}, "bert_text": "Although intravenous <e1> caffeine </e1> is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious <e2> ventricular arrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6839": {"data": {"text": "In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).", "entity1": "6-hydroxydopamine", "entity2": "PD", "span1": [132, 149], "span2": [170, 172]}, "bert_text": "In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally <e1> 6-hydroxydopamine </e1>-lesion rat model of <e2> PD </e2> treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6840": {"data": {"text": "In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).", "entity1": "L-DOPA", "entity2": "PD", "span1": [194, 200], "span2": [170, 172]}, "bert_text": "In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, <e1> L-DOPA </e1> <e2> PD </e2> treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6841": {"data": {"text": "In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).", "entity1": "bromocriptine", "entity2": "PD", "span1": [204, 217], "span2": [170, 172]}, "bert_text": "In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or <e1> bromocriptine </e1> <e2> PD </e2> treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6842": {"data": {"text": "CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.", "entity1": "carboplatin", "entity2": "ocular toxicity", "span1": [54, 65], "span2": [112, 127]}, "bert_text": "CONCLUSION: When performing intracarotid injection of <e1> carboplatin </e1>, we must be aware of its potentially blinding <e2> ocular toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6843": {"data": {"text": "CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.", "entity1": "modafinil", "entity2": "decreases daytime sleepiness", "span1": [27, 36], "span2": [98, 126]}, "bert_text": "CONCLUSIONS: Morning-dosed <e1> modafinil </e1> promotes nocturnal sleep, normalizes sleep architecture, and <e2> decreases daytime sleepiness </e2> in abstinent cocaine users.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6844": {"data": {"text": "CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.", "entity1": "cocaine", "entity2": "decreases daytime sleepiness", "span1": [140, 147], "span2": [98, 126]}, "bert_text": "CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent <e1> cocaine </e1> <e2> decreases daytime sleepiness </e2> in abstinent cocaine users.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6845": {"data": {"text": "Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.", "entity1": "Quinidine", "entity2": "hepatitis", "span1": [0, 9], "span2": [76, 85]}, "bert_text": "<e1> Quinidine </e1> itself or phenylethylbarbiturate may be responsible for fulminant <e2> hepatitis </e2> in this patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6846": {"data": {"text": "Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.", "entity1": "phenylethylbarbiturate", "entity2": "hepatitis", "span1": [20, 42], "span2": [76, 85]}, "bert_text": "Quinidine itself or <e1> phenylethylbarbiturate </e1> may be responsible for fulminant <e2> hepatitis </e2> in this patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6847": {"data": {"text": "The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.", "entity1": "vigabatrin", "entity2": "visual field loss", "span1": [107, 117], "span2": [129, 146]}, "bert_text": "The current study investigated the visual fields and visual electrophysiology of eight patients with known <e1> vigabatrin </e1>-attributed <e2> visual field loss </e2>, three of whom were reported previously.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6848": {"data": {"text": "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.\n", "entity1": "MPEP", "entity2": "neurotoxicity", "span1": [26, 30], "span2": [103, 116]}, "bert_text": "Neuroprotective action of <e1> MPEP </e1>, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic <e2> neurotoxicity </e2> is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6849": {"data": {"text": "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.\n", "entity1": "MPEP", "entity2": "hyperthermia", "span1": [26, 30], "span2": [185, 197]}, "bert_text": "Neuroprotective action of <e1> MPEP </e1>, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of <e2> hyperthermia </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6850": {"data": {"text": "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.\n", "entity1": "methamphetamine", "entity2": "neurotoxicity", "span1": [66, 81], "span2": [103, 116]}, "bert_text": "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in <e1> methamphetamine </e1>-induced dopaminergic <e2> neurotoxicity </e2> is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6851": {"data": {"text": "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.\n", "entity1": "methamphetamine", "entity2": "hyperthermia", "span1": [66, 81], "span2": [185, 197]}, "bert_text": "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in <e1> methamphetamine </e1>-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of <e2> hyperthermia </e2> in rats.\n", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6852": {"data": {"text": "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.\n", "entity1": "dopamine", "entity2": "neurotoxicity", "span1": [150, 158], "span2": [103, 116]}, "bert_text": "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in <e1> dopamine </e1> <e2> neurotoxicity </e2> is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6853": {"data": {"text": "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.\n", "entity1": "dopamine", "entity2": "hyperthermia", "span1": [150, 158], "span2": [185, 197]}, "bert_text": "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in <e1> dopamine </e1> outflow and inhibition of <e2> hyperthermia </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6854": {"data": {"text": "Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.", "entity1": "adriamycin", "entity2": "cardiomyopathy", "span1": [21, 31], "span2": [40, 54]}, "bert_text": "Using a rat model of <e1> adriamycin </e1>-induced <e2> cardiomyopathy </e2>, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6855": {"data": {"text": "Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.", "entity1": "adriamycin", "entity2": "cardiomyopathy", "span1": [21, 31], "span2": [191, 205]}, "bert_text": "Using a rat model of <e1> adriamycin </e1>-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin <e2> cardiomyopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6856": {"data": {"text": "Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.", "entity1": "adriamycin", "entity2": "cardiomyopathy", "span1": [180, 190], "span2": [40, 54]}, "bert_text": "Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in <e1> adriamycin </e1> <e2> cardiomyopathy </e2>, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6857": {"data": {"text": "Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.", "entity1": "adriamycin", "entity2": "cardiomyopathy", "span1": [180, 190], "span2": [191, 205]}, "bert_text": "Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in <e1> adriamycin </e1> <e2> cardiomyopathy </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6858": {"data": {"text": "Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.", "entity1": "Alpha-lipoic acid", "entity2": "neurotoxicity", "span1": [0, 17], "span2": [78, 91]}, "bert_text": "<e1> Alpha-lipoic acid </e1> exerts neuroprotective effects against chemotherapy induced <e2> neurotoxicity </e2> in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6859": {"data": {"text": "Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.", "entity1": "Alpha-lipoic acid", "entity2": "toxicity", "span1": [0, 17], "span2": [141, 149]}, "bert_text": "<e1> Alpha-lipoic acid </e1> exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial <e2> toxicity </e2> and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6860": {"data": {"text": "Hepatic veno-occlusive disease caused by 6-thioguanine.\n", "entity1": "6-thioguanine", "entity2": "Hepatic veno-occlusive disease", "span1": [41, 54], "span2": [0, 30]}, "bert_text": "Hepatic veno-occlusive disease caused by <e1> 6-thioguanine </e1> <e2> Hepatic veno-occlusive disease </e2> caused by 6-thioguanine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6861": {"data": {"text": "Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.", "entity1": "DFO", "entity2": "SNHL", "span1": [37, 40], "span2": [14, 18]}, "bert_text": "Subjects with SNHL were submitted to <e1> DFO </e1> <e2> SNHL </e2> were submitted to DFO reduction or temporary withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6862": {"data": {"text": "In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.", "entity1": "LTG", "entity2": "MJ", "span1": [19, 22], "span2": [35, 37]}, "bert_text": "In three patients, <e1> LTG </e1> exacerbated <e2> MJ </e2> in a dose-dependent manner with early aggravation during titration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6863": {"data": {"text": "Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.", "entity1": "Methamphetamine", "entity2": "neurotoxicity", "span1": [0, 15], "span2": [42, 55]}, "bert_text": "<e1> Methamphetamine </e1> (MA)-induced dopaminergic <e2> neurotoxicity </e2> is believed to be associated with the increased formation of free radicals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6864": {"data": {"text": "Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.", "entity1": "MA)-induced", "entity2": "neurotoxicity", "span1": [17, 28], "span2": [42, 55]}, "bert_text": "Methamphetamine (<e1> MA)-induced </e1> dopaminergic <e2> neurotoxicity </e2> is believed to be associated with the increased formation of free radicals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6865": {"data": {"text": "(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [20, 33], "span2": [49, 70]}, "bert_text": "(Anacardiaceae), on <e1> isoproterenol </e1> (ISPH)-induced <e2> myocardial infarction </e2> (MI) in rats through its antioxidative mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6866": {"data": {"text": "(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.", "entity1": "isoproterenol", "entity2": "MI", "span1": [20, 33], "span2": [72, 74]}, "bert_text": "(Anacardiaceae), on <e1> isoproterenol </e1> (ISPH)-induced myocardial infarction (<e2> MI </e2>) in rats through its antioxidative mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6867": {"data": {"text": "(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.", "entity1": "ISPH)-induced", "entity2": "myocardial infarction", "span1": [35, 48], "span2": [49, 70]}, "bert_text": "(Anacardiaceae), on isoproterenol (<e1> ISPH)-induced </e1> <e2> myocardial infarction </e2> (MI) in rats through its antioxidative mechanism.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6868": {"data": {"text": "(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.", "entity1": "ISPH)-induced", "entity2": "MI", "span1": [35, 48], "span2": [72, 74]}, "bert_text": "(Anacardiaceae), on isoproterenol (<e1> ISPH)-induced </e1> myocardial infarction (<e2> MI </e2>) in rats through its antioxidative mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6869": {"data": {"text": "Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.\n", "entity1": "gamma-hexachlorocyclohexane", "entity2": "seizures", "span1": [24, 51], "span2": [91, 99]}, "bert_text": "Differential effects of <e1> gamma-hexachlorocyclohexane </e1> (lindane) on pharmacologically-induced <e2> seizures </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6870": {"data": {"text": "Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.\n", "entity1": "lindane", "entity2": "seizures", "span1": [53, 60], "span2": [91, 99]}, "bert_text": "Differential effects of gamma-hexachlorocyclohexane (<e1> lindane </e1>) on pharmacologically-induced <e2> seizures </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6871": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "Gamma-hexachlorocyclohexane", "entity2": "seizure", "span1": [0, 27], "span2": [118, 125]}, "bert_text": "<e1> Gamma-hexachlorocyclohexane </e1> (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease <e2> seizure </e2> threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6872": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "Gamma-hexachlorocyclohexane", "entity2": "seizures", "span1": [0, 27], "span2": [242, 250]}, "bert_text": "<e1> Gamma-hexachlorocyclohexane </e1> (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced <e2> seizures </e2> 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6873": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "gamma-HCH", "entity2": "seizure", "span1": [29, 38], "span2": [118, 125]}, "bert_text": "Gamma-hexachlorocyclohexane (<e1> gamma-HCH </e1>), the active ingredient of the insecticide lindane, has been shown to decrease <e2> seizure </e2> threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6874": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "gamma-HCH", "entity2": "seizures", "span1": [29, 38], "span2": [242, 250]}, "bert_text": "Gamma-hexachlorocyclohexane (<e1> gamma-HCH </e1>), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced <e2> seizures </e2> 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6875": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "lindane", "entity2": "seizure", "span1": [82, 89], "span2": [118, 125]}, "bert_text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide <e1> lindane </e1>, has been shown to decrease <e2> seizure </e2> threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6876": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "lindane", "entity2": "seizures", "span1": [82, 89], "span2": [242, 250]}, "bert_text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide <e1> lindane </e1>, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced <e2> seizures </e2> 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6877": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "gamma-HCH", "entity2": "seizure", "span1": [183, 192], "span2": [118, 125]}, "bert_text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to <e1> gamma-HCH </e1> <e2> seizure </e2> threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6878": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "gamma-HCH", "entity2": "seizures", "span1": [183, 192], "span2": [242, 250]}, "bert_text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to <e1> gamma-HCH </e1> and conversely increase threshold to PTZ-induced <e2> seizures </e2> 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6879": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "gamma-HCH", "entity2": "seizure", "span1": [274, 283], "span2": [118, 125]}, "bert_text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to <e1> gamma-HCH </e1> <e2> seizure </e2> threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6880": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "gamma-HCH", "entity2": "seizures", "span1": [274, 283], "span2": [242, 250]}, "bert_text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to <e1> gamma-HCH </e1> <e2> seizures </e2> 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6881": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "PTZ", "entity2": "seizure", "span1": [156, 159], "span2": [118, 125]}, "bert_text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (<e1> PTZ </e1> <e2> seizure </e2> threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6882": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "PTZ", "entity2": "seizures", "span1": [156, 159], "span2": [242, 250]}, "bert_text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (<e1> PTZ </e1>) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced <e2> seizures </e2> 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6883": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "PTZ", "entity2": "seizure", "span1": [230, 233], "span2": [118, 125]}, "bert_text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to <e1> PTZ </e1> <e2> seizure </e2> threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6884": {"data": {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al.", "entity1": "PTZ", "entity2": "seizures", "span1": [230, 233], "span2": [242, 250]}, "bert_text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to <e1> PTZ </e1>-induced <e2> seizures </e2> 24 h after exposure to gamma-HCH (Vohland et al.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6885": {"data": {"text": "Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.\n", "entity1": "cibenzoline", "entity2": "ventricular arrhythmias", "span1": [40, 51], "span2": [62, 85]}, "bert_text": "Antiarrhythmic plasma concentrations of <e1> cibenzoline </e1> on canine <e2> ventricular arrhythmias </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6886": {"data": {"text": "Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.", "entity1": "adrenaline", "entity2": "ventricular arrhythmias", "span1": [52, 62], "span2": [78, 101]}, "bert_text": "Using two-stage coronary ligation-, digitalis-, and <e1> adrenaline </e1>-induced canine <e2> ventricular arrhythmias </e2>, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6887": {"data": {"text": "Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.", "entity1": "adrenaline", "entity2": "arrhythmia", "span1": [52, 62], "span2": [211, 221]}, "bert_text": "Using two-stage coronary ligation-, digitalis-, and <e1> adrenaline </e1>-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each <e2> arrhythmia </e2> model was determined.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6888": {"data": {"text": "Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.", "entity1": "cibenzoline", "entity2": "ventricular arrhythmias", "span1": [129, 140], "span2": [78, 101]}, "bert_text": "Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of <e1> cibenzoline </e1> <e2> ventricular arrhythmias </e2>, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6889": {"data": {"text": "Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.", "entity1": "cibenzoline", "entity2": "arrhythmia", "span1": [129, 140], "span2": [211, 221]}, "bert_text": "Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of <e1> cibenzoline </e1> were examined and the minimum effective plasma concentration for each <e2> arrhythmia </e2> model was determined.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6890": {"data": {"text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "entity1": "N-nitroso-N-methylurea", "entity2": "prostate adenocarcinomas", "span1": [132, 154], "span2": [75, 99]}, "bert_text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with <e1> N-nitroso-N-methylurea </e1> <e2> prostate adenocarcinomas </e2> (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6891": {"data": {"text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "entity1": "N-nitroso-N-methylurea", "entity2": "PAs", "span1": [132, 154], "span2": [101, 104]}, "bert_text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with <e1> N-nitroso-N-methylurea </e1> <e2> PAs </e2>) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6892": {"data": {"text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "entity1": "N-nitroso-N-methylurea", "entity2": "tumor", "span1": [132, 154], "span2": [236, 241]}, "bert_text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with <e1> N-nitroso-N-methylurea </e1> (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the <e2> tumor </e2>-bearing rats manifested metastatic lesions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6893": {"data": {"text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "entity1": "testosterone propionate", "entity2": "prostate adenocarcinomas", "span1": [175, 198], "span2": [75, 99]}, "bert_text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and <e1> testosterone propionate </e1> <e2> prostate adenocarcinomas </e2> (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6894": {"data": {"text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "entity1": "testosterone propionate", "entity2": "PAs", "span1": [175, 198], "span2": [101, 104]}, "bert_text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and <e1> testosterone propionate </e1> <e2> PAs </e2>) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6895": {"data": {"text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "entity1": "testosterone propionate", "entity2": "tumor", "span1": [175, 198], "span2": [236, 241]}, "bert_text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and <e1> testosterone propionate </e1> [(TP) CAS: 57-85-2], and most of the <e2> tumor </e2>-bearing rats manifested metastatic lesions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6896": {"data": {"text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "entity1": "TP", "entity2": "prostate adenocarcinomas", "span1": [201, 203], "span2": [75, 99]}, "bert_text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(<e1> TP </e1> <e2> prostate adenocarcinomas </e2> (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6897": {"data": {"text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "entity1": "TP", "entity2": "PAs", "span1": [201, 203], "span2": [101, 104]}, "bert_text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(<e1> TP </e1> <e2> PAs </e2>) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6898": {"data": {"text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "entity1": "TP", "entity2": "tumor", "span1": [201, 203], "span2": [236, 241]}, "bert_text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(<e1> TP </e1>) CAS: 57-85-2], and most of the <e2> tumor </e2>-bearing rats manifested metastatic lesions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6899": {"data": {"text": "A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.", "entity1": "phenobarbital", "entity2": "neurologic impairment", "span1": [95, 108], "span2": [30, 51]}, "bert_text": "A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting <e1> phenobarbital </e1> <e2> neurologic impairment </e2> developed a dyskinesia soon after starting phenobarbital therapy for seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6900": {"data": {"text": "A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.", "entity1": "phenobarbital", "entity2": "dyskinesia", "span1": [95, 108], "span2": [64, 74]}, "bert_text": "A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting <e1> phenobarbital </e1> <e2> dyskinesia </e2> soon after starting phenobarbital therapy for seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6901": {"data": {"text": "A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.", "entity1": "phenobarbital", "entity2": "seizures", "span1": [95, 108], "span2": [121, 129]}, "bert_text": "A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting <e1> phenobarbital </e1> therapy for <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6902": {"data": {"text": "Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.", "entity1": "Warfarin", "entity2": "calcification", "span1": [8, 16], "span2": [249, 262]}, "bert_text": "Because <e1> Warfarin </e1> treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6903": {"data": {"text": "Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.", "entity1": "Warfarin", "entity2": "calcification", "span1": [118, 126], "span2": [249, 262]}, "bert_text": "Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between <e1> Warfarin </e1> and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6904": {"data": {"text": "Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.", "entity1": "Warfarin", "entity2": "calcification", "span1": [191, 199], "span2": [249, 262]}, "bert_text": "Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that <e1> Warfarin </e1> inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6905": {"data": {"text": "Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.", "entity1": "calcium", "entity2": "calcification", "span1": [67, 74], "span2": [249, 262]}, "bert_text": "Because Warfarin treatment had no effect on the elevation in serum <e1> calcium </e1> produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6906": {"data": {"text": "Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.", "entity1": "vitamin D", "entity2": "calcification", "span1": [87, 96], "span2": [249, 262]}, "bert_text": "Because Warfarin treatment had no effect on the elevation in serum calcium produced by <e1> vitamin D </e1>, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6907": {"data": {"text": "Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.", "entity1": "vitamin D", "entity2": "calcification", "span1": [131, 140], "span2": [249, 262]}, "bert_text": "Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and <e1> vitamin D </e1> is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a <e2> calcification </e2> inhibitor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6908": {"data": {"text": "Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.", "entity1": "nifedipine", "entity2": "Prinzmetal's angina", "span1": [131, 141], "span2": [72, 91]}, "bert_text": "Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with <e1> nifedipine </e1> <e2> Prinzmetal's angina </e2>, and chest pain promptly resolved with nifedipine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6909": {"data": {"text": "Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.", "entity1": "nifedipine", "entity2": "chest pain", "span1": [131, 141], "span2": [97, 107]}, "bert_text": "Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with <e1> nifedipine </e1> <e2> chest pain </e2> promptly resolved with nifedipine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6910": {"data": {"text": "This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.", "entity1": "levodopa", "entity2": "choreic dyskinesia", "span1": [82, 90], "span2": [113, 131]}, "bert_text": "This study suggests that administration of low doses of beta-blockers may improve <e1> levodopa </e1>-induced ballistic and <e2> choreic dyskinesia </e2> in PD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"6911": {"data": {"text": "This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.", "entity1": "levodopa", "entity2": "PD", "span1": [82, 90], "span2": [135, 137]}, "bert_text": "This study suggests that administration of low doses of beta-blockers may improve <e1> levodopa </e1>-induced ballistic and choreic dyskinesia in <e2> PD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6912": {"data": {"text": "To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.", "entity1": "salbutamol", "entity2": "tremor", "span1": [133, 143], "span2": [37, 43]}, "bert_text": "To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of <e1> salbutamol </e1> <e2> tremor </e2> in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6913": {"data": {"text": "To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.", "entity1": "salbutamol", "entity2": "obstructive lung disease", "span1": [133, 143], "span2": [64, 88]}, "bert_text": "To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of <e1> salbutamol </e1> <e2> obstructive lung disease </e2> after administration of cumulative doses of salbutamol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6914": {"data": {"text": "The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.", "entity1": "fusidic acid", "entity2": "Crohn's disease", "span1": [45, 57], "span2": [103, 118]}, "bert_text": "The results of this pilot study suggest that <e1> fusidic acid </e1> may be of benefit in selected chronic active <e2> Crohn's disease </e2> patients in whom conventional treatment is ineffective.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6915": {"data": {"text": "OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.", "entity1": "amphotericin B", "entity2": "Nephrotoxicity", "span1": [57, 71], "span2": [11, 25]}, "bert_text": "OBJECTIVE: Nephrotoxicity is the major adverse effect of <e1> amphotericin B </e1> <e2> Nephrotoxicity </e2> is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6916": {"data": {"text": "OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.", "entity1": "AmB", "entity2": "Nephrotoxicity", "span1": [73, 76], "span2": [11, 25]}, "bert_text": "OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (<e1> AmB </e1> <e2> Nephrotoxicity </e2> is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6917": {"data": {"text": "Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.", "entity1": "MZ", "entity2": "stroke", "span1": [185, 187], "span2": [100, 106]}, "bert_text": "Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the <e1> MZ </e1> <e2> stroke </e2>, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6918": {"data": {"text": "Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.", "entity1": "MZ", "entity2": "myocardiopathy", "span1": [185, 187], "span2": [108, 122]}, "bert_text": "Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the <e1> MZ </e1> <e2> myocardiopathy </e2> (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6919": {"data": {"text": "Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.", "entity1": "MZ", "entity2": "MP", "span1": [185, 187], "span2": [124, 126]}, "bert_text": "Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the <e1> MZ </e1> <e2> MP </e2>), duration of the test, mitral regurgitation (MR) and the MZ dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6920": {"data": {"text": "Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.", "entity1": "MZ", "entity2": "mitral regurgitation", "span1": [185, 187], "span2": [151, 171]}, "bert_text": "Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the <e1> MZ </e1> <e2> mitral regurgitation </e2> (MR) and the MZ dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6921": {"data": {"text": "Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.", "entity1": "MZ", "entity2": "MR", "span1": [185, 187], "span2": [173, 175]}, "bert_text": "Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the <e1> MZ </e1> <e2> MR </e2>) and the MZ dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6922": {"data": {"text": "The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.\n", "entity1": "acetylcholine", "entity2": "seizures", "span1": [31, 44], "span2": [98, 106]}, "bert_text": "The alpha3 and beta4 nicotinic <e1> acetylcholine </e1> receptor subunits are necessary for nicotine-induced <e2> seizures </e2> and hypolocomotion in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6923": {"data": {"text": "The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.\n", "entity1": "acetylcholine", "entity2": "hypolocomotion", "span1": [31, 44], "span2": [111, 125]}, "bert_text": "The alpha3 and beta4 nicotinic <e1> acetylcholine </e1> receptor subunits are necessary for nicotine-induced seizures and <e2> hypolocomotion </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6924": {"data": {"text": "The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.\n", "entity1": "nicotine", "entity2": "seizures", "span1": [81, 89], "span2": [98, 106]}, "bert_text": "The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for <e1> nicotine </e1>-induced <e2> seizures </e2> and hypolocomotion in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6925": {"data": {"text": "The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.\n", "entity1": "nicotine", "entity2": "hypolocomotion", "span1": [81, 89], "span2": [111, 125]}, "bert_text": "The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for <e1> nicotine </e1>-induced seizures and <e2> hypolocomotion </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6926": {"data": {"text": "Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.", "entity1": "nicotine", "entity2": "tremors", "span1": [11, 19], "span2": [159, 166]}, "bert_text": "Binding of <e1> nicotine </e1> to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and <e2> tremors </e2>, to seizures and death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6927": {"data": {"text": "Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.", "entity1": "nicotine", "entity2": "seizures", "span1": [11, 19], "span2": [171, 179]}, "bert_text": "Binding of <e1> nicotine </e1> to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to <e2> seizures </e2> and death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6928": {"data": {"text": "Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.", "entity1": "nicotine", "entity2": "death", "span1": [11, 19], "span2": [184, 189]}, "bert_text": "Binding of <e1> nicotine </e1> to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and <e2> death </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6929": {"data": {"text": "Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.", "entity1": "acetylcholine", "entity2": "tremors", "span1": [33, 46], "span2": [159, 166]}, "bert_text": "Binding of nicotine to nicotinic <e1> acetylcholine </e1> receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and <e2> tremors </e2>, to seizures and death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6930": {"data": {"text": "Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.", "entity1": "acetylcholine", "entity2": "seizures", "span1": [33, 46], "span2": [171, 179]}, "bert_text": "Binding of nicotine to nicotinic <e1> acetylcholine </e1> receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to <e2> seizures </e2> and death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6931": {"data": {"text": "Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.", "entity1": "acetylcholine", "entity2": "death", "span1": [33, 46], "span2": [184, 189]}, "bert_text": "Binding of nicotine to nicotinic <e1> acetylcholine </e1> receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and <e2> death </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6932": {"data": {"text": "In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.", "entity1": "PG-9", "entity2": "amnesia", "span1": [37, 41], "span2": [122, 129]}, "bert_text": "In the mouse passive-avoidance test, <e1> PG-9 </e1> (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented <e2> amnesia </e2> induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6933": {"data": {"text": "In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [184, 195], "span2": [122, 129]}, "bert_text": "In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug <e1> scopolamine </e1> <e2> amnesia </e2> induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"6934": {"data": {"text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "entity1": "lisinopril", "entity2": "hypertension", "span1": [63, 73], "span2": [130, 142]}, "bert_text": "The authors present a 10-year-old boy chronically treated with <e1> lisinopril </e1>, an angiotensin converting enzyme inhibitor, to control <e2> hypertension </e2> who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6935": {"data": {"text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "entity1": "lisinopril", "entity2": "hypotension", "span1": [63, 73], "span2": [157, 168]}, "bert_text": "The authors present a 10-year-old boy chronically treated with <e1> lisinopril </e1>, an angiotensin converting enzyme inhibitor, to control hypertension who developed <e2> hypotension </e2> following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6936": {"data": {"text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "entity1": "lisinopril", "entity2": "spasticity", "span1": [63, 73], "span2": [248, 258]}, "bert_text": "The authors present a 10-year-old boy chronically treated with <e1> lisinopril </e1>, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of <e2> spasticity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6937": {"data": {"text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "entity1": "angiotensin", "entity2": "hypertension", "span1": [78, 89], "span2": [130, 142]}, "bert_text": "The authors present a 10-year-old boy chronically treated with lisinopril, an <e1> angiotensin </e1> converting enzyme inhibitor, to control <e2> hypertension </e2> who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6938": {"data": {"text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "entity1": "angiotensin", "entity2": "hypotension", "span1": [78, 89], "span2": [157, 168]}, "bert_text": "The authors present a 10-year-old boy chronically treated with lisinopril, an <e1> angiotensin </e1> converting enzyme inhibitor, to control hypertension who developed <e2> hypotension </e2> following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6939": {"data": {"text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "entity1": "angiotensin", "entity2": "spasticity", "span1": [78, 89], "span2": [248, 258]}, "bert_text": "The authors present a 10-year-old boy chronically treated with lisinopril, an <e1> angiotensin </e1> converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of <e2> spasticity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6940": {"data": {"text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "entity1": "tizanidine", "entity2": "hypertension", "span1": [195, 205], "span2": [130, 142]}, "bert_text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of <e1> tizanidine </e1> <e2> hypertension </e2> who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6941": {"data": {"text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "entity1": "tizanidine", "entity2": "hypotension", "span1": [195, 205], "span2": [157, 168]}, "bert_text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of <e1> tizanidine </e1> <e2> hypotension </e2> following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6942": {"data": {"text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "entity1": "tizanidine", "entity2": "spasticity", "span1": [195, 205], "span2": [248, 258]}, "bert_text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of <e1> tizanidine </e1>, an alpha-2 agonist, for the treatment of <e2> spasticity </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6943": {"data": {"text": "Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.\n", "entity1": "octreotide", "entity2": "gall bladder stones", "span1": [51, 61], "span2": [15, 34]}, "bert_text": "Composition of gall bladder stones associated with <e1> octreotide </e1> <e2> gall bladder stones </e2> associated with octreotide: response to oral ursodeoxycholic acid.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6944": {"data": {"text": "Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.\n", "entity1": "ursodeoxycholic acid", "entity2": "gall bladder stones", "span1": [80, 100], "span2": [15, 34]}, "bert_text": "Composition of gall bladder stones associated with octreotide: response to oral <e1> ursodeoxycholic acid </e1> <e2> gall bladder stones </e2> associated with octreotide: response to oral ursodeoxycholic acid.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6945": {"data": {"text": "Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/-", "entity1": "Cibenzoline", "entity2": "arrhythmias", "span1": [0, 11], "span2": [31, 42]}, "bert_text": "<e1> Cibenzoline </e1> suppressed all the <e2> arrhythmias </e2>, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6946": {"data": {"text": "Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/-", "entity1": "Cibenzoline", "entity2": "arrhythmias", "span1": [0, 11], "span2": [96, 107]}, "bert_text": "<e1> Cibenzoline </e1> suppressed all the arrhythmias, and the minimum effective plasma concentrations for <e2> arrhythmias </e2> induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/-", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6947": {"data": {"text": "Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/-", "entity1": "adrenaline", "entity2": "arrhythmias", "span1": [182, 192], "span2": [31, 42]}, "bert_text": "Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and <e1> adrenaline </e1> <e2> arrhythmias </e2>, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6948": {"data": {"text": "Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/-", "entity1": "adrenaline", "entity2": "arrhythmias", "span1": [182, 192], "span2": [96, 107]}, "bert_text": "Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and <e1> adrenaline </e1> <e2> arrhythmias </e2> induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"6949": {"data": {"text": "Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.", "entity1": "salbutamol", "entity2": "tachycardia", "span1": [111, 121], "span2": [139, 150]}, "bert_text": "Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like <e1> salbutamol </e1> (known to induce <e2> tachycardia </e2>) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6950": {"data": {"text": "Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.", "entity1": "atenolol", "entity2": "tachycardia", "span1": [272, 280], "span2": [139, 150]}, "bert_text": "Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as <e1> atenolol </e1> <e2> tachycardia </e2>) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6951": {"data": {"text": "METHODS: A review of admissions during a 6-year period revealed 14 patients with cocaine-related aneurysms.", "entity1": "cocaine", "entity2": "aneurysms", "span1": [81, 88], "span2": [97, 106]}, "bert_text": "METHODS: A review of admissions during a 6-year period revealed 14 patients with <e1> cocaine </e1>-related <e2> aneurysms </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6952": {"data": {"text": "Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.", "entity1": "diethylstilbestrol", "entity2": "Pituitary tumors", "span1": [76, 94], "span2": [0, 16]}, "bert_text": "Pituitary tumors were induced in F344 female rats by chronic treatment with <e1> diethylstilbestrol </e1> <e2> Pituitary tumors </e2> were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6953": {"data": {"text": "Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.", "entity1": "DES", "entity2": "Pituitary tumors", "span1": [96, 99], "span2": [0, 16]}, "bert_text": "Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (<e1> DES </e1> <e2> Pituitary tumors </e2> were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6954": {"data": {"text": "Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats.\n", "entity1": "bupivacaine-", "entity2": "toxicity", "span1": [39, 51], "span2": [9, 17]}, "bert_text": "Systemic toxicity and resuscitation in <e1> bupivacaine- </e1> <e2> toxicity </e2> and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6955": {"data": {"text": "Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats.\n", "entity1": "levobupivacaine-", "entity2": "toxicity", "span1": [53, 69], "span2": [9, 17]}, "bert_text": "Systemic toxicity and resuscitation in bupivacaine-, <e1> levobupivacaine- </e1> <e2> toxicity </e2> and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6956": {"data": {"text": "Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats.\n", "entity1": "ropivacaine", "entity2": "toxicity", "span1": [74, 85], "span2": [9, 17]}, "bert_text": "Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine-, or <e1> ropivacaine </e1> <e2> toxicity </e2> and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6957": {"data": {"text": "Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.", "entity1": "fusidic acid", "entity2": "inflammatory bowel disease", "span1": [67, 79], "span2": [105, 131]}, "bert_text": "Because there seems to exist a scientific rationale for the use of <e1> fusidic acid </e1> at the cytokine level in <e2> inflammatory bowel disease </e2>, we suggest that the role of this treatment should be further investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6958": {"data": {"text": "Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).", "entity1": "angiotensin", "entity2": "nephrotic syndrome", "span1": [54, 65], "span2": [107, 125]}, "bert_text": "Plasma concentration and urine excretion of the renin-<e1> angiotensin </e1> system proteins are altered in rats with <e2> nephrotic syndrome </e2> (NS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6959": {"data": {"text": "Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).", "entity1": "angiotensin", "entity2": "NS", "span1": [54, 65], "span2": [127, 129]}, "bert_text": "Plasma concentration and urine excretion of the renin-<e1> angiotensin </e1> system proteins are altered in rats with nephrotic syndrome (<e2> NS </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6960": {"data": {"text": "We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.", "entity1": "bupivacaine", "entity2": "toxicity", "span1": [37, 48], "span2": [25, 33]}, "bert_text": "We compared the systemic toxicity of <e1> bupivacaine </e1> <e2> toxicity </e2> of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6961": {"data": {"text": "We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.", "entity1": "levobupivacaine", "entity2": "toxicity", "span1": [50, 65], "span2": [25, 33]}, "bert_text": "We compared the systemic toxicity of bupivacaine, <e1> levobupivacaine </e1> <e2> toxicity </e2> of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6962": {"data": {"text": "We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.", "entity1": "ropivacaine", "entity2": "toxicity", "span1": [71, 82], "span2": [25, 33]}, "bert_text": "We compared the systemic toxicity of bupivacaine, levobupivacaine, and <e1> ropivacaine </e1> <e2> toxicity </e2> of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6963": {"data": {"text": "The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.", "entity1": "alprazolam", "entity2": "panic disorder", "span1": [16, 26], "span2": [42, 56]}, "bert_text": "The efficacy of <e1> alprazolam </e1> and placebo in <e2> panic disorder </e2> with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6964": {"data": {"text": "The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.", "entity1": "alprazolam", "entity2": "agoraphobia", "span1": [16, 26], "span2": [62, 73]}, "bert_text": "The efficacy of <e1> alprazolam </e1> and placebo in panic disorder with <e2> agoraphobia </e2>, and the side-effect and adverse effect profiles of both drug groups were measured.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6965": {"data": {"text": "Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.", "entity1": "Melatonin", "entity2": "narcosis", "span1": [0, 9], "span2": [103, 111]}, "bert_text": "<e1> Melatonin </e1> 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced <e2> narcosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6966": {"data": {"text": "Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.", "entity1": "ketamine-", "entity2": "narcosis", "span1": [73, 82], "span2": [103, 111]}, "bert_text": "Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of <e1> ketamine- </e1> or diazepam-induced <e2> narcosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6967": {"data": {"text": "Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.", "entity1": "diazepam", "entity2": "narcosis", "span1": [86, 94], "span2": [103, 111]}, "bert_text": "Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or <e1> diazepam </e1>-induced <e2> narcosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6968": {"data": {"text": "Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.", "entity1": "octreotide", "entity2": "Pulmonary hypertension", "span1": [82, 92], "span2": [0, 22]}, "bert_text": "Pulmonary hypertension developed after administration of a somatostatin analogue, <e1> octreotide </e1> <e2> Pulmonary hypertension </e2> developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6969": {"data": {"text": "Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.", "entity1": "octreotide", "entity2": "fistula", "span1": [82, 92], "span2": [123, 130]}, "bert_text": "Pulmonary hypertension developed after administration of a somatostatin analogue, <e1> octreotide </e1>, to enhance resolution of the <e2> fistula </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6970": {"data": {"text": "In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.", "entity1": "paclitaxel", "entity2": "toxicity", "span1": [70, 80], "span2": [28, 36]}, "bert_text": "In conclusion mitochondrial toxicity is an early common event both in <e1> paclitaxel </e1> <e2> toxicity </e2> is an early common event both in paclitaxel and cisplatin induced neurotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6971": {"data": {"text": "In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.", "entity1": "paclitaxel", "entity2": "neurotoxicity", "span1": [70, 80], "span2": [103, 116]}, "bert_text": "In conclusion mitochondrial toxicity is an early common event both in <e1> paclitaxel </e1> and cisplatin induced <e2> neurotoxicity </e2>.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6972": {"data": {"text": "In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.", "entity1": "cisplatin", "entity2": "toxicity", "span1": [85, 94], "span2": [28, 36]}, "bert_text": "In conclusion mitochondrial toxicity is an early common event both in paclitaxel and <e1> cisplatin </e1> <e2> toxicity </e2> is an early common event both in paclitaxel and cisplatin induced neurotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6973": {"data": {"text": "In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.", "entity1": "cisplatin", "entity2": "neurotoxicity", "span1": [85, 94], "span2": [103, 116]}, "bert_text": "In conclusion mitochondrial toxicity is an early common event both in paclitaxel and <e1> cisplatin </e1> induced <e2> neurotoxicity </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6974": {"data": {"text": "The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.", "entity1": "prochlorperazine", "entity2": "headache", "span1": [16, 32], "span2": [53, 61]}, "bert_text": "The efficacy of <e1> prochlorperazine </e1> in the treatment of <e2> headache </e2> and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6975": {"data": {"text": "The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.", "entity1": "prochlorperazine", "entity2": "nausea", "span1": [16, 32], "span2": [66, 72]}, "bert_text": "The efficacy of <e1> prochlorperazine </e1> in the treatment of headache and <e2> nausea </e2> likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6976": {"data": {"text": "Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.", "entity1": "propranolol", "entity2": "arrhythmia", "span1": [51, 62], "span2": [99, 109]}, "bert_text": "Its antiarrhythmic effectiveness surpasses that of <e1> propranolol </e1> and pindolol inhibiting the ouabain <e2> arrhythmia </e2> in dogs and cats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6977": {"data": {"text": "Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.", "entity1": "pindolol", "entity2": "arrhythmia", "span1": [67, 75], "span2": [99, 109]}, "bert_text": "Its antiarrhythmic effectiveness surpasses that of propranolol and <e1> pindolol </e1> inhibiting the ouabain <e2> arrhythmia </e2> in dogs and cats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6978": {"data": {"text": "Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.", "entity1": "ouabain", "entity2": "arrhythmia", "span1": [91, 98], "span2": [99, 109]}, "bert_text": "Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the <e1> ouabain </e1> <e2> arrhythmia </e2> in dogs and cats.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6979": {"data": {"text": "Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.", "entity1": "Ifosfamide", "entity2": "nephrotoxic", "span1": [0, 10], "span2": [22, 33]}, "bert_text": "<e1> Ifosfamide </e1> is a known <e2> nephrotoxic </e2> drug with demonstrated tubulopathies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6980": {"data": {"text": "Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.", "entity1": "Ifosfamide", "entity2": "tubulopathies", "span1": [0, 10], "span2": [57, 70]}, "bert_text": "<e1> Ifosfamide </e1> is a known nephrotoxic drug with demonstrated <e2> tubulopathies </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6981": {"data": {"text": "Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.\n", "entity1": "cocaine", "entity2": "subarachnoid hemorrhage", "span1": [49, 56], "span2": [68, 91]}, "bert_text": "Absence of acute cerebral vasoconstriction after <e1> cocaine </e1>-associated <e2> subarachnoid hemorrhage </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6982": {"data": {"text": "Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.\n", "entity1": "morphine", "entity2": "pain", "span1": [50, 58], "span2": [111, 115]}, "bert_text": "Sex differences in NMDA antagonist enhancement of <e1> morphine </e1> antihyperalgesia in a capsaicin model of persistent <e2> pain </e2>: comparisons to two models of acute pain.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6983": {"data": {"text": "Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.\n", "entity1": "morphine", "entity2": "acute pain", "span1": [50, 58], "span2": [146, 156]}, "bert_text": "Sex differences in NMDA antagonist enhancement of <e1> morphine </e1> antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of <e2> acute pain </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6984": {"data": {"text": "Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.\n", "entity1": "capsaicin", "entity2": "pain", "span1": [81, 90], "span2": [111, 115]}, "bert_text": "Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a <e1> capsaicin </e1> model of persistent <e2> pain </e2>: comparisons to two models of acute pain.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6985": {"data": {"text": "Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.\n", "entity1": "capsaicin", "entity2": "acute pain", "span1": [81, 90], "span2": [146, 156]}, "bert_text": "Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a <e1> capsaicin </e1> model of persistent pain: comparisons to two models of <e2> acute pain </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6986": {"data": {"text": "In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.", "entity1": "TET", "entity2": "thrombosis", "span1": [61, 64], "span2": [106, 116]}, "bert_text": "In the in vivo study, the administration (50 mg/kg, i.p.) of <e1> TET </e1> and FAN in mice showed the inhibition of <e2> thrombosis </e2> by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6987": {"data": {"text": "In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.", "entity1": "FAN", "entity2": "thrombosis", "span1": [69, 72], "span2": [106, 116]}, "bert_text": "In the in vivo study, the administration (50 mg/kg, i.p.) of TET and <e1> FAN </e1> in mice showed the inhibition of <e2> thrombosis </e2> by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6988": {"data": {"text": "In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.", "entity1": "acetylsalicylic acid", "entity2": "thrombosis", "span1": [153, 173], "span2": [106, 116]}, "bert_text": "In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while <e1> acetylsalicylic acid </e1> <e2> thrombosis </e2> by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6989": {"data": {"text": "In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.", "entity1": "ASA", "entity2": "thrombosis", "span1": [175, 178], "span2": [106, 116]}, "bert_text": "In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (<e1> ASA </e1> <e2> thrombosis </e2> by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6990": {"data": {"text": "METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.", "entity1": "enalapril", "entity2": "Left Ventricular Dysfunction", "span1": [139, 148], "span2": [45, 73]}, "bert_text": "METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of <e1> enalapril </e1> <e2> Left Ventricular Dysfunction </e2> (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6991": {"data": {"text": "METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.", "entity1": "enalapril", "entity2": "SOLVD", "span1": [139, 148], "span2": [75, 80]}, "bert_text": "METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of <e1> enalapril </e1> <e2> SOLVD </e2>), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6992": {"data": {"text": "METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.", "entity1": "enalapril", "entity2": "CHF", "span1": [139, 148], "span2": [170, 173]}, "bert_text": "METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of <e1> enalapril </e1> for the treatment of <e2> CHF </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6993": {"data": {"text": "Methimazole-induced cholestatic jaundice.\n", "entity1": "Methimazole", "entity2": "cholestatic jaundice", "span1": [0, 11], "span2": [20, 40]}, "bert_text": "<e1> Methimazole </e1>-induced <e2> cholestatic jaundice </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6994": {"data": {"text": "Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.)", "entity1": "haloperidol", "entity2": "Catalepsy", "span1": [25, 36], "span2": [0, 9]}, "bert_text": "Catalepsy was induced by <e1> haloperidol </e1> <e2> Catalepsy </e2> was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6995": {"data": {"text": "Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.)", "entity1": "apomorphine", "entity2": "Catalepsy", "span1": [59, 70], "span2": [0, 9]}, "bert_text": "Catalepsy was induced by haloperidol (2 mg/kg p.o.), while <e1> apomorphine </e1> <e2> Catalepsy </e2> was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.)", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6996": {"data": {"text": "Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.)", "entity1": "amphetamine", "entity2": "Catalepsy", "span1": [92, 103], "span2": [0, 9]}, "bert_text": "Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and <e1> amphetamine </e1> <e2> Catalepsy </e2> was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.)", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"6997": {"data": {"text": "The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.", "entity1": "neurotensin", "entity2": "parkinsonian symptoms", "span1": [63, 74], "span2": [98, 119]}, "bert_text": "The present study aimed to investigate the effects of pallidal <e1> neurotensin </e1> on haloperidol-induced <e2> parkinsonian symptoms </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6998": {"data": {"text": "The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.", "entity1": "haloperidol", "entity2": "parkinsonian symptoms", "span1": [78, 89], "span2": [98, 119]}, "bert_text": "The present study aimed to investigate the effects of pallidal neurotensin on <e1> haloperidol </e1>-induced <e2> parkinsonian symptoms </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"6999": {"data": {"text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "entity1": "creatinine", "entity2": "CRF", "span1": [84, 94], "span2": [32, 35]}, "bert_text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum <e1> creatinine </e1> <e2> CRF </e2> and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7000": {"data": {"text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "entity1": "creatinine", "entity2": "ESRD", "span1": [84, 94], "span2": [40, 44]}, "bert_text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum <e1> creatinine </e1> <e2> ESRD </e2> patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7001": {"data": {"text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "entity1": "creatinine", "entity2": "hepatorenal syndrome", "span1": [84, 94], "span2": [141, 161]}, "bert_text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum <e1> creatinine </e1> levels, a greater percentage of patients with <e2> hepatorenal syndrome </e2>, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7002": {"data": {"text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "entity1": "creatinine", "entity2": "CRF", "span1": [271, 281], "span2": [32, 35]}, "bert_text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum <e1> creatinine </e1> <e2> CRF </e2> and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7003": {"data": {"text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "entity1": "creatinine", "entity2": "ESRD", "span1": [271, 281], "span2": [40, 44]}, "bert_text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum <e1> creatinine </e1> <e2> ESRD </e2> patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7004": {"data": {"text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "entity1": "creatinine", "entity2": "hepatorenal syndrome", "span1": [271, 281], "span2": [141, 161]}, "bert_text": "Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum <e1> creatinine </e1> <e2> hepatorenal syndrome </e2>, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7005": {"data": {"text": "If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.", "entity1": "ketoprofen", "entity2": "cerebral artery aneurysms", "span1": [3, 13], "span2": [40, 65]}, "bert_text": "If <e1> ketoprofen </e1> is used before surgery on <e2> cerebral artery aneurysms </e2>, it may pose an additional risk factor for hemorrhage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7006": {"data": {"text": "If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.", "entity1": "ketoprofen", "entity2": "hemorrhage", "span1": [3, 13], "span2": [109, 119]}, "bert_text": "If <e1> ketoprofen </e1> is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for <e2> hemorrhage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7007": {"data": {"text": "Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "entity1": "AAP", "entity2": "death", "span1": [39, 42], "span2": [74, 79]}, "bert_text": "Interestingly, all the drugs, such as, <e1> AAP </e1>, AMI and DOX induced apoptotic <e2> death </e2> in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7008": {"data": {"text": "Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "entity1": "AAP", "entity2": "necrosis", "span1": [39, 42], "span2": [95, 103]}, "bert_text": "Interestingly, all the drugs, such as, <e1> AAP </e1>, AMI and DOX induced apoptotic death in addition to <e2> necrosis </e2> in the respective organs which was very effectively blocked by GSPE.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7009": {"data": {"text": "Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "entity1": "AMI", "entity2": "death", "span1": [44, 47], "span2": [74, 79]}, "bert_text": "Interestingly, all the drugs, such as, AAP, <e1> AMI </e1> and DOX induced apoptotic <e2> death </e2> in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7010": {"data": {"text": "Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "entity1": "AMI", "entity2": "necrosis", "span1": [44, 47], "span2": [95, 103]}, "bert_text": "Interestingly, all the drugs, such as, AAP, <e1> AMI </e1> and DOX induced apoptotic death in addition to <e2> necrosis </e2> in the respective organs which was very effectively blocked by GSPE.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7011": {"data": {"text": "Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "entity1": "DOX", "entity2": "death", "span1": [52, 55], "span2": [74, 79]}, "bert_text": "Interestingly, all the drugs, such as, AAP, AMI and <e1> DOX </e1> induced apoptotic <e2> death </e2> in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7012": {"data": {"text": "Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "entity1": "DOX", "entity2": "necrosis", "span1": [52, 55], "span2": [95, 103]}, "bert_text": "Interestingly, all the drugs, such as, AAP, AMI and <e1> DOX </e1> induced apoptotic death in addition to <e2> necrosis </e2> in the respective organs which was very effectively blocked by GSPE.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7013": {"data": {"text": "Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "entity1": "GSPE", "entity2": "death", "span1": [167, 171], "span2": [74, 79]}, "bert_text": "Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by <e1> GSPE </e1> <e2> death </e2> in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7014": {"data": {"text": "Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "entity1": "GSPE", "entity2": "necrosis", "span1": [167, 171], "span2": [95, 103]}, "bert_text": "Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by <e1> GSPE </e1> <e2> necrosis </e2> in the respective organs which was very effectively blocked by GSPE.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7015": {"data": {"text": "Lamivudine was added because of de nova hepatitis B infection during her follow-up.", "entity1": "Lamivudine", "entity2": "de nova hepatitis B infection", "span1": [0, 10], "span2": [32, 61]}, "bert_text": "<e1> Lamivudine </e1> was added because of <e2> de nova hepatitis B infection </e2> during her follow-up.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7016": {"data": {"text": "We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.", "entity1": "ifosfamide", "entity2": "anuria", "span1": [62, 72], "span2": [37, 43]}, "bert_text": "We strongly suspect that this lethal anuria was mainly due to <e1> ifosfamide </e1> <e2> anuria </e2> was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7017": {"data": {"text": "We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.", "entity1": "ifosfamide", "entity2": "hypotension", "span1": [62, 72], "span2": [193, 204]}, "bert_text": "We strongly suspect that this lethal anuria was mainly due to <e1> ifosfamide </e1>, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7018": {"data": {"text": "We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.", "entity1": "cisplatin", "entity2": "anuria", "span1": [122, 131], "span2": [37, 43]}, "bert_text": "We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous <e1> cisplatin </e1> <e2> anuria </e2> was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7019": {"data": {"text": "We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.", "entity1": "cisplatin", "entity2": "hypotension", "span1": [122, 131], "span2": [193, 204]}, "bert_text": "We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous <e1> cisplatin </e1> chemotherapy and with poor kidney perfusion due to transient <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7020": {"data": {"text": "METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.", "entity1": "alprazolam", "entity2": "panic disorder", "span1": [123, 133], "span2": [72, 86]}, "bert_text": "METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to <e1> alprazolam </e1> <e2> panic disorder </e2> with agoraphobia were randomised to alprazolam or placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7021": {"data": {"text": "METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.", "entity1": "alprazolam", "entity2": "agoraphobia", "span1": [123, 133], "span2": [92, 103]}, "bert_text": "METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to <e1> alprazolam </e1> <e2> agoraphobia </e2> were randomised to alprazolam or placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7022": {"data": {"text": "A measure of pupillary oscillation as a marker of cocaine-induced paranoia.\n", "entity1": "cocaine", "entity2": "pupillary oscillation", "span1": [50, 57], "span2": [13, 34]}, "bert_text": "A measure of pupillary oscillation as a marker of <e1> cocaine </e1> <e2> pupillary oscillation </e2> as a marker of cocaine-induced paranoia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"7023": {"data": {"text": "A measure of pupillary oscillation as a marker of cocaine-induced paranoia.\n", "entity1": "cocaine", "entity2": "paranoia", "span1": [50, 57], "span2": [66, 74]}, "bert_text": "A measure of pupillary oscillation as a marker of <e1> cocaine </e1>-induced <e2> paranoia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"7024": {"data": {"text": "Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.\n", "entity1": "Norepinephrine", "entity2": "anxiety", "span1": [0, 14], "span2": [105, 112]}, "bert_text": "<e1> Norepinephrine </e1> signaling through beta-adrenergic receptors is critical for expression of cocaine-induced <e2> anxiety </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7025": {"data": {"text": "Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.\n", "entity1": "cocaine", "entity2": "anxiety", "span1": [89, 96], "span2": [105, 112]}, "bert_text": "Norepinephrine signaling through beta-adrenergic receptors is critical for expression of <e1> cocaine </e1>-induced <e2> anxiety </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7026": {"data": {"text": "This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.", "entity1": "cocaine", "entity2": "ruptured aneurysms", "span1": [103, 110], "span2": [66, 84]}, "bert_text": "This group was compared with a control group of 135 patients with ruptured aneurysms and no history of <e1> cocaine </e1> <e2> ruptured aneurysms </e2> and no history of cocaine abuse.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7027": {"data": {"text": "This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.", "entity1": "cocaine", "entity2": "abuse", "span1": [103, 110], "span2": [111, 116]}, "bert_text": "This group was compared with a control group of 135 patients with ruptured aneurysms and no history of <e1> cocaine </e1> <e2> abuse </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7028": {"data": {"text": "Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.", "entity1": "amphetamine", "entity2": "Cerebral vasculitis", "span1": [36, 47], "span2": [0, 19]}, "bert_text": "Cerebral vasculitis associated with <e1> amphetamine </e1> <e2> Cerebral vasculitis </e2> associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7029": {"data": {"text": "Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.", "entity1": "amphetamine", "entity2": "abuse", "span1": [36, 47], "span2": [48, 53]}, "bert_text": "Cerebral vasculitis associated with <e1> amphetamine </e1> <e2> abuse </e2> is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7030": {"data": {"text": "Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.", "entity1": "amphetamine", "entity2": "ischaemic stroke", "span1": [36, 47], "span2": [92, 108]}, "bert_text": "Cerebral vasculitis associated with <e1> amphetamine </e1> abuse is well documented, and in rare cases <e2> ischaemic stroke </e2> has been reported after methylphenidate intake in children.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7031": {"data": {"text": "Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.", "entity1": "methylphenidate", "entity2": "Cerebral vasculitis", "span1": [133, 148], "span2": [0, 19]}, "bert_text": "Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after <e1> methylphenidate </e1> <e2> Cerebral vasculitis </e2> associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7032": {"data": {"text": "Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.", "entity1": "methylphenidate", "entity2": "abuse", "span1": [133, 148], "span2": [48, 53]}, "bert_text": "Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after <e1> methylphenidate </e1> <e2> abuse </e2> is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7033": {"data": {"text": "Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.", "entity1": "methylphenidate", "entity2": "ischaemic stroke", "span1": [133, 148], "span2": [92, 108]}, "bert_text": "Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after <e1> methylphenidate </e1> <e2> ischaemic stroke </e2> has been reported after methylphenidate intake in children.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7034": {"data": {"text": "RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).", "entity1": "argatroban", "entity2": "hepatic impairment", "span1": [45, 55], "span2": [265, 283]}, "bert_text": "RESULTS: Unexpectedly high concentrations of <e1> argatroban </e1> were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with <e2> hepatic impairment </e2>]).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7035": {"data": {"text": "RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).", "entity1": "argatroban", "entity2": "hepatic impairment", "span1": [135, 145], "span2": [265, 283]}, "bert_text": "RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma <e1> argatroban </e1> half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with <e2> hepatic impairment </e2>]).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"7036": {"data": {"text": "The data extend the findings of other investigators, further establishing the DES-induced tumor as a model for study of PRL cellular control mechanisms.", "entity1": "DES", "entity2": "tumor", "span1": [78, 81], "span2": [90, 95]}, "bert_text": "The data extend the findings of other investigators, further establishing the <e1> DES </e1>-induced <e2> tumor </e2> as a model for study of PRL cellular control mechanisms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7037": {"data": {"text": "Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.", "entity1": "thalidomide", "entity2": "lymphomas", "span1": [99, 110], "span2": [80, 89]}, "bert_text": "Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received <e1> thalidomide </e1> <e2> lymphomas </e2> received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7038": {"data": {"text": "Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.", "entity1": "Phenobarbital", "entity2": "movement disorders", "span1": [0, 13], "span2": [81, 99]}, "bert_text": "<e1> Phenobarbital </e1> should be added to the list of anticonvulsant drugs that can cause <e2> movement disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7039": {"data": {"text": "The heparin-induced platelet aggregation test was negative in these patients.", "entity1": "heparin", "entity2": "platelet aggregation", "span1": [4, 11], "span2": [20, 40]}, "bert_text": "The <e1> heparin </e1>-induced <e2> platelet aggregation </e2> test was negative in these patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7040": {"data": {"text": "Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.", "entity1": "nitric oxide", "entity2": "cocaine addiction", "span1": [56, 68], "span2": [194, 211]}, "bert_text": "Therefore NFkappaB activity, oxidative stress, neuronal <e1> nitric oxide </e1> synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for <e2> cocaine addiction </e2>, were evaluated in an experimental model of cocaine administration in rats.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7041": {"data": {"text": "Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.", "entity1": "topiramate", "entity2": "cocaine addiction", "span1": [148, 158], "span2": [194, 211]}, "bert_text": "Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of <e1> topiramate </e1>, a previously proposed therapy for <e2> cocaine addiction </e2>, were evaluated in an experimental model of cocaine administration in rats.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7042": {"data": {"text": "Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.", "entity1": "cocaine", "entity2": "cocaine addiction", "span1": [256, 263], "span2": [194, 211]}, "bert_text": "Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of <e1> cocaine </e1> <e2> cocaine addiction </e2>, were evaluated in an experimental model of cocaine administration in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7043": {"data": {"text": "Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.", "entity1": "TOTP", "entity2": "Neurotoxic", "span1": [43, 47], "span2": [0, 10]}, "bert_text": "Neurotoxic esterase activities 24 hr after <e1> TOTP </e1> <e2> Neurotoxic </e2> esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7044": {"data": {"text": "Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.", "entity1": "DFP", "entity2": "Neurotoxic", "span1": [51, 54], "span2": [0, 10]}, "bert_text": "Neurotoxic esterase activities 24 hr after TOTP or <e1> DFP </e1> <e2> Neurotoxic </e2> esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7045": {"data": {"text": "Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.", "entity1": "organophosphorous", "entity2": "Neurotoxic", "span1": [115, 132], "span2": [0, 10]}, "bert_text": "Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given <e1> organophosphorous </e1> <e2> Neurotoxic </e2> esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"7046": {"data": {"text": "Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.\n", "entity1": "N-nitroso-N-methylurea", "entity2": "prostate cancer", "span1": [85, 107], "span2": [28, 43]}, "bert_text": "Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with <e1> N-nitroso-N-methylurea </e1> <e2> prostate cancer </e2> in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7047": {"data": {"text": "Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.\n", "entity1": "testosterone", "entity2": "prostate cancer", "span1": [112, 124], "span2": [28, 43]}, "bert_text": "Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and <e1> testosterone </e1> <e2> prostate cancer </e2> in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7048": {"data": {"text": "Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.", "entity1": "vinorelbine", "entity2": "toxicity", "span1": [55, 66], "span2": [168, 176]}, "bert_text": "Recent reports indicate that single agent therapy with <e1> vinorelbine </e1> (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable <e2> toxicity </e2> and improvement in symptoms and quality of life.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7049": {"data": {"text": "Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.", "entity1": "VNB", "entity2": "toxicity", "span1": [68, 71], "span2": [168, 176]}, "bert_text": "Recent reports indicate that single agent therapy with vinorelbine (<e1> VNB </e1>) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable <e2> toxicity </e2> and improvement in symptoms and quality of life.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7050": {"data": {"text": "Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.", "entity1": "gemcitabine", "entity2": "toxicity", "span1": [76, 87], "span2": [168, 176]}, "bert_text": "Recent reports indicate that single agent therapy with vinorelbine (VNB) or <e1> gemcitabine </e1> (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable <e2> toxicity </e2> and improvement in symptoms and quality of life.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7051": {"data": {"text": "Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.", "entity1": "GEM", "entity2": "toxicity", "span1": [89, 92], "span2": [168, 176]}, "bert_text": "Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (<e1> GEM </e1>) may obtain a response rate of 20-30% in elderly patients, with acceptable <e2> toxicity </e2> and improvement in symptoms and quality of life.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7052": {"data": {"text": "Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously.", "entity1": "noradrenaline", "entity2": "hypertension", "span1": [23, 36], "span2": [44, 56]}, "bert_text": "Intrarenal infusion of <e1> noradrenaline </e1> caused <e2> hypertension </e2> at doses which did not do so when infused intravenously.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7053": {"data": {"text": "With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.", "entity1": "puromycin aminonucleoside", "entity2": "hypoxia", "span1": [74, 99], "span2": [59, 66]}, "bert_text": "With this model, we were able to identify diffuse cortical hypoxia in the <e1> puromycin aminonucleoside </e1> <e2> hypoxia </e2> in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7054": {"data": {"text": "With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.", "entity1": "puromycin aminonucleoside", "entity2": "hypoxia", "span1": [74, 99], "span2": [151, 158]}, "bert_text": "With this model, we were able to identify diffuse cortical hypoxia in the <e1> puromycin aminonucleoside </e1>-induced nephrotic syndrome and focal and segmental <e2> hypoxia </e2> in the remnant kidney model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7055": {"data": {"text": "With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic syndrome", "span1": [74, 99], "span2": [108, 126]}, "bert_text": "With this model, we were able to identify diffuse cortical hypoxia in the <e1> puromycin aminonucleoside </e1>-induced <e2> nephrotic syndrome </e2> and focal and segmental hypoxia in the remnant kidney model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7056": {"data": {"text": "Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).", "entity1": "prazosin", "entity2": "orthostatic hypotension", "span1": [124, 132], "span2": [44, 67]}, "bert_text": "Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of <e1> prazosin </e1> <e2> orthostatic hypotension </e2> when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"7057": {"data": {"text": "Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.\n", "entity1": "Paclitaxel", "entity2": "nonsmall cell lung carcinoma", "span1": [0, 10], "span2": [126, 154]}, "bert_text": "<e1> Paclitaxel </e1>, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic <e2> nonsmall cell lung carcinoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7058": {"data": {"text": "Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.\n", "entity1": "cisplatin", "entity2": "nonsmall cell lung carcinoma", "span1": [12, 21], "span2": [126, 154]}, "bert_text": "Paclitaxel, <e1> cisplatin </e1>, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic <e2> nonsmall cell lung carcinoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7059": {"data": {"text": "Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.\n", "entity1": "gemcitabine", "entity2": "nonsmall cell lung carcinoma", "span1": [27, 38], "span2": [126, 154]}, "bert_text": "Paclitaxel, cisplatin, and <e1> gemcitabine </e1> combination chemotherapy within a multidisciplinary therapeutic approach in metastatic <e2> nonsmall cell lung carcinoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7060": {"data": {"text": "BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).", "entity1": "Cisplatin", "entity2": "nonsmall cell lung carcinoma", "span1": [12, 21], "span2": [103, 131]}, "bert_text": "BACKGROUND: <e1> Cisplatin </e1>-based chemotherapy combinations improve quality of life and survival in advanced <e2> nonsmall cell lung carcinoma </e2> (NSCLC).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7061": {"data": {"text": "BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).", "entity1": "Cisplatin", "entity2": "NSCLC", "span1": [12, 21], "span2": [133, 138]}, "bert_text": "BACKGROUND: <e1> Cisplatin </e1>-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (<e2> NSCLC </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7062": {"data": {"text": "We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.", "entity1": "methylphenidate", "entity2": "hyperactivity", "span1": [64, 79], "span2": [87, 100]}, "bert_text": "We report the case of a 63-year-old female who was treated with <e1> methylphenidate </e1> due to <e2> hyperactivity </e2> and suffered from multiple ischaemic strokes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7063": {"data": {"text": "We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.", "entity1": "methylphenidate", "entity2": "ischaemic strokes", "span1": [64, 79], "span2": [128, 145]}, "bert_text": "We report the case of a 63-year-old female who was treated with <e1> methylphenidate </e1> due to hyperactivity and suffered from multiple <e2> ischaemic strokes </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7064": {"data": {"text": "Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.", "entity1": "DA", "entity2": "contralateral rotation", "span1": [89, 91], "span2": [5, 27]}, "bert_text": "Such contralateral rotation may result from either degeneration-induced breakdown of the <e1> DA </e1> <e2> contralateral rotation </e2> may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7065": {"data": {"text": "Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.", "entity1": "DA", "entity2": "contralateral rotation", "span1": [128, 130], "span2": [5, 27]}, "bert_text": "Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of <e1> DA </e1> <e2> contralateral rotation </e2> may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7066": {"data": {"text": "In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use.", "entity1": "amphetamine", "entity2": "apical ballooning syndrome", "span1": [152, 163], "span2": [109, 135]}, "bert_text": "In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after <e1> amphetamine </e1> <e2> apical ballooning syndrome </e2> occurring after amphetamine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7067": {"data": {"text": "PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden.", "entity1": "warfarin", "entity2": "cerebral haemorrhages", "span1": [67, 75], "span2": [84, 105]}, "bert_text": "PURPOSE: To evaluate the frequency, severity and preventability of <e1> warfarin </e1>-induced <e2> cerebral haemorrhages </e2> due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7068": {"data": {"text": "PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden.", "entity1": "warfarin", "entity2": "cerebral haemorrhages", "span1": [113, 121], "span2": [84, 105]}, "bert_text": "PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to <e1> warfarin </e1> <e2> cerebral haemorrhages </e2> due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"7069": {"data": {"text": "PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden.", "entity1": "warfarin", "entity2": "cerebral haemorrhages", "span1": [126, 134], "span2": [84, 105]}, "bert_text": "PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and <e1> warfarin </e1> <e2> cerebral haemorrhages </e2> due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"7070": {"data": {"text": "The hazards of optic nerve toxicity due to ethambutol are known.", "entity1": "ethambutol", "entity2": "optic nerve toxicity", "span1": [43, 53], "span2": [15, 35]}, "bert_text": "The hazards of optic nerve toxicity due to <e1> ethambutol </e1> <e2> optic nerve toxicity </e2> due to ethambutol are known.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7071": {"data": {"text": "A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.", "entity1": "verapamil", "entity2": "heart block", "span1": [149, 158], "span2": [55, 66]}, "bert_text": "A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release <e1> verapamil </e1> <e2> heart block </e2> and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7072": {"data": {"text": "A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.", "entity1": "verapamil", "entity2": "hypotension", "span1": [149, 158], "span2": [82, 93]}, "bert_text": "A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release <e1> verapamil </e1> <e2> hypotension </e2> two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7073": {"data": {"text": "A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.", "entity1": "metoprolol", "entity2": "heart block", "span1": [183, 193], "span2": [55, 66]}, "bert_text": "A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of <e1> metoprolol </e1> <e2> heart block </e2> and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7074": {"data": {"text": "A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.", "entity1": "metoprolol", "entity2": "hypotension", "span1": [183, 193], "span2": [82, 93]}, "bert_text": "A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of <e1> metoprolol </e1> <e2> hypotension </e2> two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7075": {"data": {"text": "Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.\n", "entity1": "aminophylline", "entity2": "ventricular fibrillation", "span1": [11, 24], "span2": [57, 81]}, "bert_text": "Effects of <e1> aminophylline </e1> on the threshold for initiating <e2> ventricular fibrillation </e2> during respiratory failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7076": {"data": {"text": "Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.\n", "entity1": "aminophylline", "entity2": "respiratory failure", "span1": [11, 24], "span2": [89, 108]}, "bert_text": "Effects of <e1> aminophylline </e1> on the threshold for initiating ventricular fibrillation during <e2> respiratory failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7077": {"data": {"text": "after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.", "entity1": "posaconazole", "entity2": "toxicity", "span1": [6, 18], "span2": [109, 117]}, "bert_text": "after <e1> posaconazole </e1> was substituted for AmB. It is important to recognize the rare and potentially reversible <e2> toxicity </e2> of AmB.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7078": {"data": {"text": "after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.", "entity1": "AmB.", "entity2": "toxicity", "span1": [39, 43], "span2": [109, 117]}, "bert_text": "after posaconazole was substituted for <e1> AmB. </e1> It is important to recognize the rare and potentially reversible <e2> toxicity </e2> of AmB.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7079": {"data": {"text": "Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.", "entity1": "VPU", "entity2": "seizure", "span1": [26, 29], "span2": [92, 99]}, "bert_text": "Based on the finding that <e1> VPU </e1> and VPA could protect the animals against pilocarpine-induced <e2> seizure </e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7080": {"data": {"text": "Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.", "entity1": "VPA", "entity2": "seizure", "span1": [34, 37], "span2": [92, 99]}, "bert_text": "Based on the finding that VPU and <e1> VPA </e1> could protect the animals against pilocarpine-induced <e2> seizure </e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7081": {"data": {"text": "Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [72, 83], "span2": [92, 99]}, "bert_text": "Based on the finding that VPU and VPA could protect the animals against <e1> pilocarpine </e1>-induced <e2> seizure </e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7082": {"data": {"text": "Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.", "entity1": "amino acid", "entity2": "seizure", "span1": [149, 159], "span2": [92, 99]}, "bert_text": "Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory <e1> amino acid </e1> <e2> seizure </e2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7083": {"data": {"text": "A case of genuine stress incontinence due to prazosin, a common antihypertensive drug, is presented.", "entity1": "prazosin", "entity2": "stress incontinence", "span1": [45, 53], "span2": [18, 37]}, "bert_text": "A case of genuine stress incontinence due to <e1> prazosin </e1> <e2> stress incontinence </e2> due to prazosin, a common antihypertensive drug, is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7084": {"data": {"text": "In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.", "entity1": "dopamine", "entity2": "catatonia", "span1": [48, 56], "span2": [83, 92]}, "bert_text": "In the pinealectomized chick, pretreatment with <e1> dopamine </e1> increased the duration of <e2> catatonia </e2> (DOC) after ketamine, but pretreatment with norepinephrine did not.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7085": {"data": {"text": "In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.", "entity1": "ketamine", "entity2": "catatonia", "span1": [105, 113], "span2": [83, 92]}, "bert_text": "In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after <e1> ketamine </e1> <e2> catatonia </e2> (DOC) after ketamine, but pretreatment with norepinephrine did not.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"7086": {"data": {"text": "In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.", "entity1": "norepinephrine", "entity2": "catatonia", "span1": [137, 151], "span2": [83, 92]}, "bert_text": "In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with <e1> norepinephrine </e1> <e2> catatonia </e2> (DOC) after ketamine, but pretreatment with norepinephrine did not.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7087": {"data": {"text": "Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.", "entity1": "azithromycin", "entity2": "hiccups", "span1": [19, 31], "span2": [75, 82]}, "bert_text": "Discontinuation of <e1> azithromycin </e1> and therapy with baclofen finally resolved <e2> hiccups </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7088": {"data": {"text": "Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.", "entity1": "baclofen", "entity2": "hiccups", "span1": [49, 57], "span2": [75, 82]}, "bert_text": "Discontinuation of azithromycin and therapy with <e1> baclofen </e1> finally resolved <e2> hiccups </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7089": {"data": {"text": "CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.", "entity1": "raloxifene", "entity2": "venous thromboembolism", "span1": [80, 90], "span2": [50, 72]}, "bert_text": "CONCLUSION: We suggest that the increased risk of venous thromboembolism due to <e1> raloxifene </e1> <e2> venous thromboembolism </e2> due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"7090": {"data": {"text": "In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.", "entity1": "gentamicin", "entity2": "acute renal failure", "span1": [71, 81], "span2": [40, 59]}, "bert_text": "In this study we postulated that during acute renal failure induced by <e1> gentamicin </e1> <e2> acute renal failure </e2> induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7091": {"data": {"text": "Diuretics, potassium and arrhythmias in hypertensive coronary disease.\n", "entity1": "potassium", "entity2": "arrhythmias", "span1": [11, 20], "span2": [25, 36]}, "bert_text": "Diuretics, <e1> potassium </e1> and <e2> arrhythmias </e2> in hypertensive coronary disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7092": {"data": {"text": "Diuretics, potassium and arrhythmias in hypertensive coronary disease.\n", "entity1": "potassium", "entity2": "hypertensive", "span1": [11, 20], "span2": [40, 52]}, "bert_text": "Diuretics, <e1> potassium </e1> and arrhythmias in <e2> hypertensive </e2> coronary disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7093": {"data": {"text": "Diuretics, potassium and arrhythmias in hypertensive coronary disease.\n", "entity1": "potassium", "entity2": "coronary disease", "span1": [11, 20], "span2": [53, 69]}, "bert_text": "Diuretics, <e1> potassium </e1> and arrhythmias in hypertensive <e2> coronary disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7094": {"data": {"text": "However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.", "entity1": "ezetimibe", "entity2": "hepatotoxic", "span1": [64, 73], "span2": [9, 20]}, "bert_text": "However, hepatotoxic events have not been widely published with <e1> ezetimibe </e1> <e2> hepatotoxic </e2> events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7095": {"data": {"text": "However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.", "entity1": "simvastatin-ezetimibe", "entity2": "hepatotoxic", "span1": [99, 120], "span2": [9, 20]}, "bert_text": "However, hepatotoxic events have not been widely published with ezetimibe or the combination agent <e1> simvastatin-ezetimibe </e1> <e2> hepatotoxic </e2> events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7096": {"data": {"text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "entity1": "CaCl2", "entity2": "ventricular arrhythmias", "span1": [84, 89], "span2": [17, 40]}, "bert_text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the <e1> CaCl2 </e1> <e2> ventricular arrhythmias </e2> (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7097": {"data": {"text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "entity1": "CaCl2", "entity2": "seizures", "span1": [84, 89], "span2": [57, 65]}, "bert_text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the <e1> CaCl2 </e1> <e2> seizures </e2> (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7098": {"data": {"text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "entity1": "CaCl2", "entity2": "hypotension", "span1": [84, 89], "span2": [238, 249]}, "bert_text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the <e1> CaCl2 </e1> group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced <e2> hypotension </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7099": {"data": {"text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "entity1": "CaCl2", "entity2": "ventricular arrhythmias", "span1": [164, 169], "span2": [17, 40]}, "bert_text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of <e1> CaCl2 </e1> <e2> ventricular arrhythmias </e2> (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7100": {"data": {"text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "entity1": "CaCl2", "entity2": "seizures", "span1": [164, 169], "span2": [57, 65]}, "bert_text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of <e1> CaCl2 </e1> <e2> seizures </e2> (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7101": {"data": {"text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "entity1": "CaCl2", "entity2": "hypotension", "span1": [164, 169], "span2": [238, 249]}, "bert_text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of <e1> CaCl2 </e1> or 4-aminopyridine did not reverse tricyclic antidepressant-induced <e2> hypotension </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7102": {"data": {"text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "entity1": "4-aminopyridine", "entity2": "ventricular arrhythmias", "span1": [173, 188], "span2": [17, 40]}, "bert_text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or <e1> 4-aminopyridine </e1> <e2> ventricular arrhythmias </e2> (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7103": {"data": {"text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "entity1": "4-aminopyridine", "entity2": "seizures", "span1": [173, 188], "span2": [57, 65]}, "bert_text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or <e1> 4-aminopyridine </e1> <e2> seizures </e2> (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7104": {"data": {"text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.", "entity1": "4-aminopyridine", "entity2": "hypotension", "span1": [173, 188], "span2": [238, 249]}, "bert_text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or <e1> 4-aminopyridine </e1> did not reverse tricyclic antidepressant-induced <e2> hypotension </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7105": {"data": {"text": "Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.\n", "entity1": "oxprenolol", "entity2": "hypokalemia", "span1": [64, 74], "span2": [29, 40]}, "bert_text": "Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by <e1> oxprenolol </e1> <e2> hypokalemia </e2> and its abolishment by oxprenolol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7106": {"data": {"text": "We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.", "entity1": "fucoidan", "entity2": "brain damage", "span1": [38, 46], "span2": [95, 107]}, "bert_text": "We tested the sulfated polysaccharide <e1> fucoidan </e1>, which has been reported to reduce inflammatory <e2> brain damage </e2>, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7107": {"data": {"text": "We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.", "entity1": "fucoidan", "entity2": "intracerebral hemorrhage", "span1": [38, 46], "span2": [127, 151]}, "bert_text": "We tested the sulfated polysaccharide <e1> fucoidan </e1>, which has been reported to reduce inflammatory brain damage, in a rat model of <e2> intracerebral hemorrhage </e2> induced by injection of bacterial collagenase into the caudate nucleus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7108": {"data": {"text": "BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.", "entity1": "heparin", "entity2": "bruising", "span1": [108, 115], "span2": [50, 58]}, "bert_text": "BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of <e1> heparin </e1> <e2> bruising </e2> and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 1},
+	"7109": {"data": {"text": "BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.", "entity1": "heparin", "entity2": "bruising", "span1": [108, 115], "span2": [210, 218]}, "bert_text": "BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of <e1> heparin </e1> have been widely studied and described, the effect of injection duration on the occurrence of <e2> bruising </e2> and pain is little documented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7110": {"data": {"text": "BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.", "entity1": "heparin", "entity2": "pain", "span1": [108, 115], "span2": [63, 67]}, "bert_text": "BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of <e1> heparin </e1> <e2> pain </e2> following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 1},
+	"7111": {"data": {"text": "BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.", "entity1": "heparin", "entity2": "pain", "span1": [108, 115], "span2": [223, 227]}, "bert_text": "BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of <e1> heparin </e1> have been widely studied and described, the effect of injection duration on the occurrence of bruising and <e2> pain </e2> is little documented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7112": {"data": {"text": "AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.", "entity1": "AIDA", "entity2": "muscle rigidity", "span1": [0, 4], "span2": [77, 92]}, "bert_text": "<e1> AIDA </e1> in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced <e2> muscle rigidity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7113": {"data": {"text": "AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.", "entity1": "haloperidol", "entity2": "muscle rigidity", "span1": [57, 68], "span2": [77, 92]}, "bert_text": "AIDA in doses of 7.5-15 microg/0.5 microl diminished the <e1> haloperidol </e1>-induced <e2> muscle rigidity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7114": {"data": {"text": "Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.", "entity1": "melatonin", "entity2": "narcosis", "span1": [25, 34], "span2": [54, 62]}, "bert_text": "Thus, the dual action of <e1> melatonin </e1> on pharmacological <e2> narcosis </e2> seems to be specific for the barbiturate mechanism of action.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7115": {"data": {"text": "Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.", "entity1": "barbiturate", "entity2": "narcosis", "span1": [92, 103], "span2": [54, 62]}, "bert_text": "Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the <e1> barbiturate </e1> <e2> narcosis </e2> seems to be specific for the barbiturate mechanism of action.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7116": {"data": {"text": "This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.", "entity1": "PAN", "entity2": "proteinuric injury", "span1": [90, 93], "span2": [68, 86]}, "bert_text": "This study supports the role of lipid peroxidation in mediating the proteinuric injury in <e1> PAN </e1> <e2> proteinuric injury </e2> in PAN nephropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7117": {"data": {"text": "This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.", "entity1": "PAN", "entity2": "nephropathy", "span1": [90, 93], "span2": [94, 105]}, "bert_text": "This study supports the role of lipid peroxidation in mediating the proteinuric injury in <e1> PAN </e1> <e2> nephropathy </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7118": {"data": {"text": "Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.\n", "entity1": "anthracycline", "entity2": "cardiotoxicity", "span1": [44, 57], "span2": [66, 80]}, "bert_text": "Brain natriuretic peptide is a predictor of <e1> anthracycline </e1>-induced <e2> cardiotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7119": {"data": {"text": "We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.", "entity1": "cocaine", "entity2": "delirium", "span1": [39, 46], "span2": [63, 71]}, "bert_text": "We describe an outbreak of deaths from <e1> cocaine </e1>-induced excited <e2> delirium </e2> (EDDs) in Dade County, Florida between 1979 and 1990.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7120": {"data": {"text": "We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.", "entity1": "cocaine", "entity2": "EDDs", "span1": [39, 46], "span2": [73, 77]}, "bert_text": "We describe an outbreak of deaths from <e1> cocaine </e1>-induced excited delirium (<e2> EDDs </e2>) in Dade County, Florida between 1979 and 1990.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7121": {"data": {"text": "The time course and concentration-effect relationship of terbutaline-induced hypokalemia was studied, using computer-aided pharmacokinetic-dynamic modeling.", "entity1": "terbutaline", "entity2": "hypokalemia", "span1": [57, 68], "span2": [77, 88]}, "bert_text": "The time course and concentration-effect relationship of <e1> terbutaline </e1>-induced <e2> hypokalemia </e2> was studied, using computer-aided pharmacokinetic-dynamic modeling.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7122": {"data": {"text": "In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.", "entity1": "di-o-tolylguanidine", "entity2": "toxicity", "span1": [114, 133], "span2": [280, 288]}, "bert_text": "In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist <e1> di-o-tolylguanidine </e1> (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral <e2> toxicity </e2> of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7123": {"data": {"text": "In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.", "entity1": "DTG", "entity2": "toxicity", "span1": [135, 138], "span2": [280, 288]}, "bert_text": "In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (<e1> DTG </e1>) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral <e2> toxicity </e2> of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7124": {"data": {"text": "In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.", "entity1": "3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane", "entity2": "toxicity", "span1": [185, 249], "span2": [280, 288]}, "bert_text": "In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (<e1> 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane </e1>) each worsened the behavioral <e2> toxicity </e2> of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7125": {"data": {"text": "In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.", "entity1": "cocaine", "entity2": "toxicity", "span1": [292, 299], "span2": [280, 288]}, "bert_text": "In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of <e1> cocaine </e1> <e2> toxicity </e2> of cocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7126": {"data": {"text": "These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.", "entity1": "alpha-lipoic acid", "entity2": "peripheral nerve toxicity", "span1": [28, 45], "span2": [82, 107]}, "bert_text": "These findings suggest that <e1> alpha-lipoic acid </e1> might reduce the risk of developing <e2> peripheral nerve toxicity </e2> in patients undergoing chemotherapy and encourage further confirmatory clinical trials.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7127": {"data": {"text": "It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.", "entity1": "vincristine", "entity2": "neuropathy", "span1": [46, 57], "span2": [106, 116]}, "bert_text": "It is concluded that with the above mentioned <e1> vincristine </e1> dose schedule signs and symptoms of vincristine <e2> neuropathy </e2> are reversible for a great deal and prognosis is fairly good.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7128": {"data": {"text": "It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.", "entity1": "vincristine", "entity2": "neuropathy", "span1": [94, 105], "span2": [106, 116]}, "bert_text": "It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of <e1> vincristine </e1> <e2> neuropathy </e2> are reversible for a great deal and prognosis is fairly good.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7129": {"data": {"text": "CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.", "entity1": "CaCl2", "entity2": "toxicity", "span1": [0, 5], "span2": [81, 89]}, "bert_text": "<e1> CaCl2 </e1> therapy may possibly worsen both cardiovascular and central nervous system <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7130": {"data": {"text": "It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.", "entity1": "potassium", "entity2": "cardiac arrhythmias", "span1": [51, 60], "span2": [92, 111]}, "bert_text": "It has been proposed that modest changes in plasma <e1> potassium </e1> can alter the tendency towards <e2> cardiac arrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7131": {"data": {"text": "Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.", "entity1": "selegiline", "entity2": "Orthostatic hypotension", "span1": [67, 77], "span2": [0, 23]}, "bert_text": "Orthostatic hypotension was ameliorated 4 days after withdrawal of <e1> selegiline </e1> <e2> Orthostatic hypotension </e2> was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7132": {"data": {"text": "This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).", "entity1": "methylprednisolone", "entity2": "sudden death", "span1": [100, 118], "span2": [54, 66]}, "bert_text": "This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous <e1> methylprednisolone </e1> <e2> sudden death </e2> after a high dose of intravenous methylprednisolone (IVMP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7133": {"data": {"text": "This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).", "entity1": "IVMP", "entity2": "sudden death", "span1": [120, 124], "span2": [54, 66]}, "bert_text": "This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (<e1> IVMP </e1> <e2> sudden death </e2> after a high dose of intravenous methylprednisolone (IVMP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7134": {"data": {"text": "Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.\n", "entity1": "rifampin", "entity2": "glomerulonephritis", "span1": [70, 78], "span2": [22, 40]}, "bert_text": "Crescentic fibrillary glomerulonephritis associated with intermittent <e1> rifampin </e1> <e2> glomerulonephritis </e2> associated with intermittent rifampin therapy for pulmonary tuberculosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7135": {"data": {"text": "Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.\n", "entity1": "rifampin", "entity2": "pulmonary tuberculosis", "span1": [70, 78], "span2": [91, 113]}, "bert_text": "Crescentic fibrillary glomerulonephritis associated with intermittent <e1> rifampin </e1> therapy for <e2> pulmonary tuberculosis </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7136": {"data": {"text": "Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.", "entity1": "amiodarone", "entity2": "atrial flutter", "span1": [18, 28], "span2": [77, 91]}, "bert_text": "Thirty days after <e1> amiodarone </e1> discontinuation, His bundle electrograms showed <e2> atrial flutter </e2> without intra-Hisian or infra-Hisian delay.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7137": {"data": {"text": "Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.\n", "entity1": "Ketoconazole", "entity2": "torsades de pointes", "span1": [0, 12], "span2": [21, 40]}, "bert_text": "<e1> Ketoconazole </e1> induced <e2> torsades de pointes </e2> without concomitant use of QT interval-prolonging drug.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7138": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "Mipafox", "entity2": "neuropathic damage", "span1": [155, 162], "span2": [24, 42]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to <e1> Mipafox </e1> <e2> neuropathic damage </e2> and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7139": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "Mipafox", "entity2": "neuropathy", "span1": [155, 162], "span2": [84, 94]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to <e1> Mipafox </e1> <e2> neuropathy </e2> target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7140": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "Mipafox", "entity2": "neurotoxic", "span1": [155, 162], "span2": [61, 71]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to <e1> Mipafox </e1> <e2> neurotoxic </e2> esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7141": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "Mipafox", "entity2": "neurotoxic", "span1": [155, 162], "span2": [212, 222]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to <e1> Mipafox </e1> (N, N'-diisopropylphosphorodiamidofluoridate), a <e2> neurotoxic </e2> organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7142": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "N, N'-diisopropylphosphorodiamidofluoridate", "entity2": "neuropathic damage", "span1": [164, 207], "span2": [24, 42]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (<e1> N, N'-diisopropylphosphorodiamidofluoridate </e1> <e2> neuropathic damage </e2> and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7143": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "N, N'-diisopropylphosphorodiamidofluoridate", "entity2": "neuropathy", "span1": [164, 207], "span2": [84, 94]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (<e1> N, N'-diisopropylphosphorodiamidofluoridate </e1> <e2> neuropathy </e2> target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7144": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "N, N'-diisopropylphosphorodiamidofluoridate", "entity2": "neurotoxic", "span1": [164, 207], "span2": [61, 71]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (<e1> N, N'-diisopropylphosphorodiamidofluoridate </e1> <e2> neurotoxic </e2> esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7145": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "N, N'-diisopropylphosphorodiamidofluoridate", "entity2": "neurotoxic", "span1": [164, 207], "span2": [212, 222]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (<e1> N, N'-diisopropylphosphorodiamidofluoridate </e1>), a <e2> neurotoxic </e2> organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7146": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "organophosphate", "entity2": "neuropathic damage", "span1": [223, 238], "span2": [24, 42]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic <e1> organophosphate </e1> <e2> neuropathic damage </e2> and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7147": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "organophosphate", "entity2": "neuropathy", "span1": [223, 238], "span2": [84, 94]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic <e1> organophosphate </e1> <e2> neuropathy </e2> target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7148": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "organophosphate", "entity2": "neurotoxic", "span1": [223, 238], "span2": [61, 71]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic <e1> organophosphate </e1> <e2> neurotoxic </e2> esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7149": {"data": {"text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.", "entity1": "organophosphate", "entity2": "neurotoxic", "span1": [223, 238], "span2": [212, 222]}, "bert_text": "The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic <e1> organophosphate </e1> <e2> neurotoxic </e2> organophosphate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7150": {"data": {"text": "OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.", "entity1": "dilevalol", "entity2": "liver injury", "span1": [46, 55], "span2": [162, 174]}, "bert_text": "OBJECTIVE: To assess lymphocyte reactivity to <e1> dilevalol </e1> and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced <e2> liver injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7151": {"data": {"text": "OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.", "entity1": "dilevalol", "entity2": "liver injury", "span1": [97, 106], "span2": [162, 174]}, "bert_text": "OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo <e1> dilevalol </e1> antigens or metabolites in a case of dilevalol-induced <e2> liver injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7152": {"data": {"text": "OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.", "entity1": "dilevalol", "entity2": "liver injury", "span1": [144, 153], "span2": [162, 174]}, "bert_text": "OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of <e1> dilevalol </e1>-induced <e2> liver injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7153": {"data": {"text": "Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis.\n", "entity1": "dilevalol", "entity2": "Hypersensitivity", "span1": [52, 61], "span2": [0, 16]}, "bert_text": "Hypersensitivity immune reaction as a mechanism for <e1> dilevalol </e1> <e2> Hypersensitivity </e2> immune reaction as a mechanism for dilevalol-associated hepatitis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7154": {"data": {"text": "Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis.\n", "entity1": "dilevalol", "entity2": "hepatitis", "span1": [52, 61], "span2": [73, 82]}, "bert_text": "Hypersensitivity immune reaction as a mechanism for <e1> dilevalol </e1>-associated <e2> hepatitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7155": {"data": {"text": "Nephrotic syndrome is often accompanied by sodium retention and generalized edema.", "entity1": "sodium", "entity2": "Nephrotic syndrome", "span1": [43, 49], "span2": [0, 18]}, "bert_text": "Nephrotic syndrome is often accompanied by <e1> sodium </e1> <e2> Nephrotic syndrome </e2> is often accompanied by sodium retention and generalized edema.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7156": {"data": {"text": "Nephrotic syndrome is often accompanied by sodium retention and generalized edema.", "entity1": "sodium", "entity2": "edema", "span1": [43, 49], "span2": [76, 81]}, "bert_text": "Nephrotic syndrome is often accompanied by <e1> sodium </e1> retention and generalized <e2> edema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7157": {"data": {"text": "Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.", "entity1": "terfenadine", "entity2": "TDP", "span1": [78, 89], "span2": [55, 58]}, "bert_text": "Four compounds known to increase QT interval and cause TDP were investigated: <e1> terfenadine </e1> <e2> TDP </e2> were investigated: terfenadine, terodiline, cisapride and E4031.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7158": {"data": {"text": "Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.", "entity1": "terodiline", "entity2": "TDP", "span1": [91, 101], "span2": [55, 58]}, "bert_text": "Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, <e1> terodiline </e1> <e2> TDP </e2> were investigated: terfenadine, terodiline, cisapride and E4031.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7159": {"data": {"text": "Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.", "entity1": "cisapride", "entity2": "TDP", "span1": [103, 112], "span2": [55, 58]}, "bert_text": "Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, <e1> cisapride </e1> <e2> TDP </e2> were investigated: terfenadine, terodiline, cisapride and E4031.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7160": {"data": {"text": "Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.", "entity1": "E4031", "entity2": "TDP", "span1": [117, 122], "span2": [55, 58]}, "bert_text": "Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and <e1> E4031 </e1> <e2> TDP </e2> were investigated: terfenadine, terodiline, cisapride and E4031.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7161": {"data": {"text": "We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.", "entity1": "amiodarone", "entity2": "sinoatrial block", "span1": [44, 54], "span2": [12, 28]}, "bert_text": "We observed sinoatrial block due to chronic <e1> amiodarone </e1> <e2> sinoatrial block </e2> due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7162": {"data": {"text": "We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.", "entity1": "amiodarone", "entity2": "primary cardiomyopathy", "span1": [44, 54], "span2": [95, 117]}, "bert_text": "We observed sinoatrial block due to chronic <e1> amiodarone </e1> administration in a 5-year-old boy with <e2> primary cardiomyopathy </e2>, Wolff-Parkinson-White syndrome and supraventricular tachycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7163": {"data": {"text": "We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.", "entity1": "amiodarone", "entity2": "Wolff-Parkinson-White syndrome", "span1": [44, 54], "span2": [119, 149]}, "bert_text": "We observed sinoatrial block due to chronic <e1> amiodarone </e1> administration in a 5-year-old boy with primary cardiomyopathy, <e2> Wolff-Parkinson-White syndrome </e2> and supraventricular tachycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7164": {"data": {"text": "We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.", "entity1": "amiodarone", "entity2": "supraventricular tachycardia", "span1": [44, 54], "span2": [154, 182]}, "bert_text": "We observed sinoatrial block due to chronic <e1> amiodarone </e1> administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and <e2> supraventricular tachycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7165": {"data": {"text": "Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.", "entity1": "chloroquine", "entity2": "retinopathy", "span1": [49, 60], "span2": [61, 72]}, "bert_text": "Ophthalmological assessment revealed features of <e1> chloroquine </e1> <e2> retinopathy </e2>, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7166": {"data": {"text": "Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.", "entity1": "chloroquine", "entity2": "heart failure", "span1": [49, 60], "span2": [114, 127]}, "bert_text": "Ophthalmological assessment revealed features of <e1> chloroquine </e1> retinopathy, cardiac assessment revealed features of <e2> heart failure </e2> and a complete heart block with right bundle branch block pattern.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7167": {"data": {"text": "Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.", "entity1": "chloroquine", "entity2": "heart block", "span1": [49, 60], "span2": [143, 154]}, "bert_text": "Ophthalmological assessment revealed features of <e1> chloroquine </e1> retinopathy, cardiac assessment revealed features of heart failure and a complete <e2> heart block </e2> with right bundle branch block pattern.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7168": {"data": {"text": "Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.", "entity1": "chloroquine", "entity2": "right bundle branch block", "span1": [49, 60], "span2": [160, 185]}, "bert_text": "Ophthalmological assessment revealed features of <e1> chloroquine </e1> retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with <e2> right bundle branch block </e2> pattern.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7169": {"data": {"text": "5 flourouracil-induced apical ballooning syndrome: a case report.\n", "entity1": "5 flourouracil", "entity2": "apical ballooning syndrome", "span1": [0, 14], "span2": [23, 49]}, "bert_text": "<e1> 5 flourouracil </e1>-induced <e2> apical ballooning syndrome </e2>: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7170": {"data": {"text": "In male Swiss mice, muscimol produced myoclonic jerks.", "entity1": "muscimol", "entity2": "myoclonic jerks", "span1": [20, 28], "span2": [38, 53]}, "bert_text": "In male Swiss mice, <e1> muscimol </e1> produced <e2> myoclonic jerks </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7171": {"data": {"text": "Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.\n", "entity1": "paroxetine", "entity2": "neuroleptic malignant syndrome", "span1": [78, 88], "span2": [9, 39]}, "bert_text": "Possible neuroleptic malignant syndrome related to concomitant treatment with <e1> paroxetine </e1> <e2> neuroleptic malignant syndrome </e2> related to concomitant treatment with paroxetine and alprazolam.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7172": {"data": {"text": "Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.\n", "entity1": "alprazolam", "entity2": "neuroleptic malignant syndrome", "span1": [93, 103], "span2": [9, 39]}, "bert_text": "Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and <e1> alprazolam </e1> <e2> neuroleptic malignant syndrome </e2> related to concomitant treatment with paroxetine and alprazolam.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7173": {"data": {"text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "entity1": "LEV", "entity2": "idiopathic epilepsy", "span1": [106, 109], "span2": [43, 62]}, "bert_text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with <e1> LEV </e1> <e2> idiopathic epilepsy </e2> with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7174": {"data": {"text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "entity1": "LEV", "entity2": "seizures", "span1": [106, 109], "span2": [80, 88]}, "bert_text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with <e1> LEV </e1> <e2> seizures </e2> was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7175": {"data": {"text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "entity1": "valproate", "entity2": "idiopathic epilepsy", "span1": [129, 138], "span2": [43, 62]}, "bert_text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to <e1> valproate </e1> <e2> idiopathic epilepsy </e2> with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7176": {"data": {"text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "entity1": "valproate", "entity2": "seizures", "span1": [129, 138], "span2": [80, 88]}, "bert_text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to <e1> valproate </e1> <e2> seizures </e2> was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7177": {"data": {"text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "entity1": "VPA", "entity2": "idiopathic epilepsy", "span1": [140, 143], "span2": [43, 62]}, "bert_text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (<e1> VPA </e1> <e2> idiopathic epilepsy </e2> with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7178": {"data": {"text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "entity1": "VPA", "entity2": "seizures", "span1": [140, 143], "span2": [80, 88]}, "bert_text": "FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (<e1> VPA </e1> <e2> seizures </e2> was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7179": {"data": {"text": "Bradycardia due to trihexyphenidyl hydrochloride.\n", "entity1": "trihexyphenidyl hydrochloride", "entity2": "Bradycardia", "span1": [19, 48], "span2": [0, 11]}, "bert_text": "Bradycardia due to <e1> trihexyphenidyl hydrochloride </e1> <e2> Bradycardia </e2> due to trihexyphenidyl hydrochloride.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7180": {"data": {"text": "Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.", "entity1": "timolol", "entity2": "glaucomatous", "span1": [53, 60], "span2": [6, 18]}, "bert_text": "Eight glaucomatous patients chronically treated with <e1> timolol </e1> <e2> glaucomatous </e2> patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7181": {"data": {"text": "Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.", "entity1": "timolol", "entity2": "depression", "span1": [53, 60], "span2": [86, 96]}, "bert_text": "Eight glaucomatous patients chronically treated with <e1> timolol </e1> 0.5%/12h, suffering from <e2> depression </e2> diagnosed through DMS-III-R criteria, were included in the study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7182": {"data": {"text": "Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.", "entity1": "Tamoxifen", "entity2": "breast cancer", "span1": [0, 9], "span2": [87, 100]}, "bert_text": "<e1> Tamoxifen </e1> (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of <e2> breast cancer </e2>, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7183": {"data": {"text": "Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.", "entity1": "Tamoxifen", "entity2": "hemolytic anemia", "span1": [0, 9], "span2": [162, 178]}, "bert_text": "<e1> Tamoxifen </e1> (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and <e2> hemolytic anemia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7184": {"data": {"text": "Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.", "entity1": "TAM", "entity2": "breast cancer", "span1": [11, 14], "span2": [87, 100]}, "bert_text": "Tamoxifen (<e1> TAM </e1>), the antiestrogenic drug most widely prescribed in the chemotherapy of <e2> breast cancer </e2>, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7185": {"data": {"text": "Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.", "entity1": "TAM", "entity2": "hemolytic anemia", "span1": [11, 14], "span2": [162, 178]}, "bert_text": "Tamoxifen (<e1> TAM </e1>), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and <e2> hemolytic anemia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7186": {"data": {"text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "entity1": "hexachloro-1:3-butadiene", "entity2": "renal damage", "span1": [147, 171], "span2": [29, 41]}, "bert_text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of <e1> hexachloro-1:3-butadiene </e1> <e2> renal damage </e2> to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7187": {"data": {"text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "entity1": "HCBD", "entity2": "renal damage", "span1": [173, 177], "span2": [29, 41]}, "bert_text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (<e1> HCBD </e1> <e2> renal damage </e2> to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7188": {"data": {"text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "entity1": "puromycin aminonucleoside", "entity2": "renal damage", "span1": [180, 205], "span2": [29, 41]}, "bert_text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), <e1> puromycin aminonucleoside </e1> <e2> renal damage </e2> to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7189": {"data": {"text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "entity1": "PAN", "entity2": "renal damage", "span1": [207, 210], "span2": [29, 41]}, "bert_text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (<e1> PAN </e1> <e2> renal damage </e2> to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7190": {"data": {"text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "entity1": "2-bromoethylamine", "entity2": "renal damage", "span1": [217, 234], "span2": [29, 41]}, "bert_text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and <e1> 2-bromoethylamine </e1> <e2> renal damage </e2> to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7191": {"data": {"text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "entity1": "BEA", "entity2": "renal damage", "span1": [236, 239], "span2": [29, 41]}, "bert_text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (<e1> BEA </e1> <e2> renal damage </e2> to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7192": {"data": {"text": "Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.", "entity1": "lignocaine", "entity2": "back pain", "span1": [77, 87], "span2": [11, 20]}, "bert_text": "Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% <e1> lignocaine </e1> <e2> back pain </e2> is associated with the intrathecal use of hyperbaric 5% lignocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7193": {"data": {"text": "Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions.\n", "entity1": "warfarin", "entity2": "Cerebral haemorrhage", "span1": [32, 40], "span2": [0, 20]}, "bert_text": "Cerebral haemorrhage induced by <e1> warfarin </e1> <e2> Cerebral haemorrhage </e2> induced by warfarin - the influence of drug-drug interactions.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7194": {"data": {"text": "Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.", "entity1": "amiodarone", "entity2": "sinoatrial block", "span1": [27, 37], "span2": [75, 91]}, "bert_text": "Reduction in the dosage of <e1> amiodarone </e1> resulted in the disappearance of the <e2> sinoatrial block </e2> and the persistence of asymptomatic sinus bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7195": {"data": {"text": "Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.", "entity1": "amiodarone", "entity2": "sinus bradycardia", "span1": [27, 37], "span2": [128, 145]}, "bert_text": "Reduction in the dosage of <e1> amiodarone </e1> resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic <e2> sinus bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7196": {"data": {"text": "Pseudoacromegaly induced by the long-term use of minoxidil.\n", "entity1": "minoxidil", "entity2": "Pseudoacromegaly", "span1": [49, 58], "span2": [0, 16]}, "bert_text": "Pseudoacromegaly induced by the long-term use of <e1> minoxidil </e1> <e2> Pseudoacromegaly </e2> induced by the long-term use of minoxidil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7197": {"data": {"text": "Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.).", "entity1": "haloperidol", "entity2": "Muscle rigidity", "span1": [31, 42], "span2": [0, 15]}, "bert_text": "Muscle rigidity was induced by <e1> haloperidol </e1> <e2> Muscle rigidity </e2> was induced by haloperidol (2.5 mg/kg i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7198": {"data": {"text": "Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.\n", "entity1": "calcium", "entity2": "nephrosclerosis", "span1": [22, 29], "span2": [62, 77]}, "bert_text": "Adverse effect of the <e1> calcium </e1> channel blocker nitrendipine on <e2> nephrosclerosis </e2> in rats with renovascular hypertension.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7199": {"data": {"text": "Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.\n", "entity1": "calcium", "entity2": "renovascular hypertension", "span1": [22, 29], "span2": [91, 116]}, "bert_text": "Adverse effect of the <e1> calcium </e1> channel blocker nitrendipine on nephrosclerosis in rats with <e2> renovascular hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7200": {"data": {"text": "Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.\n", "entity1": "nitrendipine", "entity2": "nephrosclerosis", "span1": [46, 58], "span2": [62, 77]}, "bert_text": "Adverse effect of the calcium channel blocker <e1> nitrendipine </e1> on <e2> nephrosclerosis </e2> in rats with renovascular hypertension.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7201": {"data": {"text": "Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.\n", "entity1": "nitrendipine", "entity2": "renovascular hypertension", "span1": [46, 58], "span2": [91, 116]}, "bert_text": "Adverse effect of the calcium channel blocker <e1> nitrendipine </e1> on nephrosclerosis in rats with <e2> renovascular hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7202": {"data": {"text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "entity1": "calcium", "entity2": "albuminuria", "span1": [42, 49], "span2": [155, 166]}, "bert_text": "The effect of a 6-week treatment with the <e1> calcium </e1> channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, <e2> albuminuria </e2>, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7203": {"data": {"text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "entity1": "calcium", "entity2": "renovascular hypertension", "span1": [42, 49], "span2": [274, 299]}, "bert_text": "The effect of a 6-week treatment with the <e1> calcium </e1> channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip <e2> renovascular hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7204": {"data": {"text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "entity1": "nitrendipine", "entity2": "albuminuria", "span1": [66, 78], "span2": [155, 166]}, "bert_text": "The effect of a 6-week treatment with the calcium channel blocker <e1> nitrendipine </e1> or the angiotensin converting enzyme inhibitor enalapril on blood pressure, <e2> albuminuria </e2>, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7205": {"data": {"text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "entity1": "nitrendipine", "entity2": "renovascular hypertension", "span1": [66, 78], "span2": [274, 299]}, "bert_text": "The effect of a 6-week treatment with the calcium channel blocker <e1> nitrendipine </e1> or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip <e2> renovascular hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7206": {"data": {"text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "entity1": "angiotensin", "entity2": "albuminuria", "span1": [86, 97], "span2": [155, 166]}, "bert_text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the <e1> angiotensin </e1> converting enzyme inhibitor enalapril on blood pressure, <e2> albuminuria </e2>, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7207": {"data": {"text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "entity1": "angiotensin", "entity2": "renovascular hypertension", "span1": [86, 97], "span2": [274, 299]}, "bert_text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the <e1> angiotensin </e1> converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip <e2> renovascular hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7208": {"data": {"text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "entity1": "enalapril", "entity2": "albuminuria", "span1": [126, 135], "span2": [155, 166]}, "bert_text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor <e1> enalapril </e1> on blood pressure, <e2> albuminuria </e2>, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7209": {"data": {"text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "entity1": "enalapril", "entity2": "renovascular hypertension", "span1": [126, 135], "span2": [274, 299]}, "bert_text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor <e1> enalapril </e1> on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip <e2> renovascular hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7210": {"data": {"text": "Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.\n", "entity1": "amoxicillin", "entity2": "Granulomatous hepatitis", "span1": [46, 57], "span2": [0, 23]}, "bert_text": "Granulomatous hepatitis due to combination of <e1> amoxicillin </e1> <e2> Granulomatous hepatitis </e2> due to combination of amoxicillin and clavulanic acid.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7211": {"data": {"text": "Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.\n", "entity1": "clavulanic acid", "entity2": "Granulomatous hepatitis", "span1": [62, 77], "span2": [0, 23]}, "bert_text": "Granulomatous hepatitis due to combination of amoxicillin and <e1> clavulanic acid </e1> <e2> Granulomatous hepatitis </e2> due to combination of amoxicillin and clavulanic acid.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7212": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "creative deficits", "span1": [53, 60], "span2": [178, 195]}, "bert_text": "RESULTS: We report seven cases where substitution of <e1> lithium </e1>, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or <e2> creative deficits </e2> attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7213": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "bipolar", "span1": [53, 60], "span2": [225, 232]}, "bert_text": "RESULTS: We report seven cases where substitution of <e1> lithium </e1>, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our <e2> bipolar </e2> patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7214": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "bipolar", "span1": [53, 60], "span2": [342, 349]}, "bert_text": "RESULTS: We report seven cases where substitution of <e1> lithium </e1>, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in <e2> bipolar </e2> patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7215": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "cognitive deficits", "span1": [53, 60], "span2": [372, 390]}, "bert_text": "RESULTS: We report seven cases where substitution of <e1> lithium </e1>, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing <e2> cognitive deficits </e2>, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7216": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "creative deficits", "span1": [210, 217], "span2": [178, 195]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to <e1> lithium </e1> <e2> creative deficits </e2> attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7217": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "bipolar", "span1": [210, 217], "span2": [225, 232]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to <e1> lithium </e1> in our <e2> bipolar </e2> patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7218": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "bipolar", "span1": [210, 217], "span2": [342, 349]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to <e1> lithium </e1> in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in <e2> bipolar </e2> patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7219": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "cognitive deficits", "span1": [210, 217], "span2": [372, 390]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to <e1> lithium </e1> in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing <e2> cognitive deficits </e2>, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7220": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "creative deficits", "span1": [331, 338], "span2": [178, 195]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to <e1> lithium </e1> <e2> creative deficits </e2> attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7221": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "bipolar", "span1": [331, 338], "span2": [225, 232]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to <e1> lithium </e1> <e2> bipolar </e2> patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7222": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "bipolar", "span1": [331, 338], "span2": [342, 349]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to <e1> lithium </e1> in <e2> bipolar </e2> patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7223": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "lithium", "entity2": "cognitive deficits", "span1": [331, 338], "span2": [372, 390]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to <e1> lithium </e1> in bipolar patients experiencing <e2> cognitive deficits </e2>, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7224": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "divalproex sodium", "entity2": "creative deficits", "span1": [94, 111], "span2": [178, 195]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with <e1> divalproex sodium </e1> was extremely helpful in reducing the cognitive, motivational, or <e2> creative deficits </e2> attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7225": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "divalproex sodium", "entity2": "bipolar", "span1": [94, 111], "span2": [225, 232]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with <e1> divalproex sodium </e1> was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our <e2> bipolar </e2> patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7226": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "divalproex sodium", "entity2": "bipolar", "span1": [94, 111], "span2": [342, 349]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with <e1> divalproex sodium </e1> was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in <e2> bipolar </e2> patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7227": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "divalproex sodium", "entity2": "cognitive deficits", "span1": [94, 111], "span2": [372, 390]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with <e1> divalproex sodium </e1> was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing <e2> cognitive deficits </e2>, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7228": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "divalproex sodium", "entity2": "creative deficits", "span1": [283, 300], "span2": [178, 195]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, <e1> divalproex sodium </e1> <e2> creative deficits </e2> attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7229": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "divalproex sodium", "entity2": "bipolar", "span1": [283, 300], "span2": [225, 232]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, <e1> divalproex sodium </e1> <e2> bipolar </e2> patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7230": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "divalproex sodium", "entity2": "bipolar", "span1": [283, 300], "span2": [342, 349]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, <e1> divalproex sodium </e1> was a superior alternative to lithium in <e2> bipolar </e2> patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7231": {"data": {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity1": "divalproex sodium", "entity2": "cognitive deficits", "span1": [283, 300], "span2": [372, 390]}, "bert_text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients. CONCLUSION: In this preliminary report, <e1> divalproex sodium </e1> was a superior alternative to lithium in bipolar patients experiencing <e2> cognitive deficits </e2>, loss of creativity, and functional impairments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7232": {"data": {"text": "However, in the ADR-nephropathy group, numerous apoptotic cells were identified in the tubulointerstitial areas.", "entity1": "ADR", "entity2": "nephropathy", "span1": [16, 19], "span2": [20, 31]}, "bert_text": "However, in the <e1> ADR </e1>-<e2> nephropathy </e2> group, numerous apoptotic cells were identified in the tubulointerstitial areas.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7233": {"data": {"text": "Neonatal pyridoxine responsive convulsions due to isoniazid therapy.\n", "entity1": "pyridoxine", "entity2": "convulsions", "span1": [9, 19], "span2": [31, 42]}, "bert_text": "Neonatal <e1> pyridoxine </e1> responsive <e2> convulsions </e2> due to isoniazid therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7234": {"data": {"text": "Neonatal pyridoxine responsive convulsions due to isoniazid therapy.\n", "entity1": "isoniazid", "entity2": "convulsions", "span1": [50, 59], "span2": [31, 42]}, "bert_text": "Neonatal pyridoxine responsive convulsions due to <e1> isoniazid </e1> <e2> convulsions </e2> due to isoniazid therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7235": {"data": {"text": "NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.", "entity1": "oxygen", "entity2": "NIN", "span1": [26, 32], "span2": [0, 3]}, "bert_text": "NIN correlated with blood <e1> oxygen </e1> <e2> NIN </e2> correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7236": {"data": {"text": "A case of ventricular tachycardia related to caffeine pretreatment.\n", "entity1": "caffeine", "entity2": "ventricular tachycardia", "span1": [45, 53], "span2": [10, 33]}, "bert_text": "A case of ventricular tachycardia related to <e1> caffeine </e1> <e2> ventricular tachycardia </e2> related to caffeine pretreatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7237": {"data": {"text": "A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.", "entity1": "isoniazid", "entity2": "tuberculosis", "span1": [23, 32], "span2": [87, 99]}, "bert_text": "A 17-day-old infant on <e1> isoniazid </e1> therapy 13 mg/kg daily from birth because of maternal <e2> tuberculosis </e2> was admitted after 4 days of clonic fits.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7238": {"data": {"text": "A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.", "entity1": "isoniazid", "entity2": "clonic fits", "span1": [23, 32], "span2": [129, 140]}, "bert_text": "A 17-day-old infant on <e1> isoniazid </e1> therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of <e2> clonic fits </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7239": {"data": {"text": "The incidence of doxorubicin-induced cardiotoxicity is high and increases with follow-up, irrespective of cumulative dose.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [17, 28], "span2": [37, 51]}, "bert_text": "The incidence of <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2> is high and increases with follow-up, irrespective of cumulative dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7240": {"data": {"text": "This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.", "entity1": "alpha-lipoic acid", "entity2": "axonal damage", "span1": [52, 69], "span2": [84, 97]}, "bert_text": "This approach allowed investigating the efficacy of <e1> alpha-lipoic acid </e1> in preventing <e2> axonal damage </e2> and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7241": {"data": {"text": "This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.", "entity1": "alpha-lipoic acid", "entity2": "axonal damage", "span1": [211, 228], "span2": [84, 97]}, "bert_text": "This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and <e1> alpha-lipoic acid </e1> <e2> axonal damage </e2> and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7242": {"data": {"text": "Little information is available to predict which patients are at highest risk for this complication. OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.", "entity1": "angiotensin", "entity2": "CHF", "span1": [224, 235], "span2": [201, 204]}, "bert_text": "Little information is available to predict which patients are at highest risk for this complication. OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed <e1> angiotensin </e1> <e2> CHF </e2> who are prescribed angiotensin-converting enzyme inhibitor therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7243": {"data": {"text": "A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.", "entity1": "paclitaxel", "entity2": "glioblastoma", "span1": [138, 148], "span2": [46, 58]}, "bert_text": "A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of <e1> paclitaxel </e1> <e2> glioblastoma </e2> multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7244": {"data": {"text": "A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.", "entity1": "carboplatin", "entity2": "glioblastoma", "span1": [153, 164], "span2": [46, 58]}, "bert_text": "A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and <e1> carboplatin </e1> <e2> glioblastoma </e2> multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7245": {"data": {"text": "In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.", "entity1": "mannitol", "entity2": "meningioma", "span1": [63, 71], "span2": [3, 13]}, "bert_text": "In meningioma and metastases patients plasma concentrations of <e1> mannitol </e1> <e2> meningioma </e2> and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7246": {"data": {"text": "In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.", "entity1": "mannitol", "entity2": "metastases", "span1": [63, 71], "span2": [18, 28]}, "bert_text": "In meningioma and metastases patients plasma concentrations of <e1> mannitol </e1> <e2> metastases </e2> patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7247": {"data": {"text": "Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.\n", "entity1": "nimodipine", "entity2": "acute stroke", "span1": [22, 32], "span2": [69, 81]}, "bert_text": "Effect of intravenous <e1> nimodipine </e1> on blood pressure and outcome after <e2> acute stroke </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7248": {"data": {"text": "BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.", "entity1": "Nimodipine", "entity2": "Stroke", "span1": [40, 50], "span2": [65, 71]}, "bert_text": "BACKGROUND AND PURPOSE: The Intravenous <e1> Nimodipine </e1> West European <e2> Stroke </e2> Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7249": {"data": {"text": "BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.", "entity1": "Nimodipine", "entity2": "acute stroke", "span1": [40, 50], "span2": [197, 209]}, "bert_text": "BACKGROUND AND PURPOSE: The Intravenous <e1> Nimodipine </e1> West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in <e2> acute stroke </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7250": {"data": {"text": "BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.", "entity1": "nimodipine", "entity2": "Stroke", "span1": [115, 125], "span2": [65, 71]}, "bert_text": "BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between <e1> nimodipine </e1> <e2> Stroke </e2> Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7251": {"data": {"text": "BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.", "entity1": "nimodipine", "entity2": "acute stroke", "span1": [115, 125], "span2": [197, 209]}, "bert_text": "BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between <e1> nimodipine </e1>-induced reduction in blood pressure (BP) and an unfavorable outcome in <e2> acute stroke </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7252": {"data": {"text": "Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).", "entity1": "hexafluorodiethyl ether", "entity2": "Seizures", "span1": [20, 43], "span2": [0, 8]}, "bert_text": "Seizures induced by <e1> hexafluorodiethyl ether </e1> <e2> Seizures </e2> induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7253": {"data": {"text": "Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).", "entity1": "hexafluorodiethyl ether", "entity2": "seizures", "span1": [20, 43], "span2": [124, 132]}, "bert_text": "Seizures induced by <e1> hexafluorodiethyl ether </e1> (HFDE) were also found to be a more sensitive measure of protection by CBZ than <e2> seizures </e2> induced by maximal electroshock (MES).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7254": {"data": {"text": "Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).", "entity1": "HFDE", "entity2": "Seizures", "span1": [45, 49], "span2": [0, 8]}, "bert_text": "Seizures induced by hexafluorodiethyl ether (<e1> HFDE </e1> <e2> Seizures </e2> induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7255": {"data": {"text": "Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).", "entity1": "HFDE", "entity2": "seizures", "span1": [45, 49], "span2": [124, 132]}, "bert_text": "Seizures induced by hexafluorodiethyl ether (<e1> HFDE </e1>) were also found to be a more sensitive measure of protection by CBZ than <e2> seizures </e2> induced by maximal electroshock (MES).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7256": {"data": {"text": "Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).", "entity1": "CBZ", "entity2": "Seizures", "span1": [115, 118], "span2": [0, 8]}, "bert_text": "Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by <e1> CBZ </e1> <e2> Seizures </e2> induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"7257": {"data": {"text": "Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).", "entity1": "CBZ", "entity2": "seizures", "span1": [115, 118], "span2": [124, 132]}, "bert_text": "Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by <e1> CBZ </e1> than <e2> seizures </e2> induced by maximal electroshock (MES).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"7258": {"data": {"text": "Most cases of ifosfamide-induced hallucinations have been reported with other mental status changes.", "entity1": "ifosfamide", "entity2": "hallucinations", "span1": [14, 24], "span2": [33, 47]}, "bert_text": "Most cases of <e1> ifosfamide </e1>-induced <e2> hallucinations </e2> have been reported with other mental status changes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7259": {"data": {"text": "In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.", "entity1": "PG-9", "entity2": "amnesia", "span1": [37, 41], "span2": [121, 128]}, "bert_text": "In the same experimental conditions, <e1> PG-9 </e1> (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced <e2> amnesia </e2>, demonstrating a central localization of the activity.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7260": {"data": {"text": "These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.", "entity1": "L-dopa", "entity2": "hyperkinetic", "span1": [106, 112], "span2": [57, 69]}, "bert_text": "These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like <e1> L-dopa </e1> <e2> hyperkinetic </e2> abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7261": {"data": {"text": "These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.", "entity1": "L-dopa", "entity2": "abnormal involuntary movement", "span1": [106, 112], "span2": [70, 99]}, "bert_text": "These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like <e1> L-dopa </e1> <e2> abnormal involuntary movement </e2>, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7262": {"data": {"text": "These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.", "entity1": "L-dopa", "entity2": "dyskinesia", "span1": [106, 112], "span2": [131, 141]}, "bert_text": "These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like <e1> L-dopa </e1>-induced peak dose <e2> dyskinesia </e2>, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7263": {"data": {"text": "Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.\n", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [15, 23], "span2": [32, 43]}, "bert_text": "Development of <e1> levodopa </e1>-induced <e2> dyskinesias </e2> in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7264": {"data": {"text": "Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.\n", "entity1": "levodopa", "entity2": "parkinsonian", "span1": [15, 23], "span2": [47, 59]}, "bert_text": "Development of <e1> levodopa </e1>-induced dyskinesias in <e2> parkinsonian </e2> monkeys may depend upon rate of symptom onset and/or duration of symptoms.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7265": {"data": {"text": "Lone atrial fibrillation associated with creatine monohydrate supplementation.\n", "entity1": "creatine", "entity2": "atrial fibrillation", "span1": [41, 49], "span2": [5, 24]}, "bert_text": "Lone atrial fibrillation associated with <e1> creatine </e1> <e2> atrial fibrillation </e2> associated with creatine monohydrate supplementation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7266": {"data": {"text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n", "entity1": "fluoxetine hydrochloride", "entity2": "adenomyosis", "span1": [76, 100], "span2": [18, 29]}, "bert_text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by <e1> fluoxetine hydrochloride </e1> <e2> adenomyosis </e2>: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7267": {"data": {"text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n", "entity1": "fluoxetine hydrochloride", "entity2": "adenomyosis", "span1": [76, 100], "span2": [147, 158]}, "bert_text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by <e1> fluoxetine hydrochloride </e1>, a selective serotonin reuptake inhibitor, on <e2> adenomyosis </e2> induction in Wistar albino rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7268": {"data": {"text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n", "entity1": "fluoxetine hydrochloride", "entity2": "hyperprolactinemia", "span1": [76, 100], "span2": [46, 64]}, "bert_text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by <e1> fluoxetine hydrochloride </e1> <e2> hyperprolactinemia </e2> induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7269": {"data": {"text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n", "entity1": "serotonin", "entity2": "adenomyosis", "span1": [114, 123], "span2": [18, 29]}, "bert_text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective <e1> serotonin </e1> <e2> adenomyosis </e2>: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7270": {"data": {"text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n", "entity1": "serotonin", "entity2": "adenomyosis", "span1": [114, 123], "span2": [147, 158]}, "bert_text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective <e1> serotonin </e1> reuptake inhibitor, on <e2> adenomyosis </e2> induction in Wistar albino rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7271": {"data": {"text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n", "entity1": "serotonin", "entity2": "hyperprolactinemia", "span1": [114, 123], "span2": [46, 64]}, "bert_text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective <e1> serotonin </e1> <e2> hyperprolactinemia </e2> induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7272": {"data": {"text": "In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.", "entity1": "fluoxetine", "entity2": "pulmonary hypertension", "span1": [26, 36], "span2": [63, 85]}, "bert_text": "In contrast to the adult, <e1> fluoxetine </e1> exposure in utero induces <e2> pulmonary hypertension </e2> in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7273": {"data": {"text": "Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.\n", "entity1": "Antithymocyte globulin", "entity2": "aplastic anemia", "span1": [0, 22], "span2": [67, 82]}, "bert_text": "<e1> Antithymocyte globulin </e1> in the treatment of D-penicillamine-induced <e2> aplastic anemia </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7274": {"data": {"text": "Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.\n", "entity1": "D-penicillamine", "entity2": "aplastic anemia", "span1": [43, 58], "span2": [67, 82]}, "bert_text": "Antithymocyte globulin in the treatment of <e1> D-penicillamine </e1>-induced <e2> aplastic anemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7275": {"data": {"text": "The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.", "entity1": "carbamazepine", "entity2": "absence epilepsy", "span1": [89, 102], "span2": [48, 64]}, "bert_text": "The authors present three patients with de novo absence epilepsy after administration of <e1> carbamazepine </e1> <e2> absence epilepsy </e2> after administration of carbamazepine and vigabatrin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7276": {"data": {"text": "The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.", "entity1": "vigabatrin", "entity2": "absence epilepsy", "span1": [107, 117], "span2": [48, 64]}, "bert_text": "The authors present three patients with de novo absence epilepsy after administration of carbamazepine and <e1> vigabatrin </e1> <e2> absence epilepsy </e2> after administration of carbamazepine and vigabatrin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7277": {"data": {"text": "This is the first documentation that metoclopramide provokes torsade de pointes clinically.", "entity1": "metoclopramide", "entity2": "torsade de pointes", "span1": [37, 51], "span2": [61, 79]}, "bert_text": "This is the first documentation that <e1> metoclopramide </e1> provokes <e2> torsade de pointes </e2> clinically.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7278": {"data": {"text": "Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.", "entity1": "scopolamine", "entity2": "Amnesia", "span1": [20, 31], "span2": [0, 7]}, "bert_text": "Amnesia produced by <e1> scopolamine </e1> <e2> Amnesia </e2> produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7279": {"data": {"text": "Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.", "entity1": "cycloheximide", "entity2": "Amnesia", "span1": [36, 49], "span2": [0, 7]}, "bert_text": "Amnesia produced by scopolamine and <e1> cycloheximide </e1> <e2> Amnesia </e2> produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7280": {"data": {"text": "Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.", "entity1": "morphine", "entity2": "Amnesia", "span1": [67, 75], "span2": [0, 7]}, "bert_text": "Amnesia produced by scopolamine and cycloheximide were reversed by <e1> morphine </e1> <e2> Amnesia </e2> produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7281": {"data": {"text": "Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.", "entity1": "morphine", "entity2": "Amnesia", "span1": [136, 144], "span2": [0, 7]}, "bert_text": "Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test <e1> morphine </e1> <e2> Amnesia </e2> produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7282": {"data": {"text": "Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.", "entity1": "naloxone", "entity2": "Amnesia", "span1": [211, 219], "span2": [0, 7]}, "bert_text": "Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered <e1> naloxone </e1> <e2> Amnesia </e2> produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7283": {"data": {"text": "Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.", "entity1": "mangiferin", "entity2": "MI", "span1": [114, 124], "span2": [168, 170]}, "bert_text": "Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon <e1> mangiferin </e1> administration as compared to ISPH-induced <e2> MI </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7284": {"data": {"text": "Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.", "entity1": "ISPH", "entity2": "MI", "span1": [155, 159], "span2": [168, 170]}, "bert_text": "Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to <e1> ISPH </e1>-induced <e2> MI </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7285": {"data": {"text": "MJ disappeared when LTG dose was decreased by 25 to 50%.", "entity1": "LTG", "entity2": "MJ", "span1": [20, 23], "span2": [0, 2]}, "bert_text": "MJ disappeared when <e1> LTG </e1> <e2> MJ </e2> disappeared when LTG dose was decreased by 25 to 50%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7286": {"data": {"text": "On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.\n", "entity1": "morphine", "entity2": "muscular rigidity", "span1": [87, 95], "span2": [57, 74]}, "bert_text": "On the mechanisms of the development of tolerance to the muscular rigidity produced by <e1> morphine </e1> <e2> muscular rigidity </e2> produced by morphine in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7287": {"data": {"text": "After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.", "entity1": "sirolimus", "entity2": "psoriasis", "span1": [101, 110], "span2": [25, 34]}, "bert_text": "After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral <e1> sirolimus </e1> <e2> psoriasis </e2> developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7288": {"data": {"text": "After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.", "entity1": "sirolimus", "entity2": "capillary leak syndrome", "span1": [101, 110], "span2": [47, 70]}, "bert_text": "After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral <e1> sirolimus </e1> <e2> capillary leak syndrome </e2> following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7289": {"data": {"text": "Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.", "entity1": "CBZ", "entity2": "seizures", "span1": [23, 26], "span2": [134, 142]}, "bert_text": "Oral administration of <e1> CBZ </e1> as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced <e2> seizures </e2> and was minimally toxic as measured by weight gain over 8 weeks of treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7290": {"data": {"text": "Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.", "entity1": "CBZ", "entity2": "weight gain", "span1": [23, 26], "span2": [182, 193]}, "bert_text": "Oral administration of <e1> CBZ </e1> as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by <e2> weight gain </e2> over 8 weeks of treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7291": {"data": {"text": "Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.", "entity1": "HFDE", "entity2": "seizures", "span1": [121, 125], "span2": [134, 142]}, "bert_text": "Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against <e1> HFDE </e1>-induced <e2> seizures </e2> and was minimally toxic as measured by weight gain over 8 weeks of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7292": {"data": {"text": "Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.", "entity1": "HFDE", "entity2": "weight gain", "span1": [121, 125], "span2": [182, 193]}, "bert_text": "Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against <e1> HFDE </e1>-induced seizures and was minimally toxic as measured by <e2> weight gain </e2> over 8 weeks of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7293": {"data": {"text": "Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.\n", "entity1": "norepinephrine", "entity2": "convulsions", "span1": [19, 33], "span2": [174, 185]}, "bert_text": "Down-regulation of <e1> norepinephrine </e1> transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced <e2> convulsions </e2> and the counteraction by co-administration with local anesthetics.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7294": {"data": {"text": "Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.\n", "entity1": "desipramine", "entity2": "convulsions", "span1": [92, 103], "span2": [174, 185]}, "bert_text": "Down-regulation of norepinephrine transporter function induced by chronic administration of <e1> desipramine </e1> linking to the alteration of sensitivity of local-anesthetics-induced <e2> convulsions </e2> and the counteraction by co-administration with local anesthetics.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7295": {"data": {"text": "Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).", "entity1": "Thorazine", "entity2": "Supraventricular tachycardia", "span1": [64, 73], "span2": [0, 28]}, "bert_text": "Supraventricular tachycardia developed in one patient receiving <e1> Thorazine </e1> <e2> Supraventricular tachycardia </e2> developed in one patient receiving Thorazine (chlorpromazine).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7296": {"data": {"text": "Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).", "entity1": "chlorpromazine", "entity2": "Supraventricular tachycardia", "span1": [75, 89], "span2": [0, 28]}, "bert_text": "Supraventricular tachycardia developed in one patient receiving Thorazine (<e1> chlorpromazine </e1> <e2> Supraventricular tachycardia </e2> developed in one patient receiving Thorazine (chlorpromazine).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7297": {"data": {"text": "The development of tolerance to the muscular rigidity produced by morphine was studied in rats.", "entity1": "morphine", "entity2": "muscular rigidity", "span1": [66, 74], "span2": [36, 53]}, "bert_text": "The development of tolerance to the muscular rigidity produced by <e1> morphine </e1> <e2> muscular rigidity </e2> produced by morphine was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7298": {"data": {"text": "Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.\n", "entity1": "tranexamic acid", "entity2": "Epileptic seizures", "span1": [80, 95], "span2": [0, 18]}, "bert_text": "Epileptic seizures following cortical application of fibrin sealants containing <e1> tranexamic acid </e1> <e2> Epileptic seizures </e2> following cortical application of fibrin sealants containing tranexamic acid in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7299": {"data": {"text": "A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.", "entity1": "ethambutol", "entity2": "optic neuropathy", "span1": [26, 36], "span2": [43, 59]}, "bert_text": "A serious complication of <e1> ethambutol </e1> is an <e2> optic neuropathy </e2> that impairs visual acuity, contrast sensitivity, and color vision.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7300": {"data": {"text": "The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.", "entity1": "enalapril", "entity2": "nephrosis", "span1": [52, 61], "span2": [125, 134]}, "bert_text": "The effect of the converting enzyme inhibitor (CEI) <e1> enalapril </e1> was assessed in Munich-Wistar rats with established adriamycin <e2> nephrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7301": {"data": {"text": "The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.", "entity1": "adriamycin", "entity2": "nephrosis", "span1": [114, 124], "span2": [125, 134]}, "bert_text": "The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established <e1> adriamycin </e1> <e2> nephrosis </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7302": {"data": {"text": "However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.", "entity1": "calcium chloride", "entity2": "hypotension", "span1": [46, 62], "span2": [79, 90]}, "bert_text": "However, shortly after the use of intravenous <e1> calcium chloride </e1>, the refractory <e2> hypotension </e2> and complete heart block resolved.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7303": {"data": {"text": "However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.", "entity1": "calcium chloride", "entity2": "heart block", "span1": [46, 62], "span2": [104, 115]}, "bert_text": "However, shortly after the use of intravenous <e1> calcium chloride </e1>, the refractory hypotension and complete <e2> heart block </e2> resolved.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7304": {"data": {"text": "Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.", "entity1": "Cocaine", "entity2": "paranoia", "span1": [0, 7], "span2": [16, 24]}, "bert_text": "<e1> Cocaine </e1>-induced <e2> paranoia </e2> (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7305": {"data": {"text": "Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.", "entity1": "Cocaine", "entity2": "CIP", "span1": [0, 7], "span2": [26, 29]}, "bert_text": "<e1> Cocaine </e1>-induced paranoia (<e2> CIP </e2>) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7306": {"data": {"text": "Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.", "entity1": "Cocaine", "entity2": "idiopathic paranoia", "span1": [0, 7], "span2": [74, 93]}, "bert_text": "<e1> Cocaine </e1>-induced paranoia (CIP) remains an important drug-induced model of <e2> idiopathic paranoia </e2> for which no psychophysiologic marker has yet emerged.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7307": {"data": {"text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.", "entity1": "gamma-cholesteryloxybutyric acid", "entity2": "toxicity", "span1": [171, 203], "span2": [319, 327]}, "bert_text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, <e1> gamma-cholesteryloxybutyric acid </e1>, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7308": {"data": {"text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.", "entity1": "acetaminophen-", "entity2": "toxicity", "span1": [229, 243], "span2": [319, 327]}, "bert_text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against <e1> acetaminophen- </e1>, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7309": {"data": {"text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.", "entity1": "adriamycin-", "entity2": "toxicity", "span1": [245, 256], "span2": [319, 327]}, "bert_text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, <e1> adriamycin- </e1>, carbon tetrachloride-, chloroform- and galactosamine-induced <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7310": {"data": {"text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.", "entity1": "carbon tetrachloride-", "entity2": "toxicity", "span1": [258, 279], "span2": [319, 327]}, "bert_text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, <e1> carbon tetrachloride- </e1>, chloroform- and galactosamine-induced <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7311": {"data": {"text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.", "entity1": "chloroform-", "entity2": "toxicity", "span1": [281, 292], "span2": [319, 327]}, "bert_text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, <e1> chloroform- </e1> and galactosamine-induced <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7312": {"data": {"text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.", "entity1": "galactosamine", "entity2": "toxicity", "span1": [297, 310], "span2": [319, 327]}, "bert_text": "To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and <e1> galactosamine </e1>-induced <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7313": {"data": {"text": "RESULTS: Among 593 patients with cerebral haemorrhage, 59 (10%) were assessed as related to warfarin treatment.", "entity1": "warfarin", "entity2": "cerebral haemorrhage", "span1": [92, 100], "span2": [33, 53]}, "bert_text": "RESULTS: Among 593 patients with cerebral haemorrhage, 59 (10%) were assessed as related to <e1> warfarin </e1> <e2> cerebral haemorrhage </e2>, 59 (10%) were assessed as related to warfarin treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7314": {"data": {"text": "METHODS: The authors interviewed six persons with ifosfamide-induced hallucinations in the presence of a clear sensorium.", "entity1": "ifosfamide", "entity2": "hallucinations", "span1": [50, 60], "span2": [69, 83]}, "bert_text": "METHODS: The authors interviewed six persons with <e1> ifosfamide </e1>-induced <e2> hallucinations </e2> in the presence of a clear sensorium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7315": {"data": {"text": "A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.", "entity1": "antithymocyte globulin", "entity2": "aplastic anemia", "span1": [23, 45], "span2": [58, 73]}, "bert_text": "A patient who received <e1> antithymocyte globulin </e1> therapy for <e2> aplastic anemia </e2> due to D-penicillamine therapy is described.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7316": {"data": {"text": "A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.", "entity1": "D-penicillamine", "entity2": "aplastic anemia", "span1": [81, 96], "span2": [58, 73]}, "bert_text": "A patient who received antithymocyte globulin therapy for aplastic anemia due to <e1> D-penicillamine </e1> <e2> aplastic anemia </e2> due to D-penicillamine therapy is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"7317": {"data": {"text": "Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.\n", "entity1": "vitamin B12", "entity2": "hematologic toxicity", "span1": [21, 32], "span2": [80, 100]}, "bert_text": "Study of the role of <e1> vitamin B12 </e1> and folinic acid supplementation in preventing <e2> hematologic toxicity </e2> of zidovudine.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7318": {"data": {"text": "Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.\n", "entity1": "folinic acid", "entity2": "hematologic toxicity", "span1": [37, 49], "span2": [80, 100]}, "bert_text": "Study of the role of vitamin B12 and <e1> folinic acid </e1> supplementation in preventing <e2> hematologic toxicity </e2> of zidovudine.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7319": {"data": {"text": "Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.\n", "entity1": "zidovudine", "entity2": "hematologic toxicity", "span1": [104, 114], "span2": [80, 100]}, "bert_text": "Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of <e1> zidovudine </e1> <e2> hematologic toxicity </e2> of zidovudine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7320": {"data": {"text": "Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.\n", "entity1": "asenapine", "entity2": "schizophrenia", "span1": [23, 32], "span2": [119, 132]}, "bert_text": "Efficacy and safety of <e1> asenapine </e1> in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of <e2> schizophrenia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7321": {"data": {"text": "Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.\n", "entity1": "haloperidol", "entity2": "schizophrenia", "span1": [51, 62], "span2": [119, 132]}, "bert_text": "Efficacy and safety of asenapine in a placebo- and <e1> haloperidol </e1>-controlled trial in patients with acute exacerbation of <e2> schizophrenia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7322": {"data": {"text": "A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.", "entity1": "amphetamine", "entity2": "contralateral rotation", "span1": [72, 83], "span2": [191, 213]}, "bert_text": "A substantial degree of contralateral preference was still evident when <e1> amphetamine </e1> was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the <e2> contralateral rotation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7323": {"data": {"text": "In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "entity1": "HFD", "entity2": "obese", "span1": [15, 18], "span2": [27, 32]}, "bert_text": "In conclusion, <e1> HFD </e1>-induced <e2> obese </e2> rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7324": {"data": {"text": "In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "entity1": "HFD", "entity2": "cardiotoxicity", "span1": [15, 18], "span2": [83, 97]}, "bert_text": "In conclusion, <e1> HFD </e1>-induced obese rats are highly sensitized to doxorubicin-induced <e2> cardiotoxicity </e2> by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7325": {"data": {"text": "In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "entity1": "doxorubicin", "entity2": "obese", "span1": [63, 74], "span2": [27, 32]}, "bert_text": "In conclusion, HFD-induced obese rats are highly sensitized to <e1> doxorubicin </e1> <e2> obese </e2> rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7326": {"data": {"text": "In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [63, 74], "span2": [83, 97]}, "bert_text": "In conclusion, HFD-induced obese rats are highly sensitized to <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2> by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7327": {"data": {"text": "In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "entity1": "ATP", "entity2": "obese", "span1": [152, 155], "span2": [27, 32]}, "bert_text": "In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial <e1> ATP </e1> <e2> obese </e2> rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7328": {"data": {"text": "In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "entity1": "ATP", "entity2": "cardiotoxicity", "span1": [152, 155], "span2": [83, 97]}, "bert_text": "In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial <e1> ATP </e1> <e2> cardiotoxicity </e2> by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7329": {"data": {"text": "The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.", "entity1": "aminophylline", "entity2": "ventricular fibrillation", "span1": [15, 28], "span2": [36, 60]}, "bert_text": "The effects of <e1> aminophylline </e1> on the <e2> ventricular fibrillation </e2> threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7330": {"data": {"text": "The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.", "entity1": "aminophylline", "entity2": "respiratory failure", "span1": [15, 28], "span2": [117, 136]}, "bert_text": "The effects of <e1> aminophylline </e1> on the ventricular fibrillation threshold during normal acid-base conditions and during <e2> respiratory failure </e2> were studied in anesthetized open chest dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7331": {"data": {"text": "Sulfasalazine-induced lupus erythematosus.\n", "entity1": "Sulfasalazine", "entity2": "lupus erythematosus", "span1": [0, 13], "span2": [22, 41]}, "bert_text": "<e1> Sulfasalazine </e1>-induced <e2> lupus erythematosus </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7332": {"data": {"text": "The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.", "entity1": "omeprazole", "entity2": "weakness", "span1": [101, 111], "span2": [22, 30]}, "bert_text": "The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with <e1> omeprazole </e1> <e2> weakness </e2>, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7333": {"data": {"text": "The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.", "entity1": "omeprazole", "entity2": "lethargy", "span1": [101, 111], "span2": [32, 40]}, "bert_text": "The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with <e1> omeprazole </e1> <e2> lethargy </e2>, and shortness of breath 2 days after starting therapy with omeprazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7334": {"data": {"text": "The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.", "entity1": "omeprazole", "entity2": "shortness of breath", "span1": [101, 111], "span2": [46, 65]}, "bert_text": "The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with <e1> omeprazole </e1> <e2> shortness of breath </e2> 2 days after starting therapy with omeprazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7335": {"data": {"text": "Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.\n", "entity1": "epinephrine", "entity2": "myocardial ischemia", "span1": [45, 56], "span2": [14, 33]}, "bert_text": "Mechanisms of myocardial ischemia induced by <e1> epinephrine </e1> <e2> myocardial ischemia </e2> induced by epinephrine: comparison with exercise-induced ischemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7336": {"data": {"text": "Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.\n", "entity1": "epinephrine", "entity2": "ischemia", "span1": [45, 56], "span2": [91, 99]}, "bert_text": "Mechanisms of myocardial ischemia induced by <e1> epinephrine </e1>: comparison with exercise-induced <e2> ischemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7337": {"data": {"text": "Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.", "entity1": "uridine", "entity2": "immunodeficiency virus", "span1": [42, 49], "span2": [221, 243]}, "bert_text": "Increased extracellular concentrations of <e1> uridine </e1> (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman <e2> immunodeficiency virus </e2> (HIV) activity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7338": {"data": {"text": "Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.", "entity1": "Urd", "entity2": "immunodeficiency virus", "span1": [51, 54], "span2": [221, 243]}, "bert_text": "Increased extracellular concentrations of uridine (<e1> Urd </e1>) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman <e2> immunodeficiency virus </e2> (HIV) activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7339": {"data": {"text": "Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.", "entity1": "azidothymidine", "entity2": "immunodeficiency virus", "span1": [96, 110], "span2": [221, 243]}, "bert_text": "Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, <e1> azidothymidine </e1> (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman <e2> immunodeficiency virus </e2> (HIV) activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7340": {"data": {"text": "Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.", "entity1": "AZT)-induced", "entity2": "immunodeficiency virus", "span1": [112, 124], "span2": [221, 243]}, "bert_text": "Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (<e1> AZT)-induced </e1> inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman <e2> immunodeficiency virus </e2> (HIV) activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7341": {"data": {"text": "We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.", "entity1": "ketoconazole", "entity2": "coronary artery disease", "span1": [137, 149], "span2": [23, 46]}, "bert_text": "We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking <e1> ketoconazole </e1> <e2> coronary artery disease </e2> who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7342": {"data": {"text": "We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.", "entity1": "ketoconazole", "entity2": "torsades de pointes", "span1": [137, 149], "span2": [98, 117]}, "bert_text": "We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking <e1> ketoconazole </e1> <e2> torsades de pointes </e2> (TdP) after taking ketoconazole for treatment of fungal infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7343": {"data": {"text": "We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.", "entity1": "ketoconazole", "entity2": "TdP", "span1": [137, 149], "span2": [119, 122]}, "bert_text": "We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking <e1> ketoconazole </e1> <e2> TdP </e2>) after taking ketoconazole for treatment of fungal infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7344": {"data": {"text": "We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.", "entity1": "ketoconazole", "entity2": "fungal infection", "span1": [137, 149], "span2": [167, 183]}, "bert_text": "We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking <e1> ketoconazole </e1> for treatment of <e2> fungal infection </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7345": {"data": {"text": "The possible beneficial effect of ribavirin during the initial days of AHF is discussed.", "entity1": "ribavirin", "entity2": "AHF", "span1": [34, 43], "span2": [71, 74]}, "bert_text": "The possible beneficial effect of <e1> ribavirin </e1> during the initial days of <e2> AHF </e2> is discussed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7346": {"data": {"text": "Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.", "entity1": "tobramycin", "entity2": "renal failure", "span1": [24, 34], "span2": [112, 125]}, "bert_text": "Five of 33 (15%) of the <e1> tobramycin </e1>-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had <e2> renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7347": {"data": {"text": "Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.", "entity1": "gentamicin", "entity2": "renal failure", "span1": [80, 90], "span2": [112, 125]}, "bert_text": "Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the <e1> gentamicin </e1>-treated patients had <e2> renal failure </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7348": {"data": {"text": "Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.", "entity1": "dexamethasone", "entity2": "postoperative myalgia", "span1": [18, 31], "span2": [60, 81]}, "bert_text": "Pretreatment with <e1> dexamethasone </e1> is not justified to prevent <e2> postoperative myalgia </e2> after succinylcholine.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7349": {"data": {"text": "Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.", "entity1": "succinylcholine", "entity2": "postoperative myalgia", "span1": [88, 103], "span2": [60, 81]}, "bert_text": "Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after <e1> succinylcholine </e1> <e2> postoperative myalgia </e2> after succinylcholine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1], "label": 1},
+	"7350": {"data": {"text": "Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.", "entity1": "ISPH", "entity2": "myocardial damage", "span1": [26, 30], "span2": [108, 125]}, "bert_text": "Subcutaneous injection of <e1> ISPH </e1> (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused <e2> myocardial damage </e2> in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7351": {"data": {"text": "Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.", "entity1": "lactate", "entity2": "myocardial damage", "span1": [196, 203], "span2": [108, 125]}, "bert_text": "Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum <e1> lactate </e1> <e2> myocardial damage </e2> in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7352": {"data": {"text": "Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.", "entity1": "creatine", "entity2": "myocardial damage", "span1": [228, 236], "span2": [108, 125]}, "bert_text": "Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and <e1> creatine </e1> <e2> myocardial damage </e2> in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7353": {"data": {"text": "Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.", "entity1": "uric acid", "entity2": "myocardial damage", "span1": [281, 290], "span2": [108, 125]}, "bert_text": "Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased <e1> uric acid </e1> <e2> myocardial damage </e2> in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7354": {"data": {"text": "Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.", "entity1": "iron", "entity2": "myocardial damage", "span1": [316, 320], "span2": [108, 125]}, "bert_text": "Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma <e1> iron </e1> <e2> myocardial damage </e2> in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7355": {"data": {"text": "Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.", "entity1": "cocaine", "entity2": "subarachnoid hemorrhage", "span1": [80, 87], "span2": [99, 122]}, "bert_text": "Information on these effects could be obtained from angiograms of patients with <e1> cocaine </e1>-associated <e2> subarachnoid hemorrhage </e2> (SAH) who underwent angiography shortly after cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7356": {"data": {"text": "Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.", "entity1": "cocaine", "entity2": "SAH", "span1": [80, 87], "span2": [124, 127]}, "bert_text": "Information on these effects could be obtained from angiograms of patients with <e1> cocaine </e1>-associated subarachnoid hemorrhage (<e2> SAH </e2>) who underwent angiography shortly after cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7357": {"data": {"text": "Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.", "entity1": "cocaine", "entity2": "subarachnoid hemorrhage", "span1": [169, 176], "span2": [99, 122]}, "bert_text": "Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after <e1> cocaine </e1> <e2> subarachnoid hemorrhage </e2> (SAH) who underwent angiography shortly after cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7358": {"data": {"text": "Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.", "entity1": "cocaine", "entity2": "SAH", "span1": [169, 176], "span2": [124, 127]}, "bert_text": "Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after <e1> cocaine </e1> <e2> SAH </e2>) who underwent angiography shortly after cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7359": {"data": {"text": "Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.\n", "entity1": "testosterone", "entity2": "carcinogenesis", "span1": [23, 35], "span2": [64, 78]}, "bert_text": "Promotional effects of <e1> testosterone </e1> and dietary fat on prostate <e2> carcinogenesis </e2> in genetically susceptible rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7360": {"data": {"text": "The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.", "entity1": "4/heparin", "entity2": "HIT", "span1": [71, 80], "span2": [19, 22]}, "bert_text": "The frequencies of HIT after liver transplantation and platelet factor <e1> 4/heparin </e1> <e2> HIT </e2> after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7361": {"data": {"text": "The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.", "entity1": "4/heparin", "entity2": "HIT", "span1": [71, 80], "span2": [100, 103]}, "bert_text": "The frequencies of HIT after liver transplantation and platelet factor <e1> 4/heparin </e1>-reactive antibody (<e2> HIT </e2> antibody) positivity in liver transplantation patients, however, are unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7362": {"data": {"text": "Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.", "entity1": "naloxazone", "entity2": "analgesia", "span1": [18, 28], "span2": [60, 69]}, "bert_text": "Pretreatment with <e1> naloxazone </e1> significantly blocked morphine <e2> analgesia </e2>, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7363": {"data": {"text": "Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.", "entity1": "naloxazone", "entity2": "catalepsy", "span1": [18, 28], "span2": [71, 80]}, "bert_text": "Pretreatment with <e1> naloxazone </e1> significantly blocked morphine analgesia, <e2> catalepsy </e2> and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7364": {"data": {"text": "Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.", "entity1": "naloxazone", "entity2": "hypothermia", "span1": [18, 28], "span2": [85, 96]}, "bert_text": "Pretreatment with <e1> naloxazone </e1> significantly blocked morphine analgesia, catalepsy and <e2> hypothermia </e2> at a dose which completely eliminated high-affinity binding in brain membranes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7365": {"data": {"text": "Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.", "entity1": "morphine", "entity2": "analgesia", "span1": [51, 59], "span2": [60, 69]}, "bert_text": "Pretreatment with naloxazone significantly blocked <e1> morphine </e1> <e2> analgesia </e2>, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7366": {"data": {"text": "Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.", "entity1": "morphine", "entity2": "catalepsy", "span1": [51, 59], "span2": [71, 80]}, "bert_text": "Pretreatment with naloxazone significantly blocked <e1> morphine </e1> analgesia, <e2> catalepsy </e2> and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7367": {"data": {"text": "Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.", "entity1": "morphine", "entity2": "hypothermia", "span1": [51, 59], "span2": [85, 96]}, "bert_text": "Pretreatment with naloxazone significantly blocked <e1> morphine </e1> analgesia, catalepsy and <e2> hypothermia </e2> at a dose which completely eliminated high-affinity binding in brain membranes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7368": {"data": {"text": "All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.", "entity1": "TXA", "entity2": "seizures", "span1": [53, 56], "span2": [21, 29]}, "bert_text": "All 24 patients with seizures received high doses of <e1> TXA </e1> <e2> seizures </e2> received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7369": {"data": {"text": "Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.", "entity1": "mannitol", "entity2": "gliomas", "span1": [11, 19], "span2": [42, 49]}, "bert_text": "Passage of <e1> mannitol </e1> into the brain around <e2> gliomas </e2>: a potential cause of rebound phenomenon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7370": {"data": {"text": "RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).", "entity1": "PGE2", "entity2": "OAB", "span1": [22, 26], "span2": [87, 90]}, "bert_text": "RESULTS: Urinary NGF, <e1> PGE2 </e1> and PGF2alpha were significantly increased in patients with <e2> OAB </e2> compared with controls (p <0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7371": {"data": {"text": "RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).", "entity1": "PGF2alpha", "entity2": "OAB", "span1": [31, 40], "span2": [87, 90]}, "bert_text": "RESULTS: Urinary NGF, PGE2 and <e1> PGF2alpha </e1> were significantly increased in patients with <e2> OAB </e2> compared with controls (p <0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7372": {"data": {"text": "A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.", "entity1": "vitamin B12", "entity2": "bone marrow suppression", "span1": [70, 81], "span2": [154, 177]}, "bert_text": "A prospective, randomized study was conducted to evaluate the role of <e1> vitamin B12 </e1> and folinic acid supplementation in preventing zidovudine (ZDV)-induced <e2> bone marrow suppression </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7373": {"data": {"text": "A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.", "entity1": "folinic acid", "entity2": "bone marrow suppression", "span1": [86, 98], "span2": [154, 177]}, "bert_text": "A prospective, randomized study was conducted to evaluate the role of vitamin B12 and <e1> folinic acid </e1> supplementation in preventing zidovudine (ZDV)-induced <e2> bone marrow suppression </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7374": {"data": {"text": "A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.", "entity1": "zidovudine", "entity2": "bone marrow suppression", "span1": [129, 139], "span2": [154, 177]}, "bert_text": "A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing <e1> zidovudine </e1> (ZDV)-induced <e2> bone marrow suppression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7375": {"data": {"text": "A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.", "entity1": "ZDV)-induced", "entity2": "bone marrow suppression", "span1": [141, 153], "span2": [154, 177]}, "bert_text": "A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (<e1> ZDV)-induced </e1> <e2> bone marrow suppression </e2>.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7376": {"data": {"text": "Acute renal failure in high dose carboplatin chemotherapy.\n", "entity1": "carboplatin", "entity2": "Acute renal failure", "span1": [33, 44], "span2": [0, 19]}, "bert_text": "Acute renal failure in high dose <e1> carboplatin </e1> <e2> Acute renal failure </e2> in high dose carboplatin chemotherapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7377": {"data": {"text": "A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.", "entity1": "kanamycin", "entity2": "cystitis", "span1": [21, 30], "span2": [101, 109]}, "bert_text": "A high percentage of <e1> kanamycin </e1>-colistin and povidone-iodine irrigations were associated with erosive <e2> cystitis </e2> and suggested a possible complication with human usage.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7378": {"data": {"text": "A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.", "entity1": "colistin", "entity2": "cystitis", "span1": [31, 39], "span2": [101, 109]}, "bert_text": "A high percentage of kanamycin-<e1> colistin </e1> and povidone-iodine irrigations were associated with erosive <e2> cystitis </e2> and suggested a possible complication with human usage.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7379": {"data": {"text": "A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.", "entity1": "povidone-iodine", "entity2": "cystitis", "span1": [44, 59], "span2": [101, 109]}, "bert_text": "A high percentage of kanamycin-colistin and <e1> povidone-iodine </e1> irrigations were associated with erosive <e2> cystitis </e2> and suggested a possible complication with human usage.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7380": {"data": {"text": "To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.", "entity1": "amikacin", "entity2": "nephrotoxicity", "span1": [12, 20], "span2": [32, 46]}, "bert_text": "To evaluate <e1> amikacin </e1>-associated <e2> nephrotoxicity </e2> in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7381": {"data": {"text": "Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.", "entity1": "midazolam", "entity2": "venous complications", "span1": [84, 93], "span2": [43, 63]}, "bert_text": "Although some studies have suggested fewer venous complications are associated with <e1> midazolam </e1> <e2> venous complications </e2> are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7382": {"data": {"text": "Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.", "entity1": "diazepam", "entity2": "venous complications", "span1": [104, 112], "span2": [43, 63]}, "bert_text": "Although some studies have suggested fewer venous complications are associated with midazolam than with <e1> diazepam </e1> <e2> venous complications </e2> are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7383": {"data": {"text": "Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.\n", "entity1": "verapamil", "entity2": "atrial fibrillation", "span1": [11, 20], "span2": [24, 43]}, "bert_text": "Effects of <e1> verapamil </e1> on <e2> atrial fibrillation </e2> and its electrophysiological determinants in dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7384": {"data": {"text": "RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].", "entity1": "creatinine", "entity2": "nephrotoxicity", "span1": [113, 123], "span2": [56, 70]}, "bert_text": "RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum <e1> creatinine </e1> <e2> nephrotoxicity </e2> there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7385": {"data": {"text": "Development of isoproterenol-induced cardiac hypertrophy.\n", "entity1": "isoproterenol", "entity2": "cardiac hypertrophy", "span1": [15, 28], "span2": [37, 56]}, "bert_text": "Development of <e1> isoproterenol </e1>-induced <e2> cardiac hypertrophy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7386": {"data": {"text": "The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).", "entity1": "galactosamine", "entity2": "hepatotoxicity", "span1": [185, 198], "span2": [199, 213]}, "bert_text": "The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against <e1> galactosamine </e1> <e2> hepatotoxicity </e2>).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7387": {"data": {"text": "Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.", "entity1": "ketamine", "entity2": "tachycardia", "span1": [123, 131], "span2": [140, 151]}, "bert_text": "Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the <e1> ketamine </e1>-induced <e2> tachycardia </e2>, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7388": {"data": {"text": "We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-", "entity1": "nicotine", "entity2": "seizures", "span1": [46, 54], "span2": [63, 71]}, "bert_text": "We examined the role of the beta4 subunits in <e1> nicotine </e1>-induced <e2> seizures </e2> and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7389": {"data": {"text": "We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-", "entity1": "nicotine", "entity2": "hypolocomotion", "span1": [46, 54], "span2": [76, 90]}, "bert_text": "We examined the role of the beta4 subunits in <e1> nicotine </e1>-induced seizures and <e2> hypolocomotion </e2> in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7390": {"data": {"text": "Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.", "entity1": "Cephalosporin", "entity2": "hematologic disturbances", "span1": [0, 13], "span2": [45, 69]}, "bert_text": "<e1> Cephalosporin </e1> antibiotics cause a variety of <e2> hematologic disturbances </e2> in man, the pathogeneses and hematopathology of which remain poorly characterized.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7391": {"data": {"text": "Delayed-onset heparin-induced thrombocytopenia.\n", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [14, 21], "span2": [30, 46]}, "bert_text": "Delayed-onset <e1> heparin </e1>-induced <e2> thrombocytopenia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7392": {"data": {"text": "Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.\n", "entity1": "metoclopramide", "entity2": "Torsade de pointes", "span1": [30, 44], "span2": [0, 18]}, "bert_text": "Torsade de pointes induced by <e1> metoclopramide </e1> <e2> Torsade de pointes </e2> induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7393": {"data": {"text": "Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.\n", "entity1": "metoclopramide", "entity2": "left bundle branch block", "span1": [30, 44], "span2": [91, 115]}, "bert_text": "Torsade de pointes induced by <e1> metoclopramide </e1> in an elderly woman with preexisting complete <e2> left bundle branch block </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7394": {"data": {"text": "Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.", "entity1": "testosterone", "entity2": "prostatitis", "span1": [53, 65], "span2": [81, 92]}, "bert_text": "Conventional SD rats fed diet L-485 and treated with <e1> testosterone </e1> developed only <e2> prostatitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7395": {"data": {"text": "BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.", "entity1": "Heparin", "entity2": "thrombocytopenia", "span1": [12, 19], "span2": [28, 44]}, "bert_text": "BACKGROUND: <e1> Heparin </e1>-induced <e2> thrombocytopenia </e2> presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7396": {"data": {"text": "BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.", "entity1": "Heparin", "entity2": "venous thromboemboli", "span1": [12, 19], "span2": [119, 139]}, "bert_text": "BACKGROUND: <e1> Heparin </e1>-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or <e2> venous thromboemboli </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7397": {"data": {"text": "BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [73, 80], "span2": [28, 44]}, "bert_text": "BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after <e1> heparin </e1> <e2> thrombocytopenia </e2> presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7398": {"data": {"text": "BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.", "entity1": "heparin", "entity2": "venous thromboemboli", "span1": [73, 80], "span2": [119, 139]}, "bert_text": "BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after <e1> heparin </e1> exposure, with or without arterial or <e2> venous thromboemboli </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7399": {"data": {"text": "CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.", "entity1": "Isoflurane", "entity2": "cholestatic hepatitis", "span1": [13, 23], "span2": [69, 90]}, "bert_text": "CONCLUSIONS: <e1> Isoflurane </e1>, a common anesthetic agent, can cause severe <e2> cholestatic hepatitis </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7400": {"data": {"text": "We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.", "entity1": "diazepam", "entity2": "venous complications", "span1": [96, 104], "span2": [44, 64]}, "bert_text": "We prospectively evaluated the incidence of venous complications after intravenous injection of <e1> diazepam </e1> <e2> venous complications </e2> after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7401": {"data": {"text": "We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.", "entity1": "midazolam", "entity2": "venous complications", "span1": [108, 117], "span2": [44, 64]}, "bert_text": "We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or <e1> midazolam </e1> <e2> venous complications </e2> after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7402": {"data": {"text": "Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.", "entity1": "pilocarpine", "entity2": "Infarcts", "span1": [70, 81], "span2": [0, 8]}, "bert_text": "Infarcts in substantia nigra pars reticulata were evoked by prolonged <e1> pilocarpine </e1> <e2> Infarcts </e2> in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7403": {"data": {"text": "Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.", "entity1": "pilocarpine", "entity2": "substantia nigra pars reticulata", "span1": [70, 81], "span2": [12, 44]}, "bert_text": "Infarcts in substantia nigra pars reticulata were evoked by prolonged <e1> pilocarpine </e1> <e2> substantia nigra pars reticulata </e2> were evoked by prolonged pilocarpine-induced status epilepticus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7404": {"data": {"text": "Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [70, 81], "span2": [90, 108]}, "bert_text": "Infarcts in substantia nigra pars reticulata were evoked by prolonged <e1> pilocarpine </e1>-induced <e2> status epilepticus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7405": {"data": {"text": "These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant-induced hypotension.", "entity1": "calcium", "entity2": "hypotension", "span1": [41, 48], "span2": [124, 135]}, "bert_text": "These findings do not support a role for <e1> calcium </e1> channel inhibition in the pathogenesis of tricyclic antidepressant-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7406": {"data": {"text": "The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.", "entity1": "tizanidine", "entity2": "hypertension", "span1": [28, 38], "span2": [137, 149]}, "bert_text": "The possible interaction of <e1> tizanidine </e1> and other antihypertensive agents should be kept in mind when prescribing therapy to treat either <e2> hypertension </e2> or spasticity in such patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7407": {"data": {"text": "The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.", "entity1": "tizanidine", "entity2": "spasticity", "span1": [28, 38], "span2": [153, 163]}, "bert_text": "The possible interaction of <e1> tizanidine </e1> and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or <e2> spasticity </e2> in such patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7408": {"data": {"text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "entity1": "AMP", "entity2": "OB", "span1": [425, 428], "span2": [34, 36]}, "bert_text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial <e1> AMP </e1> <e2> OB </e2> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7409": {"data": {"text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "entity1": "AMP", "entity2": "OB", "span1": [425, 428], "span2": [392, 394]}, "bert_text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial <e1> AMP </e1> <e2> OB </e2>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7410": {"data": {"text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "entity1": "ATP", "entity2": "OB", "span1": [480, 483], "span2": [34, 36]}, "bert_text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac <e1> ATP </e1> <e2> OB </e2> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7411": {"data": {"text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "entity1": "ATP", "entity2": "OB", "span1": [480, 483], "span2": [392, 394]}, "bert_text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac <e1> ATP </e1> <e2> OB </e2>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7412": {"data": {"text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "entity1": "ATP", "entity2": "OB", "span1": [516, 519], "span2": [34, 36]}, "bert_text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased <e1> ATP </e1> <e2> OB </e2> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7413": {"data": {"text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "entity1": "ATP", "entity2": "OB", "span1": [516, 519], "span2": [392, 394]}, "bert_text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased <e1> ATP </e1> <e2> OB </e2>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7414": {"data": {"text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "entity1": "ADP", "entity2": "OB", "span1": [520, 523], "span2": [34, 36]}, "bert_text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/<e1> ADP </e1> <e2> OB </e2> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7415": {"data": {"text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "entity1": "ADP", "entity2": "OB", "span1": [520, 523], "span2": [392, 394]}, "bert_text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/<e1> ADP </e1> <e2> OB </e2>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7416": {"data": {"text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "entity1": "doxorubicin", "entity2": "OB", "span1": [536, 547], "span2": [34, 36]}, "bert_text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after <e1> doxorubicin </e1> <e2> OB </e2> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7417": {"data": {"text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "entity1": "doxorubicin", "entity2": "OB", "span1": [536, 547], "span2": [392, 394]}, "bert_text": "Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after <e1> doxorubicin </e1> <e2> OB </e2>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7418": {"data": {"text": "The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.", "entity1": "phenytoin", "entity2": "psychosis", "span1": [69, 78], "span2": [49, 58]}, "bert_text": "The case of a nonepileptic patient who developed psychosis following <e1> phenytoin </e1> <e2> psychosis </e2> following phenytoin treatment for trigeminal neuralgia is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7419": {"data": {"text": "The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.", "entity1": "phenytoin", "entity2": "trigeminal neuralgia", "span1": [69, 78], "span2": [93, 113]}, "bert_text": "The case of a nonepileptic patient who developed psychosis following <e1> phenytoin </e1> treatment for <e2> trigeminal neuralgia </e2> is described.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7420": {"data": {"text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "entity1": "phenacetin", "entity2": "renal papillary necrosis", "span1": [135, 145], "span2": [23, 47]}, "bert_text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either <e1> phenacetin </e1> <e2> renal papillary necrosis </e2> or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7421": {"data": {"text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "entity1": "phenacetin", "entity2": "cancer", "span1": [135, 145], "span2": [51, 57]}, "bert_text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either <e1> phenacetin </e1> <e2> cancer </e2> of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7422": {"data": {"text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "entity1": "phenacetin", "entity2": "ureter", "span1": [135, 145], "span2": [79, 85]}, "bert_text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either <e1> phenacetin </e1> <e2> ureter </e2> or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7423": {"data": {"text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "entity1": "paracetamol", "entity2": "renal papillary necrosis", "span1": [149, 160], "span2": [23, 47]}, "bert_text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or <e1> paracetamol </e1> <e2> renal papillary necrosis </e2> or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7424": {"data": {"text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "entity1": "paracetamol", "entity2": "cancer", "span1": [149, 160], "span2": [51, 57]}, "bert_text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or <e1> paracetamol </e1> <e2> cancer </e2> of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7425": {"data": {"text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "entity1": "paracetamol", "entity2": "ureter", "span1": [149, 160], "span2": [79, 85]}, "bert_text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or <e1> paracetamol </e1> <e2> ureter </e2> or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7426": {"data": {"text": "The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.", "entity1": "mangiferin", "entity2": "ischemic myocardium", "span1": [23, 33], "span2": [141, 160]}, "bert_text": "The protective role of <e1> mangiferin </e1> was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the <e2> ischemic myocardium </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7427": {"data": {"text": "The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.", "entity1": "triphenyl tetrazolium chloride", "entity2": "ischemic myocardium", "span1": [50, 80], "span2": [141, 160]}, "bert_text": "The protective role of mangiferin was analyzed by <e1> triphenyl tetrazolium chloride </e1> (TTC) test used for macroscopic enzyme mapping assay of the <e2> ischemic myocardium </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7428": {"data": {"text": "The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.", "entity1": "TTC", "entity2": "ischemic myocardium", "span1": [82, 85], "span2": [141, 160]}, "bert_text": "The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (<e1> TTC </e1>) test used for macroscopic enzyme mapping assay of the <e2> ischemic myocardium </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7429": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "toxicity", "span1": [86, 95], "span2": [36, 44]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound <e1> potassium </e1> <e2> toxicity </e2> seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7430": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "toxicity", "span1": [86, 95], "span2": [213, 221]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound <e1> potassium </e1> wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular <e2> toxicity </e2> of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7431": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "hypokalemia", "span1": [86, 95], "span2": [342, 353]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound <e1> potassium </e1> wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent <e2> hypokalemia </e2> in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7432": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "neutropenic", "span1": [86, 95], "span2": [357, 368]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound <e1> potassium </e1> wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in <e2> neutropenic </e2> patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7433": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "Potassium", "entity2": "toxicity", "span1": [164, 173], "span2": [36, 44]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. <e1> Potassium </e1> <e2> toxicity </e2> seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7434": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "Potassium", "entity2": "toxicity", "span1": [164, 173], "span2": [213, 221]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. <e1> Potassium </e1> depletion also potentiates the tubular <e2> toxicity </e2> of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7435": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "Potassium", "entity2": "hypokalemia", "span1": [164, 173], "span2": [342, 353]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. <e1> Potassium </e1> depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent <e2> hypokalemia </e2> in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7436": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "Potassium", "entity2": "neutropenic", "span1": [164, 173], "span2": [357, 368]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. <e1> Potassium </e1> depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in <e2> neutropenic </e2> patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7437": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "toxicity", "span1": [304, 313], "span2": [36, 44]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce <e1> potassium </e1> <e2> toxicity </e2> seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7438": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "toxicity", "span1": [304, 313], "span2": [213, 221]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce <e1> potassium </e1> <e2> toxicity </e2> of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7439": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "hypokalemia", "span1": [304, 313], "span2": [342, 353]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce <e1> potassium </e1> requirements and to prevent <e2> hypokalemia </e2> in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7440": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "potassium", "entity2": "neutropenic", "span1": [304, 313], "span2": [357, 368]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce <e1> potassium </e1> requirements and to prevent hypokalemia in <e2> neutropenic </e2> patients on AmB treatment.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7441": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB.", "entity2": "toxicity", "span1": [159, 163], "span2": [36, 44]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with <e1> AmB. </e1> <e2> toxicity </e2> seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7442": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB.", "entity2": "toxicity", "span1": [159, 163], "span2": [213, 221]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with <e1> AmB. </e1> Potassium depletion also potentiates the tubular <e2> toxicity </e2> of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7443": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB.", "entity2": "hypokalemia", "span1": [159, 163], "span2": [342, 353]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with <e1> AmB. </e1> Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent <e2> hypokalemia </e2> in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7444": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB.", "entity2": "neutropenic", "span1": [159, 163], "span2": [357, 368]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with <e1> AmB. </e1> Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in <e2> neutropenic </e2> patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7445": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB.", "entity2": "toxicity", "span1": [225, 229], "span2": [36, 44]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of <e1> AmB. </e1> <e2> toxicity </e2> seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7446": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB.", "entity2": "toxicity", "span1": [225, 229], "span2": [213, 221]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of <e1> AmB. </e1> <e2> toxicity </e2> of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7447": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB.", "entity2": "hypokalemia", "span1": [225, 229], "span2": [342, 353]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of <e1> AmB. </e1> This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent <e2> hypokalemia </e2> in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7448": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB.", "entity2": "neutropenic", "span1": [225, 229], "span2": [357, 368]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of <e1> AmB. </e1> This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in <e2> neutropenic </e2> patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7449": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB", "entity2": "toxicity", "span1": [381, 384], "span2": [36, 44]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on <e1> AmB </e1> <e2> toxicity </e2> seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7450": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB", "entity2": "toxicity", "span1": [381, 384], "span2": [213, 221]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on <e1> AmB </e1> <e2> toxicity </e2> of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7451": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB", "entity2": "hypokalemia", "span1": [381, 384], "span2": [342, 353]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on <e1> AmB </e1> <e2> hypokalemia </e2> in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 1},
+	"7452": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "AmB", "entity2": "neutropenic", "span1": [381, 384], "span2": [357, 368]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on <e1> AmB </e1> <e2> neutropenic </e2> patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"7453": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "spironolactone", "entity2": "toxicity", "span1": [279, 293], "span2": [36, 44]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of <e1> spironolactone </e1> <e2> toxicity </e2> seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7454": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "spironolactone", "entity2": "toxicity", "span1": [279, 293], "span2": [213, 221]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of <e1> spironolactone </e1> <e2> toxicity </e2> of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7455": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "spironolactone", "entity2": "hypokalemia", "span1": [279, 293], "span2": [342, 353]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of <e1> spironolactone </e1> to reduce potassium requirements and to prevent <e2> hypokalemia </e2> in neutropenic patients on AmB treatment.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7456": {"data": {"text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity1": "spironolactone", "entity2": "neutropenic", "span1": [279, 293], "span2": [357, 368]}, "bert_text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of <e1> spironolactone </e1> to reduce potassium requirements and to prevent hypokalemia in <e2> neutropenic </e2> patients on AmB treatment.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7457": {"data": {"text": "This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.", "entity1": "6-thioguanine", "entity2": "hepatic veno-occlusive disease", "span1": [205, 218], "span2": [101, 131]}, "bert_text": "This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to <e1> 6-thioguanine </e1> <e2> hepatic veno-occlusive disease </e2> over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7458": {"data": {"text": "Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.", "entity1": "verapamil", "entity2": "AF", "span1": [34, 43], "span2": [53, 55]}, "bert_text": "Epicardial mapping suggested that <e1> verapamil </e1> promoted <e2> AF </e2> by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7459": {"data": {"text": "A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.", "entity1": "amiodarone", "entity2": "atrial tachycardia", "span1": [71, 81], "span2": [96, 114]}, "bert_text": "A case is presented of a reversible intra-Hisian block occurring under <e1> amiodarone </e1> treatment for <e2> atrial tachycardia </e2> in a patient without clear intraventricular conduction abnormalities.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7460": {"data": {"text": "OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.", "entity1": "fluoxetine", "entity2": "hyperprolactinemia", "span1": [60, 70], "span2": [119, 137]}, "bert_text": "OBJECTIVE: The aim of this study was to investigate whether <e1> fluoxetine </e1> given to castrated and noncastrated rats caused <e2> hyperprolactinemia </e2> and its effects with respect to adenomyosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7461": {"data": {"text": "OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.", "entity1": "fluoxetine", "entity2": "adenomyosis", "span1": [60, 70], "span2": [170, 181]}, "bert_text": "OBJECTIVE: The aim of this study was to investigate whether <e1> fluoxetine </e1> given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to <e2> adenomyosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7462": {"data": {"text": "We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.", "entity1": "sulindac", "entity2": "RPN", "span1": [103, 111], "span2": [35, 38]}, "bert_text": "We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of <e1> sulindac </e1> <e2> RPN </e2> to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7463": {"data": {"text": "We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.", "entity1": "sulindac", "entity2": "renal toxicity", "span1": [103, 111], "span2": [145, 159]}, "bert_text": "We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of <e1> sulindac </e1> in patients who have experienced <e2> renal toxicity </e2> from other antiinflammatory agents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7464": {"data": {"text": "Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.\n", "entity1": "Valproic acid", "entity2": "encephalopathy--19", "span1": [0, 13], "span2": [22, 40]}, "bert_text": "<e1> Valproic acid </e1> induced <e2> encephalopathy--19 </e2> new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7465": {"data": {"text": "Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.\n", "entity1": "VPA", "entity2": "encephalopathy--19", "span1": [109, 112], "span2": [22, 40]}, "bert_text": "Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to <e1> VPA </e1> <e2> encephalopathy--19 </e2> new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7466": {"data": {"text": "Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.\n", "entity1": "amine", "entity2": "catatonia", "span1": [11, 16], "span2": [42, 51]}, "bert_text": "Effects of <e1> amine </e1> pretreatment on ketamine <e2> catatonia </e2> in pinealectomized or hypophysectomized animals.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7467": {"data": {"text": "Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.\n", "entity1": "ketamine", "entity2": "catatonia", "span1": [33, 41], "span2": [42, 51]}, "bert_text": "Effects of amine pretreatment on <e1> ketamine </e1> <e2> catatonia </e2> in pinealectomized or hypophysectomized animals.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7468": {"data": {"text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "entity1": "NO", "entity2": "ototoxicity", "span1": [106, 108], "span2": [6, 17]}, "bert_text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of <e1> NO </e1> <e2> ototoxicity </e2> is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7469": {"data": {"text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "entity1": "NO", "entity2": "ototoxic", "span1": [106, 108], "span2": [60, 68]}, "bert_text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of <e1> NO </e1> <e2> ototoxic </e2> mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7470": {"data": {"text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "entity1": "NO", "entity2": "sensorineural hearing loss", "span1": [106, 108], "span2": [198, 224]}, "bert_text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of <e1> NO </e1>, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced <e2> sensorineural hearing loss </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7471": {"data": {"text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "entity1": "NO inhibitors", "entity2": "ototoxicity", "span1": [139, 152], "span2": [6, 17]}, "bert_text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of <e1> NO inhibitors </e1> <e2> ototoxicity </e2> is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7472": {"data": {"text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "entity1": "NO inhibitors", "entity2": "ototoxic", "span1": [139, 152], "span2": [60, 68]}, "bert_text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of <e1> NO inhibitors </e1> <e2> ototoxic </e2> mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7473": {"data": {"text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "entity1": "NO inhibitors", "entity2": "sensorineural hearing loss", "span1": [139, 152], "span2": [198, 224]}, "bert_text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of <e1> NO inhibitors </e1> for the prevention of aminoglycoside-induced <e2> sensorineural hearing loss </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7474": {"data": {"text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "entity1": "aminoglycoside", "entity2": "ototoxicity", "span1": [175, 189], "span2": [6, 17]}, "bert_text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of <e1> aminoglycoside </e1> <e2> ototoxicity </e2> is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7475": {"data": {"text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "entity1": "aminoglycoside", "entity2": "ototoxic", "span1": [175, 189], "span2": [60, 68]}, "bert_text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of <e1> aminoglycoside </e1> <e2> ototoxic </e2> mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7476": {"data": {"text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.", "entity1": "aminoglycoside", "entity2": "sensorineural hearing loss", "span1": [175, 189], "span2": [198, 224]}, "bert_text": "Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of <e1> aminoglycoside </e1>-induced <e2> sensorineural hearing loss </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7477": {"data": {"text": "Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.", "entity1": "cyclophosphamide", "entity2": "CHF", "span1": [41, 57], "span2": [74, 77]}, "bert_text": "Routine EKG monitoring during infusional <e1> cyclophosphamide </e1> did not predict <e2> CHF </e2> development.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"7478": {"data": {"text": "Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.", "entity1": "Carboplatin", "entity2": "acute renal failure", "span1": [0, 11], "span2": [39, 58]}, "bert_text": "<e1> Carboplatin </e1> has been reported to cause <e2> acute renal failure </e2> when administered in high doses to adult patients.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7479": {"data": {"text": "OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).", "entity1": "oxygen", "entity2": "Diabetic nephropathy", "span1": [128, 134], "span2": [11, 31]}, "bert_text": "OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive <e1> oxygen </e1> <e2> Diabetic nephropathy </e2> is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7480": {"data": {"text": "OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).", "entity1": "oxygen", "entity2": "renal failure", "span1": [128, 134], "span2": [62, 75]}, "bert_text": "OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive <e1> oxygen </e1> <e2> renal failure </e2>, which is accompanied by the production of reactive oxygen species (ROS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7481": {"data": {"text": "Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.\n", "entity1": "cocaine", "entity2": "delirium", "span1": [33, 40], "span2": [14, 22]}, "bert_text": "Fatal excited delirium following <e1> cocaine </e1> <e2> delirium </e2> following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7482": {"data": {"text": "Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.\n", "entity1": "cocaine", "entity2": "toxicity", "span1": [33, 40], "span2": [116, 124]}, "bert_text": "Fatal excited delirium following <e1> cocaine </e1> use: epidemiologic findings provide new evidence for mechanisms of cocaine <e2> toxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7483": {"data": {"text": "Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.\n", "entity1": "cocaine", "entity2": "delirium", "span1": [108, 115], "span2": [14, 22]}, "bert_text": "Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of <e1> cocaine </e1> <e2> delirium </e2> following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7484": {"data": {"text": "Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.\n", "entity1": "cocaine", "entity2": "toxicity", "span1": [108, 115], "span2": [116, 124]}, "bert_text": "Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of <e1> cocaine </e1> <e2> toxicity </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7485": {"data": {"text": "These observations suggest that rigidity should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.", "entity1": "alfentanil", "entity2": "rigidity", "span1": [66, 76], "span2": [32, 40]}, "bert_text": "These observations suggest that rigidity should be prevented when <e1> alfentanil </e1> <e2> rigidity </e2> should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7486": {"data": {"text": "CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.", "entity1": "CC", "entity2": "retinal vein occlusion", "span1": [102, 104], "span2": [58, 80]}, "bert_text": "CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with <e1> CC </e1> <e2> retinal vein occlusion </e2> after treatment with CC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7487": {"data": {"text": "The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.", "entity1": "phenacetin", "entity2": "renal papillary necrosis", "span1": [84, 94], "span2": [12, 36]}, "bert_text": "The risk of renal papillary necrosis was increased nearly 20-fold by consumption of <e1> phenacetin </e1> <e2> renal papillary necrosis </e2> was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"7488": {"data": {"text": "The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.", "entity1": "phenacetin", "entity2": "cancer", "span1": [84, 94], "span2": [130, 136]}, "bert_text": "The risk of renal papillary necrosis was increased nearly 20-fold by consumption of <e1> phenacetin </e1>, which also increased the risk for <e2> cancer </e2> of the renal pelvis and bladder but not for ureteric cancer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7489": {"data": {"text": "The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.", "entity1": "phenacetin", "entity2": "ureteric cancer", "span1": [84, 94], "span2": [181, 196]}, "bert_text": "The risk of renal papillary necrosis was increased nearly 20-fold by consumption of <e1> phenacetin </e1>, which also increased the risk for cancer of the renal pelvis and bladder but not for <e2> ureteric cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"7490": {"data": {"text": "CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.", "entity1": "DFO's", "entity2": "hearing impairment", "span1": [43, 48], "span2": [89, 107]}, "bert_text": "CONCLUSION: The findings are indicative of <e1> DFO's </e1> contributing role in the development of <e2> hearing impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7491": {"data": {"text": "This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.", "entity1": "ciprofloxacin", "entity2": "thrombocytopenia", "span1": [28, 41], "span2": [75, 91]}, "bert_text": "This case report shows that <e1> ciprofloxacin </e1> may precipitate life-threatening <e2> thrombocytopenia </e2> and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7492": {"data": {"text": "This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.", "entity1": "ciprofloxacin", "entity2": "haemolytic anaemia", "span1": [28, 41], "span2": [96, 114]}, "bert_text": "This case report shows that <e1> ciprofloxacin </e1> may precipitate life-threatening thrombocytopenia and <e2> haemolytic anaemia </e2>, even in the early phases of treatment and without apparent previous exposures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7493": {"data": {"text": "The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.", "entity1": "adriamycin", "entity2": "cardiotoxic", "span1": [27, 37], "span2": [4, 15]}, "bert_text": "The cardiotoxic effects of <e1> adriamycin </e1> <e2> cardiotoxic </e2> effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7494": {"data": {"text": "The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.", "entity1": "apraclonidine", "entity2": "ocular hypotensive", "span1": [66, 79], "span2": [4, 22]}, "bert_text": "The ocular hypotensive effects were statistically significant for <e1> apraclonidine </e1> <e2> ocular hypotensive </e2> effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7495": {"data": {"text": "The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.", "entity1": "apraclonidine", "entity2": "ocular hypotensive", "span1": [224, 237], "span2": [4, 22]}, "bert_text": "The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% <e1> apraclonidine </e1> <e2> ocular hypotensive </e2> effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7496": {"data": {"text": "Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.", "entity1": "Cyclophosphamide", "entity2": "cystitis", "span1": [0, 16], "span2": [158, 166]}, "bert_text": "<e1> Cyclophosphamide </e1> (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce <e2> cystitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7497": {"data": {"text": "Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.", "entity1": "CP", "entity2": "cystitis", "span1": [18, 20], "span2": [158, 166]}, "bert_text": "Cyclophosphamide (<e1> CP </e1>), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce <e2> cystitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7498": {"data": {"text": "Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.", "entity1": "acrolein", "entity2": "cystitis", "span1": [129, 137], "span2": [158, 166]}, "bert_text": "Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite <e1> acrolein </e1>, was used to induce <e2> cystitis </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7499": {"data": {"text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "entity1": "THP", "entity2": "catalepsy", "span1": [0, 3], "span2": [80, 89]}, "bert_text": "<e1> THP </e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2> catalepsy </e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7500": {"data": {"text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "entity1": "THP", "entity2": "hyperactivity", "span1": [0, 3], "span2": [120, 133]}, "bert_text": "<e1> THP </e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced <e2> hyperactivity </e2> and reducing apomorphine-induced climbing in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7501": {"data": {"text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [60, 71], "span2": [80, 89]}, "bert_text": "THP exhibited an antipsychotic-like profile by potentiating <e1> haloperidol </e1>-induced <e2> catalepsy </e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7502": {"data": {"text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "entity1": "haloperidol", "entity2": "hyperactivity", "span1": [60, 71], "span2": [120, 133]}, "bert_text": "THP exhibited an antipsychotic-like profile by potentiating <e1> haloperidol </e1>-induced catalepsy, reducing amphetamine-induced <e2> hyperactivity </e2> and reducing apomorphine-induced climbing in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7503": {"data": {"text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "entity1": "amphetamine", "entity2": "catalepsy", "span1": [100, 111], "span2": [80, 89]}, "bert_text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing <e1> amphetamine </e1> <e2> catalepsy </e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7504": {"data": {"text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [100, 111], "span2": [120, 133]}, "bert_text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing <e1> amphetamine </e1>-induced <e2> hyperactivity </e2> and reducing apomorphine-induced climbing in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7505": {"data": {"text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [147, 158], "span2": [80, 89]}, "bert_text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing <e1> apomorphine </e1> <e2> catalepsy </e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7506": {"data": {"text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "entity1": "apomorphine", "entity2": "hyperactivity", "span1": [147, 158], "span2": [120, 133]}, "bert_text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing <e1> apomorphine </e1> <e2> hyperactivity </e2> and reducing apomorphine-induced climbing in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7507": {"data": {"text": "Chlorpropamide-induced optic neuropathy.\n", "entity1": "Chlorpropamide", "entity2": "optic neuropathy", "span1": [0, 14], "span2": [23, 39]}, "bert_text": "<e1> Chlorpropamide </e1>-induced <e2> optic neuropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7508": {"data": {"text": "Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.", "entity1": "pentamidine", "entity2": "Torsade de pointes", "span1": [93, 104], "span2": [0, 18]}, "bert_text": "Torsade de pointes can be treated when recognized early, possibly without discontinuation of <e1> pentamidine </e1> <e2> Torsade de pointes </e2> can be treated when recognized early, possibly without discontinuation of pentamidine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7509": {"data": {"text": "Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.\n", "entity1": "levofloxacin", "entity2": "sinusitis", "span1": [25, 37], "span2": [75, 84]}, "bert_text": "Open-label assessment of <e1> levofloxacin </e1> for the treatment of acute bacterial <e2> sinusitis </e2> in adults.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7510": {"data": {"text": "Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.\n", "entity1": "epinephrine", "entity2": "left ventricular systolic and diastolic dysfunction", "span1": [99, 110], "span2": [18, 69]}, "bert_text": "Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic <e1> epinephrine </e1> <e2> left ventricular systolic and diastolic dysfunction </e2> due to accidental iatrogenic epinephrine overdose.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7511": {"data": {"text": "Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.\n", "entity1": "epinephrine", "entity2": "overdose", "span1": [99, 110], "span2": [111, 119]}, "bert_text": "Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic <e1> epinephrine </e1> <e2> overdose </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7512": {"data": {"text": "5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).", "entity1": "5,7-dichlorokynurenic acid", "entity2": "muscle rigidity", "span1": [0, 26], "span2": [220, 235]}, "bert_text": "<e1> 5,7-dichlorokynurenic acid </e1> (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced <e2> muscle rigidity </e2> (MMG) and the enhanced electromyographic activity (EMG).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7513": {"data": {"text": "5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).", "entity1": "5,7-DCKA", "entity2": "muscle rigidity", "span1": [28, 36], "span2": [220, 235]}, "bert_text": "5,7-dichlorokynurenic acid (<e1> 5,7-DCKA </e1>), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced <e2> muscle rigidity </e2> (MMG) and the enhanced electromyographic activity (EMG).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7514": {"data": {"text": "5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).", "entity1": "glycine", "entity2": "muscle rigidity", "span1": [51, 58], "span2": [220, 235]}, "bert_text": "5,7-dichlorokynurenic acid (5,7-DCKA), a selective <e1> glycine </e1> site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced <e2> muscle rigidity </e2> (MMG) and the enhanced electromyographic activity (EMG).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7515": {"data": {"text": "5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).", "entity1": "haloperidol", "entity2": "muscle rigidity", "span1": [200, 211], "span2": [220, 235]}, "bert_text": "5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the <e1> haloperidol </e1>-induced <e2> muscle rigidity </e2> (MMG) and the enhanced electromyographic activity (EMG).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7516": {"data": {"text": "Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.\n", "entity1": "succinylcholine", "entity2": "Postoperative myalgia", "span1": [28, 43], "span2": [0, 21]}, "bert_text": "Postoperative myalgia after <e1> succinylcholine </e1> <e2> Postoperative myalgia </e2> after succinylcholine: no evidence for an inflammatory origin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7517": {"data": {"text": "RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.", "entity1": "adriamycin", "entity2": "nephrotic", "span1": [25, 35], "span2": [45, 54]}, "bert_text": "RESULTS: As anticipated, <e1> adriamycin </e1> elicited <e2> nephrotic </e2> range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7518": {"data": {"text": "RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.", "entity1": "adriamycin", "entity2": "proteinuria", "span1": [25, 35], "span2": [61, 72]}, "bert_text": "RESULTS: As anticipated, <e1> adriamycin </e1> elicited nephrotic range <e2> proteinuria </e2>, renal interstitial damage and mild focal glomerulosclerosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7519": {"data": {"text": "RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.", "entity1": "adriamycin", "entity2": "renal interstitial damage", "span1": [25, 35], "span2": [74, 99]}, "bert_text": "RESULTS: As anticipated, <e1> adriamycin </e1> elicited nephrotic range proteinuria, <e2> renal interstitial damage </e2> and mild focal glomerulosclerosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7520": {"data": {"text": "RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.", "entity1": "adriamycin", "entity2": "focal glomerulosclerosis", "span1": [25, 35], "span2": [109, 133]}, "bert_text": "RESULTS: As anticipated, <e1> adriamycin </e1> elicited nephrotic range proteinuria, renal interstitial damage and mild <e2> focal glomerulosclerosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7521": {"data": {"text": "Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.\n", "entity1": "dopamine", "entity2": "parkinsonian", "span1": [43, 51], "span2": [100, 112]}, "bert_text": "Potential therapeutic use of the selective <e1> dopamine </e1> D1 receptor agonist, A-86929: an acute study in <e2> parkinsonian </e2> levodopa-primed monkeys.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7522": {"data": {"text": "Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.\n", "entity1": "A-86929", "entity2": "parkinsonian", "span1": [73, 80], "span2": [100, 112]}, "bert_text": "Potential therapeutic use of the selective dopamine D1 receptor agonist, <e1> A-86929 </e1>: an acute study in <e2> parkinsonian </e2> levodopa-primed monkeys.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7523": {"data": {"text": "Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.\n", "entity1": "levodopa", "entity2": "parkinsonian", "span1": [113, 121], "span2": [100, 112]}, "bert_text": "Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian <e1> levodopa </e1> <e2> parkinsonian </e2> levodopa-primed monkeys.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7524": {"data": {"text": "CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.", "entity1": "selegiline", "entity2": "orthostatic hypotension", "span1": [58, 68], "span2": [125, 148]}, "bert_text": "CONCLUSION: This study confirms our previous finding that <e1> selegiline </e1> in combination with L-dopa is associated with selective <e2> orthostatic hypotension </e2>.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7525": {"data": {"text": "CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.", "entity1": "L-dopa", "entity2": "orthostatic hypotension", "span1": [89, 95], "span2": [125, 148]}, "bert_text": "CONCLUSION: This study confirms our previous finding that selegiline in combination with <e1> L-dopa </e1> is associated with selective <e2> orthostatic hypotension </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7526": {"data": {"text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.", "entity1": "alpha-tocopherol", "entity2": "neurotoxicity", "span1": [34, 50], "span2": [163, 176]}, "bert_text": "This study examined the effect of <e1> alpha-tocopherol </e1> (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7527": {"data": {"text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.", "entity1": "alpha-TC", "entity2": "neurotoxicity", "span1": [52, 60], "span2": [163, 176]}, "bert_text": "This study examined the effect of alpha-tocopherol (<e1> alpha-TC </e1>), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7528": {"data": {"text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.", "entity1": "oxygen", "entity2": "neurotoxicity", "span1": [87, 93], "span2": [163, 176]}, "bert_text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive <e1> oxygen </e1> species, and deferoxamine (DFO), an iron chelator, on the MA-induced <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7529": {"data": {"text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.", "entity1": "deferoxamine", "entity2": "neurotoxicity", "span1": [107, 119], "span2": [163, 176]}, "bert_text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and <e1> deferoxamine </e1> (DFO), an iron chelator, on the MA-induced <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7530": {"data": {"text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.", "entity1": "DFO", "entity2": "neurotoxicity", "span1": [121, 124], "span2": [163, 176]}, "bert_text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1> DFO </e1>), an iron chelator, on the MA-induced <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7531": {"data": {"text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.", "entity1": "iron", "entity2": "neurotoxicity", "span1": [130, 134], "span2": [163, 176]}, "bert_text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an <e1> iron </e1> chelator, on the MA-induced <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7532": {"data": {"text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.", "entity1": "MA", "entity2": "neurotoxicity", "span1": [152, 154], "span2": [163, 176]}, "bert_text": "This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the <e1> MA </e1>-induced <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7533": {"data": {"text": "The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.", "entity1": "3'-azido-3'dideoxythymidine", "entity2": "anaemia", "span1": [23, 50], "span2": [4, 11]}, "bert_text": "The anaemia induced by <e1> 3'-azido-3'dideoxythymidine </e1> <e2> anaemia </e2> induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7534": {"data": {"text": "The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.", "entity1": "AZT", "entity2": "anaemia", "span1": [52, 55], "span2": [4, 11]}, "bert_text": "The anaemia induced by 3'-azido-3'dideoxythymidine (<e1> AZT </e1> <e2> anaemia </e2> induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7535": {"data": {"text": "The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.\n", "entity1": "streptozotocin", "entity2": "diabetic nephropathy", "span1": [31, 45], "span2": [54, 74]}, "bert_text": "The protective role of Nrf2 in <e1> streptozotocin </e1>-induced <e2> diabetic nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7536": {"data": {"text": "For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.", "entity1": "terfenadine", "entity2": "TDP", "span1": [49, 60], "span2": [30, 33]}, "bert_text": "For compounds that have shown TDP in the clinic (<e1> terfenadine </e1> <e2> TDP </e2> in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7537": {"data": {"text": "For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.", "entity1": "terodiline", "entity2": "TDP", "span1": [62, 72], "span2": [30, 33]}, "bert_text": "For compounds that have shown TDP in the clinic (terfenadine, <e1> terodiline </e1> <e2> TDP </e2> in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7538": {"data": {"text": "For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.", "entity1": "cisapride", "entity2": "TDP", "span1": [74, 83], "span2": [30, 33]}, "bert_text": "For compounds that have shown TDP in the clinic (terfenadine, terodiline, <e1> cisapride </e1> <e2> TDP </e2> in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7539": {"data": {"text": "We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.", "entity1": "epsilon-aminocaproic acid", "entity2": "sinus thrombosis", "span1": [127, 152], "span2": [84, 100]}, "bert_text": "We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged <e1> epsilon-aminocaproic acid </e1> <e2> sinus thrombosis </e2> associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7540": {"data": {"text": "We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.", "entity1": "epsilon-aminocaproic acid", "entity2": "menorrhagia", "span1": [127, 152], "span2": [165, 176]}, "bert_text": "We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged <e1> epsilon-aminocaproic acid </e1> therapy for <e2> menorrhagia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7541": {"data": {"text": "These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex-related differences in the hormonal environment.", "entity1": "estradiol", "entity2": "seizure", "span1": [43, 52], "span2": [56, 63]}, "bert_text": "These findings suggest that the effects of <e1> estradiol </e1> on <e2> seizure </e2> threshold and damage may be altered by sex-related differences in the hormonal environment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7542": {"data": {"text": "The role of nicotine in smoking-related cardiovascular disease.\n", "entity1": "nicotine", "entity2": "cardiovascular disease", "span1": [12, 20], "span2": [40, 62]}, "bert_text": "The role of <e1> nicotine </e1> in smoking-related <e2> cardiovascular disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7543": {"data": {"text": "The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.", "entity1": "dothiepin", "entity2": "blurred vision", "span1": [143, 152], "span2": [72, 86]}, "bert_text": "The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with <e1> dothiepin </e1> <e2> blurred vision </e2>, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7544": {"data": {"text": "The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.", "entity1": "dothiepin", "entity2": "dry mouth", "span1": [143, 152], "span2": [88, 97]}, "bert_text": "The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with <e1> dothiepin </e1> <e2> dry mouth </e2>, and drowsiness were significantly less with dothiepin than with amitriptyline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7545": {"data": {"text": "The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.", "entity1": "amitriptyline", "entity2": "blurred vision", "span1": [163, 176], "span2": [72, 86]}, "bert_text": "The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with <e1> amitriptyline </e1> <e2> blurred vision </e2>, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7546": {"data": {"text": "The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.", "entity1": "amitriptyline", "entity2": "dry mouth", "span1": [163, 176], "span2": [88, 97]}, "bert_text": "The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with <e1> amitriptyline </e1> <e2> dry mouth </e2>, and drowsiness were significantly less with dothiepin than with amitriptyline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7547": {"data": {"text": "Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.\n", "entity1": "ethambutol", "entity2": "Bilateral optic neuropathy", "span1": [43, 53], "span2": [0, 26]}, "bert_text": "Bilateral optic neuropathy due to combined <e1> ethambutol </e1> <e2> Bilateral optic neuropathy </e2> due to combined ethambutol and isoniazid treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7548": {"data": {"text": "Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.\n", "entity1": "isoniazid", "entity2": "Bilateral optic neuropathy", "span1": [58, 67], "span2": [0, 26]}, "bert_text": "Bilateral optic neuropathy due to combined ethambutol and <e1> isoniazid </e1> <e2> Bilateral optic neuropathy </e2> due to combined ethambutol and isoniazid treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7549": {"data": {"text": "These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.", "entity1": "tolazamide", "entity2": "Wernicke-Korsakoff syndrome", "span1": [103, 113], "span2": [54, 81]}, "bert_text": "These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with <e1> tolazamide </e1> <e2> Wernicke-Korsakoff syndrome </e2> and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7550": {"data": {"text": "These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.", "entity1": "tolazamide", "entity2": "Wernicke's encephalopathy", "span1": [103, 113], "span2": [122, 147]}, "bert_text": "These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with <e1> tolazamide </e1>-induced <e2> Wernicke's encephalopathy </e2> from the standpoint of transketolase abnormality.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7551": {"data": {"text": "All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).", "entity1": "leuprolide acetate", "entity2": "anemia", "span1": [27, 45], "span2": [154, 160]}, "bert_text": "All patients received CAB [<e1> leuprolide acetate </e1> (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for <e2> anemia </e2> by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7552": {"data": {"text": "All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).", "entity1": "LHRH-A", "entity2": "anemia", "span1": [47, 53], "span2": [154, 160]}, "bert_text": "All patients received CAB [leuprolide acetate (<e1> LHRH-A </e1>) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for <e2> anemia </e2> by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7553": {"data": {"text": "All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).", "entity1": "flutamide", "entity2": "anemia", "span1": [107, 116], "span2": [154, 160]}, "bert_text": "All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg <e1> flutamide </e1>, tid, per Os] and were evaluated for <e2> anemia </e2> by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7554": {"data": {"text": "However, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias.", "entity1": "dopamine", "entity2": "dyskinesias", "span1": [35, 43], "span2": [106, 117]}, "bert_text": "However, the long-term use of this <e1> dopamine </e1> precursor is complicated by highly disabling fluctuations and <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7555": {"data": {"text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "entity1": "risperidone", "entity2": "Mental Disorders", "span1": [140, 151], "span2": [70, 86]}, "bert_text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with <e1> risperidone </e1> <e2> Mental Disorders </e2> (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7556": {"data": {"text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "entity1": "risperidone", "entity2": "bipolar disorder", "span1": [140, 151], "span2": [104, 120]}, "bert_text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with <e1> risperidone </e1> <e2> bipolar disorder </e2> or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7557": {"data": {"text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "entity1": "risperidone", "entity2": "psychoses", "span1": [140, 151], "span2": [124, 133]}, "bert_text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with <e1> risperidone </e1> <e2> psychoses </e2>, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7558": {"data": {"text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "entity1": "cabergoline", "entity2": "Mental Disorders", "span1": [252, 263], "span2": [70, 86]}, "bert_text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with <e1> cabergoline </e1> <e2> Mental Disorders </e2> (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7559": {"data": {"text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "entity1": "cabergoline", "entity2": "bipolar disorder", "span1": [252, 263], "span2": [104, 120]}, "bert_text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with <e1> cabergoline </e1> <e2> bipolar disorder </e2> or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7560": {"data": {"text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "entity1": "cabergoline", "entity2": "psychoses", "span1": [252, 263], "span2": [124, 133]}, "bert_text": "Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with <e1> cabergoline </e1> <e2> psychoses </e2>, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7561": {"data": {"text": "Oral contraceptives and the risk of myocardial infarction.\n", "entity1": "Oral contraceptives", "entity2": "myocardial infarction", "span1": [0, 19], "span2": [36, 57]}, "bert_text": "<e1> Oral contraceptives </e1> and the risk of <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7562": {"data": {"text": "We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).", "entity1": "AZT", "entity2": "AIDS", "span1": [129, 132], "span2": [31, 35]}, "bert_text": "We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if <e1> AZT </e1> <e2> AIDS </e2>, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7563": {"data": {"text": "We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).", "entity1": "AZT", "entity2": "infection", "span1": [129, 132], "span2": [37, 46]}, "bert_text": "We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if <e1> AZT </e1> <e2> infection </e2> of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7564": {"data": {"text": "We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).", "entity1": "AZT", "entity2": "leukaemia", "span1": [129, 132], "span2": [89, 98]}, "bert_text": "We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if <e1> AZT </e1> <e2> leukaemia </e2> (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7565": {"data": {"text": "We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).", "entity1": "AZT", "entity2": "anaemia", "span1": [129, 132], "span2": [141, 148]}, "bert_text": "We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if <e1> AZT </e1>-induced <e2> anaemia </e2> is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7566": {"data": {"text": "Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.", "entity1": "trazodone", "entity2": "heart block", "span1": [56, 65], "span2": [96, 107]}, "bert_text": "Forty minutes after receiving a single starting dose of <e1> trazodone </e1>, a patient developed complete <e2> heart block </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7567": {"data": {"text": "Encephalopathy induced by levetiracetam added to valproate.\n", "entity1": "levetiracetam", "entity2": "Encephalopathy", "span1": [26, 39], "span2": [0, 14]}, "bert_text": "Encephalopathy induced by <e1> levetiracetam </e1> <e2> Encephalopathy </e2> induced by levetiracetam added to valproate.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7568": {"data": {"text": "Encephalopathy induced by levetiracetam added to valproate.\n", "entity1": "valproate", "entity2": "Encephalopathy", "span1": [49, 58], "span2": [0, 14]}, "bert_text": "Encephalopathy induced by levetiracetam added to <e1> valproate </e1> <e2> Encephalopathy </e2> induced by levetiracetam added to valproate.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7569": {"data": {"text": "RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.", "entity1": "Salbutamol", "entity2": "tremor", "span1": [9, 19], "span2": [44, 50]}, "bert_text": "RESULTS: <e1> Salbutamol </e1> significantly increased <e2> tremor </e2> severity in patients in a dose-dependent way.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7570": {"data": {"text": "We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.", "entity1": "hydrochlorothiazide", "entity2": "diastolic hypertension", "span1": [97, 116], "span2": [69, 91]}, "bert_text": "We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with <e1> hydrochlorothiazide </e1> <e2> diastolic hypertension </e2> with hydrochlorothiazide (HCTC) administered on a twice daily schedule.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7571": {"data": {"text": "We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.", "entity1": "HCTC", "entity2": "diastolic hypertension", "span1": [118, 122], "span2": [69, 91]}, "bert_text": "We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (<e1> HCTC </e1> <e2> diastolic hypertension </e2> with hydrochlorothiazide (HCTC) administered on a twice daily schedule.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7572": {"data": {"text": "Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.", "entity1": "serotonin", "entity2": "rigidity", "span1": [25, 34], "span2": [102, 110]}, "bert_text": "Pretreatment with type-2 <e1> serotonin </e1> antagonists may be clinically useful in attenuating opiate-induced <e2> rigidity </e2>, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7573": {"data": {"text": "Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.", "entity1": "serotonin", "entity2": "respiratory depression", "span1": [25, 34], "span2": [227, 249]}, "bert_text": "Pretreatment with type-2 <e1> serotonin </e1> antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and <e2> respiratory depression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7574": {"data": {"text": "Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.", "entity1": "indomethacin", "entity2": "oliguria", "span1": [101, 113], "span2": [152, 160]}, "bert_text": "Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of <e1> indomethacin </e1> caused recurrence of acute reversible <e2> oliguria </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7575": {"data": {"text": "A case of tardive dyskinesia caused by metoclopramide.\n", "entity1": "metoclopramide", "entity2": "tardive dyskinesia", "span1": [39, 53], "span2": [10, 28]}, "bert_text": "A case of tardive dyskinesia caused by <e1> metoclopramide </e1> <e2> tardive dyskinesia </e2> caused by metoclopramide.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7576": {"data": {"text": "Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)\nBACKGROUND:", "entity1": "angiotensin", "entity2": "decreased renal function", "span1": [77, 88], "span2": [14, 38]}, "bert_text": "Predictors of decreased renal function in patients with heart failure during <e1> angiotensin </e1> <e2> decreased renal function </e2> in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)\nBACKGROUND:", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7577": {"data": {"text": "Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)\nBACKGROUND:", "entity1": "angiotensin", "entity2": "heart failure", "span1": [77, 88], "span2": [56, 69]}, "bert_text": "Predictors of decreased renal function in patients with heart failure during <e1> angiotensin </e1> <e2> heart failure </e2> during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)\nBACKGROUND:", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7578": {"data": {"text": "Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)\nBACKGROUND:", "entity1": "angiotensin", "entity2": "left ventricular dysfunction", "span1": [77, 88], "span2": [154, 182]}, "bert_text": "Predictors of decreased renal function in patients with heart failure during <e1> angiotensin </e1>-converting enzyme inhibitor therapy: results from the studies of <e2> left ventricular dysfunction </e2> (SOLVD)\nBACKGROUND:", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7579": {"data": {"text": "Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.", "entity1": "angiotensin", "entity2": "congestive heart failure", "span1": [9, 20], "span2": [98, 122]}, "bert_text": "Although <e1> angiotensin </e1>-converting enzyme inhibitor therapy reduces mortality rates in patients with <e2> congestive heart failure </e2> (CHF), it may also cause decreased renal function.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7580": {"data": {"text": "Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.", "entity1": "angiotensin", "entity2": "CHF", "span1": [9, 20], "span2": [124, 127]}, "bert_text": "Although <e1> angiotensin </e1>-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (<e2> CHF </e2>), it may also cause decreased renal function.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7581": {"data": {"text": "Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.", "entity1": "angiotensin", "entity2": "decreased renal function", "span1": [9, 20], "span2": [148, 172]}, "bert_text": "Although <e1> angiotensin </e1>-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause <e2> decreased renal function </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7582": {"data": {"text": "The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.", "entity1": "chloroquine", "entity2": "heart block", "span1": [106, 117], "span2": [4, 15]}, "bert_text": "The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following <e1> chloroquine </e1> <e2> heart block </e2> was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7583": {"data": {"text": "The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.", "entity1": "chloroquine", "entity2": "heart failure", "span1": [106, 117], "span2": [59, 72]}, "bert_text": "The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following <e1> chloroquine </e1> <e2> heart failure </e2> resolved spontaneously following chloroquine discontinuation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"7584": {"data": {"text": "The univariate matched odds ratio for stroke in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).", "entity1": "cocaine", "entity2": "stroke", "span1": [76, 83], "span2": [38, 44]}, "bert_text": "The univariate matched odds ratio for stroke in women who admitted to using <e1> cocaine </e1> <e2> stroke </e2> in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7585": {"data": {"text": "The univariate matched odds ratio for stroke in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).", "entity1": "amphetamine", "entity2": "stroke", "span1": [91, 102], "span2": [38, 44]}, "bert_text": "The univariate matched odds ratio for stroke in women who admitted to using cocaine and/or <e1> amphetamine </e1> <e2> stroke </e2> in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7586": {"data": {"text": "Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.", "entity1": "PJ34", "entity2": "cardiac dysfunction", "span1": [17, 21], "span2": [45, 64]}, "bert_text": "Treatment with a <e1> PJ34 </e1> significantly improved <e2> cardiac dysfunction </e2> and increased the survival of the animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7587": {"data": {"text": "For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.", "entity1": "paclitaxel", "entity2": "glioblastoma", "span1": [127, 137], "span2": [10, 22]}, "bert_text": "For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of <e1> paclitaxel </e1> <e2> glioblastoma </e2> recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7588": {"data": {"text": "For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.", "entity1": "carboplatin", "entity2": "glioblastoma", "span1": [142, 153], "span2": [10, 22]}, "bert_text": "For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and <e1> carboplatin </e1> <e2> glioblastoma </e2> recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7589": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "TET", "entity2": "thrombosis", "span1": [63, 66], "span2": [95, 105]}, "bert_text": "The present study was undertaken to investigate the effects of <e1> TET </e1> and FAN on the experimental <e2> thrombosis </e2> induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7590": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "TET", "entity2": "platelet aggregation", "span1": [63, 66], "span2": [161, 181]}, "bert_text": "The present study was undertaken to investigate the effects of <e1> TET </e1> and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and <e2> platelet aggregation </e2> and blood coagulation in vitro.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7591": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "TET", "entity2": "blood coagulation", "span1": [63, 66], "span2": [186, 203]}, "bert_text": "The present study was undertaken to investigate the effects of <e1> TET </e1> and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and <e2> blood coagulation </e2> in vitro.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7592": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "FAN", "entity2": "thrombosis", "span1": [71, 74], "span2": [95, 105]}, "bert_text": "The present study was undertaken to investigate the effects of TET and <e1> FAN </e1> on the experimental <e2> thrombosis </e2> induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7593": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "FAN", "entity2": "platelet aggregation", "span1": [71, 74], "span2": [161, 181]}, "bert_text": "The present study was undertaken to investigate the effects of TET and <e1> FAN </e1> on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and <e2> platelet aggregation </e2> and blood coagulation in vitro.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7594": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "FAN", "entity2": "blood coagulation", "span1": [71, 74], "span2": [186, 203]}, "bert_text": "The present study was undertaken to investigate the effects of TET and <e1> FAN </e1> on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and <e2> blood coagulation </e2> in vitro.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7595": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "epinephrine", "entity2": "thrombosis", "span1": [131, 142], "span2": [95, 105]}, "bert_text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus <e1> epinephrine </e1> <e2> thrombosis </e2> induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7596": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "epinephrine", "entity2": "platelet aggregation", "span1": [131, 142], "span2": [161, 181]}, "bert_text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus <e1> epinephrine </e1> (EP) in mice, and <e2> platelet aggregation </e2> and blood coagulation in vitro.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7597": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "epinephrine", "entity2": "blood coagulation", "span1": [131, 142], "span2": [186, 203]}, "bert_text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus <e1> epinephrine </e1> (EP) in mice, and platelet aggregation and <e2> blood coagulation </e2> in vitro.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7598": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "EP", "entity2": "thrombosis", "span1": [144, 146], "span2": [95, 105]}, "bert_text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (<e1> EP </e1> <e2> thrombosis </e2> induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7599": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "EP", "entity2": "platelet aggregation", "span1": [144, 146], "span2": [161, 181]}, "bert_text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (<e1> EP </e1>) in mice, and <e2> platelet aggregation </e2> and blood coagulation in vitro.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7600": {"data": {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity1": "EP", "entity2": "blood coagulation", "span1": [144, 146], "span2": [186, 203]}, "bert_text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (<e1> EP </e1>) in mice, and platelet aggregation and <e2> blood coagulation </e2> in vitro.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7601": {"data": {"text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "entity1": "Tiopronin", "entity2": "nephritis", "span1": [76, 85], "span2": [44, 53]}, "bert_text": "A strong association has been found between nephritis and dermatitis due to <e1> Tiopronin </e1> <e2> nephritis </e2> and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7602": {"data": {"text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "entity1": "Tiopronin", "entity2": "dermatitis", "span1": [76, 85], "span2": [58, 68]}, "bert_text": "A strong association has been found between nephritis and dermatitis due to <e1> Tiopronin </e1> <e2> dermatitis </e2> due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7603": {"data": {"text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "entity1": "Tiopronin", "entity2": "dermatitis", "span1": [76, 85], "span2": [162, 172]}, "bert_text": "A strong association has been found between nephritis and dermatitis due to <e1> Tiopronin </e1> (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between <e2> dermatitis </e2> due to gold thiosulphate and B35.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7604": {"data": {"text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "entity1": "D-Penicillamine", "entity2": "nephritis", "span1": [89, 104], "span2": [44, 53]}, "bert_text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a <e1> D-Penicillamine </e1> <e2> nephritis </e2> and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7605": {"data": {"text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "entity1": "D-Penicillamine", "entity2": "dermatitis", "span1": [89, 104], "span2": [58, 68]}, "bert_text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a <e1> D-Penicillamine </e1> <e2> dermatitis </e2> due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7606": {"data": {"text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "entity1": "D-Penicillamine", "entity2": "dermatitis", "span1": [89, 104], "span2": [162, 172]}, "bert_text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a <e1> D-Penicillamine </e1> like compound) and class I antigens B35-Cw4, and between <e2> dermatitis </e2> due to gold thiosulphate and B35.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7607": {"data": {"text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "entity1": "gold", "entity2": "nephritis", "span1": [180, 184], "span2": [44, 53]}, "bert_text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to <e1> gold </e1> <e2> nephritis </e2> and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7608": {"data": {"text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "entity1": "gold", "entity2": "dermatitis", "span1": [180, 184], "span2": [58, 68]}, "bert_text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to <e1> gold </e1> <e2> dermatitis </e2> due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7609": {"data": {"text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "entity1": "gold", "entity2": "dermatitis", "span1": [180, 184], "span2": [162, 172]}, "bert_text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to <e1> gold </e1> <e2> dermatitis </e2> due to gold thiosulphate and B35.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7610": {"data": {"text": "We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.", "entity1": "aminoglycoside", "entity2": "ototoxicity", "span1": [17, 31], "span2": [43, 54]}, "bert_text": "We conclude that <e1> aminoglycoside </e1>-associated <e2> ototoxicity </e2> was less severe and more often reversible with netilmicin than with tobramycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7611": {"data": {"text": "We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.", "entity1": "netilmicin", "entity2": "ototoxicity", "span1": [102, 112], "span2": [43, 54]}, "bert_text": "We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with <e1> netilmicin </e1> <e2> ototoxicity </e2> was less severe and more often reversible with netilmicin than with tobramycin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7612": {"data": {"text": "We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.", "entity1": "tobramycin", "entity2": "ototoxicity", "span1": [123, 133], "span2": [43, 54]}, "bert_text": "We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with <e1> tobramycin </e1> <e2> ototoxicity </e2> was less severe and more often reversible with netilmicin than with tobramycin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7613": {"data": {"text": "RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.", "entity1": "neurotensin", "entity2": "parkinsonian catalepsy", "span1": [32, 43], "span2": [98, 120]}, "bert_text": "RESULTS: Bilateral infusions of <e1> neurotensin </e1> into the globus pallidus reversed haloperidol-induced <e2> parkinsonian catalepsy </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7614": {"data": {"text": "RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.", "entity1": "haloperidol", "entity2": "parkinsonian catalepsy", "span1": [78, 89], "span2": [98, 120]}, "bert_text": "RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed <e1> haloperidol </e1>-induced <e2> parkinsonian catalepsy </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7615": {"data": {"text": "Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.", "entity1": "azathioprine", "entity2": "liver damage", "span1": [60, 72], "span2": [113, 125]}, "bert_text": "Liver biopsies should be undertaken at regular intervals if <e1> azathioprine </e1> therapy is continued so that structural <e2> liver damage </e2> may be detected at an early and reversible stage.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7616": {"data": {"text": "We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.", "entity1": "indomethacin", "entity2": "oliguric renal failure", "span1": [136, 148], "span2": [33, 55]}, "bert_text": "We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after <e1> indomethacin </e1> <e2> oliguric renal failure </e2> with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7617": {"data": {"text": "We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.", "entity1": "indomethacin", "entity2": "hyperkalemia", "span1": [136, 148], "span2": [61, 73]}, "bert_text": "We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after <e1> indomethacin </e1> <e2> hyperkalemia </e2> in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7618": {"data": {"text": "We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.", "entity1": "indomethacin", "entity2": "cirrhosis", "span1": [136, 148], "span2": [92, 101]}, "bert_text": "We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after <e1> indomethacin </e1> <e2> cirrhosis </e2>, ascites, and cor pulmonale after indomethacin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7619": {"data": {"text": "We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.", "entity1": "indomethacin", "entity2": "ascites", "span1": [136, 148], "span2": [103, 110]}, "bert_text": "We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after <e1> indomethacin </e1> <e2> ascites </e2>, and cor pulmonale after indomethacin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7620": {"data": {"text": "We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.", "entity1": "indomethacin", "entity2": "cor pulmonale", "span1": [136, 148], "span2": [116, 129]}, "bert_text": "We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after <e1> indomethacin </e1> <e2> cor pulmonale </e2> after indomethacin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7621": {"data": {"text": "This study addressed the potential role of calcium channel blockade in tricyclic antidepressant-induced hypotension.", "entity1": "calcium", "entity2": "hypotension", "span1": [43, 50], "span2": [104, 115]}, "bert_text": "This study addressed the potential role of <e1> calcium </e1> channel blockade in tricyclic antidepressant-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7622": {"data": {"text": "Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.", "entity1": "MK-212", "entity2": "myoclonus", "span1": [50, 56], "span2": [104, 113]}, "bert_text": "Our present study indicated the possible value of <e1> MK-212 </e1> and (-)-baclofen in the management of clinical <e2> myoclonus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7623": {"data": {"text": "Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.", "entity1": "-)-baclofen", "entity2": "myoclonus", "span1": [62, 73], "span2": [104, 113]}, "bert_text": "Our present study indicated the possible value of MK-212 and (<e1> -)-baclofen </e1> in the management of clinical <e2> myoclonus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7624": {"data": {"text": "This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.", "entity1": "TAM", "entity2": "hemolytic anemia", "span1": [35, 38], "span2": [135, 151]}, "bert_text": "This work evaluates the effects of <e1> TAM </e1> on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced <e2> hemolytic anemia </e2> and the involvement of biomembranes in its cytostatic action mechanisms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7625": {"data": {"text": "This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.", "entity1": "TAM", "entity2": "hemolytic anemia", "span1": [123, 126], "span2": [135, 151]}, "bert_text": "This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on <e1> TAM </e1>-induced <e2> hemolytic anemia </e2> and the involvement of biomembranes in its cytostatic action mechanisms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7626": {"data": {"text": "MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having metronidazole-induced encephalopathy (age range; 43-78 years).", "entity1": "metronidazole", "entity2": "encephalopathy", "span1": [117, 130], "span2": [139, 153]}, "bert_text": "MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having <e1> metronidazole </e1>-induced <e2> encephalopathy </e2> (age range; 43-78 years).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7627": {"data": {"text": "In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.", "entity1": "amphetamine", "entity2": "contralateral rotation", "span1": [149, 160], "span2": [47, 69]}, "bert_text": "In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on <e1> amphetamine </e1> <e2> contralateral rotation </e2> we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7628": {"data": {"text": "CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.", "entity1": "mannitol", "entity2": "gliomas", "span1": [75, 83], "span2": [122, 129]}, "bert_text": "CONCLUSIONS: The results of our study show that even after a single bolus, <e1> mannitol </e1> may leak through the altered BBB near <e2> gliomas </e2>, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7629": {"data": {"text": "CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.", "entity1": "mannitol", "entity2": "edema", "span1": [75, 83], "span2": [211, 216]}, "bert_text": "CONCLUSIONS: The results of our study show that even after a single bolus, <e1> mannitol </e1> may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral <e2> edema </e2> and promoting rebound of ICP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7630": {"data": {"text": "Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.", "entity1": "amiodarone", "entity2": "pneumonitis", "span1": [87, 97], "span2": [98, 109]}, "bert_text": "Review of this and previously reported cases indicates the need for early diagnosis of <e1> amiodarone </e1> <e2> pneumonitis </e2>, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7631": {"data": {"text": "Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.", "entity1": "amiodarone", "entity2": "pneumonitis", "span1": [135, 145], "span2": [98, 109]}, "bert_text": "Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of <e1> amiodarone </e1> <e2> pneumonitis </e2>, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7632": {"data": {"text": "Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.", "entity1": "steroid", "entity2": "pneumonitis", "span1": [172, 179], "span2": [98, 109]}, "bert_text": "Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued <e1> steroid </e1> <e2> pneumonitis </e2>, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7633": {"data": {"text": "Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.\n", "entity1": "Valproate", "entity2": "chorea", "span1": [0, 9], "span2": [18, 24]}, "bert_text": "<e1> Valproate </e1>-induced <e2> chorea </e2> and encephalopathy in atypical nonketotic hyperglycinemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7634": {"data": {"text": "Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.\n", "entity1": "Valproate", "entity2": "encephalopathy", "span1": [0, 9], "span2": [29, 43]}, "bert_text": "<e1> Valproate </e1>-induced chorea and <e2> encephalopathy </e2> in atypical nonketotic hyperglycinemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7635": {"data": {"text": "Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.\n", "entity1": "Valproate", "entity2": "nonketotic hyperglycinemia", "span1": [0, 9], "span2": [56, 82]}, "bert_text": "<e1> Valproate </e1>-induced chorea and encephalopathy in atypical <e2> nonketotic hyperglycinemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7636": {"data": {"text": "Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.\n", "entity1": "prostaglandin E1-induced", "entity2": "hypotension", "span1": [30, 54], "span2": [55, 66]}, "bert_text": "Combined effects of prolonged <e1> prostaglandin E1-induced </e1> <e2> hypotension </e2> and haemodilution on human hepatic function.\n", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"7637": {"data": {"text": "In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.", "entity1": "Mipafox", "entity2": "cord damage", "span1": [24, 31], "span2": [199, 210]}, "bert_text": "In contrast, dosages of <e1> Mipafox </e1> (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of <e2> cord damage </e2> in only 9% of the animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7638": {"data": {"text": "In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.", "entity1": "flestolol", "entity2": "unstable angina", "span1": [34, 43], "span2": [17, 32]}, "bert_text": "In patients with unstable angina, <e1> flestolol </e1> <e2> unstable angina </e2>, flestolol infusion was found to be safe and effective in controlling chest pain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7639": {"data": {"text": "In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.", "entity1": "flestolol", "entity2": "chest pain", "span1": [34, 43], "span2": [103, 113]}, "bert_text": "In patients with unstable angina, <e1> flestolol </e1> infusion was found to be safe and effective in controlling <e2> chest pain </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7640": {"data": {"text": "Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.\n", "entity1": "Simvastatin-ezetimibe", "entity2": "hepatic failure", "span1": [0, 21], "span2": [30, 45]}, "bert_text": "<e1> Simvastatin-ezetimibe </e1>-induced <e2> hepatic failure </e2> necessitating liver transplantation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7641": {"data": {"text": "Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.", "entity1": "LSD", "entity2": "schizophrenic", "span1": [55, 58], "span2": [4, 17]}, "bert_text": "Two schizophrenic patients, who had a prior history of <e1> LSD </e1> <e2> schizophrenic </e2> patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7642": {"data": {"text": "Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.", "entity1": "LSD", "entity2": "EPS", "span1": [55, 58], "span2": [98, 101]}, "bert_text": "Two schizophrenic patients, who had a prior history of <e1> LSD </e1> abuse and who had previously developed <e2> EPS </e2> with classic antipsychotics, were successfully treated with risperidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7643": {"data": {"text": "Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.", "entity1": "risperidone", "entity2": "schizophrenic", "span1": [162, 173], "span2": [4, 17]}, "bert_text": "Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with <e1> risperidone </e1> <e2> schizophrenic </e2> patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7644": {"data": {"text": "Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.", "entity1": "risperidone", "entity2": "EPS", "span1": [162, 173], "span2": [98, 101]}, "bert_text": "Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with <e1> risperidone </e1> <e2> EPS </e2> with classic antipsychotics, were successfully treated with risperidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7645": {"data": {"text": "Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.", "entity1": "amino acid", "entity2": "Nonketotic hyperglycinemia", "span1": [44, 54], "span2": [0, 26]}, "bert_text": "Nonketotic hyperglycinemia is a disorder of <e1> amino acid </e1> <e2> Nonketotic hyperglycinemia </e2> is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7646": {"data": {"text": "Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.", "entity1": "glycine", "entity2": "Nonketotic hyperglycinemia", "span1": [91, 98], "span2": [0, 26]}, "bert_text": "Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the <e1> glycine </e1> <e2> Nonketotic hyperglycinemia </e2> is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7647": {"data": {"text": "Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.", "entity1": "glycine", "entity2": "Nonketotic hyperglycinemia", "span1": [143, 150], "span2": [0, 26]}, "bert_text": "Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of <e1> glycine </e1> <e2> Nonketotic hyperglycinemia </e2> is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7648": {"data": {"text": "A pyridoxine-dependent behavioral disorder unmasked by isoniazid.\n", "entity1": "pyridoxine", "entity2": "behavioral disorder", "span1": [2, 12], "span2": [23, 42]}, "bert_text": "A <e1> pyridoxine </e1>-dependent <e2> behavioral disorder </e2> unmasked by isoniazid.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7649": {"data": {"text": "A pyridoxine-dependent behavioral disorder unmasked by isoniazid.\n", "entity1": "isoniazid", "entity2": "behavioral disorder", "span1": [55, 64], "span2": [23, 42]}, "bert_text": "A pyridoxine-dependent behavioral disorder unmasked by <e1> isoniazid </e1> <e2> behavioral disorder </e2> unmasked by isoniazid.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7650": {"data": {"text": "Amiodarone-induced sinoatrial block.\n", "entity1": "Amiodarone", "entity2": "sinoatrial block", "span1": [0, 10], "span2": [19, 35]}, "bert_text": "<e1> Amiodarone </e1>-induced <e2> sinoatrial block </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7651": {"data": {"text": "Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.", "entity1": "Doxorubicin", "entity2": "tumor", "span1": [0, 11], "span2": [23, 28]}, "bert_text": "<e1> Doxorubicin </e1> is an anti-<e2> tumor </e2> agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7652": {"data": {"text": "Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.", "entity1": "bumetanide", "entity2": "hypocalcemia", "span1": [58, 68], "span2": [115, 127]}, "bert_text": "Upon additional retrospective analysis, it was noted that <e1> bumetanide </e1> is a loop diuretic that may cause significant <e2> hypocalcemia </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7653": {"data": {"text": "Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.", "entity1": "loop diuretic", "entity2": "hypocalcemia", "span1": [74, 87], "span2": [115, 127]}, "bert_text": "Upon additional retrospective analysis, it was noted that bumetanide is a <e1> loop diuretic </e1> that may cause significant <e2> hypocalcemia </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7654": {"data": {"text": "In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.", "entity1": "morphine", "entity2": "acute pain", "span1": [101, 109], "span2": [3, 13]}, "bert_text": "In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of <e1> morphine </e1> <e2> acute pain </e2> models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7655": {"data": {"text": "Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.", "entity1": "Asenapine", "entity2": "schizophrenia", "span1": [0, 9], "span2": [92, 105]}, "bert_text": "<e1> Asenapine </e1> is approved by the Food and Drugs Administration in adults for acute treatment of <e2> schizophrenia </e2> or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7656": {"data": {"text": "Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.", "entity1": "Asenapine", "entity2": "manic", "span1": [0, 9], "span2": [112, 117]}, "bert_text": "<e1> Asenapine </e1> is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of <e2> manic </e2> or mixed episodes associated with bipolar I disorder with or without psychotic features.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7657": {"data": {"text": "Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.", "entity1": "Asenapine", "entity2": "bipolar I disorder", "span1": [0, 9], "span2": [152, 170]}, "bert_text": "<e1> Asenapine </e1> is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with <e2> bipolar I disorder </e2> with or without psychotic features.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7658": {"data": {"text": "Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.", "entity1": "Asenapine", "entity2": "psychotic", "span1": [0, 9], "span2": [187, 196]}, "bert_text": "<e1> Asenapine </e1> is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without <e2> psychotic </e2> features.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7659": {"data": {"text": "The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).", "entity1": "CsA", "entity2": "fibrosis", "span1": [80, 83], "span2": [165, 173]}, "bert_text": "The semi-quantitative scoring was significantly worst in the group treated with <e1> CsA </e1> plus SRL (P<0.001 compared with controls) and the analysis of the total grade of <e2> fibrosis </e2> also showed the highest proportion in the same group and was significantly different from controls (P<0.02).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7660": {"data": {"text": "The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).", "entity1": "SRL", "entity2": "fibrosis", "span1": [89, 92], "span2": [165, 173]}, "bert_text": "The semi-quantitative scoring was significantly worst in the group treated with CsA plus <e1> SRL </e1> (P<0.001 compared with controls) and the analysis of the total grade of <e2> fibrosis </e2> also showed the highest proportion in the same group and was significantly different from controls (P<0.02).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7661": {"data": {"text": "Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.\n", "entity1": "sirolimus", "entity2": "toxicity", "span1": [46, 55], "span2": [9, 17]}, "bert_text": "Systemic toxicity following administration of <e1> sirolimus </e1> <e2> toxicity </e2> following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7662": {"data": {"text": "Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.\n", "entity1": "sirolimus", "entity2": "psoriasis", "span1": [46, 55], "span2": [81, 90]}, "bert_text": "Systemic toxicity following administration of <e1> sirolimus </e1> (formerly rapamycin) for <e2> psoriasis </e2>: association of capillary leak syndrome with apoptosis of lesional lymphocytes.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7663": {"data": {"text": "Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.\n", "entity1": "sirolimus", "entity2": "capillary leak syndrome", "span1": [46, 55], "span2": [107, 130]}, "bert_text": "Systemic toxicity following administration of <e1> sirolimus </e1> (formerly rapamycin) for psoriasis: association of <e2> capillary leak syndrome </e2> with apoptosis of lesional lymphocytes.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7664": {"data": {"text": "Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.\n", "entity1": "rapamycin", "entity2": "toxicity", "span1": [66, 75], "span2": [9, 17]}, "bert_text": "Systemic toxicity following administration of sirolimus (formerly <e1> rapamycin </e1> <e2> toxicity </e2> following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7665": {"data": {"text": "Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.\n", "entity1": "rapamycin", "entity2": "psoriasis", "span1": [66, 75], "span2": [81, 90]}, "bert_text": "Systemic toxicity following administration of sirolimus (formerly <e1> rapamycin </e1>) for <e2> psoriasis </e2>: association of capillary leak syndrome with apoptosis of lesional lymphocytes.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7666": {"data": {"text": "Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.\n", "entity1": "rapamycin", "entity2": "capillary leak syndrome", "span1": [66, 75], "span2": [107, 130]}, "bert_text": "Systemic toxicity following administration of sirolimus (formerly <e1> rapamycin </e1>) for psoriasis: association of <e2> capillary leak syndrome </e2> with apoptosis of lesional lymphocytes.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7667": {"data": {"text": "Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.\n", "entity1": "ketamine", "entity2": "hyperalgesia", "span1": [50, 58], "span2": [95, 107]}, "bert_text": "Differential effects of systemically administered <e1> ketamine </e1> and lidocaine on dynamic and static <e2> hyperalgesia </e2> induced by intradermal capsaicin in humans.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7668": {"data": {"text": "Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.\n", "entity1": "lidocaine", "entity2": "hyperalgesia", "span1": [63, 72], "span2": [95, 107]}, "bert_text": "Differential effects of systemically administered ketamine and <e1> lidocaine </e1> on dynamic and static <e2> hyperalgesia </e2> induced by intradermal capsaicin in humans.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7669": {"data": {"text": "Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.\n", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [131, 140], "span2": [95, 107]}, "bert_text": "Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal <e1> capsaicin </e1> <e2> hyperalgesia </e2> induced by intradermal capsaicin in humans.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7670": {"data": {"text": "Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.", "entity1": "tacrolimus", "entity2": "hypertensive", "span1": [33, 43], "span2": [104, 116]}, "bert_text": "Two groups of patients receiving <e1> tacrolimus </e1> were compared over a period of 1 year, one group comprising <e2> hypertensive </e2> patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7671": {"data": {"text": "Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.", "entity1": "nifedipine", "entity2": "hypertensive", "span1": [145, 155], "span2": [104, 116]}, "bert_text": "Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving <e1> nifedipine </e1> <e2> hypertensive </e2> patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7672": {"data": {"text": "Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.", "entity1": "nifedipine", "entity2": "hypertensive", "span1": [221, 231], "span2": [104, 116]}, "bert_text": "Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving <e1> nifedipine </e1> <e2> hypertensive </e2> patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7673": {"data": {"text": "Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.\n", "entity1": "octreotide", "entity2": "gallstone", "span1": [67, 77], "span2": [107, 116]}, "bert_text": "Prospective study of the long-term effects of somatostatin analog (<e1> octreotide </e1>) on gallbladder function and <e2> gallstone </e2> formation in Chinese acromegalic patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7674": {"data": {"text": "Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.\n", "entity1": "octreotide", "entity2": "acromegalic", "span1": [67, 77], "span2": [138, 149]}, "bert_text": "Prospective study of the long-term effects of somatostatin analog (<e1> octreotide </e1>) on gallbladder function and gallstone formation in Chinese <e2> acromegalic </e2> patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7675": {"data": {"text": "Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.\n", "entity1": "tincture of Crataegus", "entity2": "myocardial infarction", "span1": [27, 48], "span2": [74, 95]}, "bert_text": "Cardioprotective effect of <e1> tincture of Crataegus </e1> on isoproterenol-induced <e2> myocardial infarction </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7676": {"data": {"text": "Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.\n", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [52, 65], "span2": [74, 95]}, "bert_text": "Cardioprotective effect of tincture of Crataegus on <e1> isoproterenol </e1>-induced <e2> myocardial infarction </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7677": {"data": {"text": "This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/-", "entity1": "octreotide", "entity2": "acromegaly", "span1": [184, 194], "span2": [120, 130]}, "bert_text": "This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog <e1> octreotide </e1> <e2> acromegaly </e2> treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7678": {"data": {"text": "We investigated changes in urinary NGF and PGs in women with OAB.", "entity1": "PGs", "entity2": "OAB", "span1": [43, 46], "span2": [61, 64]}, "bert_text": "We investigated changes in urinary NGF and <e1> PGs </e1> in women with <e2> OAB </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7679": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "Rizatriptan", "entity2": "nausea", "span1": [0, 11], "span2": [92, 98]}, "bert_text": "<e1> Rizatriptan </e1> was also superior to ergotamine/caffeine in the proportions of patients with no <e2> nausea </e2>, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"7680": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "Rizatriptan", "entity2": "vomiting", "span1": [0, 11], "span2": [100, 108]}, "bert_text": "<e1> Rizatriptan </e1> was also superior to ergotamine/caffeine in the proportions of patients with no nausea, <e2> vomiting </e2>, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7681": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "Rizatriptan", "entity2": "phonophobia", "span1": [0, 11], "span2": [110, 121]}, "bert_text": "<e1> Rizatriptan </e1> was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, <e2> phonophobia </e2> or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7682": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "Rizatriptan", "entity2": "photophobia", "span1": [0, 11], "span2": [125, 136]}, "bert_text": "<e1> Rizatriptan </e1> was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or <e2> photophobia </e2> and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7683": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "ergotamine", "entity2": "nausea", "span1": [33, 43], "span2": [92, 98]}, "bert_text": "Rizatriptan was also superior to <e1> ergotamine </e1>/caffeine in the proportions of patients with no <e2> nausea </e2>, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7684": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "ergotamine", "entity2": "vomiting", "span1": [33, 43], "span2": [100, 108]}, "bert_text": "Rizatriptan was also superior to <e1> ergotamine </e1>/caffeine in the proportions of patients with no nausea, <e2> vomiting </e2>, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7685": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "ergotamine", "entity2": "phonophobia", "span1": [33, 43], "span2": [110, 121]}, "bert_text": "Rizatriptan was also superior to <e1> ergotamine </e1>/caffeine in the proportions of patients with no nausea, vomiting, <e2> phonophobia </e2> or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7686": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "ergotamine", "entity2": "photophobia", "span1": [33, 43], "span2": [125, 136]}, "bert_text": "Rizatriptan was also superior to <e1> ergotamine </e1>/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or <e2> photophobia </e2> and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7687": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "caffeine", "entity2": "nausea", "span1": [44, 52], "span2": [92, 98]}, "bert_text": "Rizatriptan was also superior to ergotamine/<e1> caffeine </e1> in the proportions of patients with no <e2> nausea </e2>, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7688": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "caffeine", "entity2": "vomiting", "span1": [44, 52], "span2": [100, 108]}, "bert_text": "Rizatriptan was also superior to ergotamine/<e1> caffeine </e1> in the proportions of patients with no nausea, <e2> vomiting </e2>, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7689": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "caffeine", "entity2": "phonophobia", "span1": [44, 52], "span2": [110, 121]}, "bert_text": "Rizatriptan was also superior to ergotamine/<e1> caffeine </e1> in the proportions of patients with no nausea, vomiting, <e2> phonophobia </e2> or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7690": {"data": {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity1": "caffeine", "entity2": "photophobia", "span1": [44, 52], "span2": [125, 136]}, "bert_text": "Rizatriptan was also superior to ergotamine/<e1> caffeine </e1> in the proportions of patients with no nausea, vomiting, phonophobia or <e2> photophobia </e2> and for patients with normal function 2 h after drug intake (p < or = 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7691": {"data": {"text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.", "entity1": "methimazole", "entity2": "jaundice", "span1": [76, 87], "span2": [31, 39]}, "bert_text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving <e1> methimazole </e1> <e2> jaundice </e2> and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7692": {"data": {"text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.", "entity1": "methimazole", "entity2": "itching", "span1": [76, 87], "span2": [44, 51]}, "bert_text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving <e1> methimazole </e1> <e2> itching </e2> 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7693": {"data": {"text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.", "entity1": "methimazole", "entity2": "hyperthyroidism", "span1": [76, 87], "span2": [145, 160]}, "bert_text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving <e1> methimazole </e1> (10 mg tid) and propranolol (20 mg tid) for treatment of <e2> hyperthyroidism </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7694": {"data": {"text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.", "entity1": "propranolol", "entity2": "jaundice", "span1": [104, 115], "span2": [31, 39]}, "bert_text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and <e1> propranolol </e1> <e2> jaundice </e2> and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7695": {"data": {"text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.", "entity1": "propranolol", "entity2": "itching", "span1": [104, 115], "span2": [44, 51]}, "bert_text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and <e1> propranolol </e1> <e2> itching </e2> 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7696": {"data": {"text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.", "entity1": "propranolol", "entity2": "hyperthyroidism", "span1": [104, 115], "span2": [145, 160]}, "bert_text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and <e1> propranolol </e1> (20 mg tid) for treatment of <e2> hyperthyroidism </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7697": {"data": {"text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.", "entity1": "paroxetine", "entity2": "neuroleptic malignant syndrome", "span1": [145, 155], "span2": [40, 70]}, "bert_text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined <e1> paroxetine </e1> <e2> neuroleptic malignant syndrome </e2> (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7698": {"data": {"text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.", "entity1": "paroxetine", "entity2": "NMS", "span1": [145, 155], "span2": [72, 75]}, "bert_text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined <e1> paroxetine </e1> <e2> NMS </e2>), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7699": {"data": {"text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.", "entity1": "paroxetine", "entity2": "NMS", "span1": [145, 155], "span2": [102, 105]}, "bert_text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined <e1> paroxetine </e1> <e2> NMS </e2>-like symptoms can occur after combined paroxetine and alprazolam treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7700": {"data": {"text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.", "entity1": "alprazolam", "entity2": "neuroleptic malignant syndrome", "span1": [160, 170], "span2": [40, 70]}, "bert_text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and <e1> alprazolam </e1> <e2> neuroleptic malignant syndrome </e2> (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7701": {"data": {"text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.", "entity1": "alprazolam", "entity2": "NMS", "span1": [160, 170], "span2": [72, 75]}, "bert_text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and <e1> alprazolam </e1> <e2> NMS </e2>), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7702": {"data": {"text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.", "entity1": "alprazolam", "entity2": "NMS", "span1": [160, 170], "span2": [102, 105]}, "bert_text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and <e1> alprazolam </e1> <e2> NMS </e2>-like symptoms can occur after combined paroxetine and alprazolam treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7703": {"data": {"text": "Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).", "entity1": "kainic acid", "entity2": "hippocampal injury", "span1": [73, 84], "span2": [43, 61]}, "bert_text": "Estrogens protect ovariectomized rats from hippocampal injury induced by <e1> kainic acid </e1> <e2> hippocampal injury </e2> induced by kainic acid-induced status epilepticus (SE).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7704": {"data": {"text": "Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).", "entity1": "kainic acid", "entity2": "status epilepticus", "span1": [73, 84], "span2": [93, 111]}, "bert_text": "Estrogens protect ovariectomized rats from hippocampal injury induced by <e1> kainic acid </e1>-induced <e2> status epilepticus </e2> (SE).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7705": {"data": {"text": "Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).", "entity1": "kainic acid", "entity2": "SE", "span1": [73, 84], "span2": [113, 115]}, "bert_text": "Estrogens protect ovariectomized rats from hippocampal injury induced by <e1> kainic acid </e1>-induced status epilepticus (<e2> SE </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7706": {"data": {"text": "In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [76, 85], "span2": [98, 109]}, "bert_text": "In each patient, the close temporal association between the commencement of <e1> sirolimus </e1> therapy and <e2> proteinuria </e2> implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7707": {"data": {"text": "In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [76, 85], "span2": [166, 177]}, "bert_text": "In each patient, the close temporal association between the commencement of <e1> sirolimus </e1> therapy and proteinuria implicated sirolimus as the most likely etiology of the <e2> proteinuria </e2>. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7708": {"data": {"text": "In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [121, 130], "span2": [98, 109]}, "bert_text": "In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated <e1> sirolimus </e1> <e2> proteinuria </e2> implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 1},
+	"7709": {"data": {"text": "In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [121, 130], "span2": [166, 177]}, "bert_text": "In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated <e1> sirolimus </e1> as the most likely etiology of the <e2> proteinuria </e2>. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7710": {"data": {"text": "In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [345, 354], "span2": [98, 109]}, "bert_text": "In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom <e1> sirolimus </e1> <e2> proteinuria </e2> implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 1},
+	"7711": {"data": {"text": "In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "entity1": "sirolimus", "entity2": "proteinuria", "span1": [345, 354], "span2": [166, 177]}, "bert_text": "In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom <e1> sirolimus </e1> <e2> proteinuria </e2>. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7712": {"data": {"text": "Indomethacin-induced renal insufficiency: recurrence on rechallenge.\n", "entity1": "Indomethacin", "entity2": "renal insufficiency", "span1": [0, 12], "span2": [21, 40]}, "bert_text": "<e1> Indomethacin </e1>-induced <e2> renal insufficiency </e2>: recurrence on rechallenge.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7713": {"data": {"text": "Severe citrate toxicity complicating volunteer apheresis platelet donation.\n", "entity1": "citrate", "entity2": "toxicity", "span1": [7, 14], "span2": [15, 23]}, "bert_text": "Severe <e1> citrate </e1> <e2> toxicity </e2> complicating volunteer apheresis platelet donation.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7714": {"data": {"text": "Cyclophosphamide therapy increases the risk of carcinoma of the bladder.", "entity1": "Cyclophosphamide", "entity2": "carcinoma of the bladder", "span1": [0, 16], "span2": [47, 71]}, "bert_text": "<e1> Cyclophosphamide </e1> therapy increases the risk of <e2> carcinoma of the bladder </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7715": {"data": {"text": "RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.", "entity1": "RAPA", "entity2": "pneumonia", "span1": [0, 4], "span2": [51, 60]}, "bert_text": "<e1> RAPA </e1> was discontinued in four patients, because of <e2> pneumonia </e2> in two, PTLD in one, and oral aphtous ulcers in one.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7716": {"data": {"text": "RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.", "entity1": "RAPA", "entity2": "PTLD", "span1": [0, 4], "span2": [69, 73]}, "bert_text": "<e1> RAPA </e1> was discontinued in four patients, because of pneumonia in two, <e2> PTLD </e2> in one, and oral aphtous ulcers in one.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7717": {"data": {"text": "RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.", "entity1": "RAPA", "entity2": "oral aphtous ulcers", "span1": [0, 4], "span2": [86, 105]}, "bert_text": "<e1> RAPA </e1> was discontinued in four patients, because of pneumonia in two, PTLD in one, and <e2> oral aphtous ulcers </e2> in one.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7718": {"data": {"text": "The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.", "entity1": "dopamine", "entity2": "Parkinson's disease", "span1": [24, 32], "span2": [79, 98]}, "bert_text": "The clinical utility of <e1> dopamine </e1> (DA) D1 receptor agonists in the treatment of <e2> Parkinson's disease </e2> (PD) is still unclear.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7719": {"data": {"text": "The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.", "entity1": "dopamine", "entity2": "PD", "span1": [24, 32], "span2": [100, 102]}, "bert_text": "The clinical utility of <e1> dopamine </e1> (DA) D1 receptor agonists in the treatment of Parkinson's disease (<e2> PD </e2>) is still unclear.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7720": {"data": {"text": "The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.", "entity1": "DA", "entity2": "Parkinson's disease", "span1": [34, 36], "span2": [79, 98]}, "bert_text": "The clinical utility of dopamine (<e1> DA </e1>) D1 receptor agonists in the treatment of <e2> Parkinson's disease </e2> (PD) is still unclear.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7721": {"data": {"text": "The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.", "entity1": "DA", "entity2": "PD", "span1": [34, 36], "span2": [100, 102]}, "bert_text": "The clinical utility of dopamine (<e1> DA </e1>) D1 receptor agonists in the treatment of Parkinson's disease (<e2> PD </e2>) is still unclear.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7722": {"data": {"text": "High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.\n", "entity1": "appetite suppressants", "entity2": "primary pulmonary hypertension", "span1": [65, 86], "span2": [18, 48]}, "bert_text": "High incidence of primary pulmonary hypertension associated with <e1> appetite suppressants </e1> <e2> primary pulmonary hypertension </e2> associated with appetite suppressants in Belgium.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7723": {"data": {"text": "Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.\n", "entity1": "ifosfamide", "entity2": "anuria", "span1": [37, 47], "span2": [7, 13]}, "bert_text": "Lethal anuria complicating high dose <e1> ifosfamide </e1> <e2> anuria </e2> complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7724": {"data": {"text": "Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.\n", "entity1": "ifosfamide", "entity2": "breast cancer", "span1": [37, 47], "span2": [66, 79]}, "bert_text": "Lethal anuria complicating high dose <e1> ifosfamide </e1> chemotherapy in a <e2> breast cancer </e2> patient with an impaired renal function.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7725": {"data": {"text": "Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.\n", "entity1": "ifosfamide", "entity2": "impaired renal function", "span1": [37, 47], "span2": [96, 119]}, "bert_text": "Lethal anuria complicating high dose <e1> ifosfamide </e1> chemotherapy in a breast cancer patient with an <e2> impaired renal function </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7726": {"data": {"text": "Pseudo-allergic reactions to corticosteroids: diagnosis and alternatives.\n", "entity1": "corticosteroids", "entity2": "allergic", "span1": [29, 44], "span2": [7, 15]}, "bert_text": "Pseudo-allergic reactions to <e1> corticosteroids </e1> <e2> allergic </e2> reactions to corticosteroids: diagnosis and alternatives.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7727": {"data": {"text": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.", "entity1": "cisplatin", "entity2": "breast cancer", "span1": [76, 85], "span2": [37, 50]}, "bert_text": "A sixty-year-old woman with advanced breast cancer, previously treated with <e1> cisplatin </e1> <e2> breast cancer </e2>, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7728": {"data": {"text": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.", "entity1": "cisplatin", "entity2": "renal failure", "span1": [76, 85], "span2": [120, 133]}, "bert_text": "A sixty-year-old woman with advanced breast cancer, previously treated with <e1> cisplatin </e1>, developed an irreversible lethal <e2> renal failure </e2> with anuria, the day after 5 g/m2 bolus ifosfamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7729": {"data": {"text": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.", "entity1": "cisplatin", "entity2": "anuria", "span1": [76, 85], "span2": [139, 145]}, "bert_text": "A sixty-year-old woman with advanced breast cancer, previously treated with <e1> cisplatin </e1>, developed an irreversible lethal renal failure with <e2> anuria </e2>, the day after 5 g/m2 bolus ifosfamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7730": {"data": {"text": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.", "entity1": "ifosfamide", "entity2": "breast cancer", "span1": [174, 184], "span2": [37, 50]}, "bert_text": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus <e1> ifosfamide </e1> <e2> breast cancer </e2>, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7731": {"data": {"text": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.", "entity1": "ifosfamide", "entity2": "renal failure", "span1": [174, 184], "span2": [120, 133]}, "bert_text": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus <e1> ifosfamide </e1> <e2> renal failure </e2> with anuria, the day after 5 g/m2 bolus ifosfamide.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7732": {"data": {"text": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.", "entity1": "ifosfamide", "entity2": "anuria", "span1": [174, 184], "span2": [139, 145]}, "bert_text": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus <e1> ifosfamide </e1> <e2> anuria </e2>, the day after 5 g/m2 bolus ifosfamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7733": {"data": {"text": "Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.", "entity1": "Flestolol", "entity2": "supraventricular tachyarrhythmia", "span1": [0, 9], "span2": [58, 90]}, "bert_text": "<e1> Flestolol </e1> effectively reduced heart rate in patients with <e2> supraventricular tachyarrhythmia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7734": {"data": {"text": "In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).", "entity1": "caffeine", "entity2": "seizures", "span1": [18, 26], "span2": [79, 87]}, "bert_text": "In the absence of <e1> caffeine </e1>, acetaminophen (up to 300 mg/kg) did not modify the <e2> seizures </e2> induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"7735": {"data": {"text": "In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).", "entity1": "acetaminophen", "entity2": "seizures", "span1": [28, 41], "span2": [79, 87]}, "bert_text": "In the absence of caffeine, <e1> acetaminophen </e1> (up to 300 mg/kg) did not modify the <e2> seizures </e2> induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7736": {"data": {"text": "In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).", "entity1": "pentylenetetrezol", "entity2": "seizures", "span1": [161, 178], "span2": [79, 87]}, "bert_text": "In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of <e1> pentylenetetrezol </e1> <e2> seizures </e2> induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"7737": {"data": {"text": "This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.", "entity1": "alpha-TC", "entity2": "neuronal damage", "span1": [19, 27], "span2": [62, 77]}, "bert_text": "This suggests that <e1> alpha-TC </e1> and DFO ameliorate the MA-induced <e2> neuronal damage </e2> by decreasing the level of oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7738": {"data": {"text": "This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.", "entity1": "DFO", "entity2": "neuronal damage", "span1": [32, 35], "span2": [62, 77]}, "bert_text": "This suggests that alpha-TC and <e1> DFO </e1> ameliorate the MA-induced <e2> neuronal damage </e2> by decreasing the level of oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7739": {"data": {"text": "This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.", "entity1": "MA", "entity2": "neuronal damage", "span1": [51, 53], "span2": [62, 77]}, "bert_text": "This suggests that alpha-TC and DFO ameliorate the <e1> MA </e1>-induced <e2> neuronal damage </e2> by decreasing the level of oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7740": {"data": {"text": "CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).", "entity1": "methotrexate", "entity2": "leukoencephalopathy syndrome", "span1": [145, 157], "span2": [48, 76]}, "bert_text": "CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose <e1> methotrexate </e1> <e2> leukoencephalopathy syndrome </e2> (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7741": {"data": {"text": "CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).", "entity1": "methotrexate", "entity2": "stroke", "span1": [145, 157], "span2": [87, 93]}, "bert_text": "CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose <e1> methotrexate </e1> <e2> stroke </e2> (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7742": {"data": {"text": "CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).", "entity1": "methotrexate", "entity2": "temporal lobe epilepsy", "span1": [145, 157], "span2": [103, 125]}, "bert_text": "CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose <e1> methotrexate </e1> <e2> temporal lobe epilepsy </e2> (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7743": {"data": {"text": "CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).", "entity1": "methotrexate", "entity2": "toxicity", "span1": [145, 157], "span2": [158, 166]}, "bert_text": "CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose <e1> methotrexate </e1> <e2> toxicity </e2> (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7744": {"data": {"text": "CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).", "entity1": "methotrexate", "entity2": "inappropriate antidiuretic hormone secretion", "span1": [145, 157], "span2": [188, 232]}, "bert_text": "CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose <e1> methotrexate </e1> toxicity (n = 2), syndrome of <e2> inappropriate antidiuretic hormone secretion </e2> (n = 1), and other unclassified events (n = 7).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7745": {"data": {"text": "Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.", "entity1": "chlormethiazole", "entity2": "overdose", "span1": [38, 53], "span2": [111, 119]}, "bert_text": "Three patients received high doses of <e1> chlormethiazole </e1> for alcohol withdrawal symptoms, and one took a suicidal <e2> overdose </e2> of nitrazepam.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7746": {"data": {"text": "Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.", "entity1": "alcohol", "entity2": "overdose", "span1": [58, 65], "span2": [111, 119]}, "bert_text": "Three patients received high doses of chlormethiazole for <e1> alcohol </e1> withdrawal symptoms, and one took a suicidal <e2> overdose </e2> of nitrazepam.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7747": {"data": {"text": "Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.", "entity1": "nitrazepam", "entity2": "overdose", "span1": [123, 133], "span2": [111, 119]}, "bert_text": "Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of <e1> nitrazepam </e1> <e2> overdose </e2> of nitrazepam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7748": {"data": {"text": "Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.\n", "entity1": "Risperidone", "entity2": "visual disturbances", "span1": [0, 11], "span2": [41, 60]}, "bert_text": "<e1> Risperidone </e1>-associated, benign transient <e2> visual disturbances </e2> in schizophrenic patients with a past history of LSD abuse.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7749": {"data": {"text": "Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.\n", "entity1": "Risperidone", "entity2": "schizophrenic", "span1": [0, 11], "span2": [64, 77]}, "bert_text": "<e1> Risperidone </e1>-associated, benign transient visual disturbances in <e2> schizophrenic </e2> patients with a past history of LSD abuse.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7750": {"data": {"text": "Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.\n", "entity1": "LSD", "entity2": "visual disturbances", "span1": [110, 113], "span2": [41, 60]}, "bert_text": "Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of <e1> LSD </e1> <e2> visual disturbances </e2> in schizophrenic patients with a past history of LSD abuse.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7751": {"data": {"text": "Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.\n", "entity1": "LSD", "entity2": "schizophrenic", "span1": [110, 113], "span2": [64, 77]}, "bert_text": "Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of <e1> LSD </e1> <e2> schizophrenic </e2> patients with a past history of LSD abuse.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7752": {"data": {"text": "Hypomania-like syndrome induced by olanzapine.\n", "entity1": "olanzapine", "entity2": "Hypomania-like syndrome", "span1": [35, 45], "span2": [0, 23]}, "bert_text": "Hypomania-like syndrome induced by <e1> olanzapine </e1> <e2> Hypomania-like syndrome </e2> induced by olanzapine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7753": {"data": {"text": "The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.", "entity1": "omeprazole", "entity2": "hemolytic anemia", "span1": [23, 33], "span2": [55, 71]}, "bert_text": "The mechanism by which <e1> omeprazole </e1> caused the patient's <e2> hemolytic anemia </e2> is uncertain, but physicians should be alerted to this possible adverse effect.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7754": {"data": {"text": "Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.\n", "entity1": "carbamazepine", "entity2": "toxicity", "span1": [8, 21], "span2": [54, 62]}, "bert_text": "Chronic <e1> carbamazepine </e1> treatment in the rat: efficacy, <e2> toxicity </e2>, and effect on plasma and tissue folate concentrations.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7755": {"data": {"text": "Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.\n", "entity1": "folate", "entity2": "toxicity", "span1": [96, 102], "span2": [54, 62]}, "bert_text": "Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue <e1> folate </e1> <e2> toxicity </e2>, and effect on plasma and tissue folate concentrations.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7756": {"data": {"text": "The areas where calcitonin is most effective in decreasing locomotor activity are located in the hypothalamus and nucleus accumbens, suggesting that these areas are the major sites of action of calcitonin in inhibiting amphetamine-induced locomotor activity.", "entity1": "amphetamine", "entity2": "hypothalamus", "span1": [219, 230], "span2": [97, 109]}, "bert_text": "The areas where calcitonin is most effective in decreasing locomotor activity are located in the hypothalamus and nucleus accumbens, suggesting that these areas are the major sites of action of calcitonin in inhibiting <e1> amphetamine </e1> <e2> hypothalamus </e2> and nucleus accumbens, suggesting that these areas are the major sites of action of calcitonin in inhibiting amphetamine-induced locomotor activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7757": {"data": {"text": "A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.\n", "entity1": "ephedrine", "entity2": "sexual dysfunction", "span1": [53, 62], "span2": [87, 105]}, "bert_text": "A randomized, placebo-controlled, crossover study of <e1> ephedrine </e1> for SSRI-induced female <e2> sexual dysfunction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7758": {"data": {"text": "When QTc interval prolongation is observed, early magnesium supplementation is advocated.", "entity1": "magnesium", "entity2": "QTc interval prolongation", "span1": [50, 59], "span2": [5, 30]}, "bert_text": "When QTc interval prolongation is observed, early <e1> magnesium </e1> <e2> QTc interval prolongation </e2> is observed, early magnesium supplementation is advocated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7759": {"data": {"text": "Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.", "entity1": "ephedrine", "entity2": "tachycardia", "span1": [131, 140], "span2": [24, 35]}, "bert_text": "Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the <e1> ephedrine </e1> <e2> tachycardia </e2> inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7760": {"data": {"text": "Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.", "entity1": "ephedrine", "entity2": "myocardial ischemia", "span1": [131, 140], "span2": [45, 64]}, "bert_text": "Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the <e1> ephedrine </e1> <e2> myocardial ischemia </e2>, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7761": {"data": {"text": "Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.", "entity1": "propofol", "entity2": "tachycardia", "span1": [141, 149], "span2": [24, 35]}, "bert_text": "Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/<e1> propofol </e1> <e2> tachycardia </e2> inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7762": {"data": {"text": "Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.", "entity1": "propofol", "entity2": "myocardial ischemia", "span1": [141, 149], "span2": [45, 64]}, "bert_text": "Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/<e1> propofol </e1> <e2> myocardial ischemia </e2>, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7763": {"data": {"text": "Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).", "entity1": "DCE", "entity2": "amnesia", "span1": [13, 16], "span2": [30, 37]}, "bert_text": "Furthermore, <e1> DCE </e1> reversed the <e2> amnesia </e2> induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7764": {"data": {"text": "Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).", "entity1": "scopolamine", "entity2": "amnesia", "span1": [49, 60], "span2": [30, 37]}, "bert_text": "Furthermore, DCE reversed the amnesia induced by <e1> scopolamine </e1> <e2> amnesia </e2> induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7765": {"data": {"text": "Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).", "entity1": "diazepam", "entity2": "amnesia", "span1": [83, 91], "span2": [30, 37]}, "bert_text": "Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and <e1> diazepam </e1> <e2> amnesia </e2> induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7766": {"data": {"text": "Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.", "entity1": "puromycin aminonucleoside", "entity2": "hypoxia", "span1": [128, 153], "span2": [18, 25]}, "bert_text": "Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the <e1> puromycin aminonucleoside </e1> <e2> hypoxia </e2>-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7767": {"data": {"text": "BACKGROUND: We report on the manifestation of a levetiracetam (LEV)-induced encephalopathy.", "entity1": "levetiracetam", "entity2": "encephalopathy", "span1": [48, 61], "span2": [76, 90]}, "bert_text": "BACKGROUND: We report on the manifestation of a <e1> levetiracetam </e1> (LEV)-induced <e2> encephalopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7768": {"data": {"text": "BACKGROUND: We report on the manifestation of a levetiracetam (LEV)-induced encephalopathy.", "entity1": "LEV)-induced", "entity2": "encephalopathy", "span1": [63, 75], "span2": [76, 90]}, "bert_text": "BACKGROUND: We report on the manifestation of a levetiracetam (<e1> LEV)-induced </e1> <e2> encephalopathy </e2>.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7769": {"data": {"text": "Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.\n", "entity1": "glycopyrrolate", "entity2": "bradycardia", "span1": [19, 33], "span2": [68, 79]}, "bert_text": "Comparison of i.v. <e1> glycopyrrolate </e1> and atropine in the prevention of <e2> bradycardia </e2> and arrhythmias following repeated doses of suxamethonium in children.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7770": {"data": {"text": "Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.\n", "entity1": "glycopyrrolate", "entity2": "arrhythmias", "span1": [19, 33], "span2": [84, 95]}, "bert_text": "Comparison of i.v. <e1> glycopyrrolate </e1> and atropine in the prevention of bradycardia and <e2> arrhythmias </e2> following repeated doses of suxamethonium in children.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7771": {"data": {"text": "Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.\n", "entity1": "atropine", "entity2": "bradycardia", "span1": [38, 46], "span2": [68, 79]}, "bert_text": "Comparison of i.v. glycopyrrolate and <e1> atropine </e1> in the prevention of <e2> bradycardia </e2> and arrhythmias following repeated doses of suxamethonium in children.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7772": {"data": {"text": "Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.\n", "entity1": "atropine", "entity2": "arrhythmias", "span1": [38, 46], "span2": [84, 95]}, "bert_text": "Comparison of i.v. glycopyrrolate and <e1> atropine </e1> in the prevention of bradycardia and <e2> arrhythmias </e2> following repeated doses of suxamethonium in children.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7773": {"data": {"text": "Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.\n", "entity1": "suxamethonium", "entity2": "bradycardia", "span1": [124, 137], "span2": [68, 79]}, "bert_text": "Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of <e1> suxamethonium </e1> <e2> bradycardia </e2> and arrhythmias following repeated doses of suxamethonium in children.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"7774": {"data": {"text": "Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.\n", "entity1": "suxamethonium", "entity2": "arrhythmias", "span1": [124, 137], "span2": [84, 95]}, "bert_text": "Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of <e1> suxamethonium </e1> <e2> arrhythmias </e2> following repeated doses of suxamethonium in children.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7775": {"data": {"text": "Morphine dose-dependently reversed these behavioral disorders.", "entity1": "Morphine", "entity2": "behavioral disorders", "span1": [0, 8], "span2": [41, 61]}, "bert_text": "<e1> Morphine </e1> dose-dependently reversed these <e2> behavioral disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7776": {"data": {"text": "The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children,", "entity1": "glycopyrrolate", "entity2": "arrhythmia", "span1": [39, 53], "span2": [183, 193]}, "bert_text": "The effectiveness of administration of <e1> glycopyrrolate </e1> 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent <e2> arrhythmia </e2> and bradycardia following repeated doses of suxamethonium in children,", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7777": {"data": {"text": "The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children,", "entity1": "glycopyrrolate", "entity2": "bradycardia", "span1": [39, 53], "span2": [198, 209]}, "bert_text": "The effectiveness of administration of <e1> glycopyrrolate </e1> 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and <e2> bradycardia </e2> following repeated doses of suxamethonium in children,", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7778": {"data": {"text": "The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children,", "entity1": "atropine", "entity2": "arrhythmia", "span1": [83, 91], "span2": [183, 193]}, "bert_text": "The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and <e1> atropine </e1> 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent <e2> arrhythmia </e2> and bradycardia following repeated doses of suxamethonium in children,", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7779": {"data": {"text": "The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children,", "entity1": "atropine", "entity2": "bradycardia", "span1": [83, 91], "span2": [198, 209]}, "bert_text": "The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and <e1> atropine </e1> 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and <e2> bradycardia </e2> following repeated doses of suxamethonium in children,", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7780": {"data": {"text": "The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children,", "entity1": "suxamethonium", "entity2": "arrhythmia", "span1": [238, 251], "span2": [183, 193]}, "bert_text": "The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of <e1> suxamethonium </e1> <e2> arrhythmia </e2> and bradycardia following repeated doses of suxamethonium in children,", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7781": {"data": {"text": "The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children,", "entity1": "suxamethonium", "entity2": "bradycardia", "span1": [238, 251], "span2": [198, 209]}, "bert_text": "The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of <e1> suxamethonium </e1> <e2> bradycardia </e2> following repeated doses of suxamethonium in children,", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"7782": {"data": {"text": "Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.", "entity1": "gentamicin", "entity2": "renal failure", "span1": [6, 16], "span2": [37, 50]}, "bert_text": "Thus, <e1> gentamicin </e1> was associated with <e2> renal failure </e2> more than three times as often as was tobramycin.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7783": {"data": {"text": "Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.", "entity1": "tobramycin", "entity2": "renal failure", "span1": [89, 99], "span2": [37, 50]}, "bert_text": "Thus, gentamicin was associated with renal failure more than three times as often as was <e1> tobramycin </e1> <e2> renal failure </e2> more than three times as often as was tobramycin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7784": {"data": {"text": "Neurosci. 9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.", "entity1": "MPTP", "entity2": "neurodegeneration", "span1": [127, 131], "span2": [140, 157]}, "bert_text": "Neurosci. 9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of <e1> MPTP </e1>-induced <e2> neurodegeneration </e2> of DA neurons.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7785": {"data": {"text": "Neurosci. 9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.", "entity1": "DA", "entity2": "neurodegeneration", "span1": [161, 163], "span2": [140, 157]}, "bert_text": "Neurosci. 9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of <e1> DA </e1> <e2> neurodegeneration </e2> of DA neurons.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7786": {"data": {"text": "Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.", "entity1": "testosterone heptylate", "entity2": "hypogonadism", "span1": [31, 53], "span2": [90, 102]}, "bert_text": "Endocrine therapy consisted of <e1> testosterone heptylate </e1> or human chorionic gonadotropin for <e2> hypogonadism </e2> and bromocriptine for hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7787": {"data": {"text": "Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.", "entity1": "testosterone heptylate", "entity2": "hyperprolactinemia", "span1": [31, 53], "span2": [125, 143]}, "bert_text": "Endocrine therapy consisted of <e1> testosterone heptylate </e1> or human chorionic gonadotropin for hypogonadism and bromocriptine for <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7788": {"data": {"text": "Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.", "entity1": "bromocriptine", "entity2": "hypogonadism", "span1": [107, 120], "span2": [90, 102]}, "bert_text": "Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and <e1> bromocriptine </e1> <e2> hypogonadism </e2> and bromocriptine for hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7789": {"data": {"text": "Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.", "entity1": "bromocriptine", "entity2": "hyperprolactinemia", "span1": [107, 120], "span2": [125, 143]}, "bert_text": "Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and <e1> bromocriptine </e1> for <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7790": {"data": {"text": "Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.", "entity1": "paclitaxel", "entity2": "brain edema", "span1": [45, 55], "span2": [93, 104]}, "bert_text": "Six of the patients received more than 15 mg <e1> paclitaxel </e1> and suffered from moderate to severe <e2> brain edema </e2>, while the remaining patients received only a total of 15 mg paclitaxel.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7791": {"data": {"text": "Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.", "entity1": "paclitaxel", "entity2": "brain edema", "span1": [166, 176], "span2": [93, 104]}, "bert_text": "Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg <e1> paclitaxel </e1> <e2> brain edema </e2>, while the remaining patients received only a total of 15 mg paclitaxel.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7792": {"data": {"text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.", "entity1": "doxorubicin", "entity2": "myocardial damage", "span1": [111, 122], "span2": [75, 92]}, "bert_text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of <e1> doxorubicin </e1> <e2> myocardial damage </e2> in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7793": {"data": {"text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [111, 122], "span2": [137, 151]}, "bert_text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of <e1> doxorubicin </e1> (DOX)-induced <e2> cardiomyopathy </e2>, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7794": {"data": {"text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.", "entity1": "doxorubicin", "entity2": "cardiac disorders", "span1": [111, 122], "span2": [239, 256]}, "bert_text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of <e1> doxorubicin </e1> (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of <e2> cardiac disorders </e2> monitored by echocardiography and histological examinations in this model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7795": {"data": {"text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.", "entity1": "DOX)-induced", "entity2": "myocardial damage", "span1": [124, 136], "span2": [75, 92]}, "bert_text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (<e1> DOX)-induced </e1> <e2> myocardial damage </e2> in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7796": {"data": {"text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.", "entity1": "DOX)-induced", "entity2": "cardiomyopathy", "span1": [124, 136], "span2": [137, 151]}, "bert_text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (<e1> DOX)-induced </e1> <e2> cardiomyopathy </e2>, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7797": {"data": {"text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.", "entity1": "DOX)-induced", "entity2": "cardiac disorders", "span1": [124, 136], "span2": [239, 256]}, "bert_text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (<e1> DOX)-induced </e1> cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of <e2> cardiac disorders </e2> monitored by echocardiography and histological examinations in this model.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7798": {"data": {"text": "No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.", "entity1": "nicotine", "entity2": "cranial hemorrhage", "span1": [181, 189], "span2": [146, 164]}, "bert_text": "No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all <e1> nicotine </e1> <e2> cranial hemorrhage </e2> occurred in all nicotine sulfate-treated chicks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7799": {"data": {"text": "Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.", "entity1": "CGRP", "entity2": "migraine", "span1": [7, 11], "span2": [70, 78]}, "bert_text": "Plasma <e1> CGRP </e1> concentration increased significantly (P<0.01) during the <e2> migraine </e2> attack and returned to baseline after the cessation of the migraine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7800": {"data": {"text": "Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.", "entity1": "CGRP", "entity2": "migraine", "span1": [7, 11], "span2": [138, 146]}, "bert_text": "Plasma <e1> CGRP </e1> concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the <e2> migraine </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7801": {"data": {"text": "Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "entity1": "METH", "entity2": "neurotoxicity", "span1": [33, 37], "span2": [113, 126]}, "bert_text": "Because the CNS damage caused by <e1> METH </e1> and MPTP is highly selective for the DA neuronal system in mouse models of <e2> neurotoxicity </e2>, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7802": {"data": {"text": "Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "entity1": "METH", "entity2": "neurotoxicity", "span1": [33, 37], "span2": [189, 202]}, "bert_text": "Because the CNS damage caused by <e1> METH </e1> and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced <e2> neurotoxicity </e2> and microglial activation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7803": {"data": {"text": "Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "entity1": "METH", "entity2": "neurotoxicity", "span1": [176, 180], "span2": [113, 126]}, "bert_text": "Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in <e1> METH </e1> <e2> neurotoxicity </e2>, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7804": {"data": {"text": "Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "entity1": "METH", "entity2": "neurotoxicity", "span1": [176, 180], "span2": [189, 202]}, "bert_text": "Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in <e1> METH </e1>-induced <e2> neurotoxicity </e2> and microglial activation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7805": {"data": {"text": "Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "entity1": "MPTP", "entity2": "neurotoxicity", "span1": [42, 46], "span2": [113, 126]}, "bert_text": "Because the CNS damage caused by METH and <e1> MPTP </e1> is highly selective for the DA neuronal system in mouse models of <e2> neurotoxicity </e2>, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7806": {"data": {"text": "Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "entity1": "MPTP", "entity2": "neurotoxicity", "span1": [42, 46], "span2": [189, 202]}, "bert_text": "Because the CNS damage caused by METH and <e1> MPTP </e1> is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced <e2> neurotoxicity </e2> and microglial activation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7807": {"data": {"text": "Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "entity1": "DA", "entity2": "neurotoxicity", "span1": [75, 77], "span2": [113, 126]}, "bert_text": "Because the CNS damage caused by METH and MPTP is highly selective for the <e1> DA </e1> neuronal system in mouse models of <e2> neurotoxicity </e2>, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7808": {"data": {"text": "Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "entity1": "DA", "entity2": "neurotoxicity", "span1": [75, 77], "span2": [189, 202]}, "bert_text": "Because the CNS damage caused by METH and MPTP is highly selective for the <e1> DA </e1> neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced <e2> neurotoxicity </e2> and microglial activation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7809": {"data": {"text": "VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.", "entity1": "VNB", "entity2": "toxicity", "span1": [0, 3], "span2": [72, 80]}, "bert_text": "<e1> VNB </e1> was well tolerated and zero instances of WHO grade 4 nonhematologic <e2> toxicity </e2> occurred.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7810": {"data": {"text": "Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.", "entity1": "creatinine", "entity2": "CRF", "span1": [135, 145], "span2": [270, 273]}, "bert_text": "Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum <e1> creatinine </e1> compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of <e2> CRF </e2> or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7811": {"data": {"text": "Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.", "entity1": "creatinine", "entity2": "ESRD", "span1": [135, 145], "span2": [277, 281]}, "bert_text": "Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum <e1> creatinine </e1> compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or <e2> ESRD </e2> with odds ratios of 2.6, 2.2, and 1.6, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7812": {"data": {"text": "In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.", "entity1": "clioquinol", "entity2": "neurological disturbance", "span1": [157, 167], "span2": [33, 57]}, "bert_text": "In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of <e1> clioquinol </e1> <e2> neurological disturbance </e2> consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7813": {"data": {"text": "In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.", "entity1": "clioquinol", "entity2": "encephalopathy", "span1": [157, 167], "span2": [91, 105]}, "bert_text": "In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of <e1> clioquinol </e1> <e2> encephalopathy </e2> usually related to the ingestion of a high dose of clioquinol over a short period.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7814": {"data": {"text": "The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.", "entity1": "gabapentin", "entity2": "neuropathic pain", "span1": [51, 61], "span2": [83, 99]}, "bert_text": "The aim of this study was to assess the effects of <e1> gabapentin </e1>, a drug effective in <e2> neuropathic pain </e2> patients, on brain processing of nociceptive information in normal and central sensitization states.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7815": {"data": {"text": "The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. \"", "entity1": "ifosfamide", "entity2": "hallucinations", "span1": [45, 55], "span2": [64, 78]}, "bert_text": "The clinician should be alerted for possible <e1> ifosfamide </e1>-induced <e2> hallucinations </e2>, which may occur without other signs of neurotoxicity. \"", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"7816": {"data": {"text": "The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. \"", "entity1": "ifosfamide", "entity2": "neurotoxicity", "span1": [45, 55], "span2": [119, 132]}, "bert_text": "The clinician should be alerted for possible <e1> ifosfamide </e1>-induced hallucinations, which may occur without other signs of <e2> neurotoxicity </e2>. \"", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7817": {"data": {"text": "Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.\n", "entity1": "fentanyl", "entity2": "muscular rigidity", "span1": [70, 78], "span2": [87, 104]}, "bert_text": "Involvement of locus coeruleus and noradrenergic neurotransmission in <e1> fentanyl </e1>-induced <e2> muscular rigidity </e2> in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7818": {"data": {"text": "Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.\n", "entity1": "amiodarone", "entity2": "pleural", "span1": [72, 82], "span2": [17, 24]}, "bert_text": "Pneumonitis with pleural and pericardial effusion and neuropathy during <e1> amiodarone </e1> <e2> pleural </e2> and pericardial effusion and neuropathy during amiodarone therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7819": {"data": {"text": "Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.\n", "entity1": "amiodarone", "entity2": "pericardial effusion", "span1": [72, 82], "span2": [29, 49]}, "bert_text": "Pneumonitis with pleural and pericardial effusion and neuropathy during <e1> amiodarone </e1> <e2> pericardial effusion </e2> and neuropathy during amiodarone therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7820": {"data": {"text": "Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.\n", "entity1": "amiodarone", "entity2": "neuropathy", "span1": [72, 82], "span2": [54, 64]}, "bert_text": "Pneumonitis with pleural and pericardial effusion and neuropathy during <e1> amiodarone </e1> <e2> neuropathy </e2> during amiodarone therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7821": {"data": {"text": "The arrhythmia resolved after therapy with atenolol, but recurred a year later.", "entity1": "atenolol", "entity2": "arrhythmia", "span1": [43, 51], "span2": [4, 14]}, "bert_text": "The arrhythmia resolved after therapy with <e1> atenolol </e1> <e2> arrhythmia </e2> resolved after therapy with atenolol, but recurred a year later.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7822": {"data": {"text": "The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.\n", "entity1": "cefonicid", "entity2": "hematotoxicity", "span1": [27, 36], "span2": [99, 113]}, "bert_text": "The hematologic effects of <e1> cefonicid </e1> and cefazedone in the dog: a potential model of cephalosporin <e2> hematotoxicity </e2> in man.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7823": {"data": {"text": "The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.\n", "entity1": "cefazedone", "entity2": "hematotoxicity", "span1": [41, 51], "span2": [99, 113]}, "bert_text": "The hematologic effects of cefonicid and <e1> cefazedone </e1> in the dog: a potential model of cephalosporin <e2> hematotoxicity </e2> in man.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7824": {"data": {"text": "The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.\n", "entity1": "cephalosporin", "entity2": "hematotoxicity", "span1": [85, 98], "span2": [99, 113]}, "bert_text": "The hematologic effects of cefonicid and cefazedone in the dog: a potential model of <e1> cephalosporin </e1> <e2> hematotoxicity </e2> in man.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7825": {"data": {"text": "Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.\n", "entity1": "furosemide--", "entity2": "Tetany", "span1": [47, 59], "span2": [0, 6]}, "bert_text": "Tetany and rhabdomyolysis due to surreptitious <e1> furosemide-- </e1> <e2> Tetany </e2> and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7826": {"data": {"text": "Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.\n", "entity1": "furosemide--", "entity2": "rhabdomyolysis", "span1": [47, 59], "span2": [11, 25]}, "bert_text": "Tetany and rhabdomyolysis due to surreptitious <e1> furosemide-- </e1> <e2> rhabdomyolysis </e2> due to surreptitious furosemide--importance of magnesium supplementation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7827": {"data": {"text": "Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.\n", "entity1": "magnesium", "entity2": "Tetany", "span1": [73, 82], "span2": [0, 6]}, "bert_text": "Tetany and rhabdomyolysis due to surreptitious furosemide--importance of <e1> magnesium </e1> <e2> Tetany </e2> and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7828": {"data": {"text": "Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.\n", "entity1": "magnesium", "entity2": "rhabdomyolysis", "span1": [73, 82], "span2": [11, 25]}, "bert_text": "Tetany and rhabdomyolysis due to surreptitious furosemide--importance of <e1> magnesium </e1> <e2> rhabdomyolysis </e2> due to surreptitious furosemide--importance of magnesium supplementation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7829": {"data": {"text": "CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.", "entity1": "paclitaxel", "entity2": "NSCLC", "span1": [32, 42], "span2": [127, 132]}, "bert_text": "CONCLUSIONS: The combination of <e1> paclitaxel </e1>, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic <e2> NSCLC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7830": {"data": {"text": "CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.", "entity1": "cisplatin", "entity2": "NSCLC", "span1": [44, 53], "span2": [127, 132]}, "bert_text": "CONCLUSIONS: The combination of paclitaxel, <e1> cisplatin </e1>, and gemcitabine is well tolerated and shows high activity in metastatic <e2> NSCLC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7831": {"data": {"text": "CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.", "entity1": "gemcitabine", "entity2": "NSCLC", "span1": [59, 70], "span2": [127, 132]}, "bert_text": "CONCLUSIONS: The combination of paclitaxel, cisplatin, and <e1> gemcitabine </e1> is well tolerated and shows high activity in metastatic <e2> NSCLC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7832": {"data": {"text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "entity1": "dexamethasone", "entity2": "hiccups", "span1": [102, 115], "span2": [76, 83]}, "bert_text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (<e1> dexamethasone </e1> <e2> hiccups </e2>. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7833": {"data": {"text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "entity1": "dexamethasone", "entity2": "hiccups", "span1": [102, 115], "span2": [311, 318]}, "bert_text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (<e1> dexamethasone </e1> and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <e2> hiccups </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7834": {"data": {"text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "entity1": "methylprednisolone", "entity2": "hiccups", "span1": [120, 138], "span2": [76, 83]}, "bert_text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and <e1> methylprednisolone </e1> <e2> hiccups </e2>. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7835": {"data": {"text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "entity1": "methylprednisolone", "entity2": "hiccups", "span1": [120, 138], "span2": [311, 318]}, "bert_text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and <e1> methylprednisolone </e1>), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <e2> hiccups </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7836": {"data": {"text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "entity1": "benzodiazepines", "entity2": "hiccups", "span1": [141, 156], "span2": [76, 83]}, "bert_text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), <e1> benzodiazepines </e1> <e2> hiccups </e2>. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7837": {"data": {"text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "entity1": "benzodiazepines", "entity2": "hiccups", "span1": [141, 156], "span2": [311, 318]}, "bert_text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), <e1> benzodiazepines </e1> (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <e2> hiccups </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7838": {"data": {"text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "entity1": "midazolam", "entity2": "hiccups", "span1": [158, 167], "span2": [76, 83]}, "bert_text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (<e1> midazolam </e1> <e2> hiccups </e2>. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7839": {"data": {"text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.", "entity1": "midazolam", "entity2": "hiccups", "span1": [158, 167], "span2": [311, 318]}, "bert_text": "DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (<e1> midazolam </e1>) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <e2> hiccups </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7840": {"data": {"text": "In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.", "entity1": "GEM", "entity2": "toxicity", "span1": [69, 72], "span2": [38, 46]}, "bert_text": "In the current study the efficacy and toxicity of the combination of <e1> GEM </e1> <e2> toxicity </e2> of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7841": {"data": {"text": "In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.", "entity1": "GEM", "entity2": "NSCLC", "span1": [69, 72], "span2": [115, 120]}, "bert_text": "In the current study the efficacy and toxicity of the combination of <e1> GEM </e1> and VNB in elderly patients with advanced <e2> NSCLC </e2> or those with some contraindication to receiving cisplatin were assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7842": {"data": {"text": "In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.", "entity1": "VNB", "entity2": "toxicity", "span1": [77, 80], "span2": [38, 46]}, "bert_text": "In the current study the efficacy and toxicity of the combination of GEM and <e1> VNB </e1> <e2> toxicity </e2> of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7843": {"data": {"text": "In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.", "entity1": "VNB", "entity2": "NSCLC", "span1": [77, 80], "span2": [115, 120]}, "bert_text": "In the current study the efficacy and toxicity of the combination of GEM and <e1> VNB </e1> in elderly patients with advanced <e2> NSCLC </e2> or those with some contraindication to receiving cisplatin were assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7844": {"data": {"text": "In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.", "entity1": "cisplatin", "entity2": "toxicity", "span1": [170, 179], "span2": [38, 46]}, "bert_text": "In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving <e1> cisplatin </e1> <e2> toxicity </e2> of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7845": {"data": {"text": "In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.", "entity1": "cisplatin", "entity2": "NSCLC", "span1": [170, 179], "span2": [115, 120]}, "bert_text": "In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving <e1> cisplatin </e1> <e2> NSCLC </e2> or those with some contraindication to receiving cisplatin were assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7846": {"data": {"text": "Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.", "entity1": "mazindol", "entity2": "dry mouth", "span1": [29, 37], "span2": [73, 82]}, "bert_text": "Side effects attributable to <e1> mazindol </e1> included decreased appetite (36%), <e2> dry mouth </e2> (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7847": {"data": {"text": "Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.", "entity1": "mazindol", "entity2": "gastrointestinal symptoms", "span1": [29, 37], "span2": [119, 144]}, "bert_text": "Side effects attributable to <e1> mazindol </e1> included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and <e2> gastrointestinal symptoms </e2> (18%); mazindol dosage was reduced in 43% of patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7848": {"data": {"text": "Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.", "entity1": "mazindol", "entity2": "dry mouth", "span1": [152, 160], "span2": [73, 82]}, "bert_text": "Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); <e1> mazindol </e1> <e2> dry mouth </e2> (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7849": {"data": {"text": "Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.", "entity1": "mazindol", "entity2": "gastrointestinal symptoms", "span1": [152, 160], "span2": [119, 144]}, "bert_text": "Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); <e1> mazindol </e1> <e2> gastrointestinal symptoms </e2> (18%); mazindol dosage was reduced in 43% of patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7850": {"data": {"text": "Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.", "entity1": "oxprenolol", "entity2": "hypokalemia", "span1": [45, 55], "span2": [77, 88]}, "bert_text": "Subsequently we investigated the efficacy of <e1> oxprenolol </e1> in antagonizing such <e2> hypokalemia </e2>, together with the pharmacokinetic interaction between both drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7851": {"data": {"text": "Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.", "entity1": "Topiramate", "entity2": "seizures", "span1": [0, 10], "span2": [147, 155]}, "bert_text": "<e1> Topiramate </e1> is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7852": {"data": {"text": "NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.\n", "entity1": "calcitonin gene-related peptide", "entity2": "migraine", "span1": [54, 85], "span2": [11, 19]}, "bert_text": "NO-induced migraine attack: strong increase in plasma <e1> calcitonin gene-related peptide </e1> <e2> migraine </e2> attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7853": {"data": {"text": "NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.\n", "entity1": "CGRP", "entity2": "migraine", "span1": [87, 91], "span2": [11, 19]}, "bert_text": "NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (<e1> CGRP </e1> <e2> migraine </e2> attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7854": {"data": {"text": "NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.\n", "entity1": "serotonin", "entity2": "migraine", "span1": [146, 155], "span2": [11, 19]}, "bert_text": "NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet <e1> serotonin </e1> <e2> migraine </e2> attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7855": {"data": {"text": "PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.", "entity1": "levofloxacin", "entity2": "sinusitis", "span1": [48, 60], "span2": [157, 166]}, "bert_text": "PURPOSE: To evaluate the efficacy and safety of <e1> levofloxacin </e1> (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial <e2> sinusitis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7856": {"data": {"text": "Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.", "entity1": "norepinephrine", "entity2": "seizures", "span1": [15, 29], "span2": [118, 126]}, "bert_text": "Alterations of <e1> norepinephrine </e1> transporter (NET) function by chronic inhibition of NET in relation to sensitization to <e2> seizures </e2> induce by cocaine and local anesthetics were studied in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7857": {"data": {"text": "Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.", "entity1": "cocaine", "entity2": "seizures", "span1": [137, 144], "span2": [118, 126]}, "bert_text": "Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by <e1> cocaine </e1> <e2> seizures </e2> induce by cocaine and local anesthetics were studied in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7858": {"data": {"text": "Does paracetamol cause urothelial cancer or renal papillary necrosis?\n", "entity1": "paracetamol", "entity2": "urothelial cancer", "span1": [5, 16], "span2": [23, 40]}, "bert_text": "Does <e1> paracetamol </e1> cause <e2> urothelial cancer </e2> or renal papillary necrosis?\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7859": {"data": {"text": "Does paracetamol cause urothelial cancer or renal papillary necrosis?\n", "entity1": "paracetamol", "entity2": "renal papillary necrosis", "span1": [5, 16], "span2": [44, 68]}, "bert_text": "Does <e1> paracetamol </e1> cause urothelial cancer or <e2> renal papillary necrosis </e2>?\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7860": {"data": {"text": "Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.", "entity1": "macrolide", "entity2": "visual hallucinations", "span1": [92, 101], "span2": [32, 53]}, "bert_text": "Unreported in the literature is visual hallucinations occurring in association with the new <e1> macrolide </e1> <e2> visual hallucinations </e2> occurring in association with the new macrolide antibiotic, clarithromycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7861": {"data": {"text": "Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.", "entity1": "clarithromycin", "entity2": "visual hallucinations", "span1": [114, 128], "span2": [32, 53]}, "bert_text": "Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, <e1> clarithromycin </e1> <e2> visual hallucinations </e2> occurring in association with the new macrolide antibiotic, clarithromycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7862": {"data": {"text": "Enhanced stimulus-induced neurotransmitter overflow in epinephrine-induced hypertensive rats is not mediated by prejunctional beta-adrenoceptor activation.\n", "entity1": "epinephrine", "entity2": "hypertensive", "span1": [55, 66], "span2": [75, 87]}, "bert_text": "Enhanced stimulus-induced neurotransmitter overflow in <e1> epinephrine </e1>-induced <e2> hypertensive </e2> rats is not mediated by prejunctional beta-adrenoceptor activation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7863": {"data": {"text": "Nitric oxide synthase expression in the course of lead-induced hypertension.\n", "entity1": "Nitric oxide", "entity2": "hypertension", "span1": [0, 12], "span2": [63, 75]}, "bert_text": "<e1> Nitric oxide </e1> synthase expression in the course of lead-induced <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7864": {"data": {"text": "Nitric oxide synthase expression in the course of lead-induced hypertension.\n", "entity1": "lead", "entity2": "hypertension", "span1": [50, 54], "span2": [63, 75]}, "bert_text": "Nitric oxide synthase expression in the course of <e1> lead </e1>-induced <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7865": {"data": {"text": "Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.", "entity1": "epsilon-aminocaproic acid", "entity2": "thromboembolic disease", "span1": [90, 115], "span2": [27, 49]}, "bert_text": "Although increased risk of thromboembolic disease has been reported during treatment with <e1> epsilon-aminocaproic acid </e1> <e2> thromboembolic disease </e2> has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"7866": {"data": {"text": "Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.", "entity1": "epsilon-aminocaproic acid", "entity2": "cerebral sinus thrombosis", "span1": [90, 115], "span2": [117, 142]}, "bert_text": "Although increased risk of thromboembolic disease has been reported during treatment with <e1> epsilon-aminocaproic acid </e1>, <e2> cerebral sinus thrombosis </e2> has not been previously described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"7867": {"data": {"text": "Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.", "entity1": "macrolide", "entity2": "hiccups", "span1": [64, 73], "span2": [26, 33]}, "bert_text": "Few cases of drug-induced hiccups have been reported related to <e1> macrolide </e1> <e2> hiccups </e2> have been reported related to macrolide antimicrobials.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7868": {"data": {"text": "Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.", "entity1": "ADR", "entity2": "L1210 leukemia", "span1": [36, 39], "span2": [62, 76]}, "bert_text": "Such treatment did not diminish the <e1> ADR </e1> antitumor activity in <e2> L1210 leukemia </e2> and in Ehrlich ascites tumor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7869": {"data": {"text": "Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.", "entity1": "ADR", "entity2": "Ehrlich ascites tumor", "span1": [36, 39], "span2": [84, 105]}, "bert_text": "Such treatment did not diminish the <e1> ADR </e1> antitumor activity in L1210 leukemia and in <e2> Ehrlich ascites tumor </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7870": {"data": {"text": "A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.", "entity1": "methysergide", "entity2": "vasospasm", "span1": [122, 134], "span2": [22, 31]}, "bert_text": "A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of <e1> methysergide </e1> <e2> vasospasm </e2>, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7871": {"data": {"text": "Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.", "entity1": "CC", "entity2": "infertility", "span1": [65, 67], "span2": [39, 50]}, "bert_text": "Extra caution is warranted in treating infertility patients with <e1> CC </e1> <e2> infertility </e2> patients with CC, and patients should be well informed of this side effect before commencement of therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7872": {"data": {"text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.", "entity1": "anthracycline", "entity2": "cardiotoxicity", "span1": [137, 150], "span2": [159, 173]}, "bert_text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of <e1> anthracycline </e1>-induced <e2> cardiotoxicity </e2> in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7873": {"data": {"text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.", "entity1": "anthracycline", "entity2": "acute leukemia", "span1": [137, 150], "span2": [191, 205]}, "bert_text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of <e1> anthracycline </e1>-induced cardiotoxicity in patients with <e2> acute leukemia </e2> treated with a daunorubicin (DNR)-containing regimen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7874": {"data": {"text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.", "entity1": "daunorubicin", "entity2": "cardiotoxicity", "span1": [221, 233], "span2": [159, 173]}, "bert_text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a <e1> daunorubicin </e1> <e2> cardiotoxicity </e2> in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7875": {"data": {"text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.", "entity1": "daunorubicin", "entity2": "acute leukemia", "span1": [221, 233], "span2": [191, 205]}, "bert_text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a <e1> daunorubicin </e1> <e2> acute leukemia </e2> treated with a daunorubicin (DNR)-containing regimen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7876": {"data": {"text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.", "entity1": "DNR)-containing", "entity2": "cardiotoxicity", "span1": [235, 250], "span2": [159, 173]}, "bert_text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (<e1> DNR)-containing </e1> <e2> cardiotoxicity </e2> in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7877": {"data": {"text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.", "entity1": "DNR)-containing", "entity2": "acute leukemia", "span1": [235, 250], "span2": [191, 205]}, "bert_text": "We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (<e1> DNR)-containing </e1> <e2> acute leukemia </e2> treated with a daunorubicin (DNR)-containing regimen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7878": {"data": {"text": "On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.", "entity1": "paroxetine", "entity2": "psychomotor retardation", "span1": [19, 29], "span2": [85, 108]}, "bert_text": "On the 10th day of <e1> paroxetine </e1> and alprazolam treatment, the patient exhibited marked <e2> psychomotor retardation </e2>, disorientation, and severe muscle rigidity with tremors.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7879": {"data": {"text": "On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.", "entity1": "paroxetine", "entity2": "muscle rigidity", "span1": [19, 29], "span2": [137, 152]}, "bert_text": "On the 10th day of <e1> paroxetine </e1> and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe <e2> muscle rigidity </e2> with tremors.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7880": {"data": {"text": "On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.", "entity1": "paroxetine", "entity2": "tremors", "span1": [19, 29], "span2": [158, 165]}, "bert_text": "On the 10th day of <e1> paroxetine </e1> and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with <e2> tremors </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7881": {"data": {"text": "On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.", "entity1": "alprazolam", "entity2": "psychomotor retardation", "span1": [34, 44], "span2": [85, 108]}, "bert_text": "On the 10th day of paroxetine and <e1> alprazolam </e1> treatment, the patient exhibited marked <e2> psychomotor retardation </e2>, disorientation, and severe muscle rigidity with tremors.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7882": {"data": {"text": "On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.", "entity1": "alprazolam", "entity2": "muscle rigidity", "span1": [34, 44], "span2": [137, 152]}, "bert_text": "On the 10th day of paroxetine and <e1> alprazolam </e1> treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe <e2> muscle rigidity </e2> with tremors.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7883": {"data": {"text": "On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.", "entity1": "alprazolam", "entity2": "tremors", "span1": [34, 44], "span2": [158, 165]}, "bert_text": "On the 10th day of paroxetine and <e1> alprazolam </e1> treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with <e2> tremors </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7884": {"data": {"text": "Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.", "entity1": "losartan", "entity2": "anuria", "span1": [41, 49], "span2": [71, 77]}, "bert_text": "Surprisingly, the first dose of 50 mg of <e1> losartan </e1> resulted in a sudden <e2> anuria </e2>, which lasted eight hours despite high-dose furosemide and amine infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7885": {"data": {"text": "Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.", "entity1": "furosemide", "entity2": "anuria", "span1": [122, 132], "span2": [71, 77]}, "bert_text": "Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose <e1> furosemide </e1> <e2> anuria </e2>, which lasted eight hours despite high-dose furosemide and amine infusion.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7886": {"data": {"text": "Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.", "entity1": "amine", "entity2": "anuria", "span1": [137, 142], "span2": [71, 77]}, "bert_text": "Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and <e1> amine </e1> <e2> anuria </e2>, which lasted eight hours despite high-dose furosemide and amine infusion.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7887": {"data": {"text": "A 58-year-old woman with a clinical diagnosis of dilevalol-induced liver injury.", "entity1": "dilevalol", "entity2": "liver injury", "span1": [49, 58], "span2": [67, 79]}, "bert_text": "A 58-year-old woman with a clinical diagnosis of <e1> dilevalol </e1>-induced <e2> liver injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7888": {"data": {"text": "In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).", "entity1": "timolol", "entity2": "depression", "span1": [74, 81], "span2": [109, 119]}, "bert_text": "In a double blind cross-over study with control group, the patients under <e1> timolol </e1> treatment presented higher <e2> depression </e2> values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7889": {"data": {"text": "Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.", "entity1": "metoclopramide", "entity2": "Abnormal involuntary movements", "span1": [123, 137], "span2": [0, 30]}, "bert_text": "Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took <e1> metoclopramide </e1> <e2> Abnormal involuntary movements </e2> appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7890": {"data": {"text": "Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.", "entity1": "metoclopramide", "entity2": "gastrointestinal disorder", "span1": [123, 137], "span2": [142, 167]}, "bert_text": "Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took <e1> metoclopramide </e1> for <e2> gastrointestinal disorder </e2> in a regimen of 30 mg per day for a total of about 260 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7891": {"data": {"text": "Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.", "entity1": "HCBD", "entity2": "glomerular damage", "span1": [27, 31], "span2": [100, 117]}, "bert_text": "Tubular damage produced by <e1> HCBD </e1> or BEA was discriminated both quantitatively and qualitatively from <e2> glomerular damage </e2> produced by PAN.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7892": {"data": {"text": "Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.", "entity1": "BEA", "entity2": "glomerular damage", "span1": [35, 38], "span2": [100, 117]}, "bert_text": "Tubular damage produced by HCBD or <e1> BEA </e1> was discriminated both quantitatively and qualitatively from <e2> glomerular damage </e2> produced by PAN.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7893": {"data": {"text": "Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.", "entity1": "PAN", "entity2": "glomerular damage", "span1": [130, 133], "span2": [100, 117]}, "bert_text": "Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by <e1> PAN </e1> <e2> glomerular damage </e2> produced by PAN.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7894": {"data": {"text": "We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.", "entity1": "paclitaxel", "entity2": "peripheral neuropathy", "span1": [191, 201], "span2": [50, 71]}, "bert_text": "We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to <e1> paclitaxel </e1> <e2> peripheral neuropathy </e2> that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"7895": {"data": {"text": "We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.", "entity1": "cisplatin", "entity2": "peripheral neuropathy", "span1": [206, 215], "span2": [50, 71]}, "bert_text": "We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and <e1> cisplatin </e1> <e2> peripheral neuropathy </e2> that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"7896": {"data": {"text": "Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.", "entity1": "prostaglandin E1", "entity2": "hypotension", "span1": [30, 46], "span2": [62, 73]}, "bert_text": "Combined effects of prolonged <e1> prostaglandin E1 </e1> (PGE1)-induced <e2> hypotension </e2> and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"7897": {"data": {"text": "Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.", "entity1": "PGE1)-induced", "entity2": "hypotension", "span1": [48, 61], "span2": [62, 73]}, "bert_text": "Combined effects of prolonged prostaglandin E1 (<e1> PGE1)-induced </e1> <e2> hypotension </e2> and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"7898": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "levobupivacaine", "entity2": "toxicity", "span1": [42, 57], "span2": [30, 38]}, "bert_text": "We conclude that the systemic toxicity of <e1> levobupivacaine </e1> <e2> toxicity </e2> of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7899": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "levobupivacaine", "entity2": "cardiac arrest", "span1": [42, 57], "span2": [182, 196]}, "bert_text": "We conclude that the systemic toxicity of <e1> levobupivacaine </e1> is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7900": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "levobupivacaine", "entity2": "toxicity", "span1": [277, 292], "span2": [30, 38]}, "bert_text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or <e1> levobupivacaine </e1> <e2> toxicity </e2> of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7901": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "levobupivacaine", "entity2": "cardiac arrest", "span1": [277, 292], "span2": [182, 196]}, "bert_text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or <e1> levobupivacaine </e1> <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7902": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "ropivacaine", "entity2": "toxicity", "span1": [90, 101], "span2": [30, 38]}, "bert_text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of <e1> ropivacaine </e1> <e2> toxicity </e2> of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7903": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "ropivacaine", "entity2": "cardiac arrest", "span1": [90, 101], "span2": [182, 196]}, "bert_text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of <e1> ropivacaine </e1> and bupivacaine when administered at the same rate and that ropivacaine-induced <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7904": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "ropivacaine", "entity2": "toxicity", "span1": [162, 173], "span2": [30, 38]}, "bert_text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that <e1> ropivacaine </e1> <e2> toxicity </e2> of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7905": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "ropivacaine", "entity2": "cardiac arrest", "span1": [162, 173], "span2": [182, 196]}, "bert_text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that <e1> ropivacaine </e1>-induced <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7906": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "bupivacaine", "entity2": "toxicity", "span1": [106, 117], "span2": [30, 38]}, "bert_text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and <e1> bupivacaine </e1> <e2> toxicity </e2> of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7907": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "bupivacaine", "entity2": "cardiac arrest", "span1": [106, 117], "span2": [182, 196]}, "bert_text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and <e1> bupivacaine </e1> when administered at the same rate and that ropivacaine-induced <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7908": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "bupivacaine", "entity2": "toxicity", "span1": [262, 273], "span2": [30, 38]}, "bert_text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by <e1> bupivacaine </e1> <e2> toxicity </e2> of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7909": {"data": {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity1": "bupivacaine", "entity2": "cardiac arrest", "span1": [262, 273], "span2": [182, 196]}, "bert_text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by <e1> bupivacaine </e1> <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7910": {"data": {"text": "Acute hepatitis attack after exposure to telithromycin.\n", "entity1": "telithromycin", "entity2": "hepatitis", "span1": [41, 54], "span2": [6, 15]}, "bert_text": "Acute hepatitis attack after exposure to <e1> telithromycin </e1> <e2> hepatitis </e2> attack after exposure to telithromycin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7911": {"data": {"text": "The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.", "entity1": "2,3,5-triphenyltetrazolium", "entity2": "neuronal injury", "span1": [48, 74], "span2": [14, 29]}, "bert_text": "The extent of neuronal injury was determined by <e1> 2,3,5-triphenyltetrazolium </e1> <e2> neuronal injury </e2> was determined by 2,3,5-triphenyltetrazolium staining.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7912": {"data": {"text": "A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.", "entity1": "thyroxine", "entity2": "hypothyroid", "span1": [38, 47], "span2": [14, 25]}, "bert_text": "A 54-year-old hypothyroid male taking <e1> thyroxine </e1> <e2> hypothyroid </e2> male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7913": {"data": {"text": "A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.", "entity1": "thyroxine", "entity2": "bilateral leg compartment syndrome and myonecrosis", "span1": [38, 47], "span2": [79, 129]}, "bert_text": "A 54-year-old hypothyroid male taking <e1> thyroxine </e1> and simvastatin presented with <e2> bilateral leg compartment syndrome and myonecrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7914": {"data": {"text": "A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.", "entity1": "simvastatin", "entity2": "hypothyroid", "span1": [52, 63], "span2": [14, 25]}, "bert_text": "A 54-year-old hypothyroid male taking thyroxine and <e1> simvastatin </e1> <e2> hypothyroid </e2> male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7915": {"data": {"text": "A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.", "entity1": "simvastatin", "entity2": "bilateral leg compartment syndrome and myonecrosis", "span1": [52, 63], "span2": [79, 129]}, "bert_text": "A 54-year-old hypothyroid male taking thyroxine and <e1> simvastatin </e1> presented with <e2> bilateral leg compartment syndrome and myonecrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7916": {"data": {"text": "Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.", "entity1": "sulfasalazine", "entity2": "inflammatory bowel disease", "span1": [19, 32], "span2": [56, 82]}, "bert_text": "Physicians who use <e1> sulfasalazine </e1> to treat patients with <e2> inflammatory bowel disease </e2> should be aware of the signs of sulfasalazine-induced lupus syndrome.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7917": {"data": {"text": "Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.", "entity1": "sulfasalazine", "entity2": "lupus syndrome", "span1": [19, 32], "span2": [137, 151]}, "bert_text": "Physicians who use <e1> sulfasalazine </e1> to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced <e2> lupus syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7918": {"data": {"text": "Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.", "entity1": "sulfasalazine", "entity2": "inflammatory bowel disease", "span1": [115, 128], "span2": [56, 82]}, "bert_text": "Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of <e1> sulfasalazine </e1> <e2> inflammatory bowel disease </e2> should be aware of the signs of sulfasalazine-induced lupus syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7919": {"data": {"text": "Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.", "entity1": "sulfasalazine", "entity2": "lupus syndrome", "span1": [115, 128], "span2": [137, 151]}, "bert_text": "Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of <e1> sulfasalazine </e1>-induced <e2> lupus syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7920": {"data": {"text": "Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.\n", "entity1": "ipratropium bromide", "entity2": "chronic obstructive pulmonary disease", "span1": [33, 52], "span2": [73, 110]}, "bert_text": "Acute bronchodilating effects of <e1> ipratropium bromide </e1> and theophylline in <e2> chronic obstructive pulmonary disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7921": {"data": {"text": "Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.\n", "entity1": "theophylline", "entity2": "chronic obstructive pulmonary disease", "span1": [57, 69], "span2": [73, 110]}, "bert_text": "Acute bronchodilating effects of ipratropium bromide and <e1> theophylline </e1> in <e2> chronic obstructive pulmonary disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7922": {"data": {"text": "We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.", "entity1": "ifosfamide", "entity2": "nephrotoxic", "span1": [28, 38], "span2": [67, 78]}, "bert_text": "We recommend careful use of <e1> ifosfamide </e1> in patients pretreated with <e2> nephrotoxic </e2> chemotherapy and inadequate renal perfusion.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7923": {"data": {"text": "Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.\n", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [99, 110], "span2": [119, 128]}, "bert_text": "Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate <e1> haloperidol </e1>-induced <e2> catalepsy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7924": {"data": {"text": "Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.\n", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [15, 23], "span2": [32, 42]}, "bert_text": "Improvement of <e1> levodopa </e1>-induced <e2> dyskinesia </e2> by propranolol in Parkinson's disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7925": {"data": {"text": "Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.\n", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [15, 23], "span2": [61, 80]}, "bert_text": "Improvement of <e1> levodopa </e1>-induced dyskinesia by propranolol in <e2> Parkinson's disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7926": {"data": {"text": "Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.\n", "entity1": "propranolol", "entity2": "dyskinesia", "span1": [46, 57], "span2": [32, 42]}, "bert_text": "Improvement of levodopa-induced dyskinesia by <e1> propranolol </e1> <e2> dyskinesia </e2> by propranolol in Parkinson's disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7927": {"data": {"text": "Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.\n", "entity1": "propranolol", "entity2": "Parkinson's disease", "span1": [46, 57], "span2": [61, 80]}, "bert_text": "Improvement of levodopa-induced dyskinesia by <e1> propranolol </e1> in <e2> Parkinson's disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7928": {"data": {"text": "The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.", "entity1": "chloramphenicol", "entity2": "aplastic anemia", "span1": [84, 99], "span2": [19, 34]}, "bert_text": "The pattern of the aplastic anemia was associated with an idiosyncratic response to <e1> chloramphenicol </e1> <e2> aplastic anemia </e2> was associated with an idiosyncratic response to chloramphenicol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7929": {"data": {"text": "We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.", "entity1": "cefonicid", "entity2": "hematotoxicity", "span1": [53, 62], "span2": [96, 110]}, "bert_text": "We conclude that the administration of high doses of <e1> cefonicid </e1> or cefazedone to dogs can induce <e2> hematotoxicity </e2> similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7930": {"data": {"text": "We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.", "entity1": "cefonicid", "entity2": "blood dyscrasias", "span1": [53, 62], "span2": [148, 164]}, "bert_text": "We conclude that the administration of high doses of <e1> cefonicid </e1> or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced <e2> blood dyscrasias </e2> described in man and thus provides a useful model for studying the mechanisms of these disorders.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7931": {"data": {"text": "We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.", "entity1": "cefazedone", "entity2": "hematotoxicity", "span1": [66, 76], "span2": [96, 110]}, "bert_text": "We conclude that the administration of high doses of cefonicid or <e1> cefazedone </e1> to dogs can induce <e2> hematotoxicity </e2> similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7932": {"data": {"text": "We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.", "entity1": "cefazedone", "entity2": "blood dyscrasias", "span1": [66, 76], "span2": [148, 164]}, "bert_text": "We conclude that the administration of high doses of cefonicid or <e1> cefazedone </e1> to dogs can induce hematotoxicity similar to the cephalosporin-induced <e2> blood dyscrasias </e2> described in man and thus provides a useful model for studying the mechanisms of these disorders.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7933": {"data": {"text": "We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.", "entity1": "cephalosporin", "entity2": "hematotoxicity", "span1": [126, 139], "span2": [96, 110]}, "bert_text": "We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the <e1> cephalosporin </e1> <e2> hematotoxicity </e2> similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7934": {"data": {"text": "We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.", "entity1": "cephalosporin", "entity2": "blood dyscrasias", "span1": [126, 139], "span2": [148, 164]}, "bert_text": "We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the <e1> cephalosporin </e1>-induced <e2> blood dyscrasias </e2> described in man and thus provides a useful model for studying the mechanisms of these disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7935": {"data": {"text": "Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.\n", "entity1": "heparin", "entity2": "thrombosis", "span1": [80, 87], "span2": [52, 62]}, "bert_text": "Higher optical density of an antigen assay predicts thrombosis in patients with <e1> heparin </e1> <e2> thrombosis </e2> in patients with heparin-induced thrombocytopenia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7936": {"data": {"text": "Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.\n", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [80, 87], "span2": [96, 112]}, "bert_text": "Higher optical density of an antigen assay predicts thrombosis in patients with <e1> heparin </e1>-induced <e2> thrombocytopenia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7937": {"data": {"text": "Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [57, 68], "span2": [186, 194]}, "bert_text": "Sprague-Dawley rats were injected intraperitoneally with <e1> pilocarpine </e1>, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7938": {"data": {"text": "Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [166, 177], "span2": [186, 194]}, "bert_text": "Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after <e1> pilocarpine </e1>-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7939": {"data": {"text": "Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.\n", "entity1": "prostaglandins", "entity2": "overactive bladder", "span1": [24, 38], "span2": [76, 94]}, "bert_text": "Nerve growth factor and <e1> prostaglandins </e1> in the urine of female patients with <e2> overactive bladder </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7940": {"data": {"text": "CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.", "entity1": "papaverine", "entity2": "vasospasm", "span1": [21, 31], "span2": [53, 62]}, "bert_text": "CONCLUSIONS: Topical <e1> papaverine </e1> for the treatment of <e2> vasospasm </e2> was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7941": {"data": {"text": "They had been taking metronidazole (total dosage, 45-120 g; duration, 30 days to 2 months) to treat the infection in various organs.", "entity1": "metronidazole", "entity2": "infection", "span1": [21, 34], "span2": [104, 113]}, "bert_text": "They had been taking <e1> metronidazole </e1> (total dosage, 45-120 g; duration, 30 days to 2 months) to treat the <e2> infection </e2> in various organs.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7942": {"data": {"text": "Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.", "entity1": "desipramine", "entity2": "convulsions", "span1": [24, 35], "span2": [95, 106]}, "bert_text": "Daily administration of <e1> desipramine </e1> increased the incidence of appearance of lidocaine-induced <e2> convulsions </e2> and decreased that of cocaine-induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7943": {"data": {"text": "Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.", "entity1": "desipramine", "entity2": "convulsions", "span1": [24, 35], "span2": [145, 156]}, "bert_text": "Daily administration of <e1> desipramine </e1> increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7944": {"data": {"text": "Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.", "entity1": "lidocaine", "entity2": "convulsions", "span1": [77, 86], "span2": [95, 106]}, "bert_text": "Daily administration of desipramine increased the incidence of appearance of <e1> lidocaine </e1>-induced <e2> convulsions </e2> and decreased that of cocaine-induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7945": {"data": {"text": "Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.", "entity1": "lidocaine", "entity2": "convulsions", "span1": [77, 86], "span2": [145, 156]}, "bert_text": "Daily administration of desipramine increased the incidence of appearance of <e1> lidocaine </e1>-induced convulsions and decreased that of cocaine-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7946": {"data": {"text": "Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.", "entity1": "cocaine", "entity2": "convulsions", "span1": [129, 136], "span2": [95, 106]}, "bert_text": "Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of <e1> cocaine </e1> <e2> convulsions </e2> and decreased that of cocaine-induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7947": {"data": {"text": "Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.", "entity1": "cocaine", "entity2": "convulsions", "span1": [129, 136], "span2": [145, 156]}, "bert_text": "Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of <e1> cocaine </e1>-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7948": {"data": {"text": "Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.", "entity1": "oral contraceptives", "entity2": "myocardial infarction", "span1": [21, 40], "span2": [257, 278]}, "bert_text": "Among women who used <e1> oral contraceptives </e1>, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of <e2> myocardial infarction </e2> was increased among women who used second-generation oral contraceptives.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7949": {"data": {"text": "Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.", "entity1": "oral contraceptives", "entity2": "myocardial infarction", "span1": [332, 351], "span2": [257, 278]}, "bert_text": "Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation <e1> oral contraceptives </e1> <e2> myocardial infarction </e2> was increased among women who used second-generation oral contraceptives.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"7950": {"data": {"text": "Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.\n", "entity1": "epinephrine", "entity2": "priapism", "span1": [15, 26], "span2": [63, 71]}, "bert_text": "Intracavernous <e1> epinephrine </e1>: a minimally invasive treatment for <e2> priapism </e2> in the emergency department.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7951": {"data": {"text": "We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.", "entity1": "ouabain", "entity2": "coronary artery disease", "span1": [165, 172], "span2": [42, 65]}, "bert_text": "We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after <e1> ouabain </e1> <e2> coronary artery disease </e2> who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7952": {"data": {"text": "We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.", "entity1": "ouabain", "entity2": "congestive heart failure", "span1": [165, 172], "span2": [90, 114]}, "bert_text": "We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after <e1> ouabain </e1> <e2> congestive heart failure </e2> left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7953": {"data": {"text": "Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.", "entity1": "dapsone", "entity2": "hemolytic anemia", "span1": [105, 112], "span2": [128, 144]}, "bert_text": "Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since <e1> dapsone </e1> does not cause <e2> hemolytic anemia </e2> at this dose in hematologically normal individuals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"7954": {"data": {"text": "Enhanced bradycardia induced by beta-adrenoceptor antagonists in rats pretreated with isoniazid.\n", "entity1": "isoniazid", "entity2": "bradycardia", "span1": [86, 95], "span2": [9, 20]}, "bert_text": "Enhanced bradycardia induced by beta-adrenoceptor antagonists in rats pretreated with <e1> isoniazid </e1> <e2> bradycardia </e2> induced by beta-adrenoceptor antagonists in rats pretreated with isoniazid.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7955": {"data": {"text": "Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.", "entity1": "Prostanoids", "entity2": "bladder hyperactivity", "span1": [0, 11], "span2": [73, 94]}, "bert_text": "<e1> Prostanoids </e1> may, via release of tachykinins, contribute to both urge and <e2> bladder hyperactivity </e2> seen in inflammatory conditions of the lower urinary tract.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7956": {"data": {"text": "Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.", "entity1": "tachykinins", "entity2": "bladder hyperactivity", "span1": [32, 43], "span2": [73, 94]}, "bert_text": "Prostanoids may, via release of <e1> tachykinins </e1>, contribute to both urge and <e2> bladder hyperactivity </e2> seen in inflammatory conditions of the lower urinary tract.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7957": {"data": {"text": "Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.", "entity1": "tacrolimus", "entity2": "Myocardial hypertrophy", "span1": [85, 95], "span2": [0, 22]}, "bert_text": "Myocardial hypertrophy completely resolved upon reducing the target concentration of <e1> tacrolimus </e1> <e2> Myocardial hypertrophy </e2> completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7958": {"data": {"text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "entity1": "CSA", "entity2": "nephrotoxic", "span1": [31, 34], "span2": [77, 88]}, "bert_text": "The combined administration of <e1> CSA </e1> and various chemotherapeutic drugs with a <e2> nephrotoxic </e2> potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"7959": {"data": {"text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "entity1": "CSA", "entity2": "toxicity", "span1": [31, 34], "span2": [267, 275]}, "bert_text": "The combined administration of <e1> CSA </e1> and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced <e2> toxicity </e2> in the rat model.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7960": {"data": {"text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "entity1": "CSA", "entity2": "nephrotoxic", "span1": [255, 258], "span2": [77, 88]}, "bert_text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the <e1> CSA </e1> <e2> nephrotoxic </e2> potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"7961": {"data": {"text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "entity1": "CSA", "entity2": "toxicity", "span1": [255, 258], "span2": [267, 275]}, "bert_text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the <e1> CSA </e1> induced <e2> toxicity </e2> in the rat model.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7962": {"data": {"text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "entity1": "gentamicin", "entity2": "nephrotoxic", "span1": [108, 118], "span2": [77, 88]}, "bert_text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as <e1> gentamicin </e1> <e2> nephrotoxic </e2> potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7963": {"data": {"text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "entity1": "gentamicin", "entity2": "toxicity", "span1": [108, 118], "span2": [267, 275]}, "bert_text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as <e1> gentamicin </e1> (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced <e2> toxicity </e2> in the rat model.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7964": {"data": {"text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "entity1": "amphothericin B", "entity2": "nephrotoxic", "span1": [143, 158], "span2": [77, 88]}, "bert_text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), <e1> amphothericin B </e1> <e2> nephrotoxic </e2> potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7965": {"data": {"text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "entity1": "amphothericin B", "entity2": "toxicity", "span1": [143, 158], "span2": [267, 275]}, "bert_text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), <e1> amphothericin B </e1> and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced <e2> toxicity </e2> in the rat model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7966": {"data": {"text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "entity1": "ketoconazole", "entity2": "nephrotoxic", "span1": [163, 175], "span2": [77, 88]}, "bert_text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and <e1> ketoconazole </e1> <e2> nephrotoxic </e2> potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"7967": {"data": {"text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "entity1": "ketoconazole", "entity2": "toxicity", "span1": [163, 175], "span2": [267, 275]}, "bert_text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and <e1> ketoconazole </e1>, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced <e2> toxicity </e2> in the rat model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"7968": {"data": {"text": "Angioedema associated with droperidol administration.\n", "entity1": "droperidol", "entity2": "Angioedema", "span1": [27, 37], "span2": [0, 10]}, "bert_text": "Angioedema associated with <e1> droperidol </e1> <e2> Angioedema </e2> associated with droperidol administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7969": {"data": {"text": "We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.", "entity1": "lidocaine", "entity2": "pain", "span1": [17, 26], "span2": [84, 88]}, "bert_text": "We conclude that <e1> lidocaine </e1> reduces the incidence and severity of propofol injection <e2> pain </e2> in ambulatory patients whereas thiopentone only reduces its severity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7970": {"data": {"text": "We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.", "entity1": "propofol", "entity2": "pain", "span1": [65, 73], "span2": [84, 88]}, "bert_text": "We conclude that lidocaine reduces the incidence and severity of <e1> propofol </e1> injection <e2> pain </e2> in ambulatory patients whereas thiopentone only reduces its severity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7971": {"data": {"text": "We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.", "entity1": "thiopentone", "entity2": "pain", "span1": [120, 131], "span2": [84, 88]}, "bert_text": "We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas <e1> thiopentone </e1> <e2> pain </e2> in ambulatory patients whereas thiopentone only reduces its severity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7972": {"data": {"text": "One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.", "entity1": "MMC", "entity2": "cardiac failure", "span1": [62, 65], "span2": [30, 45]}, "bert_text": "One of the patients developed cardiac failure after 30 mg m-2 <e1> MMC </e1> <e2> cardiac failure </e2> after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7973": {"data": {"text": "One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.", "entity1": "doxorubicin", "entity2": "cardiac failure", "span1": [86, 97], "span2": [30, 45]}, "bert_text": "One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 <e1> doxorubicin </e1> <e2> cardiac failure </e2> after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7974": {"data": {"text": "Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations.", "entity1": "Loreclezole", "entity2": "seizure", "span1": [0, 11], "span2": [102, 109]}, "bert_text": "<e1> Loreclezole </e1> (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both <e2> seizure </e2> and afterdischarge durations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7975": {"data": {"text": "Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine.\n", "entity1": "pilocarpine", "entity2": "epilepsy", "span1": [92, 103], "span2": [72, 80]}, "bert_text": "Investigation of mitochondrial involvement in the experimental model of epilepsy induced by <e1> pilocarpine </e1> <e2> epilepsy </e2> induced by pilocarpine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7976": {"data": {"text": "BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.", "entity1": "oral contraceptives", "entity2": "myocardial infarction", "span1": [46, 65], "span2": [82, 103]}, "bert_text": "BACKGROUND: An association between the use of <e1> oral contraceptives </e1> and the risk of <e2> myocardial infarction </e2> has been found in some, but not all, studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"7977": {"data": {"text": "Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.", "entity1": "alcohol", "entity2": "pain", "span1": [107, 114], "span2": [35, 39]}, "bert_text": "Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high <e1> alcohol </e1> <e2> pain </e2> and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7978": {"data": {"text": "Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.", "entity1": "alcohol", "entity2": "pain", "span1": [107, 114], "span2": [83, 87]}, "bert_text": "Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high <e1> alcohol </e1> <e2> pain </e2> admitted to a high alcohol intake, which might be a contributing factor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7979": {"data": {"text": "The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously.", "entity1": "sodium", "entity2": "proteinuria", "span1": [24, 30], "span2": [63, 74]}, "bert_text": "The kinetics of urinary <e1> sodium </e1> excretion and the appearance of <e2> proteinuria </e2> were comparable with those reported previously.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7980": {"data": {"text": "The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.\n1.", "entity1": "streptozotocin", "entity2": "diabetes mellitus", "span1": [105, 119], "span2": [128, 145]}, "bert_text": "The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by <e1> streptozotocin </e1>-induced <e2> diabetes mellitus </e2>.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7981": {"data": {"text": "The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin-diabetic rats were investigated.", "entity1": "streptozotocin", "entity2": "diabetic", "span1": [85, 99], "span2": [100, 108]}, "bert_text": "The effects of insulin treatment on in vivo and in vitro urinary bladder function in <e1> streptozotocin </e1>-<e2> diabetic </e2> rats were investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7982": {"data": {"text": "The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.", "entity1": "diltiazem", "entity2": "tetany", "span1": [117, 126], "span2": [62, 68]}, "bert_text": "The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous <e1> diltiazem </e1> <e2> tetany </e2> may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7983": {"data": {"text": "The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.", "entity1": "calcium chloride", "entity2": "tetany", "span1": [136, 152], "span2": [62, 68]}, "bert_text": "The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that <e1> calcium chloride </e1> <e2> tetany </e2> may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7984": {"data": {"text": "In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/-", "entity1": "nitrendipine", "entity2": "albuminuria", "span1": [20, 32], "span2": [47, 58]}, "bert_text": "In contrast, in the <e1> nitrendipine </e1>-treated group <e2> albuminuria </e2> increased from 12.8 +/-", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7985": {"data": {"text": "Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside-induced hypotension.\n", "entity1": "nitroprusside", "entity2": "hypotension", "span1": [60, 73], "span2": [82, 93]}, "bert_text": "Pulmonary shunt and cardiovascular responses to CPAP during <e1> nitroprusside </e1>-induced <e2> hypotension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7986": {"data": {"text": "RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.", "entity1": "clonidine", "entity2": "bradycardia", "span1": [75, 84], "span2": [38, 49]}, "bert_text": "RESULTS: There were more incidents of bradycardia in subjects treated with <e1> clonidine </e1> <e2> bradycardia </e2> in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7987": {"data": {"text": "RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.", "entity1": "clonidine", "entity2": "bradycardia", "span1": [122, 131], "span2": [38, 49]}, "bert_text": "RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with <e1> clonidine </e1> <e2> bradycardia </e2> in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7988": {"data": {"text": "Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).", "entity1": "fentanyl", "entity2": "muscular rigidity", "span1": [88, 96], "span2": [8, 25]}, "bert_text": "Whereas muscular rigidity is a well-known side effect that is associated with high-dose <e1> fentanyl </e1> <e2> muscular rigidity </e2> is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7989": {"data": {"text": "Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.", "entity1": "fluoxetine", "entity2": "adenomyosis", "span1": [99, 109], "span2": [42, 53]}, "bert_text": "Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving <e1> fluoxetine </e1> <e2> adenomyosis </e2>, all within the noncastrated group receiving fluoxetine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7990": {"data": {"text": "Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.", "entity1": "appetite suppressant", "entity2": "Primary pulmonary hypertension", "span1": [122, 142], "span2": [0, 30]}, "bert_text": "Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of <e1> appetite suppressant </e1> <e2> Primary pulmonary hypertension </e2> is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7991": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "progestagen", "entity2": "myocardial infarction", "span1": [59, 70], "span2": [424, 445]}, "bert_text": "We investigated this association, according to the type of <e1> progestagen </e1> included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7992": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "progestagen", "entity2": "myocardial infarction", "span1": [59, 70], "span2": [508, 529]}, "bert_text": "We investigated this association, according to the type of <e1> progestagen </e1> included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7993": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "desogestrel", "entity2": "myocardial infarction", "span1": [107, 118], "span2": [424, 445]}, "bert_text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., <e1> desogestrel </e1> or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7994": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "desogestrel", "entity2": "myocardial infarction", "span1": [107, 118], "span2": [508, 529]}, "bert_text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., <e1> desogestrel </e1> or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7995": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "gestodene", "entity2": "myocardial infarction", "span1": [122, 131], "span2": [424, 445]}, "bert_text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or <e1> gestodene </e1>) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7996": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "gestodene", "entity2": "myocardial infarction", "span1": [122, 131], "span2": [508, 529]}, "bert_text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or <e1> gestodene </e1>) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7997": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "levonorgestrel", "entity2": "myocardial infarction", "span1": [162, 176], "span2": [424, 445]}, "bert_text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., <e1> levonorgestrel </e1>) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"7998": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "levonorgestrel", "entity2": "myocardial infarction", "span1": [162, 176], "span2": [508, 529]}, "bert_text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., <e1> levonorgestrel </e1>) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"7999": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "oral contraceptives", "entity2": "myocardial infarction", "span1": [178, 197], "span2": [424, 445]}, "bert_text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) <e1> oral contraceptives </e1>, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8000": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "oral contraceptives", "entity2": "myocardial infarction", "span1": [178, 197], "span2": [508, 529]}, "bert_text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) <e1> oral contraceptives </e1>, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"8001": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "estrogen", "entity2": "myocardial infarction", "span1": [211, 219], "span2": [424, 445]}, "bert_text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of <e1> estrogen </e1>, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first <e2> myocardial infarction </e2> between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8002": {"data": {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity1": "estrogen", "entity2": "myocardial infarction", "span1": [211, 219], "span2": [508, 529]}, "bert_text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of <e1> estrogen </e1>, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a <e2> myocardial infarction </e2> and who were matched for age, calendar year of the index event, and area of residence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"8003": {"data": {"text": "We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.", "entity1": "mitomycin C", "entity2": "gastric adenocarcinoma", "span1": [178, 189], "span2": [82, 104]}, "bert_text": "We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with <e1> mitomycin C </e1> <e2> gastric adenocarcinoma </e2> who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8004": {"data": {"text": "We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.", "entity1": "mitomycin C", "entity2": "renal failure", "span1": [178, 189], "span2": [119, 132]}, "bert_text": "We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with <e1> mitomycin C </e1> <e2> renal failure </e2> and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8005": {"data": {"text": "We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.", "entity1": "mitomycin C", "entity2": "thrombocytopenia", "span1": [178, 189], "span2": [137, 153]}, "bert_text": "We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with <e1> mitomycin C </e1> <e2> thrombocytopenia </e2> while on treatment with mitomycin C and died in pulmonary edema.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8006": {"data": {"text": "We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.", "entity1": "mitomycin C", "entity2": "pulmonary edema", "span1": [178, 189], "span2": [202, 217]}, "bert_text": "We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with <e1> mitomycin C </e1> and died in <e2> pulmonary edema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8007": {"data": {"text": "However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.", "entity1": "creatinine", "entity2": "CRF", "span1": [30, 40], "span2": [115, 118]}, "bert_text": "However, an increase of serum <e1> creatinine </e1> at various times postoperatively is more predictive of the development of <e2> CRF </e2> or ESRD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8008": {"data": {"text": "However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.", "entity1": "creatinine", "entity2": "ESRD", "span1": [30, 40], "span2": [122, 126]}, "bert_text": "However, an increase of serum <e1> creatinine </e1> at various times postoperatively is more predictive of the development of CRF or <e2> ESRD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8009": {"data": {"text": "The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.", "entity1": "amines", "entity2": "behavioral depression", "span1": [42, 48], "span2": [254, 275]}, "bert_text": "The biochemical results of brain biogenic <e1> amines </e1> of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a <e2> behavioral depression </e2> caused by amantadine in the BALB/C mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8010": {"data": {"text": "The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.", "entity1": "catecholamine", "entity2": "behavioral depression", "span1": [103, 116], "span2": [254, 275]}, "bert_text": "The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of <e1> catecholamine </e1> turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a <e2> behavioral depression </e2> caused by amantadine in the BALB/C mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8011": {"data": {"text": "The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.", "entity1": "norepinephrine", "entity2": "behavioral depression", "span1": [215, 229], "span2": [254, 275]}, "bert_text": "The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of <e1> norepinephrine </e1> which may account for a <e2> behavioral depression </e2> caused by amantadine in the BALB/C mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8012": {"data": {"text": "The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.", "entity1": "amantadine", "entity2": "behavioral depression", "span1": [286, 296], "span2": [254, 275]}, "bert_text": "The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by <e1> amantadine </e1> <e2> behavioral depression </e2> caused by amantadine in the BALB/C mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8013": {"data": {"text": "Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.", "entity1": "corticosteroids", "entity2": "cataracts", "span1": [26, 41], "span2": [118, 127]}, "bert_text": "Systemically administered <e1> corticosteroids </e1> were used in 75 of 210 cases; a significant number of posterior subcapsular <e2> cataracts </e2> was found.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8014": {"data": {"text": "The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.", "entity1": "nitrazepam", "entity2": "overdose", "span1": [17, 27], "span2": [28, 36]}, "bert_text": "The patient with <e1> nitrazepam </e1> <e2> overdose </e2> and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8015": {"data": {"text": "The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.", "entity1": "nitrazepam", "entity2": "coma", "span1": [17, 27], "span2": [124, 128]}, "bert_text": "The patient with <e1> nitrazepam </e1> overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha <e2> coma </e2>', showing non-reactive generalized or frontally predominant alpha activity in the EEG.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8016": {"data": {"text": "The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.", "entity1": "chlormethiazole", "entity2": "overdose", "span1": [59, 74], "span2": [28, 36]}, "bert_text": "The patient with nitrazepam overdose and two of those with <e1> chlormethiazole </e1> <e2> overdose </e2> and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8017": {"data": {"text": "The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.", "entity1": "chlormethiazole", "entity2": "coma", "span1": [59, 74], "span2": [124, 128]}, "bert_text": "The patient with nitrazepam overdose and two of those with <e1> chlormethiazole </e1> intoxication conformed to the criteria of 'alpha <e2> coma </e2>', showing non-reactive generalized or frontally predominant alpha activity in the EEG.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8018": {"data": {"text": "The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).", "entity1": "isoproterenol", "entity2": "cardiac hypertrophy", "span1": [122, 135], "span2": [19, 38]}, "bert_text": "The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of <e1> isoproterenol </e1> <e2> cardiac hypertrophy </e2> was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8019": {"data": {"text": "The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).", "entity1": "ISO", "entity2": "cardiac hypertrophy", "span1": [137, 140], "span2": [19, 38]}, "bert_text": "The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (<e1> ISO </e1> <e2> cardiac hypertrophy </e2> was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8020": {"data": {"text": "Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.", "entity1": "verapamil", "entity2": "cardiogenic shock", "span1": [60, 69], "span2": [11, 28]}, "bert_text": "Refractory cardiogenic shock and complete heart block after <e1> verapamil </e1> <e2> cardiogenic shock </e2> and complete heart block after verapamil SR and metoprolol treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8021": {"data": {"text": "Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.", "entity1": "verapamil", "entity2": "heart block", "span1": [60, 69], "span2": [42, 53]}, "bert_text": "Refractory cardiogenic shock and complete heart block after <e1> verapamil </e1> <e2> heart block </e2> after verapamil SR and metoprolol treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8022": {"data": {"text": "Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.", "entity1": "metoprolol", "entity2": "cardiogenic shock", "span1": [77, 87], "span2": [11, 28]}, "bert_text": "Refractory cardiogenic shock and complete heart block after verapamil SR and <e1> metoprolol </e1> <e2> cardiogenic shock </e2> and complete heart block after verapamil SR and metoprolol treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8023": {"data": {"text": "Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.", "entity1": "metoprolol", "entity2": "heart block", "span1": [77, 87], "span2": [42, 53]}, "bert_text": "Refractory cardiogenic shock and complete heart block after verapamil SR and <e1> metoprolol </e1> <e2> heart block </e2> after verapamil SR and metoprolol treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8024": {"data": {"text": "Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.\n", "entity1": "5-fluorouracil", "entity2": "confusion", "span1": [51, 65], "span2": [6, 15]}, "bert_text": "Acute confusion induced by a high-dose infusion of <e1> 5-fluorouracil </e1> <e2> confusion </e2> induced by a high-dose infusion of 5-fluorouracil and folinic acid.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8025": {"data": {"text": "Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.\n", "entity1": "folinic acid", "entity2": "confusion", "span1": [70, 82], "span2": [6, 15]}, "bert_text": "Acute confusion induced by a high-dose infusion of 5-fluorouracil and <e1> folinic acid </e1> <e2> confusion </e2> induced by a high-dose infusion of 5-fluorouracil and folinic acid.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8026": {"data": {"text": "Topiramate-induced nephrolithiasis.\n", "entity1": "Topiramate", "entity2": "nephrolithiasis", "span1": [0, 10], "span2": [19, 34]}, "bert_text": "<e1> Topiramate </e1>-induced <e2> nephrolithiasis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8027": {"data": {"text": "A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.", "entity1": "amiodarone", "entity2": "sinuatrial disease", "span1": [75, 85], "span2": [15, 33]}, "bert_text": "A patient with sinuatrial disease and implanted pacemaker was treated with <e1> amiodarone </e1> <e2> sinuatrial disease </e2> and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8028": {"data": {"text": "A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.", "entity1": "amiodarone", "entity2": "supraventricular tachyarrhythmias", "span1": [75, 85], "span2": [170, 203]}, "bert_text": "A patient with sinuatrial disease and implanted pacemaker was treated with <e1> amiodarone </e1> (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of <e2> supraventricular tachyarrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8029": {"data": {"text": "Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.\n", "entity1": "diltiazem", "entity2": "tetany", "span1": [35, 44], "span2": [53, 59]}, "bert_text": "Rapid reversal of life-threatening <e1> diltiazem </e1>-induced <e2> tetany </e2> with calcium chloride.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8030": {"data": {"text": "Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.\n", "entity1": "calcium chloride", "entity2": "tetany", "span1": [65, 81], "span2": [53, 59]}, "bert_text": "Rapid reversal of life-threatening diltiazem-induced tetany with <e1> calcium chloride </e1> <e2> tetany </e2> with calcium chloride.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8031": {"data": {"text": "Randomized, double-blind trial of mazindol in Duchenne dystrophy.\n", "entity1": "mazindol", "entity2": "Duchenne dystrophy", "span1": [34, 42], "span2": [46, 64]}, "bert_text": "Randomized, double-blind trial of <e1> mazindol </e1> in <e2> Duchenne dystrophy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8032": {"data": {"text": "However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.", "entity1": "RAPA", "entity2": "Pneumocystis carinii pneumonia", "span1": [37, 41], "span2": [133, 163]}, "bert_text": "However, when converting patients to <e1> RAPA </e1> drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and <e2> Pneumocystis carinii pneumonia </e2> prophylaxis should be given.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8033": {"data": {"text": "Due to severe systolic dysfunction losartan was prescribed.", "entity1": "losartan", "entity2": "systolic dysfunction", "span1": [35, 43], "span2": [14, 34]}, "bert_text": "Due to severe systolic dysfunction <e1> losartan </e1> <e2> systolic dysfunction </e2> losartan was prescribed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8034": {"data": {"text": "Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).", "entity1": "ZDV", "entity2": "human immunodeficiency virus (HIV)-infected", "span1": [132, 135], "span2": [13, 56]}, "bert_text": "Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either <e1> ZDV </e1> <e2> human immunodeficiency virus (HIV)-infected </e2> patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8035": {"data": {"text": "Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).", "entity1": "folinic acid", "entity2": "human immunodeficiency virus (HIV)-infected", "span1": [198, 210], "span2": [13, 56]}, "bert_text": "Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with <e1> folinic acid </e1> <e2> human immunodeficiency virus (HIV)-infected </e2> patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8036": {"data": {"text": "Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).", "entity1": "vitamin B12", "entity2": "human immunodeficiency virus (HIV)-infected", "span1": [243, 254], "span2": [13, 56]}, "bert_text": "Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular <e1> vitamin B12 </e1> <e2> human immunodeficiency virus (HIV)-infected </e2> patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8037": {"data": {"text": "Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.", "entity1": "Valproate", "entity2": "homonymous hemianopsia", "span1": [226, 235], "span2": [60, 82]}, "bert_text": "Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with <e1> Valproate </e1> <e2> homonymous hemianopsia </e2> after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8038": {"data": {"text": "From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.", "entity1": "mangiferin", "entity2": "MI", "span1": [44, 54], "span2": [103, 105]}, "bert_text": "From the present study it is concluded that <e1> mangiferin </e1> exerts a beneficial effect against ISPH-induced <e2> MI </e2> due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8039": {"data": {"text": "From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.", "entity1": "mangiferin", "entity2": "cardiac damage", "span1": [44, 54], "span2": [191, 205]}, "bert_text": "From the present study it is concluded that <e1> mangiferin </e1> exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against <e2> cardiac damage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8040": {"data": {"text": "From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.", "entity1": "ISPH", "entity2": "MI", "span1": [90, 94], "span2": [103, 105]}, "bert_text": "From the present study it is concluded that mangiferin exerts a beneficial effect against <e1> ISPH </e1>-induced <e2> MI </e2> due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8041": {"data": {"text": "From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.", "entity1": "ISPH", "entity2": "cardiac damage", "span1": [90, 94], "span2": [191, 205]}, "bert_text": "From the present study it is concluded that mangiferin exerts a beneficial effect against <e1> ISPH </e1>-induced MI due to its antioxidant potential, which regulated the tissues defense system against <e2> cardiac damage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8042": {"data": {"text": "Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.\n", "entity1": "carbimazole", "entity2": "Toxic hepatitis", "span1": [101, 112], "span2": [0, 15]}, "bert_text": "Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between <e1> carbimazole </e1> <e2> Toxic hepatitis </e2> induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8043": {"data": {"text": "Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.\n", "entity1": "benzylthiouracil", "entity2": "Toxic hepatitis", "span1": [117, 133], "span2": [0, 15]}, "bert_text": "Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and <e1> benzylthiouracil </e1> <e2> Toxic hepatitis </e2> induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8044": {"data": {"text": "On two paradoxical side-effects of prednisolone in rats, ribosomal RNA biosyntheses, and a mechanism of action.\nLiver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.", "entity1": "prednisolone", "entity2": "Liver enlargement", "span1": [35, 47], "span2": [112, 129]}, "bert_text": "On two paradoxical side-effects of <e1> prednisolone </e1> in rats, ribosomal RNA biosyntheses, and a mechanism of action.\n<e2> Liver enlargement </e2> and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8045": {"data": {"text": "On two paradoxical side-effects of prednisolone in rats, ribosomal RNA biosyntheses, and a mechanism of action.\nLiver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.", "entity1": "prednisolone", "entity2": "Liver enlargement", "span1": [218, 230], "span2": [112, 129]}, "bert_text": "On two paradoxical side-effects of prednisolone in rats, ribosomal RNA biosyntheses, and a mechanism of action.\nLiver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of <e1> prednisolone </e1> <e2> Liver enlargement </e2> and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8046": {"data": {"text": "CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.", "entity1": "EMB", "entity2": "optic neuropathy", "span1": [52, 55], "span2": [64, 80]}, "bert_text": "CONCLUSIONS: The OCT results in these patients with <e1> EMB </e1>-induced <e2> optic neuropathy </e2> show considerable loss especially of the temporal fibers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8047": {"data": {"text": "METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose.", "entity1": "calcium", "entity2": "overdose", "span1": [103, 110], "span2": [127, 135]}, "bert_text": "METHODS: Two interventions were studied that have been shown previously to improve blood pressure with <e1> calcium </e1> channel blocker <e2> overdose </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8048": {"data": {"text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "entity1": "VPA", "entity2": "haemorrhagic pancreatitis", "span1": [117, 120], "span2": [65, 90]}, "bert_text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, <e1> VPA </e1> <e2> haemorrhagic pancreatitis </e2>, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8049": {"data": {"text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "entity1": "VPA", "entity2": "bone marrow suppression", "span1": [117, 120], "span2": [92, 115]}, "bert_text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, <e1> VPA </e1> <e2> bone marrow suppression </e2>, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8050": {"data": {"text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "entity1": "VPA", "entity2": "hepatotoxicity", "span1": [117, 120], "span2": [129, 143]}, "bert_text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, <e1> VPA </e1>-induced <e2> hepatotoxicity </e2> and VPA-induced encephalopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8051": {"data": {"text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "entity1": "VPA", "entity2": "encephalopathy", "span1": [117, 120], "span2": [160, 174]}, "bert_text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, <e1> VPA </e1>-induced hepatotoxicity and VPA-induced <e2> encephalopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8052": {"data": {"text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "entity1": "VPA", "entity2": "haemorrhagic pancreatitis", "span1": [148, 151], "span2": [65, 90]}, "bert_text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and <e1> VPA </e1> <e2> haemorrhagic pancreatitis </e2>, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8053": {"data": {"text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "entity1": "VPA", "entity2": "bone marrow suppression", "span1": [148, 151], "span2": [92, 115]}, "bert_text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and <e1> VPA </e1> <e2> bone marrow suppression </e2>, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8054": {"data": {"text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "entity1": "VPA", "entity2": "hepatotoxicity", "span1": [148, 151], "span2": [129, 143]}, "bert_text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and <e1> VPA </e1> <e2> hepatotoxicity </e2> and VPA-induced encephalopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8055": {"data": {"text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "entity1": "VPA", "entity2": "encephalopathy", "span1": [148, 151], "span2": [160, 174]}, "bert_text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and <e1> VPA </e1>-induced <e2> encephalopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8056": {"data": {"text": "After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.", "entity1": "octreotide", "entity2": "gallstones", "span1": [20, 30], "span2": [54, 64]}, "bert_text": "After withdrawal of <e1> octreotide </e1> in 10 patients without <e2> gallstones </e2>, 8 patients assessed had return of normal gallbladder contractility within 1 month.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8057": {"data": {"text": "The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.", "entity1": "pegylated interferon", "entity2": "HCV infection", "span1": [73, 93], "span2": [31, 44]}, "bert_text": "The current best treatment for HCV infection is combination therapy with <e1> pegylated interferon </e1> <e2> HCV infection </e2> is combination therapy with pegylated interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"8058": {"data": {"text": "The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.", "entity1": "ribavirin", "entity2": "HCV infection", "span1": [98, 107], "span2": [31, 44]}, "bert_text": "The current best treatment for HCV infection is combination therapy with pegylated interferon and <e1> ribavirin </e1> <e2> HCV infection </e2> is combination therapy with pegylated interferon and ribavirin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"8059": {"data": {"text": "The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.", "entity1": "cocaine", "entity2": "stroke", "span1": [11, 18], "span2": [66, 72]}, "bert_text": "The use of <e1> cocaine </e1> and/or amphetamine is a strong risk factor for <e2> stroke </e2> in this socioeconomically heterogeneous, insured urban population.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8060": {"data": {"text": "The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.", "entity1": "amphetamine", "entity2": "stroke", "span1": [26, 37], "span2": [66, 72]}, "bert_text": "The use of cocaine and/or <e1> amphetamine </e1> is a strong risk factor for <e2> stroke </e2> in this socioeconomically heterogeneous, insured urban population.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8061": {"data": {"text": "At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.", "entity1": "calcium", "entity2": "CM", "span1": [197, 204], "span2": [118, 120]}, "bert_text": "At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic <e1> calcium </e1> <e2> CM </e2> (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8062": {"data": {"text": "At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.", "entity1": "LA", "entity2": "CM", "span1": [251, 253], "span2": [118, 120]}, "bert_text": "At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma <e1> LA </e1> <e2> CM </e2> (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8063": {"data": {"text": "Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.\n", "entity1": "vigabatrin", "entity2": "visual field constriction", "span1": [120, 130], "span2": [142, 167]}, "bert_text": "Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with <e1> vigabatrin </e1>-attributed <e2> visual field constriction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8064": {"data": {"text": "Effect of converting enzyme inhibition on the course of adriamycin-induced nephropathy.\n", "entity1": "adriamycin", "entity2": "nephropathy", "span1": [56, 66], "span2": [75, 86]}, "bert_text": "Effect of converting enzyme inhibition on the course of <e1> adriamycin </e1>-induced <e2> nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8065": {"data": {"text": "Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months. Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.", "entity1": "testosterone", "entity2": "prostate cancer", "span1": [34, 46], "span2": [154, 169]}, "bert_text": "Preliminary results indicate that <e1> testosterone </e1>-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed <e2> prostate cancer </e2> after intervals of 6-12 months. Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8066": {"data": {"text": "Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months. Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.", "entity1": "testosterone", "entity2": "prostate cancer", "span1": [34, 46], "span2": [254, 269]}, "bert_text": "Preliminary results indicate that <e1> testosterone </e1>-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months. Aged GF Sprague-Dawley (SD) rats have not developed <e2> prostate cancer </e2> spontaneously.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"8067": {"data": {"text": "CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.", "entity1": "Verapamil", "entity2": "AF", "span1": [13, 22], "span2": [32, 34]}, "bert_text": "CONCLUSIONS: <e1> Verapamil </e1> promotes <e2> AF </e2> in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8068": {"data": {"text": "CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.", "entity1": "diltiazem", "entity2": "AF", "span1": [152, 161], "span2": [32, 34]}, "bert_text": "CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by <e1> diltiazem </e1> <e2> AF </e2> in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8069": {"data": {"text": "Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.\n", "entity1": "Dobutamine", "entity2": "cancer", "span1": [0, 10], "span2": [161, 167]}, "bert_text": "<e1> Dobutamine </e1> stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood <e2> cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8070": {"data": {"text": "Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.\n", "entity1": "doxorubicin", "entity2": "cancer", "span1": [108, 119], "span2": [161, 167]}, "bert_text": "Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic <e1> doxorubicin </e1>-treated long-term survivors of childhood <e2> cancer </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8071": {"data": {"text": "FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.", "entity1": "tAMCA", "entity2": "convulsive", "span1": [24, 29], "span2": [98, 108]}, "bert_text": "FINDINGS: FS containing <e1> tAMCA </e1> caused paroxysmal brain activity which was associated with distinct <e2> convulsive </e2> behaviours.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8072": {"data": {"text": "Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.", "entity1": "levodopa", "entity2": "gastrointestinal disorders", "span1": [93, 101], "span2": [40, 66]}, "bert_text": "Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, <e1> levodopa </e1> <e2> gastrointestinal disorders </e2>, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8073": {"data": {"text": "Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.", "entity1": "levodopa", "entity2": "orthostatic hypotension", "span1": [93, 101], "span2": [68, 91]}, "bert_text": "Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, <e1> levodopa </e1> <e2> orthostatic hypotension </e2>, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8074": {"data": {"text": "Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.", "entity1": "levodopa", "entity2": "psychosis", "span1": [93, 101], "span2": [110, 119]}, "bert_text": "Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, <e1> levodopa </e1>-induced <e2> psychosis </e2>, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"8075": {"data": {"text": "Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.", "entity1": "levodopa", "entity2": "sleep disturbances", "span1": [93, 101], "span2": [121, 139]}, "bert_text": "Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, <e1> levodopa </e1>-induced psychosis, <e2> sleep disturbances </e2> or parasomnias, or drug interactions--also require carefully monitored individual treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"8076": {"data": {"text": "Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.", "entity1": "levodopa", "entity2": "parasomnias", "span1": [93, 101], "span2": [143, 154]}, "bert_text": "Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, <e1> levodopa </e1>-induced psychosis, sleep disturbances or <e2> parasomnias </e2>, or drug interactions--also require carefully monitored individual treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"8077": {"data": {"text": "Clonidine for attention-deficit/hyperactivity disorder: II.", "entity1": "Clonidine", "entity2": "attention-deficit/hyperactivity disorder", "span1": [0, 9], "span2": [14, 54]}, "bert_text": "<e1> Clonidine </e1> for <e2> attention-deficit/hyperactivity disorder </e2>: II.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8078": {"data": {"text": "Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.\n", "entity1": "oral contraceptives", "entity2": "venous thromboembolism", "span1": [23, 42], "span2": [59, 81]}, "bert_text": "Recurrent use of newer <e1> oral contraceptives </e1> and the risk of <e2> venous thromboembolism </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8079": {"data": {"text": "Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.", "entity1": "gabapentin", "entity2": "hyperalgesia", "span1": [88, 98], "span2": [233, 245]}, "bert_text": "Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the <e1> gabapentin </e1>-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary <e2> hyperalgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8080": {"data": {"text": "Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [205, 214], "span2": [233, 245]}, "bert_text": "Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and <e1> capsaicin </e1>-induced secondary <e2> hyperalgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8081": {"data": {"text": "Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.", "entity1": "warfarin", "entity2": "stroke", "span1": [88, 96], "span2": [117, 123]}, "bert_text": "Pooled data from trials comparing antithrombotic treatment with placebo have shown that <e1> warfarin </e1> reduces the risk of <e2> stroke </e2> by 62%, and that aspirin alone reduces the risk by 22%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8082": {"data": {"text": "Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.", "entity1": "aspirin", "entity2": "stroke", "span1": [141, 148], "span2": [117, 123]}, "bert_text": "Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that <e1> aspirin </e1> <e2> stroke </e2> by 62%, and that aspirin alone reduces the risk by 22%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"8083": {"data": {"text": "We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.", "entity1": "carboplatin", "entity2": "embryonal rhabdomyosarcoma", "span1": [63, 74], "span2": [104, 130]}, "bert_text": "We report a 4 1/2-year-old girl who was treated with high-dose <e1> carboplatin </e1> for metastatic parameningeal <e2> embryonal rhabdomyosarcoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8084": {"data": {"text": "Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v.", "entity1": "xenon-133", "entity2": "subarachnoid haemorrhage", "span1": [143, 152], "span2": [54, 78]}, "bert_text": "Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using <e1> xenon-133 </e1> <e2> subarachnoid haemorrhage </e2> by a modification of the classical Kety-Schmidt technique using xenon-133 i.v.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8085": {"data": {"text": "Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.", "entity1": "prostaglandin E2-induced", "entity2": "hyperalgesia", "span1": [116, 140], "span2": [141, 153]}, "bert_text": "Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of <e1> prostaglandin E2-induced </e1> <e2> hyperalgesia </e2>.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8086": {"data": {"text": "We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.", "entity1": "TPP", "entity2": "diabetic", "span1": [175, 178], "span2": [57, 65]}, "bert_text": "We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for <e1> TPP </e1> <e2> diabetic </e2> kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8087": {"data": {"text": "We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.", "entity1": "TPP", "entity2": "Wernicke's encephalopathy", "span1": [175, 178], "span2": [94, 119]}, "bert_text": "We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for <e1> TPP </e1> <e2> Wernicke's encephalopathy </e2> had abnormal transketolase as determined by its Km for TPP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"8088": {"data": {"text": "Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.\n", "entity1": "fusidic acid", "entity2": "Crohn's disease", "span1": [34, 46], "span2": [13, 28]}, "bert_text": "Treatment of Crohn's disease with <e1> fusidic acid </e1> <e2> Crohn's disease </e2> with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"8089": {"data": {"text": "Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.\n", "entity1": "cyclosporin", "entity2": "Crohn's disease", "span1": [107, 118], "span2": [13, 28]}, "bert_text": "Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to <e1> cyclosporin </e1> <e2> Crohn's disease </e2> with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"8090": {"data": {"text": "The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.", "entity1": "VPA", "entity2": "encephalopathy", "span1": [21, 24], "span2": [33, 47]}, "bert_text": "The typical signs of <e1> VPA </e1>-induced <e2> encephalopathy </e2> are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8091": {"data": {"text": "The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.", "entity1": "VPA", "entity2": "impaired consciousness", "span1": [21, 24], "span2": [52, 74]}, "bert_text": "The typical signs of <e1> VPA </e1>-induced encephalopathy are <e2> impaired consciousness </e2>, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8092": {"data": {"text": "The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.", "entity1": "VPA", "entity2": "seizure", "span1": [21, 24], "span2": [127, 134]}, "bert_text": "The typical signs of <e1> VPA </e1>-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased <e2> seizure </e2> frequency, with or without hyperammonemia.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8093": {"data": {"text": "The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.", "entity1": "VPA", "entity2": "hyperammonemia", "span1": [21, 24], "span2": [162, 176]}, "bert_text": "The typical signs of <e1> VPA </e1>-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without <e2> hyperammonemia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8094": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "isoflurane", "entity2": "hypotension", "span1": [42, 52], "span2": [61, 72]}, "bert_text": "Cerebral blood flow and metabolism during <e1> isoflurane </e1>-induced <e2> hypotension </e2> in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8095": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "isoflurane", "entity2": "hypotension", "span1": [42, 52], "span2": [229, 240]}, "bert_text": "Cerebral blood flow and metabolism during <e1> isoflurane </e1>-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced <e2> hypotension </e2> in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8096": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "isoflurane", "entity2": "cerebral aneurysms", "span1": [42, 52], "span2": [110, 128]}, "bert_text": "Cerebral blood flow and metabolism during <e1> isoflurane </e1>-induced hypotension in patients subjected to surgery for <e2> cerebral aneurysms </e2>.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8097": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "isoflurane", "entity2": "cerebral aneurysm", "span1": [42, 52], "span2": [298, 315]}, "bert_text": "Cerebral blood flow and metabolism during <e1> isoflurane </e1>-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a <e2> cerebral aneurysm </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8098": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "isoflurane", "entity2": "hypotension", "span1": [210, 220], "span2": [61, 72]}, "bert_text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during <e1> isoflurane </e1> <e2> hypotension </e2> in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"8099": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "isoflurane", "entity2": "hypotension", "span1": [210, 220], "span2": [229, 240]}, "bert_text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during <e1> isoflurane </e1>-induced <e2> hypotension </e2> in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"8100": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "isoflurane", "entity2": "cerebral aneurysms", "span1": [210, 220], "span2": [110, 128]}, "bert_text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during <e1> isoflurane </e1> <e2> cerebral aneurysms </e2>.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"8101": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "isoflurane", "entity2": "cerebral aneurysm", "span1": [210, 220], "span2": [298, 315]}, "bert_text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during <e1> isoflurane </e1>-induced hypotension in 10 patients subjected to craniotomy for clipping of a <e2> cerebral aneurysm </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"8102": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "oxygen", "entity2": "hypotension", "span1": [182, 188], "span2": [61, 72]}, "bert_text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for <e1> oxygen </e1> <e2> hypotension </e2> in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8103": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "oxygen", "entity2": "hypotension", "span1": [182, 188], "span2": [229, 240]}, "bert_text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for <e1> oxygen </e1> were measured during isoflurane-induced <e2> hypotension </e2> in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8104": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "oxygen", "entity2": "cerebral aneurysms", "span1": [182, 188], "span2": [110, 128]}, "bert_text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for <e1> oxygen </e1> <e2> cerebral aneurysms </e2>.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8105": {"data": {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity1": "oxygen", "entity2": "cerebral aneurysm", "span1": [182, 188], "span2": [298, 315]}, "bert_text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.\nCerebral blood flow and cerebral metabolic rate for <e1> oxygen </e1> were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a <e2> cerebral aneurysm </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8106": {"data": {"text": "This report describes a case of cognitive deterioration resulting from prolonged use of DM.", "entity1": "DM", "entity2": "cognitive deterioration", "span1": [88, 90], "span2": [32, 55]}, "bert_text": "This report describes a case of cognitive deterioration resulting from prolonged use of <e1> DM </e1> <e2> cognitive deterioration </e2> resulting from prolonged use of DM.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8107": {"data": {"text": "Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.", "entity1": "Catecholamine", "entity2": "cardiomyopathy", "span1": [0, 13], "span2": [22, 36]}, "bert_text": "<e1> Catecholamine </e1>-induced <e2> cardiomyopathy </e2> due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8108": {"data": {"text": "Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.", "entity1": "catecholamines", "entity2": "cardiomyopathy", "span1": [73, 87], "span2": [22, 36]}, "bert_text": "Catecholamine-induced cardiomyopathy due to chronic excess of endogenous <e1> catecholamines </e1> <e2> cardiomyopathy </e2> due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8109": {"data": {"text": "We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity.", "entity1": "citrate", "entity2": "hypocalcemia", "span1": [161, 168], "span2": [93, 105]}, "bert_text": "We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to <e1> citrate </e1> <e2> hypocalcemia </e2> is recommended to help prevent severe reactions due to citrate toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8110": {"data": {"text": "We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity.", "entity1": "citrate", "entity2": "toxicity", "span1": [161, 168], "span2": [169, 177]}, "bert_text": "We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to <e1> citrate </e1> <e2> toxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8111": {"data": {"text": "Antidepressant-induced mania in bipolar patients: identification of risk factors.\n", "entity1": "Antidepressant", "entity2": "mania", "span1": [0, 14], "span2": [23, 28]}, "bert_text": "<e1> Antidepressant </e1>-induced <e2> mania </e2> in bipolar patients: identification of risk factors.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8112": {"data": {"text": "Antidepressant-induced mania in bipolar patients: identification of risk factors.\n", "entity1": "Antidepressant", "entity2": "bipolar", "span1": [0, 14], "span2": [32, 39]}, "bert_text": "<e1> Antidepressant </e1>-induced mania in <e2> bipolar </e2> patients: identification of risk factors.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8113": {"data": {"text": "To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [55, 62], "span2": [71, 87]}, "bert_text": "To avoid disastrous outcomes, physicians must consider <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8114": {"data": {"text": "To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.", "entity1": "heparin", "entity2": "thromboembolism", "span1": [55, 62], "span2": [142, 157]}, "bert_text": "To avoid disastrous outcomes, physicians must consider <e1> heparin </e1>-induced thrombocytopenia whenever a recently hospitalized patient returns with <e2> thromboembolism </e2>; therapy with alternative anticoagulants, not heparin, should be initiated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8115": {"data": {"text": "To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [204, 211], "span2": [71, 87]}, "bert_text": "To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not <e1> heparin </e1> <e2> thrombocytopenia </e2> whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8116": {"data": {"text": "To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.", "entity1": "heparin", "entity2": "thromboembolism", "span1": [204, 211], "span2": [142, 157]}, "bert_text": "To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not <e1> heparin </e1> <e2> thromboembolism </e2>; therapy with alternative anticoagulants, not heparin, should be initiated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8117": {"data": {"text": "BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.", "entity1": "antidepressants", "entity2": "mania", "span1": [80, 95], "span2": [58, 63]}, "bert_text": "BACKGROUND: Concerns about possible risks of switching to mania associated with <e1> antidepressants </e1> <e2> mania </e2> associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8118": {"data": {"text": "BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.", "entity1": "antidepressants", "entity2": "bipolar depression", "span1": [80, 95], "span2": [178, 196]}, "bert_text": "BACKGROUND: Concerns about possible risks of switching to mania associated with <e1> antidepressants </e1> continue to interfere with the establishment of an optimal treatment paradigm for <e2> bipolar depression </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 1},
+	"8119": {"data": {"text": "We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.", "entity1": "ouabain", "entity2": "coronary artery disease", "span1": [27, 34], "span2": [149, 172]}, "bert_text": "We assessed the effects of <e1> ouabain </e1> (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic <e2> coronary artery disease </e2> without clinical congestive heart failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8120": {"data": {"text": "We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.", "entity1": "ouabain", "entity2": "congestive heart failure", "span1": [27, 34], "span2": [190, 214]}, "bert_text": "We assessed the effects of <e1> ouabain </e1> (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical <e2> congestive heart failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8121": {"data": {"text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.", "entity1": "superoxide", "entity2": "MI", "span1": [45, 55], "span2": [272, 274]}, "bert_text": "The heart tissue antioxidant enzymes such as <e1> superoxide </e1> dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in <e2> MI </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8122": {"data": {"text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.", "entity1": "glutathione", "entity2": "MI", "span1": [77, 88], "span2": [272, 274]}, "bert_text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, <e1> glutathione </e1> peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in <e2> MI </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8123": {"data": {"text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.", "entity1": "glutathione", "entity2": "MI", "span1": [101, 112], "span2": [272, 274]}, "bert_text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, <e1> glutathione </e1> transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in <e2> MI </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8124": {"data": {"text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.", "entity1": "glutathione", "entity2": "MI", "span1": [129, 140], "span2": [272, 274]}, "bert_text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and <e1> glutathione </e1> reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in <e2> MI </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8125": {"data": {"text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.", "entity1": "glutathione", "entity2": "MI", "span1": [237, 248], "span2": [272, 274]}, "bert_text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and <e1> glutathione </e1> levels were altered in <e2> MI </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8126": {"data": {"text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.", "entity1": "Vitamin C", "entity2": "MI", "span1": [212, 221], "span2": [272, 274]}, "bert_text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, <e1> Vitamin C </e1>, Vitamin E and glutathione levels were altered in <e2> MI </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8127": {"data": {"text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.", "entity1": "Vitamin E", "entity2": "MI", "span1": [223, 232], "span2": [272, 274]}, "bert_text": "The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, <e1> Vitamin E </e1> and glutathione levels were altered in <e2> MI </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8128": {"data": {"text": "No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.", "entity1": "choline", "entity2": "hepatocellular carcinomas", "span1": [94, 101], "span2": [36, 61]}, "bert_text": "No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain <e1> choline </e1> <e2> hepatocellular carcinomas </e2> developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8129": {"data": {"text": "No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.", "entity1": "choline", "entity2": "hepatocellular carcinoma", "span1": [94, 101], "span2": [160, 184]}, "bert_text": "No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain <e1> choline </e1>-supplemented diet, while one preneoplastic nodule and one <e2> hepatocellular carcinoma </e2> developed in two rats fed the same diet containing phenobarbital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8130": {"data": {"text": "No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.", "entity1": "phenobarbital", "entity2": "hepatocellular carcinomas", "span1": [236, 249], "span2": [36, 61]}, "bert_text": "No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing <e1> phenobarbital </e1> <e2> hepatocellular carcinomas </e2> developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8131": {"data": {"text": "No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.", "entity1": "phenobarbital", "entity2": "hepatocellular carcinoma", "span1": [236, 249], "span2": [160, 184]}, "bert_text": "No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing <e1> phenobarbital </e1> <e2> hepatocellular carcinoma </e2> developed in two rats fed the same diet containing phenobarbital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8132": {"data": {"text": "AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.", "entity1": "AZT", "entity2": "macrocytic anemia", "span1": [0, 3], "span2": [18, 35]}, "bert_text": "<e1> AZT </e1> has induced a <e2> macrocytic anemia </e2> in AIDS patients on long term AZT therapy.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8133": {"data": {"text": "AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.", "entity1": "AZT", "entity2": "AIDS", "span1": [0, 3], "span2": [39, 43]}, "bert_text": "<e1> AZT </e1> has induced a macrocytic anemia in <e2> AIDS </e2> patients on long term AZT therapy.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8134": {"data": {"text": "AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.", "entity1": "AZT", "entity2": "macrocytic anemia", "span1": [66, 69], "span2": [18, 35]}, "bert_text": "AZT has induced a macrocytic anemia in AIDS patients on long term <e1> AZT </e1> <e2> macrocytic anemia </e2> in AIDS patients on long term AZT therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8135": {"data": {"text": "AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.", "entity1": "AZT", "entity2": "AIDS", "span1": [66, 69], "span2": [39, 43]}, "bert_text": "AZT has induced a macrocytic anemia in AIDS patients on long term <e1> AZT </e1> <e2> AIDS </e2> patients on long term AZT therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8136": {"data": {"text": "CONCLUSIONS: Delayed-onset heparin-induced thrombocytopenia is increasingly being recognized.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [27, 34], "span2": [43, 59]}, "bert_text": "CONCLUSIONS: Delayed-onset <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> is increasingly being recognized.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8137": {"data": {"text": "Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.", "entity1": "Quinidine phenylethylbarbiturate", "entity2": "hepatitis", "span1": [0, 32], "span2": [51, 60]}, "bert_text": "<e1> Quinidine phenylethylbarbiturate </e1>-induced fulminant <e2> hepatitis </e2> in a pregnant woman.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8138": {"data": {"text": "A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.", "entity1": "chlorpropamide", "entity2": "adult-onset diabetes", "span1": [59, 73], "span2": [25, 45]}, "bert_text": "A 65-year-old woman with adult-onset diabetes treated with <e1> chlorpropamide </e1> <e2> adult-onset diabetes </e2> treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8139": {"data": {"text": "A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.", "entity1": "chlorpropamide", "entity2": "optic neuropathy", "span1": [59, 73], "span2": [98, 114]}, "bert_text": "A 65-year-old woman with adult-onset diabetes treated with <e1> chlorpropamide </e1> (Diabenese) had a toxic <e2> optic neuropathy </e2> that resolved with discontinuation of chlorpropamide therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8140": {"data": {"text": "A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.", "entity1": "Diabenese", "entity2": "adult-onset diabetes", "span1": [75, 84], "span2": [25, 45]}, "bert_text": "A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (<e1> Diabenese </e1> <e2> adult-onset diabetes </e2> treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8141": {"data": {"text": "A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.", "entity1": "Diabenese", "entity2": "optic neuropathy", "span1": [75, 84], "span2": [98, 114]}, "bert_text": "A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (<e1> Diabenese </e1>) had a toxic <e2> optic neuropathy </e2> that resolved with discontinuation of chlorpropamide therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8142": {"data": {"text": "A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.", "entity1": "chlorpropamide", "entity2": "adult-onset diabetes", "span1": [153, 167], "span2": [25, 45]}, "bert_text": "A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of <e1> chlorpropamide </e1> <e2> adult-onset diabetes </e2> treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8143": {"data": {"text": "A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.", "entity1": "chlorpropamide", "entity2": "optic neuropathy", "span1": [153, 167], "span2": [98, 114]}, "bert_text": "A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of <e1> chlorpropamide </e1> <e2> optic neuropathy </e2> that resolved with discontinuation of chlorpropamide therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"8144": {"data": {"text": "After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.", "entity1": "penicillin-G potassium", "entity2": "epileptic", "span1": [106, 128], "span2": [50, 59]}, "bert_text": "After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl <e1> penicillin-G potassium </e1> <e2> epileptic </e2> focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8145": {"data": {"text": "Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.", "entity1": "MZ", "entity2": "hypoxia", "span1": [200, 202], "span2": [5, 12]}, "bert_text": "Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by <e1> MZ </e1> <e2> hypoxia </e2> (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8146": {"data": {"text": "Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.", "entity1": "MZ", "entity2": "hypoxia", "span1": [200, 202], "span2": [100, 107]}, "bert_text": "Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by <e1> MZ </e1> <e2> hypoxia </e2> due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8147": {"data": {"text": "Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.", "entity1": "MZ", "entity2": "hypoxia", "span1": [200, 202], "span2": [182, 189]}, "bert_text": "Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by <e1> MZ </e1> <e2> hypoxia </e2> caused by MZ use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8148": {"data": {"text": "Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.", "entity1": "MZ", "entity2": "airway obstruction", "span1": [200, 202], "span2": [121, 139]}, "bert_text": "Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by <e1> MZ </e1> <e2> airway obstruction </e2> by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8149": {"data": {"text": "CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.", "entity1": "Cabergoline", "entity2": "hyperprolactinemia", "span1": [13, 24], "span2": [80, 98]}, "bert_text": "CONCLUSIONS: <e1> Cabergoline </e1> may be useful for the treatment of risperidone-induced <e2> hyperprolactinemia </e2> in youth; however, further research is needed.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8150": {"data": {"text": "CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.", "entity1": "risperidone", "entity2": "hyperprolactinemia", "span1": [60, 71], "span2": [80, 98]}, "bert_text": "CONCLUSIONS: Cabergoline may be useful for the treatment of <e1> risperidone </e1>-induced <e2> hyperprolactinemia </e2> in youth; however, further research is needed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8151": {"data": {"text": "METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).", "entity1": "clonidine", "entity2": "ADHD", "span1": [103, 112], "span2": [72, 76]}, "bert_text": "METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to <e1> clonidine </e1> <e2> ADHD </e2> were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8152": {"data": {"text": "METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).", "entity1": "clonidine", "entity2": "ADHD", "span1": [149, 158], "span2": [72, 76]}, "bert_text": "METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), <e1> clonidine </e1> <e2> ADHD </e2> were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8153": {"data": {"text": "METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).", "entity1": "methylphenidate", "entity2": "ADHD", "span1": [123, 138], "span2": [72, 76]}, "bert_text": "METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), <e1> methylphenidate </e1> <e2> ADHD </e2> were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8154": {"data": {"text": "METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).", "entity1": "methylphenidate", "entity2": "ADHD", "span1": [163, 178], "span2": [72, 76]}, "bert_text": "METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and <e1> methylphenidate </e1> <e2> ADHD </e2> were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8155": {"data": {"text": "The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.", "entity1": "caffeine", "entity2": "seizures", "span1": [63, 71], "span2": [31, 39]}, "bert_text": "The frequency of sound-induced seizures after 12.5 or 25 mg/kg <e1> caffeine </e1> <e2> seizures </e2> after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8156": {"data": {"text": "The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.", "entity1": "acetaminophen", "entity2": "seizures", "span1": [101, 114], "span2": [31, 39]}, "bert_text": "The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by <e1> acetaminophen </e1> <e2> seizures </e2> after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8157": {"data": {"text": "Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.", "entity1": "creatinine", "entity2": "CRF", "span1": [95, 105], "span2": [54, 57]}, "bert_text": "Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum <e1> creatinine </e1> <e2> CRF </e2> or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"8158": {"data": {"text": "Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.", "entity1": "creatinine", "entity2": "ESRD", "span1": [95, 105], "span2": [61, 65]}, "bert_text": "Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum <e1> creatinine </e1> <e2> ESRD </e2>, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"8159": {"data": {"text": "Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.", "entity1": "creatinine", "entity2": "CRF", "span1": [95, 105], "span2": [74, 77]}, "bert_text": "Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum <e1> creatinine </e1> <e2> CRF </e2>, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"8160": {"data": {"text": "Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.", "entity1": "creatinine", "entity2": "ESRD", "span1": [95, 105], "span2": [128, 132]}, "bert_text": "Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum <e1> creatinine </e1> >2.5 mg/dl, n=41; and <e2> ESRD </e2>, n=45.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8161": {"data": {"text": "The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).", "entity1": "phenobarbital", "entity2": "carcinogenesis", "span1": [70, 83], "span2": [124, 138]}, "bert_text": "The present work has been planned in order to elucidate the effect of <e1> phenobarbital </e1> (PB: 15 mg per rat of ingested dose) on <e2> carcinogenesis </e2> when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8162": {"data": {"text": "The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).", "entity1": "PB", "entity2": "carcinogenesis", "span1": [85, 87], "span2": [124, 138]}, "bert_text": "The present work has been planned in order to elucidate the effect of phenobarbital (<e1> PB </e1>: 15 mg per rat of ingested dose) on <e2> carcinogenesis </e2> when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8163": {"data": {"text": "The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).", "entity1": "diethylnitrosamine", "entity2": "carcinogenesis", "span1": [183, 201], "span2": [124, 138]}, "bert_text": "The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with <e1> diethylnitrosamine </e1> <e2> carcinogenesis </e2> when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8164": {"data": {"text": "The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).", "entity1": "DEN", "entity2": "carcinogenesis", "span1": [203, 206], "span2": [124, 138]}, "bert_text": "The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (<e1> DEN </e1> <e2> carcinogenesis </e2> when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8165": {"data": {"text": "We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.", "entity1": "minoxidil", "entity2": "pseudoacromegaly", "span1": [83, 92], "span2": [26, 42]}, "bert_text": "We present a patient with pseudoacromegaly that resulted from the long-term use of <e1> minoxidil </e1> <e2> pseudoacromegaly </e2> that resulted from the long-term use of minoxidil at an unusually high dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8166": {"data": {"text": "In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.", "entity1": "PG", "entity2": "OAB", "span1": [50, 52], "span2": [97, 100]}, "bert_text": "In addition, correlations between urinary NGF and <e1> PG </e1>, and urodynamic parameters in patients with <e2> OAB </e2> were examined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8167": {"data": {"text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg nicotine lozenge and 4-mg nicotine gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.", "entity1": "nicotine", "entity2": "heart disease", "span1": [86, 94], "span2": [261, 274]}, "bert_text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg <e1> nicotine </e1> lozenge and 4-mg nicotine gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with <e2> heart disease </e2>, hypertension not controlled by medication, and/or diabetes mellitus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8168": {"data": {"text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg nicotine lozenge and 4-mg nicotine gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.", "entity1": "nicotine", "entity2": "hypertension", "span1": [86, 94], "span2": [276, 288]}, "bert_text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg <e1> nicotine </e1> lozenge and 4-mg nicotine gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, <e2> hypertension </e2> not controlled by medication, and/or diabetes mellitus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8169": {"data": {"text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg nicotine lozenge and 4-mg nicotine gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.", "entity1": "nicotine", "entity2": "diabetes mellitus", "span1": [86, 94], "span2": [326, 343]}, "bert_text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg <e1> nicotine </e1> lozenge and 4-mg nicotine gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or <e2> diabetes mellitus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8170": {"data": {"text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg nicotine lozenge and 4-mg nicotine gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.", "entity1": "nicotine", "entity2": "heart disease", "span1": [112, 120], "span2": [261, 274]}, "bert_text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg nicotine lozenge and 4-mg <e1> nicotine </e1> gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with <e2> heart disease </e2>, hypertension not controlled by medication, and/or diabetes mellitus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8171": {"data": {"text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg nicotine lozenge and 4-mg nicotine gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.", "entity1": "nicotine", "entity2": "hypertension", "span1": [112, 120], "span2": [276, 288]}, "bert_text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg nicotine lozenge and 4-mg <e1> nicotine </e1> gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, <e2> hypertension </e2> not controlled by medication, and/or diabetes mellitus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8172": {"data": {"text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg nicotine lozenge and 4-mg nicotine gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.", "entity1": "nicotine", "entity2": "diabetes mellitus", "span1": [112, 120], "span2": [326, 343]}, "bert_text": "OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg nicotine lozenge and 4-mg <e1> nicotine </e1> gum in smokers with selected label-restricted diseases. METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or <e2> diabetes mellitus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8173": {"data": {"text": "CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR-induced nephrosis.", "entity1": "NO", "entity2": "nephrosis", "span1": [49, 51], "span2": [119, 128]}, "bert_text": "CONCLUSION: We suggest that interactions between <e1> NO </e1> and apoptosis are important in the pathogenesis of the ADR-induced <e2> nephrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8174": {"data": {"text": "CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR-induced nephrosis.", "entity1": "ADR", "entity2": "nephrosis", "span1": [107, 110], "span2": [119, 128]}, "bert_text": "CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the <e1> ADR </e1>-induced <e2> nephrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8175": {"data": {"text": "Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.", "entity1": "prazosin", "entity2": "stress incontinence", "span1": [59, 67], "span2": [26, 45]}, "bert_text": "Patients who present with stress incontinence while taking <e1> prazosin </e1> <e2> stress incontinence </e2> while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8176": {"data": {"text": "Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.", "entity1": "prazosin", "entity2": "incontinence", "span1": [59, 67], "span2": [158, 170]}, "bert_text": "Patients who present with stress incontinence while taking <e1> prazosin </e1> should change their antihypertensive medication before considering surgery, because their <e2> incontinence </e2> may resolve spontaneously with a change in drug therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8177": {"data": {"text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.", "entity1": "paclitaxel", "entity2": "toxicity", "span1": [104, 114], "span2": [90, 98]}, "bert_text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a <e1> paclitaxel </e1> <e2> toxicity </e2> of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8178": {"data": {"text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.", "entity1": "paclitaxel", "entity2": "NSCLC", "span1": [104, 114], "span2": [175, 180]}, "bert_text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a <e1> paclitaxel </e1>, cisplatin, and gemcitabine combination to treat metastatic <e2> NSCLC </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8179": {"data": {"text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.", "entity1": "cisplatin", "entity2": "toxicity", "span1": [116, 125], "span2": [90, 98]}, "bert_text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, <e1> cisplatin </e1> <e2> toxicity </e2> of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8180": {"data": {"text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.", "entity1": "cisplatin", "entity2": "NSCLC", "span1": [116, 125], "span2": [175, 180]}, "bert_text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, <e1> cisplatin </e1>, and gemcitabine combination to treat metastatic <e2> NSCLC </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8181": {"data": {"text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.", "entity1": "gemcitabine", "entity2": "toxicity", "span1": [131, 142], "span2": [90, 98]}, "bert_text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and <e1> gemcitabine </e1> <e2> toxicity </e2> of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8182": {"data": {"text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.", "entity1": "gemcitabine", "entity2": "NSCLC", "span1": [131, 142], "span2": [175, 180]}, "bert_text": "METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and <e1> gemcitabine </e1> combination to treat metastatic <e2> NSCLC </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8183": {"data": {"text": "In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.", "entity1": "Srl", "entity2": "proteinuria", "span1": [73, 76], "span2": [45, 56]}, "bert_text": "In cardiac transplantation, the incidence of proteinuria associated with <e1> Srl </e1> <e2> proteinuria </e2> associated with Srl is unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8184": {"data": {"text": "Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.", "entity1": "DEN", "entity2": "hepatocarcinogenesis", "span1": [36, 39], "span2": [115, 135]}, "bert_text": "Wistar rats (180 g) were treated by <e1> DEN </e1> alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for <e2> hepatocarcinogenesis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8185": {"data": {"text": "Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.", "entity1": "DEN", "entity2": "hepatocarcinogenesis", "span1": [52, 55], "span2": [115, 135]}, "bert_text": "Wistar rats (180 g) were treated by DEN alone or by <e1> DEN </e1> + PB during 2, 4 and 6 weeks according to our schedule for <e2> hepatocarcinogenesis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8186": {"data": {"text": "Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.", "entity1": "PB", "entity2": "hepatocarcinogenesis", "span1": [58, 60], "span2": [115, 135]}, "bert_text": "Wistar rats (180 g) were treated by DEN alone or by DEN + <e1> PB </e1> during 2, 4 and 6 weeks according to our schedule for <e2> hepatocarcinogenesis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8187": {"data": {"text": "These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.", "entity1": "CsA", "entity2": "nephrotoxic", "span1": [54, 57], "span2": [31, 42]}, "bert_text": "These results suggest that the nephrotoxic effects of <e1> CsA </e1> <e2> nephrotoxic </e2> effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8188": {"data": {"text": "These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.", "entity1": "FK506", "entity2": "nephrotoxic", "span1": [62, 67], "span2": [31, 42]}, "bert_text": "These results suggest that the nephrotoxic effects of CsA and <e1> FK506 </e1> <e2> nephrotoxic </e2> effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8189": {"data": {"text": "TAM induces hemolysis of erythrocytes as a function of concentration.", "entity1": "TAM", "entity2": "hemolysis", "span1": [0, 3], "span2": [12, 21]}, "bert_text": "<e1> TAM </e1> induces <e2> hemolysis </e2> of erythrocytes as a function of concentration.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8190": {"data": {"text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "entity1": "isoniazid", "entity2": "hypotension", "span1": [14, 23], "span2": [33, 44]}, "bert_text": "High doses of <e1> isoniazid </e1> increase <e2> hypotension </e2> induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8191": {"data": {"text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "entity1": "isoniazid", "entity2": "tachycardia", "span1": [14, 23], "span2": [104, 115]}, "bert_text": "High doses of <e1> isoniazid </e1> increase hypotension induced by vasodilators and change the accompanying reflex <e2> tachycardia </e2> to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8192": {"data": {"text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "entity1": "isoniazid", "entity2": "bradycardia", "span1": [14, 23], "span2": [119, 130]}, "bert_text": "High doses of <e1> isoniazid </e1> increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to <e2> bradycardia </e2>, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8193": {"data": {"text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "entity1": "gamma-aminobutyric acid", "entity2": "hypotension", "span1": [190, 213], "span2": [33, 44]}, "bert_text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain <e1> gamma-aminobutyric acid </e1> <e2> hypotension </e2> induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8194": {"data": {"text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "entity1": "gamma-aminobutyric acid", "entity2": "tachycardia", "span1": [190, 213], "span2": [104, 115]}, "bert_text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain <e1> gamma-aminobutyric acid </e1> <e2> tachycardia </e2> to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8195": {"data": {"text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "entity1": "gamma-aminobutyric acid", "entity2": "bradycardia", "span1": [190, 213], "span2": [119, 130]}, "bert_text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain <e1> gamma-aminobutyric acid </e1> <e2> bradycardia </e2>, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8196": {"data": {"text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "entity1": "GABA", "entity2": "hypotension", "span1": [215, 219], "span2": [33, 44]}, "bert_text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (<e1> GABA </e1> <e2> hypotension </e2> induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8197": {"data": {"text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "entity1": "GABA", "entity2": "tachycardia", "span1": [215, 219], "span2": [104, 115]}, "bert_text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (<e1> GABA </e1> <e2> tachycardia </e2> to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8198": {"data": {"text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "entity1": "GABA", "entity2": "bradycardia", "span1": [215, 219], "span2": [119, 130]}, "bert_text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (<e1> GABA </e1> <e2> bradycardia </e2>, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8199": {"data": {"text": "The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.", "entity1": "sirolmus", "entity2": "nephrotoxic", "span1": [38, 46], "span2": [59, 70]}, "bert_text": "The novel immunosuppressive (IS) drug <e1> sirolmus </e1> (Srl) lacks <e2> nephrotoxic </e2> effects; however, proteinuria associated with Srl has been reported following renal transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8200": {"data": {"text": "The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.", "entity1": "sirolmus", "entity2": "proteinuria", "span1": [38, 46], "span2": [89, 100]}, "bert_text": "The novel immunosuppressive (IS) drug <e1> sirolmus </e1> (Srl) lacks nephrotoxic effects; however, <e2> proteinuria </e2> associated with Srl has been reported following renal transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8201": {"data": {"text": "The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.", "entity1": "Srl", "entity2": "nephrotoxic", "span1": [48, 51], "span2": [59, 70]}, "bert_text": "The novel immunosuppressive (IS) drug sirolmus (<e1> Srl </e1>) lacks <e2> nephrotoxic </e2> effects; however, proteinuria associated with Srl has been reported following renal transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8202": {"data": {"text": "The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.", "entity1": "Srl", "entity2": "proteinuria", "span1": [48, 51], "span2": [89, 100]}, "bert_text": "The novel immunosuppressive (IS) drug sirolmus (<e1> Srl </e1>) lacks nephrotoxic effects; however, <e2> proteinuria </e2> associated with Srl has been reported following renal transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8203": {"data": {"text": "The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.", "entity1": "Srl", "entity2": "nephrotoxic", "span1": [117, 120], "span2": [59, 70]}, "bert_text": "The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with <e1> Srl </e1> <e2> nephrotoxic </e2> effects; however, proteinuria associated with Srl has been reported following renal transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8204": {"data": {"text": "The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.", "entity1": "Srl", "entity2": "proteinuria", "span1": [117, 120], "span2": [89, 100]}, "bert_text": "The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with <e1> Srl </e1> <e2> proteinuria </e2> associated with Srl has been reported following renal transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8205": {"data": {"text": "On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.", "entity1": "Abbott-53693", "entity2": "bradycardia", "span1": [42, 54], "span2": [112, 123]}, "bert_text": "On the other hand, the pressor effects of <e1> Abbott-53693 </e1> were similar in both groups of SHR, but the accompanying <e2> bradycardia </e2> was greater in SHR with chronic prazosin treatment than without such treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8206": {"data": {"text": "On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.", "entity1": "prazosin", "entity2": "bradycardia", "span1": [156, 164], "span2": [112, 123]}, "bert_text": "On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic <e1> prazosin </e1> <e2> bradycardia </e2> was greater in SHR with chronic prazosin treatment than without such treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8207": {"data": {"text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.", "entity1": "CGRP", "entity2": "headache", "span1": [103, 107], "span2": [203, 211]}, "bert_text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (<e1> CGRP </e1>) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate <e2> headache </e2> and the delayed genuine migraine attack provoked by nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8208": {"data": {"text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.", "entity1": "CGRP", "entity2": "migraine", "span1": [103, 107], "span2": [236, 244]}, "bert_text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (<e1> CGRP </e1>) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine <e2> migraine </e2> attack provoked by nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8209": {"data": {"text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.", "entity1": "serotonin", "entity2": "headache", "span1": [136, 145], "span2": [203, 211]}, "bert_text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet <e1> serotonin </e1> (5-hydroxytriptamine, 5-HT) content during the immediate <e2> headache </e2> and the delayed genuine migraine attack provoked by nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8210": {"data": {"text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.", "entity1": "serotonin", "entity2": "migraine", "span1": [136, 145], "span2": [236, 244]}, "bert_text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet <e1> serotonin </e1> (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine <e2> migraine </e2> attack provoked by nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8211": {"data": {"text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.", "entity1": "5-hydroxytriptamine", "entity2": "headache", "span1": [147, 166], "span2": [203, 211]}, "bert_text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (<e1> 5-hydroxytriptamine </e1>, 5-HT) content during the immediate <e2> headache </e2> and the delayed genuine migraine attack provoked by nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8212": {"data": {"text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.", "entity1": "5-hydroxytriptamine", "entity2": "migraine", "span1": [147, 166], "span2": [236, 244]}, "bert_text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (<e1> 5-hydroxytriptamine </e1>, 5-HT) content during the immediate headache and the delayed genuine <e2> migraine </e2> attack provoked by nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8213": {"data": {"text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.", "entity1": "5-HT", "entity2": "headache", "span1": [168, 172], "span2": [203, 211]}, "bert_text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, <e1> 5-HT </e1>) content during the immediate <e2> headache </e2> and the delayed genuine migraine attack provoked by nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8214": {"data": {"text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.", "entity1": "5-HT", "entity2": "migraine", "span1": [168, 172], "span2": [236, 244]}, "bert_text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, <e1> 5-HT </e1>) content during the immediate headache and the delayed genuine <e2> migraine </e2> attack provoked by nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8215": {"data": {"text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.", "entity1": "nitroglycerin", "entity2": "headache", "span1": [264, 277], "span2": [203, 211]}, "bert_text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by <e1> nitroglycerin </e1> <e2> headache </e2> and the delayed genuine migraine attack provoked by nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8216": {"data": {"text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.", "entity1": "nitroglycerin", "entity2": "migraine", "span1": [264, 277], "span2": [236, 244]}, "bert_text": "The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by <e1> nitroglycerin </e1> <e2> migraine </e2> attack provoked by nitroglycerin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8217": {"data": {"text": "This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.", "entity1": "rifampin", "entity2": "glomerulonephritis", "span1": [161, 169], "span2": [68, 86]}, "bert_text": "This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with <e1> rifampin </e1> <e2> glomerulonephritis </e2> with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8218": {"data": {"text": "This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.", "entity1": "rifampin", "entity2": "glomerulonephritis", "span1": [161, 169], "span2": [116, 134]}, "bert_text": "This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with <e1> rifampin </e1> <e2> glomerulonephritis </e2> in a patient treated with rifampin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8219": {"data": {"text": "A common side effect associated with succinylcholine is postoperative myalgia.", "entity1": "succinylcholine", "entity2": "postoperative myalgia", "span1": [37, 52], "span2": [56, 77]}, "bert_text": "A common side effect associated with <e1> succinylcholine </e1> is <e2> postoperative myalgia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8220": {"data": {"text": "While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.", "entity1": "cocaine's", "entity2": "anxiety", "span1": [32, 41], "span2": [184, 191]}, "bert_text": "While the mechanisms underlying <e1> cocaine's </e1> rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as <e2> anxiety </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8221": {"data": {"text": "While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.", "entity1": "cocaine", "entity2": "anxiety", "span1": [167, 174], "span2": [184, 191]}, "bert_text": "While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by <e1> cocaine </e1>, such as <e2> anxiety </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8222": {"data": {"text": "Therefore, PG-9 could represent a potential useful drug able to improve the function of impaired cognitive processes.", "entity1": "PG-9", "entity2": "impaired cognitive processes", "span1": [11, 15], "span2": [88, 116]}, "bert_text": "Therefore, <e1> PG-9 </e1> could represent a potential useful drug able to improve the function of <e2> impaired cognitive processes </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8223": {"data": {"text": "In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.", "entity1": "TRI", "entity2": "hypothermia", "span1": [24, 27], "span2": [75, 86]}, "bert_text": "In the acute experiment <e1> TRI </e1> (given i.p.) does not antagonize the reserpine <e2> hypothermia </e2> in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"8224": {"data": {"text": "In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.", "entity1": "reserpine", "entity2": "hypothermia", "span1": [65, 74], "span2": [75, 86]}, "bert_text": "In the acute experiment TRI (given i.p.) does not antagonize the <e1> reserpine </e1> <e2> hypothermia </e2> in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"8225": {"data": {"text": "Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.", "entity1": "warfarin", "entity2": "cerebral haemorrhage", "span1": [65, 73], "span2": [127, 147]}, "bert_text": "Medical records were studied retrospectively to evaluate whether <e1> warfarin </e1> and warfarin-drug interactions could have caused the <e2> cerebral haemorrhage </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8226": {"data": {"text": "Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.", "entity1": "warfarin", "entity2": "cerebral haemorrhage", "span1": [78, 86], "span2": [127, 147]}, "bert_text": "Medical records were studied retrospectively to evaluate whether warfarin and <e1> warfarin </e1>-drug interactions could have caused the <e2> cerebral haemorrhage </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8227": {"data": {"text": "Dual effects of melatonin on barbiturate-induced narcosis in rats.\n", "entity1": "melatonin", "entity2": "narcosis", "span1": [16, 25], "span2": [49, 57]}, "bert_text": "Dual effects of <e1> melatonin </e1> on barbiturate-induced <e2> narcosis </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8228": {"data": {"text": "Dual effects of melatonin on barbiturate-induced narcosis in rats.\n", "entity1": "barbiturate", "entity2": "narcosis", "span1": [29, 40], "span2": [49, 57]}, "bert_text": "Dual effects of melatonin on <e1> barbiturate </e1>-induced <e2> narcosis </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8229": {"data": {"text": "In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.", "entity1": "creatinine", "entity2": "proteinuria", "span1": [139, 149], "span2": [36, 47]}, "bert_text": "In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:<e1> creatinine </e1> <e2> proteinuria </e2> was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"8230": {"data": {"text": "In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.", "entity1": "creatinine", "entity2": "proteinuria", "span1": [139, 149], "span2": [182, 193]}, "bert_text": "In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:<e1> creatinine </e1> ratios, an estimate of grams of <e2> proteinuria </e2>/day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"8231": {"data": {"text": "Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.", "entity1": "Tiopronin", "entity2": "RA", "span1": [99, 108], "span2": [81, 83]}, "bert_text": "Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the <e1> Tiopronin </e1> <e2> RA </e2> except for the Tiopronin related nephritis group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8232": {"data": {"text": "Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.", "entity1": "Tiopronin", "entity2": "nephritis", "span1": [99, 108], "span2": [117, 126]}, "bert_text": "Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the <e1> Tiopronin </e1> related <e2> nephritis </e2> group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8233": {"data": {"text": "This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.", "entity1": "L-dopa", "entity2": "coma", "span1": [39, 45], "span2": [5, 9]}, "bert_text": "This coma was prevented with 1.68 mmol <e1> L-dopa </e1> <e2> coma </e2> was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8234": {"data": {"text": "This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.", "entity1": "ammonium salt", "entity2": "coma", "span1": [96, 109], "span2": [5, 9]}, "bert_text": "This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the <e1> ammonium salt </e1> <e2> coma </e2> was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8235": {"data": {"text": "Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.\n", "entity1": "Paracetamol", "entity2": "coma", "span1": [0, 11], "span2": [23, 27]}, "bert_text": "<e1> Paracetamol </e1>-associated <e2> coma </e2>, metabolic acidosis, renal and hepatic failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8236": {"data": {"text": "Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.\n", "entity1": "Paracetamol", "entity2": "metabolic acidosis", "span1": [0, 11], "span2": [29, 47]}, "bert_text": "<e1> Paracetamol </e1>-associated coma, <e2> metabolic acidosis </e2>, renal and hepatic failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8237": {"data": {"text": "Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.\n", "entity1": "Paracetamol", "entity2": "hepatic failure", "span1": [0, 11], "span2": [59, 74]}, "bert_text": "<e1> Paracetamol </e1>-associated coma, metabolic acidosis, renal and <e2> hepatic failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8238": {"data": {"text": "The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.", "entity1": "cirazoline", "entity2": "bradycardia", "span1": [61, 71], "span2": [26, 37]}, "bert_text": "The pressor responses and bradycardia to the alpha 1-agonist <e1> cirazoline </e1> <e2> bradycardia </e2> to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8239": {"data": {"text": "The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.", "entity1": "Abbott-53693", "entity2": "bradycardia", "span1": [126, 138], "span2": [26, 37]}, "bert_text": "The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist <e1> Abbott-53693 </e1> <e2> bradycardia </e2> to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8240": {"data": {"text": "The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.", "entity1": "noradrenaline", "entity2": "bradycardia", "span1": [175, 188], "span2": [26, 37]}, "bert_text": "The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and <e1> noradrenaline </e1> <e2> bradycardia </e2> to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8241": {"data": {"text": "The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.", "entity1": "prazosin", "entity2": "bradycardia", "span1": [282, 290], "span2": [26, 37]}, "bert_text": "The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic <e1> prazosin </e1> <e2> bradycardia </e2> to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8242": {"data": {"text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [78, 85], "span2": [94, 110]}, "bert_text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8243": {"data": {"text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "entity1": "heparin", "entity2": "HIT", "span1": [78, 85], "span2": [112, 115]}, "bert_text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step <e1> heparin </e1>-induced thrombocytopenia (<e2> HIT </e2>) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8244": {"data": {"text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "entity1": "heparin", "entity2": "thrombosis", "span1": [78, 85], "span2": [136, 146]}, "bert_text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step <e1> heparin </e1>-induced thrombocytopenia (HIT) antigen assay with <e2> thrombosis </e2>; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8245": {"data": {"text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [213, 220], "span2": [94, 110]}, "bert_text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high <e1> heparin </e1> <e2> thrombocytopenia </e2> (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8246": {"data": {"text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "entity1": "heparin", "entity2": "HIT", "span1": [213, 220], "span2": [112, 115]}, "bert_text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high <e1> heparin </e1> <e2> HIT </e2>) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8247": {"data": {"text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "entity1": "heparin", "entity2": "thrombosis", "span1": [213, 220], "span2": [136, 146]}, "bert_text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high <e1> heparin </e1> <e2> thrombosis </e2>; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8248": {"data": {"text": "Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.\n", "entity1": "gentamicin", "entity2": "ototoxicity", "span1": [61, 71], "span2": [72, 83]}, "bert_text": "Nitro-L-arginine methyl ester: a potential protector against <e1> gentamicin </e1> <e2> ototoxicity </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8249": {"data": {"text": "Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).", "entity1": "cirazoline", "entity2": "bradycardia", "span1": [44, 54], "span2": [21, 32]}, "bert_text": "Both the pressor and bradycardia effects of <e1> cirazoline </e1> <e2> bradycardia </e2> effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8250": {"data": {"text": "Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).", "entity1": "prazosin", "entity2": "bradycardia", "span1": [81, 89], "span2": [21, 32]}, "bert_text": "Both the pressor and bradycardia effects of cirazoline were abolished in chronic <e1> prazosin </e1> <e2> bradycardia </e2> effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8251": {"data": {"text": "An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).", "entity1": "oral contraceptive", "entity2": "myocardial infarction", "span1": [220, 238], "span2": [156, 177]}, "bert_text": "An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined <e1> oral contraceptive </e1> <e2> myocardial infarction </e2> among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8252": {"data": {"text": "In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.", "entity1": "BD1063", "entity2": "convulsions", "span1": [58, 64], "span2": [116, 127]}, "bert_text": "In behavioral studies, pre-treatment of mice with BD1018, <e1> BD1063 </e1>, or LR132 significantly attenuated cocaine-induced <e2> convulsions </e2> and lethality.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8253": {"data": {"text": "In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.", "entity1": "cocaine", "entity2": "convulsions", "span1": [100, 107], "span2": [116, 127]}, "bert_text": "In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated <e1> cocaine </e1>-induced <e2> convulsions </e2> and lethality.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8254": {"data": {"text": "She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.", "entity1": "fluorouracil", "entity2": "colorectal cancer", "span1": [39, 51], "span2": [67, 84]}, "bert_text": "She underwent recent chemotherapy with <e1> fluorouracil </e1> for metastatic <e2> colorectal cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8255": {"data": {"text": "However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.", "entity1": "CGRP", "entity2": "headache", "span1": [16, 20], "span2": [70, 78]}, "bert_text": "However, plasma <e1> CGRP </e1> concentrations failed to change during immediate <e2> headache </e2> and in the subjects with no migraine attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8256": {"data": {"text": "However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.", "entity1": "CGRP", "entity2": "migraine", "span1": [16, 20], "span2": [107, 115]}, "bert_text": "However, plasma <e1> CGRP </e1> concentrations failed to change during immediate headache and in the subjects with no <e2> migraine </e2> attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"8257": {"data": {"text": "Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.\n", "entity1": "Estradiol", "entity2": "seizure", "span1": [0, 9], "span2": [18, 25]}, "bert_text": "<e1> Estradiol </e1> reduces <e2> seizure </e2>-induced hippocampal injury in ovariectomized female but not in male rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8258": {"data": {"text": "Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.\n", "entity1": "Estradiol", "entity2": "hippocampal injury", "span1": [0, 9], "span2": [34, 52]}, "bert_text": "<e1> Estradiol </e1> reduces seizure-induced <e2> hippocampal injury </e2> in ovariectomized female but not in male rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8259": {"data": {"text": "Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.", "entity1": "Dopamine", "entity2": "epileptic seizures", "span1": [0, 8], "span2": [95, 113]}, "bert_text": "<e1> Dopamine </e1> (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of <e2> epileptic seizures </e2> arising in the limbic system.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8260": {"data": {"text": "Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.", "entity1": "DA", "entity2": "epileptic seizures", "span1": [10, 12], "span2": [95, 113]}, "bert_text": "Dopamine (<e1> DA </e1>), through D1/D2 receptor-mediated signaling, plays a major role in the control of <e2> epileptic seizures </e2> arising in the limbic system.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8261": {"data": {"text": "METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.", "entity1": "cocaine", "entity2": "SAH", "span1": [111, 118], "span2": [35, 38]}, "bert_text": "METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for <e1> cocaine </e1> <e2> SAH </e2> retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8262": {"data": {"text": "A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.\n", "entity1": "MSH", "entity2": "dystonia-like syndrome", "span1": [45, 48], "span2": [2, 24]}, "bert_text": "A dystonia-like syndrome after neuropeptide (<e1> MSH </e1> <e2> dystonia-like syndrome </e2> after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8263": {"data": {"text": "A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.\n", "entity1": "ACTH", "entity2": "dystonia-like syndrome", "span1": [49, 53], "span2": [2, 24]}, "bert_text": "A dystonia-like syndrome after neuropeptide (MSH/<e1> ACTH </e1> <e2> dystonia-like syndrome </e2> after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8264": {"data": {"text": "This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.", "entity1": "phenytoin", "entity2": "psychotic symptoms", "span1": [68, 77], "span2": [28, 46]}, "bert_text": "This case suggests that the psychotic symptoms that occur following <e1> phenytoin </e1> <e2> psychotic symptoms </e2> that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8265": {"data": {"text": "This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.", "entity1": "phenytoin", "entity2": "epileptic", "span1": [68, 77], "span2": [96, 105]}, "bert_text": "This case suggests that the psychotic symptoms that occur following <e1> phenytoin </e1> treatment in some <e2> epileptic </e2> patients may be the direct result of medication, unrelated to seizures.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8266": {"data": {"text": "This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.", "entity1": "phenytoin", "entity2": "seizures", "span1": [68, 77], "span2": [168, 176]}, "bert_text": "This case suggests that the psychotic symptoms that occur following <e1> phenytoin </e1> treatment in some epileptic patients may be the direct result of medication, unrelated to <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8267": {"data": {"text": "Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.", "entity1": "mangiferin", "entity2": "MI", "span1": [23, 33], "span2": [138, 140]}, "bert_text": "Upon pretreatment with <e1> mangiferin </e1> (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to <e2> MI </e2> rats protected the above-mentioned parameters to fall from the normal levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8268": {"data": {"text": "Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.", "entity1": "dimethyl sulphoxide", "entity2": "MI", "span1": [78, 97], "span2": [138, 140]}, "bert_text": "Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of <e1> dimethyl sulphoxide </e1>) given intraperitoneally for 28 days to <e2> MI </e2> rats protected the above-mentioned parameters to fall from the normal levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8269": {"data": {"text": "Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.", "entity1": "penicillin", "entity2": "epileptiform activity", "span1": [38, 48], "span2": [57, 78]}, "bert_text": "Basal activity, latent period and the <e1> penicillin </e1>-induced <e2> epileptiform activity </e2> periods were then analyzed using both conventional methods and spectral analysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8270": {"data": {"text": "Seizures induced by combined levomepromazine-fluvoxamine treatment.\n", "entity1": "levomepromazine", "entity2": "Seizures", "span1": [29, 44], "span2": [0, 8]}, "bert_text": "Seizures induced by combined <e1> levomepromazine </e1> <e2> Seizures </e2> induced by combined levomepromazine-fluvoxamine treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8271": {"data": {"text": "Seizures induced by combined levomepromazine-fluvoxamine treatment.\n", "entity1": "fluvoxamine", "entity2": "Seizures", "span1": [45, 56], "span2": [0, 8]}, "bert_text": "Seizures induced by combined levomepromazine-<e1> fluvoxamine </e1> <e2> Seizures </e2> induced by combined levomepromazine-fluvoxamine treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8272": {"data": {"text": "Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.", "entity1": "desipramine", "entity2": "hypotension", "span1": [56, 67], "span2": [82, 93]}, "bert_text": "Anesthetized rats received the tricyclic antidepressant <e1> desipramine </e1> IP to produce <e2> hypotension </e2>, QRS prolongation, and bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8273": {"data": {"text": "Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.", "entity1": "desipramine", "entity2": "bradycardia", "span1": [56, 67], "span2": [117, 128]}, "bert_text": "Anesthetized rats received the tricyclic antidepressant <e1> desipramine </e1> IP to produce hypotension, QRS prolongation, and <e2> bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8274": {"data": {"text": "In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.", "entity1": "argatroban", "entity2": "HITT", "span1": [112, 122], "span2": [90, 94]}, "bert_text": "In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered <e1> argatroban </e1> <e2> HITT </e2> was administered argatroban for anticoagulation on bypass during heart transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8275": {"data": {"text": "CONCLUSION: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma.", "entity1": "steroids", "entity2": "endometrial stroma", "span1": [128, 136], "span2": [178, 196]}, "bert_text": "CONCLUSION: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian <e1> steroids </e1> that results in a myometrial invasion by <e2> endometrial stroma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8276": {"data": {"text": "The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.", "entity1": "choline", "entity2": "hepatocellular carcinomas", "span1": [125, 132], "span2": [46, 71]}, "bert_text": "The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain <e1> choline </e1> <e2> hepatocellular carcinomas </e2> was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8277": {"data": {"text": "The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.", "entity1": "choline", "entity2": "hepatocellular carcinomas", "span1": [204, 211], "span2": [46, 71]}, "bert_text": "The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing <e1> choline </e1> <e2> hepatocellular carcinomas </e2> was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8278": {"data": {"text": "The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.", "entity1": "phenobarbital", "entity2": "hepatocellular carcinomas", "span1": [179, 192], "span2": [46, 71]}, "bert_text": "The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the <e1> phenobarbital </e1> <e2> hepatocellular carcinomas </e2> was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8279": {"data": {"text": "These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia-myalgia syndrome.", "entity1": "MP", "entity2": "arthralgia", "span1": [46, 48], "span2": [112, 122]}, "bert_text": "These data demonstrate that administration of <e1> MP </e1> before and after TDI reduces the frequency and severity of the <e2> arthralgia </e2>-myalgia syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8280": {"data": {"text": "These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia-myalgia syndrome.", "entity1": "MP", "entity2": "myalgia syndrome", "span1": [46, 48], "span2": [123, 139]}, "bert_text": "These data demonstrate that administration of <e1> MP </e1> before and after TDI reduces the frequency and severity of the arthralgia-<e2> myalgia syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8281": {"data": {"text": "The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.", "entity1": "nitric oxide", "entity2": "hearing loss", "span1": [4, 16], "span2": [122, 134]}, "bert_text": "The <e1> nitric oxide </e1> (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency <e2> hearing loss </e2> caused by gentamicin, but further studies are needed to confirm this.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8282": {"data": {"text": "The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.", "entity1": "NO", "entity2": "hearing loss", "span1": [18, 20], "span2": [122, 134]}, "bert_text": "The nitric oxide (<e1> NO </e1>) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency <e2> hearing loss </e2> caused by gentamicin, but further studies are needed to confirm this.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8283": {"data": {"text": "The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.", "entity1": "gentamicin", "entity2": "hearing loss", "span1": [145, 155], "span2": [122, 134]}, "bert_text": "The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by <e1> gentamicin </e1> <e2> hearing loss </e2> caused by gentamicin, but further studies are needed to confirm this.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8284": {"data": {"text": "Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.", "entity1": "tacrolimus", "entity2": "myocardial hypertrophy", "span1": [23, 33], "span2": [53, 75]}, "bert_text": "Thus, we conclude that <e1> tacrolimus </e1> induces reversible <e2> myocardial hypertrophy </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8285": {"data": {"text": "Gentamicin at toxic doses, however, increased CSA nephrotoxicity.", "entity1": "Gentamicin", "entity2": "nephrotoxicity", "span1": [0, 10], "span2": [50, 64]}, "bert_text": "<e1> Gentamicin </e1> at toxic doses, however, increased CSA <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8286": {"data": {"text": "Gentamicin at toxic doses, however, increased CSA nephrotoxicity.", "entity1": "CSA", "entity2": "nephrotoxicity", "span1": [46, 49], "span2": [50, 64]}, "bert_text": "Gentamicin at toxic doses, however, increased <e1> CSA </e1> <e2> nephrotoxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8287": {"data": {"text": "Risperidone administration was continued and the visual disturbances gradually wore off.", "entity1": "Risperidone", "entity2": "visual disturbances", "span1": [0, 11], "span2": [49, 68]}, "bert_text": "<e1> Risperidone </e1> administration was continued and the <e2> visual disturbances </e2> gradually wore off.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8288": {"data": {"text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "entity1": "Ketanserin", "entity2": "muscle rigidity", "span1": [0, 10], "span2": [52, 67]}, "bert_text": "<e1> Ketanserin </e1> pretreatment reverses alfentanil-induced <e2> muscle rigidity </e2>.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8289": {"data": {"text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "entity1": "Ketanserin", "entity2": "muscle rigidity", "span1": [0, 10], "span2": [197, 212]}, "bert_text": "<e1> Ketanserin </e1> pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the <e2> muscle rigidity </e2> produced in rats by the potent short-acting opiate agonist alfentanil.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8290": {"data": {"text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "entity1": "ketanserin", "entity2": "muscle rigidity", "span1": [96, 106], "span2": [52, 67]}, "bert_text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with <e1> ketanserin </e1> <e2> muscle rigidity </e2>.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8291": {"data": {"text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "entity1": "ketanserin", "entity2": "muscle rigidity", "span1": [96, 106], "span2": [197, 212]}, "bert_text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with <e1> ketanserin </e1>, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the <e2> muscle rigidity </e2> produced in rats by the potent short-acting opiate agonist alfentanil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8292": {"data": {"text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "entity1": "alfentanil", "entity2": "muscle rigidity", "span1": [33, 43], "span2": [52, 67]}, "bert_text": "Ketanserin pretreatment reverses <e1> alfentanil </e1>-induced <e2> muscle rigidity </e2>.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8293": {"data": {"text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "entity1": "alfentanil", "entity2": "muscle rigidity", "span1": [33, 43], "span2": [197, 212]}, "bert_text": "Ketanserin pretreatment reverses <e1> alfentanil </e1>-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the <e2> muscle rigidity </e2> produced in rats by the potent short-acting opiate agonist alfentanil.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8294": {"data": {"text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "entity1": "alfentanil", "entity2": "muscle rigidity", "span1": [272, 282], "span2": [52, 67]}, "bert_text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist <e1> alfentanil </e1> <e2> muscle rigidity </e2>.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8295": {"data": {"text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "entity1": "alfentanil", "entity2": "muscle rigidity", "span1": [272, 282], "span2": [197, 212]}, "bert_text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist <e1> alfentanil </e1> <e2> muscle rigidity </e2> produced in rats by the potent short-acting opiate agonist alfentanil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8296": {"data": {"text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "entity1": "serotonin", "entity2": "muscle rigidity", "span1": [137, 146], "span2": [52, 67]}, "bert_text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 <e1> serotonin </e1> <e2> muscle rigidity </e2>.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8297": {"data": {"text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "entity1": "serotonin", "entity2": "muscle rigidity", "span1": [137, 146], "span2": [197, 212]}, "bert_text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.\nSystemic pretreatment with ketanserin, a relatively specific type-2 <e1> serotonin </e1> receptor antagonist, significantly attenuated the <e2> muscle rigidity </e2> produced in rats by the potent short-acting opiate agonist alfentanil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8298": {"data": {"text": "OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).", "entity1": "clonidine", "entity2": "attention-deficit/hyperactivity disorder", "span1": [53, 62], "span2": [115, 155]}, "bert_text": "OBJECTIVE: To examine the safety and tolerability of <e1> clonidine </e1> used alone or with methylphenidate in children with <e2> attention-deficit/hyperactivity disorder </e2> (ADHD).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8299": {"data": {"text": "OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).", "entity1": "clonidine", "entity2": "ADHD", "span1": [53, 62], "span2": [157, 161]}, "bert_text": "OBJECTIVE: To examine the safety and tolerability of <e1> clonidine </e1> used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (<e2> ADHD </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8300": {"data": {"text": "OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).", "entity1": "methylphenidate", "entity2": "attention-deficit/hyperactivity disorder", "span1": [82, 97], "span2": [115, 155]}, "bert_text": "OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with <e1> methylphenidate </e1> in children with <e2> attention-deficit/hyperactivity disorder </e2> (ADHD).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8301": {"data": {"text": "OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).", "entity1": "methylphenidate", "entity2": "ADHD", "span1": [82, 97], "span2": [157, 161]}, "bert_text": "OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with <e1> methylphenidate </e1> in children with attention-deficit/hyperactivity disorder (<e2> ADHD </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8302": {"data": {"text": "We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.", "entity1": "warfarin", "entity2": "pain", "span1": [52, 60], "span2": [128, 132]}, "bert_text": "We present the case of a 28-year-old man on chronic <e1> warfarin </e1> therapy who sustained a minor muscle tear and developed increasing <e2> pain </e2> and a flexure contracture of the right hip.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8303": {"data": {"text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "entity1": "atropine", "entity2": "hypotensive", "span1": [110, 118], "span2": [32, 43]}, "bert_text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous <e1> atropine </e1> <e2> hypotensive </e2> with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8304": {"data": {"text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "entity1": "atropine", "entity2": "heart block", "span1": [110, 118], "span2": [58, 69]}, "bert_text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous <e1> atropine </e1> <e2> heart block </e2>, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8305": {"data": {"text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "entity1": "dopamine", "entity2": "hypotensive", "span1": [167, 175], "span2": [32, 43]}, "bert_text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as <e1> dopamine </e1> <e2> hypotensive </e2> with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8306": {"data": {"text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "entity1": "dopamine", "entity2": "heart block", "span1": [167, 175], "span2": [58, 69]}, "bert_text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as <e1> dopamine </e1> <e2> heart block </e2>, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8307": {"data": {"text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "entity1": "dobutamine", "entity2": "hypotensive", "span1": [180, 190], "span2": [32, 43]}, "bert_text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and <e1> dobutamine </e1> <e2> hypotensive </e2> with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8308": {"data": {"text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "entity1": "dobutamine", "entity2": "heart block", "span1": [180, 190], "span2": [58, 69]}, "bert_text": "The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and <e1> dobutamine </e1> <e2> heart block </e2>, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8309": {"data": {"text": "We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.", "entity1": "ephedrine", "entity2": "hypotensive", "span1": [69, 78], "span2": [114, 125]}, "bert_text": "We investigated the safety and efficacy of adding different doses of <e1> ephedrine </e1> to propofol in order to obtund the <e2> hypotensive </e2> response.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8310": {"data": {"text": "We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.", "entity1": "propofol", "entity2": "hypotensive", "span1": [82, 90], "span2": [114, 125]}, "bert_text": "We investigated the safety and efficacy of adding different doses of ephedrine to <e1> propofol </e1> in order to obtund the <e2> hypotensive </e2> response.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8311": {"data": {"text": "In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin-induced renal damage.", "entity1": "streptozotocin", "entity2": "renal damage", "span1": [73, 87], "span2": [96, 108]}, "bert_text": "In the animal study, Nrf2 was demonstrated to be crucial in ameliorating <e1> streptozotocin </e1>-induced <e2> renal damage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8312": {"data": {"text": "Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.\n", "entity1": "Pilocarpine", "entity2": "seizures", "span1": [0, 11], "span2": [12, 20]}, "bert_text": "<e1> Pilocarpine </e1> <e2> seizures </e2> cause age-dependent impairment in auditory location discrimination.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8313": {"data": {"text": "Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.\n", "entity1": "Pilocarpine", "entity2": "impairment in auditory location discrimination", "span1": [0, 11], "span2": [41, 87]}, "bert_text": "<e1> Pilocarpine </e1> seizures cause age-dependent <e2> impairment in auditory location discrimination </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8314": {"data": {"text": "However, tAMCA has been shown to cause epileptic seizures.", "entity1": "tAMCA", "entity2": "epileptic seizures", "span1": [9, 14], "span2": [39, 57]}, "bert_text": "However, <e1> tAMCA </e1> has been shown to cause <e2> epileptic seizures </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8315": {"data": {"text": "Organophosphate-induced convulsions and prevention of neuropathological damages.\n", "entity1": "Organophosphate", "entity2": "convulsions", "span1": [0, 15], "span2": [24, 35]}, "bert_text": "<e1> Organophosphate </e1>-induced <e2> convulsions </e2> and prevention of neuropathological damages.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8316": {"data": {"text": "Organophosphate-induced convulsions and prevention of neuropathological damages.\n", "entity1": "Organophosphate", "entity2": "neuropathological damages", "span1": [0, 15], "span2": [54, 79]}, "bert_text": "<e1> Organophosphate </e1>-induced convulsions and prevention of <e2> neuropathological damages </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8317": {"data": {"text": "The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.", "entity1": "alpha-methyldopa", "entity2": "hypotensive", "span1": [36, 52], "span2": [4, 15]}, "bert_text": "The hypotensive effect of 100 mg/kg <e1> alpha-methyldopa </e1> <e2> hypotensive </e2> effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8318": {"data": {"text": "The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.", "entity1": "naloxone", "entity2": "hypotensive", "span1": [84, 92], "span2": [4, 15]}, "bert_text": "The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by <e1> naloxone </e1> <e2> hypotensive </e2> effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8319": {"data": {"text": "However, 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their <8.5 g/dl hemoglobin values decreased to or anemia-related severe side effects occurred (group B).", "entity1": "ribavirin", "entity2": "anemia", "span1": [45, 54], "span2": [152, 158]}, "bert_text": "However, 10 of 37 patients with reduction of <e1> ribavirin </e1> could not continue combination therapy because their <8.5 g/dl hemoglobin values decreased to or <e2> anemia </e2>-related severe side effects occurred (group B).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8320": {"data": {"text": "On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [3, 14], "span2": [23, 36]}, "bert_text": "On <e1> amphetamine </e1>-induced <e2> hyperactivity </e2>, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8321": {"data": {"text": "On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).", "entity1": "THP", "entity2": "hyperactivity", "span1": [38, 41], "span2": [23, 36]}, "bert_text": "On amphetamine-induced hyperactivity, <e1> THP </e1> <e2> hyperactivity </e2>, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8322": {"data": {"text": "Ethambutol is an antimycobacterial agent often used to treat tuberculosis.", "entity1": "Ethambutol", "entity2": "tuberculosis", "span1": [0, 10], "span2": [61, 73]}, "bert_text": "<e1> Ethambutol </e1> is an antimycobacterial agent often used to treat <e2> tuberculosis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8323": {"data": {"text": "INTERPRETATION: Tranexamic acid retains its convulsive action within FS.", "entity1": "Tranexamic acid", "entity2": "convulsive", "span1": [16, 31], "span2": [44, 54]}, "bert_text": "INTERPRETATION: <e1> Tranexamic acid </e1> retains its <e2> convulsive </e2> action within FS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8324": {"data": {"text": "The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.", "entity1": "catecholamines", "entity2": "catatonia", "span1": [57, 71], "span2": [114, 123]}, "bert_text": "The present studies were designed to clarify the role of <e1> catecholamines </e1> and pineal idolamines on ketamine-induced <e2> catatonia </e2> in the intact, pinealectomized or hypophysectomized chick and rat.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8325": {"data": {"text": "The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.", "entity1": "ketamine", "entity2": "catatonia", "span1": [97, 105], "span2": [114, 123]}, "bert_text": "The present studies were designed to clarify the role of catecholamines and pineal idolamines on <e1> ketamine </e1>-induced <e2> catatonia </e2> in the intact, pinealectomized or hypophysectomized chick and rat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8326": {"data": {"text": "Nicotine does not appear to enhance thrombosis among humans.", "entity1": "Nicotine", "entity2": "thrombosis", "span1": [0, 8], "span2": [36, 46]}, "bert_text": "<e1> Nicotine </e1> does not appear to enhance <e2> thrombosis </e2> among humans.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"8327": {"data": {"text": "These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.", "entity1": "desipramine", "entity2": "convulsions", "span1": [99, 110], "span2": [177, 188]}, "bert_text": "These results suggest that down-regulation of hippocampal NET induced by chronic administration of <e1> desipramine </e1> may be relevant to desipramine-induced sensitization of lidocaine <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8328": {"data": {"text": "These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.", "entity1": "desipramine", "entity2": "convulsions", "span1": [130, 141], "span2": [177, 188]}, "bert_text": "These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to <e1> desipramine </e1>-induced sensitization of lidocaine <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8329": {"data": {"text": "These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.", "entity1": "lidocaine", "entity2": "convulsions", "span1": [167, 176], "span2": [177, 188]}, "bert_text": "These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of <e1> lidocaine </e1> <e2> convulsions </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8330": {"data": {"text": "CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.", "entity1": "ethambutol", "entity2": "optic neuropathy", "span1": [38, 48], "span2": [66, 82]}, "bert_text": "CLINICAL PICTURE: Three patients with <e1> ethambutol </e1>-associated toxic <e2> optic neuropathy </e2> are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8331": {"data": {"text": "OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.", "entity1": "glyceryl trinitrate", "entity2": "sphincter of Oddi spasm", "span1": [39, 58], "span2": [95, 118]}, "bert_text": "OBJECTIVE: In this study the effect of <e1> glyceryl trinitrate </e1> on the prostigmine-morphine-induced <e2> sphincter of Oddi spasm </e2> was evaluated in nine female patients with sphincter of Oddi dyskinesia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8332": {"data": {"text": "OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.", "entity1": "glyceryl trinitrate", "entity2": "sphincter of Oddi dyskinesia", "span1": [39, 58], "span2": [162, 190]}, "bert_text": "OBJECTIVE: In this study the effect of <e1> glyceryl trinitrate </e1> on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with <e2> sphincter of Oddi dyskinesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8333": {"data": {"text": "OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.", "entity1": "prostigmine", "entity2": "sphincter of Oddi spasm", "span1": [66, 77], "span2": [95, 118]}, "bert_text": "OBJECTIVE: In this study the effect of glyceryl trinitrate on the <e1> prostigmine </e1>-morphine-induced <e2> sphincter of Oddi spasm </e2> was evaluated in nine female patients with sphincter of Oddi dyskinesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8334": {"data": {"text": "OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.", "entity1": "prostigmine", "entity2": "sphincter of Oddi dyskinesia", "span1": [66, 77], "span2": [162, 190]}, "bert_text": "OBJECTIVE: In this study the effect of glyceryl trinitrate on the <e1> prostigmine </e1>-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with <e2> sphincter of Oddi dyskinesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8335": {"data": {"text": "OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.", "entity1": "morphine", "entity2": "sphincter of Oddi spasm", "span1": [78, 86], "span2": [95, 118]}, "bert_text": "OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-<e1> morphine </e1>-induced <e2> sphincter of Oddi spasm </e2> was evaluated in nine female patients with sphincter of Oddi dyskinesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8336": {"data": {"text": "OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.", "entity1": "morphine", "entity2": "sphincter of Oddi dyskinesia", "span1": [78, 86], "span2": [162, 190]}, "bert_text": "OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-<e1> morphine </e1>-induced sphincter of Oddi spasm was evaluated in nine female patients with <e2> sphincter of Oddi dyskinesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8337": {"data": {"text": "In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.", "entity1": "clonidine", "entity2": "hypertensive", "span1": [121, 130], "span2": [33, 45]}, "bert_text": "In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous <e1> clonidine </e1> <e2> hypertensive </e2> rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8338": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "lovastatin", "entity2": "Myopathy", "span1": [130, 140], "span2": [0, 8]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with <e1> lovastatin </e1> <e2> Myopathy </e2>, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8339": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "lovastatin", "entity2": "myoglobinuria", "span1": [130, 140], "span2": [40, 53]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with <e1> lovastatin </e1> <e2> myoglobinuria </e2>, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8340": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "lovastatin", "entity2": "renal failure", "span1": [130, 140], "span2": [85, 98]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with <e1> lovastatin </e1> <e2> renal failure </e2>, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8341": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "cyclosporin", "entity2": "Myopathy", "span1": [192, 203], "span2": [0, 8]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with <e1> cyclosporin </e1> <e2> Myopathy </e2>, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8342": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "cyclosporin", "entity2": "myoglobinuria", "span1": [192, 203], "span2": [40, 53]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with <e1> cyclosporin </e1> <e2> myoglobinuria </e2>, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8343": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "cyclosporin", "entity2": "renal failure", "span1": [192, 203], "span2": [85, 98]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with <e1> cyclosporin </e1> <e2> renal failure </e2>, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8344": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "gemfibrozil", "entity2": "Myopathy", "span1": [205, 216], "span2": [0, 8]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, <e1> gemfibrozil </e1> <e2> Myopathy </e2>, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8345": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "gemfibrozil", "entity2": "myoglobinuria", "span1": [205, 216], "span2": [40, 53]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, <e1> gemfibrozil </e1> <e2> myoglobinuria </e2>, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8346": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "gemfibrozil", "entity2": "renal failure", "span1": [205, 216], "span2": [85, 98]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, <e1> gemfibrozil </e1> <e2> renal failure </e2>, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8347": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "niacin", "entity2": "Myopathy", "span1": [220, 226], "span2": [0, 8]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or <e1> niacin </e1> <e2> Myopathy </e2>, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8348": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "niacin", "entity2": "myoglobinuria", "span1": [220, 226], "span2": [40, 53]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or <e1> niacin </e1> <e2> myoglobinuria </e2>, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8349": {"data": {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity1": "niacin", "entity2": "renal failure", "span1": [220, 226], "span2": [85, 98]}, "bert_text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or <e1> niacin </e1> <e2> renal failure </e2>, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8350": {"data": {"text": "Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.\n", "entity1": "Benzylacyclouridine", "entity2": "marrow suppression", "span1": [0, 19], "span2": [52, 70]}, "bert_text": "<e1> Benzylacyclouridine </e1> reverses azidothymidine-induced <e2> marrow suppression </e2> without impairment of anti-human immunodeficiency virus activity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8351": {"data": {"text": "Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.\n", "entity1": "Benzylacyclouridine", "entity2": "immunodeficiency virus", "span1": [0, 19], "span2": [104, 126]}, "bert_text": "<e1> Benzylacyclouridine </e1> reverses azidothymidine-induced marrow suppression without impairment of anti-human <e2> immunodeficiency virus </e2> activity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8352": {"data": {"text": "Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.\n", "entity1": "azidothymidine", "entity2": "marrow suppression", "span1": [29, 43], "span2": [52, 70]}, "bert_text": "Benzylacyclouridine reverses <e1> azidothymidine </e1>-induced <e2> marrow suppression </e2> without impairment of anti-human immunodeficiency virus activity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8353": {"data": {"text": "Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.\n", "entity1": "azidothymidine", "entity2": "immunodeficiency virus", "span1": [29, 43], "span2": [104, 126]}, "bert_text": "Benzylacyclouridine reverses <e1> azidothymidine </e1>-induced marrow suppression without impairment of anti-human <e2> immunodeficiency virus </e2> activity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8354": {"data": {"text": "Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.", "entity1": "Melatonin", "entity2": "narcosis", "span1": [0, 9], "span2": [108, 116]}, "bert_text": "<e1> Melatonin </e1> affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced <e2> narcosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8355": {"data": {"text": "Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.", "entity1": "MMC", "entity2": "cardiotoxicity", "span1": [86, 89], "span2": [98, 112]}, "bert_text": "Based on the combined data from the present study and the literature, we suggest that <e1> MMC </e1>-related <e2> cardiotoxicity </e2> is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"8356": {"data": {"text": "Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [258, 269], "span2": [98, 112]}, "bert_text": "Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8357": {"data": {"text": "Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after enalapril treatment.", "entity1": "enalapril", "entity2": "glomerulosclerosis", "span1": [95, 104], "span2": [55, 73]}, "bert_text": "Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after <e1> enalapril </e1> <e2> glomerulosclerosis </e2> did not change after enalapril treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8358": {"data": {"text": "A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.", "entity1": "isosorbide dinitrate", "entity2": "necrosis", "span1": [138, 158], "span2": [33, 41]}, "bert_text": "A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of <e1> isosorbide dinitrate </e1> <e2> necrosis </e2> suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8359": {"data": {"text": "A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.", "entity1": "isosorbide dinitrate", "entity2": "myocardial infarction", "span1": [138, 158], "span2": [63, 84]}, "bert_text": "A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of <e1> isosorbide dinitrate </e1> <e2> myocardial infarction </e2> of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8360": {"data": {"text": "Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.\n", "entity1": "beta-carboline", "entity2": "seizures", "span1": [59, 73], "span2": [82, 90]}, "bert_text": "Two mouse lines selected for differential sensitivities to <e1> beta-carboline </e1>-induced <e2> seizures </e2> are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8361": {"data": {"text": "Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.\n", "entity1": "GABA(A", "entity2": "seizures", "span1": [169, 175], "span2": [82, 90]}, "bert_text": "Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other <e1> GABA(A </e1> <e2> seizures </e2> are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8362": {"data": {"text": "Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.", "entity1": "Fucoidan", "entity2": "hematomas", "span1": [0, 8], "span2": [97, 106]}, "bert_text": "<e1> Fucoidan </e1>-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger <e2> hematomas </e2>, and tended to have less inflammation in the vicinity of the hematoma after three days.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8363": {"data": {"text": "Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.", "entity1": "Fucoidan", "entity2": "hematoma", "span1": [0, 8], "span2": [168, 176]}, "bert_text": "<e1> Fucoidan </e1>-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the <e2> hematoma </e2> after three days.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8364": {"data": {"text": "Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.", "entity1": "Fucoidan", "entity2": "inflammation", "span1": [0, 8], "span2": [132, 144]}, "bert_text": "<e1> Fucoidan </e1>-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less <e2> inflammation </e2> in the vicinity of the hematoma after three days.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8365": {"data": {"text": "We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.", "entity1": "tAMCA", "entity2": "convulsive", "span1": [27, 32], "span2": [45, 55]}, "bert_text": "We wanted to study whether <e1> tAMCA </e1> retains its <e2> convulsive </e2> action if incorporated into a FS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8366": {"data": {"text": "TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).", "entity1": "TRI", "entity2": "increases the locomotor hyperactivity", "span1": [0, 3], "span2": [29, 66]}, "bert_text": "<e1> TRI </e1> given repeatedly to rats <e2> increases the locomotor hyperactivity </e2> induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8367": {"data": {"text": "TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).", "entity1": "d-amphetamine", "entity2": "increases the locomotor hyperactivity", "span1": [78, 91], "span2": [29, 66]}, "bert_text": "TRI given repeatedly to rats increases the locomotor hyperactivity induced by <e1> d-amphetamine </e1> <e2> increases the locomotor hyperactivity </e2> induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8368": {"data": {"text": "TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).", "entity1": "quinpirole", "entity2": "increases the locomotor hyperactivity", "span1": [93, 103], "span2": [29, 66]}, "bert_text": "TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, <e1> quinpirole </e1> <e2> increases the locomotor hyperactivity </e2> induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8369": {"data": {"text": "TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).", "entity1": "dopamine", "entity2": "increases the locomotor hyperactivity", "span1": [146, 154], "span2": [29, 66]}, "bert_text": "TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (<e1> dopamine </e1> <e2> increases the locomotor hyperactivity </e2> induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8370": {"data": {"text": "Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.\n", "entity1": "CaCl2-induced", "entity2": "thoracic aortic aneurysm", "span1": [89, 102], "span2": [103, 127]}, "bert_text": "Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features <e1> CaCl2-induced </e1> <e2> thoracic aortic aneurysm </e2> in a rat model.\n", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8371": {"data": {"text": "The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).", "entity1": "MZ", "entity2": "MR", "span1": [79, 81], "span2": [45, 47]}, "bert_text": "The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of <e1> MZ </e1> <e2> MR </e2>, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8372": {"data": {"text": "The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).", "entity1": "MZ", "entity2": "MP", "span1": [79, 81], "span2": [49, 51]}, "bert_text": "The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of <e1> MZ </e1> <e2> MP </e2> (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8373": {"data": {"text": "The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.", "entity1": "ipratropium bromide", "entity2": "chronic obstructive pulmonary disease", "span1": [47, 66], "span2": [288, 325]}, "bert_text": "The bronchodilator effects of a single dose of <e1> ipratropium bromide </e1> aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, <e2> chronic obstructive pulmonary disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8374": {"data": {"text": "The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.", "entity1": "theophylline", "entity2": "chronic obstructive pulmonary disease", "span1": [108, 120], "span2": [288, 325]}, "bert_text": "The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting <e1> theophylline </e1> tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, <e2> chronic obstructive pulmonary disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8375": {"data": {"text": "Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.\n", "entity1": "rizatriptan", "entity2": "migraine", "span1": [52, 63], "span2": [100, 108]}, "bert_text": "Crossover comparison of efficacy and preference for <e1> rizatriptan </e1> 10 mg versus ergotamine/caffeine in <e2> migraine </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8376": {"data": {"text": "Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.\n", "entity1": "ergotamine", "entity2": "migraine", "span1": [77, 87], "span2": [100, 108]}, "bert_text": "Crossover comparison of efficacy and preference for rizatriptan 10 mg versus <e1> ergotamine </e1>/caffeine in <e2> migraine </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8377": {"data": {"text": "Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.\n", "entity1": "caffeine", "entity2": "migraine", "span1": [88, 96], "span2": [100, 108]}, "bert_text": "Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/<e1> caffeine </e1> in <e2> migraine </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8378": {"data": {"text": "Sorafenib-induced acute myocardial infarction due to coronary artery spasm.\n", "entity1": "Sorafenib", "entity2": "myocardial infarction", "span1": [0, 9], "span2": [24, 45]}, "bert_text": "<e1> Sorafenib </e1>-induced acute <e2> myocardial infarction </e2> due to coronary artery spasm.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8379": {"data": {"text": "Sorafenib-induced acute myocardial infarction due to coronary artery spasm.\n", "entity1": "Sorafenib", "entity2": "coronary artery spasm", "span1": [0, 9], "span2": [53, 74]}, "bert_text": "<e1> Sorafenib </e1>-induced acute myocardial infarction due to <e2> coronary artery spasm </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8380": {"data": {"text": "improves scopolamine-induced amnesia but does not affect spontaneous movement.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [9, 20], "span2": [29, 36]}, "bert_text": "improves <e1> scopolamine </e1>-induced <e2> amnesia </e2> but does not affect spontaneous movement.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8381": {"data": {"text": "BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.", "entity1": "carboplatin's", "entity2": "neurotoxic", "span1": [33, 46], "span2": [120, 130]}, "bert_text": "BACKGROUND: The most striking of <e1> carboplatin's </e1> advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of <e2> neurotoxic </e2> effects.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8382": {"data": {"text": "BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.", "entity1": "CBDCA", "entity2": "neurotoxic", "span1": [59, 64], "span2": [120, 130]}, "bert_text": "BACKGROUND: The most striking of carboplatin's advantages (<e1> CBDCA </e1>) over cisplatin (CDDP) is its markedly reduced rate of <e2> neurotoxic </e2> effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8383": {"data": {"text": "BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.", "entity1": "cisplatin", "entity2": "neurotoxic", "span1": [71, 80], "span2": [120, 130]}, "bert_text": "BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over <e1> cisplatin </e1> (CDDP) is its markedly reduced rate of <e2> neurotoxic </e2> effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8384": {"data": {"text": "BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.", "entity1": "CDDP", "entity2": "neurotoxic", "span1": [82, 86], "span2": [120, 130]}, "bert_text": "BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (<e1> CDDP </e1>) is its markedly reduced rate of <e2> neurotoxic </e2> effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8385": {"data": {"text": "Azathioprine treatment benefited 19 (66%) out of 29 patients suffering from severe psoriasis.", "entity1": "Azathioprine", "entity2": "psoriasis", "span1": [0, 12], "span2": [83, 92]}, "bert_text": "<e1> Azathioprine </e1> treatment benefited 19 (66%) out of 29 patients suffering from severe <e2> psoriasis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8386": {"data": {"text": "CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.", "entity1": "glyceryl trinitrate", "entity2": "sphincter of Oddi spasm", "span1": [77, 96], "span2": [121, 144]}, "bert_text": "CONCLUSION: These results provide the first evidence of the effectiveness of <e1> glyceryl trinitrate </e1> on the morphine-induced <e2> sphincter of Oddi spasm </e2> in humans.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8387": {"data": {"text": "CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.", "entity1": "morphine", "entity2": "sphincter of Oddi spasm", "span1": [104, 112], "span2": [121, 144]}, "bert_text": "CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the <e1> morphine </e1>-induced <e2> sphincter of Oddi spasm </e2> in humans.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8388": {"data": {"text": "The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.", "entity1": "OPs", "entity2": "toxicity", "span1": [22, 25], "span2": [10, 18]}, "bert_text": "The acute toxicity of <e1> OPs </e1> <e2> toxicity </e2> of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8389": {"data": {"text": "The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.", "entity1": "AChEs", "entity2": "toxicity", "span1": [75, 80], "span2": [10, 18]}, "bert_text": "The acute toxicity of OPs is the result of their irreversible binding with <e1> AChEs </e1> <e2> toxicity </e2> of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8390": {"data": {"text": "The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.", "entity1": "acetylcholine", "entity2": "toxicity", "span1": [133, 146], "span2": [10, 18]}, "bert_text": "The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates <e1> acetylcholine </e1> <e2> toxicity </e2> of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8391": {"data": {"text": "The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.", "entity1": "ACh", "entity2": "toxicity", "span1": [148, 151], "span2": [10, 18]}, "bert_text": "The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (<e1> ACh </e1> <e2> toxicity </e2> of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8392": {"data": {"text": "Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.", "entity1": "6-OHDA", "entity2": "contralateral rotation", "span1": [21, 27], "span2": [69, 91]}, "bert_text": "Following unilateral <e1> 6-OHDA </e1> induced SN lesion, a transient period of <e2> contralateral rotation </e2> has been reported to precede the predominant ipsilateral circling.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8393": {"data": {"text": "In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.", "entity1": "calcium phosphate", "entity2": "nephrolithiasis", "span1": [165, 182], "span2": [183, 198]}, "bert_text": "In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of <e1> calcium phosphate </e1> <e2> nephrolithiasis </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8394": {"data": {"text": "Myocardial infarction following sublingual administration of isosorbide dinitrate.\n", "entity1": "isosorbide dinitrate", "entity2": "Myocardial infarction", "span1": [61, 81], "span2": [0, 21]}, "bert_text": "Myocardial infarction following sublingual administration of <e1> isosorbide dinitrate </e1> <e2> Myocardial infarction </e2> following sublingual administration of isosorbide dinitrate.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8395": {"data": {"text": "Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.", "entity1": "TP", "entity2": "PA", "span1": [93, 95], "span2": [67, 69]}, "bert_text": "Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with <e1> TP </e1> <e2> PA </e2> when treated only with TP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8396": {"data": {"text": "High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.\n", "entity1": "fat", "entity2": "obese", "span1": [5, 8], "span2": [18, 23]}, "bert_text": "High <e1> fat </e1> diet-fed <e2> obese </e2> rats are highly sensitive to doxorubicin-induced cardiotoxicity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8397": {"data": {"text": "High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.\n", "entity1": "fat", "entity2": "cardiotoxicity", "span1": [5, 8], "span2": [73, 87]}, "bert_text": "High <e1> fat </e1> diet-fed obese rats are highly sensitive to doxorubicin-induced <e2> cardiotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8398": {"data": {"text": "High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.\n", "entity1": "doxorubicin", "entity2": "obese", "span1": [53, 64], "span2": [18, 23]}, "bert_text": "High fat diet-fed obese rats are highly sensitive to <e1> doxorubicin </e1> <e2> obese </e2> rats are highly sensitive to doxorubicin-induced cardiotoxicity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8399": {"data": {"text": "High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [53, 64], "span2": [73, 87]}, "bert_text": "High fat diet-fed obese rats are highly sensitive to <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8400": {"data": {"text": "We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).", "entity1": "NO", "entity2": "nephrotic syndrome", "span1": [28, 30], "span2": [94, 112]}, "bert_text": "We have studied the role of <e1> NO </e1> and its association with apoptosis in an experimental model of <e2> nephrotic syndrome </e2> induced by a single injection of adriamycin (ADR).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8401": {"data": {"text": "We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).", "entity1": "adriamycin", "entity2": "nephrotic syndrome", "span1": [146, 156], "span2": [94, 112]}, "bert_text": "We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of <e1> adriamycin </e1> <e2> nephrotic syndrome </e2> induced by a single injection of adriamycin (ADR).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8402": {"data": {"text": "We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).", "entity1": "ADR", "entity2": "nephrotic syndrome", "span1": [158, 161], "span2": [94, 112]}, "bert_text": "We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (<e1> ADR </e1> <e2> nephrotic syndrome </e2> induced by a single injection of adriamycin (ADR).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8403": {"data": {"text": "A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.", "entity1": "cocaine", "entity2": "priapism", "span1": [40, 47], "span2": [141, 149]}, "bert_text": "A 45-year-old man, an admitted frequent <e1> cocaine </e1> user, presented to the Emergency Department (ED) on two separate occasions with a history of <e2> priapism </e2> after cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8404": {"data": {"text": "A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.", "entity1": "cocaine", "entity2": "priapism", "span1": [156, 163], "span2": [141, 149]}, "bert_text": "A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after <e1> cocaine </e1> <e2> priapism </e2> after cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8405": {"data": {"text": "Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.", "entity1": "midazolam", "entity2": "apnoea", "span1": [67, 76], "span2": [98, 104]}, "bert_text": "Somewhat fewer cardiovascular and local sequelae were found in the <e1> midazolam </e1> group, but, although <e2> apnoea </e2> occurred less often in the midazolam group it lasted longer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8406": {"data": {"text": "Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.", "entity1": "midazolam", "entity2": "apnoea", "span1": [132, 141], "span2": [98, 104]}, "bert_text": "Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the <e1> midazolam </e1> <e2> apnoea </e2> occurred less often in the midazolam group it lasted longer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8407": {"data": {"text": "Kindled seizures were induced by daily administration of 60 mg/kg cocaine for 5 days.", "entity1": "cocaine", "entity2": "seizures", "span1": [66, 73], "span2": [8, 16]}, "bert_text": "Kindled seizures were induced by daily administration of 60 mg/kg <e1> cocaine </e1> <e2> seizures </e2> were induced by daily administration of 60 mg/kg cocaine for 5 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8408": {"data": {"text": "Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.", "entity1": "enalapril", "entity2": "renal injury", "span1": [78, 87], "span2": [106, 118]}, "bert_text": "Groups 3 and 4 were studied at four and at six months to assess the effect of <e1> enalapril </e1> on progression of <e2> renal injury </e2> in adriamycin nephrosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8409": {"data": {"text": "Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.", "entity1": "enalapril", "entity2": "nephrosis", "span1": [78, 87], "span2": [133, 142]}, "bert_text": "Groups 3 and 4 were studied at four and at six months to assess the effect of <e1> enalapril </e1> on progression of renal injury in adriamycin <e2> nephrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8410": {"data": {"text": "Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.", "entity1": "adriamycin", "entity2": "renal injury", "span1": [122, 132], "span2": [106, 118]}, "bert_text": "Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in <e1> adriamycin </e1> <e2> renal injury </e2> in adriamycin nephrosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"8411": {"data": {"text": "Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.", "entity1": "adriamycin", "entity2": "nephrosis", "span1": [122, 132], "span2": [133, 142]}, "bert_text": "Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in <e1> adriamycin </e1> <e2> nephrosis </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"8412": {"data": {"text": "Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.", "entity1": "glyceryl trinitrate", "entity2": "sphincter of Oddi dyskinesia", "span1": [6, 25], "span2": [128, 156]}, "bert_text": "Since <e1> glyceryl trinitrate </e1> is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of <e2> sphincter of Oddi dyskinesia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8413": {"data": {"text": "Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.", "entity1": "morphine", "entity2": "sphincter of Oddi dyskinesia", "span1": [73, 81], "span2": [128, 156]}, "bert_text": "Since glyceryl trinitrate is able to overcome even the drastic effect of <e1> morphine </e1>, it might be of relevance in the treatment of <e2> sphincter of Oddi dyskinesia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8414": {"data": {"text": "(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.", "entity1": "R)-alpha-methylhistamine", "entity2": "catalepsy", "span1": [1, 25], "span2": [112, 121]}, "bert_text": "(<e1> R)-alpha-methylhistamine </e1> (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"8415": {"data": {"text": "(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.", "entity1": "RAMH", "entity2": "catalepsy", "span1": [27, 31], "span2": [112, 121]}, "bert_text": "(R)-alpha-methylhistamine (<e1> RAMH </e1>) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"8416": {"data": {"text": "(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.", "entity1": "thioperamide", "entity2": "catalepsy", "span1": [55, 67], "span2": [112, 121]}, "bert_text": "(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and <e1> thioperamide </e1> (THP) (15 mg/kg i.p.), per se did not cause <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"8417": {"data": {"text": "(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.", "entity1": "THP", "entity2": "catalepsy", "span1": [69, 72], "span2": [112, 121]}, "bert_text": "(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (<e1> THP </e1>) (15 mg/kg i.p.), per se did not cause <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"8418": {"data": {"text": "NS was induced by a single injection of puromycin amino-nucleoside (PAN).", "entity1": "puromycin amino-nucleoside", "entity2": "NS", "span1": [40, 66], "span2": [0, 2]}, "bert_text": "NS was induced by a single injection of <e1> puromycin amino-nucleoside </e1> <e2> NS </e2> was induced by a single injection of puromycin amino-nucleoside (PAN).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8419": {"data": {"text": "NS was induced by a single injection of puromycin amino-nucleoside (PAN).", "entity1": "PAN", "entity2": "NS", "span1": [68, 71], "span2": [0, 2]}, "bert_text": "NS was induced by a single injection of puromycin amino-nucleoside (<e1> PAN </e1> <e2> NS </e2> was induced by a single injection of puromycin amino-nucleoside (PAN).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8420": {"data": {"text": "However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.", "entity1": "CBDCA", "entity2": "neurotoxic", "span1": [20, 25], "span2": [84, 94]}, "bert_text": "However, the use of <e1> CBDCA </e1> higher-intensity schedules and the association with other <e2> neurotoxic </e2> drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8421": {"data": {"text": "However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.", "entity1": "CBDCA", "entity2": "peripheral nervous system damage", "span1": [20, 25], "span2": [177, 209]}, "bert_text": "However, the use of <e1> CBDCA </e1> higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to <e2> peripheral nervous system damage </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8422": {"data": {"text": "ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).", "entity1": "adriamycin", "entity2": "proteinuria", "span1": [70, 80], "span2": [52, 63]}, "bert_text": "ACE positively correlated with the relative rise in proteinuria after <e1> adriamycin </e1> <e2> proteinuria </e2> after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8423": {"data": {"text": "In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.", "entity1": "TP", "entity2": "tumor", "span1": [13, 15], "span2": [27, 32]}, "bert_text": "In L-W rats, <e1> TP </e1> acted as a <e2> tumor </e2> enhancement agent, with primary emphasis on the development of prostate cancer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8424": {"data": {"text": "In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.", "entity1": "TP", "entity2": "prostate cancer", "span1": [13, 15], "span2": [96, 111]}, "bert_text": "In L-W rats, <e1> TP </e1> acted as a tumor enhancement agent, with primary emphasis on the development of <e2> prostate cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"8425": {"data": {"text": "In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.", "entity1": "penicillin", "entity2": "epileptiform activity", "span1": [73, 83], "span2": [92, 113]}, "bert_text": "In the present study we aimed to portray a detailed spectral analysis of <e1> penicillin </e1>-induced <e2> epileptiform activity </e2> in comparison with basal brain activity in anesthetized Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8426": {"data": {"text": "The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.", "entity1": "NIK-247", "entity2": "Alzheimer's disease", "span1": [26, 33], "span2": [76, 95]}, "bert_text": "The findings suggest that <e1> NIK-247 </e1> may be a useful drug for the treatment of <e2> Alzheimer's disease </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8427": {"data": {"text": "Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4.", "entity1": "enalapril", "entity2": "albuminuria", "span1": [8, 17], "span2": [68, 79]}, "bert_text": "Chronic <e1> enalapril </e1> treatment reduced blood pressure without reducing <e2> albuminuria </e2> in group 4.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8428": {"data": {"text": "We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.", "entity1": "oxygen", "entity2": "hypertension", "span1": [37, 43], "span2": [203, 215]}, "bert_text": "We recently showed elevated reactive <e1> oxygen </e1> species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8429": {"data": {"text": "We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.", "entity1": "lead", "entity2": "hypertension", "span1": [190, 194], "span2": [203, 215]}, "bert_text": "We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with <e1> lead </e1>-induced <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1}
+}
\ No newline at end of file